<SEC-DOCUMENT>0001178913-22-000863.txt : 20220228
<SEC-HEADER>0001178913-22-000863.hdr.sgml : 20220228
<ACCEPTANCE-DATETIME>20220228172210
ACCESSION NUMBER:		0001178913-22-000863
CONFORMED SUBMISSION TYPE:	20-F/A
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220228
DATE AS OF CHANGE:		20220228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		22691580

	BUSINESS ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F/A
<SEQUENCE>1
<FILENAME>zk2227383.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:i="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:cgen="http://cgen.com/20211231" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217">
  <!-- XBRL Document Created with XML Edge from P3 Data Systems -->
  <head>
    <title>COMPUGEN LTD</title>
    <meta content="text/html" http-equiv="Content-Type"/>
  </head>
  <body style=" font-family:Times New Roman, Times, serif; font-size:10pt;"><div style="font-size: 10pt;">
    <div style="display: none">
      <ix:header>
        <ix:hidden>
          <ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2021-01-01to2021-12-31" id="Fact_0000000000684">true</ix:nonNumeric>
          <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2021-01-01to2021-12-31" id="Fact_0000000000685">0001119774</ix:nonNumeric>
          <ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2021-01-01to2021-12-31" id="Fact_0000000000686">FY</ix:nonNumeric>
          <ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="From2021-01-01to2021-12-31" id="Fact_0000000000011">IL</ix:nonNumeric>
          <ix:nonNumeric name="us-gaap:OperatingLossCarryforwardsExpirationDate" contextRef="From2021-01-01to2021-12-31_us-gaap_InternalRevenueServiceIRSMember_srt_MinimumMember" id="Fact_0000000000598">2023-12-31</ix:nonNumeric>
          <ix:nonNumeric name="us-gaap:OperatingLossCarryforwardsExpirationDate" contextRef="From2021-01-01to2021-12-31_us-gaap_InternalRevenueServiceIRSMember_srt_MaximumMember" id="Fact_0000000000599">2032-12-31</ix:nonNumeric>
        </ix:hidden>
        <ix:references>
          <xbrll:schemaRef xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="cgen-20211231.xsd" xlink:type="simple"></xbrll:schemaRef>
        </ix:references>
        <ix:resources>
          <i:context id="From2019-01-01to2019-12-31">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
            </i:entity>
            <i:period>
              <i:startDate>2019-01-01</i:startDate>
              <i:endDate>2019-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:unit id="usd">
            <i:measure>iso4217:USD</i:measure>
          </i:unit>
          <i:context id="From2019-01-01to2019-12-31_us-gaap_EuropeMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2019-01-01</i:startDate>
              <i:endDate>2019-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
            </i:entity>
            <i:period>
              <i:startDate>2020-01-01</i:startDate>
              <i:endDate>2020-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_srt_EuropeMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2020-01-01</i:startDate>
              <i:endDate>2020-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_srt_EuropeMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2019-01-01</i:startDate>
              <i:endDate>2019-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2020-01-01</i:startDate>
              <i:endDate>2020-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-12-31">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
            </i:entity>
            <i:period>
              <i:instant>2020-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2018-12-31">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
            </i:entity>
            <i:period>
              <i:instant>2018-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2018-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2018-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2018-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2019-12-31">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
            </i:entity>
            <i:period>
              <i:instant>2019-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2019-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2019-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2019-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2018-05-25_custom_AtTheMarketOfferingProgramMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2018-05-25</i:instant>
            </i:period>
          </i:context>
          <i:unit id="USDPerShare">
            <i:divide>
              <i:unitNumerator>
                <i:measure>iso4217:USD</i:measure>
              </i:unitNumerator>
              <i:unitDenominator>
                <i:measure>i:shares</i:measure>
              </i:unitDenominator>
            </i:divide>
          </i:unit>
          <i:unit id="ILSPerShare">
            <i:divide>
              <i:unitNumerator>
                <i:measure>iso4217:ILS</i:measure>
              </i:unitNumerator>
              <i:unitDenominator>
                <i:measure>i:shares</i:measure>
              </i:unitDenominator>
            </i:divide>
          </i:unit>
          <i:context id="AsOf2018-06-14_custom_AgreementMember_custom_RegisteredDirectOfferingMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:RegisteredDirectOfferingMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2018-06-14</i:instant>
            </i:period>
          </i:context>
          <i:unit id="Shares">
            <i:measure>i:shares</i:measure>
          </i:unit>
          <i:context id="AsOf2020-12-31_us-gaap_WarrantMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_us-gaap_WarrantMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2019-01-01to2019-12-31_us-gaap_CommonStockMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2019-01-01</i:startDate>
              <i:endDate>2019-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_us-gaap_CommonStockMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2020-01-01</i:startDate>
              <i:endDate>2020-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeesAndDirectorsMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:unit id="Item">
            <i:measure>cgen:item</i:measure>
          </i:unit>
          <i:context id="From2019-01-01to2019-12-31_custom_AtTheMarketOfferingProgramMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2019-01-01</i:startDate>
              <i:endDate>2019-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_CommonStockMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2020-03-01to2020-03-16_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2020-03-01</i:startDate>
              <i:endDate>2020-03-16</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2020-04-01to2020-04-14_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_custom_UnderwritersMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:UnderwritersMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2020-04-01</i:startDate>
              <i:endDate>2020-04-14</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_dei_BusinessContactMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_WarrantMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_us-gaap_WarrantMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2020-01-01</i:startDate>
              <i:endDate>2020-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:unit id="Pure">
            <i:measure>i:pure</i:measure>
          </i:unit>
          <i:context id="From2013-01-01to2013-12-31">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
            </i:entity>
            <i:period>
              <i:startDate>2013-01-01</i:startDate>
              <i:endDate>2013-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="I2013-12-31">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
            </i:entity>
            <i:period>
              <i:instant>2013-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2020-12-01to2020-12-18">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
            </i:entity>
            <i:period>
              <i:startDate>2020-12-01</i:startDate>
              <i:endDate>2020-12-18</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-09-01to2021-09-29">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
            </i:entity>
            <i:period>
              <i:startDate>2021-09-01</i:startDate>
              <i:endDate>2021-09-29</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_ComputerEquipmentMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember_srt_MinimumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember_srt_MaximumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_LeaseholdImprovementsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-12-31_us-gaap_ComputerEquipmentMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-12-31_custom_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_us-gaap_ComputerEquipmentMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_custom_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2018-10-10_custom_MasterClinicalAgreementMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2018-10-10</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_custom_MasterClinicalAgreementOneMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementOneMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_custom_MasterClinicalAgreementTwoMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementTwoMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-11-30_custom_MasterClinicalAgreementMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-11-30</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2019-01-01to2019-12-31_us-gaap_StockOptionMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2019-01-01</i:startDate>
              <i:endDate>2019-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_us-gaap_StockOptionMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2020-01-01</i:startDate>
              <i:endDate>2020-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_StockOptionMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2019-01-01</i:startDate>
              <i:endDate>2019-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2020-01-01</i:startDate>
              <i:endDate>2020-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact_0000000000204" toRefs="FN_6204837b941056ccc05bf22a"></ix:relationship>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2020-01-01</i:startDate>
              <i:endDate>2020-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2019-01-01to2019-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2019-01-01</i:startDate>
              <i:endDate>2019-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-11-30">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
            </i:entity>
            <i:period>
              <i:instant>2021-11-30</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_CollaborativeArrangementsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:CollaborativeArrangementsMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_MasterClinicalAgreementOneMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementOneMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_MasterClinicalAgreementTwoMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementTwoMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_CollaborativeArrangementsTwoMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:CollaborativeArrangementsTwoMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2019-01-01to2019-12-31_us-gaap_EmployeeStockOptionMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2019-01-01</i:startDate>
              <i:endDate>2019-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_us-gaap_EmployeeStockOptionMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2020-01-01</i:startDate>
              <i:endDate>2020-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_EmployeeStockOptionMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_custom_EmployeeStockPurchasePlanMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2020-01-01</i:startDate>
              <i:endDate>2020-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2019-01-01to2019-12-31_custom_EmployeeStockPurchasePlanMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2019-01-01</i:startDate>
              <i:endDate>2019-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_EmployeeStockPurchasePlanMember_srt_MinimumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_EmployeeStockPurchasePlanMember_srt_MaximumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_EmployeeStockPurchasePlanMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_ResearchAndDevelopmentGrantOneMember_srt_MaximumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_ResearchAndDevelopmentGrantOneMember_srt_MinimumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_ResearchAndDevelopmentGrantOneMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2019-01-01to2019-12-31_custom_ResearchAndDevelopmentGrantOneMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2019-01-01</i:startDate>
              <i:endDate>2019-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_custom_ResearchAndDevelopmentGrantOneMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2020-01-01</i:startDate>
              <i:endDate>2020-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_custom_ResearchAndDevelopmentGrantOneMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_srt_MinimumMember_custom_May2012AgreementMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_May2012AgreementMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="AsOf2019-12-31_us-gaap_InternalRevenueServiceIRSMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2019-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_us-gaap_DomesticCountryMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_InternalRevenueServiceIRSMember_srt_MinimumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_InternalRevenueServiceIRSMember_srt_MaximumMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_custom_TwoThousandAndTwoThousandTenOptionsPlanMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:TwoThousandAndTwoThousandTenOptionsPlanMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_us-gaap_EmployeeStockMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_custom_TwoThousandAndTwoThousandTenOptionsPlanMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:TwoThousandAndTwoThousandTenOptionsPlanMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="AsOf2019-12-31_us-gaap_DirectorMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2019-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-12-31_srt_DirectorMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_srt_DirectorMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-03-16_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-03-16</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-03-16_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_custom_UnderwritersMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:UnderwritersMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-03-16</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2018-05-01to2018-05-25_custom_AtTheMarketOfferingProgramMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2018-05-01</i:startDate>
              <i:endDate>2018-05-25</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2018-06-01to2018-06-14_custom_AgreementMember_custom_RegisteredDirectOfferingMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:RegisteredDirectOfferingMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2018-06-01</i:startDate>
              <i:endDate>2018-06-14</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2018-10-01to2018-10-10_custom_MasterClinicalAgreementMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2018-10-01</i:startDate>
              <i:endDate>2018-10-10</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-11-02to2021-11-30_custom_MasterClinicalAgreementMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-11-02</i:startDate>
              <i:endDate>2021-11-30</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_EmployeeStockMember-1750657468">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-12-31_custom_EmployeesAndDirectorsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeesAndDirectorsMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_custom_EmployeesAndDirectorsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeesAndDirectorsMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_custom_EmployeesAndDirectorsMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeesAndDirectorsMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2020-01-01</i:startDate>
              <i:endDate>2020-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2019-01-01to2019-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2019-01-01</i:startDate>
              <i:endDate>2019-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2019-01-01to2019-12-31_us-gaap_SellingAndMarketingExpenseMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2019-01-01</i:startDate>
              <i:endDate>2019-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2019-01-01to2019-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2019-01-01</i:startDate>
              <i:endDate>2019-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2020-01-01</i:startDate>
              <i:endDate>2020-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_us-gaap_SellingAndMarketingExpenseMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2020-01-01</i:startDate>
              <i:endDate>2020-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2020-01-01to2020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2020-01-01</i:startDate>
              <i:endDate>2020-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_SellingAndMarketingExpenseMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="From2021-01-01to2021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:startDate>2021-01-01</i:startDate>
              <i:endDate>2021-12-31</i:endDate>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-12-31_country_IL">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:IL</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2020-12-31_country_US">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2020-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_country_IL">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:IL</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
          <i:context id="AsOf2021-12-31_country_US">
            <i:entity>
              <i:identifier scheme="http://www.sec.gov/CIK">0001119774</i:identifier>
              <i:segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember>
              </i:segment>
            </i:entity>
            <i:period>
              <i:instant>2021-12-31</i:instant>
            </i:period>
          </i:context>
        </ix:resources>
      </ix:header>
    </div>
    <div> <div style="width:100%; clear:both;"> <hr style="border-top:3pt solid #000000; width:100%; margin-left:0pt; text-align:left; "/><hr style="border-top:0.75pt solid #000000; width:100%; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:13.03pt; text-align:left; "></p> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">UNITED STATES</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:14pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">SECURITIES AND EXCHANGE COMMISSION</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">WASHINGTON, D.C. 20549</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:14pt; text-align:center; margin-top:12pt; margin-bottom:0pt; "><span style="font-weight:bold; ">FORM </span><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000001" contextRef="From2021-01-01to2021-12-31" name="dei:DocumentType">20-F/A</ix:nonNumeric></span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:14pt; text-align:center; margin-top:12pt; margin-bottom:0pt; "><span style="font-weight:bold; ">(Amendment No. 1)</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:20pt !important; margin-bottom:0pt; "><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000002" contextRef="From2021-01-01to2021-12-31" name="dei:DocumentRegistrationStatement" format="ixt:booleanfalse">&#x2610;</ix:nonNumeric></span><span style="font-weight:bold; padding-left:11.25pt; ">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF </span><span style="font-weight:bold; ">1934</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; "><span style="font-weight:bold; ">OR</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000003" contextRef="From2021-01-01to2021-12-31" name="dei:DocumentAnnualReport" format="ixt:booleantrue">&#x2612;</ix:nonNumeric></span><span style="font-weight:bold; padding-left:10pt; ">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; "><span style="font-weight:bold; ">For the fiscal year ended </span><span style="font-weight:bold; "><span style="font-weight:bold; "><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000006" contextRef="From2021-01-01to2021-12-31" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><ix:nonNumeric id="Fact_0000000000004" contextRef="From2021-01-01to2021-12-31" name="dei:CurrentFiscalYearEndDate" format="ixt:datemonthdayen">December 31</ix:nonNumeric>, <ix:nonNumeric id="Fact_0000000000005" contextRef="From2021-01-01to2021-12-31" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric></ix:nonNumeric></span></span></span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; "><span style="font-weight:bold; ">OR</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000007" contextRef="From2021-01-01to2021-12-31" name="dei:DocumentTransitionReport" format="ixt:booleanfalse">&#x2610;</ix:nonNumeric></span><span style="font-weight:bold; padding-left:11.25pt; ">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; "><span style="font-weight:bold; ">OR</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:20pt !important; margin-bottom:0pt; "><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000008" contextRef="From2021-01-01to2021-12-31" name="dei:DocumentShellCompanyReport" format="ixt:booleanfalse">&#x2610;</ix:nonNumeric></span><span style="font-weight:bold; padding-left:11.25pt; ">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF </span><span style="font-weight:bold; ">1934</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="padding-left:20pt; ">Date of event requiring this shell company report ____________</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; "><span style="font-weight:bold; ">For the transition period from ____________ to ____________</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">Commission file number: <span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000009" contextRef="From2021-01-01to2021-12-31" name="dei:EntityFileNumber">000-30902</ix:nonNumeric></span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">_________________________________________________</p>
<p style="font-family:Times New Roman, Times, serif; font-size:16pt; text-align:center; margin-top:12pt; margin-bottom:0pt; "><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000010" contextRef="From2021-01-01to2021-12-31" name="dei:EntityRegistrantName">Compugen Ltd</ix:nonNumeric></span><span style="font-weight:bold; ">.</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">(Exact name of Registrant as specified in its charter)</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">____________________________________</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">(Translation of Registrant&#x2019;s name into English)</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">___________________________________________________________</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; "><span style="font-weight:bold; "><span style="-sec-ix-hidden:Fact_0000000000011">Israel</span></span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">(Jurisdiction of incorporation or organization)</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; "><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000012" contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine1">Azrieli Center</ix:nonNumeric></span><span style="font-weight:bold; ">, </span><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000013" contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine2">26 Harokmim Street</ix:nonNumeric></span><span style="font-weight:bold; ">, </span><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000014" contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine3">Building D</ix:nonNumeric></span><span style="font-weight:bold; ">, </span><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000015" contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressCityOrTown">Holon</ix:nonNumeric></span><span style="font-weight:bold; ">&#xA0;</span><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000016" contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressPostalZipCode">5885849</ix:nonNumeric></span><span style="font-weight:bold; ">&#xA0;</span><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000017" contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">(Address of principal executive offices)</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">________________________________________________</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; "><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000018" contextRef="From2021-01-01to2021-12-31_dei_BusinessContactMember" name="dei:ContactPersonnelName">Ari Krashin</ix:nonNumeric></span><span style="font-weight:bold; ">, Chief Financial Officer</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Phone: +</span><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000019" contextRef="From2021-01-01to2021-12-31_dei_BusinessContactMember" name="dei:CityAreaCode">972</ix:nonNumeric></span><span style="font-weight:bold; ">-</span><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000020" contextRef="From2021-01-01to2021-12-31_dei_BusinessContactMember" name="dei:LocalPhoneNumber">3-765-8585</ix:nonNumeric></span><span style="font-weight:bold; ">, Fax: +</span><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000021" contextRef="From2021-01-01to2021-12-31_dei_BusinessContactMember" name="dei:ContactPersonnelFaxNumber">972-3-765-8555</ix:nonNumeric></span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000022" contextRef="From2021-01-01to2021-12-31_dei_BusinessContactMember" name="dei:EntityAddressAddressLine1">Azrieli Center</ix:nonNumeric></span><span style="font-weight:bold; ">, </span><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000023" contextRef="From2021-01-01to2021-12-31_dei_BusinessContactMember" name="dei:EntityAddressAddressLine2">26 Harokmim Street</ix:nonNumeric></span><span style="font-weight:bold; ">, </span><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000024" contextRef="From2021-01-01to2021-12-31_dei_BusinessContactMember" name="dei:EntityAddressAddressLine3">Building D</ix:nonNumeric></span><span style="font-weight:bold; ">, </span><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000025" contextRef="From2021-01-01to2021-12-31_dei_BusinessContactMember" name="dei:EntityAddressCityOrTown">Holon</ix:nonNumeric></span><span style="font-weight:bold; ">&#xA0;</span><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000026" contextRef="From2021-01-01to2021-12-31_dei_BusinessContactMember" name="dei:EntityAddressPostalZipCode">5885849</ix:nonNumeric></span><span style="font-weight:bold; ">&#xA0;</span><span style="font-weight:bold; "><ix:nonNumeric id="Fact_0000000000027" contextRef="From2021-01-01to2021-12-31_dei_BusinessContactMember" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">________________________________________________</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Securities registered or to be registered pursuant to Section 12(b) of the Act.</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" style="border-spacing:0; "> <tbody> <tr class="odd" style=""> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Title of each class</span> </p> </td> <td style="width:20%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Trading Symbol(s)</span> </p> </td> <td style="width:40%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Name of each exchange on which registered</span> </p> </td> </tr> <tr class="even" style=""> <td style="width:40%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonNumeric id="Fact_0000000000028" contextRef="From2021-01-01to2021-12-31" name="dei:Security12bTitle">Ordinary shares, par value NIS 0.01 per share</ix:nonNumeric> </p> </td> <td style="width:20%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonNumeric id="Fact_0000000000029" contextRef="From2021-01-01to2021-12-31" name="dei:TradingSymbol">CGEN</ix:nonNumeric> </p> </td> <td style="width:40%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">The <ix:nonNumeric id="Fact_0000000000030" contextRef="From2021-01-01to2021-12-31" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Stock Market LLC</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">(The Nasdaq Global Market) </p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Securities registered or to be registered pursuant to Section 12(g) of the Act.</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">None</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">(Title of Class) </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">None</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">(Title of Class) </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:13.03pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">Indicate the number of outstanding shares of each of the issuer&#x2019;s classes of capital or common stock as of the close of the period covered by the annual report: <span style="font-weight:bold; "><ix:nonFraction id="Fact_0000000000031" contextRef="AsOf2021-12-31" name="dei:EntityCommonStockSharesOutstanding" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">86,433,432</ix:nonFraction></span><span style="font-weight:bold; "> Ordinary Shares</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">&#x2610; Yes&#x2003;&#x2002;&#x2612; <ix:nonNumeric id="Fact_0000000000032" contextRef="From2021-01-01to2021-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">&#x2610; Yes&#x2003;&#x2002;&#x2612; <ix:nonNumeric id="Fact_0000000000033" contextRef="From2021-01-01to2021-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">&#x2612; <ix:nonNumeric id="Fact_0000000000034" contextRef="From2021-01-01to2021-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric>&#x2003;&#x2002;&#x2610; No</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#xA7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">&#x2612; <ix:nonNumeric id="Fact_0000000000035" contextRef="From2021-01-01to2021-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>&#x2003;&#x2002;&#x2610; No</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or an emerging growth company. See definition of &#x201C;accelerated filer&#x201D; &#x201C;large accelerated filer&#x201D; and &#x201C;emerging growth company&#x201D; in Rule 12b-2 of the Exchange Act.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" style="border-spacing:0; margin:auto; "> <tbody> <tr class="odd" style=""> <td style="width:25%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">Large accelerated filer &#x2610; </p> </td> <td style="width:25%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonNumeric id="Fact_0000000000036" contextRef="From2021-01-01to2021-12-31" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen">Accelerated filer</ix:nonNumeric> &#x2612; </p> </td> <td style="width:25%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">Non-accelerated filer &#x2610; </p> </td> <td style="width:25%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">Emerging growth company &#x2610; </p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#x2020; provided pursuant to Section 13(a) of the Exchange Act <ix:nonNumeric id="Fact_0000000000037" contextRef="From2021-01-01to2021-12-31" name="dei:EntityEmergingGrowthCompany" format="ixt:booleanfalse">&#x2610;</ix:nonNumeric></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">&#x2020; The term &#x201C;new or revised financial accounting standard&#x201D; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric id="Fact_0000000000038" contextRef="From2021-01-01to2021-12-31" name="dei:IcfrAuditorAttestationFlag" format="ixt:booleantrue">&#x2612;</ix:nonNumeric></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" style="border-spacing:0; "> <tbody> <tr class="odd" style=""> <td style="width:25%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonNumeric id="Fact_0000000000039" contextRef="From2021-01-01to2021-12-31" name="dei:DocumentAccountingStandard">U.S. GAAP</ix:nonNumeric> &#x2612; </p> </td> <td style="width:50%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">International Financial Reporting Standards as issued </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">by the International Accounting Standards Board &#x2610; </p> </td> <td style="width:25%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">Other &#x2610; </p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">If &#x201C;Other&#x201D; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">Item 17&#x2003;&#x2610; Item 18 &#x2610;</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:12pt; margin-bottom:0pt; ">&#x2610; Yes&#x2003;&#x2002;<ix:nonNumeric id="Fact_0000000000040" contextRef="From2021-01-01to2021-12-31" name="dei:EntityShellCompany" format="ixt:booleanfalse">&#x2612;</ix:nonNumeric> No</p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:13.03pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div> <ix:nonNumeric id="Fact_0000000000041" contextRef="From2021-01-01to2021-12-31" name="dei:AmendmentDescription">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:11pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">EXPLANATORY NOTE</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">This Amendment No. 1 to the Annual Report on Form 20-F, or the Amendment, amends the Annual Report on Form 20-F of Compugen Ltd., or the Company, for the year ended December 31, 2021, which was originally filed with the Securities and Exchange Commission on February 28, 2022, or the Original Filing.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">The Company is filing this Amendment solely for the purpose of updating disclosure in Item 7.A., &#x201C;Major Shareholders and Related Party Transactions &#x2013; Major Shareholders.&#x201D; In addition, pursuant to Rule&#xA0;12b-15&#xA0;under the&#xA0;Exchange Act, the Company is filing the certifications required under the&#xA0;Sarbanes-Oxley Act&#xA0;of 2002.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">Except as described above or as otherwise expressly provided by the terms of this Amendment, no other changes have been made to the Original Filing. Except as otherwise indicated herein, this Amendment continues to speak as of the date of the Original Filing, and the Company has not updated the disclosures contained therein to reflect any events that occurred subsequent to the date of the Original Filing. </p></ix:nonNumeric>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:13.03pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:9pt; margin-bottom:0pt; "></p>

<!-- Field: Include-Text; File: ProFiler\body.htm; Date: 2022%2D02%2D28T21:46:10; Size: 0x001225CA; Options: XMLPreprocess -->
<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman,Times,serif"> </span></p>

<div>

<div><br /> </div>

<div>

<div style="text-align: center; line-height: 1.25; font-weight: bold"><span style="text-decoration: underline">TABLE OF CONTENTS</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: -72pt; margin-left: 72pt; line-height: 1.25"><a href="#CAUTIONARYSTATEMENTREGARD">CAUTIONARY STATEMENT REGARDING
FORWARD-LOOKING STATEMENTS</a></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"> <br /> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" border="0" id="z9d8cddacf26d49b5a3087499a2416f02" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top">
        <div style="text-indent: -72pt; margin-left: 72pt; line-height: 1.25"><a href="#PARTI.">PART I.</a></div> </td>
    <td rowspan="1" style="width: 87%; vertical-align: top">&#160;</td>
    <td rowspan="1" style="width: 5%; vertical-align: top">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM1.">ITEM 1.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM1.">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM2.">ITEM 2.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM2.">OFFER STATISTICS AND EXPECTED TIMETABLE</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM3.">ITEM 3.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM3.">KEY INFORMATION</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">1</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM4.">ITEM 4.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM4.">INFORMATION ON THE COMPANY</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">45<br /> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM4A.">ITEM 4A.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM4A.">UNRESOLVED STAFF COMMENTS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">64<br /> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM5">ITEM 5.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM5">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">65<br /> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM6">ITEM 6.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM6">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">75<br /> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM7">ITEM 7.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM7">MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">96<br /> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM8">ITEM 8.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM8">FINANCIAL INFORMATION</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">98<br /> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM9">ITEM 9.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM9">THE OFFER AND LISTING</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">98<br /> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM10">ITEM 10.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM10">ADDITIONAL INFORMATION</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">99<br /> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM11">ITEM 11.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM11">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">107<br /> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM12">ITEM 12.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM12">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">107<br /> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#PARTII">PART II.</a></div> </td>
    <td style="width: 87%; vertical-align: top">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM13">ITEM 13.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM13">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">108<br /> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM14">ITEM 14.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM14">MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</a></div>
        </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">108<br /> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM15">ITEM 15.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM15">CONTROLS AND PROCEDURES</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">108<br /> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16">ITEM 16.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16">RESERVED</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">109<br /> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16A">ITEM 16A.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16A">AUDIT COMMITTEE FINANCIAL EXPERT</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">109</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16B">ITEM 16B</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16B">CODE OF ETHICS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">109</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16C">ITEM 16C.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16C">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">109</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16D">ITEM 16D.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16D">EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">110<br /> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16E">ITEM 16E.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16E">PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">110</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16F">ITEM 16F.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16F">CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">110</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16G">ITEM 16G.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16G">CORPORATE GOVERNANCE</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">110</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16H">ITEM 16H.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16H">MINE SAFETY DISCLOSURE</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">110</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16I">ITEM 16I.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM16I">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">110</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#PARTIII">PART III</a></div> </td>
    <td style="width: 87%; vertical-align: top">&#160;</td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM17">ITEM 17.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM17">FINANCIAL STATEMENTS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">110</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM18">ITEM 18.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM18">FINANCIAL STATEMENTS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">110</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM19.">ITEM 19.</a></div> </td>
    <td style="width: 87%; vertical-align: top">
        <div style="line-height: 1.25"><a href="#ITEM19.">EXHIBITS</a></div> </td>
    <td style="width: 5%; vertical-align: bottom; text-align: right">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">111</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">(i)</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold"><span id="CAUTIONARYSTATEMENTREGARD"><!--Anchor--></span>CAUTIONARY
STATEMENT REGARDING</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">FORWARD-LOOKING STATEMENTS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">This annual report on Form 20-F, or the Annual Report, includes &#8220;forward-looking
statements&#8221; within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the
safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on our current
beliefs, expectations and assumptions. Forward-looking statements can be identified by the use of terminology such as &#8220;will,&#8221;
&#8220;may,&#8221; &#8220;assume,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221;
&#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;believe,&#8221; &#8220;suggest,&#8221; and &#8220;intend,&#8221; and similar expressions
that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
These forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements
to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
Factors that could cause our actual results to differ materially from those projected in the forward-looking statements include, without
limitation, the risk factors set forth under &#8220;Item 3. Key Information - D. Risk Factors,&#8221; the information about us set forth
under &#8220;Item 4. Information on the Company&#8221; and information related to our financial condition under &#8220;Item 5. Operating
and Financial Review and Prospects.&#8221; Any forward-looking statements represent our views only as of the date hereof and should not
be relied upon as representing its views as of any subsequent date. We do not assume any obligation to update any forward-looking statements
unless required by law.</div>

<div style="text-align: justify; line-height: 1.25"> <br /> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">All references in this Annual Report on Form 20-F to &#8220;Compugen,&#8221; the &#8220;Company,&#8221;
&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or similar references refer to Compugen Ltd. and our wholly owned subsidiary Compugen
USA, Inc., except where the context otherwise requires or as otherwise indicated.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have prepared our consolidated financial statements in United States dollars and
in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. All references herein to &#8220;dollars&#8221;
or &#8220;$&#8221; are to United States dollars, and all references to &#8220;Shekels&#8221; or &#8220;NIS&#8221; are to New Israeli Shekels.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">(ii)</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>
<!--PROfilePageNumberReset%Num%1%%%-->

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold"><span id="PARTI."><!--Anchor--></span>PART
I.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25"><span style="font-weight: bold">ITEM 1.</span><span style="font-family: Times New Roman,Times,serif"><span id="ITEM1."><!--Anchor--></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<span style="font-weight: bold">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25"><span style="font-weight: bold">ITEM 2.</span><span style="font-family: Times New Roman,Times,serif"><span id="ITEM2."><!--Anchor--></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<span style="font-weight: bold">OFFER STATISTICS AND EXPECTED TIMETABLE</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25"><span style="font-weight: bold">ITEM 3.</span><span style="font-family: Times New Roman,Times,serif"><span id="ITEM3."><!--Anchor--></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<span style="font-weight: bold">KEY INFORMATION</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">A. [RESERVED]</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">B. CAPITALIZATION AND INDEBTEDNESS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. REASONS FOR THE OFFER AND USE OF PROCEEDS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">D. RISK FACTORS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">An investment in our ordinary shares involves a high
degree of risk and many factors could affect our results, financial condition, cash flows and results of operations. You should carefully
consider the following risk factors, as well as the other information in this Annual Report. If we do not, or cannot, successfully address
the risks to which we are subject, we could experience a material adverse effect on our business, results of operations and financial
condition, which could include the need to limit or even discontinue our business operations, and accordingly our share price may decline,
and you could lose all or part of your investment. We can give no assurance that we will successfully address any of these risks. The
principal risks we face are described below</span><span style="font-family: Times New Roman,Times,serif">.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Summary Risk Factors </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Our business is subject to a number of risks of which you should
be aware of before making an investment decision. These risks are discussed more fully in this &#8220;Item 3. Key Information - D. Risk
Factors&#8221; section of this Annual Report. These risks include, but are not limited to, the following:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z66dad61835384845994f76f27c2a013d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We have a history of losses and we expect to incur future losses and may never achieve or sustain profitability. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ze51e7fdd3a224a94ad6e933a97a7b430" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We may need to raise additional funds in the future, and if we are unable to raise such additional funds, we may need to limit, curtail
        or cease operations. To the extent any such funding is based on the sale of equity, our existing shareholders would experience dilution
        of their shareholdings.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zeaf0546231124e6c824221e0c44d7006" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We cannot provide assurance that our business model will succeed in generating substantial revenues. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6723f74a2fd1463b9d66d090bbc7122b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>The widespread outbreak of an illness or any other communicable disease, or any other public health crisis, such as the COVID-19
        pandemic, and the governmental and societal responses thereto, may negatively impact the global economy and may also adversely affect
        our business and results of operations. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb34396d794de40c39f8977c7e12eea63" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>In the near term, we are highly dependent on the success of COM701 and of COM902. We may not be able to advance our internal clinical
        stage programs through clinical development or manufacturing or successfully partner or commercialize them, or obtain marketing approval,
        either alone or with a collaborator, or may experience significant delays in doing so.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5a6c55ad64304809988616113f194bda" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Clinical trials of any product candidates that we, or any current or future collaborators may conduct may fail to satisfactorily
        demonstrate safety and efficacy, and we, or any collaborator, may incur additional costs or experience delays in completing, or ultimately
        be unable to complete the development and commercialization of these product candidates.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z693f9c0f018f449fad74bd433ee83b97" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Clinical development involves a lengthy and expensive process, with an uncertain outcome. We may encounter substantial delays or
        even an inability to begin clinical trials for any specific product or may not be able to conduct or complete our trials on the timelines
        we expect.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd6aa9f57a80f4f7694a8e7de2b0fa9d8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>From time to time we publicly disclose preliminary data from our ongoing clinical trials. As more patient data become available the
        data and the interpretation of the data may change.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">1</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z71524be389e44d8faa45b383bc38e065" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We rely and expect to continue to rely on third parties to conduct our clinical trials. These third parties may not successfully
        carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, and we may experience significant
        delays in the conduct of our clinical trials as well as significant increased expenditures.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z653086141e24458783a9f5375a90f308" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Serious adverse events or undesirable side effects or lack of efficacy, may emerge in clinical trials conducted by other companies
        running clinical trials investigating the same target as us, which could adversely affect our development programs or our capability to
        enroll patients or partner the program for further development and commercialization.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ze2b59a0489fe4d6795c9f18ed26c47bd" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We are subject to certain manufacturing risks, any of which could either result in additional costs or delays in completing, or ultimately
        make us unable to complete, the development and commercialization of our product candidates.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4c5182df0d994cf9a1ec6c59d6fc1658" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Our current and future relationships, and/or the relationships of our collaborators through which we may market, sell, and distribute
        our products, with healthcare professionals, physicians and other parties in the United States and elsewhere may be subject, directly
        or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, health information and general
        privacy and security and other healthcare laws and regulations, which could expose us to adverse consequences.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc848a03d34e94e90a9008001b720d9f5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>There are risks that are inherent in the development and commercialization of new therapeutic products.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zeb9b515173d94696ac7f759f9e58dfba" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We have limited experience in the development of therapeutic product candidates, and we may be unable to implement our business strategy.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zbbe1de349719463f8e982f9faf54e672" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Our approach to the discovery of therapeutic products is based on our predictive computational discovery capabilities that are not
        yet fully proven clinically, and we do not know whether we will be able to discover and develop additional potential product candidates
        or products of commercial value.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8191f852b15f453fb2889c1bd9880887" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We are focusing our discovery and therapeutic development activities on therapeutic product candidates for uses in immuno-oncology.
        Our current candidates may fail, and we may fail to continue to discover and develop therapeutic product candidates of industry interest
        in this field.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z965ec81b81294ff5ba27ce826071dee8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We depend significantly on third parties to carry out the research, development and commercialization of our therapeutic product
        candidates. If we are unable to maintain our existing agreements or to enter into additional agreements with such third parties, including
        collaborators, in the future, our business will likely be materially harmed.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zbef09b600cde42eebc150676b49e49ef" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We rely and expect to continue to rely completely on third parties to manufacture and supply our preclinical and clinical drug supplies.
        Our business could be harmed if those third parties fail to provide us with sufficient quantities of drug product or fail to do so at
        acceptable quality and quantity levels, prices or timelines.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z603133a0bf344f74b912910600977e45" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Our dependence on collaboration agreements with third parties presents number of risks.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zcb0685d207ed4382bbdcc334cc3accc2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Our reliance on third parties for the performance of key activities heightens the risks faced by our business.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zbd72d5f4f5794aaf99b35602e300c05d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Our business model is challenging to implement and to date has not yielded significant revenues.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z0ac79c16c51b4e3a9215ccfb959b30fa" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We operate in a highly competitive and rapidly changing industry which may result in others discovering, developing or commercializing
        competing products before us or more successfully than we do.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zda5d61eb9c824550a21bbbf31fc08fc5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Given our level of managerial, operational, financial and other resources, our current activities and future growth may be limited.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za30287b280344680bc4ef9c0c8408550" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>We may be unable to hire or retain key personnel or sufficiently qualified management, clinical and scientific personnel. </div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb40ffe661c6146d7bcde596802ae276e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We may be unable to safeguard the integrity, security and confidentiality of our data or third parties&#8217; data.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">2</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc7d22834c1e144648ae014e3bfbc18ec" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Our internal computer systems, or those of our contract research organizations, or CROs, or other contractors or consultants, may
        fail or suffer security breaches, which could result in a material disruption of our pipeline and our business.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z39722d2445e642a0b80c80176bca15bc" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Our business and operations would suffer if our information technology systems or infrastructure or data, or our vendors&#8217; or
        partners&#8217;, are or were compromised.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf965f3873ece4a8da945526964e05ede" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We are subject to stringent and changing obligations related to data privacy and security. Failure or perceived failure to comply
        with current or future obligations could lead to government enforcement actions (which could include civil or criminal penalties), private
        litigation, and/or adverse publicity and could negatively affect our operating results and business.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd79abfd7ec744352875f1adfb46fc9d5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability
        to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8a6c7ee356bf459fbea08b43decfd661" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>In the future, we may need to obtain additional licenses of third-party technology that may not be available to us or are available
        only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that
        was not anticipated.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zac0163d609f5473cb69ddf700d8cd22f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We, or potential collaborators and licensees, may infringe third-party rights and may become involved in litigation, which may materially
        harm our business.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc3c9dff1cadb4183ae22e1278ab12c71" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time
        consuming and unsuccessful. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z092f94828dc5436097d989b19e1bc6ca" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Conditions in the Middle East and in Israel may adversely affect our operations. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zaf56e571c10343d9a30595d90243f7f4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Our results of operations may be adversely affected by the exchange rate fluctuations between the dollar and the New Israeli Shekel.
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8e9ad00e7f5c4a409c5a235b3ea02470" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Future sales of our ordinary shares or securities convertible or exchangeable for our ordinary shares may depress our share price.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z0545299070014428935480b8744e9c3a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>If we sell ordinary shares in future financings, shareholders may experience immediate dilution and, as a result, our share price
        may decline. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb0df1c88ebb249fe9800d1635811cec3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Our share price and trading volume have been volatile and may be volatile in the future and that could limit investors&#8217; ability
        to sell our shares at a profit and could limit our ability to successfully raise funds.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z294be25f78f749ad94799f56ebffb4a5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>If we are a passive foreign investment company, or PFIC, our U.S. shareholders may be subject to adverse U.S. federal income tax
        consequences.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Risks Related to our Business, Financial Results and Financing Needs</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We have a history of losses and we expect to
incur future losses and may never achieve or sustain profitability.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As of December 31, 2021, we had an accumulated deficit of approximately $422.1 million
and had incurred net losses of approximately $34.2 million in 2021, approximately $29.7 million in 2020 and approximately $27.3 million
in 2019, in large part due to the expenditures <span style="font-family: Times New Roman,Times,serif">associated with our ongoing research
and development and limited revenues received to date. In addition, we expect to continue to incur net losses in the future due to our
anticipated costs and expenses, primarily associated with our preclinical and clinical activities. We have entered into three pipeline
program-based partnership agreements under which we have received or accrued to date a total amount of $83.2 million, including a $32.0
million investment. We cannot be certain that we will receive additional revenues under our existing collaborations or that we will enter
into additional arrangements for our programs or with respect to our predictive computational discovery capabilities, or that such additional
arrangements will provide sufficient revenues to achieve profitability. Even if we do achieve profitability, we may not be able to sustain
or increase our profitability.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">3</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may need to raise additional funds in the
future, and if we are unable to raise such additional funds, we may need to limit, curtail or cease operations. To the extent any such
funding is based on the sale of equity, our existing shareholders would experience dilution of their shareholdings.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We believe that our existing cash and cash equivalents and short-term bank deposits
will be sufficient to fund our current level of operations into 2024, without considering the possible receipt of any additional funds,
such as proceeds from existing or additional licensing and/or collaborative agreements, or from financings. However, as we expand our
clinical trials and other operations and may increase our cash expenditures, our cash balances may be sufficient for a shorter period
of time. We cannot predict with any degree of certainty when, or even if, we will achieve profitability, and therefore may need additional
funds to continue financing our operations. In 2019, we received proceeds of approximately $23 million through our ATM facility. In 2020,
we received net proceeds of approximately $74 million from a public offering and approximately $34 million from warrants and option exercises.
In 2021, we received a $20 million investment pursuant to an investment from our partner, Bristol Myers Squibb Company, or Bristol Myers
Squibb. We may seek additional capital due to strategic considerations even if we believe we have sufficient funds for our current and
future operating plans. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Additional funds, including proceeds from license or collaborative agreements, or
from other financings, may not be available to us on acceptable terms, or at all. In addition, the terms of any financing may adversely
affect the holdings or the rights of our existing shareholders. For example, if we raise additional funds by issuing equity securities,
our existing shareholders will experience dilution of their shareholdings. Debt financing, if available, may involve restrictive covenants
that could limit our flexibility in conducting future business activities. If we are unable to obtain funding on a timely basis, we may
be required to significantly curtail one or more of our research or development programs or otherwise reduce our operations. We also could
be required to seek funds through arrangements with collaborators or other investors that may require us to enter into arrangements on
terms that would otherwise not be acceptable to us. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our therapeutic programs have reached more costly stages of research and development,
including preclinical and clinical drug development. If we are not able to secure the funding or the capabilities required for such activities,
we may be required to abandon, postpone, or attempt to license out certain therapeutic product candidates at an earlier than anticipated
stage, which may adversely affect us. Any failure to raise funds as and when needed would materially harm our business, financial condition
and results of operations, and result in the inability to have some or all of such therapeutic product candidates developed to fit potential
commercialization and have a negative impact on our ability to pursue our business strategy.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We cannot provide assurance that our business
model will succeed in generating substantial revenues.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our business model is primarily based on expected future revenues in various forms,
including upfront fees, research funding, in-kind funding, milestone payments, license fees, royalties on product sales and other revenue
sharing payments from commercialization of products by third parties, pursuant to various forms of collaborations for our novel targets
and related drug product candidates at various stages of research and development. Our primary focus in immuno-oncology utilizes our predictive
computational discovery capabilities to identify novel drug targets and develop potentially first-in-class therapeutics in the field of
cancer immunotherapy. Drug target candidates discovered by our predictive computational discovery capabilities undergo initial target
validation studies and, in selected cases, are advanced to the discovery and development of the therapeutic product candidate. Such drug
target candidates and their related therapeutic product candidates may serve as the basis for licensing and other forms of third-party
collaborations. Some of our existing third-party collaboration and licensing agreements have been entered into at early research and development
stages, each of which has an inherently high risk of failure. The inability to derive adequate revenues, or at all, from our business
model would materially harm our business, financial condition and results of operations and could result in the need to limit or even
discontinue our business operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The widespread outbreak of an illness or any
other communicable disease, or any other public health crisis, such as the COVID-19 pandemic, and the governmental and societal responses
thereto, may negatively impact the global economy and may also adversely affect our business and results of operations. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our business, financial condition, and results of operations could be negatively impacted
by&#160;COVID-19&#160;or other widespread outbreak of an illness or any other communicable disease, or any other public health crisis.&#160;The
severity, magnitude and duration of the current COVID-19 pandemic and future outbreaks is uncertain, rapidly changing and difficult to
predict. The COVID-19 pandemic has created macro-economic uncertainty and disruption in the business and financial markets. Many countries
around the world, including the United States and Israel, have taken measures designated to limit the spread of the COVID-19 virus, including
closing workplaces, restricting travel, prohibiting assembling, closing international borders and quarantining populated areas. The continued
spread of the COVID-19 virus and the uncertainty surrounding its variants have caused, and may continue to cause, continued changes in
the measures taken by different countries based on the change in the COVID-19 pandemic status. These measures have impacted, and may further
impact, our suppliers and other business partners from conducting business activities as usual (including, without limitation, the availability
and pricing of materials, manufacturing and delivery efforts, clinical trials and other aspects that may affect our business) for an unknown
period of time. In addition, we, our suppliers and other business partners may experience significant impairments of business activities
due to operational shutdowns or suspensions that may be requested or mandated by national or local governmental authorities or self-imposed
by us, our suppliers or other business partners. If measures, such as those listed above, are taken again or additional measures are required
in the event that the measures already taken prove to be insufficient or ineffective to slow the spread of COVID-19 or other global or
regional health pandemics or epidemics, we may face new and/or increasing concerns that may affect our ability to conduct our business
effectively, including, but not limited to, adverse effect on employees&#8217; health, a slowdown and stoppage of work, slowdown or stoppage
of our clinical trials and other activities which are essential and critical for maintaining on-going business activities. Even if the
measures taken, or that will be taken, prove themselves to be useful, we, our suppliers and other business partners may recover at different
rates, which may also affect our business activities.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">4</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">These effects could materially and adversely affect our business, financial condition,
results of operations and growth prospects. In addition, to the extent the evolving effects of the COVID-19 pandemic or such other global
or regional event adversely affect our business, financial condition, results of operations and growth prospects, they may also have the
effect of heightening many of the other risks and uncertainties described elsewhere in this &#8220;Risk Factors&#8221; section.&#160;It
is also possible that the volatility that the capital markets have experienced due to the ongoing spread of COVID-19 and its adverse effects,
including those caused as a result of government actions, shall continue and as a result, the price of our shares may be negatively impacted,
which could adversely affect our ability to raise additional capital.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have taken precautionary measures, and may take additional measures, intended to
minimize the risks of the COVID-19 pandemic to our employees and operations. The extent of the impact of the COVID-19 pandemic on our
operational and financial performance, including our ability to execute our business strategies in the expected time frame or at all,
will depend on future developments, such as the duration and spread of the COVID-19 pandemic and long-term impact on the world&#8217;s
economy, all of which are uncertain and cannot be predicted. Furthermore, future global pandemics or other widespread outbreak of an illness
or any other communicable disease, or any other public health crisis may also materially and adversely affect our business, financial
condition, results of operations and growth prospects.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We have a limited operating
history with respect to the partnering and commercialization aspects of our business model upon which investors can base an investment
decision or upon which to predict future revenues.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our ability to generate revenues from partnerships for our novel drug targets and
related therapeutic product candidates at various stages of research and development has been limited to date. Since we began focusing
our discovery capabilities on therapeutic pipeline establishment in 2010, we have entered into three partnership agreements with respect
to our pipeline programs under which we have received to date a total amount of $83.2 million, of which $32 million was an investment.
We recognized revenue of $6.0 million in 2021, $2.0 million in 2020 and no revenue in 2019 from our partnerships. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We cannot be certain that our focus on discovery, research and drug development in
the field of immuno-oncology, along with advancing selected programs to later drug development and clinical stages partially or fully
at our own expense, will generate a stable or significant revenue stream. Moreover, we have very limited experience with respect to the
financial arrangements and terms that may be available for our candidates at their various R&amp;D stages. Additionally, financial terms
for agreements by other companies, to the degree disclosed, vary greatly. The inability to derive adequate revenues within our field of
focus and for our specific drug targets or product candidates would materially harm our business, financial condition and results of operations
and could result in the need to limit or even discontinue our business operations. Moreover, our operating history with respect to the
partnering and commercialization aspects of our model provides a limited basis to assess our ability to generate significant fees, research
revenues, milestone payments, royalties or other revenue sharing payments from the licensing, development and anticipated future commercialization
of our programs based on our existing and future novel drug targets and related therapeutic products and any future product candidates.
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">5</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">Our failure to establish
and maintain effective internal control over financial reporting could result in material misstatements in our financial statements or
a failure to meet our reporting obligations. This may cause investors to lose confidence in our reported financial information, which
could result in the trading price of our shares to decline.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our management is responsible for establishing and maintaining adequate internal control
over financial reporting, as such term is defined in Rule&#160;13a-15(f) of the Exchange Act. Under the supervision and with the participation
of our management, including the Chief Executive Officer and the Chief Financial Officer, we carried out an evaluation of the effectiveness
of our internal control over financial reporting as of December&#160;31, 2021, using the criteria established in &#8220;Internal Control
- Integrated Framework&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO
criteria). Based on our assessment under that framework and the criteria established therein, our management concluded that the Company&#8217;s
internal control over financial reporting was effective as of December 31, 2021, in providing reasonable assurance regarding the reliability
of the Company&#8217;s financial reporting.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">However, if we conclude in the future that our internal controls over financial reporting
are not effective, we may fail to meet our future reporting obligations on a timely basis, our financial statements may contain material
misstatements, our operating results may be negatively impacted, and we may be subject to litigation and regulatory actions, causing investor
perceptions to be adversely affected and potentially resulting in a decline in the market price of our shares. Even if we conclude that
our internal controls over financial reporting are adequate, any internal control or procedure, no matter how well designed and operated,
can only provide reasonable assurance of achieving desired control objectives and cannot prevent all mistakes or intentional misconduct
or fraud.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Risks Related to Development, Manufacturing, Clinical Trials and Government Regulation</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">In the near term, we are
highly dependent on the success of COM701 and of COM902. We may not be able to advance our internal clinical stage programs through clinical
development or manufacturing or successfully partner or commercialize them, or obtain marketing approval, either alone or with a collaborator,
or may experience significant delays in doing so.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We currently have no products approved for sale and are investing a significant portion
of our efforts and financial resources in the clinical development of COM701 and of COM902. Our prospects are substantially dependent
on our ability, or that of any existing and future partners, to manufacture, develop, obtain marketing approval for and successfully commercialize
COM701 and COM902. <span style="font-family: Times New Roman,Times,serif">We have reported preliminary signals of antitumor activity in
our ongoing Phase 1 trial with COM701 monotherapy and in combination with nivolumab. The triplet combination of COM701, nivolumab and
BMS-986207 (anti-TIGIT antibody) was well tolerated with a favorable safety and toxicity profile. We have reported preliminary signals
of antitumor activity from our Phase 1 dose escalation monotherapy trial of COM902 with a best response of stable disease. These preliminary
clinical results may not predict the final results of the on-going clinical trials or future clinical trials or otherwise be sufficient
to attract a partner or support a future drug approval. Many companies in the pharmaceutical, biopharmaceutical and biotechnology industries
have suffered significant setbacks or failures in clinical trials after achieving positive results, and we cannot be certain that we will
not face similar setbacks or failures.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our pipeline currently consists of four clinical stage programs, which are at early
stage of clinical development. Two, COM701 and COM902 are being developed internally (COM701 under clinical collaboration with Bristol
Myers Squibb) and the other two are being developed by our collaborators. Our pipeline also consists of additional future product candidates
in early research stage and require substantial development and investment.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As we advance our clinical programs, we will need to expand our personnel and operational
capabilities to support these activities. In part because of our limited infrastructure and limited experience in conducting clinical
trials as a company and in regulatory interactions, we cannot be certain that our clinical trials will be completed on time, that our
planned clinical trials will be initiated on time, if at all, that our planned development programs and development path forward would
be acceptable to the U.S. Food and Drug Administration, or FDA, or other comparable foreign regulatory authorities, or that, even if approval
is obtained, such investigational products can be successfully commercialized.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The success of COM701 and COM902 is dependent upon several factors, including the
following:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7464fdc2019a45e4bb53b367f5edb005" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">successful clinical trial results;</div>
        </td> </tr>
  </table> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5cca807ec3054ac391a78bc478c92ae1" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">ability to fund clinical trials designed
        to obtain regulatory approval and to become commercially successful;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">6</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3853fb738d734a4d9019a8870d1a1c80" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">success of trials designed to allow for
        a path for registration/approval by regulatory authorities;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8cdab21d273f437db38cc28020f75c83" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">our selected regulatory strategy;</div>
        </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zad9a14ad76d443f8ba74083cd97a86d2" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">timely initiation, enrollment and completion
        of clinical trials;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf875d0b4c53a4eadb53b88bc241d44c4" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">demographics, past therapy and other criteria
        of patients enrolled, even if they meet the inclusion/exclusion enrollment criteria;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zcac2666b920b45ec847d4a69b4b1dfbd" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">a safety, tolerability and efficacy profile,
        alone or in combination with other approved or investigational products, that is satisfactory to the FDA or comparable foreign regulatory
        authorities;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z028e3d500d4f4f70bcbb3b85250e9ee5" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">selection of indications;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z52b8ce96a4e246a1b1db7b85564b0bad" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">selection of drug(s) for combinations;</div>
        </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc142e98ea79244d4a06dab63e2e1c400" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">successful identification of biomarkers,
        including for patient selection;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z12cf547aadcf44c7bd1bb6f4434e782f" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">timely receipt of marketing approvals from
        applicable regulatory authorities;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z81604f589ea34415a4e0bb3a2ce952d2" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">the performance of our current and future
        collaborators, if any;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf39b42687d37497dbf8460ddb2b95870" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">the extent of any required post-marketing
        approval commitments to applicable regulatory authorities;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5e26abfad3374ac9ba8f933454f7fb34" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">establishment and monitoring of manufacturing
        arrangements and processes with third-party service providers and clinical manufacturing organizations for manufacturing drug substance
        and drug product;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6d335f1439a64e0baa6c278b06feb739" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">establishment and monitoring of arrangements
        with third-party suppliers of raw materials and service for fill-finish, packaging and labeling;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf4b80092441c4fe8bda3941b1a2aa813" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">stability of our drug substance and drug
        products;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb36923cd659345fc8d1e0c3c6d935fbb" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">supply of our drugs in sufficient quantities
        and quality for our clinical trials;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z157520cab594492a8960b53eb6dcfd8e" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">establishment of arrangements with third-party
        manufacturers and processes monitoring to obtain commercial quality drug product that is appropriately packaged for sale;</div> </td>
        </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc7917f7057144217b36f4b2620c37975" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">adequate ongoing availability of raw materials
        and drug product for clinical development and any commercial sales;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z382ab9fb42fc4b2e9b4697e3d33f23e4" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">protection of our rights in our intellectual
        property portfolio;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z546e5343aeea4e458e31f8a033c76e1a" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">successful launch of commercial sales following
        any marketing approval;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z1703fb8de4314f02a0fcba9759ef367f" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">a continued acceptable safety profile following
        any marketing approval; and</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z29594727ef914902a799195553b07395" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 12.1pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">commercial acceptance by patients, the medical
        community and third-party payors.</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Many of these factors are beyond our control, including clinical development by us
and our competitors, the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing
and sales efforts of any current and future third party. If we are unable to develop, receive marketing approval for and successfully
commercialize COM701 and/or COM902, on our own or with any collaborator, or experience delays as a result of any of these factors or otherwise,
our business could be substantially harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We depend on enrollment
of patients in our clinical trials in order to continue development of our product candidates.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are conducting Phase 1 and Phase 1/2 clinical trials of COM701 in combinations
in patients with advanced solid tumors and clinical trials of COM902 monotherapy and in combination with COM701 in patients with advanced
malignancies. Our anticipated time to data in these trials is subject to our ability to enroll a sufficient number of eligible patients
that will need to be enrolled for observing clinical activity, if at all. There can be no assurance that we will complete enrollment or
have data from the trials when we anticipate or at all. The timely completion of clinical trials in accordance with their protocols depends,
among other things, on our ability to enroll a sufficient number of patients that are in line with our inclusions and exclusion criteria
and our ability to monitor these patients as required.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">7</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">We may experience difficulties in patient enrollment in our clinical trials for a
variety of reasons. Patient enrollment is affected by many factors including the size and nature of the patient population, the eligibility
criteria for the trial, the design of the clinical trial, the size of the patient population required for analysis of the trial&#8217;s
primary endpoints, the proximity of patients to clinical trial sites, our ability to recruit clinical trial investigators with the appropriate
competencies and experience, the number of enrolling clinical sites, our ability to obtain and maintain patient consents, the risk that
patients enrolled in clinical trials will drop out of the trials before completion or even before any/sufficient imaging assessment, and
competing clinical trials (including other clinical trials that we are conducting or will conduct in the future) and clinicians&#8217;
and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, or
competing drugs against the same target as well as any new drugs that may be approved for the indications we are investigating.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Many pharmaceutical companies are conducting clinical trials in patients with the
disease indications that COM701, COM902 and our future potential drug products may target. Additionally, other pharmaceutical companies
may clinically investigate their own therapeutic candidates against PVRIG, the target of COM701, or against TIGIT, the target of COM902,
which may hamper the enrollment of oncology patients in our trials for COM701 or COM902. For example, in case of COM701, Surface Oncology
announced in December 2021 that the FDA has cleared the Investigational New Drug Application (IND) for its PVRIG targeting antibody, GSK4381562
(formerly SRF813), to proceed into a first-in-human clinical trial. In the case of COM902, there is a significant number of anti-TIGIT
antibodies that are currently in clinical trials such as tiragolumab by Roche, vibostolimab by Merck, ociperlimab by Beigene, domvanalimab
and AB308 by Arcus, BMS-986207 by Bristol Myers Squibb, and others (some of which are in a more advanced clinical stage than COM902).
As a result, we must compete with them for clinical sites, clinicians&#8217; interest and the limited number of patients who fulfill the
stringent requirements for participation in clinical trials in general. Also, patient enrollment may be limited due to changes in the
regulatory landscape in the indications of interest to us. Our clinical trials may be delayed or terminated due to the inability to enroll
enough patients. The delay or inability to meet planned patient enrollment may result in increased costs and delay or termination of our
trials, which could have a harmful effect on our ability to develop products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">Clinical trials of any product
candidates that we, or any current or future collaborators may conduct may fail to satisfactorily demonstrate safety and efficacy, and
we, or any collaborator, may incur additional costs or experience delays in completing, or ultimately be unable to complete the development
and commercialization of these product candidates.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We, and any current or future collaborators, are not permitted to commercialize, market,
promote or sell any therapeutic product candidate in any jurisdiction without obtaining marketing approval from the relevant regulatory
authority, such as the FDA in case of the United States. We, and any collaborators, must complete clinical trials to demonstrate the safety
and efficacy of our therapeutic product candidates in humans before we will be able to obtain these approvals.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Clinical testing is expensive, is difficult to design and implement, can take many
years to complete and is inherently uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned
or completed on schedule, if at all. The clinical development of our therapeutic product candidates is susceptible to the risk of failure
inherent at any stage of product development, including failure to demonstrate efficacy in a clinical trial or across population of patients,
choosing the incorrect patient population or indication, the occurrence of adverse events that are severe or medically or commercially
unacceptable, failure to comply with protocols or applicable regulatory requirements and determination by the FDA that a therapeutic product
candidate may not continue development or is not approvable. The outcome of preclinical studies and early clinical trials may not predict
the success of later clinical trials and interim results of a clinical trial do not necessarily predict final results. A number of companies
in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials due to lack of efficacy
or unacceptable safety profiles, notwithstanding promising results in earlier trials. Despite the preliminary safety and anti-tumor activity
results reported from our ongoing Phase 1 trial for COM701 and COM902 so far, we do not know whether the clinical trials we or our partners
may conduct will demonstrate adequate efficacy and safety to result in the further advancement of clinical development or regulatory approval
to market of COM701 and/or COM902, or any other of our product candidates when they reach the clinic, in any particular jurisdiction or
jurisdictions. It is also possible that, even if one or more of our therapeutic product candidates has a beneficial effect, that effect
will not be detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design,
measurements, conduct or analysis of our clinical trials, patient monitoring, the dosing we choose and other factors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">8</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Any inability to successfully complete preclinical and clinical development could
result in additional costs to us, or any collaborators and impair our ability to generate revenues from product sales, development, regulatory
and commercialization milestones and royalties. Moreover, if we, or any collaborators, are required to conduct additional clinical trials
or repeat clinical trials or other testing of our product candidates beyond the trials and testing that we or they contemplate, if we,
or they, are unable to successfully complete clinical trials of our product candidates or other testing, or the results of these trials
or tests are unfavorable, uncertain or are only modestly favorable, or there are unacceptable safety concerns associated with our product
candidates, we, or any collaborators, may:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;cease
the development of the product candidates; </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;incur
additional unplanned costs;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;not
obtain approval to proceed to next development phase; </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;be
delayed in obtaining marketing approval for our product candidates;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;not
obtain marketing approval at all;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;obtain
approval for indications or patient populations that are not as broad as intended or desired;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;obtain
approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;be
subject to additional post-marketing testing or other requirements; or</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;be
required to remove the product from the market after obtaining marketing approval.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our failure to successfully initiate and complete clinical trials of our product candidates
and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market any of our product candidates would significantly
harm our business, could further result in significant harm to our financial position and results of operations and could result in the
need to limit or even discontinue our business operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Clinical development involves a lengthy and
expensive process, with an uncertain outcome. We may encounter substantial delays or even an inability to begin clinical trials for any
specific product or may not be able to conduct or complete our trials on the timelines we expect.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Obtaining marketing approval from regulatory authorities for the
sale of any therapeutic product requires substantial preclinical development and then extensive human clinical trials to demonstrate the
safety and efficacy of such product candidates. It is impossible to predict when or if any of our programs or those of our collaborators
based on our target discoveries will yield products that will be approved for human testing, or, if such testing is proven sufficiently
safe and effective to receive regulatory approval for marketing. Preclinical and clinical testing is expensive, time consuming, and subject
to uncertainty and will require significant additional financial and management resources. As a company, we have limited experience in
conducting clinical trials and have never progressed a product candidate through to regulatory approval. In part because of this lack
of experience, our clinical trials may require more time and incur greater costs than we anticipate. We cannot guarantee that any of our
therapeutic drug candidates from our pipeline will be advanced into clinical trials or that our clinical trials will be conducted as planned
or completed on schedule, if at all. The outcome of preclinical testing and early clinical trials may not be predictive of the success
of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and
clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates
performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to continue to achieve such successes at later
stages of the clinical studies or to obtain marketing approval for such products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">9</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We submitted to the FDA an Investigational New Drug application,
or IND, for COM701, which was cleared by the FDA in June 2018 and an IND for COM902, which was cleared by the FDA in October 2019. However,
there can be no assurance that we will submit additional INDs, nor if submitted, the actual timing for such submission (including amendments),
nor that such submissions will be accepted by the FDA allowing clinical trials to begin or continue. There can be no assurance that clinical
trials will begin at any predicted date or will be completed on schedule, if at all. Moreover, even if these clinical trials begin, issues
may arise that could result in the suspension of or termination of such clinical trials. A failure of one or more clinical trials can
occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8ec9c1b7dbed4018bdcd92c4f9cd190b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>inability to generate sufficient preclinical, toxicology, or other scientific data to support the initiation of clinical trials;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9ae8692b463347d1b3108deb27dd5c94" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>lack of authorization from regulators or institutional review boards, or IRBs, or ethics committees to allow us or our investigators
        to commence a clinical trial or conduct a clinical trial at a prospective trial site or continue such clinical trial;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2d77dae3a1b04f7eba57f99518fe8b8f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>delays in sufficiently developing, characterizing, or controlling a manufacturing process suitable for clinical trials;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zeba44f9e14a34eba818676f9d8844d8b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>inability to generate sufficient quantities or quality of our drug substance or drug product to support the initiation or continuation
        of clinical trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z989045f9feac4b36a19f7f546bc2e3cf" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>delays in reaching a consensus with collaborators or regulatory agencies on trial design;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6024d850ddb34890a08b194b8e77f7d8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>delays in reaching agreement on acceptable terms with prospective CROs, and clinical trial sites, the terms of which can be subject
        to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zec50adacc12a4db4b1801c5f0bd05776" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>imposition of a temporary or permanent clinical hold by the FDA, or a similar delay imposed by foreign regulatory agencies for a
        number of reasons, including after review of an IND, other application or amendment; (i) as a result of a new safety finding that presents
        unreasonable risk to clinical trial participants; (ii) a negative finding from an inspection of our clinical trial operations or trial
        sites; (iii) developments on trials conducted by competitors for related technology that raises FDA concerns about risk to patients of
        the technology broadly; or (iv) if FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9c1765fb8188459e840b2902aedd1cdf" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>clinical trials of any product candidates may fail to show safety or efficacy, produce negative or inconclusive results and we may
        decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon product
        development programs;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6f3c221b73f0493baeef861a1b54f920" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>difficulty collaborating with patient groups and investigators;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4ad173f1f179405495bad7e93d7f09e7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>failure by our CROs, other third parties, or us to adhere to clinical trial and related regulatory requirements;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zeb008a9a76744f5db3004678ffcff287" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>failure to perform in accordance with the FDA&#8217;s Good Clinical Practice, or GCP, requirements, or similar applicable regulatory
        guidelines in other countries;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zda1bef3cde1f4b10a629d302e0248353" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>failure to perform in accordance with the FDA&#8217;s Good Manufacturing Practice, or GMP, requirements, or similar applicable regulatory
        guidelines in other countries;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf3aa4c844a5f499a9c2c2c472b72a4bf" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the number of patients required for clinical trials of any product candidates may be larger than we anticipate, enrollment in these
        clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials or fail to return for post-treatment
        follow-up at a higher rate than we anticipate;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6e0aed68854c45f38c21bc221cad34e9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>delays in having patients complete their participation in a trial or return for post-treatment follow-up;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb221e42e77c340c9a16e04aec5495d5e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8230df02c5114a50a19b50801db12767" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z35abae733e61477aba7780d0a3da6d96" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>changes in the standard of care or <span style="font-family: Times New Roman,Times,serif">in the regulatory landscape on which a
        clinical development plan was based, which may require new or additional trials;</span></div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z31199c0d904842829ebdf3624d426f7d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the cost of clinical trials of our product candidates being greater than we anticipate;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7468e87894334fecb461f17dbd6e201c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>clinical trials of our product candidates producing negative or inconclusive results, or early results that will not be repeated
        in larger or future cohorts, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon
        product development programs;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd58e78bab8ca470e85c0f082ed787fe5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>choosing the wrong dosing regimen and/or the wrong drug combination;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z064537ea2b7e4a369114a101df1b39f4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>delays or failure to secure supply agreements with suitable reagent suppliers, or any failures by suppliers to meet our quantity
        or quality requirements for necessary reagents; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc4ad61c41d1143089d71e30ad4ed8dfc" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates
        for use in clinical trials or the inability to do any of the foregoing.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">10</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Our product development costs will increase if we experience delays in clinical trials
(including termination thereof) or in obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical
trials will begin as planned, and once begun whether will need to be restructured or will be completed on schedule, or at all. Significant
preclinical or clinical trial delays also may allow our competitors to bring products to market before we do, potentially impairing our
ability to be first-in-class or successfully commercialize our product candidates and harming our potential market share and business
and results of operations. Any delays in our preclinical or clinical development programs may harm our business, financial condition and
prospects significantly.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">From time to time we publicly disclose preliminary
data from our ongoing clinical trials. As more patient data become available the data and the interpretation of the data may change.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">From time to time, we publish preliminary data from our ongoing clinical trials. Preliminary
data are also subject to the risk that one or more of the clinical outcomes may materially change as time goes by and cutoff date changes,
patient enrollment continues and with further patient monitoring where more patient data become available. As a result, preliminary data
should be viewed with caution until clinical rial completion where the final data are available. Material adverse changes in the final
data could significantly harm our business prospects and eventually harm our financial condition and results of operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We rely and expect to continue to rely on third
parties to conduct our clinical trials. These third parties may not successfully carry out their contractual duties, comply with regulatory
requirements or meet expected deadlines, and we may experience significant delays in the conduct of our clinical trials as well as significant
increased expenditures.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We do not have the ability to independently conduct clinical trials. We rely and will
continue to rely on medical institutions, clinical investigators, contract manufacturing research organizations, contract laboratories,
outsourced preclinical and clinical service providers and other third parties, such as CROs and advisors, to conduct or otherwise support
our clinical trials. We rely heavily and will continue to rely heavily on these parties for execution of clinical trials for COM701 and
COM902 and any other future product candidates we may take to the clinic, and we control only certain aspects of their activities. Nevertheless,
we are responsible for ensuring that each of our internal clinical trials is conducted in accordance with the applicable protocol, legal
and regulatory requirements and scientific standards, and our reliance on these third parties, including our CROs, will not relieve us
of our regulatory responsibilities. For any violations of laws and regulations during the conduct of our clinical trials, we could be
subject to untitled and warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If clinical investigators, CROs or other third parties do not successfully carry out
their contractual duties or obligations diligently and in a professional manner or meet expected deadlines, if they need to be replaced
or if the quality or accuracy of the clinical data they obtain and store or their data analysis are compromised due to the failure to
adhere to market standards, our clinical protocols, regulatory requirements or for other reasons, any clinical trials such clinical investigators,
CROs or other third parties are associated with may be extended, delayed or terminated. As a result, we believe that our financial results
and the commercial prospects for COM701, COM902, and any other future therapeutic product candidates we may take to the clinic, would
be harmed, our costs could materially increase and our ability to generate revenue could be significantly adversely impacted.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Serious adverse events or undesirable side
effects or lack of efficacy, may emerge in clinical trials conducted by other companies running clinical trials investigating the same
target as us, which could adversely affect our development programs or our capability to enroll patients or partner the program for further
development and commercialization.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We initiated a Phase 1 clinical trial for COM902, which targets TIGIT, in March 2020.
There are additional companies that have a program targeting TIGIT in clinical trials, such as Merck, Roche, <span style="font-family: Times New Roman,Times,serif">Bristol
Myers Squibb, BeiGene, and Arcus. We have no control over their clinical trials or development program, and lack of efficacy, adverse
events or undesirable side effects experienced by subjects in their clinical trials could affect our development and regulatory path of
COM902 or the enthusiasm of clinicians recruiting patients for our clinical trials for COM902 or any other service provider, or harm its
potential to be partnered for further development and commercialization and generate revenues for the Company.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">11</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Furthermore, any negative results that may be reported in clinical
trials of other programs targeting TIGIT may make it difficult or impossible to recruit and retain subjects in our clinical trials of
COM902. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials,
which could prevent completion of these trials and adversely affect our ability to advance the development of COM902. Failures in planned
subject enrollment or retention may result in increased costs or program delays and could render further development impossible.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">The same risk will apply to COM701 once <span style="font-family: Times New Roman,Times,serif">any
anti-PVRIG antibody enters the clinic.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We are subject to certain manufacturing risks,
any of which could either result in additional costs or delays in completing, or ultimately make us unable to complete, the development
and commercialization of our product candidates.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The process of manufacturing biologics is susceptible to product loss or unavailability
due to contamination, degradation, instability, equipment failure, lack of critical reagents or disposables, improper installation or
operation of equipment, vendor or operator error leading to process deviations or any other factor. Even minor deviations from normal
manufacturing processes could result in reduced production yields, product defects and other supply disruptions up to supply termination.
If microbial, viral or other contaminations are discovered in our products or in the manufacturing facilities in which our products are
made, the products may need to be manufactured again and/or such manufacturing facilities may need to be closed for an extended time to
investigate and remediate the contamination. In addition, the product manufactured may be determined at later stage to be insufficiently
stable or qualified as a therapeutic agent, even following treatment.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have not contracted with alternate suppliers in the event we experience any problems
with our current manufacturer. If we are unable to arrange for alternative third-party manufacturing sources or are unable to reserve
another manufacturing slot with our current manufacturer, or are unable to do so on commercially reasonable terms or in a timely manner,
we may incur additional costs or be delayed in the development or delivery of our current and future product candidates, which can cause
us material harm.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">It may be difficult to manufacture therapeutic products addressing
our drug target candidates.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Our therapeutic pipeline is focused mainly on monoclonal antibodies,
or mAbs, generated against our discovered targets. These types of therapeutics can be difficult to manufacture in the quantity and quality
needed for preclinical, clinical and commercial use. The production of mAbs must be conducted pursuant to a well-controlled and reproducible
process and the resulting product testing must conform to defined quality standards. Should it prove to be difficult to manufacture or
repeat manufacturing, of any therapeutics addressing our drug candidates in sufficient quantities or commercial scale, meeting the required
quality standards or in an economical manner to conduct clinical trials and to commercialize any approved therapeutic candidate, our business,
financial condition and results of operations would be materially harmed. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We or any of our collaborators, or third-party
manufacturers, may fail to comply with regulatory and legal requirements, and we or they could be subject to enforcement or other regulatory
actions.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">If we or any of our collaborators or third-party manufacturers
with whom we work or with whom we may enter into agreements in the future fail to comply with applicable federal, state or foreign laws
or regulations, or other legal obligations we or they could be subject to enforcement or other regulatory actions. These actions may include:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z20d4b214ac3f49a7a8cc6baf2958a51f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>warning letters; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="d6ca155a3e8247f587b715a7a7943d1a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"></td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">clinical trial holds;</td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zadddf50b14014f16b7431072193b0529" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>recalls, product seizures or medical product safety alerts; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z1d33512ff683471c81a97fb5bdadc530" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>data lock or order to destroy or not use personal data;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z1a3a4ed526c843cda2cb3292537f810f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>restrictions on, or prohibitions against, marketing such products; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zee9eca02dae94a9f81b1bd4b2ff30501" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>restrictions on importation of such products; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z469e785487a54c4c9f2e4b188dea97da" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>suspension of review or refusal to accept or approve new or pending applications; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5a3a70d0da6b41898e9492c4d67c4bf1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>withdrawal of product approvals; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">12</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd035800c559246e8bca12843e4bbb7a4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>injunctions; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9e2fc4df44714170ac58f728ec55b000" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>civil and criminal penalties and fines; or </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z10f91d190e634151b0d142466f8096b4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>debarment or other exclusions from government programs. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we or our collaborators become subject to such enforcement actions, these enforcement
actions could affect the ability to successfully develop, market and sell therapeutic products based on our discoveries and could significantly
harm our financial status and/or reputation and lead to reduced acceptance of such products by the market.&#160;In addition, we may be
subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement or imprisonment.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may require companion or complimentary diagnostics
and/or biomarkers for our clinical trials, or a portion of our clinical trials, and may be required to have such to obtain marketing approval
or commercialization of our therapeutic programs. Failure to successfully discover, develop, validate and obtain regulatory clearance
or approval for such tests could harm our patients&#8217; selection strategy and may harm our clinical outcome.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Companion or complimentary diagnostics are subject to regulation by the FDA and comparable
foreign regulatory authorities and may require separate regulatory authorization prior to commercialization. We may require for our clinical
trials or for certain portions of our clinical programs, companion diagnostics and/or biomarkers to correctly identify the right patients
for the appropriate indications. We rely on access to patient tumor and blood samples for analysis of protein, DNA, and RNA biomarkers.
We may rely on third parties for the tumor and blood samples&#8217; handling, processing, and analysis, discovery, development, and validation
of these potential biomarker candidates, biomarkers and/or companion diagnostics, as well as the application for and receipt of any required
regulatory authorization. If we, or the third parties we engage for this purpose, are unable to successfully discover, validate and/or
develop the required companion diagnostics and/or biomarkers for our clinical programs, or develop with altered specifications, or experience
delays in doing so, the development of our clinical candidates may be adversely affected and this can harm our patient selection and our
clinical outcome, as well as obtaining marketing authorization for these product candidates.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our current and future relationships, and/or
the relationships of our collaborators through which we may market, sell, and distribute our products, with healthcare professionals,
physicians and other parties in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud
and abuse, false claims, physician payment transparency, health information and general privacy and security and other healthcare laws
and regulations, which could expose us to adverse consequences.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our current and future business operations, and our or our collaborators&#8217; business
and financial arrangements and relationships with healthcare providers, physicians and other parties through which we or our collaborators
may market, sell and distribute our products, once approved, may be subject to extensive U.S. federal, U.S. state and foreign healthcare
fraud and abuse, transparency, health information and general data privacy and security laws. For example, U.S. federal civil and criminal
laws and regulations prohibit, among other things: knowingly and willfully soliciting, receiving, offering or providing remuneration,
directly or indirectly, to induce or reward either the referral of an individual, or the furnishing, recommending or arranging for a good
or service, for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs; knowingly presenting
or causing to be presented, a false or fraudulent claim for payment by a federal healthcare program; and knowingly and willfully executing,
or attempting to execute, a scheme to defraud any healthcare benefit program (including a private payor), or knowingly and willfully falsifying,
concealing or covering up a material fact or making any materially false statement in connection with the delivery of, or payment for,
healthcare benefits, items or services. Many U.S. states and foreign countries have analogous prohibitions that may be broader in scope
and apply regardless of payor. In addition, we may be subject to U.S. federal, U.S. state and foreign laws that require us to report information
related to certain payments and other transfers of value to certain health care professionals, as well as ownership and investment interests
in our company held by those health care professionals and their immediate family members, and health information and general security
and privacy laws that restrict our practices with respect to the use and storage of certain health information and other data.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Efforts to ensure that our current and future business arrangements with third parties
comply with applicable healthcare laws and regulations may involve substantial costs. If we or our collaborators are found to be in violation
of any of these laws, we or our collaborators could be subject to significant civil, criminal and administrative penalties, including
damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, additional integrity oversight
and reporting obligations, contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which,
whether enforced against us or our collaborators, could significantly harm our business and our royalties from any of our products, once
approved, that we license to such collaborators.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">13</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risks Related to our Discovery and Development Activities </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">There are risks that are inherent in the development
and commercialization of new therapeutic products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We and our collaborators face a number of risks of failure that are inherent in the
lengthy and costly process of developing and commercializing new therapeutic products. These risks, which typically result in very high
failure rates even for successful biopharmaceutical companies, include, among others, the possibility that:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z37061049ed2a425aa439d7b9abac4f86" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our new target candidates will prove to be inappropriate for treatment of cancer;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd63a3854fe9d489584077e214b5e7037" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our new target candidates will prove to be inappropriate targets for therapeutic product candidates; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z29c34688d708416c821b60d030b8637f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our new target candidates will prove to be inappropriate targets for immunotherapy;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2a5e026164704e90a03846269f7c0b10" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">we will not succeed in selecting the appropriate
        indication for the therapeutic product candidate;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zfc2472f90b8c4cb0af96b896a37f18e3" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">we will not succeed in choosing the appropriate
        mAb for these targets, or the appropriate mAb lead or the appropriate mAb isotype;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zbc4a87735e2c41e69c372231b5f6b1d8" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">we will not succeed in identifying or developing
        a biomarker or companion diagnostic for our therapeutic product candidates;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6d157ae787244b8ebdea667f9c62d659" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we will not succeed in choosing the appropriate drug modality for these targets; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z680d48dd0a8d48ac9d4a2cf5147cdd1b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our therapeutic product candidates will fail to progress to preclinical studies or clinical trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc6bf9523e7c84eb7bbba17d14fd0455e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our therapeutic product candidates will be found to be therapeutically ineffective;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z11f930a35d134d8ca634e80fbcb551b6" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">we will not choose the right combinations
        for our therapeutic product candidates;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb07bb4d801444e2287e45c93bec2cc29" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our therapeutic product candidates will be found to be toxic or to have other unacceptable side effects or negative consequences;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7467e868574a406cb75d368c009fb5c6" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our therapeutic product candidates will be inferior, or not show added value, compared to competing products or the standard of care;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf12913a0f03c46f9bf3c3392116bf9bd" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our early stage development efforts may provoke competition by others; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb14d46c5c4de40d3b576ab36e76be187" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our products covered by our collaborations may face internal competition from our partners&#8217; internal pipeline;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5d3e2db7cfc34b8ca343b81d854dc567" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we or our collaborators will fail to receive required regulatory approvals; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z82140bbfec594778a21b24419d5db6c3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we or our collaborators will fail to manufacture our therapeutic product candidates in the quantity or quality needed for preclinical
        studies or clinical trials on a large or commercial scale, on time or in a cost-effective manner or with the drug stability required;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z1889e582cede43d6921ca61a1f7ea1e7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the discovery of drug targets and the discovery, development or commercialization of our therapeutic product candidates will infringe
        third-party intellectual property rights; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z1b5d015128a04f31be36b2fc3af60374" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the development, marketing or sale of our therapeutic product candidates will fail because of our inability or failure to protect
        or maintain our own intellectual property rights; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za508cd455f254bbe8880deca9f015f14" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>once a product is commercially available, there will be little or no demand for it for a number of possible reasons, including lack
        of acceptance by the medical community or by patients, lack of or insufficient coverage and payment by third-party payors, inefficient
        or insufficient marketing and sales activities or as a result of there being more attractive, less risky or less expensive, products available
        for the same use; and </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb54e0d13c84f43678363bb0211b9c5b1" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">the product will be withdrawn from the market,
        or sales limited due to side effects observed in clinical practice.</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">If one or more of these risks or any similar risks should materialize, our business, financial condition
and results of operations may be materially harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">14</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We have limited experience in the development
of therapeutic product candidates, and we may be unable to implement our business strategy.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our experience in the development of therapeutic product candidates is limited. Therefore,
we may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business
objectives. To successfully develop and commercialize therapeutic products, we must either access such expertise via collaborations, consultants
or service providers, and/or enhance and improve our internal expertise and capabilities. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we are not able to attract, retain and motivate necessary personnel or third party
service providers or collaborators to accomplish our business objectives or fail to have available, at the appropriate times, the required
experience and expertise for the further development and commercialization of our therapeutic product candidates, we may be unsuccessful
in these activities, or these activities may be significantly delayed and as a result we may be unable to implement our business strategy
and our business would be materially harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our computational target discovery activities
are primarily focused on the discovery of new drug target candidates and our therapeutic pipeline is based on our discovered targets.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">While we believe that our drug target programs represent a compelling and unique opportunity
to generate potentially first-in-class therapeutics <span style="font-family: Times New Roman,Times,serif">in the field of cancer immunotherapy,
they require significant investment in the research and validation of the drug target candidate and in the discovery and development of
the respective therapeutic product candidate and bear high risk. Our predictive computational discovery capabilities are a source for
the development of potential first-in-class therapeutics in the field of cancer immunotherapy, but the inherent lack of sufficient published
scientific and clinical data to support the potential of these new drug targets candidates to serve as therapeutic opportunities, increases
the risk of failure. Although we have built the target identification, validation and drug discovery infrastructure and capabilities that
we believe are required to scientifically validate our new drug targets and to later translate them into therapeutic antibody development
programs, we cannot be assured that our investment in such new discoveries will result in validated drug targets that will enable the
development of effective cancer immunotherapies, nor that we will realize success in product development or our ability to partner and
commercialize such opportunities and generate revenues.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our approach to the discovery of therapeutic
products is based on our predictive computational discovery capabilities that are not yet fully proven clinically, and we do not know
whether we will be able to discover and develop additional potential product candidates or products of commercial value.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our method of identifying novel drug targets is based on our predictive computational
discovery capabilities and involves first identifying unmet needs in the field of cancer immunotherapy, where we believe our predictive
computational discovery capabilities would be relevant or could be modified to be relevant. We focus on the discovery of drug targets
that could serve as the basis for the development of possible treatments for patients non-responsive, refractory or relapsing to existing
cancer immunotherapies. In this field, we apply our predictive computational target discovery capabilities, or develop new capabilities,
to identify novel drug targets for addressing such unmet patient need. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">While we believe that applying our predictive computational discovery capabilities
to identify new drug targets may potentially enable the development of potentially first-in-class therapeutics in the field of cancer
immunotherapy, our capabilities are yet not fully proven clinically and our efforts may not result in the discovery and development of
therapeutic products, or commercially viable or successful therapeutic products. Although our approach has resulted in the discovery of
several new drug targets and their related potential first-in-class therapeutic product candidates in the field of cancer immunotherapy,
they are in early stages of research and development or in clinical stage, with COM701 and bapotulimab&#160;(formerly known as BAY1905254),
having entered the clinic in 2018, COM902 which entered the clinic in March 2020 and AZD2936 which entered the clinic in the fourth quarter
of 2021. Our approach may not result in time savings, higher success rates or reduced costs, or clinically meaningful programs and if
not, we may not attract collaborators or develop new drugs as quickly or cost effectively or at all and therefore we may not be able to
partner and commercialize our products as expected. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">15</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We are focusing our discovery and therapeutic
development activities on therapeutic product candidates for uses in immuno-oncology. Our current candidates may fail, and we may fail
to continue to discover and develop therapeutic product candidates of industry interest in this field.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The focus of our discovery and therapeutic development activities is on mAb therapeutics
in the field of immuno-oncology for treatment of cancer. As a result, we are not undertaking internal discovery and development activities
in other therapeutic areas or for other drug modalities, and presently we only pursue activities in our area of focus.&#160; If our current
candidates fail, or if we fail to continue to discover and develop therapeutic product candidates of medical interest in this field or
if we are unable to discover drug targets for mAb therapeutics, or if other modalities would be more successful in treating cancer patients,
our business will likely be materially harmed. With respect to cancer immunotherapies, although there have been positive clinical results
reported by others resulting in some products gaining approval by the FDA, there can be no assurance that our therapeutic product candidates
or our earlier stage immuno-oncology target candidates in our pipeline, will provide similar clinical advantages or interest, that no
long term adverse effects will be seen, or that other classes of targets or other products will not be discovered and developed with comparable
or superior attributes or clinical activity. In the event of any of these occurrences, the actual and/or perceived value of a substantial
portion of our pipeline would likely be reduced in which case our business may be materially harmed. To date, we have signed three partnership
agreements involving our product candidates. There is no assurance that we will be able to enter into additional collaborations or agreements
on reasonable terms, if at all. In addition, if we fail to continue to discover and validate drug targets or develop product candidates
of industry interest in our field of focus, our business will likely be materially harmed. There are many risks associated with our decision
to focus on immuno-oncology that include, among others:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z749a70be1877444cac652229f422a96c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>not being able to discover new drug targets in this field; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z81570392ff874888b38b74e33b078ab6" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">our full scope of target discovery capabilities
        may not be adequate;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za07b90d33fbe4b40a2016bdb3f0daa0e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>not having chosen the right therapeutic area; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za25f872bfba9476fb843fd03fbe83ec7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>having chosen a therapeutic area with a very high degree of competition; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9054541280114adfa53e5742c02df425" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>having chosen a therapeutic area of great biological complexity and with very high failure rates in product development; </div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd9f983d129f84697b910bc2c4518cfc2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>not choosing the appropriate drug modality; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6fa6c960d88b44c19b9e8939054dd1cf" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>having insufficient knowledge, expertise, personnel or capabilities in our chosen therapeutic area to identify the right unmet medical
        needs, or drug targets, or to timely, properly and efficiently validate the targets and/or select the appropriate mAb for further development
        as therapeutic product candidates, or to timely, properly or efficiently further them in development; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zdfcc58a1cda34216899b04fcd8f33d31" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the inherent risk of high program failure rate throughout therapeutic development. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In each case, our failure could be due to lack of experience and expertise, delays
in our internal research programs or applying the wrong criteria or experimental systems and procedures, or selecting an inappropriate
drug modality, or unanticipated scientific, safety, activity or efficacy issues with our selected drug targets or product candidates,
with the possible result that none of our product candidates result in licensed or marketable products. If any of these risks should materialize,
our business, financial condition and results of operations would be materially harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We may focus our efforts
and resources on a particular target or therapeutic candidate or indication and fail to focus our efforts on targets or therapeutic candidates
or indications that may be more successful.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Due to our limited resources and experience and due to the early
stage of our discoveries, we prioritize our research programs and focus to programs that, we believe, based on limited and preliminary
amount of data, seem to have the highest potential. As a result, we might focus our limited resources on the wrong target or therapeutic
candidates or focus our candidates on the wrong therapeutic indication and delay in pursuing or fail to pursue candidates that might be
later proven (or never proven) as more successful.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Risks Related to Our Dependence on Third Parties</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We depend significantly on third parties to
carry out the research, development and commercialization of our therapeutic product candidates. If we are unable to maintain our existing
agreements or to enter into additional agreements with such third parties, including collaborators, in the future, our business will likely
be materially harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Our primary strategy for the development and commercialization
of products based on our drug target and therapeutic product candidates depends on third parties to carry out and/or finance, the research,
development and commercialization of such products, principally by pharmaceutical and biotechnology companies and other healthcare related
organizations and CROs, either on their own or in collaboration with us. To date, we have entered into three partnership agreements with
respect to our drug target candidates. We cannot be sure that any of the agreements will result in the successful development or commercialization
of any product. Further, we cannot provide assurance that we will succeed in identifying additional suitable parties or entering into
any other additional agreements on satisfactory terms or at all for the discovery, research, development and/or commercialization of our
drug target or therapeutic product candidates. If we are unable to identify such additional suitable parties or enter into new agreements
on satisfactory terms, or at all, our business will likely be materially harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">16</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We rely and expect to continue to rely completely
on third parties to manufacture and supply our preclinical and clinical drug supplies. Our business could be harmed if those third parties
fail to provide us with sufficient quantities of drug product or fail to do so at acceptable quality and quantity levels, prices or timelines.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We do not currently have, nor do we plan to acquire, the infrastructure or capability
internally to manufacture our preclinical and clinical drug supplies for use in the conduct of pre-clinical testing and our clinical trials,
and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. In order
to develop products, apply for regulatory approvals and commercialize our products, we will need to develop, contract for, or otherwise
arrange for access to the necessary manufacturing capabilities. We rely and expect to continue to rely on contract manufacturing organizations,
or CMOs, and other third-party contractors to manufacture formulations and produce larger scale amounts and/or commercial-scale of drug
substance and drug products required for any clinical trials that we initiate and other related services. Such third parties may not be
able to deliver in a timely manner, or at all, or may fail to comply with the FDA&#8217;s current Good Manufacturing Practice, or cGMP,
to manufacture our drugs in the required quality or quantity. We have entered into manufacturing and supply agreements with third parties
for the manufacturing and respective analytics of each of COM701 and COM902, for which we have ongoing Phase 1 clinical trials. In addition,
in October 2018 we entered into a master clinical trial collaboration agreement, as amended from time to time, or the MCTC, with Bristol
Myers Squibb, to evaluate combinations of COM701 with Bristol Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; and its
investigational antibody targeting TIGIT known as BMS-986207. Pursuant to the MCTC, Bristol Myers Squibb provides us at no cost Opdivo&#174;
and BMS-986207. Accordingly, if any of these third parties breach, terminate or otherwise are unable to fulfill their obligations under
the agreements for drug supply, we would need to identify an appropriately qualified alternative source, which could be time consuming,
and we may not be able to do so without incurring material delays and costs in the development of our products, including COM701 and COM902.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The manufacturing process for any products based on our technologies that we or our
partners may develop is subject to the FDA regulation and foreign regulatory authority approval process, and we will need to contract
with manufacturers who can meet cGMP requirements and foreign regulatory authority requirements on an ongoing basis. In addition, if we
receive the necessary regulatory approval for any therapeutic drug candidate, we also expect to rely on third parties, to produce materials
required for commercial supply. We may experience difficulty in obtaining adequate manufacturing capacity for our needs, adequate and
sufficient material as well as difficulties and challenges in technology transfer from one manufacturer to the other, as needed. If we
are unable to obtain or maintain adequate manufacturing sources for these product candidates, or to do so on commercially reasonable terms
and adequate timeline, quality and quantity, we may not be able to successfully develop and commercialize our products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">To the extent that we enter into manufacturing or supply arrangements with third parties,
we will depend on these third parties to perform their obligations in a timely manner and consistent with regulatory requirements, including
those related to quality control and quality assurance. We are also dependent upon these third parties with respect to critical reagents
supply, supplies required for our manufacturing and quality control, packaging, labelling, storage and others. The failure of a third-party
manufacturer or supplier to perform its obligations as expected could adversely affect our business in a number of ways, including:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2bb48a3ef6cb4c62b4ed6e90c4520672" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we may not be able to initiate or continue preclinical and clinical trials of products that are under development;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">17</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zad6241f2427b4bd68071f2a4f15df01f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we may experience significant disruption and delay to our clinical supply chain;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z1c9c82b03f404faf90aa0cd3f3cbd642" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we may experience significant adverse effect if we are unable to transfer the manufacturing process to a different third-party manufacturer
        in a timely and efficient manner;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z496ffb629ab34584b207fee89d21efef" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we may need to repeat clinical trials or stop our clinical trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z54267f9c112d409caee7e45d250dadf7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we may be delayed in submitting regulatory applications, or receiving regulatory approvals, for our product candidates;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z622bb68a4dcb48a8a7e9ac2550f07c1e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we may lose the cooperation of our collaborators;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3000d6f7d2f746189429a061ec00be3e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we may be required to cease distribution or recall some or all batches of our products; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf7dd9733ced74f48a6c2e6faf5a64154" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>ultimately, we may not be able to meet commercial demands for our products, if approved.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If a third-party manufacturer or supplier with whom we contract fails to perform its
obligations, we may be forced to manufacture or otherwise obtain the materials ourselves, for which we do not currently and may not in
the future have the capabilities or resources, or identify and qualify a different third-party manufacturer, which we may not be able
to do timely or on reasonable terms, if at all. In some cases, the technical skills or processes required to manufacture our product may
be unique to the original manufacturer and we may have difficulty transferring such skills or processes to a back-up or alternate manufacturer
or supplier, or we may be unable to transfer such skills or processes at all. In addition, if we are required to change manufacturers
for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards
and with all applicable regulations and guidelines. We will also be required to demonstrate that the newly manufactured material is similar
to the previously manufactured material, or we may need to repeat clinical trials with the newly manufactured material. The delays associated
with the verification of a new manufacturer could negatively affect our ability to develop product candidates or commercialize approved
products in a timely manner or within budget. Furthermore, a manufacturer may possess technology related to the manufacture of our product
candidate that such manufacturer owns independently, which would increase our reliance on such manufacturer or require us to obtain a
license from such manufacturer in order to have another third-party manufacture our products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our dependence on collaboration agreements
with third parties presents number of risks.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">The risks that we face in connection with our existing collaborations,
licenses and other business alliances as well as those that we may enter into in the future include, among others, the following:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8142589f5fdd415cb44672889a1b5ffa" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we may be unable to reach mutually agreeable terms and conditions with respect to potential new collaborations; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z22967288ef0f48648a7ff998d993e6e3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we or our collaborators may be unable to comply or fully comply with the obligations under collaboration agreements to which we are
        (or will become) a party, and as a result, we may not generate royalties or milestone payments from such agreements, and our ability to
        enter into additional agreements may be harmed; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z88a047b31c854b65aa937010177395af" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our obligations under existing or future collaboration agreements may harm our ability to enter into additional collaboration agreements;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc3eb3655d711406f95406bd3c04141b2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our collaborators have significant discretion in electing whether to pursue any of the planned activities and the manner in which
        it will be done, including the amount and nature of the resources to be devoted to the development and commercialization of our product
        candidates; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zfb759ec902854315a2962b7c3afc09e7" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our collaborators have significant discretion in terminating the collaborations for scientific, clinical, business or other reasons;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z0305180c926e4988b1534bd276d7d7a1" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>if our collaborators breach or terminate an agreement with us, the development and commercialization of our therapeutic product candidates
        could be adversely affected because at such time we may not have sufficient financial or other resources or capabilities or access to
        the other partner&#8217;s data and drug(s) to successfully develop and commercialize these therapeutics on our own or find other partners
        or enforce our rights under breached or terminated agreement; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z65bfcd2c60f94e61b928a4f226f406c2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our collaborators may fail to design and implement or analyze appropriate preclinical and/or clinical trials; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd4def35de09d42d998fa68952b2ef507" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our collaborators may not have an access to the drug combination treatment required for an effective treatment; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">18</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z348233af5d8c407cb5acb28689515a98" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our collaborators may not be able to identify biomarkers that may be required for further product development or approval; </div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za966f7e4b60f4ed5beb9c132b7b45fdc" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our collaborators may require us changing or adopting the trial design to fit their business priorities, standards and other objectives;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z54a887aa4e624da5b99bbf45983cda99" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our collaborators may fail to manufacture our therapeutic product candidates needed for either clinical trials or for commercial
        purposes on a sufficiently large scale, in the required quality and/or in a cost-effective manner; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z499476973cdf49f0850a05775a31c18d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our collaborators may fail to develop and market products based on our discoveries due to various development hurdles or regulatory
        restrictions; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7b955d3433064219bc85c6102a0449d2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our collaborators may fail to develop and market products based on our discoveries prior to the successful marketing of competing
        products by others or prior to expiry of the patents protecting such products; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z243e1d8bf0de4011aac17d30866c0a44" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>changes in a collaborator&#8217;s business strategy may negatively affect its willingness or ability to complete its obligations
        under its arrangement or to continue with its collaboration with us; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z29c227948e684da8b5b866a8ae2704bd" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our collaborators may terminate the program or the agreement and then compete against us in the development or commercialization
        of similar therapeutics;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za2e68b0ad261482c9e2472b01fda4ce5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our collaborators may terminate the program or the agreement due to the competitive threat we may present to them with similar products;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf9696bdce6e240198b47058248c5dced" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>ownership of the intellectual property generated under or incorporated in our collaborations may be disputed; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9b7abd1709a74f199315a9406dfb957b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our ownership of rights in any intellectual property or products that may result from our collaborations may depend on additional
        investment of resources that we may not be able or willing to make; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z1e5ef30bd45d4ecaa5345d755ee99dba" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>prospective collaborators may pursue alternative products or technologies, by internally developing them or by preferring those of
        our competitors; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5b0966c2dc70493d8806be2e9bd9eeb6" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>disagreements between us and our collaborators may lead to delays in, or termination of, the collaboration; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd4a4fa301d054b9aba56d5a716f3562e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our collaborators may fail to develop or commercialize successfully any products based on our novel drug targets or therapeutic product
        candidates to which they have obtained rights from us; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z39368158827943f898172dc85455496b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we or our collaborators may not choose the right drug combinations for our therapeutic product;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ze465bcee59e94be3a7e30ef0b30890ec" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our collaborations may face internal competition by their internal pipelines;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za064a84b1fa045958d21966eb5b4a470" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 14.2pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.15pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>prospective collaborators may hesitate to pursue collaborations on novel target candidates that lack robust validation to serve as
        a basis for the development of therapeutics; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2d2addb6b34548b496c3557ccad5d338" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our collaboration partners may be acquired by, acquire, or merge with, another company, and the resulting entity may have different
        priorities or competitive products to the collaboration product being developed previously by our partner. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">If any of these risks should materialize, our business, financial condition and results of operations may
be materially harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our existing agreements for our drug candidates
are subject to many risks. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In August 2013, we entered into a Research and Development Collaboration and License
Agreement with Bayer Pharma AG, or Bayer, for the research, development, and commercialization of antibody-based therapeutics for cancer
immunotherapy against a novel, Compugen-discovered immune checkpoint regulator CGEN-15001T/ILDR2, for which the therapeutic antibody bapotulimab&#160;(formerly
known as BAY1905254) is currently being evaluated in a Phase 1 clinical trial. The collaboration with Bayer, or the Bayer Collaboration,
continues until Bayer is no longer required to make payments under the agreement or until otherwise terminated by either party in accordance
with the terms of the agreement. Bayer may also terminate the agreement, at any time with or without cause on a product-by-product and/or
country-by country basis, upon prior written notice. Upon any termination of the agreement, depending upon the circumstances, the parties
have varying rights and obligations with respect to the continued development and commercialization of any products and or various payment
and royalty obligations in the event of such continuation of the development and commercialization.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">19</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">In March 2018, we <span style="font-family: Times New Roman,Times,serif">entered into
an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of AstraZeneca, which is currently
part of AstraZeneca, or AstraZeneca. Under the terms of the license agreement, we provided an exclusive license to AstraZeneca to use
our monospecific antibodies that bind to TIGIT, including COM902, for the development of bi-specific and multi-specific antibody products,
excluding such bi-specific and multi-specific antibodies that also bind to PVRIG, PVRL2 and/or TIGIT. In connection with such license
agreement, AstraZeneca developed AZD2936, a novel TIGIT/PD-1 bispecific antibody with a TIGIT component that is derived from our COM902.
Subject to termination rights for material breach, bankruptcy or by us for patent challenge by AstraZeneca, the term of the license agreement
continues until the expiration of the last royalty term in the territory as further specified in the license agreement. In addition, AstraZeneca
may terminate the agreement for convenience upon prior written notice.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In October 2018, we entered into a master clinical trial collaboration agreement<span style="font-family: Times New Roman,Times,serif">
with Bristol Myers Squibb, or the MCTC, to evaluate the safety and tolerability of COM701 in combination with Bristol Myers Squibb&#8217;s
PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors. In February 2020, the MCTC was amended
to include a clinical trial, sponsored by Compugen, to evaluate the safety, tolerability and antitumor activity of COM701 in combination
with Opdivo&#174; (nivolumab), and Bristol Myers Squibb&#8217;s investigational antibody targeting TIGIT known as BMS-986207, in patients
with advanced solid tumors. In February 2021, such MCTC was further amended to include an expansion of the Phase 1 combination trial designed
to evaluate the dual combination of COM701 and Opdivo&#174; in patients with advanced solid tumors and in November 2021 the MCTC was further
amended, among other things, to establish a joint steering committee (alongside the existing joint development committee which acts at
an operational level) to facilitate strategic oversight and guidance for the programs run under the collaboration. Pursuant to the terms
of the MCTC, as amended, subject to termination rights for breach, bankruptcy or a material safety issue or clinical hold, the term of
the MCTC, as amended, will continue in effect until completion by all centers or institutions participating in combined therapy trials,
the delivery of trial data to both parties and the completion of any then agreed upon protocol(s), statistical analysis and bioanalysis
plan. In the event a third-party merges with or acquires us, we are free to assign or transfer the agreement without the consent of Bristol
Myers Squibb. Such third-party must expressly assume in writing all of our rights and obligations under the MCTC, as amended.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Each of these agreements were entered into for Compugen-discovered drug candidates
and is subject to all of the risks as set forth above with respect to our dependence in general on collaboration agreements with third
parties.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If significant adverse unforeseen events occur in our collaborations or they are terminated,
particularly prior to our signing additional collaboration agreements, our business and financial condition may be materially harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our reliance on third parties for the performance
of key activities heightens the risks faced by our business. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We invest significant efforts and resources into outsourcing certain key functions
with third parties, including certain preclinical activities, drug development activities, manufacturing operations, research, validation,
discovery and others. We do not control the third parties to whom we outsourced these functions and have limited internal expertise to
appropriately manage their activities. However, we are dependent on them to undertake activities and provide services, results, our product
candidates or materials, including the production of certain biological reagents, which may be significant to us. If these third parties
fail to properly or timely perform these activities or provide us with incorrect or incomplete services or results or fail to produce
and/or provide certain materials, tests or analysis, this could lead to significant delays in the program or even program failure, along
with significant additional costs and damage. In addition, should any of these third parties fail to comply with the applicable laws and
regulations and/or research and development or manufacturing accepted standards in the course of their performance of services for us,
there is a risk that we could be held responsible for such violations of law as well. Any such failures by third parties could have a
material adverse effect on our business, financial condition or results of operations. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Moreover, we do not always independently verify the results obtained by such third
parties and in some cases, rely upon the data provided by the third-party. If we fail to identify and obtain accurate and quality data,
services and/or technologies from such third parties, or if the contractual demands of such third parties become unreasonable and we are
not able to reach satisfactory agreements with such third parties, we may lose our investment in these services, fail to receive the expected
benefits from our discoveries, and our validation and development capabilities, clinical trials or other activities or our final products,
may be significantly harmed, delayed or terminated.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">20</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may need to obtain third-party drugs for
combination with our clinical programs that may not be available to us or are available only on commercially unreasonable terms, and which
may cause us to either not perform the right clinical trial, or not perform the clinical trial for the right indication, or in a more
costly manner or otherwise adverse manner that was not anticipated. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We&#160;may&#160;need to obtain certain drugs from third&#160;parties&#160;to&#160;further&#160;develop&#160;our
drug candidates to work in combinations with other drugs for selected indications in order to commercialize&#160;our&#160;drug candidates.
If we fail to obtain these drugs or license thereof, our drug candidates may not be sufficiently efficient, and we may not be able to
pursue them through development and commercialization.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-weight: bold">Risks Related to Competition and Commercialization</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our business model is challenging to implement
and to date has not yielded significant revenues.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our discovery and development capabilities are designed to identify and develop novel
products addressing a specific unmet need and enter into collaborations with partners with respect to such novel products. Our objective
is that under these collaborations, we will have the right to receive various forms of revenue from such products. To date, we have entered
into three partnership agreements with respect to our pipeline programs. There can be no assurance that any current or future agreements
for novel targets based on our discoveries and associated product candidates will be successful and thus provide significant revenues
to us, nor can there be any assurance that we will be able to enter into additional future agreements. If we are unable to succeed in
securing additional license agreements or other collaboration arrangements related to our discoveries, our business may be materially
harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Two clinical candidates against our discovered novel targets entered Phase 1 clinical
trials in 2018, one executed by us (COM701) and the second by Bayer under the Bayer Collaboration. An additional clinical candidate (COM902)
against our discovered novel target entered into a Phase 1 clinical trial in 2020 and is pursued by us. A fourth clinical candidate pursued
by AstraZeneca (derived, among others, from COM902) entered into a Phase 1/2 clinical trial in 2021. There can be no assurance that we
will be able to establish additional collaborations for COM701 or COM902 or for our early-stage programs in the target discovery, research
and validation stage. Failure to enter into collaborations, may materially harm our business. The research and validation data generated
to date for our early-stage pipeline and the clinical data generated to date for COM701 and COM902 may not be sufficient to attract interest
from prospective collaborators and we may fail to generate data suitable to draw interest with potential partners. Furthermore, our drug
target candidates or therapeutic product candidates may not fit their corporate or clinical strategy. These companies may require more
data, including their independent testing of our early-stage therapeutic product candidate, before considering a collaboration. We are
therefore dependent on the potential fit of our programs with individual pharmaceutical company strategies and there can be no assurance
that we will be able to identify additional partners interested in our programs at their current stages. This may adversely affect our
ability to enter into additional agreements for the research, development, license or other form of collaboration or commercialization
of our therapeutic product candidates, and as a result may harm our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Additionally, we may not be able to demonstrate efficacy or safety, prove our preclinical
hypothesis or obtain approval for and commercialize our products as monotherapy treatments. We may be required to combine our product
candidates with other products to provide sufficient data for approval by FDA and other regulatory authorities, in all or in specific
indications (which may require our dependency on third-party drugs). As part of our business strategy, we are looking to establish clinical
collaborations with pharmaceutical and biotechnology companies to specifically test the hypothesis that there may be greater effects when
combining our products with other products. In October 2018, we entered into MCTC with Bristol Myers Squibb to evaluate the safety and
tolerability of COM701 in combination with Bristol Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo<span style="font-family: Times New Roman,Times,serif"><sup style="font-family: Times New Roman, serif; vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>.
Such agreement was amended several times since then and we are currently evaluating the safety, tolerability and antitumor activity of
COM701 in combination with Opdivo<sup style="font-family: Times New Roman, serif; vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>,
and of COM701 in combination with Opdivo<sup style="font-family: Times New Roman, serif; vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>
and with and Bristol Myers Squibb&#8217;s investigational antibody targeting TIGIT known as BMS-986207. See &#8220;Business Strategy and
Partnerships - Bristol Myers Squibb Collaboration&#8221; below. There can be no assurance that we will be able to establish additional
clinical collaborations or to maintain existing collaborations. Failure to enter into combination clinical collaborations may materially
harm our business. These potential combination products may include both marketed as well as investigational products, and as such, adverse
events resulting from combining the products or investigational agents are unknown and could be severe, including resulting in death of
the patient due to these unknown toxicities. There is an industry trend towards drug combinations in the field of cancer immunotherapy
which may result in a situation under which our therapeutic product candidates will serve in a combination product and may therefore be
entitled to only a fraction of the anticipated product revenues. These trends may adversely affect any revenues we may be entitled to
receive and as a result may harm our business.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">21</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We operate in a highly competitive and rapidly
changing industry which may result in others discovering, developing or commercializing competing products before us or more successfully
than we do.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The biotechnology and biopharmaceutical industries <span style="font-family: Times New Roman,Times,serif">are
highly competitive, subject to consolidation, characterized by rapid and significant technological advancements, and have a strong emphasis
on proprietary products. Our success is highly dependent upon our ability to identify, develop and obtain regulatory approval for therapeutic
products based on our discovered novel drug targets. In doing so, we face and will continue to face intense competition from a variety
of businesses, including large, fully integrated, well-established pharmaceutical companies, specialty pharmaceutical and biopharmaceutical
companies, academic institutions, government agencies and other private and public companies and research institutions.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Many of the companies against which we are competing or against which we may compete
in the future have significantly greater resources and expertise in research and development, manufacturing, preclinical testing, conducting
clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. These competitors and others may develop competing
products targeting the same mechanisms, the same drug targets and pathways as our products, or the same therapeutic indications and they
can leverage their resources or use different approaches than we do to receive marketing approval before our products. Additionally, these
third parties compete with us in recruiting and retaining qualified scientific, drug development and management personnel and advisors,
establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring technologies complementary to, or
necessary for, our programs. Mergers and acquisitions in the biopharmaceutical industry, such as the acquisition of Celgene by Bristol
Myers Squibb in 2019 could result in even more resources being concentrated among a small number of our competitors or change in potential
acquirers&#8217; preferences. In addition, increased industry interest and deals in the anti-TIGIT and anti-PVRIG field may further enhance
the competition for our clinical stage assets COM902 and COM701 and may include companies with significantly greater resources and capabilities
than we have. For example, in January 2022 Coherus exercised its option to Junshi Biosciences&#8217; TIGIT-targeted antibody JS006, in
December 2021 Novartis signed an option, collaboration and license agreement with Beigene for its TIGIT inhibitor ociperlimab, in November
2021 Gilead and Taiho each exercised its option to Arcus&#8217; anti-TIGIT antibodies domvanalimab and AB308 each pursuant to its respective
territorial rights, in June 2021 GSK and iTeos Therapeutics entered into an agreement to co-develop and co-commercialize iTeos&#8217;
anti-TIGIT antibody EOS-448, and in December 2020 GSK licensed worldwide development and commercial rights to Surface Oncology&#8217;s
preclinical program SRF813 (now GSK4381562), an antibody targeting PVRIG which has received FDA IND clearance in December 2021.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Competition may further increase as a result of advances in the commercial applicability
of technologies similar to our predictive computational discovery capabilities and greater availability of capital for investment in these
industries. Over the last several years, there has been an increase in the interest of pharmaceutical companies, the healthcare community
and the investment community in applying computational methodologies, mostly Artificial Intelligence (AI) and Machine Learning (ML) algorithms,
to the field of data-driven drug discovery/healthcare. This interest may be seen in the increase in the number of companies within the
pharmaceutical and biotech industries which focus on this area, including by way of establishing internal AI and/or ML capabilities or
receiving investments or entering into partnerships or acquisitions in furtherance thereof. Our competitors may succeed in discovering
targets and therefore also develop products that are competitive to ours.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, there is a trend towards consolidation in the pharmaceutical, diagnostic
and biotechnology industry, which may result in the remaining companies having greater financial resources and discovery and technological
capabilities, thus intensifying competition in our industry. This trend may also result in fewer potential collaborators or licensees
for our therapeutic product candidates. Also, if a consolidating company is already doing business with our competitors, we may lose existing
or potential licensees or collaborators as a result of such consolidation. In addition, if a consolidating company is already doing business
with us, we may lose the interest of the consolidating parties in our discovery capabilities or individual discoveries or product candidates
as a result of a modified strategy, new priorities, competition and revised capabilities or portfolio of such consolidated entity. This
trend may adversely affect our ability to enter into agreements for the development and commercialization of our therapeutic product candidates
or to keep current collaborations in place or on-track and as a result may harm our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">22</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Established biopharmaceutical companies may invest heavily to accelerate discovery
and development of novel drug targets or therapeutic products or to in-license novel drug targets or therapeutic products that could make
our product candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling
advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful.
Accordingly, our competitors may succeed in obtaining patent protection, discovering, developing, receiving FDA approval for or commercializing
drugs before we do, which would have an adverse impact on our business and results of operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Potential collaborators, including major pharmaceutical
companies, might be hesitant to pursue target validation and preclinical and clinical development programs based on novel targets lacking
robust experimental validation results particularly those discovered through a computational discovery approach.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">There is a need for new drug targets generating new treatment options for patients
who are non-responsive or refractory to current immunotherapies. Our business model includes selectively entering into collaborations
for novel targets and related therapeutic product candidates at various stages of research and development under various revenue-sharing
arrangements. <span style="font-family: Times New Roman,Times,serif">Entering into collaborations with product candidates and targets
at an early stage in the validation or drug discovery process is significantly more challenging than identifying partnerships for later-stage
products that would have a more complete data package to support its clinical and business potential. In addition, although we have demonstrated
success in validating our predictive computational discovery capabilities with product candidates in human clinical trials, major pharmaceutical
companies may be hesitant to enter into early-stage collaborations based on newly discovered targets, more so if discovered by computer,
as opposed to drug targets with human clinical trial data, or product candidates with significant published experimental validation. Therefore,
we cannot assure that our business model to enter into commercialization arrangements for our early-stage novel targets and product candidates
will be successful.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic"><span style="font-weight: bold">The agreement cycle for potential
collaborations is complex and long to implement and, if we are not able to establish collaborations on commercially reasonable terms,
we may expend substantial funds and management resources with no assurance of success</span><span style="font-family: Times New Roman,Times,serif">.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In general, each potential license agreement or other form of collaboration we may
enter into will require negotiating with our potential collaborator, a large number of scientific, legal and business terms and conditions
that can vary significantly in each instance due to the specific drug target or therapeutic product candidate or candidates involved,
the potential market opportunity, the potential collaborator&#8217;s licensing, development and business operations and strategy, and
competition in the partnering and business development space. The accommodation of these requirements mandates a thorough consideration
of both the scientific and business aspects of each transaction. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Whether we reach a definitive agreement for new collaborations will depend, among
other things, upon our assessment of the collaborator&#8217;s resources, capabilities and expertise, the terms and conditions of the proposed
collaboration, the proposed collaborator&#8217;s evaluation of our business, drug targets and therapeutic product candidates, and the
competition in the business development space. We may not be successful in our efforts to establish a collaboration or other alternative
arrangements for future product candidates because they may be deemed to be at too early of a stage of development for collaborative effort
and third parties may not view them as having the requisite potential to demonstrate safety and efficacy or may find any other development
hurdles and challenges as a limiting factor. If we are unable to do so, we will need to expend substantial funds and substantial key personnel
time and effort into these business development activities with no assurance of successfully entering into agreements with potential collaborators
and this could harm our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We rely on our predictive computational discovery
capabilities to identify drug targets. Our competitive position could be materially harmed if our competitors develop capabilities similar
to ours and identify and develop rival drug targets and product candidates.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We rely on know-how and other proprietary computational processes and tools to maintain
our competitive computational discovery position. We consider know-how to be our primary intellectual property with respect to our predictive
computational discovery capabilities. Know-how can be difficult to protect and enforce. In particular, we anticipate that with respect
to our capabilities, this know-how may over time be disseminated within the industry through independent development and the movement
of skilled personnel.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">23</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">We cannot rule out that our competitors may have or obtain the knowledge necessary
to identify and develop therapeutic products based on novel drug targets that could compete with the drug targets we identify. Our competitors
may have significantly greater experience in artificial intelligence, computer sciences, algorithmic tool development and alike to identify
targets and greater experience in using translational science to develop product candidates and may also have significantly greater financial,
product development, scientific, technical and human resources than we do to discover novel drug targets and develop product candidates.
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We may not be able to prohibit our competitors from using methods to identify and
develop product candidates, including such methods that are the same as or similar to our own. Since our competitors develop products
that compete with COM701 or COM902 or any future product candidates we develop, our ability to develop and commercialize these product
candidates may diminish substantially, which could have a material adverse effect on our business prospects, financial condition, and
results of operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The biotechnology and pharmaceutical industries
are highly competitive, and we may be unable to compete effectively.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The biotechnology and pharmaceutical industries in general, and the immuno-oncology
field in particular, are highly competitive. Numerous entities in the United States, Europe and elsewhere compete with our efforts to
discover, validate, develop and partner with licensees and/or collaborators to commercialize drug target and therapeutic products candidates.
Clinical trial failures of novel agents in the immuno-oncology field may adversely impact our ability to sign early-stage collaborations,
and as a result we may be required to advance our programs into clinical development and show clinical proof of concept before we may
attract potential collaborators. Our competitors include pharmaceutical and biotechnology companies, academic and research institutions
and governmental and other publicly funded agencies. We face, for COM701 and COM902, and expect to continue to face for our future therapeutic
product candidates, competition from these entities to the extent they develop products that have a function similar or identical to or
competing with the function of our therapeutic product candidates in the field of immuno-oncology that may attract our potential collaborators
or that may reach the market sooner. We also face, and expect to continue to face, competition from entities that seek to develop technologies
that enable the discovery of novel targets and therapeutic agents in the field of immuno-oncology. These competitors include traditional
pharmaceutical and biotechnology companies and additionally, an increasing number of new entities looking to apply computer science, bioinformatics,
AI or ML technologies to the field of target discovery. Many of our competitors have one or more of the following:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7104147cc0654f6e8b929c74784e995d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>much greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and
        commercialization process; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z624906fcdc7449caa07d19b5ed797ae4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>more extensive experience in computational discovery, preclinical testing, conducting clinical trials, obtaining regulatory approvals,
        and in manufacturing and marketing therapeutics; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z133140876ae14386aec9bb5b19fee12d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>more extensive experience in oncology and immuno-oncology and in the fields of mAb therapeutics; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z756abfac1a6d45b2b87badb89856dd16" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">accessibility to enhanced technologies that
        may result in better products;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zeb7bc3c4830242df94e905323914c79c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>access to and experience in the development of therapeutic modalities that are competitive to mAb therapeutics;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7fd5840339b24c4cb5d96cc47d4f8672" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>more extensive experience in oncology and immuno-oncology and in the field of target discovery;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z880cc07fd7364138862459fb70b7ea93" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>more extensive experience in the research and development of biological or genetic markers to determine response of or responders
        to therapeutic agents or for patient selection;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7fcb7fe177754767ba45778b5457659b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>greater accessibility to data and proprietary data from patients;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf43c0af9ded7412aa4edcf0f511a603c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>access to internally developed, proprietary technologies for the discovery, research, development, or manufacturing of therapeutic
        agents; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9a494324b6e642f68d5c47ad2972bb27" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>greater resources and means to compete with us on target discovery and as well as in acquiring or generating technologies complementary
        to, or necessary for, our programs as well as in recruiting and retaining qualified scientific and management personnel and establishing
        clinical trial sites;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">24</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd015f42b80c44d43814aabf9b60cf4e3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>products that have been approved or are in late stages of development; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd6a8d341186a42abb4f38f89fb1f2b2d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>reduced reliance on collaborations or partnerships with third parties in order to further develop and commercialize competitive therapeutic
        products; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc5e398d86c514c948484c841c99cd424" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>collaborative arrangements in our target markets with leading companies and research institutions. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Since we are a small company with limited human and financial resources, we are not
able to work with a large number of collaborators in parallel and/or advance a large number of drug target or therapeutic product candidates
in parallel. Our competitors may develop or commercialize products with significant advantages over any therapeutic products we, our collaborators
or third-party licensees may develop. They may also obtain patents and other intellectual property rights before us, or broader than ours,
and thereby prevent us from pursuing the development and commercialization of our discoveries. They may also develop products faster than
us and therefore limit our market share. Our competitors may therefore be more successful in developing and/or commercializing products
than we, our collaborators, or third-party licensees are, which could adversely affect our competitive position and business. If we are
unable to compete successfully against existing or potential competitors, our financial results and business may be materially harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Healthcare policy is volatile and changes in
healthcare policy could increase our expenses, decrease our revenues and impact sales of, and reimbursement for, our products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our ability to commercialize our future therapeutic product candidates successfully,
alone or with collaborators, will depend in part on the extent to which coverage and reimbursement for these product candidates will be
available from government health programs, such as Medicare and Medicaid in the United States, private health insurers and other third-party
payors. At present, significant changes in healthcare policy, in particular the continuing efforts of the U.S. and other governments,
insurance companies, managed care organizations and other payors to contain or reduce health care costs are being discussed, considered
and proposed.&#160;Drug prices in particular are under significant scrutiny and continue to be subject to intense political and societal
pressures, which we anticipate will continue and escalate on a global basis.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For example, in the United States, there have been several initiatives implemented
to achieve these aims. The Patient Protection and Affordable Care Act, or the PPACA, as amended by the Health Care and Education Affordability
Reconciliation Act, and collectively, the ACA, represents the biggest regulatory overhaul to the health care system in decades and substantially
changes the way health care is financed by both governmental and private insurers. However, the ACA has faced legislative, judicial, executive
and political challenges from Congress, the Trump administration, state governments, consumer groups and business organizations. For example,
on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety
because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. It is
possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges will impact
the ACA and our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Additionally, there has been heightened governmental scrutiny in the United States
of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several
recent congressional inquiries, presidential executive orders and proposed and enacted federal and state legislation designed to, among
other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and
reform government program reimbursement methodologies for products. In July 2021, the Biden administration released an executive order,
&#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s
executive order, on September 9, 2021, the Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing
High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress
could pursue to advance these principles. No legislation or administrative actions have been finalized to implement these principles.
In addition, Congress is considering drug pricing as part of other reform initiatives. Further, it is possible that additional governmental
action is taken in response to the COVID-19 pandemic.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">25</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The commercial success of our products depends
on the availability and sufficiency of third-party payor coverage and reimbursement.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Market acceptance of drug products is dependent on the extent to which coverage and
reimbursement is available from third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any
products for which we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost
therapeutic alternatives are already available. Even if we obtain coverage for a given product, the associated reimbursement rate may
not be adequate to cover our costs, including research, development, intellectual property, manufacture, sale and distribution expenses,
or may require co-payments that patients find unacceptably high. Patients are unlikely to use our products unless reimbursement is adequate
to cover all or a significant portion of the cost of our products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Coverage and reimbursement policies for products can differ significantly from payor
to payor as there is no uniform policy of coverage and reimbursement for products among third-party payors in the United States. There
may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time
consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately,
with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities
and third-party payors will decide with respect to coverage and reimbursement for our drug products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-weight: bold">Risks Related to our Operations and Other Risks
Related to our Business</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Given our level of managerial, operational,
financial and other resources, our current activities and future growth may be limited.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We <span style="font-family: Times New Roman,Times,serif">manage our operations, including
clinical trials and preclinical development activities of our therapeutic candidates with limited workforce and by using third parties
to provide us services that we do not possess in-house. Our personnel, systems and facilities currently in place may not be adequate to
support our current activities or future growth.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we are unable to maintain or expand our managerial, operational, financial and
other resources to the extent required to manage our development and commercialization activities, our business may be materially adversely
affected.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may be unable to hire or retain key personnel
or sufficiently qualified management, clinical and scientific personnel. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our business is highly dependent upon the continued services of our senior management
and key scientific and clinical personnel. While members of our senior management and other key personnel have entered into employment
or consulting agreements and non-competition and non-disclosure agreements, they can terminate their employment agreements with us at
any time without cause. We cannot be sure that these key personnel and others will not leave us or compete with us, which could harm our
business activities and operations. It is difficult to find suitable and highly qualified personnel in certain aspects of our industry,
mainly in the field of immuno-oncology and specifically in Israel.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25">It can also be difficult for us to find employees with appropriate experience for
our business. We require a multidisciplinary approach and some of our researchers require an understanding in both exact and biological
sciences. In addition, we require experience in drug and clinical development and immuno-oncology, for which there is significant competition
for highly qualified personnel in these fields. As a result, we may face higher than average employee turnover or challenges in hiring
due to such competition. During 2021, we added preclinical expertise and clinical expertise, which we expect to continue to expand in
2022 and which will require significant efforts to attract the required personnel with the required expertise and experience.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The competition for qualified personnel in the pharmaceutical and biotech industry
is intense. The loss of service of any of our key personnel could harm our business. Due to our limited resources, we may not be able
to effectively retain our existing key personnel or attract and recruit additional qualified key personnel.</div>

<div style="text-align: justify; line-height: 1.25"> <br /> </div> </div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">26</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> <br />

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may be unable to safeguard the integrity,
security and confidentiality of our data or third parties&#8217; data.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We rely heavily on the use and manipulation of large amounts of
data and on the secure and continuous use of our internal computers, communication networks and software and hardware systems. We have
implemented and maintain physical and software security measures to preserve and protect our computers and communication, hardware and
software systems as well as our data and third parties&#8217; data. However, these methods may not fully protect us against fire, storm,
flood, power loss, earthquakes, telecommunications failures, physical or software break-ins or similar events. In addition, these measures
may not be sufficient to prevent unauthorized access, use or publication of such proprietary data. A party who is able to circumvent our
security measures could misappropriate or destroy (partially or completely) proprietary information or cause interruptions in our operations.
In addition, a party, including an employee or a contractor, who obtains unauthorized access to our proprietary data or breaches a confidentiality
agreement with us could publish or transfer large portions or all of our proprietary data. Some of our proprietary data is maintained
in secured cloud services that may also be subject to security breach, including by employees of the cloud services provider. Such disclosure
of confidential or proprietary data could materially harm our intellectual property position, adversely affect third party&#8217;s confidential
and proprietary information and therefore subject us to significant financial and legal exposures and could materially harm our operations
and even cause our business to cease. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our internal computer systems, or those of
our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our
pipeline and our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our business is increasingly dependent on critical, complex and interdependent information
technology systems to support business processes as well as internal and external communications. Despite the implementation of security
measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer
viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While, to our knowledge,
we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions
in our operations, it could result in a material disruption to our programs and could materially harm our operations and even cause our
business to cease. For example, the loss of clinical trial data from the clinical trials of our therapeutic product candidate could result
in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, our systems
are potentially vulnerable to data security breaches, whether by employees or others, which may expose sensitive data to unauthorized
persons. Although we have invested in measures to reduce these risks, we cannot assure you that these measures will be successful in preventing
compromise and/or disruption of our information technology systems and related data. To the extent that any disruption or security breach
results in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we
could incur liability and the further development of our therapeutic candidates could be delayed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our business and operations would suffer if
our information technology systems or infrastructure or data, or our vendors&#8217; or partners&#8217;, are or were compromised. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We, our vendors and our partners collect, store, use, transmit, disclose, or otherwise
process, or Process, proprietary, confidential, and sensitive data, including personal data of our employees, clinical trial patients,
and others, intellectual property and trade secrets. We, our vendors and our partners rely on information technology systems, including
those provided by third-party service providers, to keep financial records, capture laboratory data, maintain clinical trial data and
corporate records, communicate with staff and external parties and operate other critical functions. Our ability to monitor our vendors&#8217;
and partners&#8217; information security practices is limited, and these third parties may not have adequate information security measures
in place. Our information technology systems, and those of our vendors&#8217; and partners&#8217;, are vulnerable to a variety of evolving
threats from various sources, including traditional computer hackers, personnel (such as through theft or misuse), threat actors, sophisticated
nation states, and nation-state-supported actors. These threats include but are not limited to social-engineering attacks, malicious code
(such as viruses), malware, denial-of-service attacks, ransomware attacks, supply-chain attacks, server malfunctions, software or hardware
failures, or other disruptive events including but not limited to natural disasters. The effects of the COVID-19 pandemic have intensified
our dependence on information technology systems as many of our business activities are currently being conducted remotely and our increased
reliance on personnel working from home could increase our cybersecurity risk. If we or our vendors or partners were to suffer a security
breach or other interruption, we could experience unauthorized, unlawful, or accidental acquisition, modification, destruction, loss,
alteration, encryption, disclosure of, or access to our data or data held by us or our vendors and partners (including personally identifiable
information or personal data). Although we have implemented security measures designed to protect against security breaches and other
incidents and maintain offsite back-ups of our data, such measures may fail. Security breaches, vulnerabilities, and other inappropriate
access can be difficult to detect because such threats and techniques change frequently and are often sophisticated in nature. If we or
our vendors and partners experience (or are perceived to have experienced) a security breach or other incident or disruption, we may experience
adverse consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, and
inspections), federal, state and/or foreign data breach notification obligations, additional reporting requirements and/or oversight,
restrictions on Processing data (including clinical trial data), litigation, indemnification obligations, loss of data (including clinical
trial data) or damage to the integrity of that data, negative publicity, reputational harm, monetary fund diversions, interruptions in
our operations, financial loss, and other similar harms. Such attended consequences may interrupt our clinical trials, reduce demand for
our product candidates, and delay or negatively impact the development and commercialization of our product candidates and ability to
grow and operate our business. Furthermore, our contracts may not contain limitations of liability, and even where they do, there can
be no assurances that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related
to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect
us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available
on commercially reasonable terms or at all, or that such coverage will pay future claims. Moreover, failure to maintain effective internal
accounting controls related to data security in general could impact our ability to produce timely and accurate financial statements and
could subject us to regulatory scrutiny.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">27</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We are subject to stringent and changing obligations
related to data privacy and security. Failure or perceived failure to comply with current or future obligations could lead to government
enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively
affect our operating results and business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We, our vendors and our partners Process proprietary, confidential, and sensitive
data, including personal data, data we collect about trial participants in connection with clinical trials, sensitive third-party data,
trade secrets, intellectual property, and other sensitive data. We and our vendors and partners may be subject to numerous data privacy
and security obligations, such as various federal, state, local and foreign data laws, regulations, guidance, industry standards, external
and internal privacy and security policies, contracts, and other obligations that govern the Processing of personal data by us and on
our behalf. In the United States, numerous federal and state laws and regulations, including federal health information privacy laws,
state data breach notification laws, state health information privacy laws and federal and state consumer protection laws, that govern
the collection, use, disclosure and protection of health-related and other personal data apply to our operations or the operations of
our collaborators. For example, the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health
Information Technology for Economic and Clinical Health Act, or HITECH, imposes specific requirements relating to the privacy, security,
and transmission of individually identifiable health information. Additionally, laws in all 50 states require businesses to provide notice
to parties whose personally identifiable information has been disclosed as a result of a data breach. The laws are not consistent, and
compliance in the event of a widespread data breach is costly. Furthermore, California enacted the California Consumer Privacy Act, or
the CCPA, which provides for civil penalties for violations, as well as a private right of action for data breaches. The California Privacy
Rights Act, or the CPRA, which will take effect in most material respects on January 1, 2023, significantly modifies the CCPA, potentially
resulting in further uncertainty. Other U.S. states have enacted or proposed data privacy laws. An increasing number of foreign data protection
laws may also apply to health-related and other personal data obtained from individuals outside of the United States. For example, the
European Union&#8217;s General Data Protection Regulation, or EU GDPR introduced new data protection requirements in the EU, as well as
potential fines for noncompliant companies of up to the greater of &#8364;20 million or 4% of annual global revenue. In addition, we are
also subject to the Israeli Privacy Protection Law&#160;5741-1981&#160;and the regulations promulgated thereunder, or the PPL, including
the Israeli Privacy Protection Regulations (Data Security) 2017, imposing obligations with respect to the manner personal data is processed,
maintained, transferred, disclosed, accessed and secured, as well as the guidelines of the Israeli Privacy Protection Authority. In this
respect, the PPL may require us to adjust certain data protection and data security practices, information security measures, certain
organizational procedures, applicable positions and other technical and organizational security measures. Failure to comply with the PPL
and with guidelines issued by the Israeli Privacy Protection Authority, may expose us to administrative fines, civil claims (including
class&#160;actions) and in certain cases criminal liability. Furthermore, many jurisdictions have enacted data localization laws and cross-border
personal data transfer laws, which could make it more difficult to transfer information across jurisdictions (such as transferring or
receiving personal data that originates in the European Economic Area). Existing mechanisms that may facilitate cross-border personal
data transfers may change or be invalidated. For example, absent appropriate safeguards or other circumstances, the EU GDPR regulates
transfers of personal data subject to the EU GDPR to third countries that have not been found to provide adequate protection to such personal
data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States
remains uncertain. In addition, the United Kingdom similarly restricts transfers of personal data outside of those jurisdictions to countries
such as the United States that do not provide an adequate level of personal data protection. If we cannot implement a valid compliance
mechanism for cross-border data transfers, we could experience material adverse effects. Our obligations related to privacy and security
are quickly changing in an increasingly stringent fashion, creating some uncertainty as to the effective future legal framework. Additionally,
these obligations may be subject to differing applications and interpretations, which may be inconsistent or in conflict among jurisdictions.
Preparing for and complying with these obligations requires us to devote significant resources (including, without limitation, financial
and time-related resources). These obligations may necessitate changes to our practices and to those of any third parties that Process
personal data on our behalf. In addition, these obligations may require us to change our business model. Compliance with privacy and security
obligations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data,
or in some cases, impact our ability to operate in certain jurisdictions. Failure or perceived failure by us or our collaborators to comply
with U.S. and foreign data privacy or security obligations could result in government enforcement actions (which could include civil or
criminal penalties), private litigation, bans on Processing personal data, and/or adverse publicity and could negatively affect our operating
results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the
providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we
have violated individuals&#8217; privacy rights, failed to comply with privacy or security obligations or breached our contractual obligations,
even if we are not found liable, could be expensive and time consuming to defend, could result in adverse publicity and could have a material
adverse effect on our business, financial condition, results of operations and prospects.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">28</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If a successful liability claim or other claim
for damages or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, we could be forced
to pay substantial damage awards. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The use of any of our therapeutic product candidates in clinical trials might expose
us to liability. We have obtained clinical trial insurance coverage in amounts that we believe are reasonable and customary in our industry
based on the size and design of our clinical trials. However, there can be no assurance that such insurance coverage will fully protect
us against some or all of the claims to which we might become subject. We might not be able to maintain adequate insurance coverage at
a reasonable cost or in sufficient amounts or scope to protect us against potential losses. In the event a claim is brought against us,
we might be required to pay legal and other expenses to defend the claim, as well as uncovered damages awards resulting from a claim brought
successfully against us. Furthermore, whether or not we are ultimately successful in defending any such claims, we might be required to
direct financial and managerial resources to such defense and adverse publicity could result, all of which could harm our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If we fail to comply with laws regulating the
protection of the environment and health and human safety, our business could be adversely affected.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our research and development activities involve the use of hazardous materials and
chemicals, and we maintain quantities of microbial agents, various flammable and toxic chemicals in our facilities. Although we believe
our safety and other procedures for storing, handling and disposing these materials in our facilities comply with applicable governmental
and local regulations and guidelines, the risk to our employees or others of accidental contamination or injury from these materials cannot
be eliminated. If an accident occurs, we could be held liable for resulting damages, which may exceed our financial resources and may
seriously harm our business. We are also subject to numerous environmental, health and workplace safety laws and regulations, including
those governing laboratory procedures, exposure to blood-borne pathogens and the handling of biohazardous materials. We may be subject
to liability and may be required to comply with new or existing laws and regulations regulating pharmaceuticals or be subject to substantial
fines or penalties if we violate any of these laws or regulations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risks Related to Intellectual Property. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If the scope of any patent protection we obtain
is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar
or identical product candidates would be adversely affected.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We have applied for patents covering proteins, therapeutic and
diagnostic product candidates and their method of use, and the success of our business depends, to a large extent, on our ability to obtain
and maintain such patents and any additional patents covering our future product candidates. We design our patent strategy to fit the
business competitive landscape and continual legislative changes. In addition, we periodically analyze and examine our patent portfolio
to align it with our pipeline strategy and business needs. We have issued patents and pending patent applications that are related to
our product candidates in the U.S., Europe, and other territories. We plan to continue to apply for patent protection for our therapeutic
and diagnostic inventions, but we cannot be sure that any of our patent applications will be accepted, or that they will be accepted to
the extent that we seek or that they will not be challenged. Additionally, we file for patent protection in selected countries and not
in all countries of the world. Therefore, we are exposed to competition in those countries in which we have no patent protection. Also,
due to our early-stage pipeline and various business considerations, we may be required to seek patent protection at a very early-stage.
This may cause us to file with insufficient supportive data, possibly making it difficult to obtain patents in jurisdictions that do not
accept post filing evidence to support the claims, and thus enabling others to compete with us. This may also cause issuance of a patent
at an earlier stage creating a shorter commercialization period under patent protection, possibly enabling others to compete with us.
Delays in filing patents may preclude us from obtaining protection on some or all of our product candidates due to others filing ahead
of us. Patent applications filed before us, but yet unpublished, may cause us to spend significant resources in areas that due to these
previously filed patents or applications we are not able to obtain patent protection or are only able to obtain a narrower scope of protection
than contemplated.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">29</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Because the patent position of biopharmaceutical companies involves
complex legal and factual questions, we cannot predict the validity, scope or enforceability of patents with certainty. The issuance of
a patent is not conclusive as to its inventorship, scope, validity or enforceability and our patents <span style="font-family: Times New Roman,Times,serif">may
be subject to a third party pre issuance submission of prior art to the patent authorities or become involved in opposition, derivation,
revocation, reexamination, post-grant and <span style="font-style: italic">inter partes</span> review, or other similar proceedings challenging
our patent rights in the United States and other jurisdictions which may result in such patents being narrowed, invalidated, or held unenforceable,
and thus could limit our ability to stop competitors from marketing related products or limit the length of the term of patent protection
that we may have for our product candidates. Such proceedings also may result in substantial cost and require our pending patent applications,
and those we may file in the future may not result in patents being issued. Furthermore, even if our patents do issue, and even if they
are unchallenged, our patents may not adequately protect all our intellectual property or prevent others from designing their products
in a way to avoid being covered by our claims. If the breadth or strength of protection provided by the patents we hold is threatened,
this could dissuade companies from collaborating with us to develop, and could threaten our ability to commercialize product candidates
and expose us to unexpected competition that could have a material adverse impact on our business.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Furthermore, changes in either the patent laws or interpretation
of the patent laws in the United States or other jurisdictions could weaken our ability to obtain new patents or to enforce our existing
patents and patents that we might obtain in the future and increase the uncertainties and costs surrounding the prosecution of patent
applications, and the enforcement or defense of our issued patents. Such changes could diminish the value of our patents and applications,
thereby impairing our ability to protect our product candidates, and could have a material adverse effect on our business, financial condition,
results of operations and prospects. For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing
the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In October
2017, in <span style="font-style: italic">Amgen v. Sanofi</span>, the Federal Circuit overturned the &#8220;newly characterized antigen&#8221;
test, which permitted patentees to claim a genus of antibodies by describing the structure of a corresponding antigen, on the grounds
that it failed to satisfy the written description requirement found in Section 112 of the Patent Act, 35 U.S.C. &#167; 112. In doing so,
the Federal Circuit called into question the validity of numerous existing patents. The U.S. Supreme Court declined to hear an appeal
of the Federal Circuit&#8217;s ruling, effectively changing the landscape for antibody patents for the foreseeable future. In the current
IP environment in the U.S., we may not be able to obtain or defend broad patent protection on our antibody inventions.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Moreover, because of the extensive time required for development,
testing and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized,
any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of
the patent protection.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">The process of obtaining patents for inventions that cover our
products is uncertain for a number of reasons, including but not limited to:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zfe7584013c834ec7918e358c5b4d1612" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the patenting of inventions involves complex legal issues relating to intellectual property laws, prosecution and enforcement of
        patent claims across a number or patent jurisdictions, many of which have not yet been settled; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">30</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zcc0d27f0fdda4b249925c12cc4224b5b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>legislative and judicial changes, or changes in the examination guidelines of governmental patent offices may negatively affect our
        ability to obtain patent claims to certain biological molecules- and/or use of certain therapeutic targets; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z132a4331ad8c4b50b6b347dc9303a3ef" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>if we are not the first to file a patent application on one of our inventions, we may not be able to obtain a patent on our invention,
        and may not be able to protect one or more of our therapeutic product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6f9e9556b5c142f1ac72ae41d8f8acdb" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>competition from other biotechnology and pharmaceutical companies who have already sought patent protection relating to proteins
        and protein based products, as well as therapeutic antibodies or other modulators specifically binding these proteins, and their utility
        based discoveries that we may intend to develop and commercialize; such prior patents may negatively affect our ability to obtain patent
        claims on antibodies or certain proteins or other biologic modulators, or may hinder our ability to obtain sufficiently broad patent claims
        for our inventions, and/or may limit our freedom to operate; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z60fe3a3a4e8b49f1a9f7142a416ee826" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>publication of data on gene products or proteins by non-commercial and commercial entities may hinder our ability to obtain sufficiently
        broad patent claims for our inventions; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zfad40a053c2249ebb8923a5dfda57d8e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>even if we succeed in obtaining patent protection, such protection may not be sufficient to prevent third parties from circumventing
        our patent claims; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zcf482a48a93a4134a0e0d2e01accf0b8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>even if we succeed in obtaining patent protection, we may face freedom to operate issues; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z605cec8a54c44344b4ae678a1925656a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>even if we succeed in obtaining patent claims protecting our inventions and product candidates, our patents could be subject to challenge
        and litigation by our competitors, and may be partially or wholly invalidated as a result of such legal/judicial challenges and in connection
        with such challenges, in October 2020, two parties filed oppositions in the European Patent Office, or EPO, requesting revocation of our
        granted European patent relating to anti-PVRIG antibodies, that expires in 2036;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb0f490c3c87a4cd1b50cce7571f80180" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>significant costs that may need to be incurred in registering and filing patents; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd2f387f6124d438b983d41ba6c22f7e3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>insufficient data to support our claims and/or may support others in strengthening their patents; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z633bd7495b134fa7af7f9325466f4df0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>seeking patent protection at an early stage may prevent us from providing comprehensive data supporting the patent claims and may
        prevent allowance of certain patent claims or limit the scope of patent claim coverage; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z53eb142a78a04b2a8d1b6e187ff1b07e" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">we may not be able to supply sufficient
        data to support our claims, within the legally prescribed time following our initial filing in order to support our patent claims and
        this may harm our ability to get appropriate patent protection or protection at all;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z178d89b21ef545d798249f607e8157f9" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">our claims may be too broad and not have
        sufficient enablement, in which case such claims might be rejected by patent offices or invalidated in court; and</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7fd794d9485e4cc59b1c348f44c6c19b" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">we might fail to demonstrate a unique technical
        feature for our antibodies as compared to existing prior art, in which case our claims might be rejected by the respective patent office,
        requiring superiority over prior art.</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we do not succeed in obtaining patent protection for our inventions (should it
be discoveries, drug targets candidates and product candidates) to the fullest extent for which we seek protection, or if we fail to select
the best inventions to seek such protection, our business and financial results could be materially harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We may not be able to protect
our intellectual property rights throughout the world.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Patents are of national or regional effect, and filing, prosecuting and defending
patents on all of our investigational products throughout the world would be extremely expensive. Thus, we may not be able to prevent
third parties from practicing or from selling or importing products made using our inventions in all countries. Further, the legal systems
of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property
protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation
of our proprietary rights generally. In addition, certain countries have compulsory licensing laws under which a patent owner may be compelled
to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if
we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. This
could limit our potential revenues. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate
to obtain a significant commercial advantage from the intellectual property that we develop or license.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">31</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">The existence of third-party
intellectual property rights may prevent us from developing our discoveries or require us to expend financial and other resources to be
able to continue to do so.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In selecting a drug target or a therapeutic product candidate for
development, we take into account, among other considerations, the existence of third-party intellectual property rights that may hinder
our right to develop and commercialize that product candidate. To our knowledge, third parties, including our competitors, have been filing
patent applications covering an increasing portion of the human proteome or antibodies directed thereto. As a result of the existence
of third-party intellectual property rights, we may be further required to:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd2e12e400ff44ff59d157ba9d0d1003e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>forgo the research, development and commercialization of certain drug target candidates and product candidates that we discover,
        notwithstanding their promising scientific and commercial merits; or </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z773fac6746b14b5a8030673f381846cf" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>invest substantial management and financial resources to either challenge or in-license such third-party intellectual property, and
        we cannot be sure that we will succeed in doing so on commercially reasonable terms, if at all. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We do not always have available to us, in a timely manner, information
of the existence of third-party intellectual property rights related to our own discoveries. The content of U.S. and other patent applications
remains unavailable to the public for a period of approximately 18 months from the filing date and therefore we cannot be certain that
we were the first to file any patent application related to our product candidate. In some instances, the content of U.S. patent applications
remains unavailable to the public until the patents are issued. Moreover, when patents ultimately are issued, the claims may be substantially
different from those that were originally published and may vary from country to country. Furthermore, there may be issued patents or
pending patent applications that we are aware of, but that we think are irrelevant to our therapeutic product candidates, but which may
ultimately be found to be infringed by the manufacture, sale, or use of such product candidates. As a result, we can never be certain
that programs that we commence will be free of third-party intellectual property rights. If we become aware of the existence of third-party
intellectual property rights only after we have commenced a particular program, we may have to forgo such project after having invested
substantial resources in it or, to the extent such third-party right has not expired, obtain a license which may involve substantial financial
resources.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">In the future, we may need
to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable
terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We may be required to license technology from third parties to
further develop or commercialize our investigational products. Should we be required to obtain licenses to any third-party technology,
such licenses may not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license
required to develop or commercialize any of our products could cause us to abandon any related efforts, which could seriously harm our
business and operations.<span style="font-weight: bold; font-style: italic">&#160;</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We, or potential collaborators
and licensees, may infringe third-party rights and may become involved in litigation, which may materially harm our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">If a third-party accuses us, our collaborator or a potential collaborator
and licensee of infringing its intellectual property rights or if a third-party commences litigation against us, our collaborator or a
potential collaborator and licensee for the infringement of patent or other intellectual property rights, we may incur significant costs
in obtaining a license or defending such action, whether or not we ultimately prevail. We are aware of U.S. and foreign issued patents
and pending patent applications controlled by third parties that may relate to the areas in which we are developing therapeutic products.
Because all issued patents are entitled to a presumption of validity in many countries, including the United States and many European
countries, issued patents held by others with claims related to products, may limit our freedom to operate unless and until these patents
expire or are declared invalid or unenforceable in a court of applicable jurisdiction, if we do not obtain a license or other right to
practice the claimed inventions. Typically, patent litigation in the pharmaceutical and biotechnology industry is expensive and prolonged.
Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property
litigation to a greater degree and for longer periods of time than we could. Costs that we may incur in defending third-party infringement
actions would also result in the diversion of management&#8217;s and technical personnel&#8217;s time. In addition, parties making claims
against us may be able to obtain injunctive or other equitable relief that could prevent us or our collaborators and licensees from further
developing our discoveries or commercializing our products. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">32</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In the event of a successful claim of infringement against us or
a potential collaborator and licensee, we may be required to pay damages, including treble damages and attorney&#8217;s fees if we are
found to be willfully infringing a third-party&#8217;s patent, or obtain one or more licenses from the prevailing third-party (if not
obtained prior to such litigation), which may not be available to us on commercially reasonable terms, if at all. Even if we were able
to obtain a license, the rights may be nonexclusive, which would give our competitors access to the same intellectual property. If we
are not able to obtain such a license or not able to obtain such a license at a reasonable cost, we could be prevented from commercializing
a product until the relevant patents expired, or we could be forced to redesign our products, or to cease some aspect of our business
operations, and we could encounter delays in product introductions and loss of substantial resources while we attempt to develop alternative
products. Defense of any lawsuit or failure to obtain any such license could prevent us or our partners from commercializing available
products and could cause us to incur substantial expenditures and would divert management&#8217;s attention from our core business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We may become involved in
lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Competitors may infringe, misappropriate or otherwise violate our
patents, trademarks, copyrights or other intellectual property, or those of our licensors. To counter infringement, misappropriation,
unauthorized use or other violations, we may be required to file legal claims, which can be expensive and time consuming and divert the
time and attention of our management and scientific personnel. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We may not be able to prevent, alone or with our licensees or any
future licensees, infringement, misappropriation or other violations of our intellectual property rights, particularly in countries where
the laws may not protect those rights as fully as in the United States. Any claims we assert against perceived infringers could provoke
these parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement or opposition
proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that
we do not have the right to stop the other party from using the invention at issue. In this respect, in October 2020, two parties filed
oppositions in the EPO requesting revocation of our granted European patent relating to anti-PVRIG antibodies, that expires in 2036. We
responded to this opposition in March 2021 and are awaiting a decision on this matter by the EPO. There is also a risk that, even if the
validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right
to stop the other party from using the invention at issue on the grounds that our patents do not cover the invention. An adverse outcome
in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors
and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these
occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert
trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against
whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced
to cease use of such trademarks.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In any infringement, misappropriation or other intellectual property
litigation, any award of monetary damages we receive may not be commercially valuable. Even if we establish infringement, the court may
decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be
an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation,
there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public
announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive
these results to be negative, it could have an adverse effect on our share price. Moreover, there can be no assurance that we will have
sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded.
Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management
and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">33</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Increased progress in our scientific and technological
environment may reduce our chances of obtaining a patent.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In order to obtain a patent to protect one of our therapeutic product candidates,
we must show that the underlying invention (that is, the product candidate itself or its use) is inventive. As an increasing amount of
scientific knowledge is becoming available regarding genes, proteins, biological mechanisms, and the relevance of the genes and proteins
to various clinical indications, the bar is increasingly raised to show sufficient inventiveness, as inventiveness is judged against all
publicly available information available prior to filing of the patent application (the exact date may vary by country or due to other
circumstances). As an increasing amount of scientific knowledge is becoming available for various proteins and their potential use as
drug targets, with time we may be limited or may not be able to obtain patents for our product candidates due to the increased information
published in this area.. Our own published patent applications and other publications also serve as prior art against our new inventions
and patent applications and may prevent us from obtaining new patents.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">We may become subject to claims for remuneration or royalties for
assigned service invention rights by our employees, which could result in litigation and adversely affect our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We enter into assignment of invention agreements with our employees pursuant to which
such individuals agree to assign to us all rights to any inventions created in the scope of their employment or engagement with us. A
significant portion of our intellectual property has been developed by our employees in the course of their employment for us. Under the
Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee due to and during his or her employment with a company
are regarded as &#8220;service inventions&#8221;, which belong to the employer, unless the employee and employer have entered into a specific
agreement stating otherwise, except if the employer waived the service invention within six months of receipt of a notice by the employee
regarding the creation of the service invention (in accordance with provisions of the Patent Law). The Patent Law also provides that if
there is no agreement with respect to whether the employee is entitled to remuneration for his or her service invention, to what extent
and under what conditions, such entitlement and terms shall be determined by the Israeli Compensation and Royalties Committee, or the
Committee, a body constituted under the Patent Law. Decisions by the Committee and Israeli courts have created some uncertainty in this
area. Although our employees have agreed to assign to us service invention rights and have waived any rights for additional compensation
for such service inventions, we may still face claims demanding remuneration in consideration for assigned service inventions. As a consequence
of such claims, we could be required to pay additional remuneration or royalties to our current and/or former employees, or be forced
to litigate such claims, which could negatively affect our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Obtaining and maintaining our patent protection
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent
agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The USPTO and various foreign patent agencies require compliance with a number of
procedural, documentary, fee payment and other provisions to maintain patent applications and issued patents. Noncompliance with these
requirements can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights
in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the
case.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may be subject to claims that we or our
employees or consultants have infringed, misappropriated or otherwise violated the intellectual property of a third-party, or claiming
ownership of what we regard as our own intellectual property.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We may be subject to claims that we or our employees or consultants have inadvertently
or otherwise used or disclosed confidential information of former employers, competitors or other third-parties. We may be further subject
to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing
our product candidates, resulting, among others, in disputes regarding ownership interest in our patents or other intellectual property.
Although we have implemented reasonable measures to ensure that our employees and consultants do not use the intellectual property of
others in their work for us, we may become subject to claims that we caused an employee or consultant to breach, among others, the terms
of his or her non-competition, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged proprietary
information of a former employer, competitor or other third-party.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">34</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">While we may litigate to defend ourselves against these claims, even if we are successful,
litigation could result in substantial costs and could distract the attention of our management. If our defenses to these claims fail,
in addition to requiring us to pay monetary damages, a court could deprive our rights in such technologies or features that are essential
to our investigational products, if such technologies or features are found to incorporate or be derived from the proprietary information
of third-parties and prohibit us from using them. Moreover, any such litigation may adversely affect our ability to form strategic alliances,
engage with scientific advisors or hire employees or consultants.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, while we typically require our employees, consultants and contractors
who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may
be unsuccessful in executing such an agreement with each party who in fact develops intellectual property. To the extent that we fail
to obtain such assignments, or such assignments do not contain a self-executing assignment of intellectual property rights, or such assignments
are breached, we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership
of what we regard as our intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary
damages, we may lose valuable intellectual property rights. Such intellectual property rights could be awarded to a third-party, and we
could be required to obtain a license from such third-party to commercialize our technology or products. Such a license may not be available
on commercially reasonable terms or at all. Even if we are successful in prosecuting or defending against such claims, litigation could
result in substantial costs and be a distraction to our management and scientific personnel.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may become subject to claims challenging
the inventorship or ownership of our patents.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We may be subject to claims that former employees, collaborators or other third parties
have an interest in our patents as co-inventor. The failure to name the proper inventors on a patent application can result in the patents
issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals,
the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations
of third parties involved or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary
to resolve claims challenging inventorship and/or ownership. If we fail in defending any such claims, in addition to paying monetary damages,
we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such
an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation
could result in substantial costs and be a distraction to management and other employees.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Patent
terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Patents have a limited lifespan. In the United States, if all maintenance fees are
timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions
may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates
are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars.
Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such
candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio
may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Intellectual property rights do not necessarily
address all potential threats to our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Once granted, patents may remain open to opposition (as specified above), interference,
re-examination, post-grant review, <span style="font-style: italic">inter partes</span> review, nullification or derivation action in
court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can
raise objections against such grant. In the course of such proceedings, which may continue for a protracted period of time, the patent
owner may be compelled to limit the scope of the allowed or granted claims thus attacked or may lose the allowed or granted claims altogether.
In addition, the degree of future protection afforded by our intellectual property rights is uncertain because even granted intellectual
property rights have limitations and may not adequately protect our business. The following examples are illustrative:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zdd9cc42d5c1f4e32ae633500c9c17f86" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>issued patents that we may own or that we license may be held invalid or unenforceable, as a result of legal challenges; </div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z0cdcb7b367c74e7198926f83b49ae9c8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div>others<span style="font-family: Times New Roman,Times,serif"> may be able to make products that are similar to our products but that
        are not covered by the claims of our patent rights&#894;</span></div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2ac04dde11224528932481419b3143e1" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">we or our licensors or any future strategic
        partners might not have been the first to file patent applications on the inventions covered by the issued patent or pending patent application
        that we own or have exclusively licensed&#894;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">35</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9a637a41a78348a1a881be841f01b9c9" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">others may independently develop similar
        or alternative technologies without infringing our intellectual property rights&#894;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9f6cd1c8eaf144eaa84d82f44a6b0aed" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">it is possible that our pending patent applications
        will not lead to issued patents&#894;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd4e8749beb574ce194169385dd1e9c18" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">issued patents that we may own or that we
        license may not provide us with any competitive advantage;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb1836a117f7145498c1d9f3ec3111d0b" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">our competitors might conduct research and
        development activities in countries where we do not have patent rights and then use the information learned from such activities to develop
        competitive products for sale in our major commercial markets&#894;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za34e745f513d477b926aae3ac0e95421" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">third parties performing manufacturing or
        testing for us using our product candidates or technologies could use the intellectual property of others without obtaining a proper license;</div>
        </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z16ddd05e87f94f29961f304f8f4bfbbe" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">we may not develop additional proprietary
        technologies that are patentable&#894; and</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb84ad25681844f23a9ab21ab037e601f" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">the patents of others may have an adverse
        effect on our business.</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Should any of these events occur, they could have a material adverse effect on our
business, financial condition, results of operations and prospects.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may rely on trade secret and proprietary
know-how which can be difficult to trace and enforce.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to seeking patent protection for some of our technology and investigational
products, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our
competitive position. Trade secrets and know-how can be difficult to protect. Any disclosure, either intentional or unintentional, by
our employees or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities,
or misappropriation by third parties (such as through a security breach) of our trade secrets or proprietary information could enable
competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We require our employees to enter into written employment agreements containing provisions
of confidentiality and obligations to assign to us any inventions generated in the course of their employment. We further seek to protect
our potential trade secrets and proprietary know-how by entering into non-disclosure and confidentiality agreements with any third parties
who are given access to them, including our collaborators, contract manufacturers, consultants, advisors and other third parties. With
our consultants, contractors, and collaborators, these agreements typically include invention assignment obligations. Despite these efforts,
any of these parties may breach the agreements and disclose our proprietary information or assign our inventions to third parties, which
may be difficult to trace, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally
disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we are unable to adequately protect our proprietary know-how and trade secrets,
competitors may be able to develop technologies and resulting discoveries and inventions that are identical, similar to or better than
our own discoveries and inventions, which could materially harm our business, financial condition and results of operations. Costly and
time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade
secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop
our trade secrets and proprietary information, and the existence of&#160;our own trade secrets affords no protection against such independent
discovery.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Risks Related to Operations in Israel </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Conditions in the Middle East and in Israel may adversely affect
our operations. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our headquarters and research and development facilities are located in Israel. Accordingly,
we are directly influenced by the political, economic and military conditions affecting Israel. Specifically, we could be adversely affected
by:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zfd451d8f21a04dc89de83b69768723b9" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">hostilities involving Israel;</div> </td>
        </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc234457c694641c5ba5cb695cbf1408f" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">the interruption or curtailment of trade
        between Israel and its present trading partners;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">36</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z086851c63226402bb6a0584939327b46" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">a downturn in the economic or financial
        condition in Israel; and</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5e4840f22c184fee81bfed15976b9ffb" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">a full or partial mobilization of the reserve
        forces of the Israeli army.</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Since its establishment in 1948, Israel has been subject to a number of armed conflicts
that have taken place between it and its Middle Eastern neighbors. While Israel has entered into peace agreements with both Egypt and
Jordan and has entered into several normalization agreements in 2020 with the United Arab Emirates, Bahrain, Sudan and Morocco, Israel
has no peace or arrangements with any other neighboring or Arab country. Further, all efforts to improve Israel&#8217;s relationship with
the Palestinians have failed to result in a permanent peaceful solution, and there have been numerous periods of hostility as well as
civil insurrection of Palestinians in the West Bank and the Gaza Strip in recent years. Israel is further engaged, from time to time,
in armed conflicts with Hamas (a militia group and political party controlling the Gaza Strip), which in some occasions resulted in missiles
being fired from the Gaza Strip against civilian targets in various parts of Israel, including areas in which our employees are located,
and negatively affected business conditions in Israel. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Also, relations between Israel and Iran continue to be hostile, due to the fact that
Iran is perceived by Israel as sponsor of Hamas and Hezbollah (a&#160;Shia&#160;Islamist&#160;political party and&#160;militant&#160;group
based in&#160;Lebanon), while maintaining a military presence in Syria and Lebanon, and with regard to Iran&#8217;s nuclear program. In
addition, the normalization agreements that Israel has recently entered into with some Arab countries in the Middle East may affect the
geo-political condition in the Middle East in general, and the relations between Israel and Iran in particular. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">All of the above raise a concern as to the stability in the region which may affect
the political and security situation in Israel and therefore could adversely affect our business, financial condition and results of operations.
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Furthermore, certain countries, primarily in the Middle East but also in Malaysia
and Indonesia, as well as certain companies and organizations in different parts of the world, continue to participate in a boycott of
Israeli brands and others doing business with Israel and Israeli companies. The boycott, restrictive laws, policies or practices directed
towards Israel or Israeli businesses could, individually or in the aggregate, have a material adverse effect on our business in the future.
In addition, should the BDS Movement, the movement for boycotting, divesting and sanctioning Israel and Israeli institutions (including
universities) and products become increasingly influential in the United States and Europe, this may also adversely affect our business
and financial condition. Further deterioration of Israel&#8217;s relationship with the Palestinians or countries in the Middle East could
expand the disruption of international trading activities in Israel, may materially and negatively affect our business conditions, could
harm our results of operation and adversely affect the share price of our Company. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our business may also be disturbed by the obligation of personnel to perform military
service. Our employees who are Israeli citizens are generally subject to a periodic obligation to perform reserve military service, until
they reach the age of 40 (or older, for reservists with certain occupations), but during military conflicts, these employees may be called
to active duty for longer periods of time. In response to the increase in violence and terrorist activity in the past years, there have
been periods of significant call-ups for military reservists and it is possible that there will be further military reserve duty call-ups
in the future. In case of further regional instability such employees who may include one or more of our key employees, may be absent
for extended periods of time which may materially adversely affect our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We can give no assurance that the political, economic and security situation in Israel
will not have a material adverse impact on our business in the future.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Furthermore, our Company&#8217;s insurance does not cover any loss arising of events
related to the security situation in the Middle East. While the Israeli government generally covers the reinstatement value of direct
damages caused by acts of war or terror attacks, we cannot be certain that such coverage will be maintained or that it will sufficiently
cover our damages.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our results of operations may be adversely
affected by the exchange rate fluctuations between the dollar and the New Israeli Shekel.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We hold most of our cash, cash equivalents and short-term and long-term bank deposits
in U.S. dollars but incur a significant portion of our expenses, principally salaries and related personnel expenses and administrative
expenses for our Israeli based operations, in NIS. As a result, we are exposed to exchange rate fluctuations between the U.S. dollar and
the NIS, which may have a material adverse effect on our financial condition. In 2021, the U.S. dollar depreciated against the NIS by
3.3%, in 2020 by 7.0% and in 2019 by 7.8%. As a result of these fluctuations, our NIS denominated expenses were affected. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">37</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The dollar cost of our operations in Israel
will increase to the extent increases in the rate of inflation in Israel are not offset by a devaluation of the NIS in relation to the
dollar, which would harm our results of operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Inflation, which increased significantly during 2021, has adversely
affected us by increasing the costs of materials and labor needed to operate our business and could continue to adversely affect us in
future periods. Additionally, since a considerable portion of our expenses such as employees&#8217; salaries are linked to an extent to
the rate of inflation in Israel, the dollar cost of our operations is influenced by the extent to which any increase in the rate of inflation
in Israel is or is not offset by the devaluation of the NIS in relation to the dollar. As a result, we are exposed to the risk that the
NIS, after adjustment for inflation in Israel, will appreciate in relation to the dollar. In that event, the dollar cost of our operations
in Israel will increase and our dollar-measured results of operations will be adversely affected. We cannot predict whether the NIS will
appreciate against the dollar or vice versa in the future. Any increase in the rate of inflation in Israel, unless the increase is offset
on a timely basis by a devaluation of the NIS in relation to the dollar, will increase labor and other costs, which will increase the
dollar cost of our operations in Israel and harm our results of operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We may not be entitled to certain Israeli tax
benefits.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the future, we may be entitled to benefit from certain Israeli government programs
and enjoy certain tax benefits, particularly tax exemptions, resulting from the &#8216;Benefiting Enterprise&#8217; status, or Benefiting
Enterprise, granted to us under the Israel Law for Encouragement of Capital Investments, 1959, or the Investment Law. The availability
of these tax benefits, however, is subject to us meeting certain conditions under the Investment Law, including making specified investments
in fixed assets and equipment. The tax benefits that we anticipate receiving under the &#8220;Benefiting Enterprise&#8221; program may
not be continued in the future at their current levels or at all. To date, we have not actually received any such tax benefits because
we have not yet generated any taxable income.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">It may be difficult to enforce a U.S. judgment
against us, or our officers and directors or to assert U.S. securities law claims in Israel. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are incorporated under the laws of the State of Israel. Service of process upon
our directors and officers, the majority of whom reside outside the United States, may be difficult to obtain within the United States.
Furthermore, because the majority of our assets and investments, and a majority of our directors and officers are located outside the
United States, any judgment obtained in the United States against us or any of them may not be collectible within the United States. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Furthermore, it may be difficult for an investor, or any other person or entity, to
assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged
violation of U.S. securities laws reasoning that Israel is not the most appropriate forum to bring such a claim. In addition, even if
an Israeli court agrees to hear such a claim, it is not certain whether Israeli law or U.S. law will be applicable to the claim. If U.S.
law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses, which can be a time consuming
and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel that
addresses the matters described above.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Provisions of Israeli law may delay, prevent
or make undesirable an acquisition of all or a significant portion of our shares or assets. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Israeli corporate law regulates mergers and acquisitions and requires that a tender
offer be effected when certain thresholds of percentage ownership of voting power in a company are exceeded (subject to certain conditions),
which may have the effect of delaying, preventing or making more difficult a merger with, or acquisition of, us. See &#8220;Item 10. Additional
Information - B. Memorandum and Articles of Association - Change of Control.&#8221; Further, Israeli tax considerations may make potential
transactions undesirable to us or to some of our shareholders whose country of residence does not have a tax treaty with Israel granting
tax relief to such shareholders from Israeli tax. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances
but makes the deferral contingent on the fulfillment of numerous conditions, including a holding period of two years from the date of
the transaction during which certain sales and dispositions of shares of the participating companies are restricted. Moreover, with respect
to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no
actual disposition of the shares has occurred. See &#8220;Item 10. Additional Information &#8211; E. Taxation &#8211; Israeli Taxation.&#8221;
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">38</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">In addition, in accordance with the Restrictive Trade Practices Law, 1988 and under
the Israeli Law for the Encouragement of Industrial Research and Development of 1984 and regulations promulgated thereunder, together,
the R&amp;D Law, approvals regarding a change in control (such as a merger or similar transaction) may be required in certain circumstances.
For more information regarding such required approvals please see &#8220;Item 5. Operating and Financial Review and Prospects- C. Research
and Development, Patents and Licenses - The Israel Innovation Authority.&#8221; In addition, as a corporation incorporated under the laws
of the State of Israel, we are subject to the Israeli Economic Competition Law, 1988 and the regulations promulgated thereunder (formerly
known as the Israeli Antitrust Law, 1988), under which we may be required in certain circumstances to obtain the approval of the Israel
Competition Authority (formerly known as the Israel Antitrust Authority) in order to consummate a merger or a sale of all or substantially
all of our assets. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">These provisions of Israeli law could have the effect of delaying
or preventing a change in control and may make it more difficult for a third-party to acquire us, even if doing so would be beneficial
to our shareholders and may limit the price that investors may be willing to pay in the future for our ordinary shares. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">We received grants from the IIA that may expose
us to payment of royalties and restrict the transfer of know-how that we develop. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We have received governmental grants from the Israeli Innovation
Authority, or the IIA, for the financing of a portion of our research and development expenditures. Even following full repayment of any
IIA grants, and unless agreed otherwise by the applicable authority of the IIA, we must nevertheless continue to comply with the requirements
of the R&amp;D Law with respect to technologies which were financed by such grants, or the Financed Know-How, including an obligation
for repayment of such grants from sales of products based on the Financed Know-How, if and when such sales occur. In addition to the obligation
to pay royalties to the IIA, the R&amp;D Law requires that products which incorporate Financed Know-How be manufactured in Israel and
prohibits the transfer of the Financed Know-How and any right derived therefrom to third parties, unless otherwise approved in advance
by the IIA; Such prior approval may be given by the IIA subject to payment of increased royalties. Although such restrictions do not apply
to the export from Israel of Company&#8217;s products developed with such Financed Know-How, they may prevent us from engaging in transactions
involving the sale, outsource or transfer of such Financed Know-How or of manufacturing activities with respect to any product or technology
based on Financed Know-How, outside of Israel, which might otherwise be beneficial to us. Furthermore, the consideration available to
our shareholders in a transaction involving the transfer outside of Israel of Financed Know-How (such as a merger or similar transaction)
may be reduced by any amounts that we are required to pay to the IIA. For more information regarding such restrictions please see &#8220;Item
5. Operating and Financial Review and Prospects- C. Research and Development, Patents and Licenses - The Israel Innovation Authority.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Being a foreign private issuer exempts us from
certain SEC requirements and Nasdaq rules, which may result in less protection that is afforded to investors under rules applicable to
domestic issuers. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are a &#8220;foreign private issuer&#8221; within the meaning of rules promulgated
by the SEC. As such, we are exempt from certain provisions under the Exchange Act,<span style="font-weight: bold">&#160;</span>applicable
to U.S. public companies, including:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7472db71d0114426bbd795099a7dc02d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q and current reports on Form
        8-K; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z845f7339717e4672a676e49b963dce44" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered
        under the Exchange Act, including extensive disclosure of compensation paid or payable to certain of our highly compensated executives
        as well as disclosure of the compensation determination process; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2a02cbd254f54c84baf1b96e478c7d56" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the provisions of Regulation FD aimed at preventing issuers from making selective disclosures of material information; and </div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z38ec84cf4e274d188bcaf371c733c955" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and establishing
        insider liability for profits realized from any &#8220;short-swing&#8221; trading transaction (a purchase and sale, or sale and purchase,
        of the issuer&#8217;s equity securities within less than six months). </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In addition, we may follow home country corporate governance practices
and law instead of those rules and practices otherwise required by Nasdaq for domestic issuers. For instance, we have relied on the foreign
private issuer exemption with respect to shareholder approval requirements for equity-based incentive plans for our employees. For the
list of specific exemptions that we chose to adopt, please see &#8220;Item 16G - Corporate Governance.&#8221; </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">39</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Following our home country corporate governance practices as opposed
to the requirements that would otherwise apply to a U.S. company listed on Nasdaq may provide less protection to investors than is afforded
to investors under the Nasdaq Listing Rules applicable to domestic issuers. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">We may lose our status as
a foreign private issuer, which would increase our compliance costs and could negatively impact our operations results.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">We may lose our foreign private issuer status if (a) a majority
of our outstanding voting securities are either directly or indirectly owned of record by residents of the United States and (b)(i) a
majority of our executive officers or directors are U.S. citizens or residents, (ii) more than 50% of our assets are located in the United
States or (iii) our business is administered principally in the United States. If we will not be a foreign private issuer, we will be
required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more extensive than
the forms available to a foreign private issuer. We would also be required to follow U.S. proxy disclosure requirements, including the
requirement to disclose, under U.S. law, more detailed information about the compensation of our senior executive officers on an individual
basis. We may also be required to modify certain of our policies to comply with accepted governance practices associated with U.S. domestic
issuers. Such conversion and modifications will involve increased costs. In addition, we would lose our ability to rely upon exemptions
from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers, as described in
the previous risk factor above.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">Our shareholders rights
and responsibilities are governed by Israeli law which differs in some material respects from the rights and responsibilities of shareholders
of U.S. companies.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Because we are incorporated under Israeli law, the rights and responsibilities of
our shareholders are governed by our Articles of Association, as amended from time to time, or Articles, and Israeli law. These rights
and responsibilities differ in some respects from the rights and responsibilities of shareholders in U.S.-based corporations. In particular,
a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising its rights and performing
its obligations towards the company and other shareholders and to refrain from abusing its power in the company, including, among other
things, in voting at the general meeting of shareholders on certain matters, such as an amendment to a company&#8217;s articles of association,
an increase of a company&#8217;s authorized share capital, a merger of a company and approval of interested party transactions that require
shareholder approval. A shareholder also has a general duty to refrain from discriminating against other shareholders. In addition, a
controlling shareholder or a shareholder who knows that it possesses the power to determine the outcome of a shareholders&#8217; vote
or to appoint or prevent the appointment of an office holder in a company or has another power with respect to a company, has a duty to
act in fairness towards such company. Israeli law does not define the substance of this duty of fairness and there is limited case law
available to assist us in understanding the nature of this duty or the implications of these provisions. These provisions may be interpreted
to impose additional obligations and liabilities on our shareholders that are not typically imposed on shareholders of U.S. corporations.
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Risks Related to our Ordinary Shares </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">Future sales of our ordinary
shares or securities convertible or exchangeable for our ordinary shares may depress our share price.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If our existing shareholders or holders of our options or warrants sell, or indicate
an intention to sell, substantial amounts of our ordinary shares in the public market, the trading price of our ordinary shares could
decline. The perception in the market that these sales may occur could also cause the trading price of our ordinary shares to decline.
As of December 31, 2021, we had a total of 86,433,432 ordinary shares outstanding.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Based on the number of shares subject to awards under our 2010 Share Incentive Plan,
as amended, or 2010 Plan, and our 2021 Employee Share Purchase Plan, or ESPP, as of December 31, 2021, 8,591,403 ordinary shares that
are either subject to outstanding options or reserved for future issuance under our 2010 Plan and ESPP were eligible for sale in the public
market, subject to, in the case of shares issued to directors, executive officers and other affiliates, the volume limitations under Rule
144 under the Securities Act. In addition, as of December 31, 2021, we had 297,469 warrants outstanding exercisable into 297,469 ordinary
shares. If these additional ordinary shares are sold, or if it is perceived that they will be sold, in the public market, the trading
price of our ordinary shares could decline.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">40</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">In addition, our directors, executive officers and other affiliates may establish,
and certain executive officers and directors have established, programmed selling plans under Rule 10b5-1 of the Exchange Act, for the
purpose of effecting sales of our ordinary shares. Any sales of securities by these shareholders, or the perception that those sales may
occur, including the entry into such programmed selling plans, could have a material adverse effect on the trading price of our ordinary
shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">If we sell ordinary shares
in future financings, shareholders may experience immediate dilution and, as a result, our share price may decline. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In order to raise additional capital, we may at any time offer additional ordinary
shares or other securities convertible into or exchangeable for our ordinary shares at prices that may not be the same as the price paid
for our ordinary shares by our shareholders. The price per share at which we sell additional ordinary shares, or securities convertible
or exchangeable into ordinary shares, in future transactions may be higher or lower than the price per share paid by our existing shareholders.
If we issue ordinary shares or securities convertible into ordinary shares, our shareholders will experience additional dilution and,
as a result, our share price may decline.<span style="font-weight: bold; font-style: italic">&#160;</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, as opportunities present themselves, we may enter into financing or similar
arrangements in the future, including the issuance of debt securities or ordinary shares with or without additional securities convertible
or exchangeable into ordinary shares. Whether or not we issue additional shares at a discount, any issuance of ordinary shares will, and
any issuance of other equity securities or of options, warrants or other rights to purchase ordinary shares may, result in additional
dilution of the percentage ownership of our shareholders and could cause our share price to decline. New investors could also gain rights,
preference and privileges senior to those of our shareholders, which could cause the price of our ordinary shares to decline. Debt securities
may also contain covenants that restrict our operational flexibility or impose liens or other restrictions on our assets, which could
also cause the price of our ordinary shares to decline.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-style: italic; font-weight: bold">Our share price and trading
volume have been volatile and may be volatile in the future and that could limit investors&#8217; ability to sell our shares at a profit
and could limit our ability to successfully raise funds. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">During the calendar year 2021, our closing share price on Nasdaq has ranged from a
low of $4.09 to a high of $13.77 and trading volume is volatile. The volatile price of our shares and periodic volatile trading volume
may make it difficult for investors to predict the value of their investment, to sell shares at a profit at any given time, or to plan
purchases and sales in advance. A variety of factors may affect the market price of our ordinary shares including:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z16717fa81825402e9172422c413847ac" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>global macroeconomic developments; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zab00093f7a084b39816374d543c73316" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>clinical data disclosed by us or our competitors; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6e94e6c8cf694159a1beb590730b54bf" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>massive sell of our shares by a large shareholder; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ze8ca2012bf594bdd8104540e0e6bfdd8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our success (or lack thereof) in entering into collaboration agreements and achieving certain research and developmental milestones
        thereunder; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5c1ebcb0f7e74626872dbfae2626950b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our need to raise additional capital and our success or failure in doing so; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z203e87753296471680fde311b37bfe02" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our ability (or lack thereof) to disclose key discoveries or developments due to competitive concerns or need to secure our intellectual
        property position;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z00f3f135725b49229e3e5c9737d0e929" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>achievement or denial of regulatory approvals by us or our competitors; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z59383e0fc6f043d9a3424d4b07a8b60f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>announcements of technological innovations or new commercial products by our competitors; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4404ef45ee87402e863db9f34ecb9f8d" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">trends in share price of companies in our
        field or industry;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2abb849edc664aedbd4c385d90923648" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">announcement of corporate transactions,
        merger and acquisition activities or other similar events by companies in our field or industry;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9acebce84eb545bca9082fb98837b6a8" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">changes and developments effecting our field
        or industry;</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7a296cd7b5994404bd0a971c3fd5fdf3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>developments concerning material proprietary rights, including material patents; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9ddc38df99524f7ea598d056adcaa784" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>developments concerning our existing or new collaborations; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7c01117553a1406b932fffa6d6489157" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>regulatory developments in the United States, Israel and other countries; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z09494e4c56d74fbab39c292d0b4cdb0b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>changes in the structure of healthcare payment systems;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">41</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7c96e8a9301a4e37807e814459627310" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>delay or failure by us or our partners in initiating, completing or analyzing preclinical or clinical trials or the unsatisfactory
        design or results of such trials; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb2642febf3f04875aa05392202065def" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>period to period fluctuations in our results of operations; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z45e5ac73aa3d4e209b6218039a5958ef" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>changes in estimates by securities analysts; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zab17ce598e6f4495979f131fd3d54e6e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>changes in senior management or the board of directors or changes in the size or structure of the company; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc59c2aee1bca46e8bbbc29c9ed855ff3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our ability (or lack thereof) to disclose the commercial terms of, or progress under, our collaborations; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zeb98afe95bca41a992046a43af1c6ed8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our ability (or lack thereof) to show and accurately predict revenues; and </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8b7ed03ffcfc4100b4ee985d00ddb00c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>transactions with respect to our ordinary shares by insiders or institutional investors. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are not able to control many of these factors, and we believe that period-to-period
comparisons of our financial results will not necessarily be indicative of our future performance.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In addition, the stock market in general, and the market for biotechnology
companies in particular, have experienced extreme price and volume fluctuations that may be unrelated or disproportionate to the operating
performance of individual companies. These broad market and industry factors may seriously harm the market price of our ordinary shares,
regardless of our operating performance.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Furthermore, the market prices of equity securities of companies
that have a significant presence in Israel may also be affected by the changing security situation in the Middle East and particularly
in Israel. As a result, these companies may experience volatility in their stock prices and/or difficulties in raising additional financing
required to effectively operate and grow their businesses. Thus, market and industry-wide fluctuations and political, economic and military
conditions in the Middle East, but also in the US may adversely affect the trading price of our ordinary shares, regardless of our actual
operating performance.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">As a result of the volatility of our share price, we could be subject
to securities litigation, which could result in substantial costs and divert management&#8217;s attention and company resources from our
business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Our ordinary shares are traded on more than one market and this
may result in price variations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to being traded on The Nasdaq Global Market, our ordinary shares are also
traded on the Tel Aviv Stock Exchange, or TASE. Trading in our ordinary shares on these markets take place in different currencies (U.S.
dollars on Nasdaq and NIS on the TASE), and at different times (resulting from different time zones, trading days and public holidays
in the United States and Israel). The trading prices of our ordinary shares on these two markets may differ due to these and other factors.
Any decrease in the price of our ordinary shares on one market could cause a decrease in the trading price of our ordinary shares on the
other market.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If we are a passive foreign investment company,
or PFIC, <span style="font-family: Times New Roman,Times,serif">our U.S. shareholders may be subject to adverse U.S. federal income tax
consequences. </span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For U.S. federal income tax purposes, we generally will be classified as a PFIC for
any taxable year in which, after the application of certain look-through rules with respect to our subsidiaries, either: (i) 75% or more
of our gross income is passive income or (ii) at least 50% of the average value (determined on the basis of a weighted quarterly average)
of our total assets for the taxable year produce or are held for the production of passive income. For purposes of these tests, passive
income includes dividends, interest, and gains from the sale or exchange of investment property and certain rents and royalties (excluding
rents and royalties that are received from unrelated parties in connection with the active conduct of a trade or business). Assets that
produce or are held for the production of passive income may include cash, even if held as working capital or raised in a public offering,
marketable securities, and other assets that may produce passive income. Generally, in determining whether a non-U.S. corporation is a
PFIC, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as
holding and receiving directly its proportionate share of assets and income of such corporation.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Based on our analysis of our estimated income, estimated assets,
activities and market capitalization, we do not believe that we were a PFIC for the taxable year ended December 31, 2021. However, because
the determination of whether or not we are a PFIC is a fact-intensive determination made on an annual basis and because the applicable
law is subject to varying interpretation, we cannot provide any assurance regarding our PFIC status for the past, current or any future
taxable years. Our U.S. counsel expresses no opinion with respect to our PFIC status for any taxable year. If we are a PFIC for any taxable
year during which a U.S. shareholder holds our shares, U.S. investors may be subject to adverse tax consequences regardless of whether
we continue to qualify as a PFIC, including the treatment of gains realized on the sale of our ordinary shares as ordinary income, rather
than as capital gain, the loss of the preferential rate applicable to dividends received on our ordinary shares by individuals who are
U.S. holders, the addition of interest charges on certain taxes treated as deferred and additional reporting requirements. A U.S. shareholder
of a PFIC generally may mitigate these adverse U.S. federal income tax consequences by making a &#8220;qualified electing fund&#8221;
election, or QEF, or, in some circumstances, a &#8220;mark to market&#8221; election. However, there is no assurance that we will provide
the information required by the IRS in order to enable U.S. holders to make the QEF election. Moreover, there is no assurance that we
will have timely knowledge of our status as a PFIC in the future. Accordingly, U.S. holders may be unable to make a timely QEF election
with respect to our ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">42</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">For further discussion of the PFIC rules and the adverse U.S. federal
income tax consequences in the event we are classified as a PFIC, as well as certain elections that may be available to U.S. shareholders,
see &#8220;Item 10.E. Taxation - Certain Material U.S. Federal Income Tax Considerations&#8221;.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">If we are a controlled foreign corporation,
there could be materially adverse U.S. federal income tax consequences to certain U.S. Holders of our ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Each &#8220;Ten Percent Shareholder&#8221; (as defined below) in
a non-U.S. corporation that is classified as a controlled foreign corporation, or a CFC, for U.S. federal income tax purposes generally
is required to include in income for U.S. federal tax purposes such Ten Percent Shareholder&#8217;s pro rata share of the CFC&#8217;s
&#8216;&#8216;Subpart F income,&#8217;&#8217; global intangible low taxed income, and investment of earnings in U.S. property, by the
CFC, regardless of whether we make any distributions. Subpart F income generally includes dividends, interest, rents, royalties, gains
from the sale of securities and income from certain transactions with related parties. In addition, a Ten Percent Shareholder that realizes
gain from the sale or exchange of shares in a CFC may be required to classify a portion of such gain as dividend income rather than capital
gain. An individual that is a Ten Percent Shareholder with respect to a CFC generally would not be allowed certain tax deductions or foreign
tax credits that would be allowed to a Ten Percent Shareholder that is a U.S. corporation. We cannot provide any assurance that we will
assist investors in determining whether we or any of our future non-U.S. subsidiaries are treated as a CFC or furnish to any U.S. holder
the information required to comply with the reporting and tax-paying obligations discussed above. Failure to comply with these reporting
obligations may subject a Ten Percent Shareholder to significant monetary penalties and may prevent the statute of limitations with respect
to such Ten Percent Shareholder&#8217;s U.S. federal income tax return for the year for which reporting was due from starting.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">A non-U.S. corporation generally will be classified as a CFC for
U.S. federal income tax purposes if Ten Percent Shareholders own, directly or indirectly, more than 50% of either the total combined voting
power of all classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. A &#8220;Ten
Percent Shareholder&#8221; is a United States person (as defined by the Internal Revenue Code of 1986, as amended, or, the Code) who owns
(directly or indirectly) 10% or more of the total combined voting power of all classes of stock entitled to vote or 10% or more of the
total value of all classes of stock of such corporation.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">The determination of CFC status is complex and includes attribution
rules, the application of which is not entirely certain. In addition, changes to the attribution rules relating to the determination of
CFC status may make it difficult to determine our CFC status for any taxable year. Because our group includes at least one U.S. subsidiary
(Compugen USA, Inc.), those changes to the attribution rules may cause any non-U.S. subsidiaries that we form or acquire in the future
to be treated as controlled foreign corporations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Each U.S. holder (as defined in Item 10.E below) should consult
its own tax advisors with respect to the potential adverse U.S. tax consequences of becoming a Ten Percent Shareholder in a CFC. If we
are classified as both a CFC and a PFIC (as defined above), we generally will not be treated as a PFIC with respect to those U.S. holders
that meet the definition of a Ten Percent Shareholder during the period in which we are a CFC.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our ability to use net operating losses to
offset future taxable income may be subject to limitations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As of December 31, 2021, our net operating loss, or NOL, carryforwards or other tax
attributes of our U.S. subsidiary, Compugen USA, Inc., had a federal net operating loss, or NOL, balance of $4.8 million. This NOL carryforward
could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions
under U.S. tax law. Under the Tax Act as modified by the Coronavirus Aid, Relief, and Economic Security Act, Compugen USA, Inc.&#8217;s
federal NOLs incurred in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such
federal NOLs in the tax years beginning after December 31, 2020, may be limited.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">43</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">In addition, under Section 382 of the Code and corresponding provisions of state law,
if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its
equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes
to offset its post-change income or taxes may be limited. It is possible that Compugen USA, Inc. has in the past undergone, and in the
future may undergo, ownership changes that could result in additional limitations on its NOLs.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">Consequently, Compugen USA, Inc. may not be able to utilize a material portion of its NOLs and certain
other tax attributes, which could have a material adverse effect on cash flow and results of operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Shareholder activism can negatively affect our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In recent years, shareholder activists have become involved in
numerous public companies. Shareholder activists could propose to involve themselves in the governance, strategic direction and operations
of a company. We encountered such activism prior to our 2017 annual general shareholders&#8217; meeting, when we received a formal request
from an individual private shareholder, holding approximately 1.3% of the Company&#8217;s voting rights at that time, to add to the agenda
of the meeting the proposed appointment of two new director candidates, both of whom were not recommended by management. This proposal
was rejected by the shareholders at the meeting.&#160;Shareholder activism, including potential proxy contests, divert our management&#8217;s
and board of directors&#8217; attention and resources from our business, could give rise to perceived uncertainties as to our future direction
and could result in the loss of potential business opportunities and make it more difficult to attract and retain qualified personnel
for positions in both management and on the board level and to raise funds. If nominees advanced by activist shareholders are elected
or appointed to our board of directors with a specific agenda, it may adversely affect our ability to effectively and timely implement
our strategic plans or to realize long-term value from our assets. Also, we may be required to incur significant expenses including legal
fees related to activist shareholder matters. Further, our share price could be subject to significant fluctuations or otherwise be adversely
affected by the events, risks and uncertainties of any shareholder activism.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-weight: bold">General Risks </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Environmental, social and governance matters may impact our business
and reputation.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">Increasingly, in addition to the importance of their financial
performance, companies are being judged by their performance on a variety of environmental, social and governance, or ESG, matters, which
are considered to contribute to the long-term sustainability of companies&#8217; performance.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">A variety of organizations measure the performance of companies
on such ESG topics, and the results of these assessments are widely publicized. In addition, investment in funds that specialize in companies
that perform well in such assessments are increasingly popular, and major institutional investors have publicly emphasized the importance
of such ESG measures to their investment decisions. Topics taken into account in such assessments include, among others, the company&#8217;s
efforts and impacts on&#160;climate&#160;change&#160;and human rights, ethics and compliance with law, and the role of the company&#8217;s
board of directors in supervising various sustainability issues. In addition to the topics typically considered in such assessments, in
the healthcare industry, issues of the public&#8217;s ability to access a company&#8217;s medicines are of particular importance.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25">In light of investors&#8217; increased focus on ESG matters, there
can be no certainty that we will manage such issues successfully, or that we will successfully meet society&#8217;s expectations as to
our proper role. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our
business, share price, financial condition, or results of operations, including the sustainability of our business over time.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">44</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-weight: bold">ITEM 4.<span id="ITEM4."><!--Anchor--></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
INFORMATION ON THE COMPANY</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;HISTORY AND DEVELOPMENT
OF THE COMPANY</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">History</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our legal and commercial name is Compugen Ltd. We were incorporated on February 10,
1993, as an Israeli corporation and operate under the Israeli Companies Law, 5759-1999, as amended together with all regulations promulgated
thereunder, or the Companies Law. Our principal offices are located at 26 Harokmim Street, Holon 5885849, Israel, and our telephone number
is +972-3-765-8585. Our web address is <span style="font-style: italic">www.cgen.com</span>. Information contained on our website does
not constitute a part of this Annual Report. The SEC maintains an internet site, http://www.sec.gov that contains reports, proxy and information
statements, and other information regarding issuers that file electronically with the SEC. Neither such internet addresses are a part
of this Annual Report.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our agent for service of process in the United States is Compugen USA, Inc., our wholly
owned U.S. subsidiary located at 395 Oyster Point Blvd., Suite 307 South San Francisco, CA 94080, which was incorporated in Delaware in
March 1997 and is qualified to do business in California. This subsidiary did not have any significant operations from 2008 to March 2012.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="line-height: 1.25; font-weight: bold">Principal Capital Expenditures </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the years ended December 31, 2021, 2020 and 2019, our capital expenditures were
$0.4 million, $0.1 million and $0.2 million, respectively. As of December 31, 2021, we had no significant commitments for capital expenditures.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">B. BUSINESS OVERVIEW</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Summary</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Compugen is a clinical-stage therapeutic discovery and development company utilizing
its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop
therapeutics in the field of cancer immunotherapy. Compugen&#8217;s innovative immuno-oncology pipeline consists of four clinical stage
programs, targeting immune checkpoints Compugen discovered computationally, COM701, COM902, bapotulimab&#160;(formerly known as BAY1905254)
and AZD2936. The Company&#8217;s lead product candidate, COM701, a potential first-in-class anti-PVRIG antibody, for the treatment of
solid tumors, is undergoing Phase 1 clinical trials in&#160;dual,&#160;and triple combinations under clinical collaboration with Bristol
Myers Squibb. COM902 is a potential best-in-class therapeutic antibody targeting TIGIT, developed internally and is undergoing a Phase
1 trial to evaluate it in patients with advanced malignancies as a monotherapy and in combination with COM701. Bapotulimab, an antibody
targeting ILDR2, licensed to Bayer under a research and discovery collaboration and license agreement, is also in Phase 1 trials in patients
with advanced solid tumors. AZD2936 is a novel anti-TIGIT/PD-1 bispecific antibody with a TIGIT component that is derived from Compugen&#8217;s
COM902 program and is developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is in Phase
1/2 trial in patients with advanced or metastatic non-small cell lung cancer. Compugen&#8217;s therapeutic pipeline of early-stage immuno-oncology
programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. The innovative immuno-oncology
pipeline, the strategic collaborations and the Company&#8217;s computational discovery engine serve as the corporate three key building
blocks. Compugen&#8217;s business model is to selectively enter into collaborations for its novel targets and related drug product candidates
at various stages of research and development under various revenue-sharing arrangements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Company is headquartered in Holon, Israel. Its clinical development activities
are headed from our U.S. site in South San Francisco, California.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Our Strategy</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Compugen aims to transform patient lives by developing first-in-class therapeutics
in the field of cancer immunotherapy based on our computational target discovery capabilities. Our pipeline strategy for the development
of first-in-class cancer immunotherapies is differentiated in the competitive landscape of immuno-oncology. It is based on novel targets
and biological pathways discovered by our proprietary predictive computational discovery capabilities and on robust scientific rationale
that we use to guide our drug development process. Our pipeline strategy consists of the following:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zca997d7defd04728847eaea5d7752f8a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>targeting novel pathways, identified internally, with potential to address the unmet need of patients non-responsive to cancer immunotherapies;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z34445fb91d544f8fbba5fa2f55aba179" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>applying a science-driven approach to identify drug combinations, through deep understanding of the biology of these novel pathways;
        and</div> </td> </tr>
  </table> </div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">45</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zfd8b6a9fa4214438a8fa69a6e540347f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>using the same scientific understanding of the new pathways to design a robust biomarker strategy for patient selection.</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">In our therapeutic pipeline, our most advanced programs are:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zfd87fef1cfb5453c8adaa31bae2efdea" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">COM701</span><span style="font-family: Times New Roman,Times,serif"> is our lead immuno-oncology
        pipeline program. COM701 is a humanized antibody that binds with high affinity to PVRIG, a novel immune checkpoint target candidate discovered
        by us that blocks the interaction with its ligand, PVRL2. Our data suggests that the PVRIG pathway is parallel and complementary to TIGIT,
        an immune checkpoint discovered computationally by us in 2009. These two pathways intersect with DNAM-1, a costimulatory receptor on T
        cells and NK cells. The PD-1 pathway also intersects with DNAM-1. In certain tumors, the blockade of both TIGIT and PVRIG may be required
        to stimulate an antitumor immune response, with or without additional PD-1 pathway blockade. Phase 1 trials for COM701 were initiated
        in September 2018 and are currently conducted under the collaboration with Bristol Myers Squibb (except for the COM701 and COM902 combination
        trial). See below additional information regarding Bristol Myers Squibb Collaboration.</span></div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z12f339ecac934001948a4f813c942cd4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div><span style="font-weight: bold">COM902</span><span style="font-family: Times New Roman,Times,serif"> is a high affinity, fully human
        antibody developed by us, targeting TIGIT, an immune checkpoint. COM902 blocks the interaction of TIGIT with PVR, its ligand. Our preclinical
        data suggests that in certain tumor indications the blockage of both TIGIT and PVRIG, two coinhibitory arms of the DNAM-1 axis, may be
        required to stimulate an anti-tumor immune response with or without the blockade of the PD-1 pathway. Phase 1 trials for COM902 were initiated
        in March 2020 to evaluate it as a monotherapy in patients with advanced malignancies who have exhausted all available standard therapies.</span></div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9805d77e87054f4daa6e7ed073c0abbd" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Bapotulimab (formerly known as BAY1905254) is targeting ILDR2, a new immune checkpoint identified by us, that is being developed
        by Bayer pursuant to a research and discovery collaboration and license agreement signed in 2013. Bayer initiated its Phase 1 trial in
        patients with solid tumors in September 2018, which triggered a milestone payment of $7.8 million.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z37f570b4ac0d45228a820f4189e5eee9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>AZD2936 is a novel TIGIT/PD-1 bispecific antibody with a TIGIT component that is derived from our COM902 and is developed pursuant
        to the exclusive license agreement with AstraZeneca. AstraZeneca initiated its Phase 1/2 trial in patients with advanced or metastatic
        non-small cell lung cancer in September 2021, which triggered a milestone payment of $6.0 million to us.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Research Focus - Immuno-Oncology</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our research and development efforts focus on identifying novel drug targets and developing
first-in-class therapeutics in the field of cancer immunotherapy.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Cancer immunotherapies represents a significant commercial market. Sales of therapies
targeting immune checkpoints registered approximately $36 billion worldwide in 2021. Industry analysts estimate that the cancer immunotherapy
market has a significant growth potential and annual sales&#8217; projections of some of $144 billion by 2025.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The immune system is naturally programmed to seek out and destroy abnormal cells.
Cancer is believed to thrive, in part, because of a number of cellular mechanisms that aid in the evasion of immune response. Such mechanisms
of immune system evasion include masking or reducing the expression of tumor antigens to avoid detection, recruiting T-cell suppressor
cells or expressing inhibitory molecules that suppress immune activation, inducing conditions in the tumor microenvironment that promote
tumor cell proliferation and survival, and a number of other factors. Immuno-oncology therapies that overcome immune suppression by stimulating
responses directed to cancer cells are emerging as a powerful means of counteracting the cellular mechanisms that enable the growth and
spread of tumors. Immuno-oncology agents are expanding as a potential path to durable and long-lasting responses in certain patients.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Compugen&#8217;s discovery strategy is focused on the discovery of drug targets addressing
mechanisms of immune resistance and consequently may provide new cancer immunotherapies for patients non-responsive to current cancer
therapies.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">While immunotherapy revolutionized the landscape for oncology treatments by providing
a new treatment option leading to lasting benefits for patients; the response rates to immunotherapy vary greatly across different cancer
indications, averaging only 20 to 30% across all cancer patients thereby leaving a significant unmet medical need for many patients that
may be addressed by the discovery of new biological pathways that could serve for the development of new cancer immunotherapies.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">46</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-weight: bold">Therapeutic Pipeline</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2851b1e09f64406b9b3eb5dd9473f802" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="font-style: italic; font-weight: bold">COM701 - a therapeutic antibody targeting PVRIG</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="margin-left: 36pt; line-height: 1.25; font-style: italic">Pathway expression and preclinical data</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">COM701 is a potentially first-in-class humanized antibody that
binds with high affinity to PVRIG, a novel immune checkpoint target candidate discovered by Compugen, blocking the interaction with its
ligand, PVRL2. Blockade of PVRIG by COM701 has demonstrated potent, reproducible enhancement of T cell activation, consistent with the
desired mechanism of action of activating T cells in the tumor microenvironment to generate anti-tumor immune responses. In addition,
COM701 combined with antagonist anti-PD-1 antibodies has demonstrated synergistic effects in enhancing human T cell stimulation and inhibiting
tumor growth in murine models, indicating an intersection of the PVRIG and PD-1 inhibitory pathways and the potential of these combinations
to further enhance immune response against tumors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">PVRIG and TIGIT constitute parallel immune checkpoint pathways
that interact with DNAM-1, a costimulatory molecule on T cells and NK cells. Preclinical data for COM701 suggest that PVRIG may be a dominant
checkpoint pathway in diverse patient populations with tumors that express elevated PVRL2, the ligand of PVRIG, as compared to expression
of PVR, the ligand of TIGIT. This includes patients with breast, endometrial, and ovarian cancers. In addition, expression studies showed
that PVRIG, TIGIT, and their respective ligands, are expressed in a broad variety of tumor types, such as those noted above, as well as
lung, kidney, colorectal and head &amp; neck cancers. In these tumors the blockade of both TIGIT and PVRIG may be required to stimulate
an anti-tumor immune response, with or without additional PD-1 pathway blockade. COM701 is in a Phase 1 clinical trial in patients with
advanced solid tumors, to evaluate in monotherapy, combination therapy with a PD-1 inhibitor and combination therapy with PD-1 inhibitor
and TIGIT inhibitor.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-style: italic">Clinical Development - Bristol Myers Squibb
Collaboration</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In October 2018, we entered into the MCTC with Bristol Myers Squibb
to evaluate the safety and tolerability of COM701 in combination with Bristol Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>.
In February 2020, the MCTC was amended to include a Phase 1/2 clinical trial, sponsored by Compugen, to evaluate the safety, tolerability
and antitumor activity of COM701 in combination with Opdivo&#174; (nivolumab), and Bristol Myers Squibb&#8217;s investigational antibody
targeting TIGIT known as BMS-986207, in patients with advanced solid tumors. In February 2021, the MCTC was further amended to include
an expansion of the Phase 1 combination trial designed to evaluate the dual combination of COM701 and Opdivo&#174; in patients with advanced
solid tumors and in November 2021 the MCTC was amended again to, among other things, establish a joint steering committee (alongside the
existing joint development committee which acts at an operational level) to facilitate strategic oversight and guidance for the programs
run under the collaboration. See &#8220;Business Strategy and Partnerships - Bristol Myers Squibb Collaboration&#8221; below. Bristol
Myers Squibb supplies Opdivo&#174; for the dual combination portions of the trials in accordance with our collaboration through the completion
of the expansion arms of the trial, as specified below, and supplies both Opdivo&#174; and its investigational antibody targeting TIGIT
known as BMS-986207, for the triple combination trial in accordance with our collaboration, at no cost.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-weight: bold">COM701 Clinical Programs</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In September 2018, we dosed our first patient in the Phase 1 clinical
trial of COM701.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">47</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">A schema of the trial, patient population, key trial objectives
and biomarker strategy are summarized in the chart below:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image00006.jpg" alt="" style="width: 899px; border: black 0px solid; height: 499px" /></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><span style="font-weight: bold">Phase 1 Arm A</span><span style="font-family: Times New Roman,Times,serif">
of the trial evaluated the safety and tolerability and preliminary antitumor activity of COM701 monotherapy. We completed the enrollment
to both the dose escalation and expansion cohorts.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">The patient population enrolled in the dose escalation was all
comers and included patients who have failed prior therapies including other checkpoint inhibitors and have no other available approved
therapies.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">To evaluate the long-term safety and efficacy of COM701 monotherapy,
following the completion of the COM701 monotherapy dose-escalation, we initiated a monotherapy expansion cohorts trial with the enrollment
of patients with relapsed or refractory disease and such tumor types that have been selected based on the preclinical data demonstrating
a high expression of PVRIG and PVRL2 and based on emerging clinical data from the dose-escalation cohorts of the trial. The indications
for the monotherapy expansion cohorts were ovarian, breast, endometrial, colorectal and NSCLC.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In November 2019 we presented initial clinical data from the COM701
monotherapy dose escalation study at the 34<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup> Annual Meeting
of the Society for Immunotherapy of Cancer (SITC 2019), demonstrating that COM701 is well-tolerated through 10 mg/kg IV Q3 weeks with
no dose-limiting toxicities observed. Furthermore, data showed preliminary signs of anti-tumor activity in heavily pretreated patient
population (with a median of seven prior anticancer therapies (range of 2-15)), with best timepoint response of stable disease (SD)/disease
control rate reported in 9 of 13 patients (69%) and with 5 of 6 patients (83%) with CRC microsatellite stable status, with best timepoint
response of stable disease.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><span style="font-weight: bold">Phase 1 Arm B</span><span style="font-family: Times New Roman,Times,serif">
of the trial evaluates the safety and tolerability and preliminary antitumor activity of COM701 in combination with a PD-1 inhibitor.
A patient population with the same eligibility criteria as enrolled for the dose escalation cohorts in Arm A was enrolled for this part
of the trial and enrollment was completed during 2020.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In June 2021, we announced that the first patient in the combination
expansion cohort of this Phase 1 Arm B clinical has been dosed.&#160;The indications for the combination therapy expansion cohort, ovarian,
breast, endometrial and colorectal cancers were selected based on preclinical biomarker assessments and based on emerging clinical data
from the dose-escalation cohorts of the trial.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">48</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In a poster (Abstract #TPS23) titled &#8220;A Phase 1 Study Evaluating
COM701 Monotherapy and in Combination with Nivolumab in Patients With Advanced Solid Malignancies,&#8221; featured at the 2020 ASCO-SITC
Clinical Immuno-Oncology Symposium in Orlando, FL, in February 2020, we reported the following: (i) enrollment in the eighth dose level
patient cohort of 20mg/kg at Q4 weekly dosing schedule is ongoing in the monotherapy dose escalation study; (ii) enrollment in the fourth
dose level patient cohort at Q4 weekly dosing schedule in the combination dose escalation study of COM701 with Opdivo&#174; (nivolumab)
has been completed with no dose-limiting toxicities reported; and (iii) no dose limiting toxicities have been reported in lower dose level
patient cohorts in the monotherapy and combination dose escalation arms.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In April 2020 we presented updated results from our ongoing Phase
1 dose escalation study of COM701 at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting I demonstrating that
COM701 was well-tolerated through 20 mg/kg IV Q4 weeks as a monotherapy and 10 mg/kg IV Q4 weeks in combination with Opdivo&#174;&#160;(480
mg IV Q4 weeks) with no dose-limiting toxicities reported. Furthermore, COM701 demonstrated encouraging signals of anti-tumor activity
with high disease control rate in both the monotherapy and combination therapy arms (69% and 75%, respectively), including two confirmed
partial responses and durable responses of over six months across cohorts, in the heavily pretreated patients enrolled in the study.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In February 2021 we presented updated results from our ongoing
Phase 1 dose escalation study of COM701 as a monotherapy, and in combination with Opdivo&#174; (nivolumab) and our monotherapy cohort
expansion.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Data highlights from the Phase 1 dose escalation studies as of
the data cutoff of December 14, 2020 included:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">COM701 and Opdivo&#174; combination dose escalation arm:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z21fe11f29f414b139919b175f08bd859" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>In 15 patients with a median of five prior anticancer therapies (range of 2-10), COM701 in combination with Opdivo&#174; was well-tolerated
        with no reported dose-limiting toxicities up to the fifth and final dose cohort of COM701 20 mg/kg and Opdivo&#174; 480 mg, both IV Q4
        weeks.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc70f03754fae4ce1abdace69037204df" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>The disease control rate (DCR) was 66.7% (N=10) with best responses of complete response (CR) 6.7% (N=1), partial response (PR) 6.7%
        (N=1) and stable disease (SD) 53.3% (N=8).</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za5417730761744b5bfb2946b180489f6" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>A patient with anal squamous cell carcinoma with confirmed SD as reported at American Association for Cancer Research (AACR) 2020,
        had in the cutoff date confirmed CR and remains on treatment at 79 weeks. This patient progressed on Opdivo&#174; prior to enrolling in
        our study.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7b38e67ec6a44d99b5c0e0c46b592f9e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>A patient with microsatellite stable (MSS)-colorectal cancer with durable confirmed partial response previously reported at AACR
        2020 remained on study treatment at 44 weeks.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zad32999b26dd458f9c15835be2573c11" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Durable responses of confirmed SD of six months or more in three patients. One patient with renal cell carcinoma remains on treatment
        at 58 weeks, and one patient with non-small cell lung cancer (NSCLC) (squamous) who failed prior treatment with immune checkpoint inhibitors
        remained on treatment at 36 weeks, and one patient with endometrial cancer remained on treatment at 46 weeks.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">COM701 monotherapy arm dose escalation update since AACR 2020:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z88883598ce2a42b0bbd4eb37bea89724" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>The patient with primary peritoneal cancer (platinum resistant, MSS) with durable confirmed partial response remains on study treatment
        at 62 weeks.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf1b188e13d2d4f949932d13b44b353ce" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>The patient with pancreatic cancer, refractory to all three prior lines of standard of care (SOC) therapy with durable confirmed
        SD was on study treatment for 31 weeks.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">49</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Data highlights from the monotherapy expansion cohort as of the
data cutoff of December 14, 2020 included:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7ec820b5db0242a7b5449c2ca02fb9af" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>20 patients enrolled in biomarker and data informed indications; four patients of each: endometrial cancer, NSCLC, ovarian cancer,
        breast cancer and colorectal cancer.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z1d804ff37d7f45138fd0169cb8b6a7de" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Six of the 20 patients (30%) had best responses of SD, one patient with endometrial cancer, three patients with NSCLC and two patients
        with ovarian cancer.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zca9b2279070941f88faf49688407009e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Two patients with SD remain on treatment as of the data cutoff date; one patient with NSCLC who had &gt;3 prior lines of SOC therapy;
        including prior treatment with immune checkpoint inhibitors with treatment ongoing at 26 weeks, and one patient with ovarian cancer with
        treatment ongoing at 20 weeks.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zca5ae8203f94413d9114df4bbda3f85d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Two additional patients remain on treatment as of the data cutoff date.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zca0b195e5b224d3491ef0b69927c6106" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>No new safety findings were observed.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In June 2021 we presented updated results from our ongoing Phase
1 study of COM701 as a monotherapy, and in combination with Opdivo&#174; (nivolumab) in an oral presentation at the ASCO 2021 Annual Meeting.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Data highlights as of the data cutoff of April 15, 2021&#160;included:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">COM701 and Opdivo&#174; combination arm dose escalation:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3e9b126cf95c47b9a2d5743137f680f9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>In 15 evaluable patients, COM701 in combination with Opdivo&#174; was well-tolerated with no reported dose-limiting toxicities up
        to the fifth and final dose cohort of COM701 20 mg/kg and Opdivo&#174; 480 mg, both IV Q4 weeks.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z09093cbe200843d58a41d107f26383b2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>The disease control rate (DCR) was 66.7% (N=10) with best responses of complete response (CR) 6.7% (N=1), partial response (PR) 6.7%
        (N=1) and stable disease (SD) 53.3% (N=8).</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zcb79dcf96bdc461f861229d77c966156" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Previously reported patient with anal squamous cell carcinoma with confirmed CR remains on treatment at 96 weeks (22 months). This
        patient had three prior lines of therapy and enrolled within one month after progression on Opdivo&#174; monotherapy.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2a3efd07ccc54074b6aed86f0dd08ee2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Previously reported patient with renal cell carcinoma with best response of SD remains on treatment at 75 weeks.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9573c1329aaf48dd90ef2a0d8bb5d041" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>A patient with microsatellite stable (MSS)-colorectal cancer with durable confirmed partial response previously reported at AACR
        2020 remained on study treatment for 44 weeks.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">COM701 monotherapy arm:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5c1c22ad80e9401ab959c6d2f5a61a44" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Overall 36 patients enrolled. 16 patients, all comers in dose escalation and 20 patients in dose expansion; four patients of each:
        endometrial cancer, NSCLC,&#160;ovarian cancer, breast cancer and colorectal cancer (MSS).</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf075a43980c54646b13c16a2f3bc29a3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>The disease control rate (DCR) was 47.2% (N=17) with best responses of partial response (PR) 2.7% (N=1) and stable disease (SD) 44.4%
        (N=16).</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z878bff7658ea490f9019b70e035a857a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Previously reported patient with primary peritoneal cancer (platinum resistant, MSS) with confirmed PR remains on study treatment
        at 79 weeks (18 months). Patient had three prior lines of standard-of-care treatment.<br /> - Archival pre-treatment biopsy data revealed
        the patient was PD-L1 negative, with PVRL2 expression on tumor and endothelial cells, with an immune desert phenotype (i.e, no immune
        cells detected prior to&#160;treatment).<br /> - Peripheral blood assessment showed immune activation as measured by immune cell proliferation
        and IFN&#947; induction prior to tumor shrinkage.</div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">50</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Demonstrated durable antitumor activity in extensively pretreated
population of both arms together:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf304f91d36b6403faecb266035774adf" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Durable responses to treatment (CR, PR or SD&#160;&#8805;&#160;6 months) in 10/51 (19%) patients.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z91808f9ce2574c74af7255ffa6614f38" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Best responses of CR, PR, or SD were observed in 11/21 (52%) patients with prior treatment refractory disease.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z588905458cea40e7b035f5438e63f1e3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Best response of CR, PR or SD were observed in 13/18 (72%) patients with prior treatment with immune checkpoint inhibitors.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Preliminary biomarker results demonstrate immune activation with
COM701 treatment:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z24cce32bc41440b3b293c7e3e58912ea" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Peripheral pharmacodynamic changes were measured via immune cell proliferation and cytokine levels in peripheral blood before and
        on treatment.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf407bfd2f7f349aba1caa1439db7ae2a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>After one treatment cycle, patients treated with COM701 monotherapy showed a trend of increased proliferation of effector memory
        CD8+ T cells (average change 87%), an immune cell population that expresses high level of PVRIG and are critical in driving anti-tumor
        immunity. Similar results were observed in the combination arm.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5d9c211b9739406a882c8bc4dc41b81c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Proliferation of NK-T cells, an immune cell population that expresses high level of PVRIG and plays a role in antitumor activity,
        increased significantly one day after COM701 monotherapy treatment, with a similar trend observed in the combination arm.</div> </td>
        </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z84cdfa839241405289ac0500b4cada7a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>Levels of IFN&#947;, a cyt<span style="font-family: Times New Roman,Times,serif">okine which plays a key role in antitumor immunity,
        were upregulated following combination treatment of COM701 with Opdivo&#174;, with a dose response trend with increasing doses of COM701,
        suggesting the observed activity is derived from the combination treatment and not Opdivo&#174; alone.</span></div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z62ee3e349435450b8f2a70df72e1d283" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Anti-tumor activity was observed in PD-L1 low, PVRL2 positive patients, suggesting COM701 treatment may drive anti-tumor immunity
        even in patients with less inflamed tumor microenvironment.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><span style="font-weight: bold">Phase 1/2 </span><span style="font-family: Times New Roman,Times,serif">trial
is designed to evaluate the safety, tolerability and antitumor activity of COM701 in combination with Opdivo&#174;&#160;and BMS-986207.
The trial is designed to evaluate a safe and tolerable dose of the combination during dose escalation and antitumor activity in selected
tumor types in the expansion cohorts (ovarian cancer, endometrial cancer, head and neck and a biomarker-driven arm of tumor types with
high expression of PVRL2).&#160;Dose levels for Opdivo&#174;&#160;and BMS-986207 combinations have already been determined through prior
testing by Bristol Myers Squibb, allowing for dose escalation of COM701 with fixed doses of Opdivo&#174;&#160;and BMS&#8209;986207.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In July 2021 we dosed the first patient in this trial and we are
currently enrolling patients.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In November 2021 we presented preliminary results from our ongoing
Phase 1/2 triple combination dose escalation study at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Key findings presented as of the data cutoff of September 3, 2021&#160;included:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc831dc65763e4a9ba5b7f8e605f12d61" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>The study enrolled 13 patients with a variety of advanced solid tumors cancers (all comers) who have exhausted all available standard
        treatments. All the patients received escalating doses of COM701 in combination with fixed doses of nivolumab and BMS-986207.</div> </td>
        </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z96899ece4ca444ca96995cc24a1bc110" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>The study population was heavily pretreated with a median of 10 prior therapies, with a minimum of 1 and maximum of 19.</div> </td>
        </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z74fb468e0eda49b7b92ac26d7a8d3872" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>The combination was well tolerated with no dose limiting toxicity and a favorable safety and toxicity profile.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za46a37c8ac574d1ba339622fabacca53" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>COM701 20 mg/kg was selected as the recommended dose for expansion in combination with nivolumab and BMS-986207 (both at 480 mg)
        with all the study drugs administered IV Q4W.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ze9af250970a14aa19b4dd3cf2fcc14d0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div>Translational assessment of peripheral blood from all patients showed a positive pharmacodynamic activation of the immune system<span style="font-family: Times New Roman,Times,serif">
        following treatment, including increased T and NK cell activation, memory T cell proliferation and IFN&#947; induction, which is supportive
        of immune activation following triplet blockade.</span></div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb140c7bf31404862bc84117b9aab9eaf" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Best responses of stable disease were reported in 3 patients, one patient with prostate cancer remains on study beyond 100 days of
        treatment.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><span style="font-weight: bold">Phase 1 Combination of COM902 with
COM701 </span><span style="font-family: Times New Roman,Times,serif">&#8211; For details please see information below under the header
&#8220;COM902 - a therapeutic antibody targeting TIGIT<span style="font-style: italic">&#8221;.</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">51</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4c6c550341ee458da558a499545a18ec" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="font-style: italic; font-weight: bold">COM902 - a therapeutic antibody targeting TIGIT</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-style: italic">Pathway expression and preclinical data</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">COM902, a high affinity, fully human and a potentially best-in-class
antibody targeting TIGIT, an immune checkpoint is developed by us. COM902 was shown to have superior binding affinity to T cells with
similar and or greater in vitro function compared to several clinical anti-TIGIT antibodies. COM902 is a mouse-cross reactive Ab and inhibited
tumor growth and increased survival when combined with anti-PVRIG or anti-PD-L1 antibodies in in-vivo studies. Preclinical data demonstrated
that TIGIT inhibition, either alone or in combination with other checkpoint inhibitors, can enhance T&#160;cell activation and increase
anti-tumor immune responses. In pre-clinical studies, parallel inhibition of TIGIT and PVRIG, two coinhibitory arms of the DNAM-1 axis,
resulted in synergistic effects on effector T&#160;cell function and tumor growth inhibition in various model systems that can be further
increased with the addition of PD-1 blockade. Based on preclinical data these combinations may be clinically important for enhancing anti-tumor
immune response and expanding the patient population responsive to checkpoint inhibition.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">We discovered TIGIT in 2009 with our immune checkpoint computational
discovery capabilities through which PVRIG was also discovered. The TIGIT discovery was published by us in October 2009 in the Proceedings
of the National Academy of Sciences (PNAS).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Expression studies show that PVRIG and TIGIT, and their respective
ligands, are expressed in a broad variety of tumor types, such as breast, endometrial, ovarian, lung, kidney, and head &amp; neck cancers.
These results indicate that within the same tumor indications there are variations with respect to the possible dominance of the two pathways,
and that in patient populations where the two pathways are operative, the blockade of both TIGIT and PVRIG may be required to sufficiently
stimulate an anti-tumor immune response.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-style: italic">Clinical Development</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In March 2020, we dosed our first patient in the Phase 1 clinical
trial of COM902.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">A schema of the trial, patient population and key trial objectives
are summarized in the chart below:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">52</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-weight: bold">COM902 Clinical Programs</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif"><img src="image00005.jpg" alt="" style="width: 940px; border: black 0px solid; height: 525px" /></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><span style="font-weight: bold">Phase 1 Monotherapy </span><span style="font-family: Times New Roman,Times,serif">trial
evaluates the safety and tolerability of COM902 in patients with advanced malignancies through sequential dose escalations. The patient
population enrolled to the dose escalation cohort is all comers and includes patients who have failed prior therapies including other
checkpoint inhibitors and have no other available approved therapies.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">We completed the monotherapy dose escalation trial, and we are
enrolling patients to the expansion cohort.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In November 2021 we presented preliminary results from Phase 1
dose escalation combination dose escalation study at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Data highlights as of the data cutoff of September 3, 2021&#160;included:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zac54d81d24374b909417cb0bb99ecbfa" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>The study enrolled 18 patients with advanced solid tumors who exhausted all available standard therapies.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9a4c669a35a744dc82af85f19e445b7f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>The study population was heavily pretreated with the median number of prior therapies was 7, with a minimum of 2 and maximum of 16.</div>
        </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc53e2d96b4024521a08991720df30868" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>COM902 administered IV Q3W was well tolerated with a favorable safety profile. A maximum tolerated dose of COM902 was not reached.<br />
        &#160;&#160;&#160;&#160;&#160; o&#160;&#160;&#160; One patient in the 0.01 mg/kg dose cohort reported a dose limiting toxicity (DLT) of
        Grade 2 vomiting, and one patient in the 1 mg/kg dose cohort had a DLT of Grade 3 atrial fibrillation; these were assessed by the investigator
        as possibly related to study treatment with COM902.<br /> &#160;&#160;&#160;&#160;&#160; o&#160;&#160;&#160; No DLTs were reported at
        any other COM902 doses including higher doses (3 mg/kg, 10 mg/kg).</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6167085f28784c8786505fc4355a3f50" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>COM902 3 mg/kg IV Q3W has been selected as the recommended dose for expansion.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9dd8ab945adf4876bfb1307e9a70d92b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Best response of stable disease (SD) was reported in 9 patients (50%), with 6 patients (67%) having confirmed SD and 3 patients (17%)
        with SD of at least 6 months.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb0436ad078124dfeba06eb405dbbab2d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>No depletion of major lymphocyte populations expressing TIGIT (NK, CD4 and CD8 T cells) in the peripheral blood analysis.</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">53</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25"><span style="font-weight: bold">Phase 1 Combination of COM902 with
COM701 </span>i<span style="font-family: Times New Roman,Times,serif">s designed to assess the safety, tolerability and preliminary antitumor
activity of COM902 in combination with COM701 in patients with advanced malignancies during dose escalation and in selected tumor types
in the expansion cohorts (colorectal cancer, non-small cell lung cancer and head and neck). We are now enrolling to the expansion cohorts
of this combination study.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z800e935ea74a43f6bb66b47782e4ed9a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="font-style: italic; font-weight: bold">Bapotulimab (formerly known as BAY1905254) &#8211; a therapeutic antibody targeting
        CGEN-15001T/ILDR2</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Bapotulimab (formerly known as BAY1905254, an antibody to ILDR2
(formerly CGEN-15001T), a novel immune checkpoint target discovered by Compugen, was developed with Bayer pursuant to a research and discovery
collaboration and license agreement signed in August 2013. See &#8220;Business Strategy and Partnerships - Bayer Collaboration&#8221;
below. Studies testing the immune function of ILDR2 demonstrated inhibitory effects on T cells consistent with it being an immune checkpoint
ligand. ILDR2 appears to have a unique mechanism of action relative to other immune checkpoints currently being targeted in clinical testing.
ILDR2 is expressed in lymph nodes, suggesting that bapotulimab&#160;exerts its effects on immune cell priming rather than on directly
enhancing immune cell killing effects in the tumor microenvironment.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In April 2018, Bayer disclosed bapotulimab&#160;(formerly known
as BAY1905254) a human/monkey/mouse cross-reactive antibody blocking the immunosuppressive activity of ILDR2. Bapotulimab has exhibited
anti-tumor activity as a monotherapy in various mouse models and was also shown to have additive anti-tumor effects in combination with
other cancer therapy approaches, indicating the possibility for multiple combination uses in cancer immunotherapy.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">Bapotulimab&#160;<span style="font-family: Times New Roman,Times,serif">is
currently being evaluated in a Phase 1 expansion trial in combination with Keytruda, in head and neck cancer that has returned or is discovered
to be metastatic and is expressing PDL1 to evaluate the combination treatment.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zac6a784b7fa4468ab3b050e90eb97357" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="font-style: italic; font-weight: bold">AZD2936 - a therapeutic TIGIT/PD-1 bispecific antibody with a TIGIT component that
        is derived from our COM902</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">AZD2936 is a novel TIGIT/PD-1 bispecific antibody with a TIGIT
component that is derived from our COM902 being developed by AstraZeneca pursuant to an exclusive license between us and AstraZeneca.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">In March 2018, we <span style="font-family: Times New Roman,Times,serif">entered
into an exclusive license agreement with AstraZeneca, pursuant to which, we granted to AstraZeneca an exclusive license to use our monospecific
antibodies that bind to TIGIT, including COM902, for the development of bi-specific and multi-specific antibody products, excluding such
bi-specific and multi-specific antibodies that also bind to PVRIG, PVRL2 and/or TIGIT.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25">AZD2936 is currently being evaluated by AstraZeneca in a Phase
1/2 trial in patients with advanced or metastatic non-small cell lung cancer.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Biomarker Driven Strategy</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We recognize that one of the major limitations of current immunotherapy approaches
is the lack of tools to help predict patient responses. Through the use of informed biomarker driven strategies, based on the new biological
pathways we discover, we aim to identify biomarkers that can help us predict which patients are most likely to respond to our novel therapies.
This long-term approach also seeks to improve the <span style="font-family: Times New Roman,Times,serif">probability of success of our
clinical studies.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are using three approaches in our biomarker strategy. We are computationally analyzing
omics data to identify tumor indications in which the pathway of our target is elevated. This analysis is thereafter validated experimentally,
and the validated data is used for indication selection for our clinical trials. We used this approach for COM701 to select the tumor
types for inclusion in our cohort expansion studies. Such antitumor activity further supports our biomarker-informed approach and predictive
discovery capabilities.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The second part of our biomarker strategy is the identification of biomarkers for
future patient selection. In this approach we are using different technologies and methodologies on both biopsies, liquid biopsies, and
blood samples. The different technologies include immunohistochemistry, transcriptomic and proteomic analysis. In the immunohistochemistry
analysis, we are currently evaluating the correlation between the expression of the PVRIG pathway with clinical response. The additional
technologies utilized are for other exploratory biomarker identification approaches.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">54</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Thirdly, we have a pharmacodynamic biomarker approach where we measure immune modulation
induced by COM701 and combinations in peripheral and tumor patient samples obtained before and during treatment. In this analysis we measure
both protein and sequence analytics, such as cytokine analysis, immune phenotyping, proteomic changes, transcriptomics analysis, and TCR
clonality.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Early-Stage Pipeline</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Immuno-oncology represents a paradigm shift in the treatment of cancer, and biological
drugs blocking immune checkpoint targets have already resulted in long-term patient survival in certain cancer types. Despite their potential,
current checkpoint inhibitors are limited to a few targets and are only effective in certain patients and in certain cancers. We believe
that the identification of new drug targets and new biological pathways has the potential to broaden the reach of cancer immunotherapies
to more types of cancers and many more patients</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our early-stage programs were discovered using our discovery capabilities and consists
of drug targets with the potential to address mechanisms of immune resistance and consequently may provide new cancer immunotherapies
for patients non-responsive to current cancer therapies. These early-stage programs are addressing a range of mechanisms of immune resistance,
including myeloid biology with an aim to provide new cancer immunotherapies for patients non-responsive to current cancer therapies.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Our Predictive Computational Discovery Approach</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our target discovery is a predictive, proprietary computational process that we initiate
based on a clinical need. <span style="font-family: Times New Roman,Times,serif">The unmet clinical need and the therapeutic strategy
dictate the target discovery approach, the appropriate tools and most relevant data to be employed. We have developed predictive drug
target discovery capabilities that leverage the power of computational modeling, guided by our scientific expertise and extensive public
and proprietary datasets, to identify novel drug targets and new biological pathways towards the development of new cancer immunotherapy
treatments. Our multi-omics data analysis is designed to identify first-in-class drug target candidates, which are generally difficult
to identify using traditional experimental approaches.&#160;We believe that our computational approach integrated with robust experimental
validation is a key differentiator from others employing computational discovery approaches.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our broadly applicable predictive drug target discovery capabilities employ a suite
of cloud-based computational solutions and purpose-built algorithms to sort through both public and proprietary datasets encompassing
genomics, transcriptomics, and proteomics data. From these massive datasets, our platforms analyze characteristics, such as gene structure,
protein domains, predicted cellular localization, expression pattern, as well as other characteristics to identify potential druggable
targets and predict their biological functions. Over the past decade, we have continued to refine our analysis by incorporating new public
and in-house experimental data. While our initial focus is on discovering novel immune checkpoints, we are also working to identify myeloid
targets contributing to the immunosuppressive tumor microenvironment as well as pathways driving drug resistance.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have demonstrated the applicability of our discovery approach in computationally
identifying multiple in-silico targets, including&#160;PVRIG,&#160;TIGIT&#160;and&#160;ILDR2, which now serve as the targets for therapeutic
antibodies currently being evaluated in the clinic by us and others. The antibodies designed to block these targets &#8211; COM701, COM902
and bapotulimab&#160;(formerly known as BAY1905254) (together with AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody with a TIGIT component
that is derived from our COM902 and developed by AstraZeneca) are being tested in Phase 1 studies.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Business Strategy and Partnerships</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our business strategy includes entering into various forms of revenue-sharing collaborations
with pharmaceutical or biotechnology partners for our product candidates in our pipeline at both early and later stages of development.
Through these collaborations we seek to create, further develop and commercialize therapeutic product candidates directed to our novel
drug targets. Such collaborations or other types of partnering arrangements might include one or more of our <span style="font-family: Times New Roman,Times,serif">therapeutic
pipeline programs, including our novel early-stage candidates, as well as our clinical candidates COM701 and COM902. Additionally, our
discovery capabilities are designed to allow for research and discovery collaborations aimed at harnessing our capabilities towards a
potential partner&#8217;s pipeline needs. Potential revenue sources in line with this business model could include upfront fees, research
funding, in-kind funding, milestones payments, license fees, royalties and other revenue sharing payments. We may also seek co-development
arrangements pursuant to which we would further advance partnered programs under any such partnership in order to retain higher share
from future sales revenues.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">55</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Bayer Collaboration</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On August 5, 2013, we entered into a collaboration with Bayer, or the Bayer Collaboration,
for the research, development, and commercialization of antibody-based therapeutics against two novel Compugen-discovered immune checkpoint
regulators, CGEN 15001T/ILDR2 and CGEN 15022.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the terms of the Bayer Collaboration, we received an upfront payment of $10
million, and, following the return of the CGEN 15022 program to us, we are eligible to receive an aggregate of over $250 million in potential
milestone payments for bapotulimab&#160;(formerly known as BAY1905254) (an antibody against CGEN 15001T/ILDR2), not including aggregate
milestone payments of approximately $23 million received to date. Additionally, we are eligible to receive mid-to-high single digit royalties
on global net sales of any approved products under the collaboration. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In 2014, we achieved the first and second preclinical milestones and in 2015 we achieved
the third preclinical milestone with respect to bapotulimab. Pursuant to the terms of the Bayer Collaboration, this program was transferred
to Bayer&#8217;s full control for further preclinical and clinical development activities, and worldwide commercialization under milestone
and royalty bearing licenses from us. In September 2018, the program achieved the fourth milestone, following the dosing of the first
patient in the Phase 1 clinical trial of bapotulimab.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Bayer Collaboration continues until Bayer is no longer required to make payments
under the Agreement or until otherwise terminated by either party in accordance with the terms of the Agreement. Bayer may also terminate
the Bayer Collaboration, either in whole or only with respect to one of the programs, and in each case also on a product-by-product and/or
country-by country basis, at any time without cause, upon prior written notice. Either party may also terminate the Bayer Collaboration,
either in whole or with respect to only one of the programs, if the other party is in material breach and such breach has not been cured
within the applicable cure period. Upon any termination of the Agreement, depending upon the circumstances, the parties have varying rights
and obligations with respect to the continued development and commercialization of any products and certain payment and royalty obligations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Bristol Myers Squibb Collaboration</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On October 10, 2018, we entered into a master clinical trial collaboration agreement,
or the MCTC, with Bristol Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol Myers Squibb&#8217;s
PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The collaboration was also designed to address potential future combinations, including
trials to investigate combined inhibition of checkpoint mechanisms. The clinical combination of multiple immune checkpoint inhibition
is designed to clinically test the synergistic activity demonstrated in preclinical models. The parties agreed that Bristol Myers Squibb
and Compugen will each supply the other company with its own compound for the other party&#8217;s study, and otherwise each party will
be responsible for all costs associated with the study that it is conducting. Any combination trial performed under this agreement is
referred to as a Combined Therapy Study.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On February 14, 2020, the MCTC was amended to include a triple combination clinical
trial to evaluate the safety, tolerability and antitumor activity of COM701 in combination with Opdivo&#174; (nivolumab), and Bristol
Myers Squibb&#8217;s investigational antibody targeting TIGIT known as BMS-986207, in patients with advanced solid tumors, instead of
the planned expansion of the combined therapy study designed to evaluate the dual combination of COM701 and Opdivo&#174;.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Pursuant to the MCTC, as amended, we sponsor the two-part Phase 1/2 trial, which evaluates
the triple combination of COM701, Opdivo&#174; and BMS-986207, in patients with advanced solid tumors where Bristol Myers Squibb provides
Opdivo&#174; and BMS-986207 at no cost to us.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As part of the amended MCTC, it was agreed that we will complete the dose escalation
arm of the dual combination of COM701 with Opdivo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>
under the ongoing Phase 1 study and will not continue the expansion cohorts of the dual combination. However, on February 19, 2021, such
MCTC was further amended to include an expansion of the Phase 1 combination study designed to evaluate the dual combination of COM701
and Opdivo&#174; in patients with advanced solid tumors, where we are responsible for and sponsor the expansion cohort and Bristol Myers
Squibb provides Opdivo&#174; at no cost to us for this study. The amendment also revised the exclusivity period granted to Bristol Myers
Squibb to include a specific date for termination of the exclusivity period, so that it ends at the earlier of (i) six months after the
study completion of the triple combination and the dual combination; or (ii) December 31, 2023.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">56</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">In November 2021 the MCTC was further amended to, among other things, establish a
joint steering committee (alongside the existing joint development committee which acts at an operational level) to facilitate strategic
oversight and guidance for the programs run under the collaboration.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Ownership of, and global commercial rights to, COM701 remain solely with us under
the MCTC (subject to the rights granted to Bristol Myers Squibb). If we wish to license the right to commercialize COM701 in any territory
during the time prior to the end of the exclusivity period specified above, we must first negotiate with Bristol Myers Squibb for a period
of three months, or the Negotiation Period, to grant an exclusive license to develop and commercialize COM701 in that territory. If we
and Bristol Myers Squibb do not reach an agreement for an exclusive license within the Negotiation Period, then Bristol Myers Squibb will
have no further first negotiation rights, and we will be free to license COM701 (subject to all other rights afforded to Bristol Myers
Squibb under the MCTC) to other parties, in such territory. After the expiration of the exclusivity period specified above, we are free
to license COM701 without any further obligation to Bristol Myers Squibb.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The MCTC also contains certain exclusivity provisions that run through the said exclusivity
period. We agreed not to conduct any preclinical or clinical research with, or grant rights to, certain restricted third parties regarding
the combination of an anti-PD-1 antagonist or anti-PD-L1 antagonist together with COM701. We remain free to conduct any preclinical or
clinical research involving such restricted combination on our own or in collaboration with academic or other non-profit entities.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Subject to termination rights for breach, bankruptcy or a material safety issue or
clinical hold, the term of the MCTC will continue in effect until completion by all centers or institutions participating in the combination
studies above, the delivery of study data to both parties and the completion of any then agreed upon protocol(s), statistical analysis
and bioanalysis plan. In the event a third-party merges with or acquires us, we are free to assign or transfer the Agreement without the
consent of Bristol Myers Squibb.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In conjunction with the signing of the MCTC in October 2018, Bristol Myers Squibb
made a $12&#160;million investment in us, purchasing 2,424,243 of our ordinary shares at a purchase price of $4.95 per share. The share
price represented a 33% premium over the average closing price of our ordinary shares for twenty (20) Nasdaq trading days prior to the
execution of the securities purchase agreement.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In conjunction with the signing the amendment to the MCTC in November 2021, Bristol
Myers Squibb made a $20 million investment in us, purchasing 2,332,815 of our ordinary shares at a purchase price of $8.57333 per share.
The share price represented a 33% premium over the closing price of our ordinary shares on the last trading day immediately prior to the
execution of the securities purchase agreement.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Please see &#8220;Item 5. Operating and Financial Review and Prospects Finance - B.
Liquidity and Capital Resources.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">AstraZeneca License</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In March 2018, we entered into an exclusive license agreement with AstraZeneca, to
enable the development of bi-specific and multi-specific immuno-oncology antibody products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the terms of the license agreement, we granted an exclusive license to AstraZeneca
to use our monospecific antibodies that bind to TIGIT, including COM902, for the development of bi-specific and multi-specific antibody
products, excluding such bi-specific and multi-specific antibodies that also bind to PVRIG, PVRL2 and/or TIGIT. AstraZeneca has the right
to create multiple products under this license and will be solely responsible for all research, development and commercial activities
under the agreement. In connection with such license agreement, AstraZeneca developed AZD2936, a novel TIGIT/PD-1 bispecific antibody
with a TIGIT component that is derived from our COM902 and entered the clinic in September 2021.We received a $10&#160;million upfront
payment and are eligible to receive up to $200 million in development, regulatory and commercial milestones for the first product as well
as tiered royalties on future product sales, out of which we accrued $2 million in 2020 as a preclinical milestone and $6 million in 2021
as a clinical milestone (triggered by the dosing of the first patient in a Phase 1/2 trial evaluating AZD2936). If additional products
are developed, additional milestones and royalties would be due to us for each product. We retained all other rights to our entire pipeline
of programs as monotherapies and in combination with other products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">57</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Subject to termination rights for material breach, bankruptcy or by us for patent
challenge by AstraZeneca, the term of the license agreement continues until the expiration of the last Royalty Term in the Territory,
each as defined in the license agreement. In addition, AstraZeneca may terminate the agreement for convenience upon prior written notice.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Main Academic Collaboration</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We also advance our pipeline through academic collaborations with leading researchers
and key opinion leaders in the field of immuno-oncology. Our current main academic collaboration is with Johns Hopkins University, School
of Medicine.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The collaboration focuses on the evaluation of novel T cell and myeloid checkpoint
targets identified by us for the potential treatment of cancer. The scope of the collaboration includes identifying differentiating features
of our novel targets relative to known immuno-oncology targets, and the therapeutic potential of drugs modulating the activity of those
novel drug targets. Research is conducted under the leadership of Drew Pardoll, M.D., Ph.D., Abeloff Professor of Oncology, Medicine,
Pathology, and Molecular Biology and Genetics at Johns Hopkins University, School of Medicine, and Director of the Bloomberg~Kimmel Institute
for Cancer Immunotherapy and Co-Director of the Cancer Immunology Program at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins,
and Chairman of our Scientific Advisory Board.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In May 2021, we announced an expansion to our research collaboration with Johns Hopkins
University to include studies investigating the biology of a specific novel myeloid target that was computationally-discovered by us,
with initial preclinical studies demonstrating the potential of this target to serve as a novel myeloid immunomodulator, with significant
tumor growth inhibition observed upon genetic deletion in&#160;in-vivo&#160;studies.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The research program is expected to explore the biological function and mechanism
of this novel target, which is expressed on myeloid cells and macrophages in various cancers. The expanded research plan is intended to
further evaluate and validate the role of the target in various tumors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Competition</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The biotechnology and pharmaceutical industries are highly competitive and characterized
by the rapid evolution of new technologies and the adoption of new therapies. Additionally, the oncology therapeutic space, and in particular
the immuno-oncology or cancer immunotherapy subsector, represents the therapeutic area with, what we believe to be one of the highest
industry focus and investment. In addition, in recent years, computational approaches and systems are being integrated into multiple life
science aspects, including the formation of new companies focusing on computational drug target discovery. Our competitors include biotechnology
and pharmaceutical companies both small and large, the research and discovery groups within pharmaceutical companies, computational discovery
and development companies, academic and research institutions, newly founded companies and governmental and other publicly funded agencies.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Any product candidates that we successfully develop will compete with currently approved
therapies and new therapies that may become available in the future. We face, and expect to continue to face, ongoing competition from
entities that discover novel targets and develop novel products, and that have therapeutic product candidates or products that address
the same drug targets or act by similar, or possibly identical, mechanism of action (MOA) as well as by different mechanisms but address
the same drug target or unmet clinical need. Our potential competitors are also comprised of companies that discover and develop monoclonal
antibody therapies and/or therapeutic proteins to novel targets, and/or cell therapies for oncology diseases. Specifically, in the field
of immune checkpoints and myeloid drug targets for cancer immunotherapy, there are several leading pharmaceutical and biotechnology companies
as well as smaller biotechnology companies and academic institutions that are developing cancer immunotherapies to enhance immune response
towards tumors, some of which may be based on the same targets we have discovered. For example, there are a significant number of anti-TIGIT
antibodies that are currently in advanced clinical studies such as tiragolumab by Roche, vibostolumab by Merck, ociperlimab by Beigene,
domvanalimab and AB308 by Arcus, BMS-986207 by Bristol Myers Squibb, and others at earlier stages in development. In addition, GSK/Surface
Oncology are developing the PVRIG targeting antibody GSK4381562 (formerly SRF813) and Junshi Biosciences lists an anti-PVRIG antibody
(JS009) and a TIGITxPVRIG bispecific (JS209) in its pipeline. If approved, such cancer immunotherapy products would compete with our product
candidates for commercialization or approved products in the respective fields. If in development stage, such cancer immunotherapy products
would compete with our product candidates for entering into strategic partnerships with pharmaceutical and biotechnology companies which
form the basis of our business model.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">58</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Our discovery program depends, in large part, on our discovery capabilities and other
capabilities and our proprietary data to make inventions and establish intellectual property rights in protein-based products, including
proteins and antibodies. There are additional companies exploring computational approaches and systems for drug target discovery and number
of other means by which such inventions and intellectual property can be generated. We believe that our computational capabilities, and
specifically our predictive computational discovery capabilities, provide us with a competitive advantage in predicting new protein functions
and linking proteins to specific diseases, and as a result, predicting new drug targets. We believe that this advantage is made possible
by building an infrastructure for predictive discovery based on the integration of scientific understanding and predictive models as well
as our unique team of multidisciplinary research scientists, who have vast experience in computational discovery, including developing
and handling such data analysis approaches, and who over time discovered three drug targets that are now in clinical studies and have
generated dozens of peer reviewed publications of certain of our findings and capabilities in scientific journals.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Many of our potential competitors, either alone or with their collaborative partners,
have substantially greater financial, technical and human resources than we do and significantly greater experience in computational approaches
and the discovery, development and manufacturing of therapeutics, obtaining FDA and other regulatory approvals, and commercialization
of products. Accordingly, our competitors may be more successful than we may be in identifying new drug targets and product candidates,
protecting them with patent applications, developing them, accelerating their development process, obtaining FDA and other regulatory&#160;approvals
and achieving widespread market acceptance. We anticipate that we will face intense and increasing competition as advanced technologies
or new therapy modalities become available.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Intellectual Property Rights </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our intellectual property assets are our principal assets. These assets include the
intellectual property rights subsisting in our proprietary know-how and trade secrets underlying our predictive biology capabilities and
discovery capabilities, our patents and patent applications, particularly with respect to our discovered proteins, therapeutic and diagnostic
product candidates. We seek to vigorously protect our rights and interests in our intellectual property. We expect that our commercial
success will depend on, among other things, our ability to obtain commercially valuable patents, especially for our therapeutic and diagnostic
product candidates, maintain the confidentiality of our proprietary know-how and trade secrets, and otherwise protect our intellectual
property. We design our patent strategy to fit the business competitive landscape and continual legislative changes. In addition, we periodically
analyze and examine our patent portfolio to align it with our pipeline strategy and business needs. We seek patent protection for certain
promising inventions that relate to our therapeutic and diagnostic product candidates. As of February 1, 2022, we had a total of 50 issued
and allowed patents, of which 15 are U.S. patents, 10 are European patents and additional 25 patents in other territories. Our issued
and allowed patents expire between 2028 and 2037. As of February 1, 2022, we had over 179 pending patent applications that have been filed
in the United States, Europe and in other territories as well as pending patent applications that have been filed under the Patent Cooperation
Treaty for which we have not yet designated the countries of filing. The patents issued in the U.S. and Europe for COM701 and COM902 were
issued between 2017 and 2021 and should expire no earlier than 2036. These patents include issued claims directed to, among others, the
composition of these product candidates and/or methods of using the same to treat cancer by activating T cells and/or NK cells, and/or
combinations of our product candidates with other checkpoint inhibitors. Our general policy is to continue patent filings and maintenance
for our therapeutic and diagnostic product candidates, only with respect to candidates or programs that are being actively pursued internally
or with partners, or that we believe to have future commercial value. We routinely abandon patent applications and may choose to abandon
maintenance of patents supporting candidates or programs that do not meet these criteria.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We also seek protection for our proprietary know-how and trade secrets that are not
protectable or protected by patents, by way of safeguarding them against unauthorized disclosure. This is done through the extensive use
of confidentiality agreements and assignment agreements with our employees, consultants and third parties as well as by technological
means. We use license agreements both to access third-party technologies and to grant licenses to third parties to exploit our intellectual
property rights.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In October 2020, two parties filed oppositions in the EPO requesting revocation of
our granted European patent relating to anti-PVRIG antibodies, that expires in 2036. We responded to this opposition in March 2021 and
are awaiting a decision on this matter by the EPO.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">59</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-weight: bold">Manufacturing </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We currently rely on contract manufacturers or our collaborative partners to produce
and control materials, drug substances and drug products required for our research and development activities. <span style="font-family: Times New Roman,Times,serif">We
do not currently own or operate manufacturing facilities for the production of clinical or commercial quantities of our therapeutic drug
candidates. We do not have, and we do not currently plan to acquire or develop the facilities or capabilities to manufacture bulk drug
substance or filled drug product for use in human clinical trials. We rely on CMOs, advisors and third-party contractors to generate formulations
and produce small scale and larger scale amounts of GLP, cGMP clinical and commercial drug substance and the drug product required for
our clinical trials for the foreseeable future. We also contract with CMOs and third-party contractors for the labeling, packaging, storage
and distribution of investigational drug products.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We entered into agreements with certain CMOs for the manufacturing and respective
analytics of COM701 and COM902. Our manufacturing strategy is currently structured to support the current clinical development of COM701
and COM902. Although we believe the general manufacturing strategy developed for the United States will be applicable in other geographies,
specific strategies for other geographies will be developed as part of our clinical and commercial plans for such other geographies. See
&#8220;Item 3. Key Information - D. Risk Factors - Risks Related to Our Dependence on Third Parties - We rely and expect to continue to
rely completely on third parties to manufacture and supply preclinical and clinical drug supplies. Our business could be harmed if those
third parties fail to provide us with sufficient quantities of drug product or fail to do so at acceptable quality and quantity levels,
prices or timelines.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">Government Regulation</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Regulation of Therapeutic Product Candidates </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the United States, the FDA regulates pharmaceutical and biologic products under
the Federal Food, Drug, and Cosmetic Act, or FDCA, the&#160;Public Health Service Act, other statutes and regulations and implementing
regulations. We anticipate that our product candidates will be regulated as biologics. The process of obtaining regulatory approvals and
the subsequent compliance with applicable federal, state and local statutes and regulations require the expenditure of substantial time
and financial resources. Failure to comply with the applicable United States requirements at any time during the product development process,
approval process or after approval, may subject an applicant to administrative or judicial sanctions. The process required by the FDA
before a biologic may be marketed in the United States generally involves the following:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3818f20c44e043ebb4920e710d4898b0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>completion of preclinical laboratory tests and animal studies in compliance with the FDA&#8217;s GLP or other applicable regulations;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9e4ab1132b424ec78b0a62e7a395276c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>submission to the FDA of an IND, which must become effective before human clinical trials may begin; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9b2b43f15ee148eeb35461e96c639c9e" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>performance of adequate and well-controlled human clinical trials in accordance with GCPs to establish the safety and efficacy of
        the product for its intended use; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4f9201398cc44ebebf48604e84103a62" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>submission of annual reports to regulatory authorities; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb093809ceb754b2d8ba315790175ea23" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>submission to the FDA of a biologics license application, or BLA; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z0f2a2ebca8f84c9b84321239d53b63e9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug or biologic is produced
        to assess compliance with current Good Manufacturing Practice, or cGMP, to assure that the facilities, methods and controls are adequate
        to preserve the product&#8217;s identity, strength, quality and purity; and </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ze8a63ee742214612810ed4664e7f737b" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>FDA review and approval of the BLA. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Once a pharmaceutical candidate is identified for development it enters the preclinical
testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies.
An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, among other
information, to the FDA as part of the IND. The sponsor will also include a clinical protocol detailing, among other things, the objectives
of the first phase of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated,
if the first phase lends itself to an efficacy evaluation. The IND automatically becomes effective 30 days after receipt by the FDA, unless
the FDA, within the 30-day time period, places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must
resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before
or during a clinical trial due to, among other things, safety concerns or non-compliance with applicable requirements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">60</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">All clinical trials must be conducted under the supervision of one or more qualified
investigators in accordance with GCPs. An IRB at each institution participating in the clinical trial must review and approve the study
plan for any clinical trial before it commences at that institution. An IRB considers, among other things, whether the risks to individuals
participating in the trials are minimized and are reasonable in relation to anticipated benefits. The IRB also reviews the information
regarding the trial, participant recruiting materials and the informed consent form that must be provided to each trial subject or his
or her legal representative <span style="font-family: Times New Roman,Times,serif">before participating in the trial. In addition, the
IRB will monitor the trial until completed.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Each new clinical protocol must be submitted to the FDA, and to the IRBs. Protocols
detail, among other things, the objectives of the study, dosing procedures, subject selection and exclusion criteria, and the parameters
to be used to monitor subject safety and determine efficacy.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Human clinical trials are typically conducted in three sequential phases that may
overlap or be combined:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd0a3243635234709bc892a43b25837ca" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="font-style: italic">Phase 1:
        </span>The product candidate is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption,
        metabolism, distribution and excretion. In the case of<span style="font-style: italic">&#160;</span>some products, usually for severe
        or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the
        initial human testing may be conducted in patients.</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7cdd5fddbb214c33b85755ff8d00e580" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="font-style: italic">Phase 2:
        </span>Involves studies in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate
        the efficacy of the product for specific<span style="font-style: italic">&#160;</span>targeted diseases and to determine dosage tolerance
        and optimal dosage.</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4eb80c46adcd4a98a7f85f559193987a" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 13pt">&#160;</td>
    <td style="vertical-align: top; width: 13pt">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8226;</div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="font-style: italic">Phase 3:
        </span>Involves studies undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically
        dispersed clinical trial sites.<span style="font-style: italic">&#160;</span>These studies are intended to establish the overall risk-benefit
        ratio of the product and provide an adequate basis for product labeling and approval.</div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Progress reports detailing the results of the clinical trials must be submitted at
least annually to the FDA and safety reports for serious and unexpected adverse events<span style="font-family: Times New Roman,Times,serif">
must be submitted to the FDA and the investigators more frequently. The FDA or the sponsor may suspend or terminate a clinical trial at
any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk.
Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted
in accordance with the applicable regulations or IRB requirements or if the drug has been associated with unexpected serious harm to patients.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Concurrent with clinical trials, companies usually complete additional nonclinical
studies and must also finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements.
The manufacturing process must be capable of consistently producing quality batches of the product within required specifications and,
among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the product. Additionally,
appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product does not undergo
unacceptable deterioration over its shelf life.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic">United States Review and Approval Processes</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The results of product development, nonclinical studies and clinical trials, along
with descriptions of the manufacturing process, analytical tests, proposed labeling, and other relevant information are submitted to the
FDA as part of a BLA requesting approval to market the product for one or more indications. The FDA initially reviews all BLAs submitted
to ensure that they are sufficiently complete for substantive review before it accepts them for filing. The FDA may request additional
information rather than accept a BLA for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review.
The FDA may refer the BLA to an advisory committee for review, evaluation and recommendation as to whether the application should be approved
and under what conditions. The FDA is not bound by the recommendation of an advisory committee.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">61</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">The review process is lengthy, and the FDA may issue a complete response letter rather
than approve a BLA if the applicable regulatory criteria are not satisfied or may require the submission of additional clinical or other
data and information. Even if such data and information are submitted, the FDA may ultimately decide that the BLA does not satisfy the
criteria for approval.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If a product receives regulatory approval, the approval will be limited to specific
diseases and dosages or the approved indications for use may otherwise be limited, which could restrict the commercial value of the product.
In addition, the FDA may require a company to conduct post-approval testing and clinical trials, to further assess a product&#8217;s safety
and effectiveness after BLA approval and may require testing and surveillance programs to monitor the safety of approved products which
have been commercialized including Risk Evaluation and Mitigation Strategy (REMS) programs to ensure that the benefits of a product outweigh
its risks.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic">Post-approval Requirements</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Approved biologics are subject to extensive and continuing regulation by the FDA,
including, among other things, cGMP compliance, record-keeping requirements, reporting of adverse experiences, providing the FDA with
updated safety and efficacy information, and complying with FDA promotion and advertising requirements. After an approval is granted,
the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if serious problems occur after the
product reaches the market. Biologics may be promoted for use only for the approved indication or indications and in accordance with the
provisions of the approved label. The FDA and other federal and state agencies actively enforce the laws and regulations prohibiting the
promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to criminal and civil
penalties.<span style="font-style: italic">&#160;</span>However, physicians may, in their independent medical judgment, prescribe legally
available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatments, but the FDA
does restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic">Other Healthcare Laws </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our current and future business operations, including, among other things, our clinical
research activities and our business and financial arrangements and relationships with healthcare providers, physicians and other parties
through which we may market, sell and distribute our products, once approved, may be subject to extensive U.S. federal, U.S. state and
foreign healthcare fraud and abuse, transparency, and data privacy and security laws. For example, U.S. federal civil and criminal laws
and regulations prohibit, among other things: knowingly and willfully soliciting, receiving, offering or providing remuneration, directly
or indirectly, to induce or reward either the referral of an individual, or the furnishing, recommending or arranging for a good or service,
for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs; knowingly presenting or
causing to be presented, a false or fraudulent claim for payment by a federal healthcare program; and knowingly and willfully executing,
or attempting to execute, a scheme to defraud any healthcare benefit program (including a private payor), or knowingly and willfully falsifying,
concealing or covering up a material fact or making any materially false statement in connection with the delivery of, or payment for,
healthcare benefits, items or services. Many U.S. states and foreign countries have analogous prohibitions that may be broader in scope
and apply regardless of payor. In addition, we may be subject to U.S. federal, U.S. state and foreign laws that require us to report information
related to certain payments and other transfers of value to certain health care professionals, as well as ownership and investment interests
in our company held by those health care professionals and their immediate family members, and data security and privacy laws that restrict
our practices with respect to the use and storage of certain data.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Efforts to ensure that our current and future business arrangements with third parties
comply with applicable healthcare laws and regulations may involve substantial costs. <span style="font-family: Times New Roman,Times,serif">If
we are found to be in violation of any of these laws, we could be subject to significant civil, criminal and administrative penalties,
including damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, additional integrity
oversight and reporting obligations, contractual damages, reputational harm and the curtailment or restructuring of our operations.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic">Healthcare Policy and Reform</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our ability to commercialize our future therapeutic product candidates successfully,
alone or with collaborators, will depend in part on the extent to which coverage and reimbursement for these product candidates will be
available from government health programs, such as Medicare and Medicaid in the United States, private health insurers and other third-party
payors. At present, significant changes in healthcare policy, in particular the continuing efforts of the U.S. and other governments,
insurance companies, managed care organizations and other payors to contain or reduce health care costs are being discussed, considered
and proposed.&#160;Drug prices in particular are under significant scrutiny and continue to be subject to intense political and societal
pressures, which we anticipate will continue and escalate on a global basis.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">62</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">For example, in the United States, there have been several initiatives implemented
to achieve these aims. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation
Act, collectively, the ACA,<span style="font-family: Times New Roman,Times,serif"> substantially changed the way healthcare is financed
by both governmental and private insurers and significantly affects the pharmaceutical industry. With regard to biopharmaceutical products,
the ACA has, among other things, expanded and increased industry rebates for products covered under Medicaid programs and changed the
coverage requirements under the Medicare Part D program. The Tax Act included a provision which repealed, effective January 1, 2019, the
tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for
all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. In addition, the 2020 federal spending package
permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health
coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. There are remaining judicial,
executive branch and Congressional challenges to certain aspects of the ACA. For example, on June 17, 2021, the U.S. Supreme Court dismissed
a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual
mandate&#8221; was repealed by Congress. Thus, the Affordable Care Act will remain in effect in its current form.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, other legislative changes have been proposed and adopted since the ACA
was enacted. The Budget Control Act of 2011, triggered automatic reduction to several government programs, including reductions to Medicare
payments to providers, which went into effect in April 2013 and will remain in effect through 2031, unless additional congressional action
is taken. However, pursuant to COVID-19 pandemic relief legislation, these Medicare sequester reductions have been suspended from May
1, 2020 through March 31, 2022 due to the COVID-19 pandemic. Under current legislation, the actual reduction in Medicare payments will
vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. Additionally, there has been increasing legislative and enforcement
interest in the United States with respect to drug pricing practices. Specifically, there have been several recent U.S. Congressional
inquiries, presidential executive orders and legislation designed to, among other things, bring more transparency to drug pricing, reduce
the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government
program reimbursement methodologies for drugs. For example, in July 2021, the Biden administration released an executive order, &#8220;Promoting
Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive
order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing
reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. No legislation
or administrative actions have been finalized to implement these principles.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We cannot predict what healthcare reform initiatives may be adopted in the future.
However, we anticipate that Congress, state legislatures, and third-party payors may continue to review and assess alternative healthcare
delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations effecting additional
fundamental changes in the healthcare delivery system. We also expect ongoing legislative and regulatory initiatives to increase pressure
on drug pricing. Further, it is possible that additional government action is taken in response to the COVID-19 pandemic.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Coverage and Reimbursement</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Market acceptance of products is dependent on the extent to which coverage and reimbursement
is available from third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any products for which
we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives
are already available. Even if we obtain coverage for a given product, the associated reimbursement rate may not be adequate to cover
our costs, including research, development, intellectual property, manufacture, sale and distribution expenses, or may require co-payments
that patients find unacceptably high. Coverage and reimbursement policies for products can differ significantly from payor to payor as
there is no uniform policy of coverage and reimbursement for products among third party payors in the United States. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Non-U.S. Regulations</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to regulations in the United States, biologics are subject to a variety
of foreign laws and regulations governing clinical trials and commercial sales and distribution before they may be sold outside the United
States. Whether or not we obtain FDA approval for a product, we must obtain the necessary approvals from comparable regulatory authorities
of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies
from country to country and the time may be longer or shorter than that required for FDA approval. In some countries, we will also have
to get pricing approval.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">63</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Environmental Regulation</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Some of our research and development activities involve the controlled use of biologic
and chemical materials, a small amount of which could be considered to be hazardous. We are subject to laws and regulations in the U.S.
and Israel governing the use, storage, handling and disposal of all these materials and resulting waste products. We store relatively
small amounts of biologic and chemical materials. To our knowledge, we substantially comply with these laws and regulations. However,
the risk of accidental contamination or injury from these materials cannot be entirely eliminated. In the event of an accident, we could
be held liable for any resulting damages, and any liability could exceed our resources.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Regulation of Use of Human Tissue</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We need to access and use various human or non-human tissue samples for the purpose
of research, development and or validation of some of our product candidates. Our access and use of these samples are subject to government
regulation, in the United States, Israel and elsewhere and may become subject to further regulation. The use of clinical data associated
with human tissue samples is also heavily regulated in the United States, Israel and elsewhere. United States and other governmental agencies
may also impose restrictions on the use of data derived from human or other tissue samples.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Regulations Concerning the Use of Animals in Research</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We also are subject to various laws and regulations regarding laboratory practices
and the use of animals in our research. In the United States, the FDA regulations describe good laboratory practices, or GLPs, for various
types of nonclinical laboratory studies that support or are intended to support applications for research or marketing permits for products
regulated by the FDA, including INDs. Nonclinical animal studies conducted by us or third parties on our behalf may be subject to the
U.S. Animal Welfare Act, the U.S. Public Health Service Policy on Humane Animal Care and Use, U.S. Department of Agriculture regulations
for certain animal species. In Israel, the Council on Animal Experimentation has regulatory and enforcement powers, including the ability
to suspend, change or withdraw approvals, among other powers. To our knowledge, we and the third-party service providers we work with,
as applicable, substantially comply with these regulatory requirements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Regulation of Products Developed with the Support of Research and
Development Grants</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For a discussion of regulations governing products developed with research and development
grants from the Government of Israel, see &#8220;Item 5. Operating and Financial Review and Prospects - C. - Research and Development,
Patents and Licenses - The Israel Innovation Authority.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. ORGANIZATIONAL STRUCTURE</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We were incorporated under the laws of the State of Israel on February 10, 1993, as
Compugen Ltd., which is both our legal and commercial name. Compugen USA, Inc., our wholly owned subsidiary, was incorporated in Delaware
in March 1997 and is qualified to do business in California.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">D. PROPERTY, PLANTS AND EQUIPMENT</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In December 2015, we moved to new facilities in Holon, Israel where we leased an aggregate
of approximately 35,250 square feet of office, biology laboratory facilities and warehouse. Following the exercise of our first option,
we lease 30,140 square feet under that lease that expires on March 14, 2026 (with an option to extend the lease for additional five-year
period). In addition, Compugen USA, Inc. currently leases 3,360 square feet of office space in South San Francisco, California, under
a lease that expires on September 30, 2022.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">To our knowledge, there are no environmental issues that affect our use of the properties
that we lease.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25"><span style="font-weight: bold">ITEM 4A.<span id="ITEM4A."><!--Anchor--></span></span><span style="font-family: Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<span style="font-weight: bold">UNRESOLVED STAFF COMMENTS</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">None</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">64</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25"><span style="font-weight: bold"><span id="ITEM5"><!--Anchor--></span>ITEM 5.</span><span style="font-family: Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight: bold">OPERATING
AND FINANCIAL REVIEW AND PROSPECTS</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">The following discussion of our operating and financial
review and prospects should be read in conjunction with our consolidated financial statements and related notes, prepared in accordance
with U.S. GAAP as of December 31, 2021, and with any other financial data included elsewhere in this Annual Report</span><span style="font-family: Times New Roman,Times,serif">.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Background</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Compugen is a clinical-stage therapeutic discovery and development company utilizing
its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop
therapeutics in the field of cancer immunotherapy. Compugen&#8217;s innovative immuno-oncology pipeline consists of four clinical stage
programs, targeting immune checkpoints Compugen discovered computationally, COM701, COM902, bapotulimab&#160;(formerly known as BAY1905254)
and AZD2936. The Company&#8217;s lead product candidate, COM701, a potential first-in-class anti-PVRIG antibody, for the treatment of
solid tumors, is undergoing Phase 1 clinical studies in&#160;dual,&#160;and triple combinations under clinical collaboration with Bristol
Myers Squibb. COM902, a potential best-in-class, is a therapeutic antibody targeting TIGIT, developed internally and is undergoing a Phase
1 trial to evaluate it in patients with advanced malignancies as a monotherapy and in combination with COM701. Bapotulimab, an antibody
targeting ILDR2, licensed to Bayer under a research and discovery collaboration and license agreement, is also in Phase 1 studies in patients
with advanced solid tumors. AZD2936 is a novel anti-TIGIT/PD-1 bispecific antibody with a TIGIT component that is derived from Compugen&#8217;s
COM902 program and is developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is in Phase
1/2 trial in patients with advanced or metastatic non-small cell lung cancer. Compugen&#8217;s therapeutic pipeline of early-stage immuno-oncology
programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. The innovative immuno-oncology
pipeline, the strategic collaborations and the Company&#8217;s computational discovery engine serve as the corporate three key building
blocks. Compugen&#8217;s business model is to selectively enter into collaborations for its novel targets and related drug product candidates
at various stages of research and development under various revenue-sharing arrangements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Company is headquartered in Holon, Israel. Its clinical development activities
are headed from our U.S. site in South San Francisco, California.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">A. OPERATING RESULTS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Overview</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Since our inception, we have incurred significant losses and, as of December 31, 2021,
we had an accumulated deficit of $422.1 million. We expect to continue to incur net losses for the foreseeable future.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">While our predictive computational discovery capabilities have potentially broad applicability
and is not limited to a certain indication or therapeutic field, we focus our predictive computational discovery efforts on the discovery
of novel drug targets <span style="font-family: Times New Roman,Times,serif">and new biological pathways towards the development of new
therapeutic antibodies for cancer immunotherapy, a significant unmet medical need for cancer patients. We have discovered three new targets
through computational prediction which are being clinically evaluated with four different product candidates, supporting the power and
validity of our computational capabilities.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In 2013<span style="font-family: Times New Roman,Times,serif"> we entered into our
first collaboration based on novel targets identified by us. Under the collaboration with Bayer, or the Bayer Collaboration, we jointly
worked with Bayer on the preclinical development of bapotulimab. Over the years, we have significantly increased our research activities
in the field of immuno-oncology to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy.
In 2018, we entered into two agreements with leading pharmaceutical companies - an MCTC with Bristol Myers Squibb in connection with our
lead immuno-oncology program, COM701, and an exclusive license agreement with AstraZeneca for the development of bi-specific and multi-specific
antibody products derived from our COM902. We also engage in collaborations with a leading academic research center in the United States
to advance our research and development efforts.&#160;We incurred net losses of approximately $27.3 million in 2019, approximately $29.7
million in 2020 and approximately $34.2 million in 2021. We expect to continue to incur net losses for the foreseeable future due in part
to the costs and expenses associated with our research, development and discovery activities. Our business model primarily involves establishing
collaborations for our novel targets and related therapeutic product candidates at various stages of research and development providing
us with potential milestone payments and royalties on product sales or other forms of revenue sharing payments.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">65</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Our research and development expenses are expected to continue to be our major operating
expense in 2022, expected to account for approximately 80% of our expected total 2022 operating expenses. Our research and development
expenditures have always comprised a significant portion of our total cash expenditures, and they are expected to increase by approximately
55% in 2022 compared to 2021 reflecting the planned expansions of our clinical trials.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We believe that we have sufficient cash and cash equivalents and short-term bank deposits
in order to sustain our operations into 2024, at the current level of annual expenditures. For a detailed description of our cash and
cash equivalents position, see &#8220;Item 5. Operating and Financial Review and Prospects - B. Liquidity and Capital Resources.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Years Ended December 31, 2021 and 2020</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Revenues.</span><span style="font-family: Times New Roman,Times,serif">
Revenues for the year ended December 31, 2021, were $6.0 million, compared with $2.0 million in the comparable period of 2020. The revenues
for 2021 reflect a $6.0 million clinical milestone from the license agreement with AstraZeneca.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Cost of Revenues. </span><span style="font-family: Times New Roman,Times,serif">During
the year ended December 31, 2021, the Company had approximately $0.7 million in cost of revenues compared with approximately $0.1 million
cost of revenues in the comparable period of 2020. Cost of revenues for the year ended December 31, 2021, represents milestone and royalty
payments in connection with our revenues.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Research and Development Expenses. </span><span style="font-family: Times New Roman,Times,serif">Research
and development expenses during 2021 increased by 26% and totaled approximately $28.7 million compared with approximately $22.8 million
in 2020. The increase is mainly due to higher expenses associated with our various clinical studies, preclinical and CMC activities and
headcount related as our U.S. based clinical team continues to grow to support the expansion of our various studies. Research and development
expenses, as a percentage of total operating expenses, were 71% in 2021 compared to 68% in 2020.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Marketing and Business Development Expenses</span><span style="font-family: Times New Roman,Times,serif">.
Marketing and business development expenses were approximately $0.8 million in 2021 compared with approximately $0.9 million in 2020.
Marketing and business development expenses, as a percentage of total operating expenses, were 2% in 2021 compared to 3% in 2020.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">General and Administrative Expenses. </span><span style="font-family: Times New Roman,Times,serif">General
and administrative expenses during 2021 increased by 11% and totaled approximately $10.9 million in 2021 compared with approximately $9.8
million in 2020. The increase during 2021 was attributed mostly to increased D&amp;O insurance premium costs (that effected our industry)
and non-cash stock option related expenses. General and administrative expenses, as a percentage of total operating expenses, were 27%
in 2021 compared to 29% 2020.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Financial Income (loss), Net. </span><span style="font-family: Times New Roman,Times,serif">Financial
and other income decreased to approximately $0.9 million in 2021 from approximately $1.8 million in 2020. The decrease is attributed mainly
to decreased interest income due to lower interest rates in the market and lower level of cash and deposits balances.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Years Ended December 31, 2020 and 2019</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Revenues.</span><span style="font-family: Times New Roman,Times,serif">
Revenues for the year ended December 31, 2020, were $2.0 million, compared with $0 million in the comparable period of 2019. The revenues
for 2020 reflect a $2.0 million preclinical milestone from the license agreement with AstraZeneca.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Cost of Revenues. </span><span style="font-family: Times New Roman,Times,serif">During
the year ended December 31, 2020, the Company had $60 thousands in cost of revenues compared with no cost of revenues in the comparable
period of 2019. Cost of revenues for the year ended December 31, 2020, represents royalty expenses to the IIA in connection with our revenues.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Research and Development Expenses. </span><span style="font-family: Times New Roman,Times,serif">Research
and development expenses during 2020 increased by 15% and totaled approximately $22.8 million compared with approximately $19.8 million
in 2019. The increase is mainly due to increases in expenses associated with our various Phase 1 clinical studies, COM701 and COM902 manufacturing,
other CMC activities and IP expenses, offset by the cost reduction measures taken by the Company in 2019. Research and development expenses,
as a percentage of total operating expenses, were 68% in 2020 compared to 69% in 2019.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Marketing and Business Development Expenses</span><span style="font-family: Times New Roman,Times,serif">.
Marketing and business development expenses were approximately $0.9 million in 2020 compared with approximately $0.7 million in 2019.
Marketing and business development expenses, as a percentage of total operating expenses, were 3% in 2020 compared to 2% in 2019.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">66</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">General and Administrative Expenses. </span><span style="font-family: Times New Roman,Times,serif">General
and administrative expenses during 2020 increased by 17% and totaled approximately $9.8 million in 2020 compared with approximately $8.4
million in 2019. The increase during 2020 was attributed mostly to headcount related expenses and increased D&amp;O insurance premium
costs (that effected the overall industry). General and administrative expenses, as a percentage of total operating expenses, were 29%
in 2020 and in 2019.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Financial Income (loss), Net. </span><span style="font-family: Times New Roman,Times,serif">Financial
and other income increased to approximately $1.8 million in 2020 from approximately $0.8 million in 2019. The increase is attributed mainly
to increased interest income due to higher level of cash and deposits balances during 2020 following our public offering in March 2020.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Governmental Policies that Materially Affected
or Could Materially Affect Our Operations</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">Our income tax obligations consist of those of Compugen Ltd. in Israel and of Compugen
USA, Inc. in its taxing jurisdictions.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">The corporate tax rate in Israel was 23% in 2021, 2020 and 2019.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the future, if and when we generate taxable income, our effective tax rate may
be influenced by, among others: (a) the split of taxable income between the various tax jurisdictions; (b) the availability of tax loss
carry forwards and the extent to which valuation allowance has been recorded against deferred tax assets; (c) the portion of our income
which is entitled to tax benefits pursuant to the Investment Law; <span style="font-family: Times New Roman,Times,serif">(d) the changes
in the exchange rate of the U.S. dollar to the NIS and (e) the Company&#8217;s election to submit its tax returns for 2014 and onwards
on a dollar basis, which may not be accepted by the Israeli Tax Authority. We may benefit from certain government programs and tax legislation,
particularly as a result of the Benefiting Enterprise status that resulted from our eligibility for tax benefits under the Investment
Law. To be eligible for these benefits, we need to meet certain conditions. Should we fail to meet such conditions, these benefits could
be cancelled, and we might be required to refund the amount of the benefits previously received, if any, in whole or in part, together
with interest and linkage differences to the Israeli CPI, or other monetary penalty. We also benefit from a Government of Israel program
under which we received grants from the IIA. For more information, please see &#8220;Item 5 Operating and Financial Review and Prospects
- C. Research and Development, Patents and Licenses - The Israel Innovation Authority.&#8221; There can be no assurance that these programs
and tax legislation will continue in the future or that the available benefits will not be reduced.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The termination or curtailment of these programs or the loss or reduction of benefits
under the Investment Law could have a material adverse effect on our business, financial condition and results of operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">Currently we have one Benefiting Enterprise program under the Investment Law. The
tax benefits period with respect to this program has not yet begun as we have not yet generated any taxable income. These benefits should
result in income recognized by us being tax exempt or taxed at a lower rate for a specified period of time after we begin to report taxable
income and exhaust any net operating loss carry-forward. However, these benefits may not be applied to reduce the U.S. federal tax rate
for any income that our U.S. subsidiary may generate.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In April 2005, substantive amendments to the Investment Law came into effect. Under
these amendments, eligible investment programs of the type in which we participated prior to the amendment were eligible to qualify for
substantially similar benefits as a &#8216;Benefiting Enterprise&#8217;, subject to meeting certain criteria. This replaced the previous
terminology of &#8216;Approved Enterprise&#8217;, which required pre-approval from the Investment Center of the Ministry of the Economy
of the State of Israel. As a result of these amendments, tax-exempt income generated from Benefiting Enterprises under the provisions
of the amended law will, if distributed upon liquidation or if paid to a shareholder for the purchase of his or her shares, be deemed
distributed as a dividend and will subject the Company to the applicable corporate tax that would otherwise have been payable on such
income. Therefore, a company may be required to record deferred tax liability with respect to such tax-exempt income, which would have
an adverse effect on its results of operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Additional amendments to the Investment Law became effective in January 2011 and were
further amended in August 2013, or the 2011 Amendment. Under the 2011 Amendment, income derived by &#8216;Preferred Companies&#8217; from
&#8216;Preferred Enterprises&#8217; (both as defined in the 2011 Amendment) would be subject to a uniform rate of corporate tax for an
unlimited period as opposed to the incentives prior to the 2011 Amendment that were limited to income from Approved or Benefiting Enterprises
during their benefits period. According to the 2011 Amendment, the uniform tax rate on such income, referred to as &#8216;Preferred Income&#8217;,
would be 10% in areas in Israel that are designated as Development Zone A and 15% elsewhere in Israel during 2011-2012, 7% and 12.5%,
respectively, in 2013, and 9% and 16%, respectively, thereafter. Income derived by a Preferred Company from a &#8216;Special Preferred
Enterprise&#8217; (as defined in the Investment Law) would enjoy further reduced tax rates for a period of ten years of 5% in Development
Zone A and 8% elsewhere. As of January 1, 2014, dividends distributed from Preferred Income would subject the recipient to a 20% tax (or
lower, if so provided under an applicable tax treaty), which would generally be withheld by the distributing company, provided however
that dividends distributed from &#8216;Preferred Income&#8217; from one Israeli corporation to another, would not be subject to tax. Under
the transitional provisions of the 2011 Amendment, companies may elect to irrevocably implement the 2011 Amendment with respect to their
existing Approved and Benefiting Enterprises while waiving benefits provided under the legislation prior to the 2011 Amendment or keep
implementing the legislation prior to the 2011 Amendment. Should a company elect to implement the 2011 Amendment with respect to its existing
Benefiting Enterprises prior to June 30, 2015 dividends distributed from taxable income derived from Benefiting Enterprises to another
Israeli company would not be subject to tax. While a company may incur additional tax liability in the event of distribution of dividends
from tax exempt income generated from its Benefiting Enterprise, as previously described, no additional tax liability will be incurred
by a company in the event of distribution of dividends from Preferred Income. We have not elected to implement the 2011 Amendment and
we do not currently have any Preferred Enterprises.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">67</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">In December 2016, the Economic Efficiency Law (Legislative Amendments for Applying
the Economic Policy for the 2017 and 2018 Budget Years), 2016 which includes Amendment 73 to the Law, or Amendment 73, was published.
According to Amendment 73, a Preferred Enterprise located in development area A will be subject, under certain conditions, to a tax rate
of 7.5% instead of 9% effective from January 1, 2017, and thereafter (the tax rate applicable to preferred enterprises located in other
areas remains at 16%). Amendment 73 also prescribes special tax tracks for Technological Enterprises, which are subject to regulations
issued by the Minister of Finance on May 16, 2017.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The new tax tracks under the Amendment are as follows:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Technological Preferred Enterprise - an enterprise for which total consolidated revenues
of its parent company and all subsidiaries are less than NIS 10 billion. A Technological Preferred Enterprise, as defined in the Law,
which is located in the center of Israel will be subject to tax at a rate of 12% on profits deriving from intellectual property (in development
area A - a tax rate of 7.5%).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Special Technological Preferred Enterprise - an enterprise for which total consolidated
revenues of its parent company and all subsidiaries exceed NIS 10 billion. Such enterprise will be subject to tax at a rate of 6% on profits
deriving from intellectual property, regardless of the enterprise&#8217;s geographical location.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Any dividends distributed to &#8220;foreign companies&#8221;, as defined in the Law,
deriving from income from the Technological Enterprises will be subject, under certain conditions, to tax at a rate of 4%.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">As of December 31, 2021, our net operating loss carry-forward for Israeli tax purposes
amounted to approximately $369.8 million. Under Israeli law, these net operating losses may generally be carried forward indefinitely
and offset against certain future taxable income.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As of December 31, 2021, the net operating loss carry-forward of our U.S. subsidiary
for federal income tax purposes amounted to approximately $4.8 million. Approximately $3.8 million of these losses are available to offset
any future U.S. taxable income of our U.S. subsidiary and will expire between 2023 and 2032.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Use of our U.S. net operating losses may be subject to substantial annual limitation
due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual
limitation may result in the expiration of net operating losses before utilization.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For a description of Israel government policies that affect our research and development
expenses, and the financing of our research and development, see &#8220;Item 5. Operating and Financial Review and Prospects - C. Research
and Development, Patents and Licenses - The Israel Innovation Authority.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">B. LIQUIDITY AND CAPITAL RESOURCES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Public Offering of Ordinary Shares</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-style: italic">Cantor Controlled Equity Offering<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">SM</sup>
Sales Agreement</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On May 25, 2018, we entered into a Controlled Equity Offering<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">SM</sup>&#160;Sales
Agreement, or the ATM Sales Agreement, with Cantor Fitzgerald &amp; Co., or Cantor, as sales agent, pursuant to which we could offer and
sell, from time to time through Cantor, Compugen ordinary shares having an aggregate offering price of up to $25 million. As of December
31, 2019, the Company sold 7,245,268 ordinary shares through the ATM Sales Agreement for an aggregate purchase price of approximately
$23.7 million and the ATM Sales Agreement was terminated.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">68</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Registered Direct Offering</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On June 14, 2018, we entered into a definitive securities purchase agreement with
certain institutional investors and a placement agency agreement with JMP Securities LLC, in connection with a registered direct offering
which resulted in the issuance of 5,316,457 of our ordinary shares at a purchase price of $3.95 per share. In connection with the issuance
of the ordinary shares, we also issued warrants to purchase up to approximately 4.3 million additional ordinary shares. The warrants have
an exercise price of $4.74 per share and have a term of five years from the date of issuance. Gross proceeds from the sale of the ordinary
shares were approximately $21 million, before deducting placement agent discounts and commissions and offering expenses paid by us.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">During 2020, the Company issued and sold 3,866,139 ordinary shares underlying 3,866,139
warrants (with proceeds of approximately $18.3 million). During 2021, the Company issued and sold 89,557 ordinary shares underlying 89,557
warrants (with proceeds of approximately $0.4 million). As of December 31, 2021, 297,469 warrants remained outstanding.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Shelf Registration Statement</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">On July 30, 2020, we filed a shelf registration statement on Form F-3 with the SEC
under which we may offer and sell from time to time in one or more offerings, our ordinary shares, debt securities, rights, warrants and
units having an aggregate offering price of up to $350 million. U<span style="font-family: Times New Roman,Times,serif">nder this Form
F-3 we also registered up to 749,104&#160;ordinary shares underlying the warrants issued in our registered direct offering in June 2018.
This registration statement was declared effective by the SEC on August 7, 2020.&#160;362,078 ordinary shares underlying the warrants
issued in such registered direct offering were sold in 2020 and 89,557 ordinary shares underlying the warrants issued in such registered
direct offering were sold in 2021 and as of February 15, 2022, 297,469 ordinary shares underlying the warrants are still outstanding.
We may seek additional capital or strategic considerations, even if we believe we have sufficient funds for our current or future operating
plans.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Securities Purchase Agreement</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">Bristol Myers Squibb Securities Purchase Agreement</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">On November 10, 2021, the Company and Bristol Myers Squibb entered into a securities
purchase agreement pursuant to which Bristol Myers Squibb made a $20 million investment in Compugen comprised of the purchase of 2,332,815
ordinary shares of Compugen at $8.57333 per share, which represented a 33% premium over the closing price of our ordinary shares on the
last trading day immediately prior to the execution of this agreement. This investment is in addition to Bristol Myers Squibb&#8217;s
$12 million investment that took place in October 2018.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">License Agreement</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic">AstraZeneca License Agreement</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">On March 30, 2018, the Company and <span style="font-family: Times New Roman,Times,serif">AstraZeneca,
entered into an exclusive license agreement to enable the development of bi-specific and multi-specific immuno-oncology antibody products</span>
based on the Company's monospecific antibodies that bind to TIGIT, including COM902,<span style="font-family: Times New Roman,Times,serif">
pursuant to which the Company received an upfront payment of $10 million and is eligible to receive up to $200 million in development,
regulatory and commercial milestones for the first product as well as tiered royalties on future product sales. In December 2020 and September
2021, the program achieved a preclinical milestone and clinical milestone, respectively and accordingly we accrued an additional $2 and
$6 million, respectively, out of the said $200 million.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Public Offering of Ordinary Shares</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On March 11, 2020, we entered into an underwriting agreement with SVB Leerink LLC
and Stifel,&#160;<span style="font-family: Times New Roman,Times,serif">Nicolaus &amp; Company, Incorporated, as representatives of the
several underwriters named therein, for the issuance and sale in a public offering of 8,333,334 of our ordinary shares at a price to the
public of $9.00 per share. In addition, we granted the underwriters a 30-day option to purchase up to 1,250,000 additional ordinary shares
at the public offering price, less the underwriting discounts and commissions.</span> In this underwritten public offering we issued a
total of 8,816,339 ordinary shares (including the shares issued in upon exercise of the underwriters&#8217; option) at said $9.00 per
share. Gross proceeds from the sale of the ordinary shares were approximately $79 million, before deducting underwriting discounts and
commissions and offering expenses paid by us.</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">69</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Capital Resources</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">In 2021, our primary sources of cash were:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z1117261109094aeeb6b7048b652187a3" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>cash at hand;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z1790b3be12524cd6b89af26c5c9c8898" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>proceeds from Bristol Myers Squibb&#8217;s 2021 investment in us; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z06d774266ae4492ebe70e7311db7bf29" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>proceeds from AstraZeneca in connection with its 2021 milestone payment.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -34pt; margin-left: 34pt; line-height: 1.25">We used these funds primarily to finance our
business operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We expect that our sources of cash for 2022 will include cash held in our bank accounts
and may include proceeds generated from agreements with collaborators and other third parties with respect to our novel targets and therapeutic
drug candidates and proceeds from issuance of ordinary shares as a result of exercise of options, warrants and shares pursuant to our
employee share purchase plan and/or from financing transactions.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Net Cash Used in Operating Activities</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Net cash used in operating activities was approximately $27.9 million in 2019, approximately
$28.3 million in 2020 and approximately $22.8 million in 2021. Decrease in net cash used in 2021 compared to 2020 is mainly due to the
$2 million and $6 million <span style="font-family: Times New Roman,Times,serif">AstraZeneca milestone payments, both collected in 2021,
and the $5M BMS participation in R&amp;D expenses, offset by an increase in operating expenses, mainly expenses associated with our Phase
1 studies, preclinical activities, headcount related expenses and increased D&amp;O insurance premium.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Net Cash Provided by (used in) Investing Activities</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Net cash provided by investing activities was approximately $5.3 million in 2019 and
approximately $6.6 million in 2021, compared with net cash used in investing activities of approximately $82.2 million in 2020. Changes
in net cash during the years are affected by the level of cash in the Company over the years which are deposited or withdrawn from bank
deposits based on the cash needs to fund our operating activities. During 2021 cash provided by investing activities was higher as a result
of higher operating expenses than revenues and funds raised.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic"><span style="font-weight: bold">Net Cash Provided by Financing
Activitie</span><span style="font-family: Times New Roman,Times,serif">s</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Net cash provided by financing activities was approximately $25.9 million in 2019,
approximately $108.5 million in 2020 and approximately $16.8 million in 2021. The principal source of cash provided by financing activities
in 2021 were the <span style="font-family: Times New Roman,Times,serif">Bristol Myers Squibb investment and proceeds received from stock
based awards exercises and the principal source of cash provided by financing activities in 2020 were the proceeds received from the public
offering and from options and warrants exercised.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Net Liquidity</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Liquidity refers to the liquid financial assets available to fund our business operations
and pay for near-term obligations. These liquid financial assets mostly consist of cash and cash equivalents as well as short-term bank
deposits. As of December 31, 2021, we had cash and cash equivalents and short-term bank deposits of approximately $117.0 million compared
to approximately $123.8 million on December 31, 2020. We believe that our existing cash and cash equivalents, and short-term bank deposits
will be sufficient to fund our operations over the next 12 months. We believe we will meet longer-term expected future cash requirements
into 2024 in the event that the current level of annual expenditures will not significantly increase. We believe that our working capital
is sufficient for our present requirements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">70</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">The table below summarizes our contractual obligations as of December 31, 2021 and
should be read together with the accompanying comments that follow.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="zf813cfae6acc4f5d877976feb99bf5bb" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="18" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Payments due by period</div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">(US$ in thousands)</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Total</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Less than 1 year</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">1-3 years</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">3-5 years</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">More than 5 years</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 40%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Operating Lease Obligations<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">3,045</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">895</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,390</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">760</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">-</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 40%">
        <div style="line-height: 1.25">Accrued Severance Pay, net<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">552</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">552</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 40%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Total</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">3,597</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">895</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,390</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">760</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">552</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -14.15pt; margin-left: 28.35pt; line-height: 1.25"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup>&#160;
Consists of operating leases for our facilities and for motor vehicles. Includes the first five-year option period of the lease of the
Israeli facility. The first option was exercised during 2020.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -14.15pt; margin-left: 28.35pt; line-height: 1.25"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup>&#160;
Severance pay obligations to our Israeli employees. For more information please see &#8220;Item 6. Directors, Senior Management and Employees
&#8211; D. Employees.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The above table does not include royalties that we may be required to pay to the IIA.
For more information, see &#8220;Item 5. Operating and Financial Review and Prospects - C. Research and Development, Patents and Licenses.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The above table also does not include contingent contractual obligations or commitments
that may enter into effect in the future, such as contractual undertakings to pay royalties subject to certain conditions occurring.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Although we have sufficient cash and cash equivalents and short-term bank deposits
that we believe will enable us to fund our operations into 2024 at current annual expenditures, our ability to fund our capital needs
depends on our ongoing ability to generate cash from existing and future collaborations and from our ability to raise additional funds.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. RESEARCH AND DEVELOPMENT, PATENTS AND LICENSES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We invest heavily in research and development. Research and development expenses were
our major operating expenses representing approximately 70% of total operating expenses in 2021, 2020 and 2019. Our research and development
expenses, net, were approximately $28.7 million in 2021, compared to approximately $22.8 million in 2020 and approximately $19.8 million
in 2019. As of December 31, 2021, 51 of our employees were engaged in research and development on a full-time basis. This represents approximately
70% of our entire work force at that time.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We focus our efforts on the development of our discovery capabilities and related
technologies, and the discovery and validation of our drug targets and the preclinical and clinical development of the respective therapeutic
product. Our pipeline programs continuously evaluate our computationally predicted drug target candidates and are advancing selected drug
target programs into preclinical and clinical development of therapeutic products. We expect that in 2022 our research and development
expenses will continue to be our major operating expense, representing approximately 80% of our total operating expenses.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We believe that our future success will depend, in large part, on our ability to discover
promising drug target candidates and therapeutic product candidates and to successfully advance the research and development of certain
of our product candidates under our internal pipeline towards preclinical and clinical studies and to successfully enter into revenue-sharing
partnering agreements with pharmaceutical companies with respect to such product candidates. In addition, we expect to continue to expand
our discovery infrastructure and capabilities which provide us with the underlying engine for the discovery of promising drug targets
for our pipeline as well as our clinical stage pipeline.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Research and Development Grants</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have participated in programs offered by the IIA that support research and development
activities. See Note 7b to our 2021 consolidated financial statement. We have not applied for additional grants from the IIA for research
and technological development since 2012.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">The Israel Innovation Authority</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The government of Israel encourages research and development projects in Israel through
the IIA, pursuant to and subject to the provisions of the R&amp;D Law. Under the R&amp;D Law, research and development projects which
are approved by the Research Committee of the IIA are eligible for grants, in exchange for payment of royalties from revenues generated
by the products developed within the framework of such approved project and subject to compliance with certain requirements and restrictions
under the R&amp;D Law as detailed below, which must generally continue to be complied with even following full repayment of all IIA grants.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">71</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">We received grants from the IIA for several projects and may receive additional grants
in the future. Under the terms of the grants received, we are required to pay royalties ranging between 3% to 5% of the revenues we generate
from our products which incorporate Financed Know-How, or IIA Products, until 100% of the dollar value of the grant is repaid (plus LIBOR
interest applicable to grants received on or after January 1, 1999). As of December 31, 2021, we received grants from the IIA in the principal
amount of approximately $7.3 million. Therefore, our contingent obligation for royalties, net of royalties already paid or accrued in
the sum of approximately $1.8 million, along with the accumulated LIBOR interest to date of approximately $4.0 million, totaled to approximately
$9.5 million as of December 31, 2021.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, the Company participated in four MAGNET Consortium programs - Drugs and
Diagnostic Kits, or DAAT Consortium, Tevel Biotechnology Consortium, Pharmalogica Consortium and Rimonim Consortium &#8211; for which
it received from the IIA a total amount of approximately $2.1 million, and in two MAGNETON programs, for which it received from the IIA
approximately $0.5 million. These grants do not bear any royalty obligations, but as the R&amp;D Law applies to these programs, the restrictions
on transfer of know-how or manufacturing outside of Israel, as detailed below, do apply. The R&amp;D Law requires that the manufacture
of IIA Products will be carried out in Israel, unless the IIA provides its approval to the contrary. This approval may be subject to various
conditions, including the repayment of increased royalties equal to up to 300% of the total grant amount plus applicable interest and
an increase of 1% in the royalty rate, depending on the extent of the manufacturing that is to be conducted outside of Israel. The R&amp;D
Law also provides that Financed Know-How and any right derived therefrom may not be transferred to third parties, unless such transfer
was approved in accordance with the R&amp;D Law. The Research Committee operating under the IIA may approve the transfer of Financed Know-How
between Israeli entities, provided that the transferee undertakes all the obligations in connection with the grant as prescribed under
the R&amp;D Law. In certain cases, the research committee may also approve a transfer of the Financed Know-How outside of Israel, in both
cases, subject to the receipt of certain payments calculated according to a formula set forth in the R&amp;D Law. In the case of transfer
outside of Israel, a payment of up to 600% of the total amount of grants plus applicable interest; and in the case the R&amp;D activity
related to the know-how remains in Israel, a payment of up to 300% of such total amount. These approvals are not required for the sale
or export of any products resulting from such R&amp;D activity or based on such Financed Know-How.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">At the end of 2021, the publication of the LIBOR ceased and alternative interests
were applied throughout the worldwide economy, including the SOFR interest. As of the date of this Annual Report, the IIA has not yet
published the alternative interest that will be applied on the grants that the Company received from the IIA. While the effect that the
replacement of the LIBOR interest will have on the Company remains uncertain as of the date of this Annual Report, the Company assesses
that such change will not have a material effect on its operations and financial condition in light of the common interests in the market.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For a discussion regarding the effects of the grants we received from the IIA on our
business, see &#8220;Item 3. Key Information &#8211; D. Risk Factors - <span style="font-family: Times New Roman,Times,serif">Risks Related
to Operations in Israel -<span style="font-weight: bold">&#160;</span>We received grants from the IIA that may expose us to payment of
royalties and restrict the transfer of know-how that we develop.&#8221;</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">D. TREND INFORMATION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are a development stage company and it is not possible for us to predict with any
degree of accuracy the outcome of our research and development efforts. As such, it is not possible for us to predict with any degree
of accuracy any significant trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect
on our net loss, liquidity or capital resources, or that would cause financial information to not necessarily be indicative of future
operating results or financial condition. However, subject to such limitation, we did identify certain trends that may have an effect
on us, some of which are as specified below, and as covered in the risk factors set forth under &#8220;Item 3. Key Information - D. Risk
Factors&#8221;.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Access to funds</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Should we need to secure additional sources of liquidity, we believe that we could
finance our needs through the issuance of equity securities. However, we cannot guarantee that we will be able to obtain financing through
the issuance of equity securities on reasonable terms. As of recently, the COVID-19 pandemic, including government actions implemented
as a result thereof, has caused a negative impact on the outlook for the global economy and created significant volatility and disruption
of financial markets. An extended period of economic disruption, including a continued market downfall, could materially affect our ability
to secure additional funds and could further materially affect our business, strategy, results of operations and financial condition.
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">72</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Exchange rate</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A significant portion of our expenses is denominated in currencies other than the
U.S. dollar. The Company is therefore subject to non-U.S. currency risks and non-U.S. exchange exposure, especially the NIS. Exchange
rates can be volatile and a substantial change of foreign currencies against the U.S. dollar could increase or reduce the Company&#8217;s
expenses and net loss and impact the comparability of results from period to period. The devaluation of the U.S. dollar against the NIS
was 3.3%, 7.0% and 7.8% in 2021, 2020 and 2019, respectively. For example, for the year ended December 31, 2021, assuming a 10% devaluation
of the U.S. dollar against the NIS, we would have experienced an increase in our net loss of approximately $1.5 million, while assuming
a 10% appreciation of the U.S. dollar against the NIS, we would experience a decrease in our net loss of approximately $1.2 million. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Interest rate</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A significant portion of our cash and cash equivalents is invested in bank deposits
and bear interest. The Company&#8217;s financial income is therefore subject to interest rate risk. Interest rates can be volatile, and
a substantial change in interest rates could increase or reduce the Company&#8217;s financial income and net loss. In addition to the
impact on our cash and cash equivalents, rising interest rates, or the perception thereof, may have wide economic impacts, including an
adverse impact on capital markets and the price of our shares. For more information regarding interest rate risk please see &#8220;Item
11. Quantitative And Qualitative Disclosures About Market Risk &#8211; Interest Rate Risk.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Trend towards biologics</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Biologics including monoclonal antibodies represent one of the fastest growing segments
in the drug industry, making up 18% of FDA approved drugs in 2021. The growth of this class has driven a large number of companies to
invest in new technologies (e.g., bi-specific monoclonal antibodies, multi-specific antibodies, antibody fragments) and new approaches
to fully exploit the potential of this class. In addition, the striking efficacy and recent approval ofcell therapies for the treatment
of cancer, such as CAR-T therapies, has also captured much attention in the pharma industry. The availability of such new technologies
and approaches to address drug targets may increase the differentiation and attractiveness of our novel therapeutic candidates. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">E. CRITICAL ACCOUNTING ESTIMATES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The preparation of our consolidated financial statements and other financial information
appearing in this Annual Report requires our management to make estimates and judgments that affect the reported amounts of assets, liabilities,
revenues and expenses, and related disclosure of contingent assets and liabilities. We evaluate on an on-going basis these estimates,
mainly related to share-based payments, deferred participation in research and development expenses, revenue recognition, and research
and development expenses.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We base our estimates on our experience and on various assumptions that we believe
are reasonable under the circumstances. The results of our estimates form the basis for our management&#8217;s judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under
different assumptions or conditions.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Share Based Payments</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We account for stock-based compensation in accordance with ASC 718, &#8220;Compensation
- Stock Compensation&#8221;, or ASC 718, which requires companies to estimate the fair value of equity-based payment awards on the date
of grant using an option-pricing model. <span style="font-family: Times New Roman,Times,serif">We account for forfeitures as they occur.
The value of the pro-rata portion of the award, assuming no forfeiture, is recognized in our consolidated statement of comprehensive loss
as an expense over the requisite service periods. Upon forfeiture the expense is adjusted so that expense is recognized for the portion
of the award that actually vested.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We selected the Black-Scholes-Merthon option pricing model as the most appropriate
method for estimating the fair value of our share-based awards. The resulting cost of an equity incentive award is recognized as an expense
over the requisite service period of the award, which is usually the vesting period. We recognize compensation expense over the vesting
period using the straight-line method and classify these amounts in the consolidated financial statements based on the department to which
the related employee reports.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">73</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">This model evaluates the options as if there is a single exercise point, and thus
considers expected option life (expected term). The input factored in this model is constant for the entire expected life of the option.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The determination of the grant date fair value is affected by estimates and assumptions
regarding a number of complex and subjective variables, including the expected term of the options, the expected volatility of our share
price over the expected term, risk-free interest rates and expected dividends. The computation of expected volatility is based on historical
volatility of our shares. The risk-free interest rate assumption is the implied yield currently available on United States treasury zero-coupon
issues with a remaining term equal to the expected life term of the options. We determined the expected life of the options based on historical
experience, representing the period of time that options granted are expected to be outstanding.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Share-based compensation expense recognized under ASC 718 was approximately $4.3 million,
$2.8 million and $2.4 million for the years ended December 31, 2021, 2020 and 2019, respectively.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Revenue Recognition</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our revenues are generated mainly from collaborative and license agreements. In the
agreements, revenues are typically derived mainly from upfront payment and contingent payments related to milestone achievements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Company recognizes revenue in accordance with ASC 606 - &#8220;Revenue from Contracts
with Customers&#8221;.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As such, the Company analyzes its collaborative and license agreements to assess whether
they are within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations
under each of its agreements, the Company performs the following five steps: (i) identification of the contract, or contracts, with a
customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation
of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when, or as, we satisfy a performance
obligation.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The consideration promised in a contract with a customer may include fixed amounts,
variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained.
We use assumptions to determine the standalone selling price of each performance obligation identified in the contract. We then allocate
the total transaction price to each performance obligation based on the estimated standalone selling prices of each performance obligation.
We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance
obligation is satisfied.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">After contract inception, the transaction price is reassessed at every period end
and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations
on the same basis as at contract inception.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In December 2020 the program <span style="font-family: Times New Roman,Times,serif">under
the exclusive license agreement with AstraZeneca achieved a preclinical milestone and in September 2021 such program achieved clinical
milestone and in connection with such milestones, we recognized revenues in an amount of $2 million and $6 million, in the years 2020
and 2021, respectively, in accordance with the criteria prescribed under ASC 606. See Note 2 to our 2021 consolidated financial statements.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Research and Development Expenses</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Research and development costs are charged to the statement of comprehensive loss
as incurred.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Company accrues costs for pre-clinical and clinical trial activities based upon
estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or
other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable
advance payments to vendors for goods or services that will be received in the future for use in research and development activities.
In such circumstances, the nonrefundable advance payments are deferred and capitalized, even when there is no alternative future use for
the research and development, until related goods or services are provided.<span style="font-family: Times New Roman,Times,serif">&#160;Payments
made in advance of the performance of the related services are recorded as prepaid expenses until the services are rendered.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">74</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">The portion of the Bristol Myers Squibb $12.0 million investment in 2018 over the
fair market value of the shares issued in the amount of approximately $4.1 million and the portion of the Bristol Myers Squibb $20.0 million
investment in 2018 over the fair market value of the shares issued in the amount of $5.0 million were considered as deferred participation
of Bristol Myers Squibb in research and development expenses which is amortized over the period of the clinical trial based on the progress
in the research and development, in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221;, see Note 1f and Note 8b to our 2021
consolidated financial statements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Amortization of participation in research and development expenses for the years ended
December 31, 2021 and 2020 were approximately $1.3 million and $0.8 million, respectively.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Recent Accounting Pronouncements</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">See Note 2t to our 2021 consolidated financial statement.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25"><span style="font-weight: bold"><span id="ITEM6"><!--Anchor--></span>ITEM 6.</span><span style="font-family: Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-weight: bold">DIRECTORS,
SENIOR MANAGEMENT AND EMPLOYEES</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">A. DIRECTORS AND SENIOR MANAGEMENT</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The following table sets forth information with respect to Compugen&#8217;s directors
and senior management as of February 15, 2022:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z852b458adca6484ba87997d1bf971c5d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 22%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Name</div> </div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; padding-bottom: 2px">&#160;</td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 6%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Age</div> </div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; padding-bottom: 2px">&#160;</td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 70%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Positions</div> </div> </td> </tr>
  <tr>
    <td style="width: 22%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Paul Sekhri<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup></div>
        </td>
    <td colspan="1" style="width: 1%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 6%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">63</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 70%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Chairman of the Board of Directors (Chairman of the Nomination and Corporate Governance Committee)</div>
        </td> </tr>
  <tr>
    <td style="width: 22%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">Anat Cohen-Dayag, Ph.D.</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: middle; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 6%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">55</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: middle; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 70%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="margin-right: 2.55pt; line-height: 1.25">President and Chief Executive Officer, Director</div> </td> </tr>
  <tr>
    <td style="width: 22%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Jean-Pierre Bizzari, M.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(4)</sup></div>
        </td>
    <td colspan="1" style="width: 1%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 6%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">67</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 70%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="margin-right: 2.55pt; line-height: 1.25">Director</div> </td> </tr>
  <tr>
    <td style="width: 22%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">Gilead Halevy<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td colspan="1" style="width: 1%; vertical-align: middle; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 6%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">55</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: middle; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 70%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="margin-right: 2.55pt; line-height: 1.25">Director (Chairman of the Audit Committee)</div> </td> </tr>
  <tr>
    <td style="width: 22%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Kinneret Livnat Savitzky, Ph.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)(3)</sup></div>
        </td>
    <td colspan="1" style="width: 1%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 6%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">54</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 70%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Director</div> </td> </tr>
  <tr>
    <td style="width: 22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">Eran Perry<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)(2)</sup></div>
        </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 6%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">51</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 70%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Director</div> </td> </tr>
  <tr>
    <td style="width: 22%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Sanford (Sandy) Zweifach<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)(2)(3)</sup></div>
        </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 6%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">65</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 70%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Director (Chairman of the Compensation Committee)</div> </td> </tr>
  <tr>
    <td style="width: 22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">Ari Krashin</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 6%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">49</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 70%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Chief Financial Officer and Chief Operating Officer</div> </td> </tr>
  <tr>
    <td style="width: 22%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Henry Adewoye, MD</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 6%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">57</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 70%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Senior Vice President and Chief Medical Officer</div> </td> </tr>
  <tr>
    <td style="width: 22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Oliver Froescheis, Ph.D.</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 6%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">56</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 70%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Senior Vice President, Corporate and Business Development</div> </td> </tr>
  <tr>
    <td style="width: 22%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Zurit Levine, Ph.D.</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 6%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">54</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 70%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Senior Vice President, Technology Innovation</div> </td> </tr>
  <tr>
    <td style="width: 22%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">Yaron Turpaz, Ph.D.</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 6%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">51</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 70%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Senior Vice President and Senior Advisor, Computational Discovery</div> </td> </tr>
  <tr>
    <td style="width: 22%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Eran Ophir, Ph.D.</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 6%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">44</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 70%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Vice President, Research and Drug Discovery</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 18pt; line-height: 1.25">____________________</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zddb712fdcf6d4358be9d750284dae5c7" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="vertical-align: top; width: 18pt">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">(1)</span></div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">Member of our Compensation
        Committee</span></div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z24b27a359a3245d5aa58acc9668867b1" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="vertical-align: top; width: 18pt">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">(2)</span></div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">Member of our Audit Committee</span></div>
        </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zef9f2aad5e394f328de863e990a4f147" style="font: 10pt Times New Roman, Times, serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="vertical-align: top; width: 18pt">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">(3)</span></div> </td>
    <td style="vertical-align: top; width: auto">
        <div style="text-align: justify; line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">Member of our Nomination and
        Corporate Governance Committee</span></div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z0dfabb7153774b47bc3d04069da91807" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">(4)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Dr. Jean-Pierre Bizzari is expected to retire form the board of directors of the Company effective March 1, 2022.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160; <br /> </div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">75</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Paul Sekhri </span>joined Compugen&#8217;s board of
directors as its Chairman in October 2017. Mr. Sekhri serves as the President and CEO of eGenesis, Inc. since January 2019. Prior to joining
eGenesis, Inc., Mr. Sekhri served as President and CEO of Lycera Corp. from February 2015 through December 2018. From April 2014 through
January 2015, Mr. Sekhri served as Senior Vice President, Integrated Care for Sanofi. From May 2013 through March 2014, Mr. Sekhri served
as Group Executive Vice President, Global Business Development and Chief Strategy Officer for Teva Pharmaceutical Industries Ltd. Prior
to joining Teva, Mr. Sekhri spent five years as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life
sciences venture capital arm of TPG Capital. From 2004 to 2009, Mr. Sekhri was Founder, President, and Chief Executive Officer of Cerimon
Pharmaceuticals, Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc. Previously,
Mr. Sekhri spent four years at Novartis, as Senior Vice President, and Head of Global Search and Evaluation, Business Development and
Licensing for Novartis Pharma AG. Mr. Sekhri also developed the Disease Area Strategy for Novartis, identifying those specific therapeutic
areas upon which the company would focus. Mr. Sekhri&#8217;s first role at Novartis was as Global Head, Early Commercial Development.
Mr. Sekhri completed graduate work in Neuroscience at the University of Maryland School of Medicine, where he also received his BS in
Zoology. Mr. Sekhri is currently a member of the Board of Directors of Veeva Systems Inc., Ipsen S.A., BiomX Inc., and Spring Discovery&#160;and
Chairman of the Board of Directors of Pharming N.V. and of Longboard Pharmaceuticals, Inc. Additionally, Mr. Sekhri is the Chairman of
the Board of the Knights, and a member of Boards of The Metropolitan Opera. Mr. Sekhri is also an active member of the Patrons Council
of Carnegie Hall, where he established the Life Sciences Council of Carnegie Hall.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Anat Cohen-Dayag, Ph.D. </span><span style="font-family: Times New Roman,Times,serif">joined
Compugen&#8217;s board of directors in February 2014. Dr. Cohen-Dayag joined Compugen in 2002 and held various positions. In November
2008, Dr. Cohen-Dayag was appointed as Vice President, Research and Development. In June 2009, Dr. Cohen-Dayag was appointed as co-Chief
Executive Officer of Compugen and in March 2010 Dr. Cohen-Dayag was appointed as Compugen&#8217;s President and CEO. Prior to joining
Compugen, Dr. Cohen-Dayag was head of research and development and member of the Executive Management at Mindsense Biosystems Ltd. Prior
to Mindsense Biosystems Ltd., Dr. Cohen-Dayag served as a scientist at the R&amp;D department of Orgenics Ltd. Dr. Cohen-Dayag is a member
of the Board of Directors of Pyxis Ltd. Dr. Cohen-Dayag holds a B.Sc. in Biology from the Ben-Gurion University, Israel, and an M.Sc.
in Chemical Immunology and a Ph.D. in Cellular Biology, both from the Weizmann Institute of Science, Israel. Additionally, Dr. Cohen-Dayag
is a member of the Bio-Convergence Initiative of the Israel Academy of Sciences and Humanities.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Dr. Jean-Pierre Bizzari </span><span style="font-family: Times New Roman,Times,serif">joined
Compugen&#8217;s board of directors in September 2018. Dr. Bizzari is a world-renowned oncology expert who brings to Compugen over 35
years of broad experience in oncology drug development. Dr. Bizzari served as Executive Vice President and Global Head of Oncology at
Celgene Corporation, responsible for Celgene&#8217;s clinical development and operations-statistics teams across the United States, Europe
and Asia/Japan where he oversaw the development and approval of leading oncology products, including REVLIMID&#174; (lenalidomide), VIDAZA&#174;
(azacitidine), ISTODAX&#174; (romidepsin) and ABRAXANE&#174; (nab-paclitaxel). In addition, he was chairman of Celgene&#8217;s hematology
oncology development committee and a member of the company&#8217;s management committee. Prior to Celgene, Dr. Bizzari was the Vice President,
Clinical Oncology Development for Sanofi-Aventis (formerly Rh&#244;ne-Poulenc, Rh&#244;ne-Poulenc Rorer and Aventis) where he oversaw
the approval of Eloxatin&#174; (oxaliplatin), Taxotere&#174; (docetaxel) and Elitek&#174; (rasburicase). Dr. Bizzari joined the pharmaceutical
industry in 1983 as Head of Oncology at the Institut de Recherches Internationales SERVIER (France). Dr. Bizzari is a member of the Scientific
Advisory Board of the French National Cancer Institute, and a member of the board of the European Organization for Research and Treatment
of Cancer and Chairman of the New Drug Advisory Committee. He also serves on the boards of Halozyme Therapeutics, Onxeo, Oxford BioTherapeutics,
Nordic Nanovector and Transgene. Dr. Bizzari received his medical degree from the Nice Medical School and has trained at the Piti&#233;-Salp&#234;tri&#232;re
Hospital in Paris, The Ontario Institute for Cancer Research, and The McGill Rosalind and Morris Goodman Cancer Research Centre (formerly
the McGill Cancer Center) in Montreal, Canada.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">76</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Gilead Halevy </span>joined Compugen&#8217;s board
of directors in June 2018. Mr. Halevy serves as a general partner of Kedma Capital Partners, a leading Israeli private equity fund, of
which he is also a founding member, since 2006. Prior to establishing Kedma, Mr. Halevy served as a Director at Giza Venture Capital from
2001 to 2006, where he led investments in communication and information technology companies and directed Giza&#8217;s European business
activities. From 1998 to 2001, Mr. Halevy practiced law at White &amp; Case LLP. Mr. Halevy was also a founding member of the White &amp;
Case Israel practice group during that time. Mr. Halevy currently serves as chairman of board of directors of Brand Industries Ltd. (TASE),
<span style="font-family: Times New Roman,Times,serif">Iskoor Finance Ltd., Carmel Wineries; Continuity Software Ltd. and a director of
S. AL Holdings. Mr. Halevy holds a B.A. in Humanities (multidisciplinary program for exceptional students) and an LL.B. (Magna Cum Laude)
both from the Hebrew University of Jerusalem.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Dr. Kinneret Livnat Savitzky </span>joined Compugen&#8217;s
board of directors in June 2018. <span style="font-family: Times New Roman,Times,serif">Dr. Livnat Savitzky currently serves as a managing
partner at Team8 and Director at Team8 Health, Partner 1 GP Ltd. Dr. Livnat Savitzky also serves on the boards of the following biotechnology
or healthcare companies: FutuRx and several of its portfolio companies, Ramot (TTO of Tel-Aviv University), Nutritional Growth Solutions,
DreaMed Diabetes and Biomica. Between 2017 and 2021 she served as the CEO of FutuRx Ltd., an Israeli biotechnology accelerator established
by OrbiMed Israel Partners, Johnson &amp; Johnson Innovation, Takeda Ventures Inc., and LEAPS, the venture arm of Bayer. From 2010 to
2016, Dr. Livnat Savitzky served as CEO of BioLineRX Ltd., a Nasdaq-listed drug development company focused on oncology and immunology.
During her tenure, BioLineRX signed a strategic collaboration with Novartis as well as licensing agreements with Merck (MSD), Genentech
and others. Prior to being appointed CEO of BioLineRX, Dr. Livnat Savitzky held various R&amp;D management positions at BioLineRX and
Compugen. Dr. Livnat Savitzky holds a B.Sc. in Biology from The Hebrew University of Jerusalem, and an M.S.c and Ph.D. with distinction
in Human Genetics from Tel Aviv University.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Eran Perry </span><span style="font-family: Times New Roman,Times,serif">joined
Compugen&#8217;s board of directors in July 2019. Eran Perry brings to Compugen over 20 years of diverse experience across various segments
of the healthcare industry as an entrepreneur and venture capital investor as well as in general management and strategy. In 2018, Mr.&#160;Perry
co-founded MII Fund &amp; Labs, a dermatology-focused venture capital fund where he also serves as Managing Director and Chairman of the
Investment Committee. Mr. Perry is also the co-founder and board member of several pharmaceutical companies including Musli Thyropeutics,
ICD Pharma, Seanergy Dermatology, Follicle Pharma and Upstream Bio. Mr. Perry also serves on the board of directors of MyBiotics Pharma
and Noon Aesthetics. From 2006 to 2016, he served as Managing Director and Partner of Israel Healthcare Ventures (IHCV) and represented
IHCV in numerous portfolio companies. Prior to IHCV, Mr. Perry was a consultant in McKinsey &amp; Company, serving clients worldwide in
the pharmaceutical industry, among others. Prior to that, he was a member of the Global Marketing group at Novartis Oncology.&#160;Before
moving to the private sector, Mr.&#160;Perry served in the Israeli Ministry of Justice. Mr. Perry holds an MBA from Columbia University,
and an LL.B. in Law and a B.Sc. in Mathematics and Computer Science, both from Tel Aviv University.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Sanford (Sandy) Zweifach </span>joined Compugen&#8217;s
board of directors in June 2018. Mr. Zweifach is the Founder of Nuvelution Pharma, Inc. and since 2015 through 2019 was the Chief Executive
Officer of Nuvelution Pharma, Inc. From 2010 to 2015, Mr. Zweifach served as CEO of Ascendancy Healthcare, Inc., which he also founded.
He has also been a Partner at Reedland Capital Partners, a boutique investment bank, from 2005 to 2010, where he headed its life sciences
M&amp;A and advisory efforts. From 2003 to 2005, he was CEO of Pathways Diagnostics, a biomarker development company. Mr. Zweifach was
a Managing Director/CFO of Bay City Capital, a venture capital/merchant banking firm, specializing in the biotech and the life science
industry, where he was responsible for oversight of the firm&#8217;s finance department, as well as President of the firm&#8217;s M&amp;A
and financing division. Prior to this, he was President and CFO of Epoch Biosciences, which was acquired by Nanogen in 2004. <span style="font-family: Times New Roman,Times,serif">Currently
Mr. Zweifach serves as a member of the leadership team of Palladio Biosciences and Janpix, Inc. both are subsidiaries of Centessa Pharmaceuticals
Limited, Executive Chairman of the Board of Directors of Kaerus Bioscience, Chairman of the Board of Directors of Carisma Therapeutics,
Inc., Chair of the Business Advisory Board of IMIDomics, S.L. and as a member of the Board of Directors of Essa Pharma, Inc. Earlier in
his career, Mr. Zweifach was a Certified Public Accountant (US) for Coopers &amp; Lybrand and held various investment banking positions
focusing on biotech. He received his B.A. in Biology from UC San Diego and an M.S. in Human Physiology from UC Davis.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">77</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Ari Krashin </span>joined Compugen in 2014 as Chief
Financial Officer and in 2016 was appointed also as Chief Operating Officer. Mr. Krashin has over 15 years of experience in capital markets,
finance and business development. He served as a chief financial officer for both public and private companies the most recent being AnyClip
Media and Spacenet Inc. From 2000 to 2013, Mr. Krashin also served in various financial positions at Gilat Satellite Networks (NASDAQ:
GILT), including his last position as chief financial officer, where he led the company&#8217;s global finance and related operations,
including business development, M&amp;A activities, investor relations and administration. Mr. Krashin is a certified public accountant
and began his professional career with Kesselman and Kesselman, PWC, Israel. Mr. Krashin holds a B.A. in Business Administration and Accounting
fro<span style="font-family: Times New Roman,Times,serif">m the College of Management, Rishon Le&#8217;Zion.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Dr. Henry Adewoye </span>joined Compugen in March
2018 as Chief Medical Officer, bringing to Compugen over 20 years of extensive experience in leading multiple clinical trials in Oncology
and Hematology in both the biopharmaceutical industry and academia. Before Compugen, Dr. Adewoye was with Gilead Sciences Inc., as Clinical
Director in Oncology Clinical Research and was on the Oncology Leadership Team. He most recently served as Project Team and Clinical Lead
for Idelalisib (first-in-class PI3K delta inhibitor approved for the treatment of relapsed CLL, FL/SLL) and Andecaliximab (MMP9 mAb inhibitor).
Previously, he was Clinical Research Medical Director in Oncology at Amgen Inc. Dr. Adewoye was the Global Medical Monitor for the initial
registrational trial of the bispecific antibody blinatumomab (Blincyto&#174;) and several Phase 2 and 3 studies evaluating VEGF inhibitors
(Motesanib, Trebananib) in patients with solid tumors. Dr. Adewoye completed his fellowship in Hematology/Oncology at Boston Medical Center
and completed his residency in Internal Medicine at Meharry Medical College. Dr. Adewoye received his medical degree at the University
of Jos, Nigeria and fellowship training in Hematology and Laboratory medicine at the University College Hospital Ibadan, Nigeria. <span style="font-family: Times New Roman,Times,serif">Dr.
Adewoye has initial board certifications by the American Board of Internal Medicine in Medical Oncology, Hematology and Internal Medicine.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Oliver Froescheis, Ph.D.</span><span style="font-family: Times New Roman,Times,serif">
joined Compugen in January 2020 as Senior Vice President, Corporate and Business Development. Dr. Froescheis has over 20 years of experience
in the pharmaceutical industry during which he has held positions in research, project management, marketing and business development.
Dr. Froescheis joined Compugen from Roche, where he spent the last 12 years in the Partnering organization, initially serving as Global
Due Diligence Director for in-licensing and M&amp;A projects, then acting as Director of Business Development &amp; Licensing, responsible
for oncology/immuno-oncology partnering projects and most recently leading R&amp;D out-licensing across therapeutic areas. Dr. Froescheis
holds a Diploma in Chemistry and a Ph.D. in Analytical Chemistry, both from the University of Ulm, Germany.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Zurit Levine, Ph.D. </span>was appointed as Senior
Vice President, Technology Innovation <span style="font-family: Times New Roman,Times,serif">in 2018, responsible for leading and advancing
the Company&#8217;s computational innovation towards new discovery fields and areas. In this capacity, Dr. Levine is also responsible
for the Company&#8217;s IP strategy and portfolio. Dr. Levine joined Compugen in 1999 and has held several positions in Compugen&#8217;s
Research &amp; Development department. In 2004, she was appointed Director of Therapeutic Selection &amp; Validation, which position she
held until 2007 when she was appointed Director of Therapeutic Discovery. In 2009, she was appointed Executive Director of Research &amp;
Development. From January 2010 to August 2011, she held the position of Vice President, Research and Development. In August 2011 she was
appointed Vice President, Research and Discovery. Dr. Levine holds a B.Sc. in Biology, a M.Sc. in Biochemistry and a Ph.D. in Biochemistry,
all from the Tel Aviv University, Israel.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Yaron Turpaz, Ph.D.</span><span style="font-family: Times New Roman,Times,serif">
joined Compugen in November 2019 as Senior Vice President and Senior Advisor, Computational Discovery. Dr. Turpaz has over 15 years of
experience in the fields of research and development informatics, data sciences and technology in the biotech and pharma space with hands-on
experience using cloud based high throughput computational, machine learning and genomics platforms for drug discovery and development
applications in precision medicine. In his extensive pharma and biotech career, he held senior R&amp;D Informatics roles at Human Longevity,
AstraZeneca, Eli Lilly and Affymetrix. Dr. Turpaz continues to lead data science and technology at Global Gene Corp. and serve as Chief
Information Officer and Senior Advisor at Engine Biosciences. Dr. Turpaz received a B.Sc. in Biology from Tel Aviv University, a Ph.D.
in Bioengineering from the University of Illinois and an MBA from the University of Chicago, Booth School of Business. He also held an
Adjunct Assistant Professor position at the Centre for Quantitative Medicine of Duke-National University of Singapore, Graduate Medical
School.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold">Eran Ophir, Ph.D.</span><span style="font-family: Times New Roman,Times,serif">
joined Compugen in 2015 and was appointed Vice President, of Research and Drug Discovery in March 2020. In his role, Dr. Ophir is responsible
for</span> Compugen&#8217;s<span style="font-family: Times New Roman,Times,serif"> research and drug discovery activities, overseeing
the research into the biology of Compugen&#8217;s computationally discovered targets and therapeutic lead antibody identification and
selection. Dr. Ophir brings significant expertise in immunology and immuno-oncology from his research work at the Weizmann Institute of
Science and the Ludwig Institute for Cancer Research in Lausanne, Switzerland. Dr. Ophir joined Compugen&#8217;s immuno-oncology group
as a senior scientist and has since held various positions in the Research and Development department, with increasing responsibilities.
Dr. Ophir received a B.Sc. in Bioinformatics from Tel Aviv University and a Ph.D. in Biology from the Weizmann Institute of Science.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">78</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Arrangements Involving Directors and Senior Management</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">There are no arrangements or understandings of which we are aware relating to the
election of our directors or the appointment of executive officers in our Company. In addition, there are no family relationships among
any of the individuals listed in this Item 6.A.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">B. COMPENSATION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Aggregate Executive Compensation</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">During 2021, the aggregate compensation paid or accrued by us to all persons listed
in Item 6.A above (Directors and Senior Management) was approximately $5.7 million. This amount includes approximately $0.4 million set
aside or accrued to provide pension, severance, retirement or similar benefits, but excludes expenses (including business travel, professional
and business association dues and expenses) reimbursed to our executives and other fringe benefits commonly reimbursed or paid by companies
in Israel.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">During 2021, we granted to our Directors and Senior Management listed in Item 6.A
a total of 550,000 options to purchase ordinary shares. These options are exercisable at an average exercise price of $6.45 per share,
and generally expire ten years after their respective dates of grant. As of December 31, 2021, there were a total of <span style="font-family: Times New Roman,Times,serif">4,111,124
outstanding options to purchase ordinary shares that were held by our Directors and Senior Management listed in Item 6.A.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Individual Compensation of Covered Office Holders</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25">The table below outlines the compensation granted to our five most highly compensated
Office Holders (as such term is defined in the Companies Law - see below under &#8220;Approvals Required for Office Holders Terms of Employment&#8221;)
with respect to the year ended December&#160;31, 2021. All amounts reported in the table reflect the cost to the Company, as recognized
in our financial statements for the year ended December&#160;31, 2021. We refer to the five individuals for whom disclosure is provided
herein as our &#8220;Covered Office Holders&#8221;.</div>

<div style="text-align: justify; line-height: 1.25"> <br /> </div> </div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="z132e365cb52c454f9c52f035e6845208" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-weight: bold">Information Regarding the Covered Office Holders</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="14" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Compensation for Services<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-weight: bold">Name and Principal Position<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td class="cftguttercell" colspan="1" style="font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: center">
        <div style="line-height: 1.25; font-weight: bold">Base Salary ($)</div> </td>
    <td class="cftfncell" colspan="1" style="white-space: nowrap; font-family: Times New Roman,Times,serif; text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: center">
        <div style="line-height: 1.25; font-weight: bold">Benefits and Perquisites ($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup></div>
        </td>
    <td class="cftfncell" colspan="1" style="white-space: nowrap; font-family: Times New Roman,Times,serif; text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: center">
        <div style="line-height: 1.25; font-weight: bold">Stock-Based Compensation ($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(4)</sup></div>
        </td>
    <td class="cftfncell" colspan="1" style="white-space: nowrap; font-family: Times New Roman,Times,serif; text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: center">
        <div style="line-height: 1.25; font-weight: bold">Total ($)</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 52%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Dr. Anat Cohen-Dayag</div>
        <div style="line-height: 1.25">President &amp; Chief Executive Officer</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">498,266</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">333,362</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">469,679</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,301,307</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 52%">
        <div style="line-height: 1.25">Dr. Henry Adewoye</div>
        <div style="line-height: 1.25">Senior Vice President and Chief Medical Officer</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">400,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">160,690</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">276,178</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">836,868</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 52%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Ari Krashin</div>
        <div style="line-height: 1.25">Chief Financial and Operating Officer</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">315,770</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">209,604</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">240,812</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">766,186</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 52%">
        <div style="line-height: 1.25">Dr. Oliver Froescheis</div>
        <div style="line-height: 1.25">Senior Vice President, Corporate and Business Development</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">370,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">77,238</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">219,111</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">666,349</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 52%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Dr. Zurit Levine</div>
        <div style="line-height: 1.25">Senior VP, Technology Innovations</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">204,322</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">129,862</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">144,554</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">478,738</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z56a8b33255f64d03a6e35a6af04f085f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>All Covered Office Holders listed in the table were full-time officers of the Company in 2021.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z240c3ad609f34856bc19be34aa70fa0a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Cash compensation amounts denominated in currencies other than the U.S. dollar were converted into U.S. dollars at an exchange rate
        of NIS 3.2302= $1.00, which reflects the average conversion rate for 2021, or the Representative Rate.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc1716f72cdfe471691796905c700c5ea" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Amounts reported in this column include benefits and perquisites, including those mandated by applicable law. Such benefits and perquisites
        may include, to the extent applicable to the respective Covered Office Holder, bonuses, payments, contributions and/or allocations for
        savings funds, pension, severance, vacation, car or car allowance, medical insurances and benefits, risk insurance (e.g., life, disability,
        accident), phone, convalescence pay, payments for social security, tax gross-up payments and other benefits and perquisites consistent
        with the Company&#8217;s policies.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zdf05d0858cc54699b6269c26d0dc383a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">4)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Amounts reported in this column represent the expense recorded in our financial statements for the year ended December 31, 2021,
        with respect to options to purchase our ordinary shares granted to our Covered Office Holders. Assumptions and key variables used in the
        calculation of such amounts are discussed in Note 2m to our 2021 consolidated financial statements set forth elsewhere in this report.</div>
        </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">79</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Compensation Policy</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Companies Law we are required to adopt a compensation policy, which sets
forth company&#8217;s policy regarding the terms of office and employment of office holders, including compensation, equity awards, severance
and other benefits, exemption from liability and indemnification. Such compensation policy should take into account, among other things,
the provision of proper incentives to directors and officers, management of risks by the company, the officer&#8217;s contribution to
achieving corporate objectives and increasing profits, and the function of the officer or director.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our compensation policy, or the Compensation Policy, is designed to balance between
the importance of incentivizing office holders to reach personal targets and the need to assure that the overall compensation meets our
Company&#8217;s long-term strategic performance and financial objectives. The Compensation Policy provides our compensation committee
and our board of directors with adequate measures and flexibility to tailor each of our office holder&#8217;s compensation package based,
among other matters, on geography, tasks, role, seniority and capability. Moreover, the Compensation Policy is intended to motivate our
office holders to achieve ongoing targeted results in addition to high-level business performance in the long term, without encouraging
excessive risk taking. The Company draws upon a pool of talent that is highly sought after by large and established global pharmaceutical
and biotechnology companies, as well as by other development-stage life science companies which operate both within and outside of the
Company&#8217;s geographic areas. The Company believes that it therefore must offer compensation terms, both to its executives and to
its directors that are competitive with the compensation standards that exist in the companies with whom it competes for such talents.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In accordance with the Companies Law, an Israeli public company&#8217;s compensation
policy and any amendments thereto must be approved by the board of directors, after considering the recommendations of the compensation
committee, and by a special majority of our shareholders, or a Special Majority, which should include (i) at least a majority of the shareholders
who are not controlling shareholders and who do not have a personal interest in the matter, present and voting (abstentions are disregarded),
or (ii) the non-controlling shareholders and shareholders who do not have a personal interest in the matter who were present and voted
against the matter hold two percent or less of the voting power of the company. The compensation policy must be reviewed from time to
time by the board and must be re-approved or amended by the board of directors and the shareholders no less than every three years. If
the compensation policy is not approved by the shareholders, the compensation committee and the board of directors may nonetheless approve
the policy, following further discussion of the matter and for detailed reasons.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our Compensation Policy for office holders was originally approved by our shareholders
in September 2013, with the most recent amendment adopted at the 2020 Annual General Meeting of Shareholders.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">80</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Approvals Required for Office Holders Terms of Employment</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The term &#8220;Office Holder&#8221; as defined in the Companies Law includes a <span style="font-family: Times New Roman,Times,serif">director,
the chief executive officer, chief business manager, deputy chief executive officer, vice chief executive officer, any other person fulfilling
or assuming any of the foregoing positions without regard to such person&#8217;s title, and any manager who is directly subordinated to
the chief executive officer. In addition to each person listed in the table under &#8220;Item 6. Directors, Senior Management and Employees
- A. Directors and Senior Management&#8221;, two other individuals have been Office Holders as of December 31, 2021.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">&#8220;Terms of Office and Employment&#8221; means the terms of office and employment
of our Office Holders, including exemption and release of the Office Holder from liability for breach of his or her duty of care to the
Company, an undertaking to indemnify the Office Holder, post factum indemnification or insurance; any grant, payment, remuneration, compensation,
or other benefit provided in connection with termination of service and any benefit, other payment or undertaking to provide any payment
as aforesaid.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Compensation for Office Holders subordinated to the
Chief Executive Officer.</span><span style="font-family: Times New Roman,Times,serif"> The terms of office and employment of Office Holders
(other than directors and the chief executive officer) require the approval of the compensation committee and the board of directors,
provided such terms are in accordance with the company&#8217;s compensation policy. Shareholder approval is also required if the compensation
of such officer is not in accordance with such policy. However, in special circumstances the compensation committee and then the board
of directors may nonetheless approve such compensation even if such compensation was not approved by the shareholders, following a further
discussion and for detailed reasoning.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Compensation for Office Holders who are Directors
or Chief Executive Officers.</span><span style="font-family: Times New Roman,Times,serif"> The Terms of Office and Employment of directors,
other than directors who serve as chief executive officers and/or who possess a controlling interest in a company, require the approval
of the compensation committee, board of directors and shareholders by a simple majority, as long as it complies with the compensation
policy. With respect to our president and chief executive officer, who is also a director, or with respect to any chief executive officer
who is not a director (to the extent applicable in the future), further approval of the shareholders by the Special Majority is required.
However: (A) under certain circumstances, and to the extent that the proposed Terms of Office and Employment are in compliance with the
compensation policy, a company may be exempt from receiving shareholder approval with respect to the Terms of Office and Employment of
a candidate for the position of chief executive officer (provided that the candidate is not a director) (i) provided that the company&#8217;s
compensation committee and board of directors approved such terms and that such terms: (a) are not more beneficial than the terms of the
former chief executive officer, or are essentially the same in their effect; (b) are in line with the compensation policy; and (c) are
brought for shareholder approval at the next general meeting of shareholders; and (B) a company&#8217;s compensation committee and board
of directors are permitted to approve Terms of Office and Employment of a director, without convening a general meeting of shareholders,
provided that such terms are only beneficial to the Company or that such terms are in compliance with the terms set forth in the Companies
Regulations (Rules Regarding Compensation and Expenses of External Directors), 2000.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Variable Compensation and Annual Cash Bonuses of
Office Holders</span><span style="font-family: Times New Roman,Times,serif">. The Companies Law requires that all variable compensation
of directors and chief executive officers be based on measurable criteria, with the exception of a non-substantial portion of up to 3
monthly salaries, which should take into consideration the applicable Office Holder&#8217;s contribution to the company. With respect
to Office Holders who are not directors or chief executive officers, the Companies Law allows that 100% of the variable compensation be
based on non-measurable criteria. Our Compensation Policy allows for a non-substantial portion of up to 20% of the bonus objectives for
each year to be based on non-measurable criteria, provided, however, that with respect to (i) our Office Holders who are not directors
nor our chief executive officer, our compensation committee and board of directors may increase the portion of targets based on non-measurable
criteria above the rate of 20%, up to 50% and with respect to our chief executive officer, our compensation committee and board of directors
may increase the portion of targets based on non-measurable criteria for up to three (3) monthly base salaries. Further, the annual cash
bonus of each of our Office Holders who is not a director is determined according to a formula that is consistent with the Compensation
Policy and that links the bonus payment score to measurable and qualitative objectives relating to both the Company&#8217;s performance
and to the performance by each such Office Holder of his responsibilities. In the case of our Office Holders, other than the chief executive
officer, assuming that the bonus terms conform to the Compensation Policy, the annual bonus objectives and subsequent payment scores are
determined by the compensation committee and board of directors, while the bonus terms for our chief executive officer generally require
the additional approval by our shareholders. For each fiscal year, our board of directors determines the maximum target bonus for each
of our Office Holders, including our chief executive officer.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">81</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Compensation Paid to our Non-Executive Directors (other than Mr.
Paul Sekhri)</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On August 6, 2018, our shareholders approved, following previous resolutions made
by our audit committee (then sitting as a compensation committee) and the board of directors, and consistent with our Compensation Policy,
to compensate each of our <span style="font-family: Times New Roman,Times,serif">non-executive directors whether currently in office or
appointed in the future, excluding the Chairman of the Board (each a &#8220;non-executive director&#8221;) as follows:</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic"><span style="text-decoration: underline">Cash Fee</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; margin-left: 9pt; line-height: 1.25">(i)&#160; an annual fee of $45,000; and</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; margin-left: 9pt; line-height: 1.25">(ii) an additional annual amount to be paid to non-executive directors
for service as members on each of the Company&#8217;s committees, as follows:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2c02942935e04a89b5ae4229b43d7065" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 22.5pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">(a)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Audit Committee - $2,500 for a member, or $5,000 for the chairman;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8c90e81da96041bfa2d2e0577194d5f9" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 22.5pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">(b)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Compensation Committee - $2,000 for a member, or $4,000 for the chairman; and</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4a81540650514181bcbf4edc4570edab" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 22.5pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">(c)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Nomination and Governance Committee - $1,000 for a member, or $3,000 for the chairman.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25">No additional compensation shall be paid for attendance at a board or committee meeting.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">VAT is added to the above compensation in accordance with applicable law.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic"><span style="text-decoration: underline">Equity</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to the cash compensation detailed above, each non-executive director is
entitled to a yearly grant of options to purchase the Company&#8217;s ordinary shares, so that in the first year of service as a director,
each non-executive director shall be entitled to a one-time grant of 35,000 options, or Initial Option Grant, and, in addition, to a yearly
grant of 10,000 options in each of the following years of service, or the Annual Option Grant, as detailed below.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The grant date of each Initial Option Grant is the date of appointment for service
as director, whether initially appointed by the Board or by the general meeting of shareholders, with an exercise price equal to the closing
price of the Company&#8217;s ordinary shares on the Nasdaq on the last trading day prior to the date of their initial appointment to serve
on the Board. The grant date of each Annual Option Grant shall be such date in each year on which the Board approves the annual option
grants to other management Office Holders (provided that the service as director continues at the time of each grant), with an exercise
price equal to the closing price of the Company&#8217;s ordinary shares on the Nasdaq on the last trading day prior to such Board approval.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Mr. Zweifach, a non-executive director, was granted 40,000 options to purchase the
Company&#8217;s ordinary Shares in February 2018 while serving as a consultant to the Company, which service was terminated upon his appointment
as a director by the Board. Mr. Zweifach therefore waived his right to receive the Initial Option Grant in 2018 and is entitled only to
Annual Option Grants.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Both the Initial and the Annual Option Grants are subject (other than as described
herein) to the terms and conditions of the 2010 Plan, or any other equity-based incentive plan the Company may adopt in the future and
pursuant to which these equity awards would be granted. All such grants vest over a four-year period as follows: twenty five percent (25%)
of the options granted vest on the first day of the quarter one calendar year immediately following the quarter in which the options were
granted; and an additional 6.25% of the options granted vest each quarter thereafter, for the next 36 months.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">82</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Notwithstanding the terms of the relevant plan, all options granted to non-executive
directors become fully vested immediately upon the completion of one or more of the following events, whether by way of a consolidation,
merger or reorganization of the Company or otherwise: (a) a sale of all or substantially all of Company&#8217;s issued share capital or
assets to any other company, entity, person or a group of persons, or (b) the acquisition of more than 50% of the Company&#8217;s equity
or voting power by any shareholder or group of shareholders. Further, notwithstanding the terms of the relevant plan, all options granted
which shall be vested as of the date of final termination of office as a non-executive director of the Company may be exercised within
one year following such termination of office. To the extent legally available and applicable, such options will be granted to the non-executive
directors through a trustee under Section 102 of the Israel Income Tax Ordinance [New Version], 5721-1961, or the Tax Ordinance, under
the capital gains route.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">At the Company&#8217;s Annual General Meeting of Shareholders for 2020, held on September
16, 2020, or the 2020 AGM, our shareholders approved, following previous resolutions made by our compensation committee and the board
of directors, and consistent with our Compensation Policy, that instead of an Annual Option Grant, the compensation committee and the
board may issue to all non-executive directors RSUs or other equity awards which are not options, or Other Equity,&#160;in which case
the Annual Option Grant of 10,000 options shall be&#160;adjusted to 5,000 units of Other Equity awards, provided, that with respect to
an annual equity grant that combines both types of equity awards (<span style="font-style: italic">i.e.</span>, options and Other Equity),
such grant shall be adjusted, on a&#160;pro rata&#160;basis, to give effect to the relative portion of each type of equity awarded (for
<span style="font-family: Times New Roman,Times,serif">illustration purposes, if the compensation committee and board approve the grant
of 4,000 RSUs to the non-executive directors, the relevant&#160;annual equity grant will be comprised of a total of 6,000 units, out of
which 4,000 will be RSUs and 2,000 will be options).</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The provisions relating to vesting, acceleration and exercise period applicable to
options, as specified above, shall <span style="font-family: Times New Roman,Times,serif">apply to Other Equity that may be granted,&#160;<span style="font-style: italic">mutatis
mutandis</span>.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Compensation to the Company&#8217;s Chairman of the Board of Directors,
a Non-Executive Director</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On October 19, 2017, our shareholders approved, following previous resolutions made
by our audit committee (then sitting as a compensation committee) and the board of directors, and consistent with our Compensation Policy,
the <span style="font-family: Times New Roman,Times,serif">following compensation for our non-executive Chairman of the Board, Mr. Paul
Sekhri:</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Cash Fees: </span><span style="font-family: Times New Roman,Times,serif">An
annual cash fee in the amount of $150,000. No meeting fees will be paid in addition to such annual cash fee.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Grant of Options to Purchase Ordinary Shares:</span><span style="font-family: Times New Roman,Times,serif">
In connection with his appointment as the Chairman of the Board, we issued to Mr. Sekhri an initial grant of options to purchase 500,000
ordinary shares. These options were issued pursuant to the terms and conditions applicable to options granted under the Company&#8217;s
2010 Option Plan. Such grant vested over a four-year period as follows: twenty five percent (25%) vested on the first day of the quarter
one calendar year immediately following the quarter in which the options were granted; and an additional 6.25% vested each quarter thereafter
for the next 36 months. These options will expire ten years after the grant date, unless they expire earlier in accordance with the terms
of the Company&#8217;s 2010 Option Plan. The acceleration provisions applicable to options granted to other non-executive directors also
apply to the options granted to Mr. Sekhri and all options granted which shall be vested as of the date of final termination of office
as a director of the Company may be exercised within one year following such termination date.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">At the 2020 AGM, our shareholders approved, following previous resolutions made by
our compensation committee and the board of directors, and consistent with our Compensation Policy, that Mr. Sekhri, in his role as the
non-executive chairman of the Board, shall be entitled to an annual option grant of 10,000 options to purchase Ordinary Shares each year,
or Chairman&#8217;s Annual Option Grant, starting from 2020 and for each of the following years of service, similar to the terms of the
Annual Option Grant to the other non-executive directors as specified above. The grant date for the 2020 Annual Option Grant was the day
of the 2020 AGM (i.e., September 16, 2020) and the exercise price is the closing price of the Company&#8217;s ordinary shares on the Nasdaq
on the last trading day prior to such date.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As approved for the other non-executive directors, instead of Chairman&#8217;s Annual
Option Grant, the compensation committee and the board may issue to Mr. Sekhri Other Equity,&#160;in which case the Chairman&#8217;s Annual
Option Grant of 10,000 options shall be&#160;adjusted to 5,000 units of Other Equity awards, provided, that with respect to an annual
equity grant that combines both types of equity awards, such grant shall be adjusted, on a&#160;pro rata&#160;basis, to give effect to
the relative portion of each type of equity awarded as specified above with respect to other non-executive directors.</div>

<div style="text-align: justify; line-height: 1.25"> <br /> </div>

<div style="text-align: justify; line-height: 1.25">The provisions relating to vesting, acceleration and exercise period applicable to
the options, as specified above, shall apply to Other Equity that may be granted as set forth above,&#160;<span style="font-style: italic">mutatis
mutandis</span>.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">83</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Compensation to our President and Chief Executive Officer</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Pursuant to Dr. Anat Cohen-Dayag&#8217;s employment agreement (and in accordance with
the approval of her updated compensation terms at the 2020 AGM), as the chief executive officer of the Company she is entitled to a gross
monthly salary of NIS 134,125 (approximately $41,520 according to the Representative Rate). Dr. Cohen-Dayag is also entitled to certain
benefits and perquisites customary in Israel, including those mandated by applicable law. In addition, Dr. Anat Cohen-Dayag is eligible
for an annual grant of equity-based compensation and to an annual cash bonus based upon achievement of objectives determined by the Company,
both subject to receipt of all approvals required by applicable law<span style="font-family: Times New Roman,Times,serif"> and to the
terms of our Compensation Policy.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">At the 2020 AGM, our shareholders approved that Dr. Cohen-Dayag shall be eligible
to receive an annual cash bonus of up to nine monthly salaries for each of the calendar years 2021, 2022 and 2023, without the need for
further shareholder approval, <span style="font-family: Times New Roman,Times,serif">subject to meeting the specific performance criteria
determined by the compensation committee and board with respect to each such year, in accordance with the objectives and terms thereof
and the continuous employment of Dr. Cohen-Dayag as the Company&#8217;s chief executive officer through the last day of the calendar year
with respect to which the annual cash bonus is proposed to be paid. Additionally, at the 2020 AGM, our shareholders approved an annual
equity grant plan for Dr. Cohen-Dayag for each of the calendar years 2021, 2022 and 2023, according to which Dr. Cohen-Dayag shall be
granted options to purchase up to 150,000 Ordinary Shares, or Equity Framework, in each of these years, as shall be determined by the
compensation committee and board of directors with respect to each such year. In order to align such grants (including the exercise price
and vesting period) with the annual grant of options to other executive Office Holders (for whom shareholder approval is not required),
our shareholders resolved that the annual grant to Dr. Cohen-Dayag will be made on such date in 2021, 2022 and 2023 on which the board
of directors approves the respective year&#8217;s annual option grants to management Office Holders in such year.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The compensation committee and the board of directors may nevertheless determine that
as part of an annual equity grant, they wish to issue&#160;Dr. Cohen-Dayag Other Equity. For the purpose of demining the applicability
of the Equity Framework to Other Equity, Other Equity shall be given a &#8220;double weight&#8221; relative to options, so that each unit
of Other Equity will be equal to two (2) option units. For illustration purposes, if the compensation committee and board of directors
approve an annual equity grant to Dr. Cohen-Dayag of 40,000 options and 30,000 RSUs, then for the purpose of determining whether such
grant is within the Equity Framework, the 30,000 RSUs will be given a weight of 60,000 units and the 40,000 options will be counted as
40,000 units, comprising an aggregate of 100,000 units which is within the Equity Framework. In any event, at least 30% of the value of
any annual equity grant to Dr. Cohen-Dayag shall be based on either (i) options granted with fair market value exercise price; or (ii)
Other Equity which vesting is based on both time and performance criteria, as shall be determined by the compensation committee and board
of directors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The options granted in each respective year shall be subject to the terms and conditions
applicable to options granted under the 2010 Plan (or any other option plan adopted by the Company). Each annual option grant will vest
over a four-year period as follows: twenty five percent (25%) will vest on the last day of the quarter one calendar year from the date
of grant; and an additional 6.25% will vest each quarter thereafter for the next 36 months. These options will have an exercise price
equal to the closing price of the Company&#8217;s ordinary shares on Nasdaq on the last trading day prior to the approval of each year&#8217;s
grant by the board of directors. These options will expire ten years after the grant date, unless they expire earlier in accordance with
the terms of the 2010 Plan or the terms of the option agreement to be entered into between the Company and Dr. Cohen-Dayag. If applicable,
the options will be granted through a trustee under Section 102 of the Tax Ordinance and, in accordance with the Company&#8217;s previous
election in this regard, be subject to the capital gains route for tax purposes.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">All vested options and Other Equity (to the extent applicable) granted to Dr. Cohen-Dayag
under the Equity Framework shall have a one-year exercise period following the termination of her employment as the Company&#8217;s chief
executive officer, other than in the event of termination for &#8220;cause&#8221; (as defined in her employment agreement as shall be
in effect from time to time). In addition to the foregoing, and not as part of the Equity Framework, Dr. Anat Cohen-Dayag will be entitled
to participate in the ESPP or any other employee share purchase plan(s) that may be adopted by the Company from time to time until the
end of 2023, as long as the fair market value of the benefit provided to her under such employee share purchase plan(s) (determined by
the Company at the beginning of the respective offering period) in any given twelve (12) month period does not exceed ten percent (10%)
of her annual base salary.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In 2021 Dr. Cohen-Dayag was granted with 150,000 options, with an exercise price of
$6.45, pursuant to the terms of the CEO&#8217;s three-year equity framework approved by our shareholders in 2020. As of December 31, 2021,
Dr. Cohen-Dayag held options to purchase a total of 1,210,000 ordinary shares. Out of these outstanding options: (i) options to purchase
857,500 ordinary shares, with a weighted average exercise price of $5.64 per share, were exercisable as of December 31, 2021; and (ii)
options to purchase 352,500 ordinary shares, with a weighted average exercise price of $8.23 per share, had not vested as of December
31, 2021. Of the unvested options on December 31, 2021, options to purchase 151,875 ordinary shares are expected to vest during 2022,
options to purchase 97,500 ordinary shares are expected to vest during 2023 and options to purchase the remaining 103,125 ordinary shares
are expected to vest during the period between January 1, 2024, and September 30, 2025. These unvested options were granted under the
Company&#8217;s 2010 Plan. For additional information on Dr. Cohen-Dayag&#8217;s holdings see &#8220;Item 6. Directors, Senior Management
and Employee - E. Share Ownership - Share Ownership by Directors and Other Executive Officers.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">84</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>

<div style="text-align: justify; line-height: 1.25">Dr. Cohen-Dayag&#8217;s employment agreement may generally be terminated by either
party by providing six (6) months advance written notice, provided that in the event of termination by the Company for &#8220;justifiable
cause&#8221; (as such term is defined in her employment agreement as shall be in effect from time to time) the Company may terminate Dr.
Cohen-Dayag&#8217;s employment without advance notice and that Dr. Cohen-Dayag may resign with advance notice of only two (2) months in
the event of resignation for &#8220;good reason&#8221; (as such term is defined in her employment agreement as shall be in effect from
time to time). Upon termination, Dr. Anat Cohen-Dayag will be entitled to receive certain payments associated with termination.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the event that Dr. Cohen-Dayag&#8217;s employment is: (a) terminated by the Company,
other than for &#8220;justifiable cause&#8221;; or (b) terminated by Dr. Cohen-Dayag for &#8220;good reason&#8221; (hereinafter, (a) and
(b) shall be referred to together as &#8220;Dismissal&#8221;), Dr. Cohen-Dayag will also be entitled to an additional one-time payment
equal to six (6) monthly salaries, or the Termination Payment, and upon Dismissal within one year following certain &#8220;change of control&#8221;
events (as defined in her employment agreement as shall be in effect from time to time), Dr. Cohen-Dayag will be entitled to a special
termination payment (in addition to the Termination Payment) in an amount equal to six (6) monthly salaries.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, upon Dismissal, or in the event of a &#8220;change of control&#8221;,
all outstanding unvested options granted to Dr. Cohen-Dayag as of such time will be accelerated and become immediately exercisable as
of the effective date of such Dismissal or change of control. Upon Dismissal, Dr. Cohen-Dayag will also be entitled to exercise all outstanding
vested options (including those options vested as a result of such accelerated vesting) for a period of one (1) year from the date of
such Dismissal, provided that such period does not extend beyond ten (10) years from the date of grant. Upon an event of change of control,
following which Dr. Cohen-Dayag&#8217;s employment is, within 12 months of the closing of such an event: (a) terminated by the Company,
other than for &#8220;justifiable cause&#8221;; or (b) terminated by Dr. Cohen-Dayag for any reason, Dr. Cohen-Dayag will be entitled
to exercise all outstanding vested options (including those vested as a result of such accelerated vesting) for a period of one (1) year
from the date of termination of her employment, provided that such period does not extend beyond ten (10) years from the date of grant.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Dr. Cohen-Dayag is not entitled to any compensation (including in connection with
her role as a director) in addition to that being paid to her as the chief executive officer of the Company. However, in the event of
termination of Dr. Cohen-Dayag employment agreement, she will be entitled to receive such compensation to the extent and for as long as
she will serve as a non-executive director of the Company.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Insurance, Indemnification and Exemption</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div> </div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Our Office Holder&#8217;s Insurance</span><span style="font-family: Times New Roman,Times,serif">.
Our Articles provide that, subject to the provisions of the Companies Law, we may enter into contracts to insure the liabilities of our
Office Holders for any liabilities or expenses incurred by or imposed upon them as a result of any act (or omission) carried out by them
as our Office Holders, including with respect to any of the following:</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd533dd302bf14a91bd6a1ee7b3ddabeb" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>a breach of duty of care to us or to another person;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd35bac7dbba64a399676972afd63bfdf" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>a breach of duty of loyalty to us, provided that the Office Holder acted in good faith and had reasonable grounds to assume that
        such act would not prejudice our interests;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z865ce778574648588b26a849d171276c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>monetary liabilities or obligations imposed upon him or her in favor of another person;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zba480e255f9c4c0e8bf8c38f446fa075" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>A payment which the Office Holder is obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the Israel
        Securities Law, 5728-1968, or the Securities Law, and expenses that the Office Holder incurred in connection with a proceeding under Chapters
        H&#8217;3, H&#8217;4 or I&#8217;1 of the Securities Law, including reasonable litigation expenses, including attorney&#8217;s fees, or
        in connection with Article D of Chapter Four of Part Nine of the Companies Law; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3d72cab8389b4844aff22ced722c4969" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Expenses incurred by the Office Holder in connection with a proceeding under Chapter G&#8217;1, of the Israel Restrictive Trade Practices
        Law, 5748-1988, or Restrictive Trade Law, including reasonable litigation expenses, including attorney&#8217;s fees.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">85</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Under the Companies Law, exemption and indemnification of, and procurement of insurance
coverage for, our Office Holders, must be approved by our compensation committee and our board of directors and, with respect to an Office
Holder who is the CEO or a director, also by our shareholders. However, according to regulations promulgated under the Companies Law,
shareholders and board of directors approvals for the procurement of such insurance are not required if the insurance policy is approved
by our compensation committee and: (i) the terms of such policy are within the framework for insurance coverage as approved by our shareholders
and set forth in our Compensation Policy; (ii) the premium paid under the insurance policy is at fair market value; and (iii) the insurance
policy does not and may not have a substantial effect on the Company&#8217;s profitability, assets or obligations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In accordance with our Compensation Policy, approved by our shareholders at the 2020
AGM,&#160;we are currently entitled to hold directors&#8217; and officers&#8217; liability insurance policy for the benefit of our Office
Holders with insurance coverage of up to $100 million and with such annual premium reflecting market&#160;terms&#160;and not having a
substantial effect on our profitability, assets or obligations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Our Office Holders&#8217; Indemnification.&#160;</span>Our
Articles provide that, subject to the provisions of the Companies Law, we may indemnify any of our Office Holders for all liabilities
and expenses incurred by them arising from or as a result of any act (or omission) carried out by them as Office Holders of the Company,
including as follows:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf360a0c156e045c99963b8de0cc96f19" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>For any monetary liabilities or obligations imposed on our Office Holder in favor of another person pursuant to a court judgment,
        including a compromise judgment or an arbitrator&#8217;s decision approved by a court;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z44c646f551fd45f6af5080a884584669" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>For any payments which our Office Holder is obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the
        Securities Law and expenses the Office Holder incurred in connection with a proceeding under Chapters H&#8217;3, H&#8217;4 or I&#8217;1
        of the Securities Law, including reasonable litigation expenses, including attorney&#8217;s fees, or in connection with Article D of Chapter
        Four of Part Nine of the Companies Law;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9661e9a388614a1d9da1995a4d1dae93" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>For reasonable litigation expenses, including attorney&#8217;s fees, incurred by the Office Holder in consequence of an investigation
        or proceeding instituted against the Office Holder by an authority that is authorized to conduct such investigation or proceeding, and
        which was concluded without filing of an indictment against the Office Holder and without imposing on the Office Holder a financial obligation
        in lieu of criminal proceedings, or which was concluded without filing of an indictment against the Office Holder but with imposing on
        such Office Holder a financial obligation in lieu of criminal proceedings in respect of an offense that does not require proof of criminal
        intent or in connection with a financial sanction; For the purposes hereof: (i) &#8220;a proceeding that concluded without filing an indictment
        in a matter in respect of which an investigation was conducted&#8221;; and (ii) &#8220;financial obligation in lieu of a criminal proceeding&#8221;,
        shall have the meanings specified in Section 260(a)(1A) of the Companies Law;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd69e23138aba452ab9ee4c79578f5765" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>For reasonable litigation expenses, including attorney&#8217;s fees, incurred by the Office Holder or which the Office Holder is
        ordered to pay by a court, in a proceeding filed against the Office Holder by the Company or on its behalf or by another person, or in
        a criminal action of which the Office Holder is acquitted, or in a criminal action in which the Office Holder is convicted of an offense
        that does not require proof of criminal intent;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z093732f49abd4a1687c59655d844b151" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>For expenses incurred by our Office Holder in connection with a proceeding under Chapter G&#8217;1, of the Restrictive Trade Law,
        including reasonable litigation expenses, including attorney&#8217;s fees; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb83b736d35834648b615bd1dfc81d300" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>For any other liability, obligation or expense indemnifiable or which our Officer Holders may from time to time be indemnifiable
        by law.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Company may undertake to indemnify an office holder as mentioned above: (a) prospectively,
provided that with respect of the first act (financial liability) the undertaking is limited to events which in the opinion of the board
of directors are foreseeable in light of the Company&#8217;s actual operations when the undertaking to indemnify is given, and to an amount
or criteria set by the board of directors as reasonable under the circumstances, and further provided that such events and amount or criteria
are set forth in the undertaking to indemnify, and (b) retroactively.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">86</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Indemnification letters, covering indemnification of those liabilities discussed above,
were granted to each of our present Office Holders and were amended at the Company&#8217;s Annual General Meeting of Shareholders for
2021, held on September 2, 2021, or the 2021 AGM. The indemnification letters, as amended, seek to indemnify our Office Holders to the
fullest extent permitted under the Companies Law, subject to the specific limitations specified therein.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Our Office Holder&#8217;s Exemption. </span>Our Articles
provide that, subject to the provisions of the Companies Law, we may exempt and release our Office Holders, including in advance, from
all or part of such Office Holder&#8217;s liability for monetary or other damages due to a breach of their duty of care to the Company.
Our directors are released and exempt from all liability as aforesaid to the fullest extent permitted by law with respect to any such
breach, which has been or may be committed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Limitations on Insurance, Indemnification and Exemption.</span>&#160;The
Companies Law provides that a company may not insure, exempt or indemnify an Office Holder for any breach of his or her liability arising
from any of the following:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z20340a55f78b4dc888e3b56a1924a362" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>a breach by the Office Holder of his or her duty of loyalty, except that the company may enter into an insurance contract or indemnify
        an Office Holder if the Office Holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z50437978c7ee4244bc76d323ab5c6b22" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>a breach by the Office Holder of his or her duty of care if such breach was intentional or reckless, but unless such breach was solely
        negligent;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zbee6e379b0ba4ebeb298e5624cb2a531" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>any act or omission done with the intent to derive an illegal personal benefit; or</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3e0807d1ceff42e9b61a3f10f307074d" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>any fine, civil fine, financial sanction or monetary settlement in lieu of criminal proceedings imposed on such Office Holder.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Administrative Enforcement</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Israeli Securities Law includes an administrative enforcement procedure that may
be used by the Israeli Securities Authority, to enhance the efficacy of enforcement in the securities market in Israel. Pursuant to the
Companies Law and the Israeli Securities Law, the Israeli Securities Authority is authorized to impose administrative sanctions, including
monetary fines, against companies like ours and their officers and directors for certain violations of the Israeli Securities Law or the
Companies Law (for further details see &#8220;<span style="font-style: italic">Administrative Enforcement</span>&#8221; below). Furthermore,
the Israeli Securities Law requires that the CEO of a company supervise and take all reasonable measures to prevent the company or any
of its employees from breaching the Israeli Securities Law. The CEO is presumed to have fulfilled such supervisory duty if the company
adopts internal enforcement procedures designed to prevent such breaches, appoints a representative to supervise the implementation of
such procedures and takes measures to correct the breach and prevent its reoccurrence.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Israeli Securities Law, a company cannot obtain insurance against or indemnify
a third-party (including its officers and/or employees) for any administrative procedure and/or monetary fine (other than for payment
of damages to an injured party). The Israeli Securities Law permits insurance and/or indemnification for expenses related to an administrative
procedure, such as reasonable legal fees, provided that it is permitted under the company&#8217;s articles of association.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have adopted and implemented an internal enforcement plan to reduce our exposure
to potential breaches of sections in the Companies Law and the Israeli Securities Law, applicable to us. Our Articles and letters of indemnification
permit, among others, insurance and/or indemnification as contemplated under the Israeli Securities Law (see &#8220;<span style="font-style: italic">Insurance,
Indemnification and Exemption&#8221;</span> above).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. BOARD PRACTICES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are incorporated in Israel, and, therefore, are generally subject to various corporate
governance practices under Israeli law such as with respect to external directors, independent directors, audit committee, compensation
committee, an internal auditor and approvals of interested party transactions. These matters are in addition to the requirements of the
Nasdaq Global Market and other relevant provisions of U.S. securities laws applicable to us. Under the Nasdaq Listing Rules, a foreign
private issuer may generally follow its home country practices for corporate governance in lieu of the comparable Nasdaq Global Market
requirements, except for certain matters such as composition and responsibilities of the audit committee and the SEC-mandated standards
for the independence of its members. We currently comply with all the above-mentioned requirements. See &#8220;Item 3. Key Information
- D. Risk Factors - Risks related to operations in Israel - Being a foreign private issuer exempts us from certain SEC requirements and
Nasdaq rules, which may result in less protection that is afforded to investors under rules applicable to domestic issuers&#8221;. For
information regarding home country practices followed by us see &#8220;Item 16G - Corporate Governance&#8221;.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">87</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Board of Directors</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our Articles provide that we may have no less than five nor more than fourteen directors.
Currently our board of directors consists of seven members. Our directors are elected at the annual general meeting for a term of approximately
one year, ending at the annual general meeting immediately following the annual general meeting at which they were elected or upon earlier
termination in circumstanced referred to under the Companies Law or our Articles. Our di<span style="font-family: Times New Roman,Times,serif">rectors
may further be appointed by the board of director and in this case shall hold office until the end of the immediately following annual
general meeting or upon earlier termination in circumstanced referred to under the Companies Law or our Articles.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On February 24, 2022, we announced that Dr. Jean-Pierre will retire from the board
of directors of the Company effective March 1, 2022, and that effective that date Dr. Mathias Hukkelhoven, Ph.D. will join as a member
of our board of directors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">None of our directors is party to a service contract with us that provides for any
severance or similar benefits upon termination of his or her service, other than our president and chief executive officer, Dr. Anat Cohen-Dayag,
with whom we entered into an employment agreement. For additional information on the employment agreement entered into with Dr. Cohen-Dayag,
please see &#8220;Item 6 - Directors, Senior Management and Employees - B. Compensation - Compensation to our President and Chief Executive
Officer.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Board of Directors Diversity</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">The table below provides certain information regarding the diversity of our board of directors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="3" border="0" id="z8866067e50e248b995d17be778969da2" style="font: 10pt Times New Roman,Times,serif; width: 100%; text-align: left; color: rgb(0, 0, 0)">
  <tr>
    <td colspan="5" style="border-top: rgb(0, 0, 0) 2px solid; width: 100%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">Board Diversity Matrix as of February 15, 2022</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Total Number of Directors</div> </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 2px solid; width: 64.18%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">7</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; background-color: rgb(217, 217, 217); border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; background-color: rgb(217, 217, 217); border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">Female</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; background-color: rgb(217, 217, 217); border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">Male</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; background-color: rgb(217, 217, 217); border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">Non-Binary</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; background-color: rgb(217, 217, 217); border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">Did Not Disclose Gender</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; background-color: rgb(217, 217, 217); border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Part I: Gender Identity</div> </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 2px solid; width: 64.18%; vertical-align: top; background-color: rgb(217, 217, 217); border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Directors</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">2</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">4</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">1</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; background-color: rgb(217, 217, 217); border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Part II: Demographic Background</div> </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 2px solid; width: 64.18%; vertical-align: top; background-color: rgb(217, 217, 217); border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">African American or Black</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Alaskan Native or Native American</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Asian</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Hispanic or Latinx</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Native Hawaiian or Pacific Islander</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">White</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">2</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">3</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Two or More Races or Ethnicities</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">1</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">LGBTQ+</div> </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 2px solid; width: 64.18%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">1</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Did Not Disclose Demographic Background</div> </td>
    <td colspan="4" style="border: rgb(0, 0, 0) 2px solid; width: 64.18%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">1</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Directors Under the Companies Law - General</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A nominee for service as a director in a public company may not be elected without
submitting a declaration to the company, prior to his or her election, specifying that he or she has the requisite qualifications to serve
as a director, an external director or an independent director, as applicable, and the ability to devote the appropriate time to performing
his or her duties as such.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A director, including an external director or an independent director, who ceases
to meet the statutory requirements to serve as a director, external director or independent director, as applicable, must notify the company
to that effect immediately and his or her service as a director will expire upon submission of such notice.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">88</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">External Directors and Independent Directors Under the Companies
Law</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Companies Law, Israeli public companies are generally required to have on
their board of directors at least two external directors meeting certain independence criteria, provided under Israeli law. In accordance
with the Israeli Companies Regulations (Alleviation for Public Companies whose shares are Traded on the Stock Exchange Outside of Israel),
2000, or the Alleviation Regulations, we, as an Israeli public company with no controlling shareholder (within the meaning of the Companies
Law), whose shares are listed on the Nasdaq Global Market, may exempt ourselves from the requirement of having external directors on our
board of directors and related <span style="font-family: Times New Roman,Times,serif">requirements concerning the composition of the audit
and compensation committees of the board of directors, provided that we continue to comply with the U.S. securities laws and Nasdaq Listing
Rules applicable to U.S. domestic issuers regarding the independence of the board of directors and the composition of the audit and compensation
committee. On June 7, 2018, our board of directors determined to opt out of the requirement to elect and have external directors and composition
criteria of the audit committee and compensation committee under the Companies Law pursuant to the relief available under the Alleviation
Regulations, since at that time (and since that time) we have not had a controlling shareholder and as we have been complying with the
Nasdaq majority board independence requirement, and with the Nasdaq and SEC audit and compensation committee composition requirements,
or the Opt Out Criteria. In accordance with this decision, we currently have no external directors on our board of directors.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The term controlling shareholder, as used in the Companies Law for purposes of all
matters related to external directors and for certain other purposes, means a shareholder that has the ability to direct the activities
of the company, other than by virtue of being an Office Holder. For purposes of all matters related to external directors, a shareholder
is presumed to be a controlling shareholder if the shareholder holds 50% or more of the voting rights in the company or has the right
to appoint the majority of the directors of the company or its chief executive officer.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Companies Law, an &#8216;independent director&#8217; is either an external
director or a director appointed or classified as such who meets the same non-affiliation criteria as an external director, as determined
by the company&#8217;s audit committee, and who has not served as a director of the company for more than nine consecutive years. For
these purposes, ceasing to serve as a director for a period of two years or less would not be deemed to sever the consecutive nature of
such director&#8217;s service. However, as our shares are listed on the Nasdaq Global Market, pursuant to the Alleviation Regulations,
we may also classify directors who qualify as independent directors under the relevant non-Israeli rules, as &#8216;independent directors&#8217;
under the Companies Law. In addition, the Alleviation Regulations provide that &#8216;independent directors&#8217; may be elected for
additional terms that do not exceed three years each, beyond the 9 consecutive years, provided that, if the director is being re-elected
for an additional term or terms beyond the 9 consecutive years, the audit committee and board of directors must determine that, in light
of the director&#8217;s expertise and special contribution to the board of directors and its committees, the re-election for an additional
term is to the company&#8217;s benefit and the director must be re-elected by the required majority of shareholders and subject to the
terms specified in the Companies Law. Each of our directors, other than Dr. Anat Cohen-Dayag, who also serves as our chief executive officer,
meets the &#8216;independent directors&#8217; criteria under the Companies Law.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Independent Directors Under the Nasdaq Listing
Rules</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to the requirements of the Companies Law as described above, since our
shares are listed on the Nasdaq Global Market, pursuant to the Nasdaq Listing Rules, a majority of our directors must be independent (as
defined under the Nasdaq Listing Rules). We comply with such Nasdaq independence requirement, as each of our directors, other than Dr.
Anat Cohen-Dayag, who also serves as our president and chief executive officer, has been determined by our board of directors to meet
the Nasdaq independence requirements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Financial and Accounting Expertise Under the
Companies Law</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Pursuant to the Companies Law, the board of directors of a publicly traded company
is required to make a determination as to the minimum number of directors who must have financial and accounting expertise according to
criteria set forth under the Companies Law and <span style="font-family: Times New Roman,Times,serif">regulations promulgated there under
and based, among other things, on the type of company, its size, the volume and complexity of the company&#8217;s activities and the number
of directors. Our board of directors has determined that the minimum number of directors with financial and accounting expertise is one.
Currently, each of Mr. Gilead Halevy, Mr. Eran Perry and Mr. Sanford (Sandy) Zweifach qualifies as such.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">89</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Board Committees</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Audit Committee</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Companies Law requires public companies such as ours to appoint an audit committee<span style="font-family: Times New Roman,Times,serif">,
the responsibilities of which include, among other things: (i) identifying flaws in the management of the company&#8217;s business, among
other things, in consultation with the company&#8217;s internal auditor or external auditor, and making recommendations to the board of
directors as to how to correct them, (ii) reviewing and considering certain related party transactions and certain actions involving conflicts
of interest (as well as deciding whether certain actions specified in the Companies Law are considered material or non-material and whether
certain transactions are considered exceptional or ordinary), (iii) establishing procedures to be followed with respect to related party
transactions with a &#8220;controlling shareholder&#8221; (where such are not extraordinary transactions), which may include, where applicable,
the establishment of a competitive process for such transaction, under the supervision of the audit committee, or individual, or other
committee or body selected by the audit committee, in accordance with criteria determined by the audit committee, (iv) determining procedures
for approving certain related party transactions with a &#8220;controlling shareholder&#8221;, which were determined by the audit committee
not to be extraordinary transactions, but which were also determined by the audit committee not to be negligible transactions, (v) reviewing
the internal auditor&#8217;s work program performance, examining the company&#8217;s internal control structure and processes and determining
whether the internal auditor has the requisite tools and resources required to perform his or her role, (vi) examining the external auditor&#8217;s
scope of work as well as the external auditor&#8217;s fees and providing its recommendations to the appropriate corporate organ, (vii)
overseeing the accounting and financial reporting processes of the Company, and (viii) providing arrangements regarding employee complaints
with respect to flaws in the management of the Company&#8217;s business.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Nasdaq Listing Rules, we are required to maintain an audit committee that
operates under a formal written charter and has certain responsibilities and authority, including being directly responsible for the appointment,
compensation, retention and oversight of the work of our external auditor. However, under Israeli law and our Articles, the appointment
of external auditor requires the approval of the shareholders and their compensation requires the approval of our board of directors.
In addition, as described above, pursuant to the Companies Law, the audit committee is required to examine the external auditor&#8217;s
scope of work as well as the external auditor&#8217;s fees and to provide its recommendations with respect thereto to the appropriate
corporate organ. Accordingly, the appointment of our external auditor is approved by our shareholders at the audit committee&#8217;s recommendation
and its compensation for audit and non-audit services is approved by the board of directors following the audit committee&#8217;s recommendation.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have adopted a charter for the audit committee, which sets forth the purpose and
responsibilities of such committee.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In carrying out its duties, the audit committee meets with management at least once
in each fiscal quarter at which time, among other things, it reviews, and either approves or disapproves, the financial results of the
Company for the immediately preceding fiscal quarter and conveys its conclusions in this regard to the board of directors. The audit committee
also generally monitors the services provided by the Company&#8217;s external auditor to ensure their independence and reviews all audit
and non-audit services provided by them. The Company&#8217;s external and internal auditors also report regularly to the audit committee
and the audit committee discusses with our external auditor the quality, not just the acceptability, of the accounting principles, the
reasonableness of significant judgments and the clarity of disclosures in our financial statements, as and when it deems it appropriate
to do so.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Nasdaq Listing Rules, the audit committee is required to consist of at least
three independent directors, each of whom is financially literate and at least one of whom has accounting or related financial management
expertise.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have an audit committee consisting of three directors, Mr. Gilead Halevy,<span style="font-weight: bold">&#160;</span>who<span style="font-weight: bold">&#160;</span>serves
as the chairman of our audit committee, Mr. Eran Perry and Mr. Sanford (Sandy) Zweifach, all of whom are financially literate <span style="font-family: Times New Roman,Times,serif">under
the applicable rules and regulations of the SEC and Nasdaq Listing Rules and each of whom is an audit committee financial expert, as defined
by the SEC rules, and has the requisite financial experience required under the Nasdaq Listing Rules. Additionally, each of the members
of the audit committee is &#8220;independent&#8221; as such term is defined in Rule 10A-3(b)(1) under the Exchange Act, which is different
from the general test for independence of board and committee members under the Nasdaq Listing Rules.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The audit committee composition requirements referred to under Section 115 of the
Companies Law are not applicable to the Company as our board of directors, as part of its decision to opt out of the requirement to elect
external directors pursuant to the relief available under the Alleviation Regulations, also adopted relief from such composition requirements
on the basis that the Company complies, and will continue to comply, with the U.S. Securities Law and Nasdaq Listing Rules described above.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">90</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Compensation Committee</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Companies Law generally provides that public companies such as the Company must
appoint a compensation committee, the responsibilities of which include, among others: (i) reviewing and making recommendations to the
board of directors with respect to our Compensation Policy and with respect to any updates which may be required thereto from time to
time, (ii) reviewing the implementation of the Compensation Policy by the Company, (iii) reviewing and considering arrangements with respect
to the Terms of Office and Employment of Office Holders, (iv) exempting, under certain circumstances, a transaction relating to the Terms
of Office and Employment of Office Holders from the requirement of approval of the shareholders, and (v) overseeing, subject to applicable
law, the administration of the Company&#8217;s various compensation plans and arrangements, including, incentive compensation and equity
based plans. Under the Companies Law, the compensation committee may need to seek the approval of the board of directors and the shareholders
for certain compensation-related decisions, (see &#8220;Item 6 - Directors, Senior Management and Employees - B. Compensation - Approvals
Required for Office Holders Terms of Employment&#8221;).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have adopted a charter for the compensation committee, which sets forth the purpose
and responsibilities of such committee.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Nasdaq Listing Rules, we are required to maintain a compensation committee
consisting of at least two independent directors (as defined under the Nasdaq Listing Rules). Each compensation committee member must
also be deemed by our board of directors to meet the enhanced independence requirements for members of the compensation committee under
the Nasdaq Listing Rules, which requires, among other things, that our board of directors considers the source of each such committee
member&#8217;s compensation in considering whether he or she is independent.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The compensation committee composition requirements referred to under Section 118A
of the Companies Law are not applicable to the Company as our board of directors, as part of its decision to opt out of the requirement
to elect external directors pursuant to the relief available under the Alleviation Regulations, also adopted relief from such composition
requirements on the basis that the Company complies, and will continue to comply, with the Nasdaq majority board independence requirement
and with US Securities Law and Nasdaq Listing Rules concerning the composition of the compensation committee.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have a compensation committee consisting of three directors, Mr. Sanford (Sandy)
Zweifach, who serves as the chairman of our compensation committee, Dr. Kinneret Livnat Savitzky and Eran Perry.&#160;Each member of our
compensation committee is an &#8216;independent director&#8217; in accordance with the Nasdaq listing standards.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Nomination and Corporate Governance Committee</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Nasdaq Listing Rules require that director nominees be selected or recommended
for the board&#8217;s selection either by a nomination committee composed solely of independent directors, or by a majority of independent
directors, in a vote in which only independent directors participate, subject to certain exceptions. Mr. Paul Sekhri, who serves as the
chairman of our nomination and corporate governance committee, Dr. Kinneret Livnat Savitzky and Mr. Sanford (Sandy) Zweifach, each an
independent director, are the members of our nomination and corporate governance committee, which, among other responsibilities, recommends
director nominees for our board&#8217;s approval.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Internal Auditor</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Companies Law, the board of directors must appoint an internal auditor,
recommended by the audit committee. The role of the internal auditor is to examine, among other matters, whether the company&#8217;s actions
comply with the law and orderly business procedures. Under the Companies Law, an interested party or an Office Holder of a company, or
a relative of an interested party or of an Office Holder of a company, as well as the company&#8217;s external auditor or any one on behalf
of the external auditor may not serve as a company&#8217;s internal auditor. The internal auditor&#8217;s tenure cannot be terminated
without his or her consent, nor can he or she be suspended from such position unless the board of directors has so resolved after hearing
the opinion of the audit committee and after providing the internal auditor with the opportunity to present his or her position to the
board of directors and to the audit committee. An interested party is defined in the Companies Law as a holder of 5% or more of the company&#8217;s
outstanding shares or voting rights, any person or entity who has the right to designate one or more directors or the chief executive
officer of the company or any person who serves as a director or as a chief executive officer of the company.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">91</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Ms. Sharon Cohen of Brightman, Almagor, Zohar &amp; Co., a member firm of Deloitte
Touche Tohmatsu, has served as our internal auditor since 2019 (replacing a different partner at Brightman Almagor Zohar &amp; Co., a
member firm of Deloitte Touche Tohmatsu). Ms. Sharon Cohen is not an employee, affiliate or Office Holder of the Company, or affiliated
with the Company&#8217;s external auditor.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Fiduciary Duties and Approval of Related Party Transactions Under
Israeli Law</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Fiduciary Duties of Office Holders</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Companies Law codifies the fiduciary duties that Office Holders owe to a company.
All persons listed in the table under &#8220;Item 6. Directors, Senior Management and Employees - A. Directors and Senior Management&#8221;
are Office Holders. In addition to those persons listed in the table under Item 6.A, there are two additional individuals who were Office
Holders of the Company as of December 31, 2021.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">An Office Holder&#8217;s fiduciary duties consist of a duty of care and a duty of
loyalty. The duty of care requires an Office Holder to act with the standard of skills with which a reasonable Office Holder in the same
position would have acted under the same circumstances. The duty of care includes a duty to use reasonable means to obtain:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zbefdd516667d492cb404dbc1dd222739" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>information regarding the business advisability of a given action brought for the Office Holder&#8217;s approval or performed by
        the Office Holder by virtue of his or her position; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z328483db34de49c7b204912e6d6db6a4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>all other information of importance pertaining to the aforesaid actions.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The duty of loyalty requires an Office Holder to act in good faith and for the benefit
of the company and includes the duty to:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za5f85fab397e4b808028306726895203" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>refrain from any act involving a conflict of interest between the fulfillment of his or her position in the company and the fulfillment
        of any other position or his or her personal affairs;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z720f6d3d29644475b964b498079efc5f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>refrain from any act that is competitive with the business of the company;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z33a0e20a9dbe417dbed393fd548a4259" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>refrain from exploiting any business opportunity of the company with the aim of obtaining a personal gain for himself or herself
        or for others; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb446ee3a102d4dbabb5d2ccaa1520078" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>disclose to the company all relevant information and provide it with all documents relating to the company&#8217;s affairs which
        the Office Holder obtained due to his or her position in the company.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Disclosure of Personal Interests of Office
Holders and Approval of Certain Transactions</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Companies Law requires that an Office Holder promptly discloses to the company
any personal interest that the Office Holder may have, <span style="font-family: Times New Roman,Times,serif">and all related material
information known to him or her, in connection with any existing or proposed transaction by the company. In addition, if the transaction
is an extraordinary transaction, as defined under Israeli law, the Office Holder must also disclose any personal interest held by the
Office Holder&#8217;s spouse, siblings, parents, grandparents, descendants, spouse&#8217;s descendants and the spouses of any of the foregoing,
or a Relative. In addition, the Office Holder must also disclose any interest held by any corporation in which the Office Holder: (i)
holds at least 5% of the company&#8217;s outstanding share capital or voting rights; (ii) is a director or general manager; or (iii) has
the right to appoint at least one director or the general manager. An extraordinary transaction is defined as a transaction which is either
not in the ordinary course of business, not on market terms, or likely to have a material impact on the company&#8217;s profitability,
assets or liabilities.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Companies Law, unless the articles of association of a company provide otherwise,
a transaction in which an Office Holder has a personal interest and which is not an extraordinary transaction, requires board approval,
after the Office Holder complies with the above disclosure requirement and provided the transaction is not adverse to the company&#8217;s
interest. Our Articles do not provide for a different method of approval. Furthermore, if the transaction is an extraordinary transaction,
then, in addition to any approval stipulated by the articles of association, it also must be approved by the company&#8217;s audit committee
and then by the board of directors, and, under certain circumstances, by the shareholders of the company.</div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A person with a personal interest in any matter may not generally be present at any
audit committee, compensation committee or board of directors meeting where such matter is being considered, and if he or she is a member
of the committee or a director, he or she may not generally vote on such matter at the applicable meeting.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">92</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Disclosure of Personal Interest of Controlling Shareholders and
Approval of certain Transactions</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">The Companies Law extends the disclosure requirements applicable to an Office Holder
to a &#8216;controlling shareholder&#8217; in a public company. For this purpose, a &#8216;controlling shareholder&#8217; is a shareholder
who has the ability to direct the activities of a company, including a shareholder or a group of shareholders who together own 25% or
more of the voting rights if no other shareholder holds more than 50% of the voting rights.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Extraordinary transactions of a public company with a controlling shareholder or in
which a controlling shareholder has a personal interest, as well as any engagement by a public company of a controlling shareholder or
of such controlling shareholder&#8217;s Relative, directly or indirectly, with respect to the provision of services to the company, and,
if such person is also an Office Holder of such company, with respect to such person&#8217;s Terms of Office and Employment as an Office
Holder, and if such person is an employee of the company but not an Office Holder, with respect to such person&#8217;s employment by the
company, generally require the approval of each of the audit committee (or with respect to Terms of Office and Employment, the compensation
committee), the board of directors and the shareholders of the company, in that order. The shareholder approval must fulfill one of the
following requirements: (i) it received the positive vote of at least a majority of the voting rights in the company who are present and
voting in the meeting and held by shareholders who do not have a personal interest in the transaction; (abstentions are disregarded) or
(ii) the voting rights held by shareholders who have no personal interest in the transaction and who have voted against the transaction,
do not exceed two percent of the voting rights in the company.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Any extraordinary transactions with a controlling shareholder or in which a controlling
shareholder has a personal interest with a term of more than three years generally need to be brought for re-approval in accordance with
the above procedure every three years, unless the audit committee determines that the duration of the transaction is reasonable given
the circumstances related thereto and has been approved by the shareholders for such longer duration.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Pursuant to regulations promulgated under the Companies Law, certain transactions
with a controlling shareholder or his or her Relative, or with directors, that would otherwise require approval of a company&#8217;s shareholders
may be exempt from shareholder approval upon certain determinations of the audit committee or the compensation committee and board of
directors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25">For information concerning the direct and indirect personal interests of certain of
our Office Holders and principal shareholders in certain transactions with us, see &#8220;Item 7. Major Shareholders and Related Party
Transactions - B. Related Party Transactions.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Shareholders Duties</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Pursuant to the Companies Law, a shareholder has a duty to: (i) act in good faith
in fulfilling his obligations towards the company and the other shareholders; and (ii) refrain from abusing his or her power with respect
to the company, including, when voting at a general meeting with respect to the following matters: (a) an amendment to the company&#8217;s
articles of association; (b) an increase of the company&#8217;s authorized share capital; (c) a merger; or (d) approval of interested
party transactions that require shareholders&#8217; approval.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, any controlling shareholder, any shareholder who knows that it possesses
power to determine the outcome of a shareholder vote and any shareholder who, pursuant to the provisions of a company&#8217;s articles
of association has the power to appoint or prevent the appointment of an office holder in the company, is under a duty of fairness towards
the company. The Companies Law does not describe the substance of such duty of fairness but states that the remedies generally available
upon a breach of contract will also apply in the event of a breach of the duty of fairness, taking into account such shareholder&#8217;s
position.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Approval of Significant Private Placement</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the Companies Law, a significant private placement of securities requires approval
by the board of directors and the shareholders by a simple majority. A private placement is considered a significant private placement
if it results in a person becoming a controlling shareholder, or if all of the following conditions are met: the securities issued amount
to 20% or more of the company&#8217;s outstanding voting rights before the issuance; some or all of the consideration is other than cash
or listed securities or the transaction is not on market terms; and the transaction will increase the relative holdings of a shareholder
who holds 5% or more of the company&#8217;s outstanding share capital or voting rights or will cause any person to become, as a result
of the issuance, a holder of more than 5% of the company&#8217;s outstanding share capital or voting rights.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">93</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">D. EMPLOYEES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The following table sets out the number of our full-time employees engaged in specified
activities, at the end of the fiscal years 2021, 2020 and 2019 (the numbers include employees of our wholly owned U.S. subsidiary Compugen
USA, Inc.):</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="3" border="0" id="z1157b6666e3f42a1a12f154900325117" style="font: 10pt Times New Roman,Times,serif; width: 100%; text-align: left; color: rgb(0, 0, 0)">
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 39.54%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 18.74%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">December 31, 2021</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20.94%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">December 31, 2020</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20.78%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">December 31, 2019</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 39.54%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="margin-right: 28.4pt; line-height: 1.25; font-family: Times New Roman, Times, serif">Research &amp; Development</div>
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">&#160;</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 18.74%; vertical-align: bottom; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif">51</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25">&#160;</span></div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20.94%; vertical-align: bottom; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif">45</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25">&#160;</span></div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20.78%; vertical-align: bottom; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25; font-family: Times New Roman, Times, serif">37</div>
        <div style="line-height: 1.25"><span style="line-height: 1.25">&#160;</span></div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 39.54%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Administration, Accounting and Operations</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 18.74%; vertical-align: bottom; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25">21</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20.94%; vertical-align: bottom; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25">21</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20.78%; vertical-align: bottom; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25">23</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 39.54%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Marketing and Business Development</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 18.74%; vertical-align: bottom; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25">1</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20.94%; vertical-align: bottom; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25">2</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20.78%; vertical-align: bottom; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25">1</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 39.54%; vertical-align: top; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Total</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 18.74%; vertical-align: top; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; line-height: 1.25">73</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20.94%; vertical-align: top; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; line-height: 1.25">68</div> </td>
    <td style="border: rgb(0, 0, 0) 2px solid; width: 20.78%; vertical-align: top">
        <div style="text-align: right; margin-right: 2.85pt; line-height: 1.25">61</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition to the headquarters in Holon, Israel, we maintain a subsidiary in South
San Francisco, California. On December 31, 2019, 54 of our employees were located in Israel and seven were located in the United States,
on December 31, 2020, 58 of our employees were located in Israel, nine were located in the United States and 1 employee was located in
Europe and on December 31, 2021, 58 of our employees were located in Israel, 12 were located in the United States and 3 employees were
located in Europe.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We consider our relations with our employees to be satisfactory and we have not experienced
a significant labor dispute or strike. We are not a party to any collective bargaining agreement with respect to our Israeli employees.
However, we are subject to certain labor related statutes and to certain provisions of expansion orders the Israeli Minister of the Economy
has given to collective bargaining agreements between the Histadrut (General Federation of Labor in Israel) and the Coordinating Bureau
of Economic Organizations and/or the Industrialists&#8217; Association, which are applicable to our Israeli employees. These statutes
and provisions and additional Israeli labor law provisions cover a wide range of subjects and provide certain minimum employment standards,
including the length of the workday and work week, minimum wages, travel expenses, contributions to a pension fund, insurance for work-related
accidents, determination of severance pay, annual and other vacations, sick pay and other conditions of employment. We generally provide
our employees with benefits and working conditions beyond the required minimum.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our severance pay liability to our Israeli employees, based upon the number of years
of service and the latest monthly salary, is in the large part covered by regular deposits with recognized pension funds, deposits with
severance pay funds and purchases of insurance policies. Pursuant to Section 14 of the Israeli Severance Pay Law 5723-1963, certain of
our liabilities for employee severance rights upon termination are covered by regular contributions to defined contribution plans, so
that upon termination of employment of the relevant employees, we are only required to release the payments made by us to such funds on
account of severance and by doing so are deemed to have complied with all of our severance payment obligations relating to the service
of applicable employees with respect to the period during which the provisions of such section apply. For information concerning our liability
for severance pay, see Note 2l to our 2021 consolidated financial statements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our employees are not represented by a labor union. We have written employment contracts
(including signed offers of employment) with each of our employees.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">94</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">E. SHARE OWNERSHIP</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Share Ownership by Directors and Other Executive Officers</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">All of the persons listed above under the caption &#8220;Directors and Senior Management&#8221;
own ordinary shares of the Company and/or options to purchase ordinary shares of the Company. Except as set forth in the table below,
none of the directors or executive officers beneficially owns ordinary shares and/or ordinary shares underlying options amounting to 1%
or more of the outstanding ordinary shares. The following table sets forth certain information as of February 15, 2022, regarding the
beneficial ownership by our directors and senior management. All numbers quoted in the table are inclusive of options to purchase shares
that are exercisable within 60 days after February 15, 2022. <span style="font-family: Times New Roman,Times,serif">The shares that may
be issued under these options are deemed to be outstanding for the purpose of computing the percentage of ownership of such individual
or group but are not deemed to be outstanding for the purpose of computing the percentage of ownership of the other individual or group
shown in the table. The information in this table is based on 86,459,252 ordinary shares outstanding as of February 15, 2022.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="cfttable" id="zf0bada8aaac74524a0db270f9880fd6f" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Beneficial Owner</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: center">
        <div style="line-height: 1.25; font-weight: bold">Amount Owned</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: center">
        <div style="line-height: 1.25; font-weight: bold">Percent of Class</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Anat Cohen-Dayag<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">966,122</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1.1</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="text-align: justify; line-height: 1.25">All directors and executive officers</div>
        <div style="text-align: justify; line-height: 1.25">as a group (13 persons)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">2,984,881</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3.3</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: 22.5pt; line-height: 1.25"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">___________________</sup></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zfcf315de90b64316bf85e31e0fe668ee" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 22.5pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 22.5pt; vertical-align: top">&#160;<span style="font-family: Times New Roman,Times,serif"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></span></td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Includes (i) 56,122 shares held by Dr. Cohen-Dayag, and (ii) 910,000 shares subject to options that are exercisable within 60 days
        after February 15, 2022, with a weighted average exercise price of $5.74 per share, and which expire between August 2022 and July 2030.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zcf22fdd83dc147a68b83bd6d5ce1944f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 22.5pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 22.5pt; vertical-align: top; font-family: Times New Roman,Times,serif"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;(2)</sup></td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Includes (i) a total of 78,894 ordinary shares held by directors and executive officers, and (ii) a total of 2,905,987 shares subject
        to options that are beneficially owned by directors and executive officers that are exercisable within 60 days after February 15, 2022,
        with a weighted average exercise price of $5.16 per share and which expire between August 2022 and September 2030.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Share Incentive Plan and Employee Share Purchase Plan</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We currently maintain one active share incentive plan, which is our 2010 Share Incentive
Plan, or the 2010 Plan. In addition to the discussion below, see Note 8 to our 2021 consolidated financial statements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Compugen 2010 Share Incentive Plan</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On July 25, 2010, our board of directors adopted the 2010 Plan which was also approved
by our shareholders on May 12, 2011. In addition, the board of directors and shareholders resolved that the options available for grants
under the 2000 Option Plan, at such time, as well as any options that may return to such pool in connection with terminated options, will
be made available for future grants under the 2010 Plan. Subject to applicable law, our board of directors may amend the 2010 Plan, provided
that any action by our board of directors which will alter or impair the rights or obligations of an option holder requires the prior
consent of that option holder. Our board of directors last increased the number of shares available under the 2010 Plan in May 2020. At
such time the board of directors also extended the term of the 2010 Plan by additional ten (10) years. See &#8220;Item 16G. Corporate
Governance<span style="font-style: italic">.</span>&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The compensation committee administers the 2010 Plan and has the authority to designate
the terms of the options granted thereunder, including the identity of the grantees, exercise prices, grant dates, vesting schedules and
expiration dates, which may be no more than ten years after the grant date. According to the 2010 Plan, options may not be granted with
an exercise price of less than the fair market value of our ordinary shares on the date of grant, unless otherwise determined by our board
of directors. The administration of the 2010 Plan by our compensation committee is subject to applicable law, including with respect to
the approval procedure of compensation to Office Holders required under the Companies Law (for additional information on the approval
procedure of compensation to Office Holders, see &#8220;Item 6. Directors, Senior Management and Employees - B. Approvals Required for
Office Holders Terms of Employment&#8221;).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If a grantee leaves his or her employment or other relationship with us, or if his
or her relationship with us is terminated without cause (and other than by reason of death or disability, as defined in the 2010 Plan),
the term of his or her unexercised options will generally expire in 90 days, unless determined otherwise by our board of directors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">95</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">As of December 31, 2021, options to purchase 6,976,104 ordinary shares at a weighted
average exercise price of approximately $6.39 per share were outstanding (i.e., were granted but not canceled, expired nor exercised)
under the 2010 Plan and 1,133,128 ordinary shares remained available for future grant under the 2010 Plan. Options to purchase 4,285,920
ordinary shares under the 2010 Plan have previously been exercised through December 31, 2021, at a weighted average exercise price of
approximately $4.94. As of December 31, 2021, outstanding options granted by the Company pursuant to the 2010 Plan expire between January
2022 and November 2031 (subject to terms of the plan).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Compugen 2021 Employee Share Purchase Plan</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In November 2020, we adopted the Compugen Ltd. 2021 Employee Share Purchase Plan,
or ESPP.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The ESPP currently applies to our employees and officers.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Pursuant to the ESPP, in each twelve (12) months period, there are two offering periods,
comprised of six (6) months each (except for the first offering period under the ESPP which was for five (5) months only). Each eligible
participant, has the right to contribute up to 15% of his or her monthly Compensation (as defined in the ESPP), in order to buy ordinary
shares from us at a price per share equal with respect to each offering period, to 85% of the Fair Market Value of a share on the Entry
Date or the Purchase Date (as such terms are defined in the ESPP), whichever is lower, until changed by the committee of the board administering
the ESPP prior to the commencement of the enrollment process for such offering period. The maximum number of ordinary shares a Participant
may purchase during any calendar year shall be that whole number of ordinary shares determined by dividing $40,000 by the Purchase Price.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The maximum number of shares that may be issued under the ESPP in the aggregate is
600,000.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As of December 31, 2021 (following issuance of shares in connection with offering
periods already ended), there are 482,171 ordinary shares available for issuance under the ESPP.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Taxation of Equity Granted under our 2010 Plan
and ESPP to Israeli Grantees</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our board of directors elected the &#8220;Capital Gains Track&#8221; (as defined in
Section 102(b) (2) of the Tax Ordinance) for the grant of equity under the 2010 Plan and ESPP to Israeli grantees who are eligible for
grant under said Section 102 of the Tax Ordinance.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Pursuant to such election, and provided such eligible grantees comply with all the
requirements of the &#8220;Capital Gains Track&#8221;, gains derived by them, arising from the sale of shares acquired pursuant to the
ESPP or the exercise of options granted to them, will generally be subject to a flat capital gains tax rate of 25%, although these gains,
or part of them, will also be considered part of a grantee&#8217;s regular salary and subject to such grantee&#8217;s regular tax rate
applicable to such salary. As a result of the Company&#8217;s election in the &#8220;Capital Gains Track&#8221; under Section 102, the
Company is not allowed to claim as an expense for tax purposes in Israel the amounts credited to the grantee as capital gains, although
it is generally entitled to do so in respect of the salary income component (if any) of such grant, if any, when the related tax is paid
by the grantee as long as the grantee complies with all the requirements of the &#8220;Capital Gains Track&#8221;.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM7"><!--Anchor--></span>ITEM 7. MAJOR SHAREHOLDERS
AND RELATED PARTY TRANSACTIONS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">A. MAJOR SHAREHOLDERS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">The following table sets forth share ownership information as of February 15, 2022
(unless otherwise noted below) with respect to each person who is known by us to be the beneficial owner of more than 5% of our outstanding
ordinary shares. <span style="font-family: Times New Roman,Times,serif">The information contained in the table below has been obtained
from the Company&#8217;s records or from information furnished by an individual or entity to the Company or disclosed in public filings
with the SEC. Except where otherwise indicated, and except pursuant to community property laws, we believe, based on information furnished
by such owners, that the beneficial owners of the ordinary shares listed below have sole investment and voting power with respect to such
shares. As of February 15, 2022, there were a total of 37 holders of record of our ordinary shares, of which 21 were registered with addresses
in the United States. Such United States holders were, as of such date, the holders of record of approximately 9.98% of our outstanding
ordinary shares.<span style="font-weight: bold">&#160;</span>Our ordinary shares are traded on the Nasdaq Global Market in the United
States and on the TASE in Israel. A significant portion of our shares are held in &#8220;street name&#8221;, therefore we cannot determine
who our shareholders are, their geographical location or how many shares a particular shareholder owns.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">96</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Total &#8220;Number of Ordinary Shares Beneficially Owned&#8221; in the table below
include shares that may be acquired by any of the below entities upon the exercise of options or warrants known to us, that are either
currently exercisable or will become exercisable within 60&#160;days of February 15, 2022.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="line-height: 1.25">The shareholders listed below do not have any different voting rights from any of our other shareholders.</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" id="z11a432fde9364393b564aa7ef0995c10" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="margin-right: 4.5pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Reporting Beneficial
        Owner</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: center; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Number of Ordinary Shares Beneficially Owned</div>
        </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; text-align: center; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Percent of Ordinary Shares Beneficially Owned<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">ARK Investment Management LLC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">9,222,415</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">10.7</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25">Nikko Asset Management Americas, Inc.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup>&#160;</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">6,998,382</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">8.1</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Sumitomo Mitsui Trust Holdings, Inc.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(4)</sup>&#160;</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">6,998,382</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">8.1</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="line-height: 1.25">Bristol-Myers Squibb Company<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(5)</sup>&#160;</div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">4,757,058</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">5.5</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  </table> </div> <br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc15bc5ef193c450680b82b3b625b4350" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 6.55pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.75pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>ARK Investment Management LLC&#8217;s percentage of ownership has decreased from 20.42% as of December 31, 2020 to 10.7% as stated
        above.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z964b7963cd9848fbb0291ee7909a79dc" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 6.55pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.75pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Nikko Asset Management Americas, Inc.&#8217;s percentage of ownership has decreased from 8.40% as of December 31, 2020 to 8.1% as
        stated above.</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z23ad5dd142144a3890d67ad2e785f5d0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 6.55pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.75pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Sumitomo Mitsui Trust Holdings, Inc.&#8217;s percentage of ownership has decreased from 8.40% as of December 31, 2020 to 8.1% as
        stated above.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4ee1fdd400bf41be834ab64405f29e33" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Based upon 86,459,252 ordinary shares issued and outstanding as of February 15, 2022.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2979465de29545cfad9258b57165e2c8" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">(2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Based upon information provided by the shareholder in its Form 13G/A filed with the SEC on February 9, 2022. With respect to the
        ordinary shares reported in its Schedule 13G/A, ARK Investment Management LLC, or ARK, indicated as having (i) sole voting power with
        respect to 8,879,327 ordinary shares, (ii) shared voting power with respect to 210,870 ordinary shares, (iii) sole dispositive power with
        respect to 9,222,415 ordinary shares, and (iv) no shared dispositive power with respect to ordinary shares. Furthermore, in such filing
        ARK indicated aggregate beneficial ownership of 9,222,415 ordinary shares. The address of the principal business office of ARK is 3 East
        28th Street, 7th Floor, New York, NY 10016.</div> </td> </tr>
  </table>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7f7336798ea14a4c97b729a12455c01f" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">(3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Based upon information provided by the shareholder in its Schedule 13G/A filed with the SEC on February 14, 2022. With respect to
        the ordinary shares reported in the Schedule 13G/A, Nikko Asset Management Americas, Inc., or Nikko, indicated as having (i) no sole voting
        or dispositive power with respect to ordinary shares, (ii) shared voting power with respect to 5,851,942 ordinary shares, and (iii) shared
        dispositive power with respect to 6,998,382 ordinary shares. Furthermore, in such filing Nikko indicated aggregate beneficial ownership
        of 6,998,382 ordinary shares. The address of the principal business office of Nikko is 605 Third Avenue, 38th&#160;Floor, New York, NY
        10158.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za14746fbf2ce4834bbee02467f528f4c" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">(4)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Based upon information provided by the shareholder in its Schedule 13G/A filed with the SEC on February 4, 2022. With respect to
        the ordinary shares reported in the Schedule 13G/A, Sumitomo Mitsui Trust Holdings, Inc., or Sumitomo, indicated as having (i) no sole
        voting or dispositive power with respect to ordinary shares and (ii) shared voting power and dispositive power with respect to 6,998,382
        ordinary shares. Furthermore, in such filing Sumitomo indicated aggregate beneficial ownership of 6,998,382 ordinary shares. The address
        of the principal business office of Sumitomo is 1-4-1 Marunouchi, Chiyoda-ku, Tokyo 100-8233, Japan.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top">(5)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25; font-family: Times New Roman, Times, serif">Based upon information provided by the shareholder in its Form
        13G filed with the SEC on November 19, 2021, and confirmation by the shareholder that such information is true and correct as of the date
        of this Annual Report. With respect to the ordinary shares reported in its Schedule 13G, Bristol-Myers Squibb Company, or BMS, indicated
        as having (i) sole voting power and dispositive power with respect to 4,757,058 ordinary shares, and (ii) no shared voting power nor shared
        dispositive power with respect to ordinary shares. Furthermore, in such filing BMS indicated aggregate beneficial ownership of 4,757,058
        ordinary shares. The address of the principal business office of BMS is 430 East 29<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup>&#160;Street,
        New York, NY 10016.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">B. RELATED PARTY TRANSACTIONS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">Other than as set forth below and transactions related to compensation of our executive
officers and directors as described under &#8220;Item 6. Directors, Senior Management and Employees - B. Compensation,&#8221; since January
1, 2021, we have not entered into any related party transaction.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Indemnification and Exemption Agreements</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25">Our Articles permit us to exculpate, indemnify and insure our Office Holders to the
fullest extent permitted by the Companies Law. Accordingly, we release our Office Holders from liability and indemnify them to the fullest
extent permitted by law and provide them with letters of indemnification and exemption and release for this purpose, in the form most
recently approved at our 2021 AGM. Under the letters of indemnification and exemption and release (i) our undertaking to indemnify each
Office Holder for monetary liabilities or obligations imposed by a court judgment (including a settlement or an arbitrator&#8217;s award
approved by a court) is limited to matters that result from or are connected to those events or circumstances set forth therein, and (ii)
the indemnification that we undertake towards all persons whom it resolved to indemnify for the matters and circumstances described therein,
jointly and in the aggregate, do not exceed the higher of the: (i) an amount equal to 25% of the Company&#8217;s shareholders&#8217; equity,
per the most recent financial statements (audited or reviewed) after the time that notice is provided to the Company; or (y) $20 million.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">97</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25">Our Office Holders are also covered by directors&#8217; and officers&#8217; liability
insurance. For more information see &#8220;Item 6. Directors, Senior Management and Employees - B. Compensation - Insurance, Indemnification
and Exemption.&#8221;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. INTERESTS OF EXPERTS AND COUNSEL</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM8"><!--Anchor--></span>ITEM 8. FINANCIAL INFORMATION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">A. CONSOLIDATED STATEMENTS AND OTHER FINANCIAL
INFORMATION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Consolidated Financial Statements</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our consolidated financial statements are included beginning on page F-1 of this Annual
Report. See also &#8220;Item 18. Financial Statements.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Legal Proceedings</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Currently, we are not a party to any legal or arbitration proceedings, including governmental
proceedings, that are pending or known to be contemplated, that our management believes, individually or in the aggregate, may have, or
have had in the recent past, a significant effect on our financial position or profitability, nor are we party to any material proceeding
in which any director, member of our senior management or affiliate is a party adverse to us or our subsidiary or has a material interest
adverse to us or our subsidiary.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Dividend Distribution Policy</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have never paid any cash dividends on our ordinary shares, and we do not intend
to pay cash dividends on our ordinary shares in the foreseeable future. Our current policy is to retain any earnings we have (if any)
for use in our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In the event that we decide to pay a cash dividend from income that is tax exempt
under our Benefiting Enterprises program, we would be required to pay the applicable corporate tax that would otherwise have been payable
on such income which would be in addition to the tax payable by the dividend payee. See Note 9 to our 2021 consolidated financial statements
and &#8220;Item 10. Additional Information - E. Taxation.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">B. <span style="font-style: italic">SIGNIFICANT CHANGES</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM9"><!--Anchor--></span>ITEM 9. THE OFFER AND LISTING</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">A. OFFER AND LISTING DETAILS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our ordinary shares were listed on The Nasdaq Global Market through June 16, 2009.
On June 17, 2009, the listing of our ordinary shares was transferred from The Nasdaq Global Market to The Nasdaq Capital Market, and on
January 27, 2014, the listing of our ordinary shares transferred back from The Nasdaq Capital Market to The Nasdaq Global Market. Our
trading symbol on Nasdaq is CGEN. Our ordinary shares have been dually listed on the Tel Aviv Stock Exchange since January 2002. Our trading
symbol on each of The Nasdaq Global Market and the Tel Aviv Stock Exchange is CGEN.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">B. PLAN OF DISTRIBUTION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. MARKETS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our ordinary shares are traded in the United States on The Nasdaq Global Market and
in Israel on the Tel Aviv Stock Exchange (TASE).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">98</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">D. SELLING SHAREHOLDERS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">E. DILUTION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">F. EXPENSES OF THE ISSUE</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM10"><!--Anchor--></span>ITEM 10. ADDITIONAL INFORMATION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">A. SHARE CAPITAL</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">B. MEMORANDUM AND ARTICLES OF ASSOCIATION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Copies of our Amended and Restated Articles and our Amended and Restated Memorandum
of Association, as in effect as of the date of this Annual Report, are attached as Exhibits 1.1 and 1.2, respectively, to this Annual
Report. The information called for by this Item is set forth in Exhibit 2.1 to this Annual Report and is incorporated by reference into
this Annual Report.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. MATERIAL CONTRACTS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Please see &#8220;Item 4. Information on the Company - B. Business Overview - Business
Strategy and Partnerships - Bayer Collaboration, - Bristol Myers Squibb Collaboration, - AstraZeneca License&#8221; and &#8220;Item 5.
Operating and Financial Review and Prospects Finance - B. Liquidity and Capital Resources&#8221; for a discussion of our material contracts.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">D. EXCHANGE CONTROLS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">There are currently no exchange controls in effect in Israel that restrict the repatriation
by non-residents of Israel in non-Israeli currency of any dividends, if any are declared and paid, and liquidation distributions or the
Company&#8217;s ability to import and export capital, except that such restrictions may exist with respect to citizens of countries which
are in a state of war with Israel.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">E. TAXATION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The following is a brief summary of certain material tax consequences concerning the
ownership and disposition of our ordinary shares by purchasers or holders of our ordinary shares. Because parts of this discussion are
based on new or existing tax or other legislation that has not been subject to judicial or administrative interpretation, there can be
no assurance that the views expressed herein will be accepted by the tax or other authorities in question. The summary below does not
address all of the tax consequences that may be relevant to all purchasers or holders of our ordinary shares in light of each purchaser&#8217;s
or holder&#8217;s particular circumstances and specific tax treatment. For example, the summary below does not address the tax treatment
of residents of Israel and traders in securities who are subject to specific tax regimes. As individual circumstances may differ, holders
of our ordinary shares should consult their own tax advisors as to United States, Israeli or other tax consequences of the purchase, ownership
and disposition of our ordinary shares. This discussion is not intended, nor should it be construed, as legal or professional tax advice
and it is not exhaustive of all possible tax considerations. Each individual should consult his or her own tax or legal advisor.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Israeli Taxation</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Taxation of Capital Gains Applicable to Non-Israeli
Shareholders</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Israeli law generally imposes a capital gains tax on the sale of securities of an
Israeli company traded on the TASE, on an authorized stock exchange outside Israel or on a regulated market (which includes a system through
which securities are traded pursuant to rules prescribed by the competent authority in the relevant jurisdiction) in or outside Israel,
or a &#8220;Recognized Exchange&#8221; (which includes Nasdaq). Pursuant to amendments to the Tax Ordinance, effective as of January 1,
2012, the capital gains tax rate applicable to individuals upon the sale of such securities is such individual&#8217;s marginal tax rate
but not more than 25%, or 30% with respect to an individual who meets the definition of a &#8216;Substantial Shareholder&#8217; on the
date of the sale of the securities or at any time during the 12 months preceding such date. A &#8216;Substantial Shareholder&#8217; is
defined as a person who, either alone or together with any other person, holds, directly or indirectly, at least 10% of any of the means
of control of a company (including, among other things, the right to receive profits of the company, voting rights, the right to receive
the company&#8217;s liquidation proceeds and the right to appoint a director).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">99</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">With respect to corporate investors, capital gain tax equal to the corporate tax rate
(23% in 2021) will be imposed on the sale of our traded shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, if our ordinary shares are traded on a Recognized Exchange gains on the
sale of our ordinary shares held by non-Israeli tax resident investors will generally be, subject to certain conditions, exempt from Israeli
capital gains tax so long as the shares were not held through a permanent establishment that the non-Israeli tax resident investor maintains
in Israel. <span style="font-family: Times New Roman,Times,serif">Furthermore, non-Israeli corporations will not be entitled to such exemption
if Israeli residents, whether directly or indirectly, (i) hold more than 25% of the means of control in such non-Israeli corporation or
(ii) are the beneficiaries of or are entitled to 25% or more of the revenues or profits of such corporation.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Notwithstanding the foregoing, dealers in securities in Israel are taxed at regular
tax rates applicable to business income.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In addition, persons paying consideration for shares, including purchasers of shares,
Israeli securities dealers effecting a transaction, or a financial institution through which securities being sold are held, are required,
subject to any applicable exemptions and the demonstration by the selling shareholder of its non-Israeli residency and other requirements,
to withhold tax upon the sale of publicly traded securities at a rate of 25% for individuals and at the corporate tax rate (23% in 2021)
for corporations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Israeli law also generally exempts non-Israeli residents from capital gains tax on
the sale of securities of Israeli companies that are not traded on stock exchange in Israel, provided that the securities were acquired
on or after January 1, 2009 and that (i) such gains are not generated through a permanent establishment that the non- Israeli resident
maintains in Israel; (ii) the shares were not purchased from a relative; (iii) the sale of shares is not subject to real estate tax.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Income Taxes on Dividend Distribution to Non-Israeli
Shareholders</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In principle, non-Israeli residents (whether individuals or corporations) are generally
subject to Israeli income tax on the receipt of dividends paid by Israeli publicly traded companies at the rate of 25%, if the shares
are registered with a Nominee Company, which is a company incorporated to be a holder of record and distribution agent of publicly traded
or other securities in accordance with the Israeli Securities Law, and at the rate of 30% on dividends paid to Substantial Shareholders
<span style="font-family: Times New Roman,Times,serif">and to persons who were Substantial Shareholders at any time during the 12 months
preceding the date of the distribution, whose shares are not registered with a Nominee Company, unless a lower rate is provided under
an applicable tax treaty between Israel and the shareholder&#8217;s country of residence (subject to the receipt, in advance, of a valid
tax certificate from the Israeli tax authority allowing for a reduced tax rate). The distribution of dividends to non-Israeli residents
(either individuals or corporations) from income derived from the Company&#8217;s Benefiting Enterprise during the applicable benefits
period is subject to withholding tax at a rate of 20%, unless a lower tax rate is provided under an applicable tax treaty.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A non-resident of Israel who has received dividend income derived from or accrued
in Israel, from which the full amount of tax was withheld, is generally exempt from the duty to file tax returns in Israel in respect
of such income, provided that: (i) such income was not derived from a business conducted in Israel by the taxpayer; (ii) the taxpayer
has no other taxable sources of income in Israel with respect to which a tax return is required to be filed; and <span style="font-family: Times New Roman,Times,serif">(iii)
the taxpayer is not liable for surcharge tax.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Residents of the United States generally will have withholding tax in Israel deducted
at source. As discussed below, they may be entitled to a credit or deduction for U.S. federal income tax purposes for all or part of the
amount of the taxes withheld, subject to detailed rules contained in U.S. tax legislation.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">U.S. Israel Tax Treaty</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Convention between the Government of the State of Israel and the Government of
the United States of America with Respect to Taxes on Income, or the Treaty, is generally effective as of January 1, 1995. Under the Treaty,
the maximum Israeli withholding tax on dividends paid to a holder of our ordinary shares who is a Treaty U.S. Resident (as defined below)
is generally 25%. However, pursuant to the Investment Law, dividends distributed by an Israeli company and derived from income eligible
for benefits under the Investment Law will generally be subject to a reduced dividend withholding tax rate, subject to the conditions
specified in the Treaty. The Treaty further provides that a 15% or a 12.5% Israeli dividend withholding tax will apply to dividends paid
to a U.S. corporation owning 10% or more of an Israeli company&#8217;s voting shares during, in general, the current and preceding tax
year of the Israeli company. The 15% rate applies to dividends distributed from income derived from an Approved Enterprise or, presumably,
from a Benefiting Enterprise, in each case within the applicable period or, presumably, from a Preferred Enterprise, and the lower 12.5%
rate applies to dividends distributed from income derived from other sources. However, these provisions do not apply if the company has
certain amounts of passive income. The aforementioned rates under the Treaty will not apply if the dividend income was derived through
a permanent establishment of the U.S resident in Israel.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">100</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Pursuant to the Treaty, the sale, exchange or disposition of our ordinary shares by
a person who qualifies as a resident of the United States within the meaning of the Treaty and who is entitled to claim the benefits afforded
to such residents under the Treaty, or a Treaty U.S. Resident, generally will not be subject to the Israeli capital gains tax, unless
such Treaty U.S. Resident holds, directly or indirectly, shares representing 10% or more of the voting power of the Company during any
part of the 12-month period preceding such sale, exchange or disposition subject to certain conditions. A sale, exchange or disposition
of our ordinary shares by a Treaty U.S. Resident who holds, directly or indirectly, shares representing 10% or more of the voting power
of the Company at any time during such preceding 12-month period would not be exempt under the Treaty from Israeli capital gain tax; however,
under the Treaty, such Treaty U.S. Resident would be permitted to claim a credit for such taxes against U.S. federal income tax imposed
on any gain from such sale, exchange or disposition, under the circumstances and subject to the limitations specified in the Treaty and
U.S. domestic law. As mentioned above, gains on the sale of ordinary shares held by non-Israeli tax resident investors will generally
be exempt from Israeli capital gains tax if the ordinary shares are traded on a Recognized Exchange. This exemption would generally apply
notwithstanding the Treaty (subject to the receipt in advance of a valid tax certificate from the Israeli tax authority allowing for such
exemption).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-style: italic; font-weight: bold">Surcharge Tax</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Furthermore, beginning on January 1, 2013, an additional tax liability at the rate
of 3% (as of 2017 and currently) was added to the applicable tax rate on the annual taxable income, including, but not limited to, income
derived from dividends, interest and capital gains, of individuals who are subject to tax in Israel (whether any such individual is an
Israeli resident or non-Israeli resident) exceeding NIS 651,600 in 2020, NIS 647,640 in 2021 and NIS 663,240 in 2022.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Israeli Transfer Pricing Regulations</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">On November 29, 2006, Income Tax Regulations (Determination of Market Terms), 2006,
promulgated under Section 85A of the Tax Ordinance, came into effect, or the TP Regulations. Section 85A of the Tax Ordinance and the
TP Regulations generally require that all cross-border transactions carried out between related parties be conducted on an arm&#8217;s
length principle basis and will be taxed accordingly. The TP Regulations have not had a material effect on the Company.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Certain Material U.S. Federal Income Tax Considerations</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">General</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The following is a summary of certain material U.S. federal income tax considerations
for U.S. holders (as defined below) of owning, and disposing of our ordinary shares. For this purpose, a U.S. holder is, a holder, who
for U.S. federal income tax purposes is a beneficial owner of ordinary shares and who is: (a) a citizen or individual resident of the
United States; (b) a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) created or organized
in or under the laws of the United States, any state thereof or the District of Columbia; (c) an estate the income of which is subject
to U.S. federal income tax regardless of its source; or (d) a trust that is subject to the primary supervision of a court over its administration
and one or more U.S. persons control all substantial decisions, or a trust that has validly elected to be treated as a domestic trust
under applicable Treasury Regulations. This summary does not address any tax consequences to persons other than U.S. holders.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Except where noted, this summary deals only with ordinary shares held as capital assets
within the meaning of Section 1221 of the U.S. Internal Revenue Code of 1986, as amended, or the Code (generally, property held for investment).
It does not address any tax consequences to certain types of U.S. holders that are subject to special treatment under the U.S. federal
income tax laws, such as banks, insurance companies, tax-exempt or governmental organizations, financial institutions, broker-dealers,
dealers in securities or currencies, traders in securities that elect to use the mark-to-market method of accounting for their securities,
S corporations, partnerships or other pass-through entities (or arrangements treated as a partnership) for U.S. federal tax purposes,
regulated investment companies, real estate investment trusts, expatriates, persons owning, directly, constructively or by attribution,
10% or more, by voting power or value, of our ordinary shares, persons whose &#8220;functional currency&#8221; is not the U.S. dollar,
persons holding ordinary shares as part of a hedging, constructive sale or conversion, straddle, or other risk-reducing transaction, certain
former U.S. citizens or long term residents of the United States, corporations that accumulate income to avoid U.S. federal income tax,
persons that received an interest in our ordinary shares through the exercise of an option or otherwise in exchange for services, or persons
holding our ordinary shares in connection with a trade or business, permanent establishment or fixed base outside the United States.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">101</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">This summary is a general summary and does not address all aspects of U.S. federal
income taxation that may be relevant to particular U.S. holders based on their particular investment or tax circumstances.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">This summary relates only to U.S. federal income taxes and does not address any other
tax, including but not limited to, state, local, or non-U.S. taxes and does not describe all of the U.S. federal income tax consequences
that may be relevant, including the special tax accounting rules under Section 451(b) of the Code, the U.S. federal non-income tax considerations,
including estate or gift tax considerations, the Medicare contribution tax and the alternative minimum tax.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If a partnership (including an entity or arrangement classified as a partnership for
U.S. federal income tax purposes) holds our ordinary shares, the tax treatment of a partner (including a person classified as a partner
for U.S. federal income tax purposes) will generally depend upon the status of the partner and the activities of the partnership. A partner
of a partnership holding our ordinary shares should consult its tax advisors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The statements in this summary are based on the current U.S. federal income tax laws
as contained in the Code, Treasury Regulations, and relevant judicial decisions and administrative guidance, all as of the date hereof,
and such authorities may be replaced, revoked or modified so as to result in U.S. federal income tax consequences different from those
discussed below. The U.S. federal tax laws are subject to change, and any such change may materially affect the U.S. federal income tax
consequences of purchasing, owning, or disposing of our ordinary shares. We cannot assure you that new laws, interpretations of law or
court decisions, any of which may take effect retroactively, will not cause any statement in this summary to be inaccurate. No ruling
or opinions of counsel will be sought in connection with the matters discussed herein. There can be no assurance that the positions we
take on our tax returns will be accepted by the U.S. Internal Revenue Service, or IRS.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">This summary is not a substitute for careful tax planning. Prospective
investors are urged to consult their own tax advisors regarding the specific U.S. federal, state, foreign and other tax consequences to
them, in light of their own particular circumstances, of the purchase, ownership and disposition of our ordinary shares and the effect
of potential changes in applicable tax laws.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Passive Foreign Investment Company Rules</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In general, a corporation organized outside the United States will be classified as
a passive foreign investment company, or PFIC, for U.S. federal income tax purposes for any taxable year in which, after the application
of certain look-through rules with respect to income and assets of its subsidiaries, either:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z48a783c8386c4ab08bcd89bf76c3a7f4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>at least 75% of our gross income is passive income, or</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zca51d00ddeae4dba89e47157674de221" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>at least 50% of the value (determined on the basis of a quarterly weighted average) of our total assets for the taxable year produce
        or are held for the production of passive income.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">For this purpose, passive income generally includes dividends, interest, royalties
and rents (other than royalties and rents derived in the active conduct of a trade or business and not derived from a related person).
Assets that produce or are held for the production of passive income may include cash (unless held in a non-interest bearing account for
short term working capital needs), marketable securities and other assets that may produce passive income. The 50% passive asset test
described above is generally based on the fair market value of each asset, with the value of goodwill and going concern value determined
in large part by reference to the market value of our ordinary shares, which may be volatile. <span style="font-family: Times New Roman,Times,serif">Generally,
in determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it
owns, directly or indirectly, at least a 25% interest (by value) is taken into account.&#160;Whether we are a PFIC for any taxable year
will depend on the composition of our income and the composition and value of our assets (which, may be determined in large part by reference
to the market price of the ordinary shares, which is likely to continue to fluctuate) in each year, and because this is a factual determination
made annually after the end of each taxable year, there can be no assurance that we will not be considered a PFIC in any taxable year.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">102</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Based on our analysis of our estimated income, estimated assets, activities and market
capitalization, we do not believe that we were a PFIC for the taxable year ended December 31, 2021, but we may be a PFIC in one or more
subsequent taxable years. The determination of whether or not we are a PFIC is a fact-intensive determination made on an annual basis
and the applicable law is subject to varying interpretation and we cannot provide any assurance regarding our PFIC status for the past,
current or future taxable years. In particular, our status as a PFIC in current of any future tax year is uncertain because, among other
things, (i) we currently own a substantial amount of passive assets, including cash, (ii) we may not receive milestone payments under
any of our collaboration agreements, in which case, our income may be exclusively passive, (iii) the valuation of our assets that generate
non-passive income for PFIC purposes, including our intangible assets, is uncertain and may be determined in substantial part by our market
capitalization, which may vary substantially over time, and (iv) the allocation of our goodwill between passive and non-passive for purposes
of the PFIC asset test is subject to uncertainty. Furthermore, there can be no assurance that the IRS will agree with our conclusion and
that the IRS would not successfully challenge our position. Accordingly, we cannot provide any assurances regarding our PFIC status for
the current or future taxable years. Our U.S. counsel expresses no opinion with respect to our PFIC status for any taxable year.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we are classified as a PFIC in any taxable year during a U.S. holder&#8217;s holding
period of our ordinary shares, such U.S. holder could be liable for additional taxes and interest charges upon (1) a distribution paid
during a taxable year that is greater than 125% of the average annual distributions paid in the three preceding taxable years, or, if
shorter, the U.S. holder&#8217;s holding period for the ordinary shares, and (2) any gain recognized on a sale, exchange or other taxable
disposition, including a pledge, of the ordinary shares, whether or not we continue to be a PFIC. In these circumstances, the tax will
be determined by allocating such distribution or gain ratably over the U.S. holder&#8217;s holding period for the ordinary shares. The
amount allocated to the current taxable year (i.e., the year in which the distribution occurs, or the gain is recognized) and any year
prior to the first taxable year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year. The amount
allocated to other taxable years will be taxed at the highest marginal rates in effect for individuals or corporations, as applicable,
to ordinary income for each such taxable year, and an interest charge, generally applicable to underpayments of tax, will be added to
the tax. If we are a PFIC for any year during which a U.S. holder holds the ordinary shares, we must generally continue to be treated
as a PFIC by that holder for all succeeding years during which the U.S. holder holds the ordinary shares, unless we cease to meet the
requirements for PFIC status and the U.S. holder makes a &#8220;deemed sale&#8221; election with respect to the ordinary shares. If such
election is made, the U.S. holder will be deemed to have sold the ordinary shares it holds at their fair market value on the last day
of the last taxable year in which we qualified as a PFIC, and any gain from such deemed sale would be subject to the consequences described
above. After the deemed sale election, the U.S. holder&#8217;s ordinary shares with respect to which the deemed sale election was made
will not be treated as shares in a PFIC unless we subsequently again become a PFIC.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If a U.S. holder has made a qualified electing fund, or QEF, election covering all
taxable years during which the holder holds ordinary shares and in which we are a PFIC, distributions and gains will not be taxed as described
above. Instead, a U.S. holder that makes a QEF election is required for each taxable year to include in income the holder&#8217;s pro
rata share of the PFIC&#8217;s ordinary earnings as ordinary income and net capital gain as capital gain, regardless of whether such earnings
or gain have in fact been distributed, for each taxable year that the entity is classified as a PFIC. <span style="font-family: Times New Roman,Times,serif">If
a U.S. holder makes a QEF election with respect to us, any distributions paid by us out of our earnings and profits that were previously
included in the U.S. holder&#8217;s income under the QEF election would not be taxable to the holder. A U.S. holder will increase its
tax basis in its ordinary shares by an amount equal to any income included under the QEF election and will decrease its tax basis by any
amount distributed on the ordinary shares that is not included in the holder&#8217;s income. If a U.S. holder has made a QEF election
with respect to its ordinary shares, any gain or loss recognized by the U.S. holder on a sale or other disposition of such ordinary shares
will constitute capital gain or loss. In addition, if a U.S. holder makes a timely QEF election, our ordinary shares will not be considered
shares in a PFIC in years in which we are not a PFIC, even if the U.S. holder had held ordinary shares in prior years in which we were
a PFIC. U.S. holders should consult their tax advisors regarding making QEF elections in their particular circumstances. If a U.S. holder
does not make and maintain a QEF election for the U.S. holder&#8217;s entire holding period for our ordinary shares by making the election
for the first year in which the U.S. holder owns our ordinary shares, the U.S. holder will be subject to the adverse PFIC rules discussed
above unless the U.S. holder can properly make a &#8220;purging election&#8221; with respect to our ordinary shares in connection with
the U.S. holder&#8217;s QEF election. A purging election may require the U.S. holder to recognize taxable gain on the U.S. holder&#8217;s
ordinary shares.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">103</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">In order to comply with the requirements of a QEF election, a U.S. holder must receive
certain information from us. The QEF election is made on a shareholder-by-shareholder basis and can be revoked only with the consent of
the IRS. A shareholder makes a QEF election by attaching a completed IRS Form 8621, including the information provided in the PFIC annual
information statement, to a timely filed U.S. federal income tax return and by filing a copy of the form with the IRS. There is no assurance
that we will provide the information required by the IRS in order to enable U.S. holders to make the QEF election. Moreover, there is
no assurance that we will have timely knowledge of our status as a PFIC in the future. Accordingly, U.S. holders may be unable to make
a timely QEF election with respect to our ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The tax consequences that would apply if we are a PFIC would also be different from
those described above if a timely and valid &#8220;mark-to-market&#8221; election is made by a U.S. holder for the ordinary shares held
by such U.S. holder. An electing U.S. holder would generally take into account as ordinary income or loss each year an amount equal to
the difference between the U.S. holder&#8217;s adjusted tax basis in such ordinary shares and their fair market value; however, losses
would be allowed only to the extent of the excess of amounts previously included in income over ordinary losses deducted in prior years
as a result of the mark-to-market election. The adjusted tax basis of a U.S. holder&#8217;s ordinary shares is increased by the amount
included in gross income under the mark-to-market regime, or is decreased by the amount of the deduction allowed under the regime. Any
gain from a sale, exchange or other taxable disposition of the ordinary shares in any taxable year in which we are a PFIC would be treated
as ordinary income and any loss from such sale, exchange or other taxable disposition would be treated first as ordinary loss (to the
extent of any net mark-to-market gains previously included in income) and thereafter as capital loss. If a U.S. holder makes a mark-to-market
election it will be effective for the taxable year for which the election is made and all subsequent taxable years unless the shares are
no longer regularly traded on a qualified exchange or the IRS consents to the revocation of the election.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">A mark-to-market election is available to a U.S. holder only for &#8220;marketable
stock.&#8221; Generally, stock will be considered marketable stock if it is &#8220;regularly traded&#8221; on a &#8220;qualified exchange&#8221;
within the meaning of applicable Treasury Regulations. A class of stock is regularly traded during any calendar year during which such
class of stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. The ordinary shares will
be marketable stock as long as they remain listed on a qualified exchange, such as Nasdaq, and are regularly traded. However, we can provide
no assurances that our ordinary shares will continue to be listed on a qualified exchange or will be regularly traded. A mark-to-market
election will not apply to the ordinary shares for any taxable year during which we are not a PFIC but will remain in effect with respect
to any subsequent taxable year in which we become a PFIC. Once made, the election cannot be revoked without the consent of the IRS, unless
the ordinary shares cease to be marketable. U.S. holders are urged to consult their tax advisor about the availability of the mark-to-market
election, and whether making the election would be advisable in such holder&#8217;s particular circumstances.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">If we are a PFIC and, at any time, have a non-U.S. subsidiary that is classified as
a PFIC (a &#8220;lower-tier&#8221; PFIC), U.S. holders of our ordinary shares generally would be deemed to own, and also would be subject
to the PFIC rules with respect to, their indirect ownership interests in that lower-tier PFIC. If we are a PFIC and a U.S. holder of our
ordinary shares does not make a QEF election in respect of a lower-tier PFIC, the U.S. holder could incur liability for the deferred tax
and interest charge described above if either (1) we receive a distribution from, or dispose of all or part of our interest in, the lower-tier
PFIC or (2) the U.S. holder disposes of all or part of its ordinary shares. There is no assurance that any lower-tier PFIC will provide
to a U.S. holder the information that may be required to make a QEF election with respect to the lower-tier PFIC. A mark-to-market election
under the PFIC rules with respect to our ordinary shares would not apply to a lower-tier PFIC, and a U.S. holder would not be able to
make such a mark-to-market election in respect of its indirect ownership interest in that lower-tier PFIC. Consequently, U.S. holders
of our ordinary shares could be subject to the PFIC rules with respect to income of the lower-tier PFIC the value of which already had
been taken into account indirectly via mark-to-market adjustments. U.S. holders are urged to consult their own tax advisors regarding
the issues raised by lower-tier PFICs.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Each U.S. holder who is a shareholder of a PFIC must file an annual information report
on IRS Form 8621 containing such information as the U.S. Treasury Department may require. The failure to file IRS Form 8621 could result
in the imposition of penalties and the extension of the statute of limitations with respect to U.S. federal income tax.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">THE RULES DEALING WITH PFICS AND WITH THE QEF AND MARK-TO-MARKET
ELECTIONS ARE VERY COMPLEX AND ARE AFFECTED BY VARIOUS FACTORS IN ADDITION TO THOSE DESCRIBED ABOVE, INCLUDING OUR OWNERSHIP OF ANY NON-U.S.
SUBSIDIARIES. AS A RESULT, U.S. HOLDERS OF ORDINARY SHARES ARE STRONGLY ENCOURAGED TO CONSULT THEIR TAX ADVISORS ABOUT THE PFIC RULES
IN CONNECTION WITH THEIR PURCHASING, HOLDING OR DISPOSING OF ORDINARY SHARES.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">104</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-weight: bold; font-style: italic">U.S. Federal Income Tax Consequences
If We Are Not a PFIC</span><span style="font-family: Times New Roman,Times,serif">.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The description of the U.S. federal income tax consequences of the receipt of distributions
and the sale or other taxable exchange of our ordinary shares, described in the following two section &#8220;-<span style="font-style: italic">Distributions</span>&#8221;
and &#8220;-Disposition of Ordinary Shares,&#8221; apply only if we are not a PFIC in the relevant year and our share is not subject to
the rules described above under &#8220;-<span style="font-style: italic">Passive Foreign Investment Company Rules</span>&#8221; because
we were a PFIC with respect to a U.S. holder and its ordinary shares in a prior year.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Distributions</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Subject to the discussion under &#8220;- Passive Foreign Investment Company Rules&#8221;
above, the gross amount of any distributions with respect to our ordinary shares (including any amounts withheld to reflect Israeli withholding
taxes) will be taxable as dividends, to the extent paid out of our current or accumulated earnings and profits, as determined under U.S.
federal income tax principles. Such income (including any withheld taxes) will be includable in a U.S. holder&#8217;s gross income as
ordinary income on the day actually or constructively received. <span style="font-family: Times New Roman,Times,serif">Distributions in
excess of earnings and profits will be non-taxable to the U.S. holder to the extent of, and will be applied against and reduce (but not
below zero), the U.S. holder&#8217;s adjusted tax basis in the ordinary shares. Distributions in excess of earnings and profits and such
adjusted tax basis will generally be taxable to the U.S. holder as described below under &#8220;<span style="font-style: italic">Disposition
of Ordinary Shares</span>.&#8221; However, since we do not calculate our earnings and profits under U.S. federal income tax principles,
it is expected that any distribution will be reported as a dividend, even if that distribution would otherwise be treated as a non-taxable
return of capital or as capital gain under the rules described above. The amount of any dividend paid by us will be treated as foreign-source
dividend income to U.S. holders, and the dividends received deduction will not be available to a U.S. holder that is taxed as a corporation
as a result.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">With respect to non-corporate U.S. holders, certain dividends received from a &#8220;qualified
foreign corporation&#8221; that is not a PFIC may be subject to reduced rates of taxation. A qualified foreign corporation includes a
foreign corporation that is eligible for the benefits of a comprehensive income tax treaty with the United States which the United States
Treasury Department determines to be satisfactory for these purposes and which includes an exchange of information provision. The United
States Treasury Department has determined that the US-Israel Tax Treaty meets these requirements. A foreign corporation is also treated
as a qualified foreign corporation with respect to dividends paid by that corporation on shares that are readily tradable on an established
securities market in the United States. As discussed under &#8220;- Passive Foreign Investment Company Rules&#8221; above, there can be
no assurance that our ordinary shares will be considered readily tradable on an established securities market in any year. If we are a
qualified foreign corporation, and we are not classified as a PFIC for the taxable year in which a dividend is paid or in the preceding
taxable year (as discussed above under &#8220;- Passive Foreign Investment Company Rules&#8221;), dividend income will generally qualify
as &#8220;qualified dividend income&#8221; in the hands of individual U.S. holders, which is generally taxed at the lower applicable long
term capital gains rates, provided certain holding period and other requirements for treatment of such dividends as &#8220;qualified dividend
income&#8221; are satisfied. U.S. holders should consult their own tax advisors regarding the availability of the lower rate for dividends
paid with respect to our ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Although, to the extent we pay dividends in the future, we intend to pay dividends
to U.S. holders in U.S. dollars, the amount of any dividend paid in Israeli currency will equal its U.S. dollar value for U.S. federal
income tax purposes, calculated by reference to the exchange rate in effect on the date the dividend is received by the U.S. holder, regardless
of whether the Israeli currency is converted into U.S. dollars. If the Israeli currency received as a dividend are converted into United
States dollars on the date they are received, the U.S. holder generally will not be required to recognize foreign currency gain or loss
in respect of the dividend income. If the Israeli currency is not converted into U.S. dollars on the date of receipt, the U.S. holder
will have a basis in the Israeli currency equal to its U.S. dollar value on the date of receipt. Any subsequent gain or loss upon the
conversion or other disposition of the Israeli currency will be treated as ordinary income or loss, and generally will, for U.S. federal
income tax purposes, be treated as income or loss from U.S. sources.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">105</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">Certain U.S. holders generally may claim Israeli taxes withheld from distributions
and paid over to the Israeli taxing authorities either as a deduction from gross income or as a credit against U.S. federal income tax
liability. To the extent a refund of the tax withheld is available to a U.S. holder under Israeli law or under the Treaty, the amount
of tax withheld that is refundable will not be eligible for credit against a U.S. holder&#8217;s United States federal income tax liability.
The foreign tax credit is subject to numerous complex limitations that must be determined and applied on an individual basis. U.S. holders
should consult their own tax advisors regarding the foreign tax credit rules.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Disposition of Ordinary Shares</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In general, subject to the discussion under &#8220;- Passive Foreign Investment Company
Rules&#8221;, above, a U.S. holder will recognize U.S. source capital gain or loss upon a taxable disposition of an ordinary share equal
to the difference between the sum of the fair market value of any property and the amount of cash received in such disposition (including
the amount of any foreign taxes withheld therefrom) and the U.S. holder&#8217;s adjusted tax basis in such share. A U.S. holder&#8217;s
adjusted tax basis generally will equal the U.S. holder&#8217;s acquisition cost less any distributions treated as a return of capital
as described under &#8220;- Distributions&#8221; above. Such capital gain or loss will be long-term capital gain or loss if a U.S. holder&#8217;s
holding period in the ordinary share is more than one year at the time of the taxable disposition. Under current law, subject to certain
exceptions (including but not limited to those described under &#8220;- Passive Foreign Investment Company Rules&#8221; above), long-term
capital gain realized by a non-corporate U.S. holder generally will be eligible for reduced rates of tax. The deduction of capital losses
may be subject to limitation. U.S. holders should consult their own independent tax advisors regarding the foreign tax credit rules with
respect to any foreign taxes withheld from a taxable disposition of ordinary shares, as well as regarding any foreign currency gain or
loss in connection with such a disposition.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Backup Withholding and Information Reporting</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">In general, information reporting will apply to dividends in respect of our ordinary
shares and the proceeds from the sale, exchange or redemption of our ordinary shares that are paid to a U.S. holder within the United
States (and in certain cases, outside the United States), unless such holder is an exempt recipient. A backup withholding tax generally
will apply to such payments if the U.S. holder fails to provide a taxpayer identification number and a duly executed IRS Form W-9 or certification
of other exempt status or, in the case of dividend payments, fails to report in full dividend and interest income.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Any amounts withheld under the backup withholding rules will be allowed as a refund
or a credit against a U.S. holder&#8217;s U.S. federal income tax liability provided the required information is furnished to the Internal
Revenue Service in a timely manner.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Individuals who own &#8220;specified foreign financial assets&#8221; with an aggregate
value in excess of $50,000 may be required to file an information report on IRS Form 8938, &#8220;Statement of Specified Foreign Financial
Assets,&#8221; with respect to such assets with their tax returns. &#8220;Specified foreign financial assets&#8221; include any financial
accounts maintained by foreign financial institutions, as well as any of the following, but only if they are not held in accounts maintained
by financial institutions: (i) stocks and securities issued by non-U.S. persons; (ii) financial instruments and contracts held for investment
that have non-U.S. issuers or counterparties; and (iii) interests in foreign entities. U.S. holders that are individuals are urged to
consult their tax advisors regarding the application of these rules to their ownership of our ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">F. DIVIDENDS AND PAYING AGENTS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">G. STATEMENT BY EXPERTS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">H. DOCUMENTS ON DISPLAY</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are required to file reports and other information with the SEC under the Exchange
Act, and the regulations thereunder applicable to foreign private issuers. <span style="font-family: Times New Roman,Times,serif">As a
&#8220;foreign private issuer&#8221; we are exempt from the rules and regulations under the Securities Exchange Act prescribing the furnishing
and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and &#8220;short-swing&#8221;
profit recovery provisions contained in Section 16 of the Securities Exchange Act, with respect to their purchase and sale of our shares.
In addition, we are not required to file reports and financial statements with the SEC as frequently or as promptly as U.S. companies
whose securities are registered under the Securities Exchange Act. Nasdaq rules generally require that companies send an annual report
to shareholders prior to the annual general meeting, however we rely upon an exception under the Nasdaq Listing Rules and follow the generally
accepted business practice for companies in Israel. Specifically, we file annual reports on Form 20-F, which contain financial statements
audited by an independent accounting firm, electronically with the SEC and post a copy on our website. We also furnish to the SEC reports
on Form 6-K containing unaudited financial information after the end of each of the first three quarters.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">106</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25">You may review a copy of our filings with the SEC, including any exhibits and schedules,
at the offices of the Israel Securities Authority at 22 Kanfei Nesharim St., Jerusalem, Israel. As a foreign private issuer, we were only
required to file through the SEC&#8217;s EDGAR system as of November 2002. Our periodic filings are therefore available on the SEC&#8217;s
Website <span style="font-style: italic">www.sec.gov</span> from that date. You may read and copy any reports, statements or other information
that we file with the SEC, through the SEC&#8217;s EDGAR system available on the SEC&#8217;s website. These SEC filings are also available
to the public on the Israel Securities Authority&#8217;s website at <span style="font-style: italic">www.isa.gov.il</span> and from commercial
document retrieval services.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Any statement in this Annual Report about any of our contracts or other documents
is not necessarily complete. If the contract or document is filed as an exhibit to this Annual Report, the contract or document is deemed
to modify the description contained in this Annual Report. We urge you to review the exhibits themselves for a complete description of
the contract or document.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">I. SUBSIDIARY INFORMATION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM11"><!--Anchor--></span>ITEM 11. QUANTITATIVE AND
QUALITATIVE DISCLOSURES ABOUT MARKET RISK</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We are exposed to a variety of risks, including changes in interest rates and foreign
currency exchange risk and inflation.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Interest Rate Risk</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">As of December 31, 2021, we had approximately $117.8 million in cash, cash equivalents,
restricted cash and short-term bank deposits. We mostly invest our cash surplus in bank deposits. Since these investments typically carry
fixed interest rate, financial income over the holding period is not sensitive to changes in interest rates. For more information, see
Note 2 to our 2021 consolidated financial statements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">Foreign Currency Exchange Risk and Inflation</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The cost of our Israel operations, as expressed in U.S. dollars, is influenced by
the extent to which any increase in the rate of inflation in Israel is not offset (or is offset on a lagging basis) by a devaluation of
the NIS in relation to the U.S. dollar. The inflation rate in Israel was 2.8%, (0.7%) and 0.6% in 2021, 2020 and 2019, respectively. The
devaluation of the U.S. dollar against the NIS was 3.3%, 7.0% and 7.8% in 2021, 2020 and 2019, respectively. For 2021, assuming a 10%
devaluation of the U.S. dollar against the NIS, we would experience an increase in our net loss of approximately $1.5 million, while assuming
a 10% appreciation of the U.S. dollar against the NIS, we would experience a decrease in our net loss of approximately $1.2 million. A
significant portion of our expenditures is employee compensation related. Salaries for Israel-based employees are paid in NIS and may
be adjusted for changes in the Israeli consumer price index, or CPI, through salary increases or adjustments. These upward adjustments
increase salary expenses in U.S. dollar terms. The devaluation/appreciation of the NIS against the U.S. dollar decreases/increases employee
compensation expenditures as expressed in dollars proportionally. Some of our other NIS based expenses are either currently adjusted to
U.S. dollars or are adjusted to the CPI. We currently have no foreign currency derivative contracts to hedge against currency exchange
risk fluctuation but may consider entering into such contracts in the future. For more information, see Note 2 of our 2021 consolidated
financial statements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 12<span id="ITEM12"><!--Anchor--></span>. DESCRIPTION OF SECURITIES
OTHER THAN EQUITY SECURITIES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">107</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">PART II<span id="PARTII"><!--Anchor--></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 13<span id="ITEM13"><!--Anchor--></span>. DEFAULTS, DIVIDEND
ARREARAGES AND DELINQUENCIES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">None.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -45pt; margin-left: 45pt; line-height: 1.25; font-weight: bold">ITEM 14<span id="ITEM14"><!--Anchor--></span>.
MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 15<span id="ITEM15"><!--Anchor--></span>. CONTROLS AND PROCEDURES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">A. DISCLOSURE CONTROLS AND PROCEDURES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our disclosure controls and procedures are designed to ensure that information required
to be disclosed in the reports we are required to file is recorded, processed, summarized and reported on a timely basis. Under the supervision
of our chief executive officer (principal executive officer) and chief financial officer (principal financial officer), we conducted an
evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and 15d-15(e)
promulgated under the Exchange Act. Based on this evaluation, our chief executive officer and chief financial officer concluded that our
disclosure controls and procedures were effective as of the end of the period covered by this Annual Report.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">B. MANAGEMENT&#8217;S ANNUAL REPORT ON INTERNAL
CONTROL OVER FINANCIAL REPORTING</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our management, with the involvement of our board of directors and audit committee,
is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial
reporting (as defined in Rules 13a-15(e) and 15(d) - 15(e) of the Exchange Act) has been designed to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of our consolidated financial statements for external purposes in accordance
with generally accepted accounting principles.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Under the supervision of our chief executive officer (principal executive officer)
and chief financial officer (principal financial officer), our management conducted an evaluation of the effectiveness of our internal
control over financial reporting, as such term is defined under Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act. In making
this assessment, our management used the criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO). Based on this evaluation, our chief executive officer and chief financial officer have
concluded that our internal control over financial reporting was effective as of the end of the period covered by this Annual Report.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Notwithstanding the foregoing, all internal control systems no matter how well designed
have inherent limitations. Therefore, even those systems determined to be effective may not prevent or detect misstatements and can provide
only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Kost Forer Gabbay &amp; Kasierer, a member firm of Ernst &amp; Young Global, an independent
registered public accounting firm in Israel,&#160;which has audited our financial statements for the year ended December 31, 2021 that
are included in this Annual Report, has issued an attestation report on our internal control over financial reporting as of December&#160;31,
2021.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">C. ATTESTATION REPORT OF THE REGISTERED PUBLIC
ACCOUNTING FIRM</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The attestation report of Kost Forer Gabbay &amp; Kasierer, a member firm of Ernst
&amp; Young Global, an independent registered public accounting firm in Israel, on our internal control over financial reporting as of
December 31, 2021 is provided on page F-4, as included under Item 18 of this Annual Report and is incorporated herein by reference.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">D. CHANGES IN INTERNAL CONTROL OVER FINANCIAL
REPORTING</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Based on the evaluation conducted by our management, with the participation of our
chief executive officer and chief financial officer, pursuant to Rules 13a-15(d) and 15d-15(d) promulgated under the Exchange Act, our
management (including such officers) have concluded that, there were no changes in our internal control over financial reporting that
occurred during the period covered by this Annual Report that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">108</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold"><span id="ITEM16"><!--Anchor--></span>ITEM 16. RESERVED</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16A<span id="ITEM16A"><!--Anchor--></span>. AUDIT COMMITTEE
FINANCIAL EXPERT</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our board of directors has determined that each of Mr. Gilead Halevy, Mr. Eran Perry
and Mr. Sanford (Sandy) Zweifach, each of whom serves on our audit committee and who meets the &#8220;independence&#8221; definition under
the Nasdaq Listing Rules, qualifies as an &#8220;audit committee financial expert&#8221; as defined in the instructions to this Item 16A
of Form 20-F.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16B<span id="ITEM16B"><!--Anchor--></span>. CODE OF ETHICS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We have adopted a code of business conduct that applies to all of our employees, officers
and directors as well as a code of ethics for senior financial officers that applies to our chief executive officer, chief financial officer,
director of finance, controller, assistant controller and persons performing similar functions at our subsidiary.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The code of ethics for senior financial officers is available on our website, <span style="font-style: italic"><span style="text-decoration: underline">www.cgen.com</span></span>.
However, information contained on our website does not constitute a part of this Annual Report.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">We intend to post on our website all disclosures that are required by the rules and
regulations of the SEC or by the Nasdaq Listing Rules concerning any amendments to, or waivers from, any provision of the code of business
conduct or the code of ethics.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16C<span id="ITEM16C"><!--Anchor--></span>. PRINCIPAL ACCOUNTANT
FEES AND SERVICES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The following table presents the fees billed or accrued to us by our principal accountant
for professional services rendered in the years ended December 31, 2021 and 2020:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" class="cfttable" id="z3bcaad319f644574a3d3a515080aa75a" style="font: 10pt Times New Roman, Times, serif; margin-left: auto; width: 80%; color: #000000; text-align: left; margin-right: auto">
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">2021</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">2020</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Audit Fees</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">133,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">133,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 76%">
        <div style="line-height: 1.25">Audit Related Fees</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">25,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">75,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Tax Fees</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">4,500</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">4,500</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 76%">
        <div style="line-height: 1.25">All Other Fees</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">2,500</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">2,500</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
        <div style="margin-right: 2.85pt; line-height: 1.25; font-weight: bold">Total</div> </td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold">165,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftguttercell" colspan="1" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td class="cftcurrcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold">$</div> </td>
    <td class="cftnumcell" colspan="1" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold">215,000</div> </td>
    <td class="cftfncell" colspan="1" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">&#8220;Audit Fees&#8221; are fees for professional services rendered by our principal
accountant in connection with the integrated audit (including review of internal control over financial reporting) of our consolidated
annual financial statements and review of our unaudited interim financial statements;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">&#8220;Audit Related Fees&#8221; are fees for professional services rendered by our
principal accountant in connection with the audit and other assignments, including consultancy and consents with respect to an underwritten
public offering and related prospectus supplements filed with the SEC;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">&#8220;Tax Fees&#8221; are fees for services rendered by our principal accountant
in connection with tax compliance, tax advice and tax planning which in years 2021 and 2020 were consultancy relating to withholding tax
on payments to foreign suppliers and annual Israeli tax reports; and</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">&#8220;All Other Fees&#8221; are fees for other consulting services rendered by our
principal accountant to us.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold">Pre-Approval Policies for non-Audit Services</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our audit committee is in charge of a policy and procedures for approval of audit
and non-audit services rendered by our external auditor. This policy generally provides that we will not engage our independent registered
public accounting firm to render audit or non-audit services unless the service is specifically approved in advance by our audit committee
or the engagement is entered into pursuant to the pre-approval procedure described below. Annually, our audit committee pre-approves specified
types of services that are expected to be provided to us by our independent registered public accounting firm during the next 12 months.
Any such pre-approval is detailed as to the particular service or type of services to be provided and is also generally subject to a maximum
dollar amount. All of the fees listed in the table above were approved by our audit committee.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">109</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: -81pt; margin-left: 81pt; line-height: 1.25; font-weight: bold">ITEM 16D<span id="ITEM16D"><!--Anchor--></span>.
EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not Applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -54pt; margin-left: 54pt; line-height: 1.25; font-weight: bold">ITEM 16E<span id="ITEM16E"><!--Anchor--></span>.
PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16F<span id="ITEM16F"><!--Anchor--></span>. CHANGE IN REGISTRANT&#8217;S
CERTIFYING ACCOUNTANT</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16G<span id="ITEM16G"><!--Anchor--></span>. CORPORATE GOVERNANCE</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">The Nasdaq Listing Rules require companies with securities listed thereon to comply
with its corporate governance standards. As a foreign private issuer whose shares are listed on Nasdaq, we are permitted to follow certain
home country corporate governance practices instead of those followed by U.S. companies under the Nasdaq Listing Rules, including:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Shareholder Approval.</span><span style="font-family: Times New Roman,Times,serif">
Pursuant to Israeli law, we seek shareholder approval for all corporate actions requiring such approval under the requirements of the
Companies Law, which are different from the requirements for seeking shareholder approval under Nasdaq Listing Rule 5635. We seek shareholder
approval in specified situations, including upon issuance of options to directors in their capacity as directors, as required by Israeli
law.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Quorum at an Adjourned General Meeting of Shareholders.</span><span style="font-family: Times New Roman,Times,serif">
Consistent with Israeli law, generally, a quorum for an adjourned general meeting of shareholders of the Company is any two shareholders
present in person, by proxy, by proxy card or by electronic vote at such meeting. As such, the Israeli quorum requirements for an adjourned
meeting are different from the Nasdaq requirement that an issuer listed on Nasdaq have a quorum requirement that in no case be less than
33 1/3% of the outstanding shares of the company&#8217;s common voting stock.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25"><span style="font-style: italic">Distribution of Annual Reports</span><span style="font-family: Times New Roman,Times,serif">.
We have chosen to follow our home country practice in lieu of the requirements of Nasdaq Rule 5250(d)(1), relating to an issuer&#8217;s
furnishing of its annual report to shareholders. Specifically, we file annual reports on Form 20-F, which contain financial statements
audited by an independent accounting firm, electronically with the SEC and post a copy on our website.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16H<span id="ITEM16H"><!--Anchor--></span>. MINE SAFETY DISCLOSURE</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 16I<span id="ITEM16I"><!--Anchor--></span>. DISCLOSURE REGARDING
FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-weight: bold">PART III<span id="PARTIII"><!--Anchor--></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 17<span id="ITEM17"><!--Anchor--></span>. FINANCIAL STATEMENTS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">See Item 18.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-weight: bold">ITEM 18<span id="ITEM18"><!--Anchor--></span>. FINANCIAL STATEMENTS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25">Our consolidated financial statements and related notes are included in this Annual
Report beginning on page F-1.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">110</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: -72pt; margin-left: 72pt; line-height: 1.25; font-weight: bold">ITEM 19.<span id="ITEM19."><!--Anchor--></span>
EXHIBITS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-weight: bold">Index to Exhibits</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z7bd26bb04d814575bc1066515ef00c7a" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Exhibit Number</div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Description</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891319002031/exhibit_99-4.htm">1.1</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891319002031/exhibit_99-4.htm">Articles
        of Association of Compugen, as amended (incorporated by reference to Annex A3 of Exhibit 99.4 to Compugen&#8217;s report on Form 6-K filed
        with the SEC on August5, 2019 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891319002031/exhibit_99-4.htm">1.2</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891319002031/exhibit_99-4.htm">Memorandum
        of Association of Compugen, as amended (incorporated by reference to Annex A2 of Exhibit 99.4 to Compugen&#8217;s report on Form 6-K filed
        with the SEC on August5, 2019 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_2-1.htm">2.1*</a></div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_2-1.htm">Description of Securities</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891320003355/exhibit_10-1.htm">4.1</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891320003355/exhibit_10-1.htm">Compugen
        Ltd. 2021 Employee Share Purchase Plan (incorporated by reference to Exhibit 10.1 to Compugen&#8217;s Registration Statement on Form S-8
        filed with the SEC on December 12, 2020 (File No. 333-251263)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891320002176/exhibit_4-1.htm">4.2</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891320002176/exhibit_4-1.htm">Compugen
        Ltd. 2010 Share Incentive Plan, as amended (incorporated by reference to Exhibit 4.1 to Compugen&#8217;s Registration Statement on Form
        S-8, filed with the SEC on July 30, 2020 (File No.333-240182)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_4-3.htm">4.3#*</a></div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_4-3.htm">Research and Development Collaboration and License Agreement,
        dated August 5, 2013, by and between Compugen Ltd. and BayerPharma AG (&#8220;Bayer&#8221;).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_4-4.htm">4.4#*</a></div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_4-4.htm">First Amendment to the Research and Development Collaboration
        and License Agreement, by and between Compugen Ltd. and Bayer dated as of February 5, 2014.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_4-5.htm">4.5#*</a></div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_4-5.htm">Second Amendment to the Research and Development Collaboration
        and License Agreement, by and between Compugen Ltd. and Bayer, dated as of July 27, 2015.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_4-6.htm">4.6#*</a></div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_4-6.htm">Third Amendment to Research and Development Collaboration
        and License Agreement, by and between Compugen Ltd. and Bayer, dated as of April 17, 2016.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891314000645/exhibit_4-8.htm">4.7</a></div>
        </td>
    <td style="width: 92%; vertical-align: top">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891314000645/exhibit_4-8.htm">Lease
        dated December 12, 2013, by and between Britannia Pointe Grand Limited Partnership and Compugen USA, Inc. <span style="font-family: Times New Roman,Times,serif">(incorporated
        by reference to Exhibit 4.8 to Compugen&#8217;s Annual Report on Form 20-F for the year ended December 31, 2013, filed with the SEC on
        February 18, 2014 (File No. 000-30902)).</span></a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="exhibit_4-8.htm">4.8*</a></div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_4-8.htm">Amended and Restated Form of Indemnification Undertaking
        and Exemption and Release between Compugen Ltd. and its directors and office holders.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891315001448/exhibit_99-2.htm">4.9</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891315001448/exhibit_99-2.htm">Office
        Lease Agreement (&#8220;Holon Lease&#8221;), dated March 2015, by and between Kanit Hashalom Investments Ltd. and Compugen Ltd. (incorporated
        by reference to Exhibit 99.2 to Compugen&#8217;s Form 6-K filed with the SEC on May 5, 2015 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891316004622/exhibit_4-10.htm">4.10</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891316004622/exhibit_4-10.htm">Amendment
        to Holon Lease made and entered into on November 26, 2015 by and between Kanit Hashalom Investments Ltd. and Compugen Ltd. (incorporated
        by reference to Exhibit 4.10 to Compugen&#8217;s Annual Report on Form 20-F for the year ended December 31, 2015, filed with the SEC on
        March 7, 2016 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891321000791/exhibit_4-11.htm">4.11</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891321000791/exhibit_4-11.htm">Addendum
        to Holon Lease made and entered into on October 14, 2020 by and between Kanit Hashalom Investments Ltd. and Compugen Ltd. (incorporated
        by reference to Exhibit 4.11 to Compugen&#8217;s Annual Report on Form 20-F for the year ended December 31, 2020, filed with the SEC on
        February 25, 2021 (File No. 000-30902))</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318001533/exhibit_10-1.htm">4.12@</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318001533/exhibit_10-1.htm">License
        Agreement, between the Company and MedImmune Limited (&#8220;MedImmune&#8221;), entered into as of March 30, 2018 (incorporated by reference
        to Exhibit 10.1 to Compugen&#8217;s Form 6-K, filed with the SEC on May 9, 2018 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318002228/exhibit_10-1.htm">4.13@</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318002228/exhibit_10-1.htm">Amendment
        No. 1 to the License Agreement, between the Company and MedImmune, dated May 9, 2018 (incorporated by reference to Exhibit 10.1 to Compugen&#8217;s
        Form 6-K, filed with the SEC on August 1, 2018 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891321000791/exhibit_4-14.htm">4.14</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891321000791/exhibit_4-14.htm">Amendment
        No. 2 to the License Agreement, between the Company and MedImmune, dated September 16, 2020 (incorporated by reference to Exhibit 4.14
        to Compugen&#8217;s Annual Report on Form 20-F for the year ended December 31, 2020, filed with the SEC on February 25, 2021 (File No.
        000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_4-15.htm">4.15#*</a></div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_4-15.htm">Amendment No. 3 to the License Agreement, between the Company
        and MedImmune, dated August 4, 2021.</a></div> </td> </tr>
  </table>

<div><br /> </div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">111</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" border="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318001935/exhibit_4-1.htm">4.16</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318001935/exhibit_4-1.htm">Form
        of Warrant to Purchase Ordinary Shares (incorporated by reference to Exhibit 4.1 to Compugen&#8217;s Form 6-K, filed with the SEC on June
        19, 2018 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318002831/exhibit_10-1.htm">4.17@</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318002831/exhibit_10-1.htm">Master
        Clinical Trial Collaboration Agreement, between the Company and Bristol Myers Squibb Company, dated October 10, 2018 (incorporated by
        reference to Exhibit 10.1 to Compugen&#8217;s Form 6-K, filed with the SEC on November 7, 2018 (File No. 000-30902)).</a></div> </td>
        </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_4-18.htm">4.18#*</a></div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_4-18.htm">Amendment No. 1 to Master Clinical Trial Collaboration
        Agreement, between the Company and Bristol Myers Squibb Company, dated February 14, 2020.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_4-19.htm">4.19#*</a></div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_4-19.htm">Amendment No. 2 to Master Clinical Trial Collaboration
        Agreement, between the Company and Bristol Myers Squibb Company, dated February 19, 2021.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_4-20.htm">4.20#*</a></div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_4-20.htm">Amendment No. 3 to Master Clinical Trial Collaboration
        Agreement, between the Company and Bristol Myers Squibb Company, dated November 10, 2021.</a></div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_8-1.htm">8.1*</a></div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_8-1.htm">Subsidiaries.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_12-1.htm">12.1*</a></div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_12-1.htm">Certification by Principal Executive Officer pursuant to
        Rule 13a-14(a)/Rule 15d-14(a) under the Exchange Act and Section 302 of the Sarbanes-Oxley Act of 2002.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_12-2.htm">12.2*</a></div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_12-2.htm">Certification by Principal Financial and Accounting Officer
        pursuant to Rule 13a-14(a)/Rule 15d-14(a) under the Exchange Act and Section 302 of the Sarbanes-Oxley Act of 2002.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_13-1.htm">13.1*</a></div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_13-1.htm">Certification by Principal Executive Officer and Principal
        Financial and Accounting Officer pursuant to Rule 13a-14(b)/Rule 15d-14(b) under the Exchange Act and 18 U.S.C. Section 1350, as adopted
        pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_15-1.htm">15.1*</a></div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_15-1.htm">Consent of Kost Forer Gabbay &amp; Kasierer, a member firm
        of Ernst &amp; Young Global.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">101*</div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">The following financial information from Compugen Ltd.&#8217;s Annual Report on Form
        20-F for the year ended December 31, 2021, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Statements
        of Operations for the years ended December 31, 2021, 2020 and 2019; (ii) Consolidated Balance Sheets as of December 31, 2021 and 2020;
        (iii) Consolidated Statements of Changes in Shareholders&#8217; Equity for the years ended December 31, 2021, 2020 and 2019; (iv) Consolidated
        Statements of Cash Flows for the years ended December 31, 2021, 2020 and 2019; and (v) Notes to Consolidated Financial Statements.</div>
        </td> </tr>
  </table>

<div> <br /> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"> <hr style="border-style: none; height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto" /></div>
</div>

<table cellspacing="0" cellpadding="0" id="z3fce3cacad144ad785d5f41deb6e4049" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">101.INS</div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Inline XBRL Instance Document</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">101.SCH</div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Inline XBRL Taxonomy Extension Schema Document</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">101.PRE</div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Inline XBRL Taxonomy Extension Presentation Linkbase Document</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">101.CAL</div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Inline XBRL Taxonomy Calculation Linkbase Document</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">101.LAB</div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Inline XBRL Taxonomy Label Linkbase Document</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">101.DEF</div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Inline XBRL Taxonomy Extension Definition Linkbase Document</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">104</div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Cover Page Interactive Data File&#160;(Formatted as Inline XBRL and contained in Exhibit 101).</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160; <hr style="border-style: none; height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto" /></div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z98eddf1f6ee44e548a423a63ea10c140" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">*</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Filed herewith.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zaa5a2578d3de465dbfd58e2f39135237" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">@</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Confidential treatment has been granted by the Securities and Exchange Commission as to certain portions.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5eb9222280f74ed7bdff10b93a9fe2d4" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top">#</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Portions of this exhibit (indicated by asterisks therein) have been omitted as these portions are both not material and confidential.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">112</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: center; margin-right: 28.4pt; margin-left: 18pt; line-height: 1.25; font-weight: bold">SIGNATURES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;

<div style="line-height: 1.25; font-family: Times New Roman, Times, serif">The registrant hereby certifies that it meets all of the requirements
for filing this Amendment No. 1 and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160; <br /> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" border="0" id="zd8342b8ad2b0429f8f9a742bf605aa3f" style="font: 10pt Times New Roman, Times, serif; color: #000000; width: 100%">
  <tr>
    <td style="width: 50%">
        <div>&#160;</div> </td>
    <td style="width: 50%">
        <div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">COMPUGEN LTD.</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="text-decoration: underline">Signature:
        /s/ Dr. Anat Cohen-Dayag</span></div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Name: Dr. Anat Cohen-Dayag</div>
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman,Times,serif">Title: President and Chief Executive Officer,
        Director</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Date: February 28, 2022</div> </div> </td>
        </tr>
  </table>

<div> <br /> </div> </div> </div>

<div  style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div  style="text-align: center"><span  style="font-weight: normal; font-style: normal">113</span></div>

<div  style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div><br /> </div> </div>

<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman,Times,serif"> </span></p>
<!-- Field: /Include-Text -->

<p style="font: 10pt Times New Roman, Times, serif; text-align: center; margin-top: 9pt; margin-bottom: 0pt"><span style="font-weight:bold; ">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, serif; text-align: center; margin-top: 9pt; margin-bottom: 0pt"><span style="font-weight: bold">COMPUGEN LTD. AND ITS SUBSIDIARY</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">CONSOLIDATED FINANCIAL STATEMENTS</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">AS OF DECEMBER 31, 2021</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. DOLLARS IN THOUSANDS</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">INDEX</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:90%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Page</span></p> </td> </tr> <tr class="even" style=""> <td style="width:90%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:10%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style=""> <td style="width:90%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; "><a href="#d1e431_anchor">Report of Independent Registered Public Accounting Firm</a></span></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">F-2</span><span style="font-weight:bold; ">&#x2009;&#x2013;&#x2009;F-4</span></p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:3pt; margin-bottom:10pt !important; margin-bottom:0pt; "><span style="font-style:italic; ">(PCAOB ID: </span><span style="font-style:italic; "><ix:nonNumeric id="Fact_0000000000042" contextRef="From2021-01-01to2021-12-31" name="dei:AuditorFirmId">1281</ix:nonNumeric></span><span style="font-style:italic; ">)</span></p> <div>
<table width="100%" cellpadding="0" style="border-spacing:0; margin:auto; "> <tbody> <tr class="odd" style=""> <td style="width:90%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; "><a href="#d1e668_anchor">Consolidated Balance Sheets</a></span></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">F-5</span><span style="font-weight:bold; ">&#x2009;&#x2013;&#x2009;F-6</span></p> </td> </tr> <tr class="even" style=""> <td style="width:90%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:90%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; "><a href="#d1e2155_anchor">Consolidated Statements of Comprehensive Loss</a></span></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">F-7</span></p> </td> </tr> <tr class="even" style=""> <td style="width:90%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:90%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; "><a href="#d1e3423_anchor">Statements of Changes in Shareholders&#x2019; Equity</a></span></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">F-8</span></p> </td> </tr> <tr class="even" style=""> <td style="width:90%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:90%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; "><a href="#d1e4726_anchor">Consolidated Statements of Cash Flows</a></span></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">F-9</span><span style="font-weight:bold; ">&#x2009;&#x2013;&#x2009;F-10</span></p> </td> </tr> <tr class="even" style=""> <td style="width:90%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:90%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; "><a href="#d1e6494_anchor">Notes to Consolidated Financial Statements</a></span></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">F-11</span><span style="font-weight:bold; ">&#x2009;&#x2013;&#x2009;F-38</span></p> </td> </tr> <tr class="even" style=""> <td style="width:90%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </tbody> </table> </div> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:13.03pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; " id="d1e431_anchor"></p> <div>
<table width="100%" cellpadding="0" style="border-spacing:0; "> <tbody> <tr class="odd" style=""> <td style="width:17%; vertical-align:middle; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><img src="image0.jpg" alt="image provided by client" style="width:75px; height:86.25px; "/>&#x2009;</p> </td> <td style="width:25%; vertical-align:middle; ">
<p style="font-family:Times New Roman, Times, serif; font-size:8pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Kost Forer Gabbay &amp; Kasierer</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:8pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">144 Menachem Begin Road, Building A, </p>
<p style="font-family:Times New Roman, Times, serif; font-size:8pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Tel-Aviv 6492102, Israel </p> </td> <td style="width:21%; vertical-align:middle; ">
<p style="font-family:Times New Roman, Times, serif; font-size:8pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Tel: +972-3-6232525 </p>
<p style="font-family:Times New Roman, Times, serif; font-size:8pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Fax: +972-3-5622555 </p>
<p style="font-family:Times New Roman, Times, serif; font-size:8pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">ey.com </p> </td> <td style="width:37%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">To the Shareholders and Board of Directors of</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD.</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Opinion on the Financial Statements</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">We have audited the accompanying consolidated balance sheets of Compugen Ltd. and its subsidiary (the &#x201C;Company&#x201D;) as of December 31, 2021 and 2020, the related consolidated statements of comprehensive loss, changes in shareholders&#x2019; equity and cash flows for each of the three years in the period ended December 31, 2021, and related notes (collectively referred to as the &#x201C;consolidated financial statements&#x201D;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#x2019;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 28, 2022 expressed an unqualified opinion thereon.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Basis for Opinion</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Critical audit matter</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;2</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" style="border-spacing:0; "> <tbody> <tr class="odd" style=""> <td style="width:15%; vertical-align:middle; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><img src="image0.jpg" alt="image provided by client" style="width:75px; height:86.25px; "/>&#x2009;</p> </td> <td style="width:25%; vertical-align:middle; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:21%; vertical-align:middle; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:39%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" style="border-spacing:0; "> <thead> <tr class="odd" style=""> <td style="width:15%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:84%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Accrued pre-clinical and clinical trial expenses</span></p> </td> </tr> </thead> <tbody> <tr class="odd" style=""> <td style="width:15%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:6pt; margin-bottom:0pt; ">Description of the matter</p> </td> <td style="width:2%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:84%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:6pt; margin-bottom:0pt; ">As discussed in Note 2(k) to the consolidated financial statements, the Company records costs for pre-clinical and clinical trial activities based upon estimates of costs incurred through the balance sheet date that have yet to be invoiced by the contract research organizations and other vendors. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:0pt; margin-bottom:0pt; ">Auditing the Company&#x2019;s accruals for pre-clinical and clinical trial activities is challenging due to the fact that information necessary to estimate the accruals for the services that have been received during the reporting period is accumulated from multiple sources such as Company&#x2019;s operations personnel that oversee the pre-clinical and clinical trial activities, information from service providers and terms and conditions included in the contracts with the service providers. In addition, in certain circumstances, the determination of the nature and level of services that have been received during the reporting period requires judgment because the timing and pattern of vendor invoicing does not correspond to the level of services provided and there may be delays in invoicing from pre-clinical and clinical study sites and other vendors.</p> </td> </tr> <tr class="even" style=""> <td style="width:15%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:6pt; margin-bottom:0pt; ">How we addressed the matter in our audit</p> </td> <td style="width:2%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:84%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:6pt; margin-bottom:0pt; ">We obtained an understanding of, evaluated the design and tested the operating effectiveness of internal controls that addressed the identified risks related to the Company&#x2019;s process for recording accrued pre-clinical and clinical trial expenses. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:0pt; margin-bottom:0pt; ">To test the pre-clinical and clinical trial accruals, our audit procedures included, among others, reviewing a sample of agreements with the service providers to corroborate key terms and conditions and testing the accuracy and completeness of the underlying data used in the accrual computations. We also evaluated management&#x2019;s estimates of the progress of a sample of pre-clinical and clinical trial activities by making direct inquiries of the Company&#x2019;s operations personnel that oversee the pre-clinical and clinical trial activities and obtaining information directly from certain service providers which indicated the progress of pre-clinical and clinical trial completed through the balance sheet date and compared that to the Company&#x2019;s accrual computations. To evaluate the completeness of the accruals, we also examined subsequent invoices from the service providers and cash disbursements to the service providers, to the extent such invoices were received, or payments were made prior to the date that the consolidated financial statements were issued. </p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:16pt; margin-bottom:0pt; ">/s/KOST FORER GABBAY &amp; KASIERER</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">A Member of Ernst &amp; Young Global</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">We have served as the Company&#x2019;s auditor since 2002</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Tel-Aviv, Israel</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">February 28, 2022 </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;3</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" style="border-spacing:0; "> <tbody> <tr class="odd" style=""> <td style="width:17%; vertical-align:middle; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><img src="image0.jpg" alt="image provided by client" style="width:75px; height:86.25px; "/>&#x2009;</p> </td> <td style="width:25%; vertical-align:middle; ">
<p style="font-family:Times New Roman, Times, serif; font-size:8pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Kost Forer Gabbay &amp; Kasierer</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:8pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">144 Menachem Begin Road, Building A, </p>
<p style="font-family:Times New Roman, Times, serif; font-size:8pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Tel-Aviv 6492102, Israel </p> </td> <td style="width:21%; vertical-align:middle; ">
<p style="font-family:Times New Roman, Times, serif; font-size:8pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Tel: +972-3-6232525 </p>
<p style="font-family:Times New Roman, Times, serif; font-size:8pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Fax: +972-3-5622555 </p>
<p style="font-family:Times New Roman, Times, serif; font-size:8pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">ey.com </p> </td> <td style="width:37%; vertical-align:top; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">To the Shareholders and Board of Directors of</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD.</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Opinion on Internal Control over Financial Reporting</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">We have audited Compugen Ltd. and its subsidiary&#x2019;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Compugen Ltd. and its subsidiary (the &#x201C;Company&#x201D;) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and 2020 and the related consolidated statements of comprehensive loss, changes in shareholders&#x2019; equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes and our report dated February 28, 2022 expressed an unqualified opinion thereon.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Basis for Opinion</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">The Company&#x2019;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#x2019;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#x2019;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures, as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Definition and Limitations of Internal Control Over Financial Reporting</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">A company&#x2019;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#x2019;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#x2019;s assets that could have a material effect on the financial statements.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; margin-bottom:0pt; ">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">/s/<ix:nonNumeric id="Fact_0000000000043" contextRef="From2021-01-01to2021-12-31" name="dei:AuditorName">KOST FORER GABBAY &amp; KASIERER</ix:nonNumeric> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">A Member of Ernst &amp; Young Global</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><ix:nonNumeric id="Fact_0000000000044" contextRef="From2021-01-01to2021-12-31" name="dei:AuditorLocation">Tel-Aviv, Israel</ix:nonNumeric></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">February 28, 2022 </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;4</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; " id="d1e668_anchor"><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">CONSOLIDATED BALANCE SHEETS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Note</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">ASSETS</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">CURRENT ASSETS:</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Cash and cash equivalents</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000045" contextRef="AsOf2021-12-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,801</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000046" contextRef="AsOf2020-12-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,143</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Restricted cash</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000047" contextRef="AsOf2021-12-31" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">713</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000048" contextRef="AsOf2020-12-31" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">667</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Short-term bank deposits</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000049" contextRef="AsOf2021-12-31" name="us-gaap:OtherShortTermInvestments" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">109,248</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000050" contextRef="AsOf2020-12-31" name="us-gaap:OtherShortTermInvestments" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">116,622</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Trade receivables</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000051" contextRef="AsOf2021-12-31" name="us-gaap:AccountsReceivableNetCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000052" contextRef="AsOf2020-12-31" name="us-gaap:AccountsReceivableNetCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,000</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Other accounts receivable and prepaid expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">3</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000053" contextRef="AsOf2021-12-31" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,460</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000054" contextRef="AsOf2020-12-31" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,658</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">Total</span> current assets </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000055" contextRef="AsOf2021-12-31" name="us-gaap:AssetsCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">123,222</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000056" contextRef="AsOf2020-12-31" name="us-gaap:AssetsCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">129,090</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">NON-CURRENT ASSETS:</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Long-term prepaid expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000057" contextRef="AsOf2021-12-31" name="us-gaap:PrepaidExpenseNoncurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,911</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000058" contextRef="AsOf2020-12-31" name="us-gaap:PrepaidExpenseNoncurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,880</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Severance pay fund</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000059" contextRef="AsOf2021-12-31" name="cgen:SeverancePayFundNoncurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,125</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000060" contextRef="AsOf2020-12-31" name="cgen:SeverancePayFundNoncurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,863</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Operating lease right of use asset</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">4</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000061" contextRef="AsOf2021-12-31" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,247</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000062" contextRef="AsOf2020-12-31" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,772</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Property and equipment, net</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">5</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000063" contextRef="AsOf2021-12-31" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,658</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000064" contextRef="AsOf2020-12-31" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,711</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">Total</span> non- current assets </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000065" contextRef="AsOf2021-12-31" name="us-gaap:AssetsNoncurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,941</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000066" contextRef="AsOf2020-12-31" name="us-gaap:AssetsNoncurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,226</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">Total</span> assets </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000067" contextRef="AsOf2021-12-31" name="us-gaap:Assets" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">132,163</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000068" contextRef="AsOf2020-12-31" name="us-gaap:Assets" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">138,316</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:16pt; margin-bottom:0pt; ">The accompanying notes are an integral part of the consolidated financial statements.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;5</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">CONSOLIDATED BALANCE SHEETS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Note</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">LIABILITIES AND SHAREHOLDERS&#x2019; EQUITY</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">CURRENT LIABILITIES:</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Trade payables</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000069" contextRef="AsOf2021-12-31" name="us-gaap:AccountsPayableCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,621</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000070" contextRef="AsOf2020-12-31" name="us-gaap:AccountsPayableCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,413</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Short-term deferred participation in R&amp;D expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000071" contextRef="AsOf2021-12-31" name="cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,629</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000072" contextRef="AsOf2020-12-31" name="cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">668</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Current maturity of operating lease liability</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">4</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000073" contextRef="AsOf2021-12-31" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">768</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000074" contextRef="AsOf2020-12-31" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">639</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Other accounts payable and accrued expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">6</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000075" contextRef="AsOf2021-12-31" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,078</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000076" contextRef="AsOf2020-12-31" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,803</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">Total</span> current liabilities </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000077" contextRef="AsOf2021-12-31" name="us-gaap:LiabilitiesCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,096</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000078" contextRef="AsOf2020-12-31" name="us-gaap:LiabilitiesCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,523</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">NON- CURRENT LIABILITIES:</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Long-term deferred participation in R&amp;D expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000079" contextRef="AsOf2021-12-31" name="cgen:LongTermDeferredParticipationInResearchAndDevelopmentExpenses" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,715</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000080" contextRef="AsOf2020-12-31" name="cgen:LongTermDeferredParticipationInResearchAndDevelopmentExpenses" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,968</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Long-term operating lease liability</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000081" contextRef="AsOf2021-12-31" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,982</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000082" contextRef="AsOf2020-12-31" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,527</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Accrued severance pay</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000083" contextRef="AsOf2021-12-31" name="us-gaap:PostemploymentBenefitsLiabilityNoncurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,677</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000084" contextRef="AsOf2020-12-31" name="us-gaap:PostemploymentBenefitsLiabilityNoncurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,516</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">Total</span> non-current liabilities </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000085" contextRef="AsOf2021-12-31" name="us-gaap:LiabilitiesNoncurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,374</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000086" contextRef="AsOf2020-12-31" name="us-gaap:LiabilitiesNoncurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,011</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">COMMITMENTS AND CONTINGENT LIABILITIES</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">7</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">SHAREHOLDERS&#x2019; EQUITY:</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">8</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Share capital:</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:-8pt !important; padding-left:16pt !important; margin-bottom:0pt; ">Ordinary shares of NIS <ix:nonFraction id="Fact_0000000000088" contextRef="AsOf2020-12-31" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="ILSPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction id="Fact_0000000000087" contextRef="AsOf2021-12-31" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="ILSPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction id="Fact_0000000000090" contextRef="AsOf2020-12-31" name="us-gaap:CommonStockSharesAuthorized" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction id="Fact_0000000000089" contextRef="AsOf2021-12-31" name="us-gaap:CommonStockSharesAuthorized" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December 31, 2021 and 2020; <ix:nonFraction id="Fact_0000000000092" contextRef="AsOf2021-12-31" name="us-gaap:CommonStockSharesIssued" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction id="Fact_0000000000091" contextRef="AsOf2021-12-31" name="us-gaap:CommonStockSharesOutstanding" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">86,433,432</ix:nonFraction></ix:nonFraction> and <ix:nonFraction id="Fact_0000000000094" contextRef="AsOf2020-12-31" name="us-gaap:CommonStockSharesIssued" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction id="Fact_0000000000093" contextRef="AsOf2020-12-31" name="us-gaap:CommonStockSharesOutstanding" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">83,675,856</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2021 and 2020, respectively</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000095" contextRef="AsOf2021-12-31" name="us-gaap:CommonStockValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">239</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000096" contextRef="AsOf2020-12-31" name="us-gaap:CommonStockValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">231</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Additional paid-in capital</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000097" contextRef="AsOf2021-12-31" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">528,533</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000098" contextRef="AsOf2020-12-31" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">507,427</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Accumulated deficit</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000099" contextRef="AsOf2021-12-31" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">422,079</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:1.5pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000100" contextRef="AsOf2020-12-31" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">387,876</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">)</p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">Total</span> shareholders&#x2019; equity </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000101" contextRef="AsOf2021-12-31" name="us-gaap:StockholdersEquity" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">106,693</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000102" contextRef="AsOf2020-12-31" name="us-gaap:StockholdersEquity" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">119,782</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:62%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">Total</span> liabilities and shareholders&#x2019; equity </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000103" contextRef="AsOf2021-12-31" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">132,163</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000104" contextRef="AsOf2020-12-31" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">138,316</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:16pt; margin-bottom:0pt; ">The accompanying notes are an integral part of the consolidated financial statements.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;6</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; " id="d1e2155_anchor"><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Note</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Revenue</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000105" contextRef="From2021-01-01to2021-12-31" name="us-gaap:Revenues" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,000</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000106" contextRef="From2020-01-01to2020-12-31" name="us-gaap:Revenues" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,000</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000107" contextRef="From2019-01-01to2019-12-31" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Cost of revenue</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000108" contextRef="From2021-01-01to2021-12-31" name="us-gaap:CostOfRevenue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">680</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000109" contextRef="From2020-01-01to2020-12-31" name="us-gaap:CostOfRevenue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">60</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000110" contextRef="From2019-01-01to2019-12-31" name="us-gaap:CostOfRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Gross profit</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000111" contextRef="From2021-01-01to2021-12-31" name="us-gaap:GrossProfit" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,320</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000112" contextRef="From2020-01-01to2020-12-31" name="us-gaap:GrossProfit" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,940</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000113" contextRef="From2019-01-01to2019-12-31" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"></ix:nonFraction>-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Operating expenses:</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Research and development expenses, net</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000114" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,694</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000115" contextRef="From2020-01-01to2020-12-31" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,760</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000116" contextRef="From2019-01-01to2019-12-31" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,816</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Marketing and business development expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000117" contextRef="From2021-01-01to2021-12-31" name="us-gaap:BusinessDevelopment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">842</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000118" contextRef="From2020-01-01to2020-12-31" name="us-gaap:BusinessDevelopment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">871</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000119" contextRef="From2019-01-01to2019-12-31" name="us-gaap:BusinessDevelopment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">651</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">General and administrative expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000120" contextRef="From2021-01-01to2021-12-31" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,858</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000121" contextRef="From2020-01-01to2020-12-31" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,805</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000122" contextRef="From2019-01-01to2019-12-31" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,412</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">Total</span> operating expenses </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000123" contextRef="From2021-01-01to2021-12-31" name="us-gaap:OperatingExpenses" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,394</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000124" contextRef="From2020-01-01to2020-12-31" name="us-gaap:OperatingExpenses" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,436</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000125" contextRef="From2019-01-01to2019-12-31" name="us-gaap:OperatingExpenses" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,879</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Operating loss</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000126" contextRef="From2021-01-01to2021-12-31" name="us-gaap:OperatingIncomeLoss" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">35,074</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000127" contextRef="From2020-01-01to2020-12-31" name="us-gaap:OperatingIncomeLoss" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">31,496</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000128" contextRef="From2019-01-01to2019-12-31" name="us-gaap:OperatingIncomeLoss" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">28,879</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Financial and other income, net</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">11</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000129" contextRef="From2021-01-01to2021-12-31" name="cgen:FinancialIncomeExpenseNet" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">871</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000130" contextRef="From2020-01-01to2020-12-31" name="cgen:FinancialIncomeExpenseNet" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,798</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000131" contextRef="From2019-01-01to2019-12-31" name="cgen:FinancialIncomeExpenseNet" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">820</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Loss before taxes on income</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000132" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">34,203</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000133" contextRef="From2020-01-01to2020-12-31" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">29,698</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000134" contextRef="From2019-01-01to2019-12-31" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">28,059</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Taxes on income</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">9</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000135" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000136" contextRef="From2020-01-01to2020-12-31" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000137" contextRef="From2019-01-01to2019-12-31" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">722</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net loss</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000138" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetIncomeLoss" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">34,203</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000139" contextRef="From2020-01-01to2020-12-31" name="us-gaap:NetIncomeLoss" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">29,698</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000140" contextRef="From2019-01-01to2019-12-31" name="us-gaap:NetIncomeLoss" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">27,337</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">)</p> </td> </tr> <tr class="even" style=""> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Basic net loss per share</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000141" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EarningsPerShareBasic" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal" sign="-">0.41</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000142" contextRef="From2020-01-01to2020-12-31" name="us-gaap:EarningsPerShareBasic" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal" sign="-">0.37</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000143" contextRef="From2019-01-01to2019-12-31" name="us-gaap:EarningsPerShareBasic" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal" sign="-">0.43</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> </tr> <tr class="even" style=""> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Diluted net loss per share</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000144" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EarningsPerShareDiluted" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal" sign="-">0.41</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000145" contextRef="From2020-01-01to2020-12-31" name="us-gaap:EarningsPerShareDiluted" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal" sign="-">0.37</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000146" contextRef="From2019-01-01to2019-12-31" name="us-gaap:EarningsPerShareDiluted" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal" sign="-">0.43</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> </tr> <tr class="even" style=""> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Total comprehensive loss</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000147" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">34,203</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000148" contextRef="From2020-01-01to2020-12-31" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">29,698</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000149" contextRef="From2019-01-01to2019-12-31" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">27,337</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> </tr> <tr class="even" style=""> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:-8pt !important; padding-left:8pt !important; margin-bottom:0pt; ">Weighted average number of ordinary shares used in computing basic net loss per share</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000150" contextRef="From2021-01-01to2021-12-31" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">84,203,971</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000151" contextRef="From2020-01-01to2020-12-31" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">79,591,187</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000152" contextRef="From2019-01-01to2019-12-31" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">63,636,673</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:49%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:-8pt !important; padding-left:8pt !important; margin-bottom:0pt; ">Weighted average number of ordinary shares used in computing diluted net loss per share</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000153" contextRef="From2021-01-01to2021-12-31" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">84,203,971</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000154" contextRef="From2020-01-01to2020-12-31" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">79,591,187</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000155" contextRef="From2019-01-01to2019-12-31" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">63,636,673</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:16pt; margin-bottom:0pt; ">The accompanying notes are an integral part of the consolidated financial statements.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;7</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; " id="d1e3423_anchor"><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">STATEMENTS OF CHANGES IN SHAREHOLDERS&#x2019; EQUITY</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share data)</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Ordinary shares</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Additional</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">paid-in</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Accumulated</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Total </span><span style="font-weight:bold; ">shareholders&#x2019;</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Number</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Amount</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">capital</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">deficit</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">equity</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Balance as of January 1, 2019</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000156" contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" name="us-gaap:CommonStockSharesOutstanding" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">59,849,784</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000157" contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">164</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000158" contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">367,920</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000159" contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">330,841</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000160" contextRef="AsOf2018-12-31" name="us-gaap:StockholdersEquity" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,243</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options exercised</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000161" contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">878,378</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000162" contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000163" contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,246</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000164" contextRef="From2019-01-01to2019-12-31" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,249</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Issuance of shares and warrants, net</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000165" contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" name="cgen:IssuanceOfSharesAndWarrantsNetShares" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,194,674</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000166" contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember" name="cgen:IssuanceOfSharesAndWarrantsNetValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000167" contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cgen:IssuanceOfSharesAndWarrantsNetValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,738</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000168" contextRef="From2019-01-01to2019-12-31" name="cgen:IssuanceOfSharesAndWarrantsNetValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,758</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:-8pt !important; padding-left:8pt !important; margin-bottom:0pt; ">Stock-based compensation relating to options issued to employees, directors and non-employees</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000169" contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cgen:StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,408</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000170" contextRef="From2019-01-01to2019-12-31" name="cgen:StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,408</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net loss</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000171" contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">27,337</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000172" contextRef="From2019-01-01to2019-12-31" name="us-gaap:NetIncomeLoss" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">27,337</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">)</p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Balance as of December 31, 2019</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000173" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" name="us-gaap:CommonStockSharesOutstanding" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">67,922,836</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000174" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">187</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000175" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">396,312</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000176" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">358,178</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:3px; margin-bottom:1.5pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000177" contextRef="AsOf2019-12-31" name="us-gaap:StockholdersEquity" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,321</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options exercised</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000178" contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,070,542</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000179" contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000180" contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,906</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000181" contextRef="From2020-01-01to2020-12-31" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,915</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Warrants exercised</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000182" contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" name="cgen:NumberOfWarrantsExercised" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,866,139</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000183" contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" name="cgen:StockIssuedDuringPeriodValueWarrantsExercised" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000184" contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cgen:StockIssuedDuringPeriodValueWarrantsExercised" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,314</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000185" contextRef="From2020-01-01to2020-12-31" name="cgen:StockIssuedDuringPeriodValueWarrantsExercised" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,325</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Issuance of shares, net</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000186" contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,816,339</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000187" contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000188" contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">74,123</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000189" contextRef="From2020-01-01to2020-12-31" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">74,147</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:-8pt !important; padding-left:8pt !important; margin-bottom:0pt; ">Stock-based compensation relating to options issued to employees, directors and non-employees</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000190" contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cgen:StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,772</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000191" contextRef="From2020-01-01to2020-12-31" name="cgen:StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,772</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net loss</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000192" contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">29,698</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000193" contextRef="From2020-01-01to2020-12-31" name="us-gaap:NetIncomeLoss" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">29,698</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">)</p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Balance as of December 31, 2020</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000194" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" name="us-gaap:CommonStockSharesOutstanding" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">83,675,856</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000195" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">231</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000196" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">507,427</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000197" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">387,876</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000198" contextRef="AsOf2020-12-31" name="us-gaap:StockholdersEquity" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">119,782</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Exercise of options and ESPP shares</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000199" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">335,204</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000200" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000201" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,454</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000202" contextRef="From2021-01-01to2021-12-31" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,455</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Warrants exercised</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000203" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="cgen:NumberOfWarrantsExercised" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">89,557</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000204" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="cgen:StockIssuedDuringPeriodValueWarrantsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>*</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000205" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cgen:StockIssuedDuringPeriodValueWarrantsExercised" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">425</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000206" contextRef="From2021-01-01to2021-12-31" name="cgen:StockIssuedDuringPeriodValueWarrantsExercised" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">425</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Issuance of shares, net</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000207" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,332,815</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000208" contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000209" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,951</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000210" contextRef="From2021-01-01to2021-12-31" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,958</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:-8pt !important; padding-left:8pt !important; margin-bottom:0pt; ">Stock-based compensation issued to employees, directors and non-employees</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000211" contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cgen:StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,276</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000212" contextRef="From2021-01-01to2021-12-31" name="cgen:StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,276</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net loss</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000213" contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">34,203</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000214" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetIncomeLoss" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">34,203</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">)</p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:35%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Balance as of December 31, 2021</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000215" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" name="us-gaap:CommonStockSharesOutstanding" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">86,433,432</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000216" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">239</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000217" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">528,533</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000218" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">422,079</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000219" contextRef="AsOf2021-12-31" name="us-gaap:StockholdersEquity" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">106,693</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:16pt; margin-bottom:0pt; ">(*) <ix:footnote id="FN_6204837b941056ccc05bf22a" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Representing amount lower than $1.</ix:footnote></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; ">The accompanying notes are an integral part of the consolidated financial statements.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;8</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; " id="d1e4726_anchor"><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">Cash flows from operating activities:</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net loss</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000220" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetIncomeLoss" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">34,203</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000221" contextRef="From2020-01-01to2020-12-31" name="us-gaap:NetIncomeLoss" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">29,698</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000222" contextRef="From2019-01-01to2019-12-31" name="us-gaap:NetIncomeLoss" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">27,337</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Adjustments required to reconcile net loss to net cash used in operating activities:</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Stock-based compensation</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000223" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensation" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,276</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000224" contextRef="From2020-01-01to2020-12-31" name="us-gaap:ShareBasedCompensation" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,772</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000225" contextRef="From2019-01-01to2019-12-31" name="us-gaap:ShareBasedCompensation" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,408</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Depreciation</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000226" contextRef="From2021-01-01to2021-12-31" name="us-gaap:Depreciation" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">461</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000227" contextRef="From2020-01-01to2020-12-31" name="us-gaap:Depreciation" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">715</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000228" contextRef="From2019-01-01to2019-12-31" name="us-gaap:Depreciation" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">989</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Increase (decrease) in severance pay, net</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000229" contextRef="From2021-01-01to2021-12-31" name="cgen:SeverancePayNet" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">101</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000230" contextRef="From2020-01-01to2020-12-31" name="cgen:SeverancePayNet" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">184</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000231" contextRef="From2019-01-01to2019-12-31" name="cgen:SeverancePayNet" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">22</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Gain from property and equipment sales and disposals</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000232" contextRef="From2021-01-01to2021-12-31" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000233" contextRef="From2020-01-01to2020-12-31" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000234" contextRef="From2019-01-01to2019-12-31" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">135</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Decrease (increase) in interest receivables from short-term bank deposits</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000235" contextRef="From2021-01-01to2021-12-31" name="cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">469</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000236" contextRef="From2020-01-01to2020-12-31" name="cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">532</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000237" contextRef="From2019-01-01to2019-12-31" name="cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">66</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Decrease (increase) in trade receivables</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000238" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">2,000</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000239" contextRef="From2020-01-01to2020-12-31" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,000</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000240" contextRef="From2019-01-01to2019-12-31" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Increase in other accounts receivable and prepaid expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000241" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,802</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000242" contextRef="From2020-01-01to2020-12-31" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,613</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000243" contextRef="From2019-01-01to2019-12-31" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">142</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Decrease (increase) in long-term prepaid expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000244" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000245" contextRef="From2020-01-01to2020-12-31" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,187</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000246" contextRef="From2019-01-01to2019-12-31" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">83</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Decrease in operating lease right of use asset</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000247" contextRef="From2021-01-01to2021-12-31" name="cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">525</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000248" contextRef="From2020-01-01to2020-12-31" name="cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">475</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000249" contextRef="From2019-01-01to2019-12-31" name="cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">2,165</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:-8pt !important; padding-left:16pt !important; margin-bottom:0pt; ">Increase (decrease) in trade payables and other accounts payable and accrued expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000250" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,367</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000251" contextRef="From2020-01-01to2020-12-31" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,817</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000252" contextRef="From2019-01-01to2019-12-31" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">3,502</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Increase (decrease) in deferred participation in R&amp;D expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000253" contextRef="From2021-01-01to2021-12-31" name="cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,708</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000254" contextRef="From2020-01-01to2020-12-31" name="cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">829</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000255" contextRef="From2019-01-01to2019-12-31" name="cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">627</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:8pt; margin-bottom:0pt; ">Decrease in operating lease liability</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000256" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">416</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000257" contextRef="From2020-01-01to2020-12-31" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">412</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000258" contextRef="From2019-01-01to2019-12-31" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">1,834</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net cash used in operating activities</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000259" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">22,750</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000260" contextRef="From2020-01-01to2020-12-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">28,320</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000261" contextRef="From2019-01-01to2019-12-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">27,888</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">)</p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">Cash flows from investing activities:</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Proceeds from maturity of short-term bank deposits</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000262" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">136,850</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000263" contextRef="From2020-01-01to2020-12-31" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">70,300</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000264" contextRef="From2019-01-01to2019-12-31" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">59,403</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Investment in short-term bank deposits</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000265" contextRef="From2021-01-01to2021-12-31" name="us-gaap:PaymentsToAcquireInvestments" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">129,945</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000266" contextRef="From2020-01-01to2020-12-31" name="us-gaap:PaymentsToAcquireInvestments" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">152,350</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000267" contextRef="From2019-01-01to2019-12-31" name="us-gaap:PaymentsToAcquireInvestments" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54,300</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Purchase of property and equipment</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000268" contextRef="From2021-01-01to2021-12-31" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">292</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000269" contextRef="From2020-01-01to2020-12-31" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">166</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000270" contextRef="From2019-01-01to2019-12-31" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">155</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Proceeds from sale of property and equipment</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000271" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000272" contextRef="From2020-01-01to2020-12-31" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000273" contextRef="From2019-01-01to2019-12-31" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">382</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net cash provided by (used in) investing activities</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000274" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,616</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; margin-bottom:1.5pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000275" contextRef="From2020-01-01to2020-12-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">82,172</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:1pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000276" contextRef="From2019-01-01to2019-12-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,330</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; margin-bottom:1.5pt; "></p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:16pt; margin-bottom:0pt; ">The accompanying notes are an integral part of the consolidated financial statements.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;9</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div>
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; margin:auto; "> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">Cash flows from financing activities:</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Proceeds from issuance of ordinary shares, net</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000277" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,958</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000278" contextRef="From2020-01-01to2020-12-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">74,147</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000279" contextRef="From2019-01-01to2019-12-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,758</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Proceeds from exercise of warrants</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000280" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ProceedsFromWarrantExercises" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">425</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000281" contextRef="From2020-01-01to2020-12-31" name="us-gaap:ProceedsFromWarrantExercises" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,325</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000282" contextRef="From2019-01-01to2019-12-31" name="us-gaap:ProceedsFromWarrantExercises" unitRef="usd" xsi:nil="true"></ix:nonFraction>-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Proceeds from exercise of stock-based awards</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000283" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,455</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000284" contextRef="From2020-01-01to2020-12-31" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,991</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000285" contextRef="From2019-01-01to2019-12-31" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,173</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net cash provided by financing activities</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000286" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,838</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000287" contextRef="From2020-01-01to2020-12-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">108,463</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000288" contextRef="From2019-01-01to2019-12-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,931</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Increase (decrease) in cash, cash equivalents and restricted cash</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000289" contextRef="From2021-01-01to2021-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">704</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000290" contextRef="From2020-01-01to2020-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">2,029</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000291" contextRef="From2019-01-01to2019-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,373</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Cash, cash equivalents and restricted cash at the beginning of the year</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000292" contextRef="AsOf2020-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,810</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000293" contextRef="AsOf2019-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,839</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000294" contextRef="AsOf2018-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,466</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Cash and cash equivalents and restricted cash at the end of the year</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000295" contextRef="AsOf2021-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,514</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000296" contextRef="AsOf2020-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,810</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000297" contextRef="AsOf2019-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,839</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">Supplemental disclosure of non-cash investing and financing activities:</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Purchase of property and equipment</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000298" contextRef="From2021-01-01to2021-12-31" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">116</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000299" contextRef="From2020-01-01to2020-12-31" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000300" contextRef="From2019-01-01to2019-12-31" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Receivables on account of shares</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000301" contextRef="From2021-01-01to2021-12-31" name="cgen:ReceivablesOnAccountOfShares" unitRef="usd" xsi:nil="true"></ix:nonFraction>-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000302" contextRef="From2020-01-01to2020-12-31" name="cgen:ReceivablesOnAccountOfShares" unitRef="usd" xsi:nil="true"></ix:nonFraction>-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000303" contextRef="From2019-01-01to2019-12-31" name="cgen:ReceivablesOnAccountOfShares" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">76</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Right-of-use asset obtained in exchange for operating lease liability</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000304" contextRef="From2021-01-01to2021-12-31" name="cgen:SupplementalRightOfUseAssetAndOperatingleaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>-</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:2pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000305" contextRef="From2020-01-01to2020-12-31" name="cgen:SupplementalRightOfUseAssetAndOperatingleaseLiability" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">194</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000306" contextRef="From2019-01-01to2019-12-31" name="cgen:SupplementalRightOfUseAssetAndOperatingleaseLiability" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">363</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">Cash paid (received) during the year for:</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Interest payments received from short-term bank deposits and cash equivalents</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000307" contextRef="From2021-01-01to2021-12-31" name="cgen:InterestPaidReceivedNet" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,364</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000308" contextRef="From2020-01-01to2020-12-31" name="cgen:InterestPaidReceivedNet" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,232</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000309" contextRef="From2019-01-01to2019-12-31" name="cgen:InterestPaidReceivedNet" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,002</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">Reconciliation of cash, cash equivalents and restricted cash:</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Cash and cash equivalents</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000310" contextRef="AsOf2021-12-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,801</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000311" contextRef="AsOf2020-12-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,143</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000312" contextRef="AsOf2019-12-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,187</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Restricted cash</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000313" contextRef="AsOf2021-12-31" name="us-gaap:RestrictedCashAndCashEquivalents" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">713</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000314" contextRef="AsOf2020-12-31" name="us-gaap:RestrictedCashAndCashEquivalents" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">667</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000315" contextRef="AsOf2019-12-31" name="us-gaap:RestrictedCashAndCashEquivalents" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">652</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Total cash, cash equivalents and restricted cash</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000316" contextRef="AsOf2021-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,514</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000317" contextRef="AsOf2020-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,810</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000318" contextRef="AsOf2019-12-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,839</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:16pt; margin-bottom:0pt; ">The accompanying notes are an integral part of the consolidated financial statements.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;10</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; " id="d1e6494_anchor"><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p> <ix:nonNumeric id="Fact_0000000000331" contextRef="From2021-01-01to2021-12-31" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 1: -</span><span style="font-weight:bold; padding-left:13.35pt; ">GENERAL</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">a.<span style="padding-left:13.06pt; ">Compugen Ltd. (the &#x201C;</span><span style="font-weight:bold; ">Company</span>&#x201D;) is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Compugen&#x2019;s innovative immuno-oncology pipeline consists of four clinical stage programs, targeting immune checkpoints Compugen discovered computationally, COM701, COM902, bapotulimab (formerly known as BAY1905254) and AZD2936. The Company&#x2019;s lead product candidate, COM701, a potential first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing Phase 1 clinical trials in dual, and triple combinations under clinical collaboration with Bristol Myers Squibb. COM902, a potential best-in-class, is a therapeutic antibody targeting TIGIT, developed internally and is undergoing a Phase 1 trial to evaluate it in patients with advanced malignancies as a monotherapy and in combination with COM701. Bapotulimab, an antibody targeting ILDR2, licensed to Bayer under a research and discovery collaboration and license agreement, is also in Phase 1 trials in patients with advanced solid tumors. AZD2936 is a novel anti-TIGIT/PD-1 bispecific antibody with a TIGIT component that is derived from Compugen&#x2019;s COM902 program and is developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is in Phase 1/2 trial in patients with advanced or metastatic non-small cell lung cancer. Compugen&#x2019;s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. The innovative immuno-oncology pipeline, the strategic collaborations and the Company&#x2019;s computational discovery engine serve as the corporate three key building blocks. Compugen&#x2019;s business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development under various revenue-sharing arrangements. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">b.<span style="padding-left:12.5pt; ">The Company is headquartered in Holon, Israel. Its clinical development activities are headed from its United States </span>subsidiary, Compugen USA, Inc, located in South San Francisco, CA. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">c.<span style="padding-left:13.06pt; ">The Company has incurred losses in the amount of $</span><ix:nonFraction id="Fact_0000000000319" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetIncomeLoss" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">34,203</ix:nonFraction> during the year ended December 31, 2021, has an accumulated deficit of $<ix:nonFraction id="Fact_0000000000320" contextRef="AsOf2021-12-31" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">422,079</ix:nonFraction> as of December 31, 2021 and has an accumulated negative cash flow from operating activities in the amount of $<ix:nonFraction id="Fact_0000000000321" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">22,750</ix:nonFraction> for the year ended December 31, 2021. On February 26, 2019, the Company announced a corporate restructuring to reduce costs by consolidating and streamlining R&amp;D operations. The restructuring included reducing its workforce by <ix:nonFraction id="Fact_0000000000322" contextRef="From2021-01-01to2021-12-31" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">35</ix:nonFraction>%, consolidating R&amp;D activities in one location in Israel and outsourcing certain preclinical activities to third-party service providers. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements at the current level of yearly expenditures into 2024. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">d.<span style="padding-left:12.5pt; ">On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement </span>(&#x201C;Bayer Agreement&#x201D;) with Bayer Pharma AG (&#x201C;Bayer&#x201D;) for the research, development, and commercialization of antibody-based therapeutics against two novel, Compugen-discovered immune checkpoint regulators. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Under the terms of the Bayer Agreement, the Company received an upfront payment of $<ix:nonFraction id="Fact_0000000000323" contextRef="From2013-01-01to2013-12-31" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,000</ix:nonFraction>, and, following the return of the CGEN 15022 program in 2017, the Company is eligible to receive an aggregate of over $<ix:nonFraction id="Fact_0000000000324" contextRef="I2013-12-31" name="cgen:ResearchAndDevelopmentArrangementPaymentsReceivable" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">250,000</ix:nonFraction> in potential milestone payments for Bapotulimab (formerly known as BAY1905254), not including aggregate milestone payments of approximately $<ix:nonFraction id="Fact_0000000000325" contextRef="I2013-12-31" name="cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,000</ix:nonFraction> received to date. Additionally, the Company is eligible to receive mid to high single digit royalties on global net sales of any approved products under the collaboration.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Pursuant to the terms of Bayer Agreement, Bapotulimab program was transferred to Bayer&#x2019;s full control for further preclinical and clinical development activities, and worldwide commercialization under milestone and royalty bearing license from Compugen.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;11</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 1: -</span><span style="font-weight:bold; padding-left:13.35pt; ">GENERAL (Cont.)</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">e.<span style="padding-left:13.06pt; ">Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited. the </span>global biologics research and development arm of AstraZeneca (&#x201C;AstraZeneca&#x201D;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and will be solely responsible for all research, development, and commercial activities under the agreement. Compugen received a $<ix:nonFraction id="Fact_0000000000326" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,000</ix:nonFraction> upfront payment, and received $<ix:nonFraction id="Fact_0000000000327" contextRef="From2021-01-01to2021-12-31" name="cgen:AccruedMilestonePayment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,000</ix:nonFraction> milestone payments out of up to $<ix:nonFraction id="Fact_0000000000328" contextRef="AsOf2021-12-31" name="cgen:ResearchAndDevelopmentArrangementPaymentsReceivable" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">200,000</ix:nonFraction> the Company is eligible to receive in development, regulatory and commercial milestones for the first product in addition to tiered royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">f.<span style="padding-left:14.17pt; ">On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#x201C;Agreement&#x201D;) </span>with Bristol-Myers Squibb Company (&#x201C;Bristol-Myers Squibb&#x201D;) to evaluate the safety and tolerability of Compugen&#x2019;s COM701 in combination with Bristol-Myers Squibbs&#x2019; PD-1 immune checkpoint inhibitor Opdivo&#xAE; (nivolumab), in patients with advanced solid tumors. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Pursuant to the Agreement, Compugen is responsible for and will continue sponsoring the ongoing two-part Phase 1 trial, which includes the evaluation of the combination of COM701 and Opdivo&#xAE;. The collaboration was also designed to address potential future combinations, including trials sponsored by Bristol-Myers Squibb to investigate combined inhibition of checkpoint mechanisms, such as PVRIG and TIGIT. Bristol-Myers Squibb and Compugen each supplies the other company with its own compound for the other party&#x2019;s study, and otherwise each party is responsible for all costs associated with the study that it is conducting. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In conjunction with the signing of the Agreement in October 2018, Bristol-Myers Squibb made a $<ix:nonFraction id="Fact_0000000000329" contextRef="AsOf2021-12-31" name="us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,000</ix:nonFraction> investment in Compugen, see Note 8b. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">On February 14, 2020, the Agreement was amended to include a triple combination clinical trial to evaluate the safety, tolerability and antitumor activity of COM701 in combination with Opdivo&#xAE; (nivolumab), and Bristol-Myers Squibb&#x2019;s investigational antibody targeting TIGIT known as BMS-986207, in patients with advanced solid tumors, instead of the planned expansion of the combined therapy study designed to evaluate the dual combination of COM701 and Opdivo&#xAE;. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Pursuant to the Agreement, as amended, the Company sponsors the two-part Phase 1/2 trial, which evaluates the triple combination of COM701, Opdivo&#xAE; and BMS-986207, in patients with advanced solid tumors where Bristol-Myers Squibb provides Opdivo&#xAE; and BMS-986207 at no cost to the Company. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;12</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 1: -</span><span style="font-weight:bold; padding-left:13.35pt; ">GENERAL (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">As part of the amended Agreement, it was agreed that the Company will complete the dose escalation arm of the dual combination of COM701 with Opdivo&#xAE; under the ongoing Phase 1 study and will not continue the expansion cohorts of the dual combination. However, on February 19, 2021, the Agreement was further amended to include an expansion of the Phase 1 combination study designed to evaluate the dual combination of COM701 and Opdivo&#xAE; in patients with advanced solid tumors, where the Company is responsible for and sponsors the expansion cohort and Bristol Myers Squibb provides Opdivo&#xAE; at no cost to the Company for this study. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">On November 10, 2021, the Agreement was further amended to establish a joint steering committee (alongside the existing joint development committee which acts at an operational level) to facilitate strategic oversight and guidance for the programs run under the collaboration. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In conjunction with the signing of the amendment to the Agreement in November 2021, Bristol-Myers Squibb made a $<ix:nonFraction id="Fact_0000000000330" contextRef="AsOf2021-11-30" name="us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,000</ix:nonFraction> investment in Compugen, see Note 8b. </p></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000405" contextRef="From2021-01-01to2021-12-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#x201C;U.S. GAAP&#x201D;).</p> <ix:nonNumeric id="Fact_0000000000332" contextRef="From2021-01-01to2021-12-31" name="us-gaap:UseOfEstimates" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> a.<span style="padding-left:13.06pt; ">Use of estimates:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#x2019;s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company considered the impact of COVID-19 on the estimates and assumptions and determined that there were no material adverse impacts on the consolidated financial statements for the year ended December 31, 2021. As events continue to evolve and additional information becomes available, the Company&#x2019;s estimates and assumptions may change materially in future periods. Such changes could result in future impairments of long-lived assets. </p></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000333" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> b.<span style="padding-left:12.5pt; ">Financial statements in U.S. dollars:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The reporting and functional currency of the Company is the U.S. dollar, as the Company&#x2019;s management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen USA, Inc. have operated and expect to continue to operate in the foreseeable future.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No. 830, &#x201C;Foreign Currency Matters&#x201D;. All transaction gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate. </p></ix:nonNumeric>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;13</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p> <ix:nonNumeric id="Fact_0000000000334" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ConsolidationPolicyTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> c.<span style="padding-left:13.06pt; ">Basis of consolidation:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The consolidated financial statements include the accounts of the Company and Compugen USA, Inc. Intercompany transactions and balances have been eliminated upon consolidation. </p></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000335" contextRef="From2021-01-01to2021-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> d.<span style="padding-left:12.5pt; ">Cash equivalents:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition. </p></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000336" contextRef="From2021-01-01to2021-12-31" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> e.<span style="padding-left:13.06pt; ">Restricted cash:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Restricted cash is held in interest bearing saving accounts which are used as a security for the Company&#x2019;s Israeli facility leasehold bank guarantee and credit card security for Compugen USA, Inc. </p></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000339" contextRef="From2021-01-01to2021-12-31" name="cgen:ShortTermBankDepositsPolicyTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> f.<span style="padding-left:14.17pt; ">Short-term bank deposits:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates market values. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The short-term bank deposits as of December 31, 2021 and 2020 are in U.S. dollars and bear an annual weighted average interest rate of <ix:nonFraction id="Fact_0000000000337" contextRef="From2021-01-01to2021-12-31" name="cgen:ShortTermBankDepositsWeightedAverageRateForeign" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.77</ix:nonFraction>% and <ix:nonFraction id="Fact_0000000000338" contextRef="From2020-01-01to2020-12-31" name="cgen:ShortTermBankDepositsWeightedAverageRateForeign" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.01</ix:nonFraction>%, respectively. </p></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000346" contextRef="From2021-01-01to2021-12-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> g.<span style="padding-left:12.5pt; ">Property and equipment, net:</span> </p> <ix:nonNumeric id="Fact_0000000000345" contextRef="From2021-01-01to2021-12-31" name="cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "> Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div style="margin-left:80pt; ">
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; "> <thead> <tr class="odd" style=""> <td style="width:58%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:42%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">% </p> </td> </tr> <tr class="even" style=""> <td style="width:58%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:42%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:58%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Computers, software and related equipment </p> </td> <td style="width:42%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000340" contextRef="From2021-01-01to2021-12-31_us-gaap_ComputerEquipmentMember" name="cgen:AnnualDepreciationRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">33</ix:nonFraction> </p> </td> </tr> <tr class="even" style=""> <td style="width:58%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Laboratory equipment and office furniture </p> </td> <td style="width:42%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000341" contextRef="From2021-01-01to2021-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember_srt_MinimumMember" name="cgen:AnnualDepreciationRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction> - <ix:nonFraction id="Fact_0000000000342" contextRef="From2021-01-01to2021-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember_srt_MaximumMember" name="cgen:AnnualDepreciationRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction> (mainly <ix:nonFraction id="Fact_0000000000343" contextRef="From2021-01-01to2021-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember" name="cgen:AnnualDepreciationRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:58%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Leasehold improvements </p> </td> <td style="width:42%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonNumeric id="Fact_0000000000344" contextRef="From2021-01-01to2021-12-31_us-gaap_LeaseholdImprovementsMember" name="cgen:AnnualDepreciationRateDescription">Shorter of the term of the lease or useful life</ix:nonNumeric> </p></td></tr></tbody></table></div></ix:nonNumeric></ix:nonNumeric>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;14</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p> <ix:nonNumeric id="Fact_0000000000347" contextRef="From2021-01-01to2021-12-31" name="us-gaap:PropertyPlantAndEquipmentImpairment" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> h.<span style="padding-left:12.5pt; ">Impairment of long-lived assets:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The long-lived assets of the Company and Compugen USA, Inc. are reviewed for impairment in accordance with ASC 360, &#x201C;Property, Plant, and Equipment,&#x201D; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset with the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years 2021, 2020 and 2019, no impairment losses have been identified. </p></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000353" contextRef="From2021-01-01to2021-12-31" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> i.<span style="padding-left:14.72pt; ">Revenue recognition:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company generates revenues mainly from its collaborative and license agreements. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestone achievements. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">The Company recognizes revenue in accordance with ASC 606 &#x2013; &#x201C;Revenue from Contracts with Customers&#x201D;. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">As such, the Company analyzes its contracts to assess whether they are within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">&#x2022;</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-12pt; text-indent:98pt; margin-bottom:0pt; "><span style="font-style:italic; ">Identification of the contract, or contracts, with a customer</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">&#x2022;</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:98pt; margin-bottom:0pt; "><span style="font-style:italic; ">Identification of the performance obligations in the contract</span> - At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not distinct from other promises in the contract (either because it is not capable of being distinct or because it is not distinct within the context of the contract), or if an option to acquire good or service does not provide the customer with a material right. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">&#x2022;</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:98pt; margin-bottom:0pt; "><span style="font-style:italic; ">Determination of the transaction price</span> - The Company considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;15</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">i.<span style="padding-left:14.72pt; ">Revenue recognition (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">&#x2022;</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:98pt; margin-bottom:0pt; "><span style="font-style:italic; ">Allocation of the transaction price to the performance obligations in the contract</span> - If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling prices. The relative selling price for each deliverable is estimated using observable objective evidence if it is available. If observable objective evidence is not available, the Company uses its best estimate of the selling price for the deliverable. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">&#x2022;</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:98pt; margin-bottom:0pt; "><span style="font-style:italic; ">Recognition of revenue when, or as, the Company satisfies a performance obligation</span> - Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company entered into an exclusive license agreement with AstraZeneca. Under the terms of the agreement, Compugen provided AstraZeneca with an exclusive license to intellectual property (&#x201C;IP&#x201D;) rights of the Company for the development of bi-specific and multi-specific antibody products derived from COM902. Compugen received a $<ix:nonFraction id="Fact_0000000000348" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,000</ix:nonFraction> upfront nonrefundable payment and is eligible to receive up to $<ix:nonFraction id="Fact_0000000000349" contextRef="AsOf2021-12-31" name="cgen:ResearchAndDevelopmentArrangementPaymentsReceivable" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">200,000</ix:nonFraction> for development, regulatory and commercial milestones for the first product, including $<ix:nonFraction id="Fact_0000000000350" contextRef="From2021-01-01to2021-12-31" name="cgen:AccruedMilestonePayment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,000</ix:nonFraction> received to date as well as tiered royalties on future product sales. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Under ASC 606, the Company determined the license to the IP to be a functional IP that has significant standalone functionality. The Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the IP. Therefore, the license to the IP is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to the customer. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Future milestone payments are considered variable consideration and are subject to the variable consideration constraint (i.e. will be recognized once concluded that it is &#x201C;probable&#x201D; that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable consideration is resolved). Therefore, as the milestone payments are not probable, revenue was not recognized in respect to such milestone payments prior to achievement of such milestone. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;16</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">i.<span style="padding-left:14.72pt; ">Revenue recognition (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Sales- or usage-based royalties to be received in exchange for licenses of IP are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales- or usage-based royalty has been allocated is satisfied (in whole or in part). As royalties are payable based on future Commercial Sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">On December 18, 2020 the first milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $<ix:nonFraction id="Fact_0000000000351" contextRef="From2020-12-01to2020-12-18" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,000</ix:nonFraction> in accordance with the criteria prescribed under ASC 606. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">On September 29, 2021 the second milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $<ix:nonFraction id="Fact_0000000000352" contextRef="From2021-09-01to2021-09-29" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,000</ix:nonFraction> in accordance with the criteria prescribed under ASC 606. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">For information regarding revenues, please refer to Note 10 below. </p></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000354" contextRef="From2021-01-01to2021-12-31" name="cgen:CostOfSalesContractWithCustomerPolicyTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> j.<span style="padding-left:14.72pt; ">Cost of revenues:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">Cost of revenues consist of certain royalties and milestones paid or accrued. </p></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000363" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> k.<span style="padding-left:12.5pt; ">Research and development expenses, net:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Research and development costs are charged to the statement of comprehensive loss as incurred and are presented net of the amount of any grants the Company receives for research and development in the period in which the grant was received. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">As part of the process of preparing the consolidated financial statements, the Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, and amortized as the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;17</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">k.<span style="padding-left:12.5pt; ">Research and development expenses, net (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The portion of the Bristol-Myers Squibb $<ix:nonFraction id="Fact_0000000000356" contextRef="AsOf2021-12-31_custom_MasterClinicalAgreementOneMember" name="us-gaap:EquityMethodInvestmentAggregateCost" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal"><ix:nonFraction id="Fact_0000000000355" contextRef="AsOf2021-12-31" name="us-gaap:EquityMethodInvestmentAggregateCost" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,000</ix:nonFraction></ix:nonFraction> investment over the fair market value of the shares issued in the amount of $<ix:nonFraction id="Fact_0000000000357" contextRef="From2021-01-01to2021-12-31_custom_MasterClinicalAgreementOneMember" name="cgen:DeferredParticipationOfBmsInRdExpenses" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,121</ix:nonFraction> and the portion of the $<ix:nonFraction id="Fact_0000000000358" contextRef="AsOf2021-12-31_custom_MasterClinicalAgreementTwoMember" name="us-gaap:EquityMethodInvestmentAggregateCost" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,000</ix:nonFraction> investment over the fair market value of the shares issued in the amount of $<ix:nonFraction id="Fact_0000000000359" contextRef="From2021-01-01to2021-12-31_custom_MasterClinicalAgreementTwoMember" name="cgen:DeferredParticipationOfBmsInRdExpenses" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,000</ix:nonFraction> were considered as deferred participation of Bristol-Myers Squibb in R&amp;D expenses which is amortized over the period of the clinical trial based on the progress in the R&amp;D, in accordance with ASC 808 &#x201C;Collaborative Arrangements&#x201D;, see Note 1f and Note 8b. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Amortization of participation in R&amp;D expenses for the years ended December 31, 2021, 2020 and 2019 were $<ix:nonFraction id="Fact_0000000000360" contextRef="From2021-01-01to2021-12-31" name="us-gaap:AdjustmentForAmortization" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,291</ix:nonFraction>, $<ix:nonFraction id="Fact_0000000000361" contextRef="From2020-01-01to2020-12-31" name="us-gaap:AdjustmentForAmortization" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">829</ix:nonFraction> and $<ix:nonFraction id="Fact_0000000000362" contextRef="From2019-01-01to2019-12-31" name="us-gaap:AdjustmentForAmortization" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">627</ix:nonFraction>, respectively. </p></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000367" contextRef="From2021-01-01to2021-12-31" name="cgen:ServerancePayPolicyTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> l.<span style="padding-left:14.72pt; ">Severance pay:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company&#x2019;s liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date, and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset in the Company&#x2019;s balance sheet. Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company&#x2019;s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee&#x2019;s monthly salary for each year of service, no additional calculations are conducted between the parties regarding the matter of severance pay and no additional payments are made by the Company to the employee. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Severance expenses for the years ended December 31, 2021, 2020 and 2019 amounted to approximately $<ix:nonFraction id="Fact_0000000000364" contextRef="From2021-01-01to2021-12-31" name="us-gaap:SeveranceCosts1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">383</ix:nonFraction>, $<ix:nonFraction id="Fact_0000000000365" contextRef="From2020-01-01to2020-12-31" name="us-gaap:SeveranceCosts1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">572</ix:nonFraction> and $<ix:nonFraction id="Fact_0000000000366" contextRef="From2019-01-01to2019-12-31" name="us-gaap:SeveranceCosts1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">366</ix:nonFraction>, respectively. </p></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000394" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> m.<span style="padding-left:9.72pt; ">Stock-based compensation:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company accounts for stock-based compensation to employees and non-employees in accordance with ASC 718, &#x201C;Compensation - Stock Compensation&#x201D;, (&#x201C;ASC 718&#x201D;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company accounts for forfeitures as they occur. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;18</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">m.<span style="padding-left:9.72pt; ">Stock-based compensation (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company selected the Black-Scholes-Merton (&#x201C;Black-Scholes&#x201D;) option-pricing model as the most appropriate fair value method for its share-options awards and Employee Stock Purchase Plan (&#x201C;ESPP&#x201D;). The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. </p> <ix:nonNumeric id="Fact_0000000000393" contextRef="From2021-01-01to2021-12-31" name="cgen:ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "> The Company used the following weighted-average assumptions for options granted to employees, directors and non-employees and ESPP: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div style="margin-left:80pt; ">
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; "> <thead> <tr class="odd" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="7" style="width:14%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:14%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">Employee stock Options</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Volatility </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000368" contextRef="From2021-01-01to2021-12-31_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">67.68</ix:nonFraction>% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000369" contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">63.17</ix:nonFraction>% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000370" contextRef="From2019-01-01to2019-12-31_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">54.59</ix:nonFraction>% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Risk-free interest rate </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000371" contextRef="From2021-01-01to2021-12-31_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.77</ix:nonFraction>% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000372" contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.45</ix:nonFraction>% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000373" contextRef="From2019-01-01to2019-12-31_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.92</ix:nonFraction>% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Dividend yield </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000374" contextRef="From2021-01-01to2021-12-31_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000375" contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000376" contextRef="From2019-01-01to2019-12-31_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Expected life (years) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonNumeric id="Fact_0000000000377" contextRef="From2021-01-01to2021-12-31_us-gaap_EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear">5.17</ix:nonNumeric> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonNumeric id="Fact_0000000000378" contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear">5.16</ix:nonNumeric> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonNumeric id="Fact_0000000000379" contextRef="From2019-01-01to2019-12-31_us-gaap_EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear">5.15</ix:nonNumeric> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">ESPP</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Volatility </p> </td> <td colspan="3" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="padding-left:0pt; "><ix:nonFraction id="Fact_0000000000380" contextRef="From2021-01-01to2021-12-31_custom_EmployeeStockPurchasePlanMember_srt_MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">64.68</ix:nonFraction></span><span style="padding-left:0pt; ">%-</span><span style="padding-left:0pt; "><ix:nonFraction id="Fact_0000000000381" contextRef="From2021-01-01to2021-12-31_custom_EmployeeStockPurchasePlanMember_srt_MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">69.68</ix:nonFraction></span><span style="padding-left:0pt; ">%</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000382" contextRef="From2020-01-01to2020-12-31_custom_EmployeeStockPurchasePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="Pure" scale="-2" xsi:nil="true"></ix:nonFraction>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000383" contextRef="From2019-01-01to2019-12-31_custom_EmployeeStockPurchasePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="Pure" scale="-2" xsi:nil="true"></ix:nonFraction>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Risk-free interest rate </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000384" contextRef="From2021-01-01to2021-12-31_custom_EmployeeStockPurchasePlanMember_srt_MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.04</ix:nonFraction>%-<ix:nonFraction id="Fact_0000000000385" contextRef="From2021-01-01to2021-12-31_custom_EmployeeStockPurchasePlanMember_srt_MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.10</ix:nonFraction>% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000386" contextRef="From2020-01-01to2020-12-31_custom_EmployeeStockPurchasePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="Pure" scale="-2" xsi:nil="true"></ix:nonFraction>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000387" contextRef="From2019-01-01to2019-12-31_custom_EmployeeStockPurchasePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="Pure" scale="-2" xsi:nil="true"></ix:nonFraction>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Dividend yield </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000388" contextRef="From2021-01-01to2021-12-31_custom_EmployeeStockPurchasePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000389" contextRef="From2020-01-01to2020-12-31_custom_EmployeeStockPurchasePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="Pure" scale="-2" xsi:nil="true"></ix:nonFraction>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000390" contextRef="From2019-01-01to2019-12-31_custom_EmployeeStockPurchasePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="Pure" scale="-2" xsi:nil="true"></ix:nonFraction>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Expected life (years) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonNumeric id="Fact_0000000000391" contextRef="From2021-01-01to2021-12-31_custom_EmployeeStockPurchasePlanMember_srt_MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear">0.42</ix:nonNumeric>-<ix:nonNumeric id="Fact_0000000000392" contextRef="From2021-01-01to2021-12-31_custom_EmployeeStockPurchasePlanMember_srt_MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear">0.50</ix:nonNumeric> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "></p></td></tr></tbody></table></div></ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000395" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ConcentrationRiskCreditRisk" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> n.<span style="padding-left:12.5pt; ">Concentration of credit risks:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Financial instruments that potentially subject the Company and Compugen USA, Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term bank deposits. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Cash, cash equivalents, restricted cash and short-term bank deposits are invested in major banks in Israel and in the U.S. Generally, these deposits may be redeemed upon demand and bear minimal risk. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The trade receivables of the Company derive from milestone payments under collaboration agreements between the company and its collaborators, located primarily in Europe. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;19</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">n.<span style="padding-left:12.5pt; ">Concentration of credit risks (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company&#x2019;s collaborators are major pharma companies. The amounts due to the Company by such collaborators are paid pursuant to the terms of the agreements after a short period of time and bear low risk. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company had one collaborator that accounted for 100% of the Company&#x2019;s consolidated revenues, for the years ended December 31, 2021 and 2020. The Company had no revenues in 2019. </p></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000399" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> o.<span style="padding-left:12.5pt; ">Basic and diluted loss per share:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#x201C;Earnings per Share&#x2EE;. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">All outstanding share options and warrants for the years ended December 31, 2021, 2020 and 2019 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. As of December 31, 2021, 2020 and 2019 the average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were <ix:nonFraction id="Fact_0000000000396" contextRef="From2021-01-01to2021-12-31_us-gaap_StockOptionMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,758,300</ix:nonFraction>, <ix:nonFraction id="Fact_0000000000397" contextRef="From2020-01-01to2020-12-31_us-gaap_StockOptionMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,150,648</ix:nonFraction> and <ix:nonFraction id="Fact_0000000000398" contextRef="From2019-01-01to2019-12-31_us-gaap_StockOptionMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">12,754,803</ix:nonFraction>, respectively. </p></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000400" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> p.<span style="padding-left:12.5pt; ">Income taxes:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company accounts for income taxes in accordance with ASC No. 740, &#x201C;Income Taxes&#x201D;, (&#x201C;ASC 740&#x201D;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2021 and 2020, a full valuation allowance was provided by the Company. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740-10. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;20</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000401" contextRef="From2021-01-01to2021-12-31" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> q.<span style="padding-left:12.5pt; ">Fair value of financial instruments:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company applies ASC 820, &#x201C;Fair Value Measurements and Disclosures&#x201D; (&#x201C;ASC 820&#x201D;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#x201C;exit price&#x201D;) in an orderly transaction between market participants at the measurement date. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputting that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">The hierarchy is broken down into three levels based on the inputs as follows: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-60pt !important; padding-left:140pt !important; margin-bottom:0pt; ">Level 1 -<span style="padding-left:22.24pt; ">Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can </span>access at the measurement date. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-60pt !important; padding-left:140pt !important; margin-bottom:0pt; ">Level 2 -<span style="padding-left:22.24pt; ">Valuations based on one or more quoted prices in markets that are not active or for which all </span>significant inputs are observable, either directly or indirectly. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">Level 3 -<span style="padding-left:22.24pt; ">Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, other accounts receivable and prepaid expenses, trade payable and other accounts payable and accrued expenses approximate their fair values due to the short-term maturities of such instruments. </p></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000402" contextRef="From2021-01-01to2021-12-31" name="us-gaap:DerivativesPolicyTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> r.<span style="padding-left:14.72pt; ">Derivative instruments:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company accounts for derivatives and hedging based on ASC 815, &#x201C;Derivatives and Hedging&#x201D;. ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, the Company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;21</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">r.<span style="padding-left:14.72pt; ">Derivative instruments (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">If the derivatives meet the definition of a hedge and are so designated, depending on the nature of the hedge, changes in the fair value of such derivatives will either be offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings, or recognized in other comprehensive income until the hedged item is recognized in earnings. The ineffective portion of a derivative&#x2019;s change in fair value is recognized in earnings. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In the past the Company entered into forward contracts to hedge against the risk of overall changes in future cash flow from payments of payroll and related expenses as well as other expenses denominated in NIS. As of December 31, 2021 and 2020, the Company had no outstanding forward contracts. The Company measured the fair value of the contracts in accordance with ASC 820 (classified as level 2). </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">These contracts met the requirement for cash flow hedge accounting and during each of the years ended December 31, 2021, 2020 and 2019, no amount of total gains were recognized and were classified to operating expenses as effective hedge and no unrealized gains were recognized under other comprehensive income (loss). </p></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000403" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> s.<span style="padding-left:13.61pt; ">Comprehensive income (loss):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company accounts for comprehensive income (loss) in accordance with ASC 220, &#x201C;Comprehensive Income&#x201D;. This statement establishes standards for the reporting and display of comprehensive income (loss) and its components in a full set of general-purpose financial statements. Comprehensive income (loss) generally represents all changes in shareholders&#x2019; equity during the period except those resulting from investments by, or distributions to, shareholders. The Company elected to present the comprehensive income (loss) in a single continuous statement. </p></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000404" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "> In the years 2021, 2020 and 2019 the Company has no components of other comprehensive income (loss), other than net loss. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;22</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">t.<span style="padding-left:14.72pt; ">Recently issued and recently adopted Accounting Standards:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. Among other changes, ASU 2020-06 removes from GAAP the liability and equity separation model for convertible instruments with a cash conversion feature and a beneficial conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share (EPS). ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020 and can be adopted on either a fully retrospective or modified retrospective basis. The Company adopted ASU 2020-06 as of January 1, 2021. The adoption of this standard did not have an impact to the Company&#x2019;s financial statements.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832). This ASU requires business entities to disclose information about government assistance they receive if the transactions were accounted for by analogy to either a grant or a contribution accounting model. The disclosure requirements include the nature of the transaction and the related accounting policy used, the line items on the balance sheets and statements of operations that are affected and the amounts applicable to each financial statement line item and the significant terms and conditions of the transactions. The ASU is effective for annual periods beginning after December 15, 2021. The disclosure requirements can be applied either retrospectively or prospectively to all transactions in the scope of the amendments that are reflected in the financial statements at the date of initial application and new transactions that are entered into after the date of initial application. The ASU is currently not expected to have a material impact on our consolidated financial statements. </p></ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000415" contextRef="From2021-01-01to2021-12-31" name="cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 3: -</span><span style="font-weight:bold; padding-left:13.35pt; ">OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</span></p> <ix:nonNumeric id="Fact_0000000000414" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div style="margin-left:60pt; ">
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; "> <thead> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Prepaid expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000406" contextRef="AsOf2021-12-31" name="us-gaap:PrepaidExpenseCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,272</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000407" contextRef="AsOf2020-12-31" name="us-gaap:PrepaidExpenseCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,482</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Government authorities</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000408" contextRef="AsOf2021-12-31" name="cgen:GovernmentAuthorities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">57</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000409" contextRef="AsOf2020-12-31" name="cgen:GovernmentAuthorities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Other</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000410" contextRef="AsOf2021-12-31" name="us-gaap:OtherAssetsCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">131</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000411" contextRef="AsOf2020-12-31" name="us-gaap:OtherAssetsCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">122</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000412" contextRef="AsOf2021-12-31" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,460</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000413" contextRef="AsOf2020-12-31" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,658</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "></p></td></tr></tbody></table></div></ix:nonNumeric></ix:nonNumeric>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;23</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p> <ix:nonNumeric id="Fact_0000000000441" contextRef="From2021-01-01to2021-12-31" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 4: -</span><span style="font-weight:bold; padding-left:13.35pt; ">LEASES</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">The Company leases all its real estate, storage area and cars under various operating lease agreements that expire on various dates. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">The Company&#x2019;s operating leases have original lease periods expiring between 2022 and 2024. The offices in Israel lease include two options to renew, one of which was exercised in 2020. The Company does not assume renewals in its determination of the lease term unless the renewals are deemed to be reasonably certain. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">In October 2020 the Company&#x2019;s lease of its offices in Israel was amended in connection with the exercise of the option. The amendment was not accounted for as a new lease. As a result of the amendment the operating lease right of use asset increased by $<ix:nonFraction id="Fact_0000000000416" contextRef="From2021-01-01to2021-12-31" name="cgen:IncreaseOperatingLeaseRightOfUseAsset" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">43</ix:nonFraction>, the operating lease liability decreased by $<ix:nonFraction id="Fact_0000000000417" contextRef="From2021-01-01to2021-12-31" name="cgen:DecreaseOperatingLeaseLiability" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">194</ix:nonFraction> and the Company recorded foreign currency exchange rate of $<ix:nonFraction id="Fact_0000000000418" contextRef="From2021-01-01to2021-12-31" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">237</ix:nonFraction>. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">Lease payments included in the measurement of the lease liability comprise the following: the fixed non-cancelable lease payments and payments for optional renewal periods where it is reasonably certain the renewal period will be exercised. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">Under ASC 842, all leases, including non-cancelable operating leases, are now recognized on the balance sheet. The aggregated present value of lease payments is recorded as a long-term asset titled Operating lease right of use asset. The corresponding lease liabilities are split between current maturity of operating lease liability within current liabilities and long-term operating lease liability within long-term liabilities. The Company&#x2019;s leases do not provide an implicit rate, therefore the Company uses its incremental borrowing rate based on information available on the commencement date in determining the present value of lease payments. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">The Company subleased small part of its leased premises until March 14, 2021. Sublease income in the year ended December 31, 2021 and 2020, amounted to $<ix:nonFraction id="Fact_0000000000419" contextRef="From2021-01-01to2021-12-31" name="us-gaap:SubleaseIncome" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction> and $<ix:nonFraction id="Fact_0000000000420" contextRef="From2020-01-01to2020-12-31" name="us-gaap:SubleaseIncome" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">56</ix:nonFraction>, respectively. </p> <ix:nonNumeric id="Fact_0000000000423" contextRef="From2021-01-01to2021-12-31" name="cgen:ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> The following table represents the weighted-average remaining lease term and discount rate: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div style="margin-left:60pt; ">
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; "> <thead> <tr class="odd" style=""> <td style="width:85%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Twelve months </span><span style="font-weight:bold; ">ended</span> </p> </td> </tr> <tr class="even" style=""> <td style="width:85%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:14%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31, </span><span style="font-weight:bold; ">2021</span> </p> </td> </tr> <tr class="odd" style=""> <td style="width:85%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:85%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Weighted average remaining lease term </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonNumeric id="Fact_0000000000421" contextRef="AsOf2021-12-31" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear">3.87</ix:nonNumeric> </p> </td> </tr> <tr class="even" style=""> <td style="width:85%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Weighted average discount (annual) rate </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000422" contextRef="AsOf2021-12-31" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">5.49</ix:nonFraction>% </p></td></tr></tbody></table></div></ix:nonNumeric>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">Operating lease expenses were approximately $<ix:nonFraction id="Fact_0000000000424" contextRef="From2021-01-01to2021-12-31" name="us-gaap:OperatingLeasePayments" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">956</ix:nonFraction>, $<ix:nonFraction id="Fact_0000000000425" contextRef="From2020-01-01to2020-12-31" name="us-gaap:OperatingLeasePayments" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">944</ix:nonFraction> and $<ix:nonFraction id="Fact_0000000000426" contextRef="From2019-01-01to2019-12-31" name="us-gaap:OperatingLeasePayments" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,586</ix:nonFraction> in the years ended December 31, 2021, 2020 and 2019, respectively. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">Cash paid for amounts included in the measurement of lease liabilities was approximately $<ix:nonFraction id="Fact_0000000000427" contextRef="From2021-01-01to2021-12-31" name="cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">914</ix:nonFraction>, $<ix:nonFraction id="Fact_0000000000428" contextRef="From2020-01-01to2020-12-31" name="cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">927</ix:nonFraction> and $<ix:nonFraction id="Fact_0000000000429" contextRef="From2019-01-01to2019-12-31" name="cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,577</ix:nonFraction> in the years ended December 31, 2021, 2020 and 2019, respectively. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;24</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 4: -</span><span style="font-weight:bold; padding-left:13.35pt; ">LEASES (Cont.)</span> </p> <ix:nonNumeric id="Fact_0000000000440" contextRef="From2021-01-01to2021-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> Maturities of operating lease liabilities were as follows: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div style="margin-left:60pt; ">
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; "> <thead> <tr class="odd" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31, 2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">2022 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000430" contextRef="AsOf2021-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">895</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">2023 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000431" contextRef="AsOf2021-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">726</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">2024 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000432" contextRef="AsOf2021-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">664</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">2025 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000433" contextRef="AsOf2021-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">631</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">2026 and after </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000434" contextRef="AsOf2021-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">129</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Total operating lease payments </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000435" contextRef="AsOf2021-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,045</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Less: imputed interest </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000436" contextRef="AsOf2021-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">295</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Present value of lease liabilities </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000437" contextRef="AsOf2021-12-31" name="us-gaap:OperatingLeaseLiability" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,750</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Lease liabilities, current </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000438" contextRef="AsOf2021-12-31" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">768</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Lease liabilities, non- current </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000439" contextRef="AsOf2021-12-31" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,982</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Present value of lease liabilities </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:14%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,750 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "></p></td></tr></tbody></table></div></ix:nonNumeric>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">The above annual minimum future rental commitments include the period covered by the first exercised option with respect to the leased facility of Compugen Ltd. through March 2026 and exclude the second option to extend the lease of the Company facility for additional five-year period following expiration of the current lease period. </p></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000468" contextRef="From2021-01-01to2021-12-31" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 5: -</span><span style="font-weight:bold; padding-left:13.35pt; ">PROPERTY AND EQUIPMENT, NET</span></p> <ix:nonNumeric id="Fact_0000000000460" contextRef="From2021-01-01to2021-12-31" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div style="margin-left:60pt; ">
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; "> <thead> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Cost: </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Computers, software and related equipment </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000442" contextRef="AsOf2021-12-31_us-gaap_ComputerEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,506</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000443" contextRef="AsOf2020-12-31_us-gaap_ComputerEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,431</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Laboratory equipment and office furniture </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000444" contextRef="AsOf2021-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,674</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000445" contextRef="AsOf2020-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,367</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Leasehold improvements </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000446" contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,321</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000447" contextRef="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,321</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000448" contextRef="AsOf2021-12-31" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,501</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000449" contextRef="AsOf2020-12-31" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,119</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Accumulated depreciation: </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Computers, software and related equipment </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000450" contextRef="AsOf2021-12-31_us-gaap_ComputerEquipmentMember" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,351</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000451" contextRef="AsOf2020-12-31_us-gaap_ComputerEquipmentMember" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,264</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Laboratory equipment and office furniture </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000452" contextRef="AsOf2021-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,114</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000453" contextRef="AsOf2020-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,001</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Leasehold improvements </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000454" contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,378</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000455" contextRef="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,143</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000456" contextRef="AsOf2021-12-31" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,843</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000457" contextRef="AsOf2020-12-31" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,408</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Depreciated cost </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000458" contextRef="AsOf2021-12-31" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,658</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000459" contextRef="AsOf2020-12-31" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,711</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "></p></td></tr></tbody></table></div></ix:nonNumeric>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;25</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 5: -</span><span style="font-weight:bold; padding-left:13.35pt; ">PROPERTY AND EQUIPMENT, NET (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">During 2021 and 2020 total cost of $<ix:nonFraction id="Fact_0000000000461" contextRef="AsOf2021-12-31_custom_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26</ix:nonFraction> and $<ix:nonFraction id="Fact_0000000000462" contextRef="AsOf2020-12-31_custom_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">220</ix:nonFraction>, respectively and total accumulated depreciation of $<ix:nonFraction id="Fact_0000000000463" contextRef="AsOf2021-12-31_custom_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26</ix:nonFraction> and $<ix:nonFraction id="Fact_0000000000464" contextRef="AsOf2020-12-31_custom_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">188</ix:nonFraction>, respectively were disposed from the consolidated balance sheets.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">For the years ended December 31, 2021, 2020 and 2019, depreciation expenses were approximately $<ix:nonFraction id="Fact_0000000000465" contextRef="From2021-01-01to2021-12-31" name="us-gaap:Depreciation" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">461</ix:nonFraction>, $<ix:nonFraction id="Fact_0000000000466" contextRef="From2020-01-01to2020-12-31" name="us-gaap:Depreciation" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">715</ix:nonFraction> and $<ix:nonFraction id="Fact_0000000000467" contextRef="From2019-01-01to2019-12-31" name="us-gaap:Depreciation" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">989</ix:nonFraction>, respectively. </p></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000476" contextRef="From2021-01-01to2021-12-31" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 6: -</span><span style="font-weight:bold; padding-left:13.35pt; ">OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></p> <ix:nonNumeric id="Fact_0000000000475" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div style="margin-left:60pt; ">
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; "> <thead> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Employees and related accruals</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000469" contextRef="AsOf2021-12-31" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,299</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000470" contextRef="AsOf2020-12-31" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,881</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Accrued expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000471" contextRef="AsOf2021-12-31" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,779</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000472" contextRef="AsOf2020-12-31" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,922</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000473" contextRef="AsOf2021-12-31" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,078</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000474" contextRef="AsOf2020-12-31" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,803</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "></p></td></tr></tbody></table></div></ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000498" contextRef="From2021-01-01to2021-12-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:16pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 7: - </span><span style="font-weight:bold; padding-left:10.02pt; ">COMMITMENTS AND CONTINGENCIES</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">a.<span style="padding-left:13.06pt; ">The Company provided bank guarantees in the amount of $</span><ix:nonFraction id="Fact_0000000000477" contextRef="AsOf2021-12-31" name="us-gaap:GuaranteeObligationsMaximumExposure" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">703</ix:nonFraction> related to its offices in Israel, car leases in Israel and credit card security for its U.S. subsidiary. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">b.<span style="padding-left:12.5pt; ">Under the Office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly </span>known as the Office of the Chief Scientist, (the &#x201C;IIA&#x201D;), the Company is not obligated to repay any amounts received from the IIA if it does not generate any income from the results of the funded research program(s). If income is generated from a funded research program, the Company is committed to pay royalties at a rate of between <ix:nonFraction id="Fact_0000000000478" contextRef="From2021-01-01to2021-12-31_custom_ResearchAndDevelopmentGrantOneMember_srt_MinimumMember" name="cgen:RoyaltyPercentageBasedOnFutureRevenues" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>% to <ix:nonFraction id="Fact_0000000000479" contextRef="From2021-01-01to2021-12-31_custom_ResearchAndDevelopmentGrantOneMember_srt_MaximumMember" name="cgen:RoyaltyPercentageBasedOnFutureRevenues" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>% of future revenue arising from such research program(s), and up to a maximum of 100% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum to be repaid is <ix:nonFraction id="Fact_0000000000480" contextRef="From2021-01-01to2021-12-31_custom_ResearchAndDevelopmentGrantOneMember" name="cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>% plus interest at LIBOR). For the years ended December 31, 2021, 2020 and 2019, the Company had an aggregate of paid or accrued royalties to the IIA, recorded as cost of revenue in the consolidated statements of comprehensive loss in the amount of $<ix:nonFraction id="Fact_0000000000481" contextRef="From2021-01-01to2021-12-31_custom_ResearchAndDevelopmentGrantOneMember" name="us-gaap:RoyaltyExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">180</ix:nonFraction>, $<ix:nonFraction id="Fact_0000000000482" contextRef="From2020-01-01to2020-12-31_custom_ResearchAndDevelopmentGrantOneMember" name="us-gaap:RoyaltyExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">60</ix:nonFraction> and $<ix:nonFraction id="Fact_0000000000483" contextRef="From2019-01-01to2019-12-31_custom_ResearchAndDevelopmentGrantOneMember" name="us-gaap:RoyaltyExpense" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>, respectively. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">As of December 31, 2021, the Company&#x2019;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled approximately to $<ix:nonFraction id="Fact_0000000000484" contextRef="AsOf2021-12-31_custom_ResearchAndDevelopmentGrantOneMember" name="cgen:RoyaltyContingentObligations" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,522</ix:nonFraction>.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;26</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 7: - </span><span style="font-weight:bold; padding-left:10.02pt; ">COMMITMENTS AND CONTINGENCIES (Cont.)</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">c.<span style="padding-left:13.06pt; ">On June 25, 2012 the Company entered into an Antibodies Discovery Collaboration Agreement (the &#x201C;Antibodies </span>Discovery Agreement&#x201D;) with a U.S. antibody technology company (&#x201C;mAb Technology Company&#x201D;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company will be entitled to certain royalties that could be eliminated, upon payment of certain one-time fees (all payments referred together as &#x201C;Contingent Fees&#x201D;). For the years ended December 31, 2021, 2020 and 2019, the Company incurred such Contingent Fees in the amounts of $<ix:nonFraction id="Fact_0000000000485" contextRef="AsOf2021-12-31" name="cgen:ContingentFees" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">500</ix:nonFraction>, $<ix:nonFraction id="Fact_0000000000486" contextRef="AsOf2020-12-31" name="cgen:ContingentFees" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">500</ix:nonFraction> and $<ix:nonFraction id="Fact_0000000000487" contextRef="AsOf2019-12-31" name="cgen:ContingentFees" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">d.<span style="padding-left:12.5pt; ">On </span><ix:nonNumeric id="Fact_0000000000488" contextRef="From2021-01-01to2021-12-31_custom_May2012AgreementMember" name="cgen:AgreementStartDate" format="ixt:datemonthdayyearen">May 9, 2012</ix:nonNumeric>, the Company entered into agreement (the &#x201C;May 2012 Agreement&#x201D;) with a U.S. Business Development Strategic Advisor (&#x201C;Advisor&#x201D;) for the purpose of entering into transactions with Pharma companies related to selected Pipeline Program Candidates. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Under the agreement the Advisor was entitled to <ix:nonFraction id="Fact_0000000000489" contextRef="From2021-01-01to2021-12-31_srt_MinimumMember_custom_May2012AgreementMember" name="cgen:ParticipationRights" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>% of the cash considerations that may be received under such transactions. <ix:nonNumeric id="Fact_0000000000490" contextRef="From2021-01-01to2021-12-31_custom_May2012AgreementMember" name="cgen:AgreementTerminationDescription">In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.</ix:nonNumeric></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">For the years ended December 31, 2021, 2020 and 2019, the Company has not paid and did not accrue payments under this agreement.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">e.<span style="padding-left:13.06pt; ">Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (CLA) with a European </span>cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and <ix:nonFraction id="Fact_0000000000491" contextRef="From2021-01-01to2021-12-31" name="cgen:RoyaltyPercentage" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>% royalties on annual net sales with respect to each commercialized product manufactured using the company&#x2019;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the years ended December 31, 2021, 2020 and 2019, the Company incurred in the research and development expenses in connection with such milestone payment in the amounts of $<ix:nonFraction id="Fact_0000000000492" contextRef="From2021-01-01to2021-12-31" name="cgen:ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>, $<ix:nonFraction id="Fact_0000000000493" contextRef="From2020-01-01to2020-12-31" name="cgen:ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">52</ix:nonFraction> and $<ix:nonFraction id="Fact_0000000000494" contextRef="From2019-01-01to2019-12-31" name="cgen:ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">f.<span style="padding-left:14.17pt; ">Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody </span>discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the years ended December 31, 2021, 2020 and 2019, the Company incurred in the research and development expenses such milestone payment in the amounts of $<ix:nonFraction id="Fact_0000000000495" contextRef="From2021-01-01to2021-12-31" name="cgen:ResearchAndDevelopmentExpensesMilestonePayment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">250</ix:nonFraction>, $<ix:nonFraction id="Fact_0000000000496" contextRef="From2020-01-01to2020-12-31" name="cgen:ResearchAndDevelopmentExpensesMilestonePayment" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction> and $<ix:nonFraction id="Fact_0000000000497" contextRef="From2019-01-01to2019-12-31" name="cgen:ResearchAndDevelopmentExpensesMilestonePayment" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>. </p></ix:nonNumeric>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;27</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p> <ix:nonNumeric id="Fact_0000000000590" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 8: - </span><span style="font-weight:bold; padding-left:10.02pt; ">SHAREHOLDERS&#x2019; EQUITY</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">a.<span style="padding-left:13.06pt; ">Ordinary shares:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The ordinary shares confer upon their holders the right to attend and vote at general meetings of the shareholders. Subject to the rights of holders of shares with limited or preferred rights which may be issued in the future, the ordinary shares of the Company confer upon the holders thereof equal rights to receive dividends, and to participate in the distribution of the assets of the Company upon its winding-up, in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of the nominal value, if any.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">b.<span style="padding-left:12.5pt; ">Issuance of shares:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">On May 25, 2018, the Company entered into a Controlled Equity OfferingSM sales agreement with Cantor Fitzgerald &amp; Co. (&#x201C;Cantor&#x201D;), as sales agent, pursuant to which the Company may offer and sell, from time to time through Cantor, ordinary shares, par value NIS <ix:nonFraction id="Fact_0000000000499" contextRef="AsOf2018-05-25_custom_AtTheMarketOfferingProgramMember" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction> per share, of the Company, under an &#x201C;at-the-market&#x201D; (&#x201C;ATM&#x201D;) offering, having an aggregate offering price of up to $<ix:nonFraction id="Fact_0000000000500" contextRef="From2018-05-01to2018-05-25_custom_AtTheMarketOfferingProgramMember" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,000</ix:nonFraction> (the &#x201C;ATM Shares&#x201D;). As of December 31, 2019, <ix:nonFraction id="Fact_0000000000501" contextRef="From2019-01-01to2019-12-31_custom_AtTheMarketOfferingProgramMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,245,268</ix:nonFraction> shares were issued and sold under the ATM, with proceeds of approximately $<ix:nonFraction id="Fact_0000000000502" contextRef="From2019-01-01to2019-12-31_custom_AtTheMarketOfferingProgramMember" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,914</ix:nonFraction> (net of $<ix:nonFraction id="Fact_0000000000503" contextRef="From2019-01-01to2019-12-31_custom_AtTheMarketOfferingProgramMember" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">781</ix:nonFraction> issuance expenses). The program was terminated in 2019.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">On June 14, 2018, the Company entered into securities purchase agreement with certain institutional investors and a placement agency agreement with JMP Securities LLC in connection with a registered direct offering (the &#x201C;Offering&#x201D;) of an aggregate of <ix:nonFraction id="Fact_0000000000504" contextRef="AsOf2018-06-14_custom_AgreementMember_custom_RegisteredDirectOfferingMember" name="us-gaap:CommonStockSharesAuthorized" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,316,457</ix:nonFraction> ordinary shares (the &#x201C;RD Shares&#x201D;) of the Company at a purchase price of $<ix:nonFraction id="Fact_0000000000505" contextRef="AsOf2018-06-14_custom_AgreementMember_custom_RegisteredDirectOfferingMember" name="us-gaap:SharesIssuedPricePerShare" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">3.95</ix:nonFraction> per RD Share. In connection with the issuance of the RD Shares, the Company also issued warrants to purchase an aggregate of up to <ix:nonFraction id="Fact_0000000000506" contextRef="AsOf2018-06-14_custom_AgreementMember_custom_RegisteredDirectOfferingMember" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,253,165</ix:nonFraction> additional ordinary shares. The Warrants are exercisable at a price of $<ix:nonFraction id="Fact_0000000000507" contextRef="AsOf2018-06-14_custom_AgreementMember_custom_RegisteredDirectOfferingMember" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">4.74</ix:nonFraction> per ordinary share and have a term of <ix:nonNumeric id="Fact_0000000000508" contextRef="From2018-06-01to2018-06-14_custom_AgreementMember_custom_RegisteredDirectOfferingMember" name="cgen:ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" format="ixt-sec:durwordsen">five years</ix:nonNumeric> from the date of issuance. The Offering was made pursuant to the Company&#x2019;s Registration Statement. Proceeds from the Offering were $<ix:nonFraction id="Fact_0000000000509" contextRef="From2018-06-01to2018-06-14_custom_AgreementMember_custom_RegisteredDirectOfferingMember" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,767</ix:nonFraction> (net of $<ix:nonFraction id="Fact_0000000000510" contextRef="From2018-06-01to2018-06-14_custom_AgreementMember_custom_RegisteredDirectOfferingMember" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,233</ix:nonFraction> issuance expenses).</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">During the years ended December 31, 2021, and 2020, warrants to purchase an aggregate of <ix:nonFraction id="Fact_0000000000512" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" name="us-gaap:CommonStockSharesAuthorized" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction id="Fact_0000000000511" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" name="us-gaap:CommonStockSharesAuthorized" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,955,696</ix:nonFraction></ix:nonFraction> ordinary shares were exercised with proceeds of approximately $<ix:nonFraction id="Fact_0000000000514" contextRef="From2021-01-01to2021-12-31_us-gaap_WarrantMember" name="us-gaap:ProceedsFromWarrantExercises" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal"><ix:nonFraction id="Fact_0000000000513" contextRef="From2020-01-01to2020-12-31_us-gaap_WarrantMember" name="us-gaap:ProceedsFromWarrantExercises" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,750</ix:nonFraction></ix:nonFraction> and as of December 31, 2021, warrants to purchase up to <ix:nonFraction id="Fact_0000000000515" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">297,469</ix:nonFraction> ordinary shares remain outstanding.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#x201C;Master Clinical Agreement&#x201D;) with Bristol-Myers Squibb to evaluate the safety and tolerability of the Company&#x2019;s COM701 in combination with Bristol-Myers Squibb&#x2019;s PD-1 immune checkpoint inhibitor Opdivo&#xAE; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol-Myers Squibb made a $<ix:nonFraction id="Fact_0000000000516" contextRef="AsOf2018-10-10_custom_MasterClinicalAgreementMember" name="us-gaap:EquityMethodInvestmentAggregateCost" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,000</ix:nonFraction> equity investment in the Company. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;28</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 8: - </span><span style="font-weight:bold; padding-left:10.02pt; ">SHAREHOLDERS&#x2019; EQUITY (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Under the terms of the securities purchase agreement, Bristol-Myers Squibb purchased <ix:nonFraction id="Fact_0000000000517" contextRef="From2018-10-01to2018-10-10_custom_MasterClinicalAgreementMember" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,424,243</ix:nonFraction> ordinary shares of the Company at a purchase price of $<ix:nonFraction id="Fact_0000000000518" contextRef="AsOf2018-10-10_custom_MasterClinicalAgreementMember" name="us-gaap:SharesIssuedPricePerShare" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">4.95</ix:nonFraction> per share. The share price represented a <ix:nonFraction id="Fact_0000000000519" contextRef="From2018-10-01to2018-10-10_custom_MasterClinicalAgreementMember" name="cgen:PercentageOfClosingPrice" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">33</ix:nonFraction>% premium over the average closing price of Compugen&#x2019;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The premium over the fair market value in the amount of $<ix:nonFraction id="Fact_0000000000520" contextRef="From2021-01-01to2021-12-31_custom_CollaborativeArrangementsMember" name="cgen:DeferredParticipationOfBmsInRdExpenses" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,121</ix:nonFraction> represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;D, in accordance with ASC 808 &#x201C;Collaborative Arrangements&#x201D;) and $<ix:nonFraction id="Fact_0000000000521" contextRef="From2021-01-01to2021-12-31_custom_CollaborativeArrangementsMember" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,788</ix:nonFraction> (net of $<ix:nonFraction id="Fact_0000000000522" contextRef="From2021-01-01to2021-12-31_custom_CollaborativeArrangementsMember" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91</ix:nonFraction> issuance expenses) were considered equity investment. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $<ix:nonFraction id="Fact_0000000000523" contextRef="AsOf2021-11-30_custom_MasterClinicalAgreementMember" name="us-gaap:EquityMethodInvestmentAggregateCost" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,000</ix:nonFraction> investment in the Company, purchasing <ix:nonFraction id="Fact_0000000000524" contextRef="From2021-11-02to2021-11-30_custom_MasterClinicalAgreementMember" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,332,815</ix:nonFraction> ordinary shares of the Company at a purchase price of $<ix:nonFraction id="Fact_0000000000525" contextRef="AsOf2021-11-30_custom_MasterClinicalAgreementMember" name="us-gaap:SharesIssuedPricePerShare" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">8.57333</ix:nonFraction> per share. The share price represented a <ix:nonFraction id="Fact_0000000000526" contextRef="From2021-11-02to2021-11-30_custom_MasterClinicalAgreementMember" name="cgen:PercentageOfClosingPrice" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">33</ix:nonFraction>% premium over the closing price of Company&#x2019;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The premium over the fair market value in the amount of $<ix:nonFraction id="Fact_0000000000527" contextRef="From2021-01-01to2021-12-31_custom_CollaborativeArrangementsTwoMember" name="cgen:DeferredParticipationOfBmsInRdExpenses" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,000</ix:nonFraction> represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;D, in accordance with ASC 808 &#x201C;Collaborative Arrangements&#x201D;) and $<ix:nonFraction id="Fact_0000000000528" contextRef="From2021-01-01to2021-12-31_custom_CollaborativeArrangementsTwoMember" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,958</ix:nonFraction> (net of $<ix:nonFraction id="Fact_0000000000529" contextRef="From2021-01-01to2021-12-31_custom_CollaborativeArrangementsTwoMember" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">42</ix:nonFraction> issuance expenses) were considered equity investment.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In March 2020, the Company entered into an underwriting agreement with SVB Leerink LLC and Stifel, Nicolaus &amp; Company, Incorporated, as representatives of several underwriters relating to the issuance and sale in a public offering of <ix:nonFraction id="Fact_0000000000530" contextRef="From2020-03-01to2020-03-16_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,333,334</ix:nonFraction> of the Company&#x2019;s ordinary shares at a price to the public of $<ix:nonFraction id="Fact_0000000000531" contextRef="AsOf2020-03-16_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" name="us-gaap:SharesIssuedPricePerShare" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">9.00</ix:nonFraction> per share (and a price of $<ix:nonFraction id="Fact_0000000000532" contextRef="AsOf2020-03-16_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_custom_UnderwritersMember" name="us-gaap:SharesIssuedPricePerShare" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">8.46</ix:nonFraction> per share to the underwriters). Such shares were issued on March 16, 2020. In addition, the Company granted the underwriters a 30-day option to purchase additional ordinary shares at the price set forth above. On April 14, 2020, the Company issued and sold, pursuant to that underwriting agreement additional <ix:nonFraction id="Fact_0000000000533" contextRef="From2020-04-01to2020-04-14_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_custom_UnderwritersMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">483,005</ix:nonFraction> ordinary shares pursuant to the underwriters&#x2019; option specified above. The Company sold a total of <ix:nonFraction id="Fact_0000000000534" contextRef="From2021-01-01to2021-12-31_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,816,339</ix:nonFraction> ordinary shares in the offering with proceeds of $<ix:nonFraction id="Fact_0000000000535" contextRef="From2021-01-01to2021-12-31_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">74,147</ix:nonFraction> (net of $<ix:nonFraction id="Fact_0000000000536" contextRef="From2021-01-01to2021-12-31_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,200</ix:nonFraction> issuance expenses).</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">c.<span style="padding-left:13.06pt; ">Share option plan:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Under the Company&#x2019;s 2010 Share Option Plan as amended (the &#x201C;Plan&#x201D;), options may be granted to employees, directors and non-employees of the Company and Compugen USA Inc. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Under the 2010 Share Option Plan the Company reserved for issuance up to an aggregate of <ix:nonFraction id="Fact_0000000000537" contextRef="AsOf2021-12-31_custom_TwoThousandAndTwoThousandTenOptionsPlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">12,395,152</ix:nonFraction> ordinary shares. The Company&#x2019;s Board of Directors last amended the Plan in May 2020, to increase the number of shares available under the 2010 Plan and extend the plan term by additional 10 years. As of December 31, 2021, an aggregate of <ix:nonFraction id="Fact_0000000000538" contextRef="AsOf2021-12-31_custom_TwoThousandAndTwoThousandTenOptionsPlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,133,128</ix:nonFraction> options under the 2010 Share Option Plan of the Company are still available for future grants. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;29</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 8: - </span><span style="font-weight:bold; padding-left:10.02pt; ">SHAREHOLDERS&#x2019; EQUITY (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">c.<span style="padding-left:13.06pt; ">Share option plan (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In general, options granted under the Plan vest over a <ix:nonNumeric id="Fact_0000000000539" contextRef="From2021-01-01to2021-12-31_custom_TwoThousandAndTwoThousandTenOptionsPlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen">four-year</ix:nonNumeric> period and expire <ix:nonNumeric id="Fact_0000000000540" contextRef="From2021-01-01to2021-12-31_custom_TwoThousandAndTwoThousandTenOptionsPlanMember" name="cgen:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" format="ixt-sec:duryear">10</ix:nonNumeric> years from the date of grant and are granted at an exercise price of not less than the fair market value of the Company&#x2019;s ordinary shares on the date of grant, unless otherwise determined by the Company&#x2019;s board of directors. The exercise price of the options granted under the Plan may not be less than the nominal value of the shares into which such options are exercised and the expiration date may not be later than 10 years from the date of grant. If a grantee leaves his or her employment or other relationship with the Company, or if his or her relationship with the Company is terminated without cause (and other than by reason of death or disability, as defined in the Plan), the term of his or her unexercised options will generally expire in 90 days, unless determined otherwise by the Company.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">Any options that are cancelled, forfeited or expired become available for future grants. </p> <ix:nonNumeric id="Fact_0000000000561" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "> Transactions related to the grant of options to employees, directors and non-employees under the above Plan during the year ended December 31, 2021, were as follows: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div style="margin-left:80pt; ">
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; "> <thead> <tr class="odd" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Number of </span><span style="font-weight:bold; ">options</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Weighted </span><span style="font-weight:bold; ">average </span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">exercise </span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">price</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Weighted </span><span style="font-weight:bold; ">average</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">remaining </span><span style="font-weight:bold; ">contractual </span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">life</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Aggregate </span><span style="font-weight:bold; ">intrinsic</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">value</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">$</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Years</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">$</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options outstanding at beginning of year</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000541" contextRef="AsOf2020-12-31_custom_EmployeesAndDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,960,256</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000542" contextRef="AsOf2020-12-31_custom_EmployeesAndDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">6.26</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonNumeric id="Fact_0000000000543" contextRef="From2020-01-01to2020-12-31_custom_EmployeesAndDirectorsMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear">6.94</ix:nonNumeric></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000544" contextRef="AsOf2020-12-31_custom_EmployeesAndDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,587</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options granted</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000545" contextRef="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,397,500</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000546" contextRef="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">6.72</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options exercised</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000547" contextRef="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">217,375</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000548" contextRef="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">4.19</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options forfeited</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000549" contextRef="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">154,277</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000550" contextRef="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">7.45</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options expired</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000551" contextRef="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,000</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:1pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000552" contextRef="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">6.14</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options outstanding at end of year</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000553" contextRef="AsOf2021-12-31_custom_EmployeesAndDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,976,104</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000554" contextRef="AsOf2021-12-31_custom_EmployeesAndDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">6.39</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonNumeric id="Fact_0000000000555" contextRef="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear">6.69</ix:nonNumeric></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000556" contextRef="AsOf2021-12-31_custom_EmployeesAndDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,323</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Exercisable at end of year</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000557" contextRef="AsOf2021-12-31_custom_EmployeesAndDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,693,761</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000558" contextRef="AsOf2021-12-31_custom_EmployeesAndDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">5.23</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonNumeric id="Fact_0000000000559" contextRef="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear">5.21</ix:nonNumeric></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000560" contextRef="AsOf2021-12-31_custom_EmployeesAndDirectorsMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,496</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "></p></td></tr></tbody></table></div></ix:nonNumeric>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Weighted average fair value of options granted to employees, directors and non-employees during the years 2021, 2020 and 2019 was $<ix:nonFraction id="Fact_0000000000562" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">3.81</ix:nonFraction>, $<ix:nonFraction id="Fact_0000000000563" contextRef="From2020-01-01to2020-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">7.15</ix:nonFraction> and $<ix:nonFraction id="Fact_0000000000564" contextRef="From2019-01-01to2019-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">1.73</ix:nonFraction> per share, respectively.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Aggregate intrinsic value of exercised options by employees, directors and non-employees during the years 2021, 2020 and 2019 was $<ix:nonFraction id="Fact_0000000000565" contextRef="AsOf2021-12-31_srt_DirectorMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">759</ix:nonFraction>, $<ix:nonFraction id="Fact_0000000000566" contextRef="AsOf2020-12-31_srt_DirectorMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,610</ix:nonFraction>, and $<ix:nonFraction id="Fact_0000000000567" contextRef="AsOf2019-12-31_us-gaap_DirectorMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">979</ix:nonFraction>, respectively. The aggregate intrinsic value of the exercised options represents the total intrinsic value (the difference between the sale price of the Company&#x2019;s share at the date of exercise, and the exercise price) multiplied by the number of options exercised. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company&#x2019;s closing share price on the last trading day of calendar 2020 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2021. This amount is impacted by the changes in the fair market value of the Company&#x2019;s shares. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;30</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 8: - </span><span style="font-weight:bold; padding-left:10.02pt; ">SHAREHOLDERS&#x2019; EQUITY (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">c.<span style="padding-left:13.06pt; ">Share option plan (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">As of December 31, 2021, the total unrecognized estimated compensation cost related to non-vested share options granted prior to that date was $<ix:nonFraction id="Fact_0000000000568" contextRef="AsOf2021-12-31" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,926</ix:nonFraction> which is expected to be recognized over a weighted average period of approximately <ix:nonNumeric id="Fact_0000000000569" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear">3.02</ix:nonNumeric> years. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">d.<span style="padding-left:12.5pt; ">Employee Stock Purchase Plan:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company adopted an ESPP in November 2020, with the first offering period starting at January 1, 2021. In connection with its adoption, a total of <ix:nonFraction id="Fact_0000000000570" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">600,000</ix:nonFraction> ordinary shares were reserved for issuance under this plan. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The ESPP is implemented through six-month offering periods (except for the first offering period that was <ix:nonNumeric id="Fact_0000000000571" contextRef="From2021-01-01to2021-12-31_us-gaap_EmployeeStockMember-1750657468" name="us-gaap:InitialOfferingPeriod">five months</ix:nonNumeric>). According to the ESPP, eligible employees and non-employees may use up to <ix:nonFraction id="Fact_0000000000572" contextRef="From2021-01-01to2021-12-31_us-gaap_EmployeeStockMember-1750657468" name="cgen:PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>% of their base salaries to purchase ordinary shares up to an aggregate limit of $<ix:nonFraction id="Fact_0000000000573" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockMember" name="cgen:AggregateLimitOfOrdinarySharesPerCalendarYear" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">40</ix:nonFraction> per participant for every calendar year. The price of an ordinary share purchased under the ESPP is equal to <ix:nonFraction id="Fact_0000000000574" contextRef="From2021-01-01to2021-12-31_us-gaap_EmployeeStockMember-1750657468" name="cgen:PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">85</ix:nonFraction>% of the lower of the fair market value of the ordinary share on the first day of each offering period or on the last day of such period. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Since its adoption and through December 31, 2021, <ix:nonFraction id="Fact_0000000000575" contextRef="From2021-01-01to2021-12-31_us-gaap_EmployeeStockMember-1750657468" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">117,829</ix:nonFraction> ordinary shares had been purchased under the ESPP and as of December 31, 2021, <ix:nonFraction id="Fact_0000000000576" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">482,171</ix:nonFraction> ordinary shares were available for issuance under the ESPP. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In accordance with ASC No. 718, the ESPP is compensatory and, as such, results in recognition of compensation cost.</p> <ix:nonNumeric id="Fact_0000000000589" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; "> e.<span style="padding-left:13.06pt; ">The stock-based compensation expenses related to stock options and ESPP are included as follows in the expense </span>categories: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div style="margin-left:80pt; ">
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; "> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Research and development expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000577" contextRef="From2021-01-01to2021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,971</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000578" contextRef="From2020-01-01to2020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,123</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000579" contextRef="From2019-01-01to2019-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,151</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Marketing and business development expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000580" contextRef="From2021-01-01to2021-12-31_us-gaap_SellingAndMarketingExpenseMember" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">215</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000581" contextRef="From2020-01-01to2020-12-31_us-gaap_SellingAndMarketingExpenseMember" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">172</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000582" contextRef="From2019-01-01to2019-12-31_us-gaap_SellingAndMarketingExpenseMember" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">General and administrative expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000583" contextRef="From2021-01-01to2021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,090</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000584" contextRef="From2020-01-01to2020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,477</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000585" contextRef="From2019-01-01to2019-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,211</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000586" contextRef="From2021-01-01to2021-12-31" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,276</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000587" contextRef="From2020-01-01to2020-12-31" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,772</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000588" contextRef="From2019-01-01to2019-12-31" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,408</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "></p></td></tr></tbody></table></div></ix:nonNumeric></ix:nonNumeric>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;31</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p> <ix:nonNumeric id="Fact_0000000000629" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 9: - </span><span style="font-weight:bold; padding-left:10.02pt; ">INCOME TAXES</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">a. <span style="padding-left:9.73pt; ">Israeli taxation:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">1.<span style="padding-left:12.5pt; ">Tax rates applicable to the income of the Company.</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:100pt; margin-bottom:0pt; ">Taxable income of the Company is subject to a corporate tax rate of <ix:nonFraction id="Fact_0000000000593" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction id="Fact_0000000000592" contextRef="From2020-01-01to2020-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction id="Fact_0000000000591" contextRef="From2019-01-01to2019-12-31" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">23</ix:nonFraction></ix:nonFraction></ix:nonFraction>% in 2019, 2020 and 2021.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">2.<span style="padding-left:12.5pt; ">Measurement of taxable income in US dollars:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">The Company has elected to measure its taxable income and file its tax return under the Israeli Income Tax Regulations (Principles Regarding the Management of Books of Account of Foreign Invested Companies and Certain Partnerships and the Determination of Their Taxable Income), 1986. Accordingly, results for tax purposes are measured in terms of earnings in dollars.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:-20pt !important; padding-left:100pt !important; margin-bottom:0pt; ">3.<span style="padding-left:12.5pt; ">Tax benefits under the Israeli Law for the Encouragement of Capital Investments, 1959 (the &#x201C;Investment Law&#x201D;):</span>&#x2009;&#x2009; </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">On April 1, 2005, an amendment to the Investment Law came into effect (the &#x201C;Amendment 60&#x201D;) that significantly changed the provisions of the Investment Law. The Amendment 60 limits the scope of enterprises that may be approved by the Investment Center by setting criteria for the approval of a facility as a &#x201C;Beneficiary Enterprise&#x201D; including a provision generally requiring that at least <ix:nonFraction id="Fact_0000000000594" contextRef="From2021-01-01to2021-12-31" name="cgen:ReducedTaxRate" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>% of the Beneficiary Enterprise&#x2019;s income will be derived from export.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">Another condition for receiving the benefits under the alternative track in respect of expansion programs pursuant to Amendment 60 is a minimum qualifying investment. The Company was eligible under the terms of minimum qualifying investment and elected 2012 as its &#x201C;year of election&#x201D;.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">Additionally, the Amendment 60 enacted major changes in the manner in which tax benefits are awarded under the Investment Law so that companies no longer require Investment Center approval in order to qualify for tax benefits. However, the Investment Law provides that terms and benefits included in any certificate of approval already granted will remain subject to the provisions of the Investment Law as they were on the date of such approval.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:100pt; margin-bottom:0pt; ">As of December 31, 2021, there was no taxable income attributable to the Beneficiary Enterprise. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;32</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 9: - </span><span style="font-weight:bold; padding-left:10.02pt; ">INCOME TAXES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">a. <span style="padding-left:9.73pt; ">Israeli taxation (Cont.):</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">In January 2011, another amendment to the Investment Law came into effect (&#x201C;the 2011 Amendment&#x201D;). According to the 2011 Amendment, the benefit tracks in the Investment Law were modified and a flat tax rate applies to the Company&#x2019;s entire income subject to this amendment (the &#x201C;Preferred Income&#x201D;).</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">Once an election is made, the Company&#x2019;s income will be subject to the amended tax rate of 16% from 2015 and thereafter (or 9% for a preferred enterprise located in development area A).</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">Commencing 2011 tax year, the Company can elect (without possibility of reversal) to apply the Amendment in a certain tax year and from that year and thereafter, it will be subject to the amended tax rates.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">The Company does not currently intend to adopt the 2011 Amendment and intends to continue to comply with the Investment Law as in effect prior to enactment of the 2011 Amendment. Accordingly, the Company did not adjust its deferred tax balances as of December 31, 2021. The Company&#x2019;s position may change in the future.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">In December 2016, the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2016 and 2017 Budget Years), 2016, which includes Amendment 73 to the Law (the &#x201C;Amendment 73&#x201D;) was published. According to Amendment 73, a preferred enterprise located in development area A will be subject to a tax rate of 7.5% instead of 9% effective from January 1, 2016 and thereafter (the tax rate applicable to preferred enterprises located in other areas remains at 16%).</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">Amendment 73 also prescribes special tax tracks for technological enterprises, which are subject to rules that were issued by the Minister of Finance in May 2017. The new tax tracks under the Amendment are as follows:</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">Preferred Technological Enterprise (&#x201C;PTE&#x201D;) - an enterprise for which total consolidated revenues of its parent company and all subsidiaries are less than NIS 10 billion in a tax year. A PTE, as defined in the Law, which is located in the center of Israel will be subject to tax at a rate of 12% on profits deriving from intellectual property (in development area A - a tax rate of 7.5%).</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">The above changes in the tax rates relating to PTE tax track were not taken into account in the computation of deferred taxes as of December 31, 2021 and 2020, since the Company estimates that it will not implement the PTE tax track. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;33</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 9: - </span><span style="font-weight:bold; padding-left:10.02pt; ">INCOME TAXES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">a. <span style="padding-left:9.73pt; ">Israeli taxation (Cont.):</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">4.<span style="padding-left:12.5pt; ">Tax benefits under the law for the Encouragement of Industry (Taxes), 1969 (the &#x201C;Encouragement Law&#x201D;):</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">The Encouragement Law provides several tax benefits for industrial companies. An industrial company is defined as a company resident in Israel, at least 90% of the income of which in a given tax year exclusive of income from specified Government loans, capital gains, interest and dividends, is derived from an industrial enterprise owned by it. An industrial enterprise is defined as an enterprise whose major activity in a given tax year is industrial production activity.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">Management believes that the Company is currently qualified as an &#x201C;industrial company&#x201D; under the Encouragement Law and, as such, is entitled to tax benefits, including: (1) deduction of purchase of know-how and patents and/or right to use a patent over an eight-year period; (2) the right to elect, under specified conditions, to file a consolidated tax return with additional related Israeli industrial companies and an industrial holding company; (3) accelerated depreciation rates on equipment and buildings; and (4) expenses related to a public offering on the Tel-Aviv Stock exchange and on recognized stock markets outside of Israel, are deductible in equal amounts over three years. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">Eligibility for benefits under the Encouragement Law is not subject to receipt of prior approval from any Governmental authority. No assurance can be given that the Israeli tax authorities will agree that the Company qualifies, or, that the Company will continue to qualify as an industrial company or that the benefits described above will be available to the Company in the future.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">5.<span style="padding-left:12.5pt; ">Net operating losses carryforward and capital loss:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">As of December 31, 2021, Compugen Ltd.&#x2019;s net operating losses carryforward for tax purposes in Israel amounted to approximately $<ix:nonFraction id="Fact_0000000000595" contextRef="AsOf2021-12-31_us-gaap_DomesticCountryMember" name="us-gaap:OperatingLossCarryforwards" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">369,800</ix:nonFraction>. These net operating losses may be carried forward indefinitely and may be offset against future taxable income. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;34</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 9: - </span><span style="font-weight:bold; padding-left:10.02pt; ">INCOME TAXES (Cont.)</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">b.<span style="padding-left:12.5pt; ">Non-Israeli subsidiary, Compugen USA, Inc.:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the &#x201C;U.S. Tax Reform&#x201D; or &#x201C;TCJA&#x201D;); a comprehensive tax legislation that includes significant changes to the taxation of business entities. These changes include several key tax provisions that might impact the Company, among others: (i) a permanent reduction to the statutory federal corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017; (ii) a shift of the U.S. taxation of multinational corporations from a tax on worldwide income to a territorial system (along with certain new rules designed to prevent erosion of the U.S. income tax base - &#x201C;BEAT&#x201D;); (iii) establishing immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits; and (iv) providing a permanent deduction to corporations generating revenues from non-US markets (known as a deduction for foreign derived intangible income - &#x201C;FDII&#x201D;).</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">As of December 31, 2021, Compugen USA, Inc. has net operating loss carryforwards for federal income tax purposes of approximately $<ix:nonFraction id="Fact_0000000000596" contextRef="AsOf2019-12-31_us-gaap_InternalRevenueServiceIRSMember" name="us-gaap:OperatingLossCarryforwards" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,850</ix:nonFraction>, approximately $<ix:nonFraction id="Fact_0000000000597" contextRef="AsOf2019-12-31_us-gaap_InternalRevenueServiceIRSMember" name="cgen:NetOperatingLossCarryforwardExpired" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,750</ix:nonFraction> of which expires in the years <span style="-sec-ix-hidden:Fact_0000000000598">2023</span> to <span style="-sec-ix-hidden:Fact_0000000000599">2032</span>. Utilization of the U.S. net operating losses may be subject to substantial annual limitation due to the &#x201C;change in ownership&#x201D; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Neither Israeli income taxes, foreign withholding taxes nor deferred income taxes were provided in relation to undistributed earnings of the Company&#x2019;s foreign subsidiary. This is because the Company has the intent and ability to reinvest these earnings indefinitely in the foreign subsidiary and therefore those earnings are continually redeployed in those jurisdictions.</p> <ix:nonNumeric id="Fact_0000000000609" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> c.<span style="padding-left:13.06pt; ">Loss (income) before taxes is comprised as follows:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div style="margin-left:80pt; ">
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; "> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Domestic (Israel) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000600" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">34,619</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000601" contextRef="From2020-01-01to2020-12-31" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">30,010</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000602" contextRef="From2019-01-01to2019-12-31" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">28,799</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Foreign </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000603" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">416</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000604" contextRef="From2020-01-01to2020-12-31" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">312</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000605" contextRef="From2019-01-01to2019-12-31" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">740</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000606" contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">34,203</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000607" contextRef="From2020-01-01to2020-12-31" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">29,698</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000608" contextRef="From2019-01-01to2019-12-31" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">28,059</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "></p></td></tr></tbody></table></div></ix:nonNumeric>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">d.<span style="padding-left:12.5pt; ">Taxes on income (tax benefit) for the year ended December 31, 2019 is comprised from refund of withholding tax </span>payments, which were deducted from milestone payments by the German tax authorities. There were no withholding tax payments for the years ended December 31, 2021, 2020 and 2019. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;35</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 9: - </span><span style="font-weight:bold; padding-left:10.02pt; ">INCOME TAXES (Cont.)</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">e.<span style="padding-left:13.06pt; ">Deferred taxes:</span></p> <ix:nonNumeric id="Fact_0000000000628" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "> Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company and Compugen USA, Inc.&#x2019;s deferred tax assets are comprised of operating loss carryforward and other temporary differences. Significant components of the Company and Compugen USA, Inc. deferred tax assets are as follows: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div style="margin-left:80pt; ">
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; "> <thead> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Operating loss carryforward </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000610" contextRef="AsOf2021-12-31" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">86,068</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000611" contextRef="AsOf2020-12-31" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">80,134</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Research and development </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000612" contextRef="AsOf2021-12-31" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,773</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000613" contextRef="AsOf2020-12-31" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,001</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Accrued social benefits and other </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000614" contextRef="AsOf2021-12-31" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,801</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000615" contextRef="AsOf2020-12-31" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,389</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Right of use assets </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000616" contextRef="AsOf2021-12-31" name="cgen:DeferredIncomeTaxRightOfUseAssets" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">520</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000617" contextRef="AsOf2020-12-31" name="cgen:DeferredIncomeTaxRightOfUseAssets" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">651</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Lease liabilities </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000618" contextRef="AsOf2021-12-31" name="cgen:DeferredIncomeTaxLeaseLiabilities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">636</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000619" contextRef="AsOf2020-12-31" name="cgen:DeferredIncomeTaxLeaseLiabilities" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">742</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Property and equipment </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000620" contextRef="AsOf2021-12-31" name="cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000621" contextRef="AsOf2020-12-31" name="cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:1pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Deferred tax asset before valuation allowance </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000622" contextRef="AsOf2021-12-31" name="us-gaap:DeferredTaxAssetsGross" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">98,760</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000623" contextRef="AsOf2020-12-31" name="us-gaap:DeferredTaxAssetsGross" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91,617</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Valuation allowance </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000624" contextRef="AsOf2021-12-31" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">98,760</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000625" contextRef="AsOf2020-12-31" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91,617</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net deferred tax asset </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000626" contextRef="AsOf2021-12-31" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000627" contextRef="AsOf2020-12-31" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "></p></td></tr></tbody></table></div></ix:nonNumeric>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company and Compugen USA, Inc. have provided full valuation allowances in respect of deferred tax assets resulting from operating loss carryforward and other temporary differences. Management currently believes that since the Company has a history of losses, it is more likely than not that the deferred tax regarding the operating loss carryforward and other temporary differences will not be realized in the foreseeable future.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">f.<span style="padding-left:14.17pt; ">Reconciliation of the theoretical tax expense (benefit) to the actual tax expense (benefit):</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax benefits from accumulated net operating loss carryforward among the Company and Compugen USA, Inc. due to the uncertainty of the realization of such tax benefits.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">g.<span style="padding-left:12.5pt; ">Tax assessments:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">The Company has tax assessments through 2016 that are deemed to be final. </p></ix:nonNumeric>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;36</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p> <ix:nonNumeric id="Fact_0000000000648" contextRef="From2021-01-01to2021-12-31" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 10: - </span><span style="font-weight:bold; padding-left:5.02pt; ">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">The Company&#x2019;s business is currently comprised of <ix:nonFraction id="Fact_0000000000630" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NumberOfOperatingSegments" unitRef="Item" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> operating segment, the research, development and commercialization of therapeutic and product candidates. The nature of the products and services provided by the Company and the type of customers for these products and services are similar. Operations in Israel and the United States include research and development, clinical operations, marketing and business development. The Company follows ASC 280, &#x201C;Segment Reporting&#x2EE;. Total revenues are attributed to geographic areas based on the location of the end customer. </p> <ix:nonNumeric id="Fact_0000000000643" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; "> The following represents the total revenue for the years ended December 31, 2021, 2020 and 2019 and long-lived assets as of December 31, 2021 and 2020: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div style="margin-left:60pt; ">
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; "> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Revenue from sales to customers: </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Europe </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000631" contextRef="From2021-01-01to2021-12-31_srt_EuropeMember" name="us-gaap:Revenues" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,000</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000632" contextRef="From2020-01-01to2020-12-31_srt_EuropeMember" name="us-gaap:Revenues" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,000</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000633" contextRef="From2019-01-01to2019-12-31_us-gaap_EuropeMember" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Total revenue </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000634" contextRef="From2021-01-01to2021-12-31" name="us-gaap:Revenues" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,000</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000635" contextRef="From2020-01-01to2020-12-31" name="us-gaap:Revenues" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,000</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000636" contextRef="From2019-01-01to2019-12-31" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "></p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div style="margin-left:60pt; ">
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; "> <thead> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Long-lived assets: </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Israel </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000637" contextRef="AsOf2021-12-31_country_IL" name="us-gaap:NoncurrentAssets" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,787</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000638" contextRef="AsOf2020-12-31_country_IL" name="us-gaap:NoncurrentAssets" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,240</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">United States </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000639" contextRef="AsOf2021-12-31_country_US" name="us-gaap:NoncurrentAssets" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">118</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000640" contextRef="AsOf2020-12-31_country_US" name="us-gaap:NoncurrentAssets" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">243</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Total long-lived assets </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000641" contextRef="AsOf2021-12-31" name="us-gaap:NoncurrentAssets" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,905</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000642" contextRef="AsOf2020-12-31" name="us-gaap:NoncurrentAssets" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,483</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "></p></td></tr></tbody></table></div></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000647" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div style="margin-left:60pt; ">
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; "> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Sales to a single customer exceeding 10%: </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Customer A </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000644" contextRef="From2021-01-01to2021-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember" name="us-gaap:ConcentrationRiskPercentage1" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction> </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000645" contextRef="From2020-01-01to2020-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember" name="us-gaap:ConcentrationRiskPercentage1" unitRef="Pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction> </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000646" contextRef="From2019-01-01to2019-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember" name="us-gaap:ConcentrationRiskPercentage1" unitRef="Pure" scale="-2" xsi:nil="true"></ix:nonFraction>- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "></p></td></tr></tbody></table></div></ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000665" contextRef="From2021-01-01to2021-12-31" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:14pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 11: -</span><span style="font-weight:bold; padding-left:8.9pt; ">FINANCIAL AND OTHER INCOME, NET</span> </p> <ix:nonNumeric id="Fact_0000000000664" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div style="margin-left:60pt; ">
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; "> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Interest income </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000649" contextRef="From2021-01-01to2021-12-31" name="us-gaap:InvestmentIncomeInterest" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">894</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000650" contextRef="From2020-01-01to2020-12-31" name="us-gaap:InvestmentIncomeInterest" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,765</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000651" contextRef="From2019-01-01to2019-12-31" name="us-gaap:InvestmentIncomeInterest" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">935</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Bank fees and other finance expenses </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000652" contextRef="From2021-01-01to2021-12-31" name="us-gaap:InterestAndDebtExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000653" contextRef="From2020-01-01to2020-12-31" name="us-gaap:InterestAndDebtExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">42</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000654" contextRef="From2019-01-01to2019-12-31" name="us-gaap:InterestAndDebtExpense" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Foreign currency translation adjustments </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000655" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000656" contextRef="From2020-01-01to2020-12-31" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000657" contextRef="From2019-01-01to2019-12-31" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">218</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Gain (loss) from sales and disposals of fixed assets </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000658" contextRef="From2021-01-01to2021-12-31" name="us-gaap:GainLossOnSaleOfOtherAssets" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000659" contextRef="From2020-01-01to2020-12-31" name="us-gaap:GainLossOnSaleOfOtherAssets" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:1pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000660" contextRef="From2019-01-01to2019-12-31" name="us-gaap:GainLossOnSaleOfOtherAssets" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">135</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:2pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Financial and other income, net </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000661" contextRef="From2021-01-01to2021-12-31" name="cgen:FinancialIncomeExpenseNet" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">871</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000662" contextRef="From2020-01-01to2020-12-31" name="cgen:FinancialIncomeExpenseNet" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,798</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000663" contextRef="From2019-01-01to2019-12-31" name="cgen:FinancialIncomeExpenseNet" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">820</ix:nonFraction> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "></p></td></tr></tbody></table></div></ix:nonNumeric></ix:nonNumeric>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0; </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;37</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"></div> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p> <ix:nonNumeric id="Fact_0000000000672" contextRef="From2021-01-01to2021-12-31" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 12: -</span><span style="font-weight:bold; padding-left:8.35pt; ">RELATED PARTY BALANCES AND TRANSACTIONS</span> </p> <ix:nonNumeric id="Fact_0000000000671" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div style="margin-left:60pt; ">
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; "> <thead> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Trade payables and accrued expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000666" contextRef="AsOf2021-12-31" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">94</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000667" contextRef="AsOf2020-12-31" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">83</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "></p> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div style="margin-left:60pt; ">
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; "> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Amounts charged to:</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Research and development expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000668" contextRef="From2021-01-01to2021-12-31" name="us-gaap:CostsAndExpensesRelatedParty" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">240</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000669" contextRef="From2020-01-01to2020-12-31" name="us-gaap:CostsAndExpensesRelatedParty" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">294</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000670" contextRef="From2019-01-01to2019-12-31" name="us-gaap:CostsAndExpensesRelatedParty" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">241</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "></p></td></tr></tbody></table></div></ix:nonNumeric>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">For the years ended December 31, 2021, 2020 and 2019 the Company received research and development services related with cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies. The transaction was at arm&#x2019;s length. </p></ix:nonNumeric> <ix:nonNumeric id="Fact_0000000000683" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EarningsPerShareTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 13: -</span><span style="font-weight:bold; padding-left:8.35pt; ">LOSSES PER SHARE</span></p> <ix:nonNumeric id="Fact_0000000000682" contextRef="From2021-01-01to2021-12-31" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> The following table sets forth the computation of basic and diluted losses per share: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> <div style="margin-left:60pt; ">
<table width="100%" cellpadding="0" class="fin" style="border-spacing:0; "> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Numerator:</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net loss for basic and diluted loss per share</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000673" contextRef="From2021-01-01to2021-12-31" name="us-gaap:NetIncomeLoss" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">34,203</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000674" contextRef="From2020-01-01to2020-12-31" name="us-gaap:NetIncomeLoss" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">29,698</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000675" contextRef="From2019-01-01to2019-12-31" name="us-gaap:NetIncomeLoss" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal" sign="-">27,337</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Denominator:</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:-8pt !important; padding-left:8pt !important; margin-bottom:0pt; ">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000676" contextRef="From2021-01-01to2021-12-31" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">84,203,971</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000677" contextRef="From2020-01-01to2020-12-31" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">79,591,187</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "><ix:nonFraction id="Fact_0000000000678" contextRef="From2019-01-01to2019-12-31" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="Shares" decimals="INF" scale="0" format="ixt:numdotdecimal">63,636,673</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#xA0;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "></p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Basic and diluted earnings per ordinary share</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000679" contextRef="From2021-01-01to2021-12-31" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal" sign="-">0.41</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000680" contextRef="From2020-01-01to2020-12-31" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal" sign="-">0.37</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "></p> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(<ix:nonFraction id="Fact_0000000000681" contextRef="From2019-01-01to2019-12-31" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="USDPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal" sign="-">0.43</ix:nonFraction></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">) </p></td></tr></tbody></table></div></ix:nonNumeric></ix:nonNumeric>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-bottom:0pt; "></p> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#x2009;-&#x2009;38</p> </div> <div style="width:100%; clear:both;"> <hr style="border-top:0.75pt solid #000000; width:100%; margin-left:0pt; text-align:left; "/><hr style="border-top:3pt solid #000000; width:100%; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:13.03pt; text-align:left; "></p>
<p style="font-family:Times New Roman, Times, serif; font-size:13.03pt; text-align:left; margin-bottom:0pt; "></p> </div> </div> </div>
  </div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>exhibit_2-1.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 2.1</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">DESCRIPTION OF SECURITIES</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The descriptions of the securities contained herein summarize the material terms and provisions of the ordinary shares of Compugen Ltd. (the &#8220;Company&#8221;), registered under Section 12 of the Securities
      Exchange Act of 1934.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">ORDINARY SHARES</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Our authorized share capital is NIS 2,000,000 divided into 200,000,000 ordinary shares, nominal (par) value NIS 0.01 per share. Subject to our amended and restated articles of association, or our
      Articles, fully paid ordinary shares of the Company confer on the holders thereof rights to attend and to vote at general meetings of the shareholders. Subject to the rights of holders of shares with limited or preferred rights which may be issued in
      the future, the ordinary shares of the Company confer upon the holders thereof equal rights to vote, to receive dividends and to participate in the distribution of the assets of the Company upon its winding-up, in proportion to the amount paid up or
      credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of the nominal value,
      if any. All outstanding ordinary shares are validly issued and fully paid.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">The Nasdaq Global Market and the Tel Aviv Stock Exchange</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">Our ordinary shares are listed on each of The Nasdaq Global Market and the Tel Aviv Stock Exchange&#160;under the symbol &#8220;CGEN&#8221;.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Rights Attached to Our Shares</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Subject to our Articles, fully paid ordinary shares confer on the holders thereof rights to attend and to vote at general meetings of the shareholders. Subject to the rights of holders of shares with
      limited or preferred rights which may be issued in the future, our ordinary shares confer upon the holders thereof equal rights to receive dividends and to participate in the distribution of our assets upon our winding-up, in proportion to the amount
      paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of the
      nominal value, if any. No preferred shares are currently authorized. All outstanding ordinary shares are validly issued and fully paid.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Voting Rights</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Subject to the provisions of our Articles, holders of ordinary shares have one vote for each ordinary share held by such shareholder of record, on all matters submitted to a vote of shareholders.
      Shareholders may vote in person, by proxy or by proxy card. Alternatively, shareholders who hold shares through members of the Tel Aviv Stock Exchange may vote electronically via the electronic voting system of the Israel Securities Authority, or
      Electronic Vote. These voting rights may be affected by the grant of any special voting rights to the holders of a class of shares with preferential rights that may be authorized in the future. As our ordinary shares do not have cumulative voting
      rights in the election of directors, the holders of the majority of the shares present and voting at a shareholders meeting have the power to elect all of our directors. In the event that we cease meeting the Opt Out Criteria (as defined in the
      annual report on Form 20-F to which this Exhibit 2.1 is attached), or if our board of directors shall decide to opt in the requirement to elect and have external directors and comply with the composition criteria of the audit committee and
      compensation committee under the Companies Law, the external directors will be elected by a special majority vote, as set forth under the Companies Law.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Transfer of Shares</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our ordinary shares which have been fully paid-up are transferable by submission of a proper instrument of transfer together with the certificate of the shares to be transferred and such other
      evidence of title, as our board of directors may require, unless such transfer is prohibited by another instrument or by applicable securities laws.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Dividends</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Under the Companies Law, dividends may be distributed only out of profits available for dividends as determined by the Companies Law, provided that there is no reasonable concern that the
      distribution will prevent the Company from being able to meet its existing and anticipated obligations when they become due. If the company does not meet the profit requirement, a court may nevertheless allow the company to distribute a dividend, as
      long as the court is convinced that there is no reasonable concern that such distribution will prevent the company from being able to meet its existing and anticipated obligations when they become due. Pursuant to our Articles, no dividend shall be
      paid other than out of the profits of the Company. Generally, under the Companies Law, the decision to distribute dividends and the amount to be distributed is made by a company&#8217;s board of directors.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our Articles provide that our board of directors, may, subject to the Companies Law, from time to time, declare and cause the Company to pay such dividends as may appear to the board of directors to
      be justified by the profits of our Company. Subject to the rights of the holders of shares with preferential, special or deferred rights that may be authorized in the future, our profits which shall be declared as dividends shall be distributed
      according to the proportion of the nominal (par) value paid up or credited as paid up on account of the shares held at the date so appointed by the Company and in respect of which such dividend is being paid, without regard to the premium paid in
      excess of the nominal (par) value, if any. The declaration of dividends does not require shareholders&#8217; approval.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">To date, we have not declared or distributed any dividend and we do not intend to pay cash dividends on our ordinary shares in the foreseeable future.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Liquidation Rights</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">In the event of our winding up on liquidation or dissolution, subject to applicable law and after satisfaction of liabilities to creditors, our assets available for distribution among the
      shareholders shall be distributed to the holders of ordinary shares in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such distribution is being
      made, without regard to any premium paid in excess of the nominal value, if any. This liquidation right may be affected by the grant of limited or preferential rights as to liquidation to the holders of a class of shares that may be authorized in the
      future.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Redemption Provisions</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">We may, subject to applicable law and to our Articles, issue redeemable shares and redeem the same upon such terms and conditions as determined by our board of directors.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Limitation of Liability</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Under our Articles, the liability of each shareholder for the Company&#8217;s obligations is limited to the unpaid sum, if any, owing to the Company in consideration for the issuance of the shares held by
      such shareholder.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Modification of Class Rights</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our amended and restated Memorandum of Association, or Memorandum, provides that we may amend the Memorandum in order to increase, consolidate or divide or otherwise amend our share capital by a
      simple majority of the voting power present at a shareholders meeting as currently provided in our Articles or by such other majority as shall be set forth in our Articles from time to time.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to our Articles, if at any time our share capital is divided into different classes of shares, the rights attached to any class, unless otherwise provided by our Articles, may be modified or
      abrogated by the Company, subject to the consent in writing of, or sanction of a resolution passed by, the holders of a majority of the issued shares of such class at a separate general meeting of the holders of the shares of such class.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Limitations on the Rights to Own Securities</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our Articles and Israeli law do not restrict the ownership or voting of ordinary shares by non-residents or persons who are not citizens of Israel, though such ownership is prohibited under
      applicable law with respect to subjects of nations which are in a state of war with Israel.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Changes in Authorized Share Capital</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our Articles enable us, among others, to increase or reduce our authorized share capital. Any such changes are subject to the provisions of the Companies Law and our Articles and must be approved by
      a resolution duly passed by a simple majority of our shareholders at a general meeting by voting on such change in capital.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Shareholders&#8217; Meetings and Resolutions</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Our Articles and the Companies Law provide that our annual general meeting shall be held once in every calendar year at such time (within a period of not more than fifteen months after the last
      preceding annual general meeting), and place determined by our board of directors. Our board of directors may, in its discretion, convene additional special shareholders meetings and, pursuant to the Companies Law, must convene a meeting upon the
      demand of: (a) two directors or one quarter of the directors in office; or (b) the holder or holders of (i) 5% or more of our issued share capital and one percent or more of our voting rights; or (ii) 5% or more of our voting rights. All demands for
      shareholders meetings must set forth the items to be considered at that meeting. If the board of directors does not convene a meeting upon a valid demand of any of the above, then the persons who made the demand, and in the case of shareholders, part
      of such demanding shareholders holding at least half of the voting rights of such demanding shareholders, may convene a meeting of the shareholders to be held within three months of the demand. Alternatively, upon petition by the individuals making
      the demand, a court may order that a meeting be convened.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The chairman of the board of directors, or any other director or office holder of the Company which may be designated for this purpose by the board of directors, shall preside as chairman at each of
      our general meetings. If there is no such chairman, or if the appointed chairman is unwilling to take the chair, or if he shall have indicated in advance that he will not be attending, or if at any meeting such chairman is not present within thirty
      (30) minutes after the time fixed for holding the meeting, then those present at the meeting shall choose someone present to be chairman of the meeting. The office of chairman shall not, by itself, entitle the holder thereof to vote at any general
      meeting nor shall it entitle a second or casting vote.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">According to regulations promulgated pursuant to the Companies Law and governing the terms of notice and publication of shareholder meetings of public companies, or the General Meeting Regulations,
      holder(s) of one percent or more of the Company&#8217;s voting rights may propose any matter appropriate for deliberation at a shareholder meeting to be included on the agenda of a shareholder meeting, generally by submitting a proposal within seven days
      of publicizing the convening of a shareholder meeting, or within fourteen days, if the Company publishes at least 21 days prior to publicizing the proxy materials for a shareholder meeting, a preliminary notice stating its intention to convene such
      meeting, the agenda thereof, shareholder&#8217;s right to propose a matter to be included on the agenda of such meeting and company&#8217;s right not to examine such proposals received upon termination of 14 day period from the publication of such notice. Any
      such proposal must further comply with the information requirements under applicable law and our Articles, and in the event that such shareholders propose to appoint directors for service on the Company&#8217;s board of directors, the proposal must include
      information regarding the director candidates as well as certain declarations of the director candidates, as required pursuant to the General Meeting Regulations. The agenda for a shareholder meeting is determined by the board of directors and must
      include matters in respect of which the convening of a shareholder meeting was demanded and any matter requested to be included by holder(s) of one percent of the Company&#8217;s voting rights, as detailed above.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to the Companies Law and the General Meeting Regulations shareholder meetings generally require prior notice of not less than 21 days, and not less than 35 days in certain cases. Pursuant to
      our Articles, we are not required to deliver or serve notice of a general meeting or of any adjournments thereof to any shareholder. However, subject to applicable law and stock exchange rules and regulations, we will publicize the convening of a
      general meeting in any manner reasonably determined by us, and any such publication shall be deemed duly made, given and delivered to all shareholders on the date on which it is first made, posted, filed or published in the manner so determined by us
      in our sole discretion.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The function of the general meeting is to elect directors, receive and consider the profit and loss account, the balance sheet and the ordinary reports and accounts of the directors and auditors,
      appoint external auditor, approve certain interested party transactions requiring general meeting approval as provided in the Companies Law, approve the Company&#8217;s merger, exercise of the powers of the board of directors if the board of directors is
      unable to exercise its powers and the exercise of any of its powers is vital for our proper management, approve amendments of the Articles and transact any other business which under our Articles or applicable law may be transacted by the
      shareholders of the Company in a general meeting.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to our Articles, the quorum required for a meeting of shareholders consists of at least two shareholders, present in person, by proxy, by proxy card or by Electronic Vote and holding shares
      conferring in the aggregate twenty-five percent (25%) or more of the voting power of the Company. If within half an hour from the time appointed for the meeting a quorum is not present, the meeting shall stand adjourned to the same day in the
      following week at the same time and place or to such other later day, time and place as the board of directors may determine and specify in the publication with respect to the Meeting. At the adjourned meeting, any number of participants will
      constitute a quorum present, in person, by proxy, by proxy card or by Electronic Vote; provided, however, that special general meeting which was convened by the Board upon the demand of shareholders or directors then in office, as detailed above, or
      directly by such shareholders or directors, in accordance the terms of the Companies Law, shall be cancelled.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Generally, under the Companies Law and our Articles, shareholder resolutions are deemed adopted if approved by the holders of a simple majority of the voting rights represented at the meeting, in
      person, by proxy, by proxy card or by Electronic Vote, and voting on the matter, unless a different majority is required by law or pursuant to our Articles such as a resolution for the voluntary winding up of our Company which requires the approval
      of holders of 75% of the voting power presented and voting at the meeting, or resolutions concerning certain related party transactions as set forth in Sections 267 and 270-275 of the Companies Law.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Change of Control</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Merger</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Under the Companies Law, a merger is generally required to be approved by the shareholders and board of directors of each of the merging companies. If the share capital of the company that will not
      be the surviving company is divided into different classes of shares, the approval of each class is also required, unless determined otherwise by the court. Similarly, unless an Israeli court determines otherwise, a merger will not be approved if it
      is objected to by shareholders holding a majority of the voting rights participating and voting at the meeting (abstentions are disregarded), after excluding the shares held by the other party to the merger, by any person who holds 25% or more of the
      other party to the merger or by anyone on their behalf, including by the relatives of, or corporations controlled by, these persons. In approving a merger, the board of directors of both merging companies must determine that there is no reasonable
      concern that, as a result of the merger, the surviving company will not be able to satisfy its obligations to its creditors. Similarly, upon the request of a creditor of either party to the proposed merger, an Israeli court may prevent or delay the
      merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will not be able to satisfy the obligations of the merging parties. A court may also issue other instructions for the protection of
      the creditors&#8217; rights in connection with a merger. Further, a merger may not be completed unless at least (i) 50 days have passed from the time that the requisite proposals for the approval of the merger were filed with the Israeli registrar of
      companies; and (ii) 30 days have passed since the merger was approved by the shareholders of each party.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Special Tender Offer</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a
      holder of 25% or more of the voting rights in the company. This rule does not apply if there is already another holder of 25% or more of the voting rights in the company. Similarly, the Companies Law provides that an acquisition of shares in a public
      company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the company who holds more than
      45% of the voting rights in the company. These requirements do not apply if the acquisition (i) occurs in the context of a private placement by the company that received shareholder approval for the purpose of allowing the purchaser to hold more than
      25% of the voting rights in the company if there is no other holder of 25% or more of the voting rights in the company, or 45% of the voting rights in the company if there is no other holder of 45% or more of the voting rights in the company, as the
      case may be, (ii) was from a shareholder holding 25% or more of the voting rights in the company and resulted in the acquirer becoming a holder of 25% or more of the voting rights in the company, or (iii) was from a holder of more than 45% of the
      voting rights in the company and resulted in the acquirer becoming a holder of more than 45% of the voting rights in the company. A special tender offer may be consummated only if (i) at least 5% of the voting power attached to the company&#8217;s
      outstanding shares will be acquired by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding controlling shareholders, holders of 25% or more of the voting rights
      in the company and any person having a personal interest in the acceptance of the special tender offer).</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">In the event that a special tender offer is made, a company&#8217;s board of directors is required to express its opinion on the advisability of the offer, or shall abstain from expressing any opinion if
      it is unable to do so, provided that it gives the reasons for its abstention. An office holder in a target company who, in his or her capacity as an office holder, performs an action the purpose of which is to cause the failure of an existing or
      foreseeable special tender offer or is to impair the chances of its acceptance, is liable to the potential purchaser and shareholders for damages, unless such office holder acted in good faith and had reasonable grounds to believe he or she was
      acting for the benefit of the company. However, office holders of the target company may negotiate with the potential purchaser in order to improve the terms of the special tender offer and may further negotiate with third parties in order to obtain
      a competing offer. Shares purchased in contradiction to the tender offer rules under the Companies Law will have no rights and will become dormant shares.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">If a special tender offer is accepted, then shareholders who did not respond to or that had objected the offer may accept the offer within four days of the last day set for the acceptance of the
      offer. In the event that a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the
      purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the
      initial special tender offer.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Full Tender Offer</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Under the Companies Law, a person may not acquire shares in a public company if, after the acquisition, the acquirer will hold more than 90% of the shares or more than 90% of any class of shares of
      that company, unless a tender offer is made to purchase all of the shares or all of the shares of the particular class. The Companies Law also generally provides that as long as a shareholder in a public company holds more than 90% of the company&#8217;s
      shares or of a class of shares, that shareholder shall be precluded from purchasing any additional shares. In order for all of the shares that the purchaser offered to purchase be transferred to him by operation of law, one of the following needs to
      have occurred: (i) the shareholders who declined or do not respond to the tender offer hold less than 5% of the company&#8217;s outstanding share capital or of the relevant class of shares and the majority of offerees who do not have a personal interest in
      accepting the tender offer accepted the offer, or (ii) the shareholders who declined or do not respond to the tender offer hold less than 2% of the company&#8217;s outstanding share capital or of the relevant class of shares.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">A shareholder that had his or her shares so transferred, whether he or she accepted the tender offer or not, has the right, within six months from the date of acceptance of the tender offer, to
      petition the court to determine that the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However, the purchaser may provide in its offer that shareholders who accept the tender offer will
      not be entitled to such rights.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">If the conditions set forth above are not met, the purchaser may not acquire additional shares of the company from shareholders who accepted the tender offer to the extent that following such
      acquisition, the purchaser would own more than 90% of the company&#8217;s issued and outstanding share capital. The above restrictions apply, in addition to the acquisition of shares, to the acquisition of voting power.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>3
<FILENAME>exhibit_4-3.htm
<DESCRIPTION>EXHIBIT 4.3
<TEXT>
<html>
  <head>
    <title>exhibit_4-7.htm</title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
  <div>
    <hr noshade="noshade" size="4" style="MARGIN-TOP: -5px; COLOR: #000000">
    <hr noshade="noshade" size="1" style="MARGIN-TOP: -10px; COLOR: #000000"> </div>
  <div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold; text-decoration: underline;">Exhibit 4.3</font></div>
  <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">&#160;</font></div>
  <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
      <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
        <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
          <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
            <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; font-style: italic;">
              <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
                  <div style="line-height: 1.25;">
                    <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
                      <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
                        <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; font-style: italic;">
                          <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
                            <div style="line-height: 1.25; font-weight: bold;">
                              <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
                                <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
                                  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
                                    <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; font-style: italic;">
                                      <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
                                        <div style="line-height: 1.25; font-weight: bold;">
                                          <div style="line-height: 1.25;">Pursuant to Instruction 4(a) as to Exhibits of Form 20-F, certain identified information (marked by [***]) has been excluded from the exhibit because it is both not material and is
                                            the type that the registrant treats as private or confidential.</div>
                                        </div>
                                      </div>
                                    </div>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
  <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">Research and Development Collaboration and License Agreement</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">This Research and Development Collaboration and License Agreement (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Agreement</font>&#8221;),



      effective as of 5 August, 2013 (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Effective Date</font>&#8221;), is entered into by and between Bayer Pharma AG, a company formed under the laws of Germany, having a place of business at Muellerstrasse
      178, 13353 Berlin, Germany (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Bayer</font>&#8221;) and<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Compugen Ltd a company formed under the laws of Israel, having a place of
      business at 72 Pinchas Rosen Street, Tel Aviv 69512, Israel (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Compugen</font>&#8221;).&#160;&#160;Bayer and Compugen each shall be referred to herein as a &#8220;Party&#8221; and they shall be referred to together as the
      &#8220;Parties.&#8221;</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">WHEREAS, Bayer is a global leader in the development, manufacture, marketing and sale of healthcare products; and</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">WHEREAS, Compugen is a leading drug discovery company, with a focus on the discovery of protein and antibody therapeutic
      candidates for the fields of oncology and immunology; and</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">WHEREAS, the Parties wish to enter into a collaboration for the research, development and commercialization of
      antibody-based therapeutics against certain targets<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>with respect to which Compugen has intellectual property rights; and</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -2.5pt"><font style="display: inline;">WHEREAS, the Parties further desire that Bayer develop, obtain regulatory approval for and commercialize such products,
      all subject to and in accordance with the terms herein.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">NOW, THEREFORE,</font> in consideration of the promises and mutual
      covenants set forth herein, Bayer and Compugen agree as follows:</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">1.</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">Definitions.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Whenever used in this Agreement with an initial capital letter, the terms defined in this Section 1, whether used in the
      singular or the plural, shall have the meanings specified below.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.1.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Affiliate&#8221;</font> means, with respect to a person, organization or other entity, any person, organization or other entity controlling,
                controlled by or under common control with, such person, organization or entity. For purposes of this definition, an entity shall be deemed to &#8220;control&#8221; another entity if it (i) owns directly or indirectly fifty percent (50%) or more of the
                outstanding voting securities, capital stock or other comparable equity or ownership interest of such entity having the power to vote on or direct the affairs of such entity, as applicable (or such lesser percentage which is the maximum
                allowed to be owned by a foreign corporation in a particular jurisdiction), or (ii) possesses, directly or indirectly, the power to direct or cause the direction of the policies and management of such entity, as applicable, whether by the
                ownership of stock, by contract or otherwise.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.2.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Bayer Competitor&#8221;</font> means any person, organization or other entity that is active in the field of clinical development and/or
                commercialization of prescription pharmaceuticals for indications in the area of oncology.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.3.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Bayer Development Process&#8221;</font> means Bayer&#8217;s [***] internal process for the research and development of therapeutic candidates described in
                <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 1.3</font>, or any similar internal process implemented by Bayer for its therapeutic development activities in general (i.e. not just for a Target Program)
                that succeeds or amends the process described in Exhibit 1.3.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.4.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Bayer Intellectual Property&#8221; </font>means (a) any Bayer Know-How, (b) any Bayer Product Patent Rights and (c) any other Program Know-How
                and/or Program Inventions owned by Bayer in accordance with Section 8.1.2.1.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.5.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Bayer Know-How&#8221; </font>means any and all Know How with respect to [***], Products and/or [***]developed or generated by Bayer or an Affiliate
                of Bayer in the performance of a [***] and, [***] or [***] for the [***] of the licenses granted by Bayer to Compugen under Section 3,<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>including but not limited to
                [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">&#160;</font>information relating to [***], Products and/or Product Companion Diagnostics, but for clarity specifically excluding any [***]
                and/or [***] not specific to [***] or [***].&#160;&#160;For the avoidance of doubt, the Bayer Know-How includes Program Know-How owned by Bayer to the extent that such Program Know-How relates to [***], Products and/or [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.6.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Bayer Product Patent Rights&#8221; </font>means<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>any Patents with respect to an invention
                developed or generated by Bayer or an Affiliate of Bayer in the performance of a [***] and that claim, in each case solely to the extent they claim, (a) a Product or [***]Product(s) or (b) a [***] or [***].&#160;&#160;For clarity, &#8220;Bayer Product
                Patent Rights&#8221; do not include Patents that claim [***] that [***] Product(s) nor [***] (e.g. [***]), except to the extent they include claims that are [***] Product(s) or [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.7.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Biologic&#8221; </font>means any [***] or a [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.8.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Biomarker&#8221; </font>means a distinctive biological or biologically derived indicator (including, without limitation, DNA, RNA, protein,
                peptide, antibodies and cells) by which particular normal biologic processes, pathogenic processes or pharmacologic responses to therapeutic intervention can be identified, quantified or predicted.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.9.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;BLA&#8221;</font> means (a) an FDA Biologics License Application, Product License Application or similar application filed with the United States
                FDA for approval to market a Product for use in the Field and (b) any comparable application filed with a Regulatory Authority in any other country or jurisdiction.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.10.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Business Day(s)&#8221;</font> shall mean a day other than a Friday, Saturday, Sunday and any day on which commercial banks located in Berlin,
                Germany or in Tel Aviv, Israel, are authorized or obligated by law to be closed.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.11.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Calendar Quarter&#8221;</font> means each of the periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and
                December 31, for so long as this Agreement is in effect.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.12.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;CGEN-15001T Research Program&#8221; </font>means the research and preclinical development program to be performed by the Parties until the end of
                the Research Period, i.e. until [***] or such other date as may be agreed in any amendment or change to the CGEN-15001T Workplan.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.13.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;CGEN-15001T Target&#8221;</font> means any protein encoded by the gene locus on [***] with the official gene symbol [***] as provided by HGNC
                consortium, and any [***].&#160;&#160;For purposes of this definition &#8220;[***]&#8221; means all [***] from that [***] (including any [***]) with an [***] of at least [***], in which overlap there is a [***] of at least [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.14.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;CGEN-15001T Target Biologic&#8221; </font>means any Target Biologic [***] a CGEN-15001T Target.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="font-style: italic; display: inline; font-weight: bold;">&#160;</font></div>
  </div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">2</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  &#160;
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.15.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;CGEN-15001T Target Program&#8221; </font>means the program for the research, development and commercialization of Products containing CGEN-15001T
                Target Biologics and Product Companion Diagnostics for such Products as contemplated by this Agreement.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.16.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;CGEN-15001T Workplan&#8221; </font>means the workplan attached hereto as <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 1.16</font>, which sets forth the research and preclinical development work to be performed by each of the Parties with respect to the CGEN-15001T Target Program during the relevant Research Period, as such workplan may
                be amended by Bayer and Compugen in accordance with Section 2.4.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.17.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;CGEN-15022 Research Program&#8221; </font>means the research and preclinical development program to be performed by the Parties until the end of
                the Research Period, i.e. until [***] or such other date as may be agreed in any amendment or change to the CGEN-15022 Workplan.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.18.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;CGEN-15022 Target&#8221;</font> means any protein encoded by the gene locus on [***] with the official gene symbol [***] as provided by HGNC
                consortium, and any [***]&#160;&#160;For purposes of this definition, &#8220;[***]&#8221; means all proteins derived from that [***] (including any [***]) with an [***] of at least [***] amino acids, in which overlap there is a [***] of at least [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.19.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;CGEN-15022 Target Biologic&#8221; </font>means any Target Biologic [***] a CGEN-15022 Target.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.20.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;CGEN-15022 Target Program&#8221; </font>means the program for the research, development and commercialization of Products containing CGEN-15022
                Target Biologics and Product Companion Diagnostics for such Products as contemplated by this Agreement.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.21.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;CGEN-15022 Workplan&#8221; </font>means the workplan attached hereto as <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 1.21</font>, which sets forth the research and preclinical development work to be performed by each of the Parties with respect to the CGEN-15022 Target Program during the relevant Research Period, as such workplan may
                be amended by Bayer and Compugen in accordance with Section 2.4.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.22.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Commercially Reasonable Efforts&#8221;</font> means efforts and resources, with respect to a particular Party, that are [***] by that Party
                (together with its Affiliates) in the exercise of its [***] with respect to programs it is [***] on relating to other [***] or [***] by it (and/or its Affiliates) or to which it (together with its Affiliates) has [***], which have a [***]
                and are at a [***] or [***], as appropriate, taking into account issues of [***] of the [***] and [***], the [***] or [***] of the product, and other relevant factors, including without limitation, [***], and/or [***], where such level of
                efforts and resources, in any event, shall be [***] than [***] with [***] of a [***].&#160;&#160;For clarity, in the event Bayer grants a Sublicense, the efforts exerted by Bayer and/or its Sublicensee to develop and commercialize Products will
                continue to be compared to those efforts generally exerted by a [***] of a [***] in active programs relating to other [***] or [***] by it (and/or its Affiliates) or to which it (together with its Affiliates) has [***] for purposes of this
                definition.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.23.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Companion Diagnostic&#8221; </font>means any Product Companion Diagnostic and any Other Companion Diagnostic.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.24.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Composition Of Matter Claim&#8221;</font> means a Valid Claim that covers one or more Target Biologic(s) and/or Target Biomarker(s) as composition
                of matter, regardless of whether the [***] of such Target Biologic(s) or Target Biomarker(s) is claimed.&#160;&#160;For clarity, &#8220;Composition of Matter Claims&#8221; includes, without limitation, Valid Claims covering [***] Target Biologics against a
                Target, a [***] of a Target or [***] of a Target.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">3</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160; </div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.25.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Composition Of Matter Patent Rights&#8221;</font> means any Compugen Patent Rights or Joint Patent Rights that include one or more Composition Of
                Matter Claim(s).</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.26.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Compugen Intellectual Property&#8221; </font>means (a) any Compugen Know-How, (b) any Compugen Patent Rights and (c) any other Program Know-How
                and/or Program Inventions owned by Compugen in accordance with Section 8.1.2.2 (other than [***], which are specifically excluded from this definition).</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.27.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Compugen Know-How&#8221; </font>means any and all Know How with respect to [***] (alone or together with another composition, e.g. conjugate),
                [***] or [***] that is [***] and is, in Compugen&#8217;s [***] or [***] for the [***] of the licenses granted by Compugen to Bayer under Section 3, including but not limited to [***] and [***] information relating to [***] or [***] but for
                clarity specifically excluding: (i) any and all [***] and [***] and (ii) other [***] and/or [***] to [***] or [***]. For the avoidance of doubt, the Compugen Know-How includes Program Know-How owned by Compugen to the extent that such
                Program Know-How relates to [***] and/or [***].&#160;&#160;Notwithstanding the foregoing, &#8220;Compugen Know-How&#8221; does not include Know How with respect to [***] and/or [***] that was [***] before the date of [***], but (a) was [***] before such date by
                the [***] or the [***], as applicable or (b) is/was developed by such [***] in independent activities without the use of or reference to [***] by persons who were [***], provided that those independent activities are/were made within a
                project that was started by [***] with respect to [***][***] and/or [***] in connection with the evaluation of the [***]. The Parties agree that in case of dispute, Compugen will have the burden of proof to demonstrate that all requirements
                of lit. (a) or lit. (b) are fulfilled.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.28.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Compugen Patent Rights&#8221; </font>means any Patents Controlled by Compugen or any of its Affiliates [***] or [***] that claim, in each case
                solely to the extent they claim, [***], Products (but excluding, if and to the extent that such Patents claim Products, any composition of matter that is [***] and [***]) and/or [***], or their use, or a manufacturing process [***] and/or
                one or more [***] including without limitation the Patents set forth in <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 1.28</font>. For clarity, &#8220;Compugen Product Patent Rights&#8221; do not include patents
                or patent applications that claim [***] that [***] to [***] (e.g. [***]), except to the extent they include claims that are [***]or [***].<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Notwithstanding the
                foregoing, &#8220;Compugen Patent Rights&#8221; does not include Patents to the extent they claim [***] and/or [***], or a manufacturing process specific to one or more [***] and/or one or more [***], that were not Controlled by Compugen before the
                date of [***] or [***], but (a) were Controlled before such date by the [***] or the [***], as applicable or (b) claim inventions conceived and reduced to practice by such [***] after such [***] in independent activities without the use of
                or reference to [***] by persons who were [***], provided that those independent activities are/were made within a project that was started by the [***] with respect to [***] and/or [***] in connection with the evaluation of the [***]. The
                Parties agree that in case of dispute, Compugen will have the burden of proof to demonstrate that all requirements of lit. (a) or lit. (b) are fulfilled.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.29.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Control&#8221;</font> means, with respect to intellectual property or intellectual property rights that is/are owned or in-licensed by a Party
                and/or its Affiliate(s), the right, whether directly or indirectly, and whether by ownership, license or otherwise, to assign or to grant a license or sublicense as provided for herein without violating the terms of any agreement or other
                arrangement with any Third Party (including the terms of any such in-license agreement) or any applicable law and without the need for any consent (or further consent) from such Third Party.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">4</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.30.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font> means [***] as set forth in [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.31.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">[***] </font>means [***] and a [***].&#160;&#160;[***] will entail [***] of [***], together with [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.32.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">[***] </font>means [***] of a [***] and a [***] of the [***], in accordance with [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.33.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Diagnostic&#8221;</font> means any Companion Diagnostic and any General Diagnostic that (a) is covered by a claim of a Compugen Patent Right or
                Joint Patent Right and/or (b) is/was [***] and/or [***] through the use ([***]) of [***] or [***].&#160;&#160;The Parties agree that in case of dispute, Bayer will have [***] that [***] has been [***] without the use of [***] and without the use of
                [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.34.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Field&#8221; </font>means the treatment or prevention of any [***] and/or [***], [***] in [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.35.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;First Commercial Sale&#8221;</font> means, on a [***] basis with respect to each Product and each Diagnostic, the date of the first sale for [***]
                in an arm&#8217;s length transaction by a Related Party of such Product or Diagnostic, as applicable, to an Unrelated Third Party for [***] of such Product or Diagnostic, as applicable, following receipt of all [***] required to [***] such
                Product or Diagnostic, as applicable, in such [***] to the [***].&#160;&#160;For clarity, sales or other distribution for (a) use in [***], use in [***] or [***] programs or use in similar instances in which products may be provided to patients prior
                to [***] or (b) provision of [***] for [***] or similar purposes shall not be deemed &#8220;First Commercial Sale&#8221;.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.36.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Fusion Protein&#8221;</font> means a protein created by the fusion of the extracellular domain of a protein, or fragment thereof, to any
                heterologous sequence (such as an Fc fragment of an Immunoglobulin G).</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.37.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;General Diagnostic&#8221; </font>means any diagnostic product that contains and/or detects a Target Biomarker, other than Companion Diagnostics,
                including without limitation standalone diagnostics.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.38.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Indication&#8221; </font>means: (a) for oncological diseases characterized by [***] from [***], whereby [***] from [***] shall constitute a [***]
                (e.g. by way of illustration: [***]. [***], whereas, [***] that [***]; and (b) for other oncological diseases and non-oncological diseases, Indications shall be classified as defined in [***]. By way of illustration, [***] would list nine
                different Indications.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.39.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;</font>Infringed Claim&#8221; means a claim of a Patent of a Third Party which would be infringed by [***] of, or the [***] of, [***] included in
                the relevant Product (at the date and in the country of such activity).&#160;&#160;Notwithstanding the foregoing, &#8220;Infringed Claim&#8221; does not include claims with respect to [***] or [***] that are [***] to a [***].&#160;&#160;Any risk of infringement of such
                Third Party rights will be reasonably considered in the selection of the [***] to be further developed, to the extent that such a risk is already recognizable at the time of selection of the [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.40.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Joint Intellectual Property&#8221;</font> means any Joint Patent Rights and/or Joint Know-How.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.41.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Joint Invention&#8221; </font>means any Program Invention for which (a) one or more inventors is an employee or contractor of Bayer or its
                Affiliate and (b) one or more inventors is an employee or contractor of Compugen or its Affiliate.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">5</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  &#160;
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.42.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Joint Know-How&#8221; </font>means Program Know-How developed jointly by (a) one or more employees or contractors of Bayer or its Affiliate<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>and (b) one or more employees or contractors of Compugen or its Affiliate. For the avoidance of doubt, &#8220;Joint Know-How&#8221; also includes Joint Inventions.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.43.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Joint Patent Rights&#8221; </font>means any patent or patent application that claims a Joint Invention.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.44.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Know-How&#8221;</font> means any proprietary tangible and intangible: methods, inventions, techniques, processes, specifications, materials,
                recipes, formulae, preparations, designs, plans, drawings, data, trade secrets or other technical or scientific information.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.45.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Marketing Authorization</font>&#8221; means, with respect to a Product or Diagnostic in a given country, all approvals from the relevant Regulatory
                Authority (e.g. a BLA in the case of a Product) necessary to market and sell such Product or Diagnostic, as applicable, in such country to the relevant patient population in general.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.46.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Net Sales&#8221;</font> means the [***] amount [***] or (if not [***])[***] by a Related Party for sales of a Product or Diagnostic to [***] less
                the following deductions to the extent specifically applicable to such sales of Products or Diagnostics, as applicable, and not previously deducted from such [***] amount [***]:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 54pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font face="Symbol, serif" style="DISPLAY: inline;">&#183;</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] of gross amount for [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 54pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font face="Symbol, serif" style="DISPLAY: inline;">&#183;</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] and [***] or [***] included in such [***] invoiced and paid by a [***] or any other [***] imposed upon the sale of the relevant Product or Diagnostic and paid by a [***], but
                specifically excluding [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 54pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font face="Symbol, serif" style="DISPLAY: inline;">&#183;</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] and [***] granted or allowed in the ordinary course of business by a Related Party in connection with such sale of a Product or Diagnostic;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 54pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font face="Symbol, serif" style="DISPLAY: inline;">&#183;</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] or [***] granted by a Related Party to customers on account of governmental requirements, rejection, outdating, returns, billing errors or recalls of a Product or Diagnostic;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 54pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font face="Symbol, serif" style="DISPLAY: inline;">&#183;</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] and [***] or [***] (as described below) granted by a Related Party in the ordinary course of business with respect to the sale of a Product or Diagnostic; and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 54pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font face="Symbol, serif" style="DISPLAY: inline;">&#183;</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] of [***] for [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="display: block; text-indent: 36pt;"><font style="display: inline;">For the purpose of calculating Net Sales, the Parties recognize that: (a) customers may include persons in the chain of commerce who enter into agreements with
      a Related Party as to price even though title to the Product does not pass directly from the Related Party to such customers and even though payment for such Product is not made by such customers directly to a Related Party; and (b) in such cases,
      chargebacks paid by a Related Party to or through an Unrelated Third Party (such as a wholesaler) with respect to the gross amount invoiced on such sales can be deducted by a Related Party from gross revenue in order to calculate Net Sales.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="display: block; text-indent: 36pt;"><font style="display: inline;">In the event a Product is sold in the form of a combination product containing one or more active ingredients in addition to the Product, Net Sales for such
      combination product will be adjusted by multiplying actual Net Sales of such combination product by the fraction A / (A+B) where A is the invoice price of the Product, if sold separately, and B is the invoice price of any other active ingredient(s)
      in the combination, if sold separately. If, on a country-by-country basis, the other active ingredient(s) in the combination product are not sold separately in that country, Net Sales will be calculated by multiplying actual Net Sales of such
      combination product by the fraction A / C where A is the invoice price of the Product, if sold separately, and C is the invoice price of the combination product. If, on a country-by-country basis, the Product is not sold separately in such country,
      then the value of the active ingredient(s) for the purpose of determining Net Sales shall be determined between the Parties in good faith.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">6</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  &#160;
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">For clarity, sales of Products or Diagnostics by a Related Party to another Related Party for resale by such other Related
      Party will not be deemed Net Sales.&#160;&#160;Instead, Net Sales will be determined based on the [***] invoiced by such other Related Party upon resale of such Products or Diagnostics to an Unrelated Third Party purchaser.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">In the event that a Related Party receives non-cash consideration for any Products or Diagnostics, Net Sales will be
      calculated based on the fair market value of such consideration, assuming an arm&#8217;s length transaction made in the ordinary course of business.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">In the event of a planned Sublicense, Compugen will on request of Bayer [***] with Bayer [***] of this definition of Net
      Sales, if this is [***] to reach an [***] of this term both in the relationship between Compugen and Bayer and in the relationship between Bayer and the Sublicensee, provided that such change does not, [***] Compugen&#8217;s rights.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Notwithstanding the foregoing, the following shall not be included in Net Sales: (i) sales or other transfers of Products
      and/or Diagnostics by a Related Party for administration to patients enrolled in clinical trials, provided that the Related Party receives no consideration from such clinical trials nor for such sales or other transfers and (ii) Products and
      Diagnostics used as samples to promote additional Net Sales, in amounts consistent with normal business practices of the Related Party, provided that the Related Party receives no consideration for such samples.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.47.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Non-Royalty Sublicense Income&#8221;</font> means any payments or other consideration that Bayer or any of its Affiliates receives in connection
                with a Sublicense, other than royalties (including percentage payments and fixed per unit amounts) on account of Net Sales by a Sublicensee or an Affiliate of a Sublicensee. If Bayer or its Affiliate receives non-cash consideration (e.g.
                equity, other non-cash assets)<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>in connection with a Sublicense, Non-Royalty Sublicense Income will be calculated based on the [***]. For the avoidance of doubt,
                Bayer is in no way obliged or expected to receive any payments or other consideration from Sublicensees in connection with Companion Diagnostics and that enabling or facilitating the approval and commercialization of Products shall not be
                deemed a non-cash consideration.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.48.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Other Companion Diagnostics&#8221;</font> means any diagnostic product that contains and/or detects a Target Biomarker<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>and is developed specifically for use in conjunction with a [***] that is [***] to inform the selection, initiation, dosing, monitoring, and/or avoidance of treatment with such product
                with the objective that such diagnostic be approved by the relevant Regulatory Authority in the label of such product, regardless of whether such approval is ultimately granted.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.49.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Patents&#8221;</font> means national, regional and international patents and patent applications, including provisional applications, continuations,
                continuations-in-part, continued prosecution applications, divisionals, substitutions, reissues, additions, renewals, re-examinations, extensions, term restorations, confirmations, registrations, revalidations, revisions, priority rights,
                converted provisionals, requests for continued examination and supplementary protection certificates and pediatric drug exclusivity periods granted in relation thereto, as well as utility models, innovation patents, design patents, petty
                patents, patents of addition, inventor&#8217;s certificates, and equivalents in any country or jurisdiction and any similar rights, including pipeline protection, or any importation, or introduction patent to any such foregoing patent
                applications and patents and any and all patents that have issued or in future issue from the foregoing patent applications.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">7</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.50.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Phase 1 Clinical Trial</font>&#8221; means a human clinical trial conducted on a limited number of study subjects for the purpose of gaining
                evidence of the safety and tolerability of, and information regarding, pharmacokinetics and potential pharmacological activity for a product or compound, as described in 21 C.F.R. &#167; 312.21(a) (including any such clinical study in any
                country other than the United States).</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.51.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Phase 2 Clinical Trial&#8221;</font> means a human clinical trial conducted on study subjects with the disease or condition being studied for the
                principal purpose of achieving a preliminary determination of efficacy or appropriate dosage ranges, as further described in 21 C.F.R. &#167;312.21(b) (including any such clinical study in any country other than the United States).</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.52.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Phase 3 Clinical Trial&#8221; </font>means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the
                efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for the filing for approval of a
                BLA by a Regulatory Authority and to provide an adequate basis for physician labeling, as described in 21 C.F.R. &#167;&#160;312.21(c) or the corresponding regulation in jurisdictions other than the United States, regardless of whether such trial is
                labeled by the relevant Related Entity as Phase 3 Clinical Trial.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.53.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Product&#8221; </font>means any therapeutic or prophylactic product containing or comprising a Target Biologic, in any and all forms,
                presentations, formulations and dosage forms that (a) is covered by a claim of a [***] and/or (b) is/was identified, developed and/or generated [***] of [***].<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>The Parties agree that
                in case of dispute, Bayer will have the burden of proof to demonstrate that [***] containing or comprising<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>a Target [***] has been [***] without the use of [***].
                For the avoidance of doubt, the definition of &#8220;Products&#8221; shall not include Product Companion Diagnostics.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">One Product, as opposed to another Product, shall be defined by the [***] and [***] of the [***] the [***] included in the
      Product.&#160;&#160;Two products in which such [***] have different [***] and/or different [***] (other than incidental, unintended differences caused, for instance, from the [***]) from each other shall be two different Products.&#160;&#160;For example, a [***] and an
      [***] are two different [***], and therefore a Product containing or comprising the [***] and a Product [***] would be considered [***] Products.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.54.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Product Companion Diagnostic&#8221; </font>means any diagnostic product that contains and/or detects a Target Biomarker<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>and is developed specifically for use in conjunction with a Product to inform the selection, initiation, dosing, monitoring, and/or avoidance of treatment with such Product with the
                objective that such diagnostic be approved by the relevant Regulatory Authority in the label of such Product, regardless of whether such approval is ultimately granted.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">8</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.55.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Program Know-How&#8221;</font> means any Know-How developed or generated in the performance of the Research Programs and Controlled by Bayer, an
                Affiliate of Bayer, Compugen or an Affiliate of Compugen (including but not limited to [***], and [***] and (to the extent applicable) [***] and [***]).</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.56.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Program Invention&#8221; </font>means any patentable Know-How Controlled by Bayer, an Affiliate of Bayer, Compugen or an Affiliate of Compugen that
                is [***] and/or [***] in the performance of a Research Program.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.57.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Regulatory Authority&#8221; </font>means the FDA or any other supranational, national or local agency, authority, department, inspectorate,
                ministry official, parliament or public or statutory person of any government of any country having jurisdiction over any of the activities contemplated by the Agreement or the Parties, or any successor bodies thereto.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.58.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Related Party&#8221; </font>means any of the following: (a) Bayer; (b) an Affiliate of Bayer; (c) a Sublicensee; or (d) an Affiliate of a
                Sublicensee.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.59.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Research Period&#8221; </font>means, with respect to each Research Program, the period until completion of all obligations under the Research
                Program as set forth in the Workplan for such Research Program.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.60.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Research Program&#8221;</font> means either the CGEN-15001T Research Program or the CGEN-15022 Research Program.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.61.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Sublicense&#8221; </font>means: (a) any license given (including without limitation licenses with respect to Bayer Product Patent Rights and Bayer
                Know-How) by Bayer or an Affiliate of Bayer to any Third Party (or by a Sublicensee to a further Sublicensee)&#160;to develop, manufacture, market and/or sell Products and/or Diagnostics and/or any other licenses granted by Bayer or an Affiliate
                under any of the rights granted to Bayer under this Agreement;<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>and (b) any [***] by [***] to any other person or entity (or by a Sublicensee to a further Sublicensee)&#160;[***] for or
                [***]; in each case regardless of whether such license given is referred to or is described as a license, sublicense or otherwise.&#160;&#160;&#160;&#160;For clarity, &#8220;Sublicense&#8221; does not include (i) any agreements or other grants of rights that fulfill the
                requirements of Section 3.1.2 or (ii) the engagement of a Third Party wholesale distributors who (1) purchase Products from a Related Party in arm&#8217;s length transaction and who have no sales, marketing or reporting obligation to a Related
                Party and (2) do not pay Related Parties any consideration on account of such engagement other than the sales price of the Products and/or Companion Diagnostics sold by the Related Party to such Third Party.&#160;&#160;For clarity, such wholesale
                distributors do not include those distributors whose obligations to a Related Party include responsibility for sales and/or marketing efforts in a country or sharing of costs and expenses with respect to sales and/or marketing on behalf of
                a Related Party or who pay other consideration on account of such engagement, which distributors shall be deemed to be Sublicensees for purposes of this definition.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.62.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Sublicensee&#8221;</font> means any person or entity granted a Sublicense.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.63.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Sublicense Diagnostic Sales Income&#8221; </font>means any payments or other consideration that Bayer or any of its Affiliates receives on account
                of sales of Diagnostics by a Sublicensee.&#160;&#160;If Bayer or any of its Affiliates receives non-cash consideration&#160;&#160;(e.g. equity, other non-cash assets)<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>on account of
                sales of Diagnostics by a Sublicensee, Sublicense Diagnostic Sales Income will be calculated based on [***], at the time of [***], [***]. Bayer informs and Compugen understands and acknowledges that the [***] of [***] to the [***] of [***]
                is to [***] or [***] of [***], and that [***] may [***] or [***] from Sublicensees on account of Sublicensing of [***], in which case Compugen would [***] or [***] from Bayer in relation to the [***] and [***] of [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="font-style: italic; display: inline; font-weight: bold;">&#160;</font></div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">9</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.64.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Target&#8221;</font> means any CGEN-15001T Target and/or any CGEN-15022 Target.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.65.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Target Biologic&#8221; </font>means any Biologic, including but not limited to any [***], or [***], that is [***], except that &#8220;Target Biologic&#8221;
                specifically excludes [***].&#160;&#160;The Parties (a) acknowledge that in [***] not [***] any of [***], a Party or its Affiliate may [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>and/or [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>a Biologic directed [***] another [***] which [***] inadvertently [***] to [***] and (b) agree that such [***] will not be deemed [***] for purposes of this Agreement.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.66.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Target Biomarker&#8221; </font>means (a) any Target<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">,</font> (b) any [***] and
                (c) any [***], or of such [***], that is derived from the [***] of such [***].&#160;&#160;For purposes of this definition, [***] means (i) with respect to a [***], a consecutive portion of the [***] or more [***], and (ii) with respect to [***], a
                consecutive portion of the [***] or more [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.67.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Target Fusion Protein&#8221;</font> means a protein created by the fusion of the extracellular domain of a Target, or fragment thereof, to any
                heterologous sequence (such as an Fc fragment of an Immunoglobulin G).</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.68.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Target Program&#8221; </font>means either the CGEN-15001T Target Program or the CGEN-15022 Target Program.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.69.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Third Party&#8221;</font> means any person or entity other than Bayer, Bayer&#8217;s Affiliates, Compugen and Compugen&#8217;s Affiliates.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.70.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Third Party [***] Payments&#8221; </font>means amounts paid by Bayer to a Third Party as a result of a [***] or [***] for [***] due to [***] were
                [***] in the performance of [***] (for the avoidance of doubt, including [***] of this Agreement).</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.71.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Unrelated Third Party&#8221;</font> means any person or entity that is not a Related Party.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.72.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Use Patent Rights&#8221;</font> means Compugen Patent Rights or Joint Patent Rights that are not Composition Of Matter Patent Rights.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.73.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Valid Claim&#8221; </font>means a claim of an issued and unexpired patent within the Compugen Patent Rights, Joint Patent Rights or Bayer Product
                Patent Rights that has not been (a) held permanently revoked, unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, (b)
                rendered unenforceable through disclaimer or otherwise, (c) abandoned or (d) permanently lost through an interference or opposition proceeding without any right of appeal or review.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">1.74.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Workplan&#8221;</font> means either the CGEN-15001T Workplan or the CGEN-15022 Workplan.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">2.</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">Research Program.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.1.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Purpose and Scope of Work.</font> The Parties are entering into a research and development collaboration for the Research Period, with the
                intent of developing CGEN-15001T Target Biologics and CGEN 15022 Target Biologics that will be candidates for the development of Products and of discovering and developing Target Biomarkers that can be used as research tools for the
                development of Products and/or for the development of Product Companion Diagnostics. Each Workplan sets forth certain activities to be performed by each of the Parties, details regarding each of the Parties&#8217; deliverables and timetables for
                delivery of such deliverables. Each Workplan may be amended by the Joint Steering Committee (as defined below in Section 2.2.1) in accordance with Section 2.2, provided that no such amendment may increase Compugen&#8217;s or Bayer&#8217;s obligations
                under such Workplan unless the Parties have agreed to such increase in writing, including with respect to funding to be provided by Bayer to Compugen to support additional work. To the extent any terms in a Workplan shall at any time
                conflict with the terms of this Agreement, the terms of this Agreement shall prevail.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160;</font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">10</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">2.2.</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">Management.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.2.1.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Establishment of Joint Steering Committee.</font> The Parties hereby establish a Research Program steering committee (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Joint Steering Committee</font>&#8221; or &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">JSC</font>&#8221;) that will be responsible for overall supervision and direction of, and for making decisions
                related to, the Parties&#8217; activities under the Workplans.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.2.2.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Membership</font>. The Joint Steering Committee will be comprised of [***] members, with [***] members appointed by each Party, all of whom
                shall be employees of the appointing Party and shall have appropriate authority to make the decisions assigned to the Joint Steering Committee hereunder.&#160;&#160;In addition, each Party will appoint one associate member (having no voting power in
                the JSC) with the tasks to (i) prepare and manage the JSC meetings, (ii) ensure proper communication and exchange of information between the Parties, (iii) oversee the budget and resources in the Research Programs, (iv) attempt to resolve
                conflicts, and (v) act as a point of contact for external communications (e.g. press releases) and publications taking into account company specific regulations for external communications and publications (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Alliance Manager</font>&#8221;). Each of Bayer and Compugen may replace its Alliance Manager or one or more of its Joint Steering Committee representatives at any time, upon written notice to the other Party.&#160;&#160;From
                time to time, the Joint Steering Committee may establish subcommittees, comprised of an equal number of representatives from each Party (who may be persons other than Joint Steering Committee members), to oversee particular activities.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.2.3.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Responsibilities. </font>The Joint Steering Committee will be responsible for:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(a)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">overseeing the overall progress achieved in each Research Program and directing the Research Program;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(b)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">informing each other on strategic aspects;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(c)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">making and approving go/no-go decisions regarding the attainment of Research Program&#8217;s milestones based on proposals made by the Project Managers (as defined below in Section 2.3.2);</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(d)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">deciding on amendments to or changes of the Workplan(s) (including changes to timelines and actions to be taken), from time to time, as proposed by the Project Managers (as defined below);</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(e)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">agreeing upon contractors to be used by the Parties in performing work under a Workplan in the event that the Project Managers are not able to agree upon such contractors;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">11</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
  </div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(f)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">proposing amendments to this Agreement; and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(g)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">such other matters as the Parties may assign to the Joint Steering Committee from time to time.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.2.4.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Meetings.</font> The Joint Steering Committee shall meet [***], whether in-person or by telephone or video conference as the Joint Steering
                Committee agrees, provided that at least [***] ([***] in Israel or San Francisco, CA and [***] in Germany) shall be held in each calendar year. Members of the Joint Steering Committee may participate in and vote at meetings, in person, by
                telephone or by video-conference, and may vote at meetings by proxy; in addition, the Joint Steering Committee may agree from time to time with unanimous consent to take decisions in writing. Additional employees or consultants of either
                Party may be permitted to attend meetings of the Joint Steering Committee and/or of its sub-committees&#8217; meetings with the consent of the other Party&#8217;s members of the Joint Steering Committee, such consent not to be unreasonably withheld.
                For each such Joint Steering Committee meeting (or sub-committee meeting), whether an in-person meeting or otherwise, either of the Alliance Managers (as agreed prior to the meeting) shall prepare an agenda and written minutes which shall
                document all Joint Steering Committee discussions and decisions in such meeting.&#160;&#160;Draft minutes shall be distributed to the Joint Steering Committee members [***] following the particular Joint Steering Committee meeting, revised as
                necessary, and promptly approved in writing by all Joint Steering Committee members.&#160;&#160;Thereafter, the approved minutes of each Joint Steering Committee meeting shall be distributed to each member.&#160;&#160;Each Party is responsible for the
                travelling costs of its Alliance Manager and its members of the Joint Steering Committee.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.2.5.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Decision-Making.</font> All decisions of the Joint Steering Committee shall be made by unanimous consent. In the event the Joint Steering
                Committee is unable to reach agreement on a matter relating to the activities under a Workplan (a &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Deadlock</font>&#8221;), then either Party may notify the other of the Deadlock in writing, such
                notice to describe the subject of the Deadlock in reasonable detail.&#160;&#160;In such case, the following shall apply:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">2.2.5.1.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Subject to the limitations set forth in Section 2.2.5.2, [***] shall [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>over the Deadlocked matter, such
                authority to be exercised by [***] and notified to [***] within [***] days after delivery of the applicable Deadlock notice. If [***] fails to notify [***] how [***] has elected to [***] on the Deadlocked matter, [***] may take such action
                with respect to the Deadlocked matter as [***] deems appropriate [***]. With respect to matters described in Section 2.2.5.2, for which [***] is not entitled to [***] with respect to any Deadlock, such Deadlock shall be resolved pursuant to
                the provisions of Section 2.2.5.3.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.2.5.2.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] will not have the authority under Section 2.2.5.1 or 2.2.5.4 to [***] make any decision that: (a) [***] or otherwise is [***] any term or provision of this Agreement; (b) [***] or its
                ability to meet its obligations under this Agreement; (c) [***] under a Workplan or [***] the achievability of such [***] in each case in a manner [***]; (d) [***]; (e) would require [***], in a manner material to [***], in the [***] or the
                use of [***] or [***] not currently contemplated in the relevant Workplan; (f) would [***] for which [***] is entitled to make use of [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Protein Controls (as
                defined in [***]); (g) would [***] of the [***]; or (h) [***] either Party&#8217;s [***] obligations under [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">12</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.2.5.3.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">With respect to matters described in Section 2.2.5.2 with respect to which [***] does not have authority under Section 2.2.5.1 to [***] make decisions (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Specific Deadlocked Matters</font>&#8221;), the Parties shall first try to resolve such Specific Deadlocked Matter in a second JSC meeting to be held within [***] Business Days from the meeting in which the Specific
                Deadlocked Matter has remained unsolved. In the event that the JSC is again unable to resolve the Specific Deadlocked Matter, such matter shall be promptly referred to the [***] of Compugen and the [***] of Bayer.&#160;&#160;If said officers cannot
                resolve such Specific Deadlocked Matter through [***] and [***] within [***] calendar days after the date on which the matter is referred to the Parties&#8217; executive officers listed above, the Parties will attempt in [***] to settle the
                Specific Deadlocked Matter by mediation in accordance with the [***] by a [***] mediator with [***] Program. If the Parties [***] on a [***] mediator, the mediator will be appointed by the [***]. The place of the mediation proceedings shall
                be [***], [***], and the language to be used shall be [***]. If the Parties decide to submit the Specific Deadlocked Matter to mediation, [***] shall bear [***] expenses and [***] of all costs and fees of the mediator. If the Parties can
                also not resolve the Specific Deadlocked Matter by mediation in accordance with the [***], the Parties will continue the performance of the Research Program in accordance with the relevant Workplan without any change with respect to the
                Specific Deadlocked Matter for which no agreement was reached.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.2.5.4.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Notwithstanding the above, [***] may, at any time upon one (1) month prior written notice to [***], disband the Joint Steering Committee.&#160;&#160;If [***] provides such notice of disbandment to
                [***], the Parties&#8217; obligations under this Section 2.2 will terminate, unless and until [***] provides written notice to [***] that it wishes to reinstate the Joint Steering Committee, in which case the Parties&#8217; obligations under this
                Section 2.2 will be reinstated for the period following such notice by [***].&#160;&#160;In the event of such disbandment and unless and until the Joint Steering Committee is reinstated, subject to [***], all activities and decisions assigned to the
                Joint Steering Committee as set forth above shall be performed and decided upon by [***] such authority to be exercised by [***] (taking into consideration concerns raised by [***] and the goals of the relevant Research Program).&#160;&#160;During
                the period of disbandment, [***] shall inform Compugen with written notice about proposed decisions [***].&#160;&#160;If [***] provides such written notice, each Party will promptly appoint authorized representatives with the same competencies as the
                members of the Joint Steering Committee to discuss such proposed decisions [***].&#160;&#160;If such representatives are unable to agree on such matter within [***] days of [***]&#8217;s notice to [***], such matter shall be promptly referred to the [***]
                and the [***].&#160;&#160;If said [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>cannot resolve such matter through [***] negotiations within [***] days after the date on which the matter is referred to the Parties&#8217;
                [***] listed above, the Parties will attempt to resolve the matter in accordance with the mediation process described in [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.2.5.5.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Unless earlier disbanded in accordance with [***] or agreed by the Parties otherwise in writing, the Joint Steering Committee will disband within [***] months following the end of the later to
                expire [***]. After such disbandment the Joint Steering Committee may reconvene on an ad-hoc basis solely to discuss [***]. A request by a Party for a Joint Steering Committee meeting shall be given in written form to the other Party with
                [***] notice and shall contain sufficiently detailed information about the requested topic and the required decision by the Joint Steering Committee.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.3.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Performance of Work</font>.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.3.1.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Performance.&#160;&#160;</font>Each of the Parties shall use Commercially Reasonable Efforts to perform the activities designated as its responsibility
                under each Workplan, including delivering deliverables and reports set forth in each Workplan, in accordance with the timetables set forth in such Workplan. <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Each
                Party will provide the [***] needed to perform the activities designated as its responsibility under each Workplan.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">13</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.3.2.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Project Manager.&#160;&#160;</font>The Parties acknowledge that effective communications between Parties is an essential ingredient to the success of the
                Research Programs. In order to facilitate such communications, each Party will designate a person to serve as the project manager on its behalf for purposes of each Research Program (each, a &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Project



                  Manager</font>&#8221;).&#160;&#160;A Party may designate the same person to serve as its Project Manager of both Research Programs or designate two persons to serve as Project Managers, one for each Research Program. Each Party may appoint and replace
                its Project Manager(s) by written notice to the other Party.&#160;&#160;The Project Managers for each Research Program will meet (in person, teleconference or video conference) on a monthly<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>basis,



                or more often as needed, to give each other an update on the results in the Research Program, review the progress of such Research Program and scientific issues relating to such Research Program.&#160;&#160;The Project Managers may with mutual
                agreement include members of their scientific teams in such meetings. The Project Managers will prepare and propose decisions on activities under and amendments of the Workplans, promote the performance of the work under the Research
                Programs and ensure that such work is done as agreed under the Workplans.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.3.3.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Reports.&#160;&#160;</font>Each Party&#8217;s Project Manager for the relevant Research Program shall provide the members of the Joint Steering Committee with
                written updates regarding its Party&#8217;s activities under the Workplan, including summary results and analyses thereof, prior to each JSC meeting.&#160;&#160;In addition, within [***] days after the end of each year of the relevant Research Period and
                at the end of such Research Period, each Party&#8217;s Project Manager will provide the Joint Steering Committee with a written report regarding its Party&#8217;s activities under the Workplan, including protocols, experimental procedures, results,
                analyses thereof and conclusions for the previous [***] month period (or in the case of the report at the end of the Research Period, for the period since the previous written report) in the format and containing the level of detail
                described in <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 2.3.3</font>.&#160;&#160;At the request of a Project Manager, the Project Managers for the relevant Research Program and members of the relevant
                scientific teams will discuss any questions raised by either Party regarding the contents of such reports.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
      <table width="100%" cellspacing="0" cellpadding="0" border="0" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr valign="top">
            <td align="right" style="WIDTH: 36pt">
              <div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.3.4.</font></font></div>
            </td>
            <td align="left">
              <div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Use of Contractors. </font>Each Party may use contractors
                  (including Affiliates) to perform, on its behalf and for its benefit (on a work-for-hire basis), [***] (unless agreed otherwise by the Parties) activities designated as such Party&#8217;s task under the relevant Workplan, provided that any such
                  contractor (except for Affiliates of Bayer used as contractor of Bayer or Affiliates of Compugen used as contractor of Compugen) has been approved in advance by both Project Managers or, if the Project Managers do not reach agreement on
                  the choice of contractors, by the Joint Steering Committee and enters or has entered into an agreement with such Party obligating such contractor to all confidentiality, publication and intellectual property-related provisions of this
                  Agreement, applicable to such Party (subject to exceptions with respect to the publication limitations which may be approved by the Joint Steering Committee on a case-by-case basis).&#160;&#160;Each Party shall be solely responsible for the
                  supervision and direction of contractors performing activities designated as such Party&#8217;s task under such Workplan and shall be solely liable for any damage, injury or harm caused by such contractors. Without limiting the foregoing, the
                  Parties agree that for purposes of the work to be performed by [***], a [***] of [***] in accordance with the stage entitled [***] of the CGEN-15001T Workplan and the stage entitled [***] of the CGEN-15022 Workplan, [***] will be a
                  contractor of Compugen or its Affiliate, regardless of the fact that [***].</font></div>
            </td>
          </tr>

      </table>
    </div>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.3.5.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Compliance.</font>&#160;&#160;Each Party agrees to comply with all laws, governmental regulations and guidelines applicable to the performance of the
                activities that it is responsible for under the relevant Workplan.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">14</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.3.6.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Records.</font>&#160;&#160;Each Party shall prepare and maintain, or cause to be prepared and maintained, complete and accurate written records
                pertaining to its respective activities within each Research Program in sufficient detail and in good scientific manner, which shall be complete and accurate and shall fully and properly reflect the work done and results achieved in the
                performance of its respective activities under the Research Program, and which shall be retained by such Party for at least [***] years after the expiration or termination of this Agreement, or for such longer period as may be required by
                any applicable law. Each Party shall make such records available for inspection by the other Party at all reasonable times, and deliver copies of such records to the other Party at the other Party&#8217;s reasonable request and cost.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.3.7.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Material Transfer</font>.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.3.7.1.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">General.&#160;&#160;</font>From time to time, each of Bayer (or any of its Affiliates) and Compugen (or any of its Affiliates) may transfer biological
                materials to the other for purposes of the Research Programs and the development of Products and Product Companion Diagnostics.&#160;&#160;Each Party understands that biological materials transferred by the other Party or its Affiliates are
                experimental in nature and neither Party makes any representation or warranty, express or implied, as to the identity, ownership, purity, utility, safety or activity of such biological materials.&#160;&#160;Neither Party shall be liable for any loss,
                harm, illness or other damage or injury arising from the other Party&#8217;s or its Affiliate&#8217;s receipt, handling, use or disposal of any such biological materials, except to the extent attributable to the transferring Party&#8217;s or its Affiliate&#8217;s
                own gross negligence or willful misconduct. Further, neither Party makes any representation or warranty that the use of the biological materials transferred by it or its Affiliate will not infringe any Third Party intellectual property
                rights.&#160;&#160;Each Party and its Affiliates shall use the other Party&#8217;s biological materials only for the purposes of performing its obligations or exercising its rights under this Agreement.&#160;&#160;Neither Party shall transfer the other Party&#8217;s
                material to any Third Party, except to contractors or collaborators of such Party for the purposes authorized by this Agreement.&#160;&#160;For the avoidance of doubt, after the Research Program, unless Compugen notifies Bayer of limitations on the
                transfer of any biological materials (other than Target Biologics and/or Target Biomarkers) provided by Compugen that are imposed by agreements Compugen is party to, Bayer is free to share biological materials&#160;&#160;provided by Compugen to Bayer
                (including, inter alia, Target Biologics), other than <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">[***]</font>, with Third Parties solely for the purpose of the research and development
                of Products and/or Product Companion Diagnostics without any reporting obligation to, or requirement of authorization by, Compugen and provided that Bayer remains liable to Compugen with respect to any such use. Each Party will use the
                other Party&#8217;s biological materials in accordance with all applicable laws, regulations and governmental guidelines.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.3.7.2.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***]<font style="DISPLAY: inline; FONT-WEIGHT: bold"> Protein Controls. </font>The Parties agree that the CGEN-15001T Research Program may benefit from the use, as research reagents, of
                certain Compugen proprietary material [***] (&#8220;[***]<font style="DISPLAY: inline; FONT-WEIGHT: bold"> Protein Controls</font>&#8221;) and that the CGEN-15022 Research Program may benefit from the use, as research reagents, of certain Compugen
                proprietary material [***] (&#8220;[***]<font style="DISPLAY: inline; FONT-WEIGHT: bold"> Protein Controls</font>&#8221;).&#160;&#160;Bayer understands that [***] Protein Controls and [***] Protein Controls are part of Compugen therapeutic development programs
                that are not subject to this Agreement (the &#8220;[***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Protein Program</font>&#8221; and the &#8220;[***]<font style="DISPLAY: inline; FONT-WEIGHT: bold"> Protein Program</font>&#8221;, respectively).&#160;&#160;The [***] Protein Program and the [***] Protein Program will each be referred to as a &#8220;[***]<font style="DISPLAY: inline; FONT-WEIGHT: bold"> Protein Program</font>&#8221;.&#160;&#160;The



                Parties contemplate that Compugen will provide Bayer <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>(a) certain [***] Protein Controls for [***] specifically set forth in the CGEN-15001T Workplan or [***]
                otherwise specifically agreed to by [***]; and (b) certain [***] Protein Controls for use in certain activities specifically set forth in the CGEN-15022 Workplan or [***] otherwise specifically agreed to by [***]. The [***] Protein Controls
                and [***] Protein Controls provided by Compugen or its Affiliate to Bayer or its Affiliate shall be referred to as <font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;</font>[***]<font style="DISPLAY: inline; FONT-WEIGHT: bold"> Protein
                  Controls&#8221;</font>. [***] Protein Controls provided by Compugen for purposes of the Workplans, as existing on the Effective Date, will be [***] along with information regarding the [***] and/or other [***] of the [***] Protein
                Controls.&#160;&#160;Compugen shall provide the [***] Protein Controls [***] in the [***] described in the Workplans; such [***] Protein Controls will be [***] form and quality [***]. In addition to the provisions of Section 2.3.7.1, the following
                provisions will apply to use of such [***] Protein Controls provided by Compugen to Bayer:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">15</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(a)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Notwithstanding [***], Bayer shall not be entitled to [***] Protein Controls to any [***], other than [***] of Bayer who are [***] (as described in the next sentence) on behalf of Bayer. Bayer
                and its [***] may use such [***] Protein Controls solely for performance of the [***] or otherwise specifically [***] as tasks involving the use of such [***] Protein Controls.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(b)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Bayer shall not, and shall ensure that its Affiliates, contractors and collaborators shall [***] the [***] or use [***] Confidential Information regarding the [***] and/or other [***] of the
                [***] nor any other [***] regarding the [***] provided by Compugen on a [***] any other [***] incorporating the [***] of a [***], without the prior express written consent of Compugen in each case;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(c)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Bayer shall not, and shall ensure that its Affiliates, contractors and collaborators shall not, [***] to any Third Party results of their use of the [***] Protein Controls, without Compugen&#8217;s
                prior written consent; and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(d)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Bayer shall within reasonable time, but in any case within [***] days, after becoming aware thereof, [***] to Compugen [***] with respect to Target [***] Proteins, their use or their
                production (in each case including, without limitation, [***] thereof), that are conceived and/or reduced to practice by Bayer, its Affiliates, contractors and/or collaborators, [***] Compugen or its Affiliates in the performance of work
                using a [***] Protein Control (&#8220;[***]<font style="DISPLAY: inline; FONT-WEIGHT: bold"> Protein Invention</font>&#8221;). Any such [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Protein Invention, whether made by
                Bayer, any of its Affiliates or any of its contractors or collaborators, solely by Compugen or an Affiliate of Compugen, or jointly by any of the above, shall be [***].&#160;&#160;Bayer and its Affiliates [***], and Bayer shall cause its contractors
                and collaborators [***], any and all of their [***] in and to any and all [***] to Compugen.&#160;&#160;Upon Compugen&#8217;s request and at Compugen&#8217;s expense, Bayer shall [***] and [***] that any relevant Affiliate, contractor and collaborator [***] as
                Compugen deems [***], in its [***], to enable Compugen to [***] with respect to any of the foregoing.&#160;&#160;Bayer will, and shall ensure that its Affiliates, contractors and collaborators will, at Compugen&#8217;s request, provide [***] and [***], as
                [***] to [***]. Bayer is [***] that its Affiliates, contractors and collaborators [***], and [***] by its Affiliates of, the provisions of this Section 2.3.7.2(d). Bayer shall ensure<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>that



                its contractors and collaborators are [***] of this Section 2.3.7.2(d) by [***] to which Compugen is [***], prior to [***] to [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Protein Controls or any Compugen
                Confidential Information related to Target [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Proteins.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">16</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="display: block; text-indent: 45pt;"><font style="display: inline;">For the avoidance of doubt, this clause does not limit in any way Bayer&#8217;s and its Affiliates&#8217; right to conduct independent activities that an unaffiliated
      third party would also be allowed to perform using Target [***]<font style="font-style: italic; display: inline; font-weight: bold;">&#160;</font>Proteins (e.g. based on publications) without the use of or reference to Compugen Confidential Information;
      for the avoidance of doubt, (a) Compugen [***] with respect to the results of any such independent activities and (b) [***] is granted by Compugen by implication, estoppel or otherwise with respect to [***] Proteins under any Patents Controlled by
      Compugen or any of its Affiliates (both except for the right to use [***] Protein Controls pursuant to the terms of the previous paragraph).</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.3.7.3.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Use of Target Biologics in Compugen&#8217;s </font>[***]<font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">Protein Programs. </font>The Parties agree that Compugen&#8217;s [***] as part of its [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>may benefit from the use, as research reagents, of
                certain CGEN-15001T Target Biologics [***] and that Compugen&#8217;s [***] as part of its [***] may benefit from the use, as research reagents, of certain CGEN-15022 Target Biologics [***].&#160;&#160;The Parties further agree that uses by Compugen of such
                Target Biologics must be restricted to prevent any adverse effect of such uses on the [***] of [***] and/or [***] and, in particular, the intellectual property rights in relation thereto. As a result, the Parties agree that [***], in
                accordance with the procedure set forth in Section 2.3.7.3.3, certain of such Target Biologics [***] of the Research Programs which Compugen will be entitled to use subject to [***]. The CGEN-15001T Target Biologics and the CGEN-15022
                Target Biologics that are [***] in accordance with Section 2.3.7.3.3 will be referred to as [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.3.7.3.1.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Allowed uses of Target Biologics [***]:</font> Compugen may use Target Biologics Controls only for [***].&#160;&#160;No [***] shall be allowed to be
                performed by Compugen using Target Biologic [***], unless [***] agrees on any [***] in advance.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.3.7.3.2.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Transfer to third parties:</font> Subject to sentence 2 of this Section 2.3.7.3.2, Compugen is entitled to provide Target Biologic [***] and
                data relating to such Target Biologic [***] to its Affiliates, contractors and collaborators, solely to [***] within the [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Protein Programs and with no right of
                such Affiliates, contractors and collaborators [***] the Target Biologic [***] or [***] to any further third parties; provided that Compugen ensures that any [***] relating to [***] and that Compugen imposes on such third parties
                obligations with regard to [***] than those agreed between Bayer and Compugen, including, without limitation that third parties [***] relating to such Target Biologic [***] &#8211; other than [***] specified in <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 2.3.7.3.2</font>&#8211; prior to the [***] with respect to such Target Biologic [***] by the Parties (i.e. [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>months



                after filing date), without Compugen first obtaining the [***]. In any event (including in connection with any publication of the data specified in Exhibit 2.3.7.3.2) Compugen will not make, and will ensure that third parties to which
                Compugen discloses data relating to Target Biologic [***] will not make, [***], with the exceptions that Compugen does not have to prevent such third parties from making [***] (i) solely vis-&#224;-vis Compugen within the relevant [***] Protein
                Program on a [***] basis or (ii) solely based on data that is&#160;&#160;[***], or data relating to Target Biologic Controls, provided by Compugen to such third party pursuant to sentence 1 of this Section 2.3.7.3.2. Compugen may only provide Target
                Biologic [***] to its Third Party contractors and/or collaborators if (a) such [***] have been [***] not to have [***] or (b) such [***] have been [***] to have [***], but a [***] such [***].&#160;&#160;Compugen shall be liable for any non-compliance
                of its contractors and collaborators with the obligations under this Section 2.3.7.3.2. Compugen shall ensure<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>that its contractors and collaborators are bound by the provisions of this
                Section 2.3.7.3.2 by agreements pursuant to which Bayer is named as a third party beneficiary, [***] to Target Biologic [***] or any Bayer Confidential Information related to Target Biologic [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">17</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.3.7.3.3.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Selection of Target Biologic [***]:</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 2.3.7.3.3</font>
                sets forth the criteria that a particular Target Biologic developed in the performance of a [***] needs to fulfill in order to be chosen as a [***] and the timing and procedure for such selection by [***].&#160;&#160;The Parties, through the [***],
                shall [***] suitable CGEN-15001T Target Biologics or CGEN-15022 Target Biologics to serve as Target Biologic [***]. Both Parties agree that for the selection of appropriate Target Biologics [***] for Compugen&#8217;s [***] Protein Programs [***]
                for the Target Biologics to [***] for the [***] as determined by the [***] It is understood that in no instance shall any CGEN-15001T Target Biologic or CGEN-15021 Target Biologic that is a [***] or that has, in [***], the [***] as a [***];
                provided however, that [***] as a [***], such [***] shall remain a [***] unless [***].&#160;&#160;Once any Target Biologics are chosen as Target Biologic [***], Compugen will be entitled to use the [***] such [***] in order to [***] such [***] for
                [***] in accordance with the provisions of [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.3.7.3.4.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Additional provisions on Target Biologic [***]:</font> In addition to the provisions of Section 2.3.7.1, the following provisions will apply to
                use of Target Biologic [***]:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 48pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(a)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Compugen shall only be allowed to [***] Target Biologic [***] and TBC Producing Cells [***] according to this Section 2.3.7.3 during the duration of [***].&#160;&#160;For clarity, Compugen will be [***]
                Target Biologic [***] and TBC Producing Cells in accordance with the provisions of Section 2.3.7.3, and to [***] Target Biologic [***] for such use, after [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 48pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(b)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Compugen shall not, and shall ensure that its Affiliates, contractors and collaborators shall not, [***] the Target Biologic [***] and TBC Producing Cells, except that Compugen and its
                Affiliates, contractors and collaborators may [***] for the purpose of [***] (e.g. [***] with [***] to allow [***] in certain [***]).<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>For clarity, any such
                modifications shall be deemed [***] and will be subject to the terms of this Section 2.3.7.3;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 48pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(c)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Compugen shall within reasonable time, but in any case within [***] days after becoming aware thereof, [***] to Bayer any and all [***] with respect to Target Biologics, their [***] or their
                [***] (in each case including, without limitation, [***] thereof), that are [***] by Compugen, its Affiliates, contractors and/or collaborators, alone or jointly with one another or with Bayer or its Affiliate in the performance of the work
                using a Target Biologic Control [***]. Any such [***], whether made solely by Compugen or any of its Affiliates or contractors or collaborators, solely by Bayer or a Related Party, or jointly by any of the above, shall be [***] and be [***]
                in Section [***] and [***] to [***].&#160;&#160;In the case of a [***] by a [***] or [***], Compugen shall ensure that such inventions are [***] to Compugen such that they will also be [***].&#160;&#160;Compugen will, at Bayer&#8217;s request, provide all necessary
                [***] and cooperate with Bayer, as reasonably required to [***]. Compugen is responsible for ensuring that its Affiliates, contractors and collaborators [***], and shall [***] by its Affiliates of, the provisions of this Section
                2.3.7.3.4(c).&#160;&#160;Compugen shall ensure<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>that its contractors and collaborators are bound by the provisions of this Section 2.3.7.3.4 by agreements pursuant to which Bayer is named as a
                third party beneficiary, prior to obtaining access to Target Biologics [***] or any Bayer Confidential Information related to Target Biologics [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">18</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.3.8.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Data Transfer.</font>&#160;&#160;The Parties agree that (a) the Research Programs may benefit from Know-How with respect to the [***] of Targets that
                Compugen has [***] in the [***] with respect to its [***] Protein Programs (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***] Program Target Know-How</font>&#8221;) and (b) Compugen&#8217;s [***] respect to the [***] Protein Programs [***] from
                Program Know-How relating to the [***] of Targets<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>(&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Research Program Target Know-How</font>&#8221;). The Parties agree (i) that Bayer may use
                the [***] Program Target Know-How [***] and (ii) that, other than for purposes of the Target Programs, Compugen may use such Research Program Target Know-How [***] its [***] Protein Programs.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.3.9.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Funding.</font> Subject to Section 2.4, each Party shall bear its own costs and expenses incurred in the performance of the activities to be
                performed by it under the Workplans.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">2.4.</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">Revisions or Expansions to Workplans.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.4.1.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Any revision or expansion to a Workplan that may be requested by either of the Parties during the relevant Research Period shall be discussed by the Joint Steering Committee. This includes,
                without limitation, discussions regarding the effect any such requested revision or expansion will have on the deliverables (including timing) to be provided under the relevant Workplan, the allocation of [***] resources for performance of
                [***] under the relevant Research Program, and appropriate funding to be provided by [***] to support additional work to be performed by [***] and not contemplated under the then actual Workplan.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.4.2.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">If the Joint Steering Committee determines that a Party&#8217;s request refers to matters that do not materially change the relevant Workplan (such as [***]) and such changes do not impact the [***]
                to such activity, the Joint Steering Committee shall have the authority to amend the relevant Workplan per such Party&#8217;s request, and such amendment shall be incorporated into the relevant Workplan by reference.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.4.3.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">If the [***] determines that the request refers to matters that materially change the relevant Workplan, or that such changes impact the [***] to such activity, the Steering Committee shall
                prepare and present to the Parties&#8217; authorized personnel a detailed written proposal for such revision or expansion to the relevant Workplan.&#160;&#160;If such proposal is approved by authorized personnel of each of the Parties, it shall be
                incorporated into an amendment to this Agreement and an amendment to the relevant Workplan, and will be signed by the Parties.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2.5.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Target </font>[***]<font style="DISPLAY: inline; FONT-WEIGHT: bold">.&#160;&#160;</font>If, with respect to a Research Program, the Parties [***], as
                set forth in the Workplan for such Research Program (despite also Bayer using [***] to perform its part of the Research Program for such Workplan), and Bayer terminates this Agreement with respect to the relevant Target Program in
                accordance with Section 14.3, at the request of either Party, the Parties will discuss in good faith the [***] of such [***] to be [***] (including a [***] and [***]); provided that there may be [***] for each [***].&#160;&#160;Any such other [***]
                would be [***] from [***].&#160;&#160;If the Parties agree on such a [***], including a [***] and [***] to be provided by [***] to support such [***], this Agreement will be amended accordingly and (a) if the [***] is the [***], to [***] the [***]
                with such [***], to [***] the [***] and [***] with references to the [***] in such [***] or (b) if the [***] is the [***], to [***] the [***] with such [***], to [***] the definitions of [***] and [***] with [***] to the [***] in such [***]
                Compugen [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">19</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;Licenses.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">3.1.</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">By Compugen to Bayer.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">3.1.1.</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">Exclusive Licenses.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">3.1.1.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Target Biologics. </font>Subject to the terms and conditions set forth in this Agreement, Compugen hereby grants to Bayer an exclusive (even
                as to Compugen, except as set forth in Section 3.1.1.4), worldwide, royalty-bearing license, with the right to grant sublicenses (subject to Section 3.1.3), under the Compugen Intellectual Property and Compugen&#8217;s interest in Joint
                Intellectual Property, solely to do or have done further research on and or with Target Biologics in the Field.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">3.1.1.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Products.</font> Subject to the terms and conditions set forth in this Agreement, Compugen hereby grants to Bayer an exclusive (even as to
                Compugen, except as set forth in Section 3.1.1.4), worldwide, royalty-bearing license, with the right to grant sublicenses (subject to Section 3.1.3), under the Compugen Intellectual Property and Compugen&#8217;s interest in Joint Intellectual
                Property, solely to develop, have developed, make, have made and use and have used Target Biologics solely in order to do or have done research on, develop, have developed, make, have made, use, have used, sell, have sold, offer for sale,
                have offered for sale and import and have imported Products for use in the Field. For clarity, no rights are granted by Compugen with respect to Target Biologics for any other uses.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">3.1.1.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Target Biomarkers</font>. Subject to the terms and conditions set forth in this Agreement, Compugen hereby grants to Bayer an exclusive (even
                as to Compugen, except as set forth in Sections 3.1.1.4 and 3.3), worldwide, royalty-bearing license, with the right to grant sublicenses (subject to Section 3.1.3), under the Compugen Intellectual Property and Compugen&#8217;s interest in Joint
                Intellectual Property solely to do or have done further research on, develop, have developed, make, have made, use, have used Target Biomarkers solely:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 39pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">(a)&#160;&#160;for therapeutics research and development purposes; and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 39pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">(b) subject to Section 3.1.1.4, to do or have done research on, develop, have developed, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale and import and
                have imported Diagnostics.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">3.1.1.4</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Exceptions.&#160;&#160;</font>Notwithstanding the licenses set forth above, Compugen reserves the following rights:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">(i)</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">on behalf of itself, its Affiliates and its contractors approved in accordance with Section 2.3.4 the right to use and practice the Compugen Intellectual Property and Joint Intellectual
                Property within the scope of the license granted in Sections 3.1.1.1, 3.1.1.2 and 3.1.1.3 to perform its activities under the Research Programs (for clarity, including the right to license such Affiliates and contractors approved in
                accordance with Section 2.3.4 under Joint Intellectual Property to do the same);</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">20</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 44pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">(ii)</font></div>
          </td>
          <td>
            <div align="justify">
              <div align="justify"><font style="display: inline;"><font style="display: inline;">on behalf of itself and its Affiliates, contractors and collaborators, the right to use and practice the Compugen Intellectual Property and Joint Intellectual
                    Property to [***] solely to [***] with [***], including without limitation for the [***] (for clarity, including the right to [***]), <font style="FONT-STYLE: italic; DISPLAY: inline; TEXT-DECORATION: underline">provided that</font>
                    Compugen will [***] on [***] and thereafter up until the earlier of (1) [***] with respect to a [***] from the [***] and (2) [***] years following the Effective Date, [***] provide Bayer with the following information: (x) whether [***]
                    for [***], (y) [***] of [***], and (z) to the extent that the [***] of the [***] to [***] of [***] and/or that the [***] have [***], [***], (for example: based on [***], and [***]) as a [***] of the [***] of such [***] and, upon request
                    of Bayer, further [***] including [***] of [***]; and</font></font></div>
            </div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 44pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">(iii)</font></div>
          </td>
          <td>
            <div align="justify">
              <div align="justify"><font style="display: inline;"><font style="display: inline;">on behalf of itself and its Affiliates, contractors and collaborators, the right to use and practice the Compugen Intellectual Property and Joint Intellectual
                    Property to [***] or have [***] for [***] purposes solely to support [***] and [***] of [***] (for clarity, including the right to [***]),<font style="FONT-STYLE: italic; DISPLAY: inline; TEXT-DECORATION: underline"> provided that</font>
                    if and to the extent that those studies [***] that the [***] have [***] (in Compugen&#8217;s [***]) as a [***], Compugen will [***] on [***] and thereafter up until the earlier of (1) [***] and (2) [***] years following the Effective Date,
                    [***] provide Bayer with a detailed description of the [***] of the [***] that [***] and, upon request of Bayer, with further [***] including [***].</font></font></div>
            </div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: -2.5pt"><font style="display: inline;">In addition, Bayer undertakes that it shall not, and to ensure that its Affiliates will not, [***] to use [***] to
      [***].</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">3.1.1.5</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">For the avoidance of doubt, the licenses granted above do not limit in any way the Parties&#8217; and their Affiliates&#8217; right to conduct independent activities that a Third Party would also be
                allowed to perform (e.g. based on publications or Target Biologics obtained from a Third Party who did not make use of Compugen Intellectual Property nor of Joint Intellectual Property in developing or making such Target Biologics).</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">3.1.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Affiliates and Contractors. </font>The licenses granted to Bayer under Section 3.1.1 include the right to have some or all of Bayer&#8217;s rights
                under Section 3.1.1 exercised or performed by one or more of Bayer&#8217;s Affiliates on Bayer&#8217;s behalf and/or by one or more contractors on Bayer&#8217;s behalf or on behalf of an Affiliate of Bayer without such right being deemed a Sublicense;
                provided however that:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">3.1.2.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">with respect to contractors of Bayer or of an Affiliate of Bayer, no such contractor or Affiliate shall be entitled to grant, directly or indirectly, to any Third Party any right of whatever
                nature under, or with respect to, or permitting any use or exploitation of, any of the Compugen Intellectual Property or Joint Intellectual Property, including any right to develop, manufacture, market or sell Products or Diagnostics; and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">3.1.2.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">any act or omission taken or made by an Affiliate or contractor of Bayer or by a contractor of an Affiliate of Bayer under this Agreement will be deemed an act or omission by Bayer under this
                Agreement.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">3.1.3</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">Sublicenses.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">3.1.3.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Sublicense Grant. </font>Bayer will be entitled to grant Sublicenses to third parties subject to the terms of this Section 3.1.3; provided
                that with respect to the development of Products under a Target Program, Bayer may only grant a Sublicense to a [***] that (a) in Bayer&#8217;s [***] has the [***] to [***] in accordance with the [***], and (b) is, in Bayer&#8217;s [***] and [***] all
                [***] obligations of Bayer under this Agreement.&#160;&#160;Any such Sublicense shall be on terms and conditions in compliance with and not inconsistent with the terms of this Agreement.&#160;&#160;Bayer may grant Sublicenses only pursuant to written
                agreements, which will be subject and subordinate to the terms and conditions of this Agreement.&#160;&#160;Such Sublicense agreements will contain, among other things, the following:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">21</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 34pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(a)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">all [***] to [***] to [***] under this Agreement;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 34pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(b)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">if the [***], a provision stating that<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>[***]with, and [***], including without limitation those relating to the [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="display: block; text-indent: 36pt;"><font style="display: inline;">In addition, in negotiating Sublicense agreements, Bayer will use good faith efforts to include in such Sublicense agreement a provision enabling Bayer to
      terminate such Sublicense agreement if the Sublicensee or an Affiliate of the Sublicensee commences an action in which it challenges the validity, enforceability or scope of any of the Compugen Patent Rights, provided that (in light of possible
      changes in applicable [***] law) Bayer will be [***] if and to the extent, in Bayer&#8217;s [***], there is a risk that such a [***] would [***] then applicable [***] law.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">3.1.3.2 </font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Delivery of Sublicense Agreement. </font>Bayer shall furnish Compugen with a fully executed copy of any Sublicense agreement and any amendment
                to a Sublicense agreement, promptly after its execution.&#160;&#160;Bayer may redact such copies to the extent necessary to preserve the confidentiality of proprietary information that is not relevant to Compugen&#8217;s rights or Bayer&#8217;s obligations under
                this Agreement, provided that sufficient information remains unredacted to allow Compugen to assess whether Bayer is in compliance with its obligations under this Agreement and to verify amounts owed to Compugen in connection with such
                Sublicense.&#160;&#160;Compugen shall keep all such copies of such agreements in its confidential files and shall use them solely for the purpose of monitoring Bayer&#8217;s and Sublicensees&#8217; compliance with their obligations hereunder and enforcing
                Compugen&#8217;s rights under this Agreement.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">3.1.3.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Breach by Sublicensee.</font>&#160;In the case of any act or omission by any Sublicensee of Bayer that would have constituted a material breach of
                this Agreement by Bayer entitling Compugen to terminate this Agreement in accordance with Section 14.3.3 had it been the act or omission of Bayer hereunder, (a) Bayer will take reasonable steps to cause such material breach to be cured (if
                curable) in a timely manner or (b) if such material breach cannot be cured in a timely manner, Bayer will notify Compugen of such material breach promptly after Bayer, cumulatively, becomes aware of the relevant act or omission of the
                Sublicensee and understands both that such act or omission constitutes a material breach and that such material breach is not curable, and [***] will [***] the appropriate measures to be taken, which may include termination of the
                Sublicense.&#160;&#160;Compugen will not have the right to terminate this Agreement on account of such material breach by such Sublicensee, if (i) such breach is cured in a reasonable time period or (ii) Bayer discusses with Compugen possible courses
                of action, and terminates such Sublicense agreement based on a right to terminate the Sublicense agreement (which Bayer undertakes to include in the Sublicense agreement) if such material breach is not cured within [***] days and Compugen
                requests Bayer to terminate the Sublicense agreement due to such failure to cure the material breach.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">22</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div>
      <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">3.1.4</font></div>
            </td>
            <td>
              <div align="justify"><font style="display: inline; font-weight: bold;">Technology Transfer.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
  </div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 44pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">3.1.4.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Within [***] weeks of the Effective Date, Compugen shall, [***], deliver to Bayer or its designated Affiliate or Sublicensee, in whatever form Bayer may reasonably request, true and complete
                copies of all written, graphic or electronic embodiments of the Compugen Intellectual Property. Thereafter, on a continuing basis during the term of the Agreement, Compugen shall, without [***], and shall cause its Affiliates to, [***]
                after Compugen both (a) becomes aware of any additional Compugen Intellectual Property and (b) understands that the relevant Know How is Compugen Intellectual Property,&#160;&#160;disclose and deliver to Bayer or its designated Affiliate or
                Sublicensee, in whatever form Bayer may reasonably request, true and complete copies of all written, graphic or electronic embodiments of all additional Compugen Intellectual Property which comes into existence from time to time. For
                clarity, the transfer obligation under this Section 3.1.4 excludes information specifically relating [***] and/or [***] Proteins (other than the information provided under [***]).</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 44pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">3.1.4.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Without prejudice to the generality of Section&#160;3.1.4.1, during the term<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>of the Agreement, Compugen shall, without
                [***], provide Bayer or its designated Affiliate or Sublicensee with reasonable technical assistance relating to the use of the Compugen Intellectual Property for the purposes of Related Party&#8217;s acquisition of expertise on the practical
                application of the Compugen Intellectual Property or for the provision of assistance to the applicable Related Party on issues arising during exploitation of the Compugen Intellectual Property. If visits of Compugen representatives to the
                facilities of the applicable Related Party are reasonably requested, Compugen shall send appropriate representatives to such facilities, provided that Bayer shall [***] for its [***] and [***] for such [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">3.2</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">By Bayer to Compugen.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="text-indent: 36pt;"><font style="display: inline;">Subject to the terms and conditions set forth in this Agreement, Bayer hereby grants Compugen a worldwide, fully-paid up, royalty-free, non-exclusive, not sub-licensable
      (other than to Compugen Affiliates and contractors approved in accordance with Section 2.3.4) license under (i) Program Know-How and Program Inventions owned by Bayer in accordance with Section 8.1.2.1, (ii) Bayer&#8217;s interest in Joint Intellectual
      Property and (iii) under other Know How provided by Bayer to Compugen for purposes of performance of the Research Programs, limited to the Research Period, solely for the purpose of performing Compugen&#8217;s activities under the Workplans.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">3.3</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;"><font style="display: inline;">Availability for Compugen.</font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 44pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(a)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Bayer hereby undertakes to use good faith efforts to ensure that with respect to Companion Diagnostics, Compugen and its Affiliates, collaborators and licensees will have access, under terms
                [***] (or in the event [***]), to the [***] (i.e. [***]). If Bayer is [***] Compugen, its Affiliates, collaborators and/or licensees, [***].&#160;&#160;In such case, Compugen, its Affiliates, collaborators and/or licensees (as the case may be) may
                [***] an Affiliate, collaborator or licensee [***] and will perform [***] under which Compugen, its Affiliates, collaborators and/or licensees (as the case may be) [***], under terms [***]. If, cumulatively, (i) [***] between [***] (as the
                case may be) and [***] developing [***] do not [***] within [***] of the date Compugen, its Affiliates, collaborators and/or licensees (as the case may be) [***] and (ii) Compugen, its Affiliates, collaborators and/or licensees (as the case
                may be) and [***] are [***] with respect to a [***],<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>notwithstanding the [***], Compugen and its Affiliates will have the [***] and [***] and [***] (including the
                right to [***]) solely to do or have done [***] on, [***], have [***], have [***] (i.e.&#160;&#160;a [***]).</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">23</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 44pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(b)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">If Compugen or its Affiliate wishes to [***] (for the avoidance of doubt, on [***] basis) as a commercial product (for Compugen and/or for a licensee of Compugen) a Target Biomarker for [***]
                (e.g. [***]) than the one [***] (or if [***]), the procedure will be as follows: [***] of its interest [***], and shall [***] of such a product [***]. Bayer may [***] or [***], at that time, [***] or [***] the [***]. If, following a [***]
                of [***], [***] does not (i) enter into [***] in relation to [***] refers to within [***] after this [***] (or, if [***] after [***]), or (ii) [***] with its [***] in relation to the [***] that the [***], which period will be extended by an
                additional [***] month period if Bayer and its [***]), Bayer will be [***]. If, from the date when [***], neither [***] (i) [***] with a [***] within [***] or (ii) [***] with [***] in relation to the [***] of a [***] within a period of
                [***] which will be extended by an additional [***] period if [***] (or its licensee, as applicable) and [***] are still in [***], [***] of the [***] of a [***] will be [***]. For the avoidance of doubt, if, after [***], Compugen again
                becomes [***], the process described in this Section 3.3 (b) will [***]. If, following [***], [***], its Affiliate or its licensee thereafter [***] with a [***] use [***] to ensure that [***] to such assay [***] than those agreed upon
                between [***] (or its Affiliate or licensee) and its contract partner (or in the event [***] its Affiliate or licensee develops such an assay, on reasonable terms).</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">3.4</font></font></div>
          </td>
          <td>
            <div align="left"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">No Other License or Grant of Rights.</font> Except as expressly provided in this Agreement, nothing in this Agreement shall be construed to confer
                any ownership interest, license or other rights upon a Party by implication, estoppel or otherwise as to any technology, intellectual property rights, products or biological materials of another Party or any other entity.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">4.</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">Exclusivity</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">During the Research Period of each Research Program, neither Party shall use a Target of such Research Program to [***] relating to Target Biologics directed against such Target, other than
                under such Research Program or as otherwise permitted under this Agreement (including without any limitations Sections 2.3.7.3 and 3.1.1.4). If either Party becomes aware that as a result of [***] in [***] that are not [***] that are
                directed at the [***], using [***], result in the [***], such Party, unless it is prohibited from doing so due to an obligation of confidentiality to a licensee of such Biologic(s), will promptly inform the other Party and both Parties will
                [***] to keep the Research Program and the project under which such [***] separate.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">5.</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">Development and Commercialization Diligence.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">5.1.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">General</font>.<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>With respect to each Target Program, Bayer shall use Commercially
                Reasonable Efforts [***] to develop and obtain Marketing Authorization for [***] Product from such Target Program and to commercialize such Product in each of the following major markets: [***] the [***] at least [***] of the [***] in the
                [***]; and [***] of [***] and [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">5.2.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Bayer Development Process</font>.<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>With respect to each Target Program, Bayer will at
                [***] inform Compugen about the [***] to r[***], made by the [***] in a manner consistent with [***] to [***], to enable [***] of the [***] comply with [***] to [***] to [***].&#160;&#160;Bayer will also [***] provide Compugen with [***] and about
                any [***] and/or [***].&#160;&#160;Bayer will [***] to meet the [***] of the next decision point set by the relevant committee. For the avoidance of doubt, any failure of Bayer to reach a new decision point within a specific timeline (including any
                timelines set by the relevant Bayer internal committee) does not in itself give rise to any right of Compugen to terminate the relevant Target Program, unless Bayer did not [***] to [***]. The effects of any termination of the relevant
                Target Program by Compugen against Bayer due to violation of diligence obligations will be limited to a right to terminate the relevant Target Program with the effects specified in Section 14.4 and with any other rights specifically on
                account of such violation of diligence obligations (such as damages, specific performance etc.) being excluded.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">24</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">5.3.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">[***] Report</font>.<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Within [***] days after the end of each [***] period ending June
                30th or December 31st, as applicable, during the term from completion of the relevant Research Program until termination or expiration of the relevant Target Program, Bayer shall furnish Compugen with a written report setting forth for each
                Target Program, its and other Related Parties&#8217; efforts during the prior [***] period to develop and commercialize Products for such Target Program, including without limitation: (a) [***] (including without limitation [***] described in
                Section [***]); (b) [***]; and (c) [***]. The report shall also contain a discussion [***] for the then current [***] period.&#160;&#160;In addition, if Bayer has made changes or foresees changes to the [***] and [***] pursuant to Section 5.2, Bayer
                shall include in such a report the revised or contemplated [***] and a [***].&#160;&#160;Each report shall be broken down by [***] within each Target Program and must contain a sufficient level of detail for Compugen to assess whether Bayer is in
                compliance with its obligations under Section 5.1 with respect to the relevant Target Program, however, it being understood that the [***] of Bayer&#8217;s reporting obligation to Compugen shall not [***]. Within [***] days after the delivery of
                each such report, the Joint Review Committee (as defined below) will meet to review with Bayer the contents of such report and the progress of Bayer&#8217;s efforts to meet its obligations under this Section 5.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">5.4.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Joint Review Committee</font>.<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>After the end of the first Research Program, the Parties
                will establish a joint review committee (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Joint Review Committee</font>&#8221;) comprised of an equal number of representatives from each Party. Each Party may change its representatives to the
                Joint Review Committee from time to time, in its sole discretion, effective upon notice to the other Party of such change.&#160;&#160;The representatives shall have appropriate technical credentials, experience and knowledge relevant to the
                development and commercialization of Products. The Joint Review Committee will [***] in [***] under the other provisions of [***].&#160;&#160;Additional representatives of a Party may be invited, from time to time by mutual consent of the Parties, to
                attend Joint Review Committee meetings.&#160;&#160;[***] with the Joint Review Committee; however, Bayer will [***] to the Joint Review Committee by Compugen.&#160;&#160;The Joint Review Committee will meet at least [***] (following the receipt of reports as
                set forth in Section 5.3) at such dates, times and locations as may be determined by the Joint Review Committee with unanimous consent. Alternatively, the Joint Review Committee may meet by means of teleconference, videoconference or other
                similar communications equipment.&#160;&#160;[***] will [***][***] associated with [***] participation on the Joint Review Committee.&#160;&#160;[***] may, at any time upon written notice to [***] disband the Joint Review Committee.&#160;&#160;If [***] provides such
                notice of disbandment to [***], the Parties&#8217; obligations under this Section 5.4 will terminate, unless and until [***] provides written notice to Bayer that it wishes to reinstate the Joint Review Committee, in which case the Parties&#8217;
                obligations under this Section 5.4 will be reinstated for the period following such notice by [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td align="right" style="WIDTH: 36pt">
            <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">6.&#160;</font></div>
          </td>
          <td align="left">
            <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">Consideration.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.1.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Upfront License Issuance Fee.</font>&#160;&#160;For the licenses granted to Bayer under Section 3.1.1, Bayer shall pay Compugen a non-refundable license
                issuance fee of ten Million US Dollar ($10,000,000), which Compugen is entitled to invoice upon the Effective Date.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">25</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">6.2.</font></div>
          </td>
          <td style="text-align: center;">
            <div style="text-align: left;"><font style="display: inline; font-weight: bold;">Milestone Payments.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">First Product Milestones. </font>With respect to each Target Program,<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Bayer shall pay
                Compugen the following milestone payments with respect to [***] Product [***] a Target Biologic from such Target Program (i.e. a CGEN-15001T Target Biologic in the case of the CGEN-15001T Target Program and a CGEN-15022 Target Biologic in
                the case of the CGEN-15022 Target Program) to reach such milestone, regardless of whether such milestone is achieved by Bayer or another Related Party:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] US Dollars ($[***]) upon the achievement of [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***], US Dollars ($[***]) upon the [***] of [***] as a [***]);</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] US Dollars ($[***]) upon [***] such a Product [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1.4</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] Thousand US Dollars ($[***]) upon the [***] with such a Product in a [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1.5</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] US Dollars ($[***]) upon the [***] with such a Product in a [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1.6</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] US Dollars ($[***]) upon the [***] with such a Product [***] for a [***] with such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1.7</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] US Dollars ($[***]) upon the [***] with such a Product [***] with such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1.8</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] US Dollars ($[***]) upon the [***] with respect to such a Product with a [***], [***] or [***]; for the avoidance of doubt, this milestone, [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1.9</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] US Dollars ($[***]) upon the [***] in the [***] with respect to the [***] for such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 43pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1.10</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">&#160;[***] US Dollars ($[***]) upon the [***] in the [***] with respect to the [***] for such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1.11</font></font></div>
          </td>
          <td>
            <div align="left"><font style="display: inline;">[***] US Dollars ($[***]) upon the [***] in [***] with respect to the [***] for such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div>&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1.12 </font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">&#160;[***] US Dollars ($[***]) upon [***] in the [***] with respect to the [***] for such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1.13 </font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">&#160;[***] US Dollars ($[***]) upon the [***] in the [***] with respect to the [***] for such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1.14</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>[***] US Dollars ($[***]) upon the [***] in [***] with respect to the [***] for such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1.15</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>[***] US Dollars ($[***]) upon the [***] in the [***] with respect to the [***] for such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1.16</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>[***] US Dollars ($[***]) upon the [***] in the [***] with respect to the [***] for such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1.17 </font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">&#160;[***] US Dollars ($[***]) upon the [***] in [***] with respect to the [***] for such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">26</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1.18 </font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] US Dollars ($[***]) in the [***] in which [***] for such a Product within such [***] reach [***] US Dollars ($[***]); such amount will be due [***] for the Calendar Quarter in which
                [***] for such Product in such [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1.19 </font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***]<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>US Dollars ($[***]) in the [***] in which [***] for such a Product within such [***] reach [***] US Dollars ($[***]); such amount
                will be due [***] for the Calendar Quarter in which [***] for such Product in such [***]; and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.1.20</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>[***]<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>US Dollars ($[***]) in the [***] in which [***] for such a Product within
                such calendar year reach [***] US Dollars ($[***]); such amount will be due together with the payments on royalties in accordance with Section 7.1 for the Calendar Quarter in which [***] for such Product in such [***] reach such milestone.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***]<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;Product Milestones.&#160;&#160;</font>With respect to each Target Program,<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Bayer shall pay
                Compugen the following milestone payments with respect to the [***] Product containing a Target Biologic from such Target Program to reach such milestone, regardless of whether such milestone is achieved by Bayer or another Related Party,
                provided that such [***] milestone payments shall not be paid if (a) [***], all [***] (&#8220;[***] Product&#8221;) and (b) such [***] did not [***] US Dollars ($[***]) [***] prior to [***]), it being understood that if a milestone payment is not paid
                with respect to a [***] Product due to the [***] Product becoming [***] Product, Compugen shall be entitled to such milestone payment upon the achievement of such milestone by a [***] Product containing a Target Biologic from such Target
                Program to reach such milestone.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.2.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] US Dollars ($[***]) upon the [***] with such a Product in [***] for a [***] with respect to such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.2.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] US Dollars ($[***]) upon the [***] with such a Product in a [***] for a [***] with respect to such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.2.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] US Dollars ($[***]) upon the [***] with respect to such a Product with a [***]&#160;&#160;[***], [***] and/or [***]; for the avoidance of doubt, this milestone, [***] with respect to the [***]
                with all [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.2.4</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] US Dollars ($[***]) upon the [***] in the [***] with respect to the [***] for such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.2.5</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] US Dollars ($[***]) upon the [***] in the [***] with respect to the [***] for such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.2.6</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] US Dollars ($[***]) upon the [***] in [***] with respect to the [***] for such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.2.7</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] US Dollars ($[***]) upon the [***] in the [***] with respect to the [***] for such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.2.8</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] US Dollars ($[***]) upon the [***] in the [***] with respect to the [***] for such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.2.9</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] US Dollars ($[***]) upon the [***] in [***] with respect to the [***] for such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.2.10</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>[***] US Dollars ($[***]) upon the [***] in the [***] with respect to the [***] for such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">27</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.2.11</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>[***] US Dollars ($[***]) upon the [***] in the [***] with respect to the [***] for such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.2.12</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>[***] US Dollars ($[***]) upon the [***] in [***] with respect to the [***] for such a Product;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.2.13</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>[***]<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>US Dollars ($[***]) in the [***] in which [***] for such a Product within
                such calendar year reach [***] US Dollar ($[***]); such amount will be due [***] in accordance with [***] for the Calendar Quarter in which [***] such [***] in such [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.2.14</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>[***]<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>US Dollars ($[***]) in the [***] in which [***] for such a Product within
                such [***] reach [***] US Dollar ($[***]); such amount will be due [***] in accordance with [***] for the Calendar Quarter in which [***] for such [***] in such [***]; and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.2.15</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>[***]<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>US Dollars ($[***]) in the first [***] in which [***] for such a Product
                within such [***] reach [***] US Dollar ($[***]); such amount will be due [***] in accordance with [***] for the Calendar Quarter in which [***] for such [***] in such [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">The milestones set forth in Sections 6.2.1 and 6.2.2 are intended to be [***].&#160;&#160;In the event that Bayer [***] any of such milestones for a Product (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">[***]</font>&#8221;), Bayer shall be deemed to have achieved such [***] Milestone when it achieves the [***] milestone for the relevant Product (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Achieved Milestone</font>&#8221;).&#160;&#160;Payment for
                any [***] Milestone that is owed in accordance with the provisions of this Section 6.2.3 shall be reported and paid together with the reporting and payment of the Achieved Milestone, according to Sections 7.1.2.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.2.4</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">For the avoidance of doubt, Bayer does not have to pay (a) with respect to either Target Program, any of the milestone payments set forth in Section 6.2.2 [***], or (b) in relation to a
                specific Product, for any [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">6.3</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">Royalties on Net Sales of Products.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.3.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Royalties. </font>Bayer shall pay Compugen royalties on [***] Net Sales of each Product in each calendar year, as follows:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 44pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.3.1.1 </font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">An amount [***]% of Net Sales of such Product on the [***] US Dollars ($[***]) in [***] Net Sales of such Product in such calendar year;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 44pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.3.1.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>An amount [***]% on the portion of Net Sales of such Product [***] US Dollars ($[***]) in [***] Net Sales of such Product in such [***]
                up to [***] Net Sales of such Product of [***] US Dollars ($[***]) in such [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 44pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.3.1.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>An amount [***]% on the portion of Net Sales of such Product [***] US Dollars ($[***]) in [***] Net Sales of such Product in such [***]
                up to [***] Net Sales of such Product of [***] US Dollars ($[***]) in such [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 44pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.3.1.4 </font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">An amount [***]% on the portion of Net Sales of such Product [***] US Dollars ($[***]) in [***] Net Sales of such Product in such [***] up to total Net Sales of such Product of [***] US
                Dollars ($[***]) in such [***]; and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">28</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.3.1.5</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>An amount equal to [***]% on the portion of Net Sales of such Product exceeding [***] US Dollars ($[***]) in [***] Net Sales of such
                Product in such [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.3.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Third Party Royalty Set-Off. </font>If [***] is required (a) in its reasonable judgment to obtain a license from a Third Party to an Infringed
                Claim that would be infringed&#160;&#160;by [***] research on, making or using of [***] in the research on, making, using, selling, offering for sale or importing of a [***] in a certain country, and [***] obtains such a license after good faith,
                arm&#8217;s length negotiations and consultation with [***], or (b) to make any [***] with respect to the research, making, using, selling, offering for sale or importing of a [***] in any country, [***] may offset an amount of [***] percent
                ([***]%) of any [***] due as consideration for such license (in the case of (a)) or all such [***] (in the case of (b)) with respect [***] in such country against [***] with respect to [***] on such [***] in such country; provided that in
                no event shall [***] with respect to any [***] fall below [***] percent ([***]%).</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.3.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Payments to Compugen Licensors.&#160;&#160;</font>For clarity, nothing herein shall be deemed to impose on Bayer any obligation towards licensors of
                Compugen (including [***]) on any amounts, if any, due by Compugen to any such licensor on account of consideration received by Compugen under this Agreement.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">6.4</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">Royalties on Net Sales of Diagnostics.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.4.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Bayer shall pay Compugen an amount [***] percent ([***]%)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>of all Net Sales of Diagnostics by Bayer and/or its Affiliates.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.4.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Bayer shall pay Compugen an amount [***] percent ([***]%)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>of all Sublicense Diagnostic Sales Income.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.5</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Non-Royalty Sublicense Income. </font>Bayer shall pay Compugen the following amounts on Non-Royalty Sublicense Income:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.5.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Products. </font>If the relevant Sublicense agreement includes rights with respect to one or more Products, Bayer shall pay Compugen the
                following percentages of Shared Non-Royalty Sublicense Income received for the respective Product(s) and, if applicable, Diagnostics Sublicensed with such Product(s).&#160;&#160;&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Shared Non-Royalty
                  Sublicense Income</font>&#8221; means all [***], less the sum of, cumulatively, (a) [***] under [***] prior to the date of [***] and (b) an amount equal to [***] under [***] with respect to [***] after the date of [***] and up to and including
                [***]e is received (for clarity, [***]):</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div style="font-weight: bold;"><font style="display: inline;">6<font style="display: inline;">.5.1.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">An amount equal to [***] percent ([***]%) of all [***] if the [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.5.1.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">An amount equal to [***] percent ([***]%) of all [***], if the [***], but prior to [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.5.1.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">An amount equal to [***] percent ([***]%) of all [***], but prior to the [***]; and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.5.1.4</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">An amount equal to [***] percent ([***]%) of all [***], in connection with [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">For clarity, in the event [***] upon [***] of a [***] (meaning that the [***], without [***], regardless of whether [***])
      under a [***], the effective date of such Sublicense agreement for purposes of determining [***] will be deemed to be [***].&#160;&#160;For example, if [***] ([***]%) [***].</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.5.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Diagnostics Only. </font>If the Sublicense agreement includes no rights with respect to the making, using and/or sale of Products (i.e. the
                Sublicense is solely with respect to the making, using and/or selling of Diagnostics), Bayer shall pay Compugen an amount [***] percent ([***]%) of all Non-Royalty Sublicense Income with respect to such Sublicense.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">29</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.6</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Royalty Term.&#160;&#160;</font>Royalties under Sections 6.3 and 6.4 will be payable on a Product-by-Product, Diagnostic-by-Diagnostic and
                country-by-country basis until the latest of:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(a)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">the [***], as the case may be, [***]; provided that if [***], as the case may be[***], [***], such [***] for purposes of this [***] if and when (a) [***] for such [***] or (b) [***] the [***]
                in accordance with [***]</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(b)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">the [***] of [***] with respect to [***], as the case may be, [***]; and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(c)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***], as the case may be, [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.7</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Blended Royalty Rate. </font>The Parties acknowledge and agree that [***] justify royalties of differing amounts [***], which royalties could
                be applied separately to [***], and/or [***] on the one hand and [***] and/or [***] on the other hand, and that if such royalties were calculated separately, royalties [***] would last for different terms.&#160;&#160;The Parties further acknowledge
                and agree that the royalty rate [***] would be [***] in the absence of the Parties&#8217; agreement to adopt a blended royalty rate as set forth herein and that the terms and structure set forth in this Section 6 were agreed upon for convenience
                purposes and represent the fair market value of the rights granted hereunder as determined and agreed upon by the Parties.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">6.8</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Other Third Party Payments.</font>&#160;&#160;For clarity, subject to [***], [***] will be responsible for paying [***] all royalties and other payments
                owed by [***] in performing work under this Agreement, including [***] any payments due to Third Parties under agreements [***] (e.g. [***]).</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;Reports; Payments; Records.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Reports and Payments.</font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.1.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Quarterly Reports.&#160;&#160;</font>Within [***] days after the conclusion of each Calendar Quarter commencing with the first Calendar Quarter in which
                Net Sales are generated or Non Royalty Sublicense Income or Sublicense Diagnostic Sales Income is received, Bayer shall deliver to Compugen a report containing the following information (in each instance, with a Product-by-Product or
                Diagnostic-by- Diagnostic, as applicable, and country-by-country breakdown):</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.1.1.1</font></font></div>
          </td>
          <td width="1518">
            <div align="justify"><font style="display: inline;">&#160;[***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.1.1.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.1.1.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">the total amount of Net Sales with respect to Products for the applicable Calendar Quarter;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.1.1.4 </font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.1.1.5</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.1.1.6</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">the total amount of Net Sales with respect to Diagnostics sold, leased or otherwise transferred by Bayer and/or its Affiliates for the applicable Calendar Quarter;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">30</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.1.1.7</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">a detailed accounting of all Sublicense Diagnostic Sales Income received during the applicable Calendar Quarter;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.1.1.8</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">a detailed accounting of all Non-Royalty Sublicense Income received during the applicable Calendar Quarter; and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.1.1.9</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Each such report shall be confirmed on behalf of Bayer by an authorized officer as true, correct and complete in all
      material respects.&#160;&#160;If no amounts are due to Compugen for a particular Calendar Quarter, the report shall so state.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.1.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Reports on Milestone Achievement.</font> Bayer shall provide written notice to Compugen of any occurrence of any of the milestones set forth in
                Section 6.2 of this Agreement no later than [***] days following the occurrence of the relevant milestone.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.1.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Invoices.</font> Compugen shall be entitled to invoice all amounts to be paid based on the reports provided by Bayer according to Section 7.1.1
                and 7.1.2 directly after receipt of the relevant report.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.1.4</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Payments.</font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.1.4.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Subject to the last sentence of this Section 7.1.4.1, payment will be only made upon receipt of an invoice complying with requirements provided by Bayer to Compugen in writing in advance of
                the date Compugen is entitled to issue an invoice<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>and according to the following rule: (a) if invoices are received by Bayer at the below address until the [***],
                then payments shall be made until the [***] in which the invoice was received; and (b) if invoices are received by Bayer at the below address after the [***] of [***], then payments shall be made until the [***] in which the invoice was
                received. Notwithstanding the sentences above, the upfront license issue fee according to Section 6.1 shall be paid within [***] days upon receipt of the invoice.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.1.4.2 </font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Payment Address.</font> All invoices shall be sent to the following address:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="left" style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Bayer Pharma AG</font></div>
  <div align="left" style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Attn: [***]</font></div>
  <div align="left" style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">c/o Rechnungseingangsstelle</font></div>
  <div align="left" style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">D - 51368 Leverkusen</font></div>
  <div align="left" style="TEXT-INDENT: 99pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Germany</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.1.4.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;Payments made by Wire Transfer. </font>All payments made to Compugen under the Agreement shall be made by wire transfer to the following bank
                account of Compugen, or such other bank account as notified by Compugen to Bayer from time to time:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Account Holder:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Compugen Ltd.</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Account Number:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[***]</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Bank Code:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[***]</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">SWIFT (BIC):&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[***]</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 99pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">IBAN:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;[***]</font></div>
  <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">31</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">7.2</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">Payment Currency.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="text-indent: 36pt;"><font style="display: inline;">All payments made under this Agreement will be payable in USD regardless of the countries in which Net Sales are made. Net Sales made in currencies other than USD shall be
      converted into USD using the average exchange reference rates of the European Central Bank Frankfurt/Main, Germany for the applicable Calendar Quarter as published, in the absence of manifest error, by the European Central Bank on its website (<font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.ecb.int</font>), being currently available under the following link <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://sdw.ecb.europa.eu/browse.do?node=2018794</font>. If
      no USD foreign exchange reference rate is determined by the ECB for the relevant currency, the quarterly average exchange rate based upon the currency exchange rate as published by "FT Guide to World Currencies" of the Financial Times shall be used,
      the current link of which can be found here:</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: -2.5pt"><font style="display: inline;">&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">http://markets.ft.com/ft/markets/researchArchive.asp?report=WORL</font>.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Records.</font> Bayer shall maintain, and shall cause other Related Parties to maintain, complete and accurate records of Products and
                Diagnostics that are made, used, sold, leased or transferred under this Agreement, any amounts payable to Compugen in relation to such Products and Diagnostics, and all Sublicense Diagnostic Sales Income and Non Royalty Sublicense Income
                received by Bayer and its Affiliates, which records shall contain sufficient information to permit Compugen to confirm the accuracy of any reports or notifications delivered to Compugen under Section 7.1. Each Related Party shall retain
                such records relating to a given Calendar Quarter for [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>years after the conclusion of that Calendar Quarter, during which time Compugen will have the right, at
                its expense, to cause an independent, certified public accountant to inspect such records during normal business hours for the purposes of verifying the accuracy of any reports and payments delivered under this Agreement and Bayer&#8217;s
                compliance with the terms hereof.&#160;&#160;Such accountant will be entitled to use the services of independent experts (e.g. patent lawyer), as may be needed to properly perform the audit and determine amounts due to Compugen under this Agreement.
                Such accountant and experts shall not disclose to Compugen any information other than information relating to the accuracy of reports and payments delivered under this Agreement. The Parties shall reconcile any underpayment or overpayment
                within [***] days after the accountant delivers the results of the audit.&#160;&#160;If any audit performed under this Section 7.3 reveals an underpayment in excess of [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>percent



                ([***]%) in any calendar year, [***].&#160;&#160;Compugen may exercise its rights under this Section 7.3 only once per year per audited entity and only with reasonable prior notice to the audited entity. The accounts, records and reports related to
                any particular period of time may only be audited one time under this Section 7.3.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.4</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Late Payments.</font> Any payments due under this Agreement shall be due on such date as specified in this Agreement. Any failure by Bayer to
                make a payment within [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>days after the date when due shall obligate Bayer to pay interest on the due payment to Compugen. The interest period shall commence on
                the due date (inclusive) and end on the payment date (exclusive). Interest shall be calculated based on the actual number of days in the interest period divided by [***]. The interest rate per annum shall be equal to the [***] rate
                calculated by the [***], currently published on [***], fixed [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Days prior to the due date and reset to the prevailing [***] rate in [***] intervals thereafter,
                plus a premium of [***] percent ([***]%), or shall be equal to the [***] rate allowed by local legal law provisions, whatever is [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="font-style: italic; display: inline; font-weight: bold;">&#160;</font></div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">32</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div>
      <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr valign="top">
            <td style="WIDTH: 36pt">
              <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.5</font></font></div>
            </td>
            <td>
              <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">VAT; Withholding and Similar Taxes.</font></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
  </div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.5.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">All agreed remunerations are considered to be net of VAT. VAT applies additionally as legally owed, payable after receipt of a proper invoice, which meets all legal requirements according to
                the applicable VAT law.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">7.5.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Bayer shall be entitled to deduct and withhold from the amount payable the tax which Bayer is liable under any provisions of tax law to withhold. If the withholding tax rate is reduced
                according to the regulations in the Double Tax Treaty, no deduction shall be made or a reduced amount shall be deducted only if Bayer is timely furnished with necessary documents (Freistellungsbescheid) by Compugen issued by the German Tax
                Authority (Bundeszentralamt f&#252;r Steuern), certifying that the payment is exempt from tax or subject to a reduced tax rate. Bayer shall inform Compugen promptly regarding any documentation it requires from Compugen for obtaining such
                exemption or reduction.&#160;&#160;Any withheld tax shall be treated as having been paid by Bayer to Compugen for all purposes of this Agreement. Bayer shall timely forward the tax receipts certifying the payments of withholding tax on behalf of
                Compugen. In case Bayer cannot deduct the withholding tax due to fulfillment of payment obligation by settlement or set-off with respect to taxes that should have been withheld, Compugen will pay the withholding tax to Bayer separately. If
                Bayer missed to deduct withholding tax but based on an audit performed by the relevant tax authorities during the period permitted for such audit according to applicable law, is still required by tax law to pay withholding tax on account of
                Compugen to the tax authorities and (a) promptly informs Compugen of such to enable the Parties sufficient time to appeal such decision within the time period allowed for such appeal and (b) actually pays such tax on account of Compugen,
                Compugen shall assist Bayer with regard to all procedures required in order to obtain reimbursement by tax authorities for amounts so paid or, in case tax authorities will not reimburse Bayer for such withholding tax paid by Bayer, Compugen
                will immediately refund the tax amount.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;Intellectual Property.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Ownership.</font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.1.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Determination of Inventorship.</font> Inventorship of inventions shall be determined in accordance with United States patent law.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.1.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Ownership</font>.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.1.2.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Bayer shall own all rights, title and interest in and to all Program Inventions and Program Know-How (other than Fusion Protein
                Inventions) for which each inventor or creator, as applicable, is an employee of Bayer, its Affiliate or a contractor performing a task assigned to Bayer under the Workplan [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.1.2.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Compugen or its designee shall own all rights, title and interest in and to all (a) Program Inventions and Program Know-How for which
                each inventor or creator, as applicable, is an employee of Compugen, its Affiliate or a contractor performing a task assigned to Compugen under the Workplan [***] and (b) all Fusion Protein Inventions.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.1.2.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>The Parties will jointly own all rights, title and interest in and to all Joint Know-How, other than Fusion Protein
                Inventions.&#160;&#160;Subject to the exclusive licenses specifically granted under this Agreement, [***] shall have the [***] to [***] and [***] without [***] or to [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Disclosure. </font>Each Party shall notify the other, promptly and in writing, of any Program Invention relating to Targets, Target Biologics,
                Products and/or Target Biomarkers of which it becomes aware.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">33</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Patent Filing, Prosecution and Maintenance.</font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.3.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Intellectual Property Committee</font>.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.3.1.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">The Parties hereby establish an &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Intellectual Property Committee</font>&#8221; that will be responsible for discussing intellectual property rights
                relating to Program Inventions. The Intellectual Property Committee will be comprised of [***] appointed by each Party, both of whom shall be full or part time employees of the appointing Party and shall have appropriate authority to make
                the decisions assigned to the Intellectual Property Committee hereunder. Each of Bayer and Compugen may replace its Intellectual Property Committee representative at any time, upon written notice to the other Party.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.3.1.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Responsibilities. </font>The Intellectual Property Committee responsibilities will include:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(a)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">In consultation with patent counsel, discussing, determining and coordinating patent filing and prosecution activities with respect to Joint Inventions, including timing and content of patent
                applications, country filings and abandonment decisions in various countries, and choosing counsel for preparation and prosecution of Joint Patent Rights; and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(b)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Discussing and advising Bayer with respect to patent filing and prosecution activities with respect to Program Inventions solely-owned by Bayer ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">Bayer Program Inventions</font>") and discussing and advising the Parties with respect to patent filing and prosecution activities with respect to Program Inventions solely owned by Compugen ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">Compugen Program Inventions</font>") and other Compugen Patent Rights.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.3.1.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Decision Making.</font> The Intellectual Property Committee will [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>with



                respect to Bayer Program Inventions, Compugen Program Inventions or other Compugen Patent Rights.&#160;&#160;With respect to Joint Inventions, the Intellectual Property Committee will [***]. If the Intellectual Property Committee cannot reach [***],
                the Parties shall try to [***] through [***] between the [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>and the [***].&#160;&#160;If said [***] cannot reach such a decision within [***] calendar days after the date
                on which the matter is referred to the Parties&#8217; [***] listed above, the Parties will [***] by the [***] who will be charged with the duty to [***] of [***], taking into account (a) [***] under this Agreement and [***] in a manner that will
                [***] and [***] and (b) the [***].&#160;&#160;For clarity, if one of the Parties [***], while the other Party [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.3.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Bayer Program Inventions.</font> Bayer shall have sole control, at its expense and discretion, over the preparation, filing, prosecution and
                maintenance of Patents covering the Bayer Program Inventions.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">8.3.3</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">Compugen Patent Rights.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">34</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.3.3.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Control. </font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>[***] shall be responsible for the preparation,
                filing, prosecution, defense (e.g. opposition and other stand-alone invalidity/unenforceability proceedings in accordance with Section 9.7) and maintenance of all Compugen Patent Rights not solely related to [***].&#160;&#160;[***] shall be
                responsible for the preparation, filing, prosecution and maintenance of all Compugen Patent Rights solely related to [***]. The Party responsible for preparation, filing, prosecution and maintenance of certain Compugen Patent Rights as set
                forth above (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Responsible Party</font>&#8221;)<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>shall use independent patent counsel reasonably acceptable to the
                other Party and shall file, prosecute and maintain such Compugen Patent Rights in a country scope as defined in <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 8.3.3.1</font>; provided however, that
                [***] understands that with respect to some of the Compugen Patent Rights, the [***] for [***] and that [***] such Compugen Patent Rights in all of the countries listed in Exhibit 8.3.3.1.&#160;&#160;In addition, if [***] instructs [***] to prepare,
                file, prosecute, protect and maintain Patents for which [***] is the Responsible Party in a country not included in <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit 8.3.3.1, </font>[***] will do so provided that such
                instructions are provided sufficiently in advance of the relevant filing deadline.&#160;&#160;In case such country scope is at the date of the relevant filing, prosecution, defense or maintenance no longer possible, [***] shall prepare, file,
                prosecute, defend and maintain such Patents in as many countries of the country scope as possible. With respect to Compugen Patent Rights, the Responsible Party shall: (a) [***] and [***], as well as [***]; (b) [***]; (c) [***]; (d) [***]
                with [***], together with [***] and [***]; and (e) [***].&#160;&#160;The Responsible Party shall give the other Party the opportunity to provide comments on and make requests of the Responsible Party concerning the preparation, filing, prosecution,
                protection and maintenance of the Compugen Patent Rights, and shall consider such comments and requests in good faith. In no event shall [***] abandon any claim within the Compugen Patent Rights covering a [***] without the written consent
                of [***]. With respect to Compugen Patent rights not solely related to [***] the Parties shall agree on separation of subject matter to the extent possible which shall be further prepared, filed, prosecuted, protected or maintained in
                separate divisional or continuation applications. [***] shall have full control and decision making authority on such applications not related to [***]. The Parties will reasonably inform and consult with each other and, to the extent
                possible, will undertake the filing, prosecution and defense of any Patents in a way that will not be detrimental to the prosecution, issuance and validity of Patents that are part of Compugen Patent Rights, or the development or
                commercialization of the Product.&#160;&#160;The Party that is not the Responsible Party will cooperate with the Responsible Party and will, on reasonable request of the Responsible Party within [***], provide all requested declarations and other
                support to enable the Responsible Party to prepare, file, prosecute and maintain the relevant Compugen Patent Rights in accordance with this Section 8.3.3.1.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 44pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.3.3.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">Expenses.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.3.3.2.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">The Parties acknowledge that the Compugen Patent Rights listed in <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 8.3.3.2.1</font>&#160;&#160;also claim targets and
                antibodies other than [***] will [***] prosecution and maintenance expenses with respect to such applications up to national phase (including national phase entry).&#160;&#160;However, with respect to any divisional patent applications filed with
                respect to such Compugen Patent Rights that claim [***] and do not claim targets that are not [***] shall reimburse [***], subject to Section 8.3.3.3 below, for [***] expenses incurred in connection with the [***] (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Patent Expenses</font>&#8221;) of such Compugen Patent Rights incurred by [***] after the Effective Date in the countries listed in Exhibit 8.3.3.1 and in any country not listed in Exhibit 8.3.3.1 requested by Bayer
                in accordance with Section 8.3.3.1, as follows: (a) if the [***] or [***] and/or [***] shall [***] for [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>such [***]; and (b) if such [***] or [***] subject
                matter other than [***] that is [***] according to [***], [***] shall [***] for [***] such [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.3.3.2.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>With respect to all Compugen Patent Rights, other than those described in Section 8.3.3.2.1, [***] shall <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">reimburse[***]</font>, subject to<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Section 8.3.3.3 below, for [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">&#160;</font>Patent Expenses incurred by [***] following the Effective Date or, if [***] is the Responsible Party, [***] shall [***] for patent expenses with respect to the preparation, filing, prosecution, defense
                and maintenance of such Compugen Patent Rights in the countries listed in Exhibit 8.3.3.1 and in any country not listed in Exhibit 8.3.3.1 requested by [***] in accordance with Section 8.3.3.1 or in which [***] otherwise decides to file
                applications.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">35</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 52pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.3.3.2.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Patent Expenses to be reimbursed under this Section 8.3.3.2 shall be paid in accordance with Section 7.1.4, 7.2 and 7.4, provided that
                the invoice of Compugen shall be accompanied by supporting documentation from Compugen in relation to such expenses.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 54pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.3.3.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Abandonment.</font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 54pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.3.3.3.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Should Bayer decide that it does not wish to pay for or does not wish to continue the preparation, filing, prosecution, protection or maintenance of any patent application or patent within
                Compugen Patent Rights that is a [***] Patent Right&#160;&#160;in any country listed in Exhibit 8.3.3.1 or in any country not listed in Exhibit 8.3.3.1 in which Bayer previously requested Compugen to file such Compugen Patent Rights in accordance
                with Section 8.3.3.1 or in which Bayer otherwise filed Compugen Patent Rights, Bayer shall provide Compugen with prompt written notice of such election.&#160;&#160;Upon receipt of such notice by [***] shall be released from any obligation to
                reimburse [***] for the expenses incurred thereafter as to such [***] Patent Rights; provided that expenses authorized prior to the receipt by [***] of such notice shall be deemed incurred prior to the notice. In the event of any such
                abandonment, [***], in its sole discretion, may choose to continue the preparation, filing, prosecution, protection or maintenance of such [***] Patent Right [***]. If a patent is thereafter granted with respect to such [***] Patent Rights,
                [***] shall promptly inform [***] in writing along with documentation of the relevant decision and [***] shall inform [***] in writing within [***] upon receipt of such notice (including documentation of the relevant decision) whether it
                wishes to keep or to abandon such [***] Patent Right (if abandoned, each then an &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Abandoned </font>[***]<font style="DISPLAY: inline; FONT-WEIGHT: bold"> Patent Right</font>&#8221;). If [***]
                wishes to keep such [***] Patent Right, [***] will pay to [***] to [***] costs in connection with such preparation, filing, prosecution, protection or maintenance of such [***] Patent Right [***]. If [***] decides not to pay such amount or
                fails to pay such amount when due, [***] may choose [***].&#160;&#160;In such event, the license [***] will terminate, [***]. [***] shall then [***]without [***], to [***] and to [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 54pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.3.3.3.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] is free in its sole discretion to abandon Bayer Product Patent Rights without any obligation to offer such Bayer Product Patent Rights to [***] provided that in the case of a termination
                of this Agreement in whole or of a Partial Termination by [***] in accordance with Section 14.3.3 or Section 14.3.4 or by [***] in accordance with Section 14.3.1 (without cause), [***] will not abandon those Bayer Product Patent Rights that
                would, in the case of a Transfer Notice from [***], be covered by any of the licenses granted within such Program Transfer without first allowing [***] to elect to have [***] continue prosecution, maintenance and/or protection of such Bayer
                Product Patent Rights at [***]&#8217;s cost until the [***]-day-period for provision of a Transfer Notice according to Section 14.4.2.1 has expired without receipt of any Transfer Notice by [***]. Should [***] after a Program Transfer decide that
                it does not wish to continue the prosecution of any [***] that is covered by any of the licenses granted within such Program Transfer, [***] shall provide [***] with written notice of such election.&#160;&#160;Upon receipt of such notice by [***],
                [***] shall be released from any obligation to prosecute the relevant Bayer Product Patent Right. In the event of any such abandonment, [***], in its sole discretion, may choose to continue the prosecution of such Bayer Product Patent Right
                at [***] expense. [***] will cooperate with [***] and will, on reasonable request of [***] within three months after receipt of such request, provide all requested declarations and other support to enable [***] to prepare, file, prosecute
                and maintain the relevant Bayer Product Patent Rights. For the avoidance of doubt, [***] retains full ownership of such Bayer Product Patent Rights.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">36</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.3.3.3.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Should Bayer decide that it does not wish to pay for or does not wish to continue the preparation, filing, prosecution, protection or maintenance of any patent or patent application within
                Compugen Patent Rights that is a [***] Patent Right in any country listed in Exhibit 8.3.3.1 or in any country not listed in Exhibit 8.3.3.1 in which Bayer previously requested Compugen to file such Compugen Patent Rights in accordance with
                Section 8.3.3.1 or in which Bayer otherwise filed Compugen Patent Rights (each, an &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Abandoned </font>[***]<font style="DISPLAY: inline; FONT-WEIGHT: bold"> Patent Right</font>&#8221;), Bayer shall
                provide Compugen with prompt written notice of such election.&#160;&#160;Upon receipt of such notice by [***], [***] shall [***] thereafter as to such [***]; provided that [***] shall be [***]. In the event of any such abandonment, [***] may [***] of
                such Abandoned [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Patent Rights [***].&#160;&#160;In such event, the [***] by [***] with respect to such [***] will [***], but [***] will [***] under Section [***] such
                [***] and [***] shall have the [***] and [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">8.3.4</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">Joint Patent Rights.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.3.4.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Control. </font>All Joint Patent Rights shall be filed, prosecuted, defended (e.g. opposition and other stand-alone
                invalidity/unenforceability proceedings in accordance with Section 9.7) and maintained by the Parties through patent counsel to be agreed upon by the Intellectual Property Committee. Such counsel shall confer with the members of the
                Intellectual Property Committee and attempt to achieve a consensus in all decisions made relative to the content of applications, the prosecution of the Joint Patent Rights and the content of communications with the relevant patent
                agencies, prior to any communications with such agencies.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.3.4.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Expenses. </font>Subject to Section 8.3.4.3 below,<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Bayer shall [***] with respect to
                the activities described Section 8.3.4.1.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.3.4.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Abandonment.</font>&#160;&#160;Should Bayer decide that it does not wish to pay for or does not wish to continue the preparation, filing, prosecution,
                protection or maintenance of any patent application or patent within Joint Patent Rights that is a [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Patent Right (each a &#8220;[***]<font style="DISPLAY: inline; FONT-WEIGHT: bold"> Joint Patent Right</font>&#8221;) in any country listed in Exhibit 8.3.3.1 or in any country not listed in Exhibit 8.3.3.1 in which the Parties filed such Joint Patent Rights in accordance with Section 8.3.4.1, Bayer shall
                provide Compugen with prompt written notice of such election.&#160;&#160;Upon receipt of such notice by [***], [***] shall b[***]hereafter as to such [***]; provided that [***] shall be [***]. In the event of any such abandonment, [***], may [***] of
                such [***]. If a patent is [***], [***] shall promptly [***] and [***] shall [***] within [***] (including [***] of the [***]) whether it wishes to [***] such [***] Patent Right (if [***]&#8221;). If [***] wishes to [***] such [***], [***] will
                pay [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>costs in connection with [***] which [***] is [***] after receipt of [***] request to keep the relevant [***]. If [***] decides [***] or [***] such amount
                when due, [***], may [***] to [***] hereunder with respect to [***].&#160;&#160;If [***] exercises its right to [***] and continues to [***], (a) [***] thereafter shall have the [***] and [***] under such [***] without any duty to a[***] for such
                [***] and [***] and (b) [***] shall [***] without [***] to [***], and [***] shall then be [***] (except as set forth below in [***]) [***] to [***] (through [***] of [***]) in and to such [***].&#160;&#160;In such event, [***] shall have [***] to
                [***] such [***] in the relevant country(ies) except as shall be [***] to [***] the [***] in such country of any Product for which Bayer is otherwise [***] and [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">37</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.3.4.4</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Should Bayer decide that it does not wish to pay for or does not wish to continue the preparation, filing, prosecution, protection or maintenance of any patent or patent application within
                Joint Patent Rights that is a [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Patent Right in any country listed in Exhibit 8.3.3.1 or in any country not listed in Exhibit 8.3.3.1 in which the Parties filed
                such Joint Patent Rights in accordance with Section 8.3.4.1 (each, an &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Abandoned Joint </font>[***]<font style="DISPLAY: inline; FONT-WEIGHT: bold"> Patent Right</font>&#8221;), Bayer shall
                provide Compugen with prompt written notice of such election.&#160;&#160;Upon receipt of such notice by [***], [***] shall [***] thereafter as to such [***]; provided that [***] shall be deemed [***]. In the event of any such abandonment, [***], may
                choose to continue the [***] at its or a Third Party&#8217;s [***].&#160;&#160;In such event, the [***] with respect to such [***], but [***] will [***] under [***] to enforce such [***] and [***] shall have the [***] to enforce such [***] and [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.3.5.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Compugen Program Invention.</font>&#160;&#160;Compugen shall have control, at its expense and discretion, over the preparation, filing, prosecution and
                maintenance of patents and patent applications covering Compugen solely-owned Program Inventions that are not Compugen Patent Rights.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">8.4.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Patent Challenge. </font>If a Related Party commences an action in which it challenges the validity, enforceability or scope of any of the
                Compugen Patent Rights (a &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Challenge Proceeding</font>&#8221;) and the outcome of such Challenge Proceeding is a determination in favor of Compugen, then in addition to any other rights Compugen
                may have under this Agreement or under applicable law, Bayer shall [***] for all [***]with [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">9&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;Enforcement of Patent Rights.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">9.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Notice.</font> If Bayer or Compugen becomes aware of any possible or actual infringement of any Compugen Patent Rights, Joint Patent Rights or
                Bayer Product Patent Rights with respect to the making, use or sale of Products and/or Diagnostics (an &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Infringement</font>&#8221;), that Party shall promptly, and in any event not later than one
                week after becoming aware of the Infringement,<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>notify the other Party and provide it with details of its knowledge regarding such Infringement.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">9.2</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">Compugen Patent Rights and Joint Patent Rights</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">38</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">9.2.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Suit by Bayer</font>. Bayer shall have the first right (with the right to grant such right to Sublicensees), but not the obligation, to file a
                lawsuit for patent infringement or otherwise take action in the prosecution, prevention, or termination of any Infringement, including enforcement of Compugen Patent Rights or Joint Patent Rights with respect to an Infringement.&#160;&#160;Before
                Bayer commences an action with respect to any such Infringement, Bayer shall consider in good faith the views of Compugen in making its decision whether to sue. Should Bayer elect to bring suit against such an infringer, Bayer shall keep
                Compugen reasonably informed of the progress of the action and shall give Compugen a reasonable opportunity in advance to consult with Bayer and offer its views about major decisions affecting the litigation.&#160;&#160;Bayer shall give careful
                consideration to those views, but shall have the right to control the action. Bayer agrees to vigorously defend the validity and enforceability of each patent subject to Compugen Patent Rights or to Joint Patent Rights on which it files
                suit. As to a particular patent that is subject to Joint Patent Rights, Bayer at any time may assign all of its right, title and interest in that patent to Compugen and offer Compugen the opportunity to take over the lawsuit, and after such
                offer all obligations of Bayer under this paragraph with respect to such patent shall cease. Likewise, with respect to a particular patent that is subject to Compugen Patent Rights, Bayer at any time may offer Compugen the opportunity to
                take over the lawsuit, and after such offer all rights and obligations of Bayer under this paragraph with respect to such patent shall cease. Should Bayer elect to bring suit against such an infringer Compugen agrees to join as party
                plaintiff in any such suit upon request by Bayer.&#160;&#160;[***]&#160;&#160;Bayer agrees to [***] the final decision as to the selection of counsel shall be made by Bayer. Compugen agrees to execute any retainer agreement reasonably requested by such counsel
                that provides that counsel shall take instructions regarding the lawsuit from Bayer and that waives&#160;&#160;any actual or potential conflicts of interest between Compugen and Bayer. Except as set forth in the next sentence, the expenses of such
                suit or suits that Bayer elects to bring, including any reasonable out-of-pocket expenses of Compugen, other than expenses for the time of its employees involved and disbursement involved in connection therewith, incurred in conjunction
                with the prosecution of such suits or the settlement thereof, [***] and [***] shall hold [***].&#160;&#160;Bayer shall be responsible for [***] incurred [***] only to the extent that [***].&#160;&#160;Should Compugen desire its own separate counsel, as set
                forth in Section 9.5, fees incurred by such counsel would be at Compugen&#8217;s expense. Bayer shall not settle such litigation in a manner that would adversely affect the validity or enforceability of the Compugen Patent Rights or Joint Patent
                Rights or that would admit fault or wrongdoing by, or impose liability on, Compugen without the prior written consent of Compugen, such consent not be unreasonably withheld or delayed. If Bayer exercises its right to sue pursuant to this
                Section 9.2.1, it shall first reimburse itself out of any sums recovered in such suit or in settlement thereof for all costs and expenses of every kind and character other than expenses for the time of its employees involved and
                disbursement involved in connection therewith, including reasonable attorneys&#8217; fees, incurred in the prosecution of any such suit.&#160;&#160;If, after such reimbursement, any funds shall remain from said recovery, then Compugen shall receive an
                amount equal to [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>percent ([***]%) of such funds and the remaining [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>percent
                ([***]%) of such funds shall be retained by Bayer.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">9.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Bayer Product Patent Rights. </font>Bayer shall have the sole right (with the right to grant such right to Sublicensees), at its discretion,
                to file a lawsuit for patent infringement or otherwise take action in the prosecution, prevention, or termination of any Infringement or enforcement of patent rights relating the Bayer Product Patent Rights.&#160;&#160;If Bayer exercises such right
                with respect to an Infringement occurring during a period in which royalties were due to Compugen on sales of Products covered by such Bayer Product Patent Rights in the country of the Infringement,<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>it shall first reimburse itself out of any sums recovered in such suit or in settlement thereof for all costs and expenses of every kind and character, including reasonable attorneys&#8217; fees, incurred in the prosecution of any
                such suit and if, after such reimbursement, any funds shall remain from said recovery, then Compugen shall receive an amount equal to [***] percent ([***]%) of such funds and the remaining [***]-percent ([***]%) of such funds shall be
                retained by Bayer.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">9.4</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Compugen Program Invention.</font>&#160;&#160;Compugen shall have control, at its expense and discretion, over the preparation, filing, prosecution and
                maintenance of Patents covering Compugen Program Inventions that are not Compugen Patent Rights (i.e. do not cover the Targets, Target Biologics nor Target Biomarkers).</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">9.5</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Own Counsel.</font> Each of Bayer and Compugen shall always have the right to be represented by counsel of its own selection and at its own
                expense in any suit instituted under this Section 9 by the other Party for Infringement.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">39</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">9.6</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Cooperation.</font> Each of Bayer and Compugen agrees to cooperate fully in any action under this Section 9 that is controlled by the other
                Party, provided that the controlling Party reimburses the cooperating Party promptly for any costs and expenses, other than expenses for the time of its employees involved and disbursement involved in connection therewith, incurred by the
                cooperating Party in connection with providing such assistance.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">9.7</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Declaratory Judgment.</font> If a declaratory judgment action is brought naming Bayer and/or any of its Affiliates or Sublicensees as a
                defendant and alleging invalidity or unenforceability of any claims within the Compugen Patent Rights, Bayer shall promptly notify Compugen in writing and Compugen may elect, upon written notice to Bayer within [***] days after Compugen
                receives notice of the commencement of such action, to take over the sole defense of the invalidity and/or unenforceability aspect of the action at its own expense, unless or until Bayer decides to take action according to Section 9.2.1.
                Should Compugen elect to take over such defense, Bayer shall have the right to approve the counsel selected by Compugen to represent Compugen and Bayer, such approval not to be unreasonably withheld or delayed.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">10&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Confidential Information.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">10.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Definition. </font>&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Confidential Information</font>&#8221; means information received by one Party
                or any of its Affiliates (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Receiving Party</font>&#8221;) from the other Party or any of its Affiliates (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Disclosing Party</font>&#8221;) that is
                visibly marked or otherwise indicated as confidential or proprietary or that &#8211; without such information being marked or otherwise indicated as confidential or proprietary &#8211; the Receiving Party should reasonably understand is confidential to
                the Disclosing Party, and except that Confidential Information does not include information that: (i) was known to the Receiving Party (or an Affiliate of the Receiving Party) at the time it was disclosed, other than by previous disclosure
                by or on behalf of the Disclosing Party, as evidenced by written records at the time of disclosure; (ii) is at the time of disclosure publicly known, or later becomes publicly known under circumstances involving no breach of this Agreement
                by the Receiving Party or by any person or entity to whom Receiving Party discloses such information under Section 10.2; (iii) is lawfully and in good faith made available to the Receiving Party (or an Affiliate of the Receiving Party) by a
                Third Party who is not subject to obligations of confidentiality to the Disclosing Party with respect to such information; or (iv) is independently developed by the Receiving Party (or an Affiliate of the Receiving Party) without the use of
                or reference to Confidential Information of the Disclosing Party, as demonstrated by documentary evidence. The terms and conditions of this Agreement and the relationship between Parties shall be considered Confidential Information of each
                of the Parties for purposes of this Section 10.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="text-indent: 36pt;"><font style="display: inline;">For clarity, specific aspects or details of Confidential Information shall not be deemed to be within the public domain or in the possession of the Receiving Party merely
      because such Confidential Information is embraced by more general information in the public domain or in the possession of the Receiving Party.&#160; Further, any combination of individual elements of Confidential Information shall be considered
      Confidential Information and shall not be considered in the public domain or in the possession of the Receiving Party merely because one or more individual elements of such combination are in the public domain or in the possession of the Receiving
      Party; rather, such combination shall be considered in the public domain or in the possession of the Receiving Party only if the combination of the individual elements of the combination is in the public domain or in the possession of the Receiving
      Party.</font></div>
  <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">40</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">10.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Restrictions.</font> Receiving Party agrees to maintain Confidential Information of the Disclosing Party in confidence and not disclose such
                Confidential Information without the prior written approval of the Disclosing Party, or make any use of such Confidential Information, except as required in order for such Party to perform its obligations and exercise its rights under this
                Agreement. Each Party may disclose the other Party&#8217;s Confidential Information to those employees or consultants of the Receiving Party and to contractors and (in the case of Bayer) Sublicensees who have a need to know such information for
                purposes of exercising rights and fulfilling obligations under this Agreement, and are bound by confidentiality and non-use obligations equivalent to those set forth herein. In addition, each Party may disclose the other Party&#8217;s
                Confidential Information to Affiliates who have a need to know such information for purposes of exercising rights and fulfilling obligations under this Agreement, provided that the Receiving Party is liable for any non-compliance of its
                Affiliates with the confidentiality and non-use obligations set forth herein. Receiving Party shall protect Confidential Information of the Disclosing Party by using the same degree of care, but not less than a reasonable degree of care, as
                it uses to protect its own confidential information of like nature to prevent the unauthorized disclosure of such Confidential Information.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">10.3</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">Compugen Undertakings with Respect to Certain Compugen Confidential Information.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">10.3.1</font></font></div>
          </td>
          <td>
            <div align="left"><font style="display: inline;">Subject to the exceptions set forth in this Section 10.3.1 below, with respect to any Confidential Information within Compugen Know How so long as the exclusive license granted to Bayer under
                Section 3.1.1 with respect to such [***] is in effect, Compugen shall not disclose such [***] to Third Parties (other than consultants of Compugen who are subject to confidentiality and non-use obligations at least as restrictive as those
                set forth herein) without, cumulatively, (i) having [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>and (ii) [***] such [***]the [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>and



                [***] such [***] under [***]. Notwithstanding sentence 1 of this Section 10.3.1 (for the avoidance of doubt, without this sentence 2 of Section 10.3.1 in any way limiting the [***]), Compugen is entitled (a) to disclose such Confidential
                Information as permitted under Section 2.3.7.3.2; (b) to disclose such Confidential Information under obligations of confidentiality [***] to [***] and to [***] in order to enable Compugen to [***] under [***] and to publicly disclose
                information described in Exhibit 2.3.7.3.2; (c) unrestrictedly disclose information [***]with respect to or with [***]of [***] and [***]for [***] to [***]; (d) unrestrictedly disclose information specifically with respect to [***] of
                Targets; and (e) to disclose Confidential Information with respect to [***] and the [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>under obligations of confidentiality on [***] to [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>and to [***] in support of the [***]; provided that in the case of each of (a) through (e), (x) Compugen will not disclose any such Confidential Information with
                respect to a [***] to a [***], without [***] (y) any agreement pursuant to which Compugen authorizes a Third Party to make use of any such [***] or with respect to [***]of such [***]and [***]unless [***]; and (z) [***]</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">10.3.2</font></font></div>
          </td>
          <td>
            <div align="left"><font style="display: inline;">Notwithstanding Section 10.3.1, Compugen may disclose [***] to Regulatory Authorities in order to (i) obtain, maintain or defend Compugen Patent Rights for which it is a Responsible Party or any
                Patents specifically relating to [***] or (ii) seek or obtain approval to conduct clinical trials or gain Marketing Authorisation with respect to [***] In addition, the exceptions in Section 10.4.2 and Section 10.4.3 shall apply mutatis
                mutandis. Compugen will, to the extent possible, undertake the filing, prosecution and defense of any Patents disclosing [***] pursuant to Section 10.3.2 (i) in a way that will [***]with respect to [***]</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">41</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">10.4</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Exceptions.&#160;&#160;</font>Notwithstanding the above:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">10.4.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">The Receiving Party may disclose Confidential Information of the Disclosing Party to Regulatory Authorities in order to obtain, maintain or defend Patents or seek or obtain approval to conduct
                clinical trials or gain Marketing Authorisation with respect to Products or Diagnostics or to otherwise develop, manufacture or commercialize a Product or Diagnostic.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">10.4.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">The Receiving Party may disclose Confidential Information of the Disclosing Party and this Agreement as required to comply with any order of a court or any applicable rule, regulation, or law
                of any jurisdiction or securities exchange, provided that to the extent reasonably possible it (a) shall promptly notify the Disclosing Party and allow the Disclosing Party a reasonable time to oppose such disclosure, (b) shall use
                reasonable efforts to obtain an appropriate protective order or confidential treatment authorization that preserves the confidentiality of the information to the greatest extent practical and (c) shall limit the scope of such disclosure
                only to such portion of such Confidential Information that is legally required to be disclosed.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">10.4.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">The Receiving Party may disclose a summary report describing the current status and next steps of the Target Program(s) in a general manner without any sensitive information (e.g. information
                relating to competitive, regulatory, commercial, clinical or scientific topics) and financial terms of this Agreement, which the Disclosing Party will deliver within reasonable time upon a request of the Receiving Party, as follows: (a)
                [***] and/or (b) [***]who are [***]of (i) [***]or (ii) [***]of this Agreement; provided that in the case of each of (a) and (b), [***] has entered into a written confidentiality and non-use agreement no less restrictive than the terms set
                forth herein. Such disclosure shall in any event be strictly limited to what is required by [***] for purposes of [***], or [***], and any use by [***] shall be limited to such purpose. Notwithstanding the above, if, in the event of a
                planned disclosure by Compugen, [***] is a Bayer Competitor, then a disclosure as set forth in this Section 10.4.3 shall be made to an independent attorney and/or accountant (and/or independent third party expert contracted by them) solely
                for the purpose of allowing such attorney and/or accountant to advise the Receiving Party regarding [***]this Agreement [***] or of [***] without disclosing any Bayer Confidential Information to the Bayer Competitor.&#160;&#160;The Receiving Party
                making such disclosure shall remain liable towards the Disclosing Party for compliance of [***] with the terms of confidentiality and non-use as set forth in this Agreement with respect to such Confidential Information.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">10.4.4</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Each Party (a) shall have the right to disclose this Agreement as required by any securities laws, regulations or stock exchanges, provided, however, that the Party which discloses this
                Agreement shall give reasonable advance notice, as legally permissible, to the other Party and, at the other Party&#8217;s request, shall involve the other Party in discussions with the relevant government agency with respect to the items that
                may be redacted from such disclosure (it being understood that the Parties have a common interest that Confidential Information that does not have to be disclosed, including any details relating to financial terms, will be redacted from the
                version of the Agreement provided for publications), and (b) may disclose the existence of the relationship created by this Agreement; provided that the other Party shall have the right to review and approve any press release or other
                public disclosure of such information, such approval not to be unreasonably withheld.&#160;&#160;For clarity, each Party will be entitled to freely refer to any details disclosed in the press releases to be issued pursuant to Section 10.5 or in any
                other press release issued by a Party.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">42</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">10.5</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Press Releases. </font>Promptly after the execution of this Agreement, each Party will issue a press release substantially in the form
                attached hereto (for each Party separately) as <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 10.5</font> and will coordinate press releases and other public disclosures regarding the execution of this
                Agreement and the completion of the Research Programs. Any press release or other public disclosure with respect to this Agreement or the Research Programs is subject to review and approval by the other Party (except as set forth in Section
                10.4), such approval not to be unreasonably withheld.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">10.6</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Publications.</font> The Parties acknowledge that publications or presentations relating to the Research Programs must be monitored to prevent
                any adverse effect from premature publication of results of the Research Programs. Accordingly, all abstracts, manuscripts or presentations containing data related to the activities within the Research Program or results generated in the
                performance of such Research Program, which have not been previously published, must be provided at least [***] days prior to [***] for publication or presentation in scientific journals and/or at scientific conferences by the submitting
                Party to the other Party via [***] for its review and comment. The receiving Party will provide any comments to the submitting Party within [***] days of receipt of such proposed abstract, manuscript or presentation, and the submitting
                Party will [***] as applicable. Without limiting a Party&#8217;s right under Section 10, a Party may use presentation materials that have been previously approved by a Party for a presentation by the other Party in subsequent presentations having
                a similar context without additional approvals under this Section 10.6.&#160;Notwithstanding the foregoing, Bayer may, in its sole discretion, [***]If Bayer so objects, [***]shall [***]and [***]&#160; For the avoidance of doubt, Bayer is free to
                submit any abstract, manuscript or presentation related to its activities under a Target Program after completion of the Research Program, to the extent that such publication does not contain any Confidential Information of Compugen.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">10.7</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Duration.</font> The foregoing obligations shall remain in force for a period of [***] years following the date of the disclosure of the
                relevant Confidential Information.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">11&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Warranties; Disclaimers.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">11.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Representations and Warranties by the Parties. </font>Each Party hereby represents, warrants and covenants to the other as of the Effective
                Date, as follows:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">11.1.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Such Party (a) has the power and authority and the legal right to enter into this Agreement and perform its obligations hereunder, and (b) has taken all necessary action on its part required
                to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder.&#160;&#160;This Agreement has been duly executed and delivered on behalf of such Party and constitutes a legal, valid and binding obligation
                of such Party and is enforceable against it in accordance with its terms subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights<font style="DISPLAY: inline; FONT-WEIGHT: bold">;</font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">11.1.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">The execution and delivery of this Agreement and the performance of such Party&#8217;s obligations hereunder do not conflict with, violate, or breach or constitute a default or require any consent
                under, any contractual obligation or court or administrative order by which such Party is bound; and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">11.1.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">It will comply with, and shall ensure that its Affiliates, contractors and Sublicensees comply with, all applicable laws and regulations relating to its activities and the exercise of its
                rights under this Agreement.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">43</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">11.2</font></font></div>
          </td>
          <td>
            <div align="left"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Representations, Warranties and Covenants by Compugen</font>.<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Compugen hereby represents,
                warrants and covenants that: (a) it has not granted and will not grant any rights in or to the Compugen Intellectual Property that are inconsistent with the rights granted to Bayer under this Agreement; (b) it has the right to grant the
                licenses granted by it under Section 3.1 of this Agreement; (c) it will not transfer, assign, encumber, grant, sell, lease or otherwise dispose of the Compugen Intellectual Property in a manner that will adversely affect the rights granted
                to Bayer under this Agreement; and (d) to its knowledge (it being understood that [***]), it possesses all the rights needed to perform its obligations under the Workplan as currently contemplated;<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>(e)<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>it has no knowledge as of the date hereof of any legal suit or proceeding by a third party against Compugen contesting the ownership or validity of the Compugen
                Intellectual Property; (f) it has not received as of the Effective Date, with respect to the Compugen Intellectual Property, any notice of infringement or any written communication from or on behalf of the owner of a Third Party patent
                rights relating in any way to a possible infringement of such Third Party patent rights by its activities with respect to Targets and Target Biologics prior to the date hereof or the activities of either Party contemplated under this
                Agreement; (g) to the best of Compugen&#8217;s knowledge, the Compugen Intellectual Property is not subject to any encumbrance, lien or claim of ownership of any Third Party; (h) it is the sole and exclusive owner and/or Controls the Compugen
                Intellectual Property and to the best of its knowledge the Compugen Intellectual Property has not been misappropriated from a Third Party; (i) to Compugen&#8217;s knowledge, the documents delivered or made available by Compugen to Bayer in
                connection with the transaction contemplated by this Agreement (for clarity, excluding any data that [***] do not contain any untrue statement of a material fact nor omit to state a material fact necessary in order to make the statements
                contained therein not misleading; and Compugen has not knowingly withheld from Bayer any material information concerning the transaction contemplated by this Agreement (or, with respect to documents redacted due to confidentiality
                obligations of Compugen, knowingly withheld from Bayer the information that such redacted parts contain material information concerning the transaction contemplated by this Agreement, other than the [***] to such redacted documents);<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>(j) the Compugen Patent Rights are being diligently prosecuted and maintained with the respective patent offices in accordance with the local applicable law, and to
                Compugen&#8217;s best knowledge, have been filed and maintained properly and correctly and all applicable fees have been paid on or before the final date for payment (including permissible extensions); (k) the Compugen Know-How has been kept
                confidential or has been disclosed to Third Parties only under terms of confidentiality, and Compugen and its Affiliates are not aware of any breach of such confidentiality by any Third Party; and (l) Compugen has not failed to disclose to
                Bayer any prior art or fact known to Compugen that causes Compugen to conclude that the Compugen Patent Rights Controlled by Compugen as of the Effective Date are invalid or unenforceable.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">11.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Warranty Disclaimer</font>. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY
                TECHNOLOGY, PATENTS, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT, AND EACH PARTY HEREBY DISCLAIMS WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE
                FOREGOING.&#160;&#160;THE PARTIES ACKNOWLEDGE THAT ANY INFORMATION, BIOLOGICAL MATERIAL AND KNOW-HOW PROVIDED BY ONE PARTY TO ANOTHER HEREUNDER, ARE PROVIDED &#8220;AS IS&#8221; WITH NO WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED. NEITHER PARTY MAKES ANY
                WARRANTIES, EXPRESS OR IMPLIED, AS TO ANY MATTER RELATING TO THIS AGREEMENT, INCLUDING, WITHOUT LIMITATION WITH RESPECT TO ANY COMPUGEN INTELLECTUAL PROPERTY, BAYER INTELLECTUAL PROPERTY, PROGRAM KNOW-HOW OR THE PERFORMANCE, CONDITION,
                ORIGINALITY OR ACCURACY OF THE RESULTS OF THE RESEARCH PROGRAM.&#160;&#160;SUBJECT TO SECTION 11.2, NEITHER PARTY MAKES ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY COMPUGEN INTELLECTUAL PROPERTY, BAYER
                INTELLECTUAL PROPERTY OR PROGRAM KNOW-HOW OR THAT THE USE OR PRACTICE OF ANY OF THE FOREGOING WILL NOT INFRINGE ANY PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF A THIRD PARTY.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">44</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">12&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Limitation of Liability.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="text-indent: 36pt;"><font style="display: inline;">Except with respect to a breach of confidentiality obligations under Section 10 or matters for which a Party is obligated to indemnify the other under Section 13 or in
      circumstances of gross negligence or willful misconduct,<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>neither of the Parties will be liable to the other with respect to any subject matter of this Agreement under any contract, negligence,
      strict liability or other legal or equitable theory for any indirect, incidental, consequential or punitive damages or lost profits.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="text-indent: 36pt;"><font style="display: inline;">Except with respect to any payments due by one Party to the other under this Agreement, breach of confidentiality obligations under Section 10 and a Party&#8217;s indemnification
      obligations under Section 13 or in circumstances of gross negligence or willful misconduct, under no circumstance shall a Party&#8217;s liability to another Party arising out of a breach of this Agreement exceed in the aggregate the amount of [***] US
      Dollars ($[***]).</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">13&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Indemnification</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">13.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Indemnification of Compugen</font>. Bayer shall indemnify, defend and hold harmless Compugen and its Affiliates and their respective directors,
                officers and employees, and the successors and assigns of the foregoing (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Compugen Indemnitees</font>&#8221;) from and against any and all liabilities, damages, losses, costs and expenses
                (including reasonable attorneys&#8217; and professional fees and other expenses of litigation and arbitration) resulting from a claim, suit or proceeding brought by a Third Party (including without limitation for infringement of any intellectual
                property rights) against a Compugen Indemnitee to the extent resulting directly or indirectly from: (a) [***] (b) the negligence or willful misconduct of any Bayer Indemnitee (defined below); or (c) the breach by Bayer of any warranty,
                representation, covenant or agreement made by it in this Agreement; except in each case to the extent that such claim, suit or proceeding results from the negligence or willful misconduct on the part of any of the Compugen Indemnitees or
                from the breach by Compugen of any warranty, representation, covenant or agreement made by it in this Agreement.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">13.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Indemnification of Bayer.</font> Compugen shall indemnify, defend and hold harmless Bayer and its Affiliates and their respective directors,
                officers and employees, and the successors and assigns of the foregoing (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Bayer Indemnitees</font>&#8221;) from and against any and all liabilities, damages, losses, costs and expenses
                (including reasonable attorneys&#8217; and professional fees and other expenses of litigation and arbitration) resulting from a claim, suit or proceeding brought by a Third Party (including without limitation for infringement of any intellectual
                property rights) against a Bayer Indemnitee to the extent resulting directly or indirectly from (a) [***] (b) [***] (c) a breach by Compugen of any representation, warranty, covenant or agreement made by it in this Agreement;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>and/or (d) the negligence or willful misconduct of any Compugen Indemnitee; except in each case to the extent that such claim, suit or proceeding results from the
                negligence or willful misconduct on the part of any of the Bayer Indemnitees or from the breach by Bayer of any warranty, representation, covenant or agreement made by it in this Agreement.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">45</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">13.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Procedure</font>. A Party that intends to claim indemnification under this Section 13 (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Indemnitee</font>&#8221;)



                shall promptly notify the indemnifying Party (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Indemnitor</font>&#8221;) of any loss, claim, damage, liability or action in respect of which the Indemnitee intends to claim such
                indemnification, and the Indemnitor shall have the right to participate in, and, to the extent the Indemnitor so desires, to assume sole control of the defense thereof with counsel reasonably acceptable to the other Party and with
                involvement of the Indemnitor&#8217;s insurance, including, the right to settle the action on behalf of the Indemnitee on any terms the Indemnitor deems desirable in the exercise of its sole discretion, except that the Indemnitor shall not,
                without the Indemnitee&#8217;s prior written consent, settle any such claim if such settlement contains a stipulation to or admission or acknowledgment of any liability or wrongdoing on the part of the Indemnitee or imposes any obligation on the
                Indemnitee other than a monetary obligation, and only to the extent the Indemnitor assumes in full such obligation.&#160;&#160;The failure to deliver notice to the Indemnitor within a reasonable time after the commencement of any such action shall
                not impair Indemnitor&#8217;s duty to defend such action but shall relieve Indemnitor of any liability to the Indemnitee to the extent the Indemnitor is prejudiced materially by the delay.&#160;&#160;At the Indemnitor&#8217;s request and cost, the Indemnitee
                shall cooperate reasonably with the Indemnitor and its legal representatives in the investigation and defense of any action, claim or liability covered by this indemnification and provide full information with respect thereto.&#160;&#160;Subject to
                the Indemnitee&#8217;s fulfillment of its obligations under this Section 13.3, the Indemnitor shall pay any damages, costs or other amounts awarded against the Indemnitee, or payable by the Indemnitee pursuant to a settlement agreement entered
                into by the Indemnitor, in connection with such claim.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">13.4</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Insurance.</font> Compugen represents, warrants and covenants that (a) it maintains the insurance coverage described in <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 13.4</font> hereto, (b) it will during the term of this Agreement maintain insurance sufficient to secure the performance of Compugen&#8217;s obligations under this Agreement
                including general liability/public liability (GL), in amounts not less than those set forth in Exhibit 13.4 hereto, and (c) it will upon delivery of a Transfer Notice following termination of this Agreement maintain insurance sufficient to
                secure the performance of Compugen&#8217;s obligations under this Agreement, with minimum insurance coverages as follows: (i) upon [***]$[***] (ii) upon [***], $[***], and (iii) $[***] Compugen shall provide Bayer with insurance certificates of
                the insurances mentioned under (a) to (c) above upon request.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">14&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Term and Termination.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 47px">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.1&#160;</font></font></div>
          </td>
          <td width="1518">
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Term of Agreement.</font> The term of this Agreement shall commence on the Effective Date and, unless earlier terminated in accordance with
                provisions of Section 14.3 below, shall continue until the end of the last-to-expire period during which Bayer is obligated to make payments to Compugen under Section 6.&#160;&#160;The term of this Agreement shall survive the non-renewal, termination
                or limitation of any particular license granted hereunder.&#160;&#160;Certain rights and obligations of the Parties may be terminated as provided in this Section 14.&#160;&#160;Following the expiration pursuant to this Section 14.1 (and provided the Agreement
                has not been earlier terminated pursuant to Section 14.3, in which case the provisions of Section 14.4 will apply), Bayer shall have a [***] under the Compugen [***] and Compugen&#8217;s interest in [***] with [***] as the licenses specified in
                Sections 3.1.1.1 to 3.1.1.3.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">46</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">Early Termination of Research Program.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.2.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Termination for Breach by Compugen.&#160;&#160;</font>If Compugen<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>commits a material breach of
                its obligations under Section 2.3 with respect to its obligations under the CGEN-15001T Workplan or the CGEN-15022 Workplan and fails to take reasonable measures to cure such breach within [***] days after receiving written notice thereof
                from Bayer, Bayer may terminate the relevant Research Program (i.e. if the breach is with respect to obligations under the CGEN-15001T Workplan, the CGEN-15001T Research Program; if the breach is with respect to obligations under the
                CGEN-15022 Workplan, the CGEN-15022 Research Program) upon written notice to Compugen. A breach of Compugen&#8217;s obligations under the CGEN-15001T Workplan or the CGEN-15022 Workplan (but not of both Workplans) shall entitle Bayer to terminate
                both Research Programs only if the breach is of a general nature and impacts both Research Programs.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.2.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Consequences. </font>If Bayer terminates either [***] Program (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Terminated [***] Program</font>&#8221;)



                pursuant to Section 14.2.1, without prejudice to any other rights and legal remedies that Bayer may have due to such breach of agreement, Compugen will cease all of its work under the Terminated [***] Program, and [***]</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 35.45pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.2.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Effect on Other Provisions. </font>Except as specifically set forth in this Section 14.2, early termination of the Research Program shall not
                affect the Parties&#8217; rights and obligations under this Agreement.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">14.3</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">Early Termination of Agreement or of a Target Program.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.3.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Termination for Convenience.</font> Bayer may terminate this Agreement, either in whole or with respect to one of the Target Programs only, and
                in each case also on a Product-by-Product (with its applicable Product Companion Diagnostic), and/or country-by country basis, at any time without cause, upon [***] days prior written notice stipulating whether the termination applies to
                the Agreement in whole or with respect to one of the Target Programs only, and whether it is limited to certain Product(s), and/or countries.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.3.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Termination for Breach of Compugen. </font>In the event Compugen commits a material breach of its obligations under any of the Target Programs
                or under this Agreement as a whole and fails to cure that breach within [***] days after receiving written notice thereof, Bayer may terminate at its choice either this Agreement or the Target Program that the breach relates to immediately
                upon written notice to Compugen, provided that if (i) the breach is (1) curable, (2) is not an intentional breach, and (3) not susceptible of cure within the stated period and (ii) Compugen uses [***] in a [***] to&#160;&#160;cure such breach, the
                stated period will be extended by [***] the nature of the breach and the adverse effect that such breach and any further delay in curing such breach will have on Bayer.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.3.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Termination for Breach of Bayer. </font>In the event Bayer commits a material breach of its obligations under this Agreement and fails to cure
                that breach within [***] days after receiving written notice thereof, Compugen may terminate this Agreement immediately upon written notice to Bayer; provided that</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">47</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  &#160;
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(a)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">if (i) the breach is (1) curable, (2) is not an intentional breach, and (3) not susceptible of cure within the stated period and (ii) Bayer uses [***] in a [***] to cure such breach, the
                stated period will be extended by [***] the nature of the breach and the adverse effect that such breach and any further delay in curing such breach will have on Compugen.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(b)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">if the material breach relates solely to Bayer&#8217;s breach of its diligence obligations under Section 5 with respect to one of the Target Programs (and not to the other) and at such time the
                Agreement has not been terminated with respect to the other Target Program, Compugen may only terminate this Agreement with respect to the Target Program with respect to which such material breach applies.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.3.4.</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Termination for Patent Challenge.&#160;&#160;</font>Compugen may terminate this Agreement immediately upon written notice to Bayer if Bayer or an
                Affiliate of Bayer commences an action or assists a Third Party in commencing an action in which it or such Third Party challenges the validity, enforceability or scope of any of the Compugen Patent Rights.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">14.4</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">Effect of Termination of Agreement.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">14.4.1</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">General.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.4.1.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;Termination of Agreement. </font>Upon termination of this Agreement by either Party pursuant to any of the provisions of Section 14.3,
                without prejudice to other claims and remedies, the following provisions shall apply:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(a)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">the rights and licenses granted to Bayer under this Agreement shall terminate, all rights in and to and under the Compugen Intellectual Property and Compugen&#8217;s interest in the Joint
                Intellectual Property will revert to Compugen and neither Bayer nor its Affiliates may make any further use or exploitation of the Compugen Intellectual Property;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(b)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">except with respect to a Target Program(s) for which Compugen provides Bayer a Transfer Notice in accordance with Section 14.4.2.1, the rights and licenses granted by Bayer to Compugen under
                this Agreement will terminate, all rights in and to and under the Bayer Intellectual Property and Bayer&#8217;s interest in the Joint Intellectual Property will revert to Bayer and neither Compugen nor its Affiliates may make any further use or
                exploitation of the Bayer Intellectual Property.&#160;&#160;For clarity, such rights will not terminate with respect to Targets, Target Biologics or Target Biomarkers relating to the Transferred Part (as defined in Section 14.4.2.1); and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(c)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">any existing agreements that contain a Sublicense shall terminate to the extent of such Sublicense, provided that if the Agreement is terminated by Compugen, with respect to each Sublicensee
                that is not, at the date of termination, an Affiliate of Bayer, if (i) the Sublicense was granted in conformance with the terms of this Agreement, (ii) the Sublicensee is not then in material breach of its Sublicense agreement with Bayer
                such that Bayer would have the right to terminate such Sublicense, and (iii) Compugen has been paid all consideration due to Compugen under this Agreement with respect to the Sublicense, Compugen shall be obligated, at the request of such
                Sublicensee, to enter into a direct license agreement with such Sublicensee on substantially the same terms as those set forth herein, which shall not impose any representations, warranties, obligations or liabilities on Compugen that are
                not included in this Agreement, and further provided that (x)&#160;the [***] of the license granted directly by Compugen to such Sublicensee shall be [***]; and (y)&#160;if the Sublicense granted to such Sublicensee was [***], such Sublicensee shall
                [***] under the license granted to it directly by Compugen; and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block">
    <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="font-style: italic; display: inline; font-weight: bold;">&#160;</font></div>
  </div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">48</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">&#160;</td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(d)</font></font></div>
          </td>
          <td>
            <div align="justify">
              <div align="justify"><font style="display: inline;"><font style="display: inline;">Bayer shall promptly destroy, or at Compugen&#8217;s request, deliver to Compugen, all Compugen Know-How and Compugen biological material in Bayer&#8217;s, its Affiliates&#8217;
                    and Sublicensees&#8217; possession;</font></font></div>
            </div>
          </td>
        </tr>

    </table>
  </div>
  <div align="center">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(e)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">except with respect to a Target Program(s) for which Compugen provides Bayer a Transfer Notice in accordance with Section 14.4.2.1, Compugen shall promptly destroy, or at Bayer&#8217;s request,
                deliver to Bayer, all Bayer Know-How and Bayer biological material in Compugen&#8217;s or its Affiliates&#8217; or contractors&#8217; possession. For clarity, Compugen shall not be required to destroy nor deliver to Bayer any such Bayer Know-How or Bayer
                biological material relating to or used in the Transferred Part (as defined in Section 14.4.2.1); and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(f)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Bayer will not have to pay any more milestone payments except those milestone payments with respect to milestones that were achieved prior to the termination of the Agreement<font style="FONT-STYLE: italic; DISPLAY: inline">.</font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.4.1.2 </font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Partial Termination. </font>Upon termination that is limited to one of the Target Programs (by either Party) or to certain Products (together
                with their applicable Product Companion Diagnostics) and/or countries (by Bayer) pursuant to any of the provisions of Section 14.3 (such partial termination hereinafter referred to as &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Partial



                  Termination</font>&#8221; and the subject-matter of such termination hereinafter referred to as &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Terminated Part</font>&#8221;), the following provisions shall apply:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">(a)</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">the rights and licenses granted to Bayer under this Agreement with respect to the Terminated Part, including without limitation with respect to the Targets, Target Biologics and Target
                Biomarkers to the extent they are covered by the termination, shall terminate, all rights in and to and under the Compugen Intellectual Property and Compugen&#8217;s interest in the Joint Intellectual Property relating to the subject matter of
                the Terminated Part (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Terminated Part IP</font>&#8221;) will revert to Compugen and neither Bayer nor its Affiliates may make any further use or exploitation of the Terminated Part IP;</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">(b)</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>any existing agreements that contain a Sublicense under the Terminated Part shall terminate to the extent of such Sublicense; provided
                that in the case of termination of a Target Program by Compugen, with respect to each Sublicensee of subject matter of such Target Program that is not, at the date of termination, an Affiliate of Bayer, if (a) the Sublicense was granted in
                conformance with the terms of this Agreement, (b) the Sublicensee is not then in material breach of its Sublicense agreement with Bayer such that Bayer would have the right to terminate such Sublicense, and (c) Compugen has been paid all
                consideration due to Compugen under this Agreement with respect to the Sublicense, Compugen shall be obligated, at the request of such Sublicensee, to enter into a direct license agreement with such Sublicensee on substantially the same
                terms as those set forth herein as they relate to such Terminated Program, which shall not impose any representations, warranties, obligations or liabilities on Compugen that are not included in this Agreement, and provided further that
                (x)&#160;the scope of the license granted directly by Compugen to such Sublicensee shall be co-extensive with the scope of the license granted by Bayer to such Sublicensee and (y)&#160;if the Sublicense granted to such Sublicensee was non-exclusive,
                such Sublicensee shall not have the right to participate in the prosecution or enforcement of the Compugen Patent Rights, Joint Patent Rights or Bayer Product Patent Rights under the license granted to it directly by Compugen; and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">49</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">(c)</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Bayer shall promptly destroy, or at Compugen&#8217;s request, deliver to Compugen, all Compugen Know-How and Compugen biological material in Bayer&#8217;s, its Affiliates&#8217; and Sublicensees&#8217; possession
                provided in connection with Terminated Part.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.4.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Termination by Compugen for Cause or by Bayer without Cause. </font>In addition to the above, in the case<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>of termination of the Agreement in whole or of a Partial Termination by Compugen in accordance with Section 14.3.3 or Section 14.3.4 or by Bayer in accordance with Section 14.3.1 (without cause), the following
                provisions shall apply:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.4.2.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Compugen shall have an option, exercisable by the provision of written notice to Bayer within [***]&#160;&#160;days of the effective date of such termination (<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Trigger Date&#8221;</font>), to have (a) either Target Program or both Target Programs (in the case of a termination of the Agreement) or (b) the Terminated Part (in the case of a Partial Termination), transferred to Compugen.&#160;&#160;Such
                notice (a &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Transfer Notice</font>&#8221;) will state which Terminated Part(s) is/are to be transferred (each, a &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Transferred Part</font>&#8221;).&#160;&#160;If
                Compugen provides a Transfer Notice within such [***] day period, Bayer shall, to the extent the respective transferred or licensed items referred to below are Controlled by Bayer or its Affiliates and if and to the extent Bayer or its
                Affiliates have the right to make such transfer or grant such license (with respect to each transferred or licensed item subject to [***] by Compugen of [***], including, without limitation, [***], as the case may be, that [***] relating to
                [***]), promptly&#160;&#160;(a) transfer and assign to Compugen, upon Compugen&#8217;s request, all data, study reports, biological, chemical and written materials and information relating to Target Biologics, Target Biomarkers, Products and/or Product
                Companion Diagnostics developed or used by Bayer in the Transferred Part(s), including (if [***]) any [***] performed in such Terminated Part with the exception of [***] that also include [***] which is not a Target Biologic of the
                Transferred Part; (b) to the extent permitted by applicable law, transfer and assign to Compugen or its designee all [***] with respect to Products and/or [***] from the Transferred Part(s) and grant Compugen or its designee any [***]
                reasonably required for the continuing development or commercialization of such Products and [***]; (c) grant [***] to Compugen or its designee [***] under [***], under [***] and under [***], solely to the extent that [***], solely to do or
                have done further research on, develop, have developed, make, have made and use Target Biologics solely in order to develop, have developed, make, have made, use, sell, offer for sale and import Products and [***] within the Transferred
                Part; (d) grant to Compugen or its designee a [***] license under [***] and under [***]&#160;&#160;not covered by the license set forth in (c) solely to the extent that such [***], as applicable, [***] solely to develop, have developed, make, have
                made, use, sell, offer for sale and import Products and/or [***] (or, in the case of a Partial Termination that is limited to a country, the Products and/or [***] in the countries to which the Partial Termination is limited) and provided
                that , in the case of a Product that [***],this license does not include any [***] that is/are not part of [***] included in the Product; and (e) grant to Compugen or its designee a [***] license under [***] and not covered by the licenses
                set forth in (c) and (d), solely to the extent that such [***], as applicable, [***] solely to develop, have developed, make, have made, use, sell, offer for sale and import Products and/or [***] (or, in the case of a Partial Termination
                that is limited to a certain country, the Products and/or [***] in the countries to which the Partial Termination is limited) and provided that , in the case of a Product that [***], this license does not include any [***] that is/are not
                part of [***] included in the Product.&#160;&#160;Bayer undertakes to [***]. If the Transferred Part includes any (i) [***], (ii) [***] or (iii) other [***] or [***] used by Bayer within and needed to continue the Transferred Part, in each case (i)
                to (iii) which [***] or [***] that is/are not part of [***] included in the Product and which would be part of the licenses granted under lit. (d) and lit. (e) of this Section 14.4.2.1, if they were not specifically excluded because of
                [***], the Parties will on request of Compugen negotiate in [***]in [***] with the purpose to [***] of a license by Bayer to Compugen under [***] or [***] to the extent [***] (or, in the case of [***]) and solely in order to further
                develop, have developed, make, have made, use, sell, offer for sale and import Products and/or [***] (or, in the case of a Partial Termination that is limited to a country, the Products and/or [***] in the countries to which the Partial
                Termination is limited), <font style="FONT-STYLE: italic; DISPLAY: inline; TEXT-DECORATION: underline">provided that</font> in the event of [***], Bayer will [***], except for [***] or [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">50</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  &#160; <br>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.4.2.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>With respect to Products in a Transferred Part for which clinical trials have commenced prior to such termination, Bayer will continue
                fulfilling, at [***] expense, all non-cancellable obligations undertaken by or on behalf of Bayer or its Affiliate(s) with respect to [***] prior to the Trigger Date.&#160;&#160;In addition, if Compugen provides Bayer with a Transfer Notice, at
                Compugen&#8217;s request, Bayer will use Commercially Reasonable Efforts [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.4.2.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Regardless of whether Compugen provides a Transfer Notice, Bayer and its Affiliates shall immediately cease all research, development
                and commercialization activities with respect to Products and with respect to Diagnostics (or, in the case of a Partial Termination, Products and its applicable Product Companion Diagnostics within the Terminated Part).</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.4.2.4</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>In the event of a Transfer Notice by Compugen following a Partial Termination by Bayer that is limited to certain Products (and their
                applicable Product Companion Diagnostics) or countries, the Parties will, upon either Party&#8217;s request, [***]</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.4.2.5</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Consideration by Compugen</font>.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">51</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.4.2.5.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Net Sales by Compugen</font>. With respect to Compugen Net Sales (as defined below) made by Compugen and its Affiliates (but specifically
                excluding sale by licensees or sublicensees) of Products from or developed on the basis of the Transferred Part (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Terminated Products</font>&#8221;), Compugen shall pay Bayer the royalties set
                forth in clauses (a) through (f) below, <font style="FONT-STYLE: italic; DISPLAY: inline; TEXT-DECORATION: underline">provided that</font> (i) if the Terminated Product that the Compugen Net Sales relate to is, according to the Product
                definition in Section 1.53, another [***] that [***]described in [***]the [***]will be [***] percent ([***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>%) instead of the [***], as applicable; and (ii) if the
                [***]in Section[***]for which [***]has commenced [***] prior to the [***]and the [***]to does [***](i.e. it includes the [***]) and had to [***], the [***]will be [***] percent ([***]%) instead of the rate set forth in (c), (d), (e) or (f),
                as applicable:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div>&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(a)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">If the Trigger Date with respect to the [***]occurred prior to [***],[***] will [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(b)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] percent ([***]%) of any [***]if the Trigger Date with respect to the [***]occurred after [***]but prior to [***]with respect to a [***]</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(c)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***]percent ([***]%) of any [***]if the Trigger Date with respect to the [***] occurred after [***] with respect to a [***] but prior to [***] with respect to a [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(d)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] percent ([***]%) of any [***]if the Trigger Date with respect to the [***] occurred after [***] with respect to a [***] but prior to [***] with respect to a [***]; and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(e)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] percent ([***]%) of any [***] if the Trigger Date with respect to the [***] occurred after [***] with respect to a [***] but prior to [***]; and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(f)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] percent ([***]%) of any [***] if the Trigger Date with respect to the [***] occurred after [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div>&#160;</div>
  <div align="justify" style="display: block; text-indent: 45pt;"><font style="display: inline;"><font style="display: inline; font-weight: bold;">Third Party Royalty Set-Off.&#160;</font> If prior to the Program Transfer, [***] already obtained a license from
      a<font style="display: inline; font-weight: bold;">&#160;</font>Third Party that is covered by the Third Party royalty set-off pursuant to Section 6.3.2 with respect to [***] in one or more specific countries and this license is transferred to
      [***],[***]&#160;&#160;will be entitled to offset an amount of [***] percent ([***] %) of any [***] due as consideration for such license with respect to [***] in such country against [***] with respect to [***] on such [***] in such country; provided that in
      no event shall [***].</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="text-indent: 45pt;"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Royalty Term.&#160;&#160;</font>Royalties under this Sections 14.4.2.5.1 will be payable on a Terminated Product-by-Terminated Product
      and country-by-country basis until the latest of:</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">(a)</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">the [***] of (i) the [***] and (ii) with respect [***], of the [***], within such [***] in each case (i) and (ii)<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>covering



                the [***] in the [***] in which [***]; provided that if there is [***] as [***] covering the [***] in the [***] in which such [***], such [***] will be deemed to [***] for purposes of this Section 14.4.2.5.1 if and when [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">52</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">(b)</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">the [***] or other [***] with respect to such [***]; and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">(c)</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] of [***] (if the [***], the term [***] will be read to include [***]).</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 45pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.4.2.5.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Consideration in the Event of a Third Party License.</font> In the event Compugen or any of its Affiliates grants a license to a Third Party
                under the rights transferred and/or licensed by Bayer to Compugen under Section 14.4.2.1, including without limitation [***] (a &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Third Party License</font>&#8221;), Compugen shall [***]such as
                [***] for [***]and [***]under such [***], it being understood that with respect to [***]to [***][***]shall provide [***]that such [***] are [***]and that such [***]for such [***][***]received by [***] or [***], to the extent these are
                [***]under Section [***] and shall [***]as set forth below; <font style="FONT-STYLE: italic; DISPLAY: inline; TEXT-DECORATION: underline">provided that</font> (i) if the [***]to is, according to the [***], another [***]that [***]described
                in [***]the [***]will be [***] percent ([***]%) instead of the [***], as applicable; and (ii) if the [***] in Section [***] for which [***] has commenced [***] prior to the [***] that the [***] does not [***] included in such [***]) and had
                to [***], the r[***] percent ([***]%) instead of [***], as applicable:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(a)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">If the Trigger Date with respect to the Transferred Part occurred prior to D3, Bayer will not [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(b)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] percent ([***]%) of any [***] under the [***] if the Trigger Date with respect to the Transferred Part occurred after [***] but prior to [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(c)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>percent ([***]%) of any T[***] under the [***] if [***] with respect to the [***] after start of [***] with
                respect to a [***] from the [***] but prior to [***] with respect to a [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(d)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>percent ([***]%) of any [***] if the Trigger Date with respect to the [***] occurred after [***] with respect
                to a [***] but prior to start of [***] with respect to a [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(e)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] percent ([***]%) of any [***] if the Trigger Date with respect to the [***] occurred after [***] with respect to a [***] of the [***]; and</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(f)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] percent ([***]%) of any [***] if the Trigger Date with respect to the [***] of the respective [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 42.55pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 18pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(g)</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">In addition, [***] shall [***] such as [***]<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>received [***] under the [***] to the extent these [***] under Section [***], and shall pay
                to [***] as set forth below; <font style="FONT-STYLE: italic; DISPLAY: inline; TEXT-DECORATION: underline">provided that</font> (i) if the T[***] to is, [***] in [***]the [***] as applicable, and (ii) if the Transferred Part [***]
                described in [***] for which [***] prior to the [***] and the [***] to does [***] (i.e. it includes the [***]) and had to [***] will be [***] (12[***]) instead of [***], as applicable:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 63pt; MARGIN-RIGHT: -2.5pt"><font style="display: inline;">(A) If the Trigger Date with respect to the [***] occurred prior to [***], [***] will not be [***];</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 63pt; MARGIN-RIGHT: -2.5pt"><font style="display: inline;">(B) [***] percent ([***]%) of any [***]e if the Trigger Date with respect to the [***] occurred after [***] but prior to
      [***] with respect to a [***];</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 63pt; MARGIN-RIGHT: -2.5pt"><font style="display: inline;">(C) [***] ([***]%) of any T[***] under the [***] with respect to the [***] occurred after start of [***] with respect to
      a [***] with respect to a [***];</font></div>
  <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">53</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 63pt; MARGIN-RIGHT: -2.5pt"><font style="display: inline;">(D) [***] percent ([***]%) of any [***] if the Trigger Date with respect to the [***] occurred after start of [***] with
      respect to a [***]<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>with respect to a [***]; and</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 63pt; MARGIN-RIGHT: -2.5pt"><font style="display: inline;">(E) [***] ([***]%) of any [***] if the Trigger Date with respect to the [***]ccurred after [***] with respect to a [***]
      from the [***] but prior to [***]; and</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 63pt; MARGIN-RIGHT: -2.5pt"><font style="display: inline;">(F)&#160;[***] percent ([***]%) of any [***] if the Trigger Date with respect to [***] occurred after [***] with respect to a
      [***]</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="text-indent: 0pt; margin-left: 63pt; margin-right: -2.5pt;"><font style="display: inline;">If [***] receives [***] or [***] as [***]&#160;&#160;(e.g. [***]), [***] will be calculated based on the [***].</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 54pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">14.4.2.5.3</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline; font-weight: bold;">Consideration in the Event of Sale of Compugen.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="display: block; text-indent: 36pt;"><font style="display: inline;">In the event of a sale of all or substantially all of the shares or assets of Compugen to a Third Party resulting in a company (&#8220;<font style="display: inline; font-weight: bold;">Merged Compugen</font>&#8221;) that had [***] US Dollars ($[***]) i[***], irrespective of whether such event occurred [***] shall [***] agreed upon in Section [***]and the activities detailed in Section [***]and in addition to the
      [***]according to Section [***], make to [***]for the first [***]form [***]based on the [***] would have been [***] upon attainment of such [***]had such [***]or [***], as applicable, [***]</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 27pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">(a)</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">[***] shall [***] if the Trigger Date occurred prior to [***] for the [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 27pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">(b)</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">If the Trigger Date occurred after [***] with [***] but prior to start of [***] for [***], [***] will be entitled to the [***] would have [***] to under Sections [***] upon [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 27pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">(c)</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">If the Trigger Date occurred after [***] with respect to the [***] but prior to start of [***] with respect to [***] will be entitled to [***], in each case [***], upon [***].&#160;&#160;For example,
                the [***] for the [***] of [***] with such a [***] in<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>a [***] (Section 6.2.1.5) would be $[***] (i.e. $[***]);</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 34pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 27pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">(d)&#160; </font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">If the Trigger Date occurred after the start of [***] with respect to the [***]duct but prior to [***] with respect to the relevant [***], [***] will be entitled to [***], in each case [***],
                upon [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 27pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">(e)</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">If the Trigger Date occurred after the start of a [***] with respect to the [***] but prior to the [***] with respect to [***], [***] will be entitled to [***], in each case [***], upon [***];</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td style="WIDTH: 27pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">(f)</font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">If the Trigger Date occurred after [***] with respect to the [***] Product, [***] will be entitled [***], in each case [***], upon attainment of [***].</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="text-indent: 36pt;"><font style="display: inline;">For clarity, [***]under this Section 14.4.2.5.3 in the case of a [***]Should [***] subsequently [***] then [***]: In the event that [***] would have been [***] shall [***] or
      any [***] according to [***]. whatever [***].</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 54pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.4.2.5.4</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">All payments to Bayer under Section 14.4.2.5. will be made by Compugen within [***] days of receipt of an invoice by Bayer, provided that Compugen has duly informed Bayer about the Third Party
                License Payment prior to its receipt (or about the Compugen Net Sales in accordance with the reporting obligations specified in Section 7.1.1 (with these clauses amended <font style="FONT-STYLE: italic; DISPLAY: inline">mutatis mutandis</font>
                to reflect that Compugen would be submitting the report in relation to Terminated Products)), absent such information the payment to Bayer shall be due [***] days of Compugen&#8217;s receipt of [***] from a [***] (or the [***]). Sections 7.2 to
                7.4 shall apply mutatis mutandis.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">54</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.4.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Accruing Obligations. </font>Termination or expiration of this Agreement shall not relieve the Parties of obligations accruing prior to such
                termination or expiration, including obligations to pay amounts accruing hereunder up to the date of termination or expiration.&#160;&#160;After the date of termination (except in the case of termination by Compugen for Bayer&#8217;s failure to make
                payments when due), Bayer, its Affiliates and Sublicensees may sell Products and Companion Diagnostics then in stock; provided that Bayer shall pay the applicable royalties and payments to Compugen in accordance with Section 6 and provide
                reports and audit rights to Compugen pursuant to Section 7.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">14.5</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Survival. </font>The Parties&#8217; respective rights, obligations and duties under Sections 1, 2.3.7.2 (c) and (d), 7 (with respect to sales made
                by Bayer prior to the expiration or termination of the agreement), 8.1, 8.3.3.3.2,. 10 (excluding 10.3), 11, 12, 13, 14.1, 14.4, 15 and 16 , as well as any rights, obligations and duties which by their nature extend beyond the expiration or
                termination of this Agreement, shall survive any expiration or termination of this Agreement. In addition, Section 2.3.7.3.4 (c) will survive expiration in accordance with Section 14.1, but not early termination of this Agreement.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">15&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dispute Resolution.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">15.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Arbitration</font>. Any dispute, claim or controversy arising out of or relating to this Agreement, including the breach, termination or
                validity of this Agreement, that is not settled by mutual consent, shall be finally settled by binding arbitration, conducted in accordance with the Rules of Arbitration of the International Chamber of Commerce (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">ICC Rules</font>&#8221;), by three arbitrators appointed in accordance with the following procedure: Each Party shall select one arbitrator and the two Party-selected arbitrators shall select a third arbitrator to
                constitute a panel of three arbitrators to conduct the arbitration in accordance with the ICC Rules.<font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>The place of arbitration shall be New York, US, the language to be used in the
                arbitral proceedings shall be English, and the proceedings shall be confidential.&#160;&#160;The International Bar Association Rules on the Taking of Evidence in International Commercial Arbitration shall govern the taking of evidence in any such
                proceeding. Unless the arbitrator determines that equity requires otherwise, the arbitrator shall award to the prevailing Party (as determined by the arbitrator) the costs of the arbitration, as well as the reasonable, out-of-pocket fees
                and expenses of the prevailing Party&#8217;s attorneys.&#160;&#160;A disputed performance or suspended performance pending the resolution of the arbitration must be completed within a reasonable time period following the final decision of the
                arbitrator.&#160;&#160;The decision of the arbitrator shall be the sole, exclusive and binding remedy between the Parties regarding any and all disputes, controversies, claims and counterclaims presented to the arbitrator. Any award may be entered in
                a court of competent jurisdiction for a judicial recognition of the decision and an order of enforcement.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">15.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Injunctive Relief.</font> Each of the Parties agrees that in the event of any breach of Section 10 (Confidential Information), the
                non-breaching Party may suffer severe and irreparable damage, for which no adequate remedy at law may exist, and for which damages would be difficult to determine.&#160;&#160;Each of the Parties agrees that, in such case, the injured Party shall be
                entitled to obtain from any court of competent jurisdiction preliminary injunctive relief.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">55</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">16&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Miscellaneous.</font></div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">16.1</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Force Majeure.</font> None of the Parties will be responsible for delays resulting from causes beyond its reasonable control, including,
                without limitation, fire, explosion, flood, war, strike or riot; provided that the non-performing Party uses Commercially Reasonable Efforts to avoid or remove such causes of non-performance and continues performance under this Agreement
                with reasonable dispatch whenever such causes are removed. The Party affected by the force majeure event shall upon its occurrence promptly give written notice to the other Party specifying the nature of the event and its anticipated
                duration.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">16.2</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Independent Parties. </font>The relationship of the Parties hereto to each other shall be solely that of independent parties and nothing
                contained in this Agreement shall be construed to make any of the Parties an agent, partner, co-venturer, representative or principal of another for any purpose, and none of the Parties hereto shall have any right whatsoever to incur any
                liability or obligation on behalf of or binding upon another Party.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">16.3</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Notices. </font>Any notices to be given hereunder shall be in writing and shall be sent by:&#160;&#160;(a) certified mail, return receipt requested; (b)
                delivery via an internationally recognized courier service; or (c) facsimile (with transmission confirmed) addressed the other, in any event to the other Party at the address shown hereunder or at such other address for which such Party
                gives notice hereunder :</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div>
      <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr valign="top">
            <td style="WIDTH: 211pt">
              <div><font style="display: inline;"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>&#160;If to Bayer:</font></div>
            </td>
            <td>
              <div>Bayer Pharma AG</div>
              <div><font style="display: inline;">M&#252;llerstra&#223;e 178</font></div>
              <div><font style="display: inline;">13353 Berlin</font></div>
              <div><font style="display: inline;">Attention: [***]</font></div>
              <div><font style="display: inline;">Head, Global Drug Discovery - TRG Oncology/GT</font></div>
              <div><font style="display: inline;">Fax +49 30 468 18069</font></div>
              <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">&#160;</font></div>
              <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">With a copy to Legal Department</font></div>
              <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Fax : +49 30 468 14086.</font></div>
            </td>
          </tr>

      </table>
    </div>
  </div>
  <div>&#160;</div>
  <div>
    <div>
      <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr valign="top">
            <td style="WIDTH: 211pt">
              <div><font style="display: inline;"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>&#160;If to Compugen:&#160;</font></div>
            </td>
            <td>Compugen Ltd.</td>
          </tr>

      </table>
    </div>
  </div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 211pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Pinchas Rosen Street #72</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 211pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Tel Aviv 69512, Israel</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 211pt">
            <div><font style="display: inline;">&#160; </font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;">Fax. +972 (3) 765-8111</font></div>
            <div align="justify">
              <div><font style="display: inline;">Attention: VP Business Development</font></div>
              <div><font style="display: inline;">&#160;</font></div>
              <div><font style="display: inline;">With a copy to: General Counsel</font></div>
              <div><font style="display: inline;">Fax: +972 (3) 765-8111</font></div>
            </div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">16.4</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Governing Law. </font>This Agreement will be governed by, and construed in accordance with, the substantive laws of New York, US, without
                giving effect to any choice or conflict of law provision, except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent shall have been granted.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">56</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  &#160;
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">16.5</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Severability. </font>If any provision of this Agreement is or becomes invalid or is ruled invalid by any court of competent jurisdiction or is
                deemed unenforceable, it is the intention of the Parties that the remainder of this Agreement shall not be affected. The Parties shall replace the invalid provision with a valid provision that comes closest to effectuating the economic
                and/or scientific intent of the Parties at the time of the Agreement's execution.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">16.6</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">No Assignment. </font>This Agreement or any rights hereunder (including any right to develop, manufacture, market and/or sell Products), may
                not be assigned by either Party without the consent of the other, which consent shall not be unreasonably withheld, except that (i) each Party may, without such consent, assign this Agreement and the rights, obligations and interests of
                such Party to any purchaser of all or substantially all of its assets to which the subject matter of this Agreement relates, or to any successor corporation resulting from any merger or consolidation of such Party with or into such
                corporation; provided, in each case, that the assignee agrees in writing to be bound by the terms of this Agreement; and (ii) Bayer may assign this Agreement to any of its Affiliates without the prior consent of Compugen; provided, that the
                assignee agrees in writing to be bound by the terms of this Agreement.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">16.7</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Entire Agreement. </font>This Agreement is the sole agreement with respect to the subject matter hereof and supersedes all other agreements
                and understandings among the Parties with respect to the same.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">16.8</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Modification. </font>No modification or waiver of this Agreement or of any covenant, condition or limitation herein contained shall be valid
                unless in writing and executed by duly-authorized representatives of the Parties.&#160;&#160;A failure by a Party to assert its rights under, including upon any breach or default of, this Agreement shall not be deemed a waiver of such rights.&#160;&#160;No
                such failure or waiver in writing by a Party with respect to any rights shall extend to or affect any subsequent breach or impair any right consequent thereon.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">16.9</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Interpretation. </font>Each Party hereto acknowledges and agrees that:&#160;&#160;(a) it and/or its counsel reviewed and negotiated the terms and
                provisions of this Agreement and has contributed to its revision; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement; and (c)
                the terms and provisions of this Agreement shall be construed fairly as to both Parties hereto and not in favor of or against either Party, regardless of which Party was generally responsible for the preparation of this Agreement.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">16.10</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Counterparts.</font> This Agreement may be executed in counterparts and each such counterpart shall be deemed an original hereof.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div>
    <table width="100%" cellspacing="0" cellpadding="0" border="0" align="center" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="WIDTH: 36pt">
            <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">16.11</font></font></div>
          </td>
          <td>
            <div align="justify"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Exhibits.</font>&#160;&#160;The following Exhibits shall form an integral part of this Agreement:</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">&#160;</font></div>
  <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td style="TEXT-ALIGN: left; WIDTH: 108pt">
            <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibit 1.3</font></div>
          </td>
          <td align="left">
            <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Bayer Development Process</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td align="right" style="WIDTH: 108pt">
            <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibit 1.16&#160;&#160;</font></div>
          </td>
          <td align="left">
            <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">CGEN-15001T Workplan</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td align="right" style="WIDTH: 108pt">
            <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibit 1.21&#160;</font></div>
          </td>
          <td align="left">
            <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">CGEN-15022 Workplan</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td align="right" style="WIDTH: 108pt">
            <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibit 1.28</font></div>
          </td>
          <td align="left">
            <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Compugen Patent Rights</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td align="right" style="WIDTH: 108pt">
            <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibit 2.3.3&#160;&#160;</font></div>
          </td>
          <td align="left">
            <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Research Program reports to the JSC</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td align="right" style="WIDTH: 108pt">
            <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibit 2.3.7.3.2</font></div>
          </td>
          <td align="left">
            <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">[***] publications</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">
      <table width="100%" cellspacing="0" cellpadding="0" border="0" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr valign="top">
            <td align="right" style="WIDTH: 108pt">
              <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibit 2.3.7.3.3</font></div>
            </td>
            <td align="left">
              <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Criteria [***], [***]</font></div>
            </td>
          </tr>

      </table>
    </div>
  </div>
  <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td align="right" style="WIDTH: 108pt">
            <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibit 8.3.3.1&#160;&#160;</font></div>
          </td>
          <td align="left">
            <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Patent country scope</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">
      <table width="100%" cellspacing="0" cellpadding="0" border="0" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr valign="top">
            <td align="right" style="WIDTH: 108pt">
              <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibit 8.3.3.2.1</font></div>
            </td>
            <td align="left">
              <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Patent rights claiming also targets and antibodies other than Target Biologics and Targets</font></div>
            </td>
          </tr>

      </table>
    </div>
  </div>
  <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td align="right" style="WIDTH: 108pt">
            <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibit 10.5</font></div>
          </td>
          <td align="left">
            <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Press release</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <table width="100%" cellspacing="0" cellpadding="0" border="0" id="hangingindent" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr valign="top">
          <td align="right" style="WIDTH: 108pt">
            <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibit 13.4&#160;</font></div>
          </td>
          <td align="left">
            <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Insurance</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">57</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="text-align: left; display: block; font-family: 'Times New Roman',Times,serif;">
    <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><font style="font-weight: bold;">IN WITNESS WHEREOF,</font> each Party has caused this Agreement to be executed by its duly authorized representative as of the Effective
      Date.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="zbcefdd8429424a8eb6705ce1e27a28c6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;">Bayer Pharma AG</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="line-height: 1.25;">By: ppa_____/s/ Prof. Dr. Andreas Busch_______________</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="line-height: 1.25;">Name:__Prof. Dr. Andreas Busch___________________</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="line-height: 1.25;">Title:&#160; Head of Global Drug Discovery ______________________</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="line-height: 1.25;">By: ppa, /s/ Dr. Karl Ziegelbauer ____________________</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="line-height: 1.25;">Name:__Dr. Karl Ziegelbauer ___________________</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="line-height: 1.25;">Title: ____Head GDD &#8211; TRG Oncology / Gynecological Therapy&#160; __________________</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;">Compugen Ltd.</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="line-height: 1.25;">By:___/s/ Dr. Anat Cohen-Dayag_______________________</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="line-height: 1.25;">Name:__Dr. Anat Cohen-Dayag______________________</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="line-height: 1.25;">Title:_____ President and CEO____________________</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
  </div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">58</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
  </div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">Exhibit 1.3: Bayer Development Process</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="display: inline;">[***]</font></font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">59</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">Exhibit 1.16 CGEN-15001T WORK PLAN</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">[***]</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">60</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><br>
    &#160;</div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">Exhibit 1.21 CGEN-150022 WORK PLAN</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">[***]</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">61</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><br>
    &#160;</div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit 1.28 - Compugen Patent Rights</font></font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="display: inline;">[***]</font></font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">62</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    &#160; </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Exhibit 2.3.3: </font>Research Program reports to the JSC</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">&#160;</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">[***]</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;<br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">[***]</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">63</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="display: inline; font-weight: bold;">Exhibit 2.3.7.3.2:&#160;&#160;</font>[***]<font style="display: inline; font-weight: bold;"> Publications </font>[***]</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="display: inline;">[***]</font></font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; font-style: italic;">
      <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
          <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
            <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
              <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
                <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; font-style: italic;">
                  <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
                    <div style="line-height: 1.25; font-weight: bold;">
                      <div style="line-height: 1.25;"><br>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">64</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><br>
    &#160;</div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="display: inline; font-weight: bold;">Exhibit 2.3.7.3.3.</font><font style="display: inline;">: </font><font style="display: inline; font-weight: bold;">Criteria for </font>[***]</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="display: inline;">[***]</font></font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; font-style: italic;">
      <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
          <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
            <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
              <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
                <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; font-style: italic;">
                  <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
                    <div style="line-height: 1.25; font-weight: bold;">
                      <div style="line-height: 1.25;"><br>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">65</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><br>
    &#160;</div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Exhibit 8.3.3.1: </font>Patent country scope</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">[***]</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
    <font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Exhibit 8.3.3.2.1: </font>Compugen Patent Rights also claiming targets and antibodies other than Target Biologics and Targets</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">[***]</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; font-style: italic;">
      <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
          <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
            <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
              <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
                <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; font-style: italic;">
                  <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
                    <div style="line-height: 1.25; font-weight: bold;">
                      <div style="line-height: 1.25;"><br>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">66</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Exhibit 10.5.</font>: <font style="DISPLAY: inline; FONT-WEIGHT: bold">Press Release</font></font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">News Release</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">Not intended for U.S. and UK Media</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Antibody-based Cancer Immunotherapy</font></font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-size: 14pt; font-weight: bold;">Bayer Enters Into New Cancer Immunotherapy Collaboration with Compugen</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Partners have signed collaboration and licence agreement</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Berlin, August 05, 2013 </font>&#8211;<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Bayer HealthCare has entered into a new oncology collaboration and licence agreement with Compugen Ltd. The partnership targets the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy
      against two novel immune checkpoint regulators discovered by Compugen. Under the agreement, the partners will jointly pursue a preclinical research program. Subsequently, Bayer will have full control over further development and worldwide
      commercialization rights for potential cancer therapeutics.</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">&#8220;Bayer is committed to translating the science of cancer research into effective therapies helping people affected by cancer
      live longer and improve their quality of life,&#8221; said Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee and Head of Global Drug Discovery. &#8220;Antibody-based immunotherapies are promising approaches in oncology which can stimulate
      the body&#8217;s own immune cells to fight cancer cells. Immunotherapy is one of our focus areas in oncology research. We are looking forward to expanding our portfolio in this area through partnering with Compugen.&#8221;</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">The immunotherapy approach aims at combatting cancer by stimulating the body&#180;s own immune cells. The tumor and its environment
      suppress the ability of cancer patients to develop an effective anti-tumor immune response and in this way protect both tumor growth and survival. Compugen has discovered two novel immune checkpoint regulators that potentially play a key role in
      immunosuppression. Researchers at Compugen are developing specific therapeutic antibodies that are geared to block the immunosuppressive function of these targets and to reactivate the patient&#8217;s anti-tumor immune response in order to fight cancer.</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">&#8220;We are very excited to initiate this collaboration with Bayer, a leading global life science company with a broadening
      oncology franchise, for the development of antibody-based cancer immunotherapies against these two promising novel immune checkpoint targets,&#8221; said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. &#8220;In addition, we believe that the prediction
      and validation of these two targets, through the use of our broadly applicable predictive discovery infrastructure, provides additional validation for our long-term commitment to establishing this unique capability.&#8221;</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block">
    <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; font-style: italic;">
      <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
          <div align="justify" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
            <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
              <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
                <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; font-style: italic;">
                  <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
                    <div style="line-height: 1.25; font-weight: bold;">
                      <div style="line-height: 1.25;"><br>
                      </div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">67</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">In addition to an upfront payment of USD 10 million, Compugen is eligible to receive over USD 500 million in potential
      milestone payments for both programs, not including milestone payments of up to USD 30 million associated with preclinical activities. Furthermore, Compugen is also eligible to receive mid to high single digit royalties on worldwide net sales of any
      resulting products under the collaboration.</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">About Cancer Immunotherapy</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Latest cancer immunotherapies have demonstrated impressive clinical benefit, even for end-stage patients with
      difficult-to-treat tumors such as metastatic melanoma and non-small cell lung cancer. Unlike conventional cancer therapies, which act by directly targeting cancer cells, resulting often in only transient clinical responses as cancer cells become
      resistant, clinical responses to cancer immunotherapy tend to be durable, sometimes resulting in dramatic long term survival and absence of resistance or recurrences.</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">About Compugen</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important
      unmet needs in the fields of immunology and oncology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other
      computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development
      and commercialization of selected product candidates from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of
      revenue sharing. In 2012, Compugen established operations in California for the development of oncology and immunology monoclonal antibody therapeutic candidates against Compugen drug targets. For additional information, please visit Compugen's
      corporate website at www.cgen.com.</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">68</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block">&#160; <br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;"><a name="TMTextbeginn"><!--EFPlaceholder--></a>About Bayer HealthCare</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech
      materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the world&#8217;s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company
      combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare&#8217;s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer
      HealthCare has a global workforce of 55,300 employees (Dec 31, 2012) and is represented in more than 100 countries. More information at www.healthcare.bayer.com.</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Our online press service is just a click away: press.healthcare.bayer.com</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Follow us on Facebook: http://www.facebook.com/healthcare.bayer</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Follow us on Twitter: https://twitter.com/BayerHealthCare</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Contact</font>:</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;"><a name="TMKontakt"><!--EFPlaceholder--></a>Diana Scholz, Tel. <a name="TMTelefon"><!--EFPlaceholder--></a>+49



      30 468 193183</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">E-Mail: <a name="TMMail"><!--EFPlaceholder--></a>diana.scholz@bayer.com</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Find more information at www.bayerpharma.com.</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">ds&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2013-0423E)</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Forward-Looking Statements</font></font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup
      management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These
      factors include those discussed in Bayer&#8217;s public reports which are available on the Bayer website at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.bayer.com</font>. The company assumes no liability whatsoever to update these
      forward-looking statements or to conform<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>them to future events or developments.</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="center">
    <table width="100%" cellspacing="0" cellpadding="0" bgcolor="white" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

        <tr>
          <td width="50%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid; BORDER-RIGHT: black 2px solid">
            <div>&#160;</div>
            <div><font style="display: inline; font-size: 12pt;"><font style="display: inline; text-decoration: underline;">News Release Tweet</font></font></div>
            <div>&#160;</div>
            <div>&#160;</div>
          </td>
        </tr>

    </table>
  </div>
  <div>&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">69</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="display: inline; font-weight: bold;">Text (max. 110 characters incl. spaces):</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline; font-weight: bold;">Bayer Enters Into New Immunotherapy Collaboration with Compugen in Oncology</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;"><font style="display: inline;">BHC NEWS: </font><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">&gt;&gt; more information about XY</font></font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div id="FTR">
      <div align="left" id="GLFTR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
    <div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
      <div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="display: inline;">70</font></div>
      <div style="TEXT-ALIGN: center; WIDTH: 100%">
        <hr noshade="noshade" size="3" style="COLOR: black"> </div>
    </div>
    <div id="HDR">
      <div align="right" id="GLHDR" style="WIDTH: 100%"><font style="display: inline; font-size: 8pt;">&#160; </font></div>
    </div>
  </div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Exhibit 13.4</font></div>
  <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">Insurance</font></div>
  <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
  </div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="display: inline;">[***]</font></div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
  <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
    <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
    <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-STYLE: italic; DISPLAY: inline"><font style="FONT-STYLE: normal; FONT-WEIGHT: normal">71</font></font></font></div>
    <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-STYLE: italic; DISPLAY: inline"><font style="FONT-STYLE: normal; FONT-WEIGHT: normal">
            <br>
          </font></font></font></div>
  </div>
  <div>
    <hr noshade="noshade" size="1" style="MARGIN-TOP: -5px; COLOR: #000000">
    <hr noshade="noshade" size="4" style="MARGIN-TOP: -13px; COLOR: #000000"> </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>4
<FILENAME>exhibit_4-4.htm
<DESCRIPTION>EXHIBIT 4.4
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body text="#000000" bgcolor="#ffffff" style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">
  <div>
    <hr align="center" style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 4px solid; MARGIN-RIGHT: auto"> </div>
  <div style="text-align: right; font-variant: normal; font-style: normal; font-weight: bold;"><u>Exhibit 4.4</u></div>
  <div>&#160;</div>
  <div>
    <div style="text-align: right; line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic; font-weight: bold;">Pursuant to Instruction 4(a) as to Exhibits of Form 20-F, certain identified information
        (marked by [***]) has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</div>
      &#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">First Amendment to the</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Research and Development Collaboration and License Agreement</div>
    <div style="LINE-HEIGHT: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">This is the first Amendment (hereinafter &#8220;Amendment&#8221;) to the Research and Development Collaboration and License Agreement between Bayer Pharma AG, a company formed under the laws of Germany, having a
      place of business at Muellerstrasse 178, 13353 Berlin, Germany (hereinafter: &#8220;BAYER&#8221;) and Compugen Ltd, a company formed under the laws of Israel, having a place of business at 72 Pinchas Rosen Street, Tel Aviv 69512, Israel (hereinafter: &#8220;Compugen&#8221;)
      effective as of 5 August 2013 (hereinafter: the &#8220;Agreement&#8221;).</div>
    <div style="LINE-HEIGHT: 1.25">&#160;</div>
    <div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">WHEREAS&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The parties wish to amend the exhibit specifying the Bayer Development Process.</div>
    <div style="LINE-HEIGHT: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">NOW THEREFORE IT IS AGREED AS FOLLOWS:</div>
    <div style="LINE-HEIGHT: 1.25">&#160;</div>
    <div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z733a0f72e24b4d64b4dbe3273b17984e" style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">1.</td>
            <td style="text-align: justify; width: auto; vertical-align: top;">The parties agree to replace Exhibit 1.3 of the Agreement by Exhibit 1.3 attached to this Amendment, describing the &#8220;Bayer Development Process&#8221;.</td>
          </tr>

      </table>
    </div>
    <div style="LINE-HEIGHT: 1.25">&#160;</div>
    <div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z007b16e4afe841cab1084d02aa5ea35f" style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">2.</td>
            <td style="text-align: justify; width: auto; vertical-align: top;">This Amendment shall become retroactively effective as of 5 August 2013.</td>
          </tr>

      </table>
    </div>
    <div style="LINE-HEIGHT: 1.25">&#160;</div>
    <div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zff68c7f9727c4104bdcb345b988d2bc0" style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">3.</td>
            <td style="text-align: justify; width: auto; vertical-align: top;">All capitalized terms used herein shall have the meaning set forth in the Agreement. Except as expressly amended pursuant to this Amendment, all other terms and conditions of
              the Agreement shall remain in force unchanged and apply to this Amendment.</td>
          </tr>

      </table>
    </div>
    <div style="LINE-HEIGHT: 1.25">&#160;</div>
    <div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
      <div id="DSPFPageHeader"></div>
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">&#160;</div>
    </div>
    <div id="DSPFPageBreakArea" style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both">
      <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
        <hr noshade="noshade" style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px"> </div>
    </div>
    <div style="LINE-HEIGHT: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z3f52c575711b4d2eaaf0fcd66470f4a7" style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">

        <tr>
          <td style="WIDTH: 50.2%; VERTICAL-ALIGN: top">
            <div style="text-align: left; line-height: 1.25;">SIGNED for and on behalf of</div>
            <div style="text-align: left; line-height: 1.25;">Bayer Pharma AG</div>
          </td>
          <td style="WIDTH: 49.8%; VERTICAL-ALIGN: top">
            <div style="text-align: left; line-height: 1.25;">SIGNED for and on behalf of</div>
            <div style="text-align: left; line-height: 1.25;">Compugen Ltd</div>
          </td>
        </tr>
        <tr>
          <td style="WIDTH: 50.2%; VERTICAL-ALIGN: top">&#160;</td>
          <td style="WIDTH: 49.8%; VERTICAL-ALIGN: top">&#160;</td>
        </tr>
        <tr>
          <td style="WIDTH: 50.2%; VERTICAL-ALIGN: top">
            <div style="text-align: left; line-height: 1.25;">Date: <font style="font-variant: normal; font-style: normal; font-weight: normal;"><u>February 3, 2014</u></font></div>
          </td>
          <td style="WIDTH: 49.8%; VERTICAL-ALIGN: top">
            <div style="text-align: left; line-height: 1.25;">Date: <font style="font-variant: normal; font-style: normal; font-weight: normal;"><u>February 5, 2014</u></font></div>
          </td>
        </tr>
        <tr>
          <td style="WIDTH: 50.2%; VERTICAL-ALIGN: top">&#160;</td>
          <td style="WIDTH: 49.8%; VERTICAL-ALIGN: top">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: left; line-height: 1.25;">
              <div style="line-height: 1.25;"><u>/s/ Dr. Karl Ziegelbauer</u></div>
            </div>
            <div style="text-align: left; line-height: 1.25;">
              <div style="line-height: 1.25;">Dr. Karl Ziegelbauer</div>
              <div style="line-height: 1.25;">(Head GDD - TRG Oncology / Gynecological Therapy)</div>
            </div>
          </td>
          <td style="WIDTH: 49.8%; VERTICAL-ALIGN: top">
            <div style="TEXT-ALIGN: left; FONT: 10pt/1.25 'Times New Roman', Times, serif"><u>/s/ Anat Cohen-Dayag</u></div>
            <div style="text-align: left; line-height: 1.25;">President and CEO</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50.2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="WIDTH: 49.8%; VERTICAL-ALIGN: top">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: left; line-height: 1.25;">
              <div style="line-height: 1.25;">
                <div style="line-height: 1.25;"><u>/s/ Dr. Bertolt Kreft</u></div>
              </div>
              <div style="line-height: 1.25;">Dr. Bertolt Kreft</div>
              <div style="line-height: 1.25;">(Head GDD-ONC/GT-IABDC)</div>
            </div>
          </td>
          <td style="WIDTH: 49.8%; VERTICAL-ALIGN: top">&#160;</td>
        </tr>

    </table>
    <div id="DSPFPageHeader">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div id="DSPFPageBreakArea" style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both">
        <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="font-style: normal; font-weight: normal;">2</font></div>
        <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
          <hr noshade="noshade" style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px"> </div>
      </div>
    </div>
    <div style="text-align: left; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: left; line-height: 1.25; font-weight: bold;">Exhibit 1.3: Bayer Development Process</div>
    <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
    </div>
    <div style="text-align: left; line-height: 1.25;">[***, 3 pages]</div>
    <div style="LINE-HEIGHT: 1.25">&#160;&#160; </div>
    <div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25">
      <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-style: normal; font-weight: normal;"></font>&#160;</div>
      <div style="font-style: normal; font-weight: normal;">3</div>
    </div>
    <div style="LINE-HEIGHT: 1.25">
      <hr align="center" style="BORDER-BOTTOM: black 4px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 1px solid; MARGIN-RIGHT: auto"> </div>
    <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
      &#160;</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>5
<FILENAME>exhibit_4-5.htm
<DESCRIPTION>EXHIBIT 4.5
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body text="#000000" bgcolor="#ffffff" style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">
  <div>
    <hr align="center" style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 4px solid; MARGIN-RIGHT: auto"> </div>
  <div id="DSPFPageHeader">
    <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 4.5</u></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; font-style: italic;">
        <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
          <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; font-style: italic;">
            <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
              <div style="line-height: 1.25; font-weight: bold;">
                <div style="line-height: 1.25;">Pursuant to Instruction 4(a) as to Exhibits of Form 20-F, certain identified information (marked by [***]) has been excluded from the exhibit because it is both not material and is the type that the
                  registrant treats as private or confidential.</div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="LINE-HEIGHT: 1.25">&#160;</div>
  </div>
  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Second Amendment Agreement to</div>
  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Research and Development Collaboration and License Agreement</div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <div style="text-align: justify; line-height: 1.25; text-indent: 27pt;">This Second Amendment Agreement is entered into as of this 27<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> day of July, 2015 (the &#8220;Amendment
    Date&#8221;), by and between Bayer Pharma AG, a company formed under the laws of Germany, having a place of business at M&#252;llerstra&amp;szlig;e 178, 13353 Berlin, Germany (&#8220;<font style="font-weight: bold;">Bayer</font>&#8221;) and Compugen Ltd a company formed
    under the laws of Israel, having a place of business at 72 Pinchas Rosen Street, Tel Aviv 69512, Israel (&#8220;<font style="font-weight: bold;">Compugen</font>&#8221;). Bayer and Compugen each shall be referred to herein as a &#8220;<font style="font-weight: bold;">Party</font>&#8221;
    and they shall be referred to together as the &#8220;<font style="font-weight: bold;">Parties</font>&#8221;.</div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <div style="text-align: justify; line-height: 1.25; text-indent: 27pt;">WHEREAS, the Parties are party to that certain Research and Development Collaboration and License Agreement, dated August 5, 2013, as amended on February 5, 2014, (the &#8220;<font style="font-weight: bold;">Agreement</font>&#8221;); and</div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <div style="text-align: justify; line-height: 1.25; text-indent: 27pt;">WHEREAS, the Parties believe the Target Programs (as defined in the Agreement) will benefit from Compugen granting Bayer limited rights to [***] certain Target [***] Proteins (as
    defined in the Agreement) for certain research and development purposes within the Target Programs; and</div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <div style="text-align: justify; line-height: 1.25; text-indent: 27pt;">WHEREAS, the Parties wish to amend the Agreement to grant such limited rights, all in accordance with the terms and conditions of this Second Amendment Agreement.</div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <div style="text-align: left; line-height: 1.25; text-indent: 27pt;">NOW, THEREFORE, the parties hereby agree as follows:</div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7c3fde262f7c4a88b6a7db3e8cfff736" style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">

        <tr>
          <td style="width: 27pt; vertical-align: top; font-weight: bold; align: right;">1.</td>
          <td style="text-align: left; width: auto; vertical-align: top;">The parties agree to amend the Agreement as set forth below.</td>
        </tr>

    </table>
  </div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4aad8543e621453dbcc4b573db168e35" style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">

        <tr>
          <td style="width: 27pt; vertical-align: top; font-weight: bold; align: right;">2.</td>
          <td style="text-align: left; width: auto; vertical-align: top;">Section 2.3.7.2 of the Agreement is hereby amended to read as follows:</td>
        </tr>

    </table>
  </div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <div style="text-align: justify; line-height: 1.25; text-indent: -45pt; margin-left: 72pt;"><font style="font-weight: bold;">&#8220;2.3.7.2.</font><font id="TRGRRTFtoHTMLTab" style="WIDTH: 12pt; DISPLAY: inline-block; FONT-SIZE: 1px">&#160;</font>[***] <font style="font-weight: bold;">Protein Controls.</font></div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <div style="text-align: justify; line-height: 1.25; margin-left: 72pt;">The Parties agree that the CGEN-15001T Research Program may benefit from the use, as research reagents, of certain Compugen proprietary material [***] (&#8220;[***]<font style="font-weight: bold;"> Protein Controls</font>&#8221;) and that the CGEN-15022 Research Program may benefit from the use, as research reagents, of certain Compugen proprietary material [***] (&#8220;[***] <font style="font-weight: bold;">Protein Controls</font>&#8221;).




    Bayer understands that [***] Protein Controls and [***] Protein Controls are part of Compugen therapeutic development programs that are not subject to this Agreement (the &#8220;[***] Protein Program&#8221; and the &#8220;[***] Protein Program&#8221;, respectively). The [***]
    Protein Program and the [***] Protein Program will each be referred to as a &#8220;[***] <font style="font-weight: bold;">Protein Program</font>&#8221;. The parties contemplate that Compugen and/or its Affiliate will provide Bayer and/or its Affiliate (a) certain
    [***] Protein Controls for [***] specifically set forth in the CGEN-15001T Workplan or [***] otherwise specifically agreed to by [***]; and (b) certain [***] Protein Controls for use in certain activities specifically set forth in the CGEN-15022
    Workplan or [***] otherwise specifically agreed to by [***]. Such [***] Protein Controls and [***] Protein Controls provided by Compugen and/or its Affiliate for purposes of the Workplans will be provided free of charge unless &#8211; solely with respect to
    [***] Protein Controls or [***] Protein Controls provided [***] in the Workplans after the Amendment Date <font style="font-weight: bold;">&#8211;</font> otherwise agreed upon by [***] in good faith due to [***] by Compugen relating to the [***] of such
    [***] Protein Controls or [***] Protein Controls<font style="font-style: italic; font-weight: bold;"> for </font>Bayer, and it will in each case<font style="font-style: italic; font-weight: bold;">&#160;</font>be [***] along with information regarding the
    [***] and/or other [***] of such [***] Protein Controls or [***] Protein Controls, as applicable. Compugen and/or its Affiliate shall provide such [***] Protein Controls and [***] Protein Controls ready for [***] described in the Workplans; such [***]
    Protein Controls and [***] Protein Controls will be [***] form and quality [***].</div>
  <div style="LINE-HEIGHT: 1.25">
    <div id="DSPFPageHeader"></div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; font-style: italic;">
      <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
        <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; font-style: italic;">
          <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
            <div style="line-height: 1.25; font-weight: bold;">
              <div style="line-height: 1.25;"><br>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
  <div id="DSPFPageBreakArea" style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both">
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px"> </div>
  </div>
  <div style="margin-left: 72pt; text-align: center; line-height: 1.25; font-weight: bold;"><br>
  </div>
  <div style="text-align: justify; line-height: 1.25; margin-left: 72pt;">In addition, the Parties agree that the CGEN-15001T Research Program may benefit from [***] to [***] Confidential Information of Compugen to [***] Approved [***] Protein Controls
    (defined below) solely for [***] in the CGEN-15001T Research Program and that the CGEN-15022 Research Program may benefit from [***] to [***] Confidential Information of Compugen to [***]&#160;Approved [***] Protein Controls (defined below) solely for [***]
    in the CGEN-15022 Research Program. &#8220;<font style="font-weight: bold;">Approved </font>[***] <font style="font-weight: bold;">Protein Control</font>&#8221; means any [***] whose [***] has been specifically [***] by Compugen in advance and in writing under
    this Section 2.3.7.2 and that [***] (including without limitation [***]). &#8220;<font style="font-weight: bold;">Approved </font>[***] <font style="font-weight: bold;">Protein Control</font>&#8221; means any [***] whose [***] has been specifically [***] by
    Compugen in advance and in writing under this Section 2.3.7.2 and that [***] (including without limitation [***]).</div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <div style="text-align: justify; line-height: 1.25; margin-left: 72pt;">Compugen hereby grants Bayer [***] the right (which right may <font style="font-weight: bold;">not</font> be sublicensed to any Third Party) to [***] Confidential Information of
    Compugen to [***] Approved [***] Protein Controls and Approved [***] Protein Controls solely for the CGEN-15001T Research Program and CGEN-15022 Research Program, respectively, subject to the terms and conditions set forth below. Notwithstanding the
    restriction on sublicensing in the previous sentence, Bayer [***] may allow Third Party contractors to [***] Approved [***] Protein Controls and Approved [***] Protein Controls [***] if all of the following conditions have been fulfilled: (i) in
    addition to the requirements below, the agreement between Bayer [***] and the Third Party contractor pursuant to which [***] by the Third Party contractor contains the same limitations on the use of Confidential Information and assignment and ownership
    of intellectual property, as are set forth in this Agreement; and (ii) Compugen has had the opportunity to review such agreement for compliance with this Agreement and has approved such agreement with such Third Party contractor (including, without
    limitation, the identity of such Third Party contractor) in writing in advance.</div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <div style="text-align: justify; line-height: 1.25; margin-left: 72pt;">For clarity, no rights are granted under this Section 2.3.7.2 to use Confidential Information of Compugen to [***] of a [***] or of a [***], unless the [***] of the proposed [***]
    has been specifically approved in advance by Compugen in writing.</div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <div style="text-align: justify; line-height: 1.25; margin-left: 72pt;">Each of the [***] Protein Controls and [***] Protein Controls provided by Compugen [***] to Bayer [***] and each Approved [***] Protein Controls and Approved [***] Protein Controls
    made under the rights granted above shall be referred to as a &#8220;[***] <font style="font-weight: bold;">Protein Control</font>&#8221;. In addition to the provisions of Section 2.3.7.1, the following provisions will apply to use of such [***] Protein Controls:</div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z901c41be92e94c96acb903ef80b00ddd" style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">

        <tr>
          <td style="WIDTH: 72pt"></td>
          <td style="width: 22.5pt; vertical-align: top; font-weight: bold; align: right;">(a)</td>
          <td style="text-align: justify; width: auto; vertical-align: top;">Notwithstanding Section 2.3.7.1, Bayer shall not be entitled to [***] Protein Controls to any [***] of Bayer who are [***] (as described in the next sentence) on behalf of Bayer.
            Bayer and its [***] may use such [***] Protein Controls solely for performance of the [***] or otherwise specifically [***] as tasks involving the use of such [***] Protein Controls.</td>
        </tr>

    </table>
  </div>
  <div style="LINE-HEIGHT: 1.25">&#160;</div>
  <div id="DSPFPageBreakArea" style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both">
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px"> </div>
  </div>
  <div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
  <div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2db9d10cb6c8481684012e0a753d0ad9" style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">

        <tr>
          <td style="WIDTH: 72pt"></td>
          <td style="width: 22.5pt; vertical-align: top; font-weight: bold; align: right;">(b)</td>
          <td style="text-align: justify; width: auto; vertical-align: top;">Bayer shall not, and shall ensure that its Affiliates, contractors and collaborators shall [***] the [***] Protein Controls or use [***] Confidential Information regarding the
            [***] and/or regarding other [***] of the [***] Protein Controls nor any other Confidential Information<font style="font-weight: bold;"><u>&#160;</u></font>regarding the [***] Protein Controls provided by Compugen on a need-to-know basis or [***] or
            a [***], to [***] any other [***] of a Target, without the prior express written consent of Compugen in each case. Information regarding Target [***] Proteins [***] in the [***] Approved [***] Protein Controls or Approved [***] Protein Controls
            under the rights granted above will be deemed Confidential Information of Compugen for purposes of this Agreement;</td>
        </tr>

    </table>
  </div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf53854a950b040c69767331d65a9fab4" style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">

        <tr>
          <td style="WIDTH: 72pt"></td>
          <td style="width: 22.5pt; vertical-align: top; font-weight: bold; align: right;">(c)</td>
          <td style="text-align: justify; width: auto; vertical-align: top;">Bayer shall not, and shall ensure that its Affiliates, contractors and collaborators shall not, [***] or otherwise [***] to any Third Party results of their use of the [***]
            Protein Controls, without Compugen&#8217;s prior written consent; and</td>
        </tr>

    </table>
  </div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="za86504ef454841e7b0db0843f9a6d739" style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">

        <tr>
          <td style="WIDTH: 72pt"></td>
          <td style="width: 22.5pt; vertical-align: top; font-weight: bold; align: right;">(d)</td>
          <td style="text-align: justify; width: auto; vertical-align: top;">Bayer shall within reasonable time, but in any case within [***] days, after becoming aware thereof, [***] to Compugen [***] with respect to Target [***] Proteins, their use or
            their production (in each case including, without limitation, [***] thereof), that are conceived and/or reduced to practice by Bayer, its Affiliates, contractors and/or collaborators, [***] Compugen or its Affiliates in the performance of work
            using a [***] Protein Control (&#8220;[***] Protein Invention&#8221;). Any such [***] Protein Invention, whether made by Bayer, any of its Affiliates or any of its contractors or collaborators, solely by Compugen or an Affiliate of Compugen, or jointly by
            any of the above, shall be [***]. Bayer and its Affiliates [***], and Bayer shall cause its contractors and collaborators [***], any and all of their [***] in and to any and all [***] Protein Inventions to Compugen, and any [***] Protein
            Invention [***] to Bayer, is [***] by Bayer to Compugen. Upon Compugen&#8217;s request and at Compugen&#8217;s expense, Bayer shall [***] and [***] that any relevant Affiliate, contractor and collaborator [***] as Compugen deems [***], in its [***], to
            enable Compugen to [***] with respect to any of the foregoing. Bayer will, and shall ensure that its Affiliates, contractors and collaborators will, at Compugen&#8217;s request, provide [***] and [***], as [***] to [***]. Bayer is [***] that its
            Affiliates, contractors and collaborators [***], and [***] by its Affiliates of, the provisions of this Section 2.3.7.2(d). Bayer shall ensure<font style="font-weight: bold;">&#160;</font>that its contractors and collaborators are [***] of this
            Section 2.3.7.2(d) by [***] to which Compugen is [***], prior to [***] to [***] Protein Controls or any Confidential Information of Compugen related to Target [***] Proteins.</td>
        </tr>

    </table>
  </div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <div style="text-align: justify; line-height: 1.25; text-indent: 0.45pt; margin-left: 94.5pt;">For the avoidance of doubt, this clause does not limit in any way Bayer&#8217;s and its Affiliates&#8217; right to conduct independent activities that an unaffiliated
    third party would also be allowed to perform using Target [***] Proteins (e.g. based on publications) without the use of or reference to Confidential Information of Compugen; for the avoidance of doubt, (a) Compugen [***] with respect to the results of
    any such independent activities and (b) [***] is granted by Compugen by implication, estoppel or otherwise with respect to [***] Proteins under any Patents Controlled by Compugen or any of its Affiliates (both except for the right to use [***] Protein
    Controls pursuant to the terms of the previous paragraph).</div>
  <div style="LINE-HEIGHT: 1.25">&#160;</div>
  <div id="DSPFPageBreakArea" style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both">
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px"> </div>
  </div>
  <div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
  <div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9a8c9497cf60404eb403701acce9fe95" style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">

        <tr>
          <td style="width: 27pt; vertical-align: top; font-weight: bold; align: right;">3.</td>
          <td style="text-align: left; width: auto; vertical-align: top;">The Parties agree to replace Exhibit 1.21 of the Agreement by Exhibit 1.21 attached to this Amendment, describing the &#8220;CGEN-15022 Workplan&#8221;.</td>
        </tr>

    </table>
  </div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ze0387e5907ae433bb77e519577ebd601" style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">

        <tr>
          <td style="width: 27pt; vertical-align: top; font-weight: bold; align: right;">4.</td>
          <td style="text-align: left; width: auto; vertical-align: top;">All capitalized terms used herein shall have the meaning set forth in the Agreement. Except as expressly amended pursuant to this Amendment. All other terms and conditions of the
            Agreement shall remain unchanged and in full force and effect.</td>
        </tr>

    </table>
  </div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <div style="text-align: center; line-height: 1.25; font-style: italic;">[Signature Page Follows]</div>
  <div style="LINE-HEIGHT: 1.25">&#160;</div>
  <div id="DSPFPageBreakArea" style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both">
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px"> </div>
  </div>
  <div style="text-align: left; line-height: 1.25;">&#160;</div>
  <div style="text-align: left; line-height: 1.25;"><font style="font-weight: bold;">IN WITNESS WHEREOF,</font> the parties have caused this Amendment to be executed by their duly authorized representatives as of the date first written above.</div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <table cellspacing="0" cellpadding="0" id="z707ce6068e2b47439505f0b6555eeef1" style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">

      <tr>
        <td style="WIDTH: 47.86%; VERTICAL-ALIGN: top">
          <div style="text-align: left; line-height: 1.25; font-weight: bold;">Bayer Pharma AG</div>
          <div style="text-align: justify; line-height: 1.25;"><br>
            By: /s/ Dr. Karl Ziegelbauer</div>
          <div style="text-align: justify; line-height: 1.25;"><br>
            Name: Dr. Karl Ziegelbauer</div>
          <div style="text-align: justify; line-height: 1.25;"><br>
            Title: (Head GDD - TRG ONC / GT)</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25;">By: /s/ Dr. Bertolt Kreft</div>
          <div style="text-align: justify; line-height: 1.25;"><br>
            Name: Dr. Bertolt Kreft</div>
          <div style="text-align: justify; line-height: 1.25;"><br>
            Title: (Head GDD-ONC/GT-IABDC)</div>
        </td>
        <td style="WIDTH: 52.14%; VERTICAL-ALIGN: top">
          <div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="font-weight: bold;">Compugen Ltd.<br>
            </font><font style="LINE-HEIGHT: 1.25">&#160;</font></div>
          <div style="text-align: left; line-height: 1.25;">By: <font style="font-variant: normal; font-style: normal; font-weight: normal;"><u>/s/ Dr. Anat Cohen-Dayag</u></font></div>
          <div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br>
            Name: Dr. Anat Cohen-Dayag<br>
            <font style="LINE-HEIGHT: 1.25">&#160;</font></div>
          <div style="text-align: justify; line-height: 1.25;">Title: President and CEO</div>
        </td>
      </tr>

  </table>
  <div style="LINE-HEIGHT: 1.25">&#160;</div>
  <div id="DSPFPageBreakArea" style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both">
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr noshade="noshade" style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px"> </div>
  </div>
  <div id="DSPFPageHeader">
    <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
    </div>
  </div>
  <div style="text-align: left; line-height: 1.25; font-weight: bold;">EXHIBIT 1.21 CGEN-15022 WORK PLAN</div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <div style="text-align: left; line-height: 1.25;">[***, 9 pages]</div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
    <div style="LINE-HEIGHT: 1.25">
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">&#160;</div>
    </div>
  </div>
  <div style="LINE-HEIGHT: 1.25">
    <hr align="center" style="BORDER-BOTTOM: black 4px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 1px solid; MARGIN-RIGHT: auto"> </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>6
<FILENAME>exhibit_4-6.htm
<DESCRIPTION>EXHIBIT 4.6
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body text="#000000" bgcolor="#ffffff" style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">
  <div>
    <hr align="center" style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 4px solid; MARGIN-RIGHT: auto"> </div>
  <div id="DSPFPageHeader">
    <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 4.6</u></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; font-style: italic;">
        <div align="left" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
          <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; font-style: italic;">
            <div align="center" style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
              <div style="line-height: 1.25; font-weight: bold;">
                <div style="line-height: 1.25;">Pursuant to Instruction 4(a) as to Exhibits of Form 20-F, certain identified information (marked by [***]) has been excluded from the exhibit because it is both not material and is the type that the
                  registrant treats as private or confidential.</div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="LINE-HEIGHT: 1.25">&#160;</div>
  </div>
  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Third Amendment to the</div>
  <div style="text-align: center; line-height: 1.25; font-weight: bold;">Research and Development Collaboration and License Agreement</div>
  <div style="LINE-HEIGHT: 1.25">&#160;</div>
  <div style="text-align: justify; line-height: 1.25; text-indent: 36pt;">This is the third Amendment (hereinafter &#8220;Third Amendment&#8221;) to the Research and Development Collaboration and License Agreement between Bayer Pharma AG, a company formed under the
    laws of Germany, having a place of business at Muellerstrasse 178, 13353 Berlin, Germany (hereinafter: &#8220;BAYER&#8221;) and Compugen Ltd, a company formed under the laws of Israel, having a place of business at 26 Harokmim Street, Holon 5885849, Israel
    (hereinafter: &#8220;Compugen&#8221;) effective as of 5 August 2013, as amended on February 5, 2014 and on July 27, 2015 (hereinafter: the &#8220;Agreement&#8221;).</div>
  <div style="LINE-HEIGHT: 1.25">&#160;</div>
  <div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">WHEREAS,&#160;the Parties wish to amend Exhibit 1.3 specifying the Bayer Development Process; and</div>
  <div style="LINE-HEIGHT: 1.25">&#160;</div>
  <div style="text-align: justify; line-height: 1.25; text-indent: 36pt;">WHEREAS, the Parties wish to amend the Agreement to revise certain milestone [***] as a result of the amended Exhibit 1.3, all in accordance with the terms and conditions of this
    Third Amendment.</div>
  <div style="LINE-HEIGHT: 1.25">&#160;</div>
  <div style="text-align: justify; line-height: 1.25;">NOW THEREFORE IT IS AGREED AS FOLLOWS:</div>
  <div style="LINE-HEIGHT: 1.25">&#160;</div>
  <div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
    <table cellspacing="0" cellpadding="0" style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="z5fd088261fda490e99d984f20d1e7bda" class="DSPFListTable">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">1.</td>
          <td style="text-align: justify; width: auto; vertical-align: top;">The Parties agree to replace Exhibit 1.3 of the Agreement by Exhibit 1.3 attached to this Third Amendment, describing the &#8220;Bayer Development Process&#8221;.</td>
        </tr>

    </table>
  </div>
  <div style="LINE-HEIGHT: 1.25">&#160;</div>
  <div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
    <table cellspacing="0" cellpadding="0" style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="z08a7c1996728415bbd501c82b71f4f24" class="DSPFListTable">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">2.</td>
          <td style="text-align: justify; width: auto; vertical-align: top;">The following language shall be added to the end of Section 6.2.1.1:</td>
        </tr>

    </table>
  </div>
  <div style="LINE-HEIGHT: 1.25">&#160;</div>
  <div style="text-align: left; line-height: 1.25; margin-left: 35.4pt;">&#8220;, except that solely with respect to [***] such milestone payment shall be [***] US Dollars ($[***]);&#8221;</div>
  <div style="LINE-HEIGHT: 1.25">&#160;</div>
  <div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
    <table cellspacing="0" cellpadding="0" style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="z59be66939208469abd103569e5289425" class="DSPFListTable">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">3.</td>
          <td style="text-align: justify; width: auto; vertical-align: top;">The following language shall be added to the end of Section 6.2.1.2:</td>
        </tr>

    </table>
  </div>
  <div style="LINE-HEIGHT: 1.25">&#160;</div>
  <div style="text-align: left; line-height: 1.25; margin-left: 35.4pt;">&#8216;&#8221;, except that solely with respect to [***] such milestone payment shall be [***] US Dollars ($[***]);&#8221;</div>
  <div style="LINE-HEIGHT: 1.25">&#160;</div>
  <div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
    <table cellspacing="0" cellpadding="0" style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="z7348f0630c824790b09608b7674cf9d6" class="DSPFListTable">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">4.</td>
          <td style="text-align: justify; width: auto; vertical-align: top;">This Third Amendment shall become effective on the date this Agreement is signed by the last of the Parties to sign it.</td>
        </tr>

    </table>
  </div>
  <div style="LINE-HEIGHT: 1.25">&#160;</div>
  <div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
    <table cellspacing="0" cellpadding="0" style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="z514480edda604eb8a99720bbabe2735d" class="DSPFListTable">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">5.</td>
          <td style="text-align: justify; width: auto; vertical-align: top;">All capitalized terms used herein shall have the meaning set forth in the Agreement. Except as expressly amended pursuant to this Third Amendment, all other terms and conditions
            of the Agreement shall remain in force unchanged and apply to this Third Amendment.</td>
        </tr>

    </table>
  </div>
  <div style="LINE-HEIGHT: 1.25">&#160;</div>
  <div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
    <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
      <hr noshade="noshade" style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px"> </div>
  </div>
  <div style="LINE-HEIGHT: 1.25">&#160;</div>
  <table cellspacing="0" cellpadding="0" style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="z26ce886333f04ae1a4b849136ae3ce20">

      <tr>
        <td style="WIDTH: 50.2%; VERTICAL-ALIGN: top">
          <div style="text-align: left; line-height: 1.25;">SIGNED for and on behalf of</div>
          <div style="text-align: left; line-height: 1.25;">Bayer Pharma AG</div>
        </td>
        <td style="WIDTH: 49.8%; VERTICAL-ALIGN: top">
          <div style="text-align: left; line-height: 1.25;">SIGNED for and on behalf of</div>
          <div style="text-align: left; line-height: 1.25;">Compugen Ltd</div>
        </td>
      </tr>
      <tr>
        <td style="WIDTH: 50.2%; VERTICAL-ALIGN: top">&#160;</td>
        <td style="WIDTH: 49.8%; VERTICAL-ALIGN: top">&#160;</td>
      </tr>
      <tr>
        <td style="WIDTH: 50.2%; VERTICAL-ALIGN: top">
          <div style="text-align: left; line-height: 1.25;">Date:&#160; April 17, 2016</div>
        </td>
        <td style="WIDTH: 49.8%; VERTICAL-ALIGN: top">
          <div style="text-align: left; line-height: 1.25;">Date: April 17, 2016</div>
        </td>
      </tr>
      <tr>
        <td style="WIDTH: 50.2%; VERTICAL-ALIGN: top">&#160;</td>
        <td style="WIDTH: 49.8%; VERTICAL-ALIGN: top">&#160;</td>
      </tr>
      <tr>
        <td style="width: 50.2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
          <div style="text-align: left; line-height: 1.25;">
            <div style="line-height: 1.25;">/s/ Dr. Karl Ziegelbauer</div>
          </div>
          <div style="text-align: left; line-height: 1.25;">
            <div style="line-height: 1.25;">Dr. Karl Ziegelbauer</div>
            <div style="line-height: 1.25;">(Head Therapeutic Research Groups)</div>
          </div>
          <div style="LINE-HEIGHT: 1.25">&#160;</div>
        </td>
        <td style="WIDTH: 49.8%; VERTICAL-ALIGN: top">
          <div style="text-align: left; line-height: 1.25;">/s/ Anat Cohen-Dayag</div>
          <div style="text-align: left; line-height: 1.25;">Dr. Anat Cohen-Dayag</div>
          <div style="text-align: left; line-height: 1.25;">(President &amp; CEO)</div>
        </td>
      </tr>
      <tr>
        <td style="WIDTH: 50.2%; VERTICAL-ALIGN: top">
          <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">/s/ Dr. Bertolt Kreft</div>
            </div>
            <div style="line-height: 1.25;">Dr. Bertolt Kreft</div>
            <div style="line-height: 1.25;">(Head Oncology III)</div>
          </div>
        </td>
        <td style="WIDTH: 49.8%; VERTICAL-ALIGN: top">&#160;</td>
      </tr>

  </table>
  <div style="LINE-HEIGHT: 1.25">&#160;</div>
  <div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
    <div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="font-style: normal; font-weight: normal;" id="DSPFPageNumber">2</font></div>
    <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
      <hr noshade="noshade" style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px"> </div>
  </div>
  <div id="DSPFPageHeader">
    <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
    </div>
  </div>
  <div style="text-align: left; line-height: 1.25; font-weight: bold;">Exhibit 1.3: Bayer Development Process</div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  <div style="text-align: left; line-height: 1.25;">[***, 3 pages]</div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
  &#160;
  <div style="TEXT-ALIGN: center">3</div>
  <div>
    <hr align="center" style="BORDER-BOTTOM: black 4px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 1px solid; MARGIN-RIGHT: auto"> </div>
  <div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>7
<FILENAME>exhibit_4-8.htm
<DESCRIPTION>EXHIBIT 4.8
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u> </u>
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"><u>Exhibit 4.8</u><br>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">___________________,</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Dear Sir,</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">You are _____________ of Compugen Ltd. (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) [reporting to the Chief Executive Officer of the Company], and in order to enhance your service to the Company in an effective manner, the Company desires to provide for your
      indemnification and exemption and release as set forth herein (the<font style="font-weight: bold;">&#160;</font>&#8220;<font style="font-weight: bold;">Letter of Indemnification and Exemption</font>&#8221;), to the fullest extent permitted by law and the Company's Articles of Association, as shall be in effect from time to time (the &#8220;<font style="font-weight: bold;">Articles of Association</font>&#8221;).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">In consideration of your service to the Company, the Company hereby agrees as follows:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company hereby undertakes to indemnify you to the fullest extent permitted by law in respect of any act or omission (&#8220;<font style="font-weight: bold;">action</font>&#8221;)
        taken or made by you in your capacity as an office holder of the Company, as follows:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 57pt; margin-left: 1pt; line-height: 1.25;">1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; for any monetary liability or obligation imposed on you in favor of another person by a court judgment, including a settlement or an arbitrator&#8217;s award approved by a court;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 57pt; margin-left: 1pt; line-height: 1.25;">1.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;for any payments which you are obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the Israel Securities Law, 5728-1968 (the &#8220;<font style="font-weight: bold;">Securities Law</font>&#8221;) and expenses incurred by you in connection with a proceeding under Chapters H'3, H'4 or I'1 of the Securities Law, including reasonable litigation expenses, including attorneys&#8217; fees, or in connection
        with Article D of Chapter Four of Part Nine of the Israel Companies Law, 5759-1999 (the &#8220;<font style="font-weight: bold;">Companies Law</font>&#8221;);</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 57pt; margin-left: 1.15pt; line-height: 1.25;">1.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;for reasonable litigation expenses, including attorneys&#8217; fees, incurred by you or which you are ordered to pay by a court, in a proceeding filed against you by the Company or on its behalf or by another person, or in a criminal
        action in which you are acquitted or in a criminal action in which you are convicted of an offense that does not require proof of criminal intent;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 57pt; margin-left: 1pt; line-height: 1.25;">1.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;for reasonable litigation expenses, including attorneys&#8217; fees, incurred by you in consequence of an investigation or proceeding instituted against you by an authority that is authorized to conduct such investigation or proceeding,
        and which was concluded without filing of an indictment against you and without a financial obligation imposed on you in lieu of criminal proceedings (as such terms are defined in the Companies Law), or which was concluded without filing of an
        indictment against you but with a financial obligation imposed on you in lieu of criminal proceedings in respect of an offense that does not require proof of criminal intent or in connection with a monetary sanction; and</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 57pt; margin-left: 1pt; line-height: 1.25;">1.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;for expenses incurred by you in connection with a proceeding under Chapter G'1, of the Israel Restrictive Trade Practices Law, 5748-1988, including reasonable litigation expenses, including attorneys&#8217; fees.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">The above indemnification will also apply with respect to your service as, at the request of the
      Company, and to any action taken by you in your capacity as, a director, board observer or other office holder of any other entity directly or indirectly controlled by or under common control with, the Company (a &#8220;<font style="font-weight: bold;">Subsidiary</font>&#8221;) or in your capacity as a director, board observer or other office holder of any other corporation in which the Company holds an equity interest (&#8220;<font style="font-weight: bold;">Affiliate</font>&#8221;)&#160;and references herein to the Company shall include
      Subsidiaries and Affiliates where appropriate.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company will not indemnify you for any amount you may be obligated to pay in respect of:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 57pt; margin-left: 1pt; line-height: 1.25;">2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a breach of your duty of loyalty to the Company, except for a breach of such duty of loyalty while acting in good faith and having reasonable grounds to assume that such act would not prejudice the interests of the Company or as
        otherwise permitted by law;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 57pt; margin-left: 1pt; line-height: 1.25;">2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;an intentional or reckless breach of your duty of care to the Company, unless the breach was committed only in negligence;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 57pt; margin-left: 1pt; line-height: 1.25;">2.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;an action taken by you with the intent of unlawfully realizing personal gain;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 57pt; margin-left: 1pt; line-height: 1.25;">2.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a fine, monetary sanction, forfeit or penalty imposed upon you; and</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 57pt; margin-left: 1pt; line-height: 1.25;">2.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a counterclaim brought by the Company or in its name in connection with a&#160; claim or proceeding against the Company initiated or filed voluntarily by you, other than by way of defense or by way of countersuit or third party notice in
        connection with a claim brought against you by the Company, or in specific cases in which the Company&#8217;s Board of Directors has approved the initiation or bringing of such suit by you, which approval shall not be unreasonably withheld.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company will make available all amounts payable to you in accordance with Section 1 above on the date on which such amounts are first payable by you (&#8220;<font style="font-weight: bold;">Time of Indebtedness</font>&#8221;), including with respect to any claim against you initiated by the Company or on its behalf, and with respect to items referred to in Sections 1.2, 1.3, 1.4, and 1.5 above, even prior to a court
        decision, but in any event the Company has no duty to advance payments earlier than four (4) business days following receipt of a written request therefor by you to the Company. Advances given to cover legal expenses in criminal proceedings will be
        repaid by you to the Company if you are found guilty of a crime which requires proof of criminal intent and the applicable appeal period has lapsed. Other advances will be repaid by you to the Company if it is determined that you are not lawfully
        entitled to such indemnification.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">As part of the aforementioned undertaking, the Company will make available to you any security or
      guarantee that you may be required to post in accordance with an interim decision given by a court or an arbitrator, including for the purpose of substituting liens imposed on your assets.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company will indemnify you even if at the relevant Time of Indebtedness you are no longer a director or other office holder of the Company provided that the obligations with respect to which you will be indemnified hereunder are
        in respect of actions taken by you while you were a director or other office holder of the Company as aforesaid, and in such capacity.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The indemnification will be limited to the payments and expenses mentioned in Sections 1.2, 1.3, 1.4 and 1.5 above (pursuant and subject to Section 3 above and insofar as indemnification with respect thereto is not restricted by law
        or by the provisions of Section 2 above) and to the matters mentioned in Section 1.1 above insofar as they result from, or are connected to, events and circumstances set forth in <font style="font-weight: bold;"><u>Schedule A</u>&#160;</font>hereto, which are deemed by the Company's Board of Directors, based on the current
        activities of the Company, to be foreseeable as of the date hereof.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The indemnification that the Company undertakes towards all persons whom it has resolved to indemnify for the matters&#160;mentioned in Section 1.1 above insofar as they result from, or are connected to, events and circumstances set forth
        in Schedule A hereto, jointly and in the aggregate,&#160;shall not exceed the higher of the following: (i) an amount equal to 25% of the Company&#8217;s shareholders&#8217; equity of the Company, per the most recent financial statements (audited or reviewed) after
        the time that notice is provided to the Company; or (y) $20 million&#160;(Twenty&#160;Million U.S. Dollars), provided that if such amount is insufficient to cover all amounts to which such persons are entitled pursuant to such undertaking of the Company,
        such amount shall be allocated to such persons pro rata to the amounts to which they are so entitled.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company will not indemnify you for any liability with respect to which you have received payment by virtue of an insurance policy or another indemnification agreement other than for amounts which are in excess of the amounts
        actually paid to you pursuant to any such insurance policy or other indemnity agreement (including deductible amounts not covered by insurance policies), within the limits set forth in Section 6 above.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subject to the provisions of Sections 6 and 7 above, the indemnification hereunder will, in each case, cover all sums of money that you will be obligated to pay, in those circumstances for which indemnification is permitted under
        applicable law, the Articles of Association and under this Letter of Indemnification and Exemption.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company will be entitled to any amount collected from a third party in connection with liabilities indemnified hereunder. Furthermore, by accepting this Letter of Indemnification and Exemption, you assign all rights thereto to
        the Company. In the event of payment by the Company pursuant to this Letter of Indemnification and Exemption, the Company shall be subrogated to the extent of such payment to all of your rights of recovery, and you shall execute all documents
        required, and shall do everything that may be necessary, to secure such rights, including the execution of such documents necessary to enable the Company effectively to bring suit to enforce such rights.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In all indemnifiable circumstances, indemnification will be subject to the following:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 58pt; margin-left: 1pt; line-height: 1.25;">10.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; You shall promptly notify the Company of any legal proceedings initiated against you and of all possible or threatened legal proceedings without delay following your first becoming aware thereof, however, your failure to notify the
        Company as aforesaid shall not derogate from your right to be indemnified as provided herein (except to the extent that such failure to notify causes the Company damages). You shall deliver to the Company, or to such person as it shall advise you,
        without delay all documents you receive in connection with these proceedings or possible or threatened proceedings.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">Similarly, you must advise the Company on an ongoing and current basis concerning all events which
      you suspect may give rise to the initiation of legal proceedings against you in connection with your actions as an office holder of the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 58pt; margin-left: 1pt; line-height: 1.25;">10.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Other than with respect to proceedings that have been initiated against you by the Company or in its name, the Company shall be entitled to undertake the conduct of your defense in respect of such legal proceedings and/or to hand
        over the conduct thereof to any attorney which the Company may choose for that purpose, except to an attorney who is not, upon reasonable grounds, acceptable to you. In such case, the Company shall pay the fees and expenses of such counsel. The
        Company shall notify you of any such decision to defend within ten (10) calendar days of receipt of notice of any such proceeding.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">The Company and/or the attorney as aforesaid shall be entitled, within the context of the conduct
      as aforesaid, to conclude such proceedings, all as it shall see fit, including by way of settlement. At the request of the Company, you shall execute all documents required to enable the Company and/or its attorney as aforesaid to conduct your
      defense in your name, and to represent you in all matters connected therewith, in accordance with the aforesaid.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">For the avoidance of doubt, in the case of criminal proceedings the Company and/or the attorneys as
      aforesaid will not have the right to plead guilty in your name or to agree to a plea-bargain in your name without your consent. However, the aforesaid will not prevent the Company and/or its attorneys as aforesaid, with the approval of the Company,
      to come to a financial arrangement with a plaintiff in a civil proceeding without your consent so long as such arrangement will not be an admittance of an occurrence not indemnifiable pursuant to this Letter of Indemnification and Exemption and/or
      pursuant to law. The Company shall not, without your prior written consent, consent to the entry of any judgment against you or enter into any settlement or compromise which (i) includes an admission of your fault, (ii) does not include, as an
      unconditional term thereof, the full release of you from all liability in respect of such proceeding or (iii) is not fully indemnifiable pursuant to this Letter of Indemnification and Exemption and pursuant to law. This paragraph shall not apply to a
      proceeding brought by you under Section 10.7 below.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 58pt; margin-left: 1pt; line-height: 1.25;">10.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; You will fully cooperate with the Company and/or any attorney as aforesaid in every reasonable way as may be required of you within the context of their conduct of such legal proceedings, including but not limited to the execution
        of power(s) of attorney and other documents, provided that the Company shall cover all costs incidental thereto such that you will not be required to pay the same or to finance the same yourself.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 58pt; margin-left: 1pt; line-height: 1.25;">10.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Notwithstanding the provisions of Sections 10.2 and 10.3 above, (i) if in a proceeding to which you are a party by reason of your status as a director or other office holder of the Company and the named parties to any such
        proceeding include both you and the Company, a conflict of interest or potential conflict of interest (including the availability to the Company, on the one hand, and you, on the other hand, of different or inconsistent defenses or counterclaims)
        exists between you and the Company, or (ii) if the Company fails to assume the defense of such proceeding in a timely manner, you shall be entitled to be represented by separate legal counsel, which shall represent other persons similarly situated,
        of the Company&#8217;s choice and reasonably acceptable to you and such other persons, at the expense of the Company. In addition, if the Company fails to comply with any of its material obligations under this Letter of Indemnification and Exemption or
        in the event that the Company or any other person takes any action to declare this Letter of Indemnification and Exemption void or unenforceable, or institutes any action, suit or proceeding to deny or to recover from you the benefits intended to
        be provided to you hereunder, you shall have the right to retain counsel of your choice, and reasonably acceptable to the Company to represent you in connection with any such matter, and, except with respect to such actions, suits or proceedings
        brought by the Company that are resolved in favor of the Company, at the expense of the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 58pt; margin-left: 1pt; line-height: 1.25;">10.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If, in accordance with Section 10.2 (but subject to Section 10.4) above, the Company has taken upon itself the conduct of your defense, the Company will have no liability or obligation pursuant to this Letter of Indemnification and
        Exemption or the above resolutions to indemnify you for any legal expenses, including any legal fees, that you may expend in connection with your defense, unless (i) the Company shall not have assumed the conduct of your defense as contemplated,
        (ii) the Company refers the conduct of your defense to an attorney who is not, upon reasonable grounds, acceptable to you, (iii) the named parties to any such action (including any impleaded parties) include both you and the Company, and joint
        representation is inappropriate under applicable standards of professional conduct due to a conflict of interest between you and the Company, or (iv) the Company shall agree to such expenses, in either of which events all reasonable fees and
        expenses of your counsel shall be borne by the Company.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 58pt; margin-left: 1pt; line-height: 1.25;">10.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company will have no liability or obligation pursuant to this Letter of Indemnification and Exemption to indemnify you for any amount expended by you pursuant to any compromise or settlement agreement reached in any suit, demand
        or other proceeding as aforesaid without the Company&#8217;s consent to such compromise or settlement.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 58pt; margin-left: 1pt; line-height: 1.25;">10.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If required by law, the Company&#8217;s authorized organs will consider the request for indemnification and the amount thereof and will determine if you are entitled to indemnification and the amount thereof. In the event that you make a
        request for payment of an amount of indemnification hereunder or a request for an advancement of indemnification expenses hereunder and the Company fails to timely determine your right to indemnification hereunder or fails to make such payment or
        advancement, you may petition any court which has jurisdiction to enforce the Company&#8217;s obligations hereunder. The Company agrees to reimburse you in full for any reasonable expenses incurred by you in connection with investigating, preparing for,
        litigating, defending or settling any action brought by you under the immediately preceding sentence, except where such action or any claim or counterclaim in connection therewith is resolved in favor of the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company hereby exempts and releases you, to the fullest extent permitted by law, from and against any liability for monetary or other damages due to or arising or resulting from a breach of your duty of care, as an office
        holder, to the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If for the validation of any of the undertakings in this Letter of Indemnification and Exemption any act, resolution, approval or other procedure is required, the Company undertakes to cause them to be done or adopted in a manner
        which will enable the Company to fulfill all its undertakings as aforesaid; provided that nothing in this Letter of Indemnification and Exemption shall require the Company to amend the Articles of Association.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; For the avoidance of doubt, it is hereby clarified that nothing contained in this Letter of Indemnification and Exemption derogates from the Company&#8217;s right (but in no way should the Company be obligated) to indemnify you post
        factum for any amounts which you may be obligated to pay as set forth in Section 1 above without regard to the limitations set forth in Sections 5 and 6 above.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If any undertaking included in this Letter of Indemnification and Exemption is held invalid or unenforceable, such invalidity or unenforceability will not affect any of the other undertakings which will remain in full force and
        effect. Furthermore, if such invalid or unenforceable undertaking may be modified or amended so as to be valid and enforceable as a matter of law, such undertaking will be deemed to have been modified or amended, and any competent court or
        arbitrator are hereby authorized to modify or amend such undertaking, so as to be valid and enforceable to the maximum extent permitted by law.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Letter of Indemnification and Exemption and the agreements herein shall be governed by and construed and enforced in accordance with the laws of the State of Israel, without regard to the rules of conflicts of laws and the
        competent courts in Tel Aviv, Israel will have the sole and exclusive jurisdiction over any dispute arising from or in connection with this Letter of Indemnification and Exemption.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 28.9pt; margin-left: 1.15pt; line-height: 1.25;">16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Letter of Indemnification and Exemption replaces any preceding letter of indemnification or arrangement for indemnification or release and exemption that may have been issued to you by the Company, <font style="font-style: italic;">provided however</font>, that no previous exemption or release given to you from and against any liability for monetary or other damages due to or arising
        or resulting from, a breach of your duty of care, as an office holder, to the Company shall be adversely affected.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">17.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Neither the settlement nor termination of any proceeding nor the failure of the Company to award indemnification or to determine that indemnification is payable shall create an adverse presumption that you are not entitled to
        indemnification hereunder. In addition, the termination of any proceeding by judgment or order (unless such judgment or order provides so specifically) or settlement, shall not create a presumption that you did not act in good faith and in a manner
        which you reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal action or proceeding, had reasonable cause to believe that your action was unlawful.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 29pt; margin-left: 1pt; line-height: 1.25;">18.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Letter of Indemnification and Exemption shall be (a) binding upon all successors and assigns of the Company (including any transferee of all or a substantial portion of the business, stock and/or assets of the Company and any
        direct or indirect successor by merger or consolidation or otherwise by operation of law), and (b) binding on and shall inure to the benefit of your heirs, personal representatives, executors and administrators. This Letter of Indemnification and
        Exemption shall continue for your benefit and your heirs', personal representatives', executors' and administrators' benefit after you cease to be a director or other office holder of the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 28.9pt; margin-left: 1.15pt; line-height: 1.25;">19.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except with respect to changes in the governing law which expand your right to be indemnified by the Company, no supplement, modification or amendment of this Letter of Indemnification and Exemption shall be binding unless
        executed in writing by each of the parties hereto. In the event of any change, after the date of this Letter of Indemnification and Exemption in any applicable law, statute or rule which expands the right of the Company to indemnify members of its
        Board of Directors, an officer or other corporate agent, it is the intent of the parties hereto that you shall enjoy by this Letter of Indemnification and Exemption the greater benefits so afforded by such change and such changes shall, to the
        fullest extent permitted by law, be, ipso facto, within the purview of your rights and the Company&#8217;s obligations pursuant to this Letter of Indemnification and Exemption.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 28.9pt; margin-left: 1.15pt; line-height: 1.25;">20.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No waiver of any of the provisions of this Letter of Indemnification and Exemption shall be deemed or shall constitute a waiver of any other provisions of this Letter of Indemnification and Exemption (whether or not similar),
        nor shall such waiver constitute a continuing waiver.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 28.9pt; margin-left: 1.15pt; line-height: 1.25;">21.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All notices and other communications required or permitted under this Letter of Indemnification and Exemption shall be in writing and shall be deemed delivered (i) if mailed, three (3) business days after mailing (unless
        mailed internationally, in which case it shall be deemed delivered five (5) business days after mailing), (ii) if by air courier, two (2) business days after delivery to the courier service, (iii) if sent by messenger, upon delivery, (iv) if sent
        via facsimile, upon transmission and electronic (or other) confirmation of receipt or (if transmitted and received on a non-business day) on the first business day following transmission and electronic (or other) confirmation of receipt, and (iv)
        if sent by email, on the date of transmission or (if transmitted and received on a non-business day) on the first business day following transmission, except where a notice is received stating that such mail has not been successfully delivered.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 28pt; line-height: 1.25;">This Letter of Indemnification and Exemption is being issued to you pursuant to the resolutions adopted by the
      Compensation Committee of the Board of Directors of the Company on July 26, 2021, and by the Board of Directors of the Company on July 27, 2021 and by the General Meeting of Shareholders of the Company on September 2, 2021.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 28pt; line-height: 1.25;">This Letter of Indemnification and Exemption is effective as of the first date in which you became an office holder
      of the Company.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 28pt; line-height: 1.25;">Kindly sign and return the enclosed copy of this letter to acknowledge your agreement to the contents hereof.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <table id="z38a480779c804c35a5b5f16c96a9f638" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 50%;">
              <div>
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Very truly yours,</div>
                <div style="line-height: 1.25;">&#160;</div>
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Compugen Ltd.</div>
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">By:&#160; &#160;&#160; Dr. Anat Cohen-Dayag</div>
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Title:&#160; President &amp; CEO</div>
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Date:&#160; ________ __, 202_</div>
              </div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50%;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Accepted and agreed to:</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Signature:</font>&#160;<u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
                  </u></div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">_____________</div>
              <div style="line-height: 1.25;">&#160;</div>
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Date:&#160; ______ __, 202_</div>
            </td>
            <td rowspan="1" style="width: 50%;">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <br>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Schedule A</div>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zabdf3c13236544b7875a8d9d601c6caa" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33.9pt; vertical-align: top; align: right;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Negotiations, execution, delivery and performance of agreements on behalf of the Company including, inter alia, any claim or demand made by a customer, supplier,
              contractor or other third party transacting any form of business with the Company, relating to the negotiations or performance of such transactions, representations or inducements provided in connection thereto or otherwise.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc89238fcb0c64ae5bccd69ab5583d111" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33.9pt; vertical-align: top; align: right;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any claim or demand made related to anti-competitive acts and acts of commercial wrongdoing.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8e427780a484469c82b0130271faba97" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33.9pt; vertical-align: top; align: right;">3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any claim or demand made related to acts in regard of invasion of privacy including with respect to databases and acts in regard of slander.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z950504c8bfc0498b998c14783b8ca31d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33.9pt; vertical-align: top; align: right;">4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any claim or demand made for actual or alleged infringement, misappropriation or misuse of any third party&#8217;s intellectual property rights including, but not limited to
              confidential information, patents, copyrights, design rights, service marks, trade secrets, copyrights, misappropriation of ideas by the Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9ea8544ee4304014aaa6b39ac0db75ba" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33.9pt; vertical-align: top; align: right;">5.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Actions taken in connection with the intellectual property of the Company and its protection, including the registration or assertion of rights to intellectual property
              and the defense of claims relating thereof.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zda0ee17a962c46a9a57e978883e939dc" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33.9pt; vertical-align: top; align: right;">6.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Participation and/or non-participation at the Company&#8217;s board meetings, bona fide expression of opinion and/or voting and/or abstention from voting at the Company&#8217;s
              board meetings.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zca7964479c36498b88e965f901307ebc" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33.9pt; vertical-align: top; align: right;">7.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Approval of corporate actions including the approval of the acts of the Company&#8217;s management, their guidance and their supervision.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za7ff1521cdf64075b7dba4b7d81bab77" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33.9pt; vertical-align: top; align: right;">8.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Actions concerning the approval of transactions of the Company with officers and/or directors and/or holders of controlling interests in the Company, and any other
              transactions referred to in Sections 267A and/or 270 of the Companies Law.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z59f8595968ed4190af81e5862114d8ed" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33.9pt; vertical-align: top; align: right;">9.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Claims of failure to exercise business judgment and a reasonable level of proficiency, expertise and care in regard of the Company&#8217;s business.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd94f9006362c4a9d9fdec8705539057b" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33.9pt; vertical-align: top; align: right;">10.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Violations of securities laws of any jurisdiction, including without limitation, fraudulent disclosure claims, failure to comply with the United States Securities and
              Exchange Commission and/or the Israeli Securities Authority and/or any stock exchange disclosure or other rules and any other claims relating to relationships with investors, shareholders and the investment community and any claims related to
              the Sarbanes-Oxley Act of 2002, as amended from time to time.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd6ee70f9480540ad9bd598aa715dfe4d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33.9pt; vertical-align: top; align: right;">11.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any claim or demand made under any securities laws or by reference thereto, or related to the failure to disclose any information in the manner or time such information
              is required to be disclosed pursuant to such laws, or related to inadequate or improper disclosure of information to shareholders, or prospective shareholders, or related to the purchasing, holding or disposition of securities of the Company
              or any other investment activity involving or affected by such securities, including any actions relating to an offer or issuance of securities of the Company to the public by prospectus or privately by private placement, in Israel or abroad,
              including the details that shall be set forth in the documents in connection with execution thereof.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc218b2ba604d479fa5612accc3b0cff1" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33.9pt; vertical-align: top; align: right;">12.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Actions in connection with the financial statements and/or reports of the Company, including the preparation thereof.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z60942fcb849d4ca98d704d276751ea40" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 34.1pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">13.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Violations of laws requiring the Company to obtain regulatory and governmental licenses, permits and authorizations or laws related to any governmental grants in any
              jurisdiction.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z87a8f1aa82b741d2bf060e007dd267f4" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 34.1pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">14.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Claims in connection with publishing or providing any information, including any filings with any governmental authorities, on behalf of the Company in the
              circumstances required under any applicable laws.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8a0073ca1b194db8b1a98dac8536fe00" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 34.1pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">15.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any claim or demand made by employees, consultants, agents or other individuals or entities employed by or providing services to the Company relating to compensation
              owed to them or damages or liabilities suffered by them in connection with such employment or service.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z45f991350d734cd8a22492f72db00067" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 34.1pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">16.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Resolutions and/or actions relating to employment matters of the Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb6555a13f8114d21a3689458e9f3bf7c" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 34.1pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">17.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Events, pertaining to the employment conditions of employees and to the employer - employee relations, including the promotion of workers, handling pension
              arrangements, insurance and saving funds, options and other benefits.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdf1eb98f952347029f6c5ba40d652e72" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 34.1pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">18.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any claim or demand made by any lenders or other creditors or for moneys borrowed by, or other indebtedness of, the Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3096d36478144bb2a253aca208718912" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 34.1pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">19.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any claim or demand made by any third party suffering any personal injury and/or bodily injury and/or property damage to business or personal property through any act
              or omission attributed to the Company, or their respective employees, agents or other persons acting or allegedly acting on their behalf.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd93b1446590f4afaa83a8eed20541463" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 34.1pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">20.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any claim or demand made directly or indirectly in connection with complete or partial failure, by the Company thereof, or their respective directors, officers and
              employees, to pay, report, keep applicable records or otherwise, of any foreign, federal, state, country, local, municipal or city taxes or other compulsory payments of any nature whatsoever, including without limitation, income, sales, use,
              transfer, excise, value added, registration, severance, stamp, occupation, customs, duties, real property, personal property, capital stock, social security, unemployment, disability, payroll or employee withholding or other withholding,
              including any interest, penalty or addition thereto, whether disputed or not.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z193dc059c54e4664ab8cbc2348126eb2" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 34.1pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">21.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any claim or demand made by purchasers, holders, lessors or other users of products or assets of the Company, or individuals treated with such products, for damages or
              losses related to such use or treatment.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcf7d12de05ec4d5e97e9ce9eca7c4de7" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 34.1pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">22.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any administrative, regulatory or judicial actions, orders, decrees, suits, demands, demand letters, directives, claims, liens, investigations, proceedings or notices
              of noncompliance or violation by any governmental entity or other person alleging potential responsibility or liability (including potential responsibility or liability for costs of enforcement, investigation, cleanup, governmental response,
              removal or remediation, for natural resources damages, property damage, personal injuries, or penalties or contribution, indemnification, cost recovery, compensation, or injunctive relief) arising out of, based on or related to (x) the
              presence of, release, spill, emission, leaking, dumping, pouring, deposit, disposal , discharge, leaching or migration into the environment (each a &#8220;Release&#8221;) or threatened Release of, or exposure to, any hazardous, toxic, explosive or
              radioactive substance, wastes or other substances or wastes of any nature regulated pursuant to any environmental law, at any location, whether or not owned, operated, leased or managed by the Company, or (y) circumstances forming the basis
              of any violation of any environmental law, environmental permit, license, registration or other authorization required under applicable environmental and/or public health law.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf12c687e9a1e42e184387c264ce01eea" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 34.1pt; vertical-align: top; align: right;">23.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Actions in connection with the Company&#8217;s development, use, sale, licensing, distribution, marketing or offer of products and/or services.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5677c6b2e1c048a295c1011b4629c2d2" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">24.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Resolutions and/or actions relating to a merger of the Company, the issuance of shares or securities exercisable into shares of the Company, changing the share capital
              of the Company, formation of subsidiaries, reorganization, winding up or sale of all or part of the business, operations or shares the Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcb8391854f2e4bec9d7e13b490ab46f0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 34.1pt; vertical-align: top; align: right;">25.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Resolutions and/or actions relating to investments in the Company and/or the purchase or sale of assets, including the purchase or sale of companies and/or businesses,
              and/or investments in corporate or other entities and/or investments in traded securities and/or any other form of investment.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z34eca83ec97940f1bf2ab697855be346" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 34.1pt; vertical-align: top; align: right;">26.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any administrative, regulatory or judicial actions, orders, decrees, suits, demands, demand letters, directives, claims, liens, investigations, proceedings or notices
              of noncompliance or violation by any governmental entity or other person alleging the failure of the Company, or any of the Company's business operations to comply with any statute, law, ordinance, rule, regulation, order or decree.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze85e091c7e91468faa36703bef7e503f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">27.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Class actions or derivative actions regarding the Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zeab84bdd15a04994a04b4ae9fc3f83a5" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 34.1pt; vertical-align: top; align: right;">28.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any claim or demand, not covered by any of the categories of events described above, which, pursuant to any applicable law, a director or officer of the Company may be
              held liable to any government or agency thereof, or any person or entity, in connection with actions taken by such director or officer in such capacity.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;<br style="line-height: 1.25;">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.15
<SEQUENCE>8
<FILENAME>exhibit_4-15.htm
<DESCRIPTION>PURSUANT TO INSTRUCTION 4(A) AS TO EXHIBITS OF FORM 20-F, CERTAIN IDENTIFIED INFORMATION (MARKED BY
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;">
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><font style="font-weight: bold;"><u>Exhibit


        4.15</u></font><br>
  </div>
  <div style="text-align: right;"><u> <br>
    </u></div>
  <div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Pursuant to Instruction 4(a) as to Exhibits of Form 20-F, certain identified information (marked by [*]) has been excluded from the exhibit because it is both not material and is
      the type that the registrant treats as private or confidential.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><u>AMENDMENT NO. 3 TO THE LICENSE AGREEMENT</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">THIS AMENDMENT NO. 3 TO THE LICENSE AGREEMENT (this &#8220;<font style="font-weight: bold; font-style: italic;">Amendment</font>&#8221;) is made and entered into as of August 4<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>, 2021 (the &#8220;<font style="font-weight: bold; font-style: italic;">Amendment Effective Date</font>&#8221;), by and between MedImmune Limited, a company incorporated in England and a member of the
      AstraZeneca Group having an address of Milstein Building, Granta Park, Abington, Cambridge, CB21 6GH (&#8220;<font style="font-weight: bold; font-style: italic;">MedImmune</font>&#8221;) and Compugen Ltd., a an Israeli company, having an address of Azrieli
      Center, 26 Harokmim Street, Building D, Holon 5885849, Israel (&#8220;<font style="font-weight: bold; font-style: italic;">Compugen</font>&#8221;). MedImmune and Compugen are each referred to in this Amendment as a &#8220;<font style="font-weight: bold; font-style: italic;">Party</font>&#8221; and collectively, as the &#8220;<font style="font-weight: bold; font-style: italic;">Parties</font>&#8221;.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">RECITALS</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2551272cdb5d4862b259b1a0d2fb7ada">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">A.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>WHEREAS, MedImmune and Compugen are parties to a License Agreement effective as of March 30, 2018, as amended on May 9, 2018, and on September 16, 2020 (collectively, the &#8220;<font style="font-weight: bold; font-style: italic;">Agreement</font>&#8221;<font style="font-style: italic;">)</font>.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z94a357b110804471a6ea8b7cf82737bc">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">B.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>WHEREAS, the Parties have agreed to clarify the scope of the Licensed Patents.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7af5cb079a304fc09b78de004dddb83b">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">C.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>WHEREAS, in accordance with Section 18.2 of the Agreement, the Parties hereto desire to amend and modify the Agreement in accordance with the terms and subject to the conditions set forth in this Amendment.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">NOW, THEREFORE, IN CONSIDERATION OF THE MUTUAL COVENANTS, CONDITIONS AND AGREEMENTS HEREIN CONTAINED, THE PARTIES HEREBY AGREE AS FOLLOWS:</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z04909fdd16d84e7b91dded451a8defcd">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>A new Section 1.16A is hereby added to the Agreement, to read as follows:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"><font style="font-weight: bold;">1.16A</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Compugen Reserved Patents</font>&#8221; means any Patents Controlled by Compugen as of the
      Effective Date or during the Term that do not Cover the development, manufacture, use, or commercialization of a [*]. Notwithstanding anything to the contrary herein, the Compugen Reserved Patents include any such Patents that Cover (a)&#160;any product
      that contains (i) the [*] plus (ii) another Antibody, compound, or molecule (including any fragments or peptides thereof) that binds either to PVRIG or to TIGIT (with respect to TIGIT, creating a bi-paratopic antibody); or (b)&#160;any product described
      in clause (a) that additionally contains [*].</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z51b5c8a6e7d840fd83ba9d35962bd2ea">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Section <font style="font-weight: bold;">1.42</font> of the Agreement is hereby amended and restated in its entirety to read as follows:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25;"><font style="font-weight: bold;">1.42</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; &#8220;<font style="font-weight: bold;">Licensed</font>&#160;<font style="font-weight: bold;">Patents</font>&#8221; means Patents
      Controlled by Compugen as of the Effective Date or during the Term that Cover the development, manufacture, use, or commercialization of the [*].</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcca1089dcbe041b9a40f71f534fc4200">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>A new Section <font style="font-weight: bold;">12.2(e)</font> is hereby added to the Agreement, to read as follows:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; line-height: 1.25;"><font style="font-weight: bold;">12.2(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; [*]<font style="font-weight: bold;"> of Patent Rights.</font>&#160;In order to more efficiently enable the prosecution and
      maintenance of the Licensed Patents, and subject to the Parties rights pursuant to Sections 12.2(a) and 12.2(b) above, the Parties will use good faith efforts to [*] to the extent reasonably possible and without adversely impacting such prosecution
      and maintenance or the scope of the protected patentable subject matter.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zeb6360f3c222415a9ba87cd0f1309ad9">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Except as expressly set forth herein, all of the terms and conditions of the Agreement remain unchanged and are in full force and effect. Capitalized terms not otherwise defined in this Amendment shall have the meanings respectively
              ascribed to them in the Agreement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2066d9017d734bb2963f64764c850579">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">5.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>This Amendment and the Agreement constitute the complete and final and exclusive understanding and agreement of the Parties with respect to the subject matter of the Agreement, and supersede any and all prior or contemporaneous
              negotiations, correspondence, understanding and agreements, whether oral or written, between the Parties respecting the subject matter of the Agreement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb58e004234b8407b836db6d3c980912a">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">6.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>This Amendment may be executed in counterparts, each of which will be deemed an original and both of which will together be deemed to constitute one agreement.&#160; The Parties agree that the execution of this Amendment by industry standard
              electronic signature software and/or by exchanging PDF signatures shall have the same legal force and effect as the exchange of original signatures.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">[<font style="font-style: italic;">Signature page to follow</font>]</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">2</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div id="DSPFPageHeader">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;"><font style="font-weight: bold;">IN WITNESS WHEREOF</font>, the Parties hereto have caused this Amendment to be duly executed by their respective authorized representatives as of the Amendment Effective Date set forth
      above.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z3468abc2434d4be1b4433e1071f16ca1">

        <tr>
          <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;">MEDIMMUNE LIMITED</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="line-height: 1.25;">By: <u>/s/ Adam McArthur</u></div>
            <div style="line-height: 1.25;">Name: Adam McArthur</div>
            <div style="line-height: 1.25;">Title: Assistant General Counsel, Corporate UK</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
            <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
            <div style="line-height: 1.25;">By: <u>/s/ Anat Cohen-Dayag</u></div>
            <div style="line-height: 1.25;">Name: Dr. Anat Cohen-Dayag</div>
            <div style="line-height: 1.25;">Title: President &amp; CEO</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">3</font></div>
  </div>
  <div id="DSPFPageNumberArea" style="text-align: center;">
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.18
<SEQUENCE>9
<FILENAME>exhibit_4-18.htm
<DESCRIPTION>EXHIBIT 4.18
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"> <font style="font-family: 'Times New Roman',Times,serif;"><u><font style="font-weight: bold;">Exhibit 4.18 </font></u></font></div>
    <div> <font style="font-family: 'Times New Roman',Times,serif;"><br>
      </font></div>
    <div>
      <div id="DSPFPageHeader">
        <table cellspacing="0" cellpadding="0" id="z69d70605d1a2422394a2faaf3136b44c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 100%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                <div style="text-align: right; margin-left: 1pt; line-height: 1.25;">EXECUTION COPY</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><br>
        <div style="text-align: left; line-height: 1.25;">Pursuant to Instruction 4(a) as to Exhibits of Form 20-F, certain identified information (marked by [*]) has been excluded from the exhibit because it is both not material and is the type that the
          registrant treats as private or confidential.</div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',serif; font-size: 9.5pt; font-weight: bold; text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">AMENDMENT NO. 1 TO MASTER CLINICAL TRIAL
          COLLABORATION AGREEMENT</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="margin: 0px 0px; line-height: 1.25; text-align: justify; text-indent: 41.95pt;"><font style="font-family: 'Times New Roman',Times,serif;">THIS AMENDMENT NO. 1 TO MASTER CLINICAL TRIAL COLLABORATION AGREEMENT</font> (this &#8220;<font style="font-weight: bold; font-style: italic;">Amendment</font>&#8221;) is effective as of February 14, 2020 (&#8220;<font style="font-weight: bold; font-style: italic;">Amendment Effective Date</font>&#8221;) by and between <font style="font-weight: bold;">Compugen



          Ltd.</font>, an Israeli corporation with a place of business at Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849, Israel (&#8220;<font style="font-weight: bold;">Compugen</font>&#8221;), and <font style="font-weight: bold;">Bristol-Myers Squibb
          Company</font>, a Delaware corporation, headquartered at 430 E. 29th Street, 14FL, New York, N.Y. 10016 (&#8220;<font style="font-weight: bold;">BMS</font>&#8221;).</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: center; margin-right: 173pt; margin-left: 173pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9.5pt; font-weight: bold;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">B</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">ACKGROUND</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-indent: 36pt; margin-left: 6pt; line-height: 1.25;">A.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BMS and Compugen entered into that certain Master Clinical Trial Collaboration Agreement, dated as of October
          10, 2018 (the &#8220;<font style="font-weight: bold; font-style: italic;">Agreement</font>&#8221;).</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; margin-right: 6pt; margin-left: 6pt; line-height: 1.25;">B.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Parties have mutually agreed to amend the Agreement as follows in accordance with
          Section 13.7 of the Agreement.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 5.85pt; margin-left: 5.95pt; line-height: 1.25;">NOW, THEREFORE, in consideration of the mutual covenants and undertakings contained herein, and on the terms and subject to the
        conditions set forth herein, the Parties hereby agree as follows:</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; margin-right: 5.95pt; margin-left: 6pt; line-height: 1.25;">1.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Capitalized terms used and not otherwise defined herein shall have the meaning given to
          such terms in the Agreement.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="line-height: 1.25;">
        <div>
          <table cellspacing="0" cellpadding="0" id="zb487c455b9894bcaa74aaf259a320c8c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 42pt; font-family: 'Times New Roman',Times,serif;"><br>
                </td>
                <td style="width: 29.15pt; vertical-align: top; align: right;">2.</td>
                <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div>&#160;Section 1.34 shall be deleted in its entirety from the Agreement.</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; margin-left: 6pt; line-height: 1.25;">3.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The definition of &#8220;Exclusive Collaboration Period&#8221; as set forth in Section 1.48 is hereby amended and restated
          in its entirety as follows:</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="line-height: 1.25">
        <div style="line-height: 1.25;">
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 42pt; font-family: 'Times New Roman',Times,serif;">&#8220;1.48</td>
                  <td style="width: 29.15pt; vertical-align: top; align: right;"><br>
                  </td>
                  <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                    <div>
                      <div style="text-align: justify; line-height: 1.25;">&#8220;<font style="font-weight: bold;">Exclusive Collaboration Period</font>&#8221; means the period commencing on the Effective Date and ending on the earliest of:</div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div>
          <table cellspacing="0" cellpadding="0" id="z9745a9396c5442be9e8088b795be5d8a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 73.65pt; font-family: 'Times New Roman',Times,serif;"><br>
                </td>
                <td style="width: 22.35pt; vertical-align: top; align: right;">(a)</td>
                <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div>six (6) months after Study Completion of the Triple Study as set forth in Study Plan No. 2; or</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="line-height: 1.25;">
        <div>
          <table cellspacing="0" cellpadding="0" id="z4de7652ca059467abe06847db9d4a977" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 72.95pt; font-family: 'Times New Roman',Times,serif;"><br>
                </td>
                <td style="width: 23.05pt; vertical-align: top; align: right;">(b)</td>
                <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div>the effective date of termination of this Agreement pursuant to Section 12.2, Section 12.3 or Section 12.4.&#8221;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; margin-right: 5.95pt; margin-left: 6pt; line-height: 1.25;">4.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Study Plan No. 1 previously attached to the Agreement is hereby replaced with the revised
          Study Plan No. 1 attached as <u>Attachment A </u>hereto.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-indent: 36pt; margin-left: 6pt; line-height: 1.25;">5.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Clause (a) of <u>Exhibit E </u>to the Agreement is hereby amended and restated in its entirety as follows:</font></div>
      <div style="text-indent: 36pt; margin-left: 6pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: justify; text-indent: 36pt; margin-right: 5.7pt; margin-left: 6pt; line-height: 1.25;">
        <div id="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 100%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: right; margin-left: 1pt; line-height: 1.25;">EXECUTION COPY</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 5.7pt; margin-left: 6pt; line-height: 1.25;"> <font style="font-family: 'Times New Roman',Times,serif;"><br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 5.7pt; margin-left: 6pt; line-height: 1.25;">&#8220;Neither Party is obligated to conduct additional studies of the Combined Therapy with the other Party upon completion of a Combined
        Therapy Study, subject to the following provisions of this Exhibit E; provided that the provisions of this Exhibit E are not applicable to any Combined Therapy Study other than the Triple Study. The provisions as set forth in this Exhibit E shall
        only be in effect (and the Parties will only have the rights set forth below in this Exhibit E) with respect to each Subsequent Study for which (x) the proposed protocol synopsis has been submitted by the Proposing Party to the Other Party (as set
        forth below) within the earlier of (i) [*] or (ii) [*]; provided that the proposed Subsequent Study must be commenced [*] within [*] of such protocol synopsis being provided to the Other Party and (y) at the time the proposed protocol synopsis has
        been submitted by the Proposing Party to the Other Party (as set forth below), the Other Party&#8217;s Compound is commercialized or in active development; <font style="font-style: italic;">provided </font>that, in the case of BMS, both of the BMS
        Compounds included in the Triple Study must be commercialized or in active development. For clarity, a Subsequent Study may be conducted only for a Combined Therapy for which the Parties agreed to conduct a Combined Therapy Study under this
        Agreement; provided that neither Party has the rights or obligations set forth below in this Exhibit E with respect to any Combined Therapy Study other than the Triple Study. For clarity, if Compugen conducts a study of a therapy using both the
        Compugen Compound and the BMS Compound in addition to the Combined Therapy Study as described in Study Plan No. 1 and BMS does not supply any BMS Compound pursuant to this Agreement for such study, such study shall not be considered a Combined
        Therapy Study pursuant to this Agreement.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; margin-right: 6pt; margin-left: 6pt; line-height: 1.25;">6.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Clause (d)(iv) of <u>Exhibit E </u>to the Agreement is hereby amended and restated in its
          entirety as follows:</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-right: 5.85pt; margin-left: 5.95pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">(iv) </font>for the Subsequent Studies where Compugen is the non-Participating Other Party, [*]&#8221;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; margin-right: 6pt; margin-left: 6pt; line-height: 1.25;">7.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Clause (d)(v) of <u>Exhibit E </u>to the Agreement is hereby amended and restated in its
          entirety as follows:</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; margin-right: 5.75pt; margin-left: 6pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">(v) </font>for the Subsequent Studies where BMS is the non-Participating Other Party, [*]</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; margin-right: 5.85pt; margin-left: 6pt; line-height: 1.25;">8.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as amended by this Amendment, the Agreement shall continue in full force and
          effect pursuant to its terms.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; margin-right: 5.95pt; margin-left: 6pt; line-height: 1.25;">9.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Amendment may be executed in two (2) or more counterparts, each of which shall be
          deemed an original, but all of which together shall constitute one (1) and the same instrument. This Amendment may be executed by facsimile or electronic (e.g., .pdf) signatures and such signatures shall be deemed to bind each Party hereto as if
          they were original signature.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 36pt; margin-left: 6pt; line-height: 1.25;">10.<font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Amendment shall be governed and construed in accordance with the internal laws of the State of New York,
          USA, excluding any choice of law rules that may direct the application of the laws of another jurisdiction.</font></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">[Signature page follows]</div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">
        <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; font-style: normal;"><font style="background-color: #FFFFFF;"> <br>
          </font></div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div id="DSPFPageHeader">
        <table cellspacing="0" cellpadding="0" id="z2896ca753ae44b15aeb85083129cc8b9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 100%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                <div style="text-align: right; margin-left: 1pt; line-height: 1.25;">EXECUTION COPY</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-indent: 36pt; margin-right: 5.25pt; margin-left: 9.95pt; line-height: 1.25;">IN WITNESS WHEREOF, BMS and Compugen have duly executed this Amendment as of the Amendment Effective Date.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z4edace26ace54b0c8aa06f449f95d350" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 38.89%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="margin-left: 10pt; line-height: 1.25; font-weight: bold;">COMPUGEN LTD.</div>
            </td>
            <td style="width: 61.11%; vertical-align: top;">
              <div style="margin-left: 68.25pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 9.5pt; font-weight: bold;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">B</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">RISTOL-MYERS SQUIBB COMPANY</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 38.89%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
            <td style="width: 61.11%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 38.89%; vertical-align: top;">
              <div style="margin-left: 10pt; line-height: 1.25;">By:<u>/s/ Anat Cohen-Dayag</u></div>
            </td>
            <td style="width: 61.11%; vertical-align: top;">
              <div style="margin-left: 68.25pt; line-height: 1.25;">By:<u>/s/ Jonath Cheng</u><font style="font-family: 'Times New Roman',Times,serif;"> </font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 38.89%; vertical-align: top;">
              <div style="margin-left: 10pt; line-height: 1.25;">Name: <u>Anat Cohen-Dayag</u></div>
            </td>
            <td style="width: 61.11%; vertical-align: top;">
              <div style="margin-left: 68.25pt; line-height: 1.25;">Name: <u>Jonathan Cheng, MD</u><font style="font-family: 'Times New Roman',Times,serif;"> </font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 38.89%; vertical-align: top;">
              <div style="margin-left: 10pt; line-height: 1.25;">Title: <u>President &amp; CEO</u></div>
            </td>
            <td style="width: 61.11%; vertical-align: top;">
              <div style="margin-left: 68.25pt; line-height: 1.25;">Title: <u>SVP, Head of Oncology Development</u><font style="font-family: 'Times New Roman',Times,serif;"> </font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 100%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                <div style="text-align: right; margin-left: 1pt; line-height: 1.25;">EXECUTION COPY</div>
              </td>
            </tr>

        </table>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      </div>
      <div style="text-align: center; line-height: 1.25;"><u>Attachment A</u></div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">STUDY PLAN NO. 1<br>
      </div>
      <div style="text-align: center; line-height: 1.25;">[*]</div>
      <div style="text-align: center; line-height: 1.25;"> <font style="font-family: 'Times New Roman',Times,serif;"><br>
        </font></div>
      <div style="text-align: center; line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><font style="background-color: #FFFFFF;"> <br>
          </font></div>
      </div>
    </div>
  </div>
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
  <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.19
<SEQUENCE>10
<FILENAME>exhibit_4-19.htm
<DESCRIPTION>EXHIBIT 4.19
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25; text-align: right;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u><font style="font-weight: bold;">Exhibit 4.19</font></u><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; font-weight: bold;">Pursuant to Instruction 4(a) as to Exhibits of Form 20-F, certain identified information (marked by [*]) has been excluded from the exhibit because it is both not material and is the type that the
          registrant treats as private or confidential.</div>
      </div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <div style="text-align: right; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Execution Version</div>
      <div style="text-align: right; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-variant: small-caps; font-weight: bold;">Amendment No. 2 to Master Clinical Trial Collaboration Agreement</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-variant: small-caps;">This Amendment No. 2 to Master Clinical Trial Collaboration Agreement</font> (this &#8220;<font style="font-weight: bold; font-style: italic;">Amendment</font>&#8221;)





      is effective as of February 19, 2021 (&#8220;<font style="font-weight: bold; font-style: italic;">Amendment Effective Date</font>&#8221;) by and between <font style="font-weight: bold;">Compugen Ltd.</font>, an Israeli corporation with a place of business at
      Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849, Israel&#160;(&#8220;<font style="font-weight: bold; font-style: italic;">Compugen</font>&#8221;), and <font style="font-weight: bold;">Bristol-Myers Squibb Company</font>, a Delaware corporation,
      headquartered at 430 E. 29th Street, 14FL, New York, N.Y. 10016 (&#8220;<font style="font-weight: bold; font-style: italic;">BMS</font>&#8221;).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Background</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BMS and Compugen entered into that certain Master Clinical Trial Collaboration Agreement, dated as of October 10, 2018, as amended (the &#8220;<font style="font-weight: bold; font-style: italic;">Agreement</font>&#8221;).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Parties have mutually agreed to amend the Agreement as follows in accordance with Section 13.7 of the Agreement.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-variant: small-caps;">Now, therefore</font>, in consideration of the mutual covenants and undertakings contained herein, and on the terms and subject to the
      conditions set forth herein, the Parties hereby agree as follows:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Capitalized terms used and not otherwise defined herein shall have the meaning given to such terms in the Agreement.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The definition of &#8220;Exclusive Collaboration Period&#8221; as set forth in Section 1.48 is hereby amended and restated in its entirety as follows:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#8220;1.48&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Exclusive Collaboration Period</font>&#8221; means the period commencing on the Effective Date and ending on the earliest of:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 81pt;"><br>
          </td>
          <td style="width: 27pt; vertical-align: top; align: right;">(a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the earlier of (i) six (6) months after Study Completion of both the Combination Therapy Study as set forth in Study Plan No. 1 and the Triple Study as set forth in Study Plan No. 2; or (ii) December 31, 2023.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 81pt;"><br>
          </td>
          <td style="width: 27pt; vertical-align: top; align: right;">(b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the effective date of termination of this Agreement pursuant to Section 12.2, Section 12.3 or Section 12.4.&#8221;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Study Plan No. 1 previously attached to the Agreement is hereby replaced with the Revised Study Plan No. 1 attached as <u>Attachment A</u> hereto.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Clause (a) of <u>Exhibit E</u> to the Agreement is hereby amended and restated in its entirety as follows:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8220;Neither Party is obligated to conduct additional studies of the Combined Therapy with the other Party upon completion of a Combined Therapy Study, subject to the following
      provisions of this Exhibit E.&#160; The provisions as set forth in this Exhibit E shall only be in effect (and the Parties will only have the rights set forth below in this Exhibit E) with respect to each Subsequent Study for which (x) the proposed
      protocol synopsis has been submitted by the Proposing Party to the Other Party (as set forth below) within the earlier of (i) [*] or (ii) [*]; provided that the proposed Subsequent Study must be commenced [*] within [*]of such protocol synopsis being
      provided to the Other Party and (y) at the time the proposed protocol synopsis has been submitted by the Proposing Party to the Other Party (as set forth below), the Other Party&#8217;s Compound is commercialized or in active development; <font style="font-style: italic;">provided</font> that, in the case of BMS with respect to a Subsequent Study involving both of the BMS Compounds included in the Triple Study, both of such BMS Compounds must be commercialized or in active development.&#160;
      For clarity, a Subsequent Study may be conducted only for a Combined Therapy for which the Parties agreed to conduct a Combined Therapy Study under this Agreement.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;
      <div style="text-align: right; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Execution Version</div>
      <div style="text-align: right; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Parties have agreed on a press release having the content set forth in <u>Attachment B</u> hereto, which will be issued at a time agreed by the Parties.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as amended by this Amendment, the Agreement shall continue in full force and effect pursuant to its terms.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one (1) and the
      same instrument.&#160; This Amendment may be executed by facsimile or electronic (e.g., .pdf) signatures and such signatures shall be deemed to bind each Party hereto as if they were original signature.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Amendment shall be governed and construed in accordance with the internal laws of the State of New York, USA, excluding any choice of law rules that may direct the
      application of the laws of another jurisdiction.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic;">[Signature page follows]</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;
      <div style="text-align: right; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Execution Version</div>
      <div style="text-align: right; line-height: 1.25; font-variant: small-caps; font-weight: bold;">&#160;</div>
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;"><font style="font-variant: small-caps;">In witness whereof</font>, BMS and Compugen have duly executed this Amendment as of the Amendment Effective Date.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25; font-variant: small-caps; font-weight: bold;">Compugen Ltd.</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25; font-variant: small-caps; font-weight: bold;">Bristol-Myers Squibb Company</div>
            <div style="line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">By: <u>/s/ Anat Cohen-Dayag</u></div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">By: <u>/s/ Jonath Cheng</u> </div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">Name: <u>Anat Cohen-Dayag</u>&#160;&#160;&#160;&#160;&#160; </div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">Name: <u>Jonathan Cheng, MD</u></div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">Title: <u>President &amp; CEO</u> </div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">Title: <u>SVP, Head of Oncology Development</u></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: right; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Execution Version</div>
      <div style="text-align: right; line-height: 1.25; font-variant: small-caps; font-weight: bold;">&#160;</div>
    </div>
    <div style="text-align: center; line-height: 1.25;"><u>Attachment A</u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">Revised Study Plan No. 1</div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">[*]</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: right; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Execution Version</div>
      <div style="text-align: right; line-height: 1.25; font-variant: small-caps; font-weight: bold;">&#160;</div>
    </div>
    <div style="text-align: center; line-height: 1.25;"><u>Attachment B</u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><img width="125" height="53" src="image0.jpg"></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        <br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">FOR IMMEDIATE RELEASE</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Compugen Expands Clinical Collaboration Agreement with Bristol </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Myers Squibb with Phase 1b Combination Study of COM701 with </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Opdivo&#174;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-style: italic;">Cohort expansion study expected to commence in the second quarter of 2021</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">HOLON, ISRAEL &#8211; February 22, 2021 &#8211; <u>Compugen Ltd.</u> (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the expansion of its clinical
      collaboration agreement with Bristol Myers Squibb. Under the amended agreement, Bristol Myers Squibb will supply Opdivo&#174; (nivolumab), its PD-1 inhibitor, for Compugen&#8217;s Phase 1b cohort expansion study designed to assess COM701, Compugen&#8217;s
      first-in-class anti-PVRIG antibody, in combination with Opdivo&#174; in selected cancer indications. Study initiation is expected in the second quarter of 2021.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">&#8220;We are excited to further expand our clinical program evaluating COM701, our first-in-class anti PVRIG inhibitor,&#8221; said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. &#8220;While our triple checkpoint blockade study
      of COM701 combined with Bristol Myers Squibb&#8217;s PD-1 and TIGIT inhibitors currently advancing in the clinic offers the ultimate test of our science-driven hypothesis, translational research at Compugen suggests that certain patients may not require a
      triple therapy combination. With the enrollment in the dose escalation arm of COM701 in combination with Opdivo&#174; completed and preliminary signs of antitumor activity previously disclosed, we are ready to continue our evaluation of this dual
      combination and move to the cohort expansion phase of the study. Testing COM701 in three settings &#8211; as a monotherapy, dual combination, and triple combination therapy &#8211; may provide additional insights on the contribution of components as well as the
      opportunity to broaden COM701 treatment options to address patients&#8217; needs. We are proud to be moving quickly to initiate this biomarker and data-informed study in indications we believe are most likely to respond to dual PVRIG and PD-1 blockade,
      enhancing our leadership position in the DNAM-1 axis space.&#8221;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: right; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Execution Version</div>
      <div style="text-align: right; line-height: 1.25; font-variant: small-caps; font-weight: bold;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">Dr. Cohen-Dayag continued, &#8220;Bristol Myers Squibb continues to be a valued partner for our COM701 clinical program as we advance the immunotherapy treatment landscape of patients with cancer .&#8221;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Under the terms of the amendment, Bristol Myers Squibb will continue to supply Opdivo&#174; to the Compugen-sponsored study. The Phase 1b study, a part of Compugen&#8217;s COM701 monotherapy and combination therapy dose escalation
      and expansion program (<u>NCT03667716</u>), will examine fixed doses of COM701 and Opdivo&#174;, as determined by Compugen&#8217;s Phase 1a combination dose escalation study. Based on Compugen&#8217;s translational analyses and preliminary antitumor activity in dose
      escalation, the study will enroll patients with ovarian, breast, endometrial and microsatellite-stable colorectal cancers.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Separately, Compugen and Bristol Myers Squibb are also investigating COM701 in a triple combination study with Opdivo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and BMS-986207,
      Bristol Myers Squibb&#8217;s investigational anti-TIGIT antibody.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Opdivo&#174; is a registered trademark of Bristol Myers Squibb.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">About Compugen</div>
    <div style="line-height: 1.25;">Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the
      field of cancer immunotherapy. Compugen&#8217;s lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen&#8217;s antibody targeting TIGIT, is in
      a Phase 1 clinical study. Compugen&#8217;s therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen&#8217;s shares are
      listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen&#8217;s corporate website at www.cgen.com.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: right; line-height: 1.25; font-variant: small-caps; font-weight: bold;">Execution Version</div>
      <div style="text-align: right; line-height: 1.25; font-variant: small-caps; font-weight: bold;">&#160;</div>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Forward-Looking Statement</div>
    <div style="line-height: 1.25;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities
      Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations and assumptions of Compugen. Forward-looking statements can be identified by the use of terminology such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;expects,&#8221;
      &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;potential,&#8221; &#8220;plan,&#8221; &#8220;goal,&#8221; &#8220;estimate,&#8221; &#8220;likely,&#8221; &#8220;should,&#8221; &#8220;confident,&#8221; and &#8220;intends,&#8221; and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain
      these identifying words. These forward-looking statements, including but not limited to statements about the initiation, procedures and potential results of the cohort expansion study, involve known and unknown risks and uncertainties that may cause
      the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen&#8217;s operations could be
      affected by the outbreak and spread of COVID-19, clinical development involves a lengthy and expensive process, with an uncertain outcome and Compugen may encounter substantial delays or even an inability to begin clinical trials for any specific
      product, or may not be able to conduct or complete its trials on the timelines it expects; Compugen relies, and expects to continue to rely, on third parties to conduct its clinical trials and if these third parties do not successfully carry out
      their contractual duties, comply with regulatory requirements or meet expected deadlines (including as a result of the effect of the COVID-19), Compugen may experience significant delays in the conduct of its clinical trials; Compugen&#8217;s approach to
      the discovery of therapeutic products is based on its proprietary computational target discovery infrastructure, which is unproven clinically; Compugen does not know whether it will be able to discover and develop additional potential product
      candidates or products of commercial value; Compugen&#8217;s business model is substantially dependent on entering into collaboration agreements with third parties; and Compugen may not be successful in generating adequate revenues or commercializing
      aspects of its business model. These risks and other risks are more fully discussed in the &#8220;Risk Factors&#8221; section of Compugen&#8217;s most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other
      documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen&#8217;s views only as of the date of this release and should not be relied upon as representing its views as
      of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Company contact:</div>
    <div style="line-height: 1.25;">Elana Holzman</div>
    <div style="line-height: 1.25;">Director, Investor Relations and Corporate Communications Compugen Ltd.</div>
    <div style="line-height: 1.25;">Email: <u>elanah@cgen.com</u></div>
    <div style="line-height: 1.25;">Tel: +972 (3) 765-8124</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Investor Relations contact:</div>
    <div style="line-height: 1.25;">Bob Yedid</div>
    <div style="line-height: 1.25;">LifeSci Advisors, LLC</div>
    <div style="line-height: 1.25;">Email: <u>bob@lifesciadvisors.com</u></div>
    <div style="line-height: 1.25;">Tel: +1 (646) 597-6989</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Media contact:</div>
    <div style="line-height: 1.25;">Josephine Belluardo, Ph.D.</div>
    <div style="line-height: 1.25;">LifeSci Communications</div>
    <div style="line-height: 1.25;">Email: <u>jo@lifescicomms.com</u></div>
    <div style="line-height: 1.25;">Tel: +1 (646) 751-4361</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.20
<SEQUENCE>11
<FILENAME>exhibit_4-20.htm
<DESCRIPTION>EXHIBIT 4.20
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <table cellspacing="0" cellpadding="0" border="0" id="z2994c09a34054e4eb9e6e9e65f405a8f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

      <tr>
        <td style="width: 100.00%;">
          <div style="text-align: right;">&#160;<font style="font-weight: bold;"><font style="font-family: 'Times New Roman',Times,serif;"><u>E</u><u>xhibit 4.20</u></font></font></div>
        </td>
      </tr>

  </table>
  <div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="margin-left: 5.2pt; line-height: 1.25;">
      <div style="line-height: 1.25; font-weight: bold;">Pursuant to Instruction 4(a) as to Exhibits of Form 20-F, certain identified information (marked by [*]) has been excluded from the exhibit because it is both not material and is the type that the
        registrant treats as private or confidential.</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: right; text-indent: -20.85pt; margin-right: 4.95pt; margin-left: 500.55pt; line-height: 1.25;">EXECUTION VERSION </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; margin-right: 174.85pt; margin-left: 174.95pt; line-height: 1.25; font-weight: bold;">Amendment No. 3 to Master Clinical Trial Collaboration Agreement</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 25.2pt; margin-right: 5pt; margin-left: 5.2pt; line-height: 1.25;">This Amendment No. 3 to Master Clinical Trial Collaboration Agreement (this &#8220;<font style="font-weight: bold; font-style: italic;">Amendment
        No. 3</font>&#8221;) is effective as of November 10, 2021 (&#8220;<font style="font-weight: bold; font-style: italic;">Amendment No. 3 Effective Date</font>&#8221;) by and between <font style="font-weight: bold;">Compugen Ltd.</font>, an Israeli corporation with a
      place of business at Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849, Israel (&#8220;<font style="font-weight: bold; font-style: italic;">Compugen</font>&#8221;), and <font style="font-weight: bold;">Bristol-Myers Squibb Company</font>, a Delaware
      corporation, headquartered at 430 E. 29th Street, 14FL, New York, N.Y. 10016 (&#8220;<font style="font-weight: bold; font-style: italic;">BMS</font>&#8221;).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; margin-right: 174.85pt; margin-left: 174.95pt; line-height: 1.25; font-weight: bold;">Background</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9fc9265e8cf34fd5b666e84d0c5e23cf">

        <tr>
          <td style="width: 30.35pt;"><br>
          </td>
          <td style="width: 24.35pt; vertical-align: top; align: right;">A.</td>
          <td style="width: auto; vertical-align: top;">
            <div>BMS and Compugen entered into that certain Master Clinical Trial Collaboration Agreement, dated as of October 10, 2018, as amended (the &#8220;<font style="font-weight: bold; font-style: italic;">Agreement</font>&#8221;).</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc7e5dd961dd041228515aebe6e6df401">

        <tr>
          <td style="width: 30.35pt;"><br>
          </td>
          <td style="width: 23.8pt; vertical-align: top; align: right;">B.</td>
          <td style="width: auto; vertical-align: top;">
            <div>The Parties have mutually agreed to amend the Agreement as follows in accordance with Section 13.7 of the Agreement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin-left: 30.4pt; line-height: 1.25;">Now, therefore, in consideration of the mutual covenants and undertakings contained herein, and on the terms and subject to the conditions set forth herein, the Parties hereby agree as</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="margin-left: 5.2pt; line-height: 1.25;">follows:</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6d14b77bd0d14f2ab690d6d5c491e930">

        <tr>
          <td style="width: 30.35pt;"><br>
          </td>
          <td style="width: 22.75pt; vertical-align: top; align: right;">1.</td>
          <td style="width: auto; vertical-align: top;">
            <div>Capitalized terms used and not otherwise defined herein shall have the meaning given to such terms in the Agreement.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf373941acffa4a92bac972990d3a5a24">

        <tr>
          <td style="width: 30.35pt;"><br>
          </td>
          <td style="width: 22.75pt; vertical-align: top; align: right;">2.</td>
          <td style="width: auto; vertical-align: top;">
            <div>Section 2.8 shall be deleted in its entirety, and replaced with the following:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 25.2pt; margin-right: 5.25pt; margin-left: 5.2pt; line-height: 1.25;"><font style="font-weight: bold;">2.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">JDC Dispute Resolution</font>. The representatives
      of the JDC shall attempt in good faith to reach consensus on all matters properly brought before the JDC. If, after a good faith reasonable, and open discussion among the members of the JDC, and the Alliance Managers, the JDC is unable to agree on a
      matter that has been properly brought before it for a period of [*], and that calls for a decision, either Party may refer the dispute (a &#8220;<font style="font-weight: bold;">JDC Dispute</font>&#8221;) to the JSC for resolution.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd47acbac77d14655a81c446f5fac6af3">

        <tr>
          <td style="width: 30.35pt;"><br>
          </td>
          <td style="width: 22.65pt; vertical-align: top; align: right;">3.</td>
          <td style="width: auto; vertical-align: top;">
            <div>The following shall be added to the Agreement as Section 2.9:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 25.2pt; margin-right: 5.05pt; margin-left: 5.2pt; line-height: 1.25;"><font style="font-weight: bold;">2.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Joint Steering Committee. </font>By no later than
      [*] after the Amendment No. 3 Effective Date, the Parties will establish a Joint Steering Committee (&#8220;<font style="font-weight: bold;">JSC</font>&#8221;) to provide strategic oversight to all Combined Therapy Studies, and to be the advisory body for the
      Combined Therapy Studies, the Monotherapy Arm and, if requested by Compugen, other clinical studies involving the Compugen Compound. The responsibilities of the JSC are described in Section 2.10(c) of this Agreement.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 50.4pt; margin-right: 4.95pt; margin-left: 5.2pt; line-height: 1.25;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Membership</font>. Each Party will initially
      appoint [*] voting representatives with appropriate seniority and expertise required to fulfill the responsibilities of the JSC to serve as members of the JSC. For clarity, members of the JDC may also serve as members of the JSC, as long as they meet
      the foregoing requirements. Members of the JDC, as well as employees or consultants of a Party who are not members of the JSC for either Party may be invited, subject to agreement (which agreement must be in writing and may be by email) by both
      Parties, to attend meetings of the JSC on an ad hoc basis if their attendance would helpful to the JSC in fulfilling its responsibilities. Such ad hoc attendees, however (i) shall not vote or otherwise&#160; participate in the decision-making process of
      the JSC, and (ii) shall be bound by obligations of confidentiality and non-disclosure at least as protective of the Confidential Information of both Parties as those set forth in Article 9 of this Agreement. The JSC may change its size from time to
      time by mutual consent of its members, provided that the JSC will consist of an equal number of representatives from each of Compugen and BMS. Each Party may replace, on a temporary or permanent basis, any or all of its JSC representatives by
      providing written notice to the other Party; provided that any such replacement member shall have the appropriate seniority and expertise to serve as a member of the JSC.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="line-height: 1.25">&#160;</div>
    <div id="DSPFPageHeader">
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z839ec6a608ec4f5f8eef903521c47799">

          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: right; text-indent: -20.85pt; margin-left: 21.8pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">EXECUTION VERSION </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: justify; text-indent: 50.4pt; margin-right: 5.3pt; margin-left: 5.2pt; line-height: 1.25;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Meetings</font>. The JSC will hold meetings at such
      times and places as the Parties may determine. The JSC will meet at least once quarterly during the Term unless the Parties agree otherwise. Meetings of the JSC need not be in person and may be by telephone or any other method determined by the JSC.
      Each Party will bear its own costs associated with attending such meetings.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3fe89da249754097b838da2f9a10ea64">

        <tr>
          <td style="width: 55.55pt;"><br>
          </td>
          <td style="width: 25.3pt; vertical-align: top; align: right; font-weight: bold;">(c)</td>
          <td style="width: auto; vertical-align: top;">
            <div><font style="font-weight: bold;">Responsibilities</font>.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 75.6pt; margin-right: 5.15pt; margin-left: 5.2pt; line-height: 1.25;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; overseeing and provide strategic direction to the Parties regarding the Combined Therapy, the Combined Therapy Studies, the Monotherapy Arm
      and, if requested by Compugen, other clinical studies of the Compugen Compound;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 75.6pt; margin-right: 5.2pt; margin-left: 5.2pt; line-height: 1.25;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;serving as a forum for exchanging information, and facilitating strategic discussions between the Parties regarding the Combined Therapy, the
      Combined Therapy Studies, the Monotherapy Arm and, if requested by Compugen, other clinical studies of the Compugen Compound;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 75.6pt; margin-right: 5.25pt; margin-left: 5.2pt; line-height: 1.25;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; establishing joint working groups when necessary or useful to facilitate communication and cooperation between the Parties regarding the
      Combined Therapy, the Combined Therapy Studies, and the Monotherapy Arm;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 75.6pt; margin-right: 5.1pt; margin-left: 5.2pt; line-height: 1.25;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; subject to the provisions of Section 2.4(c) with regard to approval of Budgets, or changes to Budgets for Jointly-Funded Studies by the JDC,
      reviewing and providing guidance regarding new budgets, and changes or updates to existing budgets for the Combined Therapy Studies;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 75.6pt; margin-right: 5.3pt; margin-left: 5.2pt; line-height: 1.25;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;monitoring the progress of the Combined Therapy Studies and, to the extent it may be relevant to the Combined Therapy or the Combined Therapy
      Studies, the analyses of the Monotherapy Arm;</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3e2099ab136d40319e2cbb385062f78c">

        <tr>
          <td style="width: 80.75pt;"><br>
          </td>
          <td style="width: 27.65pt; vertical-align: top; align: right;">(vi)</td>
          <td style="width: auto; vertical-align: top;">
            <div>&#160; resolving disputes between the Parties that have been referred to the JSC by the JDC as provided in Section 2.8.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6aebdaf662d3473cadadc09643f274dd">

        <tr>
          <td style="width: 80.75pt;"><br>
          </td>
          <td style="width: 32.5pt; vertical-align: top; align: right;">(vii)</td>
          <td style="width: auto; vertical-align: top;">
            <div>&#160;receiving updates and other material information regarding the Monotherapy Study Data and/or the Monotherapy Arm, in accordance with Section 8.11(a) hereof.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">2</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="margin-left: 5.2pt; line-height: 1.25;"><br>
    </div>
    <div id="DSPFPageHeader">
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z0c22211b297c41449b0a73367f015b45">

          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: right; text-indent: -20.85pt; margin-left: 21.8pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">EXECUTION VERSION </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: justify; text-indent: 50.4pt; margin-right: 5.25pt; margin-left: 5.2pt; line-height: 1.25;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Decisions</font>. The representatives of the JSC
      shall attempt in good faith to reach consensus on all matters properly brought before the JSC. If after a good faith, reasonable and open discussion among the members of the JSC and the Alliance Managers, the JSC is unable to agree on a matter that
      has been properly brought before it for [*], either Party may refer the disputed matter (a &#8220;<font style="font-weight: bold; font-style: italic;">JSC Dispute</font>&#8221;) to the Chief Executive Officer of Compugen, and the Executive Vice President,
      Research and Early Development of BMS for further discussion. If such senior officers are unable to resolve the disputed matter [*] after such referral, then:</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4764c026ee4d4d9ea154574739099e4c">

        <tr>
          <td style="width: 80.75pt;"><br>
          </td>
          <td style="width: 24.15pt; vertical-align: top; align: right;">(i)</td>
          <td style="width: auto; vertical-align: top;">
            <div>if such JSC Dispute concerns [*], then [*];</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z47270618910b4914a777254c1f4a68b6">

        <tr>
          <td style="width: 80.75pt;"><br>
          </td>
          <td style="width: 26.1pt; vertical-align: top; align: right;">(ii)</td>
          <td style="width: auto; vertical-align: top;">
            <div>if the JSC Dispute concerns [*], then [*], provided that [*];</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1832bad9a0234f8f88666cf5fcbc1818">

        <tr>
          <td style="width: 80.75pt;"><br>
          </td>
          <td style="width: 28.05pt; vertical-align: top; align: right;">(iii)</td>
          <td style="width: auto; vertical-align: top;">
            <div>if the JSC Dispute concerns [*] then [*].</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 25.2pt; margin-right: 5.15pt; margin-left: 5.2pt; line-height: 1.25;"><font style="font-weight: bold;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Limitations On JSC Authority</font>. The primary
      responsibility of the JSC shall be to provide strategic oversight and guidance, and therefore, except as expressly provided in Section 2.9(d), the JSC shall not have the authority to make decisions that are binding on the Parties. Further, the
      responsibilities and authority of JSC shall not replace the responsibilities and authority assigned to the JDC under Section 2.4, and Section 2.5, except to the extent that such matters also fall under the responsibilities and authority that are
      expressly designated to the JSC under this Section 2.9. For clarity, the JSC shall not have any decision making authority over matters [*], and any dispute regarding such matters shall [*].</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z18bd5a8bb50c4c0eb87cb0a55fd26b1c">

        <tr>
          <td style="width: 30.35pt;"><br>
          </td>
          <td style="width: 22.65pt; vertical-align: top; align: right;">4.</td>
          <td style="width: auto; vertical-align: top;">
            <div>The following shall be added to the Agreement as Section 2.4(v):</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 50.4pt; margin-right: 6.3pt; margin-left: 5.2pt; line-height: 1.25;"><font style="font-weight: bold;">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Upon a request from the JSC, preparing a report regarding the progress of any or all
      of the Combined Therapy Studies, to be used by the JSC to fulfill its responsibilities as provided in Section 2.9(c).</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0be3bd62f5044c899c557ceecbbc4e32">

        <tr>
          <td style="width: 30.35pt;"><br>
          </td>
          <td style="width: 22.75pt; vertical-align: top; align: right;">5.</td>
          <td style="width: auto; vertical-align: top;">
            <div>Section 8.11(a) (<font style="font-style: italic;">Access</font>) of the Agreement is hereby deleted in its entirety, and replaced with the following:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 50.4pt; margin-right: 6.15pt; margin-left: 5.2pt; line-height: 1.25;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Access</font>. BMS shall have access to all
      interim clinical and translational data analyses, and the final clinical and translational data analysis made by, or provided to Compugen with respect to the Monotherapy Arm (the &#8220;<font style="font-weight: bold;">Monotherapy Study Data</font>&#8221;)
      promptly following the completion of any such analysis. In addition, Compugen shall provide updates with respect to the Monotherapy Arm, including: (i) reports requested by the JSC, provided that such information is relevant to the Combined Therapy
      or the Combined Therapy Studies, and (ii) all interim Monotherapy Study Data that is available at such time of each JSC meeting. Compugen shall also provide BMS all Monotherapy Study Data produced, after the most recent JSC meeting, if requested by
      BMS, but for clarity, shall not be obligated to produce additional analysis if requested solely by BMS.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z52c4eca2d5fa4d8481a01509857393b9">

        <tr>
          <td style="width: 30.35pt;"><br>
          </td>
          <td style="width: 22.65pt; vertical-align: top; align: right;">6.</td>
          <td style="width: auto; vertical-align: top;">
            <div>The following shall be added to the Agreement as Section 10.14:</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z94417843d3d94042b01fb4e4c71bb330">

        <tr>
          <td style="width: 30.35pt;"><br>
          </td>
          <td style="width: 41.65pt; vertical-align: top; align: right; font-weight: bold;">10.14</td>
          <td style="width: auto; vertical-align: top;">
            <div><font style="font-weight: bold;">Additional Funding</font>.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 52.15pt; margin-right: 5.1pt; margin-left: 5.2pt; line-height: 1.25;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Use of Funds</font>. The entire net proceeds from
      the issuance of equity shares by Compugen under the Share Purchase Agreement dated October 15, 2021 shall be utilized by Compugen for the conduct of the Initial Studies and the Triple Study, provided that if all of such studies are completed in a
      manner reasonably satisfactory to BMS, then any remaining portion of the net proceeds of the issuance may be allocated to other &#8220;general working capital and research and development activities&#8221;. For clarity, notwithstanding the foregoing, neither the
      Initial Studies nor the Triple Study shall be deemed a Jointly-Funded Study.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">3</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div id="DSPFPageHeader">
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd8f1eca12c08417c8865810a039b559e">

          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: right; text-indent: -20.85pt; margin-left: 21.8pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">EXECUTION VERSION </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: justify; text-indent: 50.4pt; margin-right: 4.95pt; margin-left: 5.2pt; line-height: 1.25;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Annual Reports</font>. Until the earlier of: (i)
      the completion of the Initial Studies and the Triple Study, or (ii) such time that the entire net proceeds from the issuance of equity shares by Compugen pursuant to the foregoing shall have been utilized by Compugen to conduct the Initial Studies
      and the Triple Study, Compugen shall provide the JSC, on an annual basis, a report summarizing in reasonable detail the activities performed to conduct the Initial Studies, and the Triple Study, and setting forth the actual amounts spent on the
      Initial Studies and the Triple Study (including reasonably related direct and indirect expenses) during the immediately preceding calendar year. Such reports shall also include a forecast of the activities to be performed to conduct the Initial
      Studies and the Triple Study over the following year, and a good faith estimate of the amount of funding required to perform such activities (including reasonably related direct and indirect expenses) over the following year. Such report shall be
      provided [*]. In addition, the first annual report will include all of the actual amounts spent on the Initial Studies and the Triple Study as of the Amendment No. 3 Effective Date.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2f355ac334ce4192963339fd95923e3d">

        <tr>
          <td style="width: 30.35pt;"><br>
          </td>
          <td style="width: 22.75pt; vertical-align: top; align: right;">7.</td>
          <td style="width: auto; vertical-align: top;">
            <div>Except as amended by this Amendment No. 3, the Agreement shall continue in full force and effect pursuant to its terms.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 25.2pt; margin-right: 4.95pt; margin-left: 5.2pt; line-height: 1.25;">8.&#160;&#160;&#160;&#160;&#160;&#160; This Amendment No. 3 may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of
      which together shall constitute one (1) and the same instrument. This Amendment No. 3 may be executed by facsimile or electronic (e.g., .pdf) signatures and such signatures shall be deemed to bind each Party hereto as if they were original signature.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 25.2pt; margin-right: 5.15pt; margin-left: 5.2pt; line-height: 1.25;">9.&#160;&#160;&#160;&#160;&#160;&#160; This Amendment No. 3 shall be governed and construed in accordance with the internal laws of the State of New York, USA,
      excluding any choice of law rules that may direct the application of the laws of another jurisdiction.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; margin-right: 174.85pt; margin-left: 174.95pt; line-height: 1.25; font-style: italic;">[Signature page follows]</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">4</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div id="DSPFPageHeader">
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zdeacf501d9af412f9b099da2681ad6b1">

          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: right; text-indent: -20.85pt; margin-left: 21.8pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">EXECUTION VERSION <br>
              </div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="margin-left: 30.4pt; line-height: 1.25;">In witness whereof, BMS and Compugen have duly executed this Amendment No.3 as of the Amendment No. 3 Effective Date.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <table cellspacing="0" cellpadding="0" border="0" id="z68911b9c498146a9ab4696f14d55c971" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 50.00%;">
              <div><font style="font-weight: bold;">Compugen Ltd.</font></div>
              <div><font style="font-weight: bold;"> <br>
                </font></div>
              <div>By: <u>/s/ Ari Krashin</u></div>
              <div>
                <div>Name: Ari Krashin <br>
                </div>
                <div>Title: CFO &amp; COO </div>
                <font style="font-weight: bold;"> </font></div>
            </td>
            <td style="width: 50%;">
              <div><font style="font-weight: bold;">Bristol-Myers Squibb Company</font>
                <div style="line-height: 1.25">&#160;</div>
                <div style="text-align: left; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">By: <u>/s/ Jonathan Cheng, MD</u></font></div>
                <div style="text-align: left; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Name: Jonathan Cheng, MD</font></div>
                <div style="text-align: left; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Title: SVP, Head of Oncology Development</font></div>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25; text-align: center;"> <br>
      <font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">5</font></div>
  </div>
  <div id="DSPFPageNumberArea" style="text-align: center;">
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>12
<FILENAME>exhibit_8-1.htm
<DESCRIPTION>EXHIBIT 8.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"><u>Exhibit 8.1</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">SUBSIDIARIES</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <table id="z56660e5ca0234a23bcc756ccca4e146d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50.00%;">
              <div><font style="font-weight: bold;"><u>Subsidiary</u></font> <br>
              </div>
            </td>
            <td style="width: 50.00%;">
              <div><font style="font-weight: bold;"><u>Jurisdiction</u></font></div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50.00%;">Compugen USA, Inc.</td>
            <td rowspan="1" style="width: 50.00%;">Delaware</td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25"> <br>
    </div>
    <div style="line-height: 1.25">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"> </div>
    <div style="line-height: 1.25;">&#160;&#160; <br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>13
<FILENAME>exhibit_12-1.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"><u>Exhibit 12.1</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">CERTIFICATION</font>&#160;<font style="font-weight: bold;">PURSUANT TO</font></div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;"> <br>
      </font></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">RULE 13a-14(a)/RULE 15d-14(a) UNDER</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">THE EXCHANGE ACT AND SECTION 302</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">I, Dr. Anat Cohen-Dayag, certify that:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 20-F/A of Compugen Ltd.;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
      circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of
      operations and cash flows of the company as of, and for, the periods presented in this report;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
      and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
      ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
      supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">c.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the
      effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">d.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the
      annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit
      committee of the company's board of directors (or persons performing the equivalent functions):</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
      likely to adversely affect the company's ability to record, process, summarize and report financial information; and</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over
      financial reporting.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Date: February 28, 2022</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><u>/s/ Dr. Anat Cohen-Dayag</u></div>
    <div style="line-height: 1.25;">Title: President and Chief Executive Officer</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25;">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>14
<FILENAME>exhibit_12-2.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"><u>Exhibit 12.2</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">CERTIFICATION PURSUANT TO</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">RULE 13a-14(a)/RULE 15d-14(a) UNDER THE EXCHANGE ACT</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">AND SECTION 302</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">I, Ari Krashin, certify that:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 20-F/A of Compugen Ltd.;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
      circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of
      operations and cash flows of the company as of, and for, the periods presented in this report;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
      and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
      ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
      supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">c.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the
      effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;">d.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the
      annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit
      committee of the company's board of directors (or persons performing the equivalent functions):</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 30.7pt; line-height: 1.25;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
      likely to adversely affect the company's ability to record, process, summarize and report financial information; and</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 30.7pt; line-height: 1.25;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over
      financial reporting.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Date: February 28, 2022</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><u>/s/ Ari Krashin</u></div>
    <div style="text-align: justify; line-height: 1.25;">Title: Chief Financial and Operating Officer</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">
      <div>
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>15
<FILENAME>exhibit_13-1.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"><u>Exhibit 13.1</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">CERTIFICATION PURSUANT TO</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">RULE 13a-14(b)/RULE 15d-14(b)</font>&#160;<font style="font-weight: bold;">UNDER THE EXCHANGE ACT</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">AND 18 U.S.C. SECTION 1350,</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">AS ADOPTED PURSUANT TO</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SECTION 906</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">In connection with the annual report of Compugen Ltd. (the &#8220;Company&#8221;) on Form 20-F/A for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date
      hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company, certify, pursuant to Rule 13a-14(b)/Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
      Sarbanes-Oxley Act of 2002, that to such officer&#8217;s knowledge:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Sections 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><u>/s/ Dr. Anat Cohen-Dayag</u></div>
    <div style="text-align: justify; line-height: 1.25;">Title: &#160; &#160; President and Chief Executive Officer</div>
    <div style="text-align: justify; line-height: 1.25;">Date:&#160; &#160;&#160; February 28, 2022</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><u>/s/ Ari Krashin</u></div>
    <div style="text-align: justify; line-height: 1.25;">Title: &#160; &#160; Chief Financial and Operating Officer</div>
    <div style="line-height: 1.25;">Date:&#160;&#160;&#160;&#160; February 28, 2022</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>16
<FILENAME>exhibit_15-1.htm
<DESCRIPTION>EXHIBIT15.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"><u>Exhibit 15.1</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Consent of Independent Registered Public Accounting Firm</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-indent: 36pt; line-height: 1.25;">We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-169239, 333-204869, 333-223937, 333-240182, 333-251263) pertaining to the Employee&#8217;s share option
        plans of Compugen Ltd. and Registration Statements on Form F-3 (File No. 333-240183) of our report dated February 28, 2022, with respect to the consolidated financial statements of Compugen Ltd. and the effectiveness of internal control over
        financial reporting of Compugen Ltd. included in this Annual Report (Form 20-F), as amended, for the year ended December 31, 2021.</div>
      <div style="line-height: 1.25">&#160;</div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 49.86%; vertical-align: top;">
              <div style="line-height: 1.25;">February 28, 2022</div>
            </td>
            <td style="width: 50.14%; vertical-align: top;">
              <div style="line-height: 1.25;">/s/ KOST FORER GABBAY &amp; KASIERER</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.86%; vertical-align: top;">
              <div style="line-height: 1.25;">Tel-Aviv, Israel</div>
            </td>
            <td style="width: 50.14%; vertical-align: top;">
              <div style="line-height: 1.25;">A Member Firm of Ernst &amp; Young Global</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>cgen-20211231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<schema attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" targetNamespace="http://cgen.com/20211231" xmlns:cgen="http://cgen.com/20211231">
  <!-- XBRL Document Created with XML Edge from P3 Data Systems -->
  <annotation>
    <appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:roleType roleURI="http://cgen.com/role/cgen-daei1" id="cgen-daei1">
        <link:definition>00010 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>00020 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-cbsp" id="cgen-cbsp">
        <link:definition>00030 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-csocl" id="cgen-csocl">
        <link:definition>00040 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/StatementsOfChangesInShareholdersEquity" id="StatementsOfChangesInShareholdersEquity">
        <link:definition>00050 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>00060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-g" id="cgen-g">
        <link:definition>00070 - Disclosure - GENERAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sap" id="cgen-sap">
        <link:definition>00080 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oarape" id="cgen-oarape">
        <link:definition>00090 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/Leases" id="Leases">
        <link:definition>00100 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-paen" id="cgen-paen">
        <link:definition>00110 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oapaae" id="cgen-oapaae">
        <link:definition>00120 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-cac1" id="cgen-cac1">
        <link:definition>00130 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-se12" id="cgen-se12">
        <link:definition>00140 - Disclosure - SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-it" id="cgen-it">
        <link:definition>00150 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-giamc" id="cgen-giamc">
        <link:definition>00160 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-faoin" id="cgen-faoin">
        <link:definition>00170 - Disclosure - FINANCIAL AND OTHER INCOME, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-rpbat" id="cgen-rpbat">
        <link:definition>00180 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-lps" id="cgen-lps">
        <link:definition>00190 - Disclosure - LOSSES PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sapp" id="cgen-sapp">
        <link:definition>00200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sapt" id="cgen-sapt">
        <link:definition>00210 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oarapet" id="cgen-oarapet">
        <link:definition>00220 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LeasesTables" id="LeasesTables">
        <link:definition>00230 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-paent" id="cgen-paent">
        <link:definition>00240 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oapaaet" id="cgen-oapaaet">
        <link:definition>00250 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-set1" id="cgen-set1">
        <link:definition>00260 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-itt" id="cgen-itt">
        <link:definition>00270 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-giamct" id="cgen-giamct">
        <link:definition>00280 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-faoint" id="cgen-faoint">
        <link:definition>00290 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables" id="RelatedPartyBalancesAndTransactionsTables">
        <link:definition>00300 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-lpst" id="cgen-lpst">
        <link:definition>00310 - Disclosure - LOSSES PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-gd" id="cgen-gd">
        <link:definition>00320 - Disclosure - GENERAL (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sapnd" id="cgen-sapnd">
        <link:definition>00330 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sapsodrfpaed" id="cgen-sapsodrfpaed">
        <link:definition>00340 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails" id="SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails">
        <link:definition>00350 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oaraped" id="cgen-oaraped">
        <link:definition>00360 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LeasesNarrativeDetails" id="LeasesNarrativeDetails">
        <link:definition>00370 - Disclosure - LEASES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails" id="LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails">
        <link:definition>00380 - Disclosure - LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails" id="LeasesScheduleOfOperatingLeasesDetails">
        <link:definition>00390 - Disclosure - LEASES (Schedule of Operating Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-paend" id="cgen-paend">
        <link:definition>00400 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oapaaed" id="cgen-oapaaed">
        <link:definition>00410 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>00420 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sesopnd" id="cgen-sesopnd">
        <link:definition>00430 - Disclosure - SHAREHOLDERS' EQUITY (Share Option Plans) (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails" id="ShareholdersEquityScheduleOfOptionActivityDetails">
        <link:definition>00440 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sesosced" id="cgen-sesosced">
        <link:definition>00450 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/IncomeTaxesNarrativeDetails" id="IncomeTaxesNarrativeDetails">
        <link:definition>00460 - Disclosure - INCOME TAXES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails" id="IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails">
        <link:definition>00470 - Disclosure - INCOME TAXES (Encouragement Of Capital Investments) (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails" id="IncomeTaxesScheduleOfLossBeforeTaxesDetails">
        <link:definition>00480 - Disclosure - INCOME TAXES (Schedule of Loss before Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>00490 - Disclosure - INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/GeographicInformationAndMajorCustomersDetails" id="GeographicInformationAndMajorCustomersDetails">
        <link:definition>00500 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails" id="FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails">
        <link:definition>00510 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails" id="RelatedPartyBalancesAndTransactionsDetails">
        <link:definition>00520 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails" id="LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails">
        <link:definition>00530 - Disclosure - LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd"/>
  <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd"/>
  <element name="SeverancePayFundNoncurrent" id="cgen_SeverancePayFundNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" xbrli:balance="debit"/>
  <element name="ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" id="cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" xbrli:balance="credit"/>
  <element name="LongTermDeferredParticipationInResearchAndDevelopmentExpenses" id="cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" xbrli:balance="credit"/>
  <element name="FinancialIncomeExpenseNet" id="cgen_FinancialIncomeExpenseNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="credit"/>
  <element name="IssuanceOfSharesAndWarrantsNetValue" id="cgen_IssuanceOfSharesAndWarrantsNetValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="credit"/>
  <element name="IssuanceOfSharesAndWarrantsNetShares" id="cgen_IssuanceOfSharesAndWarrantsNetShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="StockIssuedDuringPeriodValueWarrantsExercised" id="cgen_StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="credit"/>
  <element name="NumberOfWarrantsExercised" id="cgen_NumberOfWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="StockIssuedDuringPeriodValueTerminationAndEquityConversionAgreementIssues" id="cgen_StockIssuedDuringPeriodValueTerminationAndEquityConversionAgreementIssues" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodSharesTerminationAndEquityConversionAgreementIssues" id="cgen_StockIssuedDuringPeriodSharesTerminationAndEquityConversionAgreementIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" id="cgen_StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="credit"/>
  <element name="SeverancePayNet" id="cgen_SeverancePayNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="debit"/>
  <element name="AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" id="cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="credit"/>
  <element name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" id="cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="credit"/>
  <element name="IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" id="cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="debit"/>
  <element name="ReceivablesOnAccountOfShares" id="cgen_ReceivablesOnAccountOfShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="debit"/>
  <element name="SupplementalRightOfUseAssetAndOperatingleaseLiability" id="cgen_SupplementalRightOfUseAssetAndOperatingleaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="debit"/>
  <element name="InterestPaidReceivedNet" id="cgen_InterestPaidReceivedNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="debit"/>
  <element name="OtherAccountsReceivableAndPrepaidExpensesTextBlock" id="cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="ShortTermBankDepositsPolicyTextBlock" id="cgen_ShortTermBankDepositsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="CostOfSalesContractWithCustomerPolicyTextBlock" id="cgen_CostOfSalesContractWithCustomerPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="ServerancePayPolicyTextBlock" id="cgen_ServerancePayPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" id="cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock" id="cgen_ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock" id="cgen_ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="AccruedMilestonePayment" id="cgen_AccruedMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="credit"/>
  <element name="ResearchAndDevelopmentArrangementPaymentsReceivable" id="cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" id="cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" id="cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" xbrli:balance="debit"/>
  <element name="MasterClinicalAgreementOneMember" id="cgen_MasterClinicalAgreementOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="MasterClinicalAgreementTwoMember" id="cgen_MasterClinicalAgreementTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="ShortTermBankDepositsWeightedAverageRateForeign" id="cgen_ShortTermBankDepositsWeightedAverageRateForeign" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" id="cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="DerivativeRelatedExpense" id="cgen_DerivativeRelatedExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="debit"/>
  <element name="DeferredParticipationOfBmsInRdExpenses" id="cgen_DeferredParticipationOfBmsInRdExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="credit"/>
  <element name="PercentageOfConsolidatedRevenuesOfCollaborator" id="cgen_PercentageOfConsolidatedRevenuesOfCollaborator" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant"/>
  <element name="LaboratoryEquipmentAndOfficeFurnitureMember" id="cgen_LaboratoryEquipmentAndOfficeFurnitureMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="AnnualDepreciationRate" id="cgen_AnnualDepreciationRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="AnnualDepreciationRateDescription" id="cgen_AnnualDepreciationRateDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="EmployeeStockPurchasePlanMember" id="cgen_EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="GovernmentAuthorities" id="cgen_GovernmentAuthorities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" xbrli:balance="debit"/>
  <element name="IncreaseOperatingLeaseRightOfUseAsset" id="cgen_IncreaseOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="debit"/>
  <element name="DecreaseOperatingLeaseLiability" id="cgen_DecreaseOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="debit"/>
  <element name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" id="cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="debit"/>
  <element name="ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" id="cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="GovernmentAndOtherGrantsAxis" id="cgen_GovernmentAndOtherGrantsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <element name="GovernmentAndOtherGrantsDomain" id="cgen_GovernmentAndOtherGrantsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <element name="ResearchAndDevelopmentGrantOneMember" id="cgen_ResearchAndDevelopmentGrantOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="May2012AgreementMember" id="cgen_May2012AgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="RoyaltyPercentageBasedOnFutureRevenues" id="cgen_RoyaltyPercentageBasedOnFutureRevenues" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="MaximumRoyaltyRepaidAsPercentageOfGrantReceived" id="cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="RoyaltyContingentObligations" id="cgen_RoyaltyContingentObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" xbrli:balance="credit"/>
  <element name="ParticipationRights" id="cgen_ParticipationRights" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="RetainerFee" id="cgen_RetainerFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="debit"/>
  <element name="AgreementStartDate" id="cgen_AgreementStartDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="AgreementTerminationDescription" id="cgen_AgreementTerminationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="ExtendLease" id="cgen_ExtendLease" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="ContingentFees" id="cgen_ContingentFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" id="cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="debit"/>
  <element name="RoyaltyPercentage" id="cgen_RoyaltyPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="ResearchAndDevelopmentExpensesMilestonePayment" id="cgen_ResearchAndDevelopmentExpensesMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="debit"/>
  <element name="AtTheMarketOfferingProgramMember" id="cgen_AtTheMarketOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="AgreementMember" id="cgen_AgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="MasterClinicalAgreementMember" id="cgen_MasterClinicalAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="CollaborativeArrangementsMember" id="cgen_CollaborativeArrangementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="CollaborativeArrangementsTwoMember" id="cgen_CollaborativeArrangementsTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="SvbLeerinkLlcAndStifelNicolausAndCompanyMember" id="cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="RegisteredDirectOfferingMember" id="cgen_RegisteredDirectOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="UnderwritersMember" id="cgen_UnderwritersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="TwoThousandAndTwoThousandTenOptionsPlanMember" id="cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" id="cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="MaximumAuthorizedProceedsFromIssuanceOfCommonStock" id="cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" xbrli:balance="debit"/>
  <element name="ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" id="cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="AgreementOptionAdditionalNumberOfSharesIssuable" id="cgen_AgreementOptionAdditionalNumberOfSharesIssuable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="PercentageOfClosingPrice" id="cgen_PercentageOfClosingPrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" id="cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="AggregateLimitOfOrdinarySharesPerCalendarYear" id="cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant"/>
  <element name="PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" id="cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="EmployeesAndDirectorsMember" id="cgen_EmployeesAndDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" id="cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <element name="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" id="cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="NetOperatingLossCarryforwardExpired" id="cgen_NetOperatingLossCarryforwardExpired" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" xbrli:balance="debit"/>
  <element name="ReducedCorporateIncomeTaxRate" id="cgen_ReducedCorporateIncomeTaxRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant"/>
  <element name="TaxExemptPeriod" id="cgen_TaxExemptPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="ReducedTaxRate" id="cgen_ReducedTaxRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="TaxRateOnDistributions" id="cgen_TaxRateOnDistributions" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="PeriodSinceApprovalWasGranted" id="cgen_PeriodSinceApprovalWasGranted" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="PeriodSinceEnterpriseBeganOperating" id="cgen_PeriodSinceEnterpriseBeganOperating" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="DeferredIncomeTaxRightOfUseAssets" id="cgen_DeferredIncomeTaxRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" xbrli:balance="debit"/>
  <element name="DeferredIncomeTaxLeaseLiabilities" id="cgen_DeferredIncomeTaxLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" xbrli:balance="debit"/>
  <element name="DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" id="cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" xbrli:balance="debit"/>
  <element name="SegmentReportingGeographicAreaTable" id="cgen_SegmentReportingGeographicAreaTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <element name="SegmentReportingGeographicAreaAxis" id="cgen_SegmentReportingGeographicAreaAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <element name="SegmentReportingGeographicAreaDomain" id="cgen_SegmentReportingGeographicAreaDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <element name="CustomerOneMember" id="cgen_CustomerOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration"/>
  <element name="SegmentReportingGeograhicAreaLineItems" id="cgen_SegmentReportingGeograhicAreaLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
  <element name="NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" id="cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>18
<FILENAME>cgen-20211231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- XBRL Document Created with XML Edge from P3 Data Systems -->
  <roleRef roleURI="http://cgen.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cgen-20211231.xsd#ConsolidatedBalanceSheets"/>
  <roleRef roleURI="http://cgen.com/role/cgen-csocl" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-csocl"/>
  <roleRef roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="cgen-20211231.xsd#ConsolidatedStatementsOfCashFlows"/>
  <roleRef roleURI="http://cgen.com/role/cgen-oaraped" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-oaraped"/>
  <roleRef roleURI="http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#LeasesScheduleOfOperatingLeasesDetails"/>
  <roleRef roleURI="http://cgen.com/role/cgen-paend" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-paend"/>
  <roleRef roleURI="http://cgen.com/role/cgen-oapaaed" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-oapaaed"/>
  <roleRef roleURI="http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#IncomeTaxesScheduleOfLossBeforeTaxesDetails"/>
  <roleRef roleURI="http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"/>
  <roleRef roleURI="http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"/>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="locator_us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="locator_us-gaap_AssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_Assets" xlink:to="locator_us-gaap_AssetsCurrent" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="locator_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_AssetsCurrent" xlink:to="locator_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="locator_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_AssetsCurrent" xlink:to="locator_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" use="optional" priority="0" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermInvestments" xlink:label="locator_us-gaap_OtherShortTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_AssetsCurrent" xlink:to="locator_us-gaap_OtherShortTermInvestments" use="optional" priority="0" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="locator_us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_AssetsCurrent" xlink:to="locator_us-gaap_AccountsReceivableNetCurrent" use="optional" priority="0" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="locator_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_AssetsCurrent" xlink:to="locator_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" priority="0" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="locator_us-gaap_AssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_Assets" xlink:to="locator_us-gaap_AssetsNoncurrent" use="optional" priority="0" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="locator_us-gaap_PrepaidExpenseNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_AssetsNoncurrent" xlink:to="locator_us-gaap_PrepaidExpenseNoncurrent" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SeverancePayFundNoncurrent" xlink:label="locator_cgen_SeverancePayFundNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_AssetsNoncurrent" xlink:to="locator_cgen_SeverancePayFundNoncurrent" use="optional" priority="0" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_AssetsNoncurrent" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentNet" use="optional" priority="0" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="locator_us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_AssetsNoncurrent" xlink:to="locator_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" priority="0" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="locator_us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="locator_us-gaap_LiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="locator_us-gaap_LiabilitiesCurrent" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="locator_us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_LiabilitiesCurrent" xlink:to="locator_us-gaap_AccountsPayableCurrent" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="locator_us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_LiabilitiesCurrent" xlink:to="locator_us-gaap_OtherAccountsPayableAndAccruedLiabilities" use="optional" priority="0" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="locator_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_LiabilitiesCurrent" xlink:to="locator_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" use="optional" priority="0" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="locator_us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_LiabilitiesCurrent" xlink:to="locator_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" priority="0" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="locator_us-gaap_LiabilitiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="locator_us-gaap_LiabilitiesNoncurrent" use="optional" priority="0" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="locator_us-gaap_PostemploymentBenefitsLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_LiabilitiesNoncurrent" xlink:to="locator_us-gaap_PostemploymentBenefitsLiabilityNoncurrent" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="locator_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_LiabilitiesNoncurrent" xlink:to="locator_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" use="optional" priority="0" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="locator_us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_LiabilitiesNoncurrent" xlink:to="locator_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" priority="0" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="locator_us-gaap_StockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="locator_us-gaap_StockholdersEquity" use="optional" priority="0" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="locator_us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_StockholdersEquity" xlink:to="locator_us-gaap_CommonStockValue" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="locator_us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_StockholdersEquity" xlink:to="locator_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" priority="0" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="locator_us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_StockholdersEquity" xlink:to="locator_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" priority="0" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-csocl">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="locator_us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="locator_us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="locator_us-gaap_NetIncomeLoss" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetIncomeLoss" xlink:to="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="locator_us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="locator_us-gaap_OperatingIncomeLoss" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="locator_us-gaap_GrossProfit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_OperatingIncomeLoss" xlink:to="locator_us-gaap_GrossProfit" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="locator_us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_GrossProfit" xlink:to="locator_us-gaap_Revenues" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="locator_us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_GrossProfit" xlink:to="locator_us-gaap_CostOfRevenue" use="optional" priority="0" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="locator_us-gaap_OperatingExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_OperatingIncomeLoss" xlink:to="locator_us-gaap_OperatingExpenses" use="optional" priority="0" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="locator_us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_OperatingExpenses" xlink:to="locator_us-gaap_ResearchAndDevelopmentExpense" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDevelopment" xlink:label="locator_us-gaap_BusinessDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_OperatingExpenses" xlink:to="locator_us-gaap_BusinessDevelopment" use="optional" priority="0" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="locator_us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_OperatingExpenses" xlink:to="locator_us-gaap_GeneralAndAdministrativeExpense" use="optional" priority="0" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="locator_cgen_FinancialIncomeExpenseNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="locator_cgen_FinancialIncomeExpenseNet" use="optional" priority="0" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="locator_us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetIncomeLoss" xlink:to="locator_us-gaap_IncomeTaxExpenseBenefit" use="optional" priority="0" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="locator_us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="locator_us-gaap_NetIncomeLoss" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="locator_us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="locator_us-gaap_ShareBasedCompensation" use="optional" priority="0" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="locator_us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="locator_us-gaap_Depreciation" use="optional" priority="0" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SeverancePayNet" xlink:label="locator_cgen_SeverancePayNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="locator_cgen_SeverancePayNet" use="optional" priority="0" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="locator_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="locator_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" use="optional" priority="0" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="locator_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="locator_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" use="optional" priority="0" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="locator_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="locator_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" priority="0" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="locator_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="locator_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" priority="0" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="locator_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="locator_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" priority="0" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="locator_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="locator_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" use="optional" priority="0" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="locator_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="locator_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" use="optional" priority="0" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="locator_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="locator_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" use="optional" priority="0" order="12" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="locator_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="locator_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" use="optional" priority="0" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="locator_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="locator_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" priority="0" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="locator_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="locator_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="locator_us-gaap_PaymentsToAcquireInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="locator_us-gaap_PaymentsToAcquireInvestments" use="optional" priority="0" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="locator_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="locator_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" priority="0" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="locator_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="locator_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" use="optional" priority="0" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="locator_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="locator_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" priority="0" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="locator_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="locator_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="locator_us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="locator_us-gaap_ProceedsFromStockOptionsExercised" use="optional" priority="0" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="locator_us-gaap_ProceedsFromWarrantExercises"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="locator_us-gaap_ProceedsFromWarrantExercises" use="optional" priority="0" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oaraped">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="locator_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="locator_us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="locator_us-gaap_PrepaidExpenseCurrent" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_GovernmentAuthorities" xlink:label="locator_cgen_GovernmentAuthorities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="locator_cgen_GovernmentAuthorities" use="optional" priority="0" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="locator_us-gaap_OtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="locator_us-gaap_OtherAssetsCurrent" use="optional" priority="0" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" priority="0" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" priority="0" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" use="optional" priority="0" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" use="optional" priority="0" order="5" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-paend">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentGross" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="locator_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="locator_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" priority="0" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oapaaed">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="locator_us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="locator_us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="locator_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="locator_us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="locator_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" priority="0" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" use="optional" priority="0" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="locator_us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="locator_us-gaap_DeferredTaxAssetsGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_DeferredTaxAssetsNet" xlink:to="locator_us-gaap_DeferredTaxAssetsGross" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_DeferredTaxAssetsGross" xlink:to="locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="locator_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_DeferredTaxAssetsGross" xlink:to="locator_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" use="optional" priority="0" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="locator_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_DeferredTaxAssetsGross" xlink:to="locator_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" priority="0" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_DeferredIncomeTaxRightOfUseAssets" xlink:label="locator_cgen_DeferredIncomeTaxRightOfUseAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_DeferredTaxAssetsGross" xlink:to="locator_cgen_DeferredIncomeTaxRightOfUseAssets" use="optional" priority="0" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_DeferredIncomeTaxLeaseLiabilities" xlink:label="locator_cgen_DeferredIncomeTaxLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_DeferredTaxAssetsGross" xlink:to="locator_cgen_DeferredIncomeTaxLeaseLiabilities" use="optional" priority="0" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="locator_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_DeferredTaxAssetsGross" xlink:to="locator_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" use="optional" priority="0" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="locator_us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_us-gaap_DeferredTaxAssetsNet" xlink:to="locator_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" priority="0" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails">
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="locator_cgen_FinancialIncomeExpenseNet"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="locator_us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_cgen_FinancialIncomeExpenseNet" xlink:to="locator_us-gaap_InvestmentIncomeInterest" use="optional" priority="0" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="locator_us-gaap_InterestAndDebtExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_cgen_FinancialIncomeExpenseNet" xlink:to="locator_us-gaap_InterestAndDebtExpense" use="optional" priority="0" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="locator_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_cgen_FinancialIncomeExpenseNet" xlink:to="locator_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" use="optional" priority="0" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="locator_us-gaap_GainLossOnSaleOfOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="locator_cgen_FinancialIncomeExpenseNet" xlink:to="locator_us-gaap_GainLossOnSaleOfOtherAssets" use="optional" priority="0" order="4" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>19
<FILENAME>cgen-20211231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- XBRL Document Created with XML Edge from P3 Data Systems -->
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <roleRef roleURI="http://cgen.com/role/cgen-daei1" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-daei1"/>
  <roleRef roleURI="http://cgen.com/role/StatementsOfChangesInShareholdersEquity" xlink:type="simple" xlink:href="cgen-20211231.xsd#StatementsOfChangesInShareholdersEquity"/>
  <roleRef roleURI="http://cgen.com/role/cgen-sapnd" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-sapnd"/>
  <roleRef roleURI="http://cgen.com/role/cgen-sapsodrfpaed" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-sapsodrfpaed"/>
  <roleRef roleURI="http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"/>
  <roleRef roleURI="http://cgen.com/role/cgen-paend" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-paend"/>
  <roleRef roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#CommitmentsAndContingenciesDetails"/>
  <roleRef roleURI="http://cgen.com/role/cgen-sesopnd" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-sesopnd"/>
  <roleRef roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#ShareholdersEquityScheduleOfOptionActivityDetails"/>
  <roleRef roleURI="http://cgen.com/role/cgen-sesosced" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-sesosced"/>
  <roleRef roleURI="http://cgen.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <roleRef roleURI="http://cgen.com/role/GeographicInformationAndMajorCustomersDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#GeographicInformationAndMajorCustomersDetails"/>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-daei1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="locator_us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="locator_dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityCentralIndexKey" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="locator_dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_CurrentFiscalYearEndDate" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="locator_dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_DocumentFiscalYearFocus" use="optional" priority="0" order="2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="locator_dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_DocumentFiscalPeriodFocus" use="optional" priority="0" order="3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="locator_dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_DocumentType" use="optional" priority="0" order="4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="locator_dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_AmendmentFlag" use="optional" priority="0" order="5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="locator_dei_AmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_AmendmentDescription" use="optional" priority="0" order="6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="locator_dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_DocumentRegistrationStatement" use="optional" priority="0" order="7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="locator_dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_DocumentAnnualReport" use="optional" priority="0" order="8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="locator_dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_DocumentTransitionReport" use="optional" priority="0" order="9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="locator_us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_StatementTable" use="optional" priority="0" order="10" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="locator_dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_us-gaap_StatementTable" xlink:to="locator_dei_EntityAddressesAddressTypeAxis" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="locator_dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_dei_EntityAddressesAddressTypeAxis" xlink:to="locator_dei_AddressTypeDomain" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember" xlink:label="locator_dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_dei_AddressTypeDomain" xlink:to="locator_dei_BusinessContactMember" use="optional" priority="0" order="11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="locator_dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_DocumentShellCompanyReport" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="locator_dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_DocumentPeriodEndDate" use="optional" priority="0" order="11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="locator_dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityFileNumber" use="optional" priority="0" order="12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName" xlink:label="locator_dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_ContactPersonnelName" use="optional" priority="0" order="13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="locator_dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityRegistrantName" use="optional" priority="0" order="14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="locator_dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityIncorporationStateCountryCode" use="optional" priority="0" order="15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="locator_dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityAddressAddressLine1" use="optional" priority="0" order="16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="locator_dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityAddressAddressLine2" use="optional" priority="0" order="17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="locator_dei_EntityAddressAddressLine3"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityAddressAddressLine3" use="optional" priority="0" order="18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="locator_dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityAddressCityOrTown" use="optional" priority="0" order="19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="locator_dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityAddressCountry" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="locator_dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityAddressPostalZipCode" use="optional" priority="0" order="21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="locator_dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_CityAreaCode" use="optional" priority="0" order="22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="locator_dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_LocalPhoneNumber" use="optional" priority="0" order="23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelFaxNumber" xlink:label="locator_dei_ContactPersonnelFaxNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_ContactPersonnelFaxNumber" use="optional" priority="0" order="24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelEmailAddress" xlink:label="locator_dei_ContactPersonnelEmailAddress"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_ContactPersonnelEmailAddress" use="optional" priority="0" order="25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="locator_dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_Security12bTitle" use="optional" priority="0" order="26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="locator_dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_TradingSymbol" use="optional" priority="0" order="27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="locator_dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_SecurityExchangeName" use="optional" priority="0" order="28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="locator_dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityCommonStockSharesOutstanding" use="optional" priority="0" order="29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="locator_dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityWellKnownSeasonedIssuer" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="locator_dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityVoluntaryFilers" use="optional" priority="0" order="31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="locator_dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityCurrentReportingStatus" use="optional" priority="0" order="32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="locator_dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityInteractiveDataCurrent" use="optional" priority="0" order="33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="locator_dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityFilerCategory" use="optional" priority="0" order="34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="locator_dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityEmergingGrowthCompany" use="optional" priority="0" order="35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="locator_dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_IcfrAuditorAttestationFlag" use="optional" priority="0" order="36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="locator_dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityExTransitionPeriod" use="optional" priority="0" order="37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="locator_dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_DocumentAccountingStandard" use="optional" priority="0" order="38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="locator_dei_OtherReportingStandardItemNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_OtherReportingStandardItemNumber" use="optional" priority="0" order="39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="locator_dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityShellCompany" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="locator_dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_AuditorName" use="optional" priority="0" order="41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="locator_dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_AuditorLocation" use="optional" priority="0" order="42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="locator_dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_AuditorFirmId" use="optional" priority="0" order="43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="locator_dei_AddressTypeDomain_a5d6b8de-25b5-29b5-7d56-2143e34bafc5_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_dei_EntityAddressesAddressTypeAxis" xlink:to="locator_dei_AddressTypeDomain_a5d6b8de-25b5-29b5-7d56-2143e34bafc5_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/StatementsOfChangesInShareholdersEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="locator_us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="locator_us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_StockholdersEquity" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="locator_us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_CommonStockSharesOutstanding" use="optional" priority="0" order="2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="locator_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" use="optional" priority="0" order="3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="locator_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" use="optional" priority="0" order="4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="locator_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" use="optional" priority="0" order="5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="locator_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" use="optional" priority="0" order="6"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_IssuanceOfSharesAndWarrantsNetValue" xlink:label="locator_cgen_IssuanceOfSharesAndWarrantsNetValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_IssuanceOfSharesAndWarrantsNetValue" use="optional" priority="0" order="7"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_IssuanceOfSharesAndWarrantsNetShares" xlink:label="locator_cgen_IssuanceOfSharesAndWarrantsNetShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_IssuanceOfSharesAndWarrantsNetShares" use="optional" priority="0" order="8"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="locator_cgen_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_StockIssuedDuringPeriodValueWarrantsExercised" use="optional" priority="0" order="9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="locator_us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_StatementTable" use="optional" priority="0" order="10" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="locator_us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_us-gaap_StatementTable" xlink:to="locator_us-gaap_StatementEquityComponentsAxis" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="locator_us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_us-gaap_StatementEquityComponentsAxis" xlink:to="locator_us-gaap_EquityComponentDomain" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="locator_us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_EquityComponentDomain" xlink:to="locator_us-gaap_CommonStockMember" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="locator_us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_EquityComponentDomain" xlink:to="locator_us-gaap_AdditionalPaidInCapitalMember" use="optional" priority="0" order="11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="locator_us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_EquityComponentDomain" xlink:to="locator_us-gaap_RetainedEarningsMember" use="optional" priority="0" order="21"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_NumberOfWarrantsExercised" xlink:label="locator_cgen_NumberOfWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_NumberOfWarrantsExercised" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="locator_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_StockIssuedDuringPeriodValueNewIssues" use="optional" priority="0" order="11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="locator_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_StockIssuedDuringPeriodSharesNewIssues" use="optional" priority="0" order="12"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_StockIssuedDuringPeriodValueTerminationAndEquityConversionAgreementIssues" xlink:label="locator_cgen_StockIssuedDuringPeriodValueTerminationAndEquityConversionAgreementIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_StockIssuedDuringPeriodValueTerminationAndEquityConversionAgreementIssues" use="optional" priority="0" order="13"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_StockIssuedDuringPeriodSharesTerminationAndEquityConversionAgreementIssues" xlink:label="locator_cgen_StockIssuedDuringPeriodSharesTerminationAndEquityConversionAgreementIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_StockIssuedDuringPeriodSharesTerminationAndEquityConversionAgreementIssues" use="optional" priority="0" order="14"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="locator_cgen_StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" use="optional" priority="0" order="15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="locator_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" use="optional" priority="0" order="16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="locator_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" use="optional" priority="0" order="17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="locator_us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_NetIncomeLoss" use="optional" priority="0" order="18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="locator_us-gaap_EquityComponentDomain_4bb80868-9c28-d3ab-33bc-eef1d7b9c8c6_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_us-gaap_StatementEquityComponentsAxis" xlink:to="locator_us-gaap_EquityComponentDomain_4bb80868-9c28-d3ab-33bc-eef1d7b9c8c6_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapnd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="locator_us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ShortTermBankDepositsWeightedAverageRateForeign" xlink:label="locator_cgen_ShortTermBankDepositsWeightedAverageRateForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_ShortTermBankDepositsWeightedAverageRateForeign" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="locator_us-gaap_AdjustmentForAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_AdjustmentForAmortization" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="locator_us-gaap_ImpairmentOfInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_ImpairmentOfInvestments" use="optional" priority="0" order="2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="locator_us-gaap_DeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_DeferredRevenue" use="optional" priority="0" order="3"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" xlink:label="locator_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" use="optional" priority="0" order="4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="locator_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" use="optional" priority="0" order="5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="locator_us-gaap_SeveranceCosts1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_SeveranceCosts1" use="optional" priority="0" order="6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="locator_us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_DerivativeGainLossOnDerivativeNet" use="optional" priority="0" order="7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:label="locator_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" use="optional" priority="0" order="8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting" xlink:label="locator_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting" use="optional" priority="0" order="9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="locator_us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_StatementTable" use="optional" priority="0" order="10" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="locator_srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_us-gaap_StatementTable" xlink:to="locator_srt_StatementScenarioAxis" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="locator_srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_srt_StatementScenarioAxis" xlink:to="locator_srt_ScenarioUnspecifiedDomain" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_MasterClinicalAgreementOneMember" xlink:label="locator_cgen_MasterClinicalAgreementOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_srt_ScenarioUnspecifiedDomain" xlink:to="locator_cgen_MasterClinicalAgreementOneMember" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_MasterClinicalAgreementTwoMember" xlink:label="locator_cgen_MasterClinicalAgreementTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_srt_ScenarioUnspecifiedDomain" xlink:to="locator_cgen_MasterClinicalAgreementTwoMember" use="optional" priority="0" order="21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="locator_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_us-gaap_StatementTable" xlink:to="locator_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" priority="0" order="2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="locator_us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="locator_us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="locator_us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="locator_us-gaap_StockOptionMember" use="optional" priority="0" order="111"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="locator_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_DerivativeRelatedExpense" xlink:label="locator_cgen_DerivativeRelatedExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_DerivativeRelatedExpense" use="optional" priority="0" order="11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="locator_us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_DerivativeFairValueOfDerivativeNet" use="optional" priority="0" order="12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="locator_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" use="optional" priority="0" order="13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="locator_us-gaap_EquityMethodInvestmentAggregateCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_EquityMethodInvestmentAggregateCost" use="optional" priority="0" order="14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="locator_us-gaap_DerivativeNotionalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_DerivativeNotionalAmount" use="optional" priority="0" order="15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="locator_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" use="optional" priority="0" order="16"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="locator_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" use="optional" priority="0" order="17"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AccruedMilestonePayment" xlink:label="locator_cgen_AccruedMilestonePayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_AccruedMilestonePayment" use="optional" priority="0" order="18"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_DeferredParticipationOfBmsInRdExpenses" xlink:label="locator_cgen_DeferredParticipationOfBmsInRdExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_DeferredParticipationOfBmsInRdExpenses" use="optional" priority="0" order="19"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_PercentageOfConsolidatedRevenuesOfCollaborator" xlink:label="locator_cgen_PercentageOfConsolidatedRevenuesOfCollaborator"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_PercentageOfConsolidatedRevenuesOfCollaborator" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="locator_srt_ScenarioUnspecifiedDomain_5e650370-3e41-7631-3adc-5994996a37f4_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_srt_StatementScenarioAxis" xlink:to="locator_srt_ScenarioUnspecifiedDomain_5e650370-3e41-7631-3adc-5994996a37f4_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="locator_us-gaap_AntidilutiveSecuritiesNameDomain_90b5d349-1e66-44a9-c9d2-ee5fa152bc75_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="locator_us-gaap_AntidilutiveSecuritiesNameDomain_90b5d349-1e66-44a9-c9d2-ee5fa152bc75_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapsodrfpaed">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AnnualDepreciationRate" xlink:label="locator_cgen_AnnualDepreciationRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="locator_cgen_AnnualDepreciationRate" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AnnualDepreciationRateDescription" xlink:label="locator_cgen_AnnualDepreciationRateDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="locator_cgen_AnnualDepreciationRateDescription" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" priority="0" order="10" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="locator_us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="locator_us-gaap_ComputerEquipmentMember" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="locator_cgen_LaboratoryEquipmentAndOfficeFurnitureMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="locator_cgen_LaboratoryEquipmentAndOfficeFurnitureMember" use="optional" priority="0" order="31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="locator_us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="locator_us-gaap_LeaseholdImprovementsMember" use="optional" priority="0" order="61"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="locator_srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="locator_srt_RangeAxis" use="optional" priority="0" order="2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="locator_srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_srt_RangeAxis" xlink:to="locator_srt_RangeMember" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="locator_srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_srt_RangeMember" xlink:to="locator_srt_MinimumMember" use="optional" priority="0" order="2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="locator_srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_srt_RangeMember" xlink:to="locator_srt_MaximumMember" use="optional" priority="0" order="12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_906b9c33-6077-d86d-3aed-673106ee8dec_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_906b9c33-6077-d86d-3aed-673106ee8dec_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="locator_srt_RangeMember_7d1ad79f-674b-8f5b-ee9e-d113801bbfc9_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_srt_RangeAxis" xlink:to="locator_srt_RangeMember_7d1ad79f-674b-8f5b-ee9e-d113801bbfc9_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" use="optional" priority="0" order="2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" use="optional" priority="0" order="3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" priority="0" order="10" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="locator_us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="locator_us-gaap_AwardTypeAxis" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_us-gaap_AwardTypeAxis" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="locator_us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="locator_us-gaap_EmployeeStockOptionMember" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_EmployeeStockPurchasePlanMember" xlink:label="locator_cgen_EmployeeStockPurchasePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="locator_cgen_EmployeeStockPurchasePlanMember" use="optional" priority="0" order="31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="locator_srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="locator_srt_RangeAxis" use="optional" priority="0" order="2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="locator_srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_srt_RangeAxis" xlink:to="locator_srt_RangeMember" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="locator_srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_srt_RangeMember" xlink:to="locator_srt_MinimumMember" use="optional" priority="0" order="32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="locator_srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_srt_RangeMember" xlink:to="locator_srt_MaximumMember" use="optional" priority="0" order="42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f534c710-7aa9-14fa-9ced-346a275e56a0_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_us-gaap_AwardTypeAxis" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f534c710-7aa9-14fa-9ced-346a275e56a0_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="locator_srt_RangeMember_d7a13484-5807-2ae2-82ab-fc706af817fe_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_srt_RangeAxis" xlink:to="locator_srt_RangeMember_d7a13484-5807-2ae2-82ab-fc706af817fe_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-paend">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentGross" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="locator_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="locator_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentNet" use="optional" priority="0" order="2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="locator_us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="locator_us-gaap_Depreciation" use="optional" priority="0" order="3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" priority="0" order="10" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="locator_us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="locator_us-gaap_ComputerEquipmentMember" use="optional" priority="0" order="31"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="locator_cgen_LaboratoryEquipmentAndOfficeFurnitureMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="locator_cgen_LaboratoryEquipmentAndOfficeFurnitureMember" use="optional" priority="0" order="41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="locator_us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="locator_us-gaap_LeaseholdImprovementsMember" use="optional" priority="0" order="51"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xlink:label="locator_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="locator_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" use="optional" priority="0" order="61"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7ce1e31-7c0d-4611-f766-5d6e41906ef7_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7ce1e31-7c0d-4611-f766-5d6e41906ef7_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="locator_us-gaap_OtherCommitmentsLineItems"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="locator_us-gaap_GuaranteeObligationsMaximumExposure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_us-gaap_GuaranteeObligationsMaximumExposure" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="locator_cgen_RoyaltyPercentageBasedOnFutureRevenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_RoyaltyPercentageBasedOnFutureRevenues" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="locator_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" use="optional" priority="0" order="2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="locator_us-gaap_RoyaltyExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_us-gaap_RoyaltyExpense" use="optional" priority="0" order="3"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_RoyaltyContingentObligations" xlink:label="locator_cgen_RoyaltyContingentObligations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_RoyaltyContingentObligations" use="optional" priority="0" order="4"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ParticipationRights" xlink:label="locator_cgen_ParticipationRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_ParticipationRights" use="optional" priority="0" order="5"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_RetainerFee" xlink:label="locator_cgen_RetainerFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_RetainerFee" use="optional" priority="0" order="6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="locator_us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" priority="0" order="7"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AgreementStartDate" xlink:label="locator_cgen_AgreementStartDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_AgreementStartDate" use="optional" priority="0" order="8"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AgreementTerminationDescription" xlink:label="locator_cgen_AgreementTerminationDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_AgreementTerminationDescription" use="optional" priority="0" order="9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="locator_us-gaap_OtherCommitmentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_us-gaap_OtherCommitmentsTable" use="optional" priority="0" order="10" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="locator_cgen_GovernmentAndOtherGrantsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_us-gaap_OtherCommitmentsTable" xlink:to="locator_cgen_GovernmentAndOtherGrantsAxis" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="locator_cgen_GovernmentAndOtherGrantsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_cgen_GovernmentAndOtherGrantsAxis" xlink:to="locator_cgen_GovernmentAndOtherGrantsDomain" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="locator_cgen_ResearchAndDevelopmentGrantOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_cgen_GovernmentAndOtherGrantsDomain" xlink:to="locator_cgen_ResearchAndDevelopmentGrantOneMember" use="optional" priority="0" order="31"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_May2012AgreementMember" xlink:label="locator_cgen_May2012AgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_cgen_GovernmentAndOtherGrantsDomain" xlink:to="locator_cgen_May2012AgreementMember" use="optional" priority="0" order="92"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="locator_srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_us-gaap_OtherCommitmentsTable" xlink:to="locator_srt_RangeAxis" use="optional" priority="0" order="2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="locator_srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_srt_RangeAxis" xlink:to="locator_srt_RangeMember" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="locator_srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_srt_RangeMember" xlink:to="locator_srt_MinimumMember" use="optional" priority="0" order="32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="locator_srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_srt_RangeMember" xlink:to="locator_srt_MaximumMember" use="optional" priority="0" order="42"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ExtendLease" xlink:label="locator_cgen_ExtendLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_ExtendLease" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ContingentFees" xlink:label="locator_cgen_ContingentFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_ContingentFees" use="optional" priority="0" order="11"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xlink:label="locator_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" use="optional" priority="0" order="12"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_RoyaltyPercentage" xlink:label="locator_cgen_RoyaltyPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_RoyaltyPercentage" use="optional" priority="0" order="13"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePayment" xlink:label="locator_cgen_ResearchAndDevelopmentExpensesMilestonePayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_ResearchAndDevelopmentExpensesMilestonePayment" use="optional" priority="0" order="14"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="locator_cgen_GovernmentAndOtherGrantsDomain_ea7b2de4-228a-7c63-aa6f-bb68854976ab_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_cgen_GovernmentAndOtherGrantsAxis" xlink:to="locator_cgen_GovernmentAndOtherGrantsDomain_ea7b2de4-228a-7c63-aa6f-bb68854976ab_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="locator_srt_RangeMember_26aa7627-1661-3c62-2544-8025d94c8996_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_srt_RangeAxis" xlink:to="locator_srt_RangeMember_26aa7627-1661-3c62-2544-8025d94c8996_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sesopnd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" use="optional" priority="0" order="2"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="locator_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" use="optional" priority="0" order="3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" use="optional" priority="0" order="4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" use="optional" priority="0" order="5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" use="optional" priority="0" order="6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" use="optional" priority="0" order="7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" use="optional" priority="0" order="8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" use="optional" priority="0" order="9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" priority="0" order="10" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="locator_srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="locator_srt_StatementScenarioAxis" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="locator_srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_srt_StatementScenarioAxis" xlink:to="locator_srt_ScenarioUnspecifiedDomain" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AtTheMarketOfferingProgramMember" xlink:label="locator_cgen_AtTheMarketOfferingProgramMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_srt_ScenarioUnspecifiedDomain" xlink:to="locator_cgen_AtTheMarketOfferingProgramMember" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AgreementMember" xlink:label="locator_cgen_AgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_srt_ScenarioUnspecifiedDomain" xlink:to="locator_cgen_AgreementMember" use="optional" priority="0" order="31"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_MasterClinicalAgreementMember" xlink:label="locator_cgen_MasterClinicalAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_srt_ScenarioUnspecifiedDomain" xlink:to="locator_cgen_MasterClinicalAgreementMember" use="optional" priority="0" order="71"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_CollaborativeArrangementsMember" xlink:label="locator_cgen_CollaborativeArrangementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_srt_ScenarioUnspecifiedDomain" xlink:to="locator_cgen_CollaborativeArrangementsMember" use="optional" priority="0" order="91"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="locator_cgen_CollaborativeArrangementsTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_srt_ScenarioUnspecifiedDomain" xlink:to="locator_cgen_CollaborativeArrangementsTwoMember" use="optional" priority="0" order="121"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="locator_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_srt_ScenarioUnspecifiedDomain" xlink:to="locator_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" use="optional" priority="0" order="131"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="locator_us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="locator_us-gaap_AwardTypeAxis" use="optional" priority="0" order="2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_us-gaap_AwardTypeAxis" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="locator_cgen_RegisteredDirectOfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="locator_cgen_RegisteredDirectOfferingMember" use="optional" priority="0" order="32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="locator_us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="locator_us-gaap_WarrantMember" use="optional" priority="0" order="51"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_UnderwritersMember" xlink:label="locator_cgen_UnderwritersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="locator_cgen_UnderwritersMember" use="optional" priority="0" order="152"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="locator_us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="locator_us-gaap_PlanNameAxis" use="optional" priority="0" order="3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="locator_us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_us-gaap_PlanNameAxis" xlink:to="locator_us-gaap_PlanNameDomain" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" xlink:label="locator_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_PlanNameDomain" xlink:to="locator_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" use="optional" priority="0" order="181"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="locator_srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="locator_srt_TitleOfIndividualAxis" use="optional" priority="0" order="4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="locator_srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_srt_TitleOfIndividualAxis" xlink:to="locator_srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="locator_srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="locator_srt_DirectorMember" use="optional" priority="0" order="241"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="locator_us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="locator_us-gaap_SubsidiarySaleOfStockAxis" use="optional" priority="0" order="5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="locator_us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="locator_us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="locator_us-gaap_EmployeeStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="locator_us-gaap_EmployeeStockMember" use="optional" priority="0" order="271"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="locator_us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_CommonStockParOrStatedValuePerShare" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="locator_us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_SharesIssuedPricePerShare" use="optional" priority="0" order="11"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="locator_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" use="optional" priority="0" order="12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="locator_us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_CommonStockSharesAuthorized" use="optional" priority="0" order="13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="locator_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" use="optional" priority="0" order="14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="locator_us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ClassOfWarrantOrRightOutstanding" use="optional" priority="0" order="15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="locator_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" use="optional" priority="0" order="16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="locator_us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ProceedsFromWarrantExercises" use="optional" priority="0" order="17"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="locator_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" use="optional" priority="0" order="18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="locator_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_StockIssuedDuringPeriodSharesNewIssues" use="optional" priority="0" order="19"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AgreementOptionAdditionalNumberOfSharesIssuable" xlink:label="locator_cgen_AgreementOptionAdditionalNumberOfSharesIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_cgen_AgreementOptionAdditionalNumberOfSharesIssuable" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="locator_us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" priority="0" order="21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="locator_us-gaap_EquityMethodInvestmentAggregateCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_EquityMethodInvestmentAggregateCost" use="optional" priority="0" order="22"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_PercentageOfClosingPrice" xlink:label="locator_cgen_PercentageOfClosingPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_cgen_PercentageOfClosingPrice" use="optional" priority="0" order="23"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_DeferredParticipationOfBmsInRdExpenses" xlink:label="locator_cgen_DeferredParticipationOfBmsInRdExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_cgen_DeferredParticipationOfBmsInRdExpenses" use="optional" priority="0" order="24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="locator_us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ProceedsFromIssuanceInitialPublicOffering" use="optional" priority="0" order="25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InitialOfferingPeriod" xlink:label="locator_us-gaap_InitialOfferingPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_InitialOfferingPeriod" use="optional" priority="0" order="26"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" xlink:label="locator_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" use="optional" priority="0" order="27"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" xlink:label="locator_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" use="optional" priority="0" order="28"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" xlink:label="locator_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" use="optional" priority="0" order="29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="locator_srt_ScenarioUnspecifiedDomain_4d5c6256-18be-6b75-1341-bcfdff963c4d_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_srt_StatementScenarioAxis" xlink:to="locator_srt_ScenarioUnspecifiedDomain_4d5c6256-18be-6b75-1341-bcfdff963c4d_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f74a39b-1ae8-9dae-9e44-29ad0c2f65b9_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_us-gaap_AwardTypeAxis" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f74a39b-1ae8-9dae-9e44-29ad0c2f65b9_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="locator_us-gaap_PlanNameDomain_46079228-c176-aac0-2396-73216f185cc8_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_us-gaap_PlanNameAxis" xlink:to="locator_us-gaap_PlanNameDomain_46079228-c176-aac0-2396-73216f185cc8_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="locator_srt_TitleOfIndividualWithRelationshipToEntityDomain_8b0e34cd-0afc-9136-3e94-d40729394335_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_srt_TitleOfIndividualAxis" xlink:to="locator_srt_TitleOfIndividualWithRelationshipToEntityDomain_8b0e34cd-0afc-9136-3e94-d40729394335_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="locator_us-gaap_SaleOfStockNameOfTransactionDomain_54422cc6-071f-e88b-e5cb-11083138b631_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="locator_us-gaap_SaleOfStockNameOfTransactionDomain_54422cc6-071f-e88b-e5cb-11083138b631_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" use="optional" priority="0" order="2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="locator_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="locator_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" use="optional" priority="0" order="3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" use="optional" priority="0" order="4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" use="optional" priority="0" order="5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" use="optional" priority="0" order="7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" use="optional" priority="0" order="8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" use="optional" priority="0" order="9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" use="optional" priority="0" order="11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" use="optional" priority="0" order="12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" use="optional" priority="0" order="13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" use="optional" priority="0" order="14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" use="optional" priority="0" order="16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" use="optional" priority="0" order="17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" priority="0" order="10" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="locator_us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="locator_us-gaap_AwardTypeAxis" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_us-gaap_AwardTypeAxis" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_EmployeesAndDirectorsMember" xlink:label="locator_cgen_EmployeesAndDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="locator_cgen_EmployeesAndDirectorsMember" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="locator_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" use="optional" priority="0" order="18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:to="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" use="optional" priority="0" order="19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="locator_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:to="locator_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" use="optional" priority="0" order="21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" use="optional" priority="0" order="22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" use="optional" priority="0" order="23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2785c5af-c150-9928-d5f6-eeaa4d636c42_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_us-gaap_AwardTypeAxis" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2785c5af-c150-9928-d5f6-eeaa4d636c42_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sesosced">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="locator_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="locator_us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="locator_us-gaap_AllocatedShareBasedCompensationExpense" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="locator_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="locator_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="locator_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" priority="0" order="10" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="locator_us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="locator_us-gaap_IncomeStatementLocationAxis" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="locator_us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_us-gaap_IncomeStatementLocationAxis" xlink:to="locator_us-gaap_IncomeStatementLocationDomain" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="locator_us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_IncomeStatementLocationDomain" xlink:to="locator_us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="locator_us-gaap_SellingAndMarketingExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_IncomeStatementLocationDomain" xlink:to="locator_us-gaap_SellingAndMarketingExpenseMember" use="optional" priority="0" order="11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="locator_us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_IncomeStatementLocationDomain" xlink:to="locator_us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" priority="0" order="21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="locator_us-gaap_IncomeStatementLocationDomain_fd2eceff-c056-4e3d-eb97-8e4b8ad2c7e1_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_us-gaap_IncomeStatementLocationAxis" xlink:to="locator_us-gaap_IncomeStatementLocationDomain_fd2eceff-c056-4e3d-eb97-8e4b8ad2c7e1_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="locator_us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="locator_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xlink:label="locator_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="locator_us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_IncomeTaxesPaid" use="optional" priority="0" order="2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="locator_us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_ProceedsFromIncomeTaxRefunds" use="optional" priority="0" order="3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="locator_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" use="optional" priority="0" order="4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="locator_us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_OperatingLossCarryforwards" use="optional" priority="0" order="5"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_NetOperatingLossCarryforwardExpired" xlink:label="locator_cgen_NetOperatingLossCarryforwardExpired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_NetOperatingLossCarryforwardExpired" use="optional" priority="0" order="6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="locator_us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_OperatingLossCarryforwardsExpirationDate" use="optional" priority="0" order="7"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ReducedCorporateIncomeTaxRate" xlink:label="locator_cgen_ReducedCorporateIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_ReducedCorporateIncomeTaxRate" use="optional" priority="0" order="8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="locator_us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_StatementTable" use="optional" priority="0" order="10" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="locator_us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_us-gaap_StatementTable" xlink:to="locator_us-gaap_IncomeTaxAuthorityAxis" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="locator_us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_us-gaap_IncomeTaxAuthorityAxis" xlink:to="locator_us-gaap_IncomeTaxAuthorityDomain" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="locator_us-gaap_InternalRevenueServiceIRSMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_IncomeTaxAuthorityDomain" xlink:to="locator_us-gaap_InternalRevenueServiceIRSMember" use="optional" priority="0" order="31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="locator_us-gaap_DomesticCountryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_IncomeTaxAuthorityDomain" xlink:to="locator_us-gaap_DomesticCountryMember" use="optional" priority="0" order="61"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="locator_srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_us-gaap_StatementTable" xlink:to="locator_srt_RangeAxis" use="optional" priority="0" order="2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="locator_srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_srt_RangeAxis" xlink:to="locator_srt_RangeMember" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="locator_srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_srt_RangeMember" xlink:to="locator_srt_MinimumMember" use="optional" priority="0" order="32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="locator_srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_srt_RangeMember" xlink:to="locator_srt_MaximumMember" use="optional" priority="0" order="42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="locator_us-gaap_IncomeTaxAuthorityDomain_c4cb6aff-78e5-187e-e332-6438b65af2fe_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_us-gaap_IncomeTaxAuthorityAxis" xlink:to="locator_us-gaap_IncomeTaxAuthorityDomain_c4cb6aff-78e5-187e-e332-6438b65af2fe_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="locator_srt_RangeMember_8400ccd3-67bb-edb9-c2cb-09aef05c932f_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_srt_RangeAxis" xlink:to="locator_srt_RangeMember_8400ccd3-67bb-edb9-c2cb-09aef05c932f_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/GeographicInformationAndMajorCustomersDetails">
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SegmentReportingGeograhicAreaLineItems" xlink:label="locator_cgen_SegmentReportingGeograhicAreaLineItems"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="locator_us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_cgen_SegmentReportingGeograhicAreaLineItems" xlink:to="locator_us-gaap_NumberOfOperatingSegments" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="locator_us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_cgen_SegmentReportingGeograhicAreaLineItems" xlink:to="locator_us-gaap_Revenues" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="locator_us-gaap_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_cgen_SegmentReportingGeograhicAreaLineItems" xlink:to="locator_us-gaap_NoncurrentAssets" use="optional" priority="0" order="2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="locator_us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_cgen_SegmentReportingGeograhicAreaLineItems" xlink:to="locator_us-gaap_ConcentrationRiskPercentage1" use="optional" priority="0" order="3"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SegmentReportingGeographicAreaTable" xlink:label="locator_cgen_SegmentReportingGeographicAreaTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="locator_cgen_SegmentReportingGeograhicAreaLineItems" xlink:to="locator_cgen_SegmentReportingGeographicAreaTable" use="optional" priority="0" order="10" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SegmentReportingGeographicAreaAxis" xlink:label="locator_cgen_SegmentReportingGeographicAreaAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_cgen_SegmentReportingGeographicAreaTable" xlink:to="locator_cgen_SegmentReportingGeographicAreaAxis" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SegmentReportingGeographicAreaDomain" xlink:label="locator_cgen_SegmentReportingGeographicAreaDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_cgen_SegmentReportingGeographicAreaAxis" xlink:to="locator_cgen_SegmentReportingGeographicAreaDomain" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember" xlink:label="locator_srt_EuropeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_cgen_SegmentReportingGeographicAreaDomain" xlink:to="locator_srt_EuropeMember" use="optional" priority="0" order="1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IL" xlink:label="locator_country_IL"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_cgen_SegmentReportingGeographicAreaDomain" xlink:to="locator_country_IL" use="optional" priority="0" order="61"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="locator_country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_cgen_SegmentReportingGeographicAreaDomain" xlink:to="locator_country_US" use="optional" priority="0" order="71"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="locator_us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_cgen_SegmentReportingGeographicAreaTable" xlink:to="locator_us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" priority="0" order="2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="locator_us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="locator_us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="locator_us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="locator_us-gaap_SalesRevenueNetMember" use="optional" priority="0" order="121"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="locator_us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_cgen_SegmentReportingGeographicAreaTable" xlink:to="locator_us-gaap_ConcentrationRiskByTypeAxis" use="optional" priority="0" order="3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="locator_us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="locator_us-gaap_ConcentrationRiskTypeDomain" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="locator_us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_us-gaap_ConcentrationRiskTypeDomain" xlink:to="locator_us-gaap_CustomerConcentrationRiskMember" use="optional" priority="0" order="122"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="locator_srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="locator_cgen_SegmentReportingGeographicAreaTable" xlink:to="locator_srt_MajorCustomersAxis" use="optional" priority="0" order="4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="locator_srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="locator_srt_MajorCustomersAxis" xlink:to="locator_srt_NameOfMajorCustomerDomain" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_CustomerOneMember" xlink:label="locator_cgen_CustomerOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="locator_srt_NameOfMajorCustomerDomain" xlink:to="locator_cgen_CustomerOneMember" use="optional" priority="0" order="123"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SegmentReportingGeographicAreaDomain" xlink:label="locator_cgen_SegmentReportingGeographicAreaDomain_1fe62ead-ddff-9d9d-9951-af386376f521_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_cgen_SegmentReportingGeographicAreaAxis" xlink:to="locator_cgen_SegmentReportingGeographicAreaDomain_1fe62ead-ddff-9d9d-9951-af386376f521_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="locator_us-gaap_ConcentrationRiskBenchmarkDomain_687b67d8-0208-5d00-2c7f-009c8778d3a5_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="locator_us-gaap_ConcentrationRiskBenchmarkDomain_687b67d8-0208-5d00-2c7f-009c8778d3a5_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="locator_us-gaap_ConcentrationRiskTypeDomain_a7af4a8c-f762-4a23-346c-aaf72624ce5b_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="locator_us-gaap_ConcentrationRiskTypeDomain_a7af4a8c-f762-4a23-346c-aaf72624ce5b_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="locator_srt_NameOfMajorCustomerDomain_d69575ba-374c-56cb-69c5-6576ca890e8b_default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="locator_srt_MajorCustomersAxis" xlink:to="locator_srt_NameOfMajorCustomerDomain_d69575ba-374c-56cb-69c5-6576ca890e8b_default" use="optional" priority="0" order="30" xbrldt:contextElement="segment"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>cgen-20211231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- XBRL Document Created with XML Edge from P3 Data Systems -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="locator_us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_StatementTable" xlink:to="label_us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="locator_dei_EntityAddressesAddressTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses Address Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_EntityAddressesAddressTypeAxis" xlink:to="label_dei_EntityAddressesAddressTypeAxis"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember" xlink:label="locator_dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_BusinessContactMember" xlink:to="label_dei_BusinessContactMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="locator_us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="label_us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="locator_dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_EntityCentralIndexKey" xlink:to="label_dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="locator_dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_CurrentFiscalYearEndDate" xlink:to="label_dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="locator_dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_DocumentFiscalYearFocus" xlink:to="label_dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="locator_dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_DocumentFiscalPeriodFocus" xlink:to="label_dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="locator_dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_DocumentType" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_DocumentType" xlink:to="label_dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="locator_dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_AmendmentFlag" xlink:to="label_dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="locator_dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_AmendmentDescription" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_AmendmentDescription" xlink:to="label_dei_AmendmentDescription"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="locator_dei_DocumentRegistrationStatement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_DocumentRegistrationStatement" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_DocumentRegistrationStatement" xlink:to="label_dei_DocumentRegistrationStatement"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="locator_dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_DocumentAnnualReport" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_DocumentAnnualReport" xlink:to="label_dei_DocumentAnnualReport"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="locator_dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_DocumentTransitionReport" xlink:to="label_dei_DocumentTransitionReport"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="locator_dei_DocumentShellCompanyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_DocumentShellCompanyReport" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_DocumentShellCompanyReport" xlink:to="label_dei_DocumentShellCompanyReport"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="locator_dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_DocumentPeriodEndDate" xlink:to="label_dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="locator_dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_EntityFileNumber" xlink:to="label_dei_EntityFileNumber"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName" xlink:label="locator_dei_ContactPersonnelName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_ContactPersonnelName" xlink:to="label_dei_ContactPersonnelName"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="locator_dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_EntityRegistrantName" xlink:to="label_dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="locator_dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation State Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_EntityIncorporationStateCountryCode" xlink:to="label_dei_EntityIncorporationStateCountryCode"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="locator_dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_EntityAddressAddressLine1" xlink:to="label_dei_EntityAddressAddressLine1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="locator_dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_EntityAddressAddressLine2" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_EntityAddressAddressLine2" xlink:to="label_dei_EntityAddressAddressLine2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="locator_dei_EntityAddressAddressLine3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_EntityAddressAddressLine3" xml:lang="en-US">Entity Address, Address Line Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_EntityAddressAddressLine3" xlink:to="label_dei_EntityAddressAddressLine3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="locator_dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_EntityAddressCityOrTown" xlink:to="label_dei_EntityAddressCityOrTown"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="locator_dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_EntityAddressCountry" xml:lang="en-US">Entity Address Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_EntityAddressCountry" xlink:to="label_dei_EntityAddressCountry"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="locator_dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_EntityAddressPostalZipCode" xlink:to="label_dei_EntityAddressPostalZipCode"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="locator_dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_CityAreaCode" xlink:to="label_dei_CityAreaCode"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="locator_dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_LocalPhoneNumber" xlink:to="label_dei_LocalPhoneNumber"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelFaxNumber" xlink:label="locator_dei_ContactPersonnelFaxNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_ContactPersonnelFaxNumber" xml:lang="en-US">Contact Personnel Fax Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_ContactPersonnelFaxNumber" xlink:to="label_dei_ContactPersonnelFaxNumber"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelEmailAddress" xlink:label="locator_dei_ContactPersonnelEmailAddress"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_ContactPersonnelEmailAddress" xml:lang="en-US">Contact Personnel Email Address</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_ContactPersonnelEmailAddress" xlink:to="label_dei_ContactPersonnelEmailAddress"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="locator_dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_Security12bTitle" xlink:to="label_dei_Security12bTitle"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="locator_dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_TradingSymbol" xlink:to="label_dei_TradingSymbol"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="locator_dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_SecurityExchangeName" xml:lang="en-US">Name of Exchange on which Security is Registered</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_SecurityExchangeName" xlink:to="label_dei_SecurityExchangeName"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="locator_dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_EntityCommonStockSharesOutstanding" xlink:to="label_dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="locator_dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_EntityWellKnownSeasonedIssuer" xlink:to="label_dei_EntityWellKnownSeasonedIssuer"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="locator_dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_EntityVoluntaryFilers" xlink:to="label_dei_EntityVoluntaryFilers"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="locator_dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_EntityCurrentReportingStatus" xlink:to="label_dei_EntityCurrentReportingStatus"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="locator_dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_EntityInteractiveDataCurrent" xlink:to="label_dei_EntityInteractiveDataCurrent"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="locator_dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_EntityFilerCategory" xlink:to="label_dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="locator_dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_EntityEmergingGrowthCompany" xlink:to="label_dei_EntityEmergingGrowthCompany"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="locator_dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_IcfrAuditorAttestationFlag" xml:lang="en-US">Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_IcfrAuditorAttestationFlag" xlink:to="label_dei_IcfrAuditorAttestationFlag"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="locator_dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_EntityExTransitionPeriod" xlink:to="label_dei_EntityExTransitionPeriod"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="locator_dei_DocumentAccountingStandard"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_DocumentAccountingStandard" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_DocumentAccountingStandard" xlink:to="label_dei_DocumentAccountingStandard"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="locator_dei_OtherReportingStandardItemNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_OtherReportingStandardItemNumber" xml:lang="en-US">Other Reporting Standard Item Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_OtherReportingStandardItemNumber" xlink:to="label_dei_OtherReportingStandardItemNumber"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="locator_dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_EntityShellCompany" xlink:to="label_dei_EntityShellCompany"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="locator_dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_AuditorName" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_AuditorName" xlink:to="label_dei_AuditorName"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="locator_dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_AuditorLocation" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_AuditorLocation" xlink:to="label_dei_AuditorLocation"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="locator_dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_dei_AuditorFirmId" xml:lang="en-US">Auditor Firm Id</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_dei_AuditorFirmId" xlink:to="label_dei_AuditorFirmId"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="locator_us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="label_us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="locator_us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_AssetsAbstract" xlink:to="label_us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="locator_us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_AssetsCurrentAbstract" xlink:to="label_us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="locator_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="locator_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermInvestments" xlink:label="locator_us-gaap_OtherShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OtherShortTermInvestments" xml:lang="en-US">Short-term bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OtherShortTermInvestments" xlink:to="label_us-gaap_OtherShortTermInvestments"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="locator_us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_AccountsReceivableNetCurrent" xlink:to="label_us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="locator_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Other accounts receivable and prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="locator_us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_AssetsCurrent" xlink:to="label_us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="locator_us-gaap_AssetsNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_AssetsNoncurrentAbstract" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_AssetsNoncurrentAbstract" xlink:to="label_us-gaap_AssetsNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="locator_us-gaap_PrepaidExpenseNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_PrepaidExpenseNoncurrent" xml:lang="en-US">Long-term prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_PrepaidExpenseNoncurrent" xlink:to="label_us-gaap_PrepaidExpenseNoncurrent"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SeverancePayFundNoncurrent" xlink:label="locator_cgen_SeverancePayFundNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_SeverancePayFundNoncurrent" xml:lang="en-US">Severance pay fund</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_SeverancePayFundNoncurrent" xml:lang="en-US">Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_SeverancePayFundNoncurrent" xlink:to="label_cgen_SeverancePayFundNoncurrent"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="locator_us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right of use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="label_us-gaap_OperatingLeaseRightOfUseAsset"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Depreciated cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="label_us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="locator_us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_AssetsNoncurrent" xml:lang="en-US">Total non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_AssetsNoncurrent" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_AssetsNoncurrent" xlink:to="label_us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="locator_us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_Assets" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_Assets" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_Assets" xlink:to="label_us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="locator_us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_LiabilitiesCurrentAbstract" xlink:to="label_us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="locator_us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_AccountsPayableCurrent" xlink:to="label_us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="locator_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xml:lang="en-US">Short-term deferred participation in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xml:lang="en-US">Short term deferred participation in R&amp;amp;amp;amp;D expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:to="label_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="locator_us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current maturity of operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Lease liabilities, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="label_us-gaap_OperatingLeaseLiabilityCurrent"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="locator_us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Other accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="label_us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="locator_us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_LiabilitiesCurrent" xlink:to="label_us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="locator_us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">NON- CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="label_us-gaap_LiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="locator_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" xml:lang="en-US">Long-term deferred participation in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" xml:lang="en-US">Long term deferred participation in R&amp;amp;amp;amp;D expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:to="label_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="locator_us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Long-term operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Lease liabilities, non- current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="label_us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="locator_us-gaap_PostemploymentBenefitsLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xml:lang="en-US">Accrued severance pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:to="label_us-gaap_PostemploymentBenefitsLiabilityNoncurrent"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="locator_us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Total non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_LiabilitiesNoncurrent" xlink:to="label_us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="locator_us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_CommitmentsAndContingencies" xlink:to="label_us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="locator_us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">SHAREHOLDERS' EQUITY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_StockholdersEquityAbstract" xlink:to="label_us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="locator_us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_CommonStockValue" xml:lang="en-US">Share capital: Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized at December 31, 2021 and 2020; 86,433,432 and 83,675,856 shares issued and outstanding at December 31, 2021 and 2020, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_CommonStockValue" xlink:to="label_us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="locator_us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="label_us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="locator_us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="label_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="label_us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="locator_us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_StockholdersEquity" xml:lang="en-US">Total shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="label_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="label_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_StockholdersEquity" xlink:to="label_us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="locator_us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="locator_us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Ordinary shares, par value per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Ordinary shares, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="label_us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="locator_us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Ordinary shares, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_CommonStockSharesAuthorized" xlink:to="label_us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="locator_us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Ordinary shares, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_CommonStockSharesIssued" xlink:to="label_us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="locator_us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Ordinary shares, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="label_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="label_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Balance, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_CommonStockSharesOutstanding" xlink:to="label_us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="locator_us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_IncomeStatementAbstract" xlink:to="label_us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="locator_us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_Revenues" xml:lang="en-US">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_us-gaap_Revenues" xml:lang="en-US">Revenue from sales to customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_Revenues" xlink:to="label_us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="locator_us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_CostOfRevenue" xlink:to="label_us-gaap_CostOfRevenue"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="locator_us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_GrossProfit" xml:lang="en-US">Gross profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_GrossProfit" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_GrossProfit" xlink:to="label_us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="locator_us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OperatingExpensesAbstract" xlink:to="label_us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="locator_us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development expenses, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ResearchAndDevelopmentExpense" xlink:to="label_us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDevelopment" xlink:label="locator_us-gaap_BusinessDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_BusinessDevelopment" xml:lang="en-US">Marketing and business development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_BusinessDevelopment" xlink:to="label_us-gaap_BusinessDevelopment"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="locator_us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_GeneralAndAdministrativeExpense" xlink:to="label_us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="locator_us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OperatingExpenses" xlink:to="label_us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="locator_us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OperatingIncomeLoss" xlink:to="label_us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="locator_cgen_FinancialIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_FinancialIncomeExpenseNet" xml:lang="en-US">Financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_cgen_FinancialIncomeExpenseNet" xml:lang="en-US">Financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_FinancialIncomeExpenseNet" xml:lang="en-US">Financial Income (Expense), Net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_FinancialIncomeExpenseNet" xlink:to="label_cgen_FinancialIncomeExpenseNet"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before taxes on income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before taxes on income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="locator_us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="label_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Taxes on income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_IncomeTaxExpenseBenefit" xlink:to="label_us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="locator_us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="label_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss for basic and diluted loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="locator_us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_EarningsPerShareBasic" xlink:to="label_us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="locator_us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_EarningsPerShareDiluted" xlink:to="label_us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="locator_us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Total comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="label_us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="locator_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average number of ordinary shares used in computing basic net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average number of ordinary shares used in computing diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="locator_us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_StatementEquityComponentsAxis" xlink:to="label_us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="locator_us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_CommonStockMember" xml:lang="en-US">Ordinary shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_CommonStockMember" xlink:to="label_us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="locator_us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional paid-in capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_AdditionalPaidInCapitalMember" xlink:to="label_us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="locator_us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated deficit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_RetainedEarningsMember" xlink:to="label_us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="locator_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="locator_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Options exercised, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="locator_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xml:lang="en-US">Exercise of options and ESPP shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="locator_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Exercise of options and ESPP shares, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_IssuanceOfSharesAndWarrantsNetValue" xlink:label="locator_cgen_IssuanceOfSharesAndWarrantsNetValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_IssuanceOfSharesAndWarrantsNetValue" xml:lang="en-US">Issuance of shares and warrants, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_IssuanceOfSharesAndWarrantsNetValue" xml:lang="en-US">Issuance of shares and warrants, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_IssuanceOfSharesAndWarrantsNetValue" xlink:to="label_cgen_IssuanceOfSharesAndWarrantsNetValue"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_IssuanceOfSharesAndWarrantsNetShares" xlink:label="locator_cgen_IssuanceOfSharesAndWarrantsNetShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_IssuanceOfSharesAndWarrantsNetShares" xml:lang="en-US">Issuance of shares and warrants, net, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_IssuanceOfSharesAndWarrantsNetShares" xml:lang="en-US">Issuance of shares and warrants, net, shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_IssuanceOfSharesAndWarrantsNetShares" xlink:to="label_cgen_IssuanceOfSharesAndWarrantsNetShares"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="locator_cgen_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_StockIssuedDuringPeriodValueWarrantsExercised" xml:lang="en-US">Warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_StockIssuedDuringPeriodValueWarrantsExercised" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="label_cgen_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_NumberOfWarrantsExercised" xlink:label="locator_cgen_NumberOfWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_NumberOfWarrantsExercised" xml:lang="en-US">Warrants exercised, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_NumberOfWarrantsExercised" xml:lang="en-US">Number of warrants exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_NumberOfWarrantsExercised" xlink:to="label_cgen_NumberOfWarrantsExercised"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="locator_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of shares, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="locator_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of shares, net, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_StockIssuedDuringPeriodValueTerminationAndEquityConversionAgreementIssues" xlink:label="locator_cgen_StockIssuedDuringPeriodValueTerminationAndEquityConversionAgreementIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_StockIssuedDuringPeriodValueTerminationAndEquityConversionAgreementIssues" xml:lang="en-US">Issuance of shares in respect to Termination and Equity Conversion Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_StockIssuedDuringPeriodValueTerminationAndEquityConversionAgreementIssues" xml:lang="en-US">Value of stock issued in respect to the Termination and Equity Conversion Agreement contributed to the entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_StockIssuedDuringPeriodValueTerminationAndEquityConversionAgreementIssues" xlink:to="label_cgen_StockIssuedDuringPeriodValueTerminationAndEquityConversionAgreementIssues"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_StockIssuedDuringPeriodSharesTerminationAndEquityConversionAgreementIssues" xlink:label="locator_cgen_StockIssuedDuringPeriodSharesTerminationAndEquityConversionAgreementIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_StockIssuedDuringPeriodSharesTerminationAndEquityConversionAgreementIssues" xml:lang="en-US">Issuance of shares in respect to Termination and Equity Conversion Agreement, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_StockIssuedDuringPeriodSharesTerminationAndEquityConversionAgreementIssues" xml:lang="en-US">Number of shares in respect to the Termination and Equity Conversion Agreement issued during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_StockIssuedDuringPeriodSharesTerminationAndEquityConversionAgreementIssues" xlink:to="label_cgen_StockIssuedDuringPeriodSharesTerminationAndEquityConversionAgreementIssues"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="locator_cgen_StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xml:lang="en-US">Stock-based compensation relating to options issued to employees, directors and non-employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xml:lang="en-US">Stock-based compensation relating to options issued to employees and directors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:to="label_cgen_StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="locator_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xml:lang="en-US">Changes in other comprehensive income from marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="label_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="locator_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xml:lang="en-US">Changes in other comprehensive income (loss) from foreign currency derivative contracts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:to="label_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="locator_us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_StatementOfCashFlowsAbstract" xlink:to="label_us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="locator_us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensation" xlink:to="label_us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="locator_us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_Depreciation" xlink:to="label_us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SeverancePayNet" xlink:label="locator_cgen_SeverancePayNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_SeverancePayNet" xml:lang="en-US">Increase (decrease) in Severance pay, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_SeverancePayNet" xml:lang="en-US">Severance pay, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_SeverancePayNet" xlink:to="label_cgen_SeverancePayNet"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="locator_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain from property and equipment sales and disposals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="locator_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="label_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xml:lang="en-US">Decrease (increase) in interest receivables from short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xml:lang="en-US">Amortization Of Cash Consideration Of Research And Development Funding Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xml:lang="en-US">Amortization research and development component</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:to="label_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="locator_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xml:lang="en-US">Decrease (increase) in trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="locator_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase in other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="locator_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Decrease (increase) in long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="locator_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="label_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xml:lang="en-US">Decrease in operating lease right of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xml:lang="en-US">Increase (decrease) in operating lease right of use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xml:lang="en-US">New Agreement With Advisor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="label_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="locator_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (decrease) in trade payables and other accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="locator_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xml:lang="en-US">Increase (decrease) in deferred participation in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xml:lang="en-US">Increase (decrease) in deferred participation in R&amp;amp;amp;D expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:to="label_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="locator_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xml:lang="en-US">Decrease in operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="label_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="locator_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xml:lang="en-US">Proceeds from maturity of short-term bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="label_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="locator_us-gaap_PaymentsToAcquireInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="label_us-gaap_PaymentsToAcquireInvestments" xml:lang="en-US">Investment in short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_PaymentsToAcquireInvestments" xml:lang="en-US">Payments to Acquire Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_PaymentsToAcquireInvestments" xlink:to="label_us-gaap_PaymentsToAcquireInvestments"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="locator_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="locator_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="locator_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="locator_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of ordinary shares, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="label_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="locator_us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from warrant exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ProceedsFromWarrantExercises" xlink:to="label_us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="locator_us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from exercise of stock-based awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="label_us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="locator_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Increase (decrease) in cash, cash equivalents and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="label_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="label_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="label_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents and restricted cash at the end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="label_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="locator_us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="label_us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ReceivablesOnAccountOfShares" xlink:label="locator_cgen_ReceivablesOnAccountOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ReceivablesOnAccountOfShares" xml:lang="en-US">Receivables on account of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ReceivablesOnAccountOfShares" xml:lang="en-US">Receivables on account of shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ReceivablesOnAccountOfShares" xlink:to="label_cgen_ReceivablesOnAccountOfShares"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SupplementalRightOfUseAssetAndOperatingleaseLiability" xlink:label="locator_cgen_SupplementalRightOfUseAssetAndOperatingleaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_SupplementalRightOfUseAssetAndOperatingleaseLiability" xml:lang="en-US">Right-of-use asset obtained in exchange for operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_SupplementalRightOfUseAssetAndOperatingleaseLiability" xml:lang="en-US">Change In right of use asset and operating lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_SupplementalRightOfUseAssetAndOperatingleaseLiability" xlink:to="label_cgen_SupplementalRightOfUseAssetAndOperatingleaseLiability"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="locator_us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Cash paid (received) during the year for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="label_us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_InterestPaidReceivedNet" xlink:label="locator_cgen_InterestPaidReceivedNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_InterestPaidReceivedNet" xml:lang="en-US">Interest payments received from short-term bank deposits and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_InterestPaidReceivedNet" xml:lang="en-US">Interest payments paid (received) from bank short-term deposits and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_InterestPaidReceivedNet" xlink:to="label_cgen_InterestPaidReceivedNet"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="label_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="locator_us-gaap_RestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="label_us-gaap_RestrictedCashAndCashEquivalents" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_RestrictedCashAndCashEquivalents" xml:lang="en-US">Restricted Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="label_us-gaap_RestrictedCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">GENERAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="locator_us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="label_us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="locator_us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="label_us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="locator_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="label_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="locator_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xml:lang="en-US">OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xml:lang="en-US">The entire disclosure for other accounts receivable and prepaid expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:to="label_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="locator_us-gaap_LesseeDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_LesseeDisclosureAbstract" xml:lang="en-US">LEASES [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_us-gaap_LesseeDisclosureAbstract" xml:lang="en-US">Lessee Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="label_us-gaap_LesseeDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="locator_us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="label_us-gaap_LesseeOperatingLeasesTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="label_us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="locator_us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_PayablesAndAccrualsAbstract" xlink:to="label_us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="locator_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US">OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="label_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="locator_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="locator_us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_StockholdersEquityNoteAbstract" xlink:to="label_us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="locator_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xml:lang="en-US">SHAREHOLDERS' EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="label_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="locator_us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="label_us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="locator_us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="label_us-gaap_IncomeTaxDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="locator_us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_SegmentReportingAbstract" xml:lang="en-US">Segment Reporting [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_SegmentReportingAbstract" xlink:to="label_us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="locator_us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="label_us-gaap_SegmentReportingDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="locator_us-gaap_OtherIncomeAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OtherIncomeAndExpensesAbstract" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="label_us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="locator_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xml:lang="en-US">FINANCIAL AND OTHER INCOME, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="label_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="locator_us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="label_us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="locator_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">RELATED PARTY BALANCES AND TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="locator_us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_EarningsPerShareAbstract" xlink:to="label_us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="locator_us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">LOSSES PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_EarningsPerShareTextBlock" xlink:to="label_us-gaap_EarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="locator_us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_UseOfEstimates" xml:lang="en-US">Use of estimates:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_UseOfEstimates" xlink:to="label_us-gaap_UseOfEstimates"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="locator_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Financial statements in U.S. dollars:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="locator_us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Basis of consolidation:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ConsolidationPolicyTextBlock" xlink:to="label_us-gaap_ConsolidationPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="locator_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash equivalents:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="locator_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Restricted cash:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="label_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ShortTermBankDepositsPolicyTextBlock" xlink:label="locator_cgen_ShortTermBankDepositsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ShortTermBankDepositsPolicyTextBlock" xml:lang="en-US">Short-term bank deposits:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ShortTermBankDepositsPolicyTextBlock" xml:lang="en-US">The entire disclosure for short-term bank deposits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ShortTermBankDepositsPolicyTextBlock" xlink:to="label_cgen_ShortTermBankDepositsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and equipment, net:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_PropertyPlantAndEquipmentImpairment" xml:lang="en-US">Impairment of long-lived assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:to="label_us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="locator_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Revenue recognition:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="label_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_CostOfSalesContractWithCustomerPolicyTextBlock" xlink:label="locator_cgen_CostOfSalesContractWithCustomerPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_CostOfSalesContractWithCustomerPolicyTextBlock" xml:lang="en-US">Cost of revenues:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_CostOfSalesContractWithCustomerPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_CostOfSalesContractWithCustomerPolicyTextBlock" xlink:to="label_cgen_CostOfSalesContractWithCustomerPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="locator_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and development expenses, net:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="label_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ServerancePayPolicyTextBlock" xlink:label="locator_cgen_ServerancePayPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ServerancePayPolicyTextBlock" xml:lang="en-US">Severance pay:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ServerancePayPolicyTextBlock" xml:lang="en-US">Serverance Pay [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ServerancePayPolicyTextBlock" xlink:to="label_cgen_ServerancePayPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="locator_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Stock-based compensation:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="locator_us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of credit risks:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ConcentrationRiskCreditRisk" xlink:to="label_us-gaap_ConcentrationRiskCreditRisk"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="locator_us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Basic and diluted loss per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="label_us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="locator_us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income taxes:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="label_us-gaap_IncomeTaxPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="locator_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair value of financial instruments:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="label_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="locator_us-gaap_DerivativesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivative instruments:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_DerivativesPolicyTextBlock" xlink:to="label_us-gaap_DerivativesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="locator_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive income (loss):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="locator_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently issued and recently adopted Accounting Standards:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" xlink:label="locator_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" xml:lang="en-US">Schedule of Depreciation Rates for Property and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" xml:lang="en-US">Tabular disclosure of the annual rates used to calculate depreciation for property, plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" xlink:to="label_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock" xlink:label="locator_cgen_ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of weighted-average assumptions for granted options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Tabular disclosure of the significant assumptions used during the year to estimate the fair value of granted stock options, including, but not limited to: (a) expected term of granted share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock" xlink:to="label_cgen_ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xml:lang="en-US">Schedule Of Other Accounts Receivable And Prepaid Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="label_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:label="locator_cgen_ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock" xml:lang="en-US">Schedule of Weighted-Average Remaining Lease Term and Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock" xml:lang="en-US">Tabular disclosure of weighted-average remaining lease term and discount rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:to="label_cgen_ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Schedule of Operating Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="label_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule of Property And Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="label_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Other Accounts Payable and Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="label_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule Of Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Schedule of Stock-Based Compensation Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="label_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule Of Loss Before Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="label_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Summary Of Deferred Tax Assets And Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xml:lang="en-US">Total Revenues And Long-Lived Assets By Geographic Area</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="label_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xml:lang="en-US">Sales To A Single Customer Exceeding 10%:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="label_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xml:lang="en-US">Schedule of Financial and Other Income, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="label_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Schedule of Related Party Balances and Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="label_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of computation of basic and diluted losses per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="label_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="locator_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xml:lang="en-US">Percentage of workforce reduction from restructuring activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="label_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="locator_us-gaap_ResearchAndDevelopmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ResearchAndDevelopmentAbstract" xml:lang="en-US">Research and Development Collaboration and Licensing Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="label_us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="locator_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xml:lang="en-US">Upfront payment received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AccruedMilestonePayment" xlink:label="locator_cgen_AccruedMilestonePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_AccruedMilestonePayment" xml:lang="en-US">Accrued milestone payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_AccruedMilestonePayment" xml:lang="en-US">Accrued milestone payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_AccruedMilestonePayment" xlink:to="label_cgen_AccruedMilestonePayment"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="locator_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xml:lang="en-US">Potential milestone compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xml:lang="en-US">Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:to="label_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="locator_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xml:lang="en-US">Potential milestone compensation company is now eligible for</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xml:lang="en-US">Potential milestone compensation company is now eligible for.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:to="label_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="locator_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xml:lang="en-US">Preclinical milestone compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xml:lang="en-US">Potential milestone revenue for preclinical stages of research from arrangements for research and development, including collaboration and licenses agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:to="label_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:label="locator_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xml:lang="en-US">Amount of investment in Compugen</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:to="label_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="locator_srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_srt_StatementScenarioAxis" xlink:to="label_srt_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_MasterClinicalAgreementOneMember" xlink:label="locator_cgen_MasterClinicalAgreementOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_MasterClinicalAgreementOneMember" xml:lang="en-US">Master Clinical Agreement One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_MasterClinicalAgreementOneMember" xml:lang="en-US">Master Clinical Agreement One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_MasterClinicalAgreementOneMember" xlink:to="label_cgen_MasterClinicalAgreementOneMember"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_MasterClinicalAgreementTwoMember" xlink:label="locator_cgen_MasterClinicalAgreementTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_MasterClinicalAgreementTwoMember" xml:lang="en-US">Master Clinical Agreement Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_MasterClinicalAgreementTwoMember" xml:lang="en-US">Master Clinical Agreement Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_MasterClinicalAgreementTwoMember" xlink:to="label_cgen_MasterClinicalAgreementTwoMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="locator_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="locator_us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_StockOptionMember" xml:lang="en-US">Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_StockOptionMember" xlink:to="label_us-gaap_StockOptionMember"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ShortTermBankDepositsWeightedAverageRateForeign" xlink:label="locator_cgen_ShortTermBankDepositsWeightedAverageRateForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ShortTermBankDepositsWeightedAverageRateForeign" xml:lang="en-US">Average interest rate, short-term bank deposits in U.S. dollars</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ShortTermBankDepositsWeightedAverageRateForeign" xml:lang="en-US">The weighted average interest rate for short-term bank deposits outside of the domestic currency.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ShortTermBankDepositsWeightedAverageRateForeign" xlink:to="label_cgen_ShortTermBankDepositsWeightedAverageRateForeign"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="locator_us-gaap_AdjustmentForAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization in R&amp;D expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_AdjustmentForAmortization" xlink:to="label_us-gaap_AdjustmentForAmortization"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="locator_us-gaap_ImpairmentOfInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ImpairmentOfInvestments" xml:lang="en-US">Marketable securities impairment losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ImpairmentOfInvestments" xlink:to="label_us-gaap_ImpairmentOfInvestments"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="locator_us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_DeferredRevenue" xml:lang="en-US">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_DeferredRevenue" xlink:to="label_us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" xlink:label="locator_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" xml:lang="en-US">Number of licensed programs to achieve substantive milestones revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" xml:lang="en-US">Represents the number of licensed programs to achieve substantive milestones revenues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" xlink:to="label_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="locator_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Revenue recognition under milestone method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="label_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="locator_us-gaap_SeveranceCosts1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_SeveranceCosts1" xml:lang="en-US">Severance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_SeveranceCosts1" xlink:to="label_us-gaap_SeveranceCosts1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="locator_us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Net gain on derivative transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="label_us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:label="locator_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xml:lang="en-US">Net gain on derivative classified to operating expenses as effective portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:to="label_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting" xlink:label="locator_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting" xml:lang="en-US">Net gain on derivative recorded as financial and other income, net for the ineffective portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting" xlink:to="label_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="locator_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">Unrealized gain (loss) arising from derivative contracts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="label_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_DerivativeRelatedExpense" xlink:label="locator_cgen_DerivativeRelatedExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_DerivativeRelatedExpense" xml:lang="en-US">Derivative related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_DerivativeRelatedExpense" xml:lang="en-US">Represents the derivative related expenses incurred during the reporting period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_DerivativeRelatedExpense" xlink:to="label_cgen_DerivativeRelatedExpense"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="locator_us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Fair value of outstanding forward contracts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="label_us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="locator_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Weighted average number of shares related to outstanding options excluded from the calculations of diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="locator_us-gaap_EquityMethodInvestmentAggregateCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_EquityMethodInvestmentAggregateCost" xml:lang="en-US">Investment amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_us-gaap_EquityMethodInvestmentAggregateCost" xml:lang="en-US">Equity investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="label_us-gaap_EquityMethodInvestmentAggregateCost"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="locator_us-gaap_DerivativeNotionalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_DerivativeNotionalAmount" xml:lang="en-US">Derivative, notional amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_DerivativeNotionalAmount" xlink:to="label_us-gaap_DerivativeNotionalAmount"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_DeferredParticipationOfBmsInRdExpenses" xlink:label="locator_cgen_DeferredParticipationOfBmsInRdExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_DeferredParticipationOfBmsInRdExpenses" xml:lang="en-US">Deferred participation of BMS in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_DeferredParticipationOfBmsInRdExpenses" xml:lang="en-US">Deferred participation of BMS in R&amp;amp;amp;amp;D expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_DeferredParticipationOfBmsInRdExpenses" xlink:to="label_cgen_DeferredParticipationOfBmsInRdExpenses"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_PercentageOfConsolidatedRevenuesOfCollaborator" xlink:label="locator_cgen_PercentageOfConsolidatedRevenuesOfCollaborator"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_PercentageOfConsolidatedRevenuesOfCollaborator" xml:lang="en-US">Percentage of consolidated revenues of collaborator</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_PercentageOfConsolidatedRevenuesOfCollaborator" xml:lang="en-US">Percentage of consolidated revenues of collaborator.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_PercentageOfConsolidatedRevenuesOfCollaborator" xlink:to="label_cgen_PercentageOfConsolidatedRevenuesOfCollaborator"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="label_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="label_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="locator_us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computers, software and related equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ComputerEquipmentMember" xlink:to="label_us-gaap_ComputerEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="locator_cgen_LaboratoryEquipmentAndOfficeFurnitureMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xml:lang="en-US">Laboratory equipment and office furniture [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xml:lang="en-US">Laboratory Equipment And Office Furniture [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:to="label_cgen_LaboratoryEquipmentAndOfficeFurnitureMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="locator_us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_LeaseholdImprovementsMember" xlink:to="label_us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="locator_srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_srt_RangeAxis" xlink:to="label_srt_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="locator_srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_srt_MinimumMember" xlink:to="label_srt_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="locator_srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_srt_MaximumMember" xlink:to="label_srt_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="label_us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AnnualDepreciationRate" xlink:label="locator_cgen_AnnualDepreciationRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_AnnualDepreciationRate" xml:lang="en-US">Annual depreciation rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_AnnualDepreciationRate" xml:lang="en-US">Annual Depreciation Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_AnnualDepreciationRate" xlink:to="label_cgen_AnnualDepreciationRate"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AnnualDepreciationRateDescription" xlink:label="locator_cgen_AnnualDepreciationRateDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_cgen_AnnualDepreciationRateDescription" xml:lang="en-US">Annual depreciation rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_AnnualDepreciationRateDescription" xml:lang="en-US">Annual Depreciation Rates, Description.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_AnnualDepreciationRateDescription" xml:lang="en-US">Annual Depreciation Rate, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_AnnualDepreciationRateDescription" xlink:to="label_cgen_AnnualDepreciationRateDescription"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="locator_us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_AwardTypeAxis" xlink:to="label_us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="locator_us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_EmployeeStockOptionMember" xlink:to="label_us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_EmployeeStockPurchasePlanMember" xlink:label="locator_cgen_EmployeeStockPurchasePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_cgen_EmployeeStockPurchasePlanMember" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_EmployeeStockPurchasePlanMember" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_EmployeeStockPurchasePlanMember" xml:lang="en-US">EmployeeStockPurchasePlanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_EmployeeStockPurchasePlanMember" xlink:to="label_cgen_EmployeeStockPurchasePlanMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected life (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="locator_us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_PrepaidExpenseCurrent" xlink:to="label_us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_GovernmentAuthorities" xlink:label="locator_cgen_GovernmentAuthorities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_GovernmentAuthorities" xml:lang="en-US">Government authorities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_GovernmentAuthorities" xml:lang="en-US">Government Authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_GovernmentAuthorities" xlink:to="label_cgen_GovernmentAuthorities"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="locator_us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OtherAssetsCurrent" xlink:to="label_us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="locator_us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_LesseeOperatingLeaseOptionToExtend" xml:lang="en-US">Period of options to extend leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="label_us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_IncreaseOperatingLeaseRightOfUseAsset" xlink:label="locator_cgen_IncreaseOperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_IncreaseOperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right of use asset increased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_IncreaseOperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right of use asset increased.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_IncreaseOperatingLeaseRightOfUseAsset" xlink:to="label_cgen_IncreaseOperatingLeaseRightOfUseAsset"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_DecreaseOperatingLeaseLiability" xlink:label="locator_cgen_DecreaseOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_DecreaseOperatingLeaseLiability" xml:lang="en-US">Operating lease liability decreased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_DecreaseOperatingLeaseLiability" xml:lang="en-US">Operating lease liability decreased.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_DecreaseOperatingLeaseLiability" xlink:to="label_cgen_DecreaseOperatingLeaseLiability"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="locator_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xml:lang="en-US">Foreign Currency Translation income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="locator_us-gaap_SubleaseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_SubleaseIncome" xml:lang="en-US">Sublease income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_SubleaseIncome" xlink:to="label_us-gaap_SubleaseIncome"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:label="locator_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xml:lang="en-US">Cash paid for amounts included in measurement of lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:to="label_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="locator_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Weighted average remaining lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="label_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="locator_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Weighted average discount (annual) rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="label_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="locator_us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating lease expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OperatingLeasePayments" xlink:to="label_us-gaap_OperatingLeasePayments"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="label_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="label_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="label_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="label_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">2026 and after</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="label_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total operating lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="label_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="label_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="locator_us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Present value of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OperatingLeaseLiability" xlink:to="label_us-gaap_OperatingLeaseLiability"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xlink:label="locator_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xml:lang="en-US">Obsolete property and equipment and certain nonfunctional Lab equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xml:lang="en-US">Represents information pertaining to obsolete property and equipment and certain nonfunctional Lab equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xlink:to="label_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="label_us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="locator_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="locator_us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employees and related accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="label_us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="locator_us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="label_us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="locator_us-gaap_OtherCommitmentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OtherCommitmentsTable" xml:lang="en-US">Other Commitments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OtherCommitmentsTable" xlink:to="label_us-gaap_OtherCommitmentsTable"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="locator_cgen_GovernmentAndOtherGrantsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_GovernmentAndOtherGrantsAxis" xml:lang="en-US">Government and Other Grants [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_GovernmentAndOtherGrantsAxis" xml:lang="en-US">Government and Other Grants [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_GovernmentAndOtherGrantsAxis" xlink:to="label_cgen_GovernmentAndOtherGrantsAxis"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="locator_cgen_ResearchAndDevelopmentGrantOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ResearchAndDevelopmentGrantOneMember" xml:lang="en-US">IIA [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ResearchAndDevelopmentGrantOneMember" xml:lang="en-US">Research and Development Grant One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ResearchAndDevelopmentGrantOneMember" xlink:to="label_cgen_ResearchAndDevelopmentGrantOneMember"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_May2012AgreementMember" xlink:label="locator_cgen_May2012AgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_May2012AgreementMember" xml:lang="en-US">May 2012 Agreement With Advisor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_May2012AgreementMember" xml:lang="en-US">May 2012 Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_May2012AgreementMember" xlink:to="label_cgen_May2012AgreementMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="locator_us-gaap_OtherCommitmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OtherCommitmentsLineItems" xml:lang="en-US">Other Commitments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="label_us-gaap_OtherCommitmentsLineItems"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="locator_us-gaap_GuaranteeObligationsMaximumExposure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_GuaranteeObligationsMaximumExposure" xml:lang="en-US">Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_GuaranteeObligationsMaximumExposure" xlink:to="label_us-gaap_GuaranteeObligationsMaximumExposure"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="locator_cgen_RoyaltyPercentageBasedOnFutureRevenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_RoyaltyPercentageBasedOnFutureRevenues" xml:lang="en-US">Royalty percentage based on future revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_RoyaltyPercentageBasedOnFutureRevenues" xml:lang="en-US">Royalty Percentage Based On Future Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:to="label_cgen_RoyaltyPercentageBasedOnFutureRevenues"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="locator_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xml:lang="en-US">Maximum royalty repaid as percentage of grant received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xml:lang="en-US">Maximum Royalty Repaid As Percentage Of Grant Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:to="label_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="locator_us-gaap_RoyaltyExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_RoyaltyExpense" xlink:to="label_us-gaap_RoyaltyExpense"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_RoyaltyContingentObligations" xlink:label="locator_cgen_RoyaltyContingentObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_RoyaltyContingentObligations" xml:lang="en-US">Contingent royalty obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_RoyaltyContingentObligations" xml:lang="en-US">The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_RoyaltyContingentObligations" xlink:to="label_cgen_RoyaltyContingentObligations"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ParticipationRights" xlink:label="locator_cgen_ParticipationRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ParticipationRights" xml:lang="en-US">Participation Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ParticipationRights" xml:lang="en-US">Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to investors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ParticipationRights" xlink:to="label_cgen_ParticipationRights"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_RetainerFee" xlink:label="locator_cgen_RetainerFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_RetainerFee" xml:lang="en-US">Retainer fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_RetainerFee" xml:lang="en-US">Represents the retainer fee per month.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_RetainerFee" xlink:to="label_cgen_RetainerFee"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="locator_us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Issuance expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Issuance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="label_us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AgreementStartDate" xlink:label="locator_cgen_AgreementStartDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_AgreementStartDate" xml:lang="en-US">Agreement, start date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_AgreementStartDate" xml:lang="en-US">Agreement start date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_AgreementStartDate" xlink:to="label_cgen_AgreementStartDate"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AgreementTerminationDescription" xlink:label="locator_cgen_AgreementTerminationDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_AgreementTerminationDescription" xml:lang="en-US">Agreement termination description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_AgreementTerminationDescription" xml:lang="en-US">Description of termination of agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_AgreementTerminationDescription" xlink:to="label_cgen_AgreementTerminationDescription"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ExtendLease" xlink:label="locator_cgen_ExtendLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ExtendLease" xml:lang="en-US">Extend the lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ExtendLease" xml:lang="en-US">Extend Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ExtendLease" xlink:to="label_cgen_ExtendLease"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ContingentFees" xlink:label="locator_cgen_ContingentFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ContingentFees" xml:lang="en-US">Contingent fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ContingentFees" xml:lang="en-US">Contingent fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ContingentFees" xlink:to="label_cgen_ContingentFees"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xlink:label="locator_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xml:lang="en-US">Research and development expenses milestone payment with connection</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xml:lang="en-US">Research and development expenses milestone payment with connection.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xlink:to="label_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_RoyaltyPercentage" xlink:label="locator_cgen_RoyaltyPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_RoyaltyPercentage" xml:lang="en-US">Royalty percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_RoyaltyPercentage" xml:lang="en-US">Royalty percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_RoyaltyPercentage" xlink:to="label_cgen_RoyaltyPercentage"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePayment" xlink:label="locator_cgen_ResearchAndDevelopmentExpensesMilestonePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ResearchAndDevelopmentExpensesMilestonePayment" xml:lang="en-US">Research and development expenses milestone payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ResearchAndDevelopmentExpensesMilestonePayment" xml:lang="en-US">Research and development expenses milestone payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ResearchAndDevelopmentExpensesMilestonePayment" xlink:to="label_cgen_ResearchAndDevelopmentExpensesMilestonePayment"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AtTheMarketOfferingProgramMember" xlink:label="locator_cgen_AtTheMarketOfferingProgramMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_AtTheMarketOfferingProgramMember" xml:lang="en-US">At The Market Offering Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_AtTheMarketOfferingProgramMember" xml:lang="en-US">At-the-Market Offering Program "ATM"</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_AtTheMarketOfferingProgramMember" xlink:to="label_cgen_AtTheMarketOfferingProgramMember"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AgreementMember" xlink:label="locator_cgen_AgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_AgreementMember" xml:lang="en-US">Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_AgreementMember" xml:lang="en-US">Agreement Member.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_AgreementMember" xlink:to="label_cgen_AgreementMember"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_MasterClinicalAgreementMember" xlink:label="locator_cgen_MasterClinicalAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_MasterClinicalAgreementMember" xml:lang="en-US">Master Clinical Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_MasterClinicalAgreementMember" xml:lang="en-US">Master Clinical Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_MasterClinicalAgreementMember" xlink:to="label_cgen_MasterClinicalAgreementMember"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_CollaborativeArrangementsMember" xlink:label="locator_cgen_CollaborativeArrangementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_CollaborativeArrangementsMember" xml:lang="en-US">Collaborative Arrangements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_CollaborativeArrangementsMember" xml:lang="en-US">Collaborative Arrangements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_CollaborativeArrangementsMember" xlink:to="label_cgen_CollaborativeArrangementsMember"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="locator_cgen_CollaborativeArrangementsTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_CollaborativeArrangementsTwoMember" xml:lang="en-US">Collaborative Arrangements Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_CollaborativeArrangementsTwoMember" xml:lang="en-US">Collaborative Arrangements Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_CollaborativeArrangementsTwoMember" xlink:to="label_cgen_CollaborativeArrangementsTwoMember"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="locator_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xml:lang="en-US">SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xml:lang="en-US">SVB Leerink LLC and Stifel, Nicolaus &amp;amp;amp;amp; Company [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:to="label_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="locator_cgen_RegisteredDirectOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_RegisteredDirectOfferingMember" xml:lang="en-US">Registered direct offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_RegisteredDirectOfferingMember" xml:lang="en-US">Registered direct offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_RegisteredDirectOfferingMember" xlink:to="label_cgen_RegisteredDirectOfferingMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="locator_us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_WarrantMember" xlink:to="label_us-gaap_WarrantMember"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_UnderwritersMember" xlink:label="locator_cgen_UnderwritersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_UnderwritersMember" xml:lang="en-US">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_UnderwritersMember" xml:lang="en-US">Underwriters [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_UnderwritersMember" xlink:to="label_cgen_UnderwritersMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="locator_us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_PlanNameAxis" xlink:to="label_us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" xlink:label="locator_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" xml:lang="en-US">2000 and 2010 Share Option Plans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" xml:lang="en-US">Two Thousand and Two Thousand Ten Options Plan [Member].</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" xlink:to="label_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="locator_srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_srt_TitleOfIndividualAxis" xlink:to="label_srt_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="locator_srt_DirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_srt_DirectorMember" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_srt_DirectorMember" xlink:to="label_srt_DirectorMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="locator_us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="label_us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="locator_us-gaap_EmployeeStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_EmployeeStockMember" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_EmployeeStockMember" xlink:to="label_us-gaap_EmployeeStockMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Ordinary shares reserved for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Ordinary shares available for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="locator_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xml:lang="en-US">Award expiration period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:to="label_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average fair value of stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unrecognized share-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Unrecognized compensation cost, recognition period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xml:lang="en-US">Maximum percentage of total shares of common stock outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xml:lang="en-US">Aggregate intrinsic value of exercised options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Total intrinsic value of options exercised during the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="locator_us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Offering price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_SharesIssuedPricePerShare" xlink:to="label_us-gaap_SharesIssuedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="locator_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Maximum Authorized Proceeds From Issuance Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:to="label_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="locator_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Warrants purchase to ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="locator_us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Warrants purchase to ordinary shares remain outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="label_us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="locator_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="locator_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xml:lang="en-US">Expiration period of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xml:lang="en-US">Expiration period of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xlink:to="label_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AgreementOptionAdditionalNumberOfSharesIssuable" xlink:label="locator_cgen_AgreementOptionAdditionalNumberOfSharesIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_AgreementOptionAdditionalNumberOfSharesIssuable" xml:lang="en-US">Agreement, additional shares issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_AgreementOptionAdditionalNumberOfSharesIssuable" xml:lang="en-US">Agreement, additional shares issuable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_AgreementOptionAdditionalNumberOfSharesIssuable" xlink:to="label_cgen_AgreementOptionAdditionalNumberOfSharesIssuable"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_PercentageOfClosingPrice" xlink:label="locator_cgen_PercentageOfClosingPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_PercentageOfClosingPrice" xml:lang="en-US">Percentage of closing price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_PercentageOfClosingPrice" xml:lang="en-US">Percentage of closing price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_PercentageOfClosingPrice" xlink:to="label_cgen_PercentageOfClosingPrice"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="locator_us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from ordinary shares in offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="label_us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InitialOfferingPeriod" xlink:label="locator_us-gaap_InitialOfferingPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_InitialOfferingPeriod" xml:lang="en-US">Offering period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_InitialOfferingPeriod" xlink:to="label_us-gaap_InitialOfferingPeriod"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" xlink:label="locator_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" xml:lang="en-US">Percentage of use of base salary to purchase ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" xml:lang="en-US">Percentage of use of base salary to purchase ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" xlink:to="label_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" xlink:label="locator_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" xml:lang="en-US">Aggregate limit of ordinary shares per calendar year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" xml:lang="en-US">Aggregate limit of ordinary shares per calendar year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" xlink:to="label_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" xlink:label="locator_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" xml:lang="en-US">Percentage of fair market value of ordinary shares at time of offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" xml:lang="en-US">Percentage of fair market value of ordinary shares at time of offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" xlink:to="label_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xml:lang="en-US">Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_EmployeesAndDirectorsMember" xlink:label="locator_cgen_EmployeesAndDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_EmployeesAndDirectorsMember" xml:lang="en-US">Employees and Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_EmployeesAndDirectorsMember" xml:lang="en-US">Represents information pertaining to employees and directors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_EmployeesAndDirectorsMember" xlink:to="label_cgen_EmployeesAndDirectorsMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Number of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options outstanding at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Options forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Options expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Options vested and expected to vest at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Exercisable at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Options outstanding at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Options outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Options vested and expected to vest at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="locator_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xml:lang="en-US">Weighted average remaining contractual life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award Options, Remaining Contractual Term [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:to="label_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="locator_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="label_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xml:lang="en-US">Aggregate intrinsic value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Options outstanding at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="locator_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="locator_us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_IncomeStatementLocationAxis" xlink:to="label_us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="locator_us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="label_us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="locator_us-gaap_SellingAndMarketingExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_SellingAndMarketingExpenseMember" xml:lang="en-US">Marketing and business development expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_SellingAndMarketingExpenseMember" xlink:to="label_us-gaap_SellingAndMarketingExpenseMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="locator_us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="label_us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="locator_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="locator_us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock-based compensation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="label_us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="locator_us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_IncomeTaxAuthorityAxis" xlink:to="label_us-gaap_IncomeTaxAuthorityAxis"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="locator_us-gaap_InternalRevenueServiceIRSMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_InternalRevenueServiceIRSMember" xml:lang="en-US">United States [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_InternalRevenueServiceIRSMember" xlink:to="label_us-gaap_InternalRevenueServiceIRSMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="locator_us-gaap_DomesticCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_DomesticCountryMember" xlink:to="label_us-gaap_DomesticCountryMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="locator_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Israeli corporate tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xlink:label="locator_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xml:lang="en-US">Israeli corporate tax rate for next fiscal year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xml:lang="en-US">Percentage of domestic federal statutory tax rate applicable to pretax income (loss) for next fiscal year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xlink:to="label_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="locator_us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Tax payment withheld</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_IncomeTaxesPaid" xlink:to="label_us-gaap_IncomeTaxesPaid"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="locator_us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ProceedsFromIncomeTaxRefunds" xml:lang="en-US">Tax receivables refunded</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="label_us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="locator_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">U.S. income state and local taxes rate (as a percent)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="label_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="locator_us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OperatingLossCarryforwards" xlink:to="label_us-gaap_OperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_NetOperatingLossCarryforwardExpired" xlink:label="locator_cgen_NetOperatingLossCarryforwardExpired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_NetOperatingLossCarryforwardExpired" xml:lang="en-US">Net operating loss carryforward, Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_NetOperatingLossCarryforwardExpired" xml:lang="en-US">Net operating loss carryforward, Expired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_NetOperatingLossCarryforwardExpired" xlink:to="label_cgen_NetOperatingLossCarryforwardExpired"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="locator_us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_OperatingLossCarryforwardsExpirationDate" xml:lang="en-US">Year of expiration of operating loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="label_us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ReducedCorporateIncomeTaxRate" xlink:label="locator_cgen_ReducedCorporateIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ReducedCorporateIncomeTaxRate" xml:lang="en-US">Reduced Corporate income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ReducedCorporateIncomeTaxRate" xml:lang="en-US">Reduced Corporate income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ReducedCorporateIncomeTaxRate" xlink:to="label_cgen_ReducedCorporateIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_TaxExemptPeriod" xlink:label="locator_cgen_TaxExemptPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_TaxExemptPeriod" xml:lang="en-US">Tax exempt period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_TaxExemptPeriod" xml:lang="en-US">Tax exempt period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_TaxExemptPeriod" xlink:to="label_cgen_TaxExemptPeriod"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ReducedTaxRate" xlink:label="locator_cgen_ReducedTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_ReducedTaxRate" xml:lang="en-US">Reduced tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_ReducedTaxRate" xml:lang="en-US">Reduced tax rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_ReducedTaxRate" xlink:to="label_cgen_ReducedTaxRate"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_TaxRateOnDistributions" xlink:label="locator_cgen_TaxRateOnDistributions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_TaxRateOnDistributions" xml:lang="en-US">Tax rate on distributions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_TaxRateOnDistributions" xml:lang="en-US">Tax rate for dividends distributed to individuals or foreign residents from the preferred enterprise's earnings.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_TaxRateOnDistributions" xlink:to="label_cgen_TaxRateOnDistributions"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_PeriodSinceApprovalWasGranted" xlink:label="locator_cgen_PeriodSinceApprovalWasGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_PeriodSinceApprovalWasGranted" xml:lang="en-US">Period since approval was granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_PeriodSinceApprovalWasGranted" xml:lang="en-US">Period since approval was granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_PeriodSinceApprovalWasGranted" xlink:to="label_cgen_PeriodSinceApprovalWasGranted"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_PeriodSinceEnterpriseBeganOperating" xlink:label="locator_cgen_PeriodSinceEnterpriseBeganOperating"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_PeriodSinceEnterpriseBeganOperating" xml:lang="en-US">Period since enterprise began operating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_PeriodSinceEnterpriseBeganOperating" xml:lang="en-US">Period since enterprise began operating.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_PeriodSinceEnterpriseBeganOperating" xlink:to="label_cgen_PeriodSinceEnterpriseBeganOperating"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Domestic (Israel)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="locator_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Operating loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="label_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="locator_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xml:lang="en-US">Accrued social benefits and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_DeferredIncomeTaxRightOfUseAssets" xlink:label="locator_cgen_DeferredIncomeTaxRightOfUseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_DeferredIncomeTaxRightOfUseAssets" xml:lang="en-US">Right of use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_DeferredIncomeTaxRightOfUseAssets" xml:lang="en-US">Amount of deferred tax Right of use assets attributable to taxable temporary differences.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_DeferredIncomeTaxRightOfUseAssets" xlink:to="label_cgen_DeferredIncomeTaxRightOfUseAssets"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_DeferredIncomeTaxLeaseLiabilities" xlink:label="locator_cgen_DeferredIncomeTaxLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_DeferredIncomeTaxLeaseLiabilities" xml:lang="en-US">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_DeferredIncomeTaxLeaseLiabilities" xml:lang="en-US">Amount of deferred tax lease liability attributable to taxable temporary differences.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_DeferredIncomeTaxLeaseLiabilities" xlink:to="label_cgen_DeferredIncomeTaxLeaseLiabilities"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="locator_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Deferred tax asset (liabilities) for property, plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:to="label_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="locator_us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred tax asset before valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_DeferredTaxAssetsGross" xlink:to="label_us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="locator_us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="label_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="label_us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="locator_us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="label_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Net deferred tax asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_DeferredTaxAssetsNet" xlink:to="label_us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SegmentReportingGeographicAreaTable" xlink:label="locator_cgen_SegmentReportingGeographicAreaTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_SegmentReportingGeographicAreaTable" xml:lang="en-US">Segment Reporting Geographic Area [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_SegmentReportingGeographicAreaTable" xml:lang="en-US">Segment Reporting Geographic Area [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_SegmentReportingGeographicAreaTable" xlink:to="label_cgen_SegmentReportingGeographicAreaTable"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SegmentReportingGeographicAreaAxis" xlink:label="locator_cgen_SegmentReportingGeographicAreaAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_SegmentReportingGeographicAreaAxis" xml:lang="en-US">Segment Reporting Geographic Area [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_SegmentReportingGeographicAreaAxis" xml:lang="en-US">Segment Reporting Geographic Area [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_SegmentReportingGeographicAreaAxis" xlink:to="label_cgen_SegmentReportingGeographicAreaAxis"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember" xlink:label="locator_srt_EuropeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_srt_EuropeMember" xml:lang="en-US">Europe [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_srt_EuropeMember" xlink:to="label_srt_EuropeMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IL" xlink:label="locator_country_IL"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_country_IL" xml:lang="en-US">Israel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_country_IL" xlink:to="label_country_IL"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="locator_country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_country_US" xml:lang="en-US">Unites States [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_country_US" xlink:to="label_country_US"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="locator_us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="label_us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="locator_us-gaap_SalesRevenueNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_SalesRevenueNetMember" xml:lang="en-US">Revenue [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_SalesRevenueNetMember" xlink:to="label_us-gaap_SalesRevenueNetMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="locator_us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="label_us-gaap_ConcentrationRiskByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="locator_us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_CustomerConcentrationRiskMember" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_CustomerConcentrationRiskMember" xlink:to="label_us-gaap_CustomerConcentrationRiskMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="locator_srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_srt_MajorCustomersAxis" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_srt_MajorCustomersAxis" xlink:to="label_srt_MajorCustomersAxis"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_CustomerOneMember" xlink:label="locator_cgen_CustomerOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_CustomerOneMember" xml:lang="en-US">Customer A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_CustomerOneMember" xml:lang="en-US">Customer One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_CustomerOneMember" xlink:to="label_cgen_CustomerOneMember"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SegmentReportingGeograhicAreaLineItems" xlink:label="locator_cgen_SegmentReportingGeograhicAreaLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_SegmentReportingGeograhicAreaLineItems" xml:lang="en-US">Segment Reporting Geograhic Area [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="label_cgen_SegmentReportingGeograhicAreaLineItems" xml:lang="en-US">Segment Reporting Geograhic Area [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_SegmentReportingGeograhicAreaLineItems" xlink:to="label_cgen_SegmentReportingGeograhicAreaLineItems"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="locator_us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of operating segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_NumberOfOperatingSegments" xlink:to="label_us-gaap_NumberOfOperatingSegments"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="locator_us-gaap_NoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_NoncurrentAssets" xml:lang="en-US">Long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_NoncurrentAssets" xlink:to="label_us-gaap_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="locator_us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Sales to a single customer exceeding 10%</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ConcentrationRiskPercentage1" xlink:to="label_us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="locator_us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_InvestmentIncomeInterest" xlink:to="label_us-gaap_InvestmentIncomeInterest"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="locator_us-gaap_InterestAndDebtExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="label_us-gaap_InterestAndDebtExpense" xml:lang="en-US">Bank fees and other finance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_InterestAndDebtExpense" xml:lang="en-US">Interest and Debt Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_InterestAndDebtExpense" xlink:to="label_us-gaap_InterestAndDebtExpense"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="locator_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign currency translation adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="label_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="locator_us-gaap_GainLossOnSaleOfOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_GainLossOnSaleOfOtherAssets" xml:lang="en-US">Gain (loss) from sales and disposals of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="label_us-gaap_GainLossOnSaleOfOtherAssets"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="locator_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Trade payables and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="label_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="locator_us-gaap_CostsAndExpensesRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_CostsAndExpensesRelatedParty" xml:lang="en-US">Amounts charged to research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_CostsAndExpensesRelatedParty" xlink:to="label_us-gaap_CostsAndExpensesRelatedParty"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" xlink:label="locator_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" xml:lang="en-US">Numerator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" xlink:to="label_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="locator_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Denominator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="label_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="locator_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="locator_us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="label_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted earnings per ordinary share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="locator_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="label_us-gaap_EarningsPerShareBasicAndDiluted"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>21
<FILENAME>cgen-20211231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- XBRL Document Created with XML Edge from P3 Data Systems -->
  <roleRef roleURI="http://cgen.com/role/cgen-daei1" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-daei1"/>
  <roleRef roleURI="http://cgen.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cgen-20211231.xsd#ConsolidatedBalanceSheets"/>
  <roleRef roleURI="http://cgen.com/role/cgen-cbsp" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-cbsp"/>
  <roleRef roleURI="http://cgen.com/role/cgen-csocl" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-csocl"/>
  <roleRef roleURI="http://cgen.com/role/StatementsOfChangesInShareholdersEquity" xlink:type="simple" xlink:href="cgen-20211231.xsd#StatementsOfChangesInShareholdersEquity"/>
  <roleRef roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="cgen-20211231.xsd#ConsolidatedStatementsOfCashFlows"/>
  <roleRef roleURI="http://cgen.com/role/cgen-g" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-g"/>
  <roleRef roleURI="http://cgen.com/role/cgen-sap" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-sap"/>
  <roleRef roleURI="http://cgen.com/role/cgen-oarape" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-oarape"/>
  <roleRef roleURI="http://cgen.com/role/Leases" xlink:type="simple" xlink:href="cgen-20211231.xsd#Leases"/>
  <roleRef roleURI="http://cgen.com/role/cgen-paen" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-paen"/>
  <roleRef roleURI="http://cgen.com/role/cgen-oapaae" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-oapaae"/>
  <roleRef roleURI="http://cgen.com/role/cgen-cac1" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-cac1"/>
  <roleRef roleURI="http://cgen.com/role/cgen-se12" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-se12"/>
  <roleRef roleURI="http://cgen.com/role/cgen-it" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-it"/>
  <roleRef roleURI="http://cgen.com/role/cgen-giamc" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-giamc"/>
  <roleRef roleURI="http://cgen.com/role/cgen-faoin" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-faoin"/>
  <roleRef roleURI="http://cgen.com/role/cgen-rpbat" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-rpbat"/>
  <roleRef roleURI="http://cgen.com/role/cgen-lps" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-lps"/>
  <roleRef roleURI="http://cgen.com/role/cgen-sapp" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-sapp"/>
  <roleRef roleURI="http://cgen.com/role/cgen-sapt" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-sapt"/>
  <roleRef roleURI="http://cgen.com/role/cgen-oarapet" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-oarapet"/>
  <roleRef roleURI="http://cgen.com/role/LeasesTables" xlink:type="simple" xlink:href="cgen-20211231.xsd#LeasesTables"/>
  <roleRef roleURI="http://cgen.com/role/cgen-paent" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-paent"/>
  <roleRef roleURI="http://cgen.com/role/cgen-oapaaet" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-oapaaet"/>
  <roleRef roleURI="http://cgen.com/role/cgen-set1" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-set1"/>
  <roleRef roleURI="http://cgen.com/role/cgen-itt" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-itt"/>
  <roleRef roleURI="http://cgen.com/role/cgen-giamct" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-giamct"/>
  <roleRef roleURI="http://cgen.com/role/cgen-faoint" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-faoint"/>
  <roleRef roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables" xlink:type="simple" xlink:href="cgen-20211231.xsd#RelatedPartyBalancesAndTransactionsTables"/>
  <roleRef roleURI="http://cgen.com/role/cgen-lpst" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-lpst"/>
  <roleRef roleURI="http://cgen.com/role/cgen-gd" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-gd"/>
  <roleRef roleURI="http://cgen.com/role/cgen-sapnd" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-sapnd"/>
  <roleRef roleURI="http://cgen.com/role/cgen-sapsodrfpaed" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-sapsodrfpaed"/>
  <roleRef roleURI="http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"/>
  <roleRef roleURI="http://cgen.com/role/cgen-oaraped" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-oaraped"/>
  <roleRef roleURI="http://cgen.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#LeasesNarrativeDetails"/>
  <roleRef roleURI="http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails"/>
  <roleRef roleURI="http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#LeasesScheduleOfOperatingLeasesDetails"/>
  <roleRef roleURI="http://cgen.com/role/cgen-paend" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-paend"/>
  <roleRef roleURI="http://cgen.com/role/cgen-oapaaed" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-oapaaed"/>
  <roleRef roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#CommitmentsAndContingenciesDetails"/>
  <roleRef roleURI="http://cgen.com/role/cgen-sesopnd" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-sesopnd"/>
  <roleRef roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#ShareholdersEquityScheduleOfOptionActivityDetails"/>
  <roleRef roleURI="http://cgen.com/role/cgen-sesosced" xlink:type="simple" xlink:href="cgen-20211231.xsd#cgen-sesosced"/>
  <roleRef roleURI="http://cgen.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <roleRef roleURI="http://cgen.com/role/IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails"/>
  <roleRef roleURI="http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#IncomeTaxesScheduleOfLossBeforeTaxesDetails"/>
  <roleRef roleURI="http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"/>
  <roleRef roleURI="http://cgen.com/role/GeographicInformationAndMajorCustomersDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#GeographicInformationAndMajorCustomersDetails"/>
  <roleRef roleURI="http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"/>
  <roleRef roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#RelatedPartyBalancesAndTransactionsDetails"/>
  <roleRef roleURI="http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails" xlink:type="simple" xlink:href="cgen-20211231.xsd#LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails"/>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-daei1">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="locator_dei_CoverAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="locator_us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_dei_CoverAbstract" xlink:to="locator_us-gaap_StatementTable" use="optional" priority="0" order="100"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="locator_dei_EntityAddressesAddressTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementTable" xlink:to="locator_dei_EntityAddressesAddressTypeAxis" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="locator_dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_dei_EntityAddressesAddressTypeAxis" xlink:to="locator_dei_AddressTypeDomain" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember" xlink:label="locator_dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_dei_AddressTypeDomain" xlink:to="locator_dei_BusinessContactMember" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="locator_us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementTable" xlink:to="locator_us-gaap_StatementLineItems" use="optional" priority="0" order="200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="locator_dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityCentralIndexKey" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="locator_dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_CurrentFiscalYearEndDate" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="locator_dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_DocumentFiscalYearFocus" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="locator_dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_DocumentFiscalPeriodFocus" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="locator_dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_DocumentType" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="locator_dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_AmendmentFlag" use="optional" priority="0" order="50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="locator_dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_AmendmentDescription" use="optional" priority="0" order="60"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="locator_dei_DocumentRegistrationStatement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_DocumentRegistrationStatement" use="optional" priority="0" order="70"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="locator_dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_DocumentAnnualReport" use="optional" priority="0" order="80"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="locator_dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_DocumentTransitionReport" use="optional" priority="0" order="90"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="locator_dei_DocumentShellCompanyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_DocumentShellCompanyReport" use="optional" priority="0" order="100"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="locator_dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_DocumentPeriodEndDate" use="optional" priority="0" order="110"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="locator_dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityFileNumber" use="optional" priority="0" order="120"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName" xlink:label="locator_dei_ContactPersonnelName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_ContactPersonnelName" use="optional" priority="0" order="130"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="locator_dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityRegistrantName" use="optional" priority="0" order="140"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="locator_dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityIncorporationStateCountryCode" use="optional" priority="0" order="150"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="locator_dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityAddressAddressLine1" use="optional" priority="0" order="160"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="locator_dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityAddressAddressLine2" use="optional" priority="0" order="170"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="locator_dei_EntityAddressAddressLine3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityAddressAddressLine3" use="optional" priority="0" order="180"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="locator_dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityAddressCityOrTown" use="optional" priority="0" order="190"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="locator_dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityAddressCountry" use="optional" priority="0" order="200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="locator_dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityAddressPostalZipCode" use="optional" priority="0" order="210"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="locator_dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_CityAreaCode" use="optional" priority="0" order="220"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="locator_dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_LocalPhoneNumber" use="optional" priority="0" order="230"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelFaxNumber" xlink:label="locator_dei_ContactPersonnelFaxNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_ContactPersonnelFaxNumber" use="optional" priority="0" order="240"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelEmailAddress" xlink:label="locator_dei_ContactPersonnelEmailAddress"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_ContactPersonnelEmailAddress" use="optional" priority="0" order="250"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="locator_dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_Security12bTitle" use="optional" priority="0" order="260"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="locator_dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_TradingSymbol" use="optional" priority="0" order="270"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="locator_dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_SecurityExchangeName" use="optional" priority="0" order="280"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="locator_dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityCommonStockSharesOutstanding" use="optional" priority="0" order="290"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="locator_dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityWellKnownSeasonedIssuer" use="optional" priority="0" order="300"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="locator_dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityVoluntaryFilers" use="optional" priority="0" order="310"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="locator_dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityCurrentReportingStatus" use="optional" priority="0" order="320"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="locator_dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityInteractiveDataCurrent" use="optional" priority="0" order="330"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="locator_dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityFilerCategory" use="optional" priority="0" order="340"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="locator_dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityEmergingGrowthCompany" use="optional" priority="0" order="350"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="locator_dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_IcfrAuditorAttestationFlag" use="optional" priority="0" order="360"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="locator_dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityExTransitionPeriod" use="optional" priority="0" order="370"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="locator_dei_DocumentAccountingStandard"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_DocumentAccountingStandard" use="optional" priority="0" order="380"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="locator_dei_OtherReportingStandardItemNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_OtherReportingStandardItemNumber" use="optional" priority="0" order="390"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="locator_dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_EntityShellCompany" use="optional" priority="0" order="400"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="locator_dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_AuditorName" use="optional" priority="0" order="410"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="locator_dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_AuditorLocation" use="optional" priority="0" order="420"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="locator_dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_dei_AuditorFirmId" use="optional" priority="0" order="430"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="locator_us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="locator_us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="locator_us-gaap_AssetsAbstract" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="locator_us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AssetsAbstract" xlink:to="locator_us-gaap_AssetsCurrentAbstract" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="locator_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AssetsCurrentAbstract" xlink:to="locator_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="locator_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AssetsCurrentAbstract" xlink:to="locator_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermInvestments" xlink:label="locator_us-gaap_OtherShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AssetsCurrentAbstract" xlink:to="locator_us-gaap_OtherShortTermInvestments" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="locator_us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AssetsCurrentAbstract" xlink:to="locator_us-gaap_AccountsReceivableNetCurrent" use="optional" priority="0" order="50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="locator_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AssetsCurrentAbstract" xlink:to="locator_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" priority="0" order="60"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="locator_us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AssetsCurrentAbstract" xlink:to="locator_us-gaap_AssetsCurrent" use="optional" priority="0" order="70" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="locator_us-gaap_AssetsNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AssetsAbstract" xlink:to="locator_us-gaap_AssetsNoncurrentAbstract" use="optional" priority="0" order="80"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="locator_us-gaap_PrepaidExpenseNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AssetsNoncurrentAbstract" xlink:to="locator_us-gaap_PrepaidExpenseNoncurrent" use="optional" priority="0" order="90"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SeverancePayFundNoncurrent" xlink:label="locator_cgen_SeverancePayFundNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AssetsNoncurrentAbstract" xlink:to="locator_cgen_SeverancePayFundNoncurrent" use="optional" priority="0" order="100"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="locator_us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AssetsNoncurrentAbstract" xlink:to="locator_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" priority="0" order="110"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AssetsNoncurrentAbstract" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentNet" use="optional" priority="0" order="120"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="locator_us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AssetsNoncurrentAbstract" xlink:to="locator_us-gaap_AssetsNoncurrent" use="optional" priority="0" order="130" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="locator_us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AssetsAbstract" xlink:to="locator_us-gaap_Assets" use="optional" priority="0" order="140" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract" use="optional" priority="0" order="150"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="locator_us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="locator_us-gaap_LiabilitiesCurrentAbstract" use="optional" priority="0" order="160"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="locator_us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LiabilitiesCurrentAbstract" xlink:to="locator_us-gaap_AccountsPayableCurrent" use="optional" priority="0" order="170"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="locator_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LiabilitiesCurrentAbstract" xlink:to="locator_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" use="optional" priority="0" order="180"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="locator_us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LiabilitiesCurrentAbstract" xlink:to="locator_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" priority="0" order="190"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="locator_us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LiabilitiesCurrentAbstract" xlink:to="locator_us-gaap_OtherAccountsPayableAndAccruedLiabilities" use="optional" priority="0" order="200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="locator_us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LiabilitiesCurrentAbstract" xlink:to="locator_us-gaap_LiabilitiesCurrent" use="optional" priority="0" order="210" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="locator_us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="locator_us-gaap_LiabilitiesNoncurrentAbstract" use="optional" priority="0" order="220"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="locator_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="locator_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" use="optional" priority="0" order="230"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="locator_us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="locator_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" priority="0" order="240"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="locator_us-gaap_PostemploymentBenefitsLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="locator_us-gaap_PostemploymentBenefitsLiabilityNoncurrent" use="optional" priority="0" order="250"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="locator_us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="locator_us-gaap_LiabilitiesNoncurrent" use="optional" priority="0" order="260" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="locator_us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="locator_us-gaap_CommitmentsAndContingencies" use="optional" priority="0" order="270"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="locator_us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="locator_us-gaap_StockholdersEquityAbstract" use="optional" priority="0" order="280"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="locator_us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StockholdersEquityAbstract" xlink:to="locator_us-gaap_CommonStockValue" use="optional" priority="0" order="290"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="locator_us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StockholdersEquityAbstract" xlink:to="locator_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" priority="0" order="300"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="locator_us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StockholdersEquityAbstract" xlink:to="locator_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" priority="0" order="310"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="locator_us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StockholdersEquityAbstract" xlink:to="locator_us-gaap_StockholdersEquity" use="optional" priority="0" order="320" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="locator_us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="locator_us-gaap_LiabilitiesAndStockholdersEquity" use="optional" priority="0" order="330" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-cbsp">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="locator_us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="locator_us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="locator_us-gaap_CommonStockParOrStatedValuePerShare" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="locator_us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="locator_us-gaap_CommonStockSharesAuthorized" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="locator_us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="locator_us-gaap_CommonStockSharesIssued" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="locator_us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="locator_us-gaap_CommonStockSharesOutstanding" use="optional" priority="0" order="30"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-csocl">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="locator_us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="locator_us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeStatementAbstract" xlink:to="locator_us-gaap_Revenues" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="locator_us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeStatementAbstract" xlink:to="locator_us-gaap_CostOfRevenue" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="locator_us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeStatementAbstract" xlink:to="locator_us-gaap_GrossProfit" use="optional" priority="0" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="locator_us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeStatementAbstract" xlink:to="locator_us-gaap_OperatingExpensesAbstract" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="locator_us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OperatingExpensesAbstract" xlink:to="locator_us-gaap_ResearchAndDevelopmentExpense" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDevelopment" xlink:label="locator_us-gaap_BusinessDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OperatingExpensesAbstract" xlink:to="locator_us-gaap_BusinessDevelopment" use="optional" priority="0" order="50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="locator_us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OperatingExpensesAbstract" xlink:to="locator_us-gaap_GeneralAndAdministrativeExpense" use="optional" priority="0" order="60"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="locator_us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OperatingExpensesAbstract" xlink:to="locator_us-gaap_OperatingExpenses" use="optional" priority="0" order="70" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="locator_us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeStatementAbstract" xlink:to="locator_us-gaap_OperatingIncomeLoss" use="optional" priority="0" order="80" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="locator_cgen_FinancialIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeStatementAbstract" xlink:to="locator_cgen_FinancialIncomeExpenseNet" use="optional" priority="0" order="90"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeStatementAbstract" xlink:to="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" priority="0" order="100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="locator_us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeStatementAbstract" xlink:to="locator_us-gaap_IncomeTaxExpenseBenefit" use="optional" priority="0" order="110" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="locator_us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeStatementAbstract" xlink:to="locator_us-gaap_NetIncomeLoss" use="optional" priority="0" order="120" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="locator_us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeStatementAbstract" xlink:to="locator_us-gaap_EarningsPerShareBasic" use="optional" priority="0" order="130"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="locator_us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeStatementAbstract" xlink:to="locator_us-gaap_EarningsPerShareDiluted" use="optional" priority="0" order="140"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="locator_us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeStatementAbstract" xlink:to="locator_us-gaap_ComprehensiveIncomeNetOfTax" use="optional" priority="0" order="150" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="locator_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeStatementAbstract" xlink:to="locator_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" use="optional" priority="0" order="160"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeStatementAbstract" xlink:to="locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" use="optional" priority="0" order="170"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/StatementsOfChangesInShareholdersEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="locator_us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="locator_us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="locator_us-gaap_StatementTable" use="optional" priority="0" order="100"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="locator_us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementTable" xlink:to="locator_us-gaap_StatementEquityComponentsAxis" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="locator_us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementEquityComponentsAxis" xlink:to="locator_us-gaap_CommonStockMember" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="locator_us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementEquityComponentsAxis" xlink:to="locator_us-gaap_AdditionalPaidInCapitalMember" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="locator_us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementEquityComponentsAxis" xlink:to="locator_us-gaap_RetainedEarningsMember" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="locator_us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementEquityComponentsAxis" xlink:to="locator_us-gaap_EquityComponentDomain" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="locator_us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementTable" xlink:to="locator_us-gaap_StatementLineItems" use="optional" priority="0" order="200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="locator_us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_StockholdersEquity" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="locator_us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_CommonStockSharesOutstanding" use="optional" priority="0" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="locator_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="locator_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="locator_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" use="optional" priority="0" order="50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="locator_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" use="optional" priority="0" order="60"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_IssuanceOfSharesAndWarrantsNetValue" xlink:label="locator_cgen_IssuanceOfSharesAndWarrantsNetValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_IssuanceOfSharesAndWarrantsNetValue" use="optional" priority="0" order="70"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_IssuanceOfSharesAndWarrantsNetShares" xlink:label="locator_cgen_IssuanceOfSharesAndWarrantsNetShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_IssuanceOfSharesAndWarrantsNetShares" use="optional" priority="0" order="80"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="locator_cgen_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_StockIssuedDuringPeriodValueWarrantsExercised" use="optional" priority="0" order="90"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_NumberOfWarrantsExercised" xlink:label="locator_cgen_NumberOfWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_NumberOfWarrantsExercised" use="optional" priority="0" order="100"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="locator_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_StockIssuedDuringPeriodValueNewIssues" use="optional" priority="0" order="110"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="locator_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_StockIssuedDuringPeriodSharesNewIssues" use="optional" priority="0" order="120"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_StockIssuedDuringPeriodValueTerminationAndEquityConversionAgreementIssues" xlink:label="locator_cgen_StockIssuedDuringPeriodValueTerminationAndEquityConversionAgreementIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_StockIssuedDuringPeriodValueTerminationAndEquityConversionAgreementIssues" use="optional" priority="0" order="130"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_StockIssuedDuringPeriodSharesTerminationAndEquityConversionAgreementIssues" xlink:label="locator_cgen_StockIssuedDuringPeriodSharesTerminationAndEquityConversionAgreementIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_StockIssuedDuringPeriodSharesTerminationAndEquityConversionAgreementIssues" use="optional" priority="0" order="140"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" xlink:label="locator_cgen_StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue" use="optional" priority="0" order="150"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="locator_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" use="optional" priority="0" order="160"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="locator_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" use="optional" priority="0" order="170"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="locator_us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_NetIncomeLoss" use="optional" priority="0" order="180"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="locator_us-gaap_StockholdersEquity_b7b2a243-c964-4585-f1c3-2e9f08687760"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_StockholdersEquity_b7b2a243-c964-4585-f1c3-2e9f08687760" use="optional" priority="0" order="190" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="locator_us-gaap_CommonStockSharesOutstanding_b93d9ec4-9300-ccb5-802a-496c60895d73"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_CommonStockSharesOutstanding_b93d9ec4-9300-ccb5-802a-496c60895d73" use="optional" priority="0" order="200" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="locator_us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementOfCashFlowsAbstract" xlink:to="locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="locator_us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="locator_us-gaap_NetIncomeLoss" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="locator_us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="locator_us-gaap_ShareBasedCompensation" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="locator_us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="locator_us-gaap_Depreciation" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SeverancePayNet" xlink:label="locator_cgen_SeverancePayNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="locator_cgen_SeverancePayNet" use="optional" priority="0" order="50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="locator_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="locator_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" use="optional" priority="0" order="60" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="locator_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="locator_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" use="optional" priority="0" order="70" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="locator_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="locator_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" use="optional" priority="0" order="80" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="locator_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="locator_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" priority="0" order="90" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="locator_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="locator_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" priority="0" order="100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="locator_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="locator_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" use="optional" priority="0" order="110" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="locator_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="locator_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" priority="0" order="120"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="locator_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="locator_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" use="optional" priority="0" order="130"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="locator_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="locator_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" use="optional" priority="0" order="140"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" priority="0" order="150" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementOfCashFlowsAbstract" xlink:to="locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" use="optional" priority="0" order="160"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="locator_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="locator_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" use="optional" priority="0" order="170"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="locator_us-gaap_PaymentsToAcquireInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="locator_us-gaap_PaymentsToAcquireInvestments" use="optional" priority="0" order="180" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="locator_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="locator_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" priority="0" order="190" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="locator_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="locator_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" use="optional" priority="0" order="200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="locator_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="locator_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" priority="0" order="210" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementOfCashFlowsAbstract" xlink:to="locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" use="optional" priority="0" order="220"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="locator_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="locator_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" priority="0" order="230"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="locator_us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="locator_us-gaap_ProceedsFromWarrantExercises" use="optional" priority="0" order="240"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="locator_us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="locator_us-gaap_ProceedsFromStockOptionsExercised" use="optional" priority="0" order="250"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="locator_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="locator_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" priority="0" order="260" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" use="optional" priority="0" order="270" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementOfCashFlowsAbstract" xlink:to="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" use="optional" priority="0" order="280" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a1821042-6011-36f2-3930-80493b97a0c7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementOfCashFlowsAbstract" xlink:to="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a1821042-6011-36f2-3930-80493b97a0c7" use="optional" priority="0" order="290" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementOfCashFlowsAbstract" xlink:to="locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" use="optional" priority="0" order="300"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="locator_us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="locator_us-gaap_CapitalExpendituresIncurredButNotYetPaid" use="optional" priority="0" order="310"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ReceivablesOnAccountOfShares" xlink:label="locator_cgen_ReceivablesOnAccountOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="locator_cgen_ReceivablesOnAccountOfShares" use="optional" priority="0" order="320"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SupplementalRightOfUseAssetAndOperatingleaseLiability" xlink:label="locator_cgen_SupplementalRightOfUseAssetAndOperatingleaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="locator_cgen_SupplementalRightOfUseAssetAndOperatingleaseLiability" use="optional" priority="0" order="330"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="locator_us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementOfCashFlowsAbstract" xlink:to="locator_us-gaap_SupplementalCashFlowInformationAbstract" use="optional" priority="0" order="340"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_InterestPaidReceivedNet" xlink:label="locator_cgen_InterestPaidReceivedNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="locator_cgen_InterestPaidReceivedNet" use="optional" priority="0" order="350"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementOfCashFlowsAbstract" xlink:to="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" use="optional" priority="0" order="360"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="locator_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="locator_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" priority="0" order="370" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="locator_us-gaap_RestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="locator_us-gaap_RestrictedCashAndCashEquivalents" use="optional" priority="0" order="380" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_302c5fbc-3b79-37fa-1ac0-41d6dbf67f38"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="locator_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_302c5fbc-3b79-37fa-1ac0-41d6dbf67f38" use="optional" priority="0" order="390" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-g">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" use="optional" priority="0" order="0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sap">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="locator_us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="locator_us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_SignificantAccountingPoliciesTextBlock" use="optional" priority="0" order="0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oarape">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="locator_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="locator_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="locator_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" use="optional" priority="0" order="0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/Leases">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="locator_us-gaap_LesseeDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="locator_us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_us-gaap_LesseeOperatingLeasesTextBlock" use="optional" priority="0" order="10"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-paen">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" use="optional" priority="0" order="0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oapaae">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="locator_us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="locator_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PayablesAndAccrualsAbstract" xlink:to="locator_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" use="optional" priority="0" order="0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-cac1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="locator_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="locator_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" use="optional" priority="0" order="0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-se12">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="locator_us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="locator_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StockholdersEquityNoteAbstract" xlink:to="locator_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" use="optional" priority="0" order="0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-it">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="locator_us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="locator_us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_us-gaap_IncomeTaxDisclosureTextBlock" use="optional" priority="0" order="0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-giamc">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="locator_us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="locator_us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_SegmentReportingAbstract" xlink:to="locator_us-gaap_SegmentReportingDisclosureTextBlock" use="optional" priority="0" order="0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-faoin">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="locator_us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="locator_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="locator_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" use="optional" priority="0" order="0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-rpbat">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="locator_us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="locator_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="locator_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" use="optional" priority="0" order="0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-lps">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="locator_us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="locator_us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_EarningsPerShareAbstract" xlink:to="locator_us-gaap_EarningsPerShareTextBlock" use="optional" priority="0" order="0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapp">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="locator_us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="locator_us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_UseOfEstimates" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="locator_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="locator_us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_ConsolidationPolicyTextBlock" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="locator_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_CashAndCashEquivalentsPolicyTextBlock" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="locator_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ShortTermBankDepositsPolicyTextBlock" xlink:label="locator_cgen_ShortTermBankDepositsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_cgen_ShortTermBankDepositsPolicyTextBlock" use="optional" priority="0" order="50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" use="optional" priority="0" order="60"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentImpairment" use="optional" priority="0" order="70"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="locator_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" use="optional" priority="0" order="80"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_CostOfSalesContractWithCustomerPolicyTextBlock" xlink:label="locator_cgen_CostOfSalesContractWithCustomerPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_cgen_CostOfSalesContractWithCustomerPolicyTextBlock" use="optional" priority="0" order="90"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="locator_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_ResearchAndDevelopmentExpensePolicy" use="optional" priority="0" order="100"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ServerancePayPolicyTextBlock" xlink:label="locator_cgen_ServerancePayPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_cgen_ServerancePayPolicyTextBlock" use="optional" priority="0" order="110"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="locator_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" use="optional" priority="0" order="120"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="locator_us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_ConcentrationRiskCreditRisk" use="optional" priority="0" order="130"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="locator_us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_EarningsPerSharePolicyTextBlock" use="optional" priority="0" order="140"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="locator_us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_IncomeTaxPolicyTextBlock" use="optional" priority="0" order="150"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="locator_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_FairValueOfFinancialInstrumentsPolicy" use="optional" priority="0" order="160"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="locator_us-gaap_DerivativesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_DerivativesPolicyTextBlock" use="optional" priority="0" order="170"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="locator_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" use="optional" priority="0" order="180"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="locator_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" use="optional" priority="0" order="190"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapt">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="locator_us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" xlink:label="locator_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock" xlink:label="locator_cgen_ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_cgen_ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock" use="optional" priority="0" order="10"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oarapet">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="locator_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="locator_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" use="optional" priority="0" order="0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="locator_us-gaap_LesseeDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:label="locator_cgen_ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_cgen_ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" use="optional" priority="0" order="10"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-paent">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentTextBlock" use="optional" priority="0" order="0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oapaaet">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="locator_us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PayablesAndAccrualsAbstract" xlink:to="locator_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" use="optional" priority="0" order="0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-set1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="locator_us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StockholdersEquityNoteAbstract" xlink:to="locator_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StockholdersEquityNoteAbstract" xlink:to="locator_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" use="optional" priority="0" order="10"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-itt">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="locator_us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" use="optional" priority="0" order="10"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-giamct">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="locator_us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_SegmentReportingAbstract" xlink:to="locator_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_SegmentReportingAbstract" xlink:to="locator_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" use="optional" priority="0" order="10"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-faoint">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="locator_us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="locator_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" use="optional" priority="0" order="0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="locator_us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="locator_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" use="optional" priority="0" order="0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-lpst">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="locator_us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="locator_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_EarningsPerShareAbstract" xlink:to="locator_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" use="optional" priority="0" order="0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-gd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="locator_us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="locator_us-gaap_NetIncomeLoss" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="locator_us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="locator_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="locator_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" priority="0" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="locator_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="locator_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="locator_us-gaap_ResearchAndDevelopmentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="locator_us-gaap_ResearchAndDevelopmentAbstract" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="locator_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="locator_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" use="optional" priority="0" order="50"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AccruedMilestonePayment" xlink:label="locator_cgen_AccruedMilestonePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="locator_cgen_AccruedMilestonePayment" use="optional" priority="0" order="60"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="locator_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="locator_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" use="optional" priority="0" order="70"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="locator_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="locator_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" use="optional" priority="0" order="80"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="locator_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="locator_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" use="optional" priority="0" order="90"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:label="locator_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="locator_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" use="optional" priority="0" order="100"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapnd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="locator_us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="locator_us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_StatementTable" use="optional" priority="0" order="100"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="locator_srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementTable" xlink:to="locator_srt_StatementScenarioAxis" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="locator_srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_StatementScenarioAxis" xlink:to="locator_srt_ScenarioUnspecifiedDomain" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_MasterClinicalAgreementOneMember" xlink:label="locator_cgen_MasterClinicalAgreementOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_ScenarioUnspecifiedDomain" xlink:to="locator_cgen_MasterClinicalAgreementOneMember" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_MasterClinicalAgreementTwoMember" xlink:label="locator_cgen_MasterClinicalAgreementTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_ScenarioUnspecifiedDomain" xlink:to="locator_cgen_MasterClinicalAgreementTwoMember" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="locator_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementTable" xlink:to="locator_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="locator_us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="locator_us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="locator_us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="locator_us-gaap_StockOptionMember" use="optional" priority="0" order="120"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="locator_us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementTable" xlink:to="locator_us-gaap_StatementLineItems" use="optional" priority="0" order="200"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ShortTermBankDepositsWeightedAverageRateForeign" xlink:label="locator_cgen_ShortTermBankDepositsWeightedAverageRateForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_ShortTermBankDepositsWeightedAverageRateForeign" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="locator_us-gaap_AdjustmentForAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_AdjustmentForAmortization" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="locator_us-gaap_ImpairmentOfInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_ImpairmentOfInvestments" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="locator_us-gaap_DeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_DeferredRevenue" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" xlink:label="locator_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="locator_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" use="optional" priority="0" order="50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="locator_us-gaap_SeveranceCosts1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_SeveranceCosts1" use="optional" priority="0" order="60"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="locator_us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_DerivativeGainLossOnDerivativeNet" use="optional" priority="0" order="70"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:label="locator_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" use="optional" priority="0" order="80"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting" xlink:label="locator_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting" use="optional" priority="0" order="90"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="locator_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" use="optional" priority="0" order="100"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_DerivativeRelatedExpense" xlink:label="locator_cgen_DerivativeRelatedExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_DerivativeRelatedExpense" use="optional" priority="0" order="110"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="locator_us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_DerivativeFairValueOfDerivativeNet" use="optional" priority="0" order="120"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="locator_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" use="optional" priority="0" order="130"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="locator_us-gaap_EquityMethodInvestmentAggregateCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_EquityMethodInvestmentAggregateCost" use="optional" priority="0" order="140"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="locator_us-gaap_DerivativeNotionalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_DerivativeNotionalAmount" use="optional" priority="0" order="150"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="locator_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" use="optional" priority="0" order="160"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="locator_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" use="optional" priority="0" order="170"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AccruedMilestonePayment" xlink:label="locator_cgen_AccruedMilestonePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_AccruedMilestonePayment" use="optional" priority="0" order="180"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_DeferredParticipationOfBmsInRdExpenses" xlink:label="locator_cgen_DeferredParticipationOfBmsInRdExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_DeferredParticipationOfBmsInRdExpenses" use="optional" priority="0" order="190"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_PercentageOfConsolidatedRevenuesOfCollaborator" xlink:label="locator_cgen_PercentageOfConsolidatedRevenuesOfCollaborator"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_PercentageOfConsolidatedRevenuesOfCollaborator" use="optional" priority="0" order="200"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapsodrfpaed">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="locator_us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" priority="0" order="100"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="locator_us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="locator_us-gaap_ComputerEquipmentMember" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="locator_cgen_LaboratoryEquipmentAndOfficeFurnitureMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="locator_cgen_LaboratoryEquipmentAndOfficeFurnitureMember" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="locator_us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="locator_us-gaap_LeaseholdImprovementsMember" use="optional" priority="0" order="70"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="locator_srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="locator_srt_RangeAxis" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="locator_srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_RangeAxis" xlink:to="locator_srt_RangeMember" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="locator_srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_RangeMember" xlink:to="locator_srt_MinimumMember" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="locator_srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_RangeMember" xlink:to="locator_srt_MaximumMember" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentLineItems" use="optional" priority="0" order="200"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AnnualDepreciationRate" xlink:label="locator_cgen_AnnualDepreciationRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="locator_cgen_AnnualDepreciationRate" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AnnualDepreciationRateDescription" xlink:label="locator_cgen_AnnualDepreciationRateDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="locator_cgen_AnnualDepreciationRateDescription" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="locator_us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AccountingPoliciesAbstract" xlink:to="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" priority="0" order="100"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="locator_us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="locator_us-gaap_AwardTypeAxis" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AwardTypeAxis" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="locator_us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="locator_us-gaap_EmployeeStockOptionMember" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_EmployeeStockPurchasePlanMember" xlink:label="locator_cgen_EmployeeStockPurchasePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="locator_cgen_EmployeeStockPurchasePlanMember" use="optional" priority="0" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="locator_srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="locator_srt_RangeAxis" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="locator_srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_RangeAxis" xlink:to="locator_srt_RangeMember" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="locator_srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_RangeMember" xlink:to="locator_srt_MinimumMember" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="locator_srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_RangeMember" xlink:to="locator_srt_MaximumMember" use="optional" priority="0" order="50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" use="optional" priority="0" order="200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" use="optional" priority="0" order="30"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oaraped">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="locator_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="locator_us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="locator_us-gaap_PrepaidExpenseCurrent" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_GovernmentAuthorities" xlink:label="locator_cgen_GovernmentAuthorities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="locator_cgen_GovernmentAuthorities" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="locator_us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="locator_us-gaap_OtherAssetsCurrent" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="locator_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="locator_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" priority="0" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LeasesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="locator_us-gaap_LesseeDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="locator_us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_us-gaap_LesseeOperatingLeaseOptionToExtend" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_IncreaseOperatingLeaseRightOfUseAsset" xlink:label="locator_cgen_IncreaseOperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_cgen_IncreaseOperatingLeaseRightOfUseAsset" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_DecreaseOperatingLeaseLiability" xlink:label="locator_cgen_DecreaseOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_cgen_DecreaseOperatingLeaseLiability" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="locator_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="locator_us-gaap_SubleaseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_us-gaap_SubleaseIncome" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:label="locator_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" use="optional" priority="0" order="50"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="locator_us-gaap_LesseeDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="locator_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="locator_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" use="optional" priority="0" order="10"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="locator_us-gaap_LesseeDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="locator_us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_us-gaap_OperatingLeasePayments" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" use="optional" priority="0" order="50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" use="optional" priority="0" order="60" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="locator_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" use="optional" priority="0" order="70"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="locator_us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_us-gaap_OperatingLeaseLiability" use="optional" priority="0" order="80"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="locator_us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" priority="0" order="90" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="locator_us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_LesseeDisclosureAbstract" xlink:to="locator_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" priority="0" order="100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-paend">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" priority="0" order="100"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="locator_us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="locator_us-gaap_ComputerEquipmentMember" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="locator_cgen_LaboratoryEquipmentAndOfficeFurnitureMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="locator_cgen_LaboratoryEquipmentAndOfficeFurnitureMember" use="optional" priority="0" order="50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="locator_us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="locator_us-gaap_LeaseholdImprovementsMember" use="optional" priority="0" order="60"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xlink:label="locator_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="locator_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" use="optional" priority="0" order="70"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentLineItems" use="optional" priority="0" order="200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentGross" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="locator_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="locator_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="locator_us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="locator_us-gaap_PropertyPlantAndEquipmentNet" use="optional" priority="0" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="locator_us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="locator_us-gaap_Depreciation" use="optional" priority="0" order="30"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oapaaed">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="locator_us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="locator_us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PayablesAndAccrualsAbstract" xlink:to="locator_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="locator_us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PayablesAndAccrualsAbstract" xlink:to="locator_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="locator_us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PayablesAndAccrualsAbstract" xlink:to="locator_us-gaap_OtherAccountsPayableAndAccruedLiabilities" use="optional" priority="0" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="locator_us-gaap_OtherCommitmentsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="locator_us-gaap_OtherCommitmentsTable" use="optional" priority="0" order="100"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="locator_cgen_GovernmentAndOtherGrantsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherCommitmentsTable" xlink:to="locator_cgen_GovernmentAndOtherGrantsAxis" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="locator_cgen_GovernmentAndOtherGrantsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_cgen_GovernmentAndOtherGrantsAxis" xlink:to="locator_cgen_GovernmentAndOtherGrantsDomain" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="locator_cgen_ResearchAndDevelopmentGrantOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_cgen_GovernmentAndOtherGrantsDomain" xlink:to="locator_cgen_ResearchAndDevelopmentGrantOneMember" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_May2012AgreementMember" xlink:label="locator_cgen_May2012AgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_cgen_GovernmentAndOtherGrantsDomain" xlink:to="locator_cgen_May2012AgreementMember" use="optional" priority="0" order="100"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="locator_srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherCommitmentsTable" xlink:to="locator_srt_RangeAxis" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="locator_srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_RangeAxis" xlink:to="locator_srt_RangeMember" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="locator_srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_RangeMember" xlink:to="locator_srt_MinimumMember" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="locator_srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_RangeMember" xlink:to="locator_srt_MaximumMember" use="optional" priority="0" order="50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="locator_us-gaap_OtherCommitmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherCommitmentsTable" xlink:to="locator_us-gaap_OtherCommitmentsLineItems" use="optional" priority="0" order="200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="locator_us-gaap_GuaranteeObligationsMaximumExposure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_us-gaap_GuaranteeObligationsMaximumExposure" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="locator_cgen_RoyaltyPercentageBasedOnFutureRevenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_RoyaltyPercentageBasedOnFutureRevenues" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="locator_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="locator_us-gaap_RoyaltyExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_us-gaap_RoyaltyExpense" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_RoyaltyContingentObligations" xlink:label="locator_cgen_RoyaltyContingentObligations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_RoyaltyContingentObligations" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ParticipationRights" xlink:label="locator_cgen_ParticipationRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_ParticipationRights" use="optional" priority="0" order="50"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_RetainerFee" xlink:label="locator_cgen_RetainerFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_RetainerFee" use="optional" priority="0" order="60"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="locator_us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" priority="0" order="70"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AgreementStartDate" xlink:label="locator_cgen_AgreementStartDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_AgreementStartDate" use="optional" priority="0" order="80"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AgreementTerminationDescription" xlink:label="locator_cgen_AgreementTerminationDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_AgreementTerminationDescription" use="optional" priority="0" order="90"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ExtendLease" xlink:label="locator_cgen_ExtendLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_ExtendLease" use="optional" priority="0" order="100"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ContingentFees" xlink:label="locator_cgen_ContingentFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_ContingentFees" use="optional" priority="0" order="110"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xlink:label="locator_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" use="optional" priority="0" order="120"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_RoyaltyPercentage" xlink:label="locator_cgen_RoyaltyPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_RoyaltyPercentage" use="optional" priority="0" order="130"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePayment" xlink:label="locator_cgen_ResearchAndDevelopmentExpensesMilestonePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherCommitmentsLineItems" xlink:to="locator_cgen_ResearchAndDevelopmentExpensesMilestonePayment" use="optional" priority="0" order="140"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sesopnd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="locator_us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StockholdersEquityNoteAbstract" xlink:to="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" priority="0" order="100"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="locator_srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="locator_srt_StatementScenarioAxis" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="locator_srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_StatementScenarioAxis" xlink:to="locator_srt_ScenarioUnspecifiedDomain" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AtTheMarketOfferingProgramMember" xlink:label="locator_cgen_AtTheMarketOfferingProgramMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_ScenarioUnspecifiedDomain" xlink:to="locator_cgen_AtTheMarketOfferingProgramMember" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AgreementMember" xlink:label="locator_cgen_AgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_ScenarioUnspecifiedDomain" xlink:to="locator_cgen_AgreementMember" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_MasterClinicalAgreementMember" xlink:label="locator_cgen_MasterClinicalAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_ScenarioUnspecifiedDomain" xlink:to="locator_cgen_MasterClinicalAgreementMember" use="optional" priority="0" order="80"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_CollaborativeArrangementsMember" xlink:label="locator_cgen_CollaborativeArrangementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_ScenarioUnspecifiedDomain" xlink:to="locator_cgen_CollaborativeArrangementsMember" use="optional" priority="0" order="100"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="locator_cgen_CollaborativeArrangementsTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_ScenarioUnspecifiedDomain" xlink:to="locator_cgen_CollaborativeArrangementsTwoMember" use="optional" priority="0" order="130"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="locator_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_ScenarioUnspecifiedDomain" xlink:to="locator_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" use="optional" priority="0" order="140"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="locator_us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="locator_us-gaap_AwardTypeAxis" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AwardTypeAxis" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="locator_cgen_RegisteredDirectOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="locator_cgen_RegisteredDirectOfferingMember" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="locator_us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="locator_us-gaap_WarrantMember" use="optional" priority="0" order="60"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_UnderwritersMember" xlink:label="locator_cgen_UnderwritersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="locator_cgen_UnderwritersMember" use="optional" priority="0" order="160"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="locator_us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="locator_us-gaap_PlanNameAxis" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="locator_us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PlanNameAxis" xlink:to="locator_us-gaap_PlanNameDomain" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" xlink:label="locator_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_PlanNameDomain" xlink:to="locator_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" use="optional" priority="0" order="190"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="locator_srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="locator_srt_TitleOfIndividualAxis" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="locator_srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_TitleOfIndividualAxis" xlink:to="locator_srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="locator_srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="locator_srt_DirectorMember" use="optional" priority="0" order="250"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="locator_us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="locator_us-gaap_SubsidiarySaleOfStockAxis" use="optional" priority="0" order="50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="locator_us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="locator_us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="locator_us-gaap_EmployeeStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="locator_us-gaap_EmployeeStockMember" use="optional" priority="0" order="280"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" use="optional" priority="0" order="200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="locator_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" use="optional" priority="0" order="50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" use="optional" priority="0" order="60"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" use="optional" priority="0" order="70"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" use="optional" priority="0" order="80"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" use="optional" priority="0" order="90"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="locator_us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_CommonStockParOrStatedValuePerShare" use="optional" priority="0" order="100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="locator_us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_SharesIssuedPricePerShare" use="optional" priority="0" order="110"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="locator_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" use="optional" priority="0" order="120"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="locator_us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_CommonStockSharesAuthorized" use="optional" priority="0" order="130"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="locator_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" use="optional" priority="0" order="140"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="locator_us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ClassOfWarrantOrRightOutstanding" use="optional" priority="0" order="150"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="locator_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" use="optional" priority="0" order="160"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="locator_us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ProceedsFromWarrantExercises" use="optional" priority="0" order="170" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="locator_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable" use="optional" priority="0" order="180"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="locator_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_StockIssuedDuringPeriodSharesNewIssues" use="optional" priority="0" order="190"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AgreementOptionAdditionalNumberOfSharesIssuable" xlink:label="locator_cgen_AgreementOptionAdditionalNumberOfSharesIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_cgen_AgreementOptionAdditionalNumberOfSharesIssuable" use="optional" priority="0" order="200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="locator_us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" priority="0" order="210" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="locator_us-gaap_EquityMethodInvestmentAggregateCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_EquityMethodInvestmentAggregateCost" use="optional" priority="0" order="220" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_PercentageOfClosingPrice" xlink:label="locator_cgen_PercentageOfClosingPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_cgen_PercentageOfClosingPrice" use="optional" priority="0" order="230"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_DeferredParticipationOfBmsInRdExpenses" xlink:label="locator_cgen_DeferredParticipationOfBmsInRdExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_cgen_DeferredParticipationOfBmsInRdExpenses" use="optional" priority="0" order="240"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="locator_us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ProceedsFromIssuanceInitialPublicOffering" use="optional" priority="0" order="250"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InitialOfferingPeriod" xlink:label="locator_us-gaap_InitialOfferingPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_InitialOfferingPeriod" use="optional" priority="0" order="260"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" xlink:label="locator_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" use="optional" priority="0" order="270"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" xlink:label="locator_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" use="optional" priority="0" order="280"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" xlink:label="locator_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" use="optional" priority="0" order="290"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" use="optional" priority="0" order="300"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="locator_us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StockholdersEquityNoteAbstract" xlink:to="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" priority="0" order="100"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="locator_us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="locator_us-gaap_AwardTypeAxis" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_AwardTypeAxis" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_EmployeesAndDirectorsMember" xlink:label="locator_cgen_EmployeesAndDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="locator_cgen_EmployeesAndDirectorsMember" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" use="optional" priority="0" order="200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" use="optional" priority="0" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="locator_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="locator_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" use="optional" priority="0" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" use="optional" priority="0" order="40" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" use="optional" priority="0" order="50" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ac141f83-95e3-c976-a96e-8aaa4101d3f5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ac141f83-95e3-c976-a96e-8aaa4101d3f5" use="optional" priority="0" order="60" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" use="optional" priority="0" order="70"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" use="optional" priority="0" order="80"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" use="optional" priority="0" order="90"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" use="optional" priority="0" order="100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" use="optional" priority="0" order="110" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" use="optional" priority="0" order="120" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" use="optional" priority="0" order="130"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" use="optional" priority="0" order="140"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3a0fe048-6266-c644-6190-4595a77c0542"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3a0fe048-6266-c644-6190-4595a77c0542" use="optional" priority="0" order="150" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" use="optional" priority="0" order="160" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" use="optional" priority="0" order="170" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="locator_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" use="optional" priority="0" order="180"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:to="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" use="optional" priority="0" order="190"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="locator_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:to="locator_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" use="optional" priority="0" order="200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" use="optional" priority="0" order="210"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" use="optional" priority="0" order="220"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" use="optional" priority="0" order="230" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sesosced">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="locator_us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="locator_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StockholdersEquityNoteAbstract" xlink:to="locator_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" priority="0" order="100"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="locator_us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="locator_us-gaap_IncomeStatementLocationAxis" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="locator_us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeStatementLocationAxis" xlink:to="locator_us-gaap_IncomeStatementLocationDomain" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="locator_us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeStatementLocationDomain" xlink:to="locator_us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="locator_us-gaap_SellingAndMarketingExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeStatementLocationDomain" xlink:to="locator_us-gaap_SellingAndMarketingExpenseMember" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="locator_us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeStatementLocationDomain" xlink:to="locator_us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="locator_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="locator_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" use="optional" priority="0" order="200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="locator_us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="locator_us-gaap_AllocatedShareBasedCompensationExpense" use="optional" priority="0" order="0"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="locator_us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="locator_us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_us-gaap_StatementTable" use="optional" priority="0" order="100"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="locator_us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementTable" xlink:to="locator_us-gaap_IncomeTaxAuthorityAxis" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="locator_us-gaap_IncomeTaxAuthorityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxAuthorityAxis" xlink:to="locator_us-gaap_IncomeTaxAuthorityDomain" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="locator_us-gaap_InternalRevenueServiceIRSMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxAuthorityDomain" xlink:to="locator_us-gaap_InternalRevenueServiceIRSMember" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="locator_us-gaap_DomesticCountryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxAuthorityDomain" xlink:to="locator_us-gaap_DomesticCountryMember" use="optional" priority="0" order="70"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="locator_srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementTable" xlink:to="locator_srt_RangeAxis" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="locator_srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_RangeAxis" xlink:to="locator_srt_RangeMember" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="locator_srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_RangeMember" xlink:to="locator_srt_MinimumMember" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="locator_srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_RangeMember" xlink:to="locator_srt_MaximumMember" use="optional" priority="0" order="50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="locator_us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementTable" xlink:to="locator_us-gaap_StatementLineItems" use="optional" priority="0" order="200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="locator_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xlink:label="locator_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="locator_us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_IncomeTaxesPaid" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="locator_us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_ProceedsFromIncomeTaxRefunds" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="locator_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="locator_us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_OperatingLossCarryforwards" use="optional" priority="0" order="50"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_NetOperatingLossCarryforwardExpired" xlink:label="locator_cgen_NetOperatingLossCarryforwardExpired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_NetOperatingLossCarryforwardExpired" use="optional" priority="0" order="60"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="locator_us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_us-gaap_OperatingLossCarryforwardsExpirationDate" use="optional" priority="0" order="70"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ReducedCorporateIncomeTaxRate" xlink:label="locator_cgen_ReducedCorporateIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_StatementLineItems" xlink:to="locator_cgen_ReducedCorporateIncomeTaxRate" use="optional" priority="0" order="80"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="locator_us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_TaxExemptPeriod" xlink:label="locator_cgen_TaxExemptPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_cgen_TaxExemptPeriod" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_ReducedTaxRate" xlink:label="locator_cgen_ReducedTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_cgen_ReducedTaxRate" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_TaxRateOnDistributions" xlink:label="locator_cgen_TaxRateOnDistributions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_cgen_TaxRateOnDistributions" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_PeriodSinceApprovalWasGranted" xlink:label="locator_cgen_PeriodSinceApprovalWasGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_cgen_PeriodSinceApprovalWasGranted" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_PeriodSinceEnterpriseBeganOperating" xlink:label="locator_cgen_PeriodSinceEnterpriseBeganOperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_cgen_PeriodSinceEnterpriseBeganOperating" use="optional" priority="0" order="40"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="locator_us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" priority="0" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="locator_us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="locator_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="locator_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_DeferredIncomeTaxRightOfUseAssets" xlink:label="locator_cgen_DeferredIncomeTaxRightOfUseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_cgen_DeferredIncomeTaxRightOfUseAssets" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_DeferredIncomeTaxLeaseLiabilities" xlink:label="locator_cgen_DeferredIncomeTaxLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_cgen_DeferredIncomeTaxLeaseLiabilities" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="locator_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" use="optional" priority="0" order="50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="locator_us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_us-gaap_DeferredTaxAssetsGross" use="optional" priority="0" order="60" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="locator_us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" priority="0" order="70" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="locator_us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="locator_us-gaap_DeferredTaxAssetsNet" use="optional" priority="0" order="80" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/GeographicInformationAndMajorCustomersDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="locator_us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SegmentReportingGeographicAreaTable" xlink:label="locator_cgen_SegmentReportingGeographicAreaTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_SegmentReportingAbstract" xlink:to="locator_cgen_SegmentReportingGeographicAreaTable" use="optional" priority="0" order="100"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SegmentReportingGeographicAreaAxis" xlink:label="locator_cgen_SegmentReportingGeographicAreaAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_cgen_SegmentReportingGeographicAreaTable" xlink:to="locator_cgen_SegmentReportingGeographicAreaAxis" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SegmentReportingGeographicAreaDomain" xlink:label="locator_cgen_SegmentReportingGeographicAreaDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_cgen_SegmentReportingGeographicAreaAxis" xlink:to="locator_cgen_SegmentReportingGeographicAreaDomain" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember" xlink:label="locator_srt_EuropeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_cgen_SegmentReportingGeographicAreaDomain" xlink:to="locator_srt_EuropeMember" use="optional" priority="0" order="10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IL" xlink:label="locator_country_IL"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_cgen_SegmentReportingGeographicAreaDomain" xlink:to="locator_country_IL" use="optional" priority="0" order="70"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="locator_country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_cgen_SegmentReportingGeographicAreaDomain" xlink:to="locator_country_US" use="optional" priority="0" order="80"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="locator_us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_cgen_SegmentReportingGeographicAreaTable" xlink:to="locator_us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="locator_us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="locator_us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="locator_us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="locator_us-gaap_SalesRevenueNetMember" use="optional" priority="0" order="130"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="locator_us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_cgen_SegmentReportingGeographicAreaTable" xlink:to="locator_us-gaap_ConcentrationRiskByTypeAxis" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="locator_us-gaap_ConcentrationRiskTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="locator_us-gaap_ConcentrationRiskTypeDomain" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="locator_us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_ConcentrationRiskTypeDomain" xlink:to="locator_us-gaap_CustomerConcentrationRiskMember" use="optional" priority="0" order="130"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="locator_srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_cgen_SegmentReportingGeographicAreaTable" xlink:to="locator_srt_MajorCustomersAxis" use="optional" priority="0" order="40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="locator_srt_NameOfMajorCustomerDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_MajorCustomersAxis" xlink:to="locator_srt_NameOfMajorCustomerDomain" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_CustomerOneMember" xlink:label="locator_cgen_CustomerOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_srt_NameOfMajorCustomerDomain" xlink:to="locator_cgen_CustomerOneMember" use="optional" priority="0" order="130"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_SegmentReportingGeograhicAreaLineItems" xlink:label="locator_cgen_SegmentReportingGeograhicAreaLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_cgen_SegmentReportingGeographicAreaTable" xlink:to="locator_cgen_SegmentReportingGeograhicAreaLineItems" use="optional" priority="0" order="200"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="locator_us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_cgen_SegmentReportingGeograhicAreaLineItems" xlink:to="locator_us-gaap_NumberOfOperatingSegments" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="locator_us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_cgen_SegmentReportingGeograhicAreaLineItems" xlink:to="locator_us-gaap_Revenues" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="locator_us-gaap_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_cgen_SegmentReportingGeograhicAreaLineItems" xlink:to="locator_us-gaap_NoncurrentAssets" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="locator_us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_cgen_SegmentReportingGeograhicAreaLineItems" xlink:to="locator_us-gaap_ConcentrationRiskPercentage1" use="optional" priority="0" order="30"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="locator_us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="locator_us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="locator_us-gaap_InvestmentIncomeInterest" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="locator_us-gaap_InterestAndDebtExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="locator_us-gaap_InterestAndDebtExpense" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="locator_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="locator_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="locator_us-gaap_GainLossOnSaleOfOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="locator_us-gaap_GainLossOnSaleOfOtherAssets" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="locator_cgen_FinancialIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="locator_cgen_FinancialIncomeExpenseNet" use="optional" priority="0" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="locator_us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="locator_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="locator_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="locator_us-gaap_CostsAndExpensesRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="locator_us-gaap_CostsAndExpensesRelatedParty" use="optional" priority="0" order="10"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="locator_us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="cgen-20211231.xsd#cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" xlink:label="locator_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_EarningsPerShareAbstract" xlink:to="locator_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" use="optional" priority="0" order="0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="locator_us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" xlink:to="locator_us-gaap_NetIncomeLoss" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="locator_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_EarningsPerShareAbstract" xlink:to="locator_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" use="optional" priority="0" order="20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="locator_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="locator_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" use="optional" priority="0" order="30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="locator_us-gaap_EarningsPerShareBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="locator_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="locator_us-gaap_EarningsPerShareBasicAndDiluted" use="optional" priority="0" order="40"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image00006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_VP!#  (! 0(! 0(" @(" @(" P4# P,# P8$! ,%!P8'
M!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_VP!# 0(" @,#
M P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# S_P  1" +)!04# 2(  A$! Q$!_\0 'P   04! 0$!
M 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0   %] 0(#
M  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B<H
M*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MA_BK2-&<H>U7PD>TCS<A]*44#BBLRPHHSBB@ H-&:"<"@!JF@KDU\1_M!?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&/X#_P LTK]N?V[HIKC]BGXLQV_^N/A'4]G_ ("R5^6'_!II<H?$_P 8H?\
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M=YYR4QOZ/7T1_P %%3_Q@;\8O^Q0U/\ ])9*_.G_ (-,O^2=_&C_ +".F?\
MHF:N"C0_V"K4[?\  .NM4_VF$#]3?C3\:O"_[//PRUCQAXOUBUT/P[HD!GO+
MN<X$8Y_[Z;_9'-?FMXN_X.L/AGIWC7['I/PU\9:IH>_RQ?S7MM:S/_M)!\^?
M^^ZR_P#@ZQ^+>I:-\&_A?X/M9I(].US5+K4[U$_Y;?94C\D?G,]?37_!,;_@
MGK\)/!_[ G@"/4/ OA/Q!?>)]#@U/5KW4=+@NI[R>ZC\R3+NF?XRO;I6E'"X
M>EAHXG$QYN8SJ5ZM2M[*D?0G[)G[4?AG]L[X#:'\1/!YO#H/B!)# EY!Y%Q
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M/=6K6D[9CDL]/@?9;8_YYR>3_P"1)*C X6EB*LIOX(CQ5>K2A&"^(^JOA_\
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M?K7C_6-8TZVU-[.TE2UCTQ)T#HD\S[QYV&'[M ]<S_P=-?\ )D/@W_L<8/\
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MA?FYAU%%%<YT!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\&_^BL?#7_PIK+_XY7&?\.I/V=O^B4^&?RD_^+IW_#J?]GG_ *)3X8_[Y?\
M^+HME_>7W1_S#_A1_N?^3'8_\-P_!L_\U8^&O_A36?\ \<I?^&X?@V/^:L?#
M7_PIK/\ ^.5QG_#JG]G?_HE/AK\G_P#BZ=_PZJ_9Y_Z)3X9_*3_XNCEP'>7W
M1_S#_A1_N?\ DQV'_#<'P;'_ #5CX:_^%-9__'*!^V]\&Q_S5CX;_P#A2V?_
M ,<KC_\ AU?^SS_T2GPS^4G_ ,71_P .K_V>?^B4^&?RD_\ BZ5L#WE]T?\
M,/\ A1_N?^3'8_\ #<'P;_Z*S\-__"EL_P#XY1_PV]\&Q_S5CX;_ /A26?\
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M._D__P 54\N"[R_\E_S#VF9_RP_\F.T_X;!^%/\ T4SX?_\ A06O_P 72_\
M#8/PG_Z*9X!_\*"U_P#BZXO_ (=E_ ?_ *)GX=_)_P#XJE_X=G_ G_HF?A[\
MG_\ BJ.7!?W_ +E_F'M,S_EA_P"3'9_\-A?"C_HIG@'_ ,*"U_\ BZ7_ (:]
M^%(_YJ7X!_\ "@M?_BZXO_AV?\"?^B9^'OR?_P"*IW_#M/X%?]$U\/?D_P#\
M51RX+^_]R_S#GS/^6'_DQV7_  UW\*?^BE> O_!_:_\ Q='_  UY\*1_S4KP
M'_X4%K_\77&_\.U_@7_T37P[^3__ !5'_#M3X%_]$U\/_D__ ,51RX+^_P#<
MO\PY\S_EA_Y,=E_PUY\*?^BE> O_  ?VO_Q='_#7?PJ_Z*5X#_\ !_:__%UQ
MO_#M;X&?]$U\/_\ C_\ \51_P[6^!G_1-?#_ /X__P#%4<N"_O\ W+_,/:9G
M_+#_ ,F.S_X:Y^%?_12? ?\ X/[7_P"+H_X:Y^%?_12? ?\ X/[7_P"+KC_^
M';?P-_Z)OX?_ "?_ .*H_P"';?P-_P"B;^'_ ,G_ /BJ.7!_W_N7^8<^9_RP
M_P#)CL?^&M_A7_T4CP'_ .#ZU_\ BZ/^&M_A7_T4CP'_ .#ZU_\ BZXW_AVW
M\#O^B;>'_P G_P#BJ=_P[=^"'_1-]!_\?_\ BJ.7!=Y?A_F3[3-/Y8?^3'8?
M\-<?"W_HI'@/_P 'UK_\73O^&M?A;_T4;P-_X/+;_P"+KC?^'<'P1_Z)QH'_
M (__ /%4?\.X/@C_ -$XT#_Q_P#^*HY<%WE^ _:9I_+#_P F.R_X:T^%O_11
MO W_ (/+;_XNC_AK3X6_]%&\#?\ @\MO_BZX[_AW#\$?^B<Z!_Y$_P#BJ/\
MAW'\$?\ HG&@?D__ ,51RX+O+\/\Q<^:?RP_\F.Q/[6OPM/_ #4;P-_X/+;_
M .+H_P"&M/A:/^:C>!O_  >6W_Q=<?\ \.Y?@G_T3G0?R?\ ^*H_X=R_!/\
MZ)SH/Y/_ /%4<N"[R_#_ ##VF:?RP_\ )CL#^UK\+3_S4;P-_P"#RV_^+H_X
M:O\ A;_T4;P-_P"#VV_^+KC_ /AW/\$_^B<Z#_X__P#%4[_AW5\%?^B=Z#_X
M_P#_ !5'+@N\_P /\PY\T_EA_P"3'8?\-7?"_P#Z*)X'_P#!Y;?_ !='_#5O
MPQ_Z*)X'_P#!Y;?_ !=<?_P[J^"O_1.]!_\ '_\ XJC_ (=U_!3_ *)WH/\
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M8_\ 10_!/_@\M?\ XNN1_P"'>WP5_P"B>:#_ ./_ /Q5._X=[_!?_HGF@_\
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M._\ X.?]$_T7\W_^*H_X=_\ P<_Z)_HOYO\ _%4N7"?WOZ^9/M,V_EA]\O\
MY$ZW_AJ#X;_]#YX._P#!U;?_ !='_#4'PW_Z'SP=_P"#JV_^+KE/^&!?@[_T
M(.B?F_\ \51_PP+\'_\ H0=%_P#'_P#XJJY<)_>_#_,/:9O_ "P^^7_R)U)_
M:>^&Y_YG[P;_ .#BV_\ BZ/^&G?AO_T/W@W_ ,'%M_\ %US/_# 7P>_Z$'1?
M_'__ (JE_P"&!/@__P!"#HO_ (__ /%4O]D[R_ 7-G'\M+[Y?_(G2_\ #3OP
MW_Z'[P;_ .#BV_\ BZ/^&G?AO_T/W@W_ ,'%M_\ %US7_# GP?\ ^A!T7_Q_
M_P"*I?\ A@?X0?\ 0@Z+^3__ !5/_9.\OP#FSC^6E]\O_D3I/^&F?AS_ -#]
MX-_\&]O_ /%T?\-,_#G_ *'[P;_X-[?_ .+KF_\ A@GX0_\ 0AZ+_P"/_P#Q
M5._X8+^$/_0AZ+^3_P#Q5+_9.\OP#GSC^6E]\O\ Y$Z+_AIGX<_]#]X-_P#!
MO;__ !=._P"&F?AS_P!#YX/_ /!Q;_\ Q=<W_P ,%_"'_H0]%_)__BJ/^&"_
MA%_T(>C_ /C_ /\ %4?[)WE^ <V<?RTOOE_\B=+_ ,-*_#O_ *'SP?\ ^#>W
M_P#BZ3_AI3X>?]#UX0_\&]O_ /%USG_#"'PC_P"A%T?\W_\ BJ/^&$?A'_T(
MNC?^/_\ Q5'^R=Y?@'-G'\M+[Y?_ ")T?_#2GP\_Z'KPA_X-[?\ ^+IW_#27
MP]_Z'KPC_P"#>W_^+KFO^&$?A'_T(NC?^/\ _P 52_\ #"7PE_Z$71__ !__
M .*H_P!D[R_#_,.?./Y:7WR_^1.D_P"&DOA[_P!#UX1_\&]O_P#%TG_#27P]
M_P"AZ\(_^#>W_P#BZYS_ (85^$O_ $(NC_\ C_\ \51_PPK\)?\ H1='_P#'
M_P#XJC_9.\OP_P PY\X_EI_?+_Y$Z3_AI+X>_P#0\>$?_!O;_P#Q='_#27P]
M_P"AY\(_^#>W_P#BZYW_ (85^$O_ $(VC_\ C_\ \52_\,,_"C_H1]'_ /'_
M /XJE_LO]X?-G'\M/[Y?_(G1?\-*?#W_ *'KPC_X-K?_ .+H_P"&E/A[_P!#
MUX1_\&UO_P#%USG_  PW\)_^A(T?_P ?_P#BJ/\ AAKX3G_F2-'_ /'_ /XJ
ME_LG]X7/G7\M+[Y?_(G3?\-&_#\_\SQX1_\ !M!_\72_\-%^ /\ H=_"7_@V
M@_\ BZYK_AASX4_]"3I/_C__ ,51_P ,.?"G_H2=)_\ '_\ XJE;"?WA<^=_
MR4O_  *7_P B=+_PT1X!_P"AV\)_^#:#_P"+H_X:(\ _]#MX3_\ !M!_\77-
M_P###WPK_P"A+TC\G_\ BJ/^&'OA7_T)>D?D_P#\51;"=Y#Y\[_DI?\ @4O_
M )$Z3_AHKP#_ -#MX4_\&T'_ ,72_P##1/@'_H=O"O\ X-H/_BZYO_AA_P"%
M?_0EZ3_X_P#_ !5+_P ,0_"O_H2])_\ '_\ XJCEPG>1/M,[_DI?^!2_^1.C
M_P"&B? /_0[>%?\ P;0?_%T?\-"^ _\ H=?"O_@U@_\ BZYS_AB'X5_]"7I/
M_C__ ,52_P##$/PK_P"A+TG_ ,?_ /BJ.7"=Y![3._Y*7_@4O_D3HO\ AH7P
M'_T.OA7_ ,&L'_Q=._X:%\!_]#IX6_\ !K!_\57-_P##$WPM_P"A,TG_ ,>_
M^*H_X8F^%O\ T)FD_P#CW_Q5'+A.\A^TSO\ DI?^!2_^1.D_X:%\!_\ 0Z>%
MO_!K!_\ %4?\-"^ _P#H=/"W_@U@_P#BJYO_ (8F^%O_ $)FD_\ CW_Q5'_#
M$WPM_P"A,TG_ ,>_^*HY<)WD'M,[_DI?^!2_^1.C_P"&A/ ?_0Z>%O\ P:P?
M_%TO_#07@/\ Z'/PO_X-8/\ XNN=_P"&*OA?_P!";I?YO_\ %4[_ (8M^%__
M $)^D_\ CW_Q5%L)WD+VF=_R4O\ P*7_ ,B=!_PT!X#_ .AS\,?^#6'_ .+I
M?^&@/ O_ $.7AC_P:P__ !5<]_PQ;\,?^A.TS_Q__P"*H_X8M^&/_0G:9_X_
M_P#%46PG>0^?//Y*7_@4O_D3H?\ AH#P+_T.7AC_ ,&L/_Q5'_#0'@7_ *'+
MPQ_X-8?_ (JN>_X8P^&/_0GZ7_X]_P#%4?\ #&'PQ_Z$_2__ ![_ .*HY<)W
MD+VF=_R4O_ I?_(G0_\ #0'@7_H<O#'_ (-8?_BJ7_A?O@;_ *''PS_X-(?_
M (JL#_AC7X:?]"?IG_CW_P 51_PQK\-/^A/TS_Q[_P"*HMA.\A\^>?R4O_ I
M?_(F_P#\+]\#?]#CX9_\&D/_ ,51_P +\\#_ /0X^&?_  9P_P#Q58'_  QK
M\-/^A/TS_P >_P#BJ/\ AC7X:?\ 0GZ9_P"/?_%46PG>0<^=_P E+_P*7_R)
MT/\ POSP/_T.'AG_ ,&4'_Q5'_"^_!/_ $.'AG_P90__ !5<_P#\,<_#7_H4
M=-_-O_BJ7_ACGX;_ /0I:9_X_P#_ !5%L)WD'/G?\E+_ ,"E_P#(F_\ \+[\
M$_\ 0X>&?_!E#_\ %4?\+[\$_P#0X>&?_!E#_P#%5@?\,<_#?_H4M,_\?_\
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M'_@?%_\ %4?\+I\(_P#0T>'_ /P/B_\ BJR?^&7_  )_T+6G_DU'_#,7@?\
MZ%O3_P FI?[+_>#GSW^2E_X%+_Y$UO\ A=/A'_H:/#__ ('Q?_%4O_"Z?"/_
M $,^@_\ @=%_\565_P ,Q^!_^A;T_P#\>H_X9C\#_P#0MZ?_ ./4?[+_ '@Y
M\]_DI?\ @4O_ )$U_P#A<OA'_H9M"_\  ^+_ .*H_P"%R^$?^AFT+_P/B_\
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M )2[7_XBH?\ AZ!\;_\ H<__ "GVO_Q%']EU@_UFPO\ )(_93[;1]MK\:_\
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M7_XBC^RZP?ZS87^29^RGVVC[;7XU_P##T#XW_P#0Y_\ E/M?_B*/^'H'QO\
M^AS_ /*?:_\ Q%']EU@_UFPO\DS]E/MM'VVOQK_X>@?&_P#Z'/\ \I]K_P#$
M4?\ #T#XW_\ 0Y_^4^U_^(H_LNL'^LV%_DF?LI]MH^VU^-?_  ] ^-__ $.?
M_E/M?_B*/^'H'QO_ .AS_P#*?:__ !%']EU@_P!9L+_),_93[;1]MK\:_P#A
MZ!\;_P#H<_\ RGVO_P 11_P] ^-__0Y_^4^U_P#B*/[+K!_K-A?Y)G[*?;:/
MMM?C7_P] ^-__0Y_^4^U_P#B*/\ AZ!\;_\ H<__ "GVO_Q%']EU@_UFPO\
M),_93[;1]MK\:_\ AZ!\;_\ H<__ "GVO_Q%'_#T#XW_ /0Y_P#E/M?_ (BC
M^RZP?ZS87^29^RGVVC[;7XU_\/0/C?\ ]#G_ .4^U_\ B*/^'H'QO_Z'/_RG
MVO\ \11_9=8/]9L+_),_93[;1]MK\:_^'H'QO_Z'/_RGVO\ \11_P] ^-_\
MT.?_ )3[7_XBC^RZP?ZS87^29^RGVVC[;7XU_P##T#XW_P#0Y_\ E/M?_B*/
M^'H'QO\ ^AS_ /*?:_\ Q%']EU@_UFPO\DS]E/MM'VVOQK_X>@?&_P#Z'/\
M\I]K_P#$4?\ #T#XW_\ 0Y_^4^U_^(H_LNL'^LV%_DF?LI]MH^VU^-?_  ]
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MP] ^-_\ T.?_ )3[7_XBC^RZP?ZS87^29^RGVVC[;7XU_P##T#XW_P#0Y_\
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MG6O_ ,17K_V/7/SB7BAEB=N2?_DO_P D?J9L]Z-GO7Y9_P##Q?XO_P#0V?\
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M']CU@_XBEEG\D_\ R7_Y(_4W[:*/MHK\LO\ AX)\6O\ H:O_ "2@_P#B*/\
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M'ZF_;11]M%?EE_P\$^+7_0U?^24'_P 11_P\$^+7_0U?^24'_P 11_8]8/\
MB*66?R2_\E_^2/U-^VBC[:*_++_AX)\6O^AJ_P#)*#_XBC_AX)\6O^AJ_P#)
M*#_XBC^QZP?\12RS^27_ )+_ /)'ZF_;11]M%?EE_P /!/BU_P!#5_Y)0?\
MQ%'_  \$^+7_ $-7_DE!_P#$4?V/6#_B*>6?R2_\E_\ DC]3?MHI?/K\L?\
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M "/6O\2?V)H/#GCCPYX,TO3?B%!K^KZTFDR:[K&EI#H-_P#WWMO^6FQ/]O\
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M:V\.>/-5L-/L]<L;.SNG@2VUA$CO[?\ V)MGR;ZQ:NG4YSEJ0Y)\AZ9^Q?\
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M_8\=IH=LDVI7DA+@#]Y^[1$10[O1]8@5_8>)Y^4\CK]5OV SC]D+P1_UZO\
M^CI*_+KQ980Z7XHO[:UAU*"VMYW1(;]/+NX_]A_]NOU$_8#_ .30?!/_ %ZR
M?^CI*\[-_P"# ^Y\,:;IYG5A_=_]NB>ST4#I17SA^[!1110 4444 !.17PC_
M ,%U/^22^!_^PS+_ .B37W;T%?"7_!=3_DDO@?\ [#,O_HDUU8'^/$\O.?\
M=)GYHO\ <DK[H^/_ /P4,U7X1_!WX3Z;\,_$OAJYN(O#D<.K[(H;Z>QF2.--
MG^P_WQCVKX7HKZ"="%7XSX/"8J>'Y^0^I_@=\?+.7]B3X]P^(/%$*^,O%EU#
M/ MS>A+[4I/DW[.[]^GK7H.D_%GX4^)_AK^S#I?C#7=-OK'PY%<IK5M'="22
MPD\A/)^T[/G1-^*^%Z*)X>$I\_\ 7P\IO3S*<?Z_O<Q^C'[0/Q>^'.E_LA_$
MSPWH_BSX3K?:Q-%/I]AX0MX[7S8?/C\O?\_[^?RT^>LWXW?$OX:ZW^SGKTGC
M7QY\/?B)XCL=/AA\,ZCH]M]EUV5T^XESL=_D\S_MGS)WK\^:*P^H+^8UJ9U.
M4_@/U,N/VKOA[\0O$_AKQYH_B[X.:/<6>GJD\GB"UE?7=-RGSPHB3I_WQ7YO
M^)+I/BU\<+^:XO\ 3=-A\2:V[O?NCP6END\_^OV?P)_'7)T5=/"PA/F.?%9E
M.O#DF?=?QK\'^!=?_8.\(?#^S^,?PTDU;P3--J$S+J(D2_\ ]>^R%,[]_P ]
M>+_\$U==\)^!/CQ-XR\8:MI>EV_A'3)KRRBNYXXY+^YD38B)_?D^_7SY15QP
M\DI+G^(53'<\X3Y/@/OO]GO]MWX6?&6_^('A36O".C_"^P^(5E<SZAJ=SKSS
MQWMU)_?\R-$23]YOKR']IGXG:+??L"_!_P (Z7XCT_4M6T2\N(]3L;.]$CQ_
MZS8[HG/^YGUKYBHJ%@X)W@:RS:M*')(^XOB!^T!X5OOB#^R8]OXJTM['PG96
MW]M[+T>7ITGEP)^^_N?QCGTJUX'_ &A/"D?[3O[3&I7OB[1_[/\ $6A36VBW
M,M[&([_]T0B0OGY^OO7PG13EA5+\?Q#^UI\_]?R\I[I_P3?E\*:#^TEI?B#Q
MIK6EZ)IGA6UFU./[?/''Y]TG[M$3_;^??_VSKZ,_9\_;]^%_Q.^)WC+2=:\%
MZ7\/;'XC6MS_ &QKEUKS31W[[/DWH\:)'^[=Z_/^BG6P\*KO,SPN93H0]P]
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M7E]T^X/A#\?/"MA\7?VHKS5/%FEI9^)[:]32)KB]'EZGQ/L\G^_^[V=*]&\
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M?/\ )\FROF6BH]A#^OZ_NFGUN</@_K^N8]E\<?'CPKKW@_3?"4%GXNOO#?\
MPE;^)=1FU6>"2[V/\GV6'Y]G^K_C_P"6E87B;XV:;\2?VG?^$T\4:==7'A_^
MT$G_ ++MW_>)9P?ZBV3?_L(B5YO16D*<(F<\7.7QGI6C_&ZVU_\ :8?XA>*O
M[5D?^V_[;\FP1'DD=)]Z0?.Z;$\OY*ZJX_:/\*:I=?$[3YH/&%KH7Q#U>'78
M[JS\B._T^Y2=Y/+V;]CQ[)G3[]>%T5G[.'P!3Q4U.4_YCN/VC/B^OQX^,&I>
M)(K.33K>X2&U@AFG\^X\F""-$>9_XW^3YZX>BBM*=/DAR&%2ISSYSTS]B_\
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M>'M)UF;6;V34)D-U/OV((4_@2/8J?^/UG0?&&SU[]HC_ (3CQ)97&H6?V_\
MM#[%"_/R?ZB'_<C^2N HJJ=,YZF;5Y_U_*=U\.?BI:Z5\<(?&OB1]4O+B'4C
MJKI9QI))/-OW[/G?Y(ZWK/XS>&SI7BG1KK_A+8])UO6H==M;FS\B"\MYDW^9
M&Z;]GE['_OUY/11]7@.GFU>']?S'4?&GXD_\+=^*.M>(_L?V%=3FWI%OW^6F
MSRTWO_&_R5^EG[ 7_)H?@GWM'_\ 1TE?E77ZJ?L"MC]D'P3_ +-K)_Z.>O*S
M:*C1A&)^@^&=:=7-:M:?Q2A_[=$]H' HH!R**^=/W0**** "BBB@!OW17G/[
M1O[,/A/]J7P=#HWBVSN+JWM9Q<P/;S&&:"0=T<=*]&.,53UK6[/P[8-=7DZ6
M\,?5FZ40[Q,ZE.,X\LSY?_X<W?!7_GR\3?\ @X>C_AS=\%?^?+Q-_P"#AZ][
M_P"%W>'?^?N7_OP_^%)_PN[P[_S]3?\ ?AZZ?;5OYCA^HX+^2)X%_P .;/@K
M_P ^?B7_ ,'#U!=_\$=?@S$/EM?$G_@W>OH+_A=>A?\ /Q)_WX>J\_QIT&7_
M )>I/^_#T_;5OY@^HX+^2)\U:A_P2(^$L7^JMO$?_@T>L2\_X)0_#&+[L/B#
M_P &+U]47'Q:T&7_ )>9/^_#U3D^(V@RG_CYD_[\/3]M6_F#ZC@_Y('RO_PZ
MG^&__/+7/_!@]'_#JOX;_P#/'7/_  8O7U%_PL'1/^>S?]^'IO\ PL'1?^>T
MG_?EZ/;5OYP^HX+^2!\O_P##JOX;_P#/'7/_  8O1_PZK^&__/'7/_!B]?4'
M_"P=%_Y[2?\ ?EZ/^%@Z+_SVD_[\O1[:M_.'U'!_R0/E_P#X=5_#?_GCKG_@
MQ>C_ (=5_#?_ )XZY_X,7KZ@_P"%@Z+_ ,]I/^_+T?\ "P=%_P">TG_?EZ/;
M5OYP^HX+^2!\O_\ #JOX;_\ /'7/_!B]'_#JOX;_ //'7/\ P8O7U!_PL'1?
M^>TG_?EZ/^%@Z+_SVD_[\O3]M6_G#ZC@OY('R_\ \.J_AO\ \\=<_P#!B]'_
M  ZK^&__ #QUS_P8O7U!_P +!T7_ )[2?]^7H_X6#HO_ #VD_P"_+TO;5OYP
M^HX+^2!\O_\ #JOX;_\ /'7/_!B]'_#JOX;_ //'7/\ P8O7U!_PL'1?^>TG
M_?EZ/^%@Z+_SVD_[\O1[:M_.'U'!?R0/E_\ X=5_#?\ YXZY_P"#%Z/^'5?P
MW_YXZY_X,7KZ@_X6#HO_ #VD_P"_+T?\+!T7_GM)_P!^7H]M6_G#ZC@OY('R
M_P#\.J_AO_SQUS_P8O1_PZK^&_\ SQUS_P &+U]0?\+!T7_GM)_WY>C_ (6#
MHO\ SVD_[\O3]M6_G#ZC@_Y('R__ ,.J_AO_ ,\=<_\ !B]'_#JOX;_\\=<_
M\&+U]0?\+!T7_GM)_P!^7H_X6#HO_/:3_OR]+VU;^</J."_D@?+_ /PZK^&_
M_/'7/_!B]'_#JOX;_P#/'7/_  8O7U!_PL'1?^>TG_?EZ/\ A8.B_P#/:3_O
MR]/VU;^</J.#_D@?+_\ PZK^&_\ SQUS_P &+T?\.J_AO_SQUS_P8O7U!_PL
M'1?^>TG_ 'Y>C_A8.B_\]I/^_+TO;5OYP^HX/^2!\O\ _#JOX;_\\=<_\&+T
M?\.J_AO_ ,\=<_\ !B]?4'_"P=%_Y[2?]^7H_P"%@Z+_ ,]I/^_+T_;5OYP^
MHX/^2!\O_P##JOX;_P#/'7/_  8O1_PZK^&__/'7/_!B]?4'_"P=%_Y[2?\
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M_#?_ )XZY_X,7KZEE\>:#_#-)_WX>HO^%@Z+_P ]I/\ OR]'MJW\X?4<%_)
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MB_\ /:3_ +\O1[:M_.'U'!?R0/E__AU7\-_^>.N?^#%Z/^'5?PW_ .>.N?\
M@Q>OJ#_A8.B_\]I/^_+T?\+!T7_GM)_WY>CVU;^</J.#_D@?+_\ PZK^&_\
MSQUS_P &+T?\.J_AO_SQUS_P8O7U!_PL'1?^>TG_ 'Y>C_A8.B_\]I/^_+T>
MVK?SA]1P7\D#Y?\ ^'5?PW_YXZY_X,7H_P"'5?PW_P">.N?^#%Z^H/\ A8.B
M_P#/:3_OR]'_  L'1?\ GM)_WY>CVU;^</J.#_D@?+__  ZK^&__ #QUS_P8
MO1_PZK^&_P#SQUS_ ,&+U]0?\+!T7_GM)_WY>C_A8.B_\]I/^_+T>VK?SA]1
MP7\D#Y?_ .'5?PW_ .>.N?\ @Q>C_AU/\-_^>6N?^#!Z^H/^%@Z+_P ]I/\
MOR]._P"%@Z)_SV;_ +\/1[:M_.'U'!_R0/F.W_X)0_#>4?-;:Y_X,7K8TO\
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M_P# VC_AWEX+_P">.J?^!M?17_"4:3_SV_\ (='_  E&D_\ /;_R'1]:Q/\
M.'^KN1_\^HGSK_P[R\%_\\=4_P# VC_AWEX+_P">.J?^!M?17_"4:3_SV_\
M(='_  E&D_\ /;_R'1]:Q/\ ./\ U=R/_GU$^=?^'>7@O_GCJG_@;1_P[R\%
M_P#/'5/_  -KZ*_X2C2?^>W_ )#J3_A*-*_Y[2?]\4?6L3_,+_5W(_\ GU$^
M<?\ AWEX+_YXZI_X&T?\.\O!?_/'5/\ P-KZ0_X2C1_^>TG_ '[>G_\ "4:)
M_P ]W_[\/1]:Q/\ ,'^KN1_\^HGS9_P[R\%_\\=4_P# VC_AWEX+_P">.J?^
M!M?3FGZ]H]_.D,4WSR?<WIY=;'_"+I_SSI?6L3_.:4^&<FG\&'B?)?\ P[R\
M%_\ /'5/_ VC_AWEX+_YXZI_X&U]1:O=Z;H4_DW4R)-_<2/?5#_A*-$_Y[O_
M -^'H^M8G^<7^KF3?\^H'S9_P[R\%_\ /'5/_ VC_AWEX+_YXZI_X&U](2>*
M-'_Y[2?]\4W_ (2C2O\ GM)_WQ3^M8G^<C_5W(_^?43YQ_X=Y>"_^>.J?^!M
M'_#O+P7_ ,\=4_\  VOHK_A*-)_Y[?\ D.C_ (2C2?\ GM_Y#H^M8G^</]7<
MC_Y]1/G7_AWEX+_YXZI_X&T?\.\O!?\ SQU3_P #:^BO^$HTG_GM_P"0Z/\
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M/6"BBB@ HHHH ;CYZ\Y_:+D_XIVQ_P"O@_\ H)KT;/SUYS^T9_R!=._Z[/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!L?#_P#Y'G2O^OI*^BT^[7SI\/\ _D>=*_Z^DKZ+3[M8USNPNQ0L?^1@O/\
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M/#_@;P-J3^&?^$/\!^)4UZ#5;:ZG^WZA#!.\]K!]FV>6C^8_SOO?_5_[=7_
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MZ>!YWFF\E-D?[E-B;'JOZ_\ 2O\ [4GW/Z_[=.\N/VD?#%AX3MM5N%\06O\
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M;ZK? ?\ 90U7X+>+/#URVI6-];Z7X-FT&Z=-Z227L][]J=T3_GA\[_QU/O\
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M#PO;ZEKD>N?\)79:1XEO[SQ0D]O&D]D\Z?9M3V/Y*3R(G^L3?'YFSY-Z5?\
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M=).B.B)\G[E'V?\ +.O7*HD**** "BBB@ HHHH **** "BBB@ HHHH ****
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MZEU_9\T%JCP7L.Q/]%\R1W39]S_OBNM_9_O_ !#X<^*'@:VU+QAXC\30^./
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M[>__ &TNGF_[]I7?^*(KGXW?'CQA?Z6GF6?PGT2ZTO2W1/\ CXUVZM?G=/\
M;@@V)_OSO2E4Y8&?(>P>%_C)X2\;^*+S1-&\3^']5UC3_P#CZL[.]2>XM]GR
M/O1*TM#\8Z/XCU#4K/3=5TV^O-'G\B]AMITDDLW_ +C_ -QZ^6OA'JGA[7K?
M]E2V\+S6,]_I^G73ZC#;.DEQ9VO]ENEUYVS[G^E;-_F?QUWG[,?_  B7AS]I
M#XNZ/X:?P_:VV_29(+.PG3]Y_HK[WV)_X_6WV^0GV?VSWRL_Q)XMTWPE9PS:
MI?VMC#<7264+S/Y?F3.^Q$_WY*^:?VJ/B7XY\)?%?6_ ?AG7KJUUOXF65E/X
M-F_UG]ES0._]H(G_ &P1'_[:5B6?[2.O?&#P6GCS2]8NK'0=0\7^&?#UE;(_
M[O?O3^T/^_D\SP_]L*B$^8N5'E/JOQ?X\T?X?>'YM5UF_@L;"W=()YG_ -7&
M[NB(G_?QTK6KX4^(_@V'0?A/^T/#;^+=<DU+_A/+6#[->:BD_P!GWW6G.EUY
M+_Q_/]__ *9I7T5\"_[5\&_M >//!EUXG\0>)M-T_3M,U>U?6)TGN+=[K[4D
MZ;]B?)^Y1]G_ "SHA/F"5/E.PU3]H+P9HWBC4M'NM>@AOM'\G[;O1_L]F[[-
MB/-LV;Y-Z?)OW_O*[&OC/5+"_P#A+X?^.NO:3XG\3?;/^%C:?9;+G4?/MXT=
M]*W_ "?W_+?9_N5T>G_&GQ)#^UAJOA5?$-]?>#-/U'4+W2+S_H,:FEKO?0?.
M_C2#>[_]-/N?P5'/[A?L?Y#ZIK,U#QEINE^*--T2XO((]5UB":>RMO\ EI<)
M!LW_ /?O>E?)?P/^*'Q.O_ ]AXVBUNUUA]0\+ZGJFHZ;<^)4OI+R]2#? EMI
MZ0I]E\N=-CIO^Y]_YZN? _4+/5/VE/@Y>1?$O4O'E_K'@W4]4O8;R]@NOL<T
MZ6N]TV)^Y223>GD_],ZO[?)_7]>Z9\A]8ZYK5MX<T>\U*_FCM;/3X'NKJ9_]
M7&B)O=Z?H^J6VO:/;7]G-'/9ZA D\$R?\M$=-Z/7RI^UIXR;6?$GQ=TW6?B%
MJ7@>P\)^#4NM(L+:Z@@CU3[5!/O>9'3_ $K]XB0[/_9WJF/'DVJ:/JMGJGQ%
MUCP!#X'\ :-J.@PV%ZEK'>.]EO>Z??\ \?2>8B0[/N?]]U'/[LI_U]K_ .1-
M/8_U_P" _P#R1]?45\LZ/\7_ !/:_$#P'KWC#4M2^S>)++1;*/1]'U=()-'U
M.>#YTO=/^_,D[OOW_P#+/^XG^LJG^ROX\^(7Q+\4>$O$EYXAM=FJ7M[!XATV
MY\4)/'L3S_W$.F>2GV6>"1$_C^YOW[ZK[7*8^S]SF/K*N=\:?%70?A]KFCZ;
MJU_Y&I>('=-.MD@>>2XV???8B/\ )'O3>_W/WE>5_&SQ&^O?M(6?A+6?&VJ^
M _#<?A=];@FL-1339-0NO/V/^^?^""/8^S_II\]>:? O^V/C)\</@GXJ\0:]
MXDCUBX\&ZM._V:Z^RV^H)!>VJ).\.S[D\>QW3_EI\E.%3F_K_%_\B5R'V#5+
MQ1XHL/!OA^\U75KR'3=-T^#S[JYF?9';I_?>N&_:_P#%NI> _P!E?XA:YHUY
M)INJZ7H-U=6MS#_K+>9$^1Z\'^,'BWQ5\%O#?Q(L[?QSXFUA[CX7OXH@FU*=
M))-/U!)]CO#L3Y$DW_<^Y1[0<:/-K_7V?_DCZ]MY4NK='5_,21-Z/2U\N>,/
MBUXJT;XN7/PMBUN^CU7X@:AI&J>'KS?^\T_3'3_B:;/^N'V9_P#P+2L34/C!
MK<NEW/C"W\=:Q_PFUO\ $/\ X1Z#P>ETGV22U_M'R/LOV+[_ )GV7]]YWW_X
M_N4?:Y2/9^Z?5?A/QQI7C>SNIM)OX+Z'3[V;3IW3_EG- ^QT_P"V<E:=?)7P
M;^(S_#[QYX>676$TGP_K'Q)\9VNHO-.D%O<.F]X$=_\ KHC[*K>$_BAKWQSU
MSX;Z;9^/-<M='\6>,O%MK/?Z5=)'<7EE:[_(1'V?(D>SY'CHC4YH1-I4?B_K
M^;_Y$^OJCN+I+6W>:5_+2-/,=_\ GG7Q_P#!_P ;^,-+M_ACXDO_ !YXFUQ]
M8\?ZAX*NK.\>#[)<64#WR([HB?/=?Z,C^=_K/OT_P/\ 'B\\3_'#PV^EZWXF
MNO#WCC3O$'GVVMZ]:W4EPEK ^QTLD_X\O+D1T_W/O_/43G[O.'L?>Y3ZQ\'^
M+=-\>>%[#6]&O(]2TK5($NK6YA_U=PC_ ''K0KXL_8G\6S>'-#_9^M=#^(6I
M>)O^$HT2:UUO09KJ">TT^&"UWHZ0HG^B^7)L3_IIYGSU]IUM/8YPHHHI %%%
M% #H/^/A/]^O?D_U8^E> P?\?"?[]>_)_JQ]*YJVYZ>6_:/&?B%_R.NH_P"]
M_P"R5Q__  F6F_\ "9_\(]]I\S6/L7]HO;(G^KAW[-__ '\KL/B'_P CMJ7^
M_P#^R5\E_$CQ;J7AC6/VHM;L[F2QUOP_X>T_^SID_P!9;PIIT\Z.G_;=YJTY
MN6',<G)S5N0^FJ*^+_%GQDUCP;X;\0S>%_B=K'C'^T/A?>^*+VY>]@NO['U!
M-GD3P[$_<^9OF_<_],*[G4+74M!\:?#WP9KWQ+\8V.C^*-'O=>O=8FU1+6[U
M"]1+79:I-L_<P>6\TWDI_P \ZO[7)_7VO_D2/9_;_K^O>/I>BOA?Q!^TWKTO
M@_PK8:SXP\0?8+R#Q FG:QINKV6CW&N?9;WR-/NGN9G2-T\O[_E_ZS[^S97I
M?POT;Q5KWQX\*^&-4^(OB.>ST/P!IFMWJ:;J*21ZYJ'VIT=WFV?/!_Z,391"
M?,*5'E/IVBOD'X!_$;XB_$'5-$\3W'B?3=-^V:CJ$&O6>I>*$DM[>%//3R$T
MSR4\EX)$1_O_ '(WW_?JSX/\9>*M0^&?B3PJOC"ZC\?Z>^F75]?WGBR"?3-8
MAG=]Z:?>[/\ 0GGC1_DV?N_D_P!^CV@YT3ZUJ.XF2UMW>7]VD:;W>OC_ %#X
MYZW\2]0\ :#X?U+Q-IN@ZAI&K3O-J7BM-*O[S4+6]\AX/[01)TF\OYW_ '?^
ML3YWWU<O/&_B'6=0L-%\??$[_A%?['\!_P!MIJ6B:I!'::Y>^?.CSN[ILF2-
M$A^39L_?U,JGN%^Q/JCPOXHL/&_ANPUC2;F.^TW5($NK6Y3_ %=PC_<>M"OF
MCPW\0=5^&G_!+?PQKVAW/D:A9^%],_T_R/,^QH_D)/=;/^F<;N__ &SKB?CG
M\4->^$MOXYT?P/\ $CQ!X@TVW\-:9JG]JW.HIJ5QH=[/JD$'R3;/^6\#N^R3
M_GG6L_BY"*<.8^S:YK_A<GA+_A/_ /A%?^$G\/\ _"3_ /0*^VI]K^YO^Y]_
M_5UP?P/_ +8\&_M">/\ P9=>)_$'B;2]/T[2=7M7UB=)[BWFNOM23HCHB?)^
MY3Y/^6=<'9^*(?@%\=+:V\/Z]X1\:>&_B)XU?S]'\Q)-:\/ZG/O\^='3[\$>
MSYTD1'C3^.H]H"I_$>WZQ\?? WASQA'X>O\ QAX9L=>D=$^P3:I!'<;W^XFS
M?]^KGQ ^+_A+X5?9O^$H\2:'X?\ MG^H_M*]2U^T?[F^OEKP/XM\#6'_  3W
M\9:/XMNM'_X2>X_MJ#Q#IMRZ?VG>:T\\^SY/OO/))Y.S_@&RM[]G?6;#P'\>
M/%2?%"_TK3?%LGA3P^EE-K$Z1^99)9?Z4D+O_P!/7G;_ /MG1[0N5,^D-#^(
M.C^(_$%YI5A?P75_9VL-\Z)_SQGW^1.C_P :2;'_ -76S7B5G?V$O[9'@:;P
MY]ADT?5/ &H?/9_\>\EJEU:_9=FS^#YWV5[;5&-0****"0HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "O9?AM_R)%C_ -<Q7C5>R_#;_D2+'_KF
M*QQ!WY;\1OCI10.E%<I[(4444 %%%% #<?/7G/[1A_XDNG?]=G_] ->C9^>O
M.?VC/^0+IW_79_\ T$U=+XS*M\!XWJFEV>O:?-9ZA;6M]9W'R3PW,"3QR?[Z
M/4/A_P +Z;X2M/LVDZ;INE6V_?Y-G:I!'O\ ]Q*O45TGF&1I?@/0="^V?8-$
MT>Q_M3_C]^S621_;/]_Y/G_[:46GP^\/6'A^;1[?0=#AT>X_U]@FG01VDG^^
MFS96O10!4\/^'+#POIZ6>EV%CI5G']R&S@2"./\ X E9NG_"_P ,:7J#WEKX
M;\.6MY)OWW,.EP1R2;_O_/LK=HH R-/^'WA_2_#\VE6N@Z':Z5>?Z^SALH([
M>X_WTV;'IC_#3PW+I]G9MX>\/R6>EOOLH7TZ#R[-_P#839\G_;.MJB@"C)X2
MTJ2W>%M*TZ2&2U^Q.GV5/+DA_P">'^Y_L56L_ >@Z7H\VFV^B:/!87">1/;0
MV21V\B?W'39LK7HH HV?A?2M,M_)M]-TV"'R$M=D-JD<?D)]Q/\ <_V*K:7X
M#T'1M'?3;/1-'M=-D?>]G#9)'!(_]_9LV5KT4 11V$,5X]RD,$=S(FQYMG[R
M1$^Y\]2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!WW[.__ "-]Y_UZ_P#LZ5Z-\4/^2?ZI_P!<#7G/[.__ "-]Y_UZ
M_P#LZ5Z-\4/^2?ZI_P!<#7/4^,[J'\(^=KRUAO[.:&X6.>&XC\MT?_EHE<EX
M8^ _AC0? ^B:#>:5IOB"V\/VOV*RFU6R@NKB.'^!/G3_ '$_[9UV5%=!PF+J
M'PY\/:IH]G8W7A[0YK#3WWVMM-IT$EO;_P"XFS8E4_C!\+[/XR?#?4O#%_-/
M:V>J(B/-#_K(]CH__LE=-10!D:?X#T'2]'O+"UT31[2PU#Y[JVALDCM[C_?3
M9\]%OX#T&UT.;38M$T>#3;A-D]FEDD=O(G^VFS96O10!1M_"^E6%N\-OINFP
M0W$"6KHEJD<<D*?<1_\ 8_V*K:/\/M!\.6?V:PT'0[&V\_[5Y-MIT$$?G_W]
MB)]__;K7HH HZAX7TW5+.\ANM-TZZAU#_CZ2:U22.\_W_P"_56W^'V@VNII?
MV^B:/:ZE;P>3!>0V4$=Q;I]S8C[*V** .?\ !_POTKP'\.T\,:6DD-A'!/!O
M=_,DD=]^]W?^-Y)'=ZH?![X(^'O@MX+TW1]+L+%WT_3H=+>_>U2.[U!$39^^
M=$^>NOHH HWGA?3;_P /_P!E7&FZ;/I6SR/L;VJ26^S^YL^Y7'_$CX!6'C>S
M\/?V3>2>%;GPO.\^EO864$EO;[TV/_HKIL_CKOJ* .0^$?P1T?X0:']FM?,O
MKRXO;K49[^Y@2.XDFNO]>Z;$1$23Y/DC_P">=;=QX#T2_P#$B:Q<:)H]QK%O
M]R_>R22[C_X'LWUJ45>H&+!\.?#UK]O\K0=#C_MC_C]V:=!']L_Z[?)\_P#V
MTIW_  K[P]_PB_\ 8G]@Z'_8_P!_[!_9T'V3_OSLV5L45 &1<?#[P]=>'X=*
MET'0Y]*LWWP6;Z=!);V[_P"PFS8E:.GV$.E6_DVL,%K#OW[(4\N.IJ*O4#(T
M?P'H.@QWB6&B:/8IJ'_'ZEM9)!]L_P!_8GSU?CT:SBN(76SM8WMX/(@=($\R
MW3^XG^Q5BBH R[SP/HFJ>((=5NM$T>?5;?\ U%_-9))<1_[C[-],USP'H/BG
M5+:\U+1-'U*\L_\ 47-S9)/);_[CNE:]% %'7_#FF^+=/^QZMIMCJMGOW^3>
M6J3Q_P#?#UC_ /"I=*_X3_1]>5/(?P_ITVG:=9PHD=I9I.Z;W1/[_P B)734
M4 %%%% !1110 4444 %%%% !1110!L?#_P#Y'G2O^OI*^BT^[7SI\/\ _D>=
M*_Z^DKZ+4_+6-<[L+L4+'_D8+S_KC#_[/5C4/^/";_KF]5['_D8+S_KC#_[/
M5C4/^/";_KF]8G4>!UDZQX#T'7M8MM2O]%T:^U*S_P!1>7-DD]Q;_P"X[IYB
M5K45Z!\N9.L?#[0?$>L6VI:EH.AZEJ5G_J;RYLH)[BW_ -QW3?5]["VEU#[2
MUM#)<[/(\[9^\V?W-_\ SSJ>BEJ!2M_#FFVMO9I%8V,":?\ /:HD"1_8_P#<
M_N5-IVEVVE^=]EMH+7[0[SOY*>7YCO\ ?=_]NIZ*8&9H_@C1/#FH7EY8:/I5
MC>:A\]U<VUDD$EY_ONGWZK:'\+_#'A?5/M^E^&_#FFWG_/S9Z7!!<?\ ?:)6
MY12U @N-&L[K4+:\EMK62\L]_D3/ DDEOO\ O['_ (*K6_A?2[73TLXM-TV.
MVCG^U)"EJGEQS;_,W[/[_F?QUH44:@9EQX(T2ZU2YO)=$T>>\O$1+JY>R222
MX1/N;WV?/5R.PMHM0>Y6&".YN$1'FV?O)$3[GSU/11J!2N/#FFW,<R2V%C(E
MY/Y\Z/ G^D/_ 'W_ +[_ ")_W[I8_"^FQ1PHNFZ;&EO/]J@3[*G[N;^^G^W\
M[_/5RBC4#)TOP'H.@:Y<ZK8:)H]CJ5Y_K[RVLDCN+C_?=$WO1H?@/0?"]P\V
MFZ)H^FS2.[N]M9)!)O?[[_(E:U%&H&9K'@[1_$>H6UYJ6CZ5J5Y9_)!-<V23
MR6_^X[_<IFL?#[0=?N+![_1-'OGTO_CR>YLDD^Q_[F]/D_[9UK44P,RX\$:)
M=>*$UR71]*DUB--B7[V2?:XT_P"NWWZ9;_#[0;#Q(^MP:)H\&L7'W[]+%([N
M3_MMLWUK44M0,SQ'X.T?QE;PPZSH^E:Q#;OO@2_M4NHXW_OIOJY_9=M]LAN?
MLT'VFW3R()MG[R-/[B?[%3T4P(-0L(=4LYK:ZA@NK:X39)#,GF1R)_MI4-YX
M<TW5/,^T6%C/YD'V5_.@23S(?[G^Y_L5=HH JR:-9RZA#>-9VLEY9H\$%SY"
M>9;H_P!]$?\ @JM_PA&B_P#"4?VY_8^E?VWLV?;_ +$GVO9_UV^_6G10!F:I
MX(T36-+>PO-$T>ZL))_M3VTUDDEO)/\ W]FS[_\ MU-;^'--M9(7BTVQ@>W=
MW@=+5(_L[O\ ?=/[GF5=HH IQ^'--CCA1;&QC2WG^U0(EJG[N;^^G^W\[_/_
M --*JZ?\/M!T;4)KRUT'0[2\N'=Y[F&R@CDD=_ON[[*UJ*6H&9H_@C1/#FH3
M7FFZ)H^FWEPB0SS6UDD$DB)]Q'=$K3HHI@%%%% !1110 Z#_ (^$_P!^O?D_
MU8^E> P?\?"?[]>_)_JQ]*YJVYZ66_:/&?B%_P CKJ/^]_[)7DOQ+_9STKXE
MW'BJ:6\OK&;QAX:?PUJ/V;9^\AWOL?\ WX][_P#?RO6OB%_R.NH_[W_LE8M;
MJGS0..I4Y*GN&!X;^%^@^$M#FT^ST?2H(;R!(+W9901_VA\FS]]\GS_]M*O^
M(/!NC^+=+2PU;2M*U6SC?>EM>6J3QQ_\ >M"BJ,3S;XF?LYIXW\6:;K>DZ]?
M>&;[3].?2(_LUE:W5O\ 97??L\F9'1'^3[\==)\)_A!HGP<\%Z5HFC6WEPZ/
M:_8H+F;9)<2)OW_._P#UT=W_ +E=+12U QHOA]X>B\23:PN@Z''K%Q\CW_\
M9T'VN3_@>S?45O\ "GPK:^'[G2HO#'AR/2KQ_/GLTTN".WN'_ONFS8];U%&H
M&-JGPY\/:SX?MM*O-!T.ZTJS_P!19S:=!);V_P#N)LV)3]0\!Z#JL=@EUHFC
MW2:/_P >23622?8_^N/R?)_VSK6HHU @M]+MK73_ +'%;01V>S9Y*)^[V?W-
ME9NE_#[P]H.CS:;8:#H=C87#[Y[:VTZ".WD?^^Z;-E;-%,"".PABU![I8;>.
MYN$1'FV?O)$3[F]ZH6?@/0;#Q)-K%OH>CP:Q<??OTLDCO)/^![-]:U% &3<?
M#[0;_P 4)K<N@Z'/K$?W+][*"2[C_P"VVS?3_%/@C1/&\<,>LZ)H^L?9WWP?
M;[)+KR_]S?6G12U YK2_A?8Z7\4-2\6[YY-2U#3H=(1'_P!79VL#N^Q/^NDC
M_/\ ]<TKI:**8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7LOPV_Y$BQ_P"N8KQJO9?AM_R)%C_US%8X@[\M^(WQTHH'2BN4]D**** "
MBBB@ KF_B/X$_P"$\T5+?SO)FA?S$>NDHH \9?\ 9[U5?^7O3_S?_P"(J"X^
M ^JVO_+S8_\ C]>TO*N/O)5.X*2_\M(ZT]I,P]C \3N/A5?6OWF@JM)\/[R(
M?\LZ]CN;6.4_\LZK26$/_3.CVE0/8P/(O^%?WG_3.C_A7]Y_TSKUK^RX?^F=
M']EP_P#3.CVE0/8P/)?^%?WG_3.C_A7]Y_TSKUK^RX?^F=']EP_],Z/:5 ]C
M \E_X5_>?],Z/^%?WG_3.O6O[+A_Z9T?V7#_ -,Z/:5 ]C \E_X5_>?],Z/^
M%?WG_3.O6O[+A_Z9T?V7#_TSH]I4#V,#R7_A7]Y_TSH_X5_>?],Z]:_LN'_I
MG1_9</\ TSH]I4#V,#R7_A7]Y_TSH_X5_>?],Z]:_LN'_IG1_9</_3.CVE0/
M8P/)?^%?WG_3.C_A7]Y_TSKUK^RX?^F=']EP_P#3.CVE0/8P/)?^%?WG_3.C
M_A7]Y_TSKUK^RX?^F=']EP_],Z/:5 ]C \E_X5_>?],Z/^%?WG_3.O6O[+A_
MZ9T?V7#_ -,Z/:5 ]C \E_X5_>?],Z/^%?WG_3.O6O[+A_Z9T?V7#_TSH]I4
M#V,#R7_A7]Y_TSH_X5_>?],Z]:_LN'_IG1_9</\ TSH]I4#V,#R7_A7]Y_TS
MH_X5_>?],Z]:_LN'_IG1_9</_3.CVE0/8P/)?^%?WG_3.C_A7]Y_TSKUK^RX
M?^F=']EP_P#3.CVE0/8P/)?^%?WG_3.C_A7]Y_TSKUK^RX?^F=']EP_],Z/:
M5 ]C \EC^'UY_P!,ZLVWPJO[K[LD%>J1V$/_ $SJS;VL,7_/.CVE0/8P/,;?
MX&:E=?\ +S8_^/U8_P"&>-5_Y^]/_P#'_P#XBO6+<I%_RTCJXDJX^\E'M)A[
M&!QOPM^%C>!9KFZN+E9[BX78-G"(E=3KVD)KFDW%G)_J[A"AJV&^6@MQ6?F:
M<JMRGC\W[.^HH_RW]BZC[@??Q5>X^ 6JQ?\ +Y8_^/U[,\J_WJAGD23^Y6GM
M)F?L8'B%Q\(-2M?O36O_ (_523X<W\7\4%>RW%LDO\=4Y+"'_IG1[2H'L8'D
M7_"O[S_IG1_PK^\_Z9UZU_9</_3.C^RX?^F='M*@>Q@>2_\ "O[S_IG1_P *
M_O/^F=>M?V7#_P!,Z/[+A_Z9T>TJ![&!Y+_PK^\_Z9T?\*_O/^F=>M?V7#_T
MSH_LN'_IG1[2H'L8'DO_  K^\_Z9T?\ "O[S_IG7K7]EP_\ 3.C^RX?^F='M
M*@>Q@>2_\*_O/^F='_"O[S_IG7K7]EP_],Z/[+A_Z9T>TJ![&!Y+_P *_O/^
MF='_  K^\_Z9UZU_9</_ $SH_LN'_IG1[2H'L8'DO_"O[S_IG1_PK^\_Z9UZ
MU_9</_3.C^RX?^F='M*@>Q@>2_\ "O[S_IG1_P *_O/^F=>M?V7#_P!,Z/[+
MA_Z9T>TJ![&!Y+_PK^\_Z9T?\*_O/^F=>M?V7#_TSH_LN'_IG1[2H'L8'DO_
M  K^\_Z9T?\ "O[S_IG7K7]EP_\ 3.C^RX?^F='M*@>Q@>2_\*_O/^F='_"O
M[S_IG7K7]EP_],Z/[+A_Z9T>TJ![&!Y+_P *_O/^F='_  K^\_Z9UZU_9</_
M $SH_LN'_IG1[2H'L8'DO_"O[S_IG1_PK^\_Z9UZU_9</_3.C^RX?^F='M*@
M>Q@>2_\ "O[S_IG1_P *_O/^F=>M?V7#_P!,Z/[+A_Z9T>TJ![&!Y+_PK^\_
MZ9U-;_#"_E_Y:05ZI]@A_P"F=6;>PAH]I4#V,#S&W^"VI77_ "\V,?\ WW5M
M/V?]5?\ Y?-._P#'_P#XBO4K.)(OXXZO02I_>CH]I,/8P/-_ _P-N-#UZWO+
MV\AD6V?>B1#&_P"M>G,N11OS]VG5FY7-(4U'1&?8_P#(P7G_ %QA_P#9ZO/%
MYL>UJHV/_(P7G_7&'_V>M"@L\ROO@I>&=_LMW;"'^#S-_F"J\_P;U*+_ )>;
M'_Q^O4F=>]03R)_?2M/K$SE^I43R6X^'-_:_Q053D\)WD7_/.O5+R))?XXZI
MR6$/_3.CZQ,/J- \Q_X1VY_NT?\ "-W/^17I'V"'_IG1_9</_3.CZQ,/J- \
MW_X1NY_R*/\ A&[G_(KTC^RX?^F=']EP_P#3.CZQ,/J- \W_ .$;N?\ (H_X
M1NY_R*](_LN'_IG1_9</_3.CZQ,/J- \W_X1NY_R*/\ A&[G_(KTC^RX?^F=
M']EP_P#3.CZQ,/J- \W_ .$;N?\ (H_X1NY_R*](_LN'_IG1_9</_3.CZQ,/
MJ- \W_X1NY_R*/\ A&[G_(KTC^RX?^F=']EP_P#3.CZQ,/J- \W_ .$;N?\
M(H_X1NY_R*](_LN'_IG1_9</_3.CZQ,/J- \W_X1NY_R*/\ A&[G_(KTC^RX
M?^F=']EP_P#3.CZQ,/J- \W_ .$;N?\ (H_X1NY_R*](_LN'_IG1_9</_3.C
MZQ,/J- \W_X1NY_R*/\ A&[G_(KTC^RX?^F=']EP_P#3.CZQ,/J- \W_ .$;
MN?\ (H_X1NY_R*](_LN'_IG1_9</_3.CZQ,/J- \W_X1NY_R*/\ A&[G_(KT
MC^RX?^F=']EP_P#3.CZQ,/J- \W_ .$;N?\ (H_X1NY_R*](_LN'_IG1_9</
M_3.CZQ,/J- \W_X1NY_R*/\ A&[G_(KTC^RX?^F=']EP_P#3.CZQ,/J- \W_
M .$;N?\ (J:W\&WDO_/.O0OL$/\ TSJ:WL(?^F='UB8?4:!PUO\ #6_NO^6T
M%7(_@MJ4O_+S8_\ C]=_9Q)_?CJ]#+&?XDH^L3#ZC0//=(^"MQ]OCDNKR'RD
M?>XA_P"6E>DH-JTP%3T-24I5'+<THT(4_@.#\;?"B;7=::\L[B&/S_\ 6)*.
MM8TGP6U*+_EXL?\ Q^O42>:C:5<?>CI^TF93P5*;YV>37'POO[7_ );6LE4+
MCP;>1?\ /.O6KR))?XZH7%A#+_SSH^L3']1H'EW_  C=S_D4?\(W<_Y%>D?8
M(?\ IG1_9</_ $SH^L3#ZC0/-_\ A&[G_(H_X1NY_P BO2/[+A_Z9T?V7#_T
MSH^L3#ZC0/-_^$;N?\BC_A&[G_(KTC^RX?\ IG1_9</_ $SH^L3#ZC0/-_\
MA&[G_(H_X1NY_P BO2/[+A_Z9T?V7#_TSH^L3#ZC0/-_^$;N?\BC_A&[G_(K
MTC^RX?\ IG1_9</_ $SH^L3#ZC0/-_\ A&[G_(H_X1NY_P BO2/[+A_Z9T?V
M7#_TSH^L3#ZC0/-_^$;N?\BC_A&[G_(KTC^RX?\ IG1_9</_ $SH^L3#ZC0/
M-_\ A&[G_(H_X1NY_P BO2/[+A_Z9T?V7#_TSH^L3#ZC0/-_^$;N?\BC_A&[
MG_(KTC^RX?\ IG1_9</_ $SH^L3#ZC0/-_\ A&[G_(H_X1NY_P BO2/[+A_Z
M9T?V7#_TSH^L3#ZC0/-_^$;N?\BC_A&[G_(KTC^RX?\ IG1_9</_ $SH^L3#
MZC0/-_\ A&[G_(H_X1NY_P BO2/[+A_Z9T?V7#_TSH^L3#ZC0/-_^$;N?\BC
M_A&[G_(KTC^RX?\ IG1_9</_ $SH^L3#ZC0/-_\ A&[G_(H_X1NY_P BO2/[
M+A_Z9T?V7#_TSH^L3#ZC0/-_^$=N?[M/C\)7,O\ SSKT7[!#_P!,ZFM["'_I
MG1]8F'U&@<!;_#F\NO\ EI!5^W^#>I2_\O-K_P"/UWEO:I_?CK2M]A_YYT?6
M)A]1H'G,?P2O]_S7=EM_X'7H?A_2$T+1[:SC^9;=-@:K D0'[U2U,Y\^YI2H
M0I_ %%%%2;!1110 4444 %9/BN5XK--O_+1ZUJQ?&!_T>'_?H P/F]J/F]J6
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH 3YO:CYO:EHH V/",C^>R?P;*U]6D:'3I
MF7[P6L7PC_Q_M_N"MC6O^01-_N4 <E2?-[4M% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4GS>U+10!:T21H]3A"_W\5UU<;I'_(4A_P!^NRH S['_ )&"\_ZXP_\
ML]7I/N&J-C_R,%Y_UQA_]GJ]-_JF^E '%22^:^]OWCTWYO:EHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "D^;VI:* )+>9[6X1U_=O7:5Q$?^LKM8_N"@#E=?E:75
MIMW_ "SJE\WM5O7/^0O-_OU5H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D^;VI:*
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MJ>;W>8KE][E/M;6/$D.C:QI5A+;:E)-K#ND#PVKO;Q[$W_OG_@_[:5I>6_\
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M/PTUK7+Y?%'BB;_A+/!]YI<WV33]_F276HPS.B>3^\1'^^Z3^9\E:_:Y"/\
MEV>_?"_XC6'Q5\%VVMZ>D\$-P\T#PS)Y=Q;S0.Z.C_[<<B/705X1^S7\0=*\
M&1^*DO[GR+;Q9\3=6T[042!Y/M$W\:?)_P!-(9OG^Y7N]1]CG#[?(3:1_P A
M2'_?KLJXW2/^0I#_ +]=E0!GV/\ R,%Y_P!<8?\ V>KTW^J;Z51L?^1@O/\
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M_OUV5<;I'_(4A_WZ[*@#/L?^1@O/^N,/_L]7IO\ 5-]*HV/_ ",%Y_UQA_\
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M^$OB_;VR>*O#'ASQ,EG\\":KIT-U]G_W-Z?)1]GD*M[W.?+W[.WQ+\,?'?\
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M'/$%Y9H\$$VI:7!=21H_WT1W3[E ?;YSP/2_&7C3XE_'CQ\[>-M4TKP]X/\
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M7_)L_<_W/W?R?N_X* /BRR_:"U[Q;J=];PZ]XQUCP?X\^&WB#7K7_A()]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** %C_UE=K']P5Q4?\
MK*[6/[@H Y/7/^0O-_OU5JUKG_(7F_WZJT %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;5G_ ,_,=7?^$;C_ +E'_"-Q_P!R@"E_;5G_ ,_,=']M6?\ S\QU=_X1N/\
MN4?\(W'_ '* *W]LVW_/:.GQ722_=>K,?AQ/[E7++1DB_@H IQVKR_=21Z?_
M &/=?\\9*WK.U\JK\<= &3X:TN:VG::5?+^396E?6WVNSD3_ )Z)BK%% '(R
M:/>1_P#+%Z9)831?>ADKKWZ57N(O-- ''R2^5]ZH1JEM$?FFCK>O-+26LV3P
MXG]R@"G_ &S;?\]HZC_MJS_Y^8ZN_P#"-Q_W*/\ A&X_[E %+^VK/_GYCH_M
MJS_Y^8ZN_P#"-Q_W*/\ A&X_[E %+^VK/_GYCH_MJS_Y^8ZN_P#"-Q_W*/\
MA&X_[E %+^VK/_GYCH_MJS_Y^8ZN_P#"-Q_W*/\ A&X_[E %+^VK/_GYCH_M
MJS_Y^8ZN_P#"-Q_W*/\ A&X_[E %+^VK/_GYCH_MJS_Y^8ZN_P#"-Q_W*/\
MA&X_[E %+^VK/_GYCH_MJS_Y^8ZN_P#"-Q_W*/\ A&X_[E %+^VK/_GYCH_M
MJS_Y^8ZN_P#"-Q_W*/\ A&X_[E %+^VK/_GYCH_MJS_Y^8ZN_P#"-Q_W*/\
MA&X_[E %+^VK/_GYCH_MJS_Y^8ZN_P#"-Q_W*/\ A&X_[E %+^VK/_GYCH_M
MJS_Y^8ZN_P#"-Q_W*/\ A&X_[E %+^VK/_GYCH_MJS_Y^8ZN_P#"-Q_W*/\
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M>='_  BZ?\\Z ,_^VK/_ )^8Z/[:L_\ GYCK0_X1=/\ GG1_PBZ?\\Z ,_\
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M1_PBZ?\ /.@#/_MJS_Y^8Z/[:L_^?F.M#_A%T_YYT?\ "+I_SSH S_[:L_\
MGYCH_MJS_P"?F.M#_A%T_P">='_"+I_SSH S_P"VK/\ Y^8Z/[:L_P#GYCK0
M_P"$73_GG1_PBZ?\\Z ,_P#MJS_Y^8Z/[:L_^?F.M#_A%T_YYT?\(NG_ #SH
M S_[:L_^?F.C^VK/_GYCK0_X1=/^>='_  BZ?\\Z ,_^VK/_ )^8Z/[:L_\
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M'VQ_[]1T4 2?;'_OT?;'_OU'10!)]L?^_1]L?^_4=% $GVQ_[]'VQ_[]1T4
M2?;'_OT?;'_OU'10!)]L?^_1]L?^_4=% $GVQ_[]'VQ_[]1T4 2?;'_OT?;'
M_OU'10!)]L?^_4GVZ;_GI5>B@"Q_:MS_ ,]FIW]KWG_/:2JM% &MI&NW)U!$
ME?S$DDV5T5<;I'_(4A_WZ[*@#/L?^1@O/^N,/_L]:%9]C_R,%Y_UQA_]GJ]-
M_JF^E &#<>+',G[M$V?[9J+_ (2R;^ZE9E% &A)XCFE_ACIO]O/_ '8ZHT4
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MQ&\?\$=3)XLFC'^I2LFB@#8_X3"7_GBM;5I<B[MDD7_EIS7&UU6@_P#()AH
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MQ/\ !OPW<?$CQ=:Z'JB>+1/JNE3)#>>*++3[V".RG>;9_&G\<?W_ /@=$/>
M^VJ*^,_ GQ"^)7Q ^-FI7D7B2QTVX\/_ !#?1)]-O_%R00?V8D_E_9?[,^R_
M///!\Z3[][O)\G[OY*I^)_V@_%OP<T?XHI_PD.I>*O&W]@ZGKV@ZE8:U#JN@
M_8DNHT1_L2)_H4\$;I\FQXW\M_G>C['.'V^0^V*;<2I:Q.\KQQI']]WKXA\8
M>-_B+\/OV?\ XEZQ8>/(_P"S?^$>T^ZTNY3QDGB/4[.]>Z1'ND?R4V021O\
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MV-/[B?W$^1*MT4 9%Q\/=!O_ !3#KEQH.ASZW;_<U)].ADNX_P#MMLWT_1_
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M7:UYCXE_:J\,Z?\ %?PQX3TG4M#\0:MKFMOHNHPV>J027&ANEK//OF1-[_\
M+'9L^2@#6\/_ +.?@SPEJ&CW-AHB03>'TU!++?=3R?9TU!]][]]_G\R3^_\
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MEX@\;6NI:QX@\5Z%XHG>VT3[+;V_]E[/]%1/.?Y'V??D?_ONOH2BC^OZ_P#
M0/"/C!^Q1#\5=8\8:DVL6,=YKGB'2?$NG)>:7]JM+.:RM?(V30N_[Y)(]_\
M<_UE>A? _P"&EU\+] O+>ZA\'6]Q>77G[/#>B?V5:;-G]S>^]_\ ;WUVM% '
MCO[6?[/'BK]H>W\/Z?HGBW1M T72[[[=JFE:EHCZC;ZXZ?ZA)MD\'[B-_GV?
M\M/DWTSXZ? ?Q_\ &[]G>3P3<>-/"MCJ6J0>1J^I)X:GDM[A-^]/)A^U?N?N
M?WWKV6B@/[YG>#[76+7PW;)KUYIM]K$:?Z5<V%J]K;R?[B.[[/\ ONM&BB@
MHHHH **** "BBB@ HHHH **** "BBB@#5\(_\?[?[@K8UK_D$3?[E8_A'_C_
M &_W!6QK7_((F_W* /*/CCX;U[QE\'_$FC^&=0M=)U[6-/FLK*\N=_EV;O\
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M .2/CSXC_L^^+=>^'_QL\+:7X2O[6\UCQE!XHTZ_A^RQV_B#3_/L9WM87?\
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M^_/_ -_* +U%4?\ A%V_OS_]_*/^$7;^_/\ ]_* +U%4?^$7;^_/_P!_*/\
MA%V_OS_]_* +U%4?^$7;^_/_ -_*/^$7;^_/_P!_* +U%4?^$7;^_/\ ]_*/
M^$7;^_/_ -_* +U%4?\ A%V_OS_]_*/^$7;^_/\ ]_* +U%4?^$7;^_/_P!_
M*/\ A%V_OS_]_* +U%4?^$7;^_/_ -_*/^$7;^_/_P!_* +U%5(_##_WY_\
MONKEGX<>(_?D_P"^Z $HK9T_1DB^]6K!8P@?ZF/_ +XH YO2(WDU.';_ 'ZZ
MZHH(4B^ZBI4M &?8_P#(P7G_ %QA_P#9ZO/]QJHV/_(P7G_7&'_V>M"@#AZ*
MZJ?0;:63?LYJK<>'(?X4H Y^BK6H:,\7W:S;BPO/X7_\<H L45G_ &74/^>W
M_D.C[+J'_/;_ ,AT :%%9_V74/\ GM_Y#H^RZA_SV_\ (= &A16?]EU#_GM_
MY#H^RZA_SV_\AT :%%9_V74/^>W_ )#H^RZA_P ]O_(= &A16?\ 9=0_Y[?^
M0Z/LNH?\]O\ R'0!H45G_9=0_P">W_D.C[+J'_/;_P AT :%%9_V74/^>W_D
M.C[+J'_/;_R'0!H45G_9=0_Y[?\ D.C[+J'_ #V_\AT :%%9_P!EU#_GM_Y#
MH^RZA_SV_P#(= &A16?]EU#_ )[?^0Z/LNH?\]O_ "'0!H45G_9=0_Y[?^0Z
M/LNH?\]O_(= &A16?]EU#_GM_P"0Z/LNH?\ /;_R'0!H45G_ &74/^>W_D.C
M[+J'_/;_ ,AT :%%9_V74/\ GM_Y#H^RZA_SV_\ (= &A15'[)??\]O_ !RI
MK>PO/XG_ /'* +%%7=/T;S?O5JV^@V_\24 <]'_K*[>J,&A6MK)O6'YJO4 <
MCKW_ "%IO]^JM=9?:-;W[[I4RWK56X\.6W\/F?\ ?= '.T5H:AHWE#Y:RKBU
MO(?NO_XY0!+15'RM0_YZ1_\ ?%,\K4/[R?\ ?% &C16=Y6H?WD_[XH\K4/[R
M?]\4 :-%9WE:A_>3_OBCRM0_O)_WQ0!HT5G>5J']Y/\ OBCRM0_O)_WQ0!HT
M5G>5J']Y/^^*/*U#^\G_ 'Q0!HT5G>5J']Y/^^*/*U#^\G_?% &C16=Y6H?W
MD_[XH\K4/[R?]\4 :-%9WE:A_>3_ +XH\K4/[R?]\4 :-%9WE:A_>3_OBCRM
M0_O)_P!\4 :-%9WE:A_>3_OBCRM0_O)_WQ0!HT5G>5J']Y/^^*/*U#^\G_?%
M &C16=Y6H?WD_P"^*/*U#^\G_?% &C16=Y6H?WD_[XH\K4/[R?\ ?% &C16=
MY6H?WD_[XH\K4/[R?]\4 :-%4?*U#_GI'_WQ3[>UO_XG_P#'* +=%3V>ES2_
M>K5@\.0R_>\S_OY0!AUU6@_\@F&H4\,6?]V3_ONM)(O*CVK0 ZBBB@ HHHH
M**** "JMU>K81Y9+A_\ <1GJU1G% &?_ &]'_P \;[_P&?\ PIKZS'_SPO?_
M  &>M*B@#(_M2'_GA??^ LE+]OA_YX7O_@+)6MNHW4 8W]JP_P#/M?\ _@*]
M']JP_P#/M?\ _@*]:4DM,^WT 4/[5A_Y]K__ ,!7H_M6'_GVO_\ P%>KGV]/
M:C[>GM0!3_M6'_GVO_\ P%>C^U8?^?:__P# 5ZN?;T]J/MZ>U %/^U8?^?:_
M_P# 5Z/[5A_Y]K__ ,!7JY]O3VH^WI[4:A<I_P!JP_\ /M?_ /@*]']JP_\
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M_P#X"O1_:L/_ #[7_P#X"O5S[>GM1]O3VH I_P!JP_\ /M?_ /@*]']JP_\
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M[7W_ ("O1]OA_P"?:^_\!7JW]O3VH^WI[4 5/M\/_/M??^ KT?;X?^?:^_\
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M_P#@*]:7V]/:C[>GM0!F_:H?^>-[_P" KT?:H?\ GC>_^ KUI?;T]J/MZ>U
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M?^ D_P!I8Y?\O9GT!_P]2_:)_P"BN>*OR@_^(IG_  ]-_:(_Z*UXJ_\ (/\
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M (>F?M#?]%:\5?\ D#_XBO$/$'A+5O"4Z0ZMI6I:5-<)YZ)>6KP22)_?^?\
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M>F?M#?\ 16O%7_D#_P"(H_X>F?M#?]%:\5?^0/\ XBO J*?]FX/_ )]1_P#
M0_M+&_\ /V?_ ($>^_\ #TS]H;_HK7BK_P @?_$4?\/3/VAO^BM>*O\ R!_\
M17@5%']FX/\ Y]1_\!#^TL;_ ,_9_P#@1[[_ ,/3/VAO^BM>*O\ R!_\11_P
M],_:&_Z*UXJ_\@?_ !%>!44?V;@_^?4?_ 0_M+&_\_9_^!'OO_#TS]H;_HK7
MBK_R!_\ $4?\/3/VAO\ HK7BK_R!_P#$5X%11_9N#_Y]1_\  0_M+&_\_9_^
M!'OO_#TS]H;_ **UXJ_\@?\ Q%'_  ],_:&_Z*UXJ_\ ('_Q%>!44?V;@_\
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M_P /3/VAO^BM>*O_ "!_\17@5%']FX+_ )]0_P# 0_M+&_\ /V?_ ($>^_\
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M_ CWW_AZ9^T-_P!%:\5?^0/_ (BC_AZ9^T-_T5KQ5_Y _P#B*\"HH_LW!_\
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M7BK_ ,@?_$5X%14_V=A?^?4/_ 0_M+&_\_9_^!'OO_#TS]H;_HK7BK_R!_\
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M "!_\17@5)YOUJO[.P7_ #ZA_P" A_:6-_Y^S_\  CW[_AZ9^T-_T5KQ5_Y
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M,_\ UTWO_P!M*]7+:F8O&S6(OR?URGF9A3R_ZG"=#X_ZYC[4^$?Q5T3XN_\
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MX9B\G_//8C_[GW^N>"C3Q%&A'V-.<9_;EW]/F>A4J4*]:7M)P]E]B)8\*_\
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M'GX=Z9XH^):^#?!ND^-[]K;6YM,>::^'VJ_AA1+;_GI)OW_[";_<CR/X1?\
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M0ZC<VUJD$GVVU_U$Z?W-G^Q7'++<0X4[/WX__:__ ",CH>885<T(_:_^V_\
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M_O*^.?B!\>/%7Q0^*$WC+6]5DNM>DGAG\Y$\B./R-GD(D*?(B)L3Y*[+PO\
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M-+^%GQ*^(_B?5M+N9M5\*?VK=WLEK=):PV+OL=+6'?\ ?3^-Y*^(/B!X7O\
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M$/\ 9JB'R^ [K_P?7O\ \>H_UXR_^28?ZD9A_/$_!*BOW6U3_@BC^SQ%_JO
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M*ST=/)LK:\O7GCLT_N0H_P!S_MG677[3?\.:?@9_T)]U_P"#>Z_^+H_X<T_
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M\6:*_:;_ (<T_ S_ *$^Z_\ !O=?_%T?\.:?@9_T)]U_X-[K_P"+H_UXR_\
MDD'^H^8?SQ/Q9HK]IO\ AS3\#/\ H3[K_P &]U_\71_PYI^!G_0GW7_@WNO_
M (NC_7C+_P"20?ZCYA_/$_%FBOVF_P"'-/P,_P"A/NO_  ;W7_Q='_#FGX&?
M]"?=?^#>Z_\ BZ/]>,O_ ))!_J/F'\\3\6:*_:;_ (<T_ S_ *$^Z_\ !O=?
M_%T?\.:?@9_T)]U_X-[K_P"+H_UXR_\ DD'^H^8?SQ/Q9HK]IO\ AS3\#/\
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MGX&?]"?=?^#>Z_\ BZ/]=\O_ ))!_J/F'\\3\6:*_:;_ (<T_ S_ *$^Z_\
M!O=?_%T?\.:?@9_T)]U_X-[K_P"+H_UXR_\ DD'^H^8?SQ/Q9HK]J;;_ ((U
M? K^+P?=?^#>]_\ BZU=/_X(M_ &7_6^#+K_ ,'5[_\ %T?Z\9?_ "2#_4?,
M/YXGX@T5^\6G_P#!$S]G*8_O? UU_P"#Z]_^/5H)_P $/_V:O^A#NO\ P?7W
M_P >I?Z\9?\ R3,_]1\P_GB?@;17[[?\./OV:O\ H0;C_P '^H?_ !^D_P"'
M'/[-/_0@W7_@_P!0_P#C]+_7C+_Y)!_J/F'\\3\"J_J&^#?/PE\+?]@BU_\
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M#/\ H3[K_P &]U_\71_KOE_\D@_U(S#^>)^+-%?M-_PYI^!G_0GW7_@WNO\
MXNC_ (<T_ S_ *$^Z_\ !O=?_%T?Z[Y?_)(/]2,P_GB?BS17[3?\.:?@9_T)
M]U_X-[K_ .+H_P"'-/P,_P"A/NO_  ;W7_Q='^N^7_R2#_4C,/YXGXLT5^TW
M_#FGX&?]"?=?^#>Z_P#BZ/\ AS3\#/\ H3[K_P &]U_\71_KQE_\D@_U'S#^
M>)^+-%?M-_PYI^!G_0GW7_@WNO\ XNC_ (<T_ S_ *$^Z_\ !O=?_%TO]=\O
M_DD/_4C,/YXGXLT5^TW_  YI^!G_ $)]U_X-[K_XNC_AS3\#/^A/NO\ P;W7
M_P 73_UXR_\ DD+_ %'S#^>)^+-%?M-_PYI^!G_0GW7_ (-[K_XNC_AS3\#/
M^A/NO_!O=?\ Q='^N^7_ ,D@_P!1\P_GB?BS17[3?\.:?@9_T)]U_P"#>Z_^
M+H_X<T_ S_H3[K_P;W7_ ,71_KOE_P#)(/\ 4?,/YXGXLT5^TW_#FGX&?]"?
M=?\ @WNO_BZ/^'-/P,_Z$^Z_\&]U_P#%T?Z[Y?\ R2'_ *D9A_/$_%FBOVF_
MX<T_ S_H3[K_ ,&]U_\ %T?\.:?@9_T)]U_X-[K_ .+H_P!=\O\ Y)"_U'S#
M^>)^+-%?M-_PYI^!G_0GW7_@WNO_ (NC_AS3\#/^A/NO_!O=?_%T?Z\9?_)(
M/]1\P_GB?BS17[3?\.:?@9_T)]U_X-[K_P"+H_X<T_ S_H3[K_P;W7_Q='^O
M&7_R2#_4?,/YXGXLT5^TW_#FGX&?]"?=?^#>Z_\ BZ/^'-/P,_Z$^Z_\&]U_
M\71_KQE_\D@_U'S#^>)^+-%?M-_PYI^!G_0GW7_@WNO_ (NC_AS3\#/^A/NO
M_!O=?_%T?Z\9?_)(/]1\P_GB?BS17[3?\.:?@9_T)]U_X-[K_P"+H_X<T_ S
M_H3[K_P;W7_Q='^O&7_R2#_4C,/YXGXLT5^TW_#FGX&?]"?=?^#>Z_\ BZ/^
M'-/P,_Z$^Z_\&]U_\71_KOE_\DA_ZD9A_/$_%FBOVF_X<T_ S_H3[K_P;W7_
M ,71_P .:?@9_P!"?=?^#>Z_^+I?Z[Y?_)(7^I&8?SQ/Q9HK]IO^'-/P,_Z$
M^Z_\&]U_\71_PYI^!G_0GW7_ (-[K_XNG_KQE_\ )(/]1\P_GB?BS17[2?\
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M\9?_ "2#_4?,/YXGXMT5^TG_  YJ^!O_ $)]U_X-[K_XNC_AS5\#?^A/NO\
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M4SNO^%@Z5_SQO/\ OBG?\+ TG_GC=?\ ?NN#HH^JP#ZU,] _X6-H_P#=NO\
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MH/\ S\O_ -^'H_X370?^?E_^_#UYI11]5@'UJ9[!H%UIOBB-_L<WG^7]]/\
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M)_WW7(T4>Q@'MIG7?\+&M_\ GSD_[[H_X6-;_P#/G)_WW7(T4>Q@'MIG7?\
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M%C3IH$L--M9X[C2Y_L3SH_G._P Z2>2^]-B>7YE>ZZS\)M$U3^P7:S_TGPG
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MYG_3-*GDGR%^TAS^^<E<>/?'/@/X/OKWBKQ5X+M9M82R_LZ:VT&ZD^QS3_\
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M\==/^R_X7NO _C3X+7D6I>)KJ;QQX&FNO$/]I:I/=1WDZ06KH^QWV(\>]_\
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MX?\ $.IZ)!?WC^9=W$-K=.B><_\ &_E_QUZC5D_W HHHH **** "O<_AJ<^
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M?:WI_P#Q]6%MJ,$EW;_[Z;]],T?XM>%=>@U6:Q\2>'[J'0_DU%X=1@DCT_\
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MVVO0W7@_Q!:ZQH^MV7AZ"P2ZM9Y-4U"Z3>D$+H^S]W'\[^9_JZV-#_:62_\
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MO5_[+@O(;I)X]03[+!/YZ;/^NW_D.J'BC]I'P]I?Q$\/>&--O]'US5=8UO\
MLB]MK;44DN-'?R)Y][HGS_\ +'9_!_K*P?V2_!&I>$H_B+<WGA63P7#XD\5S
M:IIUA^X_=PO:VJ;_ -S\B2>8C_)7E/PK^"WB32Y/@SH]Q\.KK3=5^'^KW3ZW
MXG?[+Y=QO@ND\^%]_GS).[H[T2G/W?\ MTI0A[Q],:7\4/#&O^,+GP]9^)-#
MNM>L_P#CZTV'48)+NW_WTW[Z-'^*OACQ);ZK-8>)/#]]#H?_ "$7AU""2/3_
M /KM\_R?]M*^;_AW\%?$G_"-_"CPQ<> [K2M5^'^KOJ.M^(7>#[/J"(DZ/Y,
MR/O=[OSD_P!9_P #K-U#X&>.M9^#>O>$M#T3Q%:^$M'?2;K2+/6(+*#6I$@N
MO/NM.1TWI-'Y:)L>?^/^_4\X^2!].6?QD\)7_@N;Q);^)_#D_AZW?9/J2:C!
M):1_[[[]E;>AZ]9^(]'MK_3;RUOK&\3?!<VS[X[A/[Z/7S?)\$8;_P +^(=5
MET?XMR:KJFMZ?J*3/:Z7'?V]U:H_D726R?N'2/[C^9_K*]I_9_D\22_!_1/^
M$PL[73?$.Q_M4-M D$<?SOL^1/D1_+V;T3_EIOJJ9$STWX:_\CUIO_7:O6?B
M/_R(FJ?]<#7DWPU_Y'K3?^NU>L_$;_D1-4_ZX&N.O\<3JH?PSP/4)7M;.9XH
M9+J:-/,CA1]GF?[%>8^!/VD;_P 9>/->T2Z\#:QH?_"+NB:O>7FJ67V?3]\'
MGH_R3?/^[_YYUZI7C-G\-->B\4?'N9M-D\GQ9!"FD/O3_3-FE^1\G_;3Y/WE
M=5:I./OP.6GR2.S_ .%W:)K.L:5;:#J6A^(/[0U#^SKI[/5[7_0W\AY_N;_G
M?RT^Y'\_\=:6A_%KPKXH\0)H^F^)_#^I:K)!]J2SMM1@GN/)_O[$??LKQSPO
M\ K_ ,)>!_V=;#3?#<&FOX/O;6?7DMD2/['_ ,2N>!W?^_\ OW_V_P#65YC^
MQWX-O_&_PW^"::=X#GT=/"^MWNMZCXD?[+';WD/^E)L1T?>[S[T39(G_ "SJ
MI<_/*(OL\_\ 7VCZ*^&?[3?A[Q;\#_#?C;Q!?Z5X.L_$B/Y,.I:BD<<;[W39
MO?9O^Y73_$CXH:/\*OAWJ7BK5KGR]'TN'[4[PIY\DG]S9_?>3Y-E?*_@?]GC
MQGX(\/\ PQN=4TKQ5Y.E^%+W1+VST2#3KJ[T^Z>]>?YTNMZ;)(_DWQ_\\Z]:
M^(/[/%YK/[$]CX)\,I?07^CVNGW6EVVMSI]HD>UNDND@F=/D_@V4>T]R1?)#
MGY3N?A_\5=8\47$W]O>!M<\'6WV7[:ESJ5U:R1[/[C^2[['_ -B2M+P_\9/"
M7BCP_>:KI?BKPYJ6E:>^RZO+;48)+>W?_;??\E>5_&36?&'[2/P3\0Z#:_#K
MQ'X?O)+6&Z>'6+JUCCU!TG1WLDV3/O\ ,C1TW_<_>5P?QP^"_B3XYZ?\0M5T
M/P!?>&;;6/!MKX>@TJ\2U@N-8F2]2?[B/LV0)O3?(_\ RT>CVGOD<C/H?_AH
M/P']C^T_\)MX2^S?;O[.\[^UX/+^U?\ /#[_ -__ &*Q)/VF_#^C?&#Q#X2U
MZ_T?P^^CII_V6YO]42#^U'ND=]B(_P#'\E>8_%3]EK^U/&_QCN--\&:5);:Y
M\/+72-$=+6"..2]1+KY$_N/_ *GY_P#<KF_&'P@\26VL>/\ [9\+KKQ=<^-/
M VDZ#97_ /HLGV>Z2U=)TF=WWHD<C[]\?_/.HG4G_7_;Q?)#^O\ MT^D_P#A
M9]G8>*-;L]2FTW2K/1_LO^F3:C!^\>?[B.GWT_V/,_UG\%/T_P"+_A+6?"=Y
MKUGXG\.76B:>_D75_#J,$EI;O_<=]^Q*^;_'G[,GBW6=+\8:5<:/)KD.H?\
M"&6OG.Z21ZHEDZ?;7^=_^6?S_P"LKJOB)\-/%7@WQI\2-2\)>%;62SURZ\/O
M D-E:S^8D&]+J>&%W1'GCCV;/,HYYDGI'C#]JKX>^ _"^B:W?^+=#_L?Q!J*
M:=97D-[!);R3?[^_[D?\;_\ +.MC1_BUIMU_PDES>7.E:;H_A]TWZD^J026\
MD+P)/O?Y_P!S]_\ Y:?[]?.6E_!;Q;:_#_6+^\\):QJLT?Q,LO%$-A<P64=_
M>:>B0)._DH_D(_W_ )/^F=:OBSX+>*K_ %_QGK:^$KJ^TVX\>:-XE31'>#S-
M8LH-/@1T1-^S?')_!)_'!5PJ3_K_ +=_^V*]F?0.G_%_PGJGA>'6[7Q/X?GT
M2XG\A+]-1@DMY'_N;]^S?5_P?XWT?X@Z&FI:#JNFZYIMP[HEY8723V\FS[_S
MI7S'XH_9]U[XE^,+_7O^$,DT[0=<\>>']1?1+Q(/,^RV2.EU>S0H^S]Y\GR?
M?_=U['\#_AI<^#/'GQ4\W3?[*TKQ!KR7NG>3LCCN$^Q0([HB?<_>(]$9S_K_
M +=(Y&0^!_VEIOB7JB7/A_P3XCU7PE)J+Z<GB%)[6.WD='V/.D+OY[P1R?QU
MV>G_ !0\,:IXTF\-VOB30Y_$-O\ Z_34U&"2[C_WX=^^O)?V9[KQA\$? V@_
M#?4O &N73^'YWTY->LY[7^R;BRWNZ76_?O1_+^^FS?OKC_A_\%O$T6A_#3PE
M<>";K2M;\#^+_P"V]4\5/Y'V2\A1YW>>&;?Y[O=QOLV;/[^^B-_='.F>P? ?
M]IOP]\;M#L]M_I6F^(;Q[K_B2?VBD]W&D$\D&_9]_9\G]RNJT_XJ^&-9\87/
MAZU\2:'=>(;/_7Z;#J*27=O_ +\._?7S]\)_V;M5\)>!OA3_ ,4S!INO:/XV
MU#5-7F1(/M%O:S_;OW[O_'YF^'_QRJWPW^#?B>+1_A7X5N/!-UH^L> _%']K
MZOXG?R/L]Y"GG[WAFW^>[W>]/DD3^_OJ*,Y^[SE2A#WN0]@\>?M<_#3X<Z6]
MYJ7C/PYMCGAM72'48)Y(WG?8GR;_ +GF?^BWKN9/%NE1>%_[;;4M-_L?R/M7
MV_[4GV3R?[^_[FROF;2_V:=2\.?L-V>CP^#()/%5GKT.MWMA#!!]KO$35_M3
M_/\ <=Y($_YZ5Z+^U9X#UCXM? O2ET'3=2@FL]7T_5Y]'3R([R2U@GWO B/O
M@W_Q[)/D_=TX3GR![.'.>BZ'\4/#?BC3["YTWQ%H>I6VL3_9;*:VO4DCO)O[
MB?WW^3[E0ZQ\9/!_AS3YKG4O%7ARQMK??OFN=1@CCCV/L?\ C_Y9R?(]?/WB
M3]GW5?&7PSU[3=!TWQI8Z]XX\2V5T^MZ\EE:R>'W@1/^)HD-KL^=(TV?WY'^
M_P#)7/:/I=Y\.?BQ\$[#6?AI=:K?^&_"^NVMUIMGY%U)(Z3VJ/J,/G/\_G_?
M_O\ []Z/:,/9GU%X@^,GA+PEH]A?ZMXJ\.:;8:HF^RN;G48(([S_ ''=_GI_
MBSXO^$O <D::YXG\.:/YB(Z?;-1@@\Q'^Y]]_P#EILKYCM_A+\1?"7P@T'PV
MOAB[@L+S2-:>>'2K+3KZ[T^:ZNGD@TYWNGV)!' _SO'_ !QUO_#?]FG59=02
M;Q'X5@NGC^$NG^&D>\2"?R[U//\ .@_] HE4G_7_ &\')#^O^W3Z&UCXC>'M
M!\0:;I5_KVCV.I:Q_P >5G->I'<7G^XG\=8^G_&G1[7P1-XA\07^C^&;"WO9
MK+SKG5X)+?Y)W3_7;]F_Y/N??CKPWP_\-/&'@C5/AW>:-X>\01^)X](T+2/$
M+WD%K=:+<6L'^NWN[^?#/!O?8\?^L?9]^H?!?P@\3_#FX\"ZWJG@^^\06'A_
M7O$T]UI5MY$]Q;_;;IWM;U$=]C_N_P#@<?GU4OC)A\!]":Q\7_"6A:!;:K?^
M*O#EKIMY ]U:WDVHP1V]Q"GWW1]_SI\Z5N:/K-MKVEVUYI]S!?6=XGGP7-L_
MF1W"?WT>OF+X/_LTZQ:_&#P'KFN>$H+71+?5_%6M_P!FS)!/'X;2]^R_98-G
MW-_R._[O_5^8]>N_LE^ [_X:? ^ST34K#^S;FSU'4W2V^3]W"^HSO!]S^#8Z
M44Q3@>D4445H0%%%% !1110!J^!O^1TTO_KZ2O?Z\ \#?\CII?\ U])7O]>;
MBOC.["? 9]C_ ,C!>?\ 7&'_ -GK0K/L?^1@O/\ KC#_ .SUH5RG4>:_M!_\
M>^E_[[_^R5\V_M4?$+7OA?\ "C^U?#Z21O\ VC:P:C>0Z<^I2:79._[^Z2%/
MO^7'7TE^T'_Q[Z7_ +[_ /LE>+_$'2_$FIZ.G_"+ZQINCZE'.C^=?Z=]NMY$
M_C39O1_^![Z[J7P'#6^,XSPO\7[FU^$]AK&FW,_Q?CU"=_(U+08+6UC\G_IM
MOF1$?^#_ '_X*X#XB?M(ZK\2_%GP?MO!]MXQM?#WCC[5>W5Y8?8H[C]PG^I?
MSM^SRY/G?R_X(_DJS_PP]?\ EVUXWB'0[[5;C7M0U[5+:\T1Y-%O)KI$3Y+9
M)OD>#9\GF._^L?\ OUT_PK_95_X5IIWPQMFUR.^3X=P:G ^RR\C^T/MJ?[_R
M>7_P.NCWS/W \+_MFZ#XL\2V%G9Z/KDEGX@GNK70;_?:^7KD\".[HB>=O3S-
MC['D1$D\NJ'[/_[8=S\2_!_@R\\3>$M5\,W/C34;G2[*;?!):23)Y[I]QW?]
MYY+I^\_C2IO@1^R@_P #-;TU+=_!=]H^CSS/97/_  C7EZUL??L1[G?_ ,L]
M_P!_9\]<K\4/V>/$_@/]CO6_"NEZE_;FL:/J*7O@V;3=+>.[T^Z^V^? \WSO
MO\N1_G?Y/DWUG^\Y!^Y\!UOQ0_:"?Q;\!]2N?!_VJUU77-;?PAH-R_[OS+KS
M_LKW4/\ L1[)GW_],*HZA=?$+0?VD-!\#6OCR"32M0T&ZU3SIM!AGNX_(G@1
M$W[_ )_]=]^M'P?\![GPY\1/A[I2VTG_  B/PST%WM;EW_Y"&IS_ +C?_P!L
MX_.?_MO79ZI\*OM_Q]T?QM]O\O\ L?1+K2/L?D?ZSSYX'W[_ /MC_P"1*K[7
M]?U\1G+^OZ_PG*ZA^U]H^EZY-NT'Q%)X8L]7_P"$>NO$Z00?V9;WN_R-GW_/
MV>?\F_9LWUSW@?\ :EF\.>']:_M[[=X@UB\\<ZMH.B6%MY$$DB0/OV;WV(B1
MQI]^1ZLWG[)>JW]G?^&V\56O_"O=0\2_\)+/IO\ 9?\ I^_[5]J>U^T[]GD>
M?\_W-_E_)4/B#]BC^U+=+E=5T>ZU6S\7ZGXHM4U72/M5A(E[]^UFAW_/^[_C
MWI\]3[_]?]N__;%^Y_7_ &\7W_;<T2ZM_#R:3X8\7>(-8\23ZA90:580027%
MO=66SSX)GW[$\O?]_?LKI=<_:'A\)?$C1]!U;PQXCL;/7-132+76)O(^R273
MI\B;-_G[)/N;]FRL_P )_LYS:-XX\&:]<7/A^UF\)P:FCV>CZ1]AM+C[;L^X
MF]]GE[/]OS*Y6\_8MO+_ .,MMXDN->T>>&S\7IXK2:;2/,U?Y/\ ER^T^=_J
M(_X/+2JAS\YG[A3_ &?_ -KZ\NK.&V\6Z5XFGAU#QEJ?AZ#Q(]K!'ID<WVV=
M+6U^1]_^K1$W[-F_^.H=/_:,U35/%'@G[+KVI3Z5J$GBU-1>;3H(Y)/[/W[/
MD_Z9R)\GS_O/XZV/"?[(.O:-]@T>\\9VM]X,L_%<WB_[ FD>1=R3/=/=)!YW
MG?ZB.1T?[GF?NZF\/_L;OH']@_\ %0QR?V//XFG_ ./+_CX_M=W?^_\ \L-_
M_;3_ &*GW^0W]SG,WX?_ +7VMZSXLTW2E\'^(_$&E2>"K7Q1_;"):P7%YO1_
M^6/G?)]S9LC_ (_]BO2_!_[06@^/-<\*V>D?:KK_ (2S07\0P3(G[NSM?DC_
M 'W^W)(^S_MF]<W\,_V;M5^%7BSP??Z;XAL9[;0_"]KX7U2&YTY_,U!('WI/
M"^_]R_\ UTWUC_L:?!&Y^&FL>/\ 5;R&^@M[S6YM.\/6UY!Y<EGI,$[NB)_L
M23S3.G^QLK;[?]?U_*8?8/=:***"0HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#LO@=_R.3_\ 7%Z]B'2O'?@=_P CD_\ UQ>O8ATKS<5_
M$/0POP!BN5^,/_(A7?\ O)_Z&*ZJN5^,/_(A7?\ O)_Z&*SI_&:5/A/%:R?#
M_@C1?"-Q,^DZ)H^E/<??>SLD@\S_ ']B5K45ZQY9F_\ "&Z/%K$VH+H^E?;[
MAT>>Y^Q)]HD=/N?/]^BS\$Z)I>J3:A;Z/H\%_</OGN8;)([B1_[[OLK2HH A
MTZPATNS2UM88+6VMT\M(84\N./\ X!5/1_!&B>'+BYFTW1]*L9KS_CZ>VLD@
MDN/]_9]^M*B@#*TOP'HF@Z?<V=GHNCV-G>?Z^VMK)(X[C_?39\]7)-&LY;EW
M>SM9'D@\AW\A/WB?W/\ <_V*LT4 96H> ]!UJ*%+W1-'NDM]FQ)K)'\O9]S9
M\G_+.K-YH-A?R3/<6%C.]PB)/YT"2>8B?<WU<HH IZAH-AJD=REU86-U]L3R
M+KSH$?[0G]Q_[Z56C\$:):Z'-IL6B:/'IMPFR>S2R3[/)_OILV5JT4 4(_"^
MFVMO-#%ING1PW$"03HEJGER(GR(C_P"Q3-/\':/HVEI86>CZ5:Z?&_GI;0V2
M1V\;_P!_9_?K2HH AMK"&UN)IHH8(YKC_7NB?O)/]^J=QX,T>_\ $$.JW&CZ
M5/JMO]R\>R22XC_X']^M*B@#-@\):5:^('UB+2M*CU61-CWZ6J?:Y$_W_OU-
M'H-A%;HBV%C&D<_VI$\A/W<W]_\ W_\ ;JY10!FV_A+2K7Q ^L1:5I4>JW">
M6]^EJD=Q)_P/[]6?[!L/[+FL_L%C]CN-^^V\A/(DW_?WI5FB@"G'X<TV+P__
M &4NFZ;_ &5L\C[']E3[/L_N;/N;*IZ/\/O#WAS_ )!N@Z'8^6_GI]FTZ"#Y
M_P"_\B??K8HH XGQA\ O#WC?X@:#KU_9VLG]AIJ"?8WM4DM-0>Z1$=YDV?._
M[E*Z34/!&B:S9V=M=:/I5U;:?\]K#-9))'9_[B?P5I44 5K?0;"PD1[>SL8'
MC@^RIL@2/RX?[G^Y_L53D\!Z#+J-G<MH>CR7.EILLIOL2>99I_L/L^3_ +9U
MJT4 4-1\):5JFES:?=:5IUU87#^=/;36J26\C_WW3^_3[?0;"PM[-;>PL8$T
M_P#X]42!(_L?^Y_<JY10!#9V$.GQO';PP0)([N^Q/+\QW^^]3444 %%%% !1
M110 5[G\-/\ D0]._P"N KPRO<_AI_R(>G?]<!7+BO@.K"_$=".E% Z45PG<
M%%%% !1110 8KF?BO_R(FH?[B?\ H8KIJYGXK_\ (B:A_N)_Z&*JG\:,ZGPG
MB-%9OC3Q1;> _!^L:W>)))9Z/937LZ)_K-D";W_] KQ;2_C[\0HKCPK#K.E>
M#K5/B1I=U=:"]G/=22:7=):_:D@N?^>R>7_''L^>.O6E4Y3SN1GO=%>#_L#Z
M9?\ A?\ 8[T36+^'1_[2UC3O[7GFLT?S-0?9OWW+O]^?^^]9OPG_ &H/&WC?
M3_!EYXHT'PS8Z/\ $CPU>ZIIR:;>SR7=F\$'G[)G?^"2-_\ EG_J_P#;ISJ<
MH4X<Q]%45\Q_#_\ :^N?!OP7A>\T2%'_ .$#TSQ#X:MOM4T\FJ33_N/LKN^]
MW>.=X4W_ ']D];WC3]I;QQHVC^-M>L-$\*SZ#\+W2#7H;F>=+O4)D@2>Z^S?
MP(D>_P"3S-_F>7_!2G4Y-0Y&>_5F^*/"6E>-]#FTW7--L=5L+C[]M>0)/')_
MP!Z^>_!?QDN?!OQ@^(5S:I]NMO$'Q#T+2$2Y=_\ 1X;K2[5]Z?\ 32NA^)G[
M4OB'POK&MZ;HVB:/?7^G^-=,\*627D[P1R)>VJ3^>[_],Y'H]I_7_@/_ ,D/
ME9['X7\):5X#TA--T/3;'1["W^Y;6<"01Q_\ 2M*OFF3]J_XB^'(]>N=9T'P
M7_9O@?Q1:^&M>FL[JZ\S4/M3P;)[)'^YLCN4WI)O\SYZZ3Q!^U+?^%_VB-'\
M-_:?!VJZ5JGB'_A'GMK#[4]_I[NCNCS3?ZC?\GSP_?C\S[]'M.8/9L]RHKY.
M_9O^,GC;X<^!_#USJ5AH=]X,USQSJ'A[SOM4\FK1O-J-TD$_]S9YGR;/O_Q[
M_P""O5_VG/VEW^!EQH-M:Z/XDOIM0U?3X)IK/1)[ZW\F>?8Z(Z?\M_[B40GS
MPC(4X>_R'K5%>5_M,>/+G_ACOQMXATG^V-'O/^$>NKJUWH]C?V;[/[GWT>O!
M-8^(WB'P1H_Q7L_^*_\ !:2?#S^U]$L->UM[Z[DNH-_GWMM-YT^SR]\*;-_^
MWLISJ<I<*?,?9]%?+6A_%7Q#_P *7?X7-K>I2?$7^WD\+IJ3S_Z7_9[I]J_M
M'?\ ?W_8=_S_ -^.L'1Y?$^J? CX4>,->3QYXN\$V_A!_P"VTT36YX-7L[W?
MO_M%]CH]UY<:/_'^[_N/2]H1"GS'V'17C_C#XYVWC?X5ZQHGPWU6^U+QG<>&
MGO=!F>RG\NXWVN^!_M+IY&_YT_C^_7CFA^.[GPEXHUO2M#U+Q_X+L+SX<ZAJ
M-[>>-OM4G]GZG \")>IYSN__ "V??Y?R2>6FRG.IRA3I\Q]AT5\0^%_C+XA^
M%_@_Q_K$5GXN\':KI_@.&]M=!\2:I/J5QJE[OV/J\+S.^Q(]Z)L^1_WB;T2O
M9/@O:V$7B#6/ >I6'Q&\,^(=4T%-0FO-2\4/?7&H6N_8\Z.DSI#/YGW_ "]G
M^LI>T'[/[9[U17Q_)XCUCPYX'^(5SX/\0^(X_ ?B#Q1HOAKP]J5SJD]U);^?
M.EKJ-U933.[^1\^Q'_OQNZ5Z7X+\$0Z-^T)XS^'2ZKXFG\*W'A[3];@A?7KV
M2XT^;SYT?9<^=YZ))L1]F^CV@N1GNM%>)_L=V#ZS<^,_%5KJ7B"?PQK&J?8O
M#UM?ZO=:E']EM=\#W2><[_Z^?SO^ 1I7ME:$!1110 4444 %%%% !1110 44
M44 %%%% &[\-?^1ZTW_KM7K/Q'_Y$35/^N!KR;X:_P#(]:;_ -=J]9^(W_(B
M:I_UP->?B/CB=U#^&>$T445Z!PA5/0]!L/"^C0V&FV=K8V%O\D%M;)Y<<?\
MP"KE% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5.XT&
MSNM8AU*6SM9+^W@>""Y=/WD:/]]$?_@"?]^ZN44 %%%% !1110 4444 %%%%
M !1110 4444 :O@;_D=-+_Z^DKW^O / W_(Z:7_U])7O]>;BOC.["? 9]C_R
M,%Y_UQA_]GK0K/L?^1@O/^N,/_L]:%<IU'FO[0?_ ![Z7_OO_P"R5YK7I7[0
M?_'OI?\ OO\ ^R5X%\=/B_#\$? ?]J?8)]8O[R]ATO2]-A?RY-0O9WV0)O\
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M?%3X>_"ZU\0^+K7PWKB:MK=[,^KSR7]PEJD&RR2Z_P!>D'F3;_O[_P!W]^N
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M$?\ >.[N_P#<CKUV3]G/PE+\4/$WC#['/'KWC#2/[$U&9)_W<D/W/D3^!_\
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MLJ?M\YI[AZ113+>+[+;I#ODD\M-F]_\ 624^M#$**** "BBB@ HHHH ****
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MH]O /8S.>HK;_P"$#N/[_P#Y#H_X0.X_O_\ D.CVT ]C,Q**V_\ A [C^_\
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M\ K2M_@7;2_\O\__ 'Q1[: >QF>;U[I\-3_Q06F_]<!7.P_ "S5OFOKJ1?\
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MM_OB@#F:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH T/"__ "%U_P"N=;NM
M?\@B;_<K"\+_ /(77_KG6[K7_((F_P!R@#QW]I"ZUZU_9W\?S>%?,_X2>/PU
MJ#Z1Y/\ K/MOV5_(V?[?F;*^(/BAI_PKF_X)*_"V3X?_ /",R>,9'\,S>#9K
M P_VU)X@^U6N]]_^N^U>9]I\[_MOOK]%*XKP[^S;\.?"'Q#N/&&D> /!>E>+
M;QW>?6[/1;6&_DW_ ']\R)YG[RB/NS_\!_\ )0/FCPW^TMXZN_VF%^!MUXDG
M'BCPWX\U#7M:U(QI]HG\&)!]NM?X/XY+J&RW_P#3"3^.N3^"?[7/B/6_C[X8
MDTOQ3XZUCPA\3O ?B+Q)9_\ "376ER22&R\A[6]MK:U_>64?SO\ ))_TS_CW
MU]R6_@C1+7QI-XDCT?2H_$5Q9)I\^JI9)]ODM4?>D#S??V;_ )]GW*P?!_[.
M?P]^'VL7.I:#X#\%:'?WCS275S8:):VMQ<>=_KM[HG\?\?\ STJ9Q]WE_KX>
M4O[9\=_ ?XC?$*T^$_[(OBWQ1\1-8\8ZK\9->T^ZUM+^RM8[2S1_#U]/Y%LB
M)O3]XB.[^9OD>/\ V]E0_#?]KWQ)JWQO\,7N@^*_'>J^$?B=X.\4ZW9_\)-=
M:7)YGV)(WM;JSMK7Y[5-[NFR3TCW_O*^X;?X;^'K6QT2SBT'0[>V\+NCZ)"E
MDD<>C[$V)]F39^Y_=NZ?N_X'K(\-_LY_#WP;KEYJNC> _!>E:EJ#S/=7EGHE
MK!<7'G_Z_>Z)\_F?Q_\ /2E4][FY/Z]TB/N\O.?*_P"Q?\4/B+:>*_V<M2\5
M?$O7/&EO\;/AS=:WK=GJ5K:P6FGWMK:V,Z3VWDHCI_Q].C[W?S/OUZO_ ,%*
M-9L_%'_!-3XM7^EWFFZE8:AX4FGM;F&=)[2X3Y-C[T^^E>K^*/@KX>U[P?'H
M]K86NA_8]+GT72[S3;6&"XT.UG3RW2S?9^Y_=HGW/^><=.\/_!7PKX<^#]AX
M M_#VER>#=/TM-%@T>YM4GM/L2)L\AT?Y'C\O^_55?>4N4SC[O*?,_[2?CCX
MB_!S]D^&\TO7OASX8\5:QXV\,Z)!J7@S3_,CM[6]U&"";SDF^^_EN]<C\1_C
ME\0O@=K'Q*^&X^)6MWMK9^//"&BVOC#5TM7U/P_8:VG^E?/Y"0?)(FR"1T^3
MS_\ 8KZU\'_LL_#'X?Z?<6?A_P"'?@30[.\GANIX;#P]:VL=Q- ^^!W1$^_'
M)\Z/_!6WK_PI\,>*[+6[75/#?A_48?%")!K:7FG03QZPB?(B7.]/WWE_]-*?
M]?\ I)I]CD/S_L_B;K7P1^,_QWTG1OBI>:P^L?$+P-X.U'QI>):SW?A^UNK)
MXWWNB>1]J3_4[WC^_.F]*WOB]\?OB7\+-6\<?#WPU\4-9UBWT/QYX%T33_%.
MH06M]J&G?VO=;+W3IGV)'/)''L=-Z;T\]-]?:6C_  !\!Z#X/O\ P]8>"?!U
MCH.J0):WNFPZ):QVEY"GW$>'9L=/^NE3>&_@7X)\&^$+;P_I/@OPKI6@Z?>I
MJ-KIMGI$$%I;W*/O29(439O23Y]_WZK[7]?W0F?"/Q(^*/Q:^#GA[X^:DGQE
M\8:I;_ #QCH5KHMM?6UE(^MVU['IT\\&I2)#^_3_ $V1(_+V>7\GWZ[#Q!\9
M/C=\4OVB?B8W@^^>Q_X5OXXL]!LM*N?$&GV.C2:?LM))GO;:2%YYGGCFFV.C
MI_RSV?QU]E:C\+O#>LVVL0WGA_0+J'Q!.D^KI-IT$D>J.GE['F^3]\Z;$V;_
M .XE9_BC]GWP'XW\>6?BK6?!/A'6/$^G[/LNL7FD03W]OL^YLF=-Z>74Q^S_
M %_+_7S"7PGP5K6L^+OV=?V?OVMO$GA7XH>*O^$JT_XGII]E_:4]K=1Z?Y]U
MHZ?:O(V)\_ES;/[FRO8/BO\ $S4OV3/V@+73?$WQ \3ZQX>T?X2^)O$FJ:W>
M65K=:L9H+VQV3ILA1/W:.^Q/N?<WU]+ZA\!O VL^(=8U6Z\&>$KK5?$"0PZI
M>3:1"]QJB0NCP),^SY_+=$V>9_SSCK8UGP/HNOZG]OO]'TJ^O_L4VG?:;FU2
M23[+/]^#>_\ !)L3>GW'V5/V8_U]GE_^V'UM_>_]NYC\U?V@_C)XLU?X'_M(
M>!=:UCQ5J.CZ?X.\+>);*'Q/J>G:EJ6GSWNJ2)(F^R_=HDB0POY,GW/X/DK]
M,M/\06&J:C>6=K?V-U<Z6Z)>PPS)))9NZ;T1T_@_=_/7)^&_V9/AOX-\/WFE
MZ3\/? ^E:5J$"0W5G9Z#:P6]XB/O1'1$^=(W^>KGPO\ @MH_PJUCQ5J5AY\^
MJ^--7?6]7O+G9)<7$VQ$1/\ <C@1$1/[D=4(\'_:YC\72?M]_ 7_ (0>7PS#
MKG_".^*OGUU)I+3R=FG;_P#4_/YE?,/C'X?3?%#X$_'KPO\ $6UT/46\0?M*
M^'].UJ'34=+2X2=]#1]F_P"?_5U^FEYX;TV_\0V>JW%A8SZKIZ/!:WCP))/9
MH_E[T1_]8F_8F_\ W*SY/AIX;NOMF[P]H;_VAJ*:O=;].@_TB]39LNG^3YYT
MV)L?[_[M**?N_P!?WHR"?P_U_*XGY[^&;F3X@_M9W/P-^*7B&;3=>\!_"+Q-
MX4U?Q#),D$FH:+=76G)I^K[W^3]Y!]__ *;P3UF_M"_$#6_AO^SMX_\ @YXC
ML/ M]_PB>D>%KW6_&?@>'[+'JGA*36$M;I+R%/GM9DM4F=T21T>.1W3RZ_1K
M6/AIX;\1^(9=4O\ P]H=]JMQI[Z1->7.G0R7$ED[[WM7=TW^1O\ X/N51^&_
MP'\$_!O0[S3?!_@SPKX5TW4)-]U9Z/I$%C;WC_<^=$3YZ/Y>?_\ :]Z7_P D
M']?^D_\ R)\P?\%)/^%=:#^Q?XD_X07_ (0NU22QTA-7?PW]E2[C\)?VI:_V
M@Z>3\_V7[+O_ -C[]?0G@^_^#G@BXAO_  Y<_#71_L>B;X+G39[*#R])1TV/
MO3_EU^Y_L5L?#?\ 9X\ ?!NWOT\'^!O!WA5-8_X_4T?1;6Q^V?[^Q$WUR7B#
M]AGX5ZI\.];\*Z;X)\,^%=$\43PR:U#X>TBUTW^V(4G1_(FV)\\$FSY_]BC^
MOZ_KN!#^V1\3(?!O@_PQI-OJOC'3M5\<:]#HFD)X8GLH+_4)G@GGV?:;K]Q"
MFR%WW_?_ '?R??KY=^"_[37C_P"-VC_"CP3JGQ%UCPK;>(/&7C/2-1\56UU9
M2:M>0Z+._P!BLOM.Q[7SY(_G=XT_>):/_MU]S_$#X7^&_BUX7?0_%7A[0_$V
MB2.CO8:KIR75GO3[GR.FRLK6/V<_A[XC\#IX8O\ P'X+OO#<=U]M31YM$M9+
M".;_ )[^3L\O?_MT1 ^$?V6?B#KVIZ-X#\ Z?\4[[1=%\>?$GXAW6H>-=*^R
MP7FL/9:C))!! \B/ GG[WF?8G[Q('V4[]D;QCK%U)\*?#FF^-)-2L/&GQ"^)
M]K?:]80VJ7&H>7)=R)=0OL>-)/,^?]W\E?=_B#]GCX?^+?!__"-ZIX&\':EX
M>CNO[132KG1+6>T^T_\ /;R739O_ -NM'1OA3X7T"?3WL/#>@6+Z/--=63VV
MGPI]CFG_ ->\.Q/DDD_CV?ZRL_9^[R_W>7\O\C3^O_2CX-_8S\4:Y\+_ ( ?
ML;V=GXMUCQ-#XPUN]@U"'4GANI+=$TC47^RPOLWI^\A3_;K:^$?[1GCF^\)_
M 'XB_P#"SM2\1ZW\9/$+Z7KW@QTM?[,TN%X+IYTMH43SX7L9(4WO([^9Y;[_
M +]?97ACX#^!O!-Y]IT;P;X2TFX_M%]82:ST>""2.]=-CW7R)_KY$=T=_O\
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M%^%? %_=:Y]@\'ZBFHZ??PSI'?QND^]TW[-FQ]^QTV?<HI_'SA4.7OO&6K>
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M$":Q#I^BZ1#"_F>7I]JCOO?^YYD\TW_ (TKT>@ HHHH **** "BBB@ HHHH
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M>COJ7A_4K75;"WNKK3WFMG\R..:"=X)T_P!^.1'3_MG6O7Q7^PO\2M2^'_\
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MHQ?:OXX^#GANU\,^)O'UG\38=<GG\26.D0:;';_V?>^1_P >KSO\B;_G??\
M<1'3_6;$9^RC_P %&_\ A*[DZ#XZT[Q=)>:G\0O$'@[3_$<>@^3H,<T&HW:6
M5D\W_/3R(4^?R]GF???S*T/A/^P5XN^",'P3N=!\5>&;[5?A?=>((-1^WV4_
MV?4++5[KSW\G8^])X]B;-_R??K;\-_L)ZEH/PP\-^'V\26,DGA_XKW7Q&>;[
M*_ER03:C=7WV7_?_ -)V;_\ 8H?QQ_K[4?\ VT%\']?RR_\ ;A/VK/VKM>^
M/[7GP@\.V.E^(/$6B>--'\1S7>B:%IB7U]J%S:I926NQWV>7L\Z?[[HE7-,_
M;N\)>+O$/PYURP\17FF^%?%GAKQ!XAFL[S17CGC33/(2Z\Y]^^UDM9'='A\M
M][_[E=MXX^ 5SXM_:P^&OQ(74H(+;P'I>M:=/8/!^\O/[0^R['1_X/+^S?\
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M)GTYX_[82"?R)[*%/OO?1R.B?9?O_O*I_$3_ (*3^"?AIXE\5:;?>'_B%/\
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M]<_G[/\ 5Q_)4?9YB_MGK?\ PW#\'Y;._N5^)?@Z2'2X$NKITU%)/+1_N/\
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M ,WX/_M+:K\7]<U6\LO"L$/@G1]4U#2)]8FUM/M=O-9.Z.\UGL^1/,3^_O\
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MQ-XJ\2>+))O[+T3P]91W5]<0PIYEU/\ .Z(D,:.F]WD_Y:(B?O'KQ?\ 9O\
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M1[W?>[[$_P">DE8/A/X&>!O ?]L?V#X,\(Z'_P )!O\ [4^P:1:VO]J;_O\
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MS8Z.CO'O1'_@^_7*? OX0_%+X*_L[S>$K67X0VNH:.B6OAY--TO4(-,MX?\
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MR/LOG>1Y'F?/Y.S92IZ3C_V]_P"DV"7O*7]?:/7:***8!1110 4444 %%%%
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M;XVU3P/;:IHB?VI=))>?\2^Z\Z>&'?L?RW3_ +9_[%?;5%%7WN;^\$?=G$^
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MQ6E6;XF_Y!+?[XH YFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/1G_ (JT[?08?XDH Y^ND\,1_P#$I'^_4R:#:=H15Q(_+'RT .HHHH ****
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M_P!\5K?V4O\ <H_LI?[E &3_ &I#_M_]\4?VI#_M_P#?%:W]E+_<H_LI?[E
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ,SR*^(/^#@C_E'5J'_8PZ9_Z,K[?QRM?$'_  <$?\HZM0_[
M&'3/_1E=&%_C0,:_\.1^0/[#?Q \)_"O]KGP#X@\=6T=UX3TO4TFU!'A\Z./
M]V_ENZ?Q^7)L?_MG7Z#_ /!2>S^*GQ(^%_B#Q-9?$S0OB1^S'XDU*UN]231+
M&VDU+PQ9)/&_[H]"8\??SG^^E?FO^SKXQ\(?#_XNZ/JOCSPL_C3PG;[_ .T-
M(6Y\EY]Z.B;'_P"F<GS_ /;.OI'XA_\ !0_X8>!/V5/&7PO^!_PV\0>$;7XA
MS?\ $]O==U/[5)Y/]R%-\G\'R?C7T&.ISDX3@>30J:3A,]T_X*+_ ++'P!DG
M^!.BZ'!KGA?Q#XTL],M-.&E:1;6L&IV<T\$<ES>ND?\ Q];'X/=Z\W\'_P#!
M)[P;XB_X*,_$'X-3>)/%4>@^#_#PU>UOE,'VN=]D#^6_R>7L^?\ N5ROQU_X
M*6>"_C5\*_A7<MX!U>U^*GPLM;"VT_5WOT_LW;;21R/^Y^^^_P GT^3?7LVG
M_P#!:CX-Z-\>=8^)=G\&O%$/C7Q9I']EZU?_ -K(_EHB?(D*?<_N;W^3[E<O
M+BJ4'R_WO_M1QY)<O-_=_P#MCR_X)_\ !/GX3> _V=_A]\2OC!\1/$WAF^^(
M6K^1X;M-*T])XXU1_P!V]S^[=]GR?O-GE_ZROI#]OC]B_P .?MM?MY_$#0;C
M6M:TWQUX?^'MEJ_ANVMO(\C4W3S]Z/O0O_K/(_U>S_65\Q_##_@I;\-=3_9C
M\&^!?BQ\+=6\;WWPUO7O?#EQ::H;:WD^??&EQSO']SH^?+KJO#/[>U]^UA_P
M6+^&?C[P)X?U33Y;PVVA3Z;=31[W@VR)<_.G\ C=W_[9U5:C7J5KO^]_Z3[H
MXRA2AS?X?_2CP_XT?L7:+\#/V!OAW\2M9U368_'?Q#U";[+I'R?8[?3T\SYW
M^3S/,^Y_'_RTKZ(_9J\7R?L*?\$=[CXO^";'3X_B-XZ\2/HPUJXMEF?38O,D
MC^7?_P!<7X_OR5YS_P %UOCQ#\5?VUI?"NE[$T'X;V*:)###^[CCNG^>?_T-
M$_[9US_['W_!0WPW\*_V<=<^#OQ6\"7'CWX<ZQ<_;[9+.Z\BZL)<Q_<_[:)O
M'W,.36W[RMAN;^;_ -)*GR4ZT8GT!X6^-6K_ /!13_@DM\7-3^**6>M^*OA;
M>0W6DZZUHD$QQY;[/D[_ 'XW_P"NGL*]>_;Y_91^"_[3_P"UQ\./#GCGXA^)
M/#GCSQ1X8MM/T73=)LD>WC"&>1))WD1_OOO1$^3_ %=?%/Q]_P""B7A&7]EZ
M;X,_!;P!?> O!>J74=YKD^HWOVJ^U)]\?R>Y^1.=_P#RS_/V_P 0?\%DO@;X
MR^-'ACXB:Q\%/$]]XS\#Z>EEHM__ &I G\'_ "V3?L^1W?8_S_ZQZQGAZG-S
MTX^[_P#:FD*WN\D_Z]XY#2/V4/$WP@_8-_:4T%O'VOPP^!_%2Z)=:-9QVL>F
MZV_F6Z),^]'G3.]/]7(G2O0M%_X(0>"UN]*\%ZQXN^(T?Q&U323J$E_9Z%YG
MAJSFV?ZEYO+]?^FG^%1W7BCQ+'_P21^.7Q*\<0V.AZA\9/$T.NZ%''<QR"[\
MR>W\O8G_ &S?[_S_ "?2L^]_X+>^"_B%;Z/K?BSPG\6X?%6GV:6UU9>'_'%U
MIN@W\R?QO#'-'_Z!_P!]UBZE>3E[/;W?_2?_ )(*<(0W_O?^E'E7PU_X)S?#
M;X:?LX)\2?CYXZ\2>&=/U/Q#<^'M(LO#ELDTTCPS20.[[TD^3]Q-_P!LTKV7
M]GG]GO\ 9=D_X)]?&C5+K4/$7B31] UWR;KQ4FA6W]K:?!Y\?V;^S]\>]$>/
M9O\ 7S)*\4^%W_!1KX<^*/V88?A9\:OASKGC#1]#UZ?6M%N-+U/R9X/.FDG=
M'=W\Q_\ 7/\ /_RTWTS]G_\ X*%_"OX;>!OC%X!U[X6ZW-\,_B7JZ:A9:5I>
MI[9M+A3R]D$CO_N)\^:ZI?6)0E_7\H?N?L?U\1ZCX._9FT;XM?LB?LVZ-XH^
M)GCZ/X?^/O&-_I-EI6RQC@TA]]]]E=/W/F;WD1-_F2/_ *^2N T__@E+I/A>
MZ_:*O/&6K^(+'1_@[.FGZ"]L(4DUNYF_>6J/OC_CWVOW/^>]>?\ Q@_;NTOQ
MC^QG\+?AKX=T76-#U3X:^)+G6H+^:9'@V///)"B?Q[T\]/\ OW7J'[??_!8>
MQ_:V^ FG^%?#?A?5/"VK7&JV6L:_?3/#LOYK5/DV;#_ST1/O_P#/..JJ4\0I
M2Y?M?Y_$9\\/M_U\7NGI^A_\$)?!J3:1X+UCQ=\1D^)6K:3_ &A]OM-"W^&K
M.Y";S"\WE_\ L_\ \17"? '_ ())^"M4_9P7QM\1/$7Q!-T^LWNDW4/A#3$U
M"/0/LTDD;O>)Y<DG_+/_ )9_\](ZZBY_X+?>#?'L&BZWXL\)_%Z/Q986"6UU
M:^'O&]UIN@W\R?QO#'-'WY_U?_?=>?\ [&/_  4]^&?[*VDV^MR^ O'TWQ 1
M[V;4;BP\3NFFZ^\[R.CWD+O\[Q[]F_R_^6>^L5];M(/W/NGQ#K%K#:ZQ>0VL
MWVJVCG=()MGE^8F_Y'JO6U\2/&[_ !+^(FO>(;BVM;&;Q!J-UJ+VULG^CV_G
MN[[$_P!CYZQ:]6G?D]\YZGQ^X%%%%69A1110 4444 %%%% 'Z(?\&VG_ ">#
MXV_[$Y__ $MM:_9;Q.?^)4W^\*_&G_@VT_Y/!\;?]B<__I;:U^RWB?\ Y!3?
M[PKY;,_X[/:P7\,Y>3=Y;[?O[/DKY1_9*\1WO@/XB_V#\1M0^(MC\8)+74'>
MVUO6IY_#OBQ$??Y^G_\ +JB(FSY(]DD:??2OJZXB^U6[IODC\Q-F]/\ 61UX
MK_PQ9;>(]<AO/&GCCQAX[73].O=.TN'4OLL$>GI=0>1--^YA1WG\A]F^2O,.
MHX.']N+6_&VH>-/"=C_PKVZ\26_@Z_\ $.G7/A[Q+-?6]F\/[MX9G\GY'3?O
M1T^22N5^"GQ__P"&7O@G\*_"MOIW@G2_$_CCP^/$][>:OXBN8["1/)@_?S/Y
M+N]U/(_W$39Q)\]>P>!/V'=/\':I;7%[XP\5:X^G^%+GP59)<PV4$=GI\WE_
M<2"%/G^1/GK8U']D^VM;?P+<>'_$WB+PSKWP_P!%_P"$>LM5LT@GDO++8B/#
M<I,CH_\ J4?[GWZT_K_TK_[4/Z_])_X)YEI?[5_C_P"+7Q4^"<WAG3='TO1/
M&EEJSZIINI7KQ^9-:[$?YTA?>D?WX'_Y:>9\^RNS\-_MD3:]_8.E?\(W''XP
MU#QS>^#;W2OMO_(/2UWSSWN_9\Z?9=DW_;=*Z3QA^S=-XMU#P-JLOC;Q-!XD
M\#O-Y.MHEK)<:@DZ;)X)D\G9L?Y/]6B;-E<WX'_9OFM?V^/'/Q.N+">QTVXT
M2RT[2]]TDD=Y=.G^E7J)_ _EI;0_O/\ 6>71_P O _Y=G%_\%-?B6O@FV\!P
MM;>(O$VFQW5YJ/B'PKH-U=6MWJFF):NGVIYH/G2""=X7?^_7>?L.^*8[?X7V
M?@^\\5)XP\0Z'90ZG=7D-R]]!':WKSSVL*7,G[R;RX/DWR?/^[KHOBY^SFGQ
M+^(&C^+=+\3^(/!WBK0[*;2TO]-2"?[193NCO!-#,CHZ>8B/6/\ LO\ [%N@
M_LEZAK#^%];\03V?B!_M6HV=X\$EO<7O\=TFQ$V/_!LC^3_8HIA(\Y^/'P'A
MNOVQ/AOIL7C3XIV.F^./[=NM4L[/QKJ-K;[X((WA\E$G_<IYC_<2MGQ9^USX
MG\&^'_'.M^'O"=CK'@/X1W3Z1J]S?ZV\>K:A]E2/[4\*>2Z/Y&__ ):/^\>-
MZ]C\6?""P\6_%CPEXPN+FZCO_!:7J6L*;/L]Q]J1$??_ -\5Y[XX_8=TKQEJ
MGBJ%?%GB[2_"OCR^_M'Q#X;LW@^R:I-\GG_.Z>? D^Q-Z1R?O*/[@'G.H_M.
M6WP'^)/Q^\52_P#$RMI-4\+66EVTUUY%O)->Z<B)O?Y_(3Y][OLK0E_X*%ZE
MIO@GQ'/'X:T/Q+KFB:OHNF6HT76'_LG5_P"U)O(39=30ILDCD^^CI_<_OUZ1
MXP_8W\-^,7\<O+>:Q:S>-+W3-1\ZSD2.31[K3T1+6>V^3[\>Q'_>;ZLZ_P#L
MTW/Q \'II7BSQYXG\3>7K>F:W!--!96OV=[*=)T1$AA1-CR)\] ')?M _M3>
M*OV>/ EK?Z]:_"O3M2CT^;4;JSO/%<T'VMT\S]S9_P"C;W_=[/G?8F^397%M
M\8?&7B;]K>\USP#H.GZRFL?"S2-:^S:OJTEE!;I)/=/&G[M)-\TGW/\ MG7J
M_P :/V1[/XO^/-1\0Q>)_$?AF\US0?\ A&M5_LU+63[99;W?9OF1WA?YW^=/
M^>E9&H?L,VT6IZ??^'_'_CCPK?V?A2U\&O-8/:R?:+*#?]]'A=//^?[_ /RS
M_@K/W_C_ *^U_P#:E_W/Z^S_ /;'DOQL_:;MOC3\&_&&JZ;9ZYI<WB#X%ZAX
MECWZN_V>S^>1/(^S?<\^-_\ EM]^I?C?\??$_P /?A]\5)O!OVBU\2>%_"GA
M.Z>\O]7FD@C2Z\Q/W-ML>-'^3Y_^>F__ &*]=U']@_P?=>')M'M;G6--TV3P
M _PY2&%TD^SV3OO\_P"=/]?5SQ/^QEX;\6:=XXMKK4M91/'FA:9H-ULD3_0D
MLDD2">'Y/O\ S[_G_N5M+X/=_KWF/I_7]TS?%/[7-Y\(-=\2:;X\T73=-N-#
M\&OXOM9M-U![J#5-CNDUJF^%'WQO]F_[_P!>O>!M9O\ 7O ^CW^K6$>E:KJ%
ME#/=6"3^?]CF=-[IO_C\NO!_VB/V2[_XO^(/@K87]SJOB.'PGK;WNO:]<O!!
M)<62)O\ LLT*;-Z3SI;?)''_ ,L*]:\+^'/$X^,GBW6]6U7_ (IZX@M;+1-*
M1_,CCV;WGNG_ -N21]FS^Y!5&9\<?%+Q_K.I_';XT:?X9\5?%23XJ:/XHLH/
M!VCZ5->SZ+'#]EL7V7,.S["D'F/-O\S9)_XY76^+/B]XJ\7?MF>.?@^OB36/
M#MGXLU33T36TNG3^RX4TN">:RT]_X+J?Y_\ @&]_G>OJ#X=_"6Q^&GBCQMJM
MG<WT\WCC5TUN]2;9Y=O,EK!!L3_8\N%*Y'Q[^QQX7^('_">/J%YK$=QX\OK+
M5/M,+I'/H=[90QQP75D^SY)$V;_GW_\ ?%9Q^R$_C,OXR6J_$O\ :,^&/PZB
M\R?3?#__ !6NMH[^9YD-K^XLD?\ ZZ73[_\ MTKYU_9@\?ZUXX\:>%9O"OBK
MXJ>(/&G_  G^H6OBZSOYM0N_#MOHR7MU&^_ST^RIY<:0[/(??OKZK^!?PEUO
MPE\2/'GBKQ-<PWVL>)+VULK*9'\R2/3+6#9!O^3Y'DD>:9T3_EI)71_!+X26
M?P&\ 0^']-N+Z^M+>]O;U)+QT\S?=74D[_<_Z:/1'^<SD?*/A_POXBO_ -G#
MXG?%33?B-X^TWQEX7U[Q-=60N==GNM)DALKV?9:O9O\ N/(\N'9^[V5]??#;
MQ:_CWX=^'M>:'[*^N:7:ZAY/_//SH4?9_P"/UXRG_!/_ $^:TUC1[WXA>/K[
MP/K^KW6KWOA7?:P6%P]U.\[P.Z0>>\&]_N;Z]+^'WA?Q)I?Q(\8:EJVH1QZ#
M>/:V7A[1X7\RWT^U@3YY_P#?DD?[G_+-(THC\'(:2^/G/CCQ#X_UOQ!\9?BI
M:^%O%/Q0O/BQH_Q#CLM!T>SFO9]!CT_98[TN4=/L*0;'N=_W)*]^U#]L36M*
M\4_%>\NO"NFVO@/X/O/#JFJ_VIYE_J#I91W2>3#L_P!O9^\>O4OA?\);#X5:
MAXMN;"XOI_\ A,->F\0W27+I_H\SP0)L3_8_<I659_LT>'?[+^)%A>?:M2L/
MBA=376KVTS_NX]]K':NB;/X-B5'O\O+_ '?_ ";W2_<Y^<^>O''[:=_\6O@?
M\2-!O++P['-J'PVU;7K&\\-ZQ-?1Z>Z6OSVMR[PILG^='1T^23RW_N5L7W[4
M7_"C=&\8:PNCZMK=YX/^&WAG5WMIM;>.TO/.DGCV)"Z>7"_R?/-_'^[_ +E>
MJ6?[+U_=?#/6_!^O?$CQCXDT'6/#TWAZ.&\ALHY+.&=-GG;TA3?/''_')6?X
MR_8@\->--'\3V<^K:["GBCPQIGA6Z\J6$^7;:?)))"Z?)]]_,^>M?<_KYD0_
MO_U\/_!.7UW]J_XKZ!XP\6^'F^&_A+^V/"^@IXKDF_X2A_LDED_G_N/^/7?]
MJ\R%T^YL_P!NJ?BW]LFS\-WGB/QM8:'JU\EI\*;+QK#9S:V\=O.CS2;(?)V;
M$F_Z;5[-KOP&TW7_ !QXFUZ:\OH[GQ9X>3PW=(FSRXX8_/\ G3Y/O_OGKB=0
M_8.\,:IX/O\ 1VUCQ!';:AX#M? #NCP>9'90.[I/]S_7_/\ [G^Q4_U_Z5_]
MJ']?^D__ &Q'X0_:<\82>/-8\-^*/"OAS1]4_P"$1_X2[2/)U[S+22'?Y;PW
M,SP)Y+QR;/G3?'^\KB;3_@HQ)8^$_BI<7%AX/\2ZE\-_#\/B&#_A&->>ZL-0
M1Y)$\C>\*;)D=/\ <_>1UZE\5_V0/#?QDU34KG5[S6$_M3PB_@J9+9TC_P!%
M>=)_.^Y_K]Z?[G^Q7.WG[!VF^)-/\8+KWC/Q5KEYXX\-P^%[JY=+*#[':PN[
MIY*0PHB/\]']?^E?_:A_7_I/_P!L:&E_M(^(?"/CCPEI7Q$\-Z'X9MO&&G:A
M>P7EAJ[W4=F]JB3_ &6;?"GS^1YS_N_^>#UM^!_CGJ7C;]E^V^(3:/I6CW.J
M:?\ VI:V>JZI]EM(X7?]P\UUL^3]QL=_D_Y:5S'[>'[.=Y^TC\%M$\)Z;;74
MES_PD.G[[^&Z2"32[+?LNI_]OS+7SH=B?ZSSZ[[XU_ C1?C9\&+WP/>-=:?I
M=Q'"D#6>SS+/R'22#9O^3Y)$3Y'^2A?!(']@\.MO^"C$T7PW^)&I+H_AGQ-J
MOP_O=)@3_A'M;>?3-434)D1-DSPIL>.3?O\ DJM^T;^U?\2_!WP?^,&E?V/X
M=\,>// ^BV6MVMY9ZH]W:&RNGDCWIO@_U\<D+IL=-DGWZ[R[_84TG7K?QG_;
MGBWQ5KE_X\GTF?4+R9+6#R_[+G\^!(42%$1/[]=)\5/V3_#WQ?UCQY>:I>:K
M'_PL3P]:^&KU(72/[/# \[H\/R??\R;_ ):?\\Z ,'4/BW-X2_:%\)VOC)8]
M+O)/!6IZO?7-GKT\FDV:075JGSPNB;Y/G_UTGW/G3^.N>^*'[2WB'Q3\>/@Y
M#\+]5\*ZYX2\476K0:B[WKQQWCVMKYFQW2!]GE_?_=_QUZ7X7_9]31OB!X;\
M5:IXDUSQ'KWAO1+W04N;Q((_MD-U/!.[NB(GS_N4_P!74WQE^ ,/Q;USPEK$
M&O:QX9UOP7?376G7FFQP22;)H?(FA=)D=-CI6DOL@<?XX_:^?PE\*_B=XD_L
M&.=_AWXE_P"$>2V^V^7_ &A_QZ_O]^SY/^/G[G_3.N8^,'[;GC#X?:I\3KS2
M_A_INL>&/A/JEE9:I,^M^1?Z@D\$#_Z-#Y.S?'YW_+1ZW?B;^P7I/Q*U#Q4K
M^,_&NE>'O&FJ0ZWJFB6$T*6DEZGD?O\ >\/F;'\E-Z;]G[NND\6_LE:#XNT#
MXG6%QJ6L)#\5+Z&]U1T=/,LW@@@C3R?D_P"G9/O[ZSA_?_KX?_M@J'$ZW^VQ
MKWPK_P"$_L/&_@^QM]>\)Z7IFKZ=9Z/JGVJ/5/[0G>U@M7=T39/YZ;'_ .6?
M\='C?]L7Q;\#?^$ML/'/@_0X];T/P;=>-=,31]8>>TU"&U?9-:N[PHZ2)(Z?
M/L=)/,KMOB?^R+X7^+WB3QAJ6L7&J[_&&A66@W20SI']C2UGDGAGA?9O2=)'
M_P#'$K%U#]B.S\6Z9XJ_X2[QEXJ\7:OXH\-/X4_M6\2U@N-+T]_]8D*0P(F]
MY-CN\B?P)1U [CX5^,O%GB/X:?VYXFT'1]#U*X@^VVMA;:IY\<<+IO1)IG1-
MDG]_9\E>*:!_P4=MM+UCQG;>($\':K_PB_A2;Q7YW@_6WU6/9!/Y#VK[X4_?
M^8Z;'^Y)YE?0/B?X<Z;XR^%]_P"#[_SY-*U32WTBZV/Y<DD+P>0_S_W_ "Z\
MET3]@70?,N?^$C\3>)O%T-QX-F\#?9KQ+6UM[?3'='^1(84^?Y/OT2^*7(%/
MX/?.;_:4^-_QI\$?LR:EX@_L3P=X9U;[5I$EK-9ZU/=>7#=7J(\#[[7_ %GS
MHF_[G[Q]GW*N?%C]I#5O@C\3/%U_?^'GU+5?"_@K3];U>VL_$,\FF1VKZA.D
M[PPO#]^-$=]^S?)Y>RNLU#]D&3Q3\'];\&>)?B)XX\36^J6MK!:WEY]ECN-+
M^ROOA=-D*(\F]$WO)O\ ,\NM[2/V;K#_ (3#4M>US6-5\3:EKGA=/"FHO>)
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M %%&<49S0 449HS0 449HH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ;SBOF7_@K1^SAK7[4W[#_ (H\->&X6NM?M7AU6QM$^_>2
M0/O, _VG3</J:^G*",U5.7)/G(J0YH\I_*]X@^'VO>$M8FL-4T36--O[=]D]
MM<V3P21_\ JI_8]W_P ^=U_WY>OZH+O2;>YDWR6\,C?WGCWUGWGA>SE_Y<[7
M_OPE>TLY_N'!_9W]X_EK_L6\_P"?.[_[\/1_8MY_SYW?_?AZ_IYU#P'9R_\
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MA*/[9_N!_9J_G/YGO[%O/^?.[_[\/1_8MY_SYW?_ 'X>OZ8?^%:6?_/G:_\
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MBB@ J/R:DHH KR6OFTW["E6J* */V&C[#5ZB@"C]AH^PU>HH H_8:/L-7J*
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MT_&OD/Q+^VYX^\/:GKWA>XTGP#:^,/"J:EJ&H7%WJ5U#I,]G96UC/MA?9O\
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M3_\ "$^$S-XP7;KS_P!D0;]:_P"OGY/WW_;3-=G10!P^G_L\> =)U?2-0L_
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M>/0?L7_#S2?A38^"]/\ #NFZ9H-GJ.GZO=6]E9PP'5[JRDAGADN=J?O)#)!
M[O\ ??R^M>PT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1H817AI9@  24DJ  @    % !H!!0 !
M    2@   !L!!0 !    4@   "@! P !     @   #$! @ -    6@   #(!
M @ 4    :    'P   !@     0   &     !    1TE-4" R+C$P+C$P   R
M,#$Y.C$R.C$W(#$V.C4V.C(S  @   $$  $   #>     0$$  $      0
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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MG_[Y-3+IUPW\./J#_A70!5'10/H*7%9TN%,,OXDFQO&2Z(Q$TB0GYF7\"?\
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M?:+_ +X/_P 54MM\0Y)+F))8(U1G 8A,8&>?XJ /0:*S[B^<Z0;VS"R'RO,
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MGJ:YG_A*IDT"&]E$*W$V[8NUMIP^#W]/>H]-\3:C_:$=MJL4$ E(5-@)))(
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M>AK5\" #2">Y_P#BFK>ATJSM[1[6*"-8G!# (!NR,'/%26=A;V$7EV\81?0
M#^7UH Y2[4OXT1!U:P '_?RJ^BZS9Z+>WUM?/Y;M>2N#@GCIV!]#79'3K8W@
MNC&OG!=@;:,XSG&<9ZU5N?#VFW5P9Y+:/S#U(1>3Z]/>@#"\%3I<W>I31G*M
MY6/R85V-4[+3+33M_P!EA2/?C(50.F?0>]7* "BBB@ HHHH **** /_9_^("
ML$E#0U]04D]&24Q%  $!   "H&QC;7,$,   ;6YT<E)'0B!865H@!^, #  1
M  D #@ !86-S<$U31E0                                  /;6  $
M    TRUL8VUS
M               -9&5S8P   2    ! 8W!R=    6     V=W1P=    9@
M   48VAA9    :P    L<EA96@   =@    48EA96@   >P    49UA96@
M @     4<E120P   A0    @9U120P   A0    @8E120P   A0    @8VAR
M;0   C0    D9&UN9    E@    D9&UD9    GP    D;6QU8P         !
M    #&5N55,    D    ' !' $D 30!0 "  8@!U &D ; !T "T :0!N "
M<P!2 $< 0FUL=6,          0    QE;E53    &@   !P 4 !U &( ; !I
M &, ( !$ &\ ;0!A &D ;@  6%E:(        /;6  $     TRUS9C,R
M   !#$(   7>___S)0  !Y,  /V0___[H?___:(   /<  # ;EA96B
M  !OH   ./4   .06%E:(        "2?   /A   ML1865H@        8I<
M +>'   8V7!A<F$       ,    "9F8  /*G   -60  $]    I;8VAR;0
M     P    "CUP  5'P  $S-  "9F@  )F<   ]<;6QU8P         !
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MKY].LZ!]>G6>V.6^_:KH2A5#Z=:S0#K6P'>:UK6N?__$ "81  (! P,#! ,
M          $"  ,$,2$R01 @,!$2$Q114G#_V@ ( 0,! 3\!\26U1^(EFHW:
MSV*N@'@2B]3 B67[F)21-HZMVJC/M$2R8[HEO33CIZPUJ:Y,-Y3&(;[\"&[J
M'H 3B):.V=(M"A3W&?9HKB&^7@0WKG$-Q5;F$DY[00.)\[C1=(:C-D_PW__$
M #81   $ P,'"@<!          $" P0 !081$B$B,C-1@9'1$" P,4%A<:&Q
MX4)#8G"2P?#Q_]H " $" 0$_ >A$0#$8>5%+V> GO#J#'VAY5[E7);%N!O&"
M/7*]IU%!$?'H'<V9,=,H%NKMAY67PM$]H\(=S1X^TZ@B&KLW<K?-YKAV@T+>
M7.!8>5@W3P:EO#N#C#RH)@\P,>Z&H,/>.N"D,<;"A;",FF"^8B/IZPC24P4S
M["[>$(T6'SEMP0E2K!,MVTP[>0ZA$BWCC8$/*I8MLE++'NZM\+3J=3#!LF)0
M[@_<%IR;.S7U0_(?]A&C%ATRH!X!;PA&CV)-(83>4(R&6H9J(;<?6"(II8$*
M <U0BA\ -9_=_"#29HJ:^N G'ZA$?+JA)DV0T28!L^QO_\0 .!   @$# 00$
M"P@#         0(# !$2(003(C$R46&1$!0@(S S04)SL>$T<8&2DZ'!T4!2
M\/_:  @! 0 &/P+T7/(]E<(QJY8GT&K5P+^)KB:_H.)@*X!?[ZU:P[/#HAKV
M"N)^ZN9\&IM6G$>RN%2!V"M1WFM6 K4DUT.^M !Y/2M5VNWWFM% _P C:.-O
M6-[>VO6-WU'+DS)R87YBEVB%V\7GXEL:7>.3%)PM<\NVG8'SK\*58.Y)[:5'
M-Y6XG)Z_*VGXC?.I5VF1$8O<9#LKUT7=3P:#2Z'J-,CBS*;$5")3ZI<1_=>-
M./-Q='M;R]I^(WSIG@0,H-C=K5ZI?SBA2;6NF\X6';21CFQM4<"<E'/K\O:?
MB-\Z>,0B7)LKY6K[(/ST83 ([+E?*]0?$_BMF^(OS]!))XT1FQ:V'UK[6?T_
MK7VL_I_6C,)]Y=<;8VI(S)NL6RO:]1R>-$X,&MA]?0+>"18VDW0DTM>]JR#J
M>=M>=JDS(B"*K%F(MK5Q81\?&6'NFF<3QE%Z39:"BZ2*R#W@=*+12+(![5-Z
MS21>5RI.H^^HWWR,KO@"&%3J)%&Y-F)-*QGC"MT3ES\*G=0H1,9-^&XK7O;E
M21D1[J/>V;+4Y7_NE;S;,NZ(0G1L5L:9?-JY288AN69TIY$$84"(XGD<2;UM
M6[M#)*[E.JMH>46W@6PSRY5NG$<6,+1AD-\KGVUENTWXE5\6DN#;\*VH((P'
MD652&ZK:?M4$CHMES+*6RU-NSPM%U-N,L??)T/=1&^!;-T,%NB #9O\ NNM@
MG#>,SNK.!8"W!3-!*+M'!:7$7U:MQ)M."B<H=H*CEC<=E+M6=Y0,R;<P#K^U
M3'_1#+T?=-L?Y[J$,6U[Q3,J>,!1[5)(J=-_N@\ZJ\Y T\V*B-\M6UZ^(^1R
M%7L+]=#0:5T1W5.RZ-:]ZB119<>5<JL% _"C=0;UIIY'_\0 *! !  (! P('
M 0$  P       0 1(3%!46&!$" P<9&A\-'!L>'Q_]H " $!  $_(?16BV8K
MVF<Q9'G5F>HZOH:!7P98[95%;)T;>.CREW[BS$*^<"?%!AX K!<U=]JFIGNL
M_P"A0RK>_@18#EF(O\28K]*S%[I>9*^L+G\+YI8?E/JD/+I]/0S'.#+Z3B5Z
M5^-^D(A!BORG_JXG2&W:W6,3'<]#N?[ 7<.CA\ICV^2=^T"I"@'F,XS@OV=O
M-^%RE(BI<U2?O_R5\LP'M,<XXS9)8X!ZW5UT^)>6WU?C'\\_X7*7=A09=_!
M(W4"5#V=<##\?\2LFN;Y6IS@[DW?/^%RAU3(8,!QTGZ_\@"%:]A#CK/R]4_"
MX>@X6\ VWXJ*&DW;]Y'GI$.Z(S83GK/?#0:;] ?J.PU=HN]3B9:<I#GJ#XG%
M@U;LS*]MD0JA==.LPKC ]UEJ?K&CO$Q]2.CVE$1*9IZ-IE(,87O;>TP2236A
MGVS7O-9?::]GCDE^]=N#H:U@[2$:PJ8K%=4:P*U&B!IUL]HK-Q,)"[-,0AX:
MU*P..$CJ&K--Z)9IVAG*BR\&[4.8*L=*F3L*,?<$)=;5HK71\;$4J#B*Y'C&
MK/U _M"GA(TX?&UEJXV6NGIC\RO37G;SDV'B&?J$6^6FM0V:$+EXKCZE6)75
MH2>I:[0$86CM"NH96VD_9_BC(1  O9P!91\SJ$BD&^"TFY$]>X\F>\UWIO,G
M.%-,L^M,:0&)Z>5%-[,RBZDW;0T0,5IM!P(; T04 9-FLI0!P>3_V@ , P$
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2X=''P0"*(X7OA(YX&![?)__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image00005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MQK8V-6/)R'11PO)+XCYJ_P""G7_!1;P]_P $ZO@BNNWL:ZEXBU9VM]&T[?\
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M!$F\Q:^-?^"SO[-WQ?\ VF?V=]'T?X-ZQ/I6KV>K_:M0CAU![%[R#8_R;_\
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M>.!_N5KCJ,'A8UN3DD+"SG&MR<Q]O><H]*JG7K..]^R_:(?M/_/+?\]?B_\
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MM9_\$<_CE^Q)\(]3^)G_  M^+6)-""3W45AJ=W'=1_[>7K]&?^"!7[7/B/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M %'4K%;NPDAD^[,A1Z_FW^&>OM_P3>_X+)M=>*%>UL]#\43)-,Z?\NL[_?\
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M7H4*,_?YY,X_82JS^#E&?\%B_A[-\1O^"<GQ.TZU222:/2WND1/]CYZ^(/\
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M3A0I;1#"T9\\IS/R4_X+D?\ !7ZZTO4;SX%?"6X>?Q%J#_8M:U*V?]Y;;_\
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MQ8Z2:C<A/+@39_<_CJ<5A<-"//"84*U:7N3@?*W_  =??\DI^$W_ &%-0_\
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MR\$QOL:"VO;J9"G_ %Q^Y7[!?LY? FQ_9P^!GACP'I=U-=6'A?3X]/@FN/\
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M2WM_8^D1_:O^V</SU^?/_!-C_@WZMOV8/BQ;?$7XG^)X?&GBRSD\ZRM+:/\
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MH **** "BBB@ HHHH **** "BBB@ HHS1F@ HHS1F@ HHHH **,T9H ****
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M=KP;_AJ/QQ_T2[6?^_Z4_P#X:B\<?]$OUK_P*2CZG4#_ %BP?G_X"SW;'O\
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MTW_P*2I]G4#VE(W=@]!^52;!Z#\JY[_A8FB?]!;3?_ I*/\ A8FB?]!;3?\
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M;3?_  *2C_A8FB?]!;3?_ I*/9U.P>TI&YM']V.C$?HE8?\ PL31/^@MIO\
MX%)1_P +$T3_ *"VF_\ @4E'LZ@>TI&[L7^ZE&Q?[J5A?\+$T3_H+:;_ .!2
M4S_A8VB_]!;2O_ I*/9U ]I2.@VQ_P!T4;!Z#\JPO^%@:'_T%=+_ / I*E3Q
MYHO_ $&--_\  I*.1A[2D;&P>@_*E\F/_(K)_P"$YT7_ *"VE_\ @4E'_";Z
M-_T%=-_\"4J>1CYZ1K>3'Z4>3'Z5D_\ ";Z-_P!!C3?_  *3_&C_ (3?1O\
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MUF456A/M*II_\)'?_P#/Y??]_P!Z/^$CO_\ G\OO^_[UF^;]*?2T#VE4O_\
M"1W_ /S^7W_?]Z3_ (234/\ G_NO^_SU/;^"-5EUS3;"XL[JQFU1T2U^TH\?
MF;_XZZ']HC]GW6_V:?B!_P (WKSVL]_Y"3[[9_W>QZ7/3+O7.8_MZ_\ ^?\
MNO\ O^]+_;M]_P _EU_W_>L_S?>CS?>JT,/:52__ &]?_P#/Y??]_P!Z/^$C
MO_\ G\OO^_[U0\WWH\WWI:![2J7_ /A([_\ Y_+[_O\ O3/^$CO_ /G\OO\
MO^]4ZCIZ![2J:?\ PD=__P _E]_W_>C^WK__ )_+[_O^]4(Y*DH-/:5"Y_;M
M]_S^77_?]Z/[=OO^?RZ_[_O5.BG[-&?M*A<_MV^_Y_+K_O\ O1_;M]_S^77_
M '_>J=%'LT'M*A<_MV^_Y_+K_O\ O1_;M]_S^77_ '_>J=%'LT'M*A<_MV^_
MY_+K_O\ O1_;M]_S^77_ '_>J=%'LT'M*A<_MV^_Y_+K_O\ O1_;M]_S^77_
M '_>J=%'LT'M*A<_MV^_Y_+K_O\ O1_;M]_S^77_ '_>J=%'LT'M*A<_MV^_
MY_+K_O\ O1_;M]_S^77_ '_>J=%'LT'M*A<_MV^_Y_+K_O\ O1_;M]_S^77_
M '_>J=%'LT'M*A<_MV^_Y_+K_O\ O1_;M]_S^77_ '_>J=%'LT'M*A<_MV^_
MY_+K_O\ O1_;M]_S^77_ '_>J=%'LT'M*A<_MV^_Y_+K_O\ O1_;M]_S^77_
M '_>J=%(/:5"Y_;M]_S^77_?]Z/[=OO^?RZ_[_O5.B@/:5"Y_;M]_P _EU_W
M_>C^W;[_ )_+K_O^]4Z*?LT'M*A<_MV^_P"?RZ_[_O1_;M]_S^77_?\ >J=%
M(/:5"Y_;M]_S^77_ '_>C^W;[_G\NO\ O^]4Z* ]I4+G]NWW_/Y=?]_WH_MV
M^_Y_+K_O^]4Z* ]I4+G]NWW_ #^77_?]Z/[=OO\ G\NO^_[U3HH#VE0N?V[?
M?\_EU_W_ 'H_MV^_Y_+K_O\ O5.B@/:5"Y_;M]_S^77_ '_>C^W;[_G\NO\
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M+U/C9^FX?^'$>.E% Z45F:A1110 4444 %%%% !1110 4444 %%%% !1110
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M*\B^"GQ+M_A-X[MM;OO#^E^)H;>-T^P7Z?Z/)6V&ISC\9PYA6HU9P]B?3/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%O\ T+&N?^ +U^U7_"O?^F='_"O?^F=']HS#_5F'\Y^+/_"FO%W_ $+&N?\
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MHA_JS3_G/Q:_X4_XN_Z%?7/_  ">C_A3_B[_ *%?7/\ P">OVD_X03_9I_\
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M7US_ , GK]I_^%>_],Z7_A7O_3%*?]HS#_5FG_.?BO\ \*?\7?\ 0KZY_P"
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M_G\_\<2C_A:VM_\ /XG_ 'X2L"B@/:3.@_X6KKG_ #^?^0(Z/^%JZY_S^?\
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MO?\ /S'_ -^$H_X6_KW_ #\Q_P#?A*YRBI]F9^TF;_\ PMK7O^?I/^_*4?\
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M* ]I,W_^%K:W_P _B?\ ?A*7_A:NM_\ /S'_ -\)7/T5/LP]I,Z#_A:NM_\
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M%C3_ /KBG_H K1;[U<9WQV'T444%!1110 4444 %%%% !1110 4444 %%%%
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M*** "BBB@ HHI/F]JO4#Z/\ "?\ R+&F_P#7"/\ ] K53[M97A/_ )%C3?\
MKA'_ .@5JI]VN ]2G\(M%%%!H%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &+XV/_ !2&H_\ 7!Z^=/F]J^C?&I_XI+4/^N#U\Y?-[5=./N')
M7^.)\!?LS_M!7G[/'QX^)VH>,-8U*^\*^,->UU].^V3O)'9W6G[/]%3^YYD;
MIL2KG[/_ ,:?%7P1N/C'XS\5/?:QK&H6NGZW!I4UT_V>S>Z=_(@3^XGW*^BO
M%O[!_@#QOX'F\/:I9WUU87'BC_A+_P#CZ_>1WKOO_P"^/]BNA\2?LM>#_%MQ
MXM?4K.>X3QI90Z=J,+S_ +OR8/N;/[E;_8,?<YSQGXB?MA^/_P!GW6-;T'QA
MIOA74M8_X12;Q1I$VFQSQV\GD.B/!-O=_P"^GST?\-N>,_AI<:JWCK1_#\\/
M_"&OXOTY-'=XY/D=$\B;?_OI\]=_H_[!_A*UT?6X=6U7Q5XFO/$&G?V0]_K&
MH^?=V]E_SPA?8FQ*Z?7/V6O"7BC6(;S4K.>^\OP]-X7\F9_]'DLGV;T=/[_R
M51E[AXSXX_:6^*G@.\L-!\00^$8-0\<>&M0U'1+S34G_ .)7-!!OV3;W^?\
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MK6([W5G@\0W.J>9'>.ETZ(FS?_P"MOP7^WAXDNO@?J6MZM9^'X_&'VJULO\
MA&_(GM9]'NIWV;+G>_SI'_?C_P!97I?PG_8?T3X-ZH[Z-XP^(W]FR3W4W]E3
M:NDEA'Y^_?\ )Y._^/\ OU#;_L"^#[K3_$,>M:EXJ\1WGB2"&"?4M2U%)+NW
M2#_4)"Z(FSRZ9I[0/B#\4/'/PE^&]L_B;6/A[INO:AJ/V6UF^RW4EO<?)OV)
M#OWN_P#P.O!]/_:1O_C[\5/V>_$-^EKIMY;Z]X@TZZ^S.\%I</!!LW['^?9_
MUTKWO6/V&=!U[PMH]G>>*O']UJOA_4?[4T[6WU1)-3MYMCP??V;-GENZ?<_Y
M:4>&_P!@KP!X7L_#T,2:Q.GAN]U#4;7[3?>9YDUZFR??_?JH?&%.H>:Z/^VY
MXJ\4?%A_!]K?^#M5_P"$@\/:GJ.EZEI5K=1P:?-:I_&[O^^3_;39_JZYWX%_
M'/Q;=?L[_L_:QX^?3?$VJ^*-71$O_P!_'<1IY$GSO\_SO\E>S?"/]@#P3\(/
M%FCZK9W_ (FU*3PW976EZ7;:EJ/GV^GV4Z?/ B;/N5<\!_L,^#_ >B>'M-M[
M_P 1WUAX/U3^U](MKR]\R/3W^=/(3Y/N?/\ <K.F2>>Z'^V1XYU3PGX>^(4N
ME>&?^%>^)/$/]@P6:>?_ &G;I]J>U2=WW[/]8GW-E4_#?[9OQ(U2\_MZZT?P
MK'X-C\:OX4>%//\ M\B>?Y"3[]^S_@&RO2_#_P"P?X/\.^,(=2BO_$T^E6>H
M/J]KX>FU'S-(L[UWWO.D.S?_ *QW_CK>L_V2_"5AX3?1(O[2^QR>(?\ A)7_
M -*_>?:O/\__ +X\RJ#G/2U_CIU-\NG5>IF%%%%0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 =A\"_^1\C_ .N+U[A7A_P+_P"1
M\C_ZXO7N%<]0]'"_ >$_'7_DH$W_ %P2OSI_;\AU71OVW_#'C#1GNI[SX;^#
M;KQ#]FA?_CXA2]M?/39_UP=Z_1GXY?\ (_S?]<TKR_5/A+H.L^./^$ANM-@G
MUC^SIM(^TO\ \^KOO>#_ ,<K;^69R<_(?%OQ \9P_M&?M4> _B=I>JW%UX2T
MOQ#:Z#X>\F?_ $>X3R'GNI_^VDC[/^V==@/VH/B1%X7TWXG-KVE3^&=0\7IX
M=_X1)-.@\R.%[K[+O\[_ %_G_P ?]ROH3P?^R_X#\!^#_#V@Z-X?L;'2O"=U
M]MTNVAW^79S?W_\ Q^JVG_L@_#W2_&__  DD7AZ./4H[K^T4_?O]GCNO^>_D
M[]F^J)YSYYL_VF_BQ+>7GBJX\0Z'_P (WI?Q#F\*?V(FD)YEQ:_:O(1WF^_O
M_P"N=6_BI^TW\2-+\'_$7XD:3XATNQ\/?#/5_P"SO^$5?3DDDUA$=-^^;_7H
M\F_Y/+KZ-_X9S\&?V'-IO]B0?8[C5_[>>'>__'[OW^?_ -_*RO$'[(/P]\4>
M.)O$-YX>CGO[B=+J=//>.WN)D^X[P[]CO5?;*YX'R%\=/^$SUGP/^U+>7_C.
M>^T2WTN%X-$N;&#RX]]JCI\_W_W==MX/_:1^(7[--NFF^*-2TWQCIO\ PJQ_
M&6EPVVG):R:>]JD"?9=Z??23>G^L^?\ =U]&^,/V4/ ?CSQ1K>JZIH,=U>>)
M+7[%JG[]XX[R'_;3?LK8D^ _A6ZURSU*71[62\T_1'\/0.__ "ST]]F^#_<^
M1/\ OW6=,)5(2/E?P?\ M0?&FU^'^L>)]2MI[[1[CPA>Z\EY>:7:VMOH]TD&
M^!(=C_OH/^NE;>E_&GXA6O[.?@;5?$?Q%C@\5?$A(;W3H='\+P75Q;I]EWO!
M"C_(_P#?=Y*]P\-_L@^ /"6CZE86>B3QV&J63Z=/9O>SR6_DO]]$1W^2KWBS
M]F3P3XR\+^'M'O\ 1_\ 0?":(FC^3=/!)IZ;-GR.C[_]714)/FWPG^US\2/B
MKX'^$MGINL:5H>L>.-7U#1]1O[G3DD\O[*C_ #I#_J_,K1\)_M?>,/ ?V"Z\
M9:QI6I:#X?\ %&H>%/$.JPVJ01WFR!)[6Z^3[G\:.D==Y\2/V /"OBC4/A[9
MZ;80:;X5\'ZC=7L]A#//')(\Z?P/OW[_ #*N_'#]BC0?'G[,\WPQT&SL=*T3
M4+V&>Z\YWD\Q//WSOO\ O[Y*/9E>X<C\2/CGXYNO^";_ (Y\?Q/]EUZXTN]U
M'2/LT'ER6=K\_D/_ +_E_/5_PI\.?AO^S=^S/9^/_#.CZ;JNI>'_  U_:-K?
MI/YEWJC^1O=W?^/S*^@;3PE86OA>'1%LX/[*M[5++[,Z?NY(=FS97 ^!_P!C
M+X;_  TU![G2?#T<'F(\"0O=3R6\:/\ ?1(7?8E49_8/#XOC3\2-!M_!\GB;
MQ/H_BK1_BQHE[_H%MI:0?V&_V)YT\ET^=T_@?S-]<9^QE\4/B!\#/@G\&7U+
M6]-UCPEXD\/3>1H\.G)!)I_D0;T=)OOOO_Z:5]4> _V0?A[\--4>\TGP]'!<
MR6KVJ>==3S_9X7^^D*._R?\ ;.MC1_V??!^@Z/X;L+71(([/P>CP:1#\_EV:
M.FS_ -%U,(<II.H?/'P[_:1^)$7_  JOQAJWB'2M8\/?%C4?L/\ PCT.G)'_
M &.CH[H\,R?._E[/G\RO-/B3\1OC-\5?V"]8\>7GQ%M='^V:BD%K9Z;I$$?V
M=$O=GW_OU]>^!OV1OA[\/O&$.MZ3H,<%_;N[VN^Z>2.S=_O^2COL3_MG6E)^
MSGX,E^$<W@;^Q+7_ (16X1]]AO?RY-[[_P#T94T]P]H>:?MPV&J:#_P3O^)$
M.I:K_;&JV_AJZ\Z_\A+7[0^S_8^Y7,:?%XA^ _[*>L>*M)\,>#O >L:/IT%[
M^YG\^/6(43>Z/\GR/)7O>H? OPWK/PCN? UY8277AB\LGTZ>SFG>3S(7_@W_
M 'ZYO1_V,OA[H.CO8V^B3SV$CPN]M<ZC=3QR>1]SY'>JG[TR/Y3P'3_VTO'G
MQ!_9_P#"7C;1;S1_#\WQ \90Z):V%_:I)_8=KLV;)OXWG\Q-_P#WQ6K;_M-^
M,/!UGX\\)>)O&T$FO>&];M=.T[7K#04GN-0^U)O2!+9/D\^O0OV@/V'O#WQ:
MM]-M["SL=-L_^$KA\2ZO#O>./4'1/+^3^X_W/]773V_[&_PZB\%OH*^'O+L)
M+U-1=_M4_P!H^U?\]_.W[]]:ZFI\\>'_ -KGXG>(_A_X>TVSU6Q@\27'Q#F\
M&W6JW^D)')):I!OWO"GR)/\ /_RSKI)/C=\8+7X3^*K"WOX]<\0^#_%']EZC
MK&FZ1!]K_L_8CO-#;?<>?_8KW+PW^RKX#\)6=G#8:#! FGZP^O0?OWDDCO73
M9Y_SO_K-E6?$'[-WA+Q19ZE#<:;)'_;%[_:-T]M=3P27$VS9OWH]09\Y\L>-
M/VW'\)>.;;Q/I<VF^,8;/X63:VFI3:=]EN[B9+UX-C_W$_OI70>+/VA_B=\#
M+>%]<\5:/XN_X2CP;J>O67DZ7!!_8]U:V7GILV??@_ZZ5[]H_P"RA\/= ^S?
M9_#%C']GTA]!3?O?_0G?>\'_ '\=ZI^%OV-_AUX-M]2AL_#T>S5-.FTB?SKJ
M>?\ T5_D>!-[_(G_ %SJ?ME>T]P\B_9G^-WQ1O\ Q?\ #&;QIXAT;7--^*'A
MK^U/L=MI:6O]CS(B/\CI]])-_P#RTKO_ /@H1\1M>^&G[#?Q.\0>$YI(];T_
M0;I[6:V_>26_\#SI_P!<X][_ /;.NPUCX#Z)%X;TVVT:SM=-O_#>ES:7H,WS
MR?V6CIL_]%I5_P"%_P )K#X<_">P\)RO)JMG9V7V6=[S]Y]LW_?W_P#72BH9
MT_CYSQ/4/@WX,^"/[*=YXJ\ Z;ILGB33_"\T^G:E"_F7=X_D??W_ ,;_ ,=>
M1?%SX5>#_!'_  37T'XA>&4@C\?V]EIFKZ=K<,_F7^H:F\\&]'?^/S)'=-E?
M5?P[_8\^'OPJUC[9H.@_97V.B(]U//;VZ/\ ?1$=]B50\/\ [#WPQ\+^)+;5
M;/PW''<V<_VJUA>ZGDM+>;^^D+OL3_OBJ-/:'S'<>(YO@W^W1XP^)U_<SP:;
M;ZO9:#KV^?\ T>.UGM=Z/_VSDK-TOPGXD^+_ .T9JOB32]2GTWQ)\6/ WB-]
M(F>=XX[.U2>Q@LO_ &=_^V]?9_C#]FGP3X\T?Q58:MH-K?6?C39_;<+[_P#B
M8;/N59_X4/X5^V:;=?V7#'-H^D/H-DZ.\?V>R?9O@3_OA/\ OW0'M#X&^)'_
M  DG[.=O;?V#X)D\!^)-+\ :LFHO;7J3_P!J/!!\D[HG_33^.2O8/ _PT\,?
M"_XH?L\/X4A@@?Q1X;NH-7>%_P#D*0_98'\^;^_^\_C_ .FE?1OP_P#V7_!/
MPTDOYM+T=/M.J0?9;J:\G>ZDN(?[F]W^Y5#X?_L=_#WX7W%S-H>@_97N+)].
M^>ZGD^SPO]^"'>_R)_USH#W#QGX#_#G0=>_;4O/$_P .]-M=#\&>%](FT34;
MRS_=V_B"]=_[G\?D?W_^FE<]^WQ87E_^U99_9? MCX_2S^'E[.^FW-UY'E_Z
M5]]/]NO?O@_^Q/\ #KX!:NE_X2T&?1YK?>B;-1NI(X]_W_D=]E=S>?#G1[_Q
MPGB26PCDUN/3GTN.Y_Y:1VKOO=*FI#X2><^/_AOX#T?QO<?LVZ5K-S'XNTJX
MTC4Y]]Y^\CD_<?<='_YY_<K@_BA:OX7\/_&/P3X<ADU7P-H?CS0DTBP>Z?[/
M'-.B/=62/_<\S^#_ )9^97V-X@_8M^&_B/1]'L+CP]Y=MX?GFGTY(;V>#[.\
M_P!_8Z/_ ,M*V-/_ &;O!.E^!X?#=OX>M8-'M[U-12V3?_Q](^])W?\ C>J#
MG/G+]HSP1<V'A?X7:;;_  Z\/Z5->>,DWZ#_ &C_ *)>?N)_OOL_]DKZ9^#?
MA?\ X1+X?V=LV@Z5X<?[[V%@_F6\?_ Z/BY\!_#'QST>SL_$UA)?0Z?=?:K7
M9.\$EO-_?WI\]7_AW\--*^%_AM-+T:&>"PC??LFNGGD_[[=]] 3-Z.G4GS>U
M+09A1110 4444 %%%% !2?-[4M)\WM0!]'^$_P#D6--_ZX1_^@5JI]VLKPG_
M ,BQIO\ UPC_ /0*U4^[7&>I3^$6BBB@T"BBB@ HHHH **** "BBB@ HHHH
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M&;_GC)_WQ7N'_")1_P!VH_\ A$4_N4<X?53Q/[#-_P \9/\ OBC[+-_SQ?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH KWTOE6TC_[%<M_;-S+)_KI*ZG5/^/";_<KC
MZ +']M7G_/S)1_;-S_S\R56^;VI/,H M?VK<_P#/9J;]NF_Y[R57\RG4 2?;
MYO[[TW[?=?WWIM% "_;YO[\E'V^;^_)24WS* '_;YO[\E+]ONO[[TSYO:CYO
M:@!WV^;^_)1]OF_OR4R2E^;VH ?]ONO[[T?;[K^^],^;VI: %^WS?WY*/M\W
M]^2DHH 7[?-_?DH^WS?WY*;\WM2T .^WW7]]Z/M]U_?>FT4 .^WW7]]Z3[?-
M_?DIOS>U,H E^WS?WY*/M\W]^2F_-[4?-[4 .^WS?WY*/M\W]^2F>92_-[4
M.^WS?WY*/M\W]^2F?\M*=0 [[?=?WWH^WW7]]Z9\WM2T .^WW7]]Z3[?-_?D
MIOS>U)YE #_M\W]^2C[?-_?DIOS>U1^;]: )OM\W]^2C[?-_?DIOS>U'S>U
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M5RO]NW'_ #V_\<J/^W[C_GL__?% '745R/\ ;]Q_SV?_ +XH_M^X_P">S_\
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MR/\ ;]Q_SV?_ +XH_M^X_P">S_\ ?% '745R/]OW'_/9_P#OBC^W[C_GL_\
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M3_9W\&:;JGB&3Q5?Z?I<,#ZPZ/')J'R??^?]Y71_R[ ]$HI/F]J6LP"BBB@
MHHHH T/#?_(4_P" 5TV?W=<SX;_Y"G_ *ZB@#E/%7_(3?_<KQ#X\?MK^"?V<
M_'%GX>UY/%5UK%YITVK_ &;1]!NM5\NV1]CSOY*/L3YZ]O\ %7_(3?\ W*^,
M/VB/!'CGQ;_P4HT1/!>MVOAEY/ASJ%K/J5SI?VZ.-'O;7Y$_@WUG]N('T_\
M#_XJ^'OBAX#T?Q)H>JV.I:)KD"75C>(_[NX1Z)/B7H-K\0$\,-K&FQ^))+)]
M133?._TB2%'V;]G_ %T=*^ /VM/!'AO]GCP7;?"6UT7[4WA/P,][I?B359[W
MS[RZ>=_DMDM?W?VKS/G_ .VE;?P?\&Z)_P -P?!;Q;XRL)_[;\0?"C9!J5XD
MWF7&II/:O_WWY>__ %E:?NP/N'X?_$NS^(/@NVUN*'4M*MKS[D.JP_9;B/\
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MYR^.+#QGX(\0:+\+M+_MR/1/VB/#VBHEY#O_ .)'-:[$U!-_\'F6O_H%/_:
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MF>/+#3_C'<ZU#JL?C"3PU\/$U&:%'CDDNM_^E;-G_ ]]97[;&E^'O$?PX_:
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MWLFK:@CI [SPHG[A+7Y]E;&L6&N6'QX\836L.JP)>?&[P^[O"CQ^9#]B??\
M]LZ"*?O'Z!#5+:*X\EKF#SO[F_\ >4^WU"&6Y\M9HY'^_LWU^97P'UG0?BK^
MTAI5YKUY:Z;KVE^*]6G^WWCZA]KUCYY$@M=^S[+^[_Z9R5T/[-_PEF\!^&_@
M#XSMT\3?\);KGCG4[+6[RYO;J>2XLG2^_<.COLV?(FR@L_12/5+>6X>%9H/.
MC^^F_P#>41W\,LFQ9H)'^_LWU^=?A/X@IXN_:X\#:KX?T2U\,ZE>:]J=KJ]G
M;/>SW_DHC_\ 'Z[_ ";)/X/_ !RI?V?OA!-X)\&_!'QM80^)/^$UUCQKJ=EJ
MEY<WMU(]Q9O]KV0S([[/)^1-E 'WUXX\;VW@CPOJNJRI=72:7:O=3VUG!Y]Q
M(B?W$3YW>IO#_BBVUGP_INI?O+1-4@2>"&Y3R)/G3?L='_C_ -BOSQT^7PK=
M?L;_ !.FN'\0?\+[_L37?[1^>]^W^=\__ -GW-E8GC'2]>\9?$2'2O'FMVOA
M_1[CX7Z$GA2\UM+WR[.Z>U?[;/;/"Z?Z5')L_P!9\]$P_OGZ<274,5PB,\<;
MR?<3?_K*Q/%'CRV\+^(=%TV6SU*=]<G>.":VM7DM[?8F_P#?/_!7Q5K$2?"#
M]I3P3JM_K%K\5-;O$TG1WL+E+J"_TM_N?;;;^#9_&_F5[9^V!_:47[0'P9^P
M?;OLWVW5OM7D[_+_ ./+Y-]$_@YP/H2/4(99-B31R/\ W-]<]\4/B7IOPJ^'
M^O>(;_S)[/P_9/>W4,/[R38E?"O[-?P@F\!Z/\!/&%A#X@C\8:QXAU"UU>\N
M;V>22XA?S_W$R.^S9\B5#\+XO!>O?L;^,OMZ:Q=?'*X\/:LFO)<_:I+N2;>^
M]'3[FS^Y_P".5G(*9]\_#?X@V'Q+^'^C^(;'S([/6+*'48$F_P!9&CIO3?5G
MQ1XHMO"_A^\O[I_W-O ]U\C_ +R1$3?\E?GIX&^*$WP'M_&</B-_$%JGBCX-
MZ3!X:MH;6>?[9=):NCI"B?\ +?S'2N;CBTW7K.&'XQ?\)-]C_P"%/:3_ ,(:
MB/=1R27KVK_:MGD_\O7F;/\ 65I4-#[\^#_[2VC_ !E_L=]-L-8AAUS1$UZ"
MYN;5X[>.'?LV>=_J]_\ L5Z%;W\-SOVS))Y?W]C_ .KK\J=8M?%6E_L_Z];6
M'_"36J1_LTS):HGGQR1WOVU__(_E_P# Z] ^*'@-_P!EKP_<W_@^;Q%H_P#;
MGPBFNM7F_M&>?[1J"?<G?>_^OHG\?(9GZ+6]_;7,NR*:"9_[B/YE6*^$/^"6
M^E^&-4^.&O>*+.\TW3=5U3PIIEJF@I_:,<G[C?\ :KW_ $U$_P!9),B?N_\
MGG7W?6@!11168!1110 4GS>U+2?-[4 =CIW_ !X1?[E6*KZ=_P >$7^Y5B@
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M_!6E'_#Z[X_?]#!H_P#X*TI?V/,/KT#]R_M:4?:TK\-/^'UG[0/_ $,.C_\
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M:4?\/JOV@/\ H8-'_P#!6E']EU ^O0/W,^UI3_M:U^&'_#ZK]H#_ *&#1_\
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M_P '^)/B#\0G\(ZE\0'_ .))86VEO=>9O^YO?^"FL= S^JSY#X8HK[)^&_\
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M12\LO,CU2U?9O=/[C_)7T;Y=,\KZT ?,'PS_ ."='_"N/A/\)?#/_"2?:O\
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M??LS_L,IK/Q,^/=YXFAU6/PWXHGNO#V@V=RGE_9]/F^>Z=/^NDCU]G>71Y=
M'S'\,_V&=;\)?"?4O!FI:IX.GTV3PU=>&K+4K/1/(U/8\'D)-,_]_P O_GG5
M/PQ^P-XG^#FHZ??^ ?&VFZ;?W'A2R\*:W]OT[SX[A+7?Y%U#L^X_SO7U1Y='
MET?8Y /FSX3_ /!/&P^$'CS2M2TO7IY[;2_ ;^#=DT'[RX=YYYWNG_[:3/\
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M HHHH **** "BBB@ HHHH *3YO:EI/F]J .QT[_CPB_W*L57T[_CPB_W*L4
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M5S^TG/XS2%/D^ (_OQUVT/\ JE^E<3']^.NVA_U2_2@!U%%% !1110 4444
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M:2HZ* )/M,W]Z2C[8_\ ?DJ.B@"3[8_]^2C[8_\ ?DJ.B@"3[8_]^2C[8_\
M?DJ.B@"3[8_]^2C[8_\ ?DJ.B@"3[8_]^2C[8_\ ?DJ.B@"3[8_]^2C[8_\
M?DJ.B@"3[8_]^2C[8_\ ?DJ.B@"3[8_]^2C[8_\ ?DJ.B@"3[8_]^2C[8_\
M?DJ.B@"3[8_]^2C[8_\ ?DJ.B@"3[8_]^2C[8_\ ?DJ.B@"3[8_]^2C[8_\
M?DJ.B@"3[8_]^2C[8_\ ?DJ.B@"3[8_]^2C[8_\ ?DJ.B@"3[8_]^2C[8_\
M?DJ.B@"3[8_]^2C[8_\ ?DJ.B@"3[8_]^2C[8_\ ?DJ.B@"3[8_]^2C[8_\
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MT2UO[2?5='V/>VR/^\L]Z;TWUL_-[5\+_$S]H/6/@W\:/C-XDT.SDDU76/\
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MZ5)YE #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"/R7?8G_ -E=M\$_A?9_!;X3^'O"NG_P#'OX?TZ&R39_RTV)75>72_-[4
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M&E:E'([I<PVJ1R1[_P".IM0_9I\!ZIXPFUZZ\'Z'/K=Q.D[WCVO[R29/N/\
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M03?O[UX4_P">G\'^Q7Z*>*/!NF^-_#=YHFLV%KJ6CZA!Y%U9W*>9'<)_<?\
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M3='T=/(M;9/^6:5H9F_\WM2T45F 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4GS>U+2?-[4
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M?@_^TMX2^-VH7EGHUS=0:KIZ;Y]-U*R>QO[=/[_DO\^RCV8'H?S>U+38Z=0
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M>:* .4_L"X_NT?V!<?W:ZG91LH Y"72YHOO)5:27ROO5UMQ;>;5"?1DE_@H
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M_GI6W_PB\/\ <H_X1>'^Y0!B?VS#_P ]*/[9A_YZ5M_\(O#_ '*/^$7A_N4
M8G]LP_\ /2C^V8?^>E;?_"+P_P!RC_A%X?[E &)_;,/_ #TH_MF'_GI6W_PB
M\/\ <H_X1>'^Y0!C_P!J0_WJFMY/M7W:UO\ A'(ZMV^C)%_!0!D1Z7--]U)*
M=_85Q_SP>ND@M?*JPJ;: .3_ +"NO^>-']@W,O\ !76; :-E #+2/R;=5J6F
MJNP4Z@ HHHH **** "BBB@ HHHH **** ,SQ3_R"Y*YJNE\4_P#(+DKFJ "D
M^;VI:* $^;VH^;VH^;VH^;VH 3RZ7YO:CYO:D\R@!?F]J6D^;VH^;VH 6BF^
M93J "BBD^;VH 6BBB@ HHI/F]J %HI/F]J3S* '44GS>U+0 4444 %%%)\WM
M0 M%-\RCS* '44GS>U+0 4444 %%%% !1110 4444 %%%% !']^.NVA_U2_2
MN)C^_'7;0_ZI?I0 ZBBB@ HHHH **** "BBB@ HHHH ***#0!#,6$?RCYJH[
MM1_Z=:N23>4.:\[\2?M7?#[P?JCV.I>*M&M[J/[Z&?[E7&G.?P'-7Q="C_&E
M8[G=J/\ TZT;M1_Z=?UKSC_AM?X7_P#0Z:/_ -_*/^&U_A?_ -#IH_\ W\JO
M83.;^VL%_P _8'HV=0_Z=?UHQ??].M>>?\-J?"__ *'+1?\ OY3/^&U?A?\
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M_4>D_P#$P_Z=:/\ B8?].M>:_P##:?PP_P"ART;_ +_4?\-G?#'_ *''1?\
MO[1]7F']M8#_ )_(]*Q?_P#3K1B__P"G6O./^&TOAG_T.6B_]_*;_P -I?#/
M_H<M&_[^?_6H^KS#^V<#_P _4>D_\3#_ *=:/^)A_P!.M>;_ /#:/PQ_Z'/1
M_P#ONG?\-K_#'_H=-'_[[H]A4_D*_MK!?\_8'HW_ !,/^G6C_B8?].M>:_\
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M_P#0XZ/_ -_*/J\P_MK+_P#G\CTWS+__ *=?S-'F7_\ TZ_F:\R_X;/^&/\
MT..C_P#?RC_AL_X8_P#0XZ/_ -_*/J\P_MG+_P#G\CTWS+__ *=?S-'F7_\
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M^G6C_B8?].M>:_\ #9WPQ_Z''1?^_M)_PVE\,?\ H<-&_P"_M'U>8?VUE_\
MS^7WGI?_ !,/^G6C_B8?].M>:_\ #9WPQ_Z''1?^_M'_  V=\,?^AQT7_O[1
M]7F']LY?_P _E]YZ5_Q,/^G6C_B8?].M>:_\-G?#'_H<=%_[^T?\-G?#'_H<
M=%_[^T?5YA_;.7_\_E]YZ5_Q,/\ IUH_XF'_ $ZUYK_PV=\,?^AQT7_O[1_P
MV=\,?^AQT7_O[1]7F']LY?\ \_E]YZ5_Q,/^G6C_ (F'_3K7FO\ PV=\,?\
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M'_F<M%_[^T?5YA_;."_Y^H]&VZE_TZT;=2_Z=:\]'[:WPO\ ^APT?_OY2?\
M#:_PO_Z'31_^_E9^PF']M8'_ )^P/0]NI?\ 3K4O^G^MK^1KS?\ X;6^%_\
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M /;3_4_\#HG\?(!],^*/BUHG@WP?#KUY<R1V%XB/ Z0O)))O^Y\E<Q_PU]X
MB^'Z>)Y_$,%KH_\ :/\ 9&^9'CDCNO\ G@Z?WZH?M8:#XVU3X?Z;#X%2Z_T?
M48?[1MM-NDM;^2R_C2&9_D1Z^?OA_P#L>>/+7PO-#>:)=Q_:/BA9>*/)U+5T
MU*XCT](/G=YOXWH ]F^*'[?_ (/\&_!?6_&&DS2:Q_PC]TEE=6?D/')',_\
M _\ <KL_#_QIA\6_$3P]9V&I6/V/7-(FU&.SF@>.[DV.B;T_V/GKQ;XV?LM>
M,/&]Y\=9M-L()/\ A,(-/?1$>Z2/[8\"?.G^Q_VTKK9/A5XG^*OQE\)>(=9T
M2^\,V'_"(7ND:BD.J)]KT^9W@V;'A_W/OQT!4.J_: _:ETW]GWQQX,T?4K:>
M?_A++W[+O1'D^SIL^_73_P#"\_#$O_"2?\36"/\ X0](9]7_ .G-'@\]-_\
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MQ)\CUS?F^]5"I3E\!RUJ.(I3Y)!11))6]>?#'Q!8^!8?%,FFS1Z'._DPW?\
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M?\%'8I]GP_>17_=Z$F'KRWX/^#?AOXC\/S3>,O%M]X?OXY_+2&&Q>?S$_P"
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MIO\ PA7_ $S_ %J/[5K!_P 0SRW^<_,__AC+XB_] 6/_ +_)2_\ #&?Q"_Z
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M?Q&_Z B?]_DK]*?^$.3_ &*?_P (:O\ L5/]J5 _XAGEG\Y^:?\ PQG\1O\
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M0!J45E_\)?9_WW_[]T?\)?9_WW_[]T :E%9?_"7V?]]_^_='_"7V?]]_^_=
M&I167_PE]G_??_OW1_PE]G_??_OW0!J45E_\)?9_WW_[]T?\)?9_WW_[]T :
ME%9?_"7V?]]_^_='_"7V?]]_^_= &I167_PE]G_??_OW1_PE]G_??_OW0!J4
M5E_\)?9_WW_[]T?\)?9_WW_[]T :E%9?_"7V?]]_^_='_"7V?]]_^_= &I16
M7_PE]G_??_OW4G_"46__ $T_[]T :%%5+;689?NU9M_WOW: '45/%I<TOW4J
M;^P+C^[0!3C_ -97:P_ZI?I7-V'AFX^T;Y?+1=^:Z:@ HHHH **** "BBB@
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M\7'_ 'W1_:EY_P _%Q_WW5;S?K1YOUHU#GF6?[8O?^?J?_OY1_;%[_S]3_\
M?RJWF_6CS?K1J'/,L_VQ>_\ /U/_ -_*/[8O?^?J?_OY5>BC4/:3+']L7O\
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MSP>>F]Z53W2.2'.>I:?\6M*M+?1[;7M5T#1]>U2!)_L":HDGSO\ W'^3>G_
M*U+SQYHEAKD.FRZQI4&I7#[$MGND^T2/_N5\3_&CX??9;CXV>&]2\$ZKJGC/
MQ9JD+^#;^VTYYXX[78B0>3-_RQ\B1'KT[]F/]GU[#]K#XD>)/%6B?:M5M[+2
M;73M5N8/,^=(/W[P_P#;2BG[PYT^4]%^+O[6D/PY^*D/@S2?!GB[QQXA_LY-
M7O8=$2U_XE]J[[$=_.F3_;^2/?\ ZNN\D^*&@V&H6-G?ZQINFZEJB(\%A>72
M07$F_P#@V5\W_P#!0#2]$NO%$.L:7IOCS3?BOH^G;/#6MZ#9/)'>;_\ EUF=
M/W;IYG\$E>2_M.R^/_B#X6O]*U[PE]E\81VNBSP/8:#Y]QJDV]'G?[3_  >7
M1[0I4Z9]2Q_M7IKW[5FH?#?1K/1[I/#]JD^MW]SK:07%N[_/LAAV/O\ ]OYT
MKN=8^/'@_0? ^M^))?$FCR:/X?@>?4;F&Z2>.SV?W]E?,'QP_9XUS7O'_P"T
M/?\ ASP]Y&L:QHFF)IUY#:_O+S8G[]$?^_6/\-_@%IOCSP/X_N=+_MBZO]0\
M 3:"^B3>'O[-M))MGR;_ ._/')13^ )P]\^NOAO\:?#'Q?\ #^FZEX;UK3=5
ML]4M4O;7R9_WDD+_ ,>S[]8GQ\^.</PE^$=YKVEI:ZQ?_:H=/TZV2?\ =W%T
M\^Q$^2OCSQQ=3?!;]D/X/_$CP7X>OM-\2>#]+A\*:CIKV/V62X>Z@2!_D_V)
MTWUZC\/_ (5/:_%CX2_"A7DOM-^&>E_\)?XEN7_Y>-0?Y+5'_P!N21YIO^V=
M'/S$<AU]O^WK-%\:+;P!<?!_XJ1^*+BR_M'8B:1]G\G?L>??]M^YYG_ _P#8
MKVVX^(V@VOBB'1+C6M*@UNX3>E@]TD=Q)_P"O&;SP;JO_#S?3=>^P77]B1^
M'LGO-G^CQS?:ON;Z\'\<?#ZYO]#\;>$KCP?K%U\5]8\>)JFD:Q]B>3_1?/@=
M)TN?X$C@1TH^P7*$.<^L?AO^TCI7C>\\<I>)'H=GX'U=]+GO+RZ2..X^3?O_
M -BNP_X6-H/_  C<.L?VWI7]E7'W+S[4GV>3_@=?"OQ(^$'C.UO->U"6SU6/
M1+?XDIJFJ;-.^U?:++[+L\_R?XTCDK;\0?LYV?BCX2>&+/38=8\3:)K'Q-M=
M7U&VN=+>QM[>'8^_9#_SP\RB4S/D/L/_ (6_X5^T6"?\)/X?WZI\]DGVU/\
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M .$?T^RU'^TKR]2..\\_[B(CUT]Q\6X;#XH7/AZZL_LMG;Z0FKOK#W4$=O\
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MC/X\> ]>\9?M@:;XYT'P]KDGPZTO^R8/%=ML>/\ X22;[]K.D/\ TZ;TW_\
M73_8KS?QAHUA\1O^%]^&]+\&:QJ7Q%UCQDB>'M8ALGDCLW^38Z3?\L?+^^]&
MI7L3]%[CXC:#:>*$T276]*CUB3_5V#W2?:)/^ 4R7XE^&XM<ATUM>T?^TKA]
MB6?VU/M$C_W-E?%OQXB\3^-OC0EFWAB2QUC1_'.GO ]GH.^2\LD=-]Z][_<D
MIFL?LR7/_"N_'^O+X5GD\87'Q3M=1LKSR/\ 2_LJ74'SH_\ <V;Z7M"9\A]I
M:I\2M'TO4+S35U*QNM8LX'NO[-2Z3[7)\F_[E9NC_&[1/^%=Z5XDUZYL?"L.
ML)O2'4KV#]V_]S>C^6__ &SKYI\0:->>%_VD?%MGX2TV^UR'Q0^ISZHE_I#Q
MW&CN\'WX;G^-)/X$KB?@WX-N?A5<?"[5OB=X2UC7/#%O\//[(@MGTY[[^R]3
M\_>Z/#_?DC^3?1"H5R'W)KGQ%\/>$K-+G4M;T>QMY$\])KFZ2..1/[]:NGZI
M;:SI\-S9S075M<)O2:%_,CD2O@_X%_LJZK?_ !,^#B>,O"L]WH^E^&M:=+:_
M3S(]+2>ZWVL#_P"W''7TI^P7X8O_  1^S=INE:E9W5C-9ZC>I!#-_K(X?M3[
M/^ >713(J4^4]FHHHJC(**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KUSX5?\B9;?5OYUY'7K?PJ_Y$F'ZM_.L<0=^6_&=2.E% Z45RGLA1110
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M7PK<>+;SXR?\%%/ ?BJ+4KZ3PK>:CJ?AK3K:&Z>.WO((+)_/?9_'^\JYX@^
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MF?XR_$+X+?#O5?$'_$CNO!DGQ0U;2)[-]_V^1)]4G3?O_P!C^Y6=,.4^^/\
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M^&TUZ?\ L6WF?^Y#_<_V-^S_ &*]SHH)/GW_ (=Q> _M%S;17_C*#PK>7O\
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M  '_ ,$\?!/@C6-*NKC5?&/B"P\/WO\ :.EZ5JNKO/IFGS;]^](4V(_ER/\
M)YF^O?**/9ASS.4\#_"72OA]XH\5:QIWGQWGC#44U34=[^9'YR0)!\G_ &S1
M*XGP'^QWIOPT\?W.MZ-XM\>6MM>:B^J3Z/\ V@G]F23/]_Y-G_L]>PT50>T/
M,/V;_A!?_"K3_$]YK,UK/K'BS7KK5[IX?]7'O^1$_P"_:)7IJ=*6.*EH)"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH%J%%%% :A7K?PJ_Y$F'ZM
M_.O(GZ5Z[\)?^1,AK'$'?EOQG4CI10.E%<I[04444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% %'6M/_M33IK?[OF)LKRRX^$VL13[5ACD_
M[:5[#46X5=.IR&-7#PJ?&>/_ /"J];_YX_\ C]-D^%6M_P#/&/\ [[KV/S/\
MXH\S_.*T]M,Y_J,#QF3X::Q:_>A_\?JM)X-OX_O0_P#C]>S7$22U0N=+26E[
M</J,#R(^'+R+^"F?V%<?W*]7DT:'_IG4']@PT>W#ZC \O_L>Y_YYR4?V/<_\
M\Y*]1_X1N'VH_P"$;A]J/;A]1@>7?V/<_P#/.2C^Q[G_ )YR5ZC_ ,(W#[4?
M\(W#[4>W#^SH'EW]CW/_ #SDH_L>Y_YYR5ZC_P (W#[4?\(W#[4>W#^S8'EW
M]CW/_/.2C^Q[G_GG)7J/_"-P^U'_  C</M1[<?\ 9T#R[^Q[G_GG)1_8]S_S
MSDKU'_A&X?:C_A&X?:CVXOJ,#R[^Q[G_ )YR4?V/<_\ /.2O4?\ A&X?:C_A
M&X?:CVX_[.@>7?V/<_\ /.2C^Q[G_GG)7J/_  C</M1_PC</M1[<7U&!Y=_8
M]S_SSDH_L>Y_YYR5ZC_PC</M1_PC</M1[</[.@>7?V/<_P#/.2C^Q[G_ )YR
M5ZC_ ,(W#[4?\(W#[4>W#ZC \N_L>Y_YYR4?V/<_\\Y*]1_X1N'VH_X1N'VH
M]N']G0/+O['N?^><E']CW/\ SSDKU'_A&X?:C_A&X?:CVX?V= \N_L>Y_P">
M<E']CW/_ #SDKU'_ (1N'VH_X1N'VH]N'U&!Y=_8]S_SSDH_L>Y_YYR5ZC_P
MC</M1_PC</M1[</[.@>7?V/<_P#/.2C^Q[G_ )YR5ZC_ ,(W#[4?\(W#[4>W
M#^S8'EW]CW/_ #SDH_L>Y_YYR5ZC_P (W#[4?\(W#[4>W#^SH'EW]CW/_/.2
MC^Q[G_GG)7J/_"-P^U'_  C</M1[</J,#R[^Q[G_ )YR4?V/<_\ /.2O4?\
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M0!7OI?*M)&7^Y7(^:\DN]GDKKM4_X\)O]RN/H /.;^_1YKT44 'FO1YKT44
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M!V?F4>97)?!/XR>'OV@OAO8>+?"]Y)?:#JF_[+,Z/'))L=T?Y'_Z:)76^70
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M>/-!T/2[K7O$MA9W4$'SSH\%EOW_ /;9Z\E\#_$O6_&^A_LQZ'XJMKJQ\8>
M_'][X>U>VF_>21^1IUUL=_\ @&ROTFCTN&.X>988(YI$\MW1/WDE5O\ A'+#
M[9YWV&Q\[?Y^_P A/,W_ -^H_P"79H?&W["?B/6_!'_!&>SU7P^DG]MZ?I>K
M3V6R/S)-_P!MNOX*YO6/B#HO@W]D.;6_ OQ.\0:YJ6N?V9_PE=Y_:CWTFCPS
MSHEU=;/^6+_?_P"N=?>=GI=MI=FD-O#!!:Q_<A1/+CCJGI_@C1-+CN4M='TJ
MU2\_X^DALDCCN/\ ?^3YZN1F?GC\8/&]Y\/M#^+6B?"WQYX@UGP39Z1I,\&J
MIJCWTFEZA/=;'2&;_II'L?94WQ(^$NL:#XP^-^B6OQ"^(W]F^#_ $/C+3D_M
MM_,CU/8[^?O_ +GR?<^Y7Z#Z?X(T?1M/^QV>E:5:V<C[WMH;5(XY/^ 5:_L"
MUEW[K:UD^T)Y$[^0G[Q/[C_WZ /S<\>?%KQY\<_&%@FJ>+=*\*O_ ,(-I.KZ
M#-?Z]-H\?VJ>#>\Z;/\ 7?O/X*]@^%_A/Q%\5?VT/$EMXJ\<ZY)#X'\(:%J*
M0Z;>O!IEQ>ND^^ZV?QI\GW*^NM5\!Z/KL</V_1]*OOL_^H\ZR23R_P#<_N5<
MM]'MK6X>988(WD38[I B22)1_P NP/D+_@G7X\FTOXP>+?!^K:W/XQU[[+_:
MC^)+/6_[2TS4(7G?9\G_ "ZS_P"Q7/?%CQEJO@WP_P#MGZW:WD^FZWH\%D]E
M<PO^\MX4LDV/_P!_-]?:NC^$M-\.23/INFZ;8O<?Z][:U2#S/^^*\W^*G[(/
MA[XJW'C9[B\U*Q_X6!H*:#JZ6S_NY$1]Z3_[\>]T_P"VE$@A[I\0ZA\6KSPY
M_:4WPW^)'B+Q=;:Q\+]0U?Q+--J+W7]EZ@D">0__ $Q?[_R5W_B#2[SX:?!_
MX V>O>.?%T'A7XH.E[XU\0WFJ/')YW]G(\$'G?\ +%))-_\ W[K[8\'_  OT
M3P1X;ATVSTW38TC@2U=TM4C^T;$V?/\ WZU=4\.6&LZ7]@O+"QNM/_Y]IH$D
MM_\ OBM)!3YS\T_B3^T%J7P^\'_V/;^)/$WB/X8_\)__ &797D.J/'<:II_V
M5W>!+W^Y')_'3/AOX2U[Q'K'[.7A*7XB^)O[-\<:WXJNM7_LWQ"]U<>2GD/:
MVKS?WXXZ^Y/CA^RAI7Q?D\*W-AJ5UX5U+P7=/=:1-IL$'EQ[TV/OA='1_D>M
M+X!_LTZ)\ =#O(;6:?5-2U349M4O=2O($^T7%U/]]_D38GW/^6=%,#XJ^(FJ
M>//%G[2'C;2HO&VE>$=5\'ZI967A?^V/$,]I)]E^3Y_LWW+KS/G2N_UCX@W/
MPY_;HOX=9\22:X_BAYK+2[G3=;_Y%-TM?G2YT_\ N1R([^=7V-J?@C1]9U"&
M\O-*TJZO+?\ U%S-8I))'_P.C_A"-*BUE]272M*^WW'R/<_94^T2?\#K.F!^
M<4?QS\5?#3X#_%+0=&UN?Q!XST]-/O;WQ;9ZV^I:9<64][LGG3_GUGCC^^E;
MTFO>,/AA\!_'E_I?C_2KKPE>76F0?\2?7I]8N-#1W_TJ?SG^YYD=??\ I?@C
M1]!M[F&STK2K&&\_UZ0VJ1QW'^_1I_@/1]&L)K.ST?2K6SN/]?##9)'')_OI
M0!\?_L#Z7X8T;]NCXM6W@_Q5J7B[1(_"^A;+F\O?MWE_O[KY$F_CK@_CQ\1G
MNM8^+6M7_CGQ!H_Q0\)^(OL7A#08=1>".2'>GD(EM_RV23^_7Z!:/X2TWPY'
MLTVPTVQ39L_T:U2#_P! IEQX-TN_UA+^XTW2I]2C^Y<O:I)<1_\  Z*@'Y^_
M%#_A*O$<?Q[\9WGC#Q=INL?#?4=%GT6SMM1>"TLYGM8'G39_&DF]Z^J/VL/"
M_ACXH?LSPP^,O$D?A&VD>RO8-8W^7]CO4V.C_P!S_65['+H-G+',GV.UD2X_
MU_[A/](_W_[],U30;/6=/>SO+:UNK.3[\,T"21_]\43^ *?QGYW>)_V@M;^(
MVE^&+GQI>:/XF\$_"_XFVL&J>)]*M?+L-8M7LG\BZ=/N?NYW^?\ @KK?VH=>
MMOVD?VJ/#US\&[RUUS6/#_@W74U35=*?S+>-)[79:P.Z?Q^?LV)7V]9^$M*L
M-'_LVWTW38+#_GS2U2.W_P"^/N4>'_"6E>%[=X=+TW3=-C^_LL[5(/\ T"@T
MIGS-_P $[_C[\*[7]F/X7^#[74M'L?$^GZ=#IUUHDWR:G;Z@G^OWI]_?YF_Y
MZZ3_ ()Z2M_PC_Q(2'_D&Q^.=32R_P">>S>F_P#\B;Z]O_X0/1_M\U_;Z5I5
MKJMPCH]_#9)'<?[^^L?X'_!;2O@/\.[;PWI+W$]M;R/.\TS^9)<3.^]W>@S_
M +AUB=*FIL<-.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** -#PW_P A3_@%6/&'WX:K^&_^0I_P"K/C'_66U &!.?\ 1W_W*_-7
MQQ^P?K=__P $]];FB_X3R3Q5)XE>]31/MK_9Y$_M1'_U/]SR_GK]+I*9Y7UJ
M/9^_SFGM#XV^-'[,GB3XE_'SXS:]I-M/8Z]I;Z+J_A2_>/\ =W%U:VOSIO\
M^FGW'KSWX5^$M-\1_L7^&_\ A;_@;XA>']>N/$NIZW93:):S2:GX;NGG?Y]Z
M?<\S_P B5^A?E?6E^>+[KR59F?GY\*[7XG?"7XL?#'XR?$31_$WB.WD\-7OA
M?4?)LO/U/3X?M6^UNIH4_CDC^_7I'QX\6ZKXC^+'P?\ C9I?@_Q==>&_!]UJ
M>EZI8/IS_;XX;J!$2]2'[^R.1*^O?^6E'EO_ ,]/UH X;X7_ !NL_BKX7O\
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MD?\ H#_]_*\!^*GPO^(OP@U#QG\4?!?A.^UCQAH?CR]^Q6")Y<FJ:?=(B?\
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M4 %%%% !1110!7U3_CPF_P!RN/KL-4_X\)O]RN.^;VH /F]J3RZ=10 4444
M)\WM2T44 %%%% #?+IU%% "?-[4?-[4M% "?-[4?-[4M% "?-[4?-[4M% "?
M-[4?-[4M% !2?-[4M% "?-[4?-[4M% "?-[4?-[4M% "?-[4?-[4M% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 :'AO\
MY"G_  "K/C'_ %EM5;PO_P A3_@%3>,)?WD- &312?-[4?-[4 'S>U)Y='F4
MOS>U !\WM1\WM2T4 %)\WM2T4 )\WM1\WM2T4 )\WM1\WM2T4 %%%% !2?-[
M4M% "?-[4M%% !1110 GS>U'S>U+10 WRZ7YO:EHH 3YO:CYO:EHH 3YO:CY
MO:EHH 3YO:EHHH 3YO:EHHH 3YO:EHHH **** "BBB@ HHHH **** "BBB@
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M_/..NJ^R0_\ 3.C[)#_TSH Y7[5>?\\XZ/M5Y_SSCKJOLD/_ $SH^R0_],Z
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M?]Y*/M:4 9?_  AT/_/1JT;"P6P@V+3_ +6E24 %%%% !1110 4444 %%%%
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M5Y+NWF_N/#]_S*U?@G^T%X8_:"T>_N?#-Y).^EW7V*]MKF!X+BSF_N.C_<H
M[KYO:CYO:O,]<_:E\)>'?^$J\VXNI$\'SPV6HO#:O/\ OI_N0)L^_)3/ ?[7
M/@#XC?#?5?%5AKT$>C^'YWM=1>\1X)+.9/OHZ/\ /OH ]/\ F]J6N3^"?QD\
M/?'SX?V'BKPK?_VEHFJ;_LMSLV>9L?8__D1*ZR@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH T/#?_(4_P"
M58\8??AJOX;_ .0I_P  JQXP^_#0!CTGS>U<7\;/C[X;^ 6CZ;>>)KR2U35+
MK[%:I# \\EQ-_<1$IGA?XYZ)XRU#1(;--5W^($F>U\ZR>/R_(^_O_N4 =O\
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M=$TZS_UDEQO^Y_Z!7=ITH FHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH 3YO:NH\,?\@M:Y?YO:NH\,?\@M:
M-&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>III:?N)D?[GER?P5;_8WB\6^+-4\-^)+CXD:/:^,/L6K/XOT1Y]1DU;5/\
M19_W$T+OY$/ER;'1XT3_ %?^W7Z3V^C6UK_JK."'^/Y($CIB:#9Q7CS)9VL<
MTGWYD@3S)* /S<_97^'VI:#X#_9F\57&O>.+[6_B(]UI'BC[?JD\D=Y:O _R
M.G\'E_P/7N7_  1_\$>%?A]\%_$^E:2]U'KVG^*-6@U>SN;J>>2S_P")C/Y'
MR/\ <\R/_OY7UI'80Q;-MM!']G^Y\G^KHM]+AL)'>*&"!Y'WNZ1^7YE!H?E]
M<7^F^,K+1-5\4:]XFD^,TGQ-A@U?1_M5U);V\*7OR)Y/W$@\O9L>ND\2>*/M
MZ>)];NO$/B:#]H>S^(;V6EZ5#>SQ^7IZ7J>0B6WW'M9+7YW>OT:_L:S^T>=]
MCM?.D^^_D)YE']C6?]H?:6MK7[3_ ,]MB>9_WW1R_8#VA\$_\+!UCX:?M2>,
M[?1KG_A/_%OBBRU.?2[^PU2Z^T>&YDM7=+*YLG_<>1YGW'CV5Q/[-?\ PG,O
MANV\6^%?B1H\_BW_ (0K4)_$.@PSZC=:GJFH>0FQYH9GV0SP3[_]6B?ZROTL
MCT:VM;A[E;:".YD^_,D">9)19Z#9VMR\T5G:P32?ZQT@2.22@S/S?_9OB\&:
MI^UA^S;J7A7Q)XF\1ZW<66IS^*/M]U=74=O>O9/OW[_DAG\SY-D=>\?$#X@Z
M+^SQ_P %*+GQ5X\F_LOP]X@\%0Z=H.MW,#_9+>:"=WG@W_P/)O1Z^J+?1K.U
MEWQ6=K ^_?O2!(Z?>:7;:I'LN+:"Z3^Y,GF4 ?%7P'^/'A+Q'\4/VA_&&C>-
MK'PSX>U2]T^RM=52'S/L]TB;/M7DO_!\_P!^3Y*Z3_@F/?S2^./C&C:W_P )
MY#)KR74?C/R/(_X2!W@3>FQ/D_<?<_=U]&V_P,\)6OQ ?Q/'X>TJ/7I+7[$]
MXD'ER20?W'_OUTFGV$-A;[+>&"%/[D*>71#W0J'E?[1'QD\#?L*?!_Q/X_U+
M38[6&2=)[I+.#]YJEZ_R)_W\^3YZ\B_8G\4>"8_@AXY\<^(/%7A76-5\4:H^
MM^*/)_>6&CS.GR6OSI\_EQ[/GKZTO+"&_M]EQ#!.G]QT\RJT>@V<5N\*V=K'
M#)]]$@3RY*S]F:'S3_P2'^(^B>-_V0[.VTG4K6^FT_5]3^U0I_K+??J,[I_Y
M#KZGJII^EVUA_P >MM!:_P!_R4\NK=:&84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 :'AS_D*I_N59\8?>AJ
MMX;_ .0I_P  JSXS^_#]: /D[_@H1H.L>(]<^#-MH.I2:/?_ /"9(Z7B67VK
M[/\ N'_@>N,_:9NO&?@W]I#X::;=>)-6U5Y/!OBV>]N;:#[+'<3):IY#NB?)
MYD?\%?8TD22_>2.3R_G3?3/L"2_>2.1_]M*"Z<_>YS\V?!'PI_X1S_@F7\*/
M$]_XVOH]>\065EK>O6WBK7KV"/Q0Z6O_ !Z^<C[[7_8\NNA\'V'@GQO^W)\
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M10 4444 %%%% "?-[4M%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 GS>U=1X8_P"0
M6M<O\WM74>&/^06M &C1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% $=Q#]IMF7^_7/_ /")3?PO'7244 <W_P (M-_STCH_X1:;
M_GI'7244 <I<:#-%_P \ZH7&^U_ADKLI+7S:J7.C)+0!QW]J_P#3&2C^U?\
MIC)74?V"E']@I0!R_P#:O_3&2C^U?^F,E=1_8*4?V"E '+_VK_TQDH_M7_IC
M)74?V"E']@I0!R_]J_\ 3&2C^U?^F,E=1_8*4?V"E '+_P!J_P#3&2C^U?\
MIC)74?V"E']@I0!R_P#:O_3&2C^U?^F,E=1_8*4?V"E '+_VK_TQDH_M7_IC
M)74?V"E']@I0!R_]J_\ 3&2C^U?^F,E=1_8*4?V"E '+_P!J_P#3&2C^U?\
MIC)74?V"E']@I0!R_P#:O_3&2C^U?^F,E=1_8*4?V"E '+_VK_TQDH_M7_IC
M)74?V"E']@I0!R_]J_\ 3&2C^U?^F,E=1_8*4?V"E '+_P!J_P#3&2C^U?\
MIC)74?V"E']@I0!R_P#:O_3&2C^U?^F,E=1_8*4?V"E '+_VK_TQDH_M7_IC
M)74?V"E']@I0!R_]J_\ 3&2C^U?^F,E=1_8*4?V"E '+_P!J_P#3&2C^U?\
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MT>34E% $?DT>34E% $?DT>34E% $?DT>34E% $?DT>34E% #=E.HHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0KQ367Y/QI]1Q
M(3\S=>W-'+<!RID<TZBB@ HHHH **** "BBC- !1110 449HS0 449HS0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %!.!110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 -V4ZBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ INRG44 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965821584728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001119774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">
 EXPLANATORY NOTE
This Amendment No. 1 to the Annual Report on Form 20-F, or the Amendment, amends the Annual Report on Form 20-F of Compugen Ltd., or the Company, for the year ended December 31, 2021, which was originally filed with the Securities and Exchange Commission on February 28, 2022, or the Original Filing.
The Company is filing this Amendment solely for the purpose of updating disclosure in Item 7.A., &#8220;Major Shareholders and Related Party Transactions &#8211; Major Shareholders.&#8221; In addition, pursuant to Rule&#160;12b-15&#160;under the&#160;Exchange Act, the Company is filing the certifications required under the&#160;Sarbanes-Oxley Act&#160;of 2002.
Except as described above or as otherwise expressly provided by the terms of this Amendment, no other changes have been made to the Original Filing. Except as otherwise indicated herein, this Amendment continues to speak as of the date of the Original Filing, and the Company has not updated the disclosures contained therein to reflect any events that occurred subsequent to the date of the Original Filing. <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Compugen Ltd<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Azrieli Center<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">26 Harokmim Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Building D<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Holon<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">5885849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, par value NIS 0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CGEN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of Exchange on which Security is Registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">86,433,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KOST FORER GABBAY & KASIERER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel-Aviv, Israel<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm Id</a></td>
<td class="text">1281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Ari Krashin<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Azrieli Center<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">26 Harokmim Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Building D<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Holon<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">5885849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">3-765-8585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelFaxNumber', window );">Contact Personnel Fax Number</a></td>
<td class="text">972-3-765-8555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelFaxNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fax Number of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelFaxNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965817416616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,801<span></span>
</td>
<td class="nump">$ 7,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">713<span></span>
</td>
<td class="nump">667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term bank deposits</a></td>
<td class="nump">109,248<span></span>
</td>
<td class="nump">116,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other accounts receivable and prepaid expenses</a></td>
<td class="nump">5,460<span></span>
</td>
<td class="nump">2,658<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">123,222<span></span>
</td>
<td class="nump">129,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long-term prepaid expenses</a></td>
<td class="nump">1,911<span></span>
</td>
<td class="nump">1,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_SeverancePayFundNoncurrent', window );">Severance pay fund</a></td>
<td class="nump">3,125<span></span>
</td>
<td class="nump">2,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset</a></td>
<td class="nump">2,247<span></span>
</td>
<td class="nump">2,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,658<span></span>
</td>
<td class="nump">1,711<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">8,941<span></span>
</td>
<td class="nump">9,226<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">132,163<span></span>
</td>
<td class="nump">138,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade payables</a></td>
<td class="nump">4,621<span></span>
</td>
<td class="nump">1,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses', window );">Short-term deferred participation in R&amp;D expenses</a></td>
<td class="nump">3,629<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturity of operating lease liability</a></td>
<td class="nump">768<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Other accounts payable and accrued expenses</a></td>
<td class="nump">8,078<span></span>
</td>
<td class="nump">7,803<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">17,096<span></span>
</td>
<td class="nump">10,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON- CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses', window );">Long-term deferred participation in R&amp;D expenses</a></td>
<td class="nump">2,715<span></span>
</td>
<td class="nump">1,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">1,982<span></span>
</td>
<td class="nump">2,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsLiabilityNoncurrent', window );">Accrued severance pay</a></td>
<td class="nump">3,677<span></span>
</td>
<td class="nump">3,516<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">8,374<span></span>
</td>
<td class="nump">8,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Share capital: Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized at December 31, 2021 and 2020; 86,433,432 and 83,675,856 shares issued and outstanding at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">528,533<span></span>
</td>
<td class="nump">507,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(422,079)<span></span>
</td>
<td class="num">(387,876)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">106,693<span></span>
</td>
<td class="nump">119,782<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 132,163<span></span>
</td>
<td class="nump">$ 138,316<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term deferred participation in R&amp;amp;amp;amp;D expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SeverancePayFundNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SeverancePayFundNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short term deferred participation in R&amp;amp;amp;amp;D expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79708-111665<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79691-111665<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965821941256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value per share</a></td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">86,433,432<span></span>
</td>
<td class="nump">83,675,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">86,433,432<span></span>
</td>
<td class="nump">83,675,856<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965821422232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">680<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">5,320<span></span>
</td>
<td class="nump">1,940<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses, net</a></td>
<td class="nump">28,694<span></span>
</td>
<td class="nump">22,760<span></span>
</td>
<td class="nump">19,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDevelopment', window );">Marketing and business development expenses</a></td>
<td class="nump">842<span></span>
</td>
<td class="nump">871<span></span>
</td>
<td class="nump">651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">10,858<span></span>
</td>
<td class="nump">9,805<span></span>
</td>
<td class="nump">8,412<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">40,394<span></span>
</td>
<td class="nump">33,436<span></span>
</td>
<td class="nump">28,879<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(35,074)<span></span>
</td>
<td class="num">(31,496)<span></span>
</td>
<td class="num">(28,879)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_FinancialIncomeExpenseNet', window );">Financial and other income, net</a></td>
<td class="nump">871<span></span>
</td>
<td class="nump">1,798<span></span>
</td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income</a></td>
<td class="num">(34,203)<span></span>
</td>
<td class="num">(29,698)<span></span>
</td>
<td class="num">(28,059)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">722<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (34,203)<span></span>
</td>
<td class="num">$ (29,698)<span></span>
</td>
<td class="num">$ (27,337)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share</a></td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (34,203)<span></span>
</td>
<td class="num">$ (29,698)<span></span>
</td>
<td class="num">$ (27,337)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of ordinary shares used in computing basic net loss per share</a></td>
<td class="nump">84,203,971<span></span>
</td>
<td class="nump">79,591,187<span></span>
</td>
<td class="nump">63,636,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of ordinary shares used in computing diluted net loss per share</a></td>
<td class="nump">84,203,971<span></span>
</td>
<td class="nump">79,591,187<span></span>
</td>
<td class="nump">63,636,673<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_FinancialIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Income (Expense), Net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_FinancialIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965821926968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Ordinary shares [Member]</div></th>
<th class="th"><div>Additional paid-in capital [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 367,920<span></span>
</td>
<td class="num">$ (330,841)<span></span>
</td>
<td class="nump">$ 37,243<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="nump">59,849,784<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, shares</a></td>
<td class="nump">878,378<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_IssuanceOfSharesAndWarrantsNetValue', window );">Issuance of shares and warrants, net</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_IssuanceOfSharesAndWarrantsNetShares', window );">Issuance of shares and warrants, net, shares</a></td>
<td class="nump">7,194,674<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue', window );">Stock-based compensation relating to options issued to employees, directors and non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,337)<span></span>
</td>
<td class="num">(27,337)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 187<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">396,312<span></span>
</td>
<td class="num">(358,178)<span></span>
</td>
<td class="nump">38,321<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="nump">67,922,836<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, shares</a></td>
<td class="nump">3,070,542<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_NumberOfWarrantsExercised', window );">Warrants exercised, shares</a></td>
<td class="nump">3,866,139<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares, net</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">74,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net, shares</a></td>
<td class="nump">8,816,339<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue', window );">Stock-based compensation relating to options issued to employees, directors and non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,698)<span></span>
</td>
<td class="num">(29,698)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 231<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">507,427<span></span>
</td>
<td class="num">(387,876)<span></span>
</td>
<td class="nump">$ 119,782<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">83,675,856<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,675,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Exercise of options and ESPP shares</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Exercise of options and ESPP shares, shares</a></td>
<td class="nump">335,204<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_NumberOfWarrantsExercised', window );">Warrants exercised, shares</a></td>
<td class="nump">89,557<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares, net</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net, shares</a></td>
<td class="nump">2,332,815<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue', window );">Stock-based compensation relating to options issued to employees, directors and non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,203)<span></span>
</td>
<td class="num">(34,203)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 239<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 528,533<span></span>
</td>
<td class="num">$ (422,079)<span></span>
</td>
<td class="nump">$ 106,693<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">86,433,432<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,433,432<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Representing amount lower than $1.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IssuanceOfSharesAndWarrantsNetShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares and warrants, net, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IssuanceOfSharesAndWarrantsNetShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IssuanceOfSharesAndWarrantsNetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares and warrants, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IssuanceOfSharesAndWarrantsNetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation relating to options issued to employees and directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965822637128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (34,203)<span></span>
</td>
<td class="num">$ (29,698)<span></span>
</td>
<td class="num">$ (27,337)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,276<span></span>
</td>
<td class="nump">2,772<span></span>
</td>
<td class="nump">2,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">461<span></span>
</td>
<td class="nump">715<span></span>
</td>
<td class="nump">989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_SeverancePayNet', window );">Increase (decrease) in Severance pay, net</a></td>
<td class="num">(101)<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain from property and equipment sales and disposals</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement', window );">Decrease (increase) in interest receivables from short-term bank deposits</a></td>
<td class="nump">469<span></span>
</td>
<td class="num">(532)<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Decrease (increase) in trade receivables</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in other accounts receivable and prepaid expenses</a></td>
<td class="num">(2,802)<span></span>
</td>
<td class="num">(1,613)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease (increase) in long-term prepaid expenses</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(1,187)<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Decrease in operating lease right of use asset</a></td>
<td class="nump">525<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="nump">2,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in trade payables and other accounts payable and accrued expenses</a></td>
<td class="nump">3,367<span></span>
</td>
<td class="nump">3,817<span></span>
</td>
<td class="num">(3,502)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses', window );">Increase (decrease) in deferred participation in R&amp;D expenses</a></td>
<td class="nump">3,708<span></span>
</td>
<td class="num">(829)<span></span>
</td>
<td class="num">(627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Decrease in operating lease liability</a></td>
<td class="num">(416)<span></span>
</td>
<td class="num">(412)<span></span>
</td>
<td class="num">(1,834)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(22,750)<span></span>
</td>
<td class="num">(28,320)<span></span>
</td>
<td class="num">(27,888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturity of short-term bank deposits</a></td>
<td class="nump">136,850<span></span>
</td>
<td class="nump">70,300<span></span>
</td>
<td class="nump">59,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Investment in short-term bank deposits</a></td>
<td class="num">(129,945)<span></span>
</td>
<td class="num">(152,350)<span></span>
</td>
<td class="num">(54,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(292)<span></span>
</td>
<td class="num">(166)<span></span>
</td>
<td class="num">(155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">6,616<span></span>
</td>
<td class="num">(82,172)<span></span>
</td>
<td class="nump">5,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares, net</a></td>
<td class="nump">14,958<span></span>
</td>
<td class="nump">74,147<span></span>
</td>
<td class="nump">22,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">425<span></span>
</td>
<td class="nump">18,325<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock-based awards</a></td>
<td class="nump">1,455<span></span>
</td>
<td class="nump">15,991<span></span>
</td>
<td class="nump">3,173<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">16,838<span></span>
</td>
<td class="nump">108,463<span></span>
</td>
<td class="nump">25,931<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">704<span></span>
</td>
<td class="num">(2,029)<span></span>
</td>
<td class="nump">3,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the year</a></td>
<td class="nump">7,810<span></span>
</td>
<td class="nump">9,839<span></span>
</td>
<td class="nump">6,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at the end of the year</a></td>
<td class="nump">8,514<span></span>
</td>
<td class="nump">7,810<span></span>
</td>
<td class="nump">9,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ReceivablesOnAccountOfShares', window );">Receivables on account of shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_SupplementalRightOfUseAssetAndOperatingleaseLiability', window );">Right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(194)<span></span>
</td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash paid (received) during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_InterestPaidReceivedNet', window );">Interest payments received from short-term bank deposits and cash equivalents</a></td>
<td class="nump">1,364<span></span>
</td>
<td class="nump">1,232<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">7,801<span></span>
</td>
<td class="nump">7,143<span></span>
</td>
<td class="nump">9,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">713<span></span>
</td>
<td class="nump">667<span></span>
</td>
<td class="nump">652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at the end of the year</a></td>
<td class="nump">$ 8,514<span></span>
</td>
<td class="nump">$ 7,810<span></span>
</td>
<td class="nump">$ 9,839<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Cash Consideration Of Research And Development Funding Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in deferred participation in R&amp;amp;amp;D expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_InterestPaidReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest payments paid (received) from bank short-term deposits and cash equivalents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_InterestPaidReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ReceivablesOnAccountOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables on account of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ReceivablesOnAccountOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SeverancePayNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Severance pay, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SeverancePayNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SupplementalRightOfUseAssetAndOperatingleaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In right of use asset and operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SupplementalRightOfUseAssetAndOperatingleaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965819854056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 1: -</span><span style="font-weight:bold; padding-left:13.35pt; ">GENERAL</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">a.<span style="padding-left:13.06pt; ">Compugen Ltd. (the &#8220;</span><span style="font-weight:bold; ">Company</span>&#8221;) is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Compugen&#8217;s innovative immuno-oncology pipeline consists of four clinical stage programs, targeting immune checkpoints Compugen discovered computationally, COM701, COM902, bapotulimab (formerly known as BAY1905254) and AZD2936. The Company&#8217;s lead product candidate, COM701, a potential first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing Phase 1 clinical trials in dual, and triple combinations under clinical collaboration with Bristol Myers Squibb. COM902, a potential best-in-class, is a therapeutic antibody targeting TIGIT, developed internally and is undergoing a Phase 1 trial to evaluate it in patients with advanced malignancies as a monotherapy and in combination with COM701. Bapotulimab, an antibody targeting ILDR2, licensed to Bayer under a research and discovery collaboration and license agreement, is also in Phase 1 trials in patients with advanced solid tumors. AZD2936 is a novel anti-TIGIT/PD-1 bispecific antibody with a TIGIT component that is derived from Compugen&#8217;s COM902 program and is developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is in Phase 1/2 trial in patients with advanced or metastatic non-small cell lung cancer. Compugen&#8217;s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. The innovative immuno-oncology pipeline, the strategic collaborations and the Company&#8217;s computational discovery engine serve as the corporate three key building blocks. Compugen&#8217;s business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development under various revenue-sharing arrangements. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">b.<span style="padding-left:12.5pt; ">The Company is headquartered in Holon, Israel. Its clinical development activities are headed from its United States </span>subsidiary, Compugen USA, Inc, located in South San Francisco, CA. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">c.<span style="padding-left:13.06pt; ">The Company has incurred losses in the amount of $</span>34,203 during the year ended December 31, 2021, has an accumulated deficit of $422,079 as of December 31, 2021 and has an accumulated negative cash flow from operating activities in the amount of $22,750 for the year ended December 31, 2021. On February 26, 2019, the Company announced a corporate restructuring to reduce costs by consolidating and streamlining R&amp;D operations. The restructuring included reducing its workforce by 35%, consolidating R&amp;D activities in one location in Israel and outsourcing certain preclinical activities to third-party service providers. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements at the current level of yearly expenditures into 2024. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">d.<span style="padding-left:12.5pt; ">On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement </span>(&#8220;Bayer Agreement&#8221;) with Bayer Pharma AG (&#8220;Bayer&#8221;) for the research, development, and commercialization of antibody-based therapeutics against two novel, Compugen-discovered immune checkpoint regulators. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Under the terms of the Bayer Agreement, the Company received an upfront payment of $10,000, and, following the return of the CGEN 15022 program in 2017, the Company is eligible to receive an aggregate of over $250,000 in potential milestone payments for Bapotulimab (formerly known as BAY1905254), not including aggregate milestone payments of approximately $23,000 received to date. Additionally, the Company is eligible to receive mid to high single digit royalties on global net sales of any approved products under the collaboration.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Pursuant to the terms of Bayer Agreement, Bapotulimab program was transferred to Bayer&#8217;s full control for further preclinical and clinical development activities, and worldwide commercialization under milestone and royalty bearing license from Compugen.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;11</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 1: -</span><span style="font-weight:bold; padding-left:13.35pt; ">GENERAL (Cont.)</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">e.<span style="padding-left:13.06pt; ">Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited. the </span>global biologics research and development arm of AstraZeneca (&#8220;AstraZeneca&#8221;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and will be solely responsible for all research, development, and commercial activities under the agreement. Compugen received a $10,000 upfront payment, and received $8,000 milestone payments out of up to $200,000 the Company is eligible to receive in development, regulatory and commercial milestones for the first product in addition to tiered royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">f.<span style="padding-left:14.17pt; ">On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#8220;Agreement&#8221;) </span>with Bristol-Myers Squibb Company (&#8220;Bristol-Myers Squibb&#8221;) to evaluate the safety and tolerability of Compugen&#8217;s COM701 in combination with Bristol-Myers Squibbs&#8217; PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Pursuant to the Agreement, Compugen is responsible for and will continue sponsoring the ongoing two-part Phase 1 trial, which includes the evaluation of the combination of COM701 and Opdivo&#174;. The collaboration was also designed to address potential future combinations, including trials sponsored by Bristol-Myers Squibb to investigate combined inhibition of checkpoint mechanisms, such as PVRIG and TIGIT. Bristol-Myers Squibb and Compugen each supplies the other company with its own compound for the other party&#8217;s study, and otherwise each party is responsible for all costs associated with the study that it is conducting. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In conjunction with the signing of the Agreement in October 2018, Bristol-Myers Squibb made a $12,000 investment in Compugen, see Note 8b. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">On February 14, 2020, the Agreement was amended to include a triple combination clinical trial to evaluate the safety, tolerability and antitumor activity of COM701 in combination with Opdivo&#174; (nivolumab), and Bristol-Myers Squibb&#8217;s investigational antibody targeting TIGIT known as BMS-986207, in patients with advanced solid tumors, instead of the planned expansion of the combined therapy study designed to evaluate the dual combination of COM701 and Opdivo&#174;. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Pursuant to the Agreement, as amended, the Company sponsors the two-part Phase 1/2 trial, which evaluates the triple combination of COM701, Opdivo&#174; and BMS-986207, in patients with advanced solid tumors where Bristol-Myers Squibb provides Opdivo&#174; and BMS-986207 at no cost to the Company. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;12</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 1: -</span><span style="font-weight:bold; padding-left:13.35pt; ">GENERAL (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">As part of the amended Agreement, it was agreed that the Company will complete the dose escalation arm of the dual combination of COM701 with Opdivo&#174; under the ongoing Phase 1 study and will not continue the expansion cohorts of the dual combination. However, on February 19, 2021, the Agreement was further amended to include an expansion of the Phase 1 combination study designed to evaluate the dual combination of COM701 and Opdivo&#174; in patients with advanced solid tumors, where the Company is responsible for and sponsors the expansion cohort and Bristol Myers Squibb provides Opdivo&#174; at no cost to the Company for this study. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">On November 10, 2021, the Agreement was further amended to establish a joint steering committee (alongside the existing joint development committee which acts at an operational level) to facilitate strategic oversight and guidance for the programs run under the collaboration. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In conjunction with the signing of the amendment to the Agreement in November 2021, Bristol-Myers Squibb made a $20,000 investment in Compugen, see Note 8b. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965818891256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> a.<span style="padding-left:13.06pt; ">Use of estimates:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#8217;s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company considered the impact of COVID-19 on the estimates and assumptions and determined that there were no material adverse impacts on the consolidated financial statements for the year ended December 31, 2021. As events continue to evolve and additional information becomes available, the Company&#8217;s estimates and assumptions may change materially in future periods. Such changes could result in future impairments of long-lived assets. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> b.<span style="padding-left:12.5pt; ">Financial statements in U.S. dollars:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The reporting and functional currency of the Company is the U.S. dollar, as the Company&#8217;s management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen USA, Inc. have operated and expect to continue to operate in the foreseeable future.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No. 830, &#8220;Foreign Currency Matters&#8221;. All transaction gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;13</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> c.<span style="padding-left:13.06pt; ">Basis of consolidation:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The consolidated financial statements include the accounts of the Company and Compugen USA, Inc. Intercompany transactions and balances have been eliminated upon consolidation. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> d.<span style="padding-left:12.5pt; ">Cash equivalents:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> e.<span style="padding-left:13.06pt; ">Restricted cash:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Restricted cash is held in interest bearing saving accounts which are used as a security for the Company&#8217;s Israeli facility leasehold bank guarantee and credit card security for Compugen USA, Inc. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> f.<span style="padding-left:14.17pt; ">Short-term bank deposits:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates market values. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The short-term bank deposits as of December 31, 2021 and 2020 are in U.S. dollars and bear an annual weighted average interest rate of 0.77% and 1.01%, respectively. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> g.<span style="padding-left:12.5pt; ">Property and equipment, net:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "> Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:80pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:58%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:42%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">% </p> </td> </tr> <tr class="even" style=""> <td style="width:58%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:42%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:58%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Computers, software and related equipment </p> </td> <td style="width:42%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">33 </p> </td> </tr> <tr class="even" style=""> <td style="width:58%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Laboratory equipment and office furniture </p> </td> <td style="width:42%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">6 - 20 (mainly 20) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:58%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Leasehold improvements </p> </td> <td style="width:42%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">Shorter of the term of the lease or useful life </p></td></tr></tbody></table></div>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;14</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> h.<span style="padding-left:12.5pt; ">Impairment of long-lived assets:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The long-lived assets of the Company and Compugen USA, Inc. are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant, and Equipment,&#8221; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset with the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years 2021, 2020 and 2019, no impairment losses have been identified. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> i.<span style="padding-left:14.72pt; ">Revenue recognition:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company generates revenues mainly from its collaborative and license agreements. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestone achievements. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">The Company recognizes revenue in accordance with ASC 606 &#8211; &#8220;Revenue from Contracts with Customers&#8221;. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">As such, the Company analyzes its contracts to assess whether they are within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">&#8226;</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-12pt; text-indent:98pt; margin-bottom:0pt; "><span style="font-style:italic; ">Identification of the contract, or contracts, with a customer</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">&#8226;</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:98pt; margin-bottom:0pt; "><span style="font-style:italic; ">Identification of the performance obligations in the contract</span> - At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not distinct from other promises in the contract (either because it is not capable of being distinct or because it is not distinct within the context of the contract), or if an option to acquire good or service does not provide the customer with a material right. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">&#8226;</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:98pt; margin-bottom:0pt; "><span style="font-style:italic; ">Determination of the transaction price</span> - The Company considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;15</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">i.<span style="padding-left:14.72pt; ">Revenue recognition (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">&#8226;</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:98pt; margin-bottom:0pt; "><span style="font-style:italic; ">Allocation of the transaction price to the performance obligations in the contract</span> - If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling prices. The relative selling price for each deliverable is estimated using observable objective evidence if it is available. If observable objective evidence is not available, the Company uses its best estimate of the selling price for the deliverable. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">&#8226;</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:98pt; margin-bottom:0pt; "><span style="font-style:italic; ">Recognition of revenue when, or as, the Company satisfies a performance obligation</span> - Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company entered into an exclusive license agreement with AstraZeneca. Under the terms of the agreement, Compugen provided AstraZeneca with an exclusive license to intellectual property (&#8220;IP&#8221;) rights of the Company for the development of bi-specific and multi-specific antibody products derived from COM902. Compugen received a $10,000 upfront nonrefundable payment and is eligible to receive up to $200,000 for development, regulatory and commercial milestones for the first product, including $8,000 received to date as well as tiered royalties on future product sales. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Under ASC 606, the Company determined the license to the IP to be a functional IP that has significant standalone functionality. The Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the IP. Therefore, the license to the IP is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to the customer. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Future milestone payments are considered variable consideration and are subject to the variable consideration constraint (i.e. will be recognized once concluded that it is &#8220;probable&#8221; that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable consideration is resolved). Therefore, as the milestone payments are not probable, revenue was not recognized in respect to such milestone payments prior to achievement of such milestone. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;16</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">i.<span style="padding-left:14.72pt; ">Revenue recognition (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Sales- or usage-based royalties to be received in exchange for licenses of IP are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales- or usage-based royalty has been allocated is satisfied (in whole or in part). As royalties are payable based on future Commercial Sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">On December 18, 2020 the first milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $2,000 in accordance with the criteria prescribed under ASC 606. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">On September 29, 2021 the second milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $6,000 in accordance with the criteria prescribed under ASC 606. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">For information regarding revenues, please refer to Note 10 below. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> j.<span style="padding-left:14.72pt; ">Cost of revenues:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">Cost of revenues consist of certain royalties and milestones paid or accrued. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> k.<span style="padding-left:12.5pt; ">Research and development expenses, net:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Research and development costs are charged to the statement of comprehensive loss as incurred and are presented net of the amount of any grants the Company receives for research and development in the period in which the grant was received. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">As part of the process of preparing the consolidated financial statements, the Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, and amortized as the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;17</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">k.<span style="padding-left:12.5pt; ">Research and development expenses, net (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The portion of the Bristol-Myers Squibb $12,000 investment over the fair market value of the shares issued in the amount of $4,121 and the portion of the $20,000 investment over the fair market value of the shares issued in the amount of $5,000 were considered as deferred participation of Bristol-Myers Squibb in R&amp;D expenses which is amortized over the period of the clinical trial based on the progress in the R&amp;D, in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221;, see Note 1f and Note 8b. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Amortization of participation in R&amp;D expenses for the years ended December 31, 2021, 2020 and 2019 were $1,291, $829 and $627, respectively. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> l.<span style="padding-left:14.72pt; ">Severance pay:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company&#8217;s liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date, and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset in the Company&#8217;s balance sheet. Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company&#8217;s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee&#8217;s monthly salary for each year of service, no additional calculations are conducted between the parties regarding the matter of severance pay and no additional payments are made by the Company to the employee. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Severance expenses for the years ended December 31, 2021, 2020 and 2019 amounted to approximately $383, $572 and $366, respectively. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> m.<span style="padding-left:9.72pt; ">Stock-based compensation:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company accounts for stock-based compensation to employees and non-employees in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221;, (&#8220;ASC 718&#8221;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company accounts for forfeitures as they occur. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;18</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">m.<span style="padding-left:9.72pt; ">Stock-based compensation (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company selected the Black-Scholes-Merton (&#8220;Black-Scholes&#8221;) option-pricing model as the most appropriate fair value method for its share-options awards and Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "> The Company used the following weighted-average assumptions for options granted to employees, directors and non-employees and ESPP: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:80pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="7" style="width:14%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">Employee stock Options</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Volatility </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">67.68% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">63.17% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">54.59% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Risk-free interest rate </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0.77% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0.45% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">1.92% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Dividend yield </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Expected life (years) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">5.17 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">5.16 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">5.15 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">ESPP</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Volatility </p> </td> <td colspan="3" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="padding-left:0pt; ">64.68</span><span style="padding-left:0pt; ">%-</span><span style="padding-left:0pt; ">69.68</span><span style="padding-left:0pt; ">%</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Risk-free interest rate </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0.04%-0.10% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Dividend yield </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Expected life (years) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0.42-0.50 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> n.<span style="padding-left:12.5pt; ">Concentration of credit risks:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Financial instruments that potentially subject the Company and Compugen USA, Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term bank deposits. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Cash, cash equivalents, restricted cash and short-term bank deposits are invested in major banks in Israel and in the U.S. Generally, these deposits may be redeemed upon demand and bear minimal risk. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The trade receivables of the Company derive from milestone payments under collaboration agreements between the company and its collaborators, located primarily in Europe. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;19</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">n.<span style="padding-left:12.5pt; ">Concentration of credit risks (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company&#8217;s collaborators are major pharma companies. The amounts due to the Company by such collaborators are paid pursuant to the terms of the agreements after a short period of time and bear low risk. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company had one collaborator that accounted for 100% of the Company&#8217;s consolidated revenues, for the years ended December 31, 2021 and 2020. The Company had no revenues in 2019. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> o.<span style="padding-left:12.5pt; ">Basic and diluted loss per share:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#8220;Earnings per Share&#750;. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">All outstanding share options and warrants for the years ended December 31, 2021, 2020 and 2019 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. As of December 31, 2021, 2020 and 2019 the average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were 6,758,300, 7,150,648 and 12,754,803, respectively. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> p.<span style="padding-left:12.5pt; ">Income taxes:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company accounts for income taxes in accordance with ASC No. 740, &#8220;Income Taxes&#8221;, (&#8220;ASC 740&#8221;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2021 and 2020, a full valuation allowance was provided by the Company. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740-10. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;20</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> q.<span style="padding-left:12.5pt; ">Fair value of financial instruments:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company applies ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputting that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">The hierarchy is broken down into three levels based on the inputs as follows: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-60pt !important; padding-left:140pt !important; margin-bottom:0pt; ">Level 1 -<span style="padding-left:22.24pt; ">Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can </span>access at the measurement date. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-60pt !important; padding-left:140pt !important; margin-bottom:0pt; ">Level 2 -<span style="padding-left:22.24pt; ">Valuations based on one or more quoted prices in markets that are not active or for which all </span>significant inputs are observable, either directly or indirectly. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">Level 3 -<span style="padding-left:22.24pt; ">Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, other accounts receivable and prepaid expenses, trade payable and other accounts payable and accrued expenses approximate their fair values due to the short-term maturities of such instruments. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> r.<span style="padding-left:14.72pt; ">Derivative instruments:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company accounts for derivatives and hedging based on ASC 815, &#8220;Derivatives and Hedging&#8221;. ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, the Company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;21</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">r.<span style="padding-left:14.72pt; ">Derivative instruments (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">If the derivatives meet the definition of a hedge and are so designated, depending on the nature of the hedge, changes in the fair value of such derivatives will either be offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings, or recognized in other comprehensive income until the hedged item is recognized in earnings. The ineffective portion of a derivative&#8217;s change in fair value is recognized in earnings. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In the past the Company entered into forward contracts to hedge against the risk of overall changes in future cash flow from payments of payroll and related expenses as well as other expenses denominated in NIS. As of December 31, 2021 and 2020, the Company had no outstanding forward contracts. The Company measured the fair value of the contracts in accordance with ASC 820 (classified as level 2). </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">These contracts met the requirement for cash flow hedge accounting and during each of the years ended December 31, 2021, 2020 and 2019, no amount of total gains were recognized and were classified to operating expenses as effective hedge and no unrealized gains were recognized under other comprehensive income (loss). </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> s.<span style="padding-left:13.61pt; ">Comprehensive income (loss):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company accounts for comprehensive income (loss) in accordance with ASC 220, &#8220;Comprehensive Income&#8221;. This statement establishes standards for the reporting and display of comprehensive income (loss) and its components in a full set of general-purpose financial statements. Comprehensive income (loss) generally represents all changes in shareholders&#8217; equity during the period except those resulting from investments by, or distributions to, shareholders. The Company elected to present the comprehensive income (loss) in a single continuous statement. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "> In the years 2021, 2020 and 2019 the Company has no components of other comprehensive income (loss), other than net loss. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;22</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">t.<span style="padding-left:14.72pt; ">Recently issued and recently adopted Accounting Standards:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Among other changes, ASU 2020-06 removes from GAAP the liability and equity separation model for convertible instruments with a cash conversion feature and a beneficial conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share (EPS). ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020 and can be adopted on either a fully retrospective or modified retrospective basis. The Company adopted ASU 2020-06 as of January 1, 2021. The adoption of this standard did not have an impact to the Company&#8217;s financial statements.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832). This ASU requires business entities to disclose information about government assistance they receive if the transactions were accounted for by analogy to either a grant or a contribution accounting model. The disclosure requirements include the nature of the transaction and the related accounting policy used, the line items on the balance sheets and statements of operations that are affected and the amounts applicable to each financial statement line item and the significant terms and conditions of the transactions. The ASU is effective for annual periods beginning after December 15, 2021. The disclosure requirements can be applied either retrospectively or prospectively to all transactions in the scope of the amendments that are reflected in the financial statements at the date of initial application and new transactions that are entered into after the date of initial application. The ASU is currently not expected to have a material impact on our consolidated financial statements. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965818872280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock', window );">OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 3: -</span><span style="font-weight:bold; padding-left:13.35pt; ">OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Prepaid expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">5,272</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,482</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Government authorities</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">57</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">54</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Other</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">131</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">122</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">5,460</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,658</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "/></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other accounts receivable and prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965819852632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>LEASES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 4: -</span><span style="font-weight:bold; padding-left:13.35pt; ">LEASES</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">The Company leases all its real estate, storage area and cars under various operating lease agreements that expire on various dates. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">The Company&#8217;s operating leases have original lease periods expiring between 2022 and 2024. The offices in Israel lease include two options to renew, one of which was exercised in 2020. The Company does not assume renewals in its determination of the lease term unless the renewals are deemed to be reasonably certain. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">In October 2020 the Company&#8217;s lease of its offices in Israel was amended in connection with the exercise of the option. The amendment was not accounted for as a new lease. As a result of the amendment the operating lease right of use asset increased by $43, the operating lease liability decreased by $194 and the Company recorded foreign currency exchange rate of $237. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">Lease payments included in the measurement of the lease liability comprise the following: the fixed non-cancelable lease payments and payments for optional renewal periods where it is reasonably certain the renewal period will be exercised. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">Under ASC 842, all leases, including non-cancelable operating leases, are now recognized on the balance sheet. The aggregated present value of lease payments is recorded as a long-term asset titled Operating lease right of use asset. The corresponding lease liabilities are split between current maturity of operating lease liability within current liabilities and long-term operating lease liability within long-term liabilities. The Company&#8217;s leases do not provide an implicit rate, therefore the Company uses its incremental borrowing rate based on information available on the commencement date in determining the present value of lease payments. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">The Company subleased small part of its leased premises until March 14, 2021. Sublease income in the year ended December 31, 2021 and 2020, amounted to $3 and $56, respectively. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> The following table represents the weighted-average remaining lease term and discount rate: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:85%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Twelve months </span><span style="font-weight:bold; ">ended</span> </p> </td> </tr> <tr class="even" style=""> <td style="width:85%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31, </span><span style="font-weight:bold; ">2021</span> </p> </td> </tr> <tr class="odd" style=""> <td style="width:85%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:85%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Weighted average remaining lease term </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">3.87 </p> </td> </tr> <tr class="even" style=""> <td style="width:85%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Weighted average discount (annual) rate </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">5.49% </p></td></tr></tbody></table></div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">Operating lease expenses were approximately $956, $944 and $1,586 in the years ended December 31, 2021, 2020 and 2019, respectively. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">Cash paid for amounts included in the measurement of lease liabilities was approximately $914, $927 and $1,577 in the years ended December 31, 2021, 2020 and 2019, respectively. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;24</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 4: -</span><span style="font-weight:bold; padding-left:13.35pt; ">LEASES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> Maturities of operating lease liabilities were as follows: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31, 2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">2022 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">895 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">2023 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">726 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">2024 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">664 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">2025 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">631 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">2026 and after </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">129 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Total operating lease payments </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3,045 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Less: imputed interest </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">295 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Present value of lease liabilities </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,750 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Lease liabilities, current </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">768 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Lease liabilities, non- current </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,982 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Present value of lease liabilities </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:14%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,750 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">The above annual minimum future rental commitments include the period covered by the first exercised option with respect to the leased facility of Compugen Ltd. through March 2026 and exclude the second option to extend the lease of the Company facility for additional five-year period following expiration of the current lease period. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965818815400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 5: -</span><span style="font-weight:bold; padding-left:13.35pt; ">PROPERTY AND EQUIPMENT, NET</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Cost: </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Computers, software and related equipment </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,506 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,431 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Laboratory equipment and office furniture </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3,674 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3,367 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Leasehold improvements </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,321 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,321 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">7,501 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">7,119 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Accumulated depreciation: </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Computers, software and related equipment </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,351 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,264 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Laboratory equipment and office furniture </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3,114 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3,001 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Leasehold improvements </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,378 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,143 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">5,843 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">5,408 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Depreciated cost </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,658 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,711 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;25</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 5: -</span><span style="font-weight:bold; padding-left:13.35pt; ">PROPERTY AND EQUIPMENT, NET (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">During 2021 and 2020 total cost of $26 and $220, respectively and total accumulated depreciation of $26 and $188, respectively were disposed from the consolidated balance sheets.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">For the years ended December 31, 2021, 2020 and 2019, depreciation expenses were approximately $461, $715 and $989, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965819822216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 6: -</span><span style="font-weight:bold; padding-left:13.35pt; ">OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Employees and related accruals</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3,299</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,881</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Accrued expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">4,779</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">4,922</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">8,078</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">7,803</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "/></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965818910376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:16pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 7: - </span><span style="font-weight:bold; padding-left:10.02pt; ">COMMITMENTS AND CONTINGENCIES</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">a.<span style="padding-left:13.06pt; ">The Company provided bank guarantees in the amount of $</span>703 related to its offices in Israel, car leases in Israel and credit card security for its U.S. subsidiary. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">b.<span style="padding-left:12.5pt; ">Under the Office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly </span>known as the Office of the Chief Scientist, (the &#8220;IIA&#8221;), the Company is not obligated to repay any amounts received from the IIA if it does not generate any income from the results of the funded research program(s). If income is generated from a funded research program, the Company is committed to pay royalties at a rate of between 3% to 5% of future revenue arising from such research program(s), and up to a maximum of 100% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum to be repaid is 100% plus interest at LIBOR). For the years ended December 31, 2021, 2020 and 2019, the Company had an aggregate of paid or accrued royalties to the IIA, recorded as cost of revenue in the consolidated statements of comprehensive loss in the amount of $180, $60 and $0, respectively. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">As of December 31, 2021, the Company&#8217;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled approximately to $9,522.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;26</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 7: - </span><span style="font-weight:bold; padding-left:10.02pt; ">COMMITMENTS AND CONTINGENCIES (Cont.)</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">c.<span style="padding-left:13.06pt; ">On June 25, 2012 the Company entered into an Antibodies Discovery Collaboration Agreement (the &#8220;Antibodies </span>Discovery Agreement&#8221;) with a U.S. antibody technology company (&#8220;mAb Technology Company&#8221;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company will be entitled to certain royalties that could be eliminated, upon payment of certain one-time fees (all payments referred together as &#8220;Contingent Fees&#8221;). For the years ended December 31, 2021, 2020 and 2019, the Company incurred such Contingent Fees in the amounts of $500, $500 and $0. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">d.<span style="padding-left:12.5pt; ">On </span>May 9, 2012, the Company entered into agreement (the &#8220;May 2012 Agreement&#8221;) with a U.S. Business Development Strategic Advisor (&#8220;Advisor&#8221;) for the purpose of entering into transactions with Pharma companies related to selected Pipeline Program Candidates. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Under the agreement the Advisor was entitled to 4% of the cash considerations that may be received under such transactions. In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">For the years ended December 31, 2021, 2020 and 2019, the Company has not paid and did not accrue payments under this agreement.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">e.<span style="padding-left:13.06pt; ">Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (CLA) with a European </span>cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and 1% royalties on annual net sales with respect to each commercialized product manufactured using the company&#8217;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the years ended December 31, 2021, 2020 and 2019, the Company incurred in the research and development expenses in connection with such milestone payment in the amounts of $0, $52 and $0. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">f.<span style="padding-left:14.17pt; ">Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody </span>discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the years ended December 31, 2021, 2020 and 2019, the Company incurred in the research and development expenses such milestone payment in the amounts of $250, $0 and $0. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965818799896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">SHAREHOLDERS' EQUITY</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 8: - </span><span style="font-weight:bold; padding-left:10.02pt; ">SHAREHOLDERS&#8217; EQUITY</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">a.<span style="padding-left:13.06pt; ">Ordinary shares:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The ordinary shares confer upon their holders the right to attend and vote at general meetings of the shareholders. Subject to the rights of holders of shares with limited or preferred rights which may be issued in the future, the ordinary shares of the Company confer upon the holders thereof equal rights to receive dividends, and to participate in the distribution of the assets of the Company upon its winding-up, in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of the nominal value, if any.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">b.<span style="padding-left:12.5pt; ">Issuance of shares:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">On May 25, 2018, the Company entered into a Controlled Equity OfferingSM sales agreement with Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;), as sales agent, pursuant to which the Company may offer and sell, from time to time through Cantor, ordinary shares, par value NIS 0.01 per share, of the Company, under an &#8220;at-the-market&#8221; (&#8220;ATM&#8221;) offering, having an aggregate offering price of up to $25,000 (the &#8220;ATM Shares&#8221;). As of December 31, 2019, 7,245,268 shares were issued and sold under the ATM, with proceeds of approximately $22,914 (net of $781 issuance expenses). The program was terminated in 2019.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">On June 14, 2018, the Company entered into securities purchase agreement with certain institutional investors and a placement agency agreement with JMP Securities LLC in connection with a registered direct offering (the &#8220;Offering&#8221;) of an aggregate of 5,316,457 ordinary shares (the &#8220;RD Shares&#8221;) of the Company at a purchase price of $3.95 per RD Share. In connection with the issuance of the RD Shares, the Company also issued warrants to purchase an aggregate of up to 4,253,165 additional ordinary shares. The Warrants are exercisable at a price of $4.74 per ordinary share and have a term of five years from the date of issuance. The Offering was made pursuant to the Company&#8217;s Registration Statement. Proceeds from the Offering were $19,767 (net of $1,233 issuance expenses).</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">During the years ended December 31, 2021, and 2020, warrants to purchase an aggregate of 3,955,696 ordinary shares were exercised with proceeds of approximately $18,750 and as of December 31, 2021, warrants to purchase up to 297,469 ordinary shares remain outstanding.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#8220;Master Clinical Agreement&#8221;) with Bristol-Myers Squibb to evaluate the safety and tolerability of the Company&#8217;s COM701 in combination with Bristol-Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol-Myers Squibb made a $12,000 equity investment in the Company. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;28</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 8: - </span><span style="font-weight:bold; padding-left:10.02pt; ">SHAREHOLDERS&#8217; EQUITY (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Under the terms of the securities purchase agreement, Bristol-Myers Squibb purchased 2,424,243 ordinary shares of the Company at a purchase price of $4.95 per share. The share price represented a 33% premium over the average closing price of Compugen&#8217;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The premium over the fair market value in the amount of $4,121 represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;D, in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221;) and $7,788 (net of $91 issuance expenses) were considered equity investment. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $20,000 investment in the Company, purchasing 2,332,815 ordinary shares of the Company at a purchase price of $8.57333 per share. The share price represented a 33% premium over the closing price of Company&#8217;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The premium over the fair market value in the amount of $5,000 represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;D, in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221;) and $14,958 (net of $42 issuance expenses) were considered equity investment.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In March 2020, the Company entered into an underwriting agreement with SVB Leerink LLC and Stifel, Nicolaus &amp; Company, Incorporated, as representatives of several underwriters relating to the issuance and sale in a public offering of 8,333,334 of the Company&#8217;s ordinary shares at a price to the public of $9.00 per share (and a price of $8.46 per share to the underwriters). Such shares were issued on March 16, 2020. In addition, the Company granted the underwriters a 30-day option to purchase additional ordinary shares at the price set forth above. On April 14, 2020, the Company issued and sold, pursuant to that underwriting agreement additional 483,005 ordinary shares pursuant to the underwriters&#8217; option specified above. The Company sold a total of 8,816,339 ordinary shares in the offering with proceeds of $74,147 (net of $5,200 issuance expenses).</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">c.<span style="padding-left:13.06pt; ">Share option plan:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Under the Company&#8217;s 2010 Share Option Plan as amended (the &#8220;Plan&#8221;), options may be granted to employees, directors and non-employees of the Company and Compugen USA Inc. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Under the 2010 Share Option Plan the Company reserved for issuance up to an aggregate of 12,395,152 ordinary shares. The Company&#8217;s Board of Directors last amended the Plan in May 2020, to increase the number of shares available under the 2010 Plan and extend the plan term by additional 10 years. As of December 31, 2021, an aggregate of 1,133,128 options under the 2010 Share Option Plan of the Company are still available for future grants. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;29</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 8: - </span><span style="font-weight:bold; padding-left:10.02pt; ">SHAREHOLDERS&#8217; EQUITY (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">c.<span style="padding-left:13.06pt; ">Share option plan (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In general, options granted under the Plan vest over a four-year period and expire 10 years from the date of grant and are granted at an exercise price of not less than the fair market value of the Company&#8217;s ordinary shares on the date of grant, unless otherwise determined by the Company&#8217;s board of directors. The exercise price of the options granted under the Plan may not be less than the nominal value of the shares into which such options are exercised and the expiration date may not be later than 10 years from the date of grant. If a grantee leaves his or her employment or other relationship with the Company, or if his or her relationship with the Company is terminated without cause (and other than by reason of death or disability, as defined in the Plan), the term of his or her unexercised options will generally expire in 90 days, unless determined otherwise by the Company.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">Any options that are cancelled, forfeited or expired become available for future grants. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "> Transactions related to the grant of options to employees, directors and non-employees under the above Plan during the year ended December 31, 2021, were as follows: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:80pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Number of </span><span style="font-weight:bold; ">options</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Weighted </span><span style="font-weight:bold; ">average </span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">exercise </span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">price</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Weighted </span><span style="font-weight:bold; ">average</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">remaining </span><span style="font-weight:bold; ">contractual </span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">life</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Aggregate </span><span style="font-weight:bold; ">intrinsic</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">value</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">$</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Years</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">$</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options outstanding at beginning of year</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">5,960,256</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">6.26</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">6.94</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">37,587</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options granted</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,397,500</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">6.72</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options exercised</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(217,375</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">4.19</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options forfeited</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(154,277</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">7.45</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options expired</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(10,000</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:1pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">6.14</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options outstanding at end of year</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">6,976,104</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">6.39</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">6.69</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3,323</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Exercisable at end of year</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3,693,761</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">5.23</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">5.21</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,496</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Weighted average fair value of options granted to employees, directors and non-employees during the years 2021, 2020 and 2019 was $3.81, $7.15 and $1.73 per share, respectively.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Aggregate intrinsic value of exercised options by employees, directors and non-employees during the years 2021, 2020 and 2019 was $759, $21,610, and $979, respectively. The aggregate intrinsic value of the exercised options represents the total intrinsic value (the difference between the sale price of the Company&#8217;s share at the date of exercise, and the exercise price) multiplied by the number of options exercised. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company&#8217;s closing share price on the last trading day of calendar 2020 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2021. This amount is impacted by the changes in the fair market value of the Company&#8217;s shares. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;30</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 8: - </span><span style="font-weight:bold; padding-left:10.02pt; ">SHAREHOLDERS&#8217; EQUITY (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">c.<span style="padding-left:13.06pt; ">Share option plan (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">As of December 31, 2021, the total unrecognized estimated compensation cost related to non-vested share options granted prior to that date was $11,926 which is expected to be recognized over a weighted average period of approximately 3.02 years. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">d.<span style="padding-left:12.5pt; ">Employee Stock Purchase Plan:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company adopted an ESPP in November 2020, with the first offering period starting at January 1, 2021. In connection with its adoption, a total of 600,000 ordinary shares were reserved for issuance under this plan. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The ESPP is implemented through six-month offering periods (except for the first offering period that was five months). According to the ESPP, eligible employees and non-employees may use up to 15% of their base salaries to purchase ordinary shares up to an aggregate limit of $40 per participant for every calendar year. The price of an ordinary share purchased under the ESPP is equal to 85% of the lower of the fair market value of the ordinary share on the first day of each offering period or on the last day of such period. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Since its adoption and through December 31, 2021, 117,829 ordinary shares had been purchased under the ESPP and as of December 31, 2021, 482,171 ordinary shares were available for issuance under the ESPP. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In accordance with ASC No. 718, the ESPP is compensatory and, as such, results in recognition of compensation cost.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; "> e.<span style="padding-left:13.06pt; ">The stock-based compensation expenses related to stock options and ESPP are included as follows in the expense </span>categories: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:80pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Research and development expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,971</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,123</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,151</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Marketing and business development expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">215</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">172</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">46</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">General and administrative expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,090</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,477</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,211</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">4,276</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,772</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,408</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "/></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965818955960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 9: - </span><span style="font-weight:bold; padding-left:10.02pt; ">INCOME TAXES</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">a. <span style="padding-left:9.73pt; ">Israeli taxation:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">1.<span style="padding-left:12.5pt; ">Tax rates applicable to the income of the Company.</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:100pt; margin-bottom:0pt; ">Taxable income of the Company is subject to a corporate tax rate of 23% in 2019, 2020 and 2021.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">2.<span style="padding-left:12.5pt; ">Measurement of taxable income in US dollars:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">The Company has elected to measure its taxable income and file its tax return under the Israeli Income Tax Regulations (Principles Regarding the Management of Books of Account of Foreign Invested Companies and Certain Partnerships and the Determination of Their Taxable Income), 1986. Accordingly, results for tax purposes are measured in terms of earnings in dollars.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:-20pt !important; padding-left:100pt !important; margin-bottom:0pt; ">3.<span style="padding-left:12.5pt; ">Tax benefits under the Israeli Law for the Encouragement of Capital Investments, 1959 (the &#8220;Investment Law&#8221;):</span>&#8201;&#8201; </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">On April 1, 2005, an amendment to the Investment Law came into effect (the &#8220;Amendment 60&#8221;) that significantly changed the provisions of the Investment Law. The Amendment 60 limits the scope of enterprises that may be approved by the Investment Center by setting criteria for the approval of a facility as a &#8220;Beneficiary Enterprise&#8221; including a provision generally requiring that at least 25% of the Beneficiary Enterprise&#8217;s income will be derived from export.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">Another condition for receiving the benefits under the alternative track in respect of expansion programs pursuant to Amendment 60 is a minimum qualifying investment. The Company was eligible under the terms of minimum qualifying investment and elected 2012 as its &#8220;year of election&#8221;.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">Additionally, the Amendment 60 enacted major changes in the manner in which tax benefits are awarded under the Investment Law so that companies no longer require Investment Center approval in order to qualify for tax benefits. However, the Investment Law provides that terms and benefits included in any certificate of approval already granted will remain subject to the provisions of the Investment Law as they were on the date of such approval.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:100pt; margin-bottom:0pt; ">As of December 31, 2021, there was no taxable income attributable to the Beneficiary Enterprise. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;32</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 9: - </span><span style="font-weight:bold; padding-left:10.02pt; ">INCOME TAXES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">a. <span style="padding-left:9.73pt; ">Israeli taxation (Cont.):</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">In January 2011, another amendment to the Investment Law came into effect (&#8220;the 2011 Amendment&#8221;). According to the 2011 Amendment, the benefit tracks in the Investment Law were modified and a flat tax rate applies to the Company&#8217;s entire income subject to this amendment (the &#8220;Preferred Income&#8221;).</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">Once an election is made, the Company&#8217;s income will be subject to the amended tax rate of 16% from 2015 and thereafter (or 9% for a preferred enterprise located in development area A).</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">Commencing 2011 tax year, the Company can elect (without possibility of reversal) to apply the Amendment in a certain tax year and from that year and thereafter, it will be subject to the amended tax rates.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">The Company does not currently intend to adopt the 2011 Amendment and intends to continue to comply with the Investment Law as in effect prior to enactment of the 2011 Amendment. Accordingly, the Company did not adjust its deferred tax balances as of December 31, 2021. The Company&#8217;s position may change in the future.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">In December 2016, the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2016 and 2017 Budget Years), 2016, which includes Amendment 73 to the Law (the &#8220;Amendment 73&#8221;) was published. According to Amendment 73, a preferred enterprise located in development area A will be subject to a tax rate of 7.5% instead of 9% effective from January 1, 2016 and thereafter (the tax rate applicable to preferred enterprises located in other areas remains at 16%).</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">Amendment 73 also prescribes special tax tracks for technological enterprises, which are subject to rules that were issued by the Minister of Finance in May 2017. The new tax tracks under the Amendment are as follows:</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">Preferred Technological Enterprise (&#8220;PTE&#8221;) - an enterprise for which total consolidated revenues of its parent company and all subsidiaries are less than NIS 10 billion in a tax year. A PTE, as defined in the Law, which is located in the center of Israel will be subject to tax at a rate of 12% on profits deriving from intellectual property (in development area A - a tax rate of 7.5%).</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">The above changes in the tax rates relating to PTE tax track were not taken into account in the computation of deferred taxes as of December 31, 2021 and 2020, since the Company estimates that it will not implement the PTE tax track. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;33</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 9: - </span><span style="font-weight:bold; padding-left:10.02pt; ">INCOME TAXES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">a. <span style="padding-left:9.73pt; ">Israeli taxation (Cont.):</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">4.<span style="padding-left:12.5pt; ">Tax benefits under the law for the Encouragement of Industry (Taxes), 1969 (the &#8220;Encouragement Law&#8221;):</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">The Encouragement Law provides several tax benefits for industrial companies. An industrial company is defined as a company resident in Israel, at least 90% of the income of which in a given tax year exclusive of income from specified Government loans, capital gains, interest and dividends, is derived from an industrial enterprise owned by it. An industrial enterprise is defined as an enterprise whose major activity in a given tax year is industrial production activity.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">Management believes that the Company is currently qualified as an &#8220;industrial company&#8221; under the Encouragement Law and, as such, is entitled to tax benefits, including: (1) deduction of purchase of know-how and patents and/or right to use a patent over an eight-year period; (2) the right to elect, under specified conditions, to file a consolidated tax return with additional related Israeli industrial companies and an industrial holding company; (3) accelerated depreciation rates on equipment and buildings; and (4) expenses related to a public offering on the Tel-Aviv Stock exchange and on recognized stock markets outside of Israel, are deductible in equal amounts over three years. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">Eligibility for benefits under the Encouragement Law is not subject to receipt of prior approval from any Governmental authority. No assurance can be given that the Israeli tax authorities will agree that the Company qualifies, or, that the Company will continue to qualify as an industrial company or that the benefits described above will be available to the Company in the future.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">5.<span style="padding-left:12.5pt; ">Net operating losses carryforward and capital loss:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">As of December 31, 2021, Compugen Ltd.&#8217;s net operating losses carryforward for tax purposes in Israel amounted to approximately $369,800. These net operating losses may be carried forward indefinitely and may be offset against future taxable income. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;34</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 9: - </span><span style="font-weight:bold; padding-left:10.02pt; ">INCOME TAXES (Cont.)</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">b.<span style="padding-left:12.5pt; ">Non-Israeli subsidiary, Compugen USA, Inc.:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the &#8220;U.S. Tax Reform&#8221; or &#8220;TCJA&#8221;); a comprehensive tax legislation that includes significant changes to the taxation of business entities. These changes include several key tax provisions that might impact the Company, among others: (i) a permanent reduction to the statutory federal corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017; (ii) a shift of the U.S. taxation of multinational corporations from a tax on worldwide income to a territorial system (along with certain new rules designed to prevent erosion of the U.S. income tax base - &#8220;BEAT&#8221;); (iii) establishing immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits; and (iv) providing a permanent deduction to corporations generating revenues from non-US markets (known as a deduction for foreign derived intangible income - &#8220;FDII&#8221;).</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">As of December 31, 2021, Compugen USA, Inc. has net operating loss carryforwards for federal income tax purposes of approximately $4,850, approximately $3,750 of which expires in the years <span style="-sec-ix-hidden:Fact_0000000000598">2023</span> to <span style="-sec-ix-hidden:Fact_0000000000599">2032</span>. Utilization of the U.S. net operating losses may be subject to substantial annual limitation due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Neither Israeli income taxes, foreign withholding taxes nor deferred income taxes were provided in relation to undistributed earnings of the Company&#8217;s foreign subsidiary. This is because the Company has the intent and ability to reinvest these earnings indefinitely in the foreign subsidiary and therefore those earnings are continually redeployed in those jurisdictions.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> c.<span style="padding-left:13.06pt; ">Loss (income) before taxes is comprised as follows:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:80pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Domestic (Israel) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">34,619 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">30,010 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">28,799 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Foreign </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(416 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(312 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(740 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">34,203 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">29,698 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">28,059 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; ">d.<span style="padding-left:12.5pt; ">Taxes on income (tax benefit) for the year ended December 31, 2019 is comprised from refund of withholding tax </span>payments, which were deducted from milestone payments by the German tax authorities. There were no withholding tax payments for the years ended December 31, 2021, 2020 and 2019. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;35</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 9: - </span><span style="font-weight:bold; padding-left:10.02pt; ">INCOME TAXES (Cont.)</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">e.<span style="padding-left:13.06pt; ">Deferred taxes:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "> Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company and Compugen USA, Inc.&#8217;s deferred tax assets are comprised of operating loss carryforward and other temporary differences. Significant components of the Company and Compugen USA, Inc. deferred tax assets are as follows: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:80pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Operating loss carryforward </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">86,068 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">80,134 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Research and development </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">9,773 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">9,001 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Accrued social benefits and other </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,801 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,389 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Right of use assets </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(520 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(651 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Lease liabilities </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">636 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">742 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Property and equipment </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:1pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Deferred tax asset before valuation allowance </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">98,760 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">91,617 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Valuation allowance </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(98,760 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(91,617 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net deferred tax asset </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company and Compugen USA, Inc. have provided full valuation allowances in respect of deferred tax assets resulting from operating loss carryforward and other temporary differences. Management currently believes that since the Company has a history of losses, it is more likely than not that the deferred tax regarding the operating loss carryforward and other temporary differences will not be realized in the foreseeable future.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">f.<span style="padding-left:14.17pt; ">Reconciliation of the theoretical tax expense (benefit) to the actual tax expense (benefit):</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax benefits from accumulated net operating loss carryforward among the Company and Compugen USA, Inc. due to the uncertainty of the realization of such tax benefits.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">g.<span style="padding-left:12.5pt; ">Tax assessments:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">The Company has tax assessments through 2016 that are deemed to be final. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965818896344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 10: - </span><span style="font-weight:bold; padding-left:5.02pt; ">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">The Company&#8217;s business is currently comprised of one operating segment, the research, development and commercialization of therapeutic and product candidates. The nature of the products and services provided by the Company and the type of customers for these products and services are similar. Operations in Israel and the United States include research and development, clinical operations, marketing and business development. The Company follows ASC 280, &#8220;Segment Reporting&#750;. Total revenues are attributed to geographic areas based on the location of the end customer. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; "> The following represents the total revenue for the years ended December 31, 2021, 2020 and 2019 and long-lived assets as of December 31, 2021 and 2020: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Revenue from sales to customers: </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Europe </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">6,000 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,000 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Total revenue </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">6,000 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,000 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Long-lived assets: </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Israel </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3,787 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">4,240 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">United States </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">118 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">243 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Total long-lived assets </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3,905 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">4,483 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Sales to a single customer exceeding 10%: </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Customer A </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">100 </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">100 </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965818800616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL AND OTHER INCOME, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">FINANCIAL AND OTHER INCOME, NET</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:14pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 11: -</span><span style="font-weight:bold; padding-left:8.9pt; ">FINANCIAL AND OTHER INCOME, NET</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Interest income </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">894 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,765 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">935 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Bank fees and other finance expenses </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(25 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(42 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(32 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Foreign currency translation adjustments </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(1 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">63 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(218 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Gain (loss) from sales and disposals of fixed assets </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">12 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:1pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">135 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:2pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Financial and other income, net </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">871 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,798 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">820 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI http://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965818949080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY BALANCES AND TRANSACTIONS</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 12: -</span><span style="font-weight:bold; padding-left:8.35pt; ">RELATED PARTY BALANCES AND TRANSACTIONS</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Trade payables and accrued expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">94</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">83</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Amounts charged to:</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Research and development expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">240</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">294</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">241</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; ">For the years ended December 31, 2021, 2020 and 2019 the Company received research and development services related with cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies. The transaction was at arm&#8217;s length. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965818968792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSSES PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSSES PER SHARE</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "> <span style="font-weight:bold; ">NOTE 13: -</span><span style="font-weight:bold; padding-left:8.35pt; ">LOSSES PER SHARE</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> The following table sets forth the computation of basic and diluted losses per share: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Numerator:</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net loss for basic and diluted loss per share</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(34,203</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(29,698</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(27,337</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Denominator:</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:-8pt !important; padding-left:8pt !important; margin-bottom:0pt; ">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">84,203,971</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">79,591,187</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">63,636,673</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Basic and diluted earnings per ordinary share</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(0.41</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(0.37</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(0.43</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">) </p></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965815370488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates:</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> a.<span style="padding-left:13.06pt; ">Use of estimates:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#8217;s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company considered the impact of COVID-19 on the estimates and assumptions and determined that there were no material adverse impacts on the consolidated financial statements for the year ended December 31, 2021. As events continue to evolve and additional information becomes available, the Company&#8217;s estimates and assumptions may change materially in future periods. Such changes could result in future impairments of long-lived assets. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Financial statements in U.S. dollars:</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> b.<span style="padding-left:12.5pt; ">Financial statements in U.S. dollars:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The reporting and functional currency of the Company is the U.S. dollar, as the Company&#8217;s management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen USA, Inc. have operated and expect to continue to operate in the foreseeable future.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No. 830, &#8220;Foreign Currency Matters&#8221;. All transaction gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of consolidation:</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> c.<span style="padding-left:13.06pt; ">Basis of consolidation:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The consolidated financial statements include the accounts of the Company and Compugen USA, Inc. Intercompany transactions and balances have been eliminated upon consolidation. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents:</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> d.<span style="padding-left:12.5pt; ">Cash equivalents:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash:</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> e.<span style="padding-left:13.06pt; ">Restricted cash:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Restricted cash is held in interest bearing saving accounts which are used as a security for the Company&#8217;s Israeli facility leasehold bank guarantee and credit card security for Compugen USA, Inc. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ShortTermBankDepositsPolicyTextBlock', window );">Short-term bank deposits:</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> f.<span style="padding-left:14.17pt; ">Short-term bank deposits:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates market values. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The short-term bank deposits as of December 31, 2021 and 2020 are in U.S. dollars and bear an annual weighted average interest rate of 0.77% and 1.01%, respectively. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment, net:</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> g.<span style="padding-left:12.5pt; ">Property and equipment, net:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "> Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:80pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:58%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:42%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">% </p> </td> </tr> <tr class="even" style=""> <td style="width:58%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:42%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:58%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Computers, software and related equipment </p> </td> <td style="width:42%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">33 </p> </td> </tr> <tr class="even" style=""> <td style="width:58%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Laboratory equipment and office furniture </p> </td> <td style="width:42%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">6 - 20 (mainly 20) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:58%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Leasehold improvements </p> </td> <td style="width:42%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">Shorter of the term of the lease or useful life </p></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Impairment of long-lived assets:</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> h.<span style="padding-left:12.5pt; ">Impairment of long-lived assets:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The long-lived assets of the Company and Compugen USA, Inc. are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant, and Equipment,&#8221; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset with the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years 2021, 2020 and 2019, no impairment losses have been identified. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition:</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> i.<span style="padding-left:14.72pt; ">Revenue recognition:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company generates revenues mainly from its collaborative and license agreements. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestone achievements. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">The Company recognizes revenue in accordance with ASC 606 &#8211; &#8220;Revenue from Contracts with Customers&#8221;. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">As such, the Company analyzes its contracts to assess whether they are within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">&#8226;</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-12pt; text-indent:98pt; margin-bottom:0pt; "><span style="font-style:italic; ">Identification of the contract, or contracts, with a customer</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">&#8226;</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:98pt; margin-bottom:0pt; "><span style="font-style:italic; ">Identification of the performance obligations in the contract</span> - At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not distinct from other promises in the contract (either because it is not capable of being distinct or because it is not distinct within the context of the contract), or if an option to acquire good or service does not provide the customer with a material right. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">&#8226;</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:98pt; margin-bottom:0pt; "><span style="font-style:italic; ">Determination of the transaction price</span> - The Company considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;15</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">i.<span style="padding-left:14.72pt; ">Revenue recognition (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">&#8226;</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:98pt; margin-bottom:0pt; "><span style="font-style:italic; ">Allocation of the transaction price to the performance obligations in the contract</span> - If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling prices. The relative selling price for each deliverable is estimated using observable objective evidence if it is available. If observable objective evidence is not available, the Company uses its best estimate of the selling price for the deliverable. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">&#8226;</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:98pt; margin-bottom:0pt; "><span style="font-style:italic; ">Recognition of revenue when, or as, the Company satisfies a performance obligation</span> - Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; ">After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company entered into an exclusive license agreement with AstraZeneca. Under the terms of the agreement, Compugen provided AstraZeneca with an exclusive license to intellectual property (&#8220;IP&#8221;) rights of the Company for the development of bi-specific and multi-specific antibody products derived from COM902. Compugen received a $10,000 upfront nonrefundable payment and is eligible to receive up to $200,000 for development, regulatory and commercial milestones for the first product, including $8,000 received to date as well as tiered royalties on future product sales. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Under ASC 606, the Company determined the license to the IP to be a functional IP that has significant standalone functionality. The Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the IP. Therefore, the license to the IP is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to the customer. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Future milestone payments are considered variable consideration and are subject to the variable consideration constraint (i.e. will be recognized once concluded that it is &#8220;probable&#8221; that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable consideration is resolved). Therefore, as the milestone payments are not probable, revenue was not recognized in respect to such milestone payments prior to achievement of such milestone. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;16</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">i.<span style="padding-left:14.72pt; ">Revenue recognition (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Sales- or usage-based royalties to be received in exchange for licenses of IP are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales- or usage-based royalty has been allocated is satisfied (in whole or in part). As royalties are payable based on future Commercial Sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">On December 18, 2020 the first milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $2,000 in accordance with the criteria prescribed under ASC 606. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">On September 29, 2021 the second milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $6,000 in accordance with the criteria prescribed under ASC 606. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">For information regarding revenues, please refer to Note 10 below. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_CostOfSalesContractWithCustomerPolicyTextBlock', window );">Cost of revenues:</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> j.<span style="padding-left:14.72pt; ">Cost of revenues:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">Cost of revenues consist of certain royalties and milestones paid or accrued. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses, net:</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> k.<span style="padding-left:12.5pt; ">Research and development expenses, net:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Research and development costs are charged to the statement of comprehensive loss as incurred and are presented net of the amount of any grants the Company receives for research and development in the period in which the grant was received. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">As part of the process of preparing the consolidated financial statements, the Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, and amortized as the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;17</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">k.<span style="padding-left:12.5pt; ">Research and development expenses, net (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The portion of the Bristol-Myers Squibb $12,000 investment over the fair market value of the shares issued in the amount of $4,121 and the portion of the $20,000 investment over the fair market value of the shares issued in the amount of $5,000 were considered as deferred participation of Bristol-Myers Squibb in R&amp;D expenses which is amortized over the period of the clinical trial based on the progress in the R&amp;D, in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221;, see Note 1f and Note 8b. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Amortization of participation in R&amp;D expenses for the years ended December 31, 2021, 2020 and 2019 were $1,291, $829 and $627, respectively. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ServerancePayPolicyTextBlock', window );">Severance pay:</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> l.<span style="padding-left:14.72pt; ">Severance pay:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company&#8217;s liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date, and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset in the Company&#8217;s balance sheet. Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company&#8217;s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee&#8217;s monthly salary for each year of service, no additional calculations are conducted between the parties regarding the matter of severance pay and no additional payments are made by the Company to the employee. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Severance expenses for the years ended December 31, 2021, 2020 and 2019 amounted to approximately $383, $572 and $366, respectively. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation:</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> m.<span style="padding-left:9.72pt; ">Stock-based compensation:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company accounts for stock-based compensation to employees and non-employees in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221;, (&#8220;ASC 718&#8221;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company accounts for forfeitures as they occur. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;18</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">m.<span style="padding-left:9.72pt; ">Stock-based compensation (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company selected the Black-Scholes-Merton (&#8220;Black-Scholes&#8221;) option-pricing model as the most appropriate fair value method for its share-options awards and Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "> The Company used the following weighted-average assumptions for options granted to employees, directors and non-employees and ESPP: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:80pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="7" style="width:14%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">Employee stock Options</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Volatility </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">67.68% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">63.17% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">54.59% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Risk-free interest rate </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0.77% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0.45% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">1.92% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Dividend yield </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Expected life (years) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">5.17 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">5.16 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">5.15 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">ESPP</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Volatility </p> </td> <td colspan="3" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="padding-left:0pt; ">64.68</span><span style="padding-left:0pt; ">%-</span><span style="padding-left:0pt; ">69.68</span><span style="padding-left:0pt; ">%</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Risk-free interest rate </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0.04%-0.10% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Dividend yield </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Expected life (years) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0.42-0.50 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risks:</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> n.<span style="padding-left:12.5pt; ">Concentration of credit risks:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Financial instruments that potentially subject the Company and Compugen USA, Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term bank deposits. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Cash, cash equivalents, restricted cash and short-term bank deposits are invested in major banks in Israel and in the U.S. Generally, these deposits may be redeemed upon demand and bear minimal risk. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The trade receivables of the Company derive from milestone payments under collaboration agreements between the company and its collaborators, located primarily in Europe. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;19</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">n.<span style="padding-left:12.5pt; ">Concentration of credit risks (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company&#8217;s collaborators are major pharma companies. The amounts due to the Company by such collaborators are paid pursuant to the terms of the agreements after a short period of time and bear low risk. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company had one collaborator that accounted for 100% of the Company&#8217;s consolidated revenues, for the years ended December 31, 2021 and 2020. The Company had no revenues in 2019. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and diluted loss per share:</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> o.<span style="padding-left:12.5pt; ">Basic and diluted loss per share:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#8220;Earnings per Share&#750;. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">All outstanding share options and warrants for the years ended December 31, 2021, 2020 and 2019 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. As of December 31, 2021, 2020 and 2019 the average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were 6,758,300, 7,150,648 and 12,754,803, respectively. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes:</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> p.<span style="padding-left:12.5pt; ">Income taxes:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company accounts for income taxes in accordance with ASC No. 740, &#8220;Income Taxes&#8221;, (&#8220;ASC 740&#8221;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2021 and 2020, a full valuation allowance was provided by the Company. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740-10. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;20</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments:</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> q.<span style="padding-left:12.5pt; ">Fair value of financial instruments:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company applies ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputting that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">The hierarchy is broken down into three levels based on the inputs as follows: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-60pt !important; padding-left:140pt !important; margin-bottom:0pt; ">Level 1 -<span style="padding-left:22.24pt; ">Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can </span>access at the measurement date. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-60pt !important; padding-left:140pt !important; margin-bottom:0pt; ">Level 2 -<span style="padding-left:22.24pt; ">Valuations based on one or more quoted prices in markets that are not active or for which all </span>significant inputs are observable, either directly or indirectly. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; ">Level 3 -<span style="padding-left:22.24pt; ">Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, other accounts receivable and prepaid expenses, trade payable and other accounts payable and accrued expenses approximate their fair values due to the short-term maturities of such instruments. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative instruments:</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> r.<span style="padding-left:14.72pt; ">Derivative instruments:</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company accounts for derivatives and hedging based on ASC 815, &#8220;Derivatives and Hedging&#8221;. ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, the Company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;21</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">r.<span style="padding-left:14.72pt; ">Derivative instruments (Cont.):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">If the derivatives meet the definition of a hedge and are so designated, depending on the nature of the hedge, changes in the fair value of such derivatives will either be offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings, or recognized in other comprehensive income until the hedged item is recognized in earnings. The ineffective portion of a derivative&#8217;s change in fair value is recognized in earnings. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In the past the Company entered into forward contracts to hedge against the risk of overall changes in future cash flow from payments of payroll and related expenses as well as other expenses denominated in NIS. As of December 31, 2021 and 2020, the Company had no outstanding forward contracts. The Company measured the fair value of the contracts in accordance with ASC 820 (classified as level 2). </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">These contracts met the requirement for cash flow hedge accounting and during each of the years ended December 31, 2021, 2020 and 2019, no amount of total gains were recognized and were classified to operating expenses as effective hedge and no unrealized gains were recognized under other comprehensive income (loss). </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive income (loss):</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> s.<span style="padding-left:13.61pt; ">Comprehensive income (loss):</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">The Company accounts for comprehensive income (loss) in accordance with ASC 220, &#8220;Comprehensive Income&#8221;. This statement establishes standards for the reporting and display of comprehensive income (loss) and its components in a full set of general-purpose financial statements. Comprehensive income (loss) generally represents all changes in shareholders&#8217; equity during the period except those resulting from investments by, or distributions to, shareholders. The Company elected to present the comprehensive income (loss) in a single continuous statement. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued and recently adopted Accounting Standards:</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "> In the years 2021, 2020 and 2019 the Company has no components of other comprehensive income (loss), other than net loss. </p>
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/> <div> <div style="width:100%; clear:both;">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; ">F&#8201;-&#8201;22</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </div><hr style="border-top:1.5pt solid #000000;"/><div style="page-break-after:always;"/> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">COMPUGEN LTD. AND ITS SUBSIDIARY</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "><span style="font-weight:bold; ">U.S. dollars in thousands (except share and per share data)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "><span style="font-weight:bold; ">NOTE 2: -</span><span style="font-weight:bold; padding-left:13.35pt; ">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span> </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; ">t.<span style="padding-left:14.72pt; ">Recently issued and recently adopted Accounting Standards:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Among other changes, ASU 2020-06 removes from GAAP the liability and equity separation model for convertible instruments with a cash conversion feature and a beneficial conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share (EPS). ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020 and can be adopted on either a fully retrospective or modified retrospective basis. The Company adopted ASU 2020-06 as of January 1, 2021. The adoption of this standard did not have an impact to the Company&#8217;s financial statements.</p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; ">In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832). This ASU requires business entities to disclose information about government assistance they receive if the transactions were accounted for by analogy to either a grant or a contribution accounting model. The disclosure requirements include the nature of the transaction and the related accounting policy used, the line items on the balance sheets and statements of operations that are affected and the amounts applicable to each financial statement line item and the significant terms and conditions of the transactions. The ASU is effective for annual periods beginning after December 15, 2021. The disclosure requirements can be applied either retrospectively or prospectively to all transactions in the scope of the amendments that are reflected in the financial statements at the date of initial application and new transactions that are entered into after the date of initial application. The ASU is currently not expected to have a material impact on our consolidated financial statements. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_CostOfSalesContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_CostOfSalesContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ServerancePayPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Serverance Pay [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ServerancePayPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShortTermBankDepositsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term bank deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShortTermBankDepositsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965818876280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock', window );">Schedule of Depreciation Rates for Property and Equipment</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "> Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:80pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:58%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:42%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">% </p> </td> </tr> <tr class="even" style=""> <td style="width:58%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:42%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:58%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Computers, software and related equipment </p> </td> <td style="width:42%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">33 </p> </td> </tr> <tr class="even" style=""> <td style="width:58%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Laboratory equipment and office furniture </p> </td> <td style="width:42%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">6 - 20 (mainly 20) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:58%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Leasehold improvements </p> </td> <td style="width:42%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">Shorter of the term of the lease or useful life </p></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions for granted options</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "> The Company used the following weighted-average assumptions for options granted to employees, directors and non-employees and ESPP: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:80pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="7" style="width:14%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">Employee stock Options</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Volatility </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">67.68% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">63.17% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">54.59% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Risk-free interest rate </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0.77% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0.45% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">1.92% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Dividend yield </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Expected life (years) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">5.17 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">5.16 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">5.15 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "><span style="text-decoration:underline #000000; ">ESPP</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Volatility </p> </td> <td colspan="3" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="padding-left:0pt; ">64.68</span><span style="padding-left:0pt; ">%-</span><span style="padding-left:0pt; ">69.68</span><span style="padding-left:0pt; ">%</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Risk-free interest rate </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0.04%-0.10% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Dividend yield </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:55%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Expected life (years) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">0.42-0.50 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:13%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the annual rates used to calculate depreciation for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of granted stock options, including, but not limited to: (a) expected term of granted share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965818797016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule Of Other Accounts Receivable And Prepaid Expenses</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Prepaid expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">5,272</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,482</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Government authorities</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">57</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">54</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Other</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">131</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">122</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">5,460</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,658</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "/></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965820120872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>LEASES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock', window );">Schedule of Weighted-Average Remaining Lease Term and Discount Rate</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> The following table represents the weighted-average remaining lease term and discount rate: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:85%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Twelve months </span><span style="font-weight:bold; ">ended</span> </p> </td> </tr> <tr class="even" style=""> <td style="width:85%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31, </span><span style="font-weight:bold; ">2021</span> </p> </td> </tr> <tr class="odd" style=""> <td style="width:85%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:85%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Weighted average remaining lease term </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">3.87 </p> </td> </tr> <tr class="even" style=""> <td style="width:85%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Weighted average discount (annual) rate </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">5.49% </p></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Leases</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> Maturities of operating lease liabilities were as follows: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31, 2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">2022 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">895 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">2023 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">726 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">2024 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">664 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">2025 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">631 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">2026 and after </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">129 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Total operating lease payments </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3,045 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Less: imputed interest </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">295 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Present value of lease liabilities </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,750 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Lease liabilities, current </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">768 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Lease liabilities, non- current </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,982 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:14%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:83%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Present value of lease liabilities </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:14%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,750 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of weighted-average remaining lease term and discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965818889016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property And Equipment, Net</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Cost: </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Computers, software and related equipment </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,506 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,431 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Laboratory equipment and office furniture </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3,674 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3,367 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Leasehold improvements </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,321 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,321 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">7,501 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">7,119 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Accumulated depreciation: </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Computers, software and related equipment </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,351 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,264 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Laboratory equipment and office furniture </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3,114 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3,001 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Leasehold improvements </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,378 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,143 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">5,843 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">5,408 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Depreciated cost </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,658 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,711 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965818977336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Accounts Payable and Accrued Expenses</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Employees and related accruals</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3,299</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,881</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Accrued expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">4,779</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">4,922</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">8,078</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">7,803</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "/></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965820129224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule Of Option Activity</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; "> e.<span style="padding-left:13.06pt; ">The stock-based compensation expenses related to stock options and ESPP are included as follows in the expense </span>categories: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:80pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Research and development expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,971</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,123</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,151</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Marketing and business development expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">215</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">172</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">46</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">General and administrative expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,090</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,477</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,211</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">4,276</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,772</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,408</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "/></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expenses</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "> Transactions related to the grant of options to employees, directors and non-employees under the above Plan during the year ended December 31, 2021, were as follows: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:80pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Number of </span><span style="font-weight:bold; ">options</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Weighted </span><span style="font-weight:bold; ">average </span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">exercise </span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">price</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Weighted </span><span style="font-weight:bold; ">average</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">remaining </span><span style="font-weight:bold; ">contractual </span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">life</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Aggregate </span><span style="font-weight:bold; ">intrinsic</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">value</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">$</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Years</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">$</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options outstanding at beginning of year</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">5,960,256</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">6.26</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">6.94</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">37,587</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options granted</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,397,500</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">6.72</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options exercised</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(217,375</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">4.19</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options forfeited</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(154,277</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">7.45</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options expired</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(10,000</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:1pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">6.14</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Options outstanding at end of year</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">6,976,104</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">6.39</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">6.69</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3,323</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:48%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Exercisable at end of year</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3,693,761</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">5.23</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">5.21</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,496</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965821337592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule Of Loss Before Taxes</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> c.<span style="padding-left:13.06pt; ">Loss (income) before taxes is comprised as follows:</span></p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:80pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Domestic (Israel) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">34,619 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">30,010 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">28,799 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Foreign </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(416 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(312 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(740 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">34,203 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">29,698 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">28,059 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary Of Deferred Tax Assets And Liabilities</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "> Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company and Compugen USA, Inc.&#8217;s deferred tax assets are comprised of operating loss carryforward and other temporary differences. Significant components of the Company and Compugen USA, Inc. deferred tax assets are as follows: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:80pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Operating loss carryforward </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">86,068 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">80,134 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Research and development </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">9,773 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">9,001 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Accrued social benefits and other </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,801 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,389 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Right of use assets </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(520 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(651 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Lease liabilities </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">636 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">742 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Property and equipment </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:1pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Deferred tax asset before valuation allowance </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">98,760 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">91,617 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Valuation allowance </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(98,760 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(91,617 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net deferred tax asset </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965820126440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Total Revenues And Long-Lived Assets By Geographic Area</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; "> The following represents the total revenue for the years ended December 31, 2021, 2020 and 2019 and long-lived assets as of December 31, 2021 and 2020: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Revenue from sales to customers: </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Europe </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">6,000 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,000 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Total revenue </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">6,000 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">2,000 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Long-lived assets: </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Israel </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3,787 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">4,240 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">United States </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">118 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">243 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Total long-lived assets </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3,905 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">4,483 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Sales To A Single Customer Exceeding 10%:</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Sales to a single customer exceeding 10%: </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Customer A </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">100 </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:9%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">100 </p> </td> <td style="width:2%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">% </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">- </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965818848520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL AND OTHER INCOME, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Financial and Other Income, Net</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span> </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Interest income </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">894 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,765 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">935 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Bank fees and other finance expenses </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(25 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(42 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(32 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Foreign currency translation adjustments </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(1 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">63 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(218 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">) </p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Gain (loss) from sales and disposals of fixed assets </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">3 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">12 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:1pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">135 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:2pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160; </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Financial and other income, net </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">871 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">1,798 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$ </p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">820 </p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965819857400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Balances and Transactions</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style=""> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:74%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Trade payables and accrued expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">94</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">83</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/> </td> </tr> </tbody> </table> </div>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Amounts charged to:</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Research and development expenses</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">240</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">294</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">241</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965818801336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSSES PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted losses per share</a></td>
<td class="text">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "> The following table sets forth the computation of basic and diluted losses per share: </p>
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> <div style="margin-left:60pt; ">
<table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"> <thead> <tr class="odd" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">Year ended December 31,</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2021</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2020</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "><span style="font-weight:bold; ">2019</span></p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> </thead> <tbody> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Numerator:</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td colspan="2" style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Net loss for basic and diluted loss per share</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(34,203</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(29,698</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(27,337</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Denominator:</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:-8pt !important; padding-left:8pt !important; margin-bottom:0pt; ">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">84,203,971</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">79,591,187</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">63,636,673</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="even" style=""> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">&#160;</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> <td style="width:10%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/> </td> </tr> <tr class="odd" style="background-color:#cceeff; "> <td style="width:61%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">Basic and diluted earnings per ordinary share</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(0.41</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(0.37</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">)</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/> </td> <td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; ">$</p> </td> <td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; ">(0.43</p> </td> <td style="width:1%; vertical-align:bottom; ">
<p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; ">) </p></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965821439496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 34,203<span></span>
</td>
<td class="nump">$ 29,698<span></span>
</td>
<td class="nump">$ 27,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">422,079<span></span>
</td>
<td class="nump">387,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="nump">$ 22,750<span></span>
</td>
<td class="nump">$ 28,320<span></span>
</td>
<td class="nump">$ 27,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of workforce reduction from restructuring activities</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development Collaboration and Licensing Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Upfront payment received</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_AccruedMilestonePayment', window );">Accrued milestone payment</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable', window );">Potential milestone compensation</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable', window );">Preclinical milestone compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue', window );">Amount of investment in Compugen</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AccruedMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AccruedMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential milestone revenue for preclinical stages of research from arrangements for research and development, including collaboration and licenses agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount on the investment owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 10<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6438156&amp;loc=d3e57880-113973<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 10<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6431724&amp;loc=d3e32938-113948<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965821814360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 29, 2021</div></th>
<th class="th"><div>Dec. 18, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ShortTermBankDepositsWeightedAverageRateForeign', window );">Average interest rate, short-term bank deposits in U.S. dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.77%<span></span>
</td>
<td class="nump">1.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization in R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,291<span></span>
</td>
<td class="nump">$ 829<span></span>
</td>
<td class="nump">$ 627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognition under milestone method</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="nump">$ 572<span></span>
</td>
<td class="nump">$ 366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable', window );">Potential milestone compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_AccruedMilestonePayment', window );">Accrued milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average number of shares related to outstanding options excluded from the calculations of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,758,300<span></span>
</td>
<td class="nump">7,150,648<span></span>
</td>
<td class="nump">12,754,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementOneMember', window );">Master Clinical Agreement One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_DeferredParticipationOfBmsInRdExpenses', window );">Deferred participation of BMS in R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementTwoMember', window );">Master Clinical Agreement Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_DeferredParticipationOfBmsInRdExpenses', window );">Deferred participation of BMS in R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AccruedMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AccruedMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredParticipationOfBmsInRdExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred participation of BMS in R&amp;amp;amp;amp;D expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredParticipationOfBmsInRdExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShortTermBankDepositsWeightedAverageRateForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average interest rate for short-term bank deposits outside of the domestic currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShortTermBankDepositsWeightedAverageRateForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_MasterClinicalAgreementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_MasterClinicalAgreementTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965819730792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers, software and related equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_AnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember', window );">Laboratory equipment and office furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_AnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember', window );">Laboratory equipment and office furniture [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_AnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember', window );">Laboratory equipment and office furniture [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_AnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_AnnualDepreciationRateDescription', window );">Annual depreciation rate</a></td>
<td class="text">Shorter of the term of the lease or useful life<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AnnualDepreciationRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Depreciation Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AnnualDepreciationRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AnnualDepreciationRateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Depreciation Rates, Description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AnnualDepreciationRateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965821642280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">67.68%<span></span>
</td>
<td class="nump">63.17%<span></span>
</td>
<td class="nump">54.59%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.77%<span></span>
</td>
<td class="nump">0.45%<span></span>
</td>
<td class="nump">1.92%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years 2 months 1 day<span></span>
</td>
<td class="text">5 years 1 month 28 days<span></span>
</td>
<td class="text">5 years 1 month 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cgen_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cgen_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">64.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cgen_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">69.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cgen_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cgen_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965817360328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 5,272<span></span>
</td>
<td class="nump">$ 2,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other accounts receivable and prepaid expenses</a></td>
<td class="nump">$ 5,460<span></span>
</td>
<td class="nump">$ 2,658<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Government Authorities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965821902472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>LEASES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_IncreaseOperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset increased</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_DecreaseOperatingLeaseLiability', window );">Operating lease liability decreased</a></td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign Currency Translation income</a></td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities', window );">Cash paid for amounts included in measurement of lease liabilities</a></td>
<td class="nump">$ 914<span></span>
</td>
<td class="nump">$ 927<span></span>
</td>
<td class="nump">$ 1,577<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DecreaseOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability decreased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DecreaseOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IncreaseOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease right of use asset increased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IncreaseOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965821923736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>LEASES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">3 years 10 months 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount (annual) rate</a></td>
<td class="nump">5.49%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965821655048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Schedule of Operating Leases) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>LEASES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease expenses</a></td>
<td class="nump">$ 956<span></span>
</td>
<td class="nump">$ 944<span></span>
</td>
<td class="nump">$ 1,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2026 and after</a></td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">3,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">2,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current</a></td>
<td class="nump">768<span></span>
</td>
<td class="nump">639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, non- current</a></td>
<td class="nump">$ 1,982<span></span>
</td>
<td class="nump">$ 2,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965821855976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 7,501<span></span>
</td>
<td class="nump">$ 7,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">5,843<span></span>
</td>
<td class="nump">5,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Depreciated cost</a></td>
<td class="nump">1,658<span></span>
</td>
<td class="nump">1,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">461<span></span>
</td>
<td class="nump">715<span></span>
</td>
<td class="nump">$ 989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers, software and related equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">1,506<span></span>
</td>
<td class="nump">1,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">1,351<span></span>
</td>
<td class="nump">1,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember', window );">Laboratory equipment and office furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">3,674<span></span>
</td>
<td class="nump">3,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">3,114<span></span>
</td>
<td class="nump">3,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">2,321<span></span>
</td>
<td class="nump">2,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">1,378<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember', window );">Obsolete property and equipment and certain nonfunctional Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965820544088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employees and related accruals</a></td>
<td class="nump">$ 3,299<span></span>
</td>
<td class="nump">$ 2,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">4,779<span></span>
</td>
<td class="nump">4,922<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Other accounts payable and accrued expenses</a></td>
<td class="nump">$ 8,078<span></span>
</td>
<td class="nump">$ 7,803<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965815529240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security</a></td>
<td class="nump">$ 703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ContingentFees', window );">Contingent fees</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection', window );">Research and development expenses milestone payment with connection</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentExpensesMilestonePayment', window );">Research and development expenses milestone payment</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember', window );">IIA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived', window );">Maximum royalty repaid as percentage of grant received</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 180<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_RoyaltyContingentObligations', window );">Contingent royalty obligations</a></td>
<td class="nump">$ 9,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember', window );">IIA [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_RoyaltyPercentageBasedOnFutureRevenues', window );">Royalty percentage based on future revenues</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember', window );">IIA [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_RoyaltyPercentageBasedOnFutureRevenues', window );">Royalty percentage based on future revenues</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember', window );">May 2012 Agreement With Advisor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_AgreementStartDate', window );">Agreement, start date</a></td>
<td class="text">May  09,  2012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_AgreementTerminationDescription', window );">Agreement termination description</a></td>
<td class="text">In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember', window );">May 2012 Agreement With Advisor [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ParticipationRights', window );">Participation Rights</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AgreementStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement start date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AgreementStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AgreementTerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of termination of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AgreementTerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ContingentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ContingentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Royalty Repaid As Percentage Of Grant Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ParticipationRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to investors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ParticipationRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentExpensesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentExpensesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses milestone payment with connection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RoyaltyContingentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RoyaltyContingentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RoyaltyPercentageBasedOnFutureRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Percentage Based On Future Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RoyaltyPercentageBasedOnFutureRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965811211496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Share Option Plans) (Narrative) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 14, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 10, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 14, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 16, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 25, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#8362; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of stock options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.81<span></span>
</td>
<td class="nump">$ 7.15<span></span>
</td>
<td class="nump">$ 1.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
<td class="nump">$ 18,325<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Ordinary shares reserved for issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ordinary shares available for issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialOfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">five months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares', window );">Percentage of use of base salary to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear', window );">Aggregate limit of ordinary shares per calendar year | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering', window );">Percentage of fair market value of ordinary shares at time of offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value of exercised options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 759<span></span>
</td>
<td class="nump">$ 21,610<span></span>
</td>
<td class="nump">979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cgen_TwoThousandAndTwoThousandTenOptionsPlanMember', window );">2000 and 2010 Share Option Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Ordinary shares reserved for issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,395,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ordinary shares available for issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,133,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,955,696<span></span>
</td>
<td class="nump">3,955,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants purchase to ordinary shares remain outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,750<span></span>
</td>
<td class="nump">$ 18,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_AtTheMarketOfferingProgramMember', window );">At The Market Offering Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,245,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_AgreementMember', window );">Agreement [Member] | Registered direct offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,316,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants purchase to ordinary shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,253,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable', window );">Expiration period of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementMember', window );">Master Clinical Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.57333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,424,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,332,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_PercentageOfClosingPrice', window );">Percentage of closing price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_CollaborativeArrangementsMember', window );">Collaborative Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_DeferredParticipationOfBmsInRdExpenses', window );">Deferred participation of BMS in R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_CollaborativeArrangementsTwoMember', window );">Collaborative Arrangements Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_DeferredParticipationOfBmsInRdExpenses', window );">Deferred participation of BMS in R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember', window );">SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,816,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from ordinary shares in offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember', window );">SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member] | Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net, shares | shares</a></td>
<td class="nump">483,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate limit of ordinary shares per calendar year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AggregateLimitOfOrdinarySharesPerCalendarYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration period of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredParticipationOfBmsInRdExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred participation of BMS in R&amp;amp;amp;amp;D expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredParticipationOfBmsInRdExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Authorized Proceeds From Issuance Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfClosingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of closing price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfClosingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair market value of ordinary shares at time of offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of use of base salary to purchase ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the time period when the company made its initial offering of a class of securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cgen_TwoThousandAndTwoThousandTenOptionsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cgen_TwoThousandAndTwoThousandTenOptionsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_AtTheMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_AtTheMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cgen_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cgen_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_MasterClinicalAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_CollaborativeArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_CollaborativeArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_CollaborativeArrangementsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_CollaborativeArrangementsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cgen_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cgen_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965821746472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details) - Employees and Directors [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of year</a></td>
<td class="nump">5,960,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">1,397,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="num">(217,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options forfeited</a></td>
<td class="num">(154,277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options expired</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at end of year</a></td>
<td class="nump">6,976,104<span></span>
</td>
<td class="nump">5,960,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of year</a></td>
<td class="nump">3,693,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of year</a></td>
<td class="nump">$ 6.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted</a></td>
<td class="nump">6.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised</a></td>
<td class="nump">4.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options forfeited</a></td>
<td class="nump">7.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options expired</a></td>
<td class="nump">6.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at end of year</a></td>
<td class="nump">6.39<span></span>
</td>
<td class="nump">$ 6.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercisable at end of year</a></td>
<td class="nump">$ 5.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract', window );"><strong>Weighted average remaining contractual life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options outstanding</a></td>
<td class="text">6 years 8 months 8 days<span></span>
</td>
<td class="text">6 years 11 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable at end of year</a></td>
<td class="text">5 years 2 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding at end of year</a></td>
<td class="nump">$ 3,323<span></span>
</td>
<td class="nump">$ 37,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at end of year</a></td>
<td class="nump">$ 2,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award Options, Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cgen_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cgen_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965821477336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">$ 4,276<span></span>
</td>
<td class="nump">$ 2,772<span></span>
</td>
<td class="nump">$ 2,408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">1,971<span></span>
</td>
<td class="nump">1,123<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Marketing and business development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">$ 2,090<span></span>
</td>
<td class="nump">$ 1,477<span></span>
</td>
<td class="nump">$ 1,211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965819077048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Israeli corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_NetOperatingLossCarryforwardExpired', window );">Net operating loss carryforward, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">United States [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Year of expiration of operating loss carryforward</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">United States [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Year of expiration of operating loss carryforward</a></td>
<td class="text">Dec. 31,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 369,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_NetOperatingLossCarryforwardExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforward, Expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_NetOperatingLossCarryforwardExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965818958824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Encouragement Of Capital Investments) (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_ReducedTaxRate', window );">Reduced tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ReducedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduced tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ReducedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965815364328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Schedule of Loss before Taxes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic (Israel)</a></td>
<td class="nump">$ 34,619<span></span>
</td>
<td class="nump">$ 30,010<span></span>
</td>
<td class="nump">$ 28,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(416)<span></span>
</td>
<td class="num">(312)<span></span>
</td>
<td class="num">(740)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income</a></td>
<td class="nump">$ 34,203<span></span>
</td>
<td class="nump">$ 29,698<span></span>
</td>
<td class="nump">$ 28,059<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965815550392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">$ 86,068<span></span>
</td>
<td class="nump">$ 80,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development</a></td>
<td class="nump">9,773<span></span>
</td>
<td class="nump">9,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Accrued social benefits and other</a></td>
<td class="nump">2,801<span></span>
</td>
<td class="nump">2,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_DeferredIncomeTaxRightOfUseAssets', window );">Right of use assets</a></td>
<td class="num">(520)<span></span>
</td>
<td class="num">(651)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_DeferredIncomeTaxLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">636<span></span>
</td>
<td class="nump">742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax asset before valuation allowance</a></td>
<td class="nump">98,760<span></span>
</td>
<td class="nump">91,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(98,760)<span></span>
</td>
<td class="num">(91,617)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredIncomeTaxLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax lease liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredIncomeTaxLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredIncomeTaxRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax Right of use assets attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredIncomeTaxRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset (liabilities) for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965815585464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_SegmentReportingGeograhicAreaLineItems', window );"><strong>Segment Reporting Geograhic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from sales to customers</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 3,905<span></span>
</td>
<td class="nump">$ 4,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue [Member] | Customer Concentration Risk [Member] | Customer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_SegmentReportingGeograhicAreaLineItems', window );"><strong>Segment Reporting Geograhic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Sales to a single customer exceeding 10%</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_SegmentReportingGeographicAreaAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_SegmentReportingGeograhicAreaLineItems', window );"><strong>Segment Reporting Geograhic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from sales to customers</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_SegmentReportingGeographicAreaAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_SegmentReportingGeograhicAreaLineItems', window );"><strong>Segment Reporting Geograhic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">3,787<span></span>
</td>
<td class="nump">4,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_SegmentReportingGeographicAreaAxis=country_US', window );">Unites States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_SegmentReportingGeograhicAreaLineItems', window );"><strong>Segment Reporting Geograhic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">$ 243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SegmentReportingGeograhicAreaLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Segment Reporting Geograhic Area [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SegmentReportingGeograhicAreaLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cgen_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cgen_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SegmentReportingGeographicAreaAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SegmentReportingGeographicAreaAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SegmentReportingGeographicAreaAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SegmentReportingGeographicAreaAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SegmentReportingGeographicAreaAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SegmentReportingGeographicAreaAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965815577080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 894<span></span>
</td>
<td class="nump">$ 1,765<span></span>
</td>
<td class="nump">$ 935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Bank fees and other finance expenses</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="num">(218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain (loss) from sales and disposals of fixed assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_FinancialIncomeExpenseNet', window );">Financial and other income, net</a></td>
<td class="nump">$ 871<span></span>
</td>
<td class="nump">$ 1,798<span></span>
</td>
<td class="nump">$ 820<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_FinancialIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Income (Expense), Net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_FinancialIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965820475896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Trade payables and accrued expenses</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Amounts charged to research and development expenses</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139965819073960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for basic and diluted loss per share</a></td>
<td class="num">$ (34,203)<span></span>
</td>
<td class="num">$ (29,698)<span></span>
</td>
<td class="num">$ (27,337)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</a></td>
<td class="nump">84,203,971<span></span>
</td>
<td class="nump">79,591,187<span></span>
</td>
<td class="nump">63,636,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted earnings per ordinary share</a></td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>zk2227383_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cgen="http://cgen.com/20211231"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cgen-20211231.xsd" xlink:type="simple"/>
    <context id="From2019-01-01to2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-12-31_us-gaap_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-05-25_custom_AtTheMarketOfferingProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-25</instant>
        </period>
    </context>
    <context id="AsOf2018-06-14_custom_AgreementMember_custom_RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-14</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-01to2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-12-31_custom_AtTheMarketOfferingProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-03-01to2020-03-16_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="From2020-04-01to2020-04-14_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_custom_UnderwritersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:UnderwritersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-14</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_dei_BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2013-01-01to2013-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-12-31</endDate>
        </period>
    </context>
    <context id="I2013-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2013-12-31</instant>
        </period>
    </context>
    <context id="From2020-12-01to2020-12-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-18</endDate>
        </period>
    </context>
    <context id="From2021-09-01to2021-09-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-29</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-10-10_custom_MasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-10</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MasterClinicalAgreementOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MasterClinicalAgreementTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-11-30_custom_MasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="From2019-01-01to2019-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_custom_CollaborativeArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:CollaborativeArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_custom_MasterClinicalAgreementOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_custom_MasterClinicalAgreementTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_custom_CollaborativeArrangementsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:CollaborativeArrangementsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-12-31_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_custom_EmployeeStockPurchasePlanMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_custom_EmployeeStockPurchasePlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_custom_ResearchAndDevelopmentGrantOneMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_custom_ResearchAndDevelopmentGrantOneMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_custom_ResearchAndDevelopmentGrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-12-31_custom_ResearchAndDevelopmentGrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_custom_ResearchAndDevelopmentGrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ResearchAndDevelopmentGrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_srt_MinimumMember_custom_May2012AgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_custom_May2012AgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_InternalRevenueServiceIRSMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_InternalRevenueServiceIRSMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TwoThousandAndTwoThousandTenOptionsPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:TwoThousandAndTwoThousandTenOptionsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_custom_TwoThousandAndTwoThousandTenOptionsPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:TwoThousandAndTwoThousandTenOptionsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-16_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-16</instant>
        </period>
    </context>
    <context id="AsOf2020-03-16_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_custom_UnderwritersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:UnderwritersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-16</instant>
        </period>
    </context>
    <context id="From2018-05-01to2018-05-25_custom_AtTheMarketOfferingProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-25</endDate>
        </period>
    </context>
    <context id="From2018-06-01to2018-06-14_custom_AgreementMember_custom_RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-14</endDate>
        </period>
    </context>
    <context id="From2018-10-01to2018-10-10_custom_MasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-10</endDate>
        </period>
    </context>
    <context id="From2021-11-02to2021-11-30_custom_MasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-02</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_EmployeeStockMember-1750657468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_EmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_EmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_custom_EmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-12-31_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-01to2019-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_country_IL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_country_IL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="ILSPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="Item">
        <measure>cgen:item</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000684">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000685">0001119774</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000686">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityIncorporationStateCountryCode
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000011">IL</dei:EntityIncorporationStateCountryCode>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="From2021-01-01to2021-12-31_us-gaap_InternalRevenueServiceIRSMember_srt_MinimumMember"
      id="Fact_0000000000598">2023-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="From2021-01-01to2021-12-31_us-gaap_InternalRevenueServiceIRSMember_srt_MaximumMember"
      id="Fact_0000000000599">2032-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <dei:DocumentType
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000001">20-F/A</dei:DocumentType>
    <dei:DocumentRegistrationStatement
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000002">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000003">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000006">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000005">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000007">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000008">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000009">000-30902</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000010">Compugen Ltd</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000012">Azrieli Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000013">26 Harokmim Street</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000014">Building D</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000015">Holon</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000016">5885849</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000017">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName
      contextRef="From2021-01-01to2021-12-31_dei_BusinessContactMember"
      id="Fact_0000000000018">Ari Krashin</dei:ContactPersonnelName>
    <dei:CityAreaCode
      contextRef="From2021-01-01to2021-12-31_dei_BusinessContactMember"
      id="Fact_0000000000019">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="From2021-01-01to2021-12-31_dei_BusinessContactMember"
      id="Fact_0000000000020">3-765-8585</dei:LocalPhoneNumber>
    <dei:ContactPersonnelFaxNumber
      contextRef="From2021-01-01to2021-12-31_dei_BusinessContactMember"
      id="Fact_0000000000021">972-3-765-8555</dei:ContactPersonnelFaxNumber>
    <dei:EntityAddressAddressLine1
      contextRef="From2021-01-01to2021-12-31_dei_BusinessContactMember"
      id="Fact_0000000000022">Azrieli Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="From2021-01-01to2021-12-31_dei_BusinessContactMember"
      id="Fact_0000000000023">26 Harokmim Street</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="From2021-01-01to2021-12-31_dei_BusinessContactMember"
      id="Fact_0000000000024">Building D</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown
      contextRef="From2021-01-01to2021-12-31_dei_BusinessContactMember"
      id="Fact_0000000000025">Holon</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="From2021-01-01to2021-12-31_dei_BusinessContactMember"
      id="Fact_0000000000026">5885849</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="From2021-01-01to2021-12-31_dei_BusinessContactMember"
      id="Fact_0000000000027">IL</dei:EntityAddressCountry>
    <dei:Security12bTitle
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000028">Ordinary shares, par value NIS 0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000029">CGEN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000030">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact_0000000000031"
      unitRef="Shares">86433432</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000032">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000033">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000034">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000035">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000036">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000037">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000038">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000039">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000040">false</dei:EntityShellCompany>
    <dei:AmendmentDescription
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000041">
 EXPLANATORY NOTE
This Amendment No. 1 to the Annual Report on Form 20-F, or the Amendment, amends the Annual Report on Form 20-F of Compugen Ltd., or the Company, for the year ended December 31, 2021, which was originally filed with the Securities and Exchange Commission on February 28, 2022, or the Original Filing.
The Company is filing this Amendment solely for the purpose of updating disclosure in Item 7.A., &#x201c;Major Shareholders and Related Party Transactions &#x2013; Major Shareholders.&#x201d; In addition, pursuant to Rule&#160;12b-15&#160;under the&#160;Exchange Act, the Company is filing the certifications required under the&#160;Sarbanes-Oxley Act&#160;of 2002.
Except as described above or as otherwise expressly provided by the terms of this Amendment, no other changes have been made to the Original Filing. Except as otherwise indicated herein, this Amendment continues to speak as of the date of the Original Filing, and the Company has not updated the disclosures contained therein to reflect any events that occurred subsequent to the date of the Original Filing. </dei:AmendmentDescription>
    <dei:AuditorFirmId
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000042">1281</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000043">KOST FORER GABBAY &amp; KASIERER</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000044">Tel-Aviv, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000045"
      unitRef="usd">7801000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000046"
      unitRef="usd">7143000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000047"
      unitRef="usd">713000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000048"
      unitRef="usd">667000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherShortTermInvestments
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000049"
      unitRef="usd">109248000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000050"
      unitRef="usd">116622000</us-gaap:OtherShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2021-12-31"
      id="Fact_0000000000051"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000052"
      unitRef="usd">2000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000053"
      unitRef="usd">5460000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000054"
      unitRef="usd">2658000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000055"
      unitRef="usd">123222000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000056"
      unitRef="usd">129090000</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000057"
      unitRef="usd">1911000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000058"
      unitRef="usd">1880000</us-gaap:PrepaidExpenseNoncurrent>
    <cgen:SeverancePayFundNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000059"
      unitRef="usd">3125000</cgen:SeverancePayFundNoncurrent>
    <cgen:SeverancePayFundNoncurrent
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000060"
      unitRef="usd">2863000</cgen:SeverancePayFundNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000061"
      unitRef="usd">2247000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000062"
      unitRef="usd">2772000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000063"
      unitRef="usd">1658000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000064"
      unitRef="usd">1711000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000065"
      unitRef="usd">8941000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000066"
      unitRef="usd">9226000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000067"
      unitRef="usd">132163000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000068"
      unitRef="usd">138316000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000069"
      unitRef="usd">4621000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000070"
      unitRef="usd">1413000</us-gaap:AccountsPayableCurrent>
    <cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000071"
      unitRef="usd">3629000</cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000072"
      unitRef="usd">668000</cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000073"
      unitRef="usd">768000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000074"
      unitRef="usd">639000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000075"
      unitRef="usd">8078000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000076"
      unitRef="usd">7803000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000077"
      unitRef="usd">17096000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000078"
      unitRef="usd">10523000</us-gaap:LiabilitiesCurrent>
    <cgen:LongTermDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000079"
      unitRef="usd">2715000</cgen:LongTermDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:LongTermDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000080"
      unitRef="usd">1968000</cgen:LongTermDeferredParticipationInResearchAndDevelopmentExpenses>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000081"
      unitRef="usd">1982000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000082"
      unitRef="usd">2527000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000083"
      unitRef="usd">3677000</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000084"
      unitRef="usd">3516000</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000085"
      unitRef="usd">8374000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000086"
      unitRef="usd">8011000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      id="Fact_0000000000088"
      unitRef="ILSPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact_0000000000087"
      unitRef="ILSPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2020-12-31"
      decimals="INF"
      id="Fact_0000000000090"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact_0000000000089"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact_0000000000092"
      unitRef="Shares">86433432</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact_0000000000091"
      unitRef="Shares">86433432</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2020-12-31"
      decimals="INF"
      id="Fact_0000000000094"
      unitRef="Shares">83675856</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2020-12-31"
      decimals="INF"
      id="Fact_0000000000093"
      unitRef="Shares">83675856</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000095"
      unitRef="usd">239000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000096"
      unitRef="usd">231000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000097"
      unitRef="usd">528533000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000098"
      unitRef="usd">507427000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000099"
      unitRef="usd">-422079000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000100"
      unitRef="usd">-387876000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000101"
      unitRef="usd">106693000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000102"
      unitRef="usd">119782000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000103"
      unitRef="usd">132163000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000104"
      unitRef="usd">138316000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000105"
      unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000106"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-01to2019-12-31"
      id="Fact_0000000000107"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000108"
      unitRef="usd">680000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000109"
      unitRef="usd">60000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2019-01-01to2019-12-31"
      id="Fact_0000000000110"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000111"
      unitRef="usd">5320000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000112"
      unitRef="usd">1940000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2019-01-01to2019-12-31"
      id="Fact_0000000000113"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000114"
      unitRef="usd">28694000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000115"
      unitRef="usd">22760000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000116"
      unitRef="usd">19816000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:BusinessDevelopment
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000117"
      unitRef="usd">842000</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000118"
      unitRef="usd">871000</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000119"
      unitRef="usd">651000</us-gaap:BusinessDevelopment>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000120"
      unitRef="usd">10858000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000121"
      unitRef="usd">9805000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000122"
      unitRef="usd">8412000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000123"
      unitRef="usd">40394000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000124"
      unitRef="usd">33436000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000125"
      unitRef="usd">28879000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000126"
      unitRef="usd">-35074000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000127"
      unitRef="usd">-31496000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000128"
      unitRef="usd">-28879000</us-gaap:OperatingIncomeLoss>
    <cgen:FinancialIncomeExpenseNet
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000129"
      unitRef="usd">871000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000130"
      unitRef="usd">1798000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000131"
      unitRef="usd">820000</cgen:FinancialIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000132"
      unitRef="usd">-34203000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000133"
      unitRef="usd">-29698000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000134"
      unitRef="usd">-28059000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000135"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-01to2020-12-31"
      id="Fact_0000000000136"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000137"
      unitRef="usd">-722000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000138"
      unitRef="usd">-34203000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000139"
      unitRef="usd">-29698000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000140"
      unitRef="usd">-27337000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact_0000000000141"
      unitRef="USDPerShare">-0.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      id="Fact_0000000000142"
      unitRef="USDPerShare">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      id="Fact_0000000000143"
      unitRef="USDPerShare">-0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact_0000000000144"
      unitRef="USDPerShare">-0.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      id="Fact_0000000000145"
      unitRef="USDPerShare">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      id="Fact_0000000000146"
      unitRef="USDPerShare">-0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000147"
      unitRef="usd">-34203000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000148"
      unitRef="usd">-29698000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000149"
      unitRef="usd">-27337000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact_0000000000150"
      unitRef="Shares">84203971</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      id="Fact_0000000000151"
      unitRef="Shares">79591187</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      id="Fact_0000000000152"
      unitRef="Shares">63636673</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact_0000000000153"
      unitRef="Shares">84203971</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      id="Fact_0000000000154"
      unitRef="Shares">79591187</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      id="Fact_0000000000155"
      unitRef="Shares">63636673</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2018-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact_0000000000156"
      unitRef="Shares">59849784</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact_0000000000157"
      unitRef="usd">164000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0000000000158"
      unitRef="usd">367920000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact_0000000000159"
      unitRef="usd">-330841000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31"
      decimals="-3"
      id="Fact_0000000000160"
      unitRef="usd">37243000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact_0000000000161"
      unitRef="Shares">878378</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact_0000000000162"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0000000000163"
      unitRef="usd">3246000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000164"
      unitRef="usd">3249000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <cgen:IssuanceOfSharesAndWarrantsNetShares
      contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact_0000000000165"
      unitRef="Shares">7194674</cgen:IssuanceOfSharesAndWarrantsNetShares>
    <cgen:IssuanceOfSharesAndWarrantsNetValue
      contextRef="From2019-01-01to2019-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact_0000000000166"
      unitRef="usd">20000</cgen:IssuanceOfSharesAndWarrantsNetValue>
    <cgen:IssuanceOfSharesAndWarrantsNetValue
      contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0000000000167"
      unitRef="usd">22738000</cgen:IssuanceOfSharesAndWarrantsNetValue>
    <cgen:IssuanceOfSharesAndWarrantsNetValue
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000168"
      unitRef="usd">22758000</cgen:IssuanceOfSharesAndWarrantsNetValue>
    <cgen:StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="From2019-01-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0000000000169"
      unitRef="usd">2408000</cgen:StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000170"
      unitRef="usd">2408000</cgen:StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact_0000000000171"
      unitRef="usd">-27337000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000172"
      unitRef="usd">-27337000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact_0000000000173"
      unitRef="Shares">67922836</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact_0000000000174"
      unitRef="usd">187000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0000000000175"
      unitRef="usd">396312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact_0000000000176"
      unitRef="usd">-358178000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31"
      decimals="-3"
      id="Fact_0000000000177"
      unitRef="usd">38321000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact_0000000000178"
      unitRef="Shares">3070542</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact_0000000000179"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0000000000180"
      unitRef="usd">15906000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000181"
      unitRef="usd">15915000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <cgen:NumberOfWarrantsExercised
      contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact_0000000000182"
      unitRef="Shares">3866139</cgen:NumberOfWarrantsExercised>
    <cgen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact_0000000000183"
      unitRef="usd">11000</cgen:StockIssuedDuringPeriodValueWarrantsExercised>
    <cgen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0000000000184"
      unitRef="usd">18314000</cgen:StockIssuedDuringPeriodValueWarrantsExercised>
    <cgen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000185"
      unitRef="usd">18325000</cgen:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact_0000000000186"
      unitRef="Shares">8816339</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-01to2020-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact_0000000000187"
      unitRef="usd">24000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0000000000188"
      unitRef="usd">74123000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000189"
      unitRef="usd">74147000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cgen:StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="From2020-01-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0000000000190"
      unitRef="usd">2772000</cgen:StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000191"
      unitRef="usd">2772000</cgen:StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact_0000000000192"
      unitRef="usd">-29698000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000193"
      unitRef="usd">-29698000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact_0000000000194"
      unitRef="Shares">83675856</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact_0000000000195"
      unitRef="usd">231000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0000000000196"
      unitRef="usd">507427000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact_0000000000197"
      unitRef="usd">-387876000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000198"
      unitRef="usd">119782000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact_0000000000199"
      unitRef="Shares">335204</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact_0000000000200"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0000000000201"
      unitRef="usd">1454000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000202"
      unitRef="usd">1455000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <cgen:NumberOfWarrantsExercised
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact_0000000000203"
      unitRef="Shares">89557</cgen:NumberOfWarrantsExercised>
    <cgen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      id="Fact_0000000000204"
      unitRef="usd"
      xsi:nil="true"/>
    <cgen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0000000000205"
      unitRef="usd">425000</cgen:StockIssuedDuringPeriodValueWarrantsExercised>
    <cgen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000206"
      unitRef="usd">425000</cgen:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact_0000000000207"
      unitRef="Shares">2332815</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-01to2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact_0000000000208"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0000000000209"
      unitRef="usd">14951000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000210"
      unitRef="usd">14958000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cgen:StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="From2021-01-01to2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0000000000211"
      unitRef="usd">4276000</cgen:StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <cgen:StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000212"
      unitRef="usd">4276000</cgen:StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact_0000000000213"
      unitRef="usd">-34203000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000214"
      unitRef="usd">-34203000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact_0000000000215"
      unitRef="Shares">86433432</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact_0000000000216"
      unitRef="usd">239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0000000000217"
      unitRef="usd">528533000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact_0000000000218"
      unitRef="usd">-422079000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000219"
      unitRef="usd">106693000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000220"
      unitRef="usd">-34203000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000221"
      unitRef="usd">-29698000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000222"
      unitRef="usd">-27337000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000223"
      unitRef="usd">4276000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000224"
      unitRef="usd">2772000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000225"
      unitRef="usd">2408000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000226"
      unitRef="usd">461000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000227"
      unitRef="usd">715000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000228"
      unitRef="usd">989000</us-gaap:Depreciation>
    <cgen:SeverancePayNet
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000229"
      unitRef="usd">-101000</cgen:SeverancePayNet>
    <cgen:SeverancePayNet
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000230"
      unitRef="usd">184000</cgen:SeverancePayNet>
    <cgen:SeverancePayNet
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000231"
      unitRef="usd">-22000</cgen:SeverancePayNet>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000232"
      unitRef="usd">3000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000233"
      unitRef="usd">12000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000234"
      unitRef="usd">135000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000235"
      unitRef="usd">-469000</cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement>
    <cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000236"
      unitRef="usd">532000</cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement>
    <cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000237"
      unitRef="usd">-66000</cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000238"
      unitRef="usd">-2000000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000239"
      unitRef="usd">2000000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2019-01-01to2019-12-31"
      id="Fact_0000000000240"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000241"
      unitRef="usd">2802000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000242"
      unitRef="usd">1613000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000243"
      unitRef="usd">142000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000244"
      unitRef="usd">31000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000245"
      unitRef="usd">1187000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000246"
      unitRef="usd">-83000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000247"
      unitRef="usd">-525000</cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000248"
      unitRef="usd">-475000</cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000249"
      unitRef="usd">-2165000</cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000250"
      unitRef="usd">3367000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000251"
      unitRef="usd">3817000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000252"
      unitRef="usd">-3502000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000253"
      unitRef="usd">3708000</cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000254"
      unitRef="usd">-829000</cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000255"
      unitRef="usd">-627000</cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000256"
      unitRef="usd">-416000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000257"
      unitRef="usd">-412000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000258"
      unitRef="usd">-1834000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000259"
      unitRef="usd">-22750000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000260"
      unitRef="usd">-28320000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000261"
      unitRef="usd">-27888000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000262"
      unitRef="usd">136850000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000263"
      unitRef="usd">70300000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000264"
      unitRef="usd">59403000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000265"
      unitRef="usd">129945000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000266"
      unitRef="usd">152350000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000267"
      unitRef="usd">54300000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000268"
      unitRef="usd">292000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000269"
      unitRef="usd">166000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000270"
      unitRef="usd">155000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000271"
      unitRef="usd">3000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000272"
      unitRef="usd">44000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000273"
      unitRef="usd">382000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000274"
      unitRef="usd">6616000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000275"
      unitRef="usd">-82172000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000276"
      unitRef="usd">5330000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000277"
      unitRef="usd">14958000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000278"
      unitRef="usd">74147000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000279"
      unitRef="usd">22758000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000280"
      unitRef="usd">425000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000281"
      unitRef="usd">18325000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2019-01-01to2019-12-31"
      id="Fact_0000000000282"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000283"
      unitRef="usd">1455000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000284"
      unitRef="usd">15991000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000285"
      unitRef="usd">3173000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000286"
      unitRef="usd">16838000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000287"
      unitRef="usd">108463000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000288"
      unitRef="usd">25931000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000289"
      unitRef="usd">704000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000290"
      unitRef="usd">-2029000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000291"
      unitRef="usd">3373000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000292"
      unitRef="usd">7810000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2019-12-31"
      decimals="-3"
      id="Fact_0000000000293"
      unitRef="usd">9839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2018-12-31"
      decimals="-3"
      id="Fact_0000000000294"
      unitRef="usd">6466000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000295"
      unitRef="usd">8514000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000296"
      unitRef="usd">7810000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2019-12-31"
      decimals="-3"
      id="Fact_0000000000297"
      unitRef="usd">9839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000298"
      unitRef="usd">116000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000299"
      unitRef="usd">16000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000300"
      unitRef="usd">47000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <cgen:ReceivablesOnAccountOfShares
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000301"
      unitRef="usd"
      xsi:nil="true"/>
    <cgen:ReceivablesOnAccountOfShares
      contextRef="From2020-01-01to2020-12-31"
      id="Fact_0000000000302"
      unitRef="usd"
      xsi:nil="true"/>
    <cgen:ReceivablesOnAccountOfShares
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000303"
      unitRef="usd">76000</cgen:ReceivablesOnAccountOfShares>
    <cgen:SupplementalRightOfUseAssetAndOperatingleaseLiability
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000304"
      unitRef="usd"
      xsi:nil="true"/>
    <cgen:SupplementalRightOfUseAssetAndOperatingleaseLiability
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000305"
      unitRef="usd">-194000</cgen:SupplementalRightOfUseAssetAndOperatingleaseLiability>
    <cgen:SupplementalRightOfUseAssetAndOperatingleaseLiability
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000306"
      unitRef="usd">363000</cgen:SupplementalRightOfUseAssetAndOperatingleaseLiability>
    <cgen:InterestPaidReceivedNet
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000307"
      unitRef="usd">1364000</cgen:InterestPaidReceivedNet>
    <cgen:InterestPaidReceivedNet
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000308"
      unitRef="usd">1232000</cgen:InterestPaidReceivedNet>
    <cgen:InterestPaidReceivedNet
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000309"
      unitRef="usd">1002000</cgen:InterestPaidReceivedNet>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000310"
      unitRef="usd">7801000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000311"
      unitRef="usd">7143000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2019-12-31"
      decimals="-3"
      id="Fact_0000000000312"
      unitRef="usd">9187000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000313"
      unitRef="usd">713000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000314"
      unitRef="usd">667000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="AsOf2019-12-31"
      decimals="-3"
      id="Fact_0000000000315"
      unitRef="usd">652000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000316"
      unitRef="usd">8514000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000317"
      unitRef="usd">7810000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2019-12-31"
      decimals="-3"
      id="Fact_0000000000318"
      unitRef="usd">9839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000331">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt; &lt;span style="font-weight:bold; "&gt;NOTE 1: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;GENERAL&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; "&gt;a.&lt;span style="padding-left:13.06pt; "&gt;Compugen Ltd. (the &#x201c;&lt;/span&gt;&lt;span style="font-weight:bold; "&gt;Company&lt;/span&gt;&#x201d;) is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Compugen&#x2019;s innovative immuno-oncology pipeline consists of four clinical stage programs, targeting immune checkpoints Compugen discovered computationally, COM701, COM902, bapotulimab (formerly known as BAY1905254) and AZD2936. The Company&#x2019;s lead product candidate, COM701, a potential first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing Phase 1 clinical trials in dual, and triple combinations under clinical collaboration with Bristol Myers Squibb. COM902, a potential best-in-class, is a therapeutic antibody targeting TIGIT, developed internally and is undergoing a Phase 1 trial to evaluate it in patients with advanced malignancies as a monotherapy and in combination with COM701. Bapotulimab, an antibody targeting ILDR2, licensed to Bayer under a research and discovery collaboration and license agreement, is also in Phase 1 trials in patients with advanced solid tumors. AZD2936 is a novel anti-TIGIT/PD-1 bispecific antibody with a TIGIT component that is derived from Compugen&#x2019;s COM902 program and is developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is in Phase 1/2 trial in patients with advanced or metastatic non-small cell lung cancer. Compugen&#x2019;s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. The innovative immuno-oncology pipeline, the strategic collaborations and the Company&#x2019;s computational discovery engine serve as the corporate three key building blocks. Compugen&#x2019;s business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development under various revenue-sharing arrangements. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; "&gt;b.&lt;span style="padding-left:12.5pt; "&gt;The Company is headquartered in Holon, Israel. Its clinical development activities are headed from its United States &lt;/span&gt;subsidiary, Compugen USA, Inc, located in South San Francisco, CA. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; "&gt;c.&lt;span style="padding-left:13.06pt; "&gt;The Company has incurred losses in the amount of $&lt;/span&gt;34,203 during the year ended December 31, 2021, has an accumulated deficit of $422,079 as of December 31, 2021 and has an accumulated negative cash flow from operating activities in the amount of $22,750 for the year ended December 31, 2021. On February 26, 2019, the Company announced a corporate restructuring to reduce costs by consolidating and streamlining R&amp;amp;D operations. The restructuring included reducing its workforce by 35%, consolidating R&amp;amp;D activities in one location in Israel and outsourcing certain preclinical activities to third-party service providers. The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements at the current level of yearly expenditures into 2024. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; "&gt;d.&lt;span style="padding-left:12.5pt; "&gt;On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement &lt;/span&gt;(&#x201c;Bayer Agreement&#x201d;) with Bayer Pharma AG (&#x201c;Bayer&#x201d;) for the research, development, and commercialization of antibody-based therapeutics against two novel, Compugen-discovered immune checkpoint regulators. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Under the terms of the Bayer Agreement, the Company received an upfront payment of $10,000, and, following the return of the CGEN 15022 program in 2017, the Company is eligible to receive an aggregate of over $250,000 in potential milestone payments for Bapotulimab (formerly known as BAY1905254), not including aggregate milestone payments of approximately $23,000 received to date. Additionally, the Company is eligible to receive mid to high single digit royalties on global net sales of any approved products under the collaboration.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Pursuant to the terms of Bayer Agreement, Bapotulimab program was transferred to Bayer&#x2019;s full control for further preclinical and clinical development activities, and worldwide commercialization under milestone and royalty bearing license from Compugen.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;11&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 1: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;GENERAL (Cont.)&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; "&gt;e.&lt;span style="padding-left:13.06pt; "&gt;Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited. the &lt;/span&gt;global biologics research and development arm of AstraZeneca (&#x201c;AstraZeneca&#x201d;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and will be solely responsible for all research, development, and commercial activities under the agreement. Compugen received a $10,000 upfront payment, and received $8,000 milestone payments out of up to $200,000 the Company is eligible to receive in development, regulatory and commercial milestones for the first product in addition to tiered royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; "&gt;f.&lt;span style="padding-left:14.17pt; "&gt;On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#x201c;Agreement&#x201d;) &lt;/span&gt;with Bristol-Myers Squibb Company (&#x201c;Bristol-Myers Squibb&#x201d;) to evaluate the safety and tolerability of Compugen&#x2019;s COM701 in combination with Bristol-Myers Squibbs&#x2019; PD-1 immune checkpoint inhibitor Opdivo&#xae; (nivolumab), in patients with advanced solid tumors. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Pursuant to the Agreement, Compugen is responsible for and will continue sponsoring the ongoing two-part Phase 1 trial, which includes the evaluation of the combination of COM701 and Opdivo&#xae;. The collaboration was also designed to address potential future combinations, including trials sponsored by Bristol-Myers Squibb to investigate combined inhibition of checkpoint mechanisms, such as PVRIG and TIGIT. Bristol-Myers Squibb and Compugen each supplies the other company with its own compound for the other party&#x2019;s study, and otherwise each party is responsible for all costs associated with the study that it is conducting. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;In conjunction with the signing of the Agreement in October 2018, Bristol-Myers Squibb made a $12,000 investment in Compugen, see Note 8b. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;On February 14, 2020, the Agreement was amended to include a triple combination clinical trial to evaluate the safety, tolerability and antitumor activity of COM701 in combination with Opdivo&#xae; (nivolumab), and Bristol-Myers Squibb&#x2019;s investigational antibody targeting TIGIT known as BMS-986207, in patients with advanced solid tumors, instead of the planned expansion of the combined therapy study designed to evaluate the dual combination of COM701 and Opdivo&#xae;. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Pursuant to the Agreement, as amended, the Company sponsors the two-part Phase 1/2 trial, which evaluates the triple combination of COM701, Opdivo&#xae; and BMS-986207, in patients with advanced solid tumors where Bristol-Myers Squibb provides Opdivo&#xae; and BMS-986207 at no cost to the Company. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;12&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 1: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;GENERAL (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;As part of the amended Agreement, it was agreed that the Company will complete the dose escalation arm of the dual combination of COM701 with Opdivo&#xae; under the ongoing Phase 1 study and will not continue the expansion cohorts of the dual combination. However, on February 19, 2021, the Agreement was further amended to include an expansion of the Phase 1 combination study designed to evaluate the dual combination of COM701 and Opdivo&#xae; in patients with advanced solid tumors, where the Company is responsible for and sponsors the expansion cohort and Bristol Myers Squibb provides Opdivo&#xae; at no cost to the Company for this study. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;On November 10, 2021, the Agreement was further amended to establish a joint steering committee (alongside the existing joint development committee which acts at an operational level) to facilitate strategic oversight and guidance for the programs run under the collaboration. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;In conjunction with the signing of the amendment to the Agreement in November 2021, Bristol-Myers Squibb made a $20,000 investment in Compugen, see Note 8b. &lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000319"
      unitRef="usd">-34203000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000320"
      unitRef="usd">-422079000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000321"
      unitRef="usd">-22750000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact_0000000000322"
      unitRef="Pure">0.35</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2013-01-01to2013-12-31"
      decimals="-3"
      id="Fact_0000000000323"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivable
      contextRef="I2013-12-31"
      decimals="-3"
      id="Fact_0000000000324"
      unitRef="usd">250000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivable>
    <cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable
      contextRef="I2013-12-31"
      decimals="-3"
      id="Fact_0000000000325"
      unitRef="usd">23000000</cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000326"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:AccruedMilestonePayment
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000327"
      unitRef="usd">8000000</cgen:AccruedMilestonePayment>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivable
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000328"
      unitRef="usd">200000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivable>
    <us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000329"
      unitRef="usd">12000000</us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue>
    <us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue
      contextRef="AsOf2021-11-30"
      decimals="-3"
      id="Fact_0000000000330"
      unitRef="usd">20000000</us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000405">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt; &lt;span style="font-weight:bold; "&gt;NOTE 2: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; "&gt;The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; a.&lt;span style="padding-left:13.06pt; "&gt;Use of estimates:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#x2019;s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company considered the impact of COVID-19 on the estimates and assumptions and determined that there were no material adverse impacts on the consolidated financial statements for the year ended December 31, 2021. As events continue to evolve and additional information becomes available, the Company&#x2019;s estimates and assumptions may change materially in future periods. Such changes could result in future impairments of long-lived assets. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; b.&lt;span style="padding-left:12.5pt; "&gt;Financial statements in U.S. dollars:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The reporting and functional currency of the Company is the U.S. dollar, as the Company&#x2019;s management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen USA, Inc. have operated and expect to continue to operate in the foreseeable future.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No. 830, &#x201c;Foreign Currency Matters&#x201d;. All transaction gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;13&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 2: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; c.&lt;span style="padding-left:13.06pt; "&gt;Basis of consolidation:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The consolidated financial statements include the accounts of the Company and Compugen USA, Inc. Intercompany transactions and balances have been eliminated upon consolidation. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; d.&lt;span style="padding-left:12.5pt; "&gt;Cash equivalents:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; e.&lt;span style="padding-left:13.06pt; "&gt;Restricted cash:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Restricted cash is held in interest bearing saving accounts which are used as a security for the Company&#x2019;s Israeli facility leasehold bank guarantee and credit card security for Compugen USA, Inc. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; f.&lt;span style="padding-left:14.17pt; "&gt;Short-term bank deposits:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates market values. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The short-term bank deposits as of December 31, 2021 and 2020 are in U.S. dollars and bear an annual weighted average interest rate of 0.77% and 1.01%, respectively. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; g.&lt;span style="padding-left:12.5pt; "&gt;Property and equipment, net:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt; Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:80pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:58%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:42%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;% &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:58%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:42%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:58%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Computers, software and related equipment &lt;/p&gt; &lt;/td&gt; &lt;td style="width:42%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;33 &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:58%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Laboratory equipment and office furniture &lt;/p&gt; &lt;/td&gt; &lt;td style="width:42%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;6 - 20 (mainly 20) &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:58%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Leasehold improvements &lt;/p&gt; &lt;/td&gt; &lt;td style="width:42%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;Shorter of the term of the lease or useful life &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;14&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 2: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; h.&lt;span style="padding-left:12.5pt; "&gt;Impairment of long-lived assets:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The long-lived assets of the Company and Compugen USA, Inc. are reviewed for impairment in accordance with ASC 360, &#x201c;Property, Plant, and Equipment,&#x201d; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset with the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years 2021, 2020 and 2019, no impairment losses have been identified. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; i.&lt;span style="padding-left:14.72pt; "&gt;Revenue recognition:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company generates revenues mainly from its collaborative and license agreements. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestone achievements. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;The Company recognizes revenue in accordance with ASC 606 &#x2013; &#x201c;Revenue from Contracts with Customers&#x201d;. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;As such, the Company analyzes its contracts to assess whether they are within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;&#x2022;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-12pt; text-indent:98pt; margin-bottom:0pt; "&gt;&lt;span style="font-style:italic; "&gt;Identification of the contract, or contracts, with a customer&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;&#x2022;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:98pt; margin-bottom:0pt; "&gt;&lt;span style="font-style:italic; "&gt;Identification of the performance obligations in the contract&lt;/span&gt; - At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not distinct from other promises in the contract (either because it is not capable of being distinct or because it is not distinct within the context of the contract), or if an option to acquire good or service does not provide the customer with a material right. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;&#x2022;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:98pt; margin-bottom:0pt; "&gt;&lt;span style="font-style:italic; "&gt;Determination of the transaction price&lt;/span&gt; - The Company considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;15&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 2: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;i.&lt;span style="padding-left:14.72pt; "&gt;Revenue recognition (Cont.):&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;&#x2022;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:98pt; margin-bottom:0pt; "&gt;&lt;span style="font-style:italic; "&gt;Allocation of the transaction price to the performance obligations in the contract&lt;/span&gt; - If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling prices. The relative selling price for each deliverable is estimated using observable objective evidence if it is available. If observable objective evidence is not available, the Company uses its best estimate of the selling price for the deliverable. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;&#x2022;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:98pt; margin-bottom:0pt; "&gt;&lt;span style="font-style:italic; "&gt;Recognition of revenue when, or as, the Company satisfies a performance obligation&lt;/span&gt; - Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; "&gt;After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company entered into an exclusive license agreement with AstraZeneca. Under the terms of the agreement, Compugen provided AstraZeneca with an exclusive license to intellectual property (&#x201c;IP&#x201d;) rights of the Company for the development of bi-specific and multi-specific antibody products derived from COM902. Compugen received a $10,000 upfront nonrefundable payment and is eligible to receive up to $200,000 for development, regulatory and commercial milestones for the first product, including $8,000 received to date as well as tiered royalties on future product sales. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Under ASC 606, the Company determined the license to the IP to be a functional IP that has significant standalone functionality. The Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the IP. Therefore, the license to the IP is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to the customer. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Future milestone payments are considered variable consideration and are subject to the variable consideration constraint (i.e. will be recognized once concluded that it is &#x201c;probable&#x201d; that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable consideration is resolved). Therefore, as the milestone payments are not probable, revenue was not recognized in respect to such milestone payments prior to achievement of such milestone. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;16&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 2: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;i.&lt;span style="padding-left:14.72pt; "&gt;Revenue recognition (Cont.):&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Sales- or usage-based royalties to be received in exchange for licenses of IP are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales- or usage-based royalty has been allocated is satisfied (in whole or in part). As royalties are payable based on future Commercial Sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;On December 18, 2020 the first milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $2,000 in accordance with the criteria prescribed under ASC 606. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;On September 29, 2021 the second milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $6,000 in accordance with the criteria prescribed under ASC 606. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;For information regarding revenues, please refer to Note 10 below. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; j.&lt;span style="padding-left:14.72pt; "&gt;Cost of revenues:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;Cost of revenues consist of certain royalties and milestones paid or accrued. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; k.&lt;span style="padding-left:12.5pt; "&gt;Research and development expenses, net:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Research and development costs are charged to the statement of comprehensive loss as incurred and are presented net of the amount of any grants the Company receives for research and development in the period in which the grant was received. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;As part of the process of preparing the consolidated financial statements, the Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, and amortized as the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;17&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 2: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;k.&lt;span style="padding-left:12.5pt; "&gt;Research and development expenses, net (Cont.):&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The portion of the Bristol-Myers Squibb $12,000 investment over the fair market value of the shares issued in the amount of $4,121 and the portion of the $20,000 investment over the fair market value of the shares issued in the amount of $5,000 were considered as deferred participation of Bristol-Myers Squibb in R&amp;amp;D expenses which is amortized over the period of the clinical trial based on the progress in the R&amp;amp;D, in accordance with ASC 808 &#x201c;Collaborative Arrangements&#x201d;, see Note 1f and Note 8b. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Amortization of participation in R&amp;amp;D expenses for the years ended December 31, 2021, 2020 and 2019 were $1,291, $829 and $627, respectively. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; l.&lt;span style="padding-left:14.72pt; "&gt;Severance pay:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company&#x2019;s liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date, and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset in the Company&#x2019;s balance sheet. Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company&#x2019;s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee&#x2019;s monthly salary for each year of service, no additional calculations are conducted between the parties regarding the matter of severance pay and no additional payments are made by the Company to the employee. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Severance expenses for the years ended December 31, 2021, 2020 and 2019 amounted to approximately $383, $572 and $366, respectively. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; m.&lt;span style="padding-left:9.72pt; "&gt;Stock-based compensation:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company accounts for stock-based compensation to employees and non-employees in accordance with ASC 718, &#x201c;Compensation - Stock Compensation&#x201d;, (&#x201c;ASC 718&#x201d;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company accounts for forfeitures as they occur. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;18&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 2: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;m.&lt;span style="padding-left:9.72pt; "&gt;Stock-based compensation (Cont.):&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company selected the Black-Scholes-Merton (&#x201c;Black-Scholes&#x201d;) option-pricing model as the most appropriate fair value method for its share-options awards and Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt; The Company used the following weighted-average assumptions for options granted to employees, directors and non-employees and ESPP: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:80pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="7" style="width:14%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Year ended December 31,&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2019&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="text-decoration:underline #000000; "&gt;Employee stock Options&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Volatility &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;67.68% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;63.17% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;54.59% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Risk-free interest rate &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0.77% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0.45% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;1.92% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Dividend yield &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Expected life (years) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;5.17 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;5.16 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;5.15 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="text-decoration:underline #000000; "&gt;ESPP&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Volatility &lt;/p&gt; &lt;/td&gt; &lt;td colspan="3" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="padding-left:0pt; "&gt;64.68&lt;/span&gt;&lt;span style="padding-left:0pt; "&gt;%-&lt;/span&gt;&lt;span style="padding-left:0pt; "&gt;69.68&lt;/span&gt;&lt;span style="padding-left:0pt; "&gt;%&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Risk-free interest rate &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0.04%-0.10% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Dividend yield &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Expected life (years) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0.42-0.50 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; n.&lt;span style="padding-left:12.5pt; "&gt;Concentration of credit risks:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Financial instruments that potentially subject the Company and Compugen USA, Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term bank deposits. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Cash, cash equivalents, restricted cash and short-term bank deposits are invested in major banks in Israel and in the U.S. Generally, these deposits may be redeemed upon demand and bear minimal risk. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The trade receivables of the Company derive from milestone payments under collaboration agreements between the company and its collaborators, located primarily in Europe. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;19&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 2: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;n.&lt;span style="padding-left:12.5pt; "&gt;Concentration of credit risks (Cont.):&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company&#x2019;s collaborators are major pharma companies. The amounts due to the Company by such collaborators are paid pursuant to the terms of the agreements after a short period of time and bear low risk. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company had one collaborator that accounted for 100% of the Company&#x2019;s consolidated revenues, for the years ended December 31, 2021 and 2020. The Company had no revenues in 2019. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; o.&lt;span style="padding-left:12.5pt; "&gt;Basic and diluted loss per share:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#x201c;Earnings per Share&#x2ee;. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;All outstanding share options and warrants for the years ended December 31, 2021, 2020 and 2019 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. As of December 31, 2021, 2020 and 2019 the average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were 6,758,300, 7,150,648 and 12,754,803, respectively. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; p.&lt;span style="padding-left:12.5pt; "&gt;Income taxes:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company accounts for income taxes in accordance with ASC No. 740, &#x201c;Income Taxes&#x201d;, (&#x201c;ASC 740&#x201d;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2021 and 2020, a full valuation allowance was provided by the Company. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740-10. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;20&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 2: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; q.&lt;span style="padding-left:12.5pt; "&gt;Fair value of financial instruments:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company applies ASC 820, &#x201c;Fair Value Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an orderly transaction between market participants at the measurement date. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputting that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;The hierarchy is broken down into three levels based on the inputs as follows: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-60pt !important; padding-left:140pt !important; margin-bottom:0pt; "&gt;Level 1 -&lt;span style="padding-left:22.24pt; "&gt;Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can &lt;/span&gt;access at the measurement date. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-60pt !important; padding-left:140pt !important; margin-bottom:0pt; "&gt;Level 2 -&lt;span style="padding-left:22.24pt; "&gt;Valuations based on one or more quoted prices in markets that are not active or for which all &lt;/span&gt;significant inputs are observable, either directly or indirectly. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;Level 3 -&lt;span style="padding-left:22.24pt; "&gt;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, other accounts receivable and prepaid expenses, trade payable and other accounts payable and accrued expenses approximate their fair values due to the short-term maturities of such instruments. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; r.&lt;span style="padding-left:14.72pt; "&gt;Derivative instruments:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company accounts for derivatives and hedging based on ASC 815, &#x201c;Derivatives and Hedging&#x201d;. ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, the Company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;21&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 2: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;r.&lt;span style="padding-left:14.72pt; "&gt;Derivative instruments (Cont.):&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;If the derivatives meet the definition of a hedge and are so designated, depending on the nature of the hedge, changes in the fair value of such derivatives will either be offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings, or recognized in other comprehensive income until the hedged item is recognized in earnings. The ineffective portion of a derivative&#x2019;s change in fair value is recognized in earnings. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;In the past the Company entered into forward contracts to hedge against the risk of overall changes in future cash flow from payments of payroll and related expenses as well as other expenses denominated in NIS. As of December 31, 2021 and 2020, the Company had no outstanding forward contracts. The Company measured the fair value of the contracts in accordance with ASC 820 (classified as level 2). &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;These contracts met the requirement for cash flow hedge accounting and during each of the years ended December 31, 2021, 2020 and 2019, no amount of total gains were recognized and were classified to operating expenses as effective hedge and no unrealized gains were recognized under other comprehensive income (loss). &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; s.&lt;span style="padding-left:13.61pt; "&gt;Comprehensive income (loss):&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company accounts for comprehensive income (loss) in accordance with ASC 220, &#x201c;Comprehensive Income&#x201d;. This statement establishes standards for the reporting and display of comprehensive income (loss) and its components in a full set of general-purpose financial statements. Comprehensive income (loss) generally represents all changes in shareholders&#x2019; equity during the period except those resulting from investments by, or distributions to, shareholders. The Company elected to present the comprehensive income (loss) in a single continuous statement. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt; In the years 2021, 2020 and 2019 the Company has no components of other comprehensive income (loss), other than net loss. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;22&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 2: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;t.&lt;span style="padding-left:14.72pt; "&gt;Recently issued and recently adopted Accounting Standards:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. Among other changes, ASU 2020-06 removes from GAAP the liability and equity separation model for convertible instruments with a cash conversion feature and a beneficial conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share (EPS). ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020 and can be adopted on either a fully retrospective or modified retrospective basis. The Company adopted ASU 2020-06 as of January 1, 2021. The adoption of this standard did not have an impact to the Company&#x2019;s financial statements.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832). This ASU requires business entities to disclose information about government assistance they receive if the transactions were accounted for by analogy to either a grant or a contribution accounting model. The disclosure requirements include the nature of the transaction and the related accounting policy used, the line items on the balance sheets and statements of operations that are affected and the amounts applicable to each financial statement line item and the significant terms and conditions of the transactions. The ASU is effective for annual periods beginning after December 15, 2021. The disclosure requirements can be applied either retrospectively or prospectively to all transactions in the scope of the amendments that are reflected in the financial statements at the date of initial application and new transactions that are entered into after the date of initial application. The ASU is currently not expected to have a material impact on our consolidated financial statements. &lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000332">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; a.&lt;span style="padding-left:13.06pt; "&gt;Use of estimates:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#x2019;s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company considered the impact of COVID-19 on the estimates and assumptions and determined that there were no material adverse impacts on the consolidated financial statements for the year ended December 31, 2021. As events continue to evolve and additional information becomes available, the Company&#x2019;s estimates and assumptions may change materially in future periods. Such changes could result in future impairments of long-lived assets. &lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000333">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; b.&lt;span style="padding-left:12.5pt; "&gt;Financial statements in U.S. dollars:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The reporting and functional currency of the Company is the U.S. dollar, as the Company&#x2019;s management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen USA, Inc. have operated and expect to continue to operate in the foreseeable future.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No. 830, &#x201c;Foreign Currency Matters&#x201d;. All transaction gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate. &lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000334">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; c.&lt;span style="padding-left:13.06pt; "&gt;Basis of consolidation:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The consolidated financial statements include the accounts of the Company and Compugen USA, Inc. Intercompany transactions and balances have been eliminated upon consolidation. &lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000335">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; d.&lt;span style="padding-left:12.5pt; "&gt;Cash equivalents:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000336">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; e.&lt;span style="padding-left:13.06pt; "&gt;Restricted cash:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Restricted cash is held in interest bearing saving accounts which are used as a security for the Company&#x2019;s Israeli facility leasehold bank guarantee and credit card security for Compugen USA, Inc. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <cgen:ShortTermBankDepositsPolicyTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000339">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; f.&lt;span style="padding-left:14.17pt; "&gt;Short-term bank deposits:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates market values. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The short-term bank deposits as of December 31, 2021 and 2020 are in U.S. dollars and bear an annual weighted average interest rate of 0.77% and 1.01%, respectively. &lt;/p&gt;</cgen:ShortTermBankDepositsPolicyTextBlock>
    <cgen:ShortTermBankDepositsWeightedAverageRateForeign
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact_0000000000337"
      unitRef="Pure">0.0077</cgen:ShortTermBankDepositsWeightedAverageRateForeign>
    <cgen:ShortTermBankDepositsWeightedAverageRateForeign
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      id="Fact_0000000000338"
      unitRef="Pure">0.0101</cgen:ShortTermBankDepositsWeightedAverageRateForeign>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000346">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; g.&lt;span style="padding-left:12.5pt; "&gt;Property and equipment, net:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt; Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:80pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:58%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:42%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;% &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:58%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:42%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:58%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Computers, software and related equipment &lt;/p&gt; &lt;/td&gt; &lt;td style="width:42%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;33 &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:58%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Laboratory equipment and office furniture &lt;/p&gt; &lt;/td&gt; &lt;td style="width:42%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;6 - 20 (mainly 20) &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:58%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Leasehold improvements &lt;/p&gt; &lt;/td&gt; &lt;td style="width:42%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;Shorter of the term of the lease or useful life &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000345">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt; Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:80pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:58%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:42%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;% &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:58%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:42%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:58%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Computers, software and related equipment &lt;/p&gt; &lt;/td&gt; &lt;td style="width:42%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;33 &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:58%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Laboratory equipment and office furniture &lt;/p&gt; &lt;/td&gt; &lt;td style="width:42%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;6 - 20 (mainly 20) &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:58%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Leasehold improvements &lt;/p&gt; &lt;/td&gt; &lt;td style="width:42%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;Shorter of the term of the lease or useful life &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock>
    <cgen:AnnualDepreciationRate
      contextRef="From2021-01-01to2021-12-31_us-gaap_ComputerEquipmentMember"
      decimals="INF"
      id="Fact_0000000000340"
      unitRef="Pure">0.33</cgen:AnnualDepreciationRate>
    <cgen:AnnualDepreciationRate
      contextRef="From2021-01-01to2021-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember_srt_MinimumMember"
      decimals="INF"
      id="Fact_0000000000341"
      unitRef="Pure">0.06</cgen:AnnualDepreciationRate>
    <cgen:AnnualDepreciationRate
      contextRef="From2021-01-01to2021-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember_srt_MaximumMember"
      decimals="INF"
      id="Fact_0000000000342"
      unitRef="Pure">0.20</cgen:AnnualDepreciationRate>
    <cgen:AnnualDepreciationRate
      contextRef="From2021-01-01to2021-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="INF"
      id="Fact_0000000000343"
      unitRef="Pure">0.20</cgen:AnnualDepreciationRate>
    <cgen:AnnualDepreciationRateDescription
      contextRef="From2021-01-01to2021-12-31_us-gaap_LeaseholdImprovementsMember"
      id="Fact_0000000000344">Shorter of the term of the lease or useful life</cgen:AnnualDepreciationRateDescription>
    <us-gaap:PropertyPlantAndEquipmentImpairment
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000347">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; h.&lt;span style="padding-left:12.5pt; "&gt;Impairment of long-lived assets:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The long-lived assets of the Company and Compugen USA, Inc. are reviewed for impairment in accordance with ASC 360, &#x201c;Property, Plant, and Equipment,&#x201d; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset with the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years 2021, 2020 and 2019, no impairment losses have been identified. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000353">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; i.&lt;span style="padding-left:14.72pt; "&gt;Revenue recognition:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company generates revenues mainly from its collaborative and license agreements. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestone achievements. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;The Company recognizes revenue in accordance with ASC 606 &#x2013; &#x201c;Revenue from Contracts with Customers&#x201d;. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;As such, the Company analyzes its contracts to assess whether they are within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;&#x2022;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-12pt; text-indent:98pt; margin-bottom:0pt; "&gt;&lt;span style="font-style:italic; "&gt;Identification of the contract, or contracts, with a customer&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;&#x2022;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:98pt; margin-bottom:0pt; "&gt;&lt;span style="font-style:italic; "&gt;Identification of the performance obligations in the contract&lt;/span&gt; - At contract inception, the Company assesses the goods or services promised in a contract with a customer and identifies those distinct goods and services that represent a performance obligation. A promised good or service may not be identified as a performance obligation if it is immaterial in the context of the contract with the customer, if it is not distinct from other promises in the contract (either because it is not capable of being distinct or because it is not distinct within the context of the contract), or if an option to acquire good or service does not provide the customer with a material right. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;&#x2022;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:98pt; margin-bottom:0pt; "&gt;&lt;span style="font-style:italic; "&gt;Determination of the transaction price&lt;/span&gt; - The Company considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction price when it is not considered constrained, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;15&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 2: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;i.&lt;span style="padding-left:14.72pt; "&gt;Revenue recognition (Cont.):&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;&#x2022;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:98pt; margin-bottom:0pt; "&gt;&lt;span style="font-style:italic; "&gt;Allocation of the transaction price to the performance obligations in the contract&lt;/span&gt; - If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling prices. The relative selling price for each deliverable is estimated using observable objective evidence if it is available. If observable objective evidence is not available, the Company uses its best estimate of the selling price for the deliverable. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;&#x2022;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:-12pt; padding-left:98pt; margin-bottom:0pt; "&gt;&lt;span style="font-style:italic; "&gt;Recognition of revenue when, or as, the Company satisfies a performance obligation&lt;/span&gt; - Revenue is recognized when, or as, the Company satisfies a performance obligation by transferring a promised good or service to a customer. An asset is transferred when, or as, the customer obtains control of that asset, which for a service is considered to be as the services are received and used. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; "&gt;After contract inception, the transaction price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the transaction price is allocated to the performance obligations on the same basis as at contract inception. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company entered into an exclusive license agreement with AstraZeneca. Under the terms of the agreement, Compugen provided AstraZeneca with an exclusive license to intellectual property (&#x201c;IP&#x201d;) rights of the Company for the development of bi-specific and multi-specific antibody products derived from COM902. Compugen received a $10,000 upfront nonrefundable payment and is eligible to receive up to $200,000 for development, regulatory and commercial milestones for the first product, including $8,000 received to date as well as tiered royalties on future product sales. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Under ASC 606, the Company determined the license to the IP to be a functional IP that has significant standalone functionality. The Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the IP. Therefore, the license to the IP is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to the customer. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Future milestone payments are considered variable consideration and are subject to the variable consideration constraint (i.e. will be recognized once concluded that it is &#x201c;probable&#x201d; that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable consideration is resolved). Therefore, as the milestone payments are not probable, revenue was not recognized in respect to such milestone payments prior to achievement of such milestone. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;16&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 2: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;i.&lt;span style="padding-left:14.72pt; "&gt;Revenue recognition (Cont.):&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Sales- or usage-based royalties to be received in exchange for licenses of IP are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales- or usage-based royalty has been allocated is satisfied (in whole or in part). As royalties are payable based on future Commercial Sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;On December 18, 2020 the first milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $2,000 in accordance with the criteria prescribed under ASC 606. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;On September 29, 2021 the second milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $6,000 in accordance with the criteria prescribed under ASC 606. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;For information regarding revenues, please refer to Note 10 below. &lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000348"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivable
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000349"
      unitRef="usd">200000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivable>
    <cgen:AccruedMilestonePayment
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000350"
      unitRef="usd">8000000</cgen:AccruedMilestonePayment>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2020-12-01to2020-12-18"
      decimals="-3"
      id="Fact_0000000000351"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2021-09-01to2021-09-29"
      decimals="-3"
      id="Fact_0000000000352"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <cgen:CostOfSalesContractWithCustomerPolicyTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000354">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; j.&lt;span style="padding-left:14.72pt; "&gt;Cost of revenues:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;Cost of revenues consist of certain royalties and milestones paid or accrued. &lt;/p&gt;</cgen:CostOfSalesContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000363">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; k.&lt;span style="padding-left:12.5pt; "&gt;Research and development expenses, net:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Research and development costs are charged to the statement of comprehensive loss as incurred and are presented net of the amount of any grants the Company receives for research and development in the period in which the grant was received. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;As part of the process of preparing the consolidated financial statements, the Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, and amortized as the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;17&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 2: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;k.&lt;span style="padding-left:12.5pt; "&gt;Research and development expenses, net (Cont.):&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The portion of the Bristol-Myers Squibb $12,000 investment over the fair market value of the shares issued in the amount of $4,121 and the portion of the $20,000 investment over the fair market value of the shares issued in the amount of $5,000 were considered as deferred participation of Bristol-Myers Squibb in R&amp;amp;D expenses which is amortized over the period of the clinical trial based on the progress in the R&amp;amp;D, in accordance with ASC 808 &#x201c;Collaborative Arrangements&#x201d;, see Note 1f and Note 8b. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Amortization of participation in R&amp;amp;D expenses for the years ended December 31, 2021, 2020 and 2019 were $1,291, $829 and $627, respectively. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="AsOf2021-12-31_custom_MasterClinicalAgreementOneMember"
      decimals="-3"
      id="Fact_0000000000356"
      unitRef="usd">12000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000355"
      unitRef="usd">12000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <cgen:DeferredParticipationOfBmsInRdExpenses
      contextRef="From2021-01-01to2021-12-31_custom_MasterClinicalAgreementOneMember"
      decimals="-3"
      id="Fact_0000000000357"
      unitRef="usd">4121000</cgen:DeferredParticipationOfBmsInRdExpenses>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="AsOf2021-12-31_custom_MasterClinicalAgreementTwoMember"
      decimals="-3"
      id="Fact_0000000000358"
      unitRef="usd">20000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <cgen:DeferredParticipationOfBmsInRdExpenses
      contextRef="From2021-01-01to2021-12-31_custom_MasterClinicalAgreementTwoMember"
      decimals="-3"
      id="Fact_0000000000359"
      unitRef="usd">5000000</cgen:DeferredParticipationOfBmsInRdExpenses>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000360"
      unitRef="usd">1291000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000361"
      unitRef="usd">829000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000362"
      unitRef="usd">627000</us-gaap:AdjustmentForAmortization>
    <cgen:ServerancePayPolicyTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000367">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; l.&lt;span style="padding-left:14.72pt; "&gt;Severance pay:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company&#x2019;s liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date, and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset in the Company&#x2019;s balance sheet. Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company&#x2019;s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee&#x2019;s monthly salary for each year of service, no additional calculations are conducted between the parties regarding the matter of severance pay and no additional payments are made by the Company to the employee. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Severance expenses for the years ended December 31, 2021, 2020 and 2019 amounted to approximately $383, $572 and $366, respectively. &lt;/p&gt;</cgen:ServerancePayPolicyTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000364"
      unitRef="usd">383000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000365"
      unitRef="usd">572000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000366"
      unitRef="usd">366000</us-gaap:SeveranceCosts1>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000394">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; m.&lt;span style="padding-left:9.72pt; "&gt;Stock-based compensation:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company accounts for stock-based compensation to employees and non-employees in accordance with ASC 718, &#x201c;Compensation - Stock Compensation&#x201d;, (&#x201c;ASC 718&#x201d;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company accounts for forfeitures as they occur. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;18&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 2: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;m.&lt;span style="padding-left:9.72pt; "&gt;Stock-based compensation (Cont.):&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company selected the Black-Scholes-Merton (&#x201c;Black-Scholes&#x201d;) option-pricing model as the most appropriate fair value method for its share-options awards and Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt; The Company used the following weighted-average assumptions for options granted to employees, directors and non-employees and ESPP: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:80pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="7" style="width:14%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Year ended December 31,&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2019&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="text-decoration:underline #000000; "&gt;Employee stock Options&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Volatility &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;67.68% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;63.17% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;54.59% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Risk-free interest rate &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0.77% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0.45% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;1.92% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Dividend yield &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Expected life (years) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;5.17 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;5.16 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;5.15 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="text-decoration:underline #000000; "&gt;ESPP&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Volatility &lt;/p&gt; &lt;/td&gt; &lt;td colspan="3" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="padding-left:0pt; "&gt;64.68&lt;/span&gt;&lt;span style="padding-left:0pt; "&gt;%-&lt;/span&gt;&lt;span style="padding-left:0pt; "&gt;69.68&lt;/span&gt;&lt;span style="padding-left:0pt; "&gt;%&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Risk-free interest rate &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0.04%-0.10% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Dividend yield &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Expected life (years) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0.42-0.50 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <cgen:ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000393">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt; The Company used the following weighted-average assumptions for options granted to employees, directors and non-employees and ESPP: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:80pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="7" style="width:14%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Year ended December 31,&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2019&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="text-decoration:underline #000000; "&gt;Employee stock Options&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Volatility &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;67.68% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;63.17% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;54.59% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Risk-free interest rate &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0.77% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0.45% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;1.92% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Dividend yield &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Expected life (years) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;5.17 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;5.16 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;5.15 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="text-decoration:underline #000000; "&gt;ESPP&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Volatility &lt;/p&gt; &lt;/td&gt; &lt;td colspan="3" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="padding-left:0pt; "&gt;64.68&lt;/span&gt;&lt;span style="padding-left:0pt; "&gt;%-&lt;/span&gt;&lt;span style="padding-left:0pt; "&gt;69.68&lt;/span&gt;&lt;span style="padding-left:0pt; "&gt;%&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Risk-free interest rate &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0.04%-0.10% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Dividend yield &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:55%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Expected life (years) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;0.42-0.50 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:13%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</cgen:ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-01to2021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_0000000000368"
      unitRef="Pure">0.6768</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_0000000000369"
      unitRef="Pure">0.6317</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-01-01to2019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_0000000000370"
      unitRef="Pure">0.5459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-01to2021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_0000000000371"
      unitRef="Pure">0.0077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_0000000000372"
      unitRef="Pure">0.0045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-01-01to2019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_0000000000373"
      unitRef="Pure">0.0192</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-01to2021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_0000000000374"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_0000000000375"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-01-01to2019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_0000000000376"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2021-01-01to2021-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fact_0000000000377">P5Y2M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2020-01-01to2020-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fact_0000000000378">P5Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2019-01-01to2019-12-31_us-gaap_EmployeeStockOptionMember"
      id="Fact_0000000000379">P5Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-01to2021-12-31_custom_EmployeeStockPurchasePlanMember_srt_MinimumMember"
      decimals="INF"
      id="Fact_0000000000380"
      unitRef="Pure">0.6468</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-01to2021-12-31_custom_EmployeeStockPurchasePlanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact_0000000000381"
      unitRef="Pure">0.6968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-01to2020-12-31_custom_EmployeeStockPurchasePlanMember"
      id="Fact_0000000000382"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-01-01to2019-12-31_custom_EmployeeStockPurchasePlanMember"
      id="Fact_0000000000383"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-01to2021-12-31_custom_EmployeeStockPurchasePlanMember_srt_MinimumMember"
      decimals="INF"
      id="Fact_0000000000384"
      unitRef="Pure">0.0004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-01to2021-12-31_custom_EmployeeStockPurchasePlanMember_srt_MaximumMember"
      decimals="INF"
      id="Fact_0000000000385"
      unitRef="Pure">0.0010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-01to2020-12-31_custom_EmployeeStockPurchasePlanMember"
      id="Fact_0000000000386"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-01-01to2019-12-31_custom_EmployeeStockPurchasePlanMember"
      id="Fact_0000000000387"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-01to2021-12-31_custom_EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="Fact_0000000000388"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-01to2020-12-31_custom_EmployeeStockPurchasePlanMember"
      id="Fact_0000000000389"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-01-01to2019-12-31_custom_EmployeeStockPurchasePlanMember"
      id="Fact_0000000000390"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2021-01-01to2021-12-31_custom_EmployeeStockPurchasePlanMember_srt_MinimumMember"
      id="Fact_0000000000391">P0Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2021-01-01to2021-12-31_custom_EmployeeStockPurchasePlanMember_srt_MaximumMember"
      id="Fact_0000000000392">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000395">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; n.&lt;span style="padding-left:12.5pt; "&gt;Concentration of credit risks:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Financial instruments that potentially subject the Company and Compugen USA, Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term bank deposits. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Cash, cash equivalents, restricted cash and short-term bank deposits are invested in major banks in Israel and in the U.S. Generally, these deposits may be redeemed upon demand and bear minimal risk. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The trade receivables of the Company derive from milestone payments under collaboration agreements between the company and its collaborators, located primarily in Europe. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;19&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 2: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;n.&lt;span style="padding-left:12.5pt; "&gt;Concentration of credit risks (Cont.):&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company&#x2019;s collaborators are major pharma companies. The amounts due to the Company by such collaborators are paid pursuant to the terms of the agreements after a short period of time and bear low risk. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company had one collaborator that accounted for 100% of the Company&#x2019;s consolidated revenues, for the years ended December 31, 2021 and 2020. The Company had no revenues in 2019. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000399">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; o.&lt;span style="padding-left:12.5pt; "&gt;Basic and diluted loss per share:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#x201c;Earnings per Share&#x2ee;. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;All outstanding share options and warrants for the years ended December 31, 2021, 2020 and 2019 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. As of December 31, 2021, 2020 and 2019 the average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were 6,758,300, 7,150,648 and 12,754,803, respectively. &lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-01to2021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact_0000000000396"
      unitRef="Shares">6758300</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-01to2020-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact_0000000000397"
      unitRef="Shares">7150648</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-01to2019-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact_0000000000398"
      unitRef="Shares">12754803</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000400">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; p.&lt;span style="padding-left:12.5pt; "&gt;Income taxes:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company accounts for income taxes in accordance with ASC No. 740, &#x201c;Income Taxes&#x201d;, (&#x201c;ASC 740&#x201d;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2021 and 2020, a full valuation allowance was provided by the Company. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740-10. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;20&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 2: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/span&gt; &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000401">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; q.&lt;span style="padding-left:12.5pt; "&gt;Fair value of financial instruments:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company applies ASC 820, &#x201c;Fair Value Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an orderly transaction between market participants at the measurement date. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputting that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;The hierarchy is broken down into three levels based on the inputs as follows: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-60pt !important; padding-left:140pt !important; margin-bottom:0pt; "&gt;Level 1 -&lt;span style="padding-left:22.24pt; "&gt;Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can &lt;/span&gt;access at the measurement date. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-60pt !important; padding-left:140pt !important; margin-bottom:0pt; "&gt;Level 2 -&lt;span style="padding-left:22.24pt; "&gt;Valuations based on one or more quoted prices in markets that are not active or for which all &lt;/span&gt;significant inputs are observable, either directly or indirectly. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;Level 3 -&lt;span style="padding-left:22.24pt; "&gt;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, other accounts receivable and prepaid expenses, trade payable and other accounts payable and accrued expenses approximate their fair values due to the short-term maturities of such instruments. &lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000402">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; r.&lt;span style="padding-left:14.72pt; "&gt;Derivative instruments:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company accounts for derivatives and hedging based on ASC 815, &#x201c;Derivatives and Hedging&#x201d;. ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, the Company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;21&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 2: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;r.&lt;span style="padding-left:14.72pt; "&gt;Derivative instruments (Cont.):&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;If the derivatives meet the definition of a hedge and are so designated, depending on the nature of the hedge, changes in the fair value of such derivatives will either be offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings, or recognized in other comprehensive income until the hedged item is recognized in earnings. The ineffective portion of a derivative&#x2019;s change in fair value is recognized in earnings. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;In the past the Company entered into forward contracts to hedge against the risk of overall changes in future cash flow from payments of payroll and related expenses as well as other expenses denominated in NIS. As of December 31, 2021 and 2020, the Company had no outstanding forward contracts. The Company measured the fair value of the contracts in accordance with ASC 820 (classified as level 2). &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;These contracts met the requirement for cash flow hedge accounting and during each of the years ended December 31, 2021, 2020 and 2019, no amount of total gains were recognized and were classified to operating expenses as effective hedge and no unrealized gains were recognized under other comprehensive income (loss). &lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000403">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; s.&lt;span style="padding-left:13.61pt; "&gt;Comprehensive income (loss):&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company accounts for comprehensive income (loss) in accordance with ASC 220, &#x201c;Comprehensive Income&#x201d;. This statement establishes standards for the reporting and display of comprehensive income (loss) and its components in a full set of general-purpose financial statements. Comprehensive income (loss) generally represents all changes in shareholders&#x2019; equity during the period except those resulting from investments by, or distributions to, shareholders. The Company elected to present the comprehensive income (loss) in a single continuous statement. &lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000404">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt; In the years 2021, 2020 and 2019 the Company has no components of other comprehensive income (loss), other than net loss. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;22&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 2: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;SIGNIFICANT ACCOUNTING POLICIES (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;t.&lt;span style="padding-left:14.72pt; "&gt;Recently issued and recently adopted Accounting Standards:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. Among other changes, ASU 2020-06 removes from GAAP the liability and equity separation model for convertible instruments with a cash conversion feature and a beneficial conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share (EPS). ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020 and can be adopted on either a fully retrospective or modified retrospective basis. The Company adopted ASU 2020-06 as of January 1, 2021. The adoption of this standard did not have an impact to the Company&#x2019;s financial statements.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832). This ASU requires business entities to disclose information about government assistance they receive if the transactions were accounted for by analogy to either a grant or a contribution accounting model. The disclosure requirements include the nature of the transaction and the related accounting policy used, the line items on the balance sheets and statements of operations that are affected and the amounts applicable to each financial statement line item and the significant terms and conditions of the transactions. The ASU is effective for annual periods beginning after December 15, 2021. The disclosure requirements can be applied either retrospectively or prospectively to all transactions in the scope of the amendments that are reflected in the financial statements at the date of initial application and new transactions that are entered into after the date of initial application. The ASU is currently not expected to have a material impact on our consolidated financial statements. &lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000415">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt; &lt;span style="font-weight:bold; "&gt;NOTE 3: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;December 31,&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Prepaid expenses&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;5,272&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,482&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Government authorities&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;57&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;54&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Other&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;131&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;122&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;5,460&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,658&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000414">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;December 31,&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Prepaid expenses&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;5,272&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,482&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Government authorities&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;57&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;54&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Other&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;131&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;122&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;5,460&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,658&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000406"
      unitRef="usd">5272000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000407"
      unitRef="usd">2482000</us-gaap:PrepaidExpenseCurrent>
    <cgen:GovernmentAuthorities
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000408"
      unitRef="usd">57000</cgen:GovernmentAuthorities>
    <cgen:GovernmentAuthorities
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000409"
      unitRef="usd">54000</cgen:GovernmentAuthorities>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000410"
      unitRef="usd">131000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000411"
      unitRef="usd">122000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000412"
      unitRef="usd">5460000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000413"
      unitRef="usd">2658000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000441">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt; &lt;span style="font-weight:bold; "&gt;NOTE 4: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;LEASES&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; "&gt;The Company leases all its real estate, storage area and cars under various operating lease agreements that expire on various dates. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; "&gt;The Company&#x2019;s operating leases have original lease periods expiring between 2022 and 2024. The offices in Israel lease include two options to renew, one of which was exercised in 2020. The Company does not assume renewals in its determination of the lease term unless the renewals are deemed to be reasonably certain. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; "&gt;In October 2020 the Company&#x2019;s lease of its offices in Israel was amended in connection with the exercise of the option. The amendment was not accounted for as a new lease. As a result of the amendment the operating lease right of use asset increased by $43, the operating lease liability decreased by $194 and the Company recorded foreign currency exchange rate of $237. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; "&gt;Lease payments included in the measurement of the lease liability comprise the following: the fixed non-cancelable lease payments and payments for optional renewal periods where it is reasonably certain the renewal period will be exercised. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; "&gt;Under ASC 842, all leases, including non-cancelable operating leases, are now recognized on the balance sheet. The aggregated present value of lease payments is recorded as a long-term asset titled Operating lease right of use asset. The corresponding lease liabilities are split between current maturity of operating lease liability within current liabilities and long-term operating lease liability within long-term liabilities. The Company&#x2019;s leases do not provide an implicit rate, therefore the Company uses its incremental borrowing rate based on information available on the commencement date in determining the present value of lease payments. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; "&gt;The Company subleased small part of its leased premises until March 14, 2021. Sublease income in the year ended December 31, 2021 and 2020, amounted to $3 and $56, respectively. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; The following table represents the weighted-average remaining lease term and discount rate: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:85%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Twelve months &lt;/span&gt;&lt;span style="font-weight:bold; "&gt;ended&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:85%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;December 31, &lt;/span&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:85%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:85%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Weighted average remaining lease term &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;3.87 &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:85%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Weighted average discount (annual) rate &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;5.49% &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; "&gt;Operating lease expenses were approximately $956, $944 and $1,586 in the years ended December 31, 2021, 2020 and 2019, respectively. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; "&gt;Cash paid for amounts included in the measurement of lease liabilities was approximately $914, $927 and $1,577 in the years ended December 31, 2021, 2020 and 2019, respectively. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;24&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 4: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;LEASES (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; Maturities of operating lease liabilities were as follows: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;December 31, 2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;2022 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;895 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;2023 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;726 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;2024 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;664 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;2025 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;631 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;2026 and after &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;129 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Total operating lease payments &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3,045 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Less: imputed interest &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;295 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Present value of lease liabilities &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,750 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Lease liabilities, current &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;768 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Lease liabilities, non- current &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,982 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Present value of lease liabilities &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,750 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; "&gt;The above annual minimum future rental commitments include the period covered by the first exercised option with respect to the leased facility of Compugen Ltd. through March 2026 and exclude the second option to extend the lease of the Company facility for additional five-year period following expiration of the current lease period. &lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <cgen:IncreaseOperatingLeaseRightOfUseAsset
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000416"
      unitRef="usd">43000</cgen:IncreaseOperatingLeaseRightOfUseAsset>
    <cgen:DecreaseOperatingLeaseLiability
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000417"
      unitRef="usd">194000</cgen:DecreaseOperatingLeaseLiability>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000418"
      unitRef="usd">237000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:SubleaseIncome
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000419"
      unitRef="usd">3000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000420"
      unitRef="usd">56000</us-gaap:SubleaseIncome>
    <cgen:ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000423">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; The following table represents the weighted-average remaining lease term and discount rate: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:85%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Twelve months &lt;/span&gt;&lt;span style="font-weight:bold; "&gt;ended&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:85%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;December 31, &lt;/span&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:85%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:85%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Weighted average remaining lease term &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;3.87 &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:85%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Weighted average discount (annual) rate &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;5.49% &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</cgen:ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2021-12-31" id="Fact_0000000000421">P3Y10M13D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact_0000000000422"
      unitRef="Pure">0.0549</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000424"
      unitRef="usd">956000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000425"
      unitRef="usd">944000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000426"
      unitRef="usd">1586000</us-gaap:OperatingLeasePayments>
    <cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000427"
      unitRef="usd">914000</cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000428"
      unitRef="usd">927000</cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000429"
      unitRef="usd">1577000</cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000440">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; Maturities of operating lease liabilities were as follows: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;December 31, 2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;2022 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;895 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;2023 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;726 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;2024 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;664 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;2025 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;631 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;2026 and after &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;129 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Total operating lease payments &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3,045 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Less: imputed interest &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;295 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Present value of lease liabilities &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,750 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Lease liabilities, current &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;768 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Lease liabilities, non- current &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,982 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:83%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Present value of lease liabilities &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:14%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,750 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000430"
      unitRef="usd">895000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000431"
      unitRef="usd">726000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000432"
      unitRef="usd">664000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000433"
      unitRef="usd">631000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000434"
      unitRef="usd">129000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000435"
      unitRef="usd">3045000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000436"
      unitRef="usd">295000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000437"
      unitRef="usd">2750000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000438"
      unitRef="usd">768000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000439"
      unitRef="usd">1982000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000468">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt; &lt;span style="font-weight:bold; "&gt;NOTE 5: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;December 31,&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Cost: &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Computers, software and related equipment &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,506 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,431 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Laboratory equipment and office furniture &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3,674 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3,367 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Leasehold improvements &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,321 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,321 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;7,501 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;7,119 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Accumulated depreciation: &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Computers, software and related equipment &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,351 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,264 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Laboratory equipment and office furniture &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3,114 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3,001 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Leasehold improvements &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,378 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,143 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;5,843 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;5,408 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Depreciated cost &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,658 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,711 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;25&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 5: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;PROPERTY AND EQUIPMENT, NET (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; "&gt;During 2021 and 2020 total cost of $26 and $220, respectively and total accumulated depreciation of $26 and $188, respectively were disposed from the consolidated balance sheets.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; "&gt;For the years ended December 31, 2021, 2020 and 2019, depreciation expenses were approximately $461, $715 and $989, respectively. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000460">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;December 31,&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Cost: &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Computers, software and related equipment &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,506 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,431 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Laboratory equipment and office furniture &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3,674 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3,367 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Leasehold improvements &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,321 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,321 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;7,501 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;7,119 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Accumulated depreciation: &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Computers, software and related equipment &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,351 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,264 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Laboratory equipment and office furniture &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3,114 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3,001 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Leasehold improvements &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,378 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,143 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;5,843 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;5,408 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Depreciated cost &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,658 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,711 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      id="Fact_0000000000442"
      unitRef="usd">1506000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      id="Fact_0000000000443"
      unitRef="usd">1431000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="-3"
      id="Fact_0000000000444"
      unitRef="usd">3674000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="-3"
      id="Fact_0000000000445"
      unitRef="usd">3367000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact_0000000000446"
      unitRef="usd">2321000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact_0000000000447"
      unitRef="usd">2321000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000448"
      unitRef="usd">7501000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000449"
      unitRef="usd">7119000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2021-12-31_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      id="Fact_0000000000450"
      unitRef="usd">1351000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2020-12-31_us-gaap_ComputerEquipmentMember"
      decimals="-3"
      id="Fact_0000000000451"
      unitRef="usd">1264000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2021-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="-3"
      id="Fact_0000000000452"
      unitRef="usd">3114000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2020-12-31_custom_LaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="-3"
      id="Fact_0000000000453"
      unitRef="usd">3001000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact_0000000000454"
      unitRef="usd">1378000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact_0000000000455"
      unitRef="usd">1143000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000456"
      unitRef="usd">5843000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000457"
      unitRef="usd">5408000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000458"
      unitRef="usd">1658000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000459"
      unitRef="usd">1711000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"
      decimals="-3"
      id="Fact_0000000000461"
      unitRef="usd">26000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_custom_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"
      decimals="-3"
      id="Fact_0000000000462"
      unitRef="usd">220000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2021-12-31_custom_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"
      decimals="-3"
      id="Fact_0000000000463"
      unitRef="usd">26000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2020-12-31_custom_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"
      decimals="-3"
      id="Fact_0000000000464"
      unitRef="usd">188000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000465"
      unitRef="usd">461000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000466"
      unitRef="usd">715000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000467"
      unitRef="usd">989000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000476">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt; &lt;span style="font-weight:bold; "&gt;NOTE 6: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:13.35pt; "&gt;OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;December 31,&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Employees and related accruals&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3,299&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,881&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Accrued expenses&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;4,779&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;4,922&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;8,078&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;7,803&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000475">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;December 31,&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Employees and related accruals&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3,299&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,881&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Accrued expenses&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;4,779&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;4,922&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;8,078&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;7,803&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000469"
      unitRef="usd">3299000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000470"
      unitRef="usd">2881000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000471"
      unitRef="usd">4779000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000472"
      unitRef="usd">4922000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000473"
      unitRef="usd">8078000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000474"
      unitRef="usd">7803000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000498">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:16pt; margin-bottom:0pt; "&gt; &lt;span style="font-weight:bold; "&gt;NOTE 7: - &lt;/span&gt;&lt;span style="font-weight:bold; padding-left:10.02pt; "&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; "&gt;a.&lt;span style="padding-left:13.06pt; "&gt;The Company provided bank guarantees in the amount of $&lt;/span&gt;703 related to its offices in Israel, car leases in Israel and credit card security for its U.S. subsidiary. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; "&gt;b.&lt;span style="padding-left:12.5pt; "&gt;Under the Office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly &lt;/span&gt;known as the Office of the Chief Scientist, (the &#x201c;IIA&#x201d;), the Company is not obligated to repay any amounts received from the IIA if it does not generate any income from the results of the funded research program(s). If income is generated from a funded research program, the Company is committed to pay royalties at a rate of between 3% to 5% of future revenue arising from such research program(s), and up to a maximum of 100% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum to be repaid is 100% plus interest at LIBOR). For the years ended December 31, 2021, 2020 and 2019, the Company had an aggregate of paid or accrued royalties to the IIA, recorded as cost of revenue in the consolidated statements of comprehensive loss in the amount of $180, $60 and $0, respectively. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;As of December 31, 2021, the Company&#x2019;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled approximately to $9,522.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;26&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 7: - &lt;/span&gt;&lt;span style="font-weight:bold; padding-left:10.02pt; "&gt;COMMITMENTS AND CONTINGENCIES (Cont.)&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; "&gt;c.&lt;span style="padding-left:13.06pt; "&gt;On June 25, 2012 the Company entered into an Antibodies Discovery Collaboration Agreement (the &#x201c;Antibodies &lt;/span&gt;Discovery Agreement&#x201d;) with a U.S. antibody technology company (&#x201c;mAb Technology Company&#x201d;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company will be entitled to certain royalties that could be eliminated, upon payment of certain one-time fees (all payments referred together as &#x201c;Contingent Fees&#x201d;). For the years ended December 31, 2021, 2020 and 2019, the Company incurred such Contingent Fees in the amounts of $500, $500 and $0. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; "&gt;d.&lt;span style="padding-left:12.5pt; "&gt;On &lt;/span&gt;May 9, 2012, the Company entered into agreement (the &#x201c;May 2012 Agreement&#x201d;) with a U.S. Business Development Strategic Advisor (&#x201c;Advisor&#x201d;) for the purpose of entering into transactions with Pharma companies related to selected Pipeline Program Candidates. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Under the agreement the Advisor was entitled to 4% of the cash considerations that may be received under such transactions. In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;For the years ended December 31, 2021, 2020 and 2019, the Company has not paid and did not accrue payments under this agreement.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; "&gt;e.&lt;span style="padding-left:13.06pt; "&gt;Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (CLA) with a European &lt;/span&gt;cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and 1% royalties on annual net sales with respect to each commercialized product manufactured using the company&#x2019;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the years ended December 31, 2021, 2020 and 2019, the Company incurred in the research and development expenses in connection with such milestone payment in the amounts of $0, $52 and $0. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; "&gt;f.&lt;span style="padding-left:14.17pt; "&gt;Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody &lt;/span&gt;discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the years ended December 31, 2021, 2020 and 2019, the Company incurred in the research and development expenses such milestone payment in the amounts of $250, $0 and $0. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000477"
      unitRef="usd">703000</us-gaap:GuaranteeObligationsMaximumExposure>
    <cgen:RoyaltyPercentageBasedOnFutureRevenues
      contextRef="From2021-01-01to2021-12-31_custom_ResearchAndDevelopmentGrantOneMember_srt_MinimumMember"
      decimals="INF"
      id="Fact_0000000000478"
      unitRef="Pure">0.03</cgen:RoyaltyPercentageBasedOnFutureRevenues>
    <cgen:RoyaltyPercentageBasedOnFutureRevenues
      contextRef="From2021-01-01to2021-12-31_custom_ResearchAndDevelopmentGrantOneMember_srt_MaximumMember"
      decimals="INF"
      id="Fact_0000000000479"
      unitRef="Pure">0.05</cgen:RoyaltyPercentageBasedOnFutureRevenues>
    <cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived
      contextRef="From2021-01-01to2021-12-31_custom_ResearchAndDevelopmentGrantOneMember"
      decimals="INF"
      id="Fact_0000000000480"
      unitRef="Pure">1</cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived>
    <us-gaap:RoyaltyExpense
      contextRef="From2021-01-01to2021-12-31_custom_ResearchAndDevelopmentGrantOneMember"
      decimals="-3"
      id="Fact_0000000000481"
      unitRef="usd">180000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2020-01-01to2020-12-31_custom_ResearchAndDevelopmentGrantOneMember"
      decimals="-3"
      id="Fact_0000000000482"
      unitRef="usd">60000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2019-01-01to2019-12-31_custom_ResearchAndDevelopmentGrantOneMember"
      decimals="-3"
      id="Fact_0000000000483"
      unitRef="usd">0</us-gaap:RoyaltyExpense>
    <cgen:RoyaltyContingentObligations
      contextRef="AsOf2021-12-31_custom_ResearchAndDevelopmentGrantOneMember"
      decimals="-3"
      id="Fact_0000000000484"
      unitRef="usd">9522000</cgen:RoyaltyContingentObligations>
    <cgen:ContingentFees
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000485"
      unitRef="usd">500000</cgen:ContingentFees>
    <cgen:ContingentFees
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000486"
      unitRef="usd">500000</cgen:ContingentFees>
    <cgen:ContingentFees
      contextRef="AsOf2019-12-31"
      decimals="-3"
      id="Fact_0000000000487"
      unitRef="usd">0</cgen:ContingentFees>
    <cgen:AgreementStartDate
      contextRef="From2021-01-01to2021-12-31_custom_May2012AgreementMember"
      id="Fact_0000000000488">2012-05-09</cgen:AgreementStartDate>
    <cgen:ParticipationRights
      contextRef="From2021-01-01to2021-12-31_srt_MinimumMember_custom_May2012AgreementMember"
      decimals="INF"
      id="Fact_0000000000489"
      unitRef="Pure">0.04</cgen:ParticipationRights>
    <cgen:AgreementTerminationDescription
      contextRef="From2021-01-01to2021-12-31_custom_May2012AgreementMember"
      id="Fact_0000000000490">In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.</cgen:AgreementTerminationDescription>
    <cgen:RoyaltyPercentage
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact_0000000000491"
      unitRef="Pure">0.01</cgen:RoyaltyPercentage>
    <cgen:ResearchAndDevelopmentExpensesMilestonePaymentWithConnection
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000492"
      unitRef="usd">0</cgen:ResearchAndDevelopmentExpensesMilestonePaymentWithConnection>
    <cgen:ResearchAndDevelopmentExpensesMilestonePaymentWithConnection
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000493"
      unitRef="usd">52000</cgen:ResearchAndDevelopmentExpensesMilestonePaymentWithConnection>
    <cgen:ResearchAndDevelopmentExpensesMilestonePaymentWithConnection
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000494"
      unitRef="usd">0</cgen:ResearchAndDevelopmentExpensesMilestonePaymentWithConnection>
    <cgen:ResearchAndDevelopmentExpensesMilestonePayment
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000495"
      unitRef="usd">250000</cgen:ResearchAndDevelopmentExpensesMilestonePayment>
    <cgen:ResearchAndDevelopmentExpensesMilestonePayment
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000496"
      unitRef="usd">0</cgen:ResearchAndDevelopmentExpensesMilestonePayment>
    <cgen:ResearchAndDevelopmentExpensesMilestonePayment
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000497"
      unitRef="usd">0</cgen:ResearchAndDevelopmentExpensesMilestonePayment>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000590">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "&gt; &lt;span style="font-weight:bold; "&gt;NOTE 8: - &lt;/span&gt;&lt;span style="font-weight:bold; padding-left:10.02pt; "&gt;SHAREHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;a.&lt;span style="padding-left:13.06pt; "&gt;Ordinary shares:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The ordinary shares confer upon their holders the right to attend and vote at general meetings of the shareholders. Subject to the rights of holders of shares with limited or preferred rights which may be issued in the future, the ordinary shares of the Company confer upon the holders thereof equal rights to receive dividends, and to participate in the distribution of the assets of the Company upon its winding-up, in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of the nominal value, if any.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;b.&lt;span style="padding-left:12.5pt; "&gt;Issuance of shares:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;On May 25, 2018, the Company entered into a Controlled Equity OfferingSM sales agreement with Cantor Fitzgerald &amp;amp; Co. (&#x201c;Cantor&#x201d;), as sales agent, pursuant to which the Company may offer and sell, from time to time through Cantor, ordinary shares, par value NIS 0.01 per share, of the Company, under an &#x201c;at-the-market&#x201d; (&#x201c;ATM&#x201d;) offering, having an aggregate offering price of up to $25,000 (the &#x201c;ATM Shares&#x201d;). As of December 31, 2019, 7,245,268 shares were issued and sold under the ATM, with proceeds of approximately $22,914 (net of $781 issuance expenses). The program was terminated in 2019.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;On June 14, 2018, the Company entered into securities purchase agreement with certain institutional investors and a placement agency agreement with JMP Securities LLC in connection with a registered direct offering (the &#x201c;Offering&#x201d;) of an aggregate of 5,316,457 ordinary shares (the &#x201c;RD Shares&#x201d;) of the Company at a purchase price of $3.95 per RD Share. In connection with the issuance of the RD Shares, the Company also issued warrants to purchase an aggregate of up to 4,253,165 additional ordinary shares. The Warrants are exercisable at a price of $4.74 per ordinary share and have a term of five years from the date of issuance. The Offering was made pursuant to the Company&#x2019;s Registration Statement. Proceeds from the Offering were $19,767 (net of $1,233 issuance expenses).&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;During the years ended December 31, 2021, and 2020, warrants to purchase an aggregate of 3,955,696 ordinary shares were exercised with proceeds of approximately $18,750 and as of December 31, 2021, warrants to purchase up to 297,469 ordinary shares remain outstanding.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#x201c;Master Clinical Agreement&#x201d;) with Bristol-Myers Squibb to evaluate the safety and tolerability of the Company&#x2019;s COM701 in combination with Bristol-Myers Squibb&#x2019;s PD-1 immune checkpoint inhibitor Opdivo&#xae; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol-Myers Squibb made a $12,000 equity investment in the Company. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;28&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 8: - &lt;/span&gt;&lt;span style="font-weight:bold; padding-left:10.02pt; "&gt;SHAREHOLDERS&#x2019; EQUITY (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Under the terms of the securities purchase agreement, Bristol-Myers Squibb purchased 2,424,243 ordinary shares of the Company at a purchase price of $4.95 per share. The share price represented a 33% premium over the average closing price of Compugen&#x2019;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The premium over the fair market value in the amount of $4,121 represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;amp;D, in accordance with ASC 808 &#x201c;Collaborative Arrangements&#x201d;) and $7,788 (net of $91 issuance expenses) were considered equity investment. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $20,000 investment in the Company, purchasing 2,332,815 ordinary shares of the Company at a purchase price of $8.57333 per share. The share price represented a 33% premium over the closing price of Company&#x2019;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The premium over the fair market value in the amount of $5,000 represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;amp;D, in accordance with ASC 808 &#x201c;Collaborative Arrangements&#x201d;) and $14,958 (net of $42 issuance expenses) were considered equity investment.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;In March 2020, the Company entered into an underwriting agreement with SVB Leerink LLC and Stifel, Nicolaus &amp;amp; Company, Incorporated, as representatives of several underwriters relating to the issuance and sale in a public offering of 8,333,334 of the Company&#x2019;s ordinary shares at a price to the public of $9.00 per share (and a price of $8.46 per share to the underwriters). Such shares were issued on March 16, 2020. In addition, the Company granted the underwriters a 30-day option to purchase additional ordinary shares at the price set forth above. On April 14, 2020, the Company issued and sold, pursuant to that underwriting agreement additional 483,005 ordinary shares pursuant to the underwriters&#x2019; option specified above. The Company sold a total of 8,816,339 ordinary shares in the offering with proceeds of $74,147 (net of $5,200 issuance expenses).&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;c.&lt;span style="padding-left:13.06pt; "&gt;Share option plan:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Under the Company&#x2019;s 2010 Share Option Plan as amended (the &#x201c;Plan&#x201d;), options may be granted to employees, directors and non-employees of the Company and Compugen USA Inc. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Under the 2010 Share Option Plan the Company reserved for issuance up to an aggregate of 12,395,152 ordinary shares. The Company&#x2019;s Board of Directors last amended the Plan in May 2020, to increase the number of shares available under the 2010 Plan and extend the plan term by additional 10 years. As of December 31, 2021, an aggregate of 1,133,128 options under the 2010 Share Option Plan of the Company are still available for future grants. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;29&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 8: - &lt;/span&gt;&lt;span style="font-weight:bold; padding-left:10.02pt; "&gt;SHAREHOLDERS&#x2019; EQUITY (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;c.&lt;span style="padding-left:13.06pt; "&gt;Share option plan (Cont.):&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;In general, options granted under the Plan vest over a four-year period and expire 10 years from the date of grant and are granted at an exercise price of not less than the fair market value of the Company&#x2019;s ordinary shares on the date of grant, unless otherwise determined by the Company&#x2019;s board of directors. The exercise price of the options granted under the Plan may not be less than the nominal value of the shares into which such options are exercised and the expiration date may not be later than 10 years from the date of grant. If a grantee leaves his or her employment or other relationship with the Company, or if his or her relationship with the Company is terminated without cause (and other than by reason of death or disability, as defined in the Plan), the term of his or her unexercised options will generally expire in 90 days, unless determined otherwise by the Company.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;Any options that are cancelled, forfeited or expired become available for future grants. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt; Transactions related to the grant of options to employees, directors and non-employees under the above Plan during the year ended December 31, 2021, were as follows: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:80pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Number of &lt;/span&gt;&lt;span style="font-weight:bold; "&gt;options&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Weighted &lt;/span&gt;&lt;span style="font-weight:bold; "&gt;average &lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;exercise &lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;price&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Weighted &lt;/span&gt;&lt;span style="font-weight:bold; "&gt;average&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;remaining &lt;/span&gt;&lt;span style="font-weight:bold; "&gt;contractual &lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;life&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Aggregate &lt;/span&gt;&lt;span style="font-weight:bold; "&gt;intrinsic&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;value&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Years&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Options outstanding at beginning of year&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;5,960,256&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;6.26&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;6.94&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;37,587&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Options granted&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,397,500&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;6.72&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Options exercised&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(217,375&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;)&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;4.19&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Options forfeited&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(154,277&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;)&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;7.45&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Options expired&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(10,000&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:1pt; "&gt;)&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;6.14&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Options outstanding at end of year&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;6,976,104&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;6.39&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;6.69&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3,323&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Exercisable at end of year&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3,693,761&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;5.23&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;5.21&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,496&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Weighted average fair value of options granted to employees, directors and non-employees during the years 2021, 2020 and 2019 was $3.81, $7.15 and $1.73 per share, respectively.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Aggregate intrinsic value of exercised options by employees, directors and non-employees during the years 2021, 2020 and 2019 was $759, $21,610, and $979, respectively. The aggregate intrinsic value of the exercised options represents the total intrinsic value (the difference between the sale price of the Company&#x2019;s share at the date of exercise, and the exercise price) multiplied by the number of options exercised. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company&#x2019;s closing share price on the last trading day of calendar 2020 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2021. This amount is impacted by the changes in the fair market value of the Company&#x2019;s shares. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;30&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 8: - &lt;/span&gt;&lt;span style="font-weight:bold; padding-left:10.02pt; "&gt;SHAREHOLDERS&#x2019; EQUITY (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;c.&lt;span style="padding-left:13.06pt; "&gt;Share option plan (Cont.):&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;As of December 31, 2021, the total unrecognized estimated compensation cost related to non-vested share options granted prior to that date was $11,926 which is expected to be recognized over a weighted average period of approximately 3.02 years. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;d.&lt;span style="padding-left:12.5pt; "&gt;Employee Stock Purchase Plan:&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company adopted an ESPP in November 2020, with the first offering period starting at January 1, 2021. In connection with its adoption, a total of 600,000 ordinary shares were reserved for issuance under this plan. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The ESPP is implemented through six-month offering periods (except for the first offering period that was five months). According to the ESPP, eligible employees and non-employees may use up to 15% of their base salaries to purchase ordinary shares up to an aggregate limit of $40 per participant for every calendar year. The price of an ordinary share purchased under the ESPP is equal to 85% of the lower of the fair market value of the ordinary share on the first day of each offering period or on the last day of such period. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Since its adoption and through December 31, 2021, 117,829 ordinary shares had been purchased under the ESPP and as of December 31, 2021, 482,171 ordinary shares were available for issuance under the ESPP. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;In accordance with ASC No. 718, the ESPP is compensatory and, as such, results in recognition of compensation cost.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; "&gt; e.&lt;span style="padding-left:13.06pt; "&gt;The stock-based compensation expenses related to stock options and ESPP are included as follows in the expense &lt;/span&gt;categories: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:80pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2019&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Research and development expenses&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,971&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,123&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,151&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Marketing and business development expenses&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;215&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;172&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;46&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;General and administrative expenses&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,090&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,477&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,211&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;4,276&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,772&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,408&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2018-05-25_custom_AtTheMarketOfferingProgramMember"
      decimals="INF"
      id="Fact_0000000000499"
      unitRef="USDPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="From2018-05-01to2018-05-25_custom_AtTheMarketOfferingProgramMember"
      decimals="-3"
      id="Fact_0000000000500"
      unitRef="usd">25000000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-01-01to2019-12-31_custom_AtTheMarketOfferingProgramMember"
      decimals="INF"
      id="Fact_0000000000501"
      unitRef="Shares">7245268</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="From2019-01-01to2019-12-31_custom_AtTheMarketOfferingProgramMember"
      decimals="-3"
      id="Fact_0000000000502"
      unitRef="usd">22914000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2019-01-01to2019-12-31_custom_AtTheMarketOfferingProgramMember"
      decimals="-3"
      id="Fact_0000000000503"
      unitRef="usd">781000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2018-06-14_custom_AgreementMember_custom_RegisteredDirectOfferingMember"
      decimals="INF"
      id="Fact_0000000000504"
      unitRef="Shares">5316457</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2018-06-14_custom_AgreementMember_custom_RegisteredDirectOfferingMember"
      decimals="INF"
      id="Fact_0000000000505"
      unitRef="USDPerShare">3.95</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2018-06-14_custom_AgreementMember_custom_RegisteredDirectOfferingMember"
      decimals="INF"
      id="Fact_0000000000506"
      unitRef="Shares">4253165</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2018-06-14_custom_AgreementMember_custom_RegisteredDirectOfferingMember"
      decimals="INF"
      id="Fact_0000000000507"
      unitRef="USDPerShare">4.74</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cgen:ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable
      contextRef="From2018-06-01to2018-06-14_custom_AgreementMember_custom_RegisteredDirectOfferingMember"
      id="Fact_0000000000508">P5Y</cgen:ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="From2018-06-01to2018-06-14_custom_AgreementMember_custom_RegisteredDirectOfferingMember"
      decimals="-3"
      id="Fact_0000000000509"
      unitRef="usd">19767000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2018-06-01to2018-06-14_custom_AgreementMember_custom_RegisteredDirectOfferingMember"
      decimals="-3"
      id="Fact_0000000000510"
      unitRef="usd">1233000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact_0000000000512"
      unitRef="Shares">3955696</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact_0000000000511"
      unitRef="Shares">3955696</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-01to2021-12-31_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact_0000000000514"
      unitRef="usd">18750000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2020-01-01to2020-12-31_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact_0000000000513"
      unitRef="usd">18750000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact_0000000000515"
      unitRef="Shares">297469</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="AsOf2018-10-10_custom_MasterClinicalAgreementMember"
      decimals="-3"
      id="Fact_0000000000516"
      unitRef="usd">12000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="From2018-10-01to2018-10-10_custom_MasterClinicalAgreementMember"
      decimals="-3"
      id="Fact_0000000000517"
      unitRef="usd">2424243000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2018-10-10_custom_MasterClinicalAgreementMember"
      decimals="INF"
      id="Fact_0000000000518"
      unitRef="USDPerShare">4.95</us-gaap:SharesIssuedPricePerShare>
    <cgen:PercentageOfClosingPrice
      contextRef="From2018-10-01to2018-10-10_custom_MasterClinicalAgreementMember"
      decimals="INF"
      id="Fact_0000000000519"
      unitRef="Pure">0.33</cgen:PercentageOfClosingPrice>
    <cgen:DeferredParticipationOfBmsInRdExpenses
      contextRef="From2021-01-01to2021-12-31_custom_CollaborativeArrangementsMember"
      decimals="-3"
      id="Fact_0000000000520"
      unitRef="usd">4121000</cgen:DeferredParticipationOfBmsInRdExpenses>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-01to2021-12-31_custom_CollaborativeArrangementsMember"
      decimals="-3"
      id="Fact_0000000000521"
      unitRef="usd">7788000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2021-01-01to2021-12-31_custom_CollaborativeArrangementsMember"
      decimals="-3"
      id="Fact_0000000000522"
      unitRef="usd">91000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="AsOf2021-11-30_custom_MasterClinicalAgreementMember"
      decimals="-3"
      id="Fact_0000000000523"
      unitRef="usd">20000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="From2021-11-02to2021-11-30_custom_MasterClinicalAgreementMember"
      decimals="-3"
      id="Fact_0000000000524"
      unitRef="usd">2332815000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-11-30_custom_MasterClinicalAgreementMember"
      decimals="INF"
      id="Fact_0000000000525"
      unitRef="USDPerShare">8.57333</us-gaap:SharesIssuedPricePerShare>
    <cgen:PercentageOfClosingPrice
      contextRef="From2021-11-02to2021-11-30_custom_MasterClinicalAgreementMember"
      decimals="INF"
      id="Fact_0000000000526"
      unitRef="Pure">0.33</cgen:PercentageOfClosingPrice>
    <cgen:DeferredParticipationOfBmsInRdExpenses
      contextRef="From2021-01-01to2021-12-31_custom_CollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fact_0000000000527"
      unitRef="usd">5000000</cgen:DeferredParticipationOfBmsInRdExpenses>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-01to2021-12-31_custom_CollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fact_0000000000528"
      unitRef="usd">14958000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2021-01-01to2021-12-31_custom_CollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fact_0000000000529"
      unitRef="usd">42000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-03-01to2020-03-16_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="INF"
      id="Fact_0000000000530"
      unitRef="Shares">8333334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2020-03-16_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="INF"
      id="Fact_0000000000531"
      unitRef="USDPerShare">9.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2020-03-16_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_custom_UnderwritersMember"
      decimals="INF"
      id="Fact_0000000000532"
      unitRef="USDPerShare">8.46</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-04-01to2020-04-14_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_custom_UnderwritersMember"
      decimals="INF"
      id="Fact_0000000000533"
      unitRef="Shares">483005</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-01to2021-12-31_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="INF"
      id="Fact_0000000000534"
      unitRef="Shares">8816339</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2021-01-01to2021-12-31_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="-3"
      id="Fact_0000000000535"
      unitRef="usd">74147000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2021-01-01to2021-12-31_custom_SvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="-3"
      id="Fact_0000000000536"
      unitRef="usd">5200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-12-31_custom_TwoThousandAndTwoThousandTenOptionsPlanMember"
      decimals="INF"
      id="Fact_0000000000537"
      unitRef="Shares">12395152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-12-31_custom_TwoThousandAndTwoThousandTenOptionsPlanMember"
      decimals="INF"
      id="Fact_0000000000538"
      unitRef="Shares">1133128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2021-01-01to2021-12-31_custom_TwoThousandAndTwoThousandTenOptionsPlanMember"
      id="Fact_0000000000539">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cgen:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod
      contextRef="From2021-01-01to2021-12-31_custom_TwoThousandAndTwoThousandTenOptionsPlanMember"
      id="Fact_0000000000540">P10Y</cgen:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000561">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt; Transactions related to the grant of options to employees, directors and non-employees under the above Plan during the year ended December 31, 2021, were as follows: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:80pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Number of &lt;/span&gt;&lt;span style="font-weight:bold; "&gt;options&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Weighted &lt;/span&gt;&lt;span style="font-weight:bold; "&gt;average &lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;exercise &lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;price&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Weighted &lt;/span&gt;&lt;span style="font-weight:bold; "&gt;average&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;remaining &lt;/span&gt;&lt;span style="font-weight:bold; "&gt;contractual &lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;life&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Aggregate &lt;/span&gt;&lt;span style="font-weight:bold; "&gt;intrinsic&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;value&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Years&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;$&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Options outstanding at beginning of year&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;5,960,256&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;6.26&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;6.94&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;37,587&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Options granted&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,397,500&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;6.72&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Options exercised&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(217,375&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;)&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;4.19&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Options forfeited&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(154,277&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;)&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;7.45&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Options expired&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(10,000&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:1pt; "&gt;)&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;6.14&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Options outstanding at end of year&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;6,976,104&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;6.39&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;6.69&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3,323&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:48%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Exercisable at end of year&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3,693,761&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;5.23&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;5.21&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,496&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_EmployeesAndDirectorsMember"
      decimals="INF"
      id="Fact_0000000000541"
      unitRef="Shares">5960256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_EmployeesAndDirectorsMember"
      decimals="INF"
      id="Fact_0000000000542"
      unitRef="USDPerShare">6.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="From2020-01-01to2020-12-31_custom_EmployeesAndDirectorsMember"
      id="Fact_0000000000543">P6Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_EmployeesAndDirectorsMember"
      decimals="-3"
      id="Fact_0000000000544"
      unitRef="usd">37587000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember"
      decimals="INF"
      id="Fact_0000000000545"
      unitRef="Shares">1397500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember"
      decimals="INF"
      id="Fact_0000000000546"
      unitRef="USDPerShare">6.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember"
      decimals="INF"
      id="Fact_0000000000547"
      unitRef="Shares">217375</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember"
      decimals="INF"
      id="Fact_0000000000548"
      unitRef="USDPerShare">4.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember"
      decimals="INF"
      id="Fact_0000000000549"
      unitRef="Shares">154277</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember"
      decimals="INF"
      id="Fact_0000000000550"
      unitRef="USDPerShare">7.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember"
      decimals="INF"
      id="Fact_0000000000551"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember"
      decimals="INF"
      id="Fact_0000000000552"
      unitRef="USDPerShare">6.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_EmployeesAndDirectorsMember"
      decimals="INF"
      id="Fact_0000000000553"
      unitRef="Shares">6976104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_EmployeesAndDirectorsMember"
      decimals="INF"
      id="Fact_0000000000554"
      unitRef="USDPerShare">6.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember"
      id="Fact_0000000000555">P6Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-12-31_custom_EmployeesAndDirectorsMember"
      decimals="-3"
      id="Fact_0000000000556"
      unitRef="usd">3323000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-12-31_custom_EmployeesAndDirectorsMember"
      decimals="INF"
      id="Fact_0000000000557"
      unitRef="Shares">3693761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_EmployeesAndDirectorsMember"
      decimals="INF"
      id="Fact_0000000000558"
      unitRef="USDPerShare">5.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember"
      id="Fact_0000000000559">P5Y2M15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2021-12-31_custom_EmployeesAndDirectorsMember"
      decimals="-3"
      id="Fact_0000000000560"
      unitRef="usd">2496000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact_0000000000562"
      unitRef="USDPerShare">3.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      id="Fact_0000000000563"
      unitRef="USDPerShare">7.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      id="Fact_0000000000564"
      unitRef="USDPerShare">1.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2021-12-31_srt_DirectorMember"
      decimals="-3"
      id="Fact_0000000000565"
      unitRef="usd">759000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2020-12-31_srt_DirectorMember"
      decimals="-3"
      id="Fact_0000000000566"
      unitRef="usd">21610000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2019-12-31_us-gaap_DirectorMember"
      decimals="-3"
      id="Fact_0000000000567"
      unitRef="usd">979000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000568"
      unitRef="usd">11926000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000569">P3Y7D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-12-31_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="Fact_0000000000570"
      unitRef="Shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:InitialOfferingPeriod
      contextRef="From2021-01-01to2021-12-31_us-gaap_EmployeeStockMember-1750657468"
      id="Fact_0000000000571">five months</us-gaap:InitialOfferingPeriod>
    <cgen:PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares
      contextRef="From2021-01-01to2021-12-31_us-gaap_EmployeeStockMember-1750657468"
      decimals="INF"
      id="Fact_0000000000572"
      unitRef="Pure">0.15</cgen:PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares>
    <cgen:AggregateLimitOfOrdinarySharesPerCalendarYear
      contextRef="AsOf2021-12-31_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="Fact_0000000000573"
      unitRef="USDPerShare">40</cgen:AggregateLimitOfOrdinarySharesPerCalendarYear>
    <cgen:PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering
      contextRef="From2021-01-01to2021-12-31_us-gaap_EmployeeStockMember-1750657468"
      decimals="INF"
      id="Fact_0000000000574"
      unitRef="Pure">0.85</cgen:PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2021-01-01to2021-12-31_us-gaap_EmployeeStockMember-1750657468"
      decimals="INF"
      id="Fact_0000000000575"
      unitRef="Shares">117829</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-12-31_us-gaap_EmployeeStockMember"
      decimals="INF"
      id="Fact_0000000000576"
      unitRef="Shares">482171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000589">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; "&gt; e.&lt;span style="padding-left:13.06pt; "&gt;The stock-based compensation expenses related to stock options and ESPP are included as follows in the expense &lt;/span&gt;categories: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:80pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2019&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Research and development expenses&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,971&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,123&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,151&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Marketing and business development expenses&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;215&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;172&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;46&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;General and administrative expenses&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,090&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,477&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,211&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;4,276&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,772&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,408&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-01to2021-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_0000000000577"
      unitRef="usd">1971000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-01to2020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_0000000000578"
      unitRef="usd">1123000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-01-01to2019-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_0000000000579"
      unitRef="usd">1151000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-01to2021-12-31_us-gaap_SellingAndMarketingExpenseMember"
      decimals="-3"
      id="Fact_0000000000580"
      unitRef="usd">215000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-01to2020-12-31_us-gaap_SellingAndMarketingExpenseMember"
      decimals="-3"
      id="Fact_0000000000581"
      unitRef="usd">172000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-01-01to2019-12-31_us-gaap_SellingAndMarketingExpenseMember"
      decimals="-3"
      id="Fact_0000000000582"
      unitRef="usd">46000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-01to2021-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact_0000000000583"
      unitRef="usd">2090000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-01to2020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact_0000000000584"
      unitRef="usd">1477000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-01-01to2019-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact_0000000000585"
      unitRef="usd">1211000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000586"
      unitRef="usd">4276000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000587"
      unitRef="usd">2772000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000588"
      unitRef="usd">2408000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000629">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "&gt; &lt;span style="font-weight:bold; "&gt;NOTE 9: - &lt;/span&gt;&lt;span style="font-weight:bold; padding-left:10.02pt; "&gt;INCOME TAXES&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;a. &lt;span style="padding-left:9.73pt; "&gt;Israeli taxation:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;1.&lt;span style="padding-left:12.5pt; "&gt;Tax rates applicable to the income of the Company.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:100pt; margin-bottom:0pt; "&gt;Taxable income of the Company is subject to a corporate tax rate of 23% in 2019, 2020 and 2021.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;2.&lt;span style="padding-left:12.5pt; "&gt;Measurement of taxable income in US dollars:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; "&gt;The Company has elected to measure its taxable income and file its tax return under the Israeli Income Tax Regulations (Principles Regarding the Management of Books of Account of Foreign Invested Companies and Certain Partnerships and the Determination of Their Taxable Income), 1986. Accordingly, results for tax purposes are measured in terms of earnings in dollars.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:-20pt !important; padding-left:100pt !important; margin-bottom:0pt; "&gt;3.&lt;span style="padding-left:12.5pt; "&gt;Tax benefits under the Israeli Law for the Encouragement of Capital Investments, 1959 (the &#x201c;Investment Law&#x201d;):&lt;/span&gt;&#x2009;&#x2009; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; "&gt;On April 1, 2005, an amendment to the Investment Law came into effect (the &#x201c;Amendment 60&#x201d;) that significantly changed the provisions of the Investment Law. The Amendment 60 limits the scope of enterprises that may be approved by the Investment Center by setting criteria for the approval of a facility as a &#x201c;Beneficiary Enterprise&#x201d; including a provision generally requiring that at least 25% of the Beneficiary Enterprise&#x2019;s income will be derived from export.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; "&gt;Another condition for receiving the benefits under the alternative track in respect of expansion programs pursuant to Amendment 60 is a minimum qualifying investment. The Company was eligible under the terms of minimum qualifying investment and elected 2012 as its &#x201c;year of election&#x201d;.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; "&gt;Additionally, the Amendment 60 enacted major changes in the manner in which tax benefits are awarded under the Investment Law so that companies no longer require Investment Center approval in order to qualify for tax benefits. However, the Investment Law provides that terms and benefits included in any certificate of approval already granted will remain subject to the provisions of the Investment Law as they were on the date of such approval.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:100pt; margin-bottom:0pt; "&gt;As of December 31, 2021, there was no taxable income attributable to the Beneficiary Enterprise. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;32&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 9: - &lt;/span&gt;&lt;span style="font-weight:bold; padding-left:10.02pt; "&gt;INCOME TAXES (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;a. &lt;span style="padding-left:9.73pt; "&gt;Israeli taxation (Cont.):&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; "&gt;In January 2011, another amendment to the Investment Law came into effect (&#x201c;the 2011 Amendment&#x201d;). According to the 2011 Amendment, the benefit tracks in the Investment Law were modified and a flat tax rate applies to the Company&#x2019;s entire income subject to this amendment (the &#x201c;Preferred Income&#x201d;).&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; "&gt;Once an election is made, the Company&#x2019;s income will be subject to the amended tax rate of 16% from 2015 and thereafter (or 9% for a preferred enterprise located in development area A).&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; "&gt;Commencing 2011 tax year, the Company can elect (without possibility of reversal) to apply the Amendment in a certain tax year and from that year and thereafter, it will be subject to the amended tax rates.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; "&gt;The Company does not currently intend to adopt the 2011 Amendment and intends to continue to comply with the Investment Law as in effect prior to enactment of the 2011 Amendment. Accordingly, the Company did not adjust its deferred tax balances as of December 31, 2021. The Company&#x2019;s position may change in the future.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; "&gt;In December 2016, the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2016 and 2017 Budget Years), 2016, which includes Amendment 73 to the Law (the &#x201c;Amendment 73&#x201d;) was published. According to Amendment 73, a preferred enterprise located in development area A will be subject to a tax rate of 7.5% instead of 9% effective from January 1, 2016 and thereafter (the tax rate applicable to preferred enterprises located in other areas remains at 16%).&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; "&gt;Amendment 73 also prescribes special tax tracks for technological enterprises, which are subject to rules that were issued by the Minister of Finance in May 2017. The new tax tracks under the Amendment are as follows:&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; "&gt;Preferred Technological Enterprise (&#x201c;PTE&#x201d;) - an enterprise for which total consolidated revenues of its parent company and all subsidiaries are less than NIS 10 billion in a tax year. A PTE, as defined in the Law, which is located in the center of Israel will be subject to tax at a rate of 12% on profits deriving from intellectual property (in development area A - a tax rate of 7.5%).&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; "&gt;The above changes in the tax rates relating to PTE tax track were not taken into account in the computation of deferred taxes as of December 31, 2021 and 2020, since the Company estimates that it will not implement the PTE tax track. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;33&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 9: - &lt;/span&gt;&lt;span style="font-weight:bold; padding-left:10.02pt; "&gt;INCOME TAXES (Cont.)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;a. &lt;span style="padding-left:9.73pt; "&gt;Israeli taxation (Cont.):&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;4.&lt;span style="padding-left:12.5pt; "&gt;Tax benefits under the law for the Encouragement of Industry (Taxes), 1969 (the &#x201c;Encouragement Law&#x201d;):&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; "&gt;The Encouragement Law provides several tax benefits for industrial companies. An industrial company is defined as a company resident in Israel, at least 90% of the income of which in a given tax year exclusive of income from specified Government loans, capital gains, interest and dividends, is derived from an industrial enterprise owned by it. An industrial enterprise is defined as an enterprise whose major activity in a given tax year is industrial production activity.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; "&gt;Management believes that the Company is currently qualified as an &#x201c;industrial company&#x201d; under the Encouragement Law and, as such, is entitled to tax benefits, including: (1) deduction of purchase of know-how and patents and/or right to use a patent over an eight-year period; (2) the right to elect, under specified conditions, to file a consolidated tax return with additional related Israeli industrial companies and an industrial holding company; (3) accelerated depreciation rates on equipment and buildings; and (4) expenses related to a public offering on the Tel-Aviv Stock exchange and on recognized stock markets outside of Israel, are deductible in equal amounts over three years. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; "&gt;Eligibility for benefits under the Encouragement Law is not subject to receipt of prior approval from any Governmental authority. No assurance can be given that the Israeli tax authorities will agree that the Company qualifies, or, that the Company will continue to qualify as an industrial company or that the benefits described above will be available to the Company in the future.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;5.&lt;span style="padding-left:12.5pt; "&gt;Net operating losses carryforward and capital loss:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:100pt; margin-bottom:0pt; "&gt;As of December 31, 2021, Compugen Ltd.&#x2019;s net operating losses carryforward for tax purposes in Israel amounted to approximately $369,800. These net operating losses may be carried forward indefinitely and may be offset against future taxable income. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;34&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 9: - &lt;/span&gt;&lt;span style="font-weight:bold; padding-left:10.02pt; "&gt;INCOME TAXES (Cont.)&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;b.&lt;span style="padding-left:12.5pt; "&gt;Non-Israeli subsidiary, Compugen USA, Inc.:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the &#x201c;U.S. Tax Reform&#x201d; or &#x201c;TCJA&#x201d;); a comprehensive tax legislation that includes significant changes to the taxation of business entities. These changes include several key tax provisions that might impact the Company, among others: (i) a permanent reduction to the statutory federal corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017; (ii) a shift of the U.S. taxation of multinational corporations from a tax on worldwide income to a territorial system (along with certain new rules designed to prevent erosion of the U.S. income tax base - &#x201c;BEAT&#x201d;); (iii) establishing immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits; and (iv) providing a permanent deduction to corporations generating revenues from non-US markets (known as a deduction for foreign derived intangible income - &#x201c;FDII&#x201d;).&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;As of December 31, 2021, Compugen USA, Inc. has net operating loss carryforwards for federal income tax purposes of approximately $4,850, approximately $3,750 of which expires in the years &lt;span style="-sec-ix-hidden:Fact_0000000000598"&gt;2023&lt;/span&gt; to &lt;span style="-sec-ix-hidden:Fact_0000000000599"&gt;2032&lt;/span&gt;. Utilization of the U.S. net operating losses may be subject to substantial annual limitation due to the &#x201c;change in ownership&#x201d; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;Neither Israeli income taxes, foreign withholding taxes nor deferred income taxes were provided in relation to undistributed earnings of the Company&#x2019;s foreign subsidiary. This is because the Company has the intent and ability to reinvest these earnings indefinitely in the foreign subsidiary and therefore those earnings are continually redeployed in those jurisdictions.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; c.&lt;span style="padding-left:13.06pt; "&gt;Loss (income) before taxes is comprised as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:80pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Year ended December 31,&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2019&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Domestic (Israel) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;34,619 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;30,010 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;28,799 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Foreign &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(416 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(312 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(740 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;34,203 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;29,698 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;28,059 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; text-indent:-20pt !important; padding-left:80pt !important; margin-bottom:0pt; "&gt;d.&lt;span style="padding-left:12.5pt; "&gt;Taxes on income (tax benefit) for the year ended December 31, 2019 is comprised from refund of withholding tax &lt;/span&gt;payments, which were deducted from milestone payments by the German tax authorities. There were no withholding tax payments for the years ended December 31, 2021, 2020 and 2019. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:justify; margin-bottom:0pt; "/&gt; &lt;div&gt; &lt;div style="width:100%; clear:both;"&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; "&gt;F&#x2009;-&#x2009;35&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/div&gt;&lt;hr style="border-top:1.5pt solid #000000;"/&gt;&lt;div style="page-break-after:always;"/&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:9pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;COMPUGEN LTD. AND ITS SUBSIDIARY&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:13pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/p&gt; &lt;hr style="border-top:1.5pt solid #000000; width:100%; margin-top:3pt; margin-left:0pt; text-align:left; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:-6pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;U.S. dollars in thousands (except share and per share data)&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;NOTE 9: - &lt;/span&gt;&lt;span style="font-weight:bold; padding-left:10.02pt; "&gt;INCOME TAXES (Cont.)&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;e.&lt;span style="padding-left:13.06pt; "&gt;Deferred taxes:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt; Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company and Compugen USA, Inc.&#x2019;s deferred tax assets are comprised of operating loss carryforward and other temporary differences. Significant components of the Company and Compugen USA, Inc. deferred tax assets are as follows: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:80pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;December 31,&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Operating loss carryforward &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;86,068 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;80,134 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Research and development &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;9,773 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;9,001 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Accrued social benefits and other &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,801 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,389 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Right of use assets &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(520 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(651 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Lease liabilities &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;636 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;742 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Property and equipment &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:1pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Deferred tax asset before valuation allowance &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;98,760 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;91,617 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Valuation allowance &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(98,760 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(91,617 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Net deferred tax asset &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The Company and Compugen USA, Inc. have provided full valuation allowances in respect of deferred tax assets resulting from operating loss carryforward and other temporary differences. Management currently believes that since the Company has a history of losses, it is more likely than not that the deferred tax regarding the operating loss carryforward and other temporary differences will not be realized in the foreseeable future.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;f.&lt;span style="padding-left:14.17pt; "&gt;Reconciliation of the theoretical tax expense (benefit) to the actual tax expense (benefit):&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt;The main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax benefits from accumulated net operating loss carryforward among the Company and Compugen USA, Inc. due to the uncertainty of the realization of such tax benefits.&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt;g.&lt;span style="padding-left:12.5pt; "&gt;Tax assessments:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:80pt; margin-bottom:0pt; "&gt;The Company has tax assessments through 2016 that are deemed to be final. &lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact_0000000000593"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      id="Fact_0000000000592"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      id="Fact_0000000000591"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <cgen:ReducedTaxRate
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact_0000000000594"
      unitRef="Pure">0.25</cgen:ReducedTaxRate>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2021-12-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact_0000000000595"
      unitRef="usd">369800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2019-12-31_us-gaap_InternalRevenueServiceIRSMember"
      decimals="-3"
      id="Fact_0000000000596"
      unitRef="usd">4850000</us-gaap:OperatingLossCarryforwards>
    <cgen:NetOperatingLossCarryforwardExpired
      contextRef="AsOf2019-12-31_us-gaap_InternalRevenueServiceIRSMember"
      decimals="-3"
      id="Fact_0000000000597"
      unitRef="usd">3750000</cgen:NetOperatingLossCarryforwardExpired>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000609">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; c.&lt;span style="padding-left:13.06pt; "&gt;Loss (income) before taxes is comprised as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:80pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Year ended December 31,&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2019&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Domestic (Israel) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;34,619 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;30,010 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;28,799 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Foreign &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(416 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(312 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(740 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;34,203 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;29,698 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;28,059 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000600"
      unitRef="usd">-34619000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000601"
      unitRef="usd">-30010000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000602"
      unitRef="usd">-28799000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000603"
      unitRef="usd">416000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000604"
      unitRef="usd">312000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000605"
      unitRef="usd">740000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000606"
      unitRef="usd">-34203000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000607"
      unitRef="usd">-29698000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000608"
      unitRef="usd">-28059000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000628">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:80pt; margin-bottom:0pt; "&gt; Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company and Compugen USA, Inc.&#x2019;s deferred tax assets are comprised of operating loss carryforward and other temporary differences. Significant components of the Company and Compugen USA, Inc. deferred tax assets are as follows: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:80pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;December 31,&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Operating loss carryforward &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;86,068 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;80,134 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Research and development &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;9,773 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;9,001 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Accrued social benefits and other &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,801 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,389 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Right of use assets &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(520 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(651 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Lease liabilities &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;636 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;742 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Property and equipment &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:1pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Deferred tax asset before valuation allowance &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;98,760 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;91,617 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Valuation allowance &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(98,760 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(91,617 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; margin-bottom:1.5pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Net deferred tax asset &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000610"
      unitRef="usd">86068000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000611"
      unitRef="usd">80134000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000612"
      unitRef="usd">9773000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000613"
      unitRef="usd">9001000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000614"
      unitRef="usd">2801000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000615"
      unitRef="usd">2389000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <cgen:DeferredIncomeTaxRightOfUseAssets
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000616"
      unitRef="usd">-520000</cgen:DeferredIncomeTaxRightOfUseAssets>
    <cgen:DeferredIncomeTaxRightOfUseAssets
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000617"
      unitRef="usd">-651000</cgen:DeferredIncomeTaxRightOfUseAssets>
    <cgen:DeferredIncomeTaxLeaseLiabilities
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000618"
      unitRef="usd">636000</cgen:DeferredIncomeTaxLeaseLiabilities>
    <cgen:DeferredIncomeTaxLeaseLiabilities
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000619"
      unitRef="usd">742000</cgen:DeferredIncomeTaxLeaseLiabilities>
    <cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000620"
      unitRef="usd">2000</cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment>
    <cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000621"
      unitRef="usd">2000</cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000622"
      unitRef="usd">98760000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000623"
      unitRef="usd">91617000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000624"
      unitRef="usd">98760000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000625"
      unitRef="usd">91617000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2021-12-31"
      id="Fact_0000000000626"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2020-12-31"
      id="Fact_0000000000627"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000648">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; margin-bottom:0pt; "&gt; &lt;span style="font-weight:bold; "&gt;NOTE 10: - &lt;/span&gt;&lt;span style="font-weight:bold; padding-left:5.02pt; "&gt;GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; "&gt;The Company&#x2019;s business is currently comprised of one operating segment, the research, development and commercialization of therapeutic and product candidates. The nature of the products and services provided by the Company and the type of customers for these products and services are similar. Operations in Israel and the United States include research and development, clinical operations, marketing and business development. The Company follows ASC 280, &#x201c;Segment Reporting&#x2ee;. Total revenues are attributed to geographic areas based on the location of the end customer. &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; "&gt; The following represents the total revenue for the years ended December 31, 2021, 2020 and 2019 and long-lived assets as of December 31, 2021 and 2020: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Year ended December 31,&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2019&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Revenue from sales to customers: &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Europe &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;6,000 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,000 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Total revenue &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;6,000 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,000 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;December 31,&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Long-lived assets: &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Israel &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3,787 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;4,240 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;United States &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;118 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;243 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Total long-lived assets &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3,905 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;4,483 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Year ended December 31,&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:2%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:2%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2019&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Sales to a single customer exceeding 10%: &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:2%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:2%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:2%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:2%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Customer A &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:9%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;100 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:2%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:9%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;100 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:2%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact_0000000000630"
      unitRef="Item">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000643">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; "&gt; The following represents the total revenue for the years ended December 31, 2021, 2020 and 2019 and long-lived assets as of December 31, 2021 and 2020: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Year ended December 31,&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2019&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Revenue from sales to customers: &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Europe &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;6,000 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,000 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Total revenue &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;6,000 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;2,000 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;December 31,&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Long-lived assets: &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Israel &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3,787 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;4,240 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;United States &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;118 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;243 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Total long-lived assets &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3,905 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;4,483 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2021-01-01to2021-12-31_srt_EuropeMember"
      decimals="-3"
      id="Fact_0000000000631"
      unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-01to2020-12-31_srt_EuropeMember"
      decimals="-3"
      id="Fact_0000000000632"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-01to2019-12-31_us-gaap_EuropeMember"
      id="Fact_0000000000633"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000634"
      unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000635"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-01to2019-12-31"
      id="Fact_0000000000636"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NoncurrentAssets
      contextRef="AsOf2021-12-31_country_IL"
      decimals="-3"
      id="Fact_0000000000637"
      unitRef="usd">3787000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="AsOf2020-12-31_country_IL"
      decimals="-3"
      id="Fact_0000000000638"
      unitRef="usd">4240000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="AsOf2021-12-31_country_US"
      decimals="-3"
      id="Fact_0000000000639"
      unitRef="usd">118000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="AsOf2020-12-31_country_US"
      decimals="-3"
      id="Fact_0000000000640"
      unitRef="usd">243000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000641"
      unitRef="usd">3905000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000642"
      unitRef="usd">4483000</us-gaap:NoncurrentAssets>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000647">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Year ended December 31,&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:2%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:2%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2019&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Sales to a single customer exceeding 10%: &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:2%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:2%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:2%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:2%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Customer A &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:9%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;100 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:2%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:9%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;100 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:2%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;% &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;- &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2021-01-01to2021-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember"
      decimals="INF"
      id="Fact_0000000000644"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-01to2020-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember"
      decimals="INF"
      id="Fact_0000000000645"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-01to2019-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerOneMember"
      id="Fact_0000000000646"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000665">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:14pt; margin-bottom:0pt; "&gt; &lt;span style="font-weight:bold; "&gt;NOTE 11: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:8.9pt; "&gt;FINANCIAL AND OTHER INCOME, NET&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Year ended December 31,&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2019&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Interest income &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;894 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,765 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;935 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Bank fees and other finance expenses &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(25 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(42 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(32 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Foreign currency translation adjustments &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(1 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;63 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(218 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Gain (loss) from sales and disposals of fixed assets &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;12 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:1pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;135 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:2pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Financial and other income, net &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;871 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,798 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;820 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000664">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Year ended December 31,&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2019&lt;/span&gt; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Interest income &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;894 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,765 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;935 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Bank fees and other finance expenses &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(25 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(42 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(32 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Foreign currency translation adjustments &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(1 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;63 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(218 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;) &lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Gain (loss) from sales and disposals of fixed assets &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;3 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;12 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:1pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:1.5pt solid #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;135 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:2pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160; &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Financial and other income, net &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;871 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;1,798 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$ &lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;820 &lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000649"
      unitRef="usd">894000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000650"
      unitRef="usd">1765000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000651"
      unitRef="usd">935000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestAndDebtExpense
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000652"
      unitRef="usd">25000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000653"
      unitRef="usd">42000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000654"
      unitRef="usd">32000</us-gaap:InterestAndDebtExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000655"
      unitRef="usd">-1000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000656"
      unitRef="usd">63000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000657"
      unitRef="usd">-218000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000658"
      unitRef="usd">3000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000659"
      unitRef="usd">12000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000660"
      unitRef="usd">135000</us-gaap:GainLossOnSaleOfOtherAssets>
    <cgen:FinancialIncomeExpenseNet
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000661"
      unitRef="usd">871000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000662"
      unitRef="usd">1798000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000663"
      unitRef="usd">820000</cgen:FinancialIncomeExpenseNet>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000672">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt; &lt;span style="font-weight:bold; "&gt;NOTE 12: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:8.35pt; "&gt;RELATED PARTY BALANCES AND TRANSACTIONS&lt;/span&gt; &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;December 31,&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Trade payables and accrued expenses&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;94&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;83&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2019&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Amounts charged to:&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Research and development expenses&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;240&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;294&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;241&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:justify; margin-top:11pt; padding-left:60pt; margin-bottom:0pt; "&gt;For the years ended December 31, 2021, 2020 and 2019 the Company received research and development services related with cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies. The transaction was at arm&#x2019;s length. &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000671">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="6" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;December 31,&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:74%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Trade payables and accrued expenses&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;94&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;83&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt; &lt;/div&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2019&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Amounts charged to:&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Research and development expenses&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;240&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;294&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;241&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:12pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="-3"
      id="Fact_0000000000666"
      unitRef="usd">94000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="AsOf2020-12-31"
      decimals="-3"
      id="Fact_0000000000667"
      unitRef="usd">83000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000668"
      unitRef="usd">240000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000669"
      unitRef="usd">294000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000670"
      unitRef="usd">241000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000683">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:9pt; margin-bottom:0pt; "&gt; &lt;span style="font-weight:bold; "&gt;NOTE 13: -&lt;/span&gt;&lt;span style="font-weight:bold; padding-left:8.35pt; "&gt;LOSSES PER SHARE&lt;/span&gt;&lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; The following table sets forth the computation of basic and diluted losses per share: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2019&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Numerator:&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Net loss for basic and diluted loss per share&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(34,203&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; "&gt;)&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(29,698&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; "&gt;)&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(27,337&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; "&gt;)&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Denominator:&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:-8pt !important; padding-left:8pt !important; margin-bottom:0pt; "&gt;Weighted average number of ordinary shares used in computing basic and diluted net loss per share&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;84,203,971&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;79,591,187&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;63,636,673&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Basic and diluted earnings per ordinary share&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(0.41&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; "&gt;)&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(0.37&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; "&gt;)&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(0.43&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; "&gt;) &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="From2021-01-01to2021-12-31"
      id="Fact_0000000000682">
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:11pt; text-indent:60pt; margin-bottom:0pt; "&gt; The following table sets forth the computation of basic and diluted losses per share: &lt;/p&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;div style="margin-left:60pt; "&gt;
&lt;table cellpadding="0" class="fin" style="border-spacing:0; " width="100%"&gt; &lt;thead&gt; &lt;tr class="odd" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="10" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2021&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-top:0pt; margin-bottom:0pt; "&gt;&lt;span style="font-weight:bold; "&gt;2019&lt;/span&gt;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/thead&gt; &lt;tbody&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Numerator:&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td colspan="2" style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Net loss for basic and diluted loss per share&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(34,203&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; "&gt;)&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(29,698&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; "&gt;)&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(27,337&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; "&gt;)&lt;/p&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Denominator:&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; text-indent:-8pt !important; padding-left:8pt !important; margin-bottom:0pt; "&gt;Weighted average number of ordinary shares used in computing basic and diluted net loss per share&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;84,203,971&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;79,591,187&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;63,636,673&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="even" style=""&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;&#160;&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr class="odd" style="background-color:#cceeff; "&gt; &lt;td style="width:61%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;Basic and diluted earnings per ordinary share&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(0.41&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; "&gt;)&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(0.37&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; "&gt;)&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:center; margin-bottom:0pt; "/&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:0pt; "&gt;$&lt;/p&gt; &lt;/td&gt; &lt;td style="width:10%; vertical-align:bottom; border-bottom:3px double #000000; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:right; margin-top:0pt; margin-bottom:0pt; "&gt;(0.43&lt;/p&gt; &lt;/td&gt; &lt;td style="width:1%; vertical-align:bottom; "&gt;
&lt;p style="font-family:Times New Roman, Times, serif; font-size:10pt; text-align:left; margin-top:0pt; margin-bottom:2pt; "&gt;) &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-12-31"
      decimals="-3"
      id="Fact_0000000000673"
      unitRef="usd">-34203000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      id="Fact_0000000000674"
      unitRef="usd">-29698000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-12-31"
      decimals="-3"
      id="Fact_0000000000675"
      unitRef="usd">-27337000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact_0000000000676"
      unitRef="Shares">84203971</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      id="Fact_0000000000677"
      unitRef="Shares">79591187</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      id="Fact_0000000000678"
      unitRef="Shares">63636673</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2021-01-01to2021-12-31"
      decimals="INF"
      id="Fact_0000000000679"
      unitRef="USDPerShare">-0.41</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      id="Fact_0000000000680"
      unitRef="USDPerShare">-0.37</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-01-01to2019-12-31"
      decimals="INF"
      id="Fact_0000000000681"
      unitRef="USDPerShare">-0.43</us-gaap:EarningsPerShareBasicAndDiluted>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_0000000000204"
          xlink:label="Fact_0000000000204"
          xlink:type="locator"/>
        <link:footnote id="FN_6204837b941056ccc05bf22a" xlink:label="FN_6204837b941056ccc05bf22a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Representing amount lower than $1.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_0000000000204"
          xlink:to="FN_6204837b941056ccc05bf22a"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MA G0^VO.U<O$M*SF#17_!E!+ P04    " "XBEQ46SC#&@(%   Q%   &
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M$#PI?RX8#5E6&,CKCYR+[4$Q0/V);_(_4$L#!!0    ( +B*7%2N<1R<8P@
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M7'%6<&D ^OU2"/5R8QK8??5U^0]02P,$%     @ N(I<5' [R+!9"   C!4
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MSX7R)FHQ46_W" @2"'E5%+H641,H!J%>=F4F&,BZNC9EMG7$ZDC"-BSDPDQ
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M>KW7%[P73:T!N6JI,[0_ !W @F95%7@,Y1=UTX%U"2LSU64@)FP+H-5Y.O7
M&2]!205DTV0Y:!#8/9S-Z_@MHS+%X!KDBA-8$2X77<O(I*] /+ BQTT+.1*N
MFCT+B][<]S532*M%\F858%NPBF+@JRAMT#Q?0 P!677."MH_(^UFQ\0@;,*+
MJ8#>TP'(!+0O$,)EB5;9'3G0"!<0(JC*0 ZDAF"-Z>3Y\T?TZ&PRG3T:H3V
MF@O$7;&=J)N)NJI1:[7,E<@8&R3WD0(A^W+/EP,8H?%D\F99M^X*^@[V6QL0
M$$S9Y]$[).%,%YD,[!IG@*)'B7L:HS^GU@:D7:ZJ6U,G5B(^899=H=!P\>+%
M6<ZM*-^BJ.[8,"%DU>0?'3PZ(+)$=3123;5L[YSTK U#X_=Y<'AX\$XO*GBR
M GT3[1]&5\NES5"OU^"N@7HZ. 8Q"T?W&,,Z(!WFTR<'[SS;@-55PS9(DAP0
M!\"6!&XB$'E-C(;"P6]P:78US+,?6,.L0-![$W30 F55L_/Q=VH1EM"WUMRA
MB@),!H-WG_ER>!Q,%T?Q(W4%^J9E=^J-9PNQ8$  @/N.9"D> :SC[&XTLFP-
M7  <0@K+EKG-D!^][0JBLMX2:9+=1GQ3\C;)V"\K%.BPC0Q)'^U'U KRAB5R
M\"Y!]<!84@@(*XEY8"]OP"T 563H@()HHH# /3 09HB)V&?H2G17<9A304O@
MK4:L8/3*" 8.:;2\9N!(./"E:E#$.@ZM3>(9TL-\3"8?>4]1#HV_1ES<E/;O
MNYNCA7@/\"[8] ,;C*0$4K;)V6]8PE(LN--!(+.":XPJI2$Q/1(93<)Z]F*$
M/F@$KUBPP4R!;8*+L+0&#!*+!\D^N.PH&%>.L!T:&^>NHW(AF4)6L24'%+B5
M!),5W[, 803VJ=(WH!A)S$S$/Y,IB&?!442&BJ?K-O /@BT3;/16 @GH;^@:
MCXU<<- 8%8L_C*;93!S5*'3A'O62%"-$%C1SBSI99RMTX2+8W(;]V?H=[^/4
MX^DQ,>H,6% 8UJ&3-H,RIB;?GQXYHV!PXG@T1(FCGB31Q197M^+;\Q0 /=)!
M@T:4$5])@D4XNS@7P!<;HAN!#^U8'[!PQ!,Y#!$YNLWN4'CJ#P,7%DM;% Q?
MM2CLC9;H5YFC" +,XG1D6?CC3[<(,@T#$DU/-3:MV8"\)?0<_Z0NA%*S?NB0
M,#(B*>?0,Y+@ID3< 8[[9Q$(Z#SC/00?C>;ULYP+"I-)8I\1T)D-Z,:C'U@W
M#DL']W4X)W"?J^Q^Q"!1_3-H_QBM&Y$HZCLZ?]TCK ;F:Y84H=RSECI=HK'C
M5P*3W%!@:[0'<MM0-!<YCPU,5+1;B7)A>([UW$:\T$CUBI)!R545G=M#!PO6
M+8@\4=9 $Z4/J D>!J'0C&869/<A4P*-C5Y3]-F2A4^6<7_/J> S9*Y+C 6T
M+Y!4T7$HHB_.10:B??Q?H!\RC/T3]SL+,IC![I%1,(_0^+3H!D43"/\.K0K0
MH"=18!@%3>>-<P-<,N+"9R%4C>;ZCG'F/,M8;<"0A1VC^X'"@0X1/(4V^0B\
MZ2K?XH)YEU'TBC462_</[U],YY.P+6 2PQ:B>CB;CJ;3J5=G95768$&7.47?
M1#/1FG ZX-O>.+==YH '\=W#^93GP0U$P*,VO$%O!1T!5GMKD'D4_? J+@22
ME[8&)TQV,1(O% 7NPQ.:W0..L352"J!D -\D^2W11%UM=<&.;PCT\H1 : 7Z
MF$P HG=2MDPBYLG!XMN+*]$Y.H[8XJ=HH:X B,:"$$ 1CNH>[-A<%ZC#PVBP
M05-:!K2BV2J)HKP?&FVZ#0:*1PZI*$O0#"&^)(MOD."(+Y>FKB7N>@=ZD-8A
MU==B^HDT.'JT'"; =9FUV9\<AMW1Z\45[0)(I:HE+K^+*^1G3-C 9@#Y>Z0<
M!^U9!'DKIDFT.AO_F\JR*R+Y)R<GJL([@0(!AK6C_0M 3M].U%NFBF!B>0.L
M9V'?@NE/?. ^BT!&5[Y;_"[1;%Q@SVA\A]XY /_83L CH;-(#9<*D0(#)>A"
MF[,M;D0$!QSL N=V?A0'U1)R0^350.'>_.!X O*H-V:C)3LO!;VT]41295E7
M[R9*2)O1(UXUM-O8:+T'"U:T"S#ODX1TQ&;;<Q@(C=O[*&A5[9@F.#>E"]$P
MUP U#4P)*@HE314;U8BO=/Q ;/KX_[%U=(U2<<S!$WUCQIP'#G+4F]DL>BUI
M/A85*+>%ZTB5 =-S'*'/O$@B%+@A$GH\>\)2IELT(/?(-P(@/ A,@!0=>#Q_
M<H\)@;"QY]I(O@%L#\< S3W[VI*T)C<S6"M H\XLRX%7,=%5,53P>J/K]@DY
M0@$SE%[2VRA['G3.65!TA&"B]-PL2;>([(Y,#MY%;O.( ?6]&6M2@#WM)8][
M_"MV$X7[R1CPT$_4AS+$4F<GXIX'-1SXARR>B+W"&#G\/.CL(%=BF^F=B.;3
M8)>AJ<=<F/O<^XYGFP?H$6=5ZY-VB)J'<[(*!IQ>DFNUI:0O90#AS<)+/>]R
M @:NL8:$4#!_(>%D(AY,?N8_ @Z._T4<O"7Z#FEW,-AT34:76W:D-AQ?!9EM
M2'Q>5F![S::87J[N)NIWM"V;V#?'C%'O$U8(_)ES+")6BI$-@EH#*2,[9UG=
M80#H"^5WAN,J(<=(P?>]XS#@+CH>!.I-T%G?D=L$$Z;SUE2:5I8(?A1/HYC@
M5MU@LJ?I'ZJAV#M*SKV!(A$/XKDE&7>:DPC'"62222B=?,2@KC*,OL!;+FAR
MT91O9B%[X1W"?2-H0X!ANG%6V!(,CH*M>?>FY4*28$Y&Q42A0,,)9A<'"WY(
MG$9P]34>Y6)=WV(PT<4U;7E;P1P^DNF-&(_4JK[1P#[.U:PE;Y_L 7W@= M
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M1I-LE!@&_=#@VI5C$BTQXRW,2A?+/I[X6-"2B>>0()*4W0C7)D35KZ-%"BT
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M1'Y[Z0".:_--MN+DV!J$GJM.2/;BB*_I&L2,! $Z,(WBXN&TK)UC;"SNX"2
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MYV?1O9L7D;7#93.Q["[5&W(KO7;]<%?296X8=\-E9 E?=-O8]4;,[W; +9"
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M":FUJ6_HA[+H=S?*EG]-RG^JW&]QG?)/4(7A_$->[W5]@\JW,$MX=#IY?O2
M+]9S;]IJ0S](M:C:MEK3RQ68"*;& ?#]LJI:]P87\+]0]NI_ 5!+ P04
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M8Y>B WB_TMKM;DA!_2/)V5]02P,$%     @ N(I<5$C+?E'0 P  *P@  !D
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MTWU%HTTY@)8<K1.I9@<1#F-/KI<).4K926)UQ(9V[G(0FTC&6RB-4Y5-4\X
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MM*H\\=@A/"^#J<('&W2[W#,TOJQ0 B 2$B"T+>=+YS%<<C0.6LH]Y-:T2KK
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M1F[/A137K"[T0FP_XT[/A<%+1*'L"-O&-PY<2&JE1;D+)@9ESILO>]J=PU%
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M#\VC5I1CF%:##5.C]1(G&PQ,>+"9#5OBLSON$R6GTU.2)#.0$2)1##II,Y<
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MOR::*(M]G'&(P&5;>$(@M R]<28 T3LA6P9IJ^!@\>/B1G1.[.<A\%LTH3<
M1*5!"* (1W4/AG8:9ZC#W6@PDD-:!K2B72W9VK0=\*^:':8_1@:I*$O0#"&^
M)).TD^"(+]>J+"6;< ]ZD-8AU5=C#I@T./K^'%#!=9FUV:'MAMW0Z^*&=@&D
M4I22'#O$%?(S9DUA,X#\'BG'F3,60=:*J0*MSM[)KM#L*TD2V,B)(K->J$"
MR1IO_P*0T;>3Z U3A3.QK '6<@'NP#<A/C#?>2!C+*%9_2XY&ER@9S1^PO
M /]43\!EHK,(#9<"D0(#)3Q%F],U;D0$!QSL"N<VCA[';@-R0^250.'6_."
M!O*H-6:])1LK!:VTM412)$E3'F8K29O1(U8UU'O?:!W @A;M LS[+" =L=EZ
M#@.A,7L?.:T:&Z9QWE=N@EG,-4!-'5."BD))4_A&->(K'#\YM(Y._Q];1TN4
MBF..WL2W:LS%&$Z.6C.;1:\FS<>B N6V<!VI,F!Z#G2TF1=)A")'1$)/9\]8
MRC2K"N0>^48 A 6!"9#"%T_GSP9,"(2-7>M*LFA@>Q@&J ;VM2=I37ZPLU:
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MD-UJ%CW<,(%*AV%#H[8WBW7O%!A.,6<G\?=4;6,IIZ,[.%BQNL6[&H FEAJ
MPM2$DU'$'!1Z<8$6B[R.0@5V5;UR950OMD8U<.42[U3#&N<"[XJ8Y#9?7=9\
M"_UU@X5"'=;4R^_8FGJ(9SI-*L_I]] F;BV2S@Y@VL;.GN?SM9YJ8PN>S,FN
M]A+\/YB0E)$?=JI[:Q#A :K^C)G2VPK94EZ&XLM2G5.%*5U\\T&0DJ'$W)=
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MF>$J&\)F++C8RN0)!CHGD38U=^/<K5F5Q^P\PC2E;:.3Q?>MK#SFHKEKDRU
M]:%L.Z)<"*M"W2-Y<(PF8$A#+"KTY! =HTBO@:XQWPV2;L2SI$VB.A!;B>;6
MI7>Q%_S53/^3G$F*F/3RKU6-(RHBAPUV@$,1!GOW((RL3R(A&LHL<%>3J+XO
MQG@GB>,W*(VY0I]">>:T^ 3H4RN!YFYZX"[)\G41!BYRH]DU1S,98HZN^ ]$
M6%>>FUXF7ER OT>&X;-6=5/FT6H?W/?2:T\3$4'9[E^*'#Z\7")W5H5 N$2:
M^@!D^C-&P^G./SK^^/N(@C*Y =B_]J.2#6>)MR!Y39E.L!=#?%53(68DPM.
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M1A"+2U=O8;6PJG#OSUI9?,W<-,6_#Z!) ,\3I>Q^00::/R33OP!02P,$%
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M;O&9 ^T<T+Y6RAXF+D']<([_ %!+ P04    " "XBEQ4T)H6+,<"   &!@
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M!ZCEA&@$'@S1ADGL]+RAM4DP=.8'H2@CQ2K;DO5[0[L.PC??I7_4FR7(K9U
M"L.;2K=MVMUV0V[:]O:K>SLA;ZC<LDH1#CF&!A<#?-RRG3KM08O:=OI&:)P;
M=EO@H 9I'/![+H0^' Q!-_HG_P!02P,$%     @ N(I<5#WS<^]K @  _P0
M !D   !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL?53?;]HP$'[GK["B/6P2
M:H*A)52 %"!3)ZT40;L?FO9@DH-$M>/,=D;[W^_LA)1)A1?;9]]]WW=GG\<'
MJ9YU!F#(B^"%GGB9,>6M[^LD \'TE2RAP).=5((9--7>UZ4"EKH@P7T:!#>^
M8'GA3<=N;Z6F8UD9GA>P4D170C#U.@,N#Q.OYQTWUOD^,W;#GXY+MH<-F*=R
MI=#R6Y0T%U#H7!9$P6[B1;W;V<#Z.X=O.1STR9K83+92/EOC2SKQ BL(."3&
M(C"<_L(<.+= *.-/@^FUE#;P='U$_^QRQURV3,-<\N]Y:K*)%WHDA1VKN%G+
MPQTT^5Q;O$1R[49RJ'VO;SR25-I(T02C I$7]<Q>FCJ<!(3!F0#:!%"GNR9R
M*A?,L.E8R0-1UAO1[,*EZJ)17%[82]D8A:<YQIGIP^-=O";1?/[PM'S<D%7T
M,YI]C4FT7-C-]5.\(/&/5;S<Q!OR\9%M.>A/8]\@LXWWDX9E5K/0,RP]2NYE
M83)-XB*%]'\ 'R6WNNE1]XQ>1%Q <D7ZO2ZA >U=P.NW=>@[O.LS>"OVZI(C
MK$A)E"2J8ER37]%6&X4OY_<%BD%+,7 4_3,4&VRHM.) Y(X\F R4Y9%5831I
MV-_((27Q"S:>!OU>M2\386U ;!$?Z].Q];%#T(E%R>4K-#DJX,P@#6MR[7SH
M]+MT-,*9=L.PUSGJ@$9'9] =#D<XCBA%I[ ;#$.<A]TPZ+]7'?_D40I0>]=Z
MFKB,Z_?9[K;='=6/^LV]_AKNF=KGA28<=A@:7 WQ%E7=;K5A9.F>^%8:;!BW
MS/"' F4=\'PGI3D:EJ#]\Z;_ %!+ P04    " "XBEQ4"S]2U!$$  "V"
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M@S%[W #3Y/H9Y6#!<EEC76IND>&%OD%CE0AN\-3(7IA):UHSWA1L\;!<,JZ
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MKOHNV2^,;&UG6DF#?<Y^;O#' A0)X/E:XKN\6Y"!X5=E]C=02P,$%     @
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MN<E+!1S7!/5O[BAL6;W,U42+K7T-5T*3/CO,Z#-#:0QH?RV$/DR,@^9['/X
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M8,0SCP7\,2!""\#[#8=,:Q?Z@.ZOQO0_4$L#!!0    ( +B*7%3@I=;\M 0
M &(0   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;*U8;6_B.!#^*Q;:
M/76E78@3\D*/(E%H>TC7%Y7V]L/I/KAA@*A)G+4=Z-ZOOW%( R6)CP_[I23.
M/#//O'C&[G#+Q:M< RCREL2IO.BLE<K.>ST9KB%ALLLS2/'+DHN$*7P5JY[,
M!+!% 4KBGFU97B]A4=H9#8NU!S$:\ES%40H/@L@\29CX>0DQWUYT:.=]X3%:
MK95>Z(V&&5O!'-1S]B#PK5=I640)I#+B*1&PO.B,Z?D-#32@D/@K@JT\>";:
ME1?.7_7+;''1L30CB"%46@7#GPU,((ZU)N3QHU3:J6QJX.'SN_;KPGETYH5)
MF/#X>[10ZXM.T"$+6+(\5H]\^P>4#KE:7\AC6?PEVU+6ZI PEXHG)1@9)%&Z
M^V5O92 . *BG&6"7 /L8T&\!."7 .09X+8!^">B?:L$M >ZI *\$>*<"_!+@
M%\G:1;=(S90I-AH*OB5"2Z,V_5#DMT!C1J)4E^)<"?P:(4Z-YK.;N]GU;#*^
M>R+CR>3^^>YI=G=#'N[_G$UF5W-R=L>$8+I<OI"S*2@6Q?(+^4:>YU-R]ND+
M^42BE#RM>2Y9NI##GD).6G,O+.U?[NS;+?8IN>6I6DMRE2Y@T8"?_@_>-BCH
M83"JB-CO$;FTC1KGD'6)/?A*;,NF#80F9O@4PBZA00&WFOPY >[05NM7I\.;
MK%^?#*>#!OC-Z7#'D JG*DZGT.>TZ!MO0& _Q!)3($ J@I4(7XE<<Z&^X5*"
M72A]Q<Z3<1DIJ4OQN3OOD@6/8R::JG%J-FAU??]S4]3-,-JUZ&>#O_W*W[[9
MWP0=B_YE19-&9QY_8TGV^Y3 &TX>"8T.[31ZA48]=S:X)098.9M#^G6AP!Y\
ME+FNRWBV7\E\\,>M_'&-_CS"!M(<<&2%?)5&A5LY;E.!G2S&?/(42 )JS9LV
M_J5;)V19UD?6D[J0?2CT@;97T?:,M.>@ZRX-P1CXG8[^@64G<([B[M78N;Y]
M%/>ZC.-YS0[XE0.^T8%9NL'HXH%!$9;P/%5-_/T:?]H>NJ"R'!@M/V=+@>V8
M9.QG81XS#S@[&AM[4"=@U1)\$]3KVVJE.:AH#HPT'[A"=A&+#PHQY(E.=K'Y
MFN@.:G1UN&I\!_6"=-L)4VL_IRUS;PA#D</B@' 9X\:9:=4W?#N'@[,"-7*X
MSW1P)/G[%I(7$/\86AZU]TIMH]+OQ6D1/6-EMT]SK9SP)39ZAFT?BRAF6D!Q
M@H=IJ?"D$:4KPDLV\!;&.<Y^@J67$+7&5+(XS&.V^XQZ%E&<:P4I'NUC+B7)
M4'^AO#%X=BW3GN\&SG&JKQH$?>I:7C\XVN(-@M3VW7Y@.2TIV4](:AX]MTSB
M("037(_0;3)>"8!BZ]UCB9R2J/UPHN;I=%)7H4WSJ+WT]I.$FD?)%)8@!.8P
M8S@BPRC;#4E,[N7M_-196=HXS$.?VK2%VWY<4/.\:,_!TY:?E(-]8Z>_H+/3
M>FNW#2UHW]NIN;G_FAS4&[I;Y]8[N-$D(%;%955BCT:7=^?':K6Z$(^+:^#1
M^B4]G]"&]:F^0!<WJ+WZW>W[EHE5A'TCAB6:PA,A%HW876AW+XIGQ7WJA2N\
MG16/:V!XJM$"^'W)<;J4+]I ]6^%T7]02P,$%     @ N(I<5%:5I& C P
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M'>;0G(DT!K"_%D+O)L9!V^Z3?U!+ P04    " "XBEQ4>XZJ,Q\"  "[!
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M9@"^GPJA-S<F0'FHU/\'4$L#!!0    ( +B*7%1)U]L/H@D  !,S   9
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;,U;;6_;.!+^*X1O;Z\+Y&R1%"6Y
MFP1(XW23;-+DDJ;%87$?&)FVA>C%*]%QL^B//U*63;V1EI,MX!1H9)DS?,B9
M>68X4@Z72?J4S1CCX%L4QME1;\;Y_/U@D/DS%M&LG\Q9++Z9)&E$N?B83@?9
M/&5TG M%X0!9EC.(:!#WC@_S>[?I\6&RX&$0L]L49(LHHNG+!Q8FRZ,>[*UO
MW 73&9<W!L>'<SIE]XP_S&]3\6FPT3(.(A9G01*#E$V.>B?P_96+I4 ^XDO
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MROYG (0W@' ."&L ?<W3JIB%/K-4E E@0H,4/--PP4 R 8(Q_2>0Y,25@:G
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M4'KE7?ZYR#5-IT&<@9!-A*#5=X4QT]5?8*P^\&2>OP7_F'">1/GEC%'A,G*
M^'Z2)'S]0;Y8O_D[F./_ U!+ P04    " "XBEQ4ES+0F44$   M$   &0
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MO4$/1;"DVU@]\OTM% OR#-Z"QS+[B_;%7+N'%ENI>%($:P4)2_-?^EPDXBB
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M[@>ZXB+O3?.!XINLO9MSI9O%['*M^WD09H)^ON1<'0:&H/P/P?AO4$L#!!0
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M;MLP#/T5P<" %AABQTG:H7 ,Y#8L#VV#I+L PQX4FXF%RI(GT77V]Z/DQ,N
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M\)2I_ !9SI87E7YV/#^:'Y@+3':HWM/DMY\)%<N(28AQH2F=JY8.ML@O%/E
M\75VQ'[F2K>$['.E+V$HC(#^O^!<[09&07FMZ_T+4$L#!!0    ( +B*7%3<
M.U]010,  # )   9    >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;(U6VV[;
M.!#]E8'0AP1H(TN^IK -^):M@<8)DG3[4.P#(XTL;B322])Q^O<[I!35EF4C
M+S9)S3DS9T::X7 GU8M.$0V\Y9G0(R\U9O/5]W648L[TE=R@H">)5#DSM%5K
M7V\4LMB!\LP/6ZV>GS,NO/'0G=VK\5!N3<8%WBO0VSQGZO<4,[D;>8'W?O#
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M.((I  T8$D75.;AS'H7K<RK<_%<T^@502P,$%     @ N(I<5)>*NQS
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M!UG+>UG(YN^9U?TNA$4.LI0'^4UL9M;8(O6^>EQ62GZKRH87V5I513&S[/[
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M&]0!  #&'P  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=D[3L-
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " "XBEQ4F5R<(Q &  "<)P  $P
M            @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M +B*7%3IC+]QR @  %\D   8              " @0P(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " "XBEQ4R70;5R &  "=%P  &
M            @($*$0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ N(I<5*"/ 2!^ @  K08  !@              ("!8!<  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( +B*7%1;.,,: @4  #$4
M   8              " @10:  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    " "XBEQ4@OGO%0<&  #N&P  &               @(%,'P
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ N(I<5*YQ')QC
M"    28  !@              ("!B24  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( +B*7%1P.\BP60@  (P5   8              "
M@2(N  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "XBEQ4
M6T9CW7PA  "M;   &               @(&Q-@  >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ N(I<5/TAAIEZ @  504  !@
M     ("!8U@  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M +B*7%3RIOC"-P<  # 1   9              " @1-;  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ N(I<5$C+?E'0 P  *P@  !D
M             ("!@6(  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    " "XBEQ4].*V\5H"   @!0  &0              @(&(9@  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( +B*7%3<UBY_N 0
M /P)   9              " @1EI  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ N(I<5,Z@P#-Y$   ;C   !D              ("!
M"&X  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "XBEQ4
M.@;;Z501  !>+P  &0              @(&X?@  >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( +B*7%1XV8KI]P,  /D(   9
M      " @4.0  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ N(I<5*:(Q?"\ @  N@4  !D              ("!<90  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "XBEQ42?^7P00#  !^!@
M&0              @(%DEP  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( +B*7%2L/Y3"X (  "8&   9              " @9^:  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ N(I<5.ZI4(>V
M(@  @'8  !D              ("!MIT  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    " "XBEQ4\D=:G/\#  "<"   &0
M@(&CP   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( +B*
M7%2NTSL3D (  #$%   9              " @=G$  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ N(I<5.+51_T6 P  1 <  !D
M         ("!H,<  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    " "XBEQ4T)H6+,<"   &!@  &0              @('MR@  >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( +B*7%0]\W/O:P(  /\$
M   9              " @>O-  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ N(I<5 L_4M01!   M@@  !D              ("!C=
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "XBEQ4-E_G
M!@@$  #B"   &0              @('5U   >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( +B*7%1CL)N$(P,  "H'   9
M  " @139  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
MN(I<5 "[MY[& @  I 4  !D              ("!;MP  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    " "XBEQ40330@'H"   ]!0  &0
M            @(%KWP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( +B*7%2S3W[^YP(  $ &   9              " @1SB  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ N(I<5+*F-"/J P
M=@P  !D              ("!.N4  'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    " "XBEQ4X*76_+0$  !B$   &0              @(%;
MZ0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( +B*7%16
ME:1@(P,  $<+   9              " @4;N  !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ N(I<5$6729(I!   *!,  !D
M     ("!H/$  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +B*7%2-A.6=$@0   T0   9              "
M@=$! 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ N(I<
M5/9& 9MQ @  W@4  !D              ("!&@8! 'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    " "XBEQ4LV9SFND$  !@$@  &0
M        @('"" $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( +B*7%1)U]L/H@D  !,S   9              " @>(- 0!X;"]W;W)K
M<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ N(I<5)<RT)E%!   +1
M !D              ("!NQ<! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q0
M2P$"% ,4    " "XBEQ4R5L6<E8#  "0"P  &0              @($W' $
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( +B*7%35NO.U
M$ ,  "@*   9              " @<0? 0!X;"]W;W)K<VAE971S+W-H965T
M-#8N>&UL4$L! A0#%     @ N(I<5 KT]'(B @  @00  !D
M ("!"R,! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " "X
MBEQ4MKUW3[@"  !#!P  &0              @(%D)0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( +B*7%14+U_]5@,  !D*   9
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M970U,RYX;6Q02P$"% ,4    " "XBEQ46;RHJ#$#   X$@  #0
M    @ %].0$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +B*7%27BKL<P
M !,"   +              "  =D\ 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M +B*7%3L'^P CP0  'TC   /              "  <(] 0!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " "XBEQ4?'[I&]0!  #&'P  &@
M@ %^0@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "X
MBEQ4*F32ILH!  ";'P  $P              @ &*1 $ 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     /0 ] *(0  "%1@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>124</ContextCount>
  <ElementCount>378</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-daei1</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00020 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00030 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-cbsp</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00040 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-csocl</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00050 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/StatementsOfChangesInShareholdersEquity</Role>
      <ShortName>STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00070 - Disclosure - GENERAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-g</Role>
      <ShortName>GENERAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00080 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sap</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00090 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oarape</Role>
      <ShortName>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00100 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00110 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-paen</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00120 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oapaae</Role>
      <ShortName>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00130 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-cac1</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00140 - Disclosure - SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-se12</Role>
      <ShortName>SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00150 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-it</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00160 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-giamc</Role>
      <ShortName>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00170 - Disclosure - FINANCIAL AND OTHER INCOME, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-faoin</Role>
      <ShortName>FINANCIAL AND OTHER INCOME, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00180 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-rpbat</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00190 - Disclosure - LOSSES PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-lps</Role>
      <ShortName>LOSSES PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sapp</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00210 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sapt</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-sap</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00220 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oarapet</Role>
      <ShortName>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-oarape</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00230 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/Leases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00240 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-paent</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-paen</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00250 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oapaaet</Role>
      <ShortName>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-oapaae</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00260 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-set1</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-se12</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00270 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-itt</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-it</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00280 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-giamct</Role>
      <ShortName>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-giamc</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00290 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-faoint</Role>
      <ShortName>FINANCIAL AND OTHER INCOME, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-faoin</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00300 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-rpbat</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00310 - Disclosure - LOSSES PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-lpst</Role>
      <ShortName>LOSSES PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-lps</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00320 - Disclosure - GENERAL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-gd</Role>
      <ShortName>GENERAL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-g</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00330 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sapnd</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-sapt</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00340 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sapsodrfpaed</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-sapt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00350 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-sapt</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00360 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oaraped</Role>
      <ShortName>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-oarapet</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00370 - Disclosure - LEASES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LeasesNarrativeDetails</Role>
      <ShortName>LEASES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/LeasesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00380 - Disclosure - LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails</Role>
      <ShortName>LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/LeasesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00390 - Disclosure - LEASES (Schedule of Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails</Role>
      <ShortName>LEASES (Schedule of Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/LeasesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00400 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-paend</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-paent</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00410 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oapaaed</Role>
      <ShortName>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-oapaaet</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00420 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-cac1</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00430 - Disclosure - SHAREHOLDERS' EQUITY (Share Option Plans) (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sesopnd</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Share Option Plans) (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set1</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00440 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set1</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00450 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sesosced</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set1</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00460 - Disclosure - INCOME TAXES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>INCOME TAXES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-itt</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00470 - Disclosure - INCOME TAXES (Encouragement Of Capital Investments) (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails</Role>
      <ShortName>INCOME TAXES (Encouragement Of Capital Investments) (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-itt</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00480 - Disclosure - INCOME TAXES (Schedule of Loss before Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Schedule of Loss before Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-itt</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00490 - Disclosure - INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-itt</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00500 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/GeographicInformationAndMajorCustomersDetails</Role>
      <ShortName>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-giamct</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00510 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails</Role>
      <ShortName>FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-faoint</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00520 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="zk2227383.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00530 - Disclosure - LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails</Role>
      <ShortName>LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-lpst</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F/A" original="zk2227383.htm">zk2227383.htm</File>
    <File>cgen-20211231.xsd</File>
    <File>cgen-20211231_cal.xml</File>
    <File>cgen-20211231_def.xml</File>
    <File>cgen-20211231_lab.xml</File>
    <File>cgen-20211231_pre.xml</File>
    <File>exhibit_12-1.htm</File>
    <File>exhibit_12-2.htm</File>
    <File>exhibit_13-1.htm</File>
    <File>exhibit_15-1.htm</File>
    <File>exhibit_2-1.htm</File>
    <File>exhibit_4-15.htm</File>
    <File>exhibit_4-18.htm</File>
    <File>exhibit_4-19.htm</File>
    <File>exhibit_4-20.htm</File>
    <File>exhibit_4-3.htm</File>
    <File>exhibit_4-4.htm</File>
    <File>exhibit_4-5.htm</File>
    <File>exhibit_4-6.htm</File>
    <File>exhibit_4-8.htm</File>
    <File>exhibit_8-1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image0.jpg</File>
    <File>image00005.jpg</File>
    <File>image00006.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="518">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="47">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>85
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "zk2227383.htm": {
   "axisCustom": 2,
   "axisStandard": 15,
   "contextCount": 124,
   "dts": {
    "calculationLink": {
     "local": [
      "cgen-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cgen-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "zk2227383.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cgen-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cgen-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cgen-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 460,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 2,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 6
   },
   "keyCustom": 56,
   "keyStandard": 322,
   "memberCustom": 18,
   "memberStandard": 23,
   "nsprefix": "cgen",
   "nsuri": "http://cgen.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "dei:DocumentPeriodEndDate",
       "span",
       "span",
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:CurrentFiscalYearEndDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00010 - Document - Document and Entity Information",
     "role": "http://cgen.com/role/cgen-daei1",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "dei:DocumentPeriodEndDate",
       "span",
       "span",
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:CurrentFiscalYearEndDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00100 - Disclosure - LEASES",
     "role": "http://cgen.com/role/Leases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00110 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "role": "http://cgen.com/role/cgen-paen",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00120 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
     "role": "http://cgen.com/role/cgen-oapaae",
     "shortName": "OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00130 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://cgen.com/role/cgen-cac1",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00140 - Disclosure - SHAREHOLDERS' EQUITY",
     "role": "http://cgen.com/role/cgen-se12",
     "shortName": "SHAREHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00150 - Disclosure - INCOME TAXES",
     "role": "http://cgen.com/role/cgen-it",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00160 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS",
     "role": "http://cgen.com/role/cgen-giamc",
     "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00170 - Disclosure - FINANCIAL AND OTHER INCOME, NET",
     "role": "http://cgen.com/role/cgen-faoin",
     "shortName": "FINANCIAL AND OTHER INCOME, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00180 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS",
     "role": "http://cgen.com/role/cgen-rpbat",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00190 - Disclosure - LOSSES PER SHARE",
     "role": "http://cgen.com/role/cgen-lps",
     "shortName": "LOSSES PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00020 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://cgen.com/role/ConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://cgen.com/role/cgen-sapp",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00210 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://cgen.com/role/cgen-sapt",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00220 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)",
     "role": "http://cgen.com/role/cgen-oarapet",
     "shortName": "OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cgen:ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00230 - Disclosure - LEASES (Tables)",
     "role": "http://cgen.com/role/LeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cgen:ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00240 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "role": "http://cgen.com/role/cgen-paent",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00250 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)",
     "role": "http://cgen.com/role/cgen-oapaaet",
     "shortName": "OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00260 - Disclosure - SHAREHOLDERS' EQUITY (Tables)",
     "role": "http://cgen.com/role/cgen-set1",
     "shortName": "SHAREHOLDERS' EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00270 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://cgen.com/role/cgen-itt",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00280 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Tables)",
     "role": "http://cgen.com/role/cgen-giamct",
     "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00290 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Tables)",
     "role": "http://cgen.com/role/cgen-faoint",
     "shortName": "FINANCIAL AND OTHER INCOME, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "ILSPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00030 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://cgen.com/role/cgen-cbsp",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00300 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)",
     "role": "http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00310 - Disclosure - LOSSES PER SHARE (Tables)",
     "role": "http://cgen.com/role/cgen-lpst",
     "shortName": "LOSSES PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00320 - Disclosure - GENERAL (Details)",
     "role": "http://cgen.com/role/cgen-gd",
     "shortName": "GENERAL (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "cgen:ShortTermBankDepositsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cgen:ShortTermBankDepositsWeightedAverageRateForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00330 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)",
     "role": "http://cgen.com/role/cgen-sapnd",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "cgen:ShortTermBankDepositsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cgen:ShortTermBankDepositsWeightedAverageRateForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31_us-gaap_ComputerEquipmentMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cgen:AnnualDepreciationRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00340 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)",
     "role": "http://cgen.com/role/cgen-sapsodrfpaed",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31_us-gaap_ComputerEquipmentMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cgen:AnnualDepreciationRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "cgen:ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00350 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)",
     "role": "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "cgen:ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00360 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Details)",
     "role": "http://cgen.com/role/cgen-oaraped",
     "shortName": "OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cgen:IncreaseOperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00370 - Disclosure - LEASES (Narrative) (Details)",
     "role": "http://cgen.com/role/LeasesNarrativeDetails",
     "shortName": "LEASES (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cgen:IncreaseOperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "cgen:ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00380 - Disclosure - LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)",
     "role": "http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails",
     "shortName": "LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "cgen:ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00390 - Disclosure - LEASES (Schedule of Operating Leases) (Details)",
     "role": "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails",
     "shortName": "LEASES (Schedule of Operating Leases) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00040 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://cgen.com/role/cgen-csocl",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00400 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)",
     "role": "http://cgen.com/role/cgen-paend",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00410 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)",
     "role": "http://cgen.com/role/cgen-oapaaed",
     "shortName": "OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00420 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://cgen.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00430 - Disclosure - SHAREHOLDERS' EQUITY (Share Option Plans) (Narrative) (Details)",
     "role": "http://cgen.com/role/cgen-sesopnd",
     "shortName": "SHAREHOLDERS' EQUITY (Share Option Plans) (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2020-12-31_custom_EmployeesAndDirectorsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00440 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details)",
     "role": "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
     "shortName": "SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31_custom_EmployeesAndDirectorsMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00450 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details)",
     "role": "http://cgen.com/role/cgen-sesosced",
     "shortName": "SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00460 - Disclosure - INCOME TAXES (Narrative) (Details)",
     "role": "http://cgen.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "INCOME TAXES (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cgen:ReducedTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00470 - Disclosure - INCOME TAXES (Encouragement Of Capital Investments) (Narrative) (Details)",
     "role": "http://cgen.com/role/IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails",
     "shortName": "INCOME TAXES (Encouragement Of Capital Investments) (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cgen:ReducedTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00480 - Disclosure - INCOME TAXES (Schedule of Loss before Taxes) (Details)",
     "role": "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails",
     "shortName": "INCOME TAXES (Schedule of Loss before Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00490 - Disclosure - INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details)",
     "role": "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2018-12-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00050 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "role": "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
     "shortName": "STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2018-12-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Item",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00500 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Details)",
     "role": "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails",
     "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Item",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00510 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details)",
     "role": "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails",
     "shortName": "FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00520 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details)",
     "role": "http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00530 - Disclosure - LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)",
     "role": "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
     "shortName": "LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00070 - Disclosure - GENERAL",
     "role": "http://cgen.com/role/cgen-g",
     "shortName": "GENERAL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00080 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://cgen.com/role/cgen-sap",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00090 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES",
     "role": "http://cgen.com/role/cgen-oarape",
     "shortName": "OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2227383.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 41,
   "tag": {
    "cgen_AccruedMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued milestone payment.",
        "label": "Accrued milestone payment"
       }
      }
     },
     "localname": "AccruedMilestonePayment",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-gd",
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_AggregateLimitOfOrdinarySharesPerCalendarYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate limit of ordinary shares per calendar year.",
        "label": "Aggregate limit of ordinary shares per calendar year"
       }
      }
     },
     "localname": "AggregateLimitOfOrdinarySharesPerCalendarYear",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "perShareItemType"
    },
    "cgen_AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Member.",
        "label": "Agreement [Member]"
       }
      }
     },
     "localname": "AgreementMember",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_AgreementOptionAdditionalNumberOfSharesIssuable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement, additional shares issuable.",
        "label": "Agreement, additional shares issuable"
       }
      }
     },
     "localname": "AgreementOptionAdditionalNumberOfSharesIssuable",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "sharesItemType"
    },
    "cgen_AgreementStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement start date.",
        "label": "Agreement, start date"
       }
      }
     },
     "localname": "AgreementStartDate",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "cgen_AgreementTerminationDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of termination of agreement.",
        "label": "Agreement termination description"
       }
      }
     },
     "localname": "AgreementTerminationDescription",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization Of Cash Consideration Of Research And Development Funding Arrangement",
        "label": "Amortization research and development component",
        "negatedLabel": "Decrease (increase) in interest receivables from short-term bank deposits"
       }
      }
     },
     "localname": "AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_AnnualDepreciationRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Depreciation Rate",
        "label": "Annual depreciation rate"
       }
      }
     },
     "localname": "AnnualDepreciationRate",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_AnnualDepreciationRateDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Depreciation Rates, Description.",
        "label": "Annual Depreciation Rate, Description",
        "verboseLabel": "Annual depreciation rate"
       }
      }
     },
     "localname": "AnnualDepreciationRateDescription",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "stringItemType"
    },
    "cgen_AtTheMarketOfferingProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-Market Offering Program \"ATM\"",
        "label": "At The Market Offering Program [Member]"
       }
      }
     },
     "localname": "AtTheMarketOfferingProgramMember",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities.",
        "label": "Cash paid for amounts included in measurement of lease liabilities"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration period of warrants.",
        "label": "Expiration period of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstPeriodFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "durationItemType"
    },
    "cgen_CollaborativeArrangementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements [Member]",
        "label": "Collaborative Arrangements [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementsMember",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_CollaborativeArrangementsTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements Two [Member]",
        "label": "Collaborative Arrangements Two [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementsTwoMember",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_ContingentFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent fees.",
        "label": "Contingent fees"
       }
      }
     },
     "localname": "ContingentFees",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_CostOfSalesContractWithCustomerPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.",
        "label": "Cost of revenues:"
       }
      }
     },
     "localname": "CostOfSalesContractWithCustomerPolicyTextBlock",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cgen_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer One [Member]",
        "label": "Customer A [Member]"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_DecreaseOperatingLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liability decreased.",
        "label": "Operating lease liability decreased"
       }
      }
     },
     "localname": "DecreaseOperatingLeaseLiability",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_DeferredIncomeTaxLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax lease liability attributable to taxable temporary differences.",
        "label": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLeaseLiabilities",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_DeferredIncomeTaxRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax Right of use assets attributable to taxable temporary differences.",
        "label": "Right of use assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxRightOfUseAssets",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_DeferredParticipationOfBmsInRdExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred participation of BMS in R&amp;amp;amp;amp;D expenses.",
        "label": "Deferred participation of BMS in R&amp;D expenses"
       }
      }
     },
     "localname": "DeferredParticipationOfBmsInRdExpenses",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax asset (liabilities) for property, plant and equipment.",
        "label": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_DerivativeRelatedExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the derivative related expenses incurred during the reporting period.",
        "label": "Derivative related expenses"
       }
      }
     },
     "localname": "DerivativeRelatedExpense",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss) for next fiscal year.",
        "label": "Israeli corporate tax rate for next fiscal year"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Member]",
        "label": "EmployeeStockPurchasePlanMember",
        "verboseLabel": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_EmployeesAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to employees and directors.",
        "label": "Employees and Directors [Member]"
       }
      }
     },
     "localname": "EmployeesAndDirectorsMember",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_ExtendLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extend Lease",
        "label": "Extend the lease"
       }
      }
     },
     "localname": "ExtendLease",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cgen_FinancialIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://cgen.com/role/cgen-csocl": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Income (Expense), Net.",
        "label": "Financial and other income, net",
        "totalLabel": "Financial and other income, net"
       }
      }
     },
     "localname": "FinancialIncomeExpenseNet",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_GovernmentAndOtherGrantsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government and Other Grants [Axis]",
        "label": "Government and Other Grants [Axis]"
       }
      }
     },
     "localname": "GovernmentAndOtherGrantsAxis",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cgen_GovernmentAndOtherGrantsDomain": {
     "auth_ref": [],
     "localname": "GovernmentAndOtherGrantsDomain",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_GovernmentAuthorities": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/cgen-oaraped": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Authorities",
        "label": "Government authorities"
       }
      }
     },
     "localname": "GovernmentAuthorities",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-oaraped"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in deferred participation in R&amp;amp;amp;D expenses.",
        "label": "Increase (decrease) in deferred participation in R&amp;D expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease right of use asset.",
        "label": "New Agreement With Advisor [Member]",
        "negatedLabel": "Decrease in operating lease right of use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_IncreaseOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease right of use asset increased.",
        "label": "Operating lease right of use asset increased"
       }
      }
     },
     "localname": "IncreaseOperatingLeaseRightOfUseAsset",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_InterestPaidReceivedNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest payments paid (received) from bank short-term deposits and cash equivalents",
        "label": "Interest payments received from short-term bank deposits and cash equivalents"
       }
      }
     },
     "localname": "InterestPaidReceivedNet",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_IssuanceOfSharesAndWarrantsNetShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of shares and warrants, net, shares.",
        "label": "Issuance of shares and warrants, net, shares"
       }
      }
     },
     "localname": "IssuanceOfSharesAndWarrantsNetShares",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cgen_IssuanceOfSharesAndWarrantsNetValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of shares and warrants, net.",
        "label": "Issuance of shares and warrants, net"
       }
      }
     },
     "localname": "IssuanceOfSharesAndWarrantsNetValue",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_LaboratoryEquipmentAndOfficeFurnitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment And Office Furniture [Member]",
        "label": "Laboratory equipment and office furniture [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentAndOfficeFurnitureMember",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term deferred participation in R&amp;amp;amp;amp;D expenses.",
        "label": "Long-term deferred participation in R&amp;D expenses"
       }
      }
     },
     "localname": "LongTermDeferredParticipationInResearchAndDevelopmentExpenses",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_MasterClinicalAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master Clinical Agreement [Member]",
        "label": "Master Clinical Agreement [Member]"
       }
      }
     },
     "localname": "MasterClinicalAgreementMember",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_MasterClinicalAgreementOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master Clinical Agreement One [Member]",
        "label": "Master Clinical Agreement One [Member]"
       }
      }
     },
     "localname": "MasterClinicalAgreementOneMember",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_MasterClinicalAgreementTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master Clinical Agreement Two [Member]",
        "label": "Master Clinical Agreement Two [Member]"
       }
      }
     },
     "localname": "MasterClinicalAgreementTwoMember",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Authorized Proceeds From Issuance Of Common Stock",
        "label": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "MaximumAuthorizedProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Royalty Repaid As Percentage Of Grant Received",
        "label": "Maximum royalty repaid as percentage of grant received"
       }
      }
     },
     "localname": "MaximumRoyaltyRepaidAsPercentageOfGrantReceived",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_May2012AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "May 2012 Agreement Member",
        "label": "May 2012 Agreement With Advisor [Member]"
       }
      }
     },
     "localname": "May2012AgreementMember",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cgen_NetOperatingLossCarryforwardExpired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss carryforward, Expired.",
        "label": "Net operating loss carryforward, Expired"
       }
      }
     },
     "localname": "NetOperatingLossCarryforwardExpired",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of licensed programs to achieve substantive milestones revenues.",
        "label": "Number of licensed programs to achieve substantive milestones revenues"
       }
      }
     },
     "localname": "NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "integerItemType"
    },
    "cgen_NumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised.",
        "label": "Warrants exercised, shares"
       }
      }
     },
     "localname": "NumberOfWarrantsExercised",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to obsolete property and equipment and certain nonfunctional Lab equipment.",
        "label": "Obsolete property and equipment and certain nonfunctional Lab equipment [Member]"
       }
      }
     },
     "localname": "ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-paend"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other accounts receivable and prepaid expenses.",
        "label": "OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES"
       }
      }
     },
     "localname": "OtherAccountsReceivableAndPrepaidExpensesTextBlock",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-oarape"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cgen_ParticipationRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to investors.",
        "label": "Participation Rights"
       }
      }
     },
     "localname": "ParticipationRights",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_PercentageOfClosingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of closing price.",
        "label": "Percentage of closing price"
       }
      }
     },
     "localname": "PercentageOfClosingPrice",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_PercentageOfConsolidatedRevenuesOfCollaborator": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of consolidated revenues of collaborator.",
        "label": "Percentage of consolidated revenues of collaborator"
       }
      }
     },
     "localname": "PercentageOfConsolidatedRevenuesOfCollaborator",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair market value of ordinary shares at time of offering.",
        "label": "Percentage of fair market value of ordinary shares at time of offering"
       }
      }
     },
     "localname": "PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of use of base salary to purchase ordinary shares.",
        "label": "Percentage of use of base salary to purchase ordinary shares"
       }
      }
     },
     "localname": "PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_PeriodSinceApprovalWasGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period since approval was granted.",
        "label": "Period since approval was granted"
       }
      }
     },
     "localname": "PeriodSinceApprovalWasGranted",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cgen_PeriodSinceEnterpriseBeganOperating": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period since enterprise began operating.",
        "label": "Period since enterprise began operating"
       }
      }
     },
     "localname": "PeriodSinceEnterpriseBeganOperating",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cgen_ReceivablesOnAccountOfShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables on account of shares.",
        "label": "Receivables on account of shares"
       }
      }
     },
     "localname": "ReceivablesOnAccountOfShares",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_ReducedCorporateIncomeTaxRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduced Corporate income tax rate",
        "label": "Reduced Corporate income tax rate"
       }
      }
     },
     "localname": "ReducedCorporateIncomeTaxRate",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_ReducedTaxRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduced tax rate.",
        "label": "Reduced tax rate"
       }
      }
     },
     "localname": "ReducedTaxRate",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registered direct offering [Member]",
        "label": "Registered direct offering [Member]"
       }
      }
     },
     "localname": "RegisteredDirectOfferingMember",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_ResearchAndDevelopmentArrangementPaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.",
        "label": "Potential milestone compensation"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementPaymentsReceivable",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-gd",
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone compensation company is now eligible for.",
        "label": "Potential milestone compensation company is now eligible for"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone revenue for preclinical stages of research from arrangements for research and development, including collaboration and licenses agreements.",
        "label": "Preclinical milestone compensation"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_ResearchAndDevelopmentExpensesMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenses milestone payment.",
        "label": "Research and development expenses milestone payment"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensesMilestonePayment",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenses milestone payment with connection.",
        "label": "Research and development expenses milestone payment with connection"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensesMilestonePaymentWithConnection",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_ResearchAndDevelopmentGrantOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Grant One [Member]",
        "label": "IIA [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentGrantOneMember",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_RetainerFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the retainer fee per month.",
        "label": "Retainer fee"
       }
      }
     },
     "localname": "RetainerFee",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_RoyaltyContingentObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.",
        "label": "Contingent royalty obligations"
       }
      }
     },
     "localname": "RoyaltyContingentObligations",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_RoyaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty percentage.",
        "label": "Royalty percentage"
       }
      }
     },
     "localname": "RoyaltyPercentage",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_RoyaltyPercentageBasedOnFutureRevenues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Percentage Based On Future Revenues",
        "label": "Royalty percentage based on future revenues"
       }
      }
     },
     "localname": "RoyaltyPercentageBasedOnFutureRevenues",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the annual rates used to calculate depreciation for property, plant and equipment.",
        "label": "Schedule of Depreciation Rates for Property and Equipment"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sapt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cgen_ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of granted stock options, including, but not limited to: (a) expected term of granted share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of weighted-average assumptions for granted options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardGrantedStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sapt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cgen_ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of weighted-average remaining lease term and discount rate.",
        "label": "Schedule of Weighted-Average Remaining Lease Term and Discount Rate"
       }
      }
     },
     "localname": "ScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateTableTextBlock",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cgen_SegmentReportingGeograhicAreaLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Reporting Geograhic Area [Line Items]",
        "label": "Segment Reporting Geograhic Area [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingGeograhicAreaLineItems",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cgen_SegmentReportingGeographicAreaAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Reporting Geographic Area [Axis]",
        "label": "Segment Reporting Geographic Area [Axis]"
       }
      }
     },
     "localname": "SegmentReportingGeographicAreaAxis",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cgen_SegmentReportingGeographicAreaDomain": {
     "auth_ref": [],
     "localname": "SegmentReportingGeographicAreaDomain",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_SegmentReportingGeographicAreaTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Reporting Geographic Area [Table]",
        "label": "Segment Reporting Geographic Area [Table]"
       }
      }
     },
     "localname": "SegmentReportingGeographicAreaTable",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cgen_ServerancePayPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Serverance Pay [Policy Text Block]",
        "label": "Severance pay:"
       }
      }
     },
     "localname": "ServerancePayPolicyTextBlock",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cgen_SeverancePayFundNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.",
        "label": "Severance pay fund"
       }
      }
     },
     "localname": "SeverancePayFundNoncurrent",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_SeverancePayNet": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Severance pay, net.",
        "label": "Increase (decrease) in Severance pay, net"
       }
      }
     },
     "localname": "SeverancePayNet",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period",
        "label": "Award expiration period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "durationItemType"
    },
    "cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award Options, Remaining Contractual Term [Abstract]",
        "label": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cgen_ShortTermBankDepositsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for short-term bank deposits.",
        "label": "Short-term bank deposits:"
       }
      }
     },
     "localname": "ShortTermBankDepositsPolicyTextBlock",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cgen_ShortTermBankDepositsWeightedAverageRateForeign": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average interest rate for short-term bank deposits outside of the domestic currency.",
        "label": "Average interest rate, short-term bank deposits in U.S. dollars"
       }
      }
     },
     "localname": "ShortTermBankDepositsWeightedAverageRateForeign",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term deferred participation in R&amp;amp;amp;amp;D expenses.",
        "label": "Short-term deferred participation in R&amp;D expenses"
       }
      }
     },
     "localname": "ShortTermDeferredParticipationInResearchAndDevelopmentExpenses",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_StockIssuedDuringPeriodSharesTerminationAndEquityConversionAgreementIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares in respect to the Termination and Equity Conversion Agreement issued during the period.",
        "label": "Issuance of shares in respect to Termination and Equity Conversion Agreement, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTerminationAndEquityConversionAgreementIssues",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cgen_StockIssuedDuringPeriodValueTerminationAndEquityConversionAgreementIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in respect to the Termination and Equity Conversion Agreement contributed to the entity.",
        "label": "Issuance of shares in respect to Termination and Equity Conversion Agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTerminationAndEquityConversionAgreementIssues",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Warrants exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation relating to options issued to employees and directors.",
        "label": "Stock-based compensation relating to options issued to employees, directors and non-employees"
       }
      }
     },
     "localname": "StockbasedCompensationRelatingToOptionsIssuedToEmployeesAndDirectorsValue",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_SupplementalRightOfUseAssetAndOperatingleaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In right of use asset and operating lease liability.",
        "label": "Right-of-use asset obtained in exchange for operating lease liability"
       }
      }
     },
     "localname": "SupplementalRightOfUseAssetAndOperatingleaseLiability",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SVB Leerink LLC and Stifel, Nicolaus &amp;amp;amp;amp; Company [Member]",
        "label": "SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]"
       }
      }
     },
     "localname": "SvbLeerinkLlcAndStifelNicolausAndCompanyMember",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_TaxExemptPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax exempt period.",
        "label": "Tax exempt period"
       }
      }
     },
     "localname": "TaxExemptPeriod",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cgen_TaxRateOnDistributions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax rate for dividends distributed to individuals or foreign residents from the preferred enterprise's earnings.",
        "label": "Tax rate on distributions"
       }
      }
     },
     "localname": "TaxRateOnDistributions",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_TwoThousandAndTwoThousandTenOptionsPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand and Two Thousand Ten Options Plan [Member].",
        "label": "2000 and 2010 Share Option Plans [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwoThousandTenOptionsPlanMember",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_UnderwritersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters [Member]",
        "label": "Underwriters [Member]"
       }
      }
     },
     "localname": "UnderwritersMember",
     "nsuri": "http://cgen.com/20211231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israel [Member]"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unites States [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm Id"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelEmailAddress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Email address of contact personnel.",
        "label": "Contact Personnel Email Address"
       }
      }
     },
     "localname": "ContactPersonnelEmailAddress",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelFaxNumber": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fax Number of contact personnel.",
        "label": "Contact Personnel Fax Number"
       }
      }
     },
     "localname": "ContactPersonnelFaxNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses Address Type [Axis]",
        "verboseLabel": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Name of Exchange on which Security is Registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r172",
      "r227",
      "r228",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r212",
      "r213",
      "r234",
      "r236",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r407",
      "r409",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/IncomeTaxesNarrativeDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r212",
      "r213",
      "r234",
      "r236",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r407",
      "r409",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/IncomeTaxesNarrativeDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r172",
      "r227",
      "r228",
      "r408"
     ],
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r212",
      "r213",
      "r233",
      "r234",
      "r236",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r407",
      "r409",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "verboseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/IncomeTaxesNarrativeDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r212",
      "r213",
      "r233",
      "r234",
      "r236",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r407",
      "r409",
      "r421",
      "r422"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/IncomeTaxesNarrativeDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r116",
      "r121",
      "r235"
     ],
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r116",
      "r121",
      "r196",
      "r235",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r174",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-oapaae"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r43",
      "r369"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Trade payables"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r28",
      "r175",
      "r176"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Trade receivables"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r41",
      "r186"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-paend": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-paend"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r268",
      "r269",
      "r270",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional paid-in capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r88",
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization in R&amp;D expenses"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r238",
      "r264",
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Stock-based compensation expenses"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Weighted average number of shares related to outstanding options excluded from the calculations of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r100",
      "r155",
      "r159",
      "r164",
      "r179",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r307",
      "r310",
      "r334",
      "r367",
      "r369",
      "r382",
      "r394"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r49",
      "r100",
      "r179",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r307",
      "r310",
      "r334",
      "r367",
      "r369"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r100",
      "r179",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r307",
      "r310",
      "r334",
      "r367"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r239",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDevelopment": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service.",
        "label": "Marketing and business development expenses"
       }
      }
     },
     "localname": "BusinessDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r93",
      "r94",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Purchase of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r37",
      "r90"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r15",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r15",
      "r91",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Restricted cash:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r84",
      "r90",
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash at the end of the year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of cash, cash equivalents and restricted cash:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r84",
      "r340"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Exercise price of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Warrants purchase to ordinary shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Warrants purchase to ordinary shares remain outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r46",
      "r195",
      "r385",
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "COMMITMENTS AND CONTINGENT LIABILITIES"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r197",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-cac1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r108",
      "r109",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Ordinary shares [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Ordinary shares, par value per share",
        "verboseLabel": "Ordinary shares, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-cbsp",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Ordinary shares, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-cbsp",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Ordinary shares, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-cbsp"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r27",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Ordinary shares, shares outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
      "http://cgen.com/role/cgen-cbsp"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r27",
      "r369"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Share capital: Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized at December 31, 2021 and 2020; 86,433,432 and 83,675,856 shares issued and outstanding at December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r57",
      "r59",
      "r60",
      "r68",
      "r389",
      "r403"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive income (loss):"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computers, software and related equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r142",
      "r143",
      "r172",
      "r332",
      "r333",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r142",
      "r143",
      "r172",
      "r332",
      "r333",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r142",
      "r143",
      "r172",
      "r332",
      "r333",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r138",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration of credit risks:"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r142",
      "r143",
      "r172",
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Sales to a single customer exceeding 10%"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r142",
      "r143",
      "r172",
      "r332",
      "r333",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Basis of consolidation:"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r74",
      "r100",
      "r179",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r334"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties.",
        "label": "Amounts charged to research and development expenses"
       }
      }
     },
     "localname": "CostsAndExpensesRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r141",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred revenues"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax asset before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r292",
      "r293",
      "r294"
     ],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Accrued social benefits and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r88",
      "r184"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/cgen-paend"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeNet": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.",
        "label": "Fair value of outstanding forward contracts"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Net gain on derivative transactions"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting": {
     "auth_ref": [
      "r321",
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of gains on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.",
        "label": "Net gain on derivative recorded as financial and other income, net for the ineffective portion"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r315",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r314",
      "r316",
      "r318",
      "r319",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivative instruments:"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r105",
      "r202",
      "r204",
      "r205",
      "r209",
      "r210",
      "r211",
      "r363",
      "r384",
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Trade payables and accrued expenses"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r69",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r122",
      "r124",
      "r126",
      "r127",
      "r128",
      "r132",
      "r133",
      "r327",
      "r328",
      "r390",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Basic and diluted earnings per ordinary share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r69",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r124",
      "r126",
      "r127",
      "r128",
      "r132",
      "r133",
      "r327",
      "r328",
      "r390",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Diluted net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Basic and diluted loss per share:"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "LOSSES PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-lps"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r103",
      "r282",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Israeli corporate tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r282",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "U.S. income state and local taxes rate (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-oapaaed": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employees and related accruals"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-oapaaed"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Unrecognized share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Unrecognized compensation cost, recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r62",
      "r63",
      "r64",
      "r108",
      "r109",
      "r110",
      "r112",
      "r118",
      "r120",
      "r135",
      "r180",
      "r214",
      "r216",
      "r268",
      "r269",
      "r270",
      "r296",
      "r297",
      "r326",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r410",
      "r411",
      "r412",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Investment amount",
        "verboseLabel": "Equity investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair value of financial instruments:"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r339"
     ],
     "calculation": {
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "order": 3.0,
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Financial statements in U.S. dollars:"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "order": 4.0,
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of other assets.",
        "label": "Gain (loss) from sales and disposals of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Gain from property and equipment sales and disposals"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative expenses [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r73",
      "r100",
      "r155",
      "r158",
      "r160",
      "r163",
      "r166",
      "r179",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r334"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.",
        "label": "Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security"
       }
      }
     },
     "localname": "GuaranteeObligationsMaximumExposure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfInvestments": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.",
        "label": "Marketable securities impairment losses"
       }
      }
     },
     "localname": "ImpairmentOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r102",
      "r300"
     ],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "negatedLabel": "Domestic (Israel)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r66",
      "r155",
      "r158",
      "r160",
      "r163",
      "r166",
      "r380",
      "r387",
      "r391",
      "r405"
     ],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://cgen.com/role/cgen-csocl": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "negatedTotalLabel": "Loss before taxes on income",
        "totalLabel": "Loss before taxes on income"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r102",
      "r300"
     ],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "negatedLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r189",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r103",
      "r283",
      "r285",
      "r291",
      "r298",
      "r302",
      "r304",
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-it"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r104",
      "r119",
      "r120",
      "r154",
      "r281",
      "r299",
      "r303",
      "r406"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Taxes on income"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r61",
      "r279",
      "r280",
      "r285",
      "r286",
      "r290",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income taxes:"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r85",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Tax payment withheld"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Decrease (increase) in trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (decrease) in trade payables and other accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Increase in other accounts receivable and prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Decrease in operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Decrease (increase) in long-term prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InitialOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the time period when the company made its initial offering of a class of securities.",
        "label": "Offering period"
       }
      }
     },
     "localname": "InitialOfferingPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestAndDebtExpense": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "order": 2.0,
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.",
        "label": "Interest and Debt Expense",
        "negatedLabel": "Bank fees and other finance expenses"
       }
      }
     },
     "localname": "InterestAndDebtExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "United States [Member]"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r77",
      "r153"
     ],
     "calculation": {
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "order": 1.0,
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue": {
     "auth_ref": [
      "r313",
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount on the investment owned.",
        "label": "Amount of investment in Compugen"
       }
      }
     },
     "localname": "InvestmentOwnedUnderlyingFaceAmountAtMarketValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES [Abstract]",
        "verboseLabel": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Schedule of Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2026 and after"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Period of options to extend leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r33",
      "r100",
      "r179",
      "r334",
      "r369",
      "r383",
      "r397"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r45",
      "r100",
      "r179",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r308",
      "r310",
      "r311",
      "r334",
      "r367",
      "r368",
      "r369"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r24",
      "r25",
      "r100",
      "r179",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r308",
      "r310",
      "r311",
      "r334",
      "r367",
      "r368"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON- CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r84",
      "r86",
      "r89"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/cgen-gd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r56",
      "r58",
      "r64",
      "r67",
      "r89",
      "r100",
      "r111",
      "r113",
      "r114",
      "r115",
      "r116",
      "r119",
      "r120",
      "r125",
      "r155",
      "r158",
      "r160",
      "r163",
      "r166",
      "r179",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r328",
      "r334",
      "r388",
      "r402"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://cgen.com/role/cgen-csocl": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss for basic and diluted loss per share"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
      "http://cgen.com/role/cgen-csocl",
      "http://cgen.com/role/cgen-gd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently issued and recently adopted Accounting Standards:"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncurrentAssets": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.",
        "label": "Long-lived assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r155",
      "r158",
      "r160",
      "r163",
      "r166"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Current maturity of operating lease liability",
        "verboseLabel": "Lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Long-term operating lease liability",
        "verboseLabel": "Lease liabilities, non- current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r352",
      "r355"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating lease expenses"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r350"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r357",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount (annual) rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r356",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Net operating loss carryforward"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.",
        "label": "Year of expiration of operating loss carryforward"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "GENERAL"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-g"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://cgen.com/role/cgen-oapaaed": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.",
        "label": "Other accounts payable and accrued expenses",
        "totalLabel": "Other accounts payable and accrued expenses"
       }
      }
     },
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/cgen-oapaaed"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r44"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-oapaaed": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-oapaaed"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r48",
      "r369"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-oaraped": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-oaraped"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r52",
      "r53",
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Changes in other comprehensive income from marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Changes in other comprehensive income (loss) from foreign currency derivative contracts"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r50",
      "r55",
      "r338",
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Foreign Currency Translation income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r51",
      "r54",
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Net gain on derivative classified to operating expenses as effective portion"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r52",
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Unrealized gain (loss) arising from derivative contracts"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r230",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "FINANCIAL AND OTHER INCOME, NET"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-faoin"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherShortTermInvestments": {
     "auth_ref": [
      "r48",
      "r386",
      "r400"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term investments classified as other.",
        "label": "Short-term bank deposits"
       }
      }
     },
     "localname": "OtherShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Issuance expense",
        "verboseLabel": "Issuance expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Investment in short-term bank deposits"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r239",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsLiabilityNoncurrent": {
     "auth_ref": [
      "r231",
      "r232"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer).",
        "label": "Accrued severance pay"
       }
      }
     },
     "localname": "PostemploymentBenefitsLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r35",
      "r36"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://cgen.com/role/cgen-oaraped": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Other accounts receivable and prepaid expenses",
        "totalLabel": "Other accounts receivable and prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/cgen-oaraped"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r181",
      "r182"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-oaraped": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-oaraped"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Long-term prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "auth_ref": [
      "r86",
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes.",
        "label": "Tax receivables refunded"
       }
      }
     },
     "localname": "ProceedsFromIncomeTaxRefunds",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from ordinary shares in offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of ordinary shares, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from maturity of short-term bank deposits"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r82",
      "r267"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of stock-based awards"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from exercise of warrants",
        "verboseLabel": "Proceeds from warrant exercised"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r41",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "verboseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r190",
      "r418",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-paen"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r40",
      "r185"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-paend": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-paend"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentImpairment": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.",
        "label": "Impairment of long-lived assets:"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentImpairment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r19",
      "r20",
      "r187",
      "r369",
      "r392",
      "r398"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://cgen.com/role/cgen-paend": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "totalLabel": "Depreciated cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/cgen-paend"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r39",
      "r187",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and equipment, net:"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r19",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of Property And Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-paent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r19",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "RELATED PARTY BALANCES AND TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-rpbat"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Collaboration and Licensing Agreement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Upfront payment received"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-gd",
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r276",
      "r378",
      "r423"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development expenses, net"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development expenses [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and development expenses, net:"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r15",
      "r90",
      "r96",
      "r381",
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "periodEndLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r15",
      "r90",
      "r96"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Percentage of workforce reduction from restructuring activities"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r30",
      "r216",
      "r271",
      "r369",
      "r396",
      "r413",
      "r414"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/cgen-gd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r108",
      "r109",
      "r110",
      "r112",
      "r118",
      "r120",
      "r180",
      "r268",
      "r269",
      "r270",
      "r296",
      "r297",
      "r326",
      "r410",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r151",
      "r152",
      "r157",
      "r161",
      "r162",
      "r168",
      "r169",
      "r172",
      "r226",
      "r227",
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue recognition under milestone method"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue recognition:"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r65",
      "r100",
      "r151",
      "r152",
      "r157",
      "r161",
      "r162",
      "r168",
      "r169",
      "r172",
      "r179",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r211",
      "r334",
      "r391"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenue",
        "verboseLabel": "Revenue from sales to customers"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r142",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Other Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-oapaaet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Schedule of Stock-Based Compensation Expenses"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-set1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Summary Of Deferred Tax Assets And Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-itt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of computation of basic and diluted losses per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-lpst"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r238",
      "r263",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule Of Loss Before Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-itt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule Of Other Accounts Receivable And Prepaid Expenses"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-oarapet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Financial and Other Income, Net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-faoint"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r41",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Balances and Transactions"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Sales To A Single Customer Exceeding 10%:"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-giamct"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r72",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Total Revenues And Long-Lived Assets By Geographic Area"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-giamct"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r239",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r244",
      "r252",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-set1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r147",
      "r149",
      "r150",
      "r155",
      "r156",
      "r160",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r171",
      "r172",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-giamc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Marketing and business development expenses [Member]"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance expenses"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Ordinary shares reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Ordinary shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Exercisable at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Total intrinsic value of options exercised during the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted average fair value of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Options outstanding at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r246",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding at end of year",
        "periodStartLabel": "Options outstanding at beginning of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding at end of year",
        "periodStartLabel": "Options outstanding at beginning of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercisable at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Options vested and expected to vest at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Options vested and expected to vest at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Maximum percentage of total shares of common stock outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r237",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r239",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Stock-based compensation:"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Aggregate intrinsic value of exercised options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r258",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Exercisable at end of year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Exercisable at end of year"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r217",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-se12"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Offering price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r97",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sap"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r47",
      "r62",
      "r63",
      "r64",
      "r108",
      "r109",
      "r110",
      "r112",
      "r118",
      "r120",
      "r135",
      "r180",
      "r214",
      "r216",
      "r268",
      "r269",
      "r270",
      "r296",
      "r297",
      "r326",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r410",
      "r411",
      "r412",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails",
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
      "http://cgen.com/role/cgen-daei1",
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r135",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails",
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
      "http://cgen.com/role/cgen-daei1",
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r26",
      "r27",
      "r214",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Exercise of options and ESPP shares, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r214",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of shares, net, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r26",
      "r27",
      "r214",
      "r216",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Options exercised, shares",
        "negatedLabel": "Options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r26",
      "r27",
      "r214",
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Exercise of options and ESPP shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r214",
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of shares, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r47",
      "r214",
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Options [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r27",
      "r31",
      "r32",
      "r100",
      "r177",
      "r179",
      "r334",
      "r369"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r354",
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid (received) during the year for:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r136",
      "r137",
      "r139",
      "r140",
      "r144",
      "r145",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of estimates:"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r123",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted average number of ordinary shares used in computing diluted net loss per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted average number of ordinary shares used in computing basic and diluted net loss per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r122",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average number of ordinary shares used in computing basic net loss per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79691-111665"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79708-111665"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "http://asc.fasb.org/topic&trid=2122503"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "10",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=6431724&loc=d3e32938-113948"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "10",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=6438156&loc=d3e57880-113973"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121558989&loc=d3e80720-113993"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.5)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r424": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r425": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r426": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r427": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r428": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r429": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r431": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r432": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r433": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r434": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(6))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001178913-22-000863-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-22-000863-xbrl.zip
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M[@5W&@?]3ZCKQ8!]?QG=B_[A_P%02P,$%     @ N(I<5,,MC[?K"P  TK@
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M=5%IX9<3AEQUY?/?8+GR^7]02P,$%     @ N(I<5#$--+T:)@  HFX" !4
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M[8#"@,3-M45CS:X:UJX$;?<>]9'S_^R5T-DLM9.NL.RP+@*._&L]G[D3 J@
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M-9FS"_"<"8J_^ HY-N>/H!GJ0D*1$+%6^?)^YT7D"4WPS&Z:H9?-OKI!90]
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MLJDMO^F#]X8<-ODW"=##!^BI>Q/P$]XZ_WG>9BLX@EY@E9)-C76F0S6)Z7J
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M M<LVKMRNVH&6+X8E$W2+;*&A()@UP)^&G2V%+."#3MS:,W0/TZ,RN;&GJZ
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M PRUX3#HXL1.',Y;;#,V;?V"AFCM!<:D<-D7ALCC*TZ2\VRS#=*]-D@XG5S
MA#MW(5!H:U0U]PLK8B;PT2);_X7QTH3R*)R9_/8N4-*?L1 @E>?!$Q>F=,'Y
ML!"L]:)W'E=Q@F]WBFO205/[-QT'\Q1<<D ;Q!IY<;TQ7%O>S09O69>ZU& W
MKP1G19:F.+D--M(+#5YSJY<9_/D.+C*J*_&F'8*&KJ\P)&O=N[Z0+O.BTE^?
M=-)2 05N<_M:8#!?@29HV_D !=E:\S2":)D7A<)U&F8Y,47:4^]YMDO+?'^>
M16IDR'O;!XJ*&@%N#KHQ5P:J.B+HZ060M#C%PY4FDVQ$+5;_N8E3_$X)+EX?
M9[&*O9G+ _O:L#YHC^Y2/Q D88(DG(^__I;1\MT(M'SG!5J^,T7+TZ?,4[1\
M9X:6[YRAY?L1:/G>"[1\;XP6LGB^:I?OS?#RO5V\G),?[_*G[)/LYD[4PQE6
M#F:M0@HT1EF.H+E/&!DNO00AO%6W@@]F)&F#HVKN#AG-?.6PJ"U;KP!QN-8R
M-/27V084[K.B#)+_+]YJ'8JXG9S!HC]WE<Y@[1'IX,_11\8&"58$'%C*RP8?
MSG&@P,A!,ZM>M</Y#;QI% 7D[SZPG;>6/>\9=QD78BT\R$_N7[-4[3,?-+7)
M8LX\^VRF31!MXX?/7+2VA^P6+ZLEG_E5\%G)>W$?E][S[LS5+G32V@]<*!D@
M]Z9SUMX24BXW09Q4.Y !6 ZZN<1+;_YJR- .M0'A&6IXS) #A\^'A;#SB,-=
M3G:R=]\]/\6E\#$_MZE-C'#FV<<%_3W*UNC==U\^?X7J'H[Q(%K@0PR(UW8A
MOC_E :0D>MQOGK/!JG>F?]C.)L?[,QRPF_T=L0:.N<Q=SD,6"U9R8;F^_!R^
MDE7#BFM6;G,7\MV;;Y_I\&L0\;H9RE+TZ34.7QMQ1W%1W<+B'$>>"#^/"WP%
MP&? LJ^/L\T&KN6R\./C:T!8>[<K(7L8H%7I:I!V=O N64Z+Z)$R[85HMQ/$
M.J).3R]<$#ILXCY@UN+0H@C[&2?)?Z;9I_01!\3&P=%U4>PT K]$_>SC2DR!
M %+0X?0C]$!U%\3Z> $F!4=X.%(R8U$(_90E.V(FYS1J+5?G&NJWMP^9X8P%
M4&D:(M;2"X (UIL'#.%2+[MKL;?W+(H9[*HR**4OG*7='.Q4HOF+]J@J:4+3
M ;$>7J!%S@SNKJ3@P\(A9\0X)$?N^ U#2M%J+DKL"+JY"#(3S%\87=:T9SE4
MJQY>8$?.#'XXF9P/B\>MY^=!B5\RC:O9P]9NHM>[LY4$L.>H;N<%++CK+ IC
MYRSQHB"XW.#\A6BM'_/L4_E:/:A1@H'?RSXH1+,7@*-NCEC[^B64%RB1,H*'
M%@4/%D+-=;C.5[LH)F.MRA*3XQ=$PBI2,T@ZV<2,=.Z#]_NL(>JT]"%]@WK]
M#[&BL_3+*IC/[<-.]CI+K5V&71RH%MZ\17KE<_<-+FOMAU(1+CY7HTC6?>D7
M^V$(P4C,?$ZC()>A1-+)R>M]WMS%;_B;UJAN[LDS2S$/!._Y)<N_$%SNRE><
M=T]:]+.0X%(94*#L:A,Z&G3T 42[')Z9:2>:H-2/, -=[AS"29\QB^Y3W0?E
MRAWJH+']O:DW5\&N=/#:WXOMB+?&O(V(O[Q+Y9]BUI'B6K';RFJVJ8/9B8Q4
M#UYH<I:QEU**MX++\A0BW53IQ'HM'?"V,TL1?^LF?O"XOZQ</@]7=%E>7\7Y
MYEIF-1ZV<\#G9H8B+D,#=.W:'.2N)Y?%_:5TD7[^;GT5IT$:QD%RG[&CR^H9
M7GZ'(B^XT1#.4M3+Z1(GK<_6J.F(ZI[HU[JO5XGL-7@G26VOQ3:+D%P5!2X+
M3?#U&MN&V6"N Y7T^'CY].@!6/BK.H2%:$&M Z"ZPS'"0;^/&S@,9SZ(5_[P
M\'!Y^X08.G[P!AZ"-1>A1+C<%L%R'A2OJS2"_US^;1>_!0F94;$JSX,\WY-S
M\$]!LE/5(],;PS:8="D;@(MT0.3PCT+X ;==ERA)M>T5<W1,CVVQ,4+?4(P,
M@6=1K!XPD>DX+'$TAX"9CF9;U,RI[8.T'8'"U -HCN3@$*2CF6<1KM3W^?B:
MY>43)F>I](W,&6Q;53$M<3_;$)11,#BE0+/3DK1#ST'Z$45X"X:[#PI1R8@A
MOC1X8-/X9)<QQ0,.,4'X<X)O<2D/!]/J:MT4E=/!>SJ#4=XT]@%+.JS@F*9:
M7+"(J/L<;X,XNOR\Q6F!B?ZD@#^PH!7 TAG!-K[TJ.)?O@45BSIXHP;>EHV)
M,!MT$8.U[%3#]H\\VR)F@,VAI!G!TI7_P,1O,+,0:4)-!2I:A1V%5;!W0%LO
M(1F&[@V>LXO^_<2#6&(I%!3N#(>8O264C7![<;JY\7QQYS]XL'EW>^JK TS,
M !%H9&OOS,AH)V5D672ZN34G#N8_S!:3OK##C_<;ZI /JEV4QP(=&(4O9'4
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MZ[^"E60S3E%#$LU(J9O#P[FJ ^KT\$&^-*#&$20ME+F4F(-(YRK+EDZ0O\%
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MUH[\V%X:I1''*K^(BS#)BEV.->]J)@]OVZ,RPWH,$L+NMMN$OO$.$LC,6?4
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MIJMV-0>Q[E/5I6T0EW']X^WUU?7YZO8)K<[/[S[</EW?_HCN[VZNSZ\O'SU
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ML\(<"L<\!#C'O@I!/9"KP6,S(1G'$W8-,4U!<K][3N*P=L$KSC'ZXUA/969
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M62]>1V,>%SC\^B5[(_.B^4L9FZM_4"XS/<E^\9?K&Y$J;!M8TW;=.?&S$/K
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ME[RDOH9*2 DN,@I"IN_X0QVM;4W6M$Z294[+ET/Q^RQWPG6*2ZT&LOEQ%*-
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M',NX;5H'7,/BG+2)YN"9!&X>*$!2.,I-P^@1DCI[_91M_1X4@V?-QQ;8?L.
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M>]YR4"PZK;@%"W"H]<*HW83'VGO<>Q1@ED5CX_ML6'SU2ADK.:PVT\JH*]5
M0)86([W:KK#8!UYILZ%V);E[H^P:%'M?X&\U6S2ZV=A:D+2R2VX9*8C&(A[6
M#J;Y$=Y6ZT'#JD[:1C:WS;2231TNPXVRP)AOQ?-8333)BH\='4/K5+<K(-\-
M6N#IK-1.Y4"IEADY4%^]I6T2HU![L">I><734'W45//QR%AK#6?K(+!"WSY&
M*J-CVJP37VN"(9J4X.AP9022Q0$4;Q)A6M/9R@\XTTFWBJ^7LY/0.LNM6C$H
M,+%V]9=M'G6TK3YSGZ6UQMV^A:K-]SMTS^3KU80*,)7.K;6?N\_P-@(.'5+>
M8BI^@>;:%.-*4?=95"-C<"K2LW_,)0E1Z!&9^VX:/V&:>A#=X'C]I*O^FQ']
M9@H-$4ZGJ;O^5A;VNM!=:N%Q'H'F 9'2=H%?<-:(67!T :.H^@5F'1C6+D7R
M)LK\KX\Q+*==C9#CW%4#L9MOM[.GZ6=RQO9>'R@*&0>(*_F-;W-+\3XTMF!2
MDM,&8@29O6N?O+'34-QC\7V3  2T:%5).LVL$I+AGF.MUBNI$ID&]4[=&B$G
M*=$! 3M@MMNW^PX'8O"_131^/46!>*(@H@T4!I0Q';N+K2LV";A$U8J/\E(B
MP0]1H64$L[-LKQKZZXVK1C5H*19T/"B)E8\JH&!9NZ:5>8@+ TX1#>WV7B'J
M.+%J6 P\8WL>'\54C-DMIC(Y]'H_+QZU)VGQT]DI8L03:W42)&(E79(9<?B\
M0#0DX7S5%."P62O642#X=6R@R8SO<R;^/Y-TH\IA?1(IP*["2T2H>#R'16+O
M-*:$W L]XR"2#V,OD] 7[TTH%0+B-QKE!JK<@FZI8[TJ%'W?E%@[/)=TUQV4
ME[X=^WQUL(Y4><!>AFTW[U%^QR(>!O8GO"5HCO/+/=FIV#2)68Q2[&##JG%Q
MCHTES6&S]X!"I4M!E8T%0 M#4!1J@3DT[1&F9J*"UEYOV,W.8F85.ND=HU\+
M5LLPU'_](*I^1 S_[?\#4$L#!!0    ( +B*7%2H9'XM;P<   8>   0
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M%6(L8#,7][Z2"$K%SZLJ;R'%-3-MF1P=U[KL[CXMU&?#>X6ZJLG*<U&].>N
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M2UQ3FBJ'G>I.:H7F=OTO4$L#!!0    ( +B*7%1Q<,8&41X  -"!   /
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MF H(W;K&%AHY^,IJ>B]=QL>05_P>K'<=VGWA6PU-IYA17; 0=?M%YED^3\T
MRT'@ A;?F]"D:$W1R7JU@H=-T#AJW6I64Z@ 4,]@A#Q\4_@CXP&MBDK[27#
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M)2*-=KO1=CKE;*^G(9CCL(9?=>6L"ZA2"3J2>E-0<#Z7TO@J>-I&W)9\!:)
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M7YKH8X9-BK:J1P>HTFPT8H [MPRU%6&&Z6Y W3FI:B5T)BMD?R-=DV[<T3D
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M3,"@G@AT3Z\&)5G='T((G%@0(!H95A>$&P5X5L^6F?CXX!7<N8"9%Y?[<ZQ
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M2XR'//4W##(_4Y#\#8/,#QP\^3<,5OV]@HA/QV_PAR;$0?B3&?\'4$L#!!0
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M[1F_M$REVZP1^YOG"_<8SX;66L=KH_ZYVG N/%E2B$81,"\7F)'7;'YM@<4
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M'="A=5078!M;/?E6%N9QXX="7+H2T6HIMX154O&R:VQ#.&@YR/WF$>8J(6J
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M7I<@\8LEUCIZAO8)L8:KFR?RQRG(]W6'S/8J;.;''WS'N53-:ON EP]@XL$
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M'ST_WEK/CV[)X6GT=*OI@8W*V5EQ<UK#$'R]:MVZ:;4>W(E:SR7<<%()F"K
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M=CITD0#<,9]W\CCV=F=S]^]9GLDJ;X YD!<@>-E53FLIHE2>%A,8$P:%9&4
M> 'H^TRO*EO;R@9Z&Y;WE"W/>+HH6WUYLW/P:\78PK&"@(?V:!R[UL@.A!.%
MX<CWK+&33/SH:AC;MU0%T]4P]F2'M/C>F;P%2*VU&-5,$*;0I1GKX8"N%SD3
MJF"$"CJ*-H..KF:KCG1T6P5&>]D]_WO9W@Z5IER$,4_&8R<>N9-1Q&,>1U8P
M=D>),W'C^![D=N0,=Q';VY-;<%&$)+$UMHJ*J53@PBR"[:ZQ[>/9KEY$!;K
MT@".;3S6ZG9)<PXN*GOWA[:-:X"QJC5/[LWGO,OHOXJ']UZP9LF7B?&M/MEV
M:RE6WW/N,V1?VE\AH\\]>.:L79G^S>4IKE"_WT[\_[*DA!4YCF/;H1-,(M=V
MW2"T^&0T&D\2R_9"U_N>E/@6DQ(W7..\%]])5N)8ERB4%Y4U=T+]AI:W6-9\
M0F7-:ZJ:!YVRYAVKFK$:[)*BYI.-1<W=:F8S_FV+FJF0^?)*Y=B\8^N*Y?7K
M.7$4%U<Q'TVE2-B+SR*JJ2CD79+(2"7\V_"8H55[VV]8FO >A((J1YI( *:J
M>8'5,_#$"XYT.!9G(LWG,UW'@:MDD1!)71 16G81ERDYHRH3X&[J2DDU2RTC
ME.\@UI*K+<G4!1'H,/"46)I]FRO'W,G8C2QG+(0;NW$@N.VYW@20?0#NJ7#O
MQ0]U=?9A*T!_&W!>:DGKS _43B!M6:GF* H,'CWY[CKN(&K.Q!K;?F!;H1O8
M+I],)H[G1G;B\K$?CN]#U,8J)KN=I-V2J!E[<K&D+9>U?1>^G83/]D=.R..
M6\[(3?S$]\?C<91X211&MF_[]R%\OEX2L:7TW8/X-=+W1>2LK[3J9+=$]N5
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MF VT[(1P%;C'_'P_,*OBU07N%Z?$6S>A=VW4C%"^P"5RMIV \0;67[R)ZO>
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M8Q=$BF40 0! " H #P   &5X:&EB:71?-"TS+FAT;>R]>W/<1I8O^/]$S'?
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MRXA]RH@'ARDC_(#]+VV3@_H0%19T-?YR]L<GFK%4K&O5[*_&&T>N>E(9?*G
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M'C^\5!2S3V]?]<O>.B[\-;'[/U'-KUV">5SVZSPY\BC] L\Y^L4C=68<EC(
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MI\8;1_5S\.?KDG#8F'*E8?H%?DRN.NBB=[6V$.R ^P%=?H@_+VM[CER5C?'
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M4/TK4"".MXF2'52+8?C&-T^FY )V;98-LVR89<,>?8@#QJM[$UF<>J2="GE
MI]YW)[R[.  W##*-Y\Y@2(41#&<1=*"\ET)*-M242LE-)J U>9=,0LLL!4Y!
M0R(S6^12RO29(/2EL!7ES"NFJ'X?B0C$W#2N;A*+8?-2AE(\TUR"$.L/(C,F
M%OHC3MVRX_ 1]58DM4VC76<@W6WI*AM;'^F:',RVXR'V/N\AZVQ#B;(4*/.C
MY"4_ALH)FJJ(KAG[8$($! ]U[ @VE$Y\!V;X2/1PH199_DY[GJ]1O^E=,KGP
M)'N?(W;"J8<W"V^W/8Z>>8%+WCKXFMJ/S>59S=1Q$F2+Q1-QGKDM8C'MB1&/
M#@I2[&6Y*;?8QAOW_FV\5[44@R0,J+^$=%-9#P@BMECM@ VS (V%7!N&!4@(
M@'"C^G!RRD3'28:]5#!_(")-X)1FD&FP.U(W[79!VV47>:;)^,X*G!1^XZN^
MZLIUM<&.9)PBZAHU^?&QQ@S!62N\E4^3KY.CI__'=\=,) *?2PYHR^J3'2]N
M8CN"<LF3IAD]ITPENN\F;W?NZ-%D'>EC,WZ;Z6]['GO6:?)J*82@ H Y66Q.
M#!:&V$%9>DX_,/(D.T>95(\=/)5O(18H00ZY*3?OR&ZMG=_2MC<?>UG/[N9%
M/=MZ>Z0S.\_Y0#1')M%'+EF!"[?R&\%:K;8CT5>W')^@2,35KGACNBFV?#7F
M9[)7NFNEZN!P16A4TQ2@@8%,_G)$X9RQN*^,Q3_,&8MWE[%X1UN'#OD/,*YB
MA,.3\*8)-2^K^209P[9:4N>L[AE<9MZ.D.B4(]Y?IW[Y-#&O:CCELR)VO/AR
M+-.L&CKTF548H[V1;E#X5WH]8),>3<8V3FH0OJ C@Y7ZY<C+_:ZS0+UD0J#!
MU!,)]Q591O4)F!N7EKDGLW0!0B00A]Z-%H15'CRUPU\7<*"U!F9LSU4Y?KTG
M(ZA/]RM24VYD.B=;ZV:?WKPL(LN"28.KK,8=_,:661X6DZ<=BIDNG<N)=85C
M@B](3RJ%@Z\TY$NP4,S2$%]"*=>5VG%!M420G]6#IE#$)(N&BTL*.(039"[+
MM=6?;(])[:<>>51=T5O<57B)&SZEX1@*=LL]E:/O4EE7@J$3,\^U2Y1YL>;E
MQLOM!O:S$"4<<-'[,",K:!XG1^7QD*:?I,%2M<%!:OU&3#ITPYE*HJY A=V0
M0P;D^ZINH9/<EQQ&1KE5':=U#=;*V)WDB=FA@+5XY$&C<&GKG$N3PR6740D3
M8B4T?&,&[H^XU\R,J;/5&MLBSUFS:I"G19P"OBW(1>S(ZZ.YR[JS-=%K3"&K
M7*QD3=9@SFK,:/0?-3UN JC;7\R>FL,CAYGG<7 4X3^!8O:ZV605[!-W/B6O
MZKQ91<O22(+YAOWG5F2$^XHVHF6V($?8,F26T&Y7!I"J,;Z21$(6Z X>T7A+
M?4>7QI'C$E^CU[_N,CA,;4]1DBW+]R 4X->D!\W!R)_C =K#Z9PDQKU3FP?C
M45"1=N-=@"ZC"4:/&W5A2J<;#Q_1)BCD>,SV7E!?%70]>.V\+=_^]P^P+\L.
M%E#N2:1=N4,B +=P\K>NF*A;<&2W;:45&4\!3VA)*P5$./$LPW,O&,^GWF,\
M@6O9R!SOM$;I:/3>W6 A\M"C//:BT,$25TA'2J[Q%H.9\*8[CFG1V"3#DB[/
M;8T;R>H,3')?+1F/7VSG;&+EW)L0Y'SH'>:A=W"$^#^3.(CN[<DC[^,+9-R]
MK";S4WL<5$$NPM*5!H-._M;7@4CW:)Q]"YD)'$)*953608,7QTG1:#*L5@U\
MV;3TMXP]D.:NMJ1#2<O,31SRY%]9$)[R2GEVL3?U"R-67>6B2-:ZEZ0NUGF5
M+51E74%K$RL"*S%K"TPOQ=^N+[FD/4>OC?2&V<&@UHJ#.8+ZFF7N+'/W*G,/
MCIJ?F:OB\I7CKEE%&Y(]!4*0HUKSFU!9:<G,&M):D4?!ZO^F1&%6#:Y!:5W6
MO7P<RZ'@]Y.R/EEG;6=O0^.A;;3*N5YCV#3,I3P3.7KZ!=<\X=]:56I-/#[&
M&4)?PM*EJUMUHMYG*XD_PQ>4NJX-"Q#(XU9I$&S>*):ET.QHGC3C5**/N.(+
M[V,I35&%Q](RZ\?'?Z7:C@?JC4><LPS?<+/A]9I)/7J8$H)6H8N<:L7QH9-#
MH\Q9).57X+2" Z4%D5ZT_07GS6FJ;8#V6=D4V@)LR]HZ5[G27-=03OXU,HC
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M6_0<,H162[ER"?)4-ZNQ%+"$LEB=K-DHD]ZJ3'O8-\=OS)>S(P$+H$,'D:W
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M' 5,@.TF8RI 5(.<;20.:R/]WG!@OM8TLUV3RI!*9&!F>C!X\6U\C_E3&^]
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M>>HU8G/@(,ET4].^TYU:TRF:9[UA*QJ.F0N9YCVR+AZ5D0F G[ Q"OQEM#E
MQL*^J!G7([5 HVWG<%73N?;'+026&ER+9Y"=SV:BV8%R(2C'O%_U:&!?*<0G
M+A2(<#PFKK/6&E;VP(_,+?R^[3 3KGV<=N+!T["$Z5RPELB@2;?2=&2E<7J,
MN7?XJ^@G,O.>G\%/O*0ULF8]!Q?<"MX[S+*6-THX+1,'1/W*@M9EB>XV[O@A
M;EX7;ZH !C^Y QK> 3T'IZ/C7HSBL3!X6%Q'Y3'_X.;'6U#>@L>UA=C1LB'<
M/)*BR *3DL:4X]=YVK&Q9N%]]2W\/)X+E#HY^Q[HK;DBSM.VODTWRN(3H^*W
M'?';&N<R!KZ*J=NG]Z%;3] KX5GC151D&Y,8P1,R'K\DP&KK]-AE)$6O.,T:
MGK[,RHH2+AOJ =TTZ.&]T7OF&/#^8L#G<PSX0&/ GWBCNI?@YOY>&2:^:7*#
M<1(U3R*<RGO$S3Z</ PBEDO,=KDS].Q;E5_6F'2[2=ZV6:V7V\K5QLPJ_[1R
M+\D_L<:"8KQ#9LMZ<NE^*,70!UG6#_>&7_W5U]FNE7JGC4DSI#T+_6R6)JQ@
M5[)+:VW8*5LH#1W)T!P.DCA"#;RVZ5P)Y=3[3EO1O3=&3TR3KNV5@ F1E:R+
MV!?.X8<./ $TI@A^7(,&3*E>F*+5-C5\4JM%4Y3L#]PIV>LT>6MY:%+6PA&.
M6-8]FNN@FX,^7/2M89E!==8T'"LN)#-IXKH>=)7]CVQ<#YA$,(]M@D*.K5;;
M/-F1:,B/3%9R=DC@$X:W W<2&N.^C6HI?ZSE^U]U<YW\#?X'<["]P=2W_-!\
MJAIA=+KE8MIJ5G_\ZOJHQ81W[#[%;)[Q6RIKI))Y3VC?7 E?(9J?:"#!?ZD.
M763E&THI6GERJ'B.9=\M["/"'W(EJX*>[*(&B/\NEV6>531' C (. 3Y XRA
M4QA?.#)0W(PM2;\U&ZC@3C #U+VQS>:3<X\GY[Y2&'\5J;UNU6]]031T'%2$
M7:Y:&RZ4K<;+1L[Z='A(W)[G[28LT<ZGSEB0R#$4\I[M?JJ;!!+G.D-=%P4)
M1AA+/#_R,61)^&YVR+<>!.%(V+[&UI2DB[L07/Z/OM2E\4>J]]A J3D# UM@
M_L 8#:" /'Q:MYO3P&W/+*P'SP$W9AFJ!R )^HW=*K7N\:!NX7XDMN!E,LA.
MWTE1>;5,L!-\&'F54RB\77?DSC9Q\/'XER"Q*N9*DN=-]AI5BO%QBH69!I%9
M>&P1^)4CG1&WGGGX,,+MPQ$<%R,.<IC20V6>+/OL?-+<SY/FRTG*C;L(/]GQ
M$^W%=QOG23=[[]ZL_*E'?@#J\Z.KP[IHJ2L-:X5=YI=M)6S4R3HK0?-=NRJN
MRQ;MD[JI3VP5V90"*;I?G/!!FGE R$"S]J SN]6'V5X.YMB6G&'5'"-BDL=)
M)MT)FG38NOGR57V%$6I*Y+NNF3E*L$+3C_J6B6Y2+W!VR[KFH36*=,C289X;
M:WW: V,1V0UT+/B*@_!?&:+":.&>E '7RH)*W144#TRWP(.D?3^8[ZDGD;)!
MOS;M.UBN=22I?CYRYB/'/W*^!!:(&R3MTZNLK Q0'+?'^%BZ'Z?3O$GNP@-P
ML/3\!Y1K&.@N(1)D.I_%)[8>\D/@ELYJ/.0]AC+/^(NS_7OL_G2%Q<DR HC0
M/Z!,**UMB7I4TR:\%: AM0; HE ]L;5L_(PH4!M.U:EQ/J*%;#'._+OI\[#B
M8:3#Z/^T?1:'?(!H>B6I/X@O3#^XY>1(R"\(IHB>ZX4ZQO].382?]1,VGGCM
M>N8R3;>A-/933MDE?;<=%]>2]T)EYN!E#'%VJ(AR?Q:JNT;LHKQ$;CCB />?
MY#P!'ONQ?,%<TZY*D(U_B098H'/B$PS<J*['=]/X> ;&@T?GS-9R2!]08N(F
MUV,=*>H[+/,P%@K>O@^+,PW_.@I*9D1096$-#:\TQ[#^N"DS86.9?A6DH(C%
M:8A6S.Y; &,&E^T/7!97XV=PV9</+IN5_EGI/PSV@E=>"$@")BY\=UWJ2S8
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M8B)"$"+>X_*?O+6?E_ 03'Z;]\.\'_;G2W@$Y^JA$)Y]STEGTL_3CR.B_G6
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M*>*.<OUQ%PLUUFBG6C4JJT$55&6:S+//J&NJ.EDV] <SE5+@2;T/I_S1-&E
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M111:1Q)<;M#^,MBHXW&93+)&QRPG64E)1Q;JD(1)LG.V+&9Y47"B;V:.A(1
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ME]2Z1D#.:4*1:2ZLT4@S0E ;3Q[\H[,ZF\NMQEDJ^*W^\3_*ZO+9K]5ELN>
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MF0"7M$5)L*+DC-_FV^!=,+!!T5GF W[%T),]IHGEB@/OI%C7&\(^"#(#9/.
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M"L#0^+>Y]V@;W0EH?@3,Y/$(34>BP:&Z[ 8BX<Y?'!R.9DTP34<\S:OEW_W
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MH^8F18UJ*84XIH#C,BMPI(US>8RQ/*FDHC+GLV,X^CBDS"Y BM]$EX(CRZ&
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MM'+4@$"^8@Y"O=F ':C_Y)K*/^&_5"Z*I94SG:I._4T3HYC)I*B?B!-U)76
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ML5<+J!2;PFK0L(G# J;DH0:%$DXG-LSQEF32USG'VH!@&Q!L X)M0'#MH=J
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M$GCO?D&47EV>B4\"Y47R9>-_ %!+ P04    " "XBEQ4+71 J,\4  "+:0
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M,.81]MET$PONV:$_)_&,P14AC08S:1(QH %QX&$_GA'/CX%B@&Z'NH1Z%M[
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M*(,(Z22SN\+HK>%PA(Q&$0BS* K"5W_AL3":.8'  +SM $D!-68,X2!/ #,
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M *JQ0P"< H( !HQ#F=V7(943Q,]4C6'IKB=P_,4Y$0L_<5%31SX:$=[](+T
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MH]7'W8]^#@,?'8J[Z_)'=@7_?U!+ P04    " "XBEQ4J+8^%:PP   P_0
M#P   &5X:&EB:71?-"TX+FAT;>U]^V_<1IK@[P?<_\#3W(XE@%*:_6X[,>!)
M,K/9S6:".+O XG 8%,EB-VTVV<LB6^[\]?<]JHI5;+8L68[<>Y$0.!(?Q7I\
M[^?7FV9;O/Z?_R,(OMY(D=)O\'N3-X5\_?57_']]\7]=7P<_YHDLE4R#IGH9
M)-5V)\H#WZ:?[ZJDW<JR"9):B@8>:U5>KH/OO_O;FU^RO(#?5?#S+W^'7V6P
MO(EN1C<CY^UOJ]VASM>;)HA6JUEP'8Q'XW'PE[H2:9VG:QE<7_-4O])S_3JN
MTD.@FD,AO[G(JK*YSL0V+PXO@Q>_YENI@I_D;?!+M17EBS"@*V&@9)UGKP)Z
M6N6_R9=!--HUKX)&?FBN19&ORY=!(3.XDE1%5;\,_C2BGU<70;RF2]]<_"FC
MGPN>39KOS1;!KV8Z[GBTJ%<!K%]>;R3^ 5^]&<_T-$Y/FN?L3OE6OQY71?KJ
MXO77[6O8CO:UV<6O-[690%S5J83YEU4I7P7\UW5<-4VUA:_O/@2J*O(TB N1
MO+?WFVKW,ICV;]HYCW8?NGWA38!7X9EU7;5E>MV_Y6X" $XCZU?!5M3KO+S&
M/7X9B+:I[*6:OT+7+@)Z[9L+?HU6^OV'31[G33"]6>*:OXYKL^]???P,WK6J
MR;/#Z5/H[6SP^P[_C^.?\-1WCH:\>/WG/T7ST:M'3NSB]7=2U,';O/Z=/TT7
M\S*%HWP9C%>(;AX41+M![+AX_9]5&XA:!MX^!54&I&*[:]>R#'YLTIO@LMG(
MX,]_6H[',#'<;8\F]';^6Z9:7W^%-U_36]&KJ^#_U')7U0V2JZ8*<,!O-[G,
M@N\_R*1M\KT,_IYE0/UJ_#S=YG'^;QB(,@WR,B ,PI=EN1%E(H-#U=9(;_;P
MFAV4W\+G11G(+),)#0[H7LHZ])Y)I<IK( CPZJZN]GDJ 91J&M;@.V[JMLQA
M8J+)JY*F(C_([<[^5<M""B4#H6 J#0[0; "A:PDSP'W[Z'Z9\^ZVZQZ;_*-L
M&MZJ'P9F^+V98>\00K-+65L44C6PE :YR4[6V[Q!?A(?@D+<TB#.3KU0P1LX
MN@3>P4^^4:I*<OI<2.O>B*((8HF;SCL>9'6U#1J@KO1%_/^#8.C$UWK+N3E3
MK/JA!!I>*H"GFL\$5G$'K/I B: #IR#6M83UP^YF55%4M^KEF2XVNN&O?=J_
MP:_'2P=&)^M&O&?,-!AXP"V\+_P"( )B[Q 28>]Q;(&_ L)L<Z7P2"[O"XKP
MXC'D=4(5SA-)$^P6D(^89PF?I_-.Q$XD>7/ 8Q0(!DC@@@T,?$3FPB]TU+/%
M0XXZ>M19(W'%L]B"Q-2(&HXJ%S%(K;!!>#0QS)/Q)=_N*A2"J])L9R;V5<UG
M6<&NU7CD"FXCI@"RM74#ZTO7*!N'\'Q2M"ER&H$T&41LDIGIZ\#N0,0!O*QJ
M/,QH\0J.YE;4:2!VR 08AO28)_?UBQ_$^#$'8<YA)PZX,2JXW>3)AK8:A0%]
M$*2$P(3>$[V"G<O+=VT-5W>B9I#N^!V<T%M)B!+,QI>SZ=6EN+J,\%\#YC^H
M6L@"GVKKO,D!MW\4MR&L>KR\CE;SY</X@S],7]1@)KU#14HA,+1US<>J@0F(
M<ZEG>YO#[ 6R_T1* AFB/B";B!TP6!7\\XM)"/],$7I^>!&9Y?37T8$<*&8
MF"(&#0P@VT"TF8X'G* JU*4\* V(02;Q ?B0-\>.UM!D-6L,OB,QC:<9_!6I
M#?S],QQ-\!- 3&_;F<@XNSY;P:ZO5I\BV0UO^I=&E9MH=AI;)H_%ED<?:A\*
M8<P>TJ%PRR@':.G0H)!$61="4;L'<K46>0DL$ > IUT1 BDEH"L@=BQ!-,OP
M @[HD4X#:/"9.M_FI2@Z0&.>AW?]28KDOUKFL_UW3[X"< PB#[V2:1Z(>P;S
M%4V05@!+,"O87Q@8GH95PF/PGQTW+Y'#?VGH.@U:T[,#+28>"G94HI+$VYZ7
M>Y"7S.CP60>>$(SRIFV.@0K99=MLJAI9-)U8KLR5WQA8X5-I"[*5:I/-75\)
M'>@"\LQ <@M,! ; !<)H2-ZJM@G8D&4GG@+X$/]V)T=CZ.<%O%&"0I@#N-PI
M1!2Y;#W@ZJ:G@DMD:+@(H*=;1;";2AA8DN[9H9<F?U=AA\,?7T:W^!/KB>$%
MS8L^QV+Z\N\GHMT1+S)SM!*<@JGBC5=X(F>+I+/'(NGGD2:"O[V(PAYG_@40
MIL[91O%KC3K$SS72TJ3CU5.4D);+SRADG*OBC,J@B$$(/[*[W.8%\)A"52BF
M%P?>:0/B0(8\]5K #@"8XRXCA*.BR)MNT+#3N<J4A=N#86"LSYW6X^"=( 6<
M26!;0Q",4'.H8OPRJG3P'['8(TV/V#+=@DW!D7B,XL H9O\"8&IJT (9PN >
M U!2;0'ES%U:O6\UN!3WEYW;6.5I#MC;EYL9VX\UU\<M.*GJ7:4-(58\\"P>
M\!+IQTB-F@/1GAH/[=XZ^IL,B2VH++T5,>RRE2Z#,4O$*FV;Z]D+V8;%>&/A
MQ&X5$GT<QGX(=2:)$A$JC;L:+QTC59Y^<_'=VY__^K-8R[\ RKY_ _]<F(6
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M<D!I=7^D+S)C2N+XD/5,;H(W_&T5K'-<&ADU4;DMY!HPSS']#-O:""ICV>U
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M^(]_XSO!O]^\O0F^@XT1M0+=S.?&>>8JB/A1./P6^6!..H[1'ES%U#)I>M.
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M\,_;V &<QK/Q](]A//VKP=5]E3,L8!!CU<9-:)PS2$9/)NP-@+:+^LJ)$>]
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M,&5F')G;%ILAY<;T,?*JQ=/@!SOTT<S">ZS0EH_XD&\!ET\(/F>+2X^N+?+
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M,@%BP>%E\ *[EJC@)U"L?JFVHGP14A\3-++).L]>!>P-RW^3!AGZ0.6"WT7
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MJO_!<2+)%FDT3N5H)I-I.I.KA5PE<B43L8"_Y=F; \=/6E7!::L!W#QT_:@
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M!:MVS)%;I;5W0QN862!ML.P/JXU(8]C3D=J.-J#1WX0//(OD3@;C?+%(YC'
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M:_2>/;]9O[5W.;,_XW[V!X=OO,G)>YIJ6!&>N1>R#^I_FVVT/OUU**2)W;J
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MEIF(8#51JSZ?X0XHV@O_FU#?4?/P3PI24L9J&JJR"DHROY,E\#1[<P=7=!X
M')ZXN6C(W6?4?:3'B+4 \ $QP %7 ,S4W-5)65-6"_S;<CCR1W)GD/MRKG_?
M[W\L!(\M7,T!@#%"6,+<R<4-PI=I)B$/-Z=+_!;"9.;6IH\A7 #A&RX0@Q >
MNZPW^P/_O,16O_%E)@N0N6AI2$'X,H7%:/4/;/8/;&[MX@!A 0BS/G9X LT/
MU_T#/[[$EVDO5@=[=_._LC,0X5L\>:AY60\1+9 #"D 9J %&8 ;<@0VP!VZ
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MHEQN6W/43OY8 (.6/E'PVJN;<_WMC2"<)7CK>90G)?T,.^K[_P%02P,$%
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MU$=[O>4,L$#/<YSVTK+#]4!1R^!8*7$]T$=!ZG=['PM$U\4T6IN'>)GTNHE
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M6WIVC<XE+Z)["A\"/@G X7>(%P5;WR).*"_1529! 13'),=\^Q]'AH8&[SJ
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M;E40?_]"&@6?0%1PJ\+F%2UKWM5W^OQV=Z0S(;AGV 74I%(GF!M'@%;J8FS
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MR)&,BZL'08F:C8":$HGZE)AUFE6S=;UH:UKR F_T*UL<X>3;GODVM%8@_6V
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MXO%1.6O<50Y@'RH44:^!1LB7MDYNHQ^:ZZ,L.;(@-!63 PCLCH@*D4NFBCP
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M2786^&=A:P-?/ 0![BJK=I&J/=)04W44W&[K-F"!/J(X]/0DN05;-/J4XA.
MZH'AGPA6$36']P]9]]#>V'#;^<6@7)H**HT?[PU)T"R%$5J 'S[)E^5D2S4H
M&XB_7RW2$I9\QACMCGO6L*G<Z;JFDHW/Q@O>LY#R\8>[)R]PCGA(EC( 7TV
MKUY(^GP,7M=W8EQX<NVF[?4*$/0^6)'C1Z9G]ADX'PBQZ?TY'/3$QXY2Z QM
MW?&/,/\[FZ.I79J$*&X*//[)!ZMZ;\ ?J7+,;L88 \/1-$RG7!\?6*'FJ$2
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M_^:U](L=(*',#$\!_D+B^6D*[O0(YW'4U[.)HVTCBH0*B?,/%%$YO2-2-F=
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M-@%[_+A)FA=DG!F X-NM!VB(AXL3JY+U18)H0>M$O#@;Q.L](C(S7#74V8J
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MRY_@2!2L<T]*,'53NOLT<>T'KZ#]L$E%"#ZBZ+@@0^$HR-XE:4!-%K^\.I8
M7D0#LH1W6([T2_BOP" #&!UX@SZZH[SI:3:0*+4]:HPD!?V8Y*F4N7^C K3H
MQ[O!>? G_<UETYKPO=3.#F\^J B6KYB)C$!S#D/?JH"GG(IAS CN35I9*)Y,
M6O]44G6EO\G2Z<S OO&QWH  ]1>*I&FF-U+N\!()'7F,"3.FD8(G.&_LI2?S
M"B+_T5SK@"E-*6,<A/5I+P2<=@ZZA*(Y^ 4EE9I9I<N_07#.&+1QRRU:\F:
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M<3S]I<SYP&[TV/E!%KWS@H57E@@'W^)6ZNHGI1[WG],4?N\3TNQ:SIU55U5
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MB83+&#=EE@F8E<V%,Y#O%*=A1\&HYB&,N^$!_!54+04Y^X40&Y^8]XX/M$^
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M2IX]2_"\D[,$_)"EA9?6PU 6C$="S'8-V5*G=@8XC":]I8Z-C"5*USCA^+N
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MG#%7Q@!2^HO6[UMW8U"EPP9?.7S/()8K;A,48;K'1+4T-&0KX%Q5 =:\3=)
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MRAD0=Z%\70Y9%OQT0EEPDJ_@G#MOM N_+,&:$[*.I-U:]W;V5QI4JWO A[D
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M&;=C^!HQN5\]G/A5EN_FK?P5U*T-L)G#L87%)Q-C_12.X9]LTZ"R[^)Z6I3
M9WXEWD\I(,G';S:<E3?JOH;!*FI7V+8F?-SCW3S'18-:GP6[M]ZY^34=F&B\
M%GMMRR> +>\&A5#=U_RC2^;B!E>7;Q?ZRP2T2%!JW%FEOVPQ5VBXS;SI'BM4
MW<?:,#@6C:0^9L$;SV5,$3P\_BFR#M.T%Q8A5H *:X#ZX!(NK'.$KZ-!]?Z
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M5(IDH,+84F)33!2HG:HZ:,R'0QU>ZN?0B*GS 5IUL%*#>C%.@$O<S93?TIK
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M84P1XMNSR]B6TCFE((5H2A<ZS\9N"5F(( A\NEI]-5J%B1#IO02?.EQ@KX!
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MM]VT;-?.=3F1LE=^ 9T03L)VE4/3#5<L*)_BBJ>K-K/^-HJJ.>*/00"6Y.5
M>L#^F*8HNP^,JH)<$\39+Q'B4;VBCJ<$5OF%'N.$Y_3)@A_BB@HLM_BOZW&_
M.3#9#X75L%5+:SP$X=E+]%+5CQS$=>:"''Q5F6:_P8T)?\%RK\.>#B<@=DGB
M%7-X/B3E5#).G"W440*5ELRUYK?.T(03*? !U<2Z]Q!#8F81F#0B)<B.2M<-
M7,X+S)#ZNH2/'6WIG^+F)ZK3BN_B&'E-:'>9WX*1<C==M\ ?(F2>(>8BW%WT
MGI80ZT7IV7C+U]"YJX-%JI,,%IO51R,(U&(,UI2?;"XWE>HRJQS6-UN?#2S#
MA:0XQ="Q-7B"H%']B"IZM6OF?QC_+HH(5P*#6Y&&/\,B>O2TSXE2<R6P@2#]
M_+2(,E?G!51GS-ZOBRS-DG1$>:.+4.&FI*Z4*<Z3=FVN?%-[ #43L_6ST#00
M&@1!..BP>F'@_<#X@1BX&UZI!,)?E4I-+B[+]^8$6^J5V=:F$EZXD.S@O5@%
M[(X,EJ_;C]Z0\+#=(B/T_E#URK!M(FP1Q^Z"9$_SM*TI+9K#\3:"@P6)/^TG
MQ,FF%PB4@#G-0.5"J"9N?B$-S93^V%6Z9L!6\)7TC6ZP\6+'/=Z*3&T#=B C
M='"C@432@CDM\^XD+^F'KX-/R2;5#\H-1 ?&>$'$&^5U"Q-I0^\W2[ID@DWN
M"?+@$;4>^7MB4G<QXQI"'B3LMA%-%Z+4MHJUI+0(>I=2Z7@(PY0T]0?@"5*=
MRPBUK0((WU&^*W7GN/,K^Y@WB33\S;"5H[7/]U#)%;6"\]25"V4+06Q]M$R2
M5FN@,'G*,E64E'[;UZM6E0!UE7_=FHO!<6X(O4[U[$X)>Y1E<7#DGB T"1<"
M6=(/JQ?-(AW(*=^B>+D=7B\WS.\HM>MC:GL$L;(1*.?&@]>2C=Q;9Y90^PY=
MMAL$7TM:SB-VWHT73=-=R(U$;;+%U.&.1XUG\EMCVZW-&Z)'1H0?1GB3\P.#
M,&!@!'^![+ G Z":VAG*T$XB^TCY8<&BF-21D5AGUGF98(J^40]DQXP]DIJ+
MMG$YU!O=\%0%K">\.^A;JLFC5^S1J;H S;SMU<5)=0!_%=D>$RTJ<^^OUYTZ
MRDBT=-3 JM/IB>Z3 T7[[28$+B9"4-Q!N&MQ,[DA03C&T=)%M:U@_R"RJL]Y
M?GE-I$*1$I 2:2#$1.[6'5))$B9ZB1+H>QRF*[W+86KPBG11(F[$=HQGJ'_Z
MB$5UNK>W6./HJ(:L16)BF?D1G+D5#Q(4)3FE1P:BZE!+I6HU\+9&OS*\;(>D
M*M$GA]II-!$CQM9/Z4T@J')=]?T% ET5FPEJ4'?9PFP21O\LZ:PB/9M<Z1)Q
MB!8!)@P)IO22E0#_%X^9>CE:481!B^+$MT10I0Y6YU)-5<H2D%TV]!2_*#5R
MTK('*V$/U<)#0+#Y0_Q#(@:LK,/J@!6UTK3^5S=$"]'"K&D*O\Q%P3\VGK!<
MX-?E,R4(B-[?)5F9@;#%3'Y3N8:7BXG(O)*-EMK;%=G:M\1.+MFJUXZ1='VV
M;_ #K]R.)Q$?1D\*Y]0_I'V@:HC4^;Y@O_%-H11R$:I'8O0URHN\TT?-NBO?
M##M66H[;/B$[-[5\\*.>:<?@SZ;R>+ZA@=ZN/IL>Z[7@$G0\WRV"$/E8SS\5
MIB6-2I5.X8,5*,=FFN,7O7W!299/4K[OQ5T/.D&*1"\'^]6$H0W/W--&R[>5
M%'5&9HS ^Q,"4'"U1#4!0#E]M5G%X%,U$?/CM)8A)7%Z22>%DMNENYY*T:?L
M-(\+9P:76V?7!LETO]C0.4%A!)V?'<M10$K 2X:[RS+M*/TVL)^Q0FK\MGS=
MM77/>M&.A[!-XM/PX(CP535OMV[15# BPNQW9LD=A&_#7Y'2G<AQ^ZX?+87>
M7:L7'..OQ$E6;//QY41$E!IS;*W01SL*@G7L$3N&XFB9]$2U)7/E%?/2]YCW
M;^(X+M?7W-+$^Y#P<%N,6!_JCE,];78,<T1D7QGV1?OV\9W0"H^Y$W"JS,@G
MEW1T\0[<1WSJLH@/Z;-ESY);L?I2TD'19Y[VB6+*HO2?92OK)V)W#:K.(OT>
MQI -^&L0\%%QMA^R:$#1?H"ZOP'3WBA43CI;U*B/\TO-.8:HU2/"40=G16[Z
MV9^3^DH*(68T(C\\0EBM0,%?@3R(%G/&A^,&5]/J$&752G:%]WCOUC;]1X*J
MOS/9_XKY[L:^,CH&8S8K@4O%@J3N*]CM2N!:N+,W6A?G@?I2_FUS"#J;/+6G
M<?I53G!5X>J PWNF&BB?/U %ZNH:JPU!B8P=1>41LF]'PK85TO-$$5?D8' _
MWZ6;Q+)&QV0ZGP] .O@\M=ECNMBU./#!VDV)^R=[FW"!^B=5,:DK^2D!G>=#
M^' 8HJ$PB)'!1F1BPKF(:O8+Z-8,8R'XYJOQ&2+J"=03%);PC.#V$O>=G1+P
MH<-?#L]0;ED87P=_VD5C?";_0;2H)-L;ZH*$\2S0RVHZ$6/2$.GOGP^?8K!5
M $F2G)+@D][UQ$SXYO/GX"4MPH[O1U.@OKN:MM%#1GZAV]J,<0.\#2\/#10K
M 7!P=G3P7!A9?D94QJWDHSCMD<*BFI2OVT,TW9]XFKQYFI$E:?8,NB%QU-F0
M!"?B\\3'V2NQ*\>T47>PYB,/&,O+-X'GI+C7RZ5U/Q#X15.;6L66LS(E4#(9
MRBPAILZ!UTQ#UQ%D.BGQZ0Y=[V2L[G7'HW?A^E9YRSYK=Y;EY/PDVQNHR;@'
ME1(F<)(1M2G?&FAU::"(6;UZ\5-RD8WP&4*E&D]&YY9VS$UW8T"O% V!!:(R
MG&7,/NH9*;$?MR+DA*( 8^W#H:X?B]W7!W[AX7![7P:K5-OM[=@3V40AJ!T"
M72JGMX6HIXWE58H5:)MR&6Z.8E&K-XG@+7C(J:B)GW-!URW\"];^SHE[&ZTW
M'E$".U[/+H$7=PS4%C#N()@P+">'.: 3/,[HIB!,2Y+9_J%U0R#;O1:Y,1\Q
M%9TD;RE?>95K"!'A"^5TLP@98T&8U00WWR7P)$OKI9TJOJUY1S<==Z. O<S:
MA$>_D/2C!#W&ZF[[>@HGN#T%WH9>HB+*MWTD=TT8[S1$2T]I?^EA07?$30SN
M#^7A9"*!'V*0W3^T80):/HI>3<7L4J2;5X*1NAM%_H5Y0L;A-KFM:7=4+^@V
MNOBS0)02^ -1((]G2Z_;EDH]A6"?1DK9 +1F3S_Q]K*$\ITBC>$L42T7=-_T
M1AU1%]N/6B. B4V7N;Y1 DNF"0O)%W3,F'8MKH?Z;.W]:(?@ICRS$.2&'.=C
ME0^T&Q+$2^J6K,O!P:$95_6*$&/1T/ISK.\4@4/@?YX=@D7TI14C$F/'P87C
MA(C0=.MRV?<4$Z"= 8GM ZX:@R7KH9H_2$G]1L%5037C0_U;PS9*DV3F-=KL
MV[DT<)R]O*RM)C9E7W=W*9L=;2&+&X@8?Y0>0HRK*#+3CN^XZ6_\>:]5>XQ9
MTD)=I^ 65\'-IB88GV-\!<S_(5*HOJ\TO-USQL[V>.NY-F-_PW>:_#5KCBDD
MLYH_AC)GW0]\@]TFC7Q*GGH+%43<+<@J]4DGXT\(P[+=W/I!/F4YT].@*XP
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M>*WTD<RD$G6GU!I]P^=)L&'GSKLPL5-P3.4&X*MP"UY/U_@E[P/D2HO9@>N
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M(:S6 E7#6__*C_^;6OZ%*5_C3ZC#;F Q&*@!_-1D/3\+<WC!5/#10+_YF4,
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M;\G=R^:(([.<R*[C:[[S.LG:?IWOX#]4$!9:&ID?IIAI:UQX_[@+J3T_Q'C
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M RO=M3U8B8^\IBGH<)*](X;U_+9^@=K8G*^'-TE(DZY_A44G;[:0T1WD.16
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MS-EY-,FT.?SM8-O6 QW][UV1D5L2TA>581F0;RI]@L A-)T9F&]2W4/)H,S
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MU:>5?.#]7*GW!V6D-N$1Y3\SU [&F:SUGQF2,?'Z]^!AZ?NY? 2?6S0>/;<
M&M3'W'X&#^IIAA\8D@&K]/\,WD3Z^N:HF+'@S_(-W]K^R5!?0@VY#'>X@3=)
M_S%42S+,]\6TB< ^,+EX[\C$\F<0GYD/1'?EP\2QPB&CI5SP8L?>&EC0)]T&
M@)O_5D<=$/\"MH((Y$C_M4$)63K5;&,!,^/810BV=C3I9.QW:A \N+P3&4_Z
M.O,B9$1%E_-60@I3+82]CP[W_8DD%\TS4@- TH)@U&X<2"I@9F4]GXO/D0)Q
M4/$O%LAHF?23B8X#-<B2,0A.]OTFO/T?F'3XN\F&7R;5QDV"+7\LX;^S@Q#@
M,BMR#U$N;O%+]/V9F/:_OU>:EZP"9%#/&V1UZEK0C4#4,R+1(2+ %1I+"UC3
MRA!%I., :+)+XL71H@).["\^9OS]_4!MV.0#R..2@'ELS2B&%.QW+G!HA1,W
M4MHPM4='%XV*WV$*:7TRZ1QD/!V?0<-NXG%'U*4;[95IL+01GL<@(I %XN;1
M:?B!$W#1,AR\&&<'WAU-S+4"<V1E)UAMI('RA+>'_L2-AKZ2?G/0="LHLDL"
M:?LK[$%AL;RZ#"'S1HH:!5_'O@AW'*Z1AO6_:ZH7=1/+2S_B*/ '_><$B&H%
M&#\!85"_,\2_*?WD:',):UB/W(,T*SK]$RY=Z<<:4V>.:HB_V0+K1]%*3)$(
MN =L>>'KP)%0AW7-3^Q[=?I^S4$]A'_>&\ 3!HZ;U#)&GX &'I"4ZKJ*N&*H
M%'L6!I:SB7!E1A)A:?X/:_^6R53@6AJ0:H.ZCF2,K#9*M-72C]\JJT"M_8?6
M=-0 (!U'I-8>2D%KY\#CF:P#CM3PR2/J1M X9 B:(Q5ZIB:@["]5 9[=!#PK
MY<$CJH/ ^@4F=A("451F)8'"_0B_D)"\-PYP_XQ40N*?Q<R)0%>Y?PNU')PP
M-YTR[MO?3!3I>).)@#P XJH  O5H1WXI$A>XL!.-%L^XHS;&!&D-)!72!M<Y
MTL8"/PRA%2;2WG^V] =@1I*T:U,.$R?O/4.:%4[_]K,='2'4('\ P.^5"&I
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MJ\!^N@XS*SY3HBE?\!J,#>/ .TPU1V4,W@$>*^ZN;B)D=I)^Z3,G[L7@\,8
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M!\O?4^WS\BM4L<#D7O,T/W@DU&MD^_:U*Y?U+7W7D'UD0QQN +PE^YET1C:
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MZ,FBN""!DW[77E^I02UL"'])U9(C@WN9&9ZZ3! 17<#<0+I?V?>C'<6IP>S
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ML8$OH(/RM%P30_3Q_+8W1+M"*J?@Z6%$+J\TZ)DBA[P$[_-H50%-\$]7<,K
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MHM%J V?+\\W# OR#/;]/C3)DYX%+1@FOT)R6Y[$&@\L-3,/"1F F_<X456/
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MQBDA[/]W)9K^OKK0 W_7++QV<?="BQ<(+1K;_I-]"/'D-F).5 )Z:"1=\]H
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MI@]VO'>&CC:]T2<YSOG'ROM?<:(BX+6-R #AD9 DYM)S+@*_2XM94EV@ZM8
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M O_'0W5P+DV0+C[>RE _;^>C+H]INT-!%0I>J.' H;AQG<! ?_@[N<B9.*-
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M.2[4]&RX4<YE?Q)4#;R7Z3"<P3H9EA11B;3_3<:YB3-YX&BUSJ;6/16'O/8
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M7H$]DM$ KNM=,-VGLI>1QGMMZ,$GX$[RAJR?]%MH(?QED=1\:2\K^2/(V%;
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M$K6MQ)(Z6X$QY.)RIT!CB'\]*'!WQ+M>3O/Z3>SC"V'C/'KYU6M7&?@M^=
MPVA0?;@;A9"L.#=@.XQQ[@G[VNY^1F]O7K?(OY><$.<@4?Y.5EEH88-"S!6;
M0Q3201+B#3"+7P6^-[,74P;B[%B& 541OH^*O1AECKCK!%M1:/)3QVUD6@T6
M&LMOA .[X[[<^?37_^JQ3S3(!0^I6$L0&@_VU)N,Q:B3-1[@2V,I[3_X@5\@
MR>S%W"4O2B,]34FJ PHC-W%61@E>472@)[0D)%(PX"!W#9(UX<;=M; W/VF>
M(46VP""W-<V1\$BF N"^]<M5RN"^/I(#8S'WT$917>!7XD6ZVCQIN5"WL;MY
MXWLN:^5-28.L@$'*!#\5 ^9,]8+2H$H6L]W1OTS!'H.P-VJS0!:>M46R(R9[
M<!HA$=I]FG8V;571N"7"R&?,:M>28<M[/(?L;.6#MA0IKD$%_U)MHN ]%GA5
M5>?@B9%NBK-!>0+CE F!+++MY\P>N9^&M1AU%%*<BMU9M+',$)ZGVJ"4=:J<
M60M!8\Y4G%/*>)[H&Y[*<PX!JAV/8_@(Y =T7F[[[H/RK!^T,"X]91'^6YR8
MV61F7WZ_%=PMH48#/#.VG1%SN7+T*_:B;A%WJX%)9I;++HM(Q$7:-)M?:MF:
MWI4S#MR-PG0OT@P5MW7A.@I^HV E5YR4LPAYIE-1K7L$C6(>/I+EOU3[Y,:>
M62O,^H!J< NSIT2TA7:BI]ML>A A3X4H60B@"2WJFZ>WP.^#%HJPZY(3ICJ^
MM8RJ[EGRGJ @("0TB9)HDA=:6RNMPK ^J<'06.B9\\FNQ0HH#D 3U9>*+C<3
M)X\6KXV9E^RJ8SW.]2XH_,/=GI&R5BHM5())0H'L5ANKZ%G*-A5K,R!B%XW3
M$])]/@W<4I_BU7NW1.U^R28;24P:!4$%YZ:S?#[^,DQ)X79E^+,^M<U-S0-%
M]/V0&B*-(CD'7%1 O!U^'='O6.V+;MN[[+ IBZ0NP:B2?:Q*)25I84#7\AY@
M,\=_@G#'=$.[XII@-FK3M =V#% <R:T&WX?V)K=IAK*9<YB0^:CQ.6 (D\6X
MK#"2 &=Z;8'HB&9Z4[UG,X>>@+++QXV9K"E]G,7%S7]3K9R*I=40^1]H"^QW
M2D'7)=6>&2\K2$VN)E*;'/$00(OCI6<5]\?HBEJCT_@ASG!G#U:31;TX][LW
MNC.5<3$VCJF%^4>\E?BW#KN]V2A/=VK]#>5<0-R#D_!E^X-^F?[=&2!=TF3R
MZ];DHYNXF[6P'1K5A.IAWASK]ZYU?'3S4X:K @@:X^I/TW34#F$2\R;N9<E!
M>JR=^Z'Y1N_;2V.\+41TAP['(R)JUM1!"<SVL=8HN&-&B6B;0$_[I<62WSB(
M1/SA2%V6P;.-4$0*T"QS%:9=R<^"9^[@,K#)$TKTD8'C*DS(GTN%\<I(Z+GB
MOK%CFA CQEM&\/&5G?N.]8::1JJNZ=+7MG[IL\UR[B;P!&>V@!N7H@'FF?28
MEMEK6IB;F'[/]A5+_X,R:WM]CYV@$KDA[Y$LW_I$:&7,:1<@"8KHY>JD[6<C
M?YSP'TC)Y $;!0R'GBRI:UWB$F?O9"4I&8S\466*F?TS=E%ZB1F/.F7S1"QO
M8'PO46<AV&'PV:*"Q7J$]YU9(]JE4)5UT<B,"W?S-8BL68I05+G04Q8B2='"
M[C)_UL(,@CAZ++5%1"H-$XN\6GJ31..L3?,\2BW#\/.XFF$T4(7?ND#9, ]1
MU:9@MS?Z0T##'HGY&<E3XIW7QE75A4Z=TSZ ?^<7A2BCYS.X!?SWV-!!.484
M+P3\55K8.D7(6,RMDDKDUY 'O%>,OV:53'\[76[QH#64=DG)<W&9]Y"SYD]I
M&#CA+#!OH4DD")?D5#\)MAE*F$3SIM0(=/F8._Q(7QA<L5A>5W_8QL9!TQF[
M"$] .Q#W\+K*UF:,P3<J0@XP7[H+@H'\-RLS,,PR83/S"ER_4:P[AHM3DYX(
M1S8,((ZYHP>:&/#>3 MFW>"\L\Q2)<"D:F'3%[&NF \%##U%QYLL@Y>*3C@5
MN;#/] +.8(11FM[X[,:Y@+DX&?X!J#;#MM'$CBS.AK;(M 2T.3&2UW4O/;6^
M1!#A=)=:9D.P25H] <@<>AUUFO%ZBNPSS\M[%N^;'@D^T;YH8EE%8U7712/\
M:AW)U$]M KP5V'6C<92ZF;P)0+B:94#<<K5IKYDQY;SZY>P<8XCISY);JI#)
MX$CGXC3X0W^HN\>XY9L@R";N.3[>YX(B*HLZ<VM)!OME'O4#'Y4(^52&%C94
M$F8A-][Y]/&[?U+#?QX?%( 69MX%#3G>%7\P;YB>N;R'2YLT!QCH\>P.D <9
M\V\:78C^/TSQID.TTOP+ON9Z#!271<8Q:B+DF^=&RARI*TKQS323NDVC& /O
M*TO\^+J]V=/5M&E(%GZ]Y64R\%%I*LP]FB(ES(C&N"L5OM*QV6HJ4KW7;XR$
MNA2QQ DR?+,Y;2.N? 8/B-Y,7!WT808]5/[A(2>Q B1YK=25ZKV2E8Z>L:CS
MO$SXB9?*'HX6=OSV&C10,[^OOYF?L$!!-J4:.[44Y;XIG(Z5#IZM[]G>/&;)
M#<4Q%J7T-\ FHDD#"%=T!H\+M3 X1VA 3#L-K&LLK,5>)UW4PB2?YC%=8DK:
MA>TDI-I*M*Z#!T5#M19VN18Z#[T&=+E-M><<,!()8^!X); 50O%*+EQ3D;,F
MR P0#D_:RRP_IN=!#Z';M-'XU&11+F>Z]NF^P;.=H0\^^FZC:.+DW(YB!!Q\
M[[M"0HBUKBA!MHSH]U8&M0Y^D5E%7RDW@H,-Y@.=62:2@]6M7,X>'K6YB#(?
MX&LA^8:#O5>=IVZ<#7TU*]+"@FVR""I9"E?QU(J6P#5#G0=R\A[YBVDNM3T+
MU2Y:&#7AYO0 /U0+N[;:WE(EK=]U\M,MVM89,R-%.P]IHG@J=>FNP_$TGF?8
M6MCX=%?7HN7+ZL%Y],*1GO=JOVP%]5AO\<*PISNCKIL_CSQ?E6F1U*F%O=3"
M/D8H@WAF!;S9"*[L9)6XKG\/5[ 4QI[^=LC1];I_D"95$,:_JJ()O!V4M%8?
M_DPKY+]I,9@ ^/U:S#U:HZQJ:.'1EO+GF1@2&*_B7@#&%ZN')BP'->5<*TQ3
MEC6;O-W_*TZ.IN0W!R/72[KO0/RC/8PFG'R"G@X$4N.B]HK3FBF$UU&;!DI+
MPIAQJ:<]%/:$1=I@R(\BS>,X+>RJ/@+DG-Y.FS6GDW\6>Q&E;OTVQ:&F!YHA
M1;R8\@(S)Q?A9N$J)8H%USS/OZN\GV+F,<TT4DBQ"@I/6>ES&=0UT0T_O#RA
ML:]E#LI9<DE/91$/%POJQ3@K<*H#C82QX1ON;J!AQQET)RG_&>3\W+ \1Q_(
M6P ,5PO+#< ?).N"?6+"[&?CK%4^1%J3V0YVJ&;?3WVS^#.9D)4CZ946 N:%
M?_+%J;O*VR>51QM/:A[7;<HF9I_HGJN<VLKH5M.J1%B54P:C,U9Z=9#A+I@G
M<%5O9X+&G4Y >I:'C $=A1P(Q-QE+,49#B6U(Q/+JDXP72B!H%RNKAX$/X5&
M "TT@P.J,X&,#?AU7#R4*WO#=(>W2<$[QNE>(HI.%VA[)Y*IL571WAQGS1G-
M +\OY9;;P3<%U.+C;8<-QN97+_I<6)/WH@IB!&EK5D$.(!=%>+8#*\"=Y*-,
ML5-,PM/^V;"87A2R8#H],2-D["0C:7YQ"_=S[P#!EY2TCDQ[1X**!O"+:"L6
M=9T\9 \5>TE&3?5NK6E+K7?"G$[(3#H^V#!:;05!]>P+49\LDB-(F(4N^NP\
M@!^H]6^C^)4&G1[9W"VRLU)F5Y:S1R.+"FB:<U?BZD=HV=.I'!DU&/"W#1F<
M7F<A_HDVWVWJD#WPEE:9]UO&68EE\[##645T =&LL2%*SZUD6P-G>K5Y'[IO
MI6KD(A051S1C%OLPLO!"O];DP'1TD7\A^6 _ZC/X+?5GV8&.7]D;%029CM>G
MRFLAY2!9R+I@L0_-U\@A*[T%!B# F7!WHD*T_-?E79P'>CT['#%05C+DJ'\4
MF]6/Z[F=4#G$?5/AO7.!@O \;-&]N'=4V2/'J:06<RJY%M:!F;-<>INGLE)(
MQXR:F.N);DUI65LK!PM]1]Z,F=KSF]>@(@U9FB9'_R3:I:PU^ACJ'('+*)J]
M\0=$+OY8>EO#-2:?>A^%"$I'9Q3AE<9IL:;LHU6'S4@V]A3Y!XA86D2R(S6L
M$<\4]56)B9!;$4V[6TDS"62L$'^,,J)<6U-LMYY]L=>F3D-5\<'5YA]4&$$>
MRS= C%3YC5NVPF]'[9:LJA\[O'B?NFJ:S1PL9700\BV,JO*3Z_:A)R0SX3AE
MP+Q']%&"4(U7QYV+^6#GUFRV\[F8$".R\_&:-W5P9X]*YTHO4QX,Y<E'7A(@
M>S77ID&VN@3$>DTFD'9D% HB]/KZ2MYAA-:3+DJS.L2XSGWR*;%W(V#PS:PZ
M9"SX_!S:B!F_)>-$ID4RKM> DBB>P3VPX,K1G\S>7\_NI"_* *6Y<(AT8GK8
M%/_.U3#"R9I<,PZ_[[N[FV%S3FU]WYM!/:6XE1]@G!=#=P"E.+8I9BR@''Q)
M@0);;&UE>$SQIJ0CYZ.B@=OJU:K>T0_Q$2BHS.Z\$832+B8-J+!M*N0'AA;V
M2(;GDKB  OR$"'I(]9^CG5+@6HT]$V;F<GL(HXP87'W&T4PV>+9SQ0SD554W
M3F>24\2$L3UJM(0?D^ISWI8&%R(,R/Y!^77L9QOE:S-&5H9K8:6QJMW5=\&=
M0=S-BZQ[2\$TJEV'#Z(YZWM)<+%\Z50/E(HN!3';7"BT;=CR">)4PM$K+IR3
M44BADJDT%$XGC@FL@T<"\!V'V>^@UK+"))#.T\),%(UNU0J_,;?E.5L9YRA^
MK4LQMTN+16;P%^?._BAO2YR*DPX#V>9*KA"MP;R&KD*B<)+&1D*.,&I'K5B>
M:"M:1Y)Q1NJ#PK8W>+U6F7Z3#*+J:O39&A93VGLT2O1#)"+RX5+K&Q"":1(O
M4H]PJ(YZHJ?RL,%T_R1B,7RU%G9=N)_QC29.[>T08XL97!HXL!R"&:!!@D&0
M#\$Y?7K-K*WBY\J1Q-^? D^5-Z[BE@(FR8NRS&"GQ%^>QN_Z:RW:%&:<A^'2
MHW"+?@+?%3IJLJ5J4=0.%E.LTJOX>:F:[):HK4";,%\+J]?"7GA";&7-<H')
M-32U.3= :D<M Z[4O[!<>AD^ Z$Q8/7\7S^;XK>K#TNNY? 2_&1/^V?F+I;U
MJS&\68S*$4K\9PE?!K"[$FFRX<F2O37GW]VX$7)Z IW^E(&4^+>X^[UAF$B^
M&C%29!836U4'>!11//*:KTR7/D-QMB<9-I9A0B8)&7+,0L.KS/T#)]Z3 \3R
M-^GR)N;7'Z; G=VB,.'PA>#CUM<6=7O=?%(+[%D?WWRJ8Y-V:6&H:7# <E'&
M5!HXT89 )IVXY!NOP#<A*D;JD7?45N>+%8U-B)_K[C2MR0LROD:_E/TQB':I
M?MY6E5?SJ,<!AQ0I 2$:[$P1 +H+A U!$!6PXB5XC"%C^>7OU9_E!H47Y$[O
MLHB8?"++PX9#@E '_,W]X7YR Y3X!!RK"<2O@#YCF]JYSQ9G^)%(<V='#>9/
MKPOJCTB+-W"+)'JP<%MM6=M1:;==L!!IO^' E4^S[J@OC94<X-'B4+L9W]92
M6Y<B!6F> _*L;VY3]IRY%TX1Y(U @FX_:1RKM(\202(OBGIE;S>Z,G]NAYMW
M. FX^2!7'@$)WV,*?HG:K1?UV6,%<$)BG_%XVOA0R;[. F*);9&J<W^_O(V(
MJ="W=*UC9FIAX6 9.ISKB401QDS]CSWO)E,D^T!]_ SP&42&<G.>!OZ.#2CU
M54JSN^8$+RXF&""2+[.XO6_S7N++T/EB9OPW* +OE9Z?:TVBRKUOBUN1]T,M
MS/.7Y9V7K":I>I !HHR!-];J[^A7PM&'GOCS*'LTF#8INH4Z82'WQ@C^O"9:
MKB(:I^!+#O@JW CCF<NS\ U0SF-Z]MQ&K\L%FJ*0_-R<ZT]&6(7..NWV+"5A
MQ:N99)#47ZZH69VWUF^&,\GDW2!"S$$+4QP$>,O[-JHMM+"%+U6!%/K<<J+4
M^/P"K(!0!&6BVD^$0CK-UU*B$U=1CSG:$Q;IV6_I.F<]6:LZ<31V*FX^ZA,:
MI_0_9TJ+WZKX0M+#&6I<DM\E!_"8L5EV  8K-7 /:ESZ4Z56=K-%;\Q8F18N
M1+9BVNGQ;D!_=JFUE;N"&-*BKXC0PEK,-I4-/ O%/7<O=#9MD:OBR@%N$6T=
M&JEPXWD.,GD[)3MB( Y<!>2#/?5N^ J@AL'P$F/ND_4@:;)2+DFEC@V5($"#
M2.IL/NI [L=:(& D"(=2H7$,:;ME<CGXV8MJIC_E<N-KP QUDK8>N5#BT/R"
MZ-$HN&1?YHB=/+L];>G$?LBX.-^;6IC*'UMA<Y+US!83ZXB)53N3<L[@WX0!
M_D%ZTJ< :Y-<:9BMA1F[ED'TK+^3F)*IN<NLPM[*%?,_7.Q>Q,$"$4XT=61[
M8-IIYJ7!<@4Z?-!WZ*3?,4CIK/E/W\7)\/>X\Q9GM+"![WSM?#O$0Z#+?<32
MI-5F9VZJ^I!"<'!%SH:WD5O_,1]YQ77IP)]@=PQH\?<R3MA MC^?OE>3C9G0
M_<=23W<?Y&]OJU\31PIR!H4<<G]$=&7)8F9K.\KA6PM).[CD= "RJZZ 85"A
MLD_.%=2>JM* [IF%SF80SS*@'_>Q_.-B0-2*]Z'(*LH=E^X9H!(S+I_I=T4,
M8;A*-* *.)C7*(*?(48%FW&=W_.ZYS #'W9DKKR9!# R[$_7K__,HQ'<_%S,
MR$J-\(E.3/%'?+S7M?+V#UK8Z)JSM0#$(;\*B+@SXJ4@-*96)Q&X(6O35MYP
M98K4*JN;\; V-H@@ FYB->=4Z9TG'($G33C#>W%[7R15SK[<FHMIQ.EUY T.
M5L?48;9GI:IFGE <X3800?S@3K/4E)<4[OS\MRR#GF?51.\C[&?WW/!ECI04
M5,W6Y744<T#9J6*USF-!!(H3S(C+?G/^ERP7V?M!BYOSEG)3^ZLE$3L_3Z!%
M+Y1\SVVO9H=^V#IO,'#1OF!SU'Y*T_+LK?B2' 7<N;LBG'UUP=ULP/V!O/Y/
M>]?-!ABY[.J@U\*QE<<_'-@P_O'9M]B0;5=)55'S+K@::6_%W]\X_JN'J7P&
M<DES"E\#A<B,P#=!<@!T!0L@A:M'8OV'/X7T*KJF$0WHFW65]\"N*]<V[N6]
MI':$ LHK*>U$OU',/5O$BJETO<F47,7MH489\\*+C%,O;D^/_0#<0D/TX3IF
M-O/F24_GA@O3B+5DI\(KLIL.OF;O)Y^SN922"DZH@?<0I,$R[+=[*-Z(&:QQ
MRT:*6Z.1%!?D7[C-O!.^U"9SQ(#M/G;K/WN0!YFH9R&R0]?'$%OQO!<=673E
M:M)?H^?/.LC\=<'$9VVPO;4A]H[[2_?DP9PD+&$;4/6WVQSB-BR=BG[52,@5
M/#]P_7.OVNV%V,V_YWW$:F%^D/&SU>CWY+W^LB ]G0-E55*P;V(HX+TS@J;1
MQ$((5COP]->=TV9&[#"W?6W7*H8=ITT/@.BDH)-)^U@0]66>"@815^QKT_%#
M4^E.I3D$G>0O)NR/8:]?HX5<0+_]\/37O5J8CAK94Z<CGD5]E_/L]P_8E6)"
MN-3B 3=*'@XZ)&'#"Q$ZC-6*R-'JVPO#"+?G9>'LA:G0:F;DR431,1=W&B,4
MEU6[!+D0/WH!,A<<HIWG FJO+IUFF<\0 I.\9\!)5LTYH(GZZVDSAW*Q7.8^
MD;6A1EPG0J?*-AYS)1#J[3%+5KFL\=*E>-@$6E^MWPVNNP)<KI0BZ3;(:Y6;
M1',_'YZS2!=J(G.;7%R2)Y3FRQ2L^OJHDX$6UA17?.Y*NE-+&4&.'&FW>$4%
M=<HI@<<]\[]^3MXK7J0/J4MT#E!5?B#F9L![K(RU-+L\(T76 R6X+U6-7/%]
M+>P"\/,4\ 'B+C.(P?>49% ],^B]_N1G#ZZ+58T#OHB8(VG.[_D]Q5SR1D*>
M\_;Z5UK8<\@EK@ADZP2G0??B;[T:F5%M'AV)N4_IQ[ZW!3Z;<OPJ/.[\TRNR
M7?E Z[3W60O$5:CQ"^3%*"?C+JM8GZNS?I%$5*SI%MSWPYB7M)E3\;MA'75B
M=%PA\;;I::%+-[\O6 OKQ7=>3#J'!<=GN#\-H'0>*_).5M7U5K@C3M25:V''
M0T(N)K<3P/':90_"XL63&6/#F)F(J@R_PD$1=V+$ZQG$4;EP"%W%!:%T!6Z!
M0O)H ^ "=@ G[,^=#SAGG\UE#!M"#&/;]M#>8__[XH__? &(Q_S_H3[!/U9Z
M^/Y+22X[N$*< =;47P@STSGKV/KK@FGDF:I>^H*/L>K$<C](4#\^>D-1-I=U
MX73EABF$S44A EZ!T!=NY*3F/)Z*2,WQ!W/G)]^NF;/6PCZ&NR]29JQS>M$]
M_>_;0\K;I%514G^YP_)TG:QXKUM'N(WIP27UZ0?]_#X/T,*<"BW6(*"1_0A^
M<L\+N,G!9\J\KUA'O1?M4^[ZI$S4PBA<36U6_,^7KX"KNU%[\WU]SUQ9.I4P
M^40Z?&[HK(6!+\ 0R*>K8L3,1C.C/C0W!\+N]&"^6CTH^,7Y.O3?GY[^M+[R
M<]T$XR[AL:JZ5$Z_6X<3Z,+ZW'4[)&684-*\7>2MP+M5LGNZK!W<$SE[P=[?
M<PI)USN9[[CE*M!?TA^]/G#5I=;;MFXE)R;G(>S(FI?HVY3ZMELD\0SG"!2:
MT[G$!HZU\]SIK\UK7KI@,_Q%%BXJFA/NH/&M(^/0P[P+L:C:^/WV"9 \);9<
M.@ ]DQ8&W7L;P*T]HT;F-F_>67LMP]B;)<LWG"E0U3 9M%FU2-KW=F?O5YG(
MUQ%K;Y6>FZXRWD'U*_ %Z'55+P[/V6"XH>ZB0S&C3CH-<KA]QM,K2U=[]KVJ
MKTQRWB%7B>:W!QT_]/ARD-G:;C4VW]LWT N=4N![5OV[^S\\DODQ-P@:0=.H
ML3<B*%\H%YB*^<@,B^098(Z 2P8'^RO7OW[W4GPH+FSL[L#V[H4"NUCV!7Q]
M$J74%A)JW*A'!+'*^;G$7/C+E724<7,KE^FV/G$.IPHNIP0==SNV!X4=G46T
MG!8W%D\MG2[3>R6ZA9P],?T#5R5@E *7AB@O3&CESK*,T/DMD+',<7.6J@U.
MZU_?.?8\YF1Y.F?Z:YN24L.+O[_+NGC#4A5P;(08XMZ'8E6<.<.:=)9Y2A^[
MHMJ &I"OV@ EY:(="?XV3_3&SW+:29>I*XW0^TG+WYXH^LL#"S3H/]7"&HYK
M:C34'"!X9E"FA959<F3  ('I%7ILU>6"T03#,STC#5*7[KEB"]HL+M@NR94
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M5H%I!6*J(E+ FG'XFO;13!RK)CRKGWORD4W)<3."Y06"2@O;#N'PO>W5?:%
M=+L$#QJ0U-\11H?^6)BA5+]+/NTV&\=L5X)],A><.:"QS5[2PGJ8RG7H5PJ\
M9%7CF!;VZP+7X HW$.SL,V3=Z<+9X)CE<Z?EJ5K81SNQO*%^S\'G8DS#*WC\
MZ8@),QCUC0<EWJ3M6MW+14(EYI'L(6Z$!![JS/)71:(C*L5RWJH"B?<)<6=,
MDRZP'N\]I';HM3Q,N%8Z2D*HG,%F6295.FQA@EZN<US/79Z;&(L(4N*/Q!QC
MQ!QB3];5$F>#2T9)_$=:6/CF_\7>FT<UE6W[PO'8H*48 942A*@@6*)2I0@E
MQD0+%9&B(G8H""E;I#.E@ 1(LBT1,2*D@ )*.! 5,2)*I!.!D!020$2,]! D
M(0E=")"$0!J2['P[YYQ[[KGWOC?&?>,;XVO>>']D;,B&O=9>:S:_WUISSG65
M2I2(G.^"IG+/A"CTW?G>)$OV#?Q $W5E='#W-&X'+=_'XYCW&=O>3_P9NV8[
MY@>Z+$$03:40%M,]<"5G)MS<DWZ51D2SX $A<0\L<Q*GV?V[)8,_&F!B+Z@#
MRF$%NMI#%7L;TE!E">6Y!SWD9F_6B<W=></+D!8>VO?39F!4U L20FZ/VO*6
MY1T?>!0^J:65 15<ANU%FOR9 <:DHOGT-)(UP1Z"/+7 +7_3E-0"8RRU<N6C
M^>Z_.D>'+,HN"@NKVT$2&6 O0;BT$"M?6ZE/>8Q_UQS4CJZHJ#LAS)MZ<4Z"
MB;?-+7R7Y5N#;(%_DL622RVF<>DO $OG.;D%9@CUUQ[49G$-G)UB\:X*$0IV
MRQ>_ZIXJ8>MYK8&Y*I;.U.G13#YSGSYC*CJ9OIZP*?Y]M+,C)J%I;2GC<Z"G
M#0,=D3!9I)7F6;1J\X-E)]%5TGM@MY!C'G!V/(VKSFB8#\SL(1>AE0]4*@H+
MT'EW(-*0==2]!A@?V.SE/86X%(LY@UV-VM!'V*P&7JBII[5^RFL4$RHZ/?\2
M%0@&.5@GPC7U18?:(O"S[;8PP-Q+"%\1:G6Y]Z[CW8G1[RZ[W#Q=R^NW,,:8
MO6:%ZIV]>TM0W]'(+W4^,<9] RXMT;S-^9(!1K[RWC5V+SIF.#8_ACH*_&F
MW;Z%:E0GRYT/JKT%3J]P;$NYN":B]BEN5T'+Z%[=O7MD!8.B9Y><(76#\.0&
M*1 %;BB=D9[O )LC!9(^Z7 .,+?T-\U>_L=^W;)STJF,L.C"1IFTT0/#[*K
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M5BH6(-0&&$ZU.#P,.[,T5_^A^;^N2C/###"+EG/T9C*!_BNX*UH_8(#]S#/
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MRL@.<(/8'<Y..=%$#59'H.\/==$[>N)3S.<<#B:JWMW+/RBOG?0TYL#.N26
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M:Q?D\5Y"]&34'?V/ZV?HG0/18WD(63)-IWBT O+3_SHR%6B!)48SYJG;)#;
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MH@>$P2YG>"9-U5"RJ"$06KR0'FOFQN3PCAAC:@ W,B.B,(1D(J/>9VZ$R!3
M9N[LVO:TMX)N7C@X5U=V1M-3$\7-3J<RTR'6BFK3FIDGZ0&L4N8]"++H(Z@R
M&2MEEFYM@(4 E[ -1#TEWC6;6 X&3F=("T.\G#-ME7JN7QO_M6MM,$WWM;J@
M"$)U=(L0)>G[7@=PP-KQ+>-@OT)'+N5#ROYK+P4?+$PME >?E#LDA D!*R\!
MRXJPO4OGL=X-=$HZV:5ZFJ;91<LPP&R#+NPM:$"T0/CBY =":94*4/+.ST@
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MI4I%YZ>R6!T;TB]WG,8 NSE+9.ZGUA +?-)/5E((G])HVNB9W@?H, P9*ZM
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MH!SE):(T+E/<F3DRBZ\U\>PC1P.%Q;%6-DT>S29^ :O2EK$GS=P&PK+?1PV
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M#-=*L6V=(K6=;"DB%Y- [\")$ NVOR)>',3C-)#3HN';8=OKH\R[51@(:@U
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M>"3VEIX6J3T46(!RC/<%.6J#:?Q'@TFL3:L'*9S(U]4=82,-4;Q/+5Z\MS-
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MU8Q>[.K22.LCRY=L^G=:Z-Q_!&V<8WYI<[%F+LLDJ[BTA!Y?LS7DW!X5YFU
M#EY?I]V/!BS*-TW()F6\!6[.@[LJSL<!\B7(X*W?IZ9;8ZC#_<>D?R"$XT+A
MO=E0B4J]M85;_+L^NBGG#RBO(K0I4"@!/L:&E\<O&/O'VA:A@N57QZD'_[#?
MS'VO]$);_Z-Q\Z^-_TLZ^G=MO6EM&3 P]Y?TSX!M_A04H-CU"Z^B_%G&@0Z
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M<I0#Q>3UGO16=$.+^2KE&>8UT;/SD]<;SN?G,+7<RB*9YQ-"E*NBO#\HT>!
M17^.-;\P.-:*$KV9FG6(46G;PS*ZV[A]FA&5>T']6W'**N?3@>US5X,SP346
MHR4R7A':Y2A+G*?"D6N1D&2\>+\*%YFL58GOU'O?H16UJJ"@86S@:F!A(4:R
MSTK?)I28* V\X$3A5+90M-PW#9 <S7CNY\ISRV3E=-O7C757B>X(O96BXT$B
MP;KFC%T+GX1L_?@YQ^W(3TL1!QI>A;OC+" K9[JI<%]_97T98#^A7.-/.*E5
MS$\WR<CB1/&)$'$#1E881;WDF"*DQ._87]>IC=@)67 "L!!LVS2HPNVT.M?V
M'QVEASM"-_OI$>[0>=1#>]R1_( O=LC)#=X+>2L=R=1]=:S2XR<%M<<G=T>\
MZMXM?V37]^UJ@&_PTQY802K6#[=2SJ!WV%J,/A3G]'DF/0&B'_((X0_61$8$
M9V3!H2<X^CWZ_%#; ()WJ.OXB@+=Q)^M5I'4%4J!Q34C31FQA[('P@42$JF\
M)1<\S=:&#W^>M-?HPRA2[-C#,N=C7I$"C(,U;B[31KOS5#A"]T@MZ(^'C/D1
MH ^Y ^B[7"!@W]SB2EYLZ7Y9HCD8 >3A:XMNUFZ/EMNA*EP-C _XM$\#C (Q
M*=FQ1UX)%E"NE']/[3LJ,;FQ2ER?ZQ\28%_7Q/<DK%7A+A+D:NM\Y4<PQ0?!
M;R"\K!?Z(ED_0I+L2#:ISOVN;U_C'=.MFET!6Z]1[J>=:V.:R#O%K'LA1^TT
MUQ#LP'F=L'/W</C,@+WFZ[:>TGDS#I-E\M*S] ]D\5X 1V_JT1#?;X0]6LQH
M+L+7W4W[&DO7!(7[9=1@DS*G "WIZD>-OS)G +UW7D -]/4>U":.J]NR>V)V
M]29JJ-!%QR'%M:0T&5#X]V>)%FT<^GR9=1))!GI?@'-177@Y="1S9(L*M\32
MY9#@?=I='5W'J)GKTH<Y<_"IUMQRDFBT;S!42)P#5CB4SX<L9#>A&Y(9^U]#
M#0+D4'6:>8I;'D7+1:-]R@,09>2.Y;&3$+03!=ENSHM2PO:4EL)LS'[?8HDK
MW"G=P52V)(.XCZ).R7>V,JXRQ<XJG!9\L)EN/)*$U[[+%Y"K.IN;>B5K(N/7
MC':4UL>S:R\P@7&X&DL-%TKE,C$2>1JY54":XW&,&D$X(B#I#0WN;PBRV=#S
M40"7I30(P->#H7A.T9YI4,"%ES$K)!C&=#_/?@15590OE<@RD].20,'9""N_
M%7=F]\:GXONU3&XS^- TKYXI/D#I$%7Q"Y;E"I83-C^C.;5.JG":'?4)'E#E
M@$Y)LG>@(GZ50GL\J.^K:;I&=!VQ6(M"=PYQ%\"*N/-'5K[:>CP,S_B]4'0_
MZ3'0>X6\+#],%*T;=<4?UGGHSH_5%1UN)CBN#Y%W1(D6.GP+7K*,(T'Z],LG
M?()MN3<-ZNM7F)26EE&_CP!:=X\K%YF.8(QR#7\,% .R=6FD)5 R7WB$%U<P
MSSUUTX09L:<CW&*T?FAUR,EN//C!AIM+XTG4];4NTD[<E0KV]I@SJD C69/?
MP)+F]&*E",WJ5ZIPE]Z(D^*\CT\ 84E-V171=^Z29TOA3=B ]W%0_3R)%+V!
MCP/$W[Y =>F?DENSE*Z0JR#X9GZW<Y5;YLO<X\<\.SVR$@B+ZK"[R:=%"_)C
MQJAPDX?I1ACZ',"0]EVK 4/"J)ZV?A=NS3'#("7I1OZ;MJ#E%-%XVK#0Z0&8
M$,:N5X_BT4N9[P4-??+32ZPS]?2K:!=9?"#606:(9!A##KWX&= R?&2/9G[D
M1_F.-XV+TENOWW8TC (A/#FG'$T4\A< O6F>&JWE\[YB44LTA??E08Z/X!WL
MWR OY\(F_ '0B.V("DV^?$&F1\LMT3;R*^^QL#XS@,-<3-"1''*6Y-^M^2[7
M^V&M1EN0\<ZV*]WW@1F_2!27POTL=B%%H#=?_>3H*AT/GQ G59L>@?S"K6'#
M"2B42JY[%:Q8E>RHWH0^;)$*-Y*&(",#ZH='5;LLL^LW*R^)AJ2P5D;N^J5^
MSAW[%D>UW;".!'MCBHI4N +76W3=X31"T8N"!IIEN7%C4+[ZT9'Y@*7T-KNF
M08ZH<,7)!>IG1_>@@\SO1E'C;<I=QRRJ@MZ$$Z6NX=_(4QB;:V-7N:AP '=,
M3J2'M@ZHQ6"4."Y/>012X=Z'EE\3:EI7A;*NL 4+/YMMZ(T+BVA[US!0FVD3
M/TV9YEWC*LE43Q*TIH550<GSY8L3'817GI7V; ^/JEF,[^.S0: KAV3-M+!D
MMJ-D)74@%TF:XWR7P->1@AM"P(D+7J,6D EGE&0]BMVULVR:80ODC4ZT99F?
M8*P^)]/79?;U? O"'&7US+@MEUGW45.PPHI@<5()0%'"X"K\S;OLA:X5NJ_<
MJ5=G-NFVFCJ&: ]$R+_ 13^#G7NF;N(A4U&5';[3I$J]5<$KVDES1@9, .?6
M73C_X'A_J7([QE/MRP>T]50X2?W4( 9!%[A704WV:6 9S0:R$(!ZQSUINYH%
M9;PSO Z=N+I%#3W+/8P4Z.#=1.Z^-)^QLF?%"H1/^OTQ4O"NXZ=?-*;+Z!;P
M74 +*0T='%NJ_ 9*D'&0-\9B[SCZAGDC(DV8$.51T,*K^NS&T44>O#\9Z*B\
M%ZX<&61WZ*!S:@4 #OVT'SX,@9)3/ YJ4,A+V-YR0<\E;&ON&2FA# N#(;T^
MQKC!U)CZ!3>.()4W=D^H%>V<!34$>K@+/HA_78<PM3H62[G\LJ9Z)7.,=PU>
MB!3!Z\0YZ)QAHDZ/CVU<MG M[.,M)*WJ)8W6IISSONH8P5<_.CK-K.@IK.#\
MD+&\0W:B?"#U2YU\N?#+W7T',50O&Z>,<Y)4.&/[35J08=&UT@"QO)J7-@LJ
MSJ8FD<4#MZ8+VTL-@\X\YH^Z*%>5@MVO,5%)]W9KD@2/!BD)G6#%VM(?^J(D
MAX9*WC77&=$-7;[S?M-BL05S^6(.J9>T64X/1C:S7'GLWD+V=ZSG\)'L]^SE
MSTTD9R.GO64N'SN=TH<L^D<-]JXS<:4;[ ,7)$[PJQB=V@)C]<]<;4709HFV
MH^1E:ZE=2$#V.9ZM18+L^,#IA _25'ZHR3T3[L11Z[KUE5,VZ%85S@(I^QR
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M.*9L$RY_,7?Q96DY^8^8R?GY!&=,CWQXP3@?.@+T'>95H?H5HG5E@LWMRY6
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MD:D;GR5X]V-)<Z-R>5%:#?:^<1<EW^1N5N'J]J]++?1#K3NLW'PN.I-:J8%
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MO_ZA#XGV[0.&^F%IZ+,#>H3Y<.A-=@6 Z')O*J-4N"V?70<O\(;]L2$TH22
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MF-1$WT,?0&'&:5;5=J.":.O4K;'I#9D?C!MGVQI)/!-DJOA20.NWFPU$W-1
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M$:Y_HJ10=E_P;GDFS?>@B"*AWE0<#Q3D1P3:Y1;N/X:<K'I%-P3+7MG].IA
M721%3!$/(B?X,HHDIE5A(X'4 LI/9P\39$[LOIHY,ICU)KV<V Z^X"\P1$J9
M@@<[E8SC+_.N/^,>5::B7]/Z!;R;"OO@[#-^88.?=1.#7]#H+<BIA8#6BKX'
M;0<!J74X9,R#%5C^N%5)D?RNS. /7:J/"@I,ER7(@QP\VH=2 NVUZ#.@<;C$
MUB!+48H.']^P6/WU9H%P09]S*)PR]]5($R2[ .O2HEW0GE8A(- O+^<,LBZ
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MB+-J(9WE^XW)1T3Y<;'4G(#M/BK<7&GB217N4-H07T(U\14:DH5_^T?VH6M
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M[ #SEY:/[\U025K-_VN23.]_B_4WXM]:;U+R_K^U[/^[]O_--2PEW_YT HT
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M;NT,_MQSFDYME-<#JMD XXKP0.G=Y14I /TO=J!\.ZN*".MJ,=MT1ECZ2/N
M4Y4FQW@P5!1O;;Y=(6'MT8_V[OP]2!4/;WK$J!2!Q 2/%R&H1.Y834RH(,8
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MT\ WY6#B8"3=BA4XY EX=]G2SQED!:MH6VH2/!,4\CD85"\2KU\4+@:=)N!
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MG][,O8[_BK8Y!-K45RDU#_$I:'%G(L@A:]_;/H':HVIFE)-N69^O?Z^<O.8
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M4"!O,&0I.@1)-0!+]+,P-O'9YV&))6F?9 7>K8!@MZU9)[D"5'$YP( %M-)
MJ+6O"\P=\Q(LGZ_?_[.L]WXXRYG0E&U!-N\-[G2@/'C^X^P6@!MU5S"]A63Q
MB/26ND&('B *Z;>A'05Q=FRCZ(6>YI[>K!"X(J7GAQ!CKUJH)S24/#9"<+Q
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MAB-\A/G+A:[Z=$6T-AM6HWS\,(-H8N]>LK_)W[)S3C^JK49^-,A+T-]/,:<
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M]ALG:UR%F1WAL#3Y+?0$U.%^"L<_5R\XK[H[9*P22 BJL5,FB9-[PKXI*!"
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M-<(T(%K$-#K-H1:34Q6];]Z<!;X[--=^TL&%/:(R=S,/SC*"?-S\4 WHWQX
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MX?3B9>&B&Q?]:!E1"HO/VO:Y-'.9C?!]KOC$.#AP3YB?W@D/OITXZNY\,J>
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M,U[C)+L;"BS0X\SMJ0>^]X1RMXY2$W6%)CS'6D"E'+&I3C_*;-!?ZTI1]\U
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M;$^XS&?IA+EN:"R@3BC!;N$BXI;#C<]WDK58X8[G6V]EDSM*2LH>&AUXE^4
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M<]M(EBCX71'Z#QC-]*PKEI()OFE7^0:MAXO3MN0KR=U==W>C(@$D1+1!@ V
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M1H$[ -UJ\"U(#]X!\WAC'OS7UY5KS^_O]:(-;@V"SJ-/HVZPZ?J6L -UJ =
M6YW]Y:%-PFY'J&M"J.N+.E6Z[<83JOUP:-NK@O:.4->*4-<5=>Y5R"YYQH*(
M>Z<LB0#8Z78@DK(7R4;'54[_-44_1SR>Q!'\,Q5HI!ZK!L(Z(-5&J6D[I-H,
MI-HHE6*'5!N"5.LG_@;IA;_A1J2(EF4E"E2?/@.P-EF1-X!EOP2P[-Y6 $L=
MXV6 I?DYL+@Q1E%B]^M/R<KGSK\J+KYR3!AX7H"1&Q9^9H$WC([9),A8^%-B
MQ;VP^&DQ9*?[K9WN]^(XL<FA00-8_9<$UD[8KK&P70TF[(3MY@C;U6#(3MBN
ML[!]$9R8\^CNY,?:R8\7<@B5,6$G/S9&?JP(0W;R8XWEQ\NZD7?R8XWEQXOX
MR.<P82<_-D=^K 9#=O)CG>7'2T76ZNW#1OM/=YIF\?C/078]XI]8\I5G%[X/
MBT<WGQ-,"QMO!W)@/IM&C"N71PS@)Q""<N*^=_[5XX6ZL1^)%[IZX<O5R6>>
M7(U8PBMNV@MNX6:JMH<+4/$-R^)Y8- C#RB!4+N]?U7YVA,>Q>,@6N+%;U(\
M5[K,6Q<OBD]4P$']<"%DAQ^O7@JR\*J? ++5O*QS:+<T+[M).-&Y+"V3'U_R
MFR#->,*]DR#AKJ;SGX3!%8&R+#][B. =8)T@UA@;K[T?Z.O!51%WGH6K$M6G
M]Y6%?8> EJ>!.1_!WUF2,'7;FX[<"S!,?5PXZ^IQ:D4>@-V-;ZW.OD29P<[_
MLR;^G\TO+MBATAJBTF:5%$B5^W0\">,9Y^D@DOI?G&R9MZE*Z;WGV&N!2NM1
M2)";R$"4]RC)!-( GGF*EGR/!-UYP-;: [89\O2^NJJ=/%U'>;H>3+!:-6OF
MJAG\;7<4C[JZ=3YR),VO'T,7A,L5W"\/SP,W#MD4I0U> 8MFVX%FW^-8#X/&
M6B"=O-N'*7&$ L^/="T#Z5J&._5A8%:_^A)Y/+E+0&YOB\:W&G1\JBXZ?P_K
M0@BMAQ-"2WIJ5V/-[+COAG/?M17Y54CG\>#/]],TB'B:8@-7YFZ):S?O]CGP
MO 1.!W:R^"-G7?A,Y>%W>*17?Z 5L@L/[%#F@8[@'<KL'+[:2_=Y6IG!DH>R
M)_"?'^"B:QHNNN8&5Z06_%;-A_NMFL]+_L,-!Z^1PM%\B>"KH"V34=J]C01<
MB<?0H1[,8^S>\VLR_5R3@;\;_<V'MCS4PY0 .OMJO=>3:<83]/%.\@2R;5$'
M/F./RR2;?0Z!;X#5JH_Y?C:O)"R Q5JH"VNK8=[C4?G(G)A246<:HG %%[X?
MN/QLFH#" (J$]"O.ST'XF3"07"X/ ->/="^B)^B213<\;PU;N(@=^NO5GQG]
M"_,Q=NB_.O0W+V*'_GKU9T/_';+_ &3?(6!9M_W(6<I'<>@-QY,DOJ50QY9$
M*Q^EW]X#CQV2Z=67Z^:R,YK6TVA:6?>.G=3;"JFW\NXO.Z&U]D)KU3SFPDGC
MD&=<P=$$(?Q]'D?^-')%8PP@N9]92A';>1J\?AHLV[F&-U'+>=D>,SLM9]NT
MG-7T*-II.9NDY:R$Q^RTG)],RWFQF3.@3M45EGUBV+_D. RBP&5AJ8W*IB/1
M]Y*\[SW\ZC%"W=7+\IT%0+F(MD2A>212Z/.O'B]6(X\6P.7Z+OZI\4*?_V?"
M"_NPN9,@&R!!U%T];_+HO9U[J##Z8H)ZUW:@A,ZTA_6]()QFP2V_XNXT";*
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MP=;S@\L_]#"GR],/@\N3@W?Y5\:@)_'E\/S#_M[9Q>7?X>_#CQ<7?X4/\H<
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MZKW>+F%AU4((Z<./710+-\(%J(E)ABXU819T*:1#068BY'^/;"+?WS05=E6
M^<+Q81RYU&OX*-^1:4T:/U;Y2P4)IQ*:S)!*)35^9V= ;V"C 1R3F8C0\M1@
M%:H:T@]XZ&TV'?8[;>[V;*=G-_HMWV\[K-%U>:_1J7=!;O*=(V75="CR=\U
MUZ( H1G10R<D9XD[JBWO(ZP@"3->J!V'LI- L5)LC+V?F>RYH$NS&+96T(%"
M>(RB_4A1L2D/C<?(.T,U (4#JO;PU/97[\ET$-7*-6T%K98D=!A\Q;!&L;7T
MB"5CON%$['"_WG<Z];KK\5:#<\>UV_5.M^.T^AS^G[\CX@T(^BO/_@+RSH,0
M7+CIII.)[%@!^J^.^A&%ZW3#9'HC'H1%2A)5DX;PVCE<4@+6@8I^Y<4M*,FJ
M*MBFFE8QC$FI3_^:HO=2R'Y?O-S(&50+@ Z--34&;Q&]68D(8(E0^1[E<C-
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MR9KU1J_K-'IU,"([O;KCMCC6@KJ]5KT':+]#\R>C^:(F6X5X.NC:U%X 2[F
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MD:V /U"BS5)C7D2JFHRS58K-(^N,HFH,F_O4)$XLT!D<8(5I.L4EA#@VXG1
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MZUA2/ DW"VX39:,H7#9*61!#3,2&+9) *ID+9O%+J2.S+IDI#1_(4ST*@1+
M?A3LLX48+\4[7 !J3OF\UQ$);3U4#B4TL#CJEHL/24E/<]F+8A:=5!3* *T%
MHRB*IQF&5RTWR^<DP./T FNA6F DGA1U@X(+53EV]O<(Y:0WIB"7#2U_+<7.
MTI(9;^P.&% *1,[0.9>1%U]8O19(8'%<S%P&?-73N(&1R &> "+TS=7D,VJ
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M5;^7S;6DOB'BAZF:EH$^8] Q4/>,)S*3A&&D0-R(XMQHM-ZS;\UVS$L!,!!
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MT("Y,8D090.6!F7 P2,)O5^.]O<&N2]#S/@#1B*]2;DQ,2Y&_Z4HG9,#8LP
M3I91CB(UR*#">+@;8:_@$-.D!4_!>2K1#:<![:2DR-G25(UM3!ZMNB?X2(R\
M!D09A&E<J](!)5]7>_*F9(N*(:AJ&@Q.Q=:.LQ".D;K .904--D==0J1QX5E
MIM+<+>],OI0\1Z)##PXU0ZLZWT)6GK8N-KV_QR,:.J9@)HQ"6DJT^C%M)VRI
MI<8G+#A\/F<7E -4=&D"7YJIT0IR7;7!/.:MQDRHX2K"@466+2.W%08$Q:S(
M"FM2NFLTNU\+.?E#/5S'\UX5DKGBP#0A40D=J78)P6+X18U)2&95J9J*2;J8
M.7_3Z.(4T( Q,)Y%5TYS\)3J*R751?.]!3<GK@PX@?>63XX1J%'I 17.(5)>
MT0$,SZ#U-18I=8[IP]5N$6&^:,>=8(!S$^!S1^HF>?1J>1+4_==9L]1DU0D2
M628G01;<U<J?7D,++!['PBV4DKX:S:HFVN<P(OX/#_US"K(#9W(IUQW9((Z:
M,EWE1U?.*5"W.2KFA<Y?JEIS5LM%HE0B#(V$9JU$Q%RO,KHQJP";(B2TI"'T
MF#-/X@)."PT>\5H@CFZ8)OV_]T*%\)6T"FUZ*:^=,0]2FH)R?H]JAK"N2)>S
M'#GU$%0@I-,HI6F].')%>44$+,EQ0(Y=A+BP(=&IB5-5R96QOS<#53 M$"T]
MC^!#+8N4)-0KQ< @)F-&&?;HIXEV<JC0S90E@$!<.DCIZA?.%"+.AH'S5$DO
M&F59&#:4@K;E34->=LLN'-*X#$:@<I>2@6I,"B(C'R>,B5EIZ%H7)[?D0?0@
M,;6D9PYQ-7K(B 7*:*S1EO2TD@^$9OPE<9J:#AM#9<)1NZ,XUJ/)X6TQ<!LW
MJW+TD'Z@M!5AM,2NX$YR&*^86TQN!].72Z-YB.7(N&PX*XXMQ?@:\'>=Z% S
M#TOW-A.*8^Y_CI,%5> %34\H(:;V(<>D(YL1^ZNZ54.\ZHF$U:&B!&\=OY;4
M[81BT*%"8G&OW%"8IY[V-=&@M"KMSIB B&&'PBPDG/4[KQ.*\ HZ^<;FI,0Y
MA/!B6CSBN!PC.:]&+1;&+(+.:VC8AG5<.>'PWG&&UA+3#!%WYXP+U4]?:+0A
M/$A^.(GO1-,FTI2R8U(<.)TAUF \E"@(95^0FE.^Y;BZ@"N#^0B,VW022/%0
MF*"9JT!D_Q4G:**2+Y;4XS?U3,WJZ:.&96[,M4K!@F$)F4WRJKY&."Q[Q&5\
M95ZLW1%E4<12#G65/@RIX@FOH<$Q=/ZV9ATBQ$[G(W^JTNF%FRX1'C)Q/XH?
M5O/)I&KT"DW7E"/)"\.\"J%SH4,*Y\S""*P(<%'#7S VW)$!D)I25(1E-\59
ME06=!;UYY@<X1D\XX''4X028I&#;A;EKLE$JF;_+28$1A?(=,!W1U<J4$2.;
MI8I_@-I,840Q+@\9E"MLMZ3@+P.E*9P*ME7*#RAMBUE&N*%Z !IY\6OX"LF^
MA?@& 3 &JVTJ&69-8TW)EU\1Z<@-XKQV1H84A$#!F8 H7+C1VUEN[J</NO5V
M0;=!-"OZ&\IS"H6^:$K/0KJ!R7A<,:HQYUQS-B?Y4RI-U52IL"Q(RGX&X0'*
M4,$ AC#EHI&9)GM*2ZH5%;:"C5-ICXY1.F5 PN+-23QCH1CK^0GH.09=B;32
M!9:U-/ATU$UDL=!VS$,7:96$)4@FSLIALCRM2*O]B[FO3"HSPD[DE9._4^$?
M$=L@ 91QN$7XJ3H0[0._K)7RLJKOOB*U9,'.RH>0(S2Y51P;K5-#Q$9X*D>K
M3R,]9+MFV",(?N2P$6QJ' /'1'/%>%*\(]%)9G.Z"(  UJ)H51J[03[5VSB&
MZ<NIW7/K(--?:G3EO:1,'P8T>?.-=8C)KII_AMQ'AM*I='WI5%/QQL?]KXLN
M1J$3EPPT&4<N(<;;M<C<7"G(R D'O"AG#M-(S]9%WKC@)#\1B$ 1 X8@X_;*
M?66$D^#/"/97'!6,VOP.O=XZ&+N5H0ADF?=Z!)6A,D^G/ST<31RL )WP4>W
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MC#AR,A9+89;%HCXB IEZ0> GIB/<Q<U:).^@<[XLF#6KV(/%D)E>$SNLXF/
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MWA >=9S],#>/0U.T].>'N(HQZ8$#TE23AZ=-%NCPB^/S'II5@7))4$=<0>+
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MA-2BA0K R%APXA';^S"HNQ)_<M]"[(^W#.?"U./]:G^\F<&?G;#J_L$ 2C(
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MEDM07$PL.(^PV.ZI-U@2D.XNPJDDP3[J-]87U?,SZ:?L!TDHB,( MM(-HZ8
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MT_QTP77&S;V^M=M9N5:[JZXV@CC7C Q_V5,$@K/_FH2GT'.!]7W]\C6#BMZ
MD\#"XE_A]2B ^?K-7^$GFTNL^EU=4^=7Y^<.L8+XHD9 SE8"&[T@W]HWDE*X
MF0S=1X*39B;*GSA[ /MG#_\8]N?!,IY[A^?-UW35?I!:(V5H/4 $!!00L>(W
M>?&5Z1E]^5KW)+WYJV]D& KQIN8/Z"6B((%\HCRH<W&.@V%?< (CV4B2SB<(
M-]_/W= #I\WB]=R<CH:;.-@'BFZ):DM[7U]3S+DUL10D;;2C+>![ 933?NCG
MNKW$BFGS]$P%XN^VN-QV R4CIN5?&XS.I=,8@W$M\;TU38AK\!^TR[']AGY0
MY&.,O80.WGG</BV"C7(> ^;$2<SI5^/&,AZL;#">#$.[:8?=J#M,$CAE%1<5
M9=L'E&!B/Y[/A[O2!G,Q;4.Y?#/M9E;N:7TV,"%P*'+NQM3Q;<..M6Z_:TY7
MG^!@<,=MALF)2P_:Y9\\FMC2FL,X"/\- Y=6X/UHL&-'KUE1[)/UY;'UDUWW
M8W_BXIQ<\+%5!/1Y/T:G+4+VY;YID!);V).6;GOI61'?5F\IT!R/Y*;K=PV\
M03<SFZH6DF^V.T2O&L.;@3HM#B"=IO"F1Q&@?MPXR6K@&SXH=6-06:-B)-[>
M-AC[H;EO7R"0\,.189R.MJ@3_=&+.E_]Z<].&GB:T? !F4+F ?'0;;NA78"M
M^!N!G6I?P(?1B)SST<)7NGX/AJ OJI_P68H(*B&>_R!LHS-%W UZ;R=J&/E4
M=)[L;_B3\EA*F&E.MJU-6NI?(SHH%WU''R'I49@4O$(0H%((O0B7MW09(V<0
M-9I+S.FYPTFFSF_PAI6:^$%DZW(O*)M[I\AU<7[VDOBO84B8&1PGA4:1F<WA
M"ILG\GDQC^GR4"ENN;"A)"'PW +*M$S''8JF-$<93QVRW#DD"5O3^]F"24ZY
M$71Q8(8'X2@CP4>74]_.!SMNY']=_ \>=(=+,=?4 $5T%J@:P_D,W0;)^.Y1
MW[U'H(,'F &\._O:((=-!<SO$D&%&5IB49FATD-+2=B-^X5ZV3SF*58S=<II
MNE6S.'ASUNGSXUQQ*M[J<)^:Y:AK"[[.<VV"X\=UQ9\9%*UDSPRYKN:]O.KH
M"K2%LU_SE-PJ)@4A=$E'^6X3/;C@&$X,S+1*<K9TD/Y?>!YB +U[H!^$S#6@
M\7Z4[JF'(37%SG3D,>1<A)WG^6 8KZ,_(&B7%P-8/_M9IWWKXK<6O__\P,L*
M_';F-=#[\MO#,##PXQX$25++K<NQ^ZX?I1KPJ;J*[>>F*>_O]:]B(EH7L75H
M;F[FN!PX]3WW/[@5,<+8.8Y5'JU9C9@?!38N%:RPK^X&(VA*LWH>P=B,N=6,
M#]$-<BM>7IF^2>=DK,_/3,%^:Z;$@(H_+4=V:#W@R5=[6-IIR>@C#E/G=5QO
MZ<3[;F/)R#2L(U1W"$%PO!<;QE)@)QW>VYP?E_?RKJI?TGVH@VD?I*/(=0_T
MLG.OQ00T\S>L2;6#:^L4]!UPR@+)PT,9!G1'@$UB64"TID UNZGKF( I1]<>
MK[ERKM5JZD3FKD73%M6CA@#,'?;ZUC)W:>&3_[U'55K=5T(_Y13KQG=!7>C\
ME2L]W:C1'?^5,@:"-G I@IR^@XF.G!=-3BA$R#QPRZ I8<RZ+Y&9BQNA]HA5
M'!6&;2Z)[-+# /,E'1=5+^AO\^!';0^4!A12TJ64M,:Y(5_CYJ%N*)Y]PI?J
MC4?[0_>J;-5E!T\F_VHR5O,Y-%08(-B0D[=V2_X;=3EV_ZP3P4D.H20;I#<-
MP0^H(S,ZR_#Z4PB"A];<HH,MIX#C]#[:<+C@?G/K]V^[S2UQF?I=>8R>(-?:
M[ZCTL!SU[;ES80#UO"#N-<?D=<PL.$)E=&TS:2N"S(\RGKLK0QB@L1;F0>XW
MH'ZAXBY65"VZ!A?K"A\,IIN*W2F2A7$@@L$S!\NZI=&VR!'0G*;:K*L_@H)J
MJ12#T3(1=3+#E(^75^=*T0:Y4T)UANH9#1R/##?U)!HPJIY$=)N-X 6E&QNF
M:N>2I%L((:+L!D?X<MYFC(M;3NMY!H%EN<#'&T@_&_&.& :,//W2^^'\"'3/
MCLTU6AK!"=SI,3V35*Z:L>2'3/?O7H.B0R@A"63-!3OBH)]T>PJSVX9*65SG
MGT02 H2;B7Y*Q:Q6",G2L5V-%J&S)=CZUDE@QPEH#D:P+NB\5.,EZ]&R>/RZ
MO.G"J_1KW[9XB4.JH<)45[CXPH4SU_N,>C<=&0NWC9/JU>U6R#B9L<D.\OSL
M:M_7&PU>T>HK4E<@(EEJ"J&;X3R51MUI="KM"TU1]>#I[OXK,O8:[!?X8!1%
MDY>@F\36=(+,FH[#W_=0>,"P5O]6.F9>.5 H,NME>3A/HOWW4R#XQ'K9;1]Y
MH?*+=EX3N8]?=DNY)'/:";+-] =-N+PQWASG&0UFT_U6@4I0;1Y+N R3F:,E
M0I#P9@:T.:WN'>4Z>@N$O5 OKKH[#P1M4>[^@DE^0"<;NFXSN,UNG.]VU^?0
M!5JO&[EH'238L;!;9-MIKPL!]FTP&[3G8> 1=C_/;V2LC8^+C]W?+Q;_H;]6
MF@(1$(MYP)UT>^^4]%0I9+BO.%MODX7<16TZIR3%X8Q,6]1B7)D&!V!>&=UJ
M1R 9]%<T"IAH+21I(1M.>YHD)%T.BG& B!^X1J0<N6;T7A_ IV+-0#O(YRK<
MZKD*]W>37^GW&^*$MQF6<7V&<FF6H0$M#(T8C JO;1K1S#)1<\YSMG VRN![
MKM4IJGF@<2IT>[DI9;YQ OIA=M$'NA0X#Z45.PH+\6H=B-?29,D6&C2[M+@N
M>"%TB9--" OPP6-&\6%&\R/8$\L=77XVVH')=W*@YH&1QGE@@UUYX(T-N&9I
M\K-^#X9[\R:,C4F^<@+0YE'\;@'M9^<6T[6$F?/RD"$?PXDY0W4";T#XY,E&
MH28I7D+&$/I!#=W*#T^#6UPCR(AYAD:<F1:0@HK1(Y1G=P<'ZSLB53@4^>B=
MIU,E[L::(]K"8/_P#>?.0$Z68Z"*CUEV <L<@\\1KU!;#;S2%J]C3FB_,6BR
MRJL@/(Z^WO!9S1/92Z[D2ZSASG=M'FS99(WWN=[+PO)^E>Z539L/3SP5[(YS
MRCYY+A:MDRDU*&(J8K[H!.U^?L8PWM:/"N<G\6+QMSUL JP=$O:KM:CN_]R2
MRLJ['?N /^\QS.7 <S.H.^:M<#>JG\*P@C!&)T;Y[:62].,/6PR@P')]'."8
M7=G+B![(V0R^*W\UXM_6:A0&CR-<#SJP]6?5Z<NQ8#@-OO!]#*FL'2Z+"<>*
M"TB[FR6$$IB]3TO&E:0Y_ $E'NC>X'0XH-]HN"7J9N? 2BA%KHGV#B0&IE!E
MW3CT>+8EI_'U8+\JSX?MA)4GRNV/VEXWI'I$XLK2)4M7->SR6,[3"RY-<M$T
M9_O-Q+K<)L?(7#.S=P9.FH[YP#"[1E+VL.^I0P:3:_,0;3DFM+"1.2T1)THG
M<L7)+^'#EP98$V.:SST*,SEA!1F;M:'2U\9PN!PB $S] 4XMTY6.*PE#U\%V
M9FY #/9X=1Y>AIEYM3.*WP0NX8-[<+OM)!(M*''\5P[LSN[J0XE=?[<?FI^Y
MCEN]"V"^+/_.)Q"0<?^GVY)J6TP(Z&**39B<-]/AL*)1?\@D^%_B-[9;TOC!
M!BYP-"]?+[C#P>O"&7=[C"E)+Q:Z1WL<K_%M:ZL,8X1DYALPD^X.1O<OO\<Y
MRUR>%=R#,+$.W_IO7\'M$_]^@_.J_[XIAN'?OOKAW=L?_]H.N_?XH:]@B_W;
M5_](PR .X[2J@G42-VN5E7F45VF<9K'*\Z3^RKVV\ZU_2FO%8]3L5MX%VCW]
M-ZK9C6_1F$)8+/YUU]-_\4^U_D;]G!5F'SZ!6JWLX?J]^-=O=_5'GCFAX>IN
M<(JS*%I_]^#'B_VNF_VX_[XFVOD4;>N%_!_:S)^N\8XQO18^\M+'[G6'#<+]
MO:U<>-YAQ+-IN_L51]UZ.%/$AJ0<OY/2'T\X_G]>2O@#FMFQV_\ZBO-@W50U
MV'R<5T41I'68EXFJTSPM5/QL_T]J_^A8*8X@\**?B#F00_XH)\44]O4P)<72
M#DKZ<T>R<QYCA7.PGOK>"%>K, ZR=%VH,%YE\)\J+\ND#/-&J3!Z/AN.=V^8
MH)8L=A3HBA6;P(<N?M<ORR.RW7]B@).LBQ(V:UBLZS@IHS)+RZ(NLSQ+UG4=
MKC_/B(V)ZJ?,VLU#IF9??LZH9NW(^[1O%;\I3_7()1+;MT;Q2:/%??'[C;8@
M*$#KMN41<T@]"O_ATF2'Y'?"EFJW<UB+OWMX._PN *C/W@RJ3,MJ5<79*HCB
MJ&YR"/*#9!6M\C"NTKQZ]NA/Z='9:.E6J]%@QJ&/FT<YCC=7>$0 ;IQ<P4SS
M^\3!GW1LDC9UDL7!:I6745S%59G4^;JJXK2.FVR=1L^6_&7$)G-)F=.VW"P+
MJBH ^TU7ZSA<91E<09.\*=.@3%61KYXM]V@M=S>6#1IY9$>EONNI.D6^&>^&
M7+BI%2L'*RT=3@D9%NJ&O]8*,\MZ/)R;'&=I15M)D^!))UZW/>U-D395F38J
M3-,TB=,UA.AQDJ99F<!_UDE>/F^*I]P4AFAJ'%534Z @+ TRD3572*=*NE%/
MVS:;>%4%19/7JD[C,"J*6-55$S1)"'?*8/4<-!])T*P)K3:FW(B<QJYE>G<_
M0\DRE9\;)<4)6^]F_/S@VTD/DHL^\:Q?7L1YO(KB<JW6<=2LLSJ!L+JHHSR-
MRC)*G\W]&%RQ3[MUK8JM1H9XY+W("3>*GC4'T"PWKH0MPC-PF"G7C5)8XOTP
M8^[HRSZ)3/AAZF"7S\XI5<T0!S_I"734(.OX"P-9?[;_JX,P:>*HA&M:'-?(
M@1H71=GDY3JHFE@]W\^>U/_- (B8FE1S+B$DMJ?;VH9ZY0QOB'.DG_@)7:^+
MK%[%89BMBS@JRC)N5EF3Y4T9-E'Y7)=[6@OM%1BH(HZ;ED&+VPES0N^SL@BB
MS6T3=8F]- GQ8<2VE^J=BTQ-%0,_?-+&7R5JE6=UMJZ2,*[R.(/_55D<5GE>
MU7'T#-AX4N/WNZ"]5FSI[)9PE $38OK($._3S1Y$R%X\J>O^#;!V[O:07FJM
MOJ")6 7O?4WP<H9QX9O/L.LN'6H65%9F>/]=UW\0VL$)/8>/&F<(/#9];S2L
M7(.JIQ_]%(Z-@01G]+/G.9VUXQJQ_#EZ@Q,>(H<5D3J6<+9F@>UW2K,53N&Y
M5GC78NJ=\1"B]=ZV9$GC'%,:NN)#\SVNPK)OM,/H'E3V74%N&S%XV*R\-!SG
MO2J1R(MT&/%NQBDR)-O3O?^/9H=UJ'/'+S%!6C?%L),!G9_MQP3:9'ST3 U=
MOB(^\[EEM)\JU5@EC?BZK>R:Z5SPI=>\YJ;M_-J)DL[<VA6H+^GV&<V2\<ZV
MH;M,)@Z[ <S(I%?&XQ'04DM&+;3S,>$.O3-!Z-V=2^U*'H6*M#9,6N&/LR?G
MT6U,?['4_C<=_!(Q3-]VV!ZY49IO8LL,I^=G5Y/?YL4T#/G4/8.D$J1;5BOG
MGXV&)=<.J>=D*#84X2_EU&BO2]A4AM?%)"-8 NDH9_JK/_WL-\Y,U=2GS1ES
M/0ZN[:+GV0A"G?SK:)LYY#:Z0XHU!&SK1F=VFRA5S<ZPWS XT41%B5.1J$"B
M,O1ZCM8;6X-)%EF)I#?(%E P#EG^TM8'.K*T.IP\#';LOE>N(ICK4,[/;HI[
M:NIYB52E,'3JJ74.'VNMBXFQ+OUN,LV%CJT<Z!YTUY?@K/_SXMV%,PK[WG@N
MT##I"'8I62G9A73EV%/07\(__\,AD))6('H!W452T&5AP1<//0<BM#&(9"\+
M0N&YL1\&S(MK;@?D$-(5'"0-NF!K_@%# "(2'D8OS)PP>,:Y4S94/=CD]E[S
M%9G6%J+W,<*06K<0Y]*VAPQ=A1GZ#:G2$(_@L'3D[RR#@R^&R"E > A1?:&D
MZ.6F*U'Z#'4ACW6GC[6A9LQ9RZ[HY(9692'>*@JM!\O=ITCT?H'*)NI6-^\6
M[35'!HNW4BA^:QB::=Y>HIW6M"-?X8J^K'9&PN[MVY>O7I)^FE:%+^GP7["?
MYP_@0_X,!L=QB7Z<B-W\HK#/#OXB/\6'LV%L#'$L<U71-_5*MB$+HY7MY27R
MB3M@;-PW5\5^HQMV7",?[B' N>8 !#OL)L1#1DQ6\?-1#<5] !Q6?&[SFQ(1
MVJ0'3[L8[5LN%G_I[A3U=,I[D$X.=G+52(?7$CL ]N;^S[YNN6U#_:JJO;!4
MX2/-)G#HF,@_ONJVESTQ<N&SW_?[:[CUU]1WO=-,7P,:B^=1:$]C#^L"$Z8W
MH]C#\R6^1!E)J)(05I@N60S+.*]W^QODD8,A[7NJ(EPC_4F-9%QZT O=#5+O
MT4HY6VN :)=[)OJE*8*IWF]QF/I"1U9-)+(84O4D7.K0<FG)>4<V0MCLM'C\
M'0E/W<!R\NKIJ4/KWP]V<83Y$!EQA&<=79)\MR9!QH8QB [AWU$AJ\-:]T9X
M8[SG^$Y-+S UYLO7\ZLYZ^JI<LIWX%Q@5GR!O:HL06$_0%_$(0[S%>*WTQ%P
M]'Q47_UIHC/IRDCQKRH4I/.VF3E#YKPBD>2,6@OQ?.)K!7*#R5&U(4YS.7_[
M=N#$@BA4P=)4?<MR<\PO+^V)A-L9T-QA%<Q 6-4, WGFO1='S*I()+GAKG:[
MI3(:!R1JX!96^'>S[3FE9SBIF*2/^8M0'ADN_JHF1\]4D;B_C2?! 2N1\<.:
MVRP;84E%/+J:$4$)'-MJ6]T+(P9%9S)G2])%80HZIN-&MW#5WB#N^0Y724^N
M5.!T6YB%'MF03?@9B(74">VTK)P?,'K278QE,O*DK]$-;4@G,>2M^SW.XLCW
MX7A97A*9M/W)!5\F+@,.O.N.KFRNJ)N8UDOPDABX+/X,2]A=WR^-.\% ^1H6
MO 7'B".[;0<.OEJD+"MV,S9$XS: +IAK&K25VAL/$?WE.W6S8SF\?.F\[@\*
M(RV-)Y/S%E?@+Y0<>J?ZVY:R03!M?_G+NZ4S%?2:O;H2Y-K;3<&RF+ 5R431
M6OX">V-!H=U;#NV$3&B'6QAY.. .AB_.ZU+K&) [HVAYR3)):6._LV+3M+<L
M4:T]_3AH-K!D[1VQG1NO?%IJP';XZZN$'LC%XF^=MPDH<66M ;.,%8?'-E["
MTWQ#6N,>R?'DV>=G'C&Y'AW3)7-X3%&S.P_%(#>E1F)QF1@G-H/#E3/V$-^1
MF_=/$MOP[+D_5%AE$T5YX@^L'.=:%=K'JY__Z_4/+\(<QK E+H%GEK#D"RM@
M_]^RS3@"E9IH7W**)F'(*8&!@D*T.4]>DD-KI.%KZ62A<];FZNAB^D"ZX%CC
ME3><_$0PV<U.$XK*OI=I:?7,D'/^>)X$3T3WW$-Y#S\+,IDXC#^<.S5$AZK'
MV_WNGO./!*413_! 2@8CASVM:[&]=R0>T*=[DO&2\)YI>KT 9RC/ATN5'(&:
M9ZLI;H4NV6;AK[0&M7)THU!LHD-A/HR_*(BU:&9+V<L)"BU(9^;H8O%GU-QD
M4GH9J7EI?!6X[I,JIPR"#]!BP&0"43/ZDT+,N<3UHJG":O6_>Z*%[/BYDCP>
M=A[-UP%,X&Q)P.N?7U)BDF'B>%BU)5UX;&:3BA3<<\9\[%4'QG!_+?=@##4$
M/\NTOONMF&>)>6.PW@M]N1\D*8-T=JR_M1]\Y7?\(>[UJ4G*+% .@:<!"U0T
MO9XN1-<[#.,FH#Z%U.JKPSO%1"=N&$ILHT@UZJ>XD'B'0<WW'7/1LK-C-7=.
M(VQAYN'W,1Z0U#85XAY,GIJO98'VJ5.8O0Z)# >S)Y8>DR 8Z@8..%^GZX%!
MB!R]EI@AJ RW*7SD@RW^,CA 8D;%D ZS#_K*4+$DK_@;5W9@/\A]Y!9EK$=8
M/RO@+OHR&J:[EUX)UZAWHB;."S%@[ QS0YGO*4.TT.G)VU 8*0[ ?RM]P>>Y
M4[6^JX_(9XG+E@C"29@49@#>%?[JW'^*/=+MBT"\80+WUU:2\!5.Q9@T]R.&
M0X5 ]X@ZB@TH 6 O7X<QX:$!^-')+^WP85C\HI6AF##Q9U\^X6>*N.DW,<GH
M_>KWDA(YADGX[3':3W2DX?ML\+BASGRJ"/24033,AT0.:JN-MC3@( ;H/)/,
MED.>3@@#KB9!7'JWN])E20$B'(49S3-]_D;-%YY!9N T!N4<\N"[?$H0R="H
M>78Y.Y4SQ&-C<26-[D"H!I%4<\;I7O/(NJ@O/E7$,:+HF5SWA;F::%PQ>L'[
M)$MDO;CJP#%RN=Y@HY>2$I>E+BI-I"[&P%(K+ [K<J?:@ A5N-C]'K A*ZO
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M;G/I;11U^Z3;K7\.C#0!'%QA2B?WMD6?A:. Y_B56R0E\08%KE,5+V1+Z67
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MB>X'(<JF&@]RJF''D3+_M1))'0OEHA?SSN%Z@0RK]U8G?4XB:YN$'!DNXB.
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M/FYR=U-MX][X0-X3#II$.4!"I<K4%#E&+==.'6F]RG/!'K5GC;1QV7B*#H'
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M*IC52J;:_=/SHHT&WUDKV1_J-WS 1B74V\MX7_D=^0)W)# "W;$'NK+<YB2
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MQ_6#W:1?0DR+?J!?P?S?AH4[L,I!^A9 /8* \WYDL&;&2?>SNZO3%3#;^8B
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MX(JTOHIW/,104N-O)73B(080H\9E!.A(E=BN(P,C1.34M!VH\70;"&?9$7+
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MH@^+XK-&"QOBCQOMMG:;G)HP;9&G,*I6)=8PPX"*TJUR!L"#5L[^'L?BCRJ
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M'M0^4!QSESN16=X"J<,*D,-$U$ QZ8MM]8+^!338WEVJRX9ID@DO@&0TI!2
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MII[)BY^>O049@W.,F56R89Y$L%RRO$1RJ\CH8*99<YJ]Y<:_R2/ _@-7!(6
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MWI4@1'R/HJ=LL>]8.=.$() /B1)B3#V3/;91RP8DPH'BB+,DJ;1J!Q*U^LQ
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M=RTQ"%YX_4X;6V^UVKT)]\'" L(_&2R@4Y/D90K7 @JX9"*:5)Q6E*P&(&*
M&].L5$?O5^#U\"% 'Q \(,DL\35 +4M=_A*_7ZFE7#%*B)5 4,1U1"0ZMIFI
M3LK;$)[54_I&M.,#K5(PSV&M<DY)<1%BHOCCX" XC ^FKZH]_S)!&"H8I;L-
M 8.M.I$&KDVE4SD/(***IV_1,,(3C4TF[_ERN9N'\3PJE[NSRQH;<;[)-PJ_
M=:"W(->ZG15K/!Q7"(N62CP,&R&I4)I?K8)JD6<&M.UUB=/P"]P:UZ1G^F*3
M+]F7/FWT[7$IAZS];419LT)A1%R5*,\FVHV&T'GP#'1_SD'JO+247#T3>^]F
M::([@'PH <\$&:RX'J%N@%JLESJ)B?$29Q#6V6 XBS\XMNYBD *%5A(Y+MWV
M!/I%N'#>JWUGR3*(+ 3B:V:)(R<V%KDVJ5S [I'G#>;H!,+G5Z@*V(HT'Q3#
M ]'I]&<]NP.5X-=@M"DZ<!4=N(W4\#/PWDG/LZV%-MX>TB'6K9219LB/MQ>F
MDLA;<+ OT#:Q.>?*82"&O^18L98H\VPNVP9!0C(7]!]!"FB+]VU29G5Y1?&7
M!HN4EFLW>Y>+T8=8JZZ506F6@5.R/2BI63 "+F^?1H^HN"06M]JI99'K8Z_C
MQVOMM']\<L'GSNT@E3[*X1OC#3$21#NSP3,C<1=R_Q_P:6H@6W:<0[">'MW:
M&R1\0N2@Y[7C7Q(&'B(?$VI).%O@1H'UH"- D;75UPI]\,\,GJ!YOUV#@^0_
M3W-8>=DB[<NADYK4.H_9FJ@VSIB0B7[:($V4D@@9*<:"$/0800#9U"&)&(X:
M&%K%#B?TL]B!-B=B%X^4"NC>YJL;]&>$AI=>WJQT;KALT5]N0@.0(74%;B!;
MBJCA*N*$HF@XQ2[JW)#4@?*B T8,:0F',MS]Q!E5"L/N;J2%@V1WOISJXB8J
MTZHK_+]''^R0U\AV-D(YY+"^$_IQXS0NV-6,D@B4#/.F.UQ\94JAFDH3R*,6
MO%)KM)M!'Z-_G"?P1KH7S1,EF(5VD"RY&PMR/4$^??:FEU MA6+<+3,. -@@
MZLJI$BR+&$%<[O./CR3 1($=W?+7N/(Y^JF2C\-5K$0&I:^O\]*VB!]\-!$E
M@,R9)0T:9)62_HV3U#[#WD'B]<!6F]L<E1 >H&6Q3<]8&_F+5!7++3M5=":V
MY::HP'G=YDO,(5T5)>S2BD*_%8;6-!4+NT5TFH)]ARD -PE95>G"/3X"L2.Q
M;CD[/3_&PG)_'OP@#9 1_Q,QUL@>4Q2Q#7B,&)X3;^E7)L2*$K"?B;33<<Q0
MY%$?;A,,5L&-KCVZM"#&^IY>8EP?M5QND3,6['C8LE\C(46U 1DX\? .^)TN
M?46.">%#]0;@G5-K0N$>7N'&:I58N6%%,>0=#:/AAJ@BKH6L?8-50ZE"MD;K
M@X.Q5>?K+2N(4F7HBN)*&1T2([@J*6"32PY!H6)RE2*HD05!KKP3SQOR\R)?
M\O/X@H.!%<F6%!-A\U@8Z:G=\%$;#J.DPDU1OA<$NEDDL:_LPN"4RCS>U@Y6
MO0U"ZT;XN?MCM#3F:2C^B ?)6GF'&K&UUZH#,)6+FM2#2:3X1KZC<9LY!K!G
M9;G)HM5 -MCZ"AZ6%/JR<]+;/!-.(_._*7UL>KWR/PC^IV\:K#*@MM.Z+%/O
M:&88",A,\7+LMZ+%*%Q*5H_PFU*!-=T!$O>T#W)O2G+(19/H06@ N;1HE_0]
MGX&/P2F;8/23NH!GXO%G: )GJ"V,VK)'?RIT1QSG6W H%-':@T(YI:,FJ%Y5
MR2IJQ)U-KQV@7_%Q#/>!'E>ZP/7@;3)%4XE1W)G[!(%@:I K7V)PA$MLF[Y5
M9Q5<(VS/./AT\(NYZ0J'6>GP($TD714FS+^CQ,Y:TC-\3S*FQ+$&=;YL(W$Z
MK$.E&YT\9T;>$T\Z^= T-,>@I62Q28D3B8$[3-3QF"\F;Y8827HFS29/T1%=
M.%1)CG>L[[AT#)B1W\K/7W/$39]I2?(U!F.2'";@(^M#08"2@@!D?L/M ?MH
M<D-"?4[!(%&NG\N-Y^HZL^(Z+N%BB&QBWHU@N$:\:W"X&55GI9R8N= Y!!<F
M'X0!>\JR[XL&8?3(K:C#%E(D2-TU&\W5CG)*EB((MUQ+I(4&ZCEZXB=%R-.G
M;2+9%=++T^\K*YKHWB*3O?FD'!*P1[=EPK),'Y18%5HY^@ RRWI2;)>&SB_8
M;D"'(L^YP@75T\(\)O&8XWZ<O4?<E/D%[#%H3Q (M")V*^Z%I)%C\IAB%RU-
M/(T%SHQ3#K/^+KG*& DSR H8X9ESOI#NU9'+%KH-#]@-S4D?*T$NZ44DWUO"
M7MS>!^.:9 MOK HE)5!2\Q\T%BEX*^0;.&0P3NFRD?QN%6%"1>9T[V[4P68"
MQW_<3."=F*GW%/*UBJL.];HV963C'E62D8<B<%2^I"-?QSE5;;U L)X=\^UQ
M$)M3$JQB>NX=VFM=@28AHFU"<=>=ZP.TRQ5ZJS71JO--H8OOSIR@?T<56:FN
M,,%*W3FPV"]P2R'YLI#?#@^#6[MCL_YI.I5AALS0.G:M/NZB:0L.!ULK?='!
M^-5O!_WCHQ46C.'G805Z;L=$VC>L(=%OL<NC=2N#AHU+"[?5%9'GDS:E5U-B
MX.H*UAZCJ6A%H/?^[7#<#^3%E,G6-QL-AV\:<UG0W?O)#HE;[JE%IK7KISTB
MV++FAQEJYT!0,M&G_ ##J!%4^.UP9*9AUAHFCV9(T^:X98U6>0HJ_(QZ#:&]
M0+PL5WEM[]3C(WC#U;*(*=A=RU5$)V5G"7,U<MII:.<=W/,]3?^^NEB_P/XA
M@Y 7*5E@&)4]?&;&9\P!0[:<UBZ.42()6'C(V'T&.H]H5^?EGF^V>D X<@8&
MEV-VW.W,D>VE#P?6Z5&<+U.EKKNB;QD+#]M)<7BG6)*8:VO&'2QI2=/.Q@FJ
M"X)/P[\PF+1,;S#WUE:J+!%FWNSELWAAH('-,S'HA'=WRP@ORQ'+)0X4>9,9
M^GM5X.#M.YK*)"TJAWB7=I8@P+<U/0A,SP-W8PY4BM]U2X4)2>*YK/.E?";'
MU">A'<A0MKT]5M%[JW..C^Q9OC#U'R I_"@RLV\PR8.RB> @#H%(^RHT=:F6
M-$H2,+#(0#;Y;$^:S;//97C&.C</YL/4*?;R.@+A%DOR&@DUT3Q=#H#=.G]R
M=@FUD.#VTVLI82@*[2S>G6F'F$LWL$X)5J $"P$=,/HG8LT)+5235JQA>VD
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M:::F)-'4F'S];ZU%XW OMEE()326P!UN87[>+FCN"9?TQ673PI\S>"[80<P
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M#"JY5:7+GO:UC%_%]"TMY %)LJ6&U;4M>!6RG0P7.2P OB:*85C%NO-<\7*
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MHB@F ";%S.%-A,;'W2:?U1*RFM@-YU8%P2O?UUQ^:0_6I3V4)?4/!J]6+;-
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MU8B?<<\RN35VWKV:]T!@=*UT/3@Q?336 >[\2ZPHC"KLQ#,<F%<ZGOEO$V?
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M:;;DQBZM-I/XV_4-K[E9U5?;LS%HJ@6N5(W[-T\)[/[=4P+M(OH<X_XL=@[
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MS.G/G/X43O\Z0XN?EA?"J.0"0C5T-SO=K09: TY,WYH#V/ G]'OQ'I:7]GG
M8\6S_[7C+,..,X?0?I4,THPGD-(04?CQJ)C G[?F)AT(_"<A(U0>G.A5>FM6
ML9E1,0!YVI+BT]$[+/KA454F)DOU53.>!LL/DJ_C6%H[I52G/-.0QD68[[E
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MT6O"D5G(C9!P("?&P>ZQ(6&E.*'D.'@P\,]9BE33\1C4Z3URV(?NN@#7_;0
MU;/3U]B*P!7F-/>,D4*M^PY$,#%L5^H"T:$%D0QRC.-LGM=PS4 ]%N 'UX@?
MT:4)R*!5W'7U ^0*L@:LK_6%)K>'70\,!W#("H1$7MRR"=*;@L-:+B[:#Z[Z
M&@5(KF)=]F#R 1 *B(-JOA( .OV=@CM L_*UR4V)_CEZU40+<0#/2HZXBT (
M5M0MR"R*/K"UI9B3Q\E=)WI+&J3VX_@12R)A"L2G/L6M8R,K+/8IZC(Q&O E
MXL5O@/B[3M'_1TIF"B?5;-X/"-N/?B[XFOA=%U\A/K#X=1:(=WE)WJWFE2Y:
M$ @UK@-<;\C,AX=R<$?7+ANK'R&JL"PE?<W8OA+4\7%IQ(8&S9,.!(EIVG:L
MJ Z&!KZ>X5DA>DDL.FD$%"2;R1A_R3?K> V*I8A[%]01U$2HK]&V<X<%CZ"#
MYG-]!LWI/H/F_&H<5-P\A5)1OB!S'*[PU_+-IE(BO]Z%2WUA@G% *W#DC;H"
MLNM0"M2CY([+X0O72-Q],[DS0.X;W^%GMKYS#J,( 'B2R@ PPS0*9X4 <Q=H
MP*(<%Q3:XR@ZO//?>7&W^A.R(.P=S^!,OA2#-3A),[HY?=\00WXENKY3$^PJ
MXA!#D@ZC%^,,3,KCHY=OS@E?RZ!$8*T^4/BVVDF0^P':'LDN^CG)IXC6W8VC
M[M[>WLK]V&GW7J=<BT4<!#$](ES?)FS:C@-YI>1;:8 63&RQE"2T[L+I;'SH
M35%H*930288@2N!SXZ'@[F30 'HRN*IJ.FJ#;W/AHA@>4<#E^^A+T]&4$8GI
M?"-[O.BPD=/?>."F0X.+V:MMB6<M+WV[YV%7S@&)6DS#Z9L? U_)1[*MV[M7
M>)LGO=>GAY<1IG[!M$WA%JP9O!H=@#]3,1C609I<YT6%#NV_4V0'N,.#7L__
M9AQ=$B[<R[2PAN<L^/T9.8)LC_JO1)ERGHZ*/!WY/];D(-*6&!;II 7=DNP'
MB5',)>GU3M<C)0*NCB9WA1S FU.[[]B]+YKWN@;:Z9JC%T53%!8<%F3']S'W
MC;? +!&D7N.H/YT@F34L S+^%0NR,MX:)4S@&1<8XX-75E?H^U]%[U"2W11W
M>%% 9],K3%21>UY,)Q6ZNM;JC-M,D"$Q12;)=W]5(J KAPOHGF\H+N$+SDCA
M#0=)6:*Y J]WEBN*U8Q!)/@>Q0\'XU9CLR!>U6KEA%LYDRBN_;7D5ST#[38I
MTV(*I^+2;+$D!Q4/.K".'(JY$UFP37[U=(Q_;GB2GVF-9;U0',EY3ZX[64_@
MV!YJ.SRC^YU*8R4'5$.QQ*/HD@2 \?W$BXB&]\CQP<J:@SF>-Q]P>+_!%2XO
M$65AUM2>-3VIH0,Y_(DDB^(%UE82'TQ('2 SX+$S;5O*$[T-IG4Y9(%C*GO'
M9%KK)Y>7++3P+<LCA-,KA\ZH;G@EEW.\"!N6=/8UDA(N3Y[/E^9Q1V.SX"J(
M56$+($#-\?(M%*\E>'V4,3;Q2SHNH]_Z66;.].9FP&4KNB\A'8K#58,R[</3
MZ4FL#8-M@T"W2>.$$C=!C'!@#X(VC!>KNTZ"/>.WFI?<(@W@16BM O/PZVJ^
M(TG$L1^,5*>L@@5F ]')?)U$J 4F8L#PAM^ 04EPGA,+M%[?JV"DLT5EB:5-
M:/F^(//H=H-'G3X0>3R/3W^P2D'?[R]. CM@&DA61 _#BEGP^N D*E^TM2Q0
MA0BS@K="U1HJTQBI'KG+VL,:?*S :($#0>A9"D<1#NO,F;>,^$Y>(.%0XZOJ
M^T"M8%'IZ1,-REA4^Z;'+&ARJAYCT]=A7-L4%/Z(S<(!"W:29AG%PRFGI!>/
M"+R2 R5W6F(IJ*;P&7=%F0WOD/0,,'(QFM7UR,6;5\[T5/.<W ,Q02>HJWI<
MHW!N\,IB*Z-N$JY;F9G)\A+MH+IA&=NZ5JDH$HVJ*Q9=(01NA93:?:T63"?Z
M]2;-F,BERD6_B#0^SI*!\9-Q-0N;ED!!2GFY>QFSP317V9 \^D#T&0@[C?\O
M12)$GA(!LN#"].XD0ONKQ/"I[ '3SQ,?_IH+,6R4U9H#E/(AO2:+0S%*/Q:J
M4%$ _OP[,UE49L"JL832$=,*PWEP_M=):6F33Z7N<ON.8F!$<]X+5*' B#?K
MSS8ZT;_-#,2T*P3T2OC.T^I=]"JAXC]P'P)XB<>?"SZE L+0['.A)6^%+UZC
MU>;CP]"PGB^%>1Z*=;CJ+Q"JE98@.?D-3.%\62^PU[ LK$+0 B<).;JRNK:P
MTV+0TZ.C[G#7E^>'IP?1T>FK-^<GO<NC-Z<+N2,*<E$T.DQ_4,9MH/(&%3^9
MTBA9X/HK&X46,N!" 3;?X!M8-H8Y3E*]6+R7##C.#$H#'FHT;3XW7BYU&:0M
M4+S%3WM_Q*\G7\N^'W_N0:X#46)A6^PD,1NS0Q#0]'.O^!&M 8)Z%^W!8;BD
M*K <;P:G^@Z=7%A(N]0EWQ/WFQ/D/,J-+ 6C92B&AI;<P7' IP:&HP?,'P2Q
M/4BFE?&DM%]G/&'_&2QH$$C@U67DZJ4@Q@>L&^$,.-((R["> -M M+$6X=^)
MP+[!P&9@VY*>R5(XE,0FFH<ID ;6<0-Y66N73]:)##Z5W#^-*<I.H00.)1 1
MPFV/S0!NR/G99)9@U<HMY1S5+41)>B62U)G,[. \()!7510O+XDL%M&SF$KL
MT4*GQX4;4LRYJ-GE"T:-!]K!"E.B*S.@P@,7*!<V0.*PC!+[Q;"J.P;XK.4E
M)F$C/&:(]LA()5I)*\ST#8C6T%< IJ-72A[:DCH^+\F1F:ZG":I XUYD34H)
M21=]HG3A';(FO SCO6^,R H1X2$Q?S6+407GDVPF]MZ;7XX.5KM[$99MF%$Z
M\$UK+SV:#$3WC\89&:5H%F#P0-B<0Q+%54SF- D3X"DXJ6NQGD',LVTH,CHK
MBG?6G;K.BCZ*,K;NN3X$UH\^GB].;PNP1[@>B*1Y6I53ZD4A*>R$#-N+N..<
MHS<8.'#=+OR:=. ]P-]U8K-\0WE2-"SN\JLDRV*F!BM\L69(C%Y7JT3F4I/@
MB&%X:_2,JVF)9S;G69[Y-\&XU/4L=@+UZA'&=6=>9NIOE%]<_[OG%Q\MUP\U
MO8^TMJ!2O1?( G19O4I75Y"-871D[UQS+-RB,""Q2!Q'N'[D9+_M7'0DA<BA
M375_TTIBK$49Q+3S(E^E+\E#9V0E,!/:W]E:"?)CJ%V%ZNN8R5'>G1[!Q_3,
MP:VADD'8%HI_$7)<)9?@R\%2!GF$S,V/15D'ZX+#\/>67*/3S\Z0MR^1-B[R
MC2;Q<"I5CK)?\A]W?JB\*E;:D=B2;)VS!!<_?0S:2THS2:>P9")W3@0MVLST
M-S[9H90!>Z$A?Y7^ZN%T.#*]T=GX+HYV.FO?T0IV.KO?S2FXC[U*9<R7O*+0
M7(+**K9:AGH?61FTI&X34*@CEO]=>*&W7M(N#RR85#M;TF2*XCF6J:%HGI]X
M2$,KO37?NN629'<4(-*E@<:EM>$WD)P>>9C>VMRRR!M[PJ+676YM(>7#HT7=
MD<;/OE91-[_;*ZVD=X8%7ZW;"[]"*5 7*+ULBH# !21'>IXL3/V#)#F(N0/O
M9PV1%DLBKDVHI7GXP.I)@JNY:E]^!<7+DC587G(FZ;VG&N/64"Z$RQ/_V:"0
M&QCNB+8VL/5(O: UV)O\QB +FH!T289@9E>^C:S>NABR7NM&.K"1#2S[GML:
M[&*0S6N:TS>\O-3M=J+_QHI%<K]A^3UX+_P@TW\?I-4@(Y561;T^AN=/V$"F
MJ*-&(2T1G.,;\5<+W<_Z^#I7C#G8ZOU^RE6]B^H$O]3U>=0V D*$"\RIX6"2
M]@MJ,[#])T!ZMHCJ*@$Q@K6/)5<S5N9:FG0E/$*%]FD^A"64,R3Y=Y3^'4?=
M74JOO3KHN=3RD*I81'>SW,$'3VYL+H(F8I#S.,0<-_:-<3M(/B5%C9E.V[0P
M*7 9U"4(S\SA$/W^J.B%Z5QW8KBA50GU#-IW#JO&+)W[E/\K^?L,2U-YZRLB
M5.YX7\G@AO(C122=&>_'69&RUAT76#. XBC87ZV+@C*)DS*EDS/8SLM!Q*$X
MZ:ZZHKC"*2$1][2D,@J"P][@)G/A.YX01@1*UQV]WSM?O73?8N><TM,@83!>
M!ZXL?71"R^64#*V?JH3L]?*-);=)FGE6'[VE?OBL9]P!4>9Y."PQ;!2THZ&,
MM,*=""JEFG\\-EH*/6="W=U($(8-$S)4BENCA\$-/GZCRD+RX^,]L4ZT?WYT
M>;3?.XYZ^_MOWIY>'IV^C@XO+H].>I<+V[9[R8V%Z!8$MLH#C1:LVM@M:XT]
M4Y67H?XFILUZVM*50G&/G9UR 70',@FT+RQZ9%N^?I\.F9DERJYI5ZI%@L>A
MN4[% &P%5Y694"C=]BK%F)J5&E=\H&OE]?HU*1O(BI(%ERW7Y"?29[V'<LNA
M[9-$VH<_5[D/GIIFI?C,;@:6@4G>;!9YQ1!D$:QR38&6@V"V08J"7/&A</K\
MW(C=E.P5!5(!%NG$ENZ%72YM7U[,4#<W)I)!B6$#2QQB!OH.4DYI?2EC8R=L
M+'-:PL$)W&SA!5Q=$=0@+0?3$1J[ U.Q&/7#>,$2D.CI2WSCVKOF:-I:NXZ*
MD[X626!MWXR<1"J&]NBW3FTNP<2U+<D0,SK 9PF-<N!B;6))"9)WHAY/V-"E
MH^QF<6TSN#YQ:AF5E>C!X='0#ZT(7$PB>;2TOD".BUX2QYT)QRWDCC@).QA0
M)18U%4R*P3N1%6A8 <M:N5"O NQ=[$<[W=U8O85][_/+2ZO1!3XK\G\J]CXY
M2?;;G(2S\MHWYRSMB.V9>B7]G-T(Q5J4L!&N3?749: %9M&T8M=*)E6MHMO$
MYN\0*S$_L":B=H#PORO#DTZD;GC&4V0ZRTO(YD%+ EA#JZ 9$]^7IP(CW(87
M>\H+[[DQ]S"0X/V#7?J&3K6:5 WDTMS ):"SAIXOYVARE<D1)G1$V\&I5ND$
MO<#R%KU*#M8!K[\=<R^!K$)J8/G[6/$[1"K#5Q<L2+S?>8M5 U4V;&-HM&.1
M0"140/1PR**SR&49=/UV\@!NY&66  -=#&Z*S%2K)Z:<W!2Y':WF4YR6E8^*
M2DQZ^#51[,C E_BLA &T:BAD >ON"Q<P]?OJ!+\WP.=3):)F!+'#-"?/G8\]
MO** -.""'J*-&M%*>3Y(^VIJ(]MXE;@6#?W^:MP;0SG3($GYZO*2O(VY6'RD
M!*]BE5JXY="X8QXX!\L"6 &IY:85I \:G[;\DH0(6J\3M1VEV8'/@RTLG7\B
MIN)S ]_.QM\]P8:.#W  L[D:\,SMA9@[P&4I#QIA\8E]W]>9L:,304*F. >.
M8WS2+X%UUF4E,Q:01%FL9.F5B5[8GV)>?X6E0)J/P0[D:A4M8;$+2VDB"T5<
MK5R6R3KV6?1H87!^VV*:9NQJ#@WN'7-\GC)EY4\5KI[XQ#,G+X_;H$-WT+-+
MT:_3F&E2BSIEYKW??HP"%=T"M/4;/2W![80G*FT#]A->/8,OY'' "<5Y53(&
MCZ1X]+O5*ZQ]JT7,U1_EZ3@I-DSDJB:\P3MD5+6L(?4$(A /4!+.+ !_HGV9
MJG_:5^,=K600J'8$JZYFJ<&",YX<AYX'QY4R\GS?@I.)X,<39B1TJJ;E+/K#
M@ 4%QM>8AE;!HW5T22+ESG3\>.*V92@X.2+OEALA#:74))K]'IZ8<T+.:ZQ-
M\Y$$@2I/G('%PW#D:42RAB<<N5N6D4$3Y-CA L\DO/!,DE;=[AD;[!*++Q#9
MOB._+=3VN\;+2]_ZT\R0KN$'F_8'?D:WFI_2O2]%_)F/],-=S'.)P)R[",R"
MD@//O-/86.D:P+%@BF)5%"SPIC3>&HE-T-A3;VB1=B&!_V)_%H</G\S&R'S9
MS';%^2^9CN$_F#M5?Y'JKFP8SC9+>=$S."407I@"208W&-;AE2SH8?O5*I;-
M*ANOF^/%;Z]M1ZOJQBMET8'MRR!5;,7!3^_#NXN16?#"U6]^M-7;0?=*GF2S
M/Z2#]3'T1ED*:GD!P]^@L4:F_XPHS1M34@V*,:D$.4RB4U4?*O ]%\_K?=.;
M8>D>NF'^VJ^FV16(.5Z[U\:HHTL,4">URV)@SV,._QF@<C"8*-._W402/ !P
MM<?5/Z(7Z8I65=<ZMG2D;BR1.B:+6-0MF*="&3_ ,^8^1%; %:IA+Z;_#GH&
M/*35GJ.6#BX\Y<PW?OIV!7L\BT%8F=/XJ!VR\]AU(%V\@(=[@6[_UH J<CJ0
MI*)R&E1T%3B>B?\&6(Y]Q:+RRZ4XQNA@R!1QFITF_;_V1-2ZTMO6?!V-=KY*
MW[M$28P19S:&[8^HMQ&<M4[TB_XJ?"D5.Q>Y=A+08VWE??,V\?B]_@Q]%MD=
M.84'P'CK+"_]BEU#)HS5%\Z^DV@"W#4.LJ" 3D;1"JVK(.9JIQE+Z&Z=>E9D
M1$YPB4*:A@,'W%S:2IOWO2B(2JB_,IR[[NJ!A?.QN"A,XK0$22LKH>8PDK2X
MZ]9LVZTW&W3.1NC6:ESH\P@^EADII?#?0C),CV; 6+; D-K8I>^;YT4Q-FF?
MQ 0V=O64,_4"#$\B 'MX+'$I%+)4 E79M#TVZ613%4&NC9/[@["L?>:53<U=
M1N/&Y@A#GEN!G)'HC%Z*#4Y:=KVHMP1JV#H 9/9+U!U'=7QHP-\;!F#>@X3B
MJ'K==A#C"H70;V#O#A(U'[%ZUQ_QZ=F7W.5^ 4=J5]RUDS=IR?89^O7EI<;W
MZT,-Z 'V4Y5.(U([PUK/*>67'=]_NQYZ6MNN_E3(B_TL/%<F7G:O?'\JGC<]
M8E"FU-_0F++@3"@[I7']24,:JR^4,/@85V[.K,Y#29DO*'/-';*.&0?VQD <
ME==.TCPF+04R!4- "ROX?0^+1V55LF&:@5B:U?;IO1-JRW1C2$6?<^C**SA@
MA2LI%F_TF%]'XLV9Y\-B=4RUI3,S$6<BS6^+=.#&/%JQ;0L\BO(Z 2E@83=
MY%."/]A%4=8W 0)CB-V/]%+1'FPT>$-6_=DH?K5#Z)*06G13Y:@T)R_RTF!?
M%!J(5 >KJ#C6*=,5T#C*HAA2^8 ]LV 4@SW 8/:=M/":>^M=O.TL+QW)-(Z6
MS00+CAKK14:PU38RY)C$P1\X6X_&0ZI)Q,F O A&3,B*J1&W*#7YU+YF'8:G
ME-(\'%R-CLWI?* *9#[2R@:L.1IR;$&VWN;MZ2! 7E>P'-1&Y9!]WK%,Y[,D
MSOL)>(*_DY.E_[FE_<(FW3:?DVZ7KK! Z>UEB?'X+#J98>+L B1-OQ]]VUUW
MPP:E-X(8GF$O=FV*97F),D;2[AF4;G"N@_IMG6R9.^)NTXVX<U7[CUGI^II;
MJ18WMRXU^M"5?KOEG06-V_'<:)H^UU8G2"&6UB4_IH#0%0G .N"I:(?:C815
M!375$SC!9!6;RA6?SY>*<P*?NVN[KGK)CP?V2AQIR@:EK5JJU"+M7M$;Z.^[
MP0QQ3M,^9)\NI&'3XZNPL;:GUX6V)6"6EQH9&,F]@#?6AG#3=0D?]CO6_$FC
M7S)9\U'C^*EPO\>%8ABC.2N+O$ ??I&+ YT+-GG:H/PO[7NI&IT_@HA_GP[_
M]<W1Y>')-OS@_ZRN]O+!35&NKOXHNA1_%6U;$^-CC*4/^_.A71P<G1_N7[XY
MOXB7ERX.3X_>G$<GO=/>ZT,$^")<K\.3L^,W_SG$#@$Q#Q:WFN[Q\T8ZD=TY
M[;*Q]X7<'ULH+O'",(E4BZUS%UVK7AV!!3VFZ;7);;7W4,$\.?A2,:"GU^K
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M<,J?IK NGK.^R.,I'Y:=\V(8GU5V^O@AZ&_AHKQ@2H)63S9<!<.CN,MIF/*
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MM-.+)Z(5/?W7C&P@YJG%&_1B&FAW\66H^\ Q.UDU/XOOU-FXJLK"L)-GJ[M
MY\FT GUQ>3-#$UTC'D?[6HD18V$$G"T%[NPYQ-$KD'PI^)-:[X"K>#NNT,$?
MH1SP%SY/;3=LXY,9EL(@=_-360Z>%O"E'AS-#7&^JW?99G\!=4>@']O/^\PY
M=:+K?G)D:'78BZ.?]G]9$?Q?A,M&B0QLA#]&0LNG(U-RLK-A'GBB&C\>>T=
M+@DAN8%]G#"BY,D ++W*S-258445,_(JK'Z0I:PH,(, WKJAXH9F--'R4(P
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M"7V"#\$2/8*S[\YW*>PM)ZWQ1#UD8H^R55]4?IJWZ^N7*17H("T2YV":@_[
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MS&.C6=5\">HMX#6 .6%]K?P$YGQ24!#M$K>.FTX,.O>2JS:M&EBR-G$VU<G
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MSODUN*5968D#KI>!9+CM];>"Y/1/#'-?Q^XWR6:%B6&&ERK'^%F=-G037^?
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MG6^B\3*+31[#Z])@%6OCF/9ZD=%^8RZ(@?XDZ )'Z"JKEZ91)3Y\,<G!P,G
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M/;:B?O=R+TD-TR?;%3&J*:.+[?O@[GKK#@IYY$]'/7\VK%EFFLU$/\B,:?>
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M@@D^D(S4PLDJ-,.7<G5]E::Z7V[^JQ/W;WID%_^Q(A-&UM<D<1C4:2%85KS
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MS5[>M;93H8"O15VD"(H='&-S*R3I=GXA=Y2BRK4#GM.A&Q WR<*$1]DQ%;E
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MA;57<PQD=HWH&5X7V2-ZE-K^VAV!Q\"+ET)2HHH1W2USHJ3^S1=,_VLV[?7
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MITK)(KZ-DVF&*#1RQ\8&*9(]<D&VQ<Y?J(N<I$]2A"$_",MM9X0_/#0E'4:
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M%ZA[H&_8"=>A42NK$)G#@-R%UHR]I(K :W)NHB!,9A4EO4BPMYE@\^F5>7'
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MZHSIVXZ0;'M]S0/!=>J0'J1/:UK8D_1)%"M,4X/!SLDGV"4<%^*L97HP#L;
M:"KI'072W-F:C'N"F"2IAU UYP2V!35%B,A&P"P>:3BQ;X17\8@'Z:;5';1H
MA[K7[,W1D,_*LZENCZP^031CD !X)8?+V>9F1]\N7U:)4X^14-J&Y-F*Y(8'
MZT^#O0B/0#M/#U@=H^6&S@VEN,Q^3%W)MC;">XP5=*>T6>]LE,H'R):O5[=.
M=?&4T%[A]<)2IE$LI26A'\@3HY8PZ>-T*%CT:3+B->0H WDJ(2>1P1]Y MZ=
MZF;P^&ULB:/J1F%B??;X55D[]3G3XO>W?G=;G*<CO4;7]G4ZG@O'/FHKGH>D
MT 0>@?U9P<V:;/_^*MO_9S*5GOC;&.[48I<B^3*@J2\$O8%((XQ7W8".TGT:
MO1L53;DM0;(7K($ROQ+&E7<-R?LCU&M0KP>_AZ.^BH'"4&3%PZ SV:X$?U/I
M%"4]L*$6" V:GEBHD2MF$"2ZK68DBQ7[P!!80Z?W9((YS9-WC7:0W8-\'E)-
M3C\X!V5&,;IZM5KG^6><RHE[YGQ"1H9.%2['J160VB+G#>MK?[!(*+!'<LTF
M=W=WVZ ZMJ^36R%3K9.Q0R-$J6(O+XS$!QX3?KX6*A57E9D")4=Z6-19.A?_
MHA<[I0=V:^7?%;FO*.[<,R.1:!Y@4JOC:1=.0#_O 8K)OP<I:*%SC;,0SW4[
M'NBC)66%QPO*9ZA2#JA$28\"#!BJ26-UB[J#@W E=:TY&FKNG"/!,9P8JTG.
M9@B<EC>H4H=.;!&;;!TK_KAL;Z0PU@8L22.8&(C9U/KI)Q!DD#XU#&L2?'(H
ML7>2%*S[\HNJ//@8!H8B AD"Y_6Y;-/MNO8LS-G'DP;&*$QP#SQ#@6^2=UP"
M)!(,?AAF:G"KD=O,-G/]W3(JL6"MY:2*A7W.%IA9&O'BSZ!U?GK1_M! S(E2
M;FNI''[_H%E(Q=%?7[6NFA]J-?C-?VQM-48]D&M;6[^)4,*_!;7:=O _'QOG
M5ZTKN(J_-S$0MKX&OSG3OSAI=8[/+CH?"76$\$,83"5HMSJ_E_),3+Q ?<9"
M5<D&WH)L45S"G\;9)W\:+[E$/)9&IZ4XT<]>!ED!>AHQ%OV:JG!XDF2S^NQ[
M+Q&9M/16VVC;M&$KI5P[14G@U@IF:M\IFNT"3)HFGVG4-VB/_ZK5#K8/<8;R
M0&#&>-@R%3^AJ7:+2*43-")Q]VE,?:WT5S(R*?9 M3C=</0)A#/5(V0DXX?@
MA!$^,4;^6;GA][)I.AY,B7YRW^G$W$F%]HG-%X RN!^+H]<+4TR*]^//*O*I
MK^*Y9!:;FWI[<G4_ E.!'8,$8XR5.?.(>AL=0:X(<FPU,.84&$D@]%10UUTK
M>,Q4D9(,XBCTO41K^RT1S>L4V[%F91,/:6M6;FE6+N6N&!&&JMC$O!(+%HO^
MG$F>>G!R--MN0W5W_0&!Q&!H@@T.*54V4P9EZI9,T1*D%&EC,-+.AE T"8)#
MAN.N-QA577ZB2LA!>$V3;ZB ;Y/+L2+ESAKGA9RW.EP^(J]P6^UY#UQW91>A
M>W-D)3@&L;Y]^$LEV*AN'_S"18G5[?U?\#,L..!_J_3K>K5V5-$Q0$);D*&T
M_LKR*S!9>[U@?.?.]@Z\\V"[^@L]&H30HF]$?N2/8??ED,=\U*J_/'49[)E2
M&1DV[(/"0^E#D2=[D4@S",).A5B,1.U)S^T]+3LIQL63VFE1B-%:P]V-L4,R
M_LI5.3/:%EA472\*7//UM0RXA,)UB!B"\6-;&(2O&$4QMJ71Q  %1G9RKQ29
MVR ?=8:>>KY 0(<#- S8)F<"VNK2' #]Q<R6%<%"\;)E2#WA6)O:5 HM6I'K
M]>5@5A;</HPC4(5%I#X3_.GQ9<OZP1FNQ/(<>4L>!"1[N=/Q79A&[E^H.X=/
M4IY!9Y"I?*M=@%HMTU6+AK!>%]TG[=.Y1_<Q^N*RUW:Q^K0P!^V<LW<;>;&D
MV[*P8IDO$34BW(E ;5**@?Q%7(W<BMX:&7C<R"&UJ1@E-Y7"R?J:W_J5<DS
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M<"?:"?=J>]7#:A@>[(6O7#G+?M_,0OD76+D.2\V5$X;326*<JD/TJ?)NE$L
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MM>/YTU*V@\X4; CGPV8[ZC-0UP@>54'6#(%LL@FR:@Q+41@0Q ,'V@[3B,$
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MMQPQ6> ZU$@[&43<KO?*<)(=FTQ"I>JHS#5F3@U4MMMJ3^QYI759KJABZ$[
M'_W -?T%7D5W5B846R8;F1;\4:7=*ZSQ2(.)3YC0DSVWMAHFMSP>]7.D?G87
M^NB4XV@Z-ID$.]5AM]40N+W#KMTHA9=VHO'&6W_*7='2",/1429:--J %]V
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M/O4&V0?C-O ]G]EX!6=7/3(:>KO3TKLMFBQP6H2>+#9;N\'F7F;"UQO41Y5
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M_FL_/CBW\@*^-%4?G*@<WNO;QE5D0PBK=1?Y3;VN>*O,PF"E,(26$=1T"I'
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M3#T81'*]RR['']IZ.V.*K4IXV2ACRR_%O8Q5HIVP7GBLY\LI9U^J>/UH@[V
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MS^_B/W;CXAUL:3OW\%J9T=E]U*/LP,/KZJT:%9@0V GLKP-[FU(Q!'8"^VF
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MQJ3K&O\]"7G)@(#X*SA6(/1:_S=M^6/)FR-%%AG*>MJ2DQ$).-)G@#9PS,(
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MK5WQ.3EI]\/R1C;'8Z1CJ!X6?J[U0:TD$>X<4CHSQ:>GYN,4#%'[$?YJP+M
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M1.:N0N/[CF$+:G,NG)W;R<>9-[#OC3!ZXNV PTV]5E^?RQ5'KU?0DX\UW3<
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M-<SO'U9UX+I.S'%FY,Y1KJK^2\?&K9#W1S!>>^ER RQB^.E,XV -SWED !_
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M%U4V*:4X"S7(3#2&-/_)J7@^GVML#NM!:UNP=NP\VN9_(S&2HB%^2TDL@BX
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M5?O&]4P1+ 2>O+;\@>WB9Y$)G;:@X4F1!:VG-"-N3@]C-()&"@8=*8!";YT
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M_AX#3<7WTU?S]^B"#BA:1]'[GQ/RR@ R\$J\@YDZOM!(G6+XN2A)'&):M_@
ML_3X[QQ/F ''BPX)]Q1=PV@9 *6!@<1S\U6 *S/ 554!+A7@4@$N%>!2 :YC
M*&I[EX):GG*V6U$9D- *QZ@%\@^'8,Y&Z4U"D9"YAF MQ^J0+O0XRM+GJHN#
MYE*45"DUE(6JHS2IDI!0)I!PS?3QDB'E7))ZR4$4&4'PN/2CHE>:PDNG)WUT
MI!@-+;#I!NYX;$7)1YX;/H,%*Y*DZ:I(>:9P!S<QL9S/8V#!^WS;*9L(]6,[
M^5XK8&/TQZ:?(!_.%6O+X3F7O!K&BU$=8R%1NI:UUB4O*"[-\<V?&'[:44K:
M%ZT"K!902[%S&%G&F$9.^7&" A,$0)U(T!TCW%() AN&1("Q4DS!EJA!!-P$
MOWNNS;MLR,R]V$4 ]$=Q25]L>_0-B YW;'$S -YS?_N4)Q,UN5)1,IBL;9E;
M;SHS+\KLG6<;WL)"8FE!UC3&]4ZIER.:3Q29M;FG]D.!*:5'/4[BQ8V%9!*F
M+ADQ9)&F#9^DP4JIAXE"-(&P5<JL*)=0Y%SB[6Y@V,+&I?JA! -291)^ED U
M%C%QVPIA2)!7S/NQ9(4WA4Z4M9G]$M[:9(DL.D6[^\,[/%*9D\7RM8E*@,,3
M\[EGJFS^*7_9\5\_;U;Y=5>+T5_\LW^ADVH)42TLU4QFFJ2QPLD@]E?U1G!H
M@=P+./\FLPU(&H(4C,LAT[40IN5/;(.WF5H"8]S(9SQQ'9+VW-6!I0 4'AYJ
MS[R3TMDD]";H^HDS?R+00 0OV5_Y!!N3$D3]HZ_-G$%D!HQ 66:>+T]R<I%C
M6#KT9-!:5.@+2X+[HG@&-!T->&[%;AO,@R#=!+ 1>%8_Y%&=P-53KTN?'\R.
M4O(%K%'KHV4[K6$=B<U%L.6$F#L2H><=\B7W_+%9^0*,THED^X/G.BZF=2>R
MTG8N9][/AIK0A_B1M*A6-E8=,(L^2=JH_;QU%LCX"J^0$'6PRM&7Z>BK*4>?
M<O0I1Y]R]"E'WS$X^H)\CKY'AH<&-G_T_5!8>I[\S##="6I7L6ZB/4E5]F.2
MMXNH?X#ZT0F?,3P9.RJ^=IZ^R)5VGKY3T35OY]#4DZM$-1WVF-HJ8[)%HDI
MM)5-^B4<[89R:F*?5O<5/N/J\"F^1[P#]!6>Q>5;XXD(^ 89@6A1T)>9M<]M
M$]#%\?V 1D#3@)2EV<)IKHXGZSH'B159,RL:S*R(S:P(TR[Y$^'T&KOH#^7*
M&3<*="VQ3""@L4OUB:CA_];I/,P4H,?@ 25,#-$[;>R:S!:&6C:@M'2#NT7X
M-3[>.&3<)TLN7%%<2FB;OT;G%V&<F1LBNFPJ9O(N+#I?N27=M*"3VK!:E(@<
M4BQ"E::&)7%"&!OWF8E^EPS(<%'"#=P' ^/) NXP/-'N=NF=,T#TJ<T:H.8_
MTJ$H]&'#CV=2"V<,.0\%YH>12RW&YSF1-3/,V37+>G_JAI/:# 0_F>7P"D:9
M38D"]$WHV)@'>EK],'-?XI:HP%NL,,JE)M>7UK>&H3<0B<M^.KV".XC0+.^Y
M$[#!*)]D01X)69*GM5E YA: >!.2+T"[,.RCL4[=FV"7QU8X!GH'@8, \0;%
M:4)/Y*90A<H@59)M#<_$VYDIVRY@_VG9D(I?!!;0(.#&?S;=4VL%WNR')=M%
M\4/Z].;AZ<-Y"BXKZ84;4E0 >YT(6ZS/ $-45<%I/W(4(CZYH4:<QI!$(\[
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M@!##7#B5,&OV8&O70_ .</[3P+61]O]VTCR9!UILE'A IH^RL-.BWI0TR;R
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M65<V][UC1MGKJAOOKJN^N^G$]=)[[GV[I.M7LB6*3?M&+0\L&CUFV-25-F
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M:Z.J_K>3VLD\T&*CQ ,RC>T]K@L9?C%SOVWL1?[@?,;>R6<A"5)NB?+M>&D
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MWU0ORZI>;X- RV@W6"2R5(Z(H@!:>C9?N5/H)MG<7XG/=^>8:,TW #P,<E6
M'I8 .$2,*D 5C18,H\MR(0\OB!TUS2GE7I47T"+KDJ>YE,F5)ZBMHDPN&VE
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MC,.=9YU5Q]]N81SN80UYJJHA3VK(4]R.4@UY4D.>UACR]'9OUV9M[=ZNM\[
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MQI0 V_K!;!S(93B:XP;\4?B0U(H\]FQX? 87?/6.E6BO%B 47]1G\%38U__
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MZR@8VY__'U!+ 0(4 Q0    ( +B*7%2P+JJE:!,  ++!   1
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M8FET7S$R+3(N:'1M4$L! A0#%     @ N(I<5'(:N:.,!    A   !
M         ( !5?,  &5X:&EB:71?,3,M,2YH=&U02P$"% ,4    " "XBEQ4
M2SV+..0#  !F"P  $               @ $/^   97AH:6)I=%\Q-2TQ+FAT
M;5!+ 0(4 Q0    ( +B*7%1Q<,8&41X  -"!   /              "  2'\
M  !E>&AI8FET7S(M,2YH=&U02P$"% ,4    " "XBEQ4'\9JA\<-  !9/0
M$               @ &?&@$ 97AH:6)I=%\T+3$U+FAT;5!+ 0(4 Q0    (
M +B*7%1@RM*_21   #MC   0              "  90H 0!E>&AI8FET7S0M
M,3@N:'1M4$L! A0#%     @ N(I<5-UB!9[,&   [&\  !
M ( !"SD! &5X:&EB:71?-"TQ.2YH=&U02P$"% ,4    " "XBEQ4>$@:0\H9
M  "ZBP  $               @ $%4@$ 97AH:6)I=%\T+3(P+FAT;5!+ 0(4
M Q0    ( +B*7%1C%T2*91 ! $ ("@ /              "  ?UK 0!E>&AI
M8FET7S0M,RYH=&U02P$"% ,4    " "XBEQ42R@V=*((  #B*   #P
M        @ &/? ( 97AH:6)I=%\T+30N:'1M4$L! A0#%     @ N(I<5"UT
M0*C/%   BVD   \              ( !7H4" &5X:&EB:71?-"TU+FAT;5!+
M 0(4 Q0    ( +B*7%3[@MX&] D  (LO   /              "  5J: @!E
M>&AI8FET7S0M-BYH=&U02P$"% ,4    " "XBEQ4J+8^%:PP   P_0  #P
M            @ %[I ( 97AH:6)I=%\T+3@N:'1M4$L! A0#%     @ N(I<
M5+'+Y,F@ @  ;0@   \              ( !5-4" &5X:&EB:71?."TQ+FAT
M;5!+ 0(4 Q0    ( +B*7%3_?1,F4R<   0L   *              "  2'8
M @!I;6%G93 N:G!G4$L! A0#%     @ N(I<5*Z\^06(2 $ #+ !  X
M         ( !G/\" &EM86=E,# P,#4N:G!G4$L! A0#%     @ N(I<5%6+
M'Y&W? ( Q@(#  X              ( !4$@$ &EM86=E,# P,#8N:G!G4$L!
M A0#%     @ N(I<5"NZFOL#] , KT(B  T              ( !,\4& 'IK
A,C(R-S,X,RYH=&U02P4&     !@ & #1!0  8;D*

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
